data_1gm1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1gm1 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 12.6 t70 . . . . . 0 N--CA 1.43 -1.428 0 CA-C-O 120.539 0.209 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.84 154.26 20.39 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.648 -1.907 . . . . 0.0 112.467 -175.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -146.15 141.38 27.45 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.131 0.967 . . . . 0.0 109.505 167.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -92.7 119.73 32.4 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.776 1.63 . . . . 0.0 107.276 163.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 10.9 t -107.65 101.57 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 122.485 1.136 . . . . 0.0 108.029 -174.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -92.43 79.6 4.94 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.461 1.505 . . . . 0.0 108.749 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.9 tp -104.64 133.52 49.36 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-O 122.643 1.211 . . . . 0.0 111.264 -166.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.7 146.32 27.9 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.167 -1.583 . . . . 0.0 108.848 170.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.76 158.67 34.99 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.205 -1.559 . . . . 0.0 114.558 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.2 t -112.05 105.33 13.69 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 170.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . 0.256 22.9 t70 29.64 63.29 0.15 Allowed 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.94 2.896 . . . . 0.0 117.37 -165.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.74 10.09 85.56 Favored Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 117.244 1.658 . . . . 0.0 117.244 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.6 m -121.1 134.15 55.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 119.586 1.693 . . . . 0.0 113.499 176.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.6 mt -89.98 -63.01 1.34 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.552 1.141 . . . . 0.0 111.857 167.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.35 34.35 2.51 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 119.684 -1.885 . . . . 0.0 114.378 173.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.9 pt -125.92 131.47 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.686 1.594 . . . . 0.0 110.769 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 22.4 t -105.63 106.9 17.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 166.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.7 m -110.02 152.77 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 C-N-CA 124.548 1.139 . . . . 0.0 111.414 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.1 t -150.7 175.61 11.8 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.167 -0.958 . . . . 0.0 110.974 -172.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.01 -127.5 7.13 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 121.054 -1.029 . . . . 0.0 113.527 170.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.61 -170.52 20.27 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.36 1.457 . . . . 0.0 112.174 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.43 -1.456 0 C-N-CA 124.896 1.278 . . . . 0.0 114.343 -177.968 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.704 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.4 mm -103.75 129.08 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.842 1.257 . . . . 0.0 108.155 -178.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -127.68 149.47 50.19 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 121.312 -0.868 . . . . 0.0 109.574 -171.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.5 t -77.09 122.62 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 O-C-N 120.845 -1.159 . . . . 0.0 111.684 172.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -88.33 -50.44 6.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.827 -1.171 . . . . 0.0 110.816 176.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.51 158.65 44.4 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 122.162 -0.337 . . . . 0.0 111.829 -175.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.41 120.47 64.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.706 1.202 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.68 119.55 77.9 Favored Pre-proline 0 N--CA 1.429 -1.477 0 CA-C-O 116.794 -1.574 . . . . 0.0 113.37 -169.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -63.66 128.18 21.58 Favored 'Trans proline' 0 N--CA 1.434 -2.018 0 C-N-CA 123.207 2.605 . . . . 0.0 113.931 -173.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.264 54.3 mttm 82.47 21.33 0.25 Allowed 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 128.063 2.545 . . . . 0.0 113.642 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.1 160.83 37.18 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 119.897 -1.752 . . . . 0.0 114.428 170.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -52.44 -59.78 4.02 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.341 1.856 . . . . 0.0 115.402 164.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.49 -45.23 88.23 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 128.823 2.849 . . . . 0.0 111.225 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -44.42 -64.2 0.73 Allowed 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 170.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 m -70.2 -22.37 62.94 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.565 1.691 . . . . 0.0 115.565 -177.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.45 -61.61 2.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.829 1.652 . . . . 0.0 112.603 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.88 5.0 64.71 Favored Glycine 0 N--CA 1.43 -1.717 0 N-CA-C 116.14 1.216 . . . . 0.0 116.14 169.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -77.17 -32.92 56.53 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 118.767 1.283 . . . . 0.0 109.635 160.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.7 mt -92.27 135.91 26.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.966 1.306 . . . . 0.0 109.161 170.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -159.47 160.97 35.33 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.589 -1.319 . . . . 0.0 110.014 178.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.5 pttt -64.87 135.49 55.79 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.383 -2.073 . . . . 0.0 114.628 -171.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.46 4.93 67.62 Favored Glycine 0 N--CA 1.43 -1.744 0 CA-C-O 118.295 -1.28 . . . . 0.0 115.436 -172.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.344 1.6 p30 -80.15 166.13 21.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 121.468 2.634 . . . . 0.0 114.375 171.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 9.9 tpt85 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.496 1.118 . . . . 0.0 109.186 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 5.0 t -85.68 139.27 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 123.748 0.819 . . . . 0.0 109.805 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.17 -53.23 2.7 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.862 -1.149 . . . . 0.0 109.291 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.69 150.62 31.31 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 112.744 -175.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 2.5 p -119.38 107.74 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 125.45 1.5 . . . . 0.0 110.266 177.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.1 t30 58.93 37.05 24.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.672 -1.893 . . . . 0.0 113.282 173.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.07 -29.69 11.59 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.891 1.234 . . . . 0.0 114.023 -172.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 44.5 t -87.98 119.55 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 119.734 1.767 . . . . 0.0 110.777 -163.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.8 m -69.87 117.63 11.71 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.1 -1.0 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 18.2 mt -83.84 -4.65 58.83 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.573 -1.329 . . . . 0.0 113.873 -169.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -74.05 116.37 14.6 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.217 -1.552 . . . . 0.0 112.044 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 107.93 -20.87 30.62 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 124.175 0.893 . . . . 0.0 112.064 -175.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.35 148.79 46.68 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.772 -1.428 . . . . 0.0 112.902 172.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.21 -179.14 5.58 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.301 -1.499 . . . . 0.0 112.008 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -61.23 -47.6 85.35 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.463 1.905 . . . . 0.0 112.765 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.68 -46.96 80.85 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 115.173 1.546 . . . . 0.0 115.173 173.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 15.9 mp0 -55.88 -51.13 68.65 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.681 1.593 . . . . 0.0 113.822 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.05 -36.42 83.51 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.1 t -67.29 -49.39 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 O-C-N 120.661 -1.274 . . . . 0.0 110.941 176.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -62.5 -37.12 84.78 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.126 0.97 . . . . 0.0 113.285 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 54.0 m -58.59 -52.28 66.32 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.261 1.824 . . . . 0.0 112.57 173.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -63.27 -37.02 85.61 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 175.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.44 -42.88 99.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.108 1.363 . . . . 0.0 111.608 175.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -88.97 43.16 1.13 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.716 1.606 . . . . 0.0 112.663 177.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.6 p -100.53 156.19 17.43 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.203 -1.56 . . . . 0.0 110.184 169.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.32 -146.42 20.32 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.656 1.122 . . . . 0.0 113.141 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -69.97 -57.41 5.04 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.757 -1.437 . . . . 0.0 114.331 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.38 131.91 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 CA-C-O 122.454 1.121 . . . . 0.0 108.534 176.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -124.57 120.73 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 127.611 2.364 . . . . 0.0 108.977 -167.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -107.2 93.41 4.54 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 119.878 -1.764 . . . . 0.0 112.523 -171.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.449 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 1.1 mm? -91.54 160.04 15.62 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 118.782 -2.448 . . . . 0.0 113.794 -177.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 38.8 tp -127.87 128.92 46.03 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.289 1.436 . . . . 0.0 108.867 162.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.72 169.89 18.11 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.292 -1.505 . . . . 0.0 113.041 177.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -126.96 134.94 50.28 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.149 0.979 . . . . 0.0 112.873 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.47 0 C-N-CA 126.415 1.886 . . . . 0.0 113.444 -177.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.429 -1.478 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 48.4 p -100.14 162.59 12.87 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.416 -1.427 . . . . 0.0 113.276 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.62 149.86 34.34 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 168.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -104.03 119.11 38.23 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-O 122.719 1.247 . . . . 0.0 109.242 167.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.8 t -98.07 108.48 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.588 1.955 . . . . 0.0 108.344 -175.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -104.42 86.47 2.53 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.196 1.398 . . . . 0.0 108.443 173.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 52.5 tp -120.38 142.29 49.31 Favored 'General case' 0 N--CA 1.431 -1.379 0 C-N-CA 125.111 1.364 . . . . 0.0 110.609 -165.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 140.59 35.9 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.651 1.58 . . . . 0.0 110.585 173.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -69.71 158.79 34.72 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.9 p -112.61 105.7 13.95 Favored 'General case' 0 N--CA 1.429 -1.518 0 C-N-CA 125.076 1.35 . . . . 0.0 108.761 172.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.2 t70 55.34 45.38 25.62 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.437 1.895 . . . . 0.0 113.656 -176.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.44 -5.26 64.61 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.349 -1.47 . . . . 0.0 115.563 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 60.5 p -107.92 149.78 27.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -174.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.0 mt -100.83 -56.25 2.37 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.229 1.411 . . . . 0.0 108.278 172.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.06 55.71 0.68 Allowed Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.324 -1.485 . . . . 0.0 111.863 173.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.5 tt -143.39 142.26 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 CA-C-O 122.295 1.045 . . . . 0.0 110.401 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 44.3 t -112.79 115.09 27.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.435 1.894 . . . . 0.0 107.441 171.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.6 m -101.4 160.1 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 122.43 1.11 . . . . 0.0 111.84 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.5 t -144.05 -179.46 6.51 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 125.253 1.421 . . . . 0.0 107.906 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.1 -155.43 16.3 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 121.085 -1.009 . . . . 0.0 113.722 173.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.2 152.68 22.55 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.692 1.139 . . . . 0.0 114.173 176.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.43 -1.456 0 N-CA-C 115.208 1.559 . . . . 0.0 115.208 -170.247 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.752 0 CA-C-O 121.661 0.59 . . . . 0.0 114.313 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 46.7 mm -103.69 127.72 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 125.487 1.515 . . . . 0.0 108.082 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -130.92 157.01 44.08 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 121.07 -1.019 . . . . 0.0 112.6 -168.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.4 t -75.87 124.4 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.97 -1.081 . . . . 0.0 111.168 169.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -93.15 -46.43 7.43 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.246 -0.909 . . . . 0.0 110.61 170.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.53 153.5 34.68 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 111.121 177.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.43 HG22 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.16 121.68 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-O 123.016 1.389 . . . . 0.0 109.052 176.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 33.2 mm -76.53 126.27 86.37 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 127.028 2.131 . . . . 0.0 113.157 -166.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -60.63 138.42 79.83 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 124.722 2.722 . . . . 0.0 113.976 -173.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm 53.43 37.08 24.73 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 116.822 2.156 . . . . 0.0 116.822 -169.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.74 35.97 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.078 -1.639 . . . . 0.0 113.225 159.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.75 -56.37 12.34 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.252 -1.734 . . . . 0.0 115.658 163.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.71 -47.65 77.57 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.196 2.999 . . . . 0.0 112.517 -179.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.43 ' HG2' HG22 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -40.81 -64.88 0.48 Allowed 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.656 1.582 . . . . 0.0 113.975 164.696 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 12.9 t -67.65 -34.89 77.84 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.456 1.102 . . . . 0.0 113.887 -170.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -53.46 -65.43 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.616 1.966 . . . . 0.0 113.906 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.22 -10.78 24.45 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 115.496 0.959 . . . . 0.0 115.496 172.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -72.72 -24.75 61.03 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 119.634 1.717 . . . . 0.0 113.194 172.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 67.5 mt -105.4 135.93 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.542 1.537 . . . . 0.0 108.452 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -154.15 158.25 40.1 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.844 -1.16 . . . . 0.0 112.169 -170.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -51.83 122.78 8.85 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.007 -1.683 . . . . 0.0 115.49 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.59 -5.51 64.63 Favored Glycine 0 N--CA 1.429 -1.771 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 0.3 OUTLIER -80.19 171.83 14.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.923 1.861 . . . . 0.0 114.343 -175.823 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -119.74 125.73 49.35 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.402 -1.436 . . . . 0.0 112.709 -169.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.0 t -82.61 127.85 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.734 -1.229 . . . . 0.0 110.027 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.41 -46.45 5.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 110.525 176.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.79 136.57 17.13 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.556 -1.34 . . . . 0.0 114.003 -177.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -104.37 116.93 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 124.536 1.135 . . . . 0.0 108.525 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.5 t30 59.38 39.47 22.13 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.137 -1.602 . . . . 0.0 113.767 175.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.09 -33.5 5.21 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 121.209 -0.932 . . . . 0.0 113.889 -174.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -87.03 117.75 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 C-N-CA 124.725 1.21 . . . . 0.0 111.471 -167.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 t -76.55 139.32 40.68 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.318 -1.489 . . . . 0.0 112.628 -174.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.2 mt -89.69 20.86 3.79 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -171.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -62.17 117.71 6.4 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 119.829 -1.794 . . . . 0.0 114.591 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 84.94 10.8 78.02 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 124.483 1.039 . . . . 0.0 113.65 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.72 157.14 38.46 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.3 p -91.22 170.03 10.34 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.863 -1.148 . . . . 0.0 109.677 170.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -53.91 -55.2 29.09 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.889 1.276 . . . . 0.0 113.322 170.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -56.44 -44.34 80.34 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.049 1.499 . . . . 0.0 115.049 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -61.06 -46.05 92.25 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -175.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.98 -33.43 75.71 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.809 1.244 . . . . 0.0 112.669 172.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.06 -48.34 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.463 1.105 . . . . 0.0 110.381 178.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -59.05 -42.24 89.81 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.714 -1.241 . . . . 0.0 113.043 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.6 m -62.03 -48.06 81.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.036 2.134 . . . . 0.0 112.858 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 33.4 mt -65.54 -37.12 85.82 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.109 1.364 . . . . 0.0 114.246 175.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -68.69 -31.54 70.71 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.337 -1.477 . . . . 0.0 112.474 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -88.51 48.58 1.66 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 124.828 1.251 . . . . 0.0 112.139 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.6 p -98.82 154.48 17.98 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.132 1.773 . . . . 0.0 107.894 166.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.66 -157.76 30.82 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.803 -1.186 . . . . 0.0 112.007 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? -69.43 -49.08 58.46 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 121.099 -1.236 . . . . 0.0 112.6 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 56.4 t -99.16 132.72 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.43 1.092 . . . . 0.0 108.325 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 74.4 t -120.3 124.8 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 126.556 1.943 . . . . 0.0 109.649 -165.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -113.58 87.46 2.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.627 1.171 . . . . 0.0 112.196 -174.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.279 3.1 pp -123.5 148.28 46.4 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 117.794 2.516 . . . . 0.0 117.794 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 49.9 tp -105.82 128.31 53.65 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.878 1.671 . . . . 0.0 108.433 -176.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.34 158.68 43.65 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 121.999 0.904 . . . . 0.0 110.822 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -95.52 150.98 19.72 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 165.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 122.221 1.01 . . . . 0.0 109.791 165.393 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t70 . . . . . 0 N--CA 1.43 -1.474 0 N-CA-C 113.113 0.782 . . . . 0.0 113.113 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 38.5 p -121.86 154.42 37.09 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 121.077 -1.014 . . . . 0.0 112.79 -174.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.2 139.65 27.36 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.072 -1.017 . . . . 0.0 109.082 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -92.72 131.0 38.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.86 -1.15 . . . . 0.0 109.899 168.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.8 t -116.71 111.83 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.057 1.343 . . . . 0.0 108.656 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -102.55 78.06 1.68 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.419 -1.425 . . . . 0.0 109.288 172.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.5 tp -94.74 146.83 23.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 124.297 1.039 . . . . 0.0 111.063 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.48 127.59 50.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.085 -1.634 . . . . 0.0 108.932 167.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.1 ptmt -70.15 149.55 47.44 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 p -106.55 111.44 23.99 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.272 -1.517 . . . . 0.0 111.635 -174.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.0 t0 54.26 39.46 30.85 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.424 2.29 . . . . 0.0 113.522 -175.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.02 -7.22 78.71 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.281 -1.512 . . . . 0.0 115.713 -176.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.8 t -109.39 150.38 28.14 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-N 119.15 1.475 . . . . 0.0 112.005 -172.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.4 mt -100.71 -61.59 1.35 Allowed 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.237 -1.539 . . . . 0.0 112.151 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.53 33.81 0.91 Allowed Glycine 0 N--CA 1.43 -1.746 0 O-C-N 119.914 -1.741 . . . . 0.0 111.497 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 pt -124.38 150.36 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.429 1.092 . . . . 0.0 111.261 -174.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 35.4 m -126.67 134.33 50.74 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 156.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 m -117.84 161.58 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 CA-C-O 122.346 1.07 . . . . 0.0 112.102 -170.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.64 -173.35 4.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 124.2 1.0 . . . . 0.0 109.595 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.06 -152.41 20.25 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.994 -1.067 . . . . 0.0 115.437 171.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.67 172.66 30.62 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 125.593 1.568 . . . . 0.0 111.621 -176.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.43 -1.463 0 C-N-CA 125.065 1.346 . . . . 0.0 113.065 176.169 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.682 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.2 mm -95.32 127.72 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.239 1.416 . . . . 0.0 108.584 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -125.7 155.58 40.69 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 120.757 -1.214 . . . . 0.0 111.404 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.5 t -75.96 122.26 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.999 -1.063 . . . . 0.0 110.945 169.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.0 ttmm -87.9 -42.06 12.76 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.376 1.47 . . . . 0.0 109.703 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.24 160.0 38.2 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.77 -0.581 . . . . 0.0 109.946 175.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -119.17 121.36 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 C-N-CA 124.348 1.059 . . . . 0.0 108.841 174.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.46 119.38 77.22 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 115.872 -2.013 . . . . 0.0 116.144 -169.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -59.86 123.24 12.83 Favored 'Trans proline' 0 N--CA 1.434 -2.024 0 CA-C-N 124.659 2.7 . . . . 0.0 114.916 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.254 83.7 mttt 81.74 26.53 0.19 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 128.229 2.612 . . . . 0.0 111.921 -172.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.61 157.49 31.39 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 119.768 -1.833 . . . . 0.0 111.812 164.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.57 -58.74 5.47 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.59 -2.123 . . . . 0.0 114.287 160.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.1 -40.12 95.54 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 127.45 2.3 . . . . 0.0 112.826 -177.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 -52.07 -59.74 4.01 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 166.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.5 t -68.82 -25.21 64.56 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 125.837 1.655 . . . . 0.0 114.905 -167.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -46.48 -63.15 1.08 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.1 1.76 . . . . 0.0 113.964 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 114.48 -2.51 23.5 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.217 -0.927 . . . . 0.0 114.324 171.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.6 mtm180 -85.81 -28.64 24.36 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.006 -1.29 . . . . 0.0 113.095 171.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.1 mt -108.61 132.07 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 C-N-CA 126.445 1.898 . . . . 0.0 110.664 -170.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.12 -176.71 4.91 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.356 -1.465 . . . . 0.0 112.424 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -68.43 121.19 15.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.416 -1.428 . . . . 0.0 112.738 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 105.41 -2.52 39.88 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 121.418 -0.801 . . . . 0.0 114.393 -175.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -80.35 147.8 30.91 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 119.419 1.609 . . . . 0.0 112.393 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 23.5 ttm180 -97.07 134.34 40.56 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.838 -1.164 . . . . 0.0 110.452 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.1 t -86.45 127.39 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.96 -1.087 . . . . 0.0 109.196 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.47 -45.94 4.71 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.496 -1.377 . . . . 0.0 111.253 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.0 128.69 12.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.489 -1.382 . . . . 0.0 111.584 -176.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 t -108.9 124.04 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 66.55 28.1 9.47 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.521 -1.362 . . . . 0.0 113.666 170.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.74 -12.53 66.92 Favored Glycine 0 N--CA 1.429 -1.809 0 O-C-N 119.962 -1.712 . . . . 0.0 113.773 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.9 t -96.14 116.09 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.155 -1.203 . . . . 0.0 109.026 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 92.7 p -75.36 140.83 43.27 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.357 -1.464 . . . . 0.0 111.592 177.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.2 mt -88.29 50.93 2.06 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.652 -1.28 . . . . 0.0 112.744 -166.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -73.67 125.07 27.21 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.977 -1.702 . . . . 0.0 112.19 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.79 10.64 61.51 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.237 1.399 . . . . 0.0 115.453 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.26 139.4 50.0 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 115.898 1.814 . . . . 0.0 115.898 -170.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.8 p -91.64 173.26 7.98 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 124.868 1.267 . . . . 0.0 110.27 176.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -58.96 -49.41 77.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.962 -1.086 . . . . 0.0 113.531 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -56.33 -40.29 74.2 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 175.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -53.9 51.56 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.565 1.546 . . . . 0.0 113.766 179.069 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.5 87.73 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.472 1.509 . . . . 0.0 113.86 177.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.62 -48.15 88.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.772 1.229 . . . . 0.0 110.894 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -63.21 -41.27 99.11 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 175.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.3 m -61.48 -45.95 92.08 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 125.96 1.704 . . . . 0.0 113.277 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.64 -30.4 67.02 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.269 -1.519 . . . . 0.0 113.91 176.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.58 -45.03 92.29 Favored 'General case' 0 CA--C 1.488 -1.419 0 O-C-N 120.453 -1.405 . . . . 0.0 112.025 167.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -78.02 48.81 0.75 Allowed 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 128.116 2.567 . . . . 0.0 113.679 176.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 35.3 p -106.03 156.0 18.84 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.268 -1.52 . . . . 0.0 110.218 174.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.21 -164.19 38.35 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.778 -1.201 . . . . 0.0 111.036 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -69.78 -47.81 61.52 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 118.922 1.361 . . . . 0.0 112.236 172.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.27 123.82 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-O 123.171 1.463 . . . . 0.0 107.505 169.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.4 t -113.2 103.59 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 126.956 2.103 . . . . 0.0 109.019 -168.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.6 t-160 -89.2 101.57 14.23 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 123.784 0.834 . . . . 0.0 111.523 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.6 mt -102.97 162.12 13.2 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-O 122.665 1.221 . . . . 0.0 113.822 172.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.5 tt -129.04 132.19 47.44 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.036 1.335 . . . . 0.0 108.021 159.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.01 164.64 28.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.012 -1.055 . . . . 0.0 113.23 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -113.88 142.47 46.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.405 1.882 . . . . 0.0 109.918 177.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 19.7 tptt . . . . . 0 N--CA 1.43 -1.442 0 C-N-CA 125.818 1.647 . . . . 0.0 112.794 177.58 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.6 t0 . . . . . 0 N--CA 1.431 -1.423 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.0 p -101.83 150.47 23.14 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.375 -1.453 . . . . 0.0 112.532 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.76 134.88 22.76 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.903 -1.123 . . . . 0.0 108.72 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -91.04 121.4 32.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.334 1.454 . . . . 0.0 109.615 174.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.19 102.77 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.803 -1.186 . . . . 0.0 108.236 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -104.46 81.88 1.85 Allowed 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.123 1.369 . . . . 0.0 108.226 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.6 tp -111.78 149.27 31.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.694 1.198 . . . . 0.0 110.325 -165.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.89 144.81 30.72 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.347 -1.471 . . . . 0.0 108.869 170.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -70.12 154.64 41.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.609 -1.307 . . . . 0.0 112.638 173.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.6 p -112.92 100.79 8.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.836 -1.165 . . . . 0.0 109.066 175.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 22.0 t0 58.01 45.42 18.01 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 126.014 1.726 . . . . 0.0 113.248 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.54 -10.99 67.4 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 125.049 1.309 . . . . 0.0 115.226 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 62.1 m -104.04 148.78 25.83 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.787 1.293 . . . . 0.0 113.561 -169.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.0 mt -119.31 -54.03 2.21 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.999 1.32 . . . . 0.0 109.354 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.5 43.32 1.86 Allowed Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 127.036 2.255 . . . . 0.0 113.877 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 pt -121.52 121.15 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 CA-C-N 119.394 1.597 . . . . 0.0 115.031 -167.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.4 m -116.72 123.83 48.16 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.549 -1.345 . . . . 0.0 109.202 165.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.46 173.91 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.072 1.349 . . . . 0.0 111.709 -171.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.7 t -146.31 168.47 21.01 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.059 1.344 . . . . 0.0 108.515 174.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.67 -154.18 17.15 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.842 -1.161 . . . . 0.0 115.149 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 101.5 165.99 27.43 Favored Glycine 0 N--CA 1.429 -1.785 0 C-N-CA 125.247 1.403 . . . . 0.0 112.379 -179.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 N--CA 1.43 -1.467 0 N-CA-C 115.937 1.829 . . . . 0.0 115.937 -171.173 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.714 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.72 125.76 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.876 1.271 . . . . 0.0 107.972 178.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -128.88 157.49 41.42 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.602 -1.312 . . . . 0.0 111.398 -172.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.8 t -76.39 126.54 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.495 1.518 . . . . 0.0 111.181 172.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -109.79 -51.67 2.85 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.338 -1.477 . . . . 0.0 113.164 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.0 157.01 43.49 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 121.226 -0.921 . . . . 0.0 109.975 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -125.77 126.09 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 C-N-CA 123.988 0.915 . . . . 0.0 109.195 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.6 mm -77.26 122.45 86.16 Favored Pre-proline 0 N--CA 1.429 -1.493 0 CA-C-O 116.238 -1.839 . . . . 0.0 114.507 -173.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -57.28 127.6 26.24 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 CA-C-N 124.506 2.645 . . . . 0.0 116.18 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.292 50.8 mttp 79.36 22.64 0.56 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 127.545 2.338 . . . . 0.0 113.385 -177.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.17 156.3 30.76 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.9 -1.75 . . . . 0.0 112.16 165.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.09 -55.33 12.53 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.824 1.65 . . . . 0.0 115.268 170.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.36 -48.51 75.25 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.89 2.476 . . . . 0.0 111.448 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 tm-20 -47.49 -59.15 3.44 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 173.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.0 t -68.37 -30.37 69.29 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.647 1.179 . . . . 0.0 113.387 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -65.02 -60.43 3.05 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.963 1.305 . . . . 0.0 111.199 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.96 31.07 15.73 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.45 -1.406 . . . . 0.0 116.431 167.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -83.3 -39.82 20.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 121.458 -1.025 . . . . 0.0 108.747 159.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mt -79.17 99.81 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 123.933 0.893 . . . . 0.0 110.313 175.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -122.81 156.77 33.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.82 1.295 . . . . 0.0 109.627 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.1 pttt -67.78 131.27 45.24 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.136 -1.602 . . . . 0.0 113.379 -171.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.87 -19.52 32.84 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.164 -0.96 . . . . 0.0 114.1 -172.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -79.51 157.1 27.51 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 120.152 1.976 . . . . 0.0 113.312 -173.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 70.6 ttt-85 -108.88 134.93 50.9 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.154 -1.591 . . . . 0.0 111.289 -173.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.11 132.75 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 119.945 -1.722 . . . . 0.0 110.986 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.72 -52.4 4.9 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.914 -1.116 . . . . 0.0 111.788 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.96 140.14 20.3 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.907 -0.496 . . . . 0.0 112.016 -165.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.1 t -109.22 118.24 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 171.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 63.18 20.89 12.55 Favored 'General case' 0 N--CA 1.429 -1.514 0 C-N-CA 125.968 1.707 . . . . 0.0 113.974 -178.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 86.52 -0.55 86.94 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.279 -1.513 . . . . 0.0 114.069 -174.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -86.05 117.56 30.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.853 1.261 . . . . 0.0 109.045 176.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.0 p -75.63 132.36 40.55 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.774 -1.204 . . . . 0.0 113.702 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 67.6 mt -84.77 -13.19 51.95 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -168.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -63.63 131.74 48.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.595 -1.941 . . . . 0.0 112.72 174.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.18 -30.35 9.22 Favored Glycine 0 N--CA 1.431 -1.697 0 C-N-CA 124.518 1.056 . . . . 0.0 113.674 -171.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.23 156.87 39.04 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -88.23 172.61 9.34 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.244 1.018 . . . . 0.0 111.681 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -63.82 -43.35 96.48 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.554 -1.341 . . . . 0.0 112.151 175.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -54.8 -44.87 74.18 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 126.646 1.978 . . . . 0.0 114.416 171.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -56.03 -55.05 37.48 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.93 -34.85 78.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.61 -53.76 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.33 1.052 . . . . 0.0 110.566 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -61.92 -39.43 92.01 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.011 0.91 . . . . 0.0 113.036 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 97.0 m -66.86 -42.38 85.78 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.452 1.901 . . . . 0.0 113.219 179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 65.5 mt -69.54 -36.92 76.83 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.068 -1.02 . . . . 0.0 113.082 173.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -53.55 56.4 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.789 -1.195 . . . . 0.0 113.03 173.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -81.04 43.06 0.68 Allowed 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.863 1.665 . . . . 0.0 112.748 -177.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 p -91.76 155.37 18.3 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 127.425 2.29 . . . . 0.0 108.814 168.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.98 -140.7 7.01 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.973 -1.079 . . . . 0.0 114.078 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 2.1 tm0? -71.02 -53.48 14.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.329 -1.101 . . . . 0.0 111.993 177.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 95.0 t -97.89 135.89 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.397 1.57 . . . . 0.0 109.17 169.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 48.2 t -111.43 117.66 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 128.574 2.75 . . . . 0.0 108.131 -176.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 52.9 m170 -105.23 104.41 14.14 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.872 -1.143 . . . . 0.0 111.244 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -106.73 163.75 12.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.884 -1.135 . . . . 0.0 113.799 171.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.3 tp -128.2 134.11 48.97 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 124.856 1.263 . . . . 0.0 108.36 158.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.8 pp -145.17 164.87 29.98 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.637 -1.29 . . . . 0.0 111.285 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -121.42 149.72 42.59 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.023 1.729 . . . . 0.0 110.894 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.463 0 C-N-CA 125.482 1.513 . . . . 0.0 110.761 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.7 t70 . . . . . 0 N--CA 1.43 -1.453 0 N-CA-C 114.867 1.432 . . . . 0.0 114.867 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -123.56 154.73 38.82 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-N 119.419 1.009 . . . . 0.0 110.596 163.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -144.43 149.92 36.83 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 123.882 0.873 . . . . 0.0 109.438 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -99.63 125.85 45.53 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.123 1.369 . . . . 0.0 109.275 167.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.46 94.88 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 O-C-N 120.481 -1.387 . . . . 0.0 107.954 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -90.62 81.54 5.87 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.658 -1.276 . . . . 0.0 109.387 169.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 49.2 tp -96.39 133.6 40.6 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.652 1.181 . . . . 0.0 111.642 -171.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.16 138.72 38.73 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 119.878 -1.764 . . . . 0.0 110.147 172.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -68.25 156.51 37.49 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.726 1.21 . . . . 0.0 113.721 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.4 t -129.25 135.8 49.27 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 172.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.0 t70 33.34 52.12 0.35 Allowed 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 128.248 2.619 . . . . 0.0 116.57 -173.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.68 -5.45 69.49 Favored Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 117.678 1.831 . . . . 0.0 117.678 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.7 m -121.57 150.63 41.38 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.535 1.668 . . . . 0.0 113.988 -169.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 46.9 mt -101.28 -60.24 1.56 Allowed 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.232 1.413 . . . . 0.0 109.606 168.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.18 41.82 2.02 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.874 1.702 . . . . 0.0 114.63 175.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.3 pt -112.53 156.58 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 CA-C-N 118.417 1.109 . . . . 0.0 111.994 177.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -131.39 132.52 44.46 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.115 -1.615 . . . . 0.0 109.258 149.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.5 m -114.75 160.2 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.478 1.511 . . . . 0.0 110.882 -175.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 t -148.8 -178.96 6.64 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.541 -1.349 . . . . 0.0 110.651 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.4 -123.97 7.07 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 120.763 -1.21 . . . . 0.0 114.463 167.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.47 171.27 26.9 Favored Glycine 0 N--CA 1.43 -1.75 0 CA-C-O 122.671 1.151 . . . . 0.0 113.208 178.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -172.977 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.73 0 CA-C-O 122.067 0.815 . . . . 0.0 113.55 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.1 mm -102.81 117.18 47.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 125.798 1.639 . . . . 0.0 108.222 -176.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.23 149.81 44.23 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.166 -0.958 . . . . 0.0 109.947 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -78.12 122.59 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.506 -1.371 . . . . 0.0 113.14 177.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.52 -39.26 10.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.614 -1.304 . . . . 0.0 112.799 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.26 158.86 42.28 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.441 -1.412 . . . . 0.0 111.466 -177.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -122.46 120.8 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-O 122.965 1.364 . . . . 0.0 110.824 176.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.75 121.66 85.18 Favored Pre-proline 0 N--CA 1.43 -1.468 0 C-N-CA 125.802 1.641 . . . . 0.0 113.189 -171.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.42 134.37 41.39 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 CA-C-N 123.98 2.457 . . . . 0.0 112.689 179.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 56.7 mttm 82.29 20.35 0.29 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 129.173 2.989 . . . . 0.0 113.785 -172.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.51 154.85 30.23 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 119.966 -1.709 . . . . 0.0 115.938 169.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.47 -58.72 5.1 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.986 2.115 . . . . 0.0 115.562 158.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.06 -46.54 86.98 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.99 2.916 . . . . 0.0 111.612 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -41.73 -59.58 1.62 Allowed 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 169.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.0 t -69.54 -34.6 74.46 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -62.08 -46.81 87.44 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.015 -1.678 . . . . 0.0 113.542 -171.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 108.07 -6.69 34.86 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.359 -1.463 . . . . 0.0 116.08 155.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.4 mmp_? -70.23 -35.48 73.87 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.918 -1.342 . . . . 0.0 111.131 169.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.5 mt -87.22 128.94 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 126.396 1.878 . . . . 0.0 108.766 176.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -164.28 123.21 1.89 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.6 -1.312 . . . . 0.0 107.798 -176.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.17 112.92 0.31 Allowed 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 116.846 2.165 . . . . 0.0 116.846 -167.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.15 -8.66 12.32 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 118.552 -1.138 . . . . 0.0 113.616 -164.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -79.84 164.34 23.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 120.799 2.299 . . . . 0.0 113.019 175.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.1 ttt180 -125.57 124.79 42.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.153 -0.967 . . . . 0.0 110.877 -171.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.5 t -87.74 135.49 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 O-C-N 120.106 -1.621 . . . . 0.0 109.815 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.4 mp -106.24 -44.06 4.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.721 1.208 . . . . 0.0 111.111 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.96 132.54 15.79 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.705 -1.247 . . . . 0.0 111.255 -177.064 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 t -109.97 119.39 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.524 1.13 . . . . 0.0 108.518 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.87 24.6 9.7 Favored 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 126.146 1.778 . . . . 0.0 114.125 173.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 90.48 -9.9 76.15 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 120.147 -1.596 . . . . 0.0 114.182 -173.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.66 119.99 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.552 1.141 . . . . 0.0 108.098 -176.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.7 t -76.04 145.93 39.81 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.444 -1.41 . . . . 0.0 112.476 -174.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 95.9 mt -91.49 8.13 37.91 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.516 -1.365 . . . . 0.0 113.251 -175.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 77.1 mt-10 -68.27 107.73 2.92 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 119.535 -1.978 . . . . 0.0 113.934 -176.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.27 4.3 68.68 Favored Glycine 0 N--CA 1.429 -1.782 0 O-C-N 120.773 -1.205 . . . . 0.0 113.715 -175.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.52 148.11 45.34 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 121.139 -1.213 . . . . 0.0 113.79 168.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.3 p -80.51 173.92 12.12 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.852 -1.155 . . . . 0.0 111.845 169.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -55.54 -52.29 64.21 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.364 1.865 . . . . 0.0 112.368 168.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -57.14 -43.12 82.14 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 115.043 1.498 . . . . 0.0 115.043 173.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -56.27 -42.72 77.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.806 1.78 . . . . 0.0 115.806 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.6 -36.12 83.2 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.804 -1.185 . . . . 0.0 112.904 175.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.9 -44.36 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 O-C-N 120.662 -1.274 . . . . 0.0 111.191 177.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -54.04 -37.91 64.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.977 1.711 . . . . 0.0 113.247 171.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -73.36 -52.21 14.64 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.901 2.08 . . . . 0.0 112.224 177.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 48.3 mt -64.41 -31.47 72.7 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -70.05 -26.46 64.03 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.18 -1.575 . . . . 0.0 112.982 174.336 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.3 t30 -91.6 39.71 1.01 Allowed 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.563 1.545 . . . . 0.0 112.887 178.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 p -94.28 155.47 17.0 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 126.29 1.836 . . . . 0.0 111.786 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -146.59 20.65 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.038 -1.039 . . . . 0.0 112.587 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -69.68 -56.27 7.68 Favored 'General case' 0 N--CA 1.429 -1.523 0 O-C-N 121.2 -1.176 . . . . 0.0 112.38 173.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.1 t -98.54 128.47 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.826 1.298 . . . . 0.0 108.418 178.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.7 t -114.46 109.41 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 128.385 2.674 . . . . 0.0 109.024 -171.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -88.84 109.37 20.14 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 120.634 -1.291 . . . . 0.0 110.597 174.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -101.23 153.66 19.43 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.641 -1.287 . . . . 0.0 111.136 161.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -123.02 128.2 49.85 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 157.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -142.46 163.44 32.84 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 121.473 -0.767 . . . . 0.0 111.779 -171.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.51 136.02 53.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.399 1.88 . . . . 0.0 109.145 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.1 tptm . . . . . 0 N--CA 1.43 -1.452 0 O-C-N 119.766 -1.834 . . . . 0.0 112.707 176.3 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 44.0 t0 . . . . . 0 N--CA 1.43 -1.451 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -104.96 160.75 14.78 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 121.02 -1.05 . . . . 0.0 110.593 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.86 139.12 26.09 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 170.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.34 131.71 37.31 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.964 1.306 . . . . 0.0 109.412 165.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.1 t -119.73 115.04 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -177.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 -107.53 91.17 3.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.227 1.411 . . . . 0.0 107.81 177.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.23 132.77 54.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.593 1.157 . . . . 0.0 112.241 -162.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.15 137.96 33.5 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.14 -1.6 . . . . 0.0 111.871 176.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 27.9 mttp -70.13 148.42 48.73 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 115.214 1.561 . . . . 0.0 115.214 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 37.3 p -113.59 118.78 35.37 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.965 1.306 . . . . 0.0 109.76 173.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.7 t0 59.49 32.51 21.74 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.532 1.933 . . . . 0.0 114.172 -176.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.62 79.03 Favored Glycine 0 N--CA 1.429 -1.832 0 O-C-N 119.763 -1.835 . . . . 0.0 114.869 -173.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.4 p -121.5 144.56 48.63 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.72 -1.459 . . . . 0.0 112.151 178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 74.2 mt -85.62 -60.42 2.03 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.923 -1.11 . . . . 0.0 109.943 165.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.04 46.87 0.5 Allowed Glycine 0 N--CA 1.43 -1.708 0 O-C-N 119.983 -1.698 . . . . 0.0 109.749 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.2 tt -140.73 144.71 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 123.337 1.541 . . . . 0.0 110.296 -175.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.6 t -118.83 133.3 55.93 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 166.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 m -108.44 164.67 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.49 1.116 . . . . 0.0 110.449 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 t -147.85 178.36 8.57 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.554 1.142 . . . . 0.0 108.481 176.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.99 -162.41 27.42 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.515 -1.366 . . . . 0.0 113.548 176.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.56 165.93 22.67 Favored Glycine 0 N--CA 1.431 -1.665 0 C-N-CA 124.753 1.168 . . . . 0.0 110.707 -173.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.2 t . . . . . 0 N--CA 1.43 -1.45 0 O-C-N 121.073 -1.251 . . . . 0.0 113.941 -176.231 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.73 0 CA-C-O 121.118 0.288 . . . . 0.0 113.272 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.64 127.8 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 170.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -128.03 157.64 40.1 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.465 -1.397 . . . . 0.0 111.218 -169.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.3 t -75.44 120.65 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 O-C-N 121.02 -1.05 . . . . 0.0 111.044 169.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -90.84 -52.09 5.04 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.626 1.571 . . . . 0.0 110.542 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.08 154.72 36.48 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.15 124.16 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 174.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.72 121.31 84.59 Favored Pre-proline 0 N--CA 1.429 -1.523 0 C-N-CA 126.671 1.989 . . . . 0.0 113.956 -167.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -57.7 123.41 13.67 Favored 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 124.448 2.624 . . . . 0.0 116.408 -172.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.268 3.9 mtpm? 76.84 25.99 0.82 Allowed 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 128.137 2.575 . . . . 0.0 114.855 -178.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.42 169.18 47.14 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.175 -1.578 . . . . 0.0 113.495 168.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.5 -58.76 5.01 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.084 2.154 . . . . 0.0 114.668 165.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.59 -47.71 77.63 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 128.861 2.864 . . . . 0.0 112.762 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -46.1 -59.03 3.12 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 116.845 2.165 . . . . 0.0 116.845 172.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 t -69.82 -27.71 65.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 124.848 1.259 . . . . 0.0 113.556 -175.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -50.79 -62.6 1.51 Allowed 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.838 2.055 . . . . 0.0 113.305 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.28 -45.36 1.16 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.969 -0.457 . . . . 0.0 113.087 168.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.46 -19.01 65.68 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 115.079 1.511 . . . . 0.0 115.079 -172.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.8 mt -96.31 117.19 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.519 0 C-N-CA 124.967 1.307 . . . . 0.0 109.06 172.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.7 m80 -118.57 159.45 23.54 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.773 -1.204 . . . . 0.0 110.879 -178.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -62.29 129.26 39.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.015 -1.678 . . . . 0.0 113.099 173.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.14 -0.3 72.0 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.886 -1.134 . . . . 0.0 114.831 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -79.62 152.23 30.14 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.768 -1.43 . . . . 0.0 111.289 178.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.8 ttt-85 -105.28 131.13 53.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.031 -1.668 . . . . 0.0 111.261 -168.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 38.3 t -85.34 136.88 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.963 -1.71 . . . . 0.0 110.941 -174.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -105.97 -56.65 2.15 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.908 -1.12 . . . . 0.0 109.386 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.7 137.22 18.79 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.186 -0.946 . . . . 0.0 111.925 -173.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.55 125.8 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 67.73 14.72 9.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.078 -1.639 . . . . 0.0 115.263 169.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.13 -13.26 52.26 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 119.748 -1.845 . . . . 0.0 112.913 -175.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -92.85 104.87 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 124.369 1.068 . . . . 0.0 109.333 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.3 t -74.26 126.71 31.23 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.665 -1.272 . . . . 0.0 109.589 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 85.1 mt -83.51 55.18 3.09 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.019 1.118 . . . . 0.0 114.019 -158.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -71.43 122.16 19.89 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 119.543 -1.973 . . . . 0.0 114.342 -172.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.63 5.09 72.59 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.186 -1.571 . . . . 0.0 115.437 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.62 140.59 49.81 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.255 1.946 . . . . 0.0 116.255 -171.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.2 p -93.3 178.86 5.59 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.496 2.319 . . . . 0.0 111.747 172.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 20.9 t-160 -57.48 -48.16 79.98 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 126.656 1.982 . . . . 0.0 114.463 179.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.3 tptt -56.66 -42.92 79.81 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 174.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.4 -50.48 73.8 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.868 1.667 . . . . 0.0 114.515 178.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.25 -38.31 83.07 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.038 1.335 . . . . 0.0 113.518 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 70.4 t -66.42 -46.92 85.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 O-C-N 120.792 -1.192 . . . . 0.0 111.851 173.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -54.65 -48.5 72.23 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.689 1.596 . . . . 0.0 112.359 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 13.6 m -64.84 -45.97 83.87 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.856 2.463 . . . . 0.0 114.048 175.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.1 mt -64.04 -34.1 77.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 119.29 -2.131 . . . . 0.0 114.675 174.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 17.6 mtp-105 -65.21 -36.58 84.63 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 112.851 172.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -86.52 46.22 1.33 Allowed 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 125.62 1.568 . . . . 0.0 112.712 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.1 p -107.12 155.99 19.27 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.65 1.58 . . . . 0.0 109.657 173.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.33 -156.4 32.29 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.647 -1.283 . . . . 0.0 112.53 178.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -68.88 -54.94 12.77 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.175 -1.191 . . . . 0.0 111.772 176.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 130.8 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 CA-C-O 122.497 1.141 . . . . 0.0 108.314 170.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 63.6 t -118.47 121.27 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 127.029 2.132 . . . . 0.0 109.743 -168.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -97.28 113.68 25.34 Favored 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 121.314 -0.866 . . . . 0.0 111.244 173.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.2 155.76 19.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.581 1.152 . . . . 0.0 112.639 169.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 40.3 tp -127.11 128.79 46.77 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 158.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.7 pp -142.3 170.15 16.25 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.671 -1.268 . . . . 0.0 111.213 175.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -114.7 145.74 41.71 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.267 1.827 . . . . 0.0 109.165 178.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.2 tptt . . . . . 0 N--CA 1.43 -1.454 0 C-N-CA 124.804 1.241 . . . . 0.0 111.308 -179.944 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.7 t0 . . . . . 0 N--CA 1.431 -1.391 0 CA-C-O 121.77 0.795 . . . . 0.0 109.171 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -114.01 149.8 34.84 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.805 1.242 . . . . 0.0 109.451 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -145.85 127.79 15.48 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -87.88 113.55 23.65 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 164.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 t -99.05 110.38 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 124.512 1.125 . . . . 0.0 109.702 -169.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.7 mt-10 -104.94 87.25 2.61 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.381 1.086 . . . . 0.0 110.242 -177.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.21 147.6 23.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.073 -1.017 . . . . 0.0 110.593 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.88 112.79 25.91 Favored 'General case' 0 N--CA 1.428 -1.544 0 C-N-CA 124.107 0.963 . . . . 0.0 108.593 160.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.6 ttmt -70.16 126.12 28.74 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.442 1.497 . . . . 0.0 112.608 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.8 p -104.27 123.35 47.21 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.045 -1.659 . . . . 0.0 110.894 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.8 t70 63.61 24.7 14.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.591 1.557 . . . . 0.0 113.861 170.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.6 4.81 89.95 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 119.51 -1.994 . . . . 0.0 115.189 -175.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.5 m -105.35 104.21 13.89 Favored 'General case' 0 N--CA 1.429 -1.477 0 CA-C-N 119.195 1.497 . . . . 0.0 111.629 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 11.9 tp -80.81 -45.51 16.81 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 120.563 -1.336 . . . . 0.0 111.475 173.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.06 28.08 3.23 Favored Glycine 0 N--CA 1.429 -1.773 0 C-N-CA 125.574 1.559 . . . . 0.0 113.547 170.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.9 tt -148.99 136.02 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 120.014 1.907 . . . . 0.0 114.694 -168.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.3 m -110.83 126.6 54.82 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.847 1.659 . . . . 0.0 108.48 167.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -104.24 172.01 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.219 1.007 . . . . 0.0 111.905 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.4 t -157.3 176.96 12.0 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.504 -1.372 . . . . 0.0 110.803 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 115.35 -128.33 8.03 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.457 1.027 . . . . 0.0 112.276 169.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.32 134.84 8.16 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.163 0.887 . . . . 0.0 111.279 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.7 m . . . . . 0 N--CA 1.43 -1.438 0 N-CA-C 115.702 1.741 . . . . 0.0 115.702 -170.244 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.702 0 N-CA-C 112.166 -0.374 . . . . 0.0 112.166 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.7 mm -104.13 125.59 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.945 1.298 . . . . 0.0 109.664 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -126.84 158.81 35.68 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 120.276 -1.515 . . . . 0.0 112.182 -172.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.2 t -76.23 120.35 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 125.135 1.374 . . . . 0.0 112.689 175.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -93.93 -47.05 6.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.586 -1.321 . . . . 0.0 112.109 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.71 152.25 24.99 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 121.113 -0.992 . . . . 0.0 111.435 178.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.39 122.29 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 C-N-CA 126.136 1.774 . . . . 0.0 109.378 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 9.3 mm -77.58 123.93 86.66 Favored Pre-proline 0 N--CA 1.429 -1.495 0 C-N-CA 127.014 2.126 . . . . 0.0 114.352 -175.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -57.55 125.74 19.71 Favored 'Trans proline' 0 N--CA 1.434 -1.998 0 CA-C-N 124.607 2.681 . . . . 0.0 116.526 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.313 63.1 mttm 83.01 16.34 0.32 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 128.46 2.704 . . . . 0.0 113.72 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.06 162.48 38.83 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.116 -1.615 . . . . 0.0 114.128 169.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.41 -55.78 11.89 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.02 1.728 . . . . 0.0 114.977 170.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.89 -47.78 81.8 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.735 2.814 . . . . 0.0 112.59 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -48.44 -61.08 2.19 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 173.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.7 m -69.1 -32.59 72.11 Favored 'General case' 0 N--CA 1.429 -1.507 0 CA-C-N 115.499 -0.773 . . . . 0.0 112.859 -173.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -58.91 -70.28 0.16 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.947 1.699 . . . . 0.0 113.411 175.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.27 14.76 43.75 Favored Glycine 0 N--CA 1.43 -1.712 0 O-C-N 120.38 -1.45 . . . . 0.0 114.9 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -65.27 -26.47 68.1 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.707 -1.467 . . . . 0.0 111.691 159.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 71.6 mt -106.55 130.75 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 C-N-CA 126.686 1.994 . . . . 0.0 109.223 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -126.95 170.01 12.72 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-O 123.062 1.411 . . . . 0.0 110.835 169.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -60.59 129.69 42.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.01 -1.681 . . . . 0.0 113.388 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.31 4.15 86.44 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.291 -1.506 . . . . 0.0 115.608 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -75.46 161.98 28.74 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-N 119.835 1.817 . . . . 0.0 111.665 175.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.1 tpt85 -108.57 116.83 32.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.892 -1.13 . . . . 0.0 110.945 -170.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.6 t -84.66 130.6 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 O-C-N 120.511 -1.368 . . . . 0.0 108.283 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.31 -36.58 5.53 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.824 1.25 . . . . 0.0 112.401 -166.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 152.36 33.53 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.234 -1.541 . . . . 0.0 110.11 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.1 t -120.79 114.64 44.31 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 170.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 54.04 48.53 20.88 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.906 2.083 . . . . 0.0 115.535 170.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.06 -18.45 44.61 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 120.834 -1.166 . . . . 0.0 114.571 -177.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.6 t -94.21 105.8 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 O-C-N 120.82 -1.4 . . . . 0.0 109.004 -178.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.8 p -72.23 138.8 47.77 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.688 -1.257 . . . . 0.0 111.761 178.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 53.7 mt -87.15 32.62 0.68 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.636 -1.29 . . . . 0.0 112.777 -169.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -69.61 130.21 41.78 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.189 -2.195 . . . . 0.0 112.66 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.03 8.73 44.12 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 125.645 1.593 . . . . 0.0 116.253 -176.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.33 142.08 50.43 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -171.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 40.6 p -87.32 175.25 8.1 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.051 1.34 . . . . 0.0 110.312 173.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.1 t-160 -61.82 -40.22 94.5 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.644 -1.285 . . . . 0.0 111.757 174.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -54.93 -47.16 74.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.355 1.862 . . . . 0.0 114.928 173.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -56.6 -51.81 67.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 -179.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.32 -42.38 95.45 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.233 1.013 . . . . 0.0 113.28 177.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.08 -48.07 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.984 -1.073 . . . . 0.0 111.137 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -63.97 -41.31 97.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 3.5 m -61.0 -47.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 126.225 1.81 . . . . 0.0 112.874 175.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.7 mt -68.43 -29.67 68.38 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 175.33 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.4 ttt180 -62.76 -36.26 82.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.382 -1.449 . . . . 0.0 113.039 173.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -94.83 49.82 1.27 Allowed 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.643 -1.286 . . . . 0.0 111.76 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 37.0 p -107.34 139.68 41.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.325 1.45 . . . . 0.0 110.256 170.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.26 -142.95 12.25 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 123.564 0.602 . . . . 0.0 112.654 173.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -69.38 -60.98 1.98 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.303 -1.116 . . . . 0.0 113.401 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 t -92.02 118.24 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 122.701 1.239 . . . . 0.0 109.773 -176.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.6 t -117.93 111.1 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 126.122 1.769 . . . . 0.0 109.525 -166.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.8 m170 -99.71 103.01 14.65 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.092 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.5 mt -92.85 168.16 11.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.75 -1.844 . . . . 0.0 112.153 171.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.6 tp -129.05 137.67 51.43 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.016 1.326 . . . . 0.0 107.63 157.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.7 161.2 39.78 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.732 -1.23 . . . . 0.0 112.845 174.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -96.46 144.89 26.15 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 164.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.9 tmtt? . . . . . 0 N--CA 1.43 -1.451 0 O-C-N 120.859 -1.151 . . . . 0.0 108.279 162.913 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.9 t0 . . . . . 0 N--CA 1.429 -1.496 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -88.94 139.22 30.68 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.368 -1.458 . . . . 0.0 110.837 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.27 0.0 OUTLIER -147.4 140.48 25.12 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.277 1.513 . . . . 0.0 110.637 175.155 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -90.32 146.51 24.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.483 1.913 . . . . 0.0 109.323 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.5 t -122.81 110.46 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 125.008 1.323 . . . . 0.0 107.488 -174.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -105.83 84.2 2.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 CA-C-O 122.214 1.007 . . . . 0.0 108.458 174.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.3 tp -110.84 145.1 38.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.01 1.324 . . . . 0.0 110.283 -167.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.31 138.38 40.16 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 119.842 -1.786 . . . . 0.0 110.109 168.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -70.86 149.02 47.21 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 169.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.9 t -109.72 111.56 23.1 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.733 -1.229 . . . . 0.0 109.225 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.9 t0 43.34 50.27 5.98 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.923 2.489 . . . . 0.0 114.778 -178.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.97 -39.42 2.79 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.452 1.025 . . . . 0.0 115.043 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 m -102.03 148.72 25.03 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.731 -1.452 . . . . 0.0 114.793 -161.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -106.65 -61.37 1.54 Allowed 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.161 -0.962 . . . . 0.0 112.041 176.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.91 32.32 1.58 Allowed Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.669 -1.895 . . . . 0.0 112.798 175.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 pt -124.09 139.71 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 C-N-CA 125.105 1.362 . . . . 0.0 108.693 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.1 t -129.28 125.64 37.27 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 36.0 m -108.38 168.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.986 0.898 . . . . 0.0 112.63 -172.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.8 160.08 43.55 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.853 1.661 . . . . 0.0 109.095 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.86 -142.9 15.44 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.729 -1.232 . . . . 0.0 113.614 169.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.37 166.42 13.68 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 116.039 1.176 . . . . 0.0 116.039 174.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.431 -1.401 0 O-C-N 120.757 -1.437 . . . . 0.0 114.64 -179.015 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 31.7 mm -103.41 120.85 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 172.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -124.57 160.98 27.17 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.788 -1.195 . . . . 0.0 109.119 -175.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.37 128.3 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.731 -1.231 . . . . 0.0 110.475 171.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 29.1 ttmt -89.94 -50.45 6.02 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.87 -1.144 . . . . 0.0 110.325 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.58 150.79 33.92 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 123.396 0.678 . . . . 0.0 109.873 -174.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -110.31 121.82 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 170.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 20.9 mm -76.64 121.0 84.08 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 126.219 1.808 . . . . 0.0 113.256 -171.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -58.31 122.93 12.52 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.83 2.353 . . . . 0.0 116.184 -175.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.321 64.7 mttt 82.5 20.16 0.27 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.367 2.267 . . . . 0.0 113.801 176.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.07 161.89 40.07 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.227 -0.921 . . . . 0.0 114.832 170.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.81 -57.04 7.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.131 2.172 . . . . 0.0 114.396 170.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.87 -52.55 62.67 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.58 2.352 . . . . 0.0 112.278 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -42.56 -64.86 0.54 Allowed 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.553 2.057 . . . . 0.0 116.553 174.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.9 m -69.94 -14.21 62.61 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -175.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.84 -64.32 1.03 Allowed 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.712 -1.243 . . . . 0.0 110.353 174.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.33 48.01 7.1 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 117.292 1.677 . . . . 0.0 117.292 170.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.7 mtt180 -84.56 -39.87 18.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 146.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 55.8 mt -83.42 121.47 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 126.162 1.785 . . . . 0.0 111.45 176.509 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 46.7 m-70 -122.08 171.75 8.75 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.243 1.497 . . . . 0.0 111.398 170.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -60.62 127.79 33.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.555 -1.34 . . . . 0.0 112.428 175.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.73 0.91 71.53 Favored Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 115.684 1.034 . . . . 0.0 115.684 -178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -82.17 150.05 27.61 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.83 1.815 . . . . 0.0 112.505 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -90.17 127.82 36.2 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.126 -1.609 . . . . 0.0 113.548 -177.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 30.4 t -83.12 132.79 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.787 177.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.93 -51.86 2.86 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.124 -0.985 . . . . 0.0 111.775 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.27 141.33 22.13 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.096 -1.627 . . . . 0.0 112.799 -175.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.8 t -114.94 120.28 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.343 1.057 . . . . 0.0 108.963 177.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 74.35 16.49 3.35 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.931 1.692 . . . . 0.0 114.558 169.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.54 -1.48 81.74 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.622 -1.299 . . . . 0.0 112.745 -170.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -98.28 117.36 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 125.353 1.461 . . . . 0.0 108.114 176.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t -74.21 125.86 29.34 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.3 -1.5 . . . . 0.0 109.346 178.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . 0.327 0.7 OUTLIER -92.27 39.32 1.02 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.314 1.531 . . . . 0.0 112.183 -176.251 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -76.36 121.37 22.91 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.135 -1.603 . . . . 0.0 110.753 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 81.5 17.79 70.2 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.757 1.17 . . . . 0.0 113.731 -172.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.25 154.26 41.09 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 123.226 1.489 . . . . 0.0 115.001 171.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.2 p -91.57 173.6 7.8 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.337 -1.477 . . . . 0.0 110.892 171.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -51.68 -51.93 52.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.439 1.896 . . . . 0.0 112.416 168.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.27 -53.19 61.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 115.446 1.647 . . . . 0.0 115.446 172.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -60.62 -42.74 97.46 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 -170.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.24 -29.65 68.91 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.168 1.387 . . . . 0.0 114.162 171.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.4 t -79.74 -44.28 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 125.033 1.333 . . . . 0.0 111.49 174.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -58.2 -37.24 74.4 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.335 -1.478 . . . . 0.0 112.745 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.7 m -65.83 -41.23 92.06 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 127.176 2.191 . . . . 0.0 113.54 172.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.9 mt -71.23 -40.14 71.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 175.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -72.08 -20.05 61.72 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.544 -1.973 . . . . 0.0 112.453 178.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -94.39 53.48 1.7 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.511 -1.368 . . . . 0.0 112.019 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.0 p -107.05 143.34 35.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.135 -1.603 . . . . 0.0 110.9 176.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.34 -154.97 18.49 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.76 -1.212 . . . . 0.0 111.242 171.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -66.5 -52.96 40.43 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.604 -1.527 . . . . 0.0 114.009 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.3 t -95.74 126.23 48.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 123.138 1.447 . . . . 0.0 109.567 177.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -109.82 109.36 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 127.298 2.239 . . . . 0.0 107.833 -175.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -93.73 111.44 23.13 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.091 -1.006 . . . . 0.0 108.988 172.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.9 mt -110.14 160.71 16.25 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.182 0.993 . . . . 0.0 112.457 170.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.95 133.11 49.2 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.413 1.485 . . . . 0.0 108.157 164.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.83 166.12 29.46 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.469 0.652 . . . . 0.0 112.536 178.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -101.86 144.74 30.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 121.046 -1.033 . . . . 0.0 111.179 173.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.6 tttt . . . . . 0 N--CA 1.43 -1.47 0 C-N-CA 125.615 1.566 . . . . 0.0 112.48 167.013 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.9 t0 . . . . . 0 N--CA 1.429 -1.503 0 CA-C-O 121.134 0.493 . . . . 0.0 110.745 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -119.93 137.72 53.88 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.42 1.488 . . . . 0.0 108.993 -174.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.08 140.76 28.28 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-O 122.827 1.298 . . . . 0.0 109.739 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -100.52 112.53 24.91 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.297 1.839 . . . . 0.0 108.039 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.8 t -103.81 102.08 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 O-C-N 120.608 -1.307 . . . . 0.0 108.769 -172.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.73 102.1 14.85 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 167.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.8 tp -120.03 138.02 53.76 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.701 1.201 . . . . 0.0 110.002 -172.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.17 122.3 43.37 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.27 -1.519 . . . . 0.0 109.486 173.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -71.42 171.51 11.14 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.289 -1.507 . . . . 0.0 114.408 177.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.2 t -97.03 -149.81 0.33 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.711 -1.243 . . . . 0.0 108.287 169.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.39 74.67 3.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.03 -2.294 . . . . 0.0 112.571 -175.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.36 -4.8 77.38 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.531 1.539 . . . . 0.0 115.509 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.2 t -121.57 135.83 54.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.104 -1.233 . . . . 0.0 112.015 -173.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.3 mt -103.92 -55.31 2.4 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.851 1.66 . . . . 0.0 110.113 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.0 30.03 0.59 Allowed Glycine 0 N--CA 1.431 -1.693 0 C-N-CA 125.369 1.462 . . . . 0.0 112.56 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.1 pt -125.95 141.44 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 CA-C-N 118.586 1.193 . . . . 0.0 113.477 -163.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.2 m -129.47 138.13 51.23 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.375 1.07 . . . . 0.0 109.005 158.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.4 m -118.34 169.58 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.525 0 C-N-CA 124.949 1.299 . . . . 0.0 112.49 -174.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.25 169.84 18.53 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 172.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 133.41 -147.94 19.19 Favored Glycine 0 N--CA 1.428 -1.836 0 O-C-N 120.572 -1.33 . . . . 0.0 115.53 165.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.17 172.26 24.17 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.43 1.014 . . . . 0.0 112.998 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.1 t . . . . . 0 N--CA 1.429 -1.501 0 C-N-CA 124.828 1.251 . . . . 0.0 112.917 -172.454 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.751 0 N-CA-C 115.932 1.133 . . . . 0.0 115.932 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 mm -99.17 129.18 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.833 2.053 . . . . 0.0 107.819 175.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -126.71 158.07 37.42 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.903 -1.123 . . . . 0.0 109.521 -174.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.9 t -75.95 117.36 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 O-C-N 121.023 -1.048 . . . . 0.0 111.377 174.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.8 tttp -88.33 -45.12 10.28 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.871 1.268 . . . . 0.0 110.83 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.0 163.19 39.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 121.252 -0.905 . . . . 0.0 108.995 173.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 tp -117.95 121.73 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 170.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.64 124.08 87.73 Favored Pre-proline 0 N--CA 1.429 -1.482 0 C-N-CA 126.076 1.75 . . . . 0.0 113.749 -165.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -59.26 127.42 23.93 Favored 'Trans proline' 0 C--N 1.299 -2.057 0 C-N-CA 122.778 2.319 . . . . 0.0 114.904 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.281 11.7 mptt 82.07 21.76 0.27 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 128.538 2.735 . . . . 0.0 112.649 -177.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.91 153.39 29.57 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.962 -1.711 . . . . 0.0 113.711 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.93 -54.87 13.69 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 126.464 1.906 . . . . 0.0 113.877 166.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -54.08 45.97 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 127.576 2.35 . . . . 0.0 112.265 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -40.95 -59.58 1.41 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 177.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.0 t -70.2 -29.99 66.98 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -66.2 -52.5 47.39 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.751 -1.218 . . . . 0.0 113.44 -172.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.11 21.7 9.86 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 120.663 -1.273 . . . . 0.0 115.946 158.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -85.15 -36.87 20.79 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.716 -1.461 . . . . 0.0 109.557 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.9 mt -100.48 124.73 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 125.781 1.632 . . . . 0.0 109.098 -176.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.516 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 3.4 t-80 -142.36 -175.39 4.43 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.117 1.437 . . . . 0.0 112.274 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.516 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.4 ttpp -68.95 123.56 21.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.027 -1.67 . . . . 0.0 113.307 -170.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.71 3.7 62.37 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.418 -0.801 . . . . 0.0 114.492 -178.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -78.72 156.38 28.94 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 119.423 1.612 . . . . 0.0 111.743 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -102.5 123.36 46.11 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.208 -1.558 . . . . 0.0 110.446 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 7.4 t -88.86 119.23 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 O-C-N 120.371 -1.456 . . . . 0.0 110.814 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 98.2 mt -94.09 -46.32 7.17 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.01 -1.056 . . . . 0.0 112.118 -175.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.37 144.01 25.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.855 -1.153 . . . . 0.0 112.484 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.42 111.71 37.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 C-N-CA 125.938 1.695 . . . . 0.0 112.504 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.9 t30 57.23 34.75 25.25 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.771 -1.83 . . . . 0.0 113.674 170.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.19 -28.56 13.32 Favored Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.314 1.435 . . . . 0.0 114.336 -172.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -98.07 129.45 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.235 2.017 . . . . 0.0 110.627 -163.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 26.6 p -71.37 132.33 44.68 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.164 -1.585 . . . . 0.0 112.607 -177.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 47.9 mt -99.45 35.96 1.86 Allowed 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.498 -1.376 . . . . 0.0 111.912 -178.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -89.67 144.26 26.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.714 -1.241 . . . . 0.0 109.486 167.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.26 -32.07 2.31 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.914 -1.117 . . . . 0.0 114.778 -176.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.66 152.28 44.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -175.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.8 p -91.76 175.36 6.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.985 -1.072 . . . . 0.0 112.012 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -58.64 -46.8 86.32 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.514 1.525 . . . . 0.0 112.249 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 30.0 tttp -54.69 -47.93 73.07 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 115.574 1.694 . . . . 0.0 115.574 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -58.67 -47.5 84.29 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.667 1.187 . . . . 0.0 113.652 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -61.67 -38.74 88.89 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.613 1.565 . . . . 0.0 114.22 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.22 -49.03 76.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 C-N-CA 124.866 1.266 . . . . 0.0 111.251 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -68.32 -30.13 69.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.771 -1.205 . . . . 0.0 112.168 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 38.8 m -64.33 -43.41 94.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.199 1.4 . . . . 0.0 114.691 167.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 67.3 mt -63.63 -37.03 85.8 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.074 -1.641 . . . . 0.0 114.171 173.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -67.09 -31.79 72.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.552 -1.342 . . . . 0.0 113.401 170.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -85.26 51.09 2.09 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.852 1.661 . . . . 0.0 112.1 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 p -106.59 148.48 28.24 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.442 -1.411 . . . . 0.0 109.867 171.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.66 -164.22 36.37 Favored Glycine 0 N--CA 1.43 -1.737 0 C-N-CA 123.778 0.704 . . . . 0.0 111.75 168.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -69.7 -46.27 66.38 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.732 -1.452 . . . . 0.0 114.65 -177.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 47.3 t -103.95 118.7 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 CA-C-O 122.437 1.113 . . . . 0.0 108.761 176.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.2 t -111.6 119.17 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 127.928 2.491 . . . . 0.0 109.926 -164.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -104.3 91.89 4.11 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.772 -1.205 . . . . 0.0 113.308 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -91.5 160.78 15.26 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.046 -2.284 . . . . 0.0 113.694 179.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.8 tp -127.0 128.06 45.77 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 161.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.32 158.48 44.32 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.989 -1.069 . . . . 0.0 112.213 176.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -110.07 140.71 43.83 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.047 1.339 . . . . 0.0 108.7 172.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.8 tptm . . . . . 0 N--CA 1.43 -1.434 0 C-N-CA 124.832 1.253 . . . . 0.0 111.476 -177.31 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 42.7 t0 . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.3 p -120.83 150.14 41.48 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.48 -1.388 . . . . 0.0 110.985 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 p90 -147.4 136.26 22.11 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.307 1.527 . . . . 0.0 109.412 172.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 21.4 mp0 -89.13 128.01 35.75 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 126.899 2.08 . . . . 0.0 108.581 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.404 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 74.6 t -109.82 94.87 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.497 0 O-C-N 121.036 -1.04 . . . . 0.0 108.252 -174.071 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -90.54 102.78 15.52 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-O 123.399 1.571 . . . . 0.0 109.61 169.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.6 tp -124.75 143.41 50.8 Favored 'General case' 0 N--CA 1.431 -1.395 0 C-N-CA 124.597 1.159 . . . . 0.0 110.678 -169.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.95 39.53 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.061 -1.649 . . . . 0.0 109.642 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -69.68 153.21 43.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.537 -1.352 . . . . 0.0 112.231 172.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.0 t -141.28 133.95 28.64 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 174.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 33.6 t0 50.93 39.48 22.83 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.959 2.104 . . . . 0.0 113.142 -172.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.13 3.05 55.52 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 120.11 -1.619 . . . . 0.0 116.898 -176.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 84.7 p -112.82 144.49 42.27 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 118.895 1.348 . . . . 0.0 114.03 -167.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 54.0 mt -102.84 -63.15 1.19 Allowed 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.92 1.288 . . . . 0.0 109.598 169.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.03 11.21 10.2 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 119.371 -2.081 . . . . 0.0 115.208 172.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 pt -100.56 131.58 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 CA-C-N 118.922 1.361 . . . . 0.0 111.188 174.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -110.8 121.61 45.76 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.055 -1.028 . . . . 0.0 108.7 168.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.9 m -105.49 165.68 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.702 1.201 . . . . 0.0 113.02 -173.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -149.25 162.53 39.83 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.328 1.451 . . . . 0.0 109.737 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.77 -135.14 12.45 Favored Glycine 0 N--CA 1.431 -1.698 0 CA-C-O 122.658 1.143 . . . . 0.0 115.853 163.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.55 172.6 44.27 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 121.253 -1.145 . . . . 0.0 113.407 -176.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.43 -1.443 0 N-CA-C 115.973 1.842 . . . . 0.0 115.973 -174.391 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.728 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -100.22 123.24 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.5 m-85 -123.59 157.21 34.24 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 121.059 -1.026 . . . . 0.0 110.667 -175.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.44 125.53 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 O-C-N 120.573 -1.329 . . . . 0.0 112.038 168.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -95.75 -35.62 11.47 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 120.397 -1.44 . . . . 0.0 112.457 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.51 158.03 36.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.854 -1.154 . . . . 0.0 112.221 -176.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -116.69 123.05 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.59 1.556 . . . . 0.0 109.881 175.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.2 mm -77.01 119.49 77.72 Favored Pre-proline 0 N--CA 1.43 -1.431 0 C-N-CA 125.93 1.692 . . . . 0.0 113.714 -176.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.74 124.39 12.27 Favored 'Trans proline' 0 C--N 1.299 -2.06 0 CA-C-N 124.744 2.73 . . . . 0.0 113.981 -172.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 10.5 mmmm 79.07 29.67 0.35 Allowed 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 129.334 3.054 . . . . 0.0 113.587 -175.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 162.66 38.14 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.507 -1.37 . . . . 0.0 113.102 162.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.08 -60.01 3.15 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 126.947 2.099 . . . . 0.0 114.911 166.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.32 -46.09 88.27 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 129.517 3.127 . . . . 0.0 112.391 -179.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -43.31 -65.67 0.46 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 171.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.5 t -67.72 -26.99 66.43 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -175.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.89 -56.82 16.99 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.265 -1.522 . . . . 0.0 111.8 174.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.19 2.57 64.03 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.72 -1.238 . . . . 0.0 114.733 157.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 65.0 mtt85 -56.04 -44.11 78.47 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.025 1.33 . . . . 0.0 110.793 159.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.5 mt -82.03 131.09 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 127.698 2.399 . . . . 0.0 111.759 -176.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 11.6 m-70 -122.72 155.44 36.45 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 128.314 2.646 . . . . 0.0 109.228 174.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 pttt -73.15 106.81 5.16 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.931 -1.73 . . . . 0.0 111.631 173.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.29 -31.35 2.06 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-O 119.16 -0.8 . . . . 0.0 113.733 -165.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.371 4.0 p30 -80.24 159.44 25.9 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 120.109 1.955 . . . . 0.0 116.112 -166.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.4 ttt85 -110.02 125.85 53.34 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.562 -1.336 . . . . 0.0 112.151 -162.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.5 t -82.11 135.07 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.488 -1.383 . . . . 0.0 111.173 -173.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 95.9 mt -103.83 -54.01 2.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.126 -0.983 . . . . 0.0 111.213 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.78 146.06 26.14 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.189 -1.569 . . . . 0.0 111.927 -174.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.0 t -114.04 107.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 123.704 0.802 . . . . 0.0 108.964 175.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.5 t30 61.81 45.17 7.93 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.967 2.107 . . . . 0.0 113.86 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.35 -24.25 14.89 Favored Glycine 0 N--CA 1.431 -1.68 0 O-C-N 121.136 -0.977 . . . . 0.0 113.571 -174.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.3 t -87.08 111.66 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.482 -1.599 . . . . 0.0 109.981 -175.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 p -69.31 128.62 37.24 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.721 1.209 . . . . 0.0 111.837 178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 50.5 mt -86.03 52.18 2.41 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.168 -1.583 . . . . 0.0 111.869 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -78.9 121.16 24.51 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.592 -1.942 . . . . 0.0 113.48 -169.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.64 24.0 65.72 Favored Glycine 0 N--CA 1.431 -1.679 0 C-N-CA 124.873 1.225 . . . . 0.0 114.753 -176.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.96 42.34 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -170.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 74.6 p -91.65 170.5 9.87 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 124.688 1.195 . . . . 0.0 111.096 171.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 7.3 t-160 -58.44 -58.14 9.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.357 1.463 . . . . 0.0 114.41 -175.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -58.02 -29.74 65.55 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 116.169 1.914 . . . . 0.0 116.169 176.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.52 -52.18 66.46 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.411 1.484 . . . . 0.0 113.017 178.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.64 -45.13 89.93 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.066 1.746 . . . . 0.0 113.624 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.8 t -64.53 -48.73 83.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.146 1.378 . . . . 0.0 111.27 -179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.3 mm-40 -65.75 -33.02 74.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.0 m -67.52 -45.37 75.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.525 1.93 . . . . 0.0 112.413 174.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.4 mt -58.89 -42.85 90.53 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 124.791 1.236 . . . . 0.0 113.508 172.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -69.97 -14.72 62.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 115.26 1.578 . . . . 0.0 115.26 178.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -95.65 36.63 1.26 Allowed 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.478 -2.014 . . . . 0.0 112.023 172.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 77.4 p -107.27 144.8 33.56 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.249 -1.532 . . . . 0.0 110.651 172.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.53 23.66 Favored Glycine 0 N--CA 1.429 -1.774 0 C-N-CA 123.965 0.793 . . . . 0.0 112.514 -177.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -60.9 -56.2 23.94 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.3 t -101.49 126.29 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 CA-C-O 122.282 1.039 . . . . 0.0 109.561 172.117 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 67.4 t -115.45 137.33 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 129.664 3.186 . . . . 0.0 108.662 -166.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 13.5 t-160 -124.22 106.33 10.21 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.505 -1.372 . . . . 0.0 111.394 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.404 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 18.7 mt -97.06 160.17 14.5 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 119.356 -2.09 . . . . 0.0 113.239 170.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 64.9 tp -127.96 131.87 49.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 161.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.0 pp -148.19 169.03 20.94 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.933 -1.104 . . . . 0.0 112.833 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -117.01 143.46 45.71 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.576 1.55 . . . . 0.0 111.371 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.3 tptm . . . . . 0 N--CA 1.429 -1.52 0 C-N-CA 126.921 2.088 . . . . 0.0 113.386 -175.883 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.8 t0 . . . . . 0 N--CA 1.43 -1.454 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 p -106.96 149.53 27.41 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.13 -0.982 . . . . 0.0 112.524 -177.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -145.01 132.78 21.09 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.914 -1.116 . . . . 0.0 108.178 -176.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.87 120.01 28.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.39 1.476 . . . . 0.0 108.255 169.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.424 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 84.6 t -116.44 100.87 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 124.627 1.171 . . . . 0.0 109.328 -168.149 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -90.18 104.92 17.44 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.352 -1.468 . . . . 0.0 108.999 170.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.2 tp -119.95 130.67 54.89 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 124.91 1.284 . . . . 0.0 110.543 -169.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 146.12 28.54 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.722 -1.861 . . . . 0.0 109.64 173.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -67.93 166.02 16.55 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.933 1.827 . . . . 0.0 115.933 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 28.6 p -132.23 130.73 41.35 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.681 1.592 . . . . 0.0 108.163 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 46.6 44.43 13.5 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.925 2.09 . . . . 0.0 114.905 -175.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.88 -14.63 30.77 Favored Glycine 0 N--CA 1.429 -1.818 0 O-C-N 119.855 -1.778 . . . . 0.0 117.041 178.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 t -121.84 175.18 6.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 119.716 1.758 . . . . 0.0 112.113 -174.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 94.2 mt -99.96 -60.58 1.5 Allowed 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.702 1.201 . . . . 0.0 110.46 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.15 44.04 0.38 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.15 -1.594 . . . . 0.0 111.222 174.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 tt -144.06 147.86 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.068 1.413 . . . . 0.0 110.985 -172.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -124.57 117.69 24.89 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 125.071 1.348 . . . . 0.0 108.532 170.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 m -95.93 166.17 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 124.496 1.118 . . . . 0.0 112.726 -178.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.1 t -151.85 172.43 16.2 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.472 1.509 . . . . 0.0 110.247 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.47 -144.3 16.98 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.256 -0.902 . . . . 0.0 113.74 172.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.82 162.52 23.11 Favored Glycine 0 N--CA 1.43 -1.722 0 CA-C-O 122.489 1.049 . . . . 0.0 112.677 -177.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.43 -1.474 0 C-N-CA 125.497 1.519 . . . . 0.0 114.508 -174.84 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.711 0 CA-C-O 121.426 0.459 . . . . 0.0 113.564 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.5 mm -90.98 114.22 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.511 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 171.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -113.93 151.84 31.68 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.315 1.055 . . . . 0.0 110.012 -171.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.9 t -76.18 120.58 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.625 -1.297 . . . . 0.0 110.357 169.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -93.72 -48.59 6.25 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.707 -1.246 . . . . 0.0 110.587 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.43 157.99 43.92 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.491 -0.755 . . . . 0.0 109.51 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -124.47 123.92 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -77.33 122.46 86.12 Favored Pre-proline 0 N--CA 1.43 -1.446 0 CA-C-O 116.454 -1.736 . . . . 0.0 112.817 -170.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -58.11 128.6 29.39 Favored 'Trans proline' 0 N--CA 1.434 -1.991 0 CA-C-N 124.39 2.604 . . . . 0.0 115.797 -174.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.296 52.1 mtmt 76.07 17.52 2.12 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.283 2.233 . . . . 0.0 113.629 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.96 160.25 38.62 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.386 -1.446 . . . . 0.0 111.705 170.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.58 -56.47 8.32 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.14 -1.8 . . . . 0.0 115.837 168.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.0 -44.51 95.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.567 1.947 . . . . 0.0 112.399 -177.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -51.06 -65.21 0.6 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.297 1.592 . . . . 0.0 115.297 167.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 94.1 p -65.66 -26.94 68.02 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -169.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -55.47 -57.77 10.52 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.977 1.711 . . . . 0.0 113.228 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.63 -9.91 25.89 Favored Glycine 0 N--CA 1.43 -1.741 0 O-C-N 120.822 -1.174 . . . . 0.0 114.643 159.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.4 mtt180 -64.61 -32.4 74.05 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.763 1.225 . . . . 0.0 111.454 167.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 mt -96.91 124.76 49.89 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 C-N-CA 125.932 1.693 . . . . 0.0 110.762 -177.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 10.0 m80 -128.77 166.85 18.21 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.391 1.477 . . . . 0.0 109.487 170.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.0 ptpt -68.06 132.99 48.24 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.125 -1.609 . . . . 0.0 111.661 174.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 99.36 -7.9 60.19 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.026 -1.046 . . . . 0.0 114.524 -171.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -78.89 156.27 28.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-N 119.58 1.69 . . . . 0.0 112.41 -178.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -114.36 124.27 51.54 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.743 -1.223 . . . . 0.0 110.725 -168.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 10.7 t -87.67 131.29 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.296 -1.502 . . . . 0.0 110.162 -174.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.64 -44.8 5.46 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.684 -1.26 . . . . 0.0 110.307 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.32 143.22 25.67 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.598 -0.689 . . . . 0.0 110.814 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 39.9 t -124.93 124.06 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 173.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 63.82 33.79 12.42 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.966 1.707 . . . . 0.0 114.214 170.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.99 -15.76 62.75 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 120.693 -1.254 . . . . 0.0 113.698 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.38 116.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 121.554 -0.968 . . . . 0.0 110.202 -173.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -73.98 130.71 40.41 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.778 -1.202 . . . . 0.0 110.831 176.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.5 mt -85.48 44.2 1.08 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.866 -1.147 . . . . 0.0 114.065 -165.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -80.85 133.04 35.52 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.996 -2.315 . . . . 0.0 112.046 -177.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.53 13.07 67.78 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.488 -1.382 . . . . 0.0 114.793 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.31 142.72 48.85 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.767 1.395 . . . . 0.0 114.767 -178.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 36.0 p -90.56 178.18 6.16 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.013 1.725 . . . . 0.0 110.061 171.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -60.31 -48.98 79.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.837 -1.164 . . . . 0.0 112.971 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.0 mmtt -54.58 -38.51 66.78 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 126.365 1.866 . . . . 0.0 115.523 175.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -51.05 71.34 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.223 1.809 . . . . 0.0 113.187 -177.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.58 -34.05 73.6 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.516 1.527 . . . . 0.0 113.386 176.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.05 -53.44 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.375 0 C-N-CA 124.768 1.227 . . . . 0.0 110.127 178.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -60.79 -39.27 88.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 121.22 -0.925 . . . . 0.0 112.947 178.132 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 69.7 m -63.65 -40.64 97.37 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 124.828 1.251 . . . . 0.0 113.605 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 64.6 mt -72.0 -37.09 69.9 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.764 -1.21 . . . . 0.0 113.748 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 27.3 mtp180 -64.02 -47.35 80.59 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.188 -1.57 . . . . 0.0 112.793 176.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -88.14 58.97 5.05 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.716 1.246 . . . . 0.0 111.712 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.8 p -105.11 157.02 17.54 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.895 2.078 . . . . 0.0 110.052 176.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.26 -146.21 9.35 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.509 -1.37 . . . . 0.0 111.741 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.2 tt0 -71.85 -56.64 5.36 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.604 -1.527 . . . . 0.0 113.139 170.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 14.2 p -100.53 140.02 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.961 1.304 . . . . 0.0 109.316 179.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 72.5 t -124.22 122.85 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 127.496 2.318 . . . . 0.0 108.273 -170.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.8 m170 -100.52 101.36 12.27 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.058 -1.651 . . . . 0.0 110.561 177.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.424 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 8.7 mt -92.87 160.39 14.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.862 -1.774 . . . . 0.0 111.655 172.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.29 131.21 46.92 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 157.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.7 pp -143.4 166.85 23.62 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.993 -1.692 . . . . 0.0 112.312 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -112.73 146.24 39.11 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.406 1.882 . . . . 0.0 108.589 175.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.43 -1.427 0 O-C-N 120.784 -1.197 . . . . 0.0 110.57 176.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.6 t0 . . . . . 0 N--CA 1.43 -1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.7 p -97.43 162.32 13.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 122.11 0.957 . . . . 0.0 112.534 -176.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -144.82 138.19 26.9 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -93.66 115.38 27.83 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 126.301 1.84 . . . . 0.0 107.149 166.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.435 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 32.7 t -111.87 99.78 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -175.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -90.05 100.09 12.98 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.351 -1.468 . . . . 0.0 109.593 176.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.0 tp -116.59 136.91 52.59 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.744 1.218 . . . . 0.0 111.032 -162.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.66 145.81 29.51 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.443 -1.41 . . . . 0.0 109.006 169.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -70.81 141.66 51.34 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.924 -1.11 . . . . 0.0 113.677 174.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.9 t -137.95 142.7 40.53 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.426 -1.421 . . . . 0.0 109.619 174.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.1 t0 54.55 34.71 21.84 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.107 2.163 . . . . 0.0 113.906 -177.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.55 63.26 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 124.877 1.227 . . . . 0.0 115.948 -174.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 71.7 p -121.32 142.41 49.99 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-N 118.886 1.343 . . . . 0.0 114.033 -171.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.4 mt -89.72 -61.61 1.65 Allowed 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 159.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.79 48.19 0.55 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 118.98 -2.325 . . . . 0.0 112.711 163.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.3 tt -145.94 150.11 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.334 1.064 . . . . 0.0 110.006 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.4 t -122.94 125.66 45.74 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 164.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 m -106.15 157.74 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 125.338 1.455 . . . . 0.0 110.025 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.9 t -141.95 170.34 15.9 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.094 0.958 . . . . 0.0 109.71 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -132.09 10.96 Favored Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 123.885 0.755 . . . . 0.0 113.228 173.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.45 -179.83 42.07 Favored Glycine 0 N--CA 1.431 -1.696 0 CA-C-O 122.46 1.033 . . . . 0.0 111.747 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.429 -1.499 0 O-C-N 120.923 -1.339 . . . . 0.0 113.274 -169.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.784 0 N-CA-C 115.401 0.92 . . . . 0.0 115.401 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.2 mm -103.7 117.56 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.716 1.607 . . . . 0.0 107.373 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -124.98 150.0 47.13 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.795 -1.19 . . . . 0.0 110.171 -168.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 32.2 t -75.66 122.31 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.456 -1.402 . . . . 0.0 113.201 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -89.3 -56.48 3.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.363 1.065 . . . . 0.0 109.686 173.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.46 156.19 43.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.117 -0.989 . . . . 0.0 111.454 -173.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.437 HG22 ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -119.2 117.97 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.06 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 28.7 mm -76.89 125.06 87.49 Favored Pre-proline 0 N--CA 1.43 -1.451 0 CA-C-O 115.391 -2.242 . . . . 0.0 113.0 -165.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -53.33 136.95 64.08 Favored 'Trans proline' 0 C--N 1.3 -1.979 0 C-N-CA 123.628 2.886 . . . . 0.0 116.899 -171.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.277 6.6 mtpm? 51.67 26.1 3.21 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 119.168 3.025 . . . . 0.0 119.168 -169.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.31 169.65 54.91 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 118.995 -2.316 . . . . 0.0 113.201 170.083 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.21 -60.86 2.55 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.121 1.768 . . . . 0.0 114.136 165.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.9 -45.48 92.33 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 129.01 2.924 . . . . 0.0 112.646 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.437 ' HG2' HG22 ' A' ' 47' ' ' ILE . 1.5 tm-20 -43.66 -68.25 0.21 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.826 1.65 . . . . 0.0 114.818 166.143 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 74.9 m -69.89 -14.84 62.93 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 116.367 1.988 . . . . 0.0 116.367 -174.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -61.38 -55.72 28.4 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.82 1.248 . . . . 0.0 111.751 170.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.29 4.7 77.1 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 120.301 -1.5 . . . . 0.0 115.699 167.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -75.17 -38.3 60.91 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.243 -1.739 . . . . 0.0 110.326 163.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.5 mt -77.59 120.63 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 126.352 1.861 . . . . 0.0 111.122 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -117.99 166.09 12.94 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 125.895 1.678 . . . . 0.0 111.153 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 48.0 tttm -63.98 127.3 30.81 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 119.966 -1.709 . . . . 0.0 111.936 171.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.59 0.94 68.98 Favored Glycine 0 N--CA 1.431 -1.662 0 O-C-N 121.29 -0.882 . . . . 0.0 113.992 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.06 153.47 43.59 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 119.178 1.489 . . . . 0.0 112.792 179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 65.1 ttt-85 -105.46 122.06 45.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.832 0.825 . . . . 0.0 109.299 -176.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.4 t -82.89 134.95 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.751 -1.218 . . . . 0.0 109.81 -177.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.2 mp -105.64 -50.08 3.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.856 -1.152 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.15 151.2 32.74 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.369 -1.457 . . . . 0.0 111.88 -175.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 3.4 p -118.06 110.21 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 122.379 1.085 . . . . 0.0 112.393 172.058 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 55.26 39.68 31.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.943 -1.723 . . . . 0.0 114.913 164.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.96 -13.42 60.55 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-O 119.324 -0.709 . . . . 0.0 114.5 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.9 t -102.17 111.12 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.614 2.207 . . . . 0.0 109.302 -176.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 43.6 m -76.27 119.73 20.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.213 -1.554 . . . . 0.0 110.625 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 87.2 mt -92.41 35.47 1.01 Allowed 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.66 -1.275 . . . . 0.0 112.223 -167.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -88.61 91.19 8.71 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 119.619 -1.926 . . . . 0.0 112.52 -168.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 96.93 10.55 54.99 Favored Glycine 0 N--CA 1.429 -1.812 0 C-N-CA 125.202 1.382 . . . . 0.0 112.157 -171.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.85 157.7 37.4 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-O 122.532 1.158 . . . . 0.0 113.535 171.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 41.5 p -83.49 172.91 11.94 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.255 -1.528 . . . . 0.0 113.169 -175.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-80 -58.41 -46.17 86.96 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.386 1.474 . . . . 0.0 113.613 170.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -57.96 -43.06 86.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 172.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.91 -55.15 36.04 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 114.432 1.271 . . . . 0.0 114.432 -175.136 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.3 -43.3 64.41 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 116.284 1.957 . . . . 0.0 116.284 171.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.57 -52.04 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.756 -1.215 . . . . 0.0 111.461 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -64.64 -30.63 71.65 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.19 -0.944 . . . . 0.0 111.886 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.4 m -63.87 -51.41 64.7 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.186 1.394 . . . . 0.0 113.509 170.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.6 mt -60.42 -37.01 79.51 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 120.565 1.53 . . . . 0.0 113.789 176.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -61.93 -44.41 96.83 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.493 1.517 . . . . 0.0 113.763 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -94.54 55.91 2.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.539 1.536 . . . . 0.0 112.682 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.45 145.36 31.87 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.533 -1.355 . . . . 0.0 109.983 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.02 -141.32 4.8 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.658 -1.276 . . . . 0.0 111.889 176.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -70.69 -58.31 3.78 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.383 -1.657 . . . . 0.0 113.791 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 t -109.57 137.76 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.533 1.133 . . . . 0.0 110.947 -176.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.6 t -125.13 122.56 63.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 C-N-CA 128.924 2.89 . . . . 0.0 110.911 -173.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.0 t-160 -100.81 95.9 6.94 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.139 -2.226 . . . . 0.0 113.085 176.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.435 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 23.5 mt -88.2 154.83 20.12 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 118.92 -2.363 . . . . 0.0 113.328 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 39.0 tp -127.25 135.46 50.64 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 163.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -150.63 168.91 22.89 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.889 -1.132 . . . . 0.0 111.942 175.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.92 141.68 47.63 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.078 2.151 . . . . 0.0 109.142 172.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.453 0 C-N-CA 125.13 1.372 . . . . 0.0 112.305 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.5 t0 . . . . . 0 N--CA 1.431 -1.404 0 CA-C-O 121.276 0.56 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.86 139.61 44.73 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.364 -1.46 . . . . 0.0 110.325 -176.48 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -146.52 154.99 42.18 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-O 123.037 1.398 . . . . 0.0 110.298 174.172 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -108.6 142.24 39.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.893 1.677 . . . . 0.0 107.362 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.5 t -122.63 106.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.684 1.193 . . . . 0.0 108.648 -171.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -95.16 97.78 10.15 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 121.002 -1.061 . . . . 0.0 109.275 169.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.9 tp -119.79 129.93 54.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 123.787 0.835 . . . . 0.0 112.601 -168.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.71 123.55 44.08 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.365 -1.46 . . . . 0.0 109.452 171.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -69.61 114.83 8.19 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.507 1.523 . . . . 0.0 113.183 -177.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.3 t -96.53 129.67 43.86 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.323 -1.486 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.6 t70 41.48 49.41 3.55 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.337 2.655 . . . . 0.0 114.917 -175.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.29 10.61 70.01 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 117.336 1.695 . . . . 0.0 117.336 -178.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 85.3 p -120.97 129.12 53.3 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 119.86 1.83 . . . . 0.0 113.977 -175.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 82.5 mt -85.8 -58.31 2.7 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.823 -1.173 . . . . 0.0 111.077 168.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.37 23.05 4.25 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 119.4 -2.062 . . . . 0.0 113.598 176.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 pt -122.41 141.28 43.44 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 CA-C-O 123.092 1.425 . . . . 0.0 113.348 -174.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.9 t -113.45 126.61 55.53 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 159.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 m -115.59 159.54 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.03 1.332 . . . . 0.0 110.749 -177.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.21 166.11 28.01 Favored 'General case' 0 N--CA 1.428 -1.532 0 C-N-CA 124.862 1.265 . . . . 0.0 109.424 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.35 -143.0 16.79 Favored Glycine 0 N--CA 1.429 -1.815 0 O-C-N 120.155 -1.591 . . . . 0.0 114.674 160.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 103.56 161.63 25.09 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.548 1.07 . . . . 0.0 111.514 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.43 -1.45 0 O-C-N 120.547 -1.56 . . . . 0.0 114.068 -171.405 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.748 0 CA-C-O 121.639 0.577 . . . . 0.0 114.128 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.0 mm -84.97 129.87 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.923 1.689 . . . . 0.0 109.104 174.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -122.89 150.37 43.0 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.166 -0.959 . . . . 0.0 109.271 -175.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -77.77 127.7 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.433 -1.417 . . . . 0.0 112.019 170.106 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.7 ttpp -94.91 -44.1 7.88 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.704 -1.247 . . . . 0.0 111.747 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.91 153.85 33.86 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.878 -1.139 . . . . 0.0 112.926 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.271 1.0 OUTLIER -102.94 118.14 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 CA-C-O 122.644 1.211 . . . . 0.0 110.038 168.822 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.9 mm -76.38 124.11 87.98 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 126.436 1.894 . . . . 0.0 112.366 -173.18 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -56.29 129.96 37.62 Favored 'Trans proline' 0 N--CA 1.434 -1.992 0 C-N-CA 122.835 2.357 . . . . 0.0 115.166 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.8 mtmt 75.4 22.34 1.67 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.265 1.826 . . . . 0.0 114.771 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.44 167.17 42.65 Favored Glycine 0 N--CA 1.43 -1.743 0 O-C-N 119.722 -1.861 . . . . 0.0 115.26 169.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.63 -63.35 1.15 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.3 98.09 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 129.087 2.955 . . . . 0.0 112.824 -176.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -42.21 -55.72 3.18 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 168.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.0 t -68.53 -38.15 80.61 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.74 -51.66 68.01 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 126.067 1.747 . . . . 0.0 112.171 177.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.31 1.02 72.6 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.606 -1.309 . . . . 0.0 114.421 159.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -67.87 -44.11 77.82 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.315 1.446 . . . . 0.0 110.498 166.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 36.0 mt -85.64 129.66 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 125.532 1.533 . . . . 0.0 109.8 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.38 167.33 29.09 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.288 1.035 . . . . 0.0 110.961 -171.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.0 tttm -50.72 121.41 5.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -178.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.07 7.6 67.83 Favored Glycine 0 N--CA 1.429 -1.804 0 CA-C-O 117.904 -1.498 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.296 1.7 p30 -77.51 152.64 34.02 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-N 120.786 2.293 . . . . 0.0 112.767 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -102.17 120.59 40.7 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -176.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.11 128.74 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.077 -1.015 . . . . 0.0 109.768 -176.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.1 mt -99.26 -45.29 5.93 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.435 -1.416 . . . . 0.0 111.446 -175.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.67 145.17 25.67 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.673 -1.267 . . . . 0.0 111.658 -178.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.1 t -112.31 108.52 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.051 0.94 . . . . 0.0 109.445 173.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.0 t30 60.08 38.82 20.32 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.879 1.672 . . . . 0.0 114.547 166.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -16.21 60.14 Favored Glycine 0 N--CA 1.43 -1.718 0 C-N-CA 125.307 1.432 . . . . 0.0 114.214 -177.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.4 t -97.14 120.68 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 121.008 -1.29 . . . . 0.0 110.58 -176.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.9 t -75.33 133.89 41.15 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.486 -1.384 . . . . 0.0 111.956 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 88.2 mt -88.21 12.62 13.34 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.908 -1.12 . . . . 0.0 113.628 -176.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 39.2 mm-40 -64.96 128.43 35.74 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 119.934 -1.729 . . . . 0.0 112.414 173.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.25 -6.57 67.29 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 125.314 1.435 . . . . 0.0 116.115 -176.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.6 149.71 45.37 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 116.953 2.205 . . . . 0.0 116.953 -174.524 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 30.5 p -93.19 -179.61 5.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 125.704 1.602 . . . . 0.0 110.943 171.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -63.91 -50.35 69.07 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.541 -1.349 . . . . 0.0 111.765 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 38.0 mttp -56.46 -39.35 73.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.915 1.45 . . . . 0.0 114.915 175.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -57.37 -54.3 48.41 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 114.51 1.3 . . . . 0.0 114.51 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.51 -36.13 81.97 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 124.63 1.172 . . . . 0.0 113.124 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.6 t -64.18 -51.27 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 120.949 -1.094 . . . . 0.0 110.706 174.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.581 -1.324 . . . . 0.0 113.608 178.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 87.8 m -62.87 -51.14 68.14 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.702 2.001 . . . . 0.0 112.874 173.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 74.3 mt -65.84 -32.05 73.35 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.95 -1.719 . . . . 0.0 114.988 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -68.18 -28.46 67.29 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.497 -1.377 . . . . 0.0 111.667 173.062 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -93.25 41.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.215 -1.553 . . . . 0.0 112.543 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -98.88 153.96 18.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.147 -1.596 . . . . 0.0 110.907 172.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -106.78 -138.33 8.93 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 124.777 1.18 . . . . 0.0 110.81 174.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -70.05 -66.9 0.54 Allowed 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -177.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.3 120.65 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 122.287 1.041 . . . . 0.0 109.256 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 71.3 t -114.54 119.53 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 128.51 2.724 . . . . 0.0 108.966 -167.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.1 t-160 -107.38 88.87 2.83 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.733 -1.229 . . . . 0.0 113.298 -174.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.1 mt -92.37 157.13 16.78 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.82 -1.8 . . . . 0.0 113.868 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 55.4 tp -127.47 129.09 46.82 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.743 1.217 . . . . 0.0 108.177 170.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.43 161.52 37.83 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-O 122.307 1.051 . . . . 0.0 113.715 179.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -120.35 132.07 55.12 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.108 1.363 . . . . 0.0 109.645 175.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.2 tptm . . . . . 0 N--CA 1.43 -1.426 0 O-C-N 120.803 -1.186 . . . . 0.0 113.758 -164.773 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.7 t0 . . . . . 0 N--CA 1.431 -1.417 0 CA-C-O 122.063 0.935 . . . . 0.0 112.661 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 45.0 p -105.41 161.45 14.31 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.211 1.405 . . . . 0.0 113.181 -175.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.22 140.66 25.46 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 167.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -88.54 132.96 34.3 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-O 122.264 1.031 . . . . 0.0 109.471 163.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 t -120.8 98.18 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 126.053 1.741 . . . . 0.0 109.727 -169.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.411 ' HG2' ' CD2' ' A' ' 93' ' ' HIS . 42.8 mt-10 -91.09 102.29 15.04 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.355 -1.466 . . . . 0.0 109.972 174.026 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -123.1 128.64 50.38 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.85 -1.156 . . . . 0.0 111.33 -166.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.23 125.19 47.83 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 119.967 -1.708 . . . . 0.0 110.354 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 47.9 mtpt -69.69 150.17 47.26 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.517 1.673 . . . . 0.0 115.517 -173.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.8 p -102.91 87.39 2.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.852 1.261 . . . . 0.0 109.407 178.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.2 t0 45.92 64.83 1.32 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.348 2.659 . . . . 0.0 116.127 -175.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.74 -29.54 9.04 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 121.06 -1.025 . . . . 0.0 113.549 -178.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.9 m -97.42 136.19 38.21 Favored 'General case' 0 N--CA 1.43 -1.445 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -169.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.2 mt -85.26 -60.5 2.02 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.23 1.412 . . . . 0.0 110.691 171.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.35 27.58 1.79 Allowed Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.404 -2.06 . . . . 0.0 111.292 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 pt -124.88 155.96 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.555 1.142 . . . . 0.0 110.961 -170.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.6 t -129.8 130.38 45.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 152.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -104.82 157.93 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.914 1.286 . . . . 0.0 109.617 -177.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -140.33 169.71 17.17 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.717 -1.24 . . . . 0.0 109.111 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.52 -140.29 15.32 Favored Glycine 0 N--CA 1.43 -1.734 0 CA-C-O 122.372 0.984 . . . . 0.0 114.876 164.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.23 157.53 32.23 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 122.235 0.908 . . . . 0.0 112.838 -174.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 N--CA 1.431 -1.408 0 N-CA-C 116.951 2.204 . . . . 0.0 116.951 -166.179 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.726 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.8 mm -99.67 119.27 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -120.36 149.79 41.79 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.898 -1.126 . . . . 0.0 110.366 -171.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.8 t -76.75 112.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 O-C-N 121.022 -1.049 . . . . 0.0 111.67 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.36 -41.92 11.22 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 120.804 -1.185 . . . . 0.0 112.109 -174.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.61 151.99 35.97 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.82 -1.175 . . . . 0.0 110.411 176.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.98 119.91 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.5 1.143 . . . . 0.0 108.819 173.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.21 125.61 86.3 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 117.042 2.238 . . . . 0.0 117.042 -166.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -53.84 119.08 5.68 Favored 'Trans proline' 0 N--CA 1.434 -2.011 0 C-N-CA 123.645 2.897 . . . . 0.0 116.512 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.255 67.2 mmtt 76.16 30.0 0.73 Allowed 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 128.267 2.627 . . . . 0.0 112.421 -177.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 158.07 33.7 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.617 -1.302 . . . . 0.0 111.119 168.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -59.23 3.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.794 -1.416 . . . . 0.0 113.346 166.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.24 -46.69 85.77 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 128.553 2.741 . . . . 0.0 113.914 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -42.78 -60.62 1.51 Allowed 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 172.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.17 -30.96 69.29 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -60.93 -62.79 1.6 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 125.655 1.582 . . . . 0.0 113.336 -178.079 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.94 6.17 49.42 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 116.987 1.555 . . . . 0.0 116.987 166.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.7 mmt85 -72.33 -37.22 68.93 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-N 119.541 1.67 . . . . 0.0 110.805 164.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.9 mt -92.27 124.28 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.922 1.289 . . . . 0.0 108.11 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -145.6 176.86 9.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.387 -1.446 . . . . 0.0 111.619 175.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -65.59 126.4 28.23 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.298 1.039 . . . . 0.0 113.023 -170.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.24 80.65 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 121.128 -0.983 . . . . 0.0 115.533 -179.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.51 157.97 25.97 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 119.117 1.458 . . . . 0.0 111.911 -177.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -105.12 121.66 44.28 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.088 -1.008 . . . . 0.0 111.212 -172.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 58.9 t -82.31 134.39 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.406 0 C-N-CA 125.727 1.611 . . . . 0.0 107.895 -176.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -119.42 -52.14 2.27 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.96 -1.087 . . . . 0.0 113.715 -167.237 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.85 113.28 4.96 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.626 -1.296 . . . . 0.0 111.138 -173.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -93.59 111.64 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.164 -0.96 . . . . 0.0 108.945 -175.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 61.68 36.15 16.66 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.901 2.08 . . . . 0.0 113.407 177.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.39 -9.89 75.34 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 125.001 1.286 . . . . 0.0 113.669 -176.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.4 t -90.94 101.96 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.11 -1.818 . . . . 0.0 109.019 -176.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.3 m -66.79 133.21 49.67 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.707 -1.246 . . . . 0.0 112.125 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.2 mt -85.97 45.95 1.27 Allowed 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.293 1.037 . . . . 0.0 112.262 -171.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -74.82 118.99 18.4 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.93 -1.731 . . . . 0.0 112.295 -171.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.52 22.88 75.23 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 124.031 0.824 . . . . 0.0 114.825 -175.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.92 145.34 50.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -176.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.3 p -90.13 170.84 9.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.872 1.269 . . . . 0.0 110.835 168.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.3 t-160 -53.04 -50.58 64.01 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.324 1.85 . . . . 0.0 113.563 175.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -56.42 -43.25 79.23 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.436 1.494 . . . . 0.0 113.776 175.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.75 -47.04 77.67 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.302 1.841 . . . . 0.0 114.198 -175.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.31 -45.51 93.15 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.791 1.636 . . . . 0.0 113.176 174.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.1 t -66.29 -43.34 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 125.166 1.386 . . . . 0.0 111.717 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -59.37 -43.69 92.85 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.971 -1.08 . . . . 0.0 113.027 177.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -72.04 -36.54 69.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.3 1.04 . . . . 0.0 113.724 176.535 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.9 mt -63.81 -35.62 81.21 Favored 'General case' 0 CA--C 1.489 -1.393 0 O-C-N 120.056 -1.653 . . . . 0.0 114.832 171.181 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -71.57 -30.9 66.38 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.134 -1.604 . . . . 0.0 112.308 173.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -84.85 50.31 1.9 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.968 1.707 . . . . 0.0 112.628 174.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.3 p -106.3 164.28 12.14 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 125.512 1.525 . . . . 0.0 110.923 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -100.6 -168.99 28.81 Favored Glycine 0 N--CA 1.429 -1.786 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 164.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -68.56 -46.76 68.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-N 118.348 1.074 . . . . 0.0 113.71 -175.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.7 t -95.99 118.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 122.864 1.316 . . . . 0.0 109.843 172.01 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.6 t -109.74 118.88 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 127.09 2.156 . . . . 0.0 110.143 -169.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . 0.411 ' CD2' ' HG2' ' A' ' 17' ' ' GLU . 33.2 m170 -101.7 94.61 5.94 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.505 -1.372 . . . . 0.0 112.249 -179.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 tp -96.92 141.47 30.06 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 119.353 -2.092 . . . . 0.0 110.375 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 9.0 tt -104.98 130.45 53.18 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.97 -1.706 . . . . 0.0 108.823 162.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.9 pp -134.74 165.71 24.63 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.911 -1.118 . . . . 0.0 112.58 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -112.92 142.2 45.87 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.172 1.789 . . . . 0.0 109.44 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.429 -1.498 0 O-C-N 120.64 -1.288 . . . . 0.0 111.056 178.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.0 t0 . . . . . 0 N--CA 1.429 -1.51 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.19 146.99 33.25 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.842 1.257 . . . . 0.0 108.758 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.19 140.67 26.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.998 0.904 . . . . 0.0 108.875 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -88.92 136.87 32.78 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-O 122.615 1.198 . . . . 0.0 107.901 161.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.3 t -117.98 114.06 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -104.31 88.76 3.05 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 169.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.9 tp -105.18 139.42 39.86 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 121.408 -0.808 . . . . 0.0 109.4 -173.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.64 123.63 45.96 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.495 -1.378 . . . . 0.0 107.85 167.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -68.22 128.91 38.27 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.885 2.474 . . . . 0.0 112.427 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.3 p -101.24 125.93 47.92 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.702 -1.248 . . . . 0.0 110.952 -178.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.4 t70 56.96 32.66 21.98 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.105 1.762 . . . . 0.0 114.837 177.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.57 -5.83 67.45 Favored Glycine 0 N--CA 1.431 -1.675 0 O-C-N 119.744 -1.848 . . . . 0.0 116.269 -179.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 74.3 m -112.04 135.23 52.94 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 118.77 1.285 . . . . 0.0 111.549 -171.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.6 mt -86.47 -62.86 1.42 Allowed 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.634 -1.292 . . . . 0.0 109.481 167.134 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.15 51.71 0.43 Allowed Glycine 0 N--CA 1.43 -1.764 0 O-C-N 119.291 -2.131 . . . . 0.0 111.52 170.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tt -142.69 142.7 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.505 0 CA-C-O 122.601 1.191 . . . . 0.0 111.008 -176.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.9 t -117.7 132.53 56.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 124.983 1.313 . . . . 0.0 107.667 167.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.4 m -113.15 164.5 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.681 1.192 . . . . 0.0 111.965 -176.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -144.09 172.53 12.76 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.119 1.368 . . . . 0.0 109.435 174.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.72 -143.12 16.54 Favored Glycine 0 N--CA 1.429 -1.828 0 C-N-CA 124.541 1.067 . . . . 0.0 115.243 171.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.7 -149.67 18.07 Favored Glycine 0 N--CA 1.429 -1.813 0 C-N-CA 124.823 1.201 . . . . 0.0 112.502 178.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 N--CA 1.43 -1.426 0 O-C-N 120.578 -1.542 . . . . 0.0 112.57 178.424 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.724 0 CA-C-O 121.386 0.437 . . . . 0.0 112.048 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 15.0 mm -86.6 126.03 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 172.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -122.42 154.02 38.31 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.996 -1.065 . . . . 0.0 109.461 -174.008 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.6 t -76.16 118.86 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.967 -1.083 . . . . 0.0 111.524 175.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -88.53 -43.01 11.72 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.919 1.288 . . . . 0.0 110.123 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.66 150.82 23.36 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 121.105 -0.997 . . . . 0.0 109.123 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.438 HG22 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.2 117.66 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 170.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.04 117.67 65.67 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 115.296 -2.287 . . . . 0.0 113.369 -161.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -53.74 129.59 34.76 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 124.025 3.15 . . . . 0.0 116.387 -169.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 34.9 mttt 77.56 14.71 1.72 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.374 1.87 . . . . 0.0 114.474 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.85 165.81 46.16 Favored Glycine 0 N--CA 1.429 -1.794 0 O-C-N 119.658 -1.901 . . . . 0.0 113.421 173.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.31 -58.9 4.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 167.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.01 -50.18 71.74 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 128.935 2.894 . . . . 0.0 112.175 -178.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.438 ' HG2' HG22 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -41.78 -71.04 0.09 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.782 2.033 . . . . 0.0 114.997 166.515 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.9 t -70.02 -14.96 62.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -170.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -64.9 -59.25 4.4 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.743 -1.848 . . . . 0.0 111.946 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 97.78 29.46 7.71 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.046 -1.659 . . . . 0.0 116.682 165.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -92.92 -41.57 9.96 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.392 -1.064 . . . . 0.0 108.864 160.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.0 mt -97.88 118.76 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.399 1.88 . . . . 0.0 110.811 -170.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -128.59 174.77 9.1 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-O 123.085 1.421 . . . . 0.0 111.438 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -62.41 130.44 45.22 Favored 'General case' 0 N--CA 1.431 -1.387 0 O-C-N 119.579 -1.951 . . . . 0.0 112.583 176.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.8 -5.35 61.84 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.712 -0.618 . . . . 0.0 113.697 -177.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -77.54 156.37 30.99 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 118.661 1.23 . . . . 0.0 111.641 -176.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -106.93 123.0 47.55 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.579 1.181 . . . . 0.0 110.185 -172.479 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.5 t -85.64 133.68 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 O-C-N 120.217 -1.552 . . . . 0.0 111.089 -175.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.47 -51.62 2.88 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.025 -1.047 . . . . 0.0 111.073 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.76 148.26 28.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.958 -1.089 . . . . 0.0 113.137 -176.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.97 111.04 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.096 0.958 . . . . 0.0 110.303 173.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.6 t30 61.01 39.9 15.87 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.78 2.032 . . . . 0.0 113.323 172.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.07 -27.34 19.66 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 125.309 1.433 . . . . 0.0 113.459 -178.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.2 t -84.64 119.8 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 124.95 1.3 . . . . 0.0 110.817 -172.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.2 p -72.23 136.5 46.37 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.462 -1.399 . . . . 0.0 112.296 177.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 35.9 mt -87.95 -6.16 58.17 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.475 -1.391 . . . . 0.0 113.896 -175.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -68.71 95.26 0.65 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 119.581 -1.949 . . . . 0.0 115.878 -174.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.96 -15.13 5.14 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.819 1.2 . . . . 0.0 111.151 -177.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.4 158.88 35.52 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.8 p -87.52 179.12 6.61 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.712 -1.242 . . . . 0.0 111.115 172.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -67.21 -46.75 72.91 Favored 'General case' 0 N--CA 1.431 -1.393 0 O-C-N 120.703 -1.248 . . . . 0.0 110.755 173.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.7 tppt? -57.4 -40.93 79.28 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.201 1.401 . . . . 0.0 113.972 174.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.8 mm100 -56.93 -51.39 69.32 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.555 1.142 . . . . 0.0 114.076 176.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.99 -40.52 96.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.255 1.422 . . . . 0.0 113.519 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -66.17 -45.98 88.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.846 -1.159 . . . . 0.0 111.329 176.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -58.81 -40.07 83.04 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.629 -1.294 . . . . 0.0 112.95 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 84.2 m -68.2 -42.63 79.59 Favored 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 125.963 1.705 . . . . 0.0 113.569 178.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 72.9 mt -68.99 -33.55 73.86 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.987 -1.696 . . . . 0.0 114.391 176.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -72.35 -33.04 66.99 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 119.644 -1.91 . . . . 0.0 112.675 171.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -78.58 44.73 0.54 Allowed 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.854 2.061 . . . . 0.0 114.25 170.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -105.79 154.88 19.89 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.224 -2.172 . . . . 0.0 108.842 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.23 -146.56 17.64 Favored Glycine 0 N--CA 1.429 -1.776 0 O-C-N 120.916 -1.115 . . . . 0.0 112.921 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -70.85 -61.06 1.9 Allowed 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.402 1.081 . . . . 0.0 112.312 169.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.72 127.5 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 123.567 1.651 . . . . 0.0 110.244 177.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 73.3 t -120.61 114.17 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.398 1.879 . . . . 0.0 108.772 -162.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 m170 -101.86 94.1 5.64 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.044 0.938 . . . . 0.0 112.144 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -102.37 160.07 14.86 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.638 -1.914 . . . . 0.0 114.297 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.2 tp -128.35 132.8 48.59 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 124.869 1.268 . . . . 0.0 108.505 163.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.08 164.5 31.93 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.929 -1.107 . . . . 0.0 113.371 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -116.97 134.84 54.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 127.021 2.129 . . . . 0.0 107.773 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? . . . . . 0 N--CA 1.43 -1.463 0 O-C-N 120.355 -1.466 . . . . 0.0 112.671 -175.237 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.5 t70 . . . . . 0 N--CA 1.43 -1.462 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.8 p -105.62 150.63 25.24 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-N 120.166 1.348 . . . . 0.0 110.206 166.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE1' ' HB3' ' A' ' 58' ' ' ARG . 27.1 p90 -147.69 164.43 33.58 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.635 1.207 . . . . 0.0 108.918 161.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -126.19 143.0 51.3 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.205 1.802 . . . . 0.0 106.858 -168.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.69 111.91 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 O-C-N 120.848 -1.157 . . . . 0.0 109.118 -173.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -103.1 94.16 5.39 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 125.762 1.625 . . . . 0.0 107.998 169.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.1 tp -123.86 134.36 53.59 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-O 122.208 1.004 . . . . 0.0 113.521 -167.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.62 137.37 39.11 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 125.67 1.588 . . . . 0.0 110.352 177.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -69.11 162.12 27.63 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 115.19 1.552 . . . . 0.0 115.19 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 39.5 p -130.97 114.91 15.8 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 26.9 t70 50.65 59.49 4.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.461 1.904 . . . . 0.0 113.844 -177.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.65 -36.05 2.83 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.13 -1.606 . . . . 0.0 115.663 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 61.5 m -106.38 149.31 27.12 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.346 1.458 . . . . 0.0 112.059 -162.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -96.22 -57.12 2.42 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 172.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.61 23.46 1.88 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 120.153 -1.592 . . . . 0.0 113.075 172.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 pt -115.21 125.53 72.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.085 1.354 . . . . 0.0 110.178 -176.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 t -112.39 128.49 56.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.302 -0.874 . . . . 0.0 108.796 170.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 163.55 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 111.896 -174.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.6 t -133.51 164.78 26.38 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.677 1.191 . . . . 0.0 108.015 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.39 -154.92 20.17 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.899 -1.125 . . . . 0.0 112.913 171.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.94 145.83 18.6 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.192 1.377 . . . . 0.0 110.445 -169.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.43 -1.447 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -172.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 107.959 -2.057 . . . . 0.0 107.959 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.8 mm -103.3 120.15 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -128.0 153.76 46.38 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.924 -1.11 . . . . 0.0 110.496 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 20.5 t -76.0 121.96 29.04 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.577 -1.327 . . . . 0.0 112.687 178.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmt? -97.84 -45.94 6.13 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.741 1.216 . . . . 0.0 112.503 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.51 154.79 27.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.104 -0.998 . . . . 0.0 110.466 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -111.3 126.14 68.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 CA-C-O 122.235 1.017 . . . . 0.0 109.742 175.461 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 14.1 mm -77.09 118.78 74.24 Favored Pre-proline 0 N--CA 1.43 -1.467 0 CA-C-O 116.043 -1.932 . . . . 0.0 113.761 -174.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -60.19 123.79 13.88 Favored 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 125.003 2.822 . . . . 0.0 115.763 -176.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.378 39.8 mtmt 75.59 31.76 0.73 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 127.372 2.269 . . . . 0.0 114.426 -175.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.09 162.39 36.89 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.819 -1.176 . . . . 0.0 112.96 159.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.07 -56.23 11.67 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 126.715 2.006 . . . . 0.0 114.489 165.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.22 -48.79 74.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 128.33 2.652 . . . . 0.0 111.813 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -41.84 -59.21 1.76 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 116.22 1.933 . . . . 0.0 116.22 176.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -69.86 -28.32 65.57 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.535 1.534 . . . . 0.0 114.359 -172.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.32 -56.57 20.15 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.981 1.712 . . . . 0.0 113.687 -173.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.54 -4.88 26.34 Favored Glycine 0 N--CA 1.429 -1.801 0 O-C-N 120.587 -1.32 . . . . 0.0 115.42 164.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.467 ' HB3' ' CE1' ' A' ' 14' ' ' PHE . 95.1 mtt180 -74.84 -61.86 1.74 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.628 -1.513 . . . . 0.0 110.605 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.69 125.69 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.886 1.674 . . . . 0.0 113.527 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -141.7 159.49 42.11 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.49 1.614 . . . . 0.0 114.089 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 ttpt -52.55 127.21 22.0 Favored 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.521 2.328 . . . . 0.0 114.918 177.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 98.06 -7.31 62.43 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.031 0.824 . . . . 0.0 114.571 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.72 160.6 24.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 119.363 1.581 . . . . 0.0 112.508 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.7 ttt-85 -105.23 132.92 50.82 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.943 1.697 . . . . 0.0 111.192 -174.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.77 136.21 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 119.85 -1.781 . . . . 0.0 111.231 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -100.83 -60.66 1.48 Allowed 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.37 -1.457 . . . . 0.0 110.945 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.81 125.94 10.66 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.907 -1.12 . . . . 0.0 112.366 -171.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.9 t -99.04 114.33 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 123.837 0.855 . . . . 0.0 109.367 177.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.7 t30 59.52 35.28 22.7 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.042 1.737 . . . . 0.0 115.1 168.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.51 -10.74 66.98 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 124.971 1.272 . . . . 0.0 114.186 -177.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.31 107.88 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.782 -1.422 . . . . 0.0 109.659 -176.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.5 t -73.04 126.33 29.72 Favored 'General case' 0 N--CA 1.431 -1.391 0 O-C-N 120.777 -1.202 . . . . 0.0 111.177 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.4 mt -84.95 37.74 0.68 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -169.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -74.77 120.54 20.46 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.929 1.691 . . . . 0.0 110.656 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.11 11.95 79.3 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 120.49 -1.381 . . . . 0.0 114.412 -175.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.89 140.64 51.12 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 114.652 1.353 . . . . 0.0 114.652 -175.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.8 p -90.86 -179.28 5.45 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.689 1.195 . . . . 0.0 111.19 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -69.23 -45.43 69.81 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.752 -1.217 . . . . 0.0 110.317 179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -56.89 -41.63 78.4 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 170.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -53.1 62.05 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.671 -1.268 . . . . 0.0 113.915 178.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.95 -44.02 73.86 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.82 1.248 . . . . 0.0 113.575 178.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.4 -49.07 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.64 -1.288 . . . . 0.0 111.806 -177.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -65.73 -32.42 73.96 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.744 -1.222 . . . . 0.0 112.087 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 36.0 m -66.98 -45.06 78.79 Favored 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 125.774 1.63 . . . . 0.0 113.101 173.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 54.3 mt -68.64 -29.31 67.77 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.123 -1.611 . . . . 0.0 114.293 174.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.6 mtp180 -73.68 -47.46 39.5 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.227 -1.546 . . . . 0.0 113.159 171.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -89.18 55.67 3.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.148 -1.595 . . . . 0.0 113.543 -176.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.4 p -84.5 177.91 7.92 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.126 1.771 . . . . 0.0 111.531 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.8 -157.66 27.67 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 120.123 -1.61 . . . . 0.0 110.375 164.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.5 tm0? -71.33 -50.52 31.53 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.819 -1.989 . . . . 0.0 110.861 169.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.51 135.99 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.309 1.444 . . . . 0.0 109.844 174.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.7 t -107.72 126.16 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 C-N-CA 129.047 2.939 . . . . 0.0 108.448 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.9 t-160 -105.21 110.07 22.3 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.389 4.0 pp -125.1 151.24 45.97 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 117.032 2.234 . . . . 0.0 117.032 166.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.8 tp -114.97 134.23 55.36 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.839 2.056 . . . . 0.0 107.527 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -152.75 174.37 14.12 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.035 -1.041 . . . . 0.0 113.639 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -119.39 132.47 55.84 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 125.712 1.605 . . . . 0.0 111.146 -175.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.435 0 O-C-N 120.112 -1.617 . . . . 0.0 113.644 -179.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.6 t0 . . . . . 0 N--CA 1.43 -1.462 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.7 p -95.97 153.67 17.64 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.869 -1.769 . . . . 0.0 111.863 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -146.6 137.51 24.11 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 173.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -94.72 128.06 41.15 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.593 -1.317 . . . . 0.0 109.942 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.41 88.85 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -178.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.442 ' HG2' ' CD2' ' A' ' 93' ' ' HIS . 61.0 mt-10 -93.85 83.33 4.37 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 169.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.288 1.8 pp -109.2 162.75 13.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.771 1.272 . . . . 0.0 111.233 -178.035 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 133.73 46.88 Favored 'General case' 0 N--CA 1.428 -1.527 0 C-N-CA 124.728 1.211 . . . . 0.0 107.924 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -70.6 121.87 18.69 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.458 -1.401 . . . . 0.0 112.32 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 29.2 p -94.7 119.61 33.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.669 -1.269 . . . . 0.0 110.039 -174.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 t70 61.13 7.7 1.7 Allowed 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.056 2.142 . . . . 0.0 116.416 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 107.41 2.27 35.34 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.984 -1.698 . . . . 0.0 114.846 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 63.2 m -121.93 132.02 54.33 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.911 1.855 . . . . 0.0 113.306 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 85.5 mt -73.7 -44.24 57.03 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.712 -1.242 . . . . 0.0 111.425 164.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.5 29.74 3.31 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 119.767 -1.833 . . . . 0.0 111.719 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 pt -107.31 135.22 46.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.625 1.202 . . . . 0.0 114.215 -162.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 17.7 m -131.3 109.68 10.54 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.758 -1.839 . . . . 0.0 108.969 155.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.03 163.82 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-O 122.153 0.978 . . . . 0.0 112.145 -177.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.6 t -145.81 172.6 13.07 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.13 1.372 . . . . 0.0 108.28 175.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 -175.61 33.68 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.734 -1.229 . . . . 0.0 114.125 176.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 149.6 177.61 23.83 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -171.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.434 1.272 . . . . 0.0 114.434 -173.828 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.691 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.7 mm -102.39 123.34 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.894 1.678 . . . . 0.0 107.464 175.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -124.4 155.16 39.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.935 -1.103 . . . . 0.0 111.307 -170.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.1 t -76.05 119.31 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.883 -1.136 . . . . 0.0 110.789 169.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.9 pttt -95.51 -36.59 11.24 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.471 -1.393 . . . . 0.0 112.445 173.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -155.88 160.95 40.6 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.921 -1.112 . . . . 0.0 110.539 177.1 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -120.15 125.88 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 124.404 1.082 . . . . 0.0 109.216 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.8 mm -77.42 124.93 86.85 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.623 1.969 . . . . 0.0 114.265 -176.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_exo -56.57 133.87 60.73 Favored 'Trans proline' 0 N--CA 1.435 -1.968 0 CA-C-N 124.034 2.476 . . . . 0.0 116.237 176.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt 83.53 0.77 1.06 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 129.012 2.925 . . . . 0.0 114.71 -177.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.05 156.08 46.88 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.121 -1.612 . . . . 0.0 113.104 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.35 -53.14 23.78 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 172.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.2 -45.76 86.91 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 128.951 2.901 . . . . 0.0 112.622 177.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -50.21 -57.99 6.57 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 123.101 1.429 . . . . 0.0 114.656 171.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.4 t -68.02 -25.39 65.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.193 1.397 . . . . 0.0 113.717 -171.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -61.56 -71.94 0.13 Allowed 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.695 1.598 . . . . 0.0 112.501 173.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.76 -6.52 37.98 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 121.108 -0.995 . . . . 0.0 115.284 177.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.1 mtm180 -65.22 -35.47 81.15 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.867 -1.961 . . . . 0.0 111.893 165.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 73.3 mt -85.36 134.21 27.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 124.884 1.273 . . . . 0.0 109.683 176.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -139.17 161.31 37.73 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.807 -1.183 . . . . 0.0 108.922 177.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -54.71 125.05 18.37 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.985 1.714 . . . . 0.0 113.934 172.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.84 -2.25 66.41 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 124.286 0.946 . . . . 0.0 114.802 -178.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -82.12 160.18 23.19 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-N 119.614 1.707 . . . . 0.0 110.535 178.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -112.37 132.48 54.98 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.619 -1.3 . . . . 0.0 112.151 -168.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.7 t -87.14 127.68 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.319 -1.488 . . . . 0.0 110.657 178.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 88.1 mt -98.15 -48.1 5.23 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 121.132 -0.98 . . . . 0.0 111.253 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.44 134.6 18.16 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.995 -1.065 . . . . 0.0 109.787 -176.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.7 t -114.23 125.85 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 67.25 30.06 7.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.259 1.424 . . . . 0.0 111.721 175.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 85.19 -18.84 25.84 Favored Glycine 0 N--CA 1.431 -1.682 0 C-N-CA 125.058 1.313 . . . . 0.0 114.802 -173.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.85 123.27 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 O-C-N 120.776 -1.426 . . . . 0.0 110.521 -171.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.5 m -63.88 135.27 56.42 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.776 -1.202 . . . . 0.0 113.956 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 78.1 mt -86.17 56.52 4.02 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.754 -1.216 . . . . 0.0 111.65 177.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -78.85 123.11 26.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.571 -1.331 . . . . 0.0 112.508 -175.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 58.59 20.87 48.03 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 125.349 1.452 . . . . 0.0 115.139 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.64 144.66 51.04 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -164.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -76.58 178.45 6.67 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.611 1.164 . . . . 0.0 110.511 169.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -68.25 -48.84 63.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.427 -1.421 . . . . 0.0 111.738 172.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 41.2 mmtm -58.48 -31.67 68.05 Favored 'General case' 0 N--CA 1.429 -1.512 0 N-CA-C 116.012 1.856 . . . . 0.0 116.012 174.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 mm100 -56.35 -55.74 29.76 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 120.324 1.42 . . . . 0.0 114.181 175.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.53 87.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.198 0.999 . . . . 0.0 113.195 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -68.35 -48.39 73.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.028 1.331 . . . . 0.0 111.208 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -62.94 -36.82 84.68 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.482 -1.386 . . . . 0.0 112.791 177.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.1 m -67.26 -45.88 75.38 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.646 1.578 . . . . 0.0 113.188 175.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 20.8 mt -66.28 -34.74 78.68 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.399 -1.438 . . . . 0.0 114.031 175.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.51 -31.64 65.51 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.32 -1.488 . . . . 0.0 113.684 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -88.68 48.93 1.7 Allowed 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 122.185 0.993 . . . . 0.0 112.066 173.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 p -107.17 154.33 21.35 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.102 -1.624 . . . . 0.0 109.14 170.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -108.83 -132.5 6.61 Favored Glycine 0 N--CA 1.43 -1.718 0 CA-C-O 121.964 0.758 . . . . 0.0 113.823 -172.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.0 tm0? -70.82 -68.84 0.4 Allowed 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 121.308 -1.113 . . . . 0.0 113.54 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 9.2 p -98.33 131.98 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.873 1.32 . . . . 0.0 109.882 174.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.6 t -125.23 111.96 29.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 126.139 1.776 . . . . 0.0 110.209 -162.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . 0.442 ' CD2' ' HG2' ' A' ' 17' ' ' GLU . 30.4 m170 -93.14 101.15 13.44 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -178.243 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -92.73 146.19 23.84 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 120.113 -1.617 . . . . 0.0 112.602 168.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 60.5 tp -113.87 127.54 56.03 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 155.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -136.22 151.69 49.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 121.098 -1.001 . . . . 0.0 111.356 -171.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -117.34 131.63 56.75 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 123.404 1.573 . . . . 0.0 111.622 176.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? . . . . . 0 N--CA 1.43 -1.445 0 C-N-CA 127.133 2.173 . . . . 0.0 110.798 177.318 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.3 t0 . . . . . 0 N--CA 1.43 -1.443 0 CA-C-O 121.585 0.707 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 p -100.1 158.43 15.85 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.884 1.674 . . . . 0.0 112.541 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -144.67 146.71 32.37 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 171.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -89.57 113.19 24.58 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 165.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 t -98.77 99.66 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -90.38 94.36 9.7 Favored 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 174.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -105.14 126.48 52.12 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-O 122.464 1.126 . . . . 0.0 110.045 -174.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.82 139.25 38.64 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.133 -1.604 . . . . 0.0 110.225 176.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -66.18 130.86 44.66 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.002 -1.061 . . . . 0.0 113.075 175.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.9 p -91.09 84.72 5.75 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.228 -1.545 . . . . 0.0 110.378 177.161 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.1 t70 59.27 53.43 5.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.457 1.903 . . . . 0.0 113.487 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.96 -11.31 72.47 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.746 -1.221 . . . . 0.0 115.295 -176.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.5 t -94.53 112.92 24.69 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.419 -1.636 . . . . 0.0 113.519 -173.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 7.5 tp -125.84 63.03 1.22 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.662 1.585 . . . . 0.0 109.985 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -85.64 62.21 4.46 Favored Glycine 0 N--CA 1.43 -1.717 0 O-C-N 119.43 -2.043 . . . . 0.0 113.462 -164.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.93 127.34 55.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 124.74 1.216 . . . . 0.0 107.975 168.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.43 121.79 45.85 Favored 'General case' 0 CA--C 1.489 -1.371 0 C-N-CA 123.626 0.77 . . . . 0.0 109.442 177.438 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.0 m -104.46 170.42 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.724 1.209 . . . . 0.0 112.736 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -150.24 173.79 13.55 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.198 1.399 . . . . 0.0 108.51 173.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.83 -138.03 14.67 Favored Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 167.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.87 162.31 27.79 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.52 1.533 . . . . 0.0 113.023 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 N--CA 1.43 -1.445 0 C-N-CA 125.603 1.561 . . . . 0.0 114.988 177.453 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.742 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.9 mm -97.85 131.98 43.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.69 1.196 . . . . 0.0 108.577 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.84 159.4 33.99 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.777 -1.202 . . . . 0.0 110.305 -175.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.68 119.53 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.694 -1.253 . . . . 0.0 111.023 174.28 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 57.2 tttm -91.43 -50.85 5.57 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 124.11 0.964 . . . . 0.0 111.85 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.09 155.83 31.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.038 -1.039 . . . . 0.0 110.904 -177.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.09 120.63 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-O 122.611 1.196 . . . . 0.0 109.643 172.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 34.6 mm -76.06 128.22 83.52 Favored Pre-proline 0 N--CA 1.43 -1.447 0 CA-C-O 116.09 -1.909 . . . . 0.0 113.252 -170.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -55.0 133.85 60.42 Favored 'Trans proline' 0 N--CA 1.434 -2.002 0 C-N-CA 124.416 3.411 . . . . 0.0 115.65 178.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? 67.76 13.76 9.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.526 1.53 . . . . 0.0 114.478 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.31 173.13 47.9 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 119.592 -1.942 . . . . 0.0 112.517 172.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.87 9.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 169.32 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.81 -40.1 95.83 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 126.595 1.958 . . . . 0.0 115.273 -173.022 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -41.35 -60.08 1.37 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 129.423 3.089 . . . . 0.0 113.607 178.02 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.5 t -70.2 -33.84 72.21 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 111.693 -2.503 . . . . 0.0 115.847 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -62.43 -48.57 79.1 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.272 1.429 . . . . 0.0 113.129 -165.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.64 -19.92 45.9 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.506 -1.371 . . . . 0.0 115.421 162.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.2 mmt-85 -75.74 -4.34 39.89 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 118.429 1.115 . . . . 0.0 112.764 172.308 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.5 mt -117.91 126.97 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.525 0 C-N-CA 125.259 1.423 . . . . 0.0 107.981 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -132.25 163.83 27.73 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.617 -1.302 . . . . 0.0 109.797 170.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -67.91 123.29 20.17 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.215 -1.553 . . . . 0.0 112.773 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 100.01 0.83 56.09 Favored Glycine 0 N--CA 1.431 -1.7 0 O-C-N 121.678 -0.639 . . . . 0.0 114.099 -174.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -80.17 164.86 22.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-N 119.555 1.678 . . . . 0.0 110.455 173.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.18 136.68 51.29 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.602 1.192 . . . . 0.0 111.722 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -91.15 125.12 43.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 126.113 1.765 . . . . 0.0 109.76 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 49.1 mt -103.89 -56.89 2.12 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.42 -1.425 . . . . 0.0 110.589 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.74 118.62 6.66 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 121.165 -0.959 . . . . 0.0 111.163 -176.157 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.47 115.79 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -176.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.9 t30 60.84 42.41 13.23 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 124.796 1.238 . . . . 0.0 114.321 165.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.17 -18.35 57.01 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.53 1.062 . . . . 0.0 114.05 -177.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.66 117.93 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.851 -1.381 . . . . 0.0 109.331 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 54.9 m -72.79 105.89 4.53 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 121.138 -0.976 . . . . 0.0 110.959 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 33.8 mt -89.8 25.67 2.0 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.695 -1.253 . . . . 0.0 112.092 -175.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -77.83 122.55 25.59 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.088 -1.632 . . . . 0.0 109.563 173.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 76.11 15.08 81.66 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 120.657 -1.277 . . . . 0.0 115.672 -170.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.28 163.11 28.28 Favored 'General case' 0 N--CA 1.429 -1.492 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 178.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.6 p -93.5 171.13 9.1 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.128 1.371 . . . . 0.0 111.196 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 64.8 t-80 -62.47 -51.06 68.95 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.476 -1.39 . . . . 0.0 114.185 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 mtmt -57.12 -42.58 81.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 174.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -56.58 -45.91 81.09 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.355 1.862 . . . . 0.0 114.241 -173.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.69 -39.63 94.59 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.902 1.681 . . . . 0.0 114.732 172.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.2 t -68.7 -49.26 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.011 1.324 . . . . 0.0 110.415 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 82.3 mt-10 -66.41 -33.33 75.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.341 -1.474 . . . . 0.0 113.552 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.8 m -61.2 -41.6 97.11 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.744 1.618 . . . . 0.0 113.072 169.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 76.0 mt -71.7 -30.69 65.94 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.361 -1.462 . . . . 0.0 114.276 173.126 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -67.28 -46.51 73.41 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.073 -1.642 . . . . 0.0 112.587 173.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -93.74 64.75 3.53 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.644 -1.285 . . . . 0.0 110.653 177.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 p -101.46 164.42 11.77 Favored 'General case' 0 N--CA 1.429 -1.512 0 C-N-CA 128.043 2.537 . . . . 0.0 109.329 173.16 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -92.8 -139.75 9.38 Favored Glycine 0 N--CA 1.431 -1.678 0 O-C-N 121.043 -1.035 . . . . 0.0 110.689 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -71.14 -68.47 0.44 Allowed 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.189 -1.183 . . . . 0.0 114.039 170.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.4 t -105.51 128.77 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 CA-C-O 122.509 1.147 . . . . 0.0 108.619 -176.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.04 117.99 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 128.409 2.683 . . . . 0.0 108.996 -170.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -98.2 102.13 13.79 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.486 -1.383 . . . . 0.0 111.192 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.7 tp -99.93 132.88 45.01 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.207 -1.558 . . . . 0.0 111.388 175.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -87.44 121.55 30.02 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.163 -1.792 . . . . 0.0 106.163 163.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.0 tt -123.45 143.63 50.02 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 123.689 0.796 . . . . 0.0 109.804 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -111.22 136.33 50.45 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 109.22 174.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? . . . . . 0 N--CA 1.43 -1.433 0 O-C-N 121.196 -0.94 . . . . 0.0 111.851 175.366 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 35.5 t70 . . . . . 0 N--CA 1.43 -1.463 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.31 135.16 43.26 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.338 -0.851 . . . . 0.0 109.653 158.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.251 0.0 OUTLIER -146.77 146.51 30.3 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 122.458 1.123 . . . . 0.0 109.454 159.235 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.34 145.89 24.27 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.405 -1.434 . . . . 0.0 109.035 174.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 47.9 t -106.01 93.44 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 74.9 mt-10 -92.2 89.77 7.03 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.978 1.711 . . . . 0.0 108.426 175.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 65.6 tp -124.91 148.39 48.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 121.304 -0.873 . . . . 0.0 110.629 -171.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.66 48.48 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.219 1.408 . . . . 0.0 109.015 171.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -71.17 154.86 41.37 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 115.871 1.804 . . . . 0.0 115.871 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 77.5 p -121.08 131.55 54.34 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.849 -1.157 . . . . 0.0 109.482 171.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.1 t70 57.78 38.83 27.43 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 176.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.65 -16.14 16.06 Favored Glycine 0 N--CA 1.431 -1.656 0 O-C-N 119.477 -2.015 . . . . 0.0 114.985 -176.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.8 p -115.14 157.93 22.92 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.779 2.032 . . . . 0.0 112.551 -164.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -102.06 -60.64 1.5 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.677 -1.264 . . . . 0.0 108.957 173.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.86 56.64 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.555 -1.966 . . . . 0.0 110.838 169.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tt -147.24 145.29 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 CA-C-O 122.43 1.11 . . . . 0.0 110.784 -171.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.6 t -108.94 132.36 54.15 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 166.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.1 m -112.92 155.92 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 O-C-N 121.14 -0.975 . . . . 0.0 111.344 -175.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 t -129.0 168.02 16.63 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 124.084 0.954 . . . . 0.0 109.33 174.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.09 -151.68 18.31 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.418 -0.801 . . . . 0.0 113.928 167.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.48 139.63 10.65 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 123.975 0.798 . . . . 0.0 112.481 -176.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.43 -1.465 0 O-C-N 120.829 -1.395 . . . . 0.0 113.933 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.772 0 N-CA-C 107.133 -2.387 . . . . 0.0 107.133 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.4 mm -103.78 114.79 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.286 1.434 . . . . 0.0 107.573 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.1 m-85 -123.58 157.05 34.57 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.206 1.003 . . . . 0.0 110.52 -171.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -75.03 122.5 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 C-N-CA 124.542 1.137 . . . . 0.0 110.713 175.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -93.18 -51.83 4.84 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.846 -1.159 . . . . 0.0 111.574 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.86 158.9 41.48 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -113.56 125.27 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 CA-C-O 122.565 1.174 . . . . 0.0 109.057 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -76.58 124.19 87.8 Favored Pre-proline 0 N--CA 1.429 -1.487 0 CA-C-O 116.344 -1.788 . . . . 0.0 113.679 -167.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_exo -58.9 124.64 16.16 Favored 'Trans proline' 0 N--CA 1.433 -2.036 0 CA-C-N 124.566 2.667 . . . . 0.0 115.396 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 47.9 mtpt 74.88 30.74 0.93 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 127.101 2.16 . . . . 0.0 114.069 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.33 160.72 33.49 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.204 -0.935 . . . . 0.0 114.097 161.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.07 -54.03 14.48 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.982 2.113 . . . . 0.0 114.444 160.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.93 -46.48 87.56 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 127.586 2.354 . . . . 0.0 113.416 179.095 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -41.6 -64.57 0.55 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 116.415 2.005 . . . . 0.0 116.415 173.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 57.8 m -68.51 -18.46 64.38 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.557 1.943 . . . . 0.0 115.843 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.16 -56.84 16.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 CA-C-N 119.657 1.117 . . . . 0.0 112.52 -174.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 107.04 -25.81 21.06 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 115.151 0.82 . . . . 0.0 115.151 176.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -72.36 -29.17 63.54 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.951 1.875 . . . . 0.0 112.221 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.0 mt -90.34 120.71 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 120.591 -1.318 . . . . 0.0 111.024 174.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -124.32 168.67 12.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.937 1.351 . . . . 0.0 111.435 173.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -65.72 117.54 8.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.726 1.61 . . . . 0.0 113.43 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.13 11.21 57.75 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.744 -1.222 . . . . 0.0 114.563 -176.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -81.22 159.45 24.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.22 1.51 . . . . 0.0 111.909 173.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -112.97 124.49 52.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.109 1.363 . . . . 0.0 111.163 -166.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 39.0 t -92.08 121.31 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.381 0 O-C-N 120.288 -1.508 . . . . 0.0 110.716 179.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 78.3 mt -89.11 -45.52 9.54 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.102 -0.999 . . . . 0.0 110.749 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.63 143.47 24.62 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 121.378 -0.826 . . . . 0.0 110.709 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 44.9 t -111.14 114.45 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.7 t30 63.88 34.04 12.06 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 165.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.16 -17.35 59.45 Favored Glycine 0 N--CA 1.431 -1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 113.83 -175.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.6 t -99.03 121.34 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.41 . . . . 0.0 109.983 -175.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 20.3 t -75.32 138.69 41.97 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.255 -1.528 . . . . 0.0 112.03 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 76.8 mt -90.4 13.56 15.25 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.223 -0.923 . . . . 0.0 113.447 -176.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -61.15 111.99 1.93 Allowed 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 119.94 -1.725 . . . . 0.0 114.348 -177.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.95 0.29 83.53 Favored Glycine 0 N--CA 1.43 -1.704 0 C-N-CA 124.903 1.239 . . . . 0.0 115.463 -178.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.63 147.41 47.56 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 115.68 1.733 . . . . 0.0 115.68 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.9 p -92.79 178.68 5.7 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.797 1.239 . . . . 0.0 112.529 176.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -56.33 -56.61 18.93 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.977 1.711 . . . . 0.0 114.673 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 tppt? -57.39 -39.79 76.85 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.812 1.245 . . . . 0.0 113.317 -178.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.58 -50.4 72.03 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 126.634 1.974 . . . . 0.0 113.852 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.21 -41.45 99.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.862 1.665 . . . . 0.0 114.165 174.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.02 -49.03 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.215 1.406 . . . . 0.0 111.051 177.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -60.82 -39.17 88.0 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 124.691 1.196 . . . . 0.0 112.85 177.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.1 m -63.41 -49.79 72.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 126.998 2.119 . . . . 0.0 113.033 173.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 63.8 mt -66.66 -29.57 69.62 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.196 -1.565 . . . . 0.0 114.405 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -68.8 -49.25 60.12 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.598 -1.314 . . . . 0.0 112.274 169.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -85.02 64.65 8.82 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.414 -1.429 . . . . 0.0 111.641 177.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 p -106.18 160.08 15.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 128.792 2.837 . . . . 0.0 109.258 173.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.69 -163.61 39.08 Favored Glycine 0 N--CA 1.429 -1.77 0 O-C-N 121.046 -1.033 . . . . 0.0 111.584 176.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -66.69 -52.55 43.46 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.757 -1.437 . . . . 0.0 113.152 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.34 130.07 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 CA-C-O 122.695 1.236 . . . . 0.0 108.054 170.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.0 t -117.92 128.54 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 127.597 2.359 . . . . 0.0 108.029 -166.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.2 m80 -120.67 92.54 3.79 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -170.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.18 146.55 25.32 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 119.398 -2.064 . . . . 0.0 112.068 175.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 24.9 tp -104.6 116.56 32.28 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 162.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.4 tt -132.44 137.14 47.16 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.564 0.697 . . . . 0.0 111.927 -164.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.5 tt0 -108.87 126.65 53.29 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.866 -1.146 . . . . 0.0 109.267 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.5 tmtt? . . . . . 0 N--CA 1.43 -1.436 0 O-C-N 120.674 -1.266 . . . . 0.0 112.433 -174.027 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 N--CA 1.429 -1.479 0 N-CA-C 115.655 1.724 . . . . 0.0 115.655 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -119.35 148.2 43.47 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 121.121 1.782 . . . . 0.0 109.618 164.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 11.1 p90 -146.8 147.02 30.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 123.21 1.481 . . . . 0.0 109.23 171.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -104.1 120.5 41.22 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.317 2.247 . . . . 0.0 107.738 -178.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.3 t -114.04 103.69 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 119.975 -1.703 . . . . 0.0 109.83 -171.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -90.08 88.67 7.37 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.306 -1.496 . . . . 0.0 109.239 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 tp -100.92 130.39 46.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.761 -1.212 . . . . 0.0 112.702 -167.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.47 128.23 49.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.279 -1.513 . . . . 0.0 109.456 170.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -69.73 132.66 46.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.217 1.562 . . . . 0.0 115.217 -172.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 47.6 p -107.48 114.89 29.19 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.503 -1.373 . . . . 0.0 111.498 -176.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.4 t70 55.66 39.35 30.88 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.214 2.205 . . . . 0.0 113.12 172.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.73 4.5 90.29 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 119.514 -1.991 . . . . 0.0 115.583 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.6 t -121.48 134.59 55.07 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-N 118.549 1.175 . . . . 0.0 111.345 -176.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 86.2 mt -89.65 -42.52 11.32 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.826 -1.171 . . . . 0.0 109.99 173.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.28 9.27 22.2 Favored Glycine 0 N--CA 1.43 -1.731 0 O-C-N 120.833 -1.167 . . . . 0.0 114.503 175.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.8 pt -129.42 125.65 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 CA-C-N 118.466 1.133 . . . . 0.0 112.555 -166.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -110.15 139.83 44.88 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.974 -1.079 . . . . 0.0 109.233 166.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 m -111.05 170.71 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.81 1.244 . . . . 0.0 112.725 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -150.96 172.26 15.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.559 1.943 . . . . 0.0 108.2 174.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.1 -131.37 10.58 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 121.052 -1.03 . . . . 0.0 113.731 169.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 72.22 -175.36 42.75 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.936 1.255 . . . . 0.0 113.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.1 t . . . . . 0 N--CA 1.43 -1.447 0 C-N-CA 126.4 1.88 . . . . 0.0 113.325 177.937 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.745 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.79 114.74 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.507 1.123 . . . . 0.0 109.238 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -111.9 153.62 26.41 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.261 -0.899 . . . . 0.0 110.225 -173.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.5 t -76.57 116.85 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 124.924 1.289 . . . . 0.0 112.473 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.2 ttpp -92.26 -40.88 10.71 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.272 1.029 . . . . 0.0 112.36 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.68 153.75 31.81 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.165 -1.584 . . . . 0.0 112.687 -177.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.265 1.0 OUTLIER -109.33 115.89 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-O 123.123 1.44 . . . . 0.0 109.988 171.776 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.1 mm -77.36 125.23 86.59 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 127.111 2.164 . . . . 0.0 113.79 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -55.69 124.34 16.03 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 C-N-CA 123.625 2.883 . . . . 0.0 116.115 -177.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.3 4.5 mptp? 74.38 24.59 1.81 Allowed 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.692 1.997 . . . . 0.0 113.22 176.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.01 159.11 35.54 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.439 -1.413 . . . . 0.0 111.785 165.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.6 -55.44 11.17 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.62 1.711 . . . . 0.0 115.62 175.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.53 -46.44 86.01 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 128.065 2.546 . . . . 0.0 112.561 179.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -48.9 -60.63 2.6 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.317 1.447 . . . . 0.0 113.944 174.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.2 m -69.39 -20.05 63.82 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -69.43 -64.03 0.95 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.511 -1.368 . . . . 0.0 110.996 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.72 11.09 41.74 Favored Glycine 0 N--CA 1.429 -1.771 0 O-C-N 119.862 -1.774 . . . . 0.0 114.849 164.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 71.9 mtt85 -62.45 -51.68 66.56 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.88 1.272 . . . . 0.0 109.905 159.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 2.8 mt -79.17 128.13 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 126.104 1.762 . . . . 0.0 112.132 -176.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.93 169.65 16.0 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 123.561 1.648 . . . . 0.0 111.641 174.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 14.7 ttpp -66.23 132.06 47.57 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.675 -1.891 . . . . 0.0 112.115 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.03 5.37 68.01 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 120.971 -1.08 . . . . 0.0 114.156 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -79.59 166.36 21.97 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 118.889 1.344 . . . . 0.0 109.586 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -134.08 148.34 51.01 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.172 -1.58 . . . . 0.0 112.772 176.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.0 t -102.82 134.0 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 C-N-CA 124.769 1.228 . . . . 0.0 111.171 -166.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.9 mp -99.07 -50.65 4.09 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.5 1.12 . . . . 0.0 110.662 -177.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.84 136.54 18.07 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.314 -0.866 . . . . 0.0 112.677 -175.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.2 t -113.36 125.77 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 124.671 1.189 . . . . 0.0 108.424 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 65.86 30.91 9.73 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.645 1.178 . . . . 0.0 112.521 168.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 91.96 -22.74 29.95 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.897 -1.127 . . . . 0.0 113.899 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.53 121.75 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 125.633 1.573 . . . . 0.0 110.666 -167.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.9 p -71.23 131.62 43.77 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.746 -1.221 . . . . 0.0 112.433 178.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.9 mt -84.23 64.65 8.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.089 -1.632 . . . . 0.0 112.083 -175.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -89.34 116.3 27.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.466 -1.396 . . . . 0.0 112.723 -173.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.83 17.79 79.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.004 -1.06 . . . . 0.0 113.256 179.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.97 143.21 50.92 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -168.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 70.6 p -93.71 179.69 5.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.248 1.819 . . . . 0.0 110.597 173.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 49.3 t-80 -68.35 -42.7 78.86 Favored 'General case' 0 N--CA 1.428 -1.53 0 O-C-N 119.775 -1.828 . . . . 0.0 110.001 173.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.2 tppm? -53.64 -46.34 70.5 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 125.389 1.476 . . . . 0.0 113.781 172.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.65 -51.28 67.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.208 1.403 . . . . 0.0 113.674 176.686 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.926 1.691 . . . . 0.0 113.686 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.7 t -66.35 -49.09 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 O-C-N 120.835 -1.165 . . . . 0.0 110.676 178.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.2 mm-40 -64.04 -31.22 72.33 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.669 -1.269 . . . . 0.0 114.03 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.3 m -69.47 -44.3 71.47 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.486 1.514 . . . . 0.0 112.234 175.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 82.6 mt -69.51 -32.31 71.08 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 172.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.61 -46.34 79.69 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.245 -1.534 . . . . 0.0 112.426 176.625 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.7 t30 -86.06 45.68 1.25 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.83 1.252 . . . . 0.0 112.648 -178.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.0 p -101.6 171.71 7.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.303 1.841 . . . . 0.0 108.658 172.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -125.38 -119.35 2.35 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.594 -1.316 . . . . 0.0 110.737 172.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -70.84 -70.25 0.32 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 124.288 1.035 . . . . 0.0 113.7 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 40.1 t -100.66 129.45 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 CA-C-O 123.136 1.446 . . . . 0.0 111.223 -175.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 96.9 t -122.6 104.61 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 128.466 2.706 . . . . 0.0 108.944 -174.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.0 t-160 -88.56 107.37 18.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.624 -1.923 . . . . 0.0 110.802 176.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.7 mt -94.04 144.23 25.66 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.775 -1.203 . . . . 0.0 111.242 169.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 31.6 tp -119.65 124.91 47.44 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 164.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.0 pp -150.58 168.29 24.7 Favored 'General case' 0 N--CA 1.429 -1.501 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -176.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -113.52 129.4 56.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.137 1.775 . . . . 0.0 111.041 -175.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? . . . . . 0 N--CA 1.431 -1.401 0 C-N-CA 125.455 1.502 . . . . 0.0 112.691 179.233 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.7 t0 . . . . . 0 N--CA 1.431 -1.414 0 CA-C-O 121.152 0.501 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 2.1 p -93.07 156.43 16.88 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.748 1.619 . . . . 0.0 113.433 -177.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -147.48 134.23 20.02 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 173.361 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -90.98 137.26 32.5 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 162.46 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.7 t -124.6 93.47 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.9 -1.125 . . . . 0.0 109.011 -175.226 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.47 85.43 5.75 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.544 1.537 . . . . 0.0 110.906 173.286 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.292 1.7 pp -117.88 156.6 28.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 122.668 1.223 . . . . 0.0 112.554 -176.859 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.85 133.43 46.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.074 1.75 . . . . 0.0 112.074 -177.188 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -70.6 134.41 47.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.679 1.592 . . . . 0.0 115.228 -178.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.3 p -107.21 118.45 36.74 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.525 -1.359 . . . . 0.0 111.592 -178.086 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.3 t70 47.83 43.96 17.66 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.329 2.252 . . . . 0.0 115.678 175.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.41 -5.05 85.71 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.447 -1.408 . . . . 0.0 114.956 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 80.6 p -121.59 137.68 54.63 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.176 1.488 . . . . 0.0 114.072 -172.713 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 89.8 mt -90.61 -61.84 1.59 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.804 -1.185 . . . . 0.0 110.219 167.298 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.82 36.05 1.2 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.625 -1.922 . . . . 0.0 113.189 169.836 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -123.79 124.17 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.031 1.333 . . . . 0.0 109.986 -176.208 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.0 t -101.73 112.49 25.1 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.817 -1.177 . . . . 0.0 107.867 170.349 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.0 m -104.19 161.79 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.934 1.293 . . . . 0.0 111.664 -178.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -149.72 174.11 12.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.677 -1.264 . . . . 0.0 109.767 -175.172 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.42 -131.87 10.66 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 124.355 0.979 . . . . 0.0 113.519 168.334 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.83 176.89 51.04 Favored Glycine 0 N--CA 1.43 -1.758 0 N-CA-C 115.787 1.075 . . . . 0.0 115.787 174.659 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.43 -1.468 0 N-CA-C 117.356 2.354 . . . . 0.0 117.356 -170.127 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.762 0 CA-C-O 120.932 0.185 . . . . 0.0 113.354 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 35.4 mm -93.71 123.44 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.498 -1.001 . . . . 0.0 109.16 174.501 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -123.33 154.25 39.17 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.889 -1.132 . . . . 0.0 110.215 -175.315 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.0 t -76.72 129.87 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.765 -1.21 . . . . 0.0 111.562 168.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -100.32 -50.11 4.04 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.374 1.47 . . . . 0.0 111.449 176.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.24 161.05 43.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.686 -1.259 . . . . 0.0 111.401 -175.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.76 125.78 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.431 1.092 . . . . 0.0 110.01 179.766 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.3 mm -77.13 115.99 53.57 Favored Pre-proline 0 N--CA 1.43 -1.455 0 C-N-CA 125.748 1.619 . . . . 0.0 112.816 -177.389 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -64.91 136.37 48.47 Favored 'Trans proline' 0 C--N 1.3 -1.988 0 CA-C-N 124.074 2.491 . . . . 0.0 113.044 -175.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.251 45.4 mtmt 83.94 7.0 0.63 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.852 2.861 . . . . 0.0 114.42 -175.318 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 160.22 35.93 Favored Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.97 -1.706 . . . . 0.0 114.983 176.142 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.34 -56.65 8.84 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.009 2.123 . . . . 0.0 115.994 169.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -45.98 83.66 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 128.231 2.612 . . . . 0.0 111.697 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -47.62 -64.61 0.74 Allowed 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.968 1.84 . . . . 0.0 115.968 169.492 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.0 m -70.13 -21.45 63.09 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 115.448 1.647 . . . . 0.0 115.448 -173.01 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.0 -65.8 0.56 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.295 1.438 . . . . 0.0 112.361 173.189 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.58 0.04 42.96 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 114.847 170.557 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -66.32 -51.73 54.32 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 118.766 1.283 . . . . 0.0 110.32 162.294 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.7 mt -78.26 134.96 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 124.902 1.281 . . . . 0.0 111.053 179.322 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.6 t-80 -147.59 156.78 43.15 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 122.063 0.935 . . . . 0.0 109.46 -178.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -65.61 126.02 27.05 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 119.501 -2.0 . . . . 0.0 114.37 -174.23 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.03 -4.86 35.98 Favored Glycine 0 N--CA 1.43 -1.758 0 CA-C-O 118.244 -1.309 . . . . 0.0 115.665 -173.229 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.363 3.1 p30 -81.58 163.41 22.63 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 121.207 2.503 . . . . 0.0 114.565 178.464 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.4 tpt85 -112.21 121.92 46.29 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.343 -1.473 . . . . 0.0 111.018 -167.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.6 t -87.94 136.24 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.105 -1.622 . . . . 0.0 110.277 -173.434 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 9.6 mp -102.3 -53.03 3.0 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 124.583 1.153 . . . . 0.0 110.494 175.776 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.93 147.43 27.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.825 -1.172 . . . . 0.0 112.209 -168.865 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.28 116.14 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 176.594 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 61.63 37.35 16.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.572 1.949 . . . . 0.0 115.073 167.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.18 59.62 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.522 1.058 . . . . 0.0 113.906 -175.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.6 t -95.44 112.62 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-N 118.546 1.173 . . . . 0.0 111.029 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.1 m -70.13 121.76 18.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.98 -1.075 . . . . 0.0 110.083 171.091 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.0 mt -72.85 -34.16 66.58 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -169.069 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -8.85 93.53 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 121.114 3.746 . . . . 0.0 121.114 -173.704 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.48 20.87 12.3 Favored Glycine 0 N--CA 1.43 -1.763 0 C-N-CA 125.134 1.35 . . . . 0.0 111.608 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.33 164.45 26.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 175.018 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -92.74 170.32 9.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.358 -1.464 . . . . 0.0 111.121 161.776 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -51.36 -56.7 11.71 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.293 1.837 . . . . 0.0 113.146 169.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -56.67 -36.19 69.3 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 174.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.7 mm-40 -55.59 -48.39 74.91 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 121.102 1.774 . . . . 0.0 113.79 175.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.95 -42.37 94.67 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.195 0.998 . . . . 0.0 113.26 177.889 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.4 t -65.43 -45.68 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 124.603 1.161 . . . . 0.0 111.266 178.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -62.38 -40.23 95.78 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.724 -1.235 . . . . 0.0 112.83 177.712 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.0 m -65.79 -42.27 90.95 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.435 2.294 . . . . 0.0 113.295 175.575 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.12 -36.85 84.26 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.303 1.441 . . . . 0.0 113.299 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -68.76 -30.14 68.68 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.245 -1.534 . . . . 0.0 113.133 172.032 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -84.81 45.96 1.21 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.02 1.728 . . . . 0.0 112.777 175.495 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 p -105.55 163.58 12.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 126.696 1.998 . . . . 0.0 110.214 177.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.92 -144.2 15.73 Favored Glycine 0 N--CA 1.43 -1.732 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 168.411 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -70.95 -60.71 2.09 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 121.191 -1.181 . . . . 0.0 113.666 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 29.5 t -98.42 119.85 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.948 1.356 . . . . 0.0 109.293 -175.345 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.1 t -112.78 114.87 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 C-N-CA 126.305 1.842 . . . . 0.0 109.306 -165.79 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -97.69 99.03 10.38 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.961 -1.087 . . . . 0.0 110.617 -177.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.0 mt -92.93 160.24 14.98 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 119.797 -1.814 . . . . 0.0 112.711 173.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.46 131.99 48.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.417 1.087 . . . . 0.0 108.09 165.814 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -147.86 172.98 13.3 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.395 -1.44 . . . . 0.0 112.415 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -127.49 148.63 50.31 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.162 1.785 . . . . 0.0 109.258 174.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 27.5 tptt . . . . . 0 N--CA 1.429 -1.492 0 O-C-N 120.34 -1.475 . . . . 0.0 111.312 175.716 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 t0 . . . . . 0 N--CA 1.43 -1.46 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.8 p -106.07 154.41 20.68 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 124.725 1.21 . . . . 0.0 112.184 178.414 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.46 143.9 29.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.694 -1.254 . . . . 0.0 108.567 -177.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -99.43 105.35 17.29 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.2 1.0 . . . . 0.0 109.636 -179.186 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.72 99.54 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.3 1.44 . . . . 0.0 109.457 -169.809 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -90.09 95.76 10.36 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.379 -1.451 . . . . 0.0 107.749 173.721 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -111.02 130.04 55.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.171 0.988 . . . . 0.0 110.467 -169.862 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.89 141.25 35.04 Favored 'General case' 0 CA--C 1.489 -1.372 0 O-C-N 120.471 -1.393 . . . . 0.0 109.727 172.937 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -64.42 147.22 53.13 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 178.699 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 31.3 p -116.15 122.87 46.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 167.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.2 t0 43.3 46.22 5.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 128.577 2.751 . . . . 0.0 114.422 -176.726 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.14 11.58 75.18 Favored Glycine 0 N--CA 1.431 -1.65 0 N-CA-C 117.891 1.917 . . . . 0.0 117.891 -178.357 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.0 m -117.32 153.67 32.58 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 119.473 1.637 . . . . 0.0 111.898 178.438 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 72.2 mt -96.11 -60.56 1.6 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.435 1.094 . . . . 0.0 108.9 165.429 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 119.14 37.58 0.8 Allowed Glycine 0 N--CA 1.43 -1.765 0 O-C-N 119.829 -1.794 . . . . 0.0 113.142 174.639 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 pt -129.5 139.17 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.173 1.389 . . . . 0.0 108.742 -175.493 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.5 m -111.79 117.7 33.56 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 157.668 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.5 m -99.05 162.59 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 124.351 1.061 . . . . 0.0 112.017 -174.631 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -150.11 -177.72 6.09 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.842 1.257 . . . . 0.0 110.001 178.168 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.53 -149.55 19.27 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.985 -1.072 . . . . 0.0 113.745 174.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.43 168.03 30.07 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 124.513 1.054 . . . . 0.0 112.924 -177.449 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.431 -1.419 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -172.218 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.769 0 CA-C-O 121.42 0.456 . . . . 0.0 113.429 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -96.93 121.88 47.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 175.591 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -126.71 154.26 44.36 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.854 -1.154 . . . . 0.0 110.522 -168.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.8 t -75.88 125.57 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.603 -1.31 . . . . 0.0 110.757 169.223 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.1 tttm -91.88 -44.92 8.65 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.738 -1.226 . . . . 0.0 110.671 178.662 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.44 148.11 29.93 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 123.129 0.572 . . . . 0.0 110.694 178.432 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -102.89 121.36 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.612 1.196 . . . . 0.0 110.121 173.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.4 mm -77.1 120.27 80.92 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 125.893 1.677 . . . . 0.0 114.219 -171.902 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -59.72 126.35 20.3 Favored 'Trans proline' 0 C--N 1.3 -2.013 0 CA-C-N 124.451 2.625 . . . . 0.0 115.325 -177.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.265 7.3 mtpm? 78.29 28.02 0.5 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.454 2.302 . . . . 0.0 112.598 -178.04 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.14 159.72 34.26 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.531 -1.356 . . . . 0.0 113.646 162.472 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.06 -60.83 2.45 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.054 2.142 . . . . 0.0 114.847 164.464 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.16 -49.19 78.63 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.191 2.996 . . . . 0.0 111.96 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -46.76 -61.58 1.78 Allowed 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 115.55 1.685 . . . . 0.0 115.55 171.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.8 m -68.27 -32.97 73.51 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 -173.594 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -51.01 -66.96 0.29 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.093 1.757 . . . . 0.0 113.323 176.368 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.25 -17.59 10.48 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 115.051 0.78 . . . . 0.0 115.051 174.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 56.9 mtt85 -71.27 -33.62 69.94 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 120.081 1.941 . . . . 0.0 112.491 170.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.8 mt -95.12 113.5 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.228 1.011 . . . . 0.0 109.628 176.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.675 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 79.9 t60 -143.65 -174.04 4.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.165 -1.584 . . . . 0.0 110.508 174.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.675 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.3 ttpt -60.15 127.65 32.89 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.32 1.848 . . . . 0.0 113.853 -174.753 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.95 -6.35 83.75 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 120.659 -1.275 . . . . 0.0 114.793 178.792 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -81.65 149.27 28.62 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.638 1.719 . . . . 0.0 112.893 -173.685 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -92.29 141.01 29.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.907 -1.745 . . . . 0.0 112.049 -170.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.38 119.11 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.63 1.172 . . . . 0.0 108.322 176.491 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.54 -52.46 2.99 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.355 -1.466 . . . . 0.0 111.072 -166.078 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.47 117.18 5.82 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 109.006 175.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.6 t -90.91 115.18 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.718 -173.134 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.0 t30 64.13 32.39 12.69 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.139 1.376 . . . . 0.0 111.853 174.909 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.42 -23.94 33.67 Favored Glycine 0 N--CA 1.429 -1.804 0 C-N-CA 124.764 1.173 . . . . 0.0 114.663 -173.495 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.5 t -87.03 111.9 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.689 -1.477 . . . . 0.0 111.698 -167.817 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.4 m -61.63 120.55 10.81 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.729 -1.232 . . . . 0.0 114.118 -179.013 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 38.9 mt -87.57 42.9 1.07 Allowed 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 112.371 -178.203 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -85.29 110.49 19.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 119.193 -2.192 . . . . 0.0 112.169 -174.335 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.3 -0.6 71.89 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 124.782 1.182 . . . . 0.0 114.228 179.412 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.03 155.09 41.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.3 1.963 . . . . 0.0 116.3 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.3 p -81.04 175.36 10.75 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.147 1.379 . . . . 0.0 112.428 174.253 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -67.28 -39.89 86.08 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.401 -1.437 . . . . 0.0 111.712 174.105 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -57.3 -48.53 78.69 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 113.607 174.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -56.46 -46.35 80.42 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.225 1.41 . . . . 0.0 114.503 179.044 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.08 -39.4 94.61 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.862 1.665 . . . . 0.0 114.364 175.577 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.5 t -76.19 -45.24 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.052 1.341 . . . . 0.0 111.388 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -58.99 -33.03 70.22 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 127.691 2.396 . . . . 0.0 112.19 175.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.6 m -72.53 -49.32 33.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.334 1.854 . . . . 0.0 113.752 170.662 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.8 mt -58.43 -45.36 88.62 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 120.641 1.564 . . . . 0.0 115.149 176.938 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 37.5 ptt85 -66.57 -28.23 68.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.831 -1.168 . . . . 0.0 113.798 -177.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -93.18 32.94 1.24 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.8 1.24 . . . . 0.0 113.616 -179.369 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 22.4 p -92.02 148.48 22.15 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.981 1.712 . . . . 0.0 111.384 174.142 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.25 -143.56 9.03 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.819 -1.176 . . . . 0.0 112.59 174.516 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -68.61 -59.79 2.88 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 114.871 1.434 . . . . 0.0 114.871 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.9 p -98.39 134.77 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.384 0 CA-C-O 122.919 1.342 . . . . 0.0 110.648 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.1 t -124.08 115.95 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 C-N-CA 127.525 2.33 . . . . 0.0 107.993 -171.414 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -97.19 89.09 4.65 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.366 -1.459 . . . . 0.0 112.229 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.6 tp -93.46 130.09 39.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.376 -2.077 . . . . 0.0 110.935 -178.134 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.3 tp -87.75 126.09 34.79 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 161.474 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 6.5 tt -122.32 148.54 44.92 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.543 1.137 . . . . 0.0 109.084 -170.106 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -125.3 142.79 51.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 171.608 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.6 tptm . . . . . 0 N--CA 1.43 -1.463 0 O-C-N 120.517 -1.365 . . . . 0.0 111.916 -177.29 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t0 . . . . . 0 N--CA 1.43 -1.442 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -98.52 155.85 17.07 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.575 -1.328 . . . . 0.0 111.638 176.599 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 133.6 21.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 122.231 1.015 . . . . 0.0 108.839 177.329 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -87.49 133.55 33.74 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.326 1.45 . . . . 0.0 109.347 169.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.4 t -126.3 107.15 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.853 1.261 . . . . 0.0 108.4 -169.438 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -91.38 102.05 14.73 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 120.383 -1.448 . . . . 0.0 108.393 166.376 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.2 tp -113.32 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.945 0.878 . . . . 0.0 110.509 -171.608 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 139.85 36.99 Favored 'General case' 0 N--CA 1.428 -1.527 0 O-C-N 120.223 -1.548 . . . . 0.0 107.549 170.203 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -65.23 152.75 42.9 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 115.131 1.53 . . . . 0.0 115.131 -178.487 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 30.5 p -102.48 75.57 1.47 Allowed 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.19 -1.569 . . . . 0.0 108.542 175.313 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.3 t0 61.26 61.53 1.53 Allowed 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.126 1.77 . . . . 0.0 112.321 -177.055 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.41 -30.0 5.45 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.249 -1.532 . . . . 0.0 115.191 -175.291 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.7 m -92.27 136.14 33.43 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.256 -1.732 . . . . 0.0 112.802 -167.112 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 51.9 mt -102.0 -49.17 4.02 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.627 1.571 . . . . 0.0 110.539 177.413 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 -15.87 39.3 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 120.228 -1.545 . . . . 0.0 113.967 -179.087 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.8 pt -96.39 121.83 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 CA-C-N 119.355 1.578 . . . . 0.0 112.959 -176.579 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.3 m -114.06 137.77 51.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 166.228 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.5 m -124.85 165.3 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.307 1.043 . . . . 0.0 112.946 -165.619 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.7 t -144.91 177.89 8.42 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.572 1.549 . . . . 0.0 110.567 -179.346 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.16 -136.68 12.82 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 115.945 1.138 . . . . 0.0 115.945 166.894 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.48 176.21 35.58 Favored Glycine 0 N--CA 1.43 -1.715 0 C-N-CA 126.351 1.929 . . . . 0.0 113.85 -179.025 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.43 -1.43 0 O-C-N 120.437 -1.625 . . . . 0.0 113.481 179.813 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.746 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 mm -93.74 122.06 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 124.823 1.249 . . . . 0.0 108.367 -175.498 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -121.36 152.58 38.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.79 -1.194 . . . . 0.0 109.6 -175.096 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.9 129.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 O-C-N 120.455 -1.403 . . . . 0.0 111.739 174.211 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -96.21 -46.32 6.49 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 126.031 1.733 . . . . 0.0 111.761 -176.507 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.3 152.8 32.58 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.89 -1.131 . . . . 0.0 109.673 -176.846 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.27 1.0 OUTLIER -112.61 116.02 51.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 CA-C-O 122.72 1.247 . . . . 0.0 109.457 170.885 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.5 mm -76.43 127.59 84.26 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 116.218 -1.849 . . . . 0.0 114.161 -173.789 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -58.08 132.54 49.97 Favored 'Trans proline' 0 N--CA 1.433 -2.052 0 CA-C-N 124.474 2.634 . . . . 0.0 116.725 -179.035 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.278 53.8 mttp 72.15 18.97 4.66 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.35 2.26 . . . . 0.0 114.551 -174.087 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.84 157.17 45.07 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 119.394 -2.067 . . . . 0.0 112.227 170.863 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.36 -59.91 3.3 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.573 -1.545 . . . . 0.0 114.679 169.143 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.94 93.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.915 2.486 . . . . 0.0 112.263 -179.717 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -45.0 -61.75 1.5 Allowed 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.111 1.764 . . . . 0.0 114.15 173.001 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.5 t -67.75 -43.18 80.51 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -175.419 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.58 -58.08 6.65 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 127.202 2.201 . . . . 0.0 114.081 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.58 31.6 7.38 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.299 -1.5 . . . . 0.0 115.037 163.146 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 53.4 mtt180 -96.98 -29.98 13.35 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 125.291 1.436 . . . . 0.0 109.151 162.786 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.7 mt -108.54 130.01 62.0 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 125.361 1.464 . . . . 0.0 111.076 -179.486 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -141.58 170.55 15.5 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.894 -1.129 . . . . 0.0 109.579 172.842 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.8 pttm -66.59 140.96 57.98 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 118.604 -2.56 . . . . 0.0 113.74 178.119 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.5 -11.21 65.05 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.602 -0.686 . . . . 0.0 113.163 -171.535 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -79.71 154.37 28.62 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 119.162 1.481 . . . . 0.0 112.27 -177.316 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -97.73 123.75 41.79 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.241 1.416 . . . . 0.0 109.698 -174.895 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.8 t -88.11 130.63 37.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 O-C-N 120.053 -1.655 . . . . 0.0 110.17 -178.398 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -99.06 -52.29 3.59 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.079 -1.013 . . . . 0.0 111.001 -178.036 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.96 144.28 24.83 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.13 -0.981 . . . . 0.0 112.862 -172.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.3 t -113.51 111.72 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 66.44 35.78 5.46 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.433 1.893 . . . . 0.0 113.353 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.93 60.01 Favored Glycine 0 N--CA 1.431 -1.659 0 O-C-N 119.931 -1.73 . . . . 0.0 114.238 -175.03 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.35 104.42 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 125.308 1.443 . . . . 0.0 108.508 178.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.2 m -72.45 139.87 47.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.628 -1.295 . . . . 0.0 112.552 -175.29 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 98.9 mt -90.24 -2.4 58.03 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -169.297 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -67.81 105.2 1.88 Allowed 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.219 -1.551 . . . . 0.0 113.927 -176.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 115.1 -20.99 13.72 Favored Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 125.454 1.502 . . . . 0.0 112.969 -174.698 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.04 153.92 40.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 179.237 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 80.4 p -92.16 176.93 6.31 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.558 -1.339 . . . . 0.0 112.843 -179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.9 t-80 -56.21 -53.01 62.25 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.162 1.785 . . . . 0.0 112.359 172.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -55.45 -46.97 76.74 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.622 1.169 . . . . 0.0 113.548 177.55 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.87 -51.59 68.98 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.896 1.443 . . . . 0.0 114.896 177.772 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.22 -36.69 84.95 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.448 -1.408 . . . . 0.0 114.563 176.759 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 95.6 t -72.82 -40.62 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.383 -1.448 . . . . 0.0 111.618 178.186 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -57.63 -44.98 85.96 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.258 -1.526 . . . . 0.0 111.879 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 63.7 m -61.64 -46.71 88.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.718 2.007 . . . . 0.0 114.643 178.157 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . 0.258 0.1 OUTLIER -73.15 -30.85 63.88 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 121.723 2.056 . . . . 0.0 113.893 -178.673 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.36 -39.48 92.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.795 -1.19 . . . . 0.0 111.437 169.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -88.94 55.68 3.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 123.02 1.39 . . . . 0.0 111.233 177.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.4 p -106.32 156.95 17.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.615 1.566 . . . . 0.0 109.624 174.184 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.15 -162.63 32.96 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 121.374 -0.828 . . . . 0.0 111.987 176.294 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -70.79 -48.96 51.49 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.213 1.405 . . . . 0.0 111.551 175.335 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.4 134.03 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.512 1.149 . . . . 0.0 108.044 167.515 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 82.8 t -124.4 134.95 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 128.562 2.745 . . . . 0.0 107.778 -170.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 23.2 t-160 -122.73 95.23 4.54 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.856 -1.778 . . . . 0.0 110.497 -173.009 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.6 mt -99.58 157.3 16.55 Favored 'General case' 0 N--CA 1.429 -1.517 0 O-C-N 120.02 -1.675 . . . . 0.0 114.023 -177.122 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.4 tp -127.2 131.64 50.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 162.335 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.14 163.48 32.75 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.889 -1.132 . . . . 0.0 111.165 176.251 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -117.17 144.73 44.43 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.535 1.934 . . . . 0.0 108.181 176.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.4 tptt . . . . . 0 N--CA 1.431 -1.419 0 O-C-N 120.623 -1.298 . . . . 0.0 112.407 -177.201 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 46.4 t0 . . . . . 0 N--CA 1.429 -1.484 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 36.3 p -120.7 165.08 15.59 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.069 -1.644 . . . . 0.0 111.76 -178.725 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.51 144.36 28.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 121.889 0.852 . . . . 0.0 109.677 165.018 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.97 130.2 35.5 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 125.643 1.577 . . . . 0.0 109.835 168.929 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.2 t -118.49 113.12 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 124.819 1.248 . . . . 0.0 108.461 -177.283 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -94.94 108.46 20.52 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 165.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 21.7 tp -123.65 128.69 50.03 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.693 1.235 . . . . 0.0 110.394 -176.162 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.99 137.45 39.34 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.757 -1.839 . . . . 0.0 109.569 169.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -69.41 136.17 51.26 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.122 -0.986 . . . . 0.0 113.101 177.006 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.9 p -90.02 93.1 9.26 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.41 -1.431 . . . . 0.0 111.448 -171.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.7 t70 56.29 41.92 28.53 Favored 'General case' 0 N--CA 1.429 -1.523 0 C-N-CA 125.812 1.645 . . . . 0.0 113.26 178.023 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.03 -20.43 40.81 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.766 1.174 . . . . 0.0 115.372 -174.707 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -94.11 110.68 22.38 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.254 1.527 . . . . 0.0 114.163 -170.535 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.5 tt -125.53 64.79 1.17 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 169.856 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -82.16 74.99 2.4 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 126.754 2.121 . . . . 0.0 111.259 -164.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.2 pt -100.65 156.49 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 125.332 1.453 . . . . 0.0 111.149 169.774 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 46.7 t -129.05 127.6 41.89 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.138 -1.601 . . . . 0.0 107.318 158.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 m -120.49 168.2 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 124.676 1.19 . . . . 0.0 110.141 -178.525 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -149.97 -175.31 5.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.614 -1.304 . . . . 0.0 107.566 176.031 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.89 -168.7 12.62 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.888 -1.132 . . . . 0.0 114.631 168.608 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.1 161.76 18.65 Favored Glycine 0 N--CA 1.431 -1.652 0 CA-C-O 122.901 1.278 . . . . 0.0 115.039 173.076 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.43 -1.438 0 C-N-CA 127.405 2.282 . . . . 0.0 115.646 -178.151 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.701 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.9 mm -99.47 126.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 177.339 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -127.11 152.63 47.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 119.657 1.117 . . . . 0.0 111.3 -170.322 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.42 126.18 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 O-C-N 120.555 -1.34 . . . . 0.0 112.964 172.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 39.6 tttp -97.93 -39.5 8.94 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.191 1.396 . . . . 0.0 111.81 -175.483 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -161.29 154.69 21.55 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.226 -0.921 . . . . 0.0 110.291 173.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.23 120.72 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 124.252 1.021 . . . . 0.0 108.436 168.59 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.2 mm -76.62 127.1 85.1 Favored Pre-proline 0 N--CA 1.43 -1.437 0 CA-C-O 116.752 -1.594 . . . . 0.0 113.993 -169.666 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -55.26 119.89 7.28 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 123.737 2.958 . . . . 0.0 115.942 177.3 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.37 5.3 mmmp? 78.92 23.14 0.59 Allowed 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.562 2.745 . . . . 0.0 116.059 -175.155 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.04 164.46 40.66 Favored Glycine 0 N--CA 1.431 -1.673 0 O-C-N 120.544 -1.347 . . . . 0.0 112.14 163.303 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -58.71 4.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.857 1.428 . . . . 0.0 114.857 168.323 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.39 -26.85 68.64 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.376 1.871 . . . . 0.0 114.576 -177.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.66 -54.26 45.07 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.688 1.709 . . . . 0.0 113.057 177.156 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 t -65.88 -44.01 86.62 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 125.511 1.524 . . . . 0.0 112.985 -176.167 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -45.01 -55.79 5.23 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.232 2.613 . . . . 0.0 116.272 -172.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.49 6.93 35.26 Favored Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 116.965 1.546 . . . . 0.0 116.965 162.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -90.17 -49.42 6.57 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.804 -1.41 . . . . 0.0 109.354 167.75 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 87.3 mt -79.31 128.99 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.351 1.46 . . . . 0.0 112.242 -171.647 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -132.94 153.55 51.31 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.876 1.67 . . . . 0.0 111.047 -178.418 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -51.49 123.19 9.28 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.134 1.774 . . . . 0.0 113.763 170.436 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 93.04 0.11 68.61 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 120.868 -1.145 . . . . 0.0 115.906 -178.429 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 1.7 p30 -82.05 159.07 23.54 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 120.119 1.959 . . . . 0.0 113.936 176.006 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -100.32 130.03 46.38 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.592 -1.318 . . . . 0.0 112.788 -177.004 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -85.7 125.37 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.934 1.294 . . . . 0.0 110.014 176.112 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.36 -42.7 6.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.777 -1.202 . . . . 0.0 111.825 -174.464 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 148.9 29.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.716 -1.24 . . . . 0.0 111.647 179.795 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 t -118.73 109.4 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 171.093 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.3 t30 45.13 67.47 0.71 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.297 2.639 . . . . 0.0 116.11 173.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 88.48 -29.38 5.75 Favored Glycine 0 N--CA 1.43 -1.725 0 C-N-CA 124.098 0.856 . . . . 0.0 113.555 -179.476 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -94.5 111.27 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 121.084 -1.245 . . . . 0.0 109.109 -171.771 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 73.6 m -69.99 133.49 47.31 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 176.677 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.1 mt -86.5 50.06 1.92 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.847 -1.158 . . . . 0.0 111.064 -178.411 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -89.7 133.23 34.77 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.599 2.36 . . . . 0.0 109.715 178.133 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.67 3.83 22.82 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 117.232 1.653 . . . . 0.0 117.232 -179.543 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.84 148.7 45.94 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 115.645 1.72 . . . . 0.0 115.645 -170.763 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 69.2 p -90.01 174.51 7.62 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.838 -1.164 . . . . 0.0 110.481 165.063 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -52.92 -52.71 56.82 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.172 1.789 . . . . 0.0 113.715 174.758 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -55.64 -40.4 72.14 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 126.074 1.75 . . . . 0.0 114.598 -179.503 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -54.95 -57.23 12.5 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 126.883 2.073 . . . . 0.0 113.146 177.654 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.61 -37.8 83.03 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.57 1.148 . . . . 0.0 113.815 178.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.5 t -68.35 -48.18 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.653 -1.279 . . . . 0.0 110.722 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 53.2 mm-40 -66.52 -26.86 67.36 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.249 -1.532 . . . . 0.0 112.855 178.316 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 66.5 m -69.68 -46.19 66.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.814 1.646 . . . . 0.0 113.085 170.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 47.7 mt -72.23 -22.35 61.26 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 119.779 -1.826 . . . . 0.0 114.822 176.475 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -68.3 -50.72 51.62 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.137 -1.602 . . . . 0.0 111.057 166.217 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.52 60.01 5.43 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.273 1.429 . . . . 0.0 113.281 -174.071 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 44.0 p -92.23 -175.9 4.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.422 -1.424 . . . . 0.0 110.73 171.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.22 -150.95 23.51 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 157.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -71.25 -52.57 18.24 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.771 1.228 . . . . 0.0 113.358 174.596 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 17.3 t -104.74 120.48 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 122.338 1.066 . . . . 0.0 110.613 -176.915 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.8 t -109.29 139.6 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 127.623 2.369 . . . . 0.0 109.676 -169.668 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -115.49 112.97 23.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.248 -1.533 . . . . 0.0 109.325 174.178 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -107.03 158.55 16.96 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.279 1.432 . . . . 0.0 113.034 176.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 67.2 tp -126.29 130.8 51.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 164.119 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.78 159.23 41.98 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 121.084 -1.01 . . . . 0.0 112.713 174.528 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -101.58 137.16 40.27 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 126.137 1.775 . . . . 0.0 108.443 175.029 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.431 -1.41 0 O-C-N 120.607 -1.308 . . . . 0.0 111.071 -171.746 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.6 t0 . . . . . 0 N--CA 1.43 -1.436 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -92.5 146.23 23.84 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.261 -1.524 . . . . 0.0 109.934 176.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -146.41 137.36 24.27 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 123.048 1.404 . . . . 0.0 109.192 179.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.15 141.25 34.3 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.703 1.601 . . . . 0.0 109.128 -178.795 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.5 t -130.66 113.18 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -171.824 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -107.39 75.16 1.0 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.879 1.324 . . . . 0.0 107.845 173.411 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.7 tp -94.8 135.11 36.68 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.357 1.463 . . . . 0.0 111.864 -168.552 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.49 146.08 28.63 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.269 -1.519 . . . . 0.0 111.796 173.373 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -70.27 157.97 36.74 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 115.192 1.552 . . . . 0.0 115.192 176.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.4 t -134.57 125.77 27.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.77 -1.206 . . . . 0.0 108.578 168.758 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 1.2 t70 50.55 40.82 24.43 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.985 2.514 . . . . 0.0 114.25 -170.49 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.1 -9.98 50.8 Favored Glycine 0 N--CA 1.431 -1.688 0 O-C-N 120.224 -1.547 . . . . 0.0 116.302 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.01 144.19 34.01 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.693 -1.475 . . . . 0.0 113.146 -166.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.8 mt -99.78 -62.28 1.26 Allowed 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.287 -0.883 . . . . 0.0 110.458 173.8 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.71 47.52 0.73 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 119.574 -1.954 . . . . 0.0 112.923 168.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.6 tt -147.53 137.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.666 1.222 . . . . 0.0 112.016 -178.741 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.7 m -105.42 133.89 49.43 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.928 1.291 . . . . 0.0 108.855 168.162 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.8 m -107.7 170.68 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.39 1.09 . . . . 0.0 110.766 178.806 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -150.41 -172.49 4.19 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.458 -1.401 . . . . 0.0 108.508 174.775 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.98 -144.84 18.56 Favored Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 124.893 1.235 . . . . 0.0 111.309 179.316 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.36 146.44 13.7 Favored Glycine 0 N--CA 1.43 -1.757 0 C-N-CA 124.098 0.856 . . . . 0.0 112.367 177.434 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t . . . . . 0 N--CA 1.43 -1.441 0 O-C-N 120.929 -1.336 . . . . 0.0 114.126 -170.154 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.797 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.6 mm -101.9 129.0 53.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.832 1.253 . . . . 0.0 109.091 -179.243 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -125.55 156.96 38.24 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.632 -1.293 . . . . 0.0 109.952 -170.823 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -75.31 121.07 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.398 -1.439 . . . . 0.0 111.929 173.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -88.33 -59.42 2.24 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.092 -1.63 . . . . 0.0 110.793 179.2 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.58 154.55 34.46 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.633 -0.667 . . . . 0.0 110.187 -172.193 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.53 125.88 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 CA-C-O 121.848 0.832 . . . . 0.0 109.541 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 16.5 mm -77.67 125.18 86.21 Favored Pre-proline 0 N--CA 1.429 -1.497 0 C-N-CA 126.259 1.823 . . . . 0.0 113.473 -173.594 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.58 130.32 39.35 Favored 'Trans proline' 0 N--CA 1.434 -1.996 0 CA-C-N 124.356 2.591 . . . . 0.0 116.568 -175.492 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.275 1.8 mptp? 73.59 13.95 4.35 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 127.592 2.357 . . . . 0.0 115.004 178.916 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.12 164.21 52.64 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 119.615 -1.928 . . . . 0.0 113.767 174.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.43 -56.76 10.05 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 126.325 1.85 . . . . 0.0 114.733 168.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.28 -46.68 82.6 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 128.673 2.789 . . . . 0.0 112.351 178.522 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -47.71 -61.97 1.68 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.996 1.851 . . . . 0.0 115.996 170.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 65.4 m -69.0 -26.71 65.15 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -175.654 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -55.61 -68.05 0.23 Allowed 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.942 1.697 . . . . 0.0 111.651 174.349 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.48 30.33 33.63 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.043 -1.036 . . . . 0.0 114.925 171.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -78.48 -47.76 16.75 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 120.727 -1.455 . . . . 0.0 108.48 147.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.3 111.85 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 C-N-CA 125.956 1.703 . . . . 0.0 112.636 -175.099 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -117.21 160.35 21.21 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 123.922 1.82 . . . . 0.0 113.151 -178.503 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -60.94 129.49 41.68 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.259 1.423 . . . . 0.0 113.949 -174.42 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 87.54 -4.85 85.77 Favored Glycine 0 N--CA 1.431 -1.675 0 CA-C-O 118.91 -0.939 . . . . 0.0 114.06 176.108 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -80.96 162.69 23.76 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 119.508 1.654 . . . . 0.0 112.3 -173.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 14.9 ttt180 -106.19 123.97 48.86 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.535 -1.353 . . . . 0.0 111.87 -159.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.1 123.28 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.976 -1.077 . . . . 0.0 110.099 -175.2 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -94.47 -44.05 8.06 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.876 -1.14 . . . . 0.0 110.625 -177.563 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.89 137.93 19.18 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.577 -0.702 . . . . 0.0 112.205 -173.043 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -111.42 126.71 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 174.422 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 71.02 14.81 6.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.267 1.827 . . . . 0.0 111.424 -179.623 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.21 89.62 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 125.956 1.741 . . . . 0.0 114.156 -170.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -91.77 124.62 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-N 118.868 1.334 . . . . 0.0 109.568 -179.83 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 25.4 m -72.92 135.02 45.01 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.767 -1.208 . . . . 0.0 112.817 -172.127 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.5 mt -87.34 36.34 0.74 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.684 -1.26 . . . . 0.0 114.364 -174.118 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -72.71 116.91 13.76 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.143 -2.223 . . . . 0.0 113.572 -170.933 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.23 13.09 79.78 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.13 -0.981 . . . . 0.0 114.26 -177.643 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.32 144.33 51.74 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -177.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 64.7 p -81.73 173.33 12.41 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.252 -1.53 . . . . 0.0 110.493 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -59.52 -48.14 82.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.874 -1.141 . . . . 0.0 111.648 172.182 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.12 -47.96 77.14 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.119 1.368 . . . . 0.0 114.23 174.145 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -58.86 -47.16 85.88 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.235 1.939 . . . . 0.0 116.235 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.35 -35.43 80.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.723 -1.235 . . . . 0.0 112.215 173.166 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.62 -45.02 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.012 -1.055 . . . . 0.0 111.077 178.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -58.65 -40.77 84.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.625 -1.297 . . . . 0.0 113.232 173.545 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.7 m -66.43 -38.81 88.27 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.702 1.601 . . . . 0.0 113.017 178.668 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 38.9 mt -72.61 -31.73 65.39 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.353 -1.467 . . . . 0.0 113.945 172.569 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.1 -42.16 76.49 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.485 -1.385 . . . . 0.0 112.876 173.692 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -79.04 58.17 2.38 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 124.086 1.898 . . . . 0.0 111.415 174.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 p -107.7 143.9 35.56 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.898 2.479 . . . . 0.0 108.88 170.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.77 -141.85 8.23 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 121.154 -0.966 . . . . 0.0 112.063 172.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.5 tt0 -62.44 -57.56 10.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.581 1.552 . . . . 0.0 113.118 174.304 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.21 142.54 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 CA-C-O 122.695 1.236 . . . . 0.0 110.487 178.231 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 64.8 t -124.23 112.35 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 128.268 2.627 . . . . 0.0 109.16 -170.834 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -97.47 108.1 20.75 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.783 -1.198 . . . . 0.0 111.637 176.744 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.1 mt -105.38 146.52 29.32 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.904 -1.122 . . . . 0.0 113.251 172.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.9 tp -116.33 126.59 53.74 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 162.864 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.1 pp -146.81 163.95 34.37 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.246 -0.909 . . . . 0.0 110.949 179.556 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -123.31 143.08 50.31 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.252 1.021 . . . . 0.0 112.151 -176.855 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.4 tptm . . . . . 0 N--CA 1.43 -1.43 0 C-N-CA 125.662 1.585 . . . . 0.0 109.177 174.199 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.2 t70 . . . . . 0 CA--C 1.489 -1.394 0 CA-C-O 121.489 0.661 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.0 p -91.01 159.67 16.02 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.328 1.051 . . . . 0.0 113.812 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -144.32 138.95 28.23 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -87.78 122.73 31.79 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.649 -1.282 . . . . 0.0 108.988 164.673 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.457 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 53.7 t -107.18 88.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -96.54 89.19 4.91 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.039 1.736 . . . . 0.0 108.034 177.949 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.0 tp -125.48 151.74 45.87 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.513 1.525 . . . . 0.0 109.758 -171.309 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.04 153.74 19.96 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.194 -1.566 . . . . 0.0 110.76 167.816 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -67.22 156.25 36.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 115.364 1.616 . . . . 0.0 115.364 -179.552 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 63.1 p -116.18 114.42 24.42 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.834 -1.166 . . . . 0.0 108.657 169.487 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.6 t0 40.56 56.91 2.69 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.843 2.457 . . . . 0.0 115.293 -176.701 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.75 -30.32 5.43 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 125.015 1.293 . . . . 0.0 115.488 -177.003 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.49 142.76 33.16 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.729 -1.454 . . . . 0.0 114.783 -162.749 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 95.9 mt -94.54 -60.55 1.69 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.223 1.409 . . . . 0.0 107.98 164.645 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.9 36.38 0.89 Allowed Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.873 -1.767 . . . . 0.0 112.504 167.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 pt -118.78 124.42 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 122.577 1.179 . . . . 0.0 111.179 -174.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.2 m -100.05 125.24 46.09 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 164.165 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -107.48 170.1 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 124.192 0.997 . . . . 0.0 111.438 -175.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -153.34 178.78 9.41 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.467 -1.396 . . . . 0.0 108.146 177.005 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.22 13.73 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.627 1.108 . . . . 0.0 114.139 175.537 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.68 152.73 10.93 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 126.239 1.876 . . . . 0.0 111.527 -177.222 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.43 -1.441 0 O-C-N 120.592 -1.534 . . . . 0.0 114.755 -175.325 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.713 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.65 131.25 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 174.751 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -128.14 154.81 45.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 120.964 -1.085 . . . . 0.0 109.466 -173.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.6 t -77.06 122.74 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 O-C-N 120.348 -1.47 . . . . 0.0 112.656 175.029 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -92.0 -47.47 7.27 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.803 1.241 . . . . 0.0 112.18 178.862 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.69 161.83 37.14 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.174 -0.954 . . . . 0.0 110.786 -179.753 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -118.03 124.57 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.742 1.217 . . . . 0.0 109.487 -178.384 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.5 mm -77.19 121.02 83.94 Favored Pre-proline 0 N--CA 1.43 -1.454 0 CA-C-O 116.45 -1.738 . . . . 0.0 114.454 -175.214 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_exo -58.2 122.86 12.41 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 123.275 2.65 . . . . 0.0 116.202 -178.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.323 72.0 mmtt 76.73 31.36 0.56 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 127.064 2.146 . . . . 0.0 113.812 -177.57 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.5 162.68 38.21 Favored Glycine 0 N--CA 1.431 -1.685 0 CA-C-O 122.262 0.923 . . . . 0.0 112.117 159.107 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.98 -59.44 4.15 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.253 1.821 . . . . 0.0 114.653 166.585 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.73 -49.37 76.69 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 129.395 3.078 . . . . 0.0 111.705 -176.676 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -41.74 -66.53 0.34 Allowed 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 172.179 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.3 m -70.04 -10.82 59.96 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -176.35 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -75.55 -57.19 4.03 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 119.374 -2.079 . . . . 0.0 111.313 177.37 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.18 0.79 54.37 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.909 -1.12 . . . . 0.0 115.411 170.236 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.3 mmt-85 -66.88 -33.69 76.15 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.68 -1.482 . . . . 0.0 110.941 162.97 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 81.6 mt -90.67 113.14 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 C-N-CA 126.066 1.746 . . . . 0.0 110.727 -178.696 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -113.11 156.46 23.13 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-O 123.625 1.679 . . . . 0.0 112.698 179.352 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -69.57 128.08 35.23 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 119.999 -1.688 . . . . 0.0 111.994 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 89.14 8.01 69.36 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.628 -1.295 . . . . 0.0 114.567 -177.137 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -79.83 173.42 12.61 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 119.672 1.736 . . . . 0.0 113.34 175.617 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.8 ttt-85 -101.55 140.74 35.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 123.104 1.431 . . . . 0.0 110.644 174.956 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -99.69 136.11 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.172 -1.58 . . . . 0.0 107.507 178.768 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -100.71 -57.4 2.11 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.931 -1.73 . . . . 0.0 113.063 -176.988 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.57 139.19 20.64 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.762 -1.211 . . . . 0.0 109.596 -174.678 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.29 113.28 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-O 121.884 0.85 . . . . 0.0 109.153 179.022 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 6.7 t30 67.35 21.7 9.7 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.31 1.844 . . . . 0.0 114.648 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.81 -13.64 41.77 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 120.897 -1.127 . . . . 0.0 112.777 -175.219 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.0 t -94.14 116.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 121.218 -1.166 . . . . 0.0 109.257 -176.796 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.6 p -74.51 133.99 42.28 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.628 -1.295 . . . . 0.0 111.615 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.0 mt -86.67 22.12 2.01 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.729 -1.232 . . . . 0.0 113.531 -172.813 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.0 mm-40 -68.08 119.69 13.09 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.87 -1.769 . . . . 0.0 111.982 174.085 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.33 8.65 83.89 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 121.214 -0.929 . . . . 0.0 115.369 -176.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.16 144.56 46.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.796 1.776 . . . . 0.0 115.796 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 73.0 p -87.1 178.3 6.95 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.566 -1.333 . . . . 0.0 109.717 168.451 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -62.98 -46.95 85.27 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.823 -1.798 . . . . 0.0 112.12 171.477 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 4.7 tmtm? -55.0 -39.53 69.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.612 1.965 . . . . 0.0 115.436 174.686 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -58.61 -51.12 71.27 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 173.573 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.07 -35.29 79.52 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 124.651 1.18 . . . . 0.0 112.985 -178.765 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.9 t -64.89 -48.57 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 124.653 1.181 . . . . 0.0 110.846 173.94 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 75.6 mt-10 -58.81 -45.42 89.98 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.923 -1.111 . . . . 0.0 113.286 176.882 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 94.5 m -62.59 -43.75 98.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.765 2.026 . . . . 0.0 112.741 178.386 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 22.8 mt -61.48 -45.55 93.79 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.702 -1.249 . . . . 0.0 114.326 172.148 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 55.7 mtp85 -73.2 -27.56 61.69 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.444 -1.41 . . . . 0.0 113.934 -177.467 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -84.32 50.56 1.89 Allowed 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.121 -1.612 . . . . 0.0 112.039 172.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.7 149.88 26.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.409 1.884 . . . . 0.0 109.966 174.911 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.41 -153.46 20.79 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.959 -1.088 . . . . 0.0 112.496 173.478 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -68.34 -53.48 23.86 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.384 -1.657 . . . . 0.0 113.62 178.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 54.1 t -93.07 136.51 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.502 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 173.837 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.7 t -124.39 126.56 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 C-N-CA 125.633 1.573 . . . . 0.0 109.239 -170.183 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -105.38 95.5 5.87 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.904 -1.748 . . . . 0.0 113.329 -178.128 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.457 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 34.8 mt -94.22 153.4 18.08 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 118.581 -2.574 . . . . 0.0 113.305 176.7 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 25.3 tp -116.43 138.79 51.09 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 158.86 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.89 153.67 49.52 Favored 'General case' 0 N--CA 1.429 -1.522 0 C-N-CA 124.941 1.297 . . . . 0.0 109.878 -164.959 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -133.13 136.06 45.56 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 119.938 1.245 . . . . 0.0 111.053 169.441 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? . . . . . 0 N--CA 1.43 -1.472 0 O-C-N 120.328 -1.483 . . . . 0.0 111.553 -178.196 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.6 t0 . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 p -109.98 150.21 28.83 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.743 1.217 . . . . 0.0 111.69 -175.304 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.79 131.14 18.59 Favored 'General case' 0 N--CA 1.431 -1.425 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.907 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -88.51 113.55 24.21 Favored 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.4 t -99.82 100.82 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 O-C-N 120.637 -1.289 . . . . 0.0 108.964 -171.217 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.67 95.96 8.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.88 1.672 . . . . 0.0 108.559 177.427 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 51.6 tp -124.74 145.09 49.89 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.751 1.22 . . . . 0.0 111.315 -166.885 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.08 137.68 40.93 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.427 -1.421 . . . . 0.0 111.052 173.165 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -70.64 149.42 47.04 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 117.414 2.375 . . . . 0.0 117.414 -177.715 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 72.0 p -127.14 132.62 50.51 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.355 -1.466 . . . . 0.0 109.695 176.403 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 13.1 t70 64.73 16.12 10.2 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.883 2.073 . . . . 0.0 114.352 -177.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.37 6.93 89.0 Favored Glycine 0 N--CA 1.43 -1.734 0 O-C-N 119.647 -1.908 . . . . 0.0 114.63 -174.259 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -123.24 173.63 7.8 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 121.27 -1.135 . . . . 0.0 110.774 176.121 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -109.71 -57.57 2.17 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.534 1.134 . . . . 0.0 108.173 171.45 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.4 50.24 0.11 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 119.841 -1.787 . . . . 0.0 111.861 163.297 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.7 tt -137.51 140.63 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.102 0.953 . . . . 0.0 111.191 -171.304 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.3 t -121.81 139.08 54.06 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.11 1.364 . . . . 0.0 108.284 170.39 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.6 m -116.95 170.31 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.929 -1.107 . . . . 0.0 113.74 -167.597 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -152.59 160.06 43.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.613 -1.304 . . . . 0.0 109.776 175.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.29 -148.25 19.58 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.909 -1.12 . . . . 0.0 115.02 172.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.45 -174.23 20.96 Favored Glycine 0 N--CA 1.43 -1.719 0 C-N-CA 125.443 1.497 . . . . 0.0 109.474 -169.604 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 N--CA 1.431 -1.422 0 O-C-N 120.539 -1.565 . . . . 0.0 113.753 -178.683 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.816 0 N-CA-C 112.236 -0.346 . . . . 0.0 112.236 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.1 mm -85.53 116.83 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 C-N-CA 124.97 1.308 . . . . 0.0 110.615 -176.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -114.78 156.36 25.0 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.536 -1.353 . . . . 0.0 109.68 -177.822 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -76.99 123.14 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.214 -1.554 . . . . 0.0 111.029 170.599 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 12.7 ttmm -91.15 -45.41 8.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.198 -1.564 . . . . 0.0 111.084 175.788 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.17 156.49 42.25 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 120.172 -1.58 . . . . 0.0 111.414 -179.734 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -119.32 128.13 75.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 124.485 1.114 . . . . 0.0 108.642 177.392 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.91 121.27 84.49 Favored Pre-proline 0 N--CA 1.429 -1.513 0 N-CA-C 117.004 2.224 . . . . 0.0 117.004 -171.086 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -56.01 122.95 12.67 Favored 'Trans proline' 0 N--CA 1.434 -2.017 0 C-N-CA 123.44 2.76 . . . . 0.0 116.549 -177.288 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.4 mtmm 78.43 13.0 1.52 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 128.367 2.667 . . . . 0.0 114.465 -176.168 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.95 157.77 47.45 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 120.007 -1.683 . . . . 0.0 111.682 172.852 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.21 -55.81 7.88 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.873 1.669 . . . . 0.0 114.735 170.166 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.9 -47.76 79.32 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 127.659 2.384 . . . . 0.0 113.327 178.82 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -47.48 -61.97 1.66 Allowed 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.219 1.563 . . . . 0.0 115.219 170.299 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -65.39 -31.64 72.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.993 1.317 . . . . 0.0 113.62 -171.853 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -54.89 -63.56 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.186 2.194 . . . . 0.0 113.097 174.388 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.53 47.49 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.972 -1.08 . . . . 0.0 115.344 171.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . 0.408 ' HE ' ' HA ' ' A' ' 58' ' ' ARG . 2.0 mmp_? -76.64 -22.05 54.64 Favored 'General case' 0 N--CA 1.429 -1.481 0 CA-C-N 119.817 1.809 . . . . 0.0 112.438 171.368 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.3 mt -103.26 123.58 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.537 1.135 . . . . 0.0 108.252 171.656 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.738 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 25.9 t-80 -146.67 -171.25 3.71 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.63 1.681 . . . . 0.0 111.717 176.692 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.738 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 44.4 tttp -72.2 123.87 23.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.015 1.726 . . . . 0.0 113.785 -166.105 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.12 76.59 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.721 -1.237 . . . . 0.0 113.935 -176.266 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . 0.406 ' CG ' ' HZ3' ' A' ' 98' ' ' LYS . 86.5 m-20 -80.62 155.53 26.83 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 119.313 1.556 . . . . 0.0 112.309 173.114 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.1 tpt85 -106.07 118.73 37.37 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.681 -1.262 . . . . 0.0 109.034 -174.01 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 59.2 t -91.46 122.63 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.451 -1.405 . . . . 0.0 108.522 -178.24 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -87.08 -45.0 11.12 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.157 0.983 . . . . 0.0 110.287 -177.099 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.45 139.73 21.29 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.885 0.85 . . . . 0.0 110.621 -173.829 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.8 t -118.2 122.41 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 177.845 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 64.11 25.66 13.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.582 -1.323 . . . . 0.0 114.152 172.754 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.03 -5.44 84.49 Favored Glycine 0 N--CA 1.429 -1.787 0 O-C-N 120.191 -1.568 . . . . 0.0 114.102 -175.719 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.5 t -95.41 126.08 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 C-N-CA 125.031 1.332 . . . . 0.0 109.547 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.1 t -76.8 127.57 33.0 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.52 -1.363 . . . . 0.0 110.634 -178.866 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.4 mt -82.82 2.62 33.22 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.28 -1.513 . . . . 0.0 114.227 -175.793 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -65.07 126.05 26.84 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.105 -2.247 . . . . 0.0 112.668 -178.857 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.65 -8.36 77.78 Favored Glycine 0 N--CA 1.429 -1.79 0 O-C-N 121.013 -1.054 . . . . 0.0 114.839 -175.776 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.09 146.0 46.08 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 177.216 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 24.1 p -92.37 -179.38 5.2 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.041 1.736 . . . . 0.0 111.441 171.227 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-160 -57.08 -52.93 63.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.817 1.647 . . . . 0.0 114.693 -177.881 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.3 tmtp? -56.73 -38.23 72.08 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -58.95 -53.27 60.27 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.886 1.674 . . . . 0.0 115.127 177.767 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.76 -37.26 86.69 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.255 1.422 . . . . 0.0 112.464 178.711 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.22 -51.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.577 1.151 . . . . 0.0 111.047 175.202 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -64.84 -33.53 76.22 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 178.959 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 35.3 m -75.37 -43.2 51.6 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.682 1.593 . . . . 0.0 113.252 179.568 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 27.5 mt -66.2 -42.09 89.29 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.623 -1.298 . . . . 0.0 113.062 173.03 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.9 ptt85 -72.71 -37.41 67.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.898 -1.127 . . . . 0.0 113.869 -176.854 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -85.71 59.78 5.84 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 123.412 1.577 . . . . 0.0 111.5 176.41 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 p -107.61 153.69 22.52 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.545 1.938 . . . . 0.0 108.916 173.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.35 -151.89 21.87 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.846 -1.159 . . . . 0.0 112.624 -174.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -50.73 38.73 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.873 -1.369 . . . . 0.0 113.332 -179.572 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.14 137.09 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.511 1.148 . . . . 0.0 109.177 169.129 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 40.3 t -125.3 127.1 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 127.023 2.129 . . . . 0.0 110.293 -166.917 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 18.3 m170 -105.11 114.52 28.77 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.669 -1.27 . . . . 0.0 112.432 172.623 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 9.5 mt -103.26 164.96 11.31 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.087 -1.633 . . . . 0.0 112.261 163.02 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 58.7 tp -127.28 124.63 39.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.65 1.18 . . . . 0.0 107.838 158.407 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.99 162.16 32.84 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.257 -0.902 . . . . 0.0 112.387 175.677 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -117.51 144.69 44.82 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.407 1.883 . . . . 0.0 109.64 175.108 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.406 ' HZ3' ' CG ' ' A' ' 63' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.431 -1.408 0 C-N-CA 127.458 2.303 . . . . 0.0 113.223 -174.174 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 36.3 t70 . . . . . 0 N--CA 1.431 -1.391 0 N-CA-C 116.007 1.855 . . . . 0.0 116.007 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.7 p -123.11 149.35 44.61 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 121.827 2.103 . . . . 0.0 111.585 168.372 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.3 p90 -147.84 148.87 31.35 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.037 1.399 . . . . 0.0 109.592 171.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -92.88 141.62 28.22 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.334 1.854 . . . . 0.0 109.346 176.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.423 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 55.3 t -125.74 90.31 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.63 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.2 84.63 4.47 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.401 -1.437 . . . . 0.0 108.22 177.073 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.9 tp -113.73 145.16 41.77 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.113 1.365 . . . . 0.0 111.424 -162.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.58 122.43 44.37 Favored 'General case' 0 N--CA 1.429 -1.501 0 O-C-N 120.257 -1.527 . . . . 0.0 108.981 171.291 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -71.68 165.99 22.84 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 179.264 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.4 p -134.23 139.95 46.13 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 124.724 1.21 . . . . 0.0 108.53 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.6 t70 66.77 8.55 6.05 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.944 1.698 . . . . 0.0 115.081 174.205 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.99 -8.47 63.2 Favored Glycine 0 N--CA 1.431 -1.69 0 O-C-N 120.097 -1.627 . . . . 0.0 113.762 -176.279 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 66.8 m -119.47 152.06 37.54 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 118.729 1.264 . . . . 0.0 111.814 -172.346 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.6 mt -86.95 -55.24 3.92 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.259 -1.525 . . . . 0.0 111.734 176.397 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 20.05 1.78 Allowed Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.414 -1.428 . . . . 0.0 112.107 177.25 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.6 pt -115.25 150.21 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 124.941 1.296 . . . . 0.0 110.18 -177.358 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 7.7 t -127.82 123.45 35.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 163.356 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.91 163.54 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.544 1.138 . . . . 0.0 111.683 -172.207 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -150.05 173.9 13.34 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.882 1.273 . . . . 0.0 109.409 -175.441 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.86 -136.11 13.2 Favored Glycine 0 N--CA 1.43 -1.761 0 O-C-N 120.872 -1.142 . . . . 0.0 113.761 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.54 167.73 43.47 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.246 0.927 . . . . 0.0 114.41 177.258 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.43 -1.442 0 N-CA-C 115.548 1.685 . . . . 0.0 115.548 -175.17 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.778 0 CA-C-O 121.924 0.736 . . . . 0.0 114.829 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.8 mm -100.41 125.4 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 C-N-CA 125.2 1.4 . . . . 0.0 107.38 175.18 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.1 m-85 -126.48 153.52 44.99 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.566 -1.334 . . . . 0.0 111.319 -171.562 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.5 t -75.86 122.83 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.861 -1.149 . . . . 0.0 111.987 172.195 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -91.1 -47.17 7.69 Favored 'General case' 0 N--CA 1.429 -1.498 0 C-N-CA 125.639 1.576 . . . . 0.0 110.857 177.419 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.15 165.19 37.12 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.651 -0.656 . . . . 0.0 110.402 -176.702 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -116.13 132.73 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.309 1.043 . . . . 0.0 108.342 175.021 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.5 mm -77.8 121.49 84.25 Favored Pre-proline 0 N--CA 1.429 -1.491 0 C-N-CA 126.137 1.775 . . . . 0.0 114.37 -174.854 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -59.32 123.76 14.1 Favored 'Trans proline' 0 N--CA 1.434 -2.007 0 CA-C-N 124.97 2.811 . . . . 0.0 116.795 -176.104 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.314 59.9 mmtt 68.98 30.9 4.36 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 127.773 2.429 . . . . 0.0 114.534 -176.144 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.02 163.33 39.69 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.31 -1.494 . . . . 0.0 112.8 167.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.36 -58.49 5.57 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.479 1.912 . . . . 0.0 114.593 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.83 -46.94 79.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.775 2.03 . . . . 0.0 112.433 -177.107 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -45.44 -62.32 1.32 Allowed 'General case' 0 N--CA 1.429 -1.506 0 C-N-CA 126.87 2.068 . . . . 0.0 115.842 170.657 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.4 m -69.55 -32.07 70.64 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -176.02 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -56.6 -56.4 21.84 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.16 1.784 . . . . 0.0 113.703 173.92 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.88 25.25 32.63 Favored Glycine 0 N--CA 1.431 -1.698 0 O-C-N 120.602 -1.311 . . . . 0.0 116.232 164.49 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.6 mmt-85 -78.89 -52.48 8.24 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.775 -1.426 . . . . 0.0 107.675 160.723 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 74.9 mt -77.82 122.08 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.1 1.36 . . . . 0.0 110.873 178.282 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.477 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 9.4 t-160 -131.27 -176.47 4.03 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.033 1.397 . . . . 0.0 112.019 174.95 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 81.4 tttt -69.07 128.32 36.26 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 119.816 -1.803 . . . . 0.0 112.083 -172.295 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.91 1.8 79.26 Favored Glycine 0 N--CA 1.429 -1.772 0 CA-C-O 118.507 -1.163 . . . . 0.0 114.849 -179.408 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.16 158.61 31.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 120.092 1.946 . . . . 0.0 112.057 178.426 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.23 119.59 39.92 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.656 -1.278 . . . . 0.0 110.305 -169.286 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.4 t -85.35 124.8 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 125.985 1.714 . . . . 0.0 110.764 -169.773 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 74.0 mt -106.44 -51.45 2.95 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.319 -1.488 . . . . 0.0 113.888 -173.626 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.16 138.32 20.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.069 -1.644 . . . . 0.0 112.606 -172.042 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 2.2 p -108.77 108.71 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.387 1.475 . . . . 0.0 112.204 -178.877 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.4 t30 58.46 36.94 25.66 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.17 1.788 . . . . 0.0 113.376 168.853 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.95 -9.39 68.09 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 125.829 1.681 . . . . 0.0 115.473 -172.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.4 t -103.0 116.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-N 120.808 2.304 . . . . 0.0 111.085 -174.895 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.3 p -69.07 126.05 28.58 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 120.355 -1.466 . . . . 0.0 113.571 179.852 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.5 mt -87.97 46.94 1.43 Allowed 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.633 -1.292 . . . . 0.0 112.852 -176.421 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -89.46 123.02 33.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.326 -2.109 . . . . 0.0 111.189 -178.448 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.58 1.97 89.36 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 121.058 -1.027 . . . . 0.0 114.798 175.041 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.86 162.9 28.77 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.737 1.754 . . . . 0.0 115.737 -178.288 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 p -83.63 173.72 11.14 Favored 'General case' 0 N--CA 1.431 -1.395 0 O-C-N 120.525 -1.359 . . . . 0.0 111.723 176.906 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-160 -56.43 -53.57 55.91 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.755 1.222 . . . . 0.0 112.798 168.298 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.35 -46.26 89.11 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.744 1.387 . . . . 0.0 114.744 179.259 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.99 -48.24 76.23 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.059 1.344 . . . . 0.0 114.505 -173.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.85 -42.02 96.98 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 124.833 1.253 . . . . 0.0 113.561 174.366 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.7 t -66.27 -48.84 79.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 125.126 1.371 . . . . 0.0 111.121 179.101 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -60.39 -46.32 90.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.736 1.214 . . . . 0.0 112.775 179.062 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.3 m -60.03 -43.99 94.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.372 1.469 . . . . 0.0 113.844 172.62 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 37.2 mt -69.72 -34.36 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.119 -1.613 . . . . 0.0 114.725 178.09 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . 0.271 42.9 ptt85 -71.95 -38.93 69.7 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.035 -1.665 . . . . 0.0 113.19 172.801 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.9 t30 -84.34 48.4 1.49 Allowed 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.787 -1.195 . . . . 0.0 113.722 175.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 p -99.58 150.46 22.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.032 2.133 . . . . 0.0 109.97 174.311 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.79 -163.46 17.29 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.579 1.085 . . . . 0.0 113.34 177.099 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -68.99 -47.63 65.06 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.522 -1.575 . . . . 0.0 113.799 -178.465 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.25 118.74 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 CA-C-O 122.091 0.948 . . . . 0.0 108.721 179.836 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 65.4 t -124.11 119.26 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 126.457 1.903 . . . . 0.0 110.395 -161.283 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -103.32 97.57 7.61 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.076 -1.64 . . . . 0.0 113.845 -178.433 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.423 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 15.8 mt -93.39 148.58 21.94 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.703 -1.873 . . . . 0.0 111.342 176.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -127.75 127.97 44.53 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 171.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . 0.273 0.0 OUTLIER -146.13 169.59 18.41 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.349 -1.469 . . . . 0.0 113.739 -177.07 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.54 131.6 56.88 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.362 1.865 . . . . 0.0 110.493 -173.414 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.485 0 O-C-N 120.304 -1.498 . . . . 0.0 113.467 179.182 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.431 -1.419 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.3 p -94.29 144.52 25.46 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.473 -1.392 . . . . 0.0 112.379 -177.203 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -147.29 140.45 25.23 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 122.74 1.257 . . . . 0.0 107.974 177.337 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -99.43 127.05 45.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.367 1.067 . . . . 0.0 109.765 178.017 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.9 t -116.44 93.32 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.717 1.207 . . . . 0.0 108.364 -170.591 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -89.63 103.82 16.43 Favored 'General case' 0 N--CA 1.429 -1.5 0 CA-C-O 123.221 1.486 . . . . 0.0 107.831 168.668 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.7 tp -121.59 144.52 48.69 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.24 1.416 . . . . 0.0 109.047 -165.55 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.41 120.26 40.02 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 124.672 1.189 . . . . 0.0 109.333 172.059 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -69.43 129.01 38.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.202 1.401 . . . . 0.0 112.412 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.9 t -92.7 104.74 16.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.641 1.21 . . . . 0.0 110.737 -172.31 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.4 t70 33.04 60.29 0.43 Allowed 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 129.339 3.056 . . . . 0.0 116.85 -173.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.67 -10.27 74.21 Favored Glycine 0 N--CA 1.43 -1.767 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 178.357 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -111.64 127.11 55.65 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 120.494 2.147 . . . . 0.0 111.519 -179.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.0 tp -92.32 -61.49 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.05 -1.031 . . . . 0.0 111.921 -178.844 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.92 -11.8 3.12 Favored Glycine 0 N--CA 1.429 -1.78 0 O-C-N 119.663 -1.898 . . . . 0.0 115.209 170.617 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.0 pt -105.9 141.03 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 119.321 1.561 . . . . 0.0 113.29 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 m -113.23 122.74 48.38 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 159.856 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.72 170.04 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.696 1.236 . . . . 0.0 112.622 -172.933 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 t -152.52 172.35 16.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.755 -1.215 . . . . 0.0 109.602 176.354 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.71 -142.26 15.64 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 113.67 171.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.57 150.7 27.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.56 1.076 . . . . 0.0 112.834 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.9 p . . . . . 0 N--CA 1.429 -1.485 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -174.272 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.801 0 CA-C-O 121.259 0.366 . . . . 0.0 113.31 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.1 mm -101.69 122.04 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 124.824 1.249 . . . . 0.0 108.412 179.859 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 75.3 m-85 -127.34 152.64 47.21 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.202 -0.936 . . . . 0.0 109.706 -173.552 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -75.82 125.84 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 O-C-N 120.483 -1.386 . . . . 0.0 111.341 171.661 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -98.93 -40.69 7.95 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.634 -1.292 . . . . 0.0 112.316 -179.399 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.61 155.33 40.1 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 121.453 -0.779 . . . . 0.0 111.222 179.699 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.95 124.87 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 CA-C-O 122.465 1.126 . . . . 0.0 111.28 -179.827 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp -76.33 122.97 87.72 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.848 2.059 . . . . 0.0 116.136 -169.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -58.25 112.9 1.32 Allowed 'Trans proline' 0 N--CA 1.434 -1.997 0 C-N-CA 123.767 2.978 . . . . 0.0 117.232 -175.588 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.305 48.5 mtmt 79.06 32.27 0.27 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.875 2.87 . . . . 0.0 113.8 -178.124 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.8 159.99 35.08 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 121.418 -0.801 . . . . 0.0 112.026 167.234 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.45 -60.39 2.88 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.519 1.528 . . . . 0.0 114.426 169.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.75 99.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 127.396 2.278 . . . . 0.0 112.677 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.8 tm-20 -51.49 -65.36 0.57 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 125.771 1.628 . . . . 0.0 114.626 174.678 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.0 t -69.15 -23.22 63.93 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -174.345 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -51.5 -63.94 0.97 Allowed 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.079 1.752 . . . . 0.0 113.019 172.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.24 -12.64 28.66 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 121.288 -0.883 . . . . 0.0 114.647 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 -64.22 -56.02 17.58 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 124.409 1.084 . . . . 0.0 111.002 168.614 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.8 mt -78.55 128.73 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 124.957 1.303 . . . . 0.0 110.839 179.074 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -145.7 171.11 15.21 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.132 -0.98 . . . . 0.0 110.113 177.862 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . 0.264 0.0 OUTLIER -64.45 139.67 58.79 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 119.398 -2.064 . . . . 0.0 113.829 179.445 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.78 -7.8 67.99 Favored Glycine 0 N--CA 1.43 -1.709 0 CA-C-O 118.509 -1.162 . . . . 0.0 114.278 -172.67 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -80.75 138.65 36.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 119.8 1.8 . . . . 0.0 113.363 -176.269 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -98.2 133.43 42.63 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.57 -1.331 . . . . 0.0 111.668 -174.408 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -82.89 148.73 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.494 -1.379 . . . . 0.0 112.942 -179.384 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -109.39 -51.37 2.88 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.752 1.221 . . . . 0.0 109.689 171.028 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 143.77 25.24 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.801 -1.187 . . . . 0.0 110.925 -175.35 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 58.8 t -117.6 129.09 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.39 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 77.18 -30.46 0.17 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.407 2.683 . . . . 0.0 113.983 173.236 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.09 -17.11 1.54 Allowed Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 126.316 1.913 . . . . 0.0 109.265 -169.937 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.72 116.53 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 125.379 1.472 . . . . 0.0 109.275 -176.196 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.3 m -71.12 127.42 32.53 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.807 -1.183 . . . . 0.0 111.104 176.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 22.9 mt -93.88 43.02 1.1 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.027 -1.046 . . . . 0.0 112.699 -171.057 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -75.79 119.93 20.46 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.19 -2.194 . . . . 0.0 112.21 -178.344 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.23 13.2 82.26 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.117 -1.615 . . . . 0.0 115.306 -178.33 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.94 151.42 44.69 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -82.09 172.83 12.76 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.207 1.003 . . . . 0.0 111.148 176.345 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -61.08 -50.0 75.05 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.909 1.284 . . . . 0.0 113.118 175.057 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.3 -42.01 80.93 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 171.695 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -55.36 -48.78 73.72 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 114.499 1.296 . . . . 0.0 114.499 -175.428 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.96 98.38 Favored 'General case' 0 N--CA 1.431 -1.4 0 C-N-CA 125.126 1.37 . . . . 0.0 113.855 177.2 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.1 -49.87 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 C-N-CA 125.112 1.365 . . . . 0.0 110.451 177.609 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -64.26 -32.26 73.78 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.692 -1.255 . . . . 0.0 113.96 179.632 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 53.0 m -67.65 -46.48 72.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.61 1.964 . . . . 0.0 112.236 173.501 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 70.1 mt -64.02 -38.94 92.89 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.98 -1.075 . . . . 0.0 113.727 173.531 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.12 -45.22 83.67 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.967 1.707 . . . . 0.0 112.444 175.39 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -85.39 44.58 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.265 1.426 . . . . 0.0 113.224 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.3 p -106.81 160.27 15.61 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.075 -1.641 . . . . 0.0 108.739 170.02 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.82 -131.05 4.79 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.474 1.035 . . . . 0.0 110.856 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -69.77 -69.01 0.37 Allowed 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 114.729 1.381 . . . . 0.0 114.729 178.029 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 52.8 t -92.25 124.65 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 CA-C-O 122.853 1.311 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.8 t -124.15 120.82 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 127.574 2.349 . . . . 0.0 109.272 -169.622 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -100.46 113.02 25.46 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.796 -1.815 . . . . 0.0 112.212 173.683 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -97.57 149.32 22.34 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.747 -1.845 . . . . 0.0 111.672 163.336 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.9 124.64 48.77 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 161.773 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -150.28 168.46 23.98 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.874 -1.141 . . . . 0.0 113.149 -178.423 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -119.34 144.96 46.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.478 1.511 . . . . 0.0 111.503 -177.905 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.6 tppt? . . . . . 0 N--CA 1.43 -1.459 0 C-N-CA 125.487 1.515 . . . . 0.0 112.755 -179.687 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 t0 . . . . . 0 N--CA 1.43 -1.431 0 CA-C-O 121.296 0.569 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.0 p -102.55 157.57 16.84 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.339 1.055 . . . . 0.0 110.972 -178.857 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -146.16 124.35 12.2 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.713 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -88.94 108.6 19.65 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 122.69 1.233 . . . . 0.0 109.287 162.77 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.2 t -99.06 108.9 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 128.287 2.635 . . . . 0.0 109.303 -168.766 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.4 101.14 13.82 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.845 -1.159 . . . . 0.0 109.737 173.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -108.64 158.06 17.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.872 1.32 . . . . 0.0 108.849 172.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.41 145.84 29.38 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 104.406 -2.442 . . . . 0.0 104.406 152.609 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -70.03 146.82 50.75 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.899 -1.126 . . . . 0.0 112.501 171.384 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.7 p -106.07 94.72 5.32 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.47 1.129 . . . . 0.0 108.876 178.683 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.0 t0 54.75 60.07 3.72 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.339 1.856 . . . . 0.0 114.023 -178.998 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.63 -34.66 3.64 Favored Glycine 0 N--CA 1.43 -1.739 0 O-C-N 120.701 -1.25 . . . . 0.0 115.693 -176.865 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -94.19 145.63 24.57 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.191 -1.182 . . . . 0.0 113.435 -167.513 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.04 -18.49 13.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.986 -1.071 . . . . 0.0 111.714 176.648 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.63 4.73 54.57 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.483 -2.011 . . . . 0.0 114.756 175.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.4 pt -120.06 133.02 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 124.862 1.265 . . . . 0.0 111.293 -171.87 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -113.51 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 126.194 1.798 . . . . 0.0 107.165 168.639 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.69 162.7 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.467 1.127 . . . . 0.0 113.777 -169.014 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.2 t -144.1 178.48 7.84 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.562 1.545 . . . . 0.0 110.055 176.424 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.46 -143.22 16.6 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.979 1.276 . . . . 0.0 113.85 171.487 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.46 158.97 19.31 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 124.488 1.042 . . . . 0.0 113.028 -177.638 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m . . . . . 0 N--CA 1.43 -1.44 0 N-CA-C 116.353 1.983 . . . . 0.0 116.353 -171.744 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.747 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.6 mm -94.67 129.22 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.034 -1.862 . . . . 0.0 107.721 174.387 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.37 157.19 40.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.314 -1.491 . . . . 0.0 109.165 -176.223 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.6 130.27 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 O-C-N 121.179 -0.95 . . . . 0.0 111.066 171.202 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -99.66 -59.82 1.65 Allowed 'General case' 0 N--CA 1.431 -1.392 0 O-C-N 120.313 -1.492 . . . . 0.0 111.398 177.564 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.17 153.69 47.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 -174.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.43 122.78 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.383 1.087 . . . . 0.0 108.917 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.4 117.92 67.81 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 116.244 -1.836 . . . . 0.0 112.596 -173.23 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -64.72 124.47 13.23 Favored 'Trans proline' 0 N--CA 1.433 -2.043 0 C-N-CA 123.577 2.851 . . . . 0.0 114.131 -171.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.262 91.7 mttt 70.15 37.47 1.66 Allowed 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.379 2.672 . . . . 0.0 112.473 -170.989 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.54 164.54 36.27 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.018 -1.051 . . . . 0.0 113.073 163.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.83 -63.02 1.21 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.523 1.529 . . . . 0.0 114.68 170.415 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.82 -48.5 76.57 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 127.69 2.396 . . . . 0.0 113.738 178.543 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -43.7 -55.07 4.62 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.975 1.842 . . . . 0.0 115.975 -177.695 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.8 t -67.55 -28.01 67.43 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 114.472 -1.24 . . . . 0.0 113.785 -174.272 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -73.45 -65.54 0.8 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.499 1.12 . . . . 0.0 111.559 -178.808 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.18 10.19 34.8 Favored Glycine 0 N--CA 1.43 -1.755 0 N-CA-C 116.527 1.371 . . . . 0.0 116.527 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 67.2 mtt85 -64.3 -36.2 83.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.945 1.372 . . . . 0.0 111.022 162.265 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.6 mt -94.78 129.45 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.336 1.454 . . . . 0.0 108.82 177.326 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.0 170.07 16.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.81 1.767 . . . . 0.0 110.685 176.737 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 51.2 mtpt -61.6 123.88 19.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.605 1.562 . . . . 0.0 112.001 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 0.3 62.74 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 120.303 -1.498 . . . . 0.0 115.26 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -74.0 157.11 36.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.175 1.487 . . . . 0.0 112.339 178.089 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.5 ttt180 -88.14 125.81 34.8 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.248 1.419 . . . . 0.0 111.101 178.128 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 50.0 t -91.6 128.72 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 124.223 1.009 . . . . 0.0 109.13 178.681 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -105.41 -57.4 2.04 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.684 -1.26 . . . . 0.0 111.305 -179.305 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.95 138.0 20.32 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.857 -1.152 . . . . 0.0 111.663 -170.825 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.8 t -107.45 107.43 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.417 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 27.1 t30 57.73 52.07 8.59 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.785 1.634 . . . . 0.0 114.311 167.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.43 -29.4 10.33 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.95 1.262 . . . . 0.0 114.095 -176.541 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.7 118.18 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-N 118.805 1.303 . . . . 0.0 111.235 -170.443 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 57.7 m -69.76 131.67 44.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.493 -1.38 . . . . 0.0 112.413 176.196 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 25.7 mt -93.36 -6.03 48.18 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 121.026 -1.046 . . . . 0.0 112.433 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -55.22 127.52 29.68 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.576 1.55 . . . . 0.0 114.831 -179.084 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.67 -10.82 70.61 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 115.888 1.115 . . . . 0.0 115.888 -178.005 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.5 178.39 4.07 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 116.989 2.218 . . . . 0.0 116.989 -177.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 47.1 p -92.19 171.22 9.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.282 -1.511 . . . . 0.0 110.835 165.678 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -54.2 -42.07 69.33 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.261 1.824 . . . . 0.0 112.883 168.594 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 43.5 tptt -57.54 -42.4 82.87 Favored 'General case' 0 N--CA 1.429 -1.506 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -58.93 -49.43 77.87 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.537 -1.352 . . . . 0.0 114.102 175.109 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.43 -44.29 84.53 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.441 1.497 . . . . 0.0 114.052 174.276 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.01 -45.54 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 124.987 1.315 . . . . 0.0 111.886 177.278 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 -64.43 -37.71 88.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 123.811 0.844 . . . . 0.0 112.586 176.602 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.8 m -63.4 -45.6 90.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.788 2.035 . . . . 0.0 113.018 174.204 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.7 mt -69.21 -21.64 63.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.031 -1.668 . . . . 0.0 114.269 174.193 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -72.15 -53.34 13.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.228 -1.545 . . . . 0.0 111.328 168.684 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -92.68 43.37 1.12 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.946 1.698 . . . . 0.0 112.842 -174.409 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . 0.287 6.2 t -106.39 160.01 15.71 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.48 -1.387 . . . . 0.0 110.905 173.164 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.75 -164.8 38.79 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.929 1.252 . . . . 0.0 113.317 -166.052 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -69.8 -49.84 48.86 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.732 -1.452 . . . . 0.0 112.66 174.095 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 59.0 t -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.907 0.86 . . . . 0.0 108.78 179.611 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -123.97 120.39 59.43 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.568 1.547 . . . . 0.0 109.725 -163.065 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 11.8 t-160 -104.82 95.48 5.9 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.633 -1.292 . . . . 0.0 112.435 -175.867 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 27.1 mt -89.99 134.58 34.15 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.762 -1.836 . . . . 0.0 113.397 -176.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 66.1 tp -104.89 123.0 46.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.613 -1.304 . . . . 0.0 109.114 167.748 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.37 163.9 30.69 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.47 -0.769 . . . . 0.0 111.54 175.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -127.38 140.07 52.43 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.642 1.577 . . . . 0.0 109.629 -178.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.476 0 O-C-N 120.762 -1.211 . . . . 0.0 114.033 -170.344 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.7 t0 . . . . . 0 N--CA 1.431 -1.421 0 CA-C-O 120.567 0.222 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -114.58 148.09 38.54 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.654 -1.278 . . . . 0.0 111.22 -176.479 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.69 149.39 32.36 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-O 121.982 0.896 . . . . 0.0 108.963 178.664 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -90.82 145.11 25.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.409 -0.807 . . . . 0.0 109.249 160.811 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.0 t -120.53 94.44 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.086 1.354 . . . . 0.0 107.613 -178.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 -90.47 95.66 10.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.929 1.347 . . . . 0.0 107.92 171.669 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 29.2 tp -123.99 138.36 54.47 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 125.315 1.446 . . . . 0.0 110.594 -164.136 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.62 138.59 39.33 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.699 -1.251 . . . . 0.0 108.658 173.857 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -69.48 145.55 52.63 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.22 1.563 . . . . 0.0 115.22 -178.283 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.6 p -100.09 102.21 13.48 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.962 -1.086 . . . . 0.0 109.157 176.192 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.5 t0 55.8 38.46 30.09 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.551 1.54 . . . . 0.0 114.166 179.314 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.48 -20.51 47.86 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.471 -1.393 . . . . 0.0 114.944 -176.699 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -93.56 137.95 32.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.7 -1.47 . . . . 0.0 112.248 -173.182 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.3 mt -87.58 -60.66 1.91 Allowed 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.249 -0.907 . . . . 0.0 110.306 172.21 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.6 8.93 2.69 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.365 -1.46 . . . . 0.0 113.158 175.29 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 pt -123.59 142.53 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-N 119.325 1.563 . . . . 0.0 112.052 -176.177 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.3 t -116.67 139.17 50.84 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 155.486 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.87 169.46 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 124.828 1.251 . . . . 0.0 112.293 -174.321 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -150.3 -179.22 7.02 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 126.053 1.741 . . . . 0.0 109.0 -177.999 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.65 -144.36 17.17 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.611 -1.306 . . . . 0.0 112.301 177.174 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 108.23 150.35 15.08 Favored Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 124.728 1.156 . . . . 0.0 112.937 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -174.805 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.737 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.99 136.61 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.899 1.28 . . . . 0.0 108.408 178.46 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -133.89 157.45 45.93 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 121.246 -0.908 . . . . 0.0 108.869 -175.313 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.1 t -76.48 129.73 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 119.872 -1.767 . . . . 0.0 112.338 175.504 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -93.91 -48.88 6.07 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.375 -1.453 . . . . 0.0 112.542 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.92 152.93 32.03 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 123.111 0.565 . . . . 0.0 110.572 -174.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -103.43 120.55 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 CA-C-O 122.841 1.305 . . . . 0.0 110.243 174.09 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.81 127.85 83.03 Favored Pre-proline 0 N--CA 1.431 -1.402 0 C-N-CA 126.331 1.852 . . . . 0.0 113.604 -172.002 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -55.73 126.3 21.97 Favored 'Trans proline' 0 N--CA 1.433 -2.042 0 C-N-CA 122.916 2.411 . . . . 0.0 117.034 -177.869 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? 77.22 13.58 2.01 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 128.864 2.866 . . . . 0.0 114.166 176.143 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.48 161.42 51.55 Favored Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.618 -1.301 . . . . 0.0 114.805 179.073 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.21 -57.67 6.34 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 126.843 2.057 . . . . 0.0 114.808 171.505 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.55 -48.53 77.09 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 128.399 2.68 . . . . 0.0 112.233 179.54 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -41.97 -63.07 0.79 Allowed 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 126.836 2.055 . . . . 0.0 114.386 173.497 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.7 m -70.22 -35.05 73.6 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.029 1.492 . . . . 0.0 115.029 -172.044 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -56.43 -68.66 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.238 1.815 . . . . 0.0 113.213 176.536 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.73 6.17 23.34 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 168.575 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -65.94 -49.52 67.64 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 119.09 1.445 . . . . 0.0 110.461 165.046 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.85 134.01 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.506 0 C-N-CA 125.58 1.552 . . . . 0.0 110.032 177.911 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 -145.61 142.36 29.03 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.409 1.084 . . . . 0.0 109.889 -174.862 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -43.74 116.02 0.9 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.231 1.812 . . . . 0.0 115.739 -178.883 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 103.99 -2.95 44.53 Favored Glycine 0 N--CA 1.428 -1.834 0 O-C-N 120.652 -1.28 . . . . 0.0 115.946 179.731 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.276 1.4 p30 -76.95 175.26 9.71 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 120.099 1.949 . . . . 0.0 115.549 -175.166 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -101.94 121.32 41.91 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.677 -1.264 . . . . 0.0 112.564 -175.395 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.12 114.75 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 123.868 0.867 . . . . 0.0 110.288 179.125 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 mp -93.75 -43.93 8.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.321 -1.487 . . . . 0.0 111.17 -176.585 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.6 142.34 24.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.864 -1.147 . . . . 0.0 111.625 -175.256 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.5 t -118.12 117.67 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 124.02 0.928 . . . . 0.0 109.01 175.763 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.3 37.31 14.07 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.985 2.114 . . . . 0.0 113.072 170.515 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.81 -33.23 6.67 Favored Glycine 0 N--CA 1.43 -1.75 0 C-N-CA 124.852 1.215 . . . . 0.0 113.444 -174.73 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -91.58 119.67 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 C-N-CA 124.974 1.309 . . . . 0.0 112.501 -165.292 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.9 m -65.81 130.3 42.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.881 -1.137 . . . . 0.0 112.88 177.796 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 44.2 mt -90.11 62.05 5.39 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.526 -1.359 . . . . 0.0 112.46 -174.892 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -90.09 136.09 33.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.642 -1.286 . . . . 0.0 111.71 174.365 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 71.32 11.47 71.5 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 121.024 -1.047 . . . . 0.0 115.454 175.366 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.0 143.03 49.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -176.236 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 48.1 p -82.35 173.64 11.86 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.995 -1.066 . . . . 0.0 111.118 167.443 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -62.26 -41.65 98.64 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.724 -1.235 . . . . 0.0 112.754 174.496 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -58.74 -47.01 86.08 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 126.069 1.748 . . . . 0.0 114.2 170.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -56.07 -47.82 77.24 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 126.524 1.93 . . . . 0.0 114.335 -176.447 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -56.83 -39.73 74.77 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.222 1.809 . . . . 0.0 115.025 173.192 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 79.1 t -69.01 -53.38 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 124.941 1.296 . . . . 0.0 110.862 177.947 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -59.95 -44.18 94.55 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 114.757 1.391 . . . . 0.0 114.757 -176.815 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.7 m -57.67 -40.9 80.44 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.013 2.525 . . . . 0.0 114.545 170.656 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 28.3 mt -68.77 -42.34 77.59 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 119.652 -1.905 . . . . 0.0 113.805 170.956 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 85.8 mmt-85 -60.7 -39.24 87.78 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.698 -1.251 . . . . 0.0 113.501 178.652 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -85.93 48.49 1.61 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.479 -1.388 . . . . 0.0 113.156 178.873 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.9 p -106.86 158.03 17.31 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.281 1.832 . . . . 0.0 109.657 173.293 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -98.75 -141.1 11.9 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 121.12 -0.988 . . . . 0.0 112.821 -176.383 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -69.09 -65.26 0.73 Allowed 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 121.058 -1.26 . . . . 0.0 113.251 175.727 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.2 p -98.66 133.66 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 123.14 1.448 . . . . 0.0 110.173 176.523 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.0 t -124.62 128.78 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 128.297 2.639 . . . . 0.0 108.745 -162.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -108.9 93.93 4.78 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.752 -1.218 . . . . 0.0 112.578 -176.537 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 mt -95.27 162.14 13.81 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 119.538 -1.976 . . . . 0.0 112.411 178.002 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.9 tt -130.27 133.04 46.2 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.825 -1.172 . . . . 0.0 110.641 165.917 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.04 162.56 35.18 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 113.609 0.966 . . . . 0.0 113.609 178.527 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -113.54 138.58 49.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 125.712 1.605 . . . . 0.0 107.647 172.249 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.2 tppp? . . . . . 0 N--CA 1.429 -1.495 0 CA-C-O 122.216 1.007 . . . . 0.0 111.214 -173.209 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t70 . . . . . 0 N--CA 1.43 -1.439 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.0 p -125.98 155.42 41.42 Favored 'General case' 0 N--CA 1.431 -1.384 0 O-C-N 120.126 -1.609 . . . . 0.0 113.011 -179.107 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -145.52 142.42 29.19 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 122.943 1.354 . . . . 0.0 109.182 170.324 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -95.45 126.59 40.85 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.413 1.485 . . . . 0.0 107.955 171.22 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.3 t -118.49 117.77 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.295 1.038 . . . . 0.0 108.488 -174.722 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -100.79 88.08 3.49 Favored 'General case' 0 N--CA 1.432 -1.369 0 O-C-N 120.62 -1.3 . . . . 0.0 108.703 168.976 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 63.2 tp -95.7 137.69 34.4 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.593 1.157 . . . . 0.0 110.214 -174.226 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.32 128.95 47.25 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.185 -1.572 . . . . 0.0 108.566 172.012 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -70.42 136.43 49.55 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 121.344 -0.848 . . . . 0.0 113.123 178.416 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.0 p -107.2 121.03 43.71 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 174.376 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.9 t70 55.17 49.0 18.27 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.982 1.713 . . . . 0.0 113.753 -176.019 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.21 -9.64 6.94 Favored Glycine 0 N--CA 1.429 -1.789 0 N-CA-C 117.739 1.856 . . . . 0.0 117.739 174.315 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -121.43 156.18 33.27 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 119.207 1.503 . . . . 0.0 111.131 -168.531 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 16.4 mt -93.91 -60.4 1.76 Allowed 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.54 1.136 . . . . 0.0 110.925 -177.268 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.03 38.78 0.48 Allowed Glycine 0 N--CA 1.431 -1.657 0 O-C-N 119.373 -2.079 . . . . 0.0 110.54 174.588 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.3 pt -128.93 141.12 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 CA-C-O 121.871 0.843 . . . . 0.0 112.146 -163.208 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 29.7 t -117.77 117.36 29.1 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 166.33 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.47 160.64 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 124.529 1.132 . . . . 0.0 111.158 179.398 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.0 t -150.61 155.63 39.77 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.121 -0.987 . . . . 0.0 111.621 -178.527 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 124.03 -130.13 7.48 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 121.129 -0.982 . . . . 0.0 113.219 168.8 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 124.01 -148.81 16.83 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.182 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.6 t . . . . . 0 N--CA 1.429 -1.496 0 CA-C-O 123.451 1.596 . . . . 0.0 107.332 171.418 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 113.887 0.315 . . . . 0.0 113.887 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.7 mm -95.99 119.76 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 C-N-CA 125.851 1.66 . . . . 0.0 107.526 171.476 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -123.06 154.4 38.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.145 -0.972 . . . . 0.0 110.303 -174.528 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.6 t -76.8 119.38 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 124.387 1.075 . . . . 0.0 110.555 169.919 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -88.5 -46.83 8.79 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 124.858 1.263 . . . . 0.0 110.38 -176.471 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.75 161.39 37.01 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 123.316 0.647 . . . . 0.0 110.37 177.599 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.53 127.08 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.469 1.107 . . . . 0.0 110.303 176.329 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.1 mp -77.43 122.28 85.75 Favored Pre-proline 0 N--CA 1.43 -1.47 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -169.971 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_exo -55.29 122.13 11.16 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 C-N-CA 123.551 2.834 . . . . 0.0 116.6 179.952 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 17.6 mmtt 80.89 18.82 0.49 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 129.253 3.021 . . . . 0.0 113.488 -177.682 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.76 156.8 33.46 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.127 -1.608 . . . . 0.0 111.942 172.877 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.61 -56.28 7.53 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 125.949 1.699 . . . . 0.0 114.468 171.293 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.31 -51.14 67.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 128.308 2.643 . . . . 0.0 112.832 178.059 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.9 tm-20 -44.92 -59.65 2.46 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 172.441 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.3 t -68.1 -30.36 69.51 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.832 1.253 . . . . 0.0 113.436 -174.078 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -61.36 -55.61 29.62 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.857 1.263 . . . . 0.0 113.869 -177.141 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.59 1.43 29.18 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.516 1.367 . . . . 0.0 116.516 162.108 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.2 mmp_? -74.67 -54.6 7.09 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.5 -1.588 . . . . 0.0 110.367 164.475 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mt -78.25 128.04 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.339 1.456 . . . . 0.0 112.648 -173.607 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.01 172.64 12.71 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-O 124.14 1.924 . . . . 0.0 112.629 177.298 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -56.14 124.04 16.51 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.031 1.732 . . . . 0.0 113.822 172.136 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.88 4.2 61.79 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 113.903 178.759 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -79.11 162.31 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 119.054 1.427 . . . . 0.0 111.794 174.406 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -120.57 123.46 42.92 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.233 -1.542 . . . . 0.0 111.02 -172.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.6 t -83.06 125.48 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 O-C-N 120.278 -1.514 . . . . 0.0 111.83 -171.872 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 80.5 mt -103.3 -44.57 5.13 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.743 -1.223 . . . . 0.0 112.324 -177.005 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.97 140.9 22.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.504 -1.373 . . . . 0.0 112.329 -177.874 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -112.75 115.49 49.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 174.72 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 57.86 41.97 23.92 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.641 1.976 . . . . 0.0 114.993 170.606 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.45 -25.62 26.42 Favored Glycine 0 N--CA 1.431 -1.655 0 O-C-N 120.964 -1.085 . . . . 0.0 113.563 -177.008 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 t -94.06 112.25 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.926 -1.338 . . . . 0.0 110.412 -172.947 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . 0.25 81.1 p -76.36 140.66 41.51 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.212 -1.555 . . . . 0.0 112.998 176.851 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.0 mt -85.44 41.68 0.91 Allowed 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.426 1.09 . . . . 0.0 112.29 -168.9 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -72.72 121.53 19.99 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.101 -1.624 . . . . 0.0 112.047 -178.413 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 70.37 11.58 68.17 Favored Glycine 0 N--CA 1.429 -1.821 0 C-N-CA 125.191 1.377 . . . . 0.0 115.764 179.374 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.94 143.57 47.62 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -178.138 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.1 p -91.82 178.81 5.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.644 1.578 . . . . 0.0 111.728 174.34 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 30.8 t-80 -57.3 -52.73 64.16 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 115.873 1.805 . . . . 0.0 115.873 -169.6 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.6 -40.66 79.57 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 178.124 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.4 mp0 -56.92 -51.33 69.54 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.792 2.037 . . . . 0.0 113.209 -172.229 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.49 -39.09 79.06 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.556 1.942 . . . . 0.0 113.823 175.453 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 87.7 t -67.55 -53.04 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.044 1.337 . . . . 0.0 110.727 177.467 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -61.69 -38.69 88.76 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 121.009 -1.057 . . . . 0.0 113.78 -178.609 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.5 m -66.53 -40.42 89.11 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 127.032 2.133 . . . . 0.0 112.682 177.213 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.49 -42.24 87.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.431 -1.418 . . . . 0.0 113.231 171.139 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -68.2 -42.76 79.39 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.523 -1.361 . . . . 0.0 114.605 179.846 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 38.9 t-20 -86.32 57.2 4.35 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 123.036 1.398 . . . . 0.0 111.712 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -98.12 163.59 12.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.017 2.527 . . . . 0.0 109.617 175.115 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.46 -160.11 33.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.422 1.011 . . . . 0.0 110.923 168.931 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 60.1 tt0 -68.74 -52.07 34.53 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.75 -1.441 . . . . 0.0 112.998 -174.234 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.81 119.9 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 C-N-CA 124.894 1.278 . . . . 0.0 109.63 177.008 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 84.5 t -112.18 110.26 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 128.066 2.547 . . . . 0.0 110.153 -167.216 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.1 t-160 -92.8 96.7 10.3 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.7 -1.25 . . . . 0.0 112.779 -178.205 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.3 mt -89.11 156.71 18.65 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.217 -2.177 . . . . 0.0 112.677 175.773 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 57.9 tp -127.01 129.41 48.02 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 157.611 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.0 pp -150.86 167.34 27.8 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.715 -1.24 . . . . 0.0 111.745 177.784 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -108.89 123.16 48.63 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.17 1.388 . . . . 0.0 110.345 -173.541 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.1 tptm . . . . . 0 N--CA 1.429 -1.484 0 C-N-CA 125.365 1.466 . . . . 0.0 111.37 -178.681 . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.3 t70 . . . . . 0 N--CA 1.429 -1.49 0 CA-C-O 121.306 0.574 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -96.96 149.24 22.13 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.689 -1.257 . . . . 0.0 111.256 177.102 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -147.8 143.52 27.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 122.923 1.344 . . . . 0.0 109.186 -179.087 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.6 mp0 -102.53 129.53 49.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.536 1.934 . . . . 0.0 108.12 179.12 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.7 t -125.0 97.69 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.825 -1.172 . . . . 0.0 109.753 -170.429 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -97.81 77.24 2.5 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 119.938 -1.726 . . . . 0.0 108.899 173.906 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.4 130.47 52.75 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 125.372 1.469 . . . . 0.0 109.992 -170.159 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.7 154.79 17.04 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 127.074 2.15 . . . . 0.0 112.336 176.656 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -69.12 152.03 45.66 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -175.484 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.2 p -98.77 100.48 11.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.855 -1.153 . . . . 0.0 108.689 171.114 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.3 t0 52.41 52.99 13.08 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.636 1.574 . . . . 0.0 113.798 176.19 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.14 -27.32 10.48 Favored Glycine 0 N--CA 1.429 -1.779 0 O-C-N 120.859 -1.151 . . . . 0.0 115.71 -176.122 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.0 m -98.47 128.18 44.72 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-N 119.64 1.72 . . . . 0.0 113.106 -169.849 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.6 tp -84.63 -56.3 3.67 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.487 -1.383 . . . . 0.0 109.537 175.717 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.93 28.76 0.85 Allowed Glycine 0 N--CA 1.43 -1.764 0 C-N-CA 125.205 1.383 . . . . 0.0 113.249 168.091 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.1 tt -147.19 143.94 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 CA-C-N 119.619 1.709 . . . . 0.0 112.645 -166.26 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.6 t -123.76 138.21 54.55 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.041 1.336 . . . . 0.0 108.889 165.106 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 m -113.74 163.28 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 126.153 1.781 . . . . 0.0 112.313 -177.308 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -145.35 178.15 8.31 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 126.917 2.087 . . . . 0.0 109.556 -179.255 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.97 -145.19 16.22 Favored Glycine 0 N--CA 1.431 -1.669 0 O-C-N 120.562 -1.336 . . . . 0.0 114.65 173.978 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.09 156.51 31.33 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 125.539 1.542 . . . . 0.0 114.622 176.156 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.429 -1.487 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -178.586 . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.679 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.9 mm -102.91 125.18 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 124.932 1.293 . . . . 0.0 108.255 179.884 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -128.42 155.33 44.93 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.928 -1.107 . . . . 0.0 111.341 -170.724 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.41 125.83 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.358 -1.464 . . . . 0.0 111.8 173.452 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.6 ttmt -89.02 -55.6 3.62 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.005 1.322 . . . . 0.0 110.115 177.203 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.73 150.09 30.61 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 121.502 -0.749 . . . . 0.0 110.607 -171.017 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -106.89 123.66 62.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.406 1.098 . . . . 0.0 108.306 172.373 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.3 mm -77.49 121.92 85.15 Favored Pre-proline 0 CA--C 1.489 -1.395 0 CA-C-O 115.755 -2.069 . . . . 0.0 114.346 -172.143 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -57.55 115.01 2.2 Favored 'Trans proline' 0 C--N 1.3 -1.996 0 C-N-CA 123.866 3.044 . . . . 0.0 117.151 -174.153 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.382 26.7 mtpp 71.07 41.81 0.78 Allowed 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.157 2.583 . . . . 0.0 114.913 -172.813 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.9 168.21 42.99 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.167 -1.583 . . . . 0.0 112.177 153.294 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.14 -60.02 3.55 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.23 1.812 . . . . 0.0 114.844 165.576 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.83 -42.71 97.56 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.31 2.244 . . . . 0.0 112.904 -178.026 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -47.91 -61.98 1.69 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.833 1.79 . . . . 0.0 115.833 171.376 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.5 t -68.03 -31.25 70.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.759 1.224 . . . . 0.0 112.515 -173.168 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -64.41 -65.94 0.61 Allowed 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.889 -1.132 . . . . 0.0 111.201 171.548 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 20.6 33.56 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 119.228 -2.17 . . . . 0.0 114.421 162.582 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -63.01 -44.37 96.19 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 121.341 -1.093 . . . . 0.0 109.866 157.442 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 52.0 mt -92.57 131.81 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.233 1.813 . . . . 0.0 110.495 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . 0.666 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 6.9 t-80 -145.24 -169.99 3.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-O 123.172 1.463 . . . . 0.0 112.727 167.828 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.666 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 40.4 ttpt -61.99 122.83 16.45 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 126.217 1.807 . . . . 0.0 113.378 -176.551 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 101.83 -4.74 53.32 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.384 -0.823 . . . . 0.0 114.073 179.725 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -74.66 161.61 29.51 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 118.925 1.363 . . . . 0.0 112.868 -177.28 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -122.09 121.3 36.63 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.771 -1.205 . . . . 0.0 111.047 -165.194 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 8.4 t -89.35 125.73 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 120.78 -1.2 . . . . 0.0 111.772 -169.103 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -102.27 -44.57 5.37 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.113 -0.992 . . . . 0.0 111.466 -177.231 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 139.36 21.21 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.681 -1.262 . . . . 0.0 111.67 -178.079 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.7 t -114.34 117.96 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.214 1.006 . . . . 0.0 109.877 177.729 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.3 t30 62.18 29.05 17.41 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 128.274 2.63 . . . . 0.0 114.24 168.808 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.01 -17.99 40.53 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.422 1.487 . . . . 0.0 113.58 -177.386 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.3 t -101.78 123.78 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 O-C-N 120.854 -1.38 . . . . 0.0 110.401 -172.97 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 m -71.27 138.15 49.16 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.105 -1.622 . . . . 0.0 112.825 179.457 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.2 mt -88.41 62.54 6.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.286 -1.509 . . . . 0.0 111.067 179.194 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -89.62 118.12 29.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.35 -1.469 . . . . 0.0 112.039 -178.18 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.34 6.72 70.65 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 125.121 1.343 . . . . 0.0 115.239 177.808 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 150.62 44.4 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 116.157 1.91 . . . . 0.0 116.157 -172.557 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 55.9 p -88.77 174.15 8.16 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.556 1.942 . . . . 0.0 111.235 175.968 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 -58.84 -48.58 80.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.646 -1.284 . . . . 0.0 113.238 177.319 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -53.55 -46.93 70.41 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.691 1.597 . . . . 0.0 114.21 176.572 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -54.89 -49.93 69.99 Favored 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 125.57 1.548 . . . . 0.0 113.633 -179.059 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.25 -38.79 88.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 176.346 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.8 t -67.71 -51.16 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.434 -1.416 . . . . 0.0 111.18 -179.058 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -33.01 74.72 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.35 1.06 . . . . 0.0 112.929 179.799 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 64.0 m -65.31 -49.65 68.66 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.459 1.904 . . . . 0.0 112.671 171.174 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -62.91 -32.48 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.168 -1.583 . . . . 0.0 114.145 174.427 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -65.07 -45.29 85.9 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.383 -1.448 . . . . 0.0 112.925 168.658 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -82.86 45.71 1.02 Allowed 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.218 -1.551 . . . . 0.0 113.755 -179.143 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 p -100.94 160.67 14.17 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 126.819 2.048 . . . . 0.0 109.251 175.485 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.71 -142.37 10.7 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.561 -1.337 . . . . 0.0 112.376 172.919 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -71.21 -59.86 2.54 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 126.294 1.838 . . . . 0.0 111.34 172.319 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 11.0 p -94.46 134.16 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.078 1.351 . . . . 0.0 111.465 -179.868 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 87.5 t -125.65 123.23 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.857 -1.152 . . . . 0.0 109.986 -169.685 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -103.61 89.79 3.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.122 -1.611 . . . . 0.0 114.204 -176.035 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.7 mt -89.0 155.91 19.19 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.665 -2.522 . . . . 0.0 112.934 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.7 tt -129.98 128.28 41.73 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 161.297 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -154.04 170.69 20.51 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.892 -1.13 . . . . 0.0 112.934 -174.963 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -119.23 144.3 46.82 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.815 1.646 . . . . 0.0 110.461 -178.691 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? . . . . . 0 N--CA 1.43 -1.447 0 O-C-N 120.626 -1.297 . . . . 0.0 111.132 174.977 . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.4 t0 . . . . . 0 N--CA 1.429 -1.478 0 CA-C-O 121.187 0.518 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -108.04 155.3 20.52 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.76 1.224 . . . . 0.0 112.855 -177.933 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -144.83 143.31 30.56 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.492 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -93.5 137.89 32.33 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 168.114 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.442 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 26.4 t -126.07 99.53 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -175.407 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -99.39 89.79 4.31 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-O 123.049 1.404 . . . . 0.0 109.046 176.527 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.0 tp -118.11 141.14 48.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.983 1.713 . . . . 0.0 110.844 -160.499 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.59 136.85 42.53 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.509 -1.37 . . . . 0.0 111.057 175.916 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -66.84 161.46 23.81 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 117.035 2.235 . . . . 0.0 117.035 -173.267 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.5 p -113.2 99.4 7.79 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 126.532 1.933 . . . . 0.0 109.333 174.675 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.9 t70 50.14 49.91 19.57 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.726 1.61 . . . . 0.0 114.92 171.643 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.05 -18.95 55.72 Favored Glycine 0 N--CA 1.431 -1.682 0 O-C-N 120.05 -1.656 . . . . 0.0 116.345 179.873 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.7 p -113.16 161.23 17.38 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 119.312 1.556 . . . . 0.0 113.239 -177.079 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 mt -97.05 -54.97 3.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 166.508 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.22 50.34 0.34 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.005 -1.684 . . . . 0.0 110.438 171.722 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tt -146.13 142.83 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 CA-C-O 122.618 1.199 . . . . 0.0 109.751 -174.147 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.0 t -111.17 129.77 55.84 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 168.571 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 m -111.07 165.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 C-N-CA 124.642 1.177 . . . . 0.0 110.547 -178.794 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 t -151.19 170.14 20.19 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.768 -1.207 . . . . 0.0 109.865 177.996 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.72 -154.68 20.35 Favored Glycine 0 N--CA 1.431 -1.696 0 O-C-N 121.337 -0.852 . . . . 0.0 112.73 178.069 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.63 147.85 23.28 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 121.698 -0.883 . . . . 0.0 113.008 -178.068 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 N--CA 1.431 -1.421 0 N-CA-C 116.728 2.122 . . . . 0.0 116.728 -167.678 . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.689 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.6 mm -99.97 128.51 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 177.338 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -127.12 159.06 35.35 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.795 -1.191 . . . . 0.0 109.684 -173.674 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.26 125.53 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 O-C-N 121.089 -1.007 . . . . 0.0 111.897 176.493 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -91.9 -49.11 6.41 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.381 177.879 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -159.12 157.76 31.59 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.412 -1.43 . . . . 0.0 111.33 177.602 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.39 121.38 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.656 1.217 . . . . 0.0 110.056 174.404 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 22.0 mm -77.47 133.28 67.66 Favored Pre-proline 0 N--CA 1.429 -1.477 0 C-N-CA 127.527 2.331 . . . . 0.0 115.671 -165.901 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -54.07 118.19 4.71 Favored 'Trans proline' 0 N--CA 1.434 -1.973 0 C-N-CA 123.864 3.043 . . . . 0.0 118.335 -178.704 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 61.85 40.74 12.37 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 128.949 2.9 . . . . 0.0 113.646 -177.274 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.29 164.23 36.45 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.114 -1.616 . . . . 0.0 112.86 162.785 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.62 -57.37 7.29 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.359 1.864 . . . . 0.0 114.87 164.472 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.6 -43.32 97.26 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 127.341 2.256 . . . . 0.0 112.517 -179.03 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.96 -62.38 1.56 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 167.143 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.4 t -69.52 -23.21 63.57 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.244 1.418 . . . . 0.0 114.719 -170.781 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -59.54 -58.32 9.11 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 125.837 1.655 . . . . 0.0 113.495 178.81 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.9 -13.02 10.68 Favored Glycine 0 N--CA 1.43 -1.729 0 CA-C-N 120.419 1.463 . . . . 0.0 115.651 168.347 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.5 mmt180 -75.16 -52.64 10.47 Favored 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 120.515 -1.58 . . . . 0.0 111.258 177.034 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 57.3 mt -81.06 116.38 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 126.231 1.812 . . . . 0.0 112.789 -168.738 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -117.88 164.91 14.34 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.37 1.868 . . . . 0.0 112.039 -179.262 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.76 124.34 20.46 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.551 -1.968 . . . . 0.0 114.019 176.459 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.12 6.8 68.67 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.686 -1.259 . . . . 0.0 114.736 -176.25 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -75.56 160.65 29.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.341 1.57 . . . . 0.0 111.273 174.024 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.7 ttt180 -101.44 126.71 48.26 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.794 -1.191 . . . . 0.0 110.29 -175.503 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.8 t -86.66 111.64 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.429 1.092 . . . . 0.0 108.494 -177.087 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.3 mt -91.14 -53.95 4.15 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.005 -1.684 . . . . 0.0 111.996 -171.571 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.11 146.99 27.96 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.807 -1.183 . . . . 0.0 108.881 -176.774 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.54 110.34 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 177.02 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.0 t30 63.17 34.99 13.09 Favored 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 126.424 1.89 . . . . 0.0 114.989 167.026 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 92.97 -6.01 76.24 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 121.083 -1.011 . . . . 0.0 113.884 -174.93 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.4 t -96.94 113.31 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-N 118.909 1.354 . . . . 0.0 109.719 179.057 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.3 m -70.94 123.89 23.07 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 124.551 1.14 . . . . 0.0 111.047 176.642 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 23.8 mt -84.23 0.76 47.62 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.306 -1.496 . . . . 0.0 114.381 -172.613 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.31 111.98 0.99 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.277 -1.514 . . . . 0.0 114.135 179.263 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.28 12.97 79.84 Favored Glycine 0 N--CA 1.429 -1.78 0 C-N-CA 124.499 1.047 . . . . 0.0 114.473 -179.081 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.72 160.69 31.8 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.208 -1.76 . . . . 0.0 115.742 173.085 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.9 p -89.87 173.88 8.0 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.488 -1.382 . . . . 0.0 111.131 171.505 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -59.59 -49.42 77.83 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.347 1.459 . . . . 0.0 112.186 170.179 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -55.35 -46.15 76.43 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 125.067 1.347 . . . . 0.0 114.102 173.716 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -55.92 -54.06 49.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 178.202 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.62 87.43 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 178.343 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.9 t -66.11 -49.51 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.859 -1.151 . . . . 0.0 111.372 176.377 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -66.99 -31.47 72.06 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.5 -1.375 . . . . 0.0 113.624 -179.083 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 100.0 m -65.82 -49.93 66.47 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 127.315 2.246 . . . . 0.0 111.667 171.525 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.8 mt -59.89 -41.15 90.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.466 -1.396 . . . . 0.0 113.97 174.083 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -60.33 -41.04 92.7 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.749 -1.22 . . . . 0.0 113.515 172.628 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -83.23 25.68 0.7 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.487 -1.383 . . . . 0.0 114.584 -179.618 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.0 p -87.23 150.9 23.6 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.13 -1.606 . . . . 0.0 109.056 168.783 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.74 -152.31 21.4 Favored Glycine 0 N--CA 1.429 -1.788 0 O-C-N 121.243 -0.911 . . . . 0.0 112.854 -179.667 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -69.59 -50.94 39.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.972 -1.31 . . . . 0.0 112.955 -177.409 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.0 p -97.79 134.25 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 123.094 1.426 . . . . 0.0 109.625 166.19 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -122.89 123.37 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 126.735 2.014 . . . . 0.0 109.027 -164.897 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -100.59 103.05 14.33 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.53 -1.357 . . . . 0.0 111.242 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 28.8 mt -100.45 158.61 15.78 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.608 -1.932 . . . . 0.0 112.554 175.87 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 45.9 tp -127.57 130.68 49.5 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 161.278 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -141.84 167.25 22.6 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.469 -1.395 . . . . 0.0 112.814 176.168 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -122.26 147.71 45.88 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 124.671 1.188 . . . . 0.0 110.099 179.28 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? . . . . . 0 N--CA 1.43 -1.448 0 C-N-CA 126.371 1.868 . . . . 0.0 110.559 179.803 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.1 t0 . . . . . 0 N--CA 1.43 -1.475 0 CA-C-O 121.073 0.463 . . . . 0.0 112.13 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.6 p -103.45 146.13 28.98 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.796 -1.19 . . . . 0.0 111.592 -179.445 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -148.29 144.97 27.96 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-O 122.552 1.167 . . . . 0.0 109.244 171.683 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -89.8 146.16 24.66 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.99 1.716 . . . . 0.0 108.799 172.728 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 20.0 t -124.89 102.55 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.106 -1.621 . . . . 0.0 107.92 177.636 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -96.18 99.13 10.89 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 168.179 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 54.0 tp -123.44 138.51 54.57 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.279 1.432 . . . . 0.0 110.905 -167.374 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 133.84 45.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.44 -1.413 . . . . 0.0 109.763 172.151 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -65.77 153.3 42.19 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 177.627 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 62.3 p -119.88 116.47 25.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 172.236 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.1 t0 56.98 48.74 15.17 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.855 1.662 . . . . 0.0 113.723 178.598 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 -7.37 30.19 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 125.744 1.64 . . . . 0.0 116.55 177.722 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.9 m -121.19 150.23 41.62 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.266 -1.138 . . . . 0.0 111.25 -162.287 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.8 mt -97.16 -62.67 1.22 Allowed 'General case' 0 N--CA 1.429 -1.521 0 O-C-N 120.665 -1.272 . . . . 0.0 111.447 178.52 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.02 46.88 0.32 Allowed Glycine 0 N--CA 1.43 -1.755 0 O-C-N 120.4 -1.438 . . . . 0.0 111.979 171.573 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.4 tt -147.49 150.4 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 CA-C-O 122.578 1.18 . . . . 0.0 111.217 -172.883 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -123.84 132.73 53.82 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.639 1.176 . . . . 0.0 108.699 168.943 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -102.61 163.81 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.812 1.245 . . . . 0.0 113.179 -179.604 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 t -147.5 169.98 18.41 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 126.095 1.758 . . . . 0.0 109.3 -177.363 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.57 -139.31 14.34 Favored Glycine 0 N--CA 1.43 -1.708 0 O-C-N 120.707 -1.246 . . . . 0.0 113.833 171.154 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.3 -177.36 34.89 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 121.415 -1.05 . . . . 0.0 113.206 -178.656 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.43 -1.465 0 N-CA-C 116.695 2.109 . . . . 0.0 116.695 -172.078 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.758 0 N-CA-C 114.115 0.406 . . . . 0.0 114.115 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.2 mm -93.92 130.26 43.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 126.485 1.914 . . . . 0.0 109.477 -178.882 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -126.44 163.03 24.21 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.807 -1.183 . . . . 0.0 110.222 -178.37 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.6 t -76.69 126.55 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.765 -1.209 . . . . 0.0 112.016 169.559 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -91.91 -52.05 4.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.943 -1.098 . . . . 0.0 111.875 176.937 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.6 155.57 39.67 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.079 -1.013 . . . . 0.0 109.977 -177.762 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.68 123.58 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.156 0.979 . . . . 0.0 108.484 175.455 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 23.2 mm -77.76 121.86 84.83 Favored Pre-proline 0 N--CA 1.43 -1.459 0 C-N-CA 125.866 1.666 . . . . 0.0 113.399 -172.399 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -59.19 131.51 41.66 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 CA-C-N 124.323 2.58 . . . . 0.0 115.821 -176.547 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 92.5 mttt 77.39 17.33 1.51 Allowed 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 127.331 2.252 . . . . 0.0 112.822 -178.613 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.1 158.78 42.66 Favored Glycine 0 N--CA 1.429 -1.8 0 O-C-N 119.864 -1.772 . . . . 0.0 113.048 173.462 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.83 -59.38 3.89 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.625 1.97 . . . . 0.0 114.193 166.674 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.5 -48.0 81.5 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.271 2.228 . . . . 0.0 112.136 179.854 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -44.7 -66.0 0.45 Allowed 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 116.318 1.97 . . . . 0.0 116.318 170.442 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 44.8 t -63.32 -25.96 68.54 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -172.895 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -54.33 -53.19 57.19 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 124.983 1.313 . . . . 0.0 113.602 179.319 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.46 -8.16 54.67 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.507 -0.746 . . . . 0.0 113.204 167.234 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -68.12 -44.84 75.22 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.229 -1.16 . . . . 0.0 111.153 168.605 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.0 mt -91.56 131.56 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.927 1.691 . . . . 0.0 112.47 -175.65 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.22 179.47 7.75 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.245 -1.534 . . . . 0.0 112.922 170.579 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -60.09 129.44 41.78 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.761 -1.837 . . . . 0.0 114.956 -175.005 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.51 3.12 78.43 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.919 -1.113 . . . . 0.0 115.07 -179.693 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -76.03 145.75 39.95 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 119.617 1.708 . . . . 0.0 111.739 176.266 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -95.3 125.5 39.97 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.252 -1.53 . . . . 0.0 110.384 -173.711 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 54.1 t -81.43 132.3 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.243 -1.535 . . . . 0.0 109.107 -178.884 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -103.24 -52.96 2.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.079 -1.013 . . . . 0.0 109.299 177.406 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.88 134.77 17.79 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 111.638 -171.799 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.1 t -110.36 120.2 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.532 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 67.81 18.54 9.7 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.51 1.924 . . . . 0.0 113.525 174.9 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.39 -17.22 54.09 Favored Glycine 0 N--CA 1.428 -1.839 0 O-C-N 120.771 -1.206 . . . . 0.0 112.981 -175.719 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.5 t -88.66 114.03 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 O-C-N 120.657 -1.496 . . . . 0.0 109.833 -178.372 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.2 m -75.65 127.85 33.95 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 120.727 -1.233 . . . . 0.0 111.279 -179.947 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.26 51.27 2.19 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.847 -1.158 . . . . 0.0 113.583 -165.302 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -74.49 111.32 9.57 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 119.162 -2.212 . . . . 0.0 115.182 -170.42 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.45 13.24 83.07 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.634 -1.291 . . . . 0.0 114.14 -179.751 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.34 159.44 34.56 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.715 1.245 . . . . 0.0 113.991 -179.133 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 45.6 p -84.68 169.77 13.97 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.512 -1.368 . . . . 0.0 111.448 172.288 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -56.25 -47.12 79.15 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.437 1.495 . . . . 0.0 112.176 168.452 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.6 tptp -50.72 -50.03 56.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.976 1.71 . . . . 0.0 113.973 174.501 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -56.27 -49.04 75.36 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 174.92 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.41 88.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.726 1.21 . . . . 0.0 114.182 174.951 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.31 -46.8 86.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 O-C-N 120.732 -1.23 . . . . 0.0 111.62 175.638 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -61.47 -34.45 75.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.557 -1.34 . . . . 0.0 114.094 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 1.5 m -77.82 -35.39 51.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.525 1.53 . . . . 0.0 113.091 174.832 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 53.1 mt -70.2 -24.29 63.09 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 119.694 -1.879 . . . . 0.0 114.783 168.997 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -69.64 -48.65 59.18 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 119.68 -1.888 . . . . 0.0 111.984 168.064 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -85.44 52.58 2.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 114.394 1.257 . . . . 0.0 114.394 -176.402 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 56.6 p -88.99 178.78 6.31 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.112 -1.617 . . . . 0.0 109.941 170.691 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.89 -165.31 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 160.836 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -70.56 -42.7 70.77 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.52 -0.988 . . . . 0.0 112.714 175.067 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 41.8 t -94.83 126.59 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 166.5 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 53.0 t -114.45 132.29 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 129.22 3.008 . . . . 0.0 108.653 -168.148 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -120.73 91.25 3.49 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 111.557 -170.845 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.9 mt -94.51 155.01 17.13 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.619 -1.926 . . . . 0.0 112.637 177.786 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.0 tt -129.62 133.13 46.98 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.456 -0.777 . . . . 0.0 109.103 161.984 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -152.63 170.41 20.3 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 120.143 -1.598 . . . . 0.0 112.669 -175.083 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -116.53 145.51 43.28 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 125.576 1.55 . . . . 0.0 110.235 179.647 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 18.4 tptt . . . . . 0 N--CA 1.43 -1.441 0 C-N-CA 125.955 1.702 . . . . 0.0 112.524 -177.446 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 pttp . . . . . 0 N--CA 1.43 -1.469 0 CA-C-O 119.204 -0.427 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -84.05 178.5 5.28 Favored 'Trans proline' 0 N--CA 1.434 -2.019 0 C-N-CA 122.639 2.226 . . . . 0.0 111.908 163.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.47 49.87 3.11 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 116.593 1.397 . . . . 0.0 116.593 163.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -96.14 135.07 38.43 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-N 119.104 1.452 . . . . 0.0 110.484 173.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.84 154.26 20.39 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.648 -1.907 . . . . 0.0 112.467 -175.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -146.15 141.38 27.45 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.131 0.967 . . . . 0.0 109.505 167.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -92.7 119.73 32.4 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.776 1.63 . . . . 0.0 107.276 163.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 10.9 t -107.65 101.57 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 122.485 1.136 . . . . 0.0 108.029 -174.053 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -92.43 79.6 4.94 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.461 1.505 . . . . 0.0 108.749 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.9 tp -104.64 133.52 49.36 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-O 122.643 1.211 . . . . 0.0 111.264 -166.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.7 146.32 27.9 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.167 -1.583 . . . . 0.0 108.848 170.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.76 158.67 34.99 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.205 -1.559 . . . . 0.0 114.558 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.2 t -112.05 105.33 13.69 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 170.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . 0.256 22.9 t70 29.64 63.29 0.15 Allowed 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.94 2.896 . . . . 0.0 117.37 -165.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.74 10.09 85.56 Favored Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 117.244 1.658 . . . . 0.0 117.244 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.6 m -121.1 134.15 55.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 119.586 1.693 . . . . 0.0 113.499 176.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.6 mt -89.98 -63.01 1.34 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.552 1.141 . . . . 0.0 111.857 167.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.35 34.35 2.51 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 119.684 -1.885 . . . . 0.0 114.378 173.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.9 pt -125.92 131.47 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.686 1.594 . . . . 0.0 110.769 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 22.4 t -105.63 106.9 17.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 166.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.7 m -110.02 152.77 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 C-N-CA 124.548 1.139 . . . . 0.0 111.414 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.1 t -150.7 175.61 11.8 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.167 -0.958 . . . . 0.0 110.974 -172.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.01 -127.5 7.13 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 121.054 -1.029 . . . . 0.0 113.527 170.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.61 -170.52 20.27 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.36 1.457 . . . . 0.0 112.174 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.7 p -104.5 -34.16 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.896 1.278 . . . . 0.0 114.343 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -94.06 -4.2 49.87 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.437 -2.039 . . . . 0.0 113.959 -166.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 30.2 p -94.76 -139.97 0.24 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.49 1.116 . . . . 0.0 110.866 -167.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 27.2 t -74.19 -39.89 62.87 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.749 -1.844 . . . . 0.0 112.821 177.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.8 m -77.24 129.08 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.786 -1.196 . . . . 0.0 114.098 -172.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -72.6 -29.44 63.51 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 126.119 1.768 . . . . 0.0 113.237 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -63.48 -25.98 68.51 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 116.955 2.205 . . . . 0.0 116.955 -166.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.85 68.05 1.68 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.016 -1.052 . . . . 0.0 114.748 171.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 179.05 171.12 41.88 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 121.113 -1.228 . . . . 0.0 110.772 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.4 mm -103.75 129.08 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.842 1.257 . . . . 0.0 108.155 -178.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -127.68 149.47 50.19 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 121.312 -0.868 . . . . 0.0 109.574 -171.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.5 t -77.09 122.62 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 O-C-N 120.845 -1.159 . . . . 0.0 111.684 172.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -88.33 -50.44 6.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.827 -1.171 . . . . 0.0 110.816 176.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.51 158.65 44.4 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 122.162 -0.337 . . . . 0.0 111.829 -175.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.41 120.47 64.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.706 1.202 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.68 119.55 77.9 Favored Pre-proline 0 N--CA 1.429 -1.477 0 CA-C-O 116.794 -1.574 . . . . 0.0 113.37 -169.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -63.66 128.18 21.58 Favored 'Trans proline' 0 N--CA 1.434 -2.018 0 C-N-CA 123.207 2.605 . . . . 0.0 113.931 -173.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.264 54.3 mttm 82.47 21.33 0.25 Allowed 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 128.063 2.545 . . . . 0.0 113.642 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.1 160.83 37.18 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 119.897 -1.752 . . . . 0.0 114.428 170.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -52.44 -59.78 4.02 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.341 1.856 . . . . 0.0 115.402 164.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.49 -45.23 88.23 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 128.823 2.849 . . . . 0.0 111.225 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -44.42 -64.2 0.73 Allowed 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 170.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 m -70.2 -22.37 62.94 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.565 1.691 . . . . 0.0 115.565 -177.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.45 -61.61 2.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.829 1.652 . . . . 0.0 112.603 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.88 5.0 64.71 Favored Glycine 0 N--CA 1.43 -1.717 0 N-CA-C 116.14 1.216 . . . . 0.0 116.14 169.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -77.17 -32.92 56.53 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 118.767 1.283 . . . . 0.0 109.635 160.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.7 mt -92.27 135.91 26.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.966 1.306 . . . . 0.0 109.161 170.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -159.47 160.97 35.33 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.589 -1.319 . . . . 0.0 110.014 178.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.5 pttt -64.87 135.49 55.79 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.383 -2.073 . . . . 0.0 114.628 -171.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.46 4.93 67.62 Favored Glycine 0 N--CA 1.43 -1.744 0 CA-C-O 118.295 -1.28 . . . . 0.0 115.436 -172.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.344 1.6 p30 -80.15 166.13 21.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 121.468 2.634 . . . . 0.0 114.375 171.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 9.9 tpt85 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.496 1.118 . . . . 0.0 109.186 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 5.0 t -85.68 139.27 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 123.748 0.819 . . . . 0.0 109.805 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.17 -53.23 2.7 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.862 -1.149 . . . . 0.0 109.291 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.69 150.62 31.31 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 112.744 -175.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 2.5 p -119.38 107.74 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 125.45 1.5 . . . . 0.0 110.266 177.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.1 t30 58.93 37.05 24.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.672 -1.893 . . . . 0.0 113.282 173.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.07 -29.69 11.59 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.891 1.234 . . . . 0.0 114.023 -172.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 44.5 t -87.98 119.55 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 119.734 1.767 . . . . 0.0 110.777 -163.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.8 m -69.87 117.63 11.71 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.1 -1.0 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 18.2 mt -83.84 -4.65 58.83 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.573 -1.329 . . . . 0.0 113.873 -169.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -74.05 116.37 14.6 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.217 -1.552 . . . . 0.0 112.044 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 107.93 -20.87 30.62 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 124.175 0.893 . . . . 0.0 112.064 -175.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.35 148.79 46.68 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.772 -1.428 . . . . 0.0 112.902 172.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -90.21 -179.14 5.58 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.301 -1.499 . . . . 0.0 112.008 -179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -61.23 -47.6 85.35 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.463 1.905 . . . . 0.0 112.765 -174.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.68 -46.96 80.85 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 115.173 1.546 . . . . 0.0 115.173 173.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 15.9 mp0 -55.88 -51.13 68.65 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.681 1.593 . . . . 0.0 113.822 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.05 -36.42 83.51 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.1 t -67.29 -49.39 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 O-C-N 120.661 -1.274 . . . . 0.0 110.941 176.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -62.5 -37.12 84.78 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.126 0.97 . . . . 0.0 113.285 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 54.0 m -58.59 -52.28 66.32 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.261 1.824 . . . . 0.0 112.57 173.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -63.27 -37.02 85.61 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 175.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.44 -42.88 99.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.108 1.363 . . . . 0.0 111.608 175.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -88.97 43.16 1.13 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.716 1.606 . . . . 0.0 112.663 177.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.6 p -100.53 156.19 17.43 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.203 -1.56 . . . . 0.0 110.184 169.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.32 -146.42 20.32 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.656 1.122 . . . . 0.0 113.141 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -69.97 -57.41 5.04 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.757 -1.437 . . . . 0.0 114.331 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.38 131.91 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 CA-C-O 122.454 1.121 . . . . 0.0 108.534 176.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -124.57 120.73 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 127.611 2.364 . . . . 0.0 108.977 -167.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -107.2 93.41 4.54 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 119.878 -1.764 . . . . 0.0 112.523 -171.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.449 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 1.1 mm? -91.54 160.04 15.62 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 118.782 -2.448 . . . . 0.0 113.794 -177.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 38.8 tp -127.87 128.92 46.03 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.289 1.436 . . . . 0.0 108.867 162.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.72 169.89 18.11 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.292 -1.505 . . . . 0.0 113.041 177.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -126.96 134.94 50.28 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.149 0.979 . . . . 0.0 112.873 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 76.71 4.16 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 126.415 1.886 . . . . 0.0 113.444 -177.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 84.5 145.35 7.06 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 125.146 1.355 . . . . 0.0 115.368 168.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -97.01 -62.01 1.32 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.744 1.259 . . . . 0.0 110.024 164.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.6 m -102.75 134.08 20.07 Favored Pre-proline 0 N--CA 1.43 -1.446 0 C-N-CA 125.345 1.458 . . . . 0.0 110.029 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo . . . . . 0 C--N 1.3 -1.995 0 C-N-CA 122.241 1.96 . . . . 0.0 114.691 173.891 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.479 0 CA-C-O 119.809 -0.138 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -82.07 61.78 7.9 Favored 'Trans proline' 0 N--CA 1.435 -1.969 0 C-N-CA 124.005 3.137 . . . . 0.0 114.439 -168.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.38 61.41 0.18 Allowed Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.707 -1.246 . . . . 0.0 116.037 176.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -98.34 -179.02 4.22 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 155.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 48.4 p -100.14 162.59 12.87 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.416 -1.427 . . . . 0.0 113.276 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.62 149.86 34.34 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 168.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -104.03 119.11 38.23 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-O 122.719 1.247 . . . . 0.0 109.242 167.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.8 t -98.07 108.48 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.588 1.955 . . . . 0.0 108.344 -175.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -104.42 86.47 2.53 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.196 1.398 . . . . 0.0 108.443 173.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 52.5 tp -120.38 142.29 49.31 Favored 'General case' 0 N--CA 1.431 -1.379 0 C-N-CA 125.111 1.364 . . . . 0.0 110.609 -165.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 140.59 35.9 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.651 1.58 . . . . 0.0 110.585 173.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -69.71 158.79 34.72 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.9 p -112.61 105.7 13.95 Favored 'General case' 0 N--CA 1.429 -1.518 0 C-N-CA 125.076 1.35 . . . . 0.0 108.761 172.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.2 t70 55.34 45.38 25.62 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.437 1.895 . . . . 0.0 113.656 -176.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.44 -5.26 64.61 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.349 -1.47 . . . . 0.0 115.563 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 60.5 p -107.92 149.78 27.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -174.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.0 mt -100.83 -56.25 2.37 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.229 1.411 . . . . 0.0 108.278 172.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.06 55.71 0.68 Allowed Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.324 -1.485 . . . . 0.0 111.863 173.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.5 tt -143.39 142.26 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 CA-C-O 122.295 1.045 . . . . 0.0 110.401 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 44.3 t -112.79 115.09 27.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.435 1.894 . . . . 0.0 107.441 171.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.6 m -101.4 160.1 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 122.43 1.11 . . . . 0.0 111.84 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.5 t -144.05 -179.46 6.51 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 125.253 1.421 . . . . 0.0 107.906 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.1 -155.43 16.3 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 121.085 -1.009 . . . . 0.0 113.722 173.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.2 152.68 22.55 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.692 1.139 . . . . 0.0 114.173 176.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.1 p -79.06 -17.21 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 115.208 1.559 . . . . 0.0 115.208 -170.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.5 -21.7 44.97 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 119.391 -2.068 . . . . 0.0 111.202 -178.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.05 168.59 10.67 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 126.937 2.095 . . . . 0.0 109.541 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 79.1 p -81.1 53.6 2.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.99 -1.694 . . . . 0.0 112.68 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 75.6 t -94.3 134.92 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 O-C-N 119.871 -1.768 . . . . 0.0 109.185 -171.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -70.52 110.5 5.43 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.149 -0.969 . . . . 0.0 110.807 -177.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.278 1.8 t-80 72.81 2.75 4.48 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 127.405 2.282 . . . . 0.0 116.57 -170.106 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.86 63.85 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 118.873 2.309 . . . . 0.0 118.873 167.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -80.2 179.29 53.42 Favored Glycine 0 N--CA 1.43 -1.752 0 CA-C-N 118.944 1.372 . . . . 0.0 114.313 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 46.7 mm -103.69 127.72 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 125.487 1.515 . . . . 0.0 108.082 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -130.92 157.01 44.08 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 121.07 -1.019 . . . . 0.0 112.6 -168.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.4 t -75.87 124.4 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.97 -1.081 . . . . 0.0 111.168 169.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -93.15 -46.43 7.43 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.246 -0.909 . . . . 0.0 110.61 170.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.53 153.5 34.68 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 111.121 177.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.43 HG22 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.16 121.68 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-O 123.016 1.389 . . . . 0.0 109.052 176.008 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 33.2 mm -76.53 126.27 86.37 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 127.028 2.131 . . . . 0.0 113.157 -166.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -60.63 138.42 79.83 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 124.722 2.722 . . . . 0.0 113.976 -173.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm 53.43 37.08 24.73 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 116.822 2.156 . . . . 0.0 116.822 -169.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.72 160.74 35.97 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.078 -1.639 . . . . 0.0 113.225 159.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.75 -56.37 12.34 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.252 -1.734 . . . . 0.0 115.658 163.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.71 -47.65 77.57 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.196 2.999 . . . . 0.0 112.517 -179.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.43 ' HG2' HG22 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -40.81 -64.88 0.48 Allowed 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.656 1.582 . . . . 0.0 113.975 164.696 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 12.9 t -67.65 -34.89 77.84 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.456 1.102 . . . . 0.0 113.887 -170.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -53.46 -65.43 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.616 1.966 . . . . 0.0 113.906 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.22 -10.78 24.45 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 115.496 0.959 . . . . 0.0 115.496 172.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -72.72 -24.75 61.03 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 119.634 1.717 . . . . 0.0 113.194 172.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 67.5 mt -105.4 135.93 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.542 1.537 . . . . 0.0 108.452 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -154.15 158.25 40.1 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.844 -1.16 . . . . 0.0 112.169 -170.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -51.83 122.78 8.85 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.007 -1.683 . . . . 0.0 115.49 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.59 -5.51 64.63 Favored Glycine 0 N--CA 1.429 -1.771 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 0.3 OUTLIER -80.19 171.83 14.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.923 1.861 . . . . 0.0 114.343 -175.823 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -119.74 125.73 49.35 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.402 -1.436 . . . . 0.0 112.709 -169.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.0 t -82.61 127.85 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.734 -1.229 . . . . 0.0 110.027 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.41 -46.45 5.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 110.525 176.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.79 136.57 17.13 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.556 -1.34 . . . . 0.0 114.003 -177.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -104.37 116.93 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 124.536 1.135 . . . . 0.0 108.525 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.5 t30 59.38 39.47 22.13 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.137 -1.602 . . . . 0.0 113.767 175.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.09 -33.5 5.21 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 121.209 -0.932 . . . . 0.0 113.889 -174.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -87.03 117.75 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 C-N-CA 124.725 1.21 . . . . 0.0 111.471 -167.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 t -76.55 139.32 40.68 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.318 -1.489 . . . . 0.0 112.628 -174.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.2 mt -89.69 20.86 3.79 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -171.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -62.17 117.71 6.4 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 119.829 -1.794 . . . . 0.0 114.591 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 84.94 10.8 78.02 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 124.483 1.039 . . . . 0.0 113.65 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.72 157.14 38.46 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.3 p -91.22 170.03 10.34 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.863 -1.148 . . . . 0.0 109.677 170.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -53.91 -55.2 29.09 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.889 1.276 . . . . 0.0 113.322 170.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -56.44 -44.34 80.34 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.049 1.499 . . . . 0.0 115.049 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -61.06 -46.05 92.25 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -175.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.98 -33.43 75.71 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.809 1.244 . . . . 0.0 112.669 172.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.06 -48.34 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.463 1.105 . . . . 0.0 110.381 178.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -59.05 -42.24 89.81 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.714 -1.241 . . . . 0.0 113.043 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.6 m -62.03 -48.06 81.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.036 2.134 . . . . 0.0 112.858 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 33.4 mt -65.54 -37.12 85.82 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.109 1.364 . . . . 0.0 114.246 175.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -68.69 -31.54 70.71 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.337 -1.477 . . . . 0.0 112.474 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -88.51 48.58 1.66 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 124.828 1.251 . . . . 0.0 112.139 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.6 p -98.82 154.48 17.98 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.132 1.773 . . . . 0.0 107.894 166.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.66 -157.76 30.82 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.803 -1.186 . . . . 0.0 112.007 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? -69.43 -49.08 58.46 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 121.099 -1.236 . . . . 0.0 112.6 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 56.4 t -99.16 132.72 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.43 1.092 . . . . 0.0 108.325 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 74.4 t -120.3 124.8 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 126.556 1.943 . . . . 0.0 109.649 -165.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -113.58 87.46 2.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.627 1.171 . . . . 0.0 112.196 -174.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.279 3.1 pp -123.5 148.28 46.4 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 117.794 2.516 . . . . 0.0 117.794 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 49.9 tp -105.82 128.31 53.65 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.878 1.671 . . . . 0.0 108.433 -176.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.34 158.68 43.65 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 121.999 0.904 . . . . 0.0 110.822 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -95.52 150.98 19.72 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 165.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? -75.82 152.89 37.19 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.221 1.01 . . . . 0.0 109.791 165.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -115.72 164.75 12.17 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.94 1.257 . . . . 0.0 110.87 178.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -75.58 179.48 5.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 114.688 1.366 . . . . 0.0 114.688 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 30.9 m -87.47 143.61 34.39 Favored Pre-proline 0 N--CA 1.431 -1.409 0 O-C-N 120.545 -1.347 . . . . 0.0 112.682 -177.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo . . . . . 0 N--CA 1.434 -2.011 0 C-N-CA 123.309 2.672 . . . . 0.0 112.725 161.209 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.7 pttm . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 119.326 -0.368 . . . . 0.0 111.387 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.04 176.5 9.95 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 121.894 1.73 . . . . 0.0 112.173 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.95 12.18 62.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.859 -0.526 . . . . 0.0 112.759 -176.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -81.1 156.02 25.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.321 1.848 . . . . 0.0 113.113 -168.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 38.5 p -121.86 154.42 37.09 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 121.077 -1.014 . . . . 0.0 112.79 -174.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.2 139.65 27.36 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.072 -1.017 . . . . 0.0 109.082 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -92.72 131.0 38.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.86 -1.15 . . . . 0.0 109.899 168.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.8 t -116.71 111.83 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.057 1.343 . . . . 0.0 108.656 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -102.55 78.06 1.68 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.419 -1.425 . . . . 0.0 109.288 172.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.5 tp -94.74 146.83 23.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 124.297 1.039 . . . . 0.0 111.063 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.48 127.59 50.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.085 -1.634 . . . . 0.0 108.932 167.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.1 ptmt -70.15 149.55 47.44 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 p -106.55 111.44 23.99 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.272 -1.517 . . . . 0.0 111.635 -174.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.0 t0 54.26 39.46 30.85 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.424 2.29 . . . . 0.0 113.522 -175.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.02 -7.22 78.71 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.281 -1.512 . . . . 0.0 115.713 -176.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.8 t -109.39 150.38 28.14 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-N 119.15 1.475 . . . . 0.0 112.005 -172.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.4 mt -100.71 -61.59 1.35 Allowed 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.237 -1.539 . . . . 0.0 112.151 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.53 33.81 0.91 Allowed Glycine 0 N--CA 1.43 -1.746 0 O-C-N 119.914 -1.741 . . . . 0.0 111.497 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 pt -124.38 150.36 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.429 1.092 . . . . 0.0 111.261 -174.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 35.4 m -126.67 134.33 50.74 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 156.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 m -117.84 161.58 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 CA-C-O 122.346 1.07 . . . . 0.0 112.102 -170.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.64 -173.35 4.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 124.2 1.0 . . . . 0.0 109.595 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.06 -152.41 20.25 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.994 -1.067 . . . . 0.0 115.437 171.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.67 172.66 30.62 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 125.593 1.568 . . . . 0.0 111.621 -176.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t -60.24 -37.26 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 125.065 1.346 . . . . 0.0 113.065 176.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -73.88 -22.68 59.64 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 126.283 1.833 . . . . 0.0 113.809 -173.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 26.8 m -98.72 141.9 30.95 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 124.627 1.171 . . . . 0.0 108.444 -174.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 14.2 m -78.02 61.02 2.5 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 119.975 -1.703 . . . . 0.0 114.112 -176.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.4 m -100.58 7.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 127.1 2.16 . . . . 0.0 114.548 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 58.1 ttp85 78.71 120.62 0.05 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.556 2.342 . . . . 0.0 112.064 -171.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 39.6 t60 72.47 -69.77 0.18 Allowed 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.947 1.699 . . . . 0.0 115.512 172.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 144.97 95.57 0.19 Allowed Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -174.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.17 152.14 23.46 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.2 mm -95.32 127.72 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.239 1.416 . . . . 0.0 108.584 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -125.7 155.58 40.69 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 120.757 -1.214 . . . . 0.0 111.404 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.5 t -75.96 122.26 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.999 -1.063 . . . . 0.0 110.945 169.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.0 ttmm -87.9 -42.06 12.76 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.376 1.47 . . . . 0.0 109.703 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.24 160.0 38.2 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.77 -0.581 . . . . 0.0 109.946 175.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -119.17 121.36 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 C-N-CA 124.348 1.059 . . . . 0.0 108.841 174.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.46 119.38 77.22 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 115.872 -2.013 . . . . 0.0 116.144 -169.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -59.86 123.24 12.83 Favored 'Trans proline' 0 N--CA 1.434 -2.024 0 CA-C-N 124.659 2.7 . . . . 0.0 114.916 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.254 83.7 mttt 81.74 26.53 0.19 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 128.229 2.612 . . . . 0.0 111.921 -172.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.61 157.49 31.39 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 119.768 -1.833 . . . . 0.0 111.812 164.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.57 -58.74 5.47 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.59 -2.123 . . . . 0.0 114.287 160.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.1 -40.12 95.54 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 127.45 2.3 . . . . 0.0 112.826 -177.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 -52.07 -59.74 4.01 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 166.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.5 t -68.82 -25.21 64.56 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 125.837 1.655 . . . . 0.0 114.905 -167.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -46.48 -63.15 1.08 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.1 1.76 . . . . 0.0 113.964 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 114.48 -2.51 23.5 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.217 -0.927 . . . . 0.0 114.324 171.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.6 mtm180 -85.81 -28.64 24.36 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.006 -1.29 . . . . 0.0 113.095 171.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.1 mt -108.61 132.07 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 C-N-CA 126.445 1.898 . . . . 0.0 110.664 -170.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.12 -176.71 4.91 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.356 -1.465 . . . . 0.0 112.424 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -68.43 121.19 15.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.416 -1.428 . . . . 0.0 112.738 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 105.41 -2.52 39.88 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 121.418 -0.801 . . . . 0.0 114.393 -175.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -80.35 147.8 30.91 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 119.419 1.609 . . . . 0.0 112.393 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 23.5 ttm180 -97.07 134.34 40.56 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.838 -1.164 . . . . 0.0 110.452 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.1 t -86.45 127.39 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.96 -1.087 . . . . 0.0 109.196 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.47 -45.94 4.71 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.496 -1.377 . . . . 0.0 111.253 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.0 128.69 12.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.489 -1.382 . . . . 0.0 111.584 -176.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 t -108.9 124.04 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 66.55 28.1 9.47 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.521 -1.362 . . . . 0.0 113.666 170.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.74 -12.53 66.92 Favored Glycine 0 N--CA 1.429 -1.809 0 O-C-N 119.962 -1.712 . . . . 0.0 113.773 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.9 t -96.14 116.09 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.155 -1.203 . . . . 0.0 109.026 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 92.7 p -75.36 140.83 43.27 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.357 -1.464 . . . . 0.0 111.592 177.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.2 mt -88.29 50.93 2.06 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.652 -1.28 . . . . 0.0 112.744 -166.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -73.67 125.07 27.21 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.977 -1.702 . . . . 0.0 112.19 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.79 10.64 61.51 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.237 1.399 . . . . 0.0 115.453 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.26 139.4 50.0 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 115.898 1.814 . . . . 0.0 115.898 -170.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.8 p -91.64 173.26 7.98 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 124.868 1.267 . . . . 0.0 110.27 176.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -58.96 -49.41 77.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.962 -1.086 . . . . 0.0 113.531 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -56.33 -40.29 74.2 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 175.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -53.9 51.56 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.565 1.546 . . . . 0.0 113.766 179.069 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.5 87.73 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.472 1.509 . . . . 0.0 113.86 177.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.62 -48.15 88.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.772 1.229 . . . . 0.0 110.894 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -63.21 -41.27 99.11 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 175.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.3 m -61.48 -45.95 92.08 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 125.96 1.704 . . . . 0.0 113.277 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.64 -30.4 67.02 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.269 -1.519 . . . . 0.0 113.91 176.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.58 -45.03 92.29 Favored 'General case' 0 CA--C 1.488 -1.419 0 O-C-N 120.453 -1.405 . . . . 0.0 112.025 167.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -78.02 48.81 0.75 Allowed 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 128.116 2.567 . . . . 0.0 113.679 176.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 35.3 p -106.03 156.0 18.84 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.268 -1.52 . . . . 0.0 110.218 174.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.21 -164.19 38.35 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.778 -1.201 . . . . 0.0 111.036 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -69.78 -47.81 61.52 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 118.922 1.361 . . . . 0.0 112.236 172.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.27 123.82 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-O 123.171 1.463 . . . . 0.0 107.505 169.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.4 t -113.2 103.59 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 126.956 2.103 . . . . 0.0 109.019 -168.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.6 t-160 -89.2 101.57 14.23 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 123.784 0.834 . . . . 0.0 111.523 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.6 mt -102.97 162.12 13.2 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-O 122.665 1.221 . . . . 0.0 113.822 172.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.5 tt -129.04 132.19 47.44 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.036 1.335 . . . . 0.0 108.021 159.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.01 164.64 28.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.012 -1.055 . . . . 0.0 113.23 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -113.88 142.47 46.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.405 1.882 . . . . 0.0 109.918 177.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 19.7 tptt -75.31 133.14 41.35 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.818 1.647 . . . . 0.0 112.794 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.32 127.87 40.27 Favored Glycine 0 N--CA 1.43 -1.709 0 C-N-CA 127.519 2.485 . . . . 0.0 117.211 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -73.22 -39.97 65.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.652 2.381 . . . . 0.0 114.127 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.4 p -141.16 126.35 10.89 Favored Pre-proline 0 N--CA 1.429 -1.484 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 170.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo . . . . . 0 N--CA 1.434 -2.028 0 CA-C-N 122.853 2.055 . . . . 0.0 113.904 175.148 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 91.3 mttt . . . . . 0 N--CA 1.431 -1.406 0 CA-C-O 118.824 -0.608 . . . . 0.0 111.028 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_exo -67.07 179.11 2.49 Favored 'Trans proline' 0 N--CA 1.434 -1.999 0 C-N-CA 122.725 2.283 . . . . 0.0 115.592 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.44 24.04 5.49 Favored Glycine 0 N--CA 1.429 -1.777 0 C-N-CA 124.008 0.813 . . . . 0.0 114.585 -175.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -85.72 131.99 34.23 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.33 1.452 . . . . 0.0 109.342 175.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.0 p -101.83 150.47 23.14 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.375 -1.453 . . . . 0.0 112.532 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.76 134.88 22.76 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.903 -1.123 . . . . 0.0 108.72 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -91.04 121.4 32.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.334 1.454 . . . . 0.0 109.615 174.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.19 102.77 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.803 -1.186 . . . . 0.0 108.236 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -104.46 81.88 1.85 Allowed 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.123 1.369 . . . . 0.0 108.226 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.6 tp -111.78 149.27 31.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.694 1.198 . . . . 0.0 110.325 -165.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.89 144.81 30.72 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.347 -1.471 . . . . 0.0 108.869 170.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -70.12 154.64 41.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.609 -1.307 . . . . 0.0 112.638 173.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.6 p -112.92 100.79 8.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.836 -1.165 . . . . 0.0 109.066 175.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 22.0 t0 58.01 45.42 18.01 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 126.014 1.726 . . . . 0.0 113.248 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.54 -10.99 67.4 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 125.049 1.309 . . . . 0.0 115.226 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 62.1 m -104.04 148.78 25.83 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.787 1.293 . . . . 0.0 113.561 -169.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.0 mt -119.31 -54.03 2.21 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.999 1.32 . . . . 0.0 109.354 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.5 43.32 1.86 Allowed Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 127.036 2.255 . . . . 0.0 113.877 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 pt -121.52 121.15 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 CA-C-N 119.394 1.597 . . . . 0.0 115.031 -167.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.4 m -116.72 123.83 48.16 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.549 -1.345 . . . . 0.0 109.202 165.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.46 173.91 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.072 1.349 . . . . 0.0 111.709 -171.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.7 t -146.31 168.47 21.01 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.059 1.344 . . . . 0.0 108.515 174.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.67 -154.18 17.15 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.842 -1.161 . . . . 0.0 115.149 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 101.5 165.99 27.43 Favored Glycine 0 N--CA 1.429 -1.785 0 C-N-CA 125.247 1.403 . . . . 0.0 112.379 -179.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.7 m -84.28 17.13 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 115.937 1.829 . . . . 0.0 115.937 -171.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -97.88 -64.29 1.05 Allowed 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 119.421 -2.049 . . . . 0.0 110.507 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 51.9 m -79.75 155.91 27.73 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.545 1.538 . . . . 0.0 108.81 -176.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 65.6 p -75.09 60.99 1.06 Allowed 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.665 -1.897 . . . . 0.0 114.642 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 14.8 t -99.4 89.41 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.24 -1.537 . . . . 0.0 108.772 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? 38.75 67.24 0.44 Allowed 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 128.599 2.759 . . . . 0.0 115.961 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 69.27 -3.21 1.62 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.9 84.7 1.7 Allowed Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.577 -1.327 . . . . 0.0 111.417 -169.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -137.53 168.66 24.37 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 167.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.72 125.76 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.876 1.271 . . . . 0.0 107.972 178.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -128.88 157.49 41.42 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.602 -1.312 . . . . 0.0 111.398 -172.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.8 t -76.39 126.54 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.495 1.518 . . . . 0.0 111.181 172.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -109.79 -51.67 2.85 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.338 -1.477 . . . . 0.0 113.164 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.0 157.01 43.49 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 121.226 -0.921 . . . . 0.0 109.975 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -125.77 126.09 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 C-N-CA 123.988 0.915 . . . . 0.0 109.195 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.6 mm -77.26 122.45 86.16 Favored Pre-proline 0 N--CA 1.429 -1.493 0 CA-C-O 116.238 -1.839 . . . . 0.0 114.507 -173.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -57.28 127.6 26.24 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 CA-C-N 124.506 2.645 . . . . 0.0 116.18 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.292 50.8 mttp 79.36 22.64 0.56 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 127.545 2.338 . . . . 0.0 113.385 -177.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.17 156.3 30.76 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.9 -1.75 . . . . 0.0 112.16 165.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.09 -55.33 12.53 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.824 1.65 . . . . 0.0 115.268 170.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.36 -48.51 75.25 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.89 2.476 . . . . 0.0 111.448 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 tm-20 -47.49 -59.15 3.44 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 173.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.0 t -68.37 -30.37 69.29 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.647 1.179 . . . . 0.0 113.387 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -65.02 -60.43 3.05 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.963 1.305 . . . . 0.0 111.199 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.96 31.07 15.73 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.45 -1.406 . . . . 0.0 116.431 167.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -83.3 -39.82 20.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 121.458 -1.025 . . . . 0.0 108.747 159.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mt -79.17 99.81 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 123.933 0.893 . . . . 0.0 110.313 175.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -122.81 156.77 33.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.82 1.295 . . . . 0.0 109.627 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.1 pttt -67.78 131.27 45.24 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.136 -1.602 . . . . 0.0 113.379 -171.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.87 -19.52 32.84 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.164 -0.96 . . . . 0.0 114.1 -172.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -79.51 157.1 27.51 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 120.152 1.976 . . . . 0.0 113.312 -173.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 70.6 ttt-85 -108.88 134.93 50.9 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.154 -1.591 . . . . 0.0 111.289 -173.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.11 132.75 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 119.945 -1.722 . . . . 0.0 110.986 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.72 -52.4 4.9 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.914 -1.116 . . . . 0.0 111.788 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.96 140.14 20.3 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.907 -0.496 . . . . 0.0 112.016 -165.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.1 t -109.22 118.24 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 171.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 63.18 20.89 12.55 Favored 'General case' 0 N--CA 1.429 -1.514 0 C-N-CA 125.968 1.707 . . . . 0.0 113.974 -178.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 86.52 -0.55 86.94 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.279 -1.513 . . . . 0.0 114.069 -174.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -86.05 117.56 30.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.853 1.261 . . . . 0.0 109.045 176.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.0 p -75.63 132.36 40.55 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.774 -1.204 . . . . 0.0 113.702 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 67.6 mt -84.77 -13.19 51.95 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -168.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -63.63 131.74 48.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.595 -1.941 . . . . 0.0 112.72 174.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.18 -30.35 9.22 Favored Glycine 0 N--CA 1.431 -1.697 0 C-N-CA 124.518 1.056 . . . . 0.0 113.674 -171.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.23 156.87 39.04 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -88.23 172.61 9.34 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.244 1.018 . . . . 0.0 111.681 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -63.82 -43.35 96.48 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.554 -1.341 . . . . 0.0 112.151 175.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -54.8 -44.87 74.18 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 126.646 1.978 . . . . 0.0 114.416 171.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -56.03 -55.05 37.48 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.93 -34.85 78.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.61 -53.76 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.33 1.052 . . . . 0.0 110.566 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -61.92 -39.43 92.01 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.011 0.91 . . . . 0.0 113.036 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 97.0 m -66.86 -42.38 85.78 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.452 1.901 . . . . 0.0 113.219 179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 65.5 mt -69.54 -36.92 76.83 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.068 -1.02 . . . . 0.0 113.082 173.214 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -53.55 56.4 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.789 -1.195 . . . . 0.0 113.03 173.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -81.04 43.06 0.68 Allowed 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.863 1.665 . . . . 0.0 112.748 -177.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 26.1 p -91.76 155.37 18.3 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 127.425 2.29 . . . . 0.0 108.814 168.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.98 -140.7 7.01 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.973 -1.079 . . . . 0.0 114.078 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 2.1 tm0? -71.02 -53.48 14.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.329 -1.101 . . . . 0.0 111.993 177.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 95.0 t -97.89 135.89 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.397 1.57 . . . . 0.0 109.17 169.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 48.2 t -111.43 117.66 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 128.574 2.75 . . . . 0.0 108.131 -176.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 52.9 m170 -105.23 104.41 14.14 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.872 -1.143 . . . . 0.0 111.244 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -106.73 163.75 12.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.884 -1.135 . . . . 0.0 113.799 171.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.3 tp -128.2 134.11 48.97 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 124.856 1.263 . . . . 0.0 108.36 158.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.8 pp -145.17 164.87 29.98 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.637 -1.29 . . . . 0.0 111.285 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -121.42 149.72 42.59 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.023 1.729 . . . . 0.0 110.894 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.01 121.28 20.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.482 1.513 . . . . 0.0 110.761 176.178 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -76.39 -178.19 44.98 Favored Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 125.593 1.568 . . . . 0.0 114.22 -178.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -81.69 178.71 8.17 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.842 -1.387 . . . . 0.0 112.615 -175.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.2 t -113.26 102.57 54.97 Favored Pre-proline 0 N--CA 1.43 -1.472 0 O-C-N 120.793 -1.192 . . . . 0.0 110.377 -171.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 C--N 1.301 -1.97 0 C-N-CA 121.958 1.772 . . . . 0.0 110.591 155.664 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.7 tttt . . . . . 0 N--CA 1.43 -1.461 0 CA-C-O 117.451 -1.261 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -76.2 23.22 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.079 0 C-N-CA 122.853 2.369 . . . . 0.0 118.069 -170.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.13 59.8 1.45 Allowed Glycine 0 N--CA 1.431 -1.688 0 N-CA-C 108.965 -1.654 . . . . 0.0 108.965 -170.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -53.86 -58.47 7.14 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.867 1.432 . . . . 0.0 114.867 -163.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -123.56 154.73 38.82 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-N 119.419 1.009 . . . . 0.0 110.596 163.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -144.43 149.92 36.83 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 123.882 0.873 . . . . 0.0 109.438 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -99.63 125.85 45.53 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.123 1.369 . . . . 0.0 109.275 167.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.46 94.88 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 O-C-N 120.481 -1.387 . . . . 0.0 107.954 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -90.62 81.54 5.87 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.658 -1.276 . . . . 0.0 109.387 169.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 49.2 tp -96.39 133.6 40.6 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.652 1.181 . . . . 0.0 111.642 -171.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.16 138.72 38.73 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 119.878 -1.764 . . . . 0.0 110.147 172.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -68.25 156.51 37.49 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.726 1.21 . . . . 0.0 113.721 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.4 t -129.25 135.8 49.27 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 172.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.0 t70 33.34 52.12 0.35 Allowed 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 128.248 2.619 . . . . 0.0 116.57 -173.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.68 -5.45 69.49 Favored Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 117.678 1.831 . . . . 0.0 117.678 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.7 m -121.57 150.63 41.38 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.535 1.668 . . . . 0.0 113.988 -169.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 46.9 mt -101.28 -60.24 1.56 Allowed 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.232 1.413 . . . . 0.0 109.606 168.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.18 41.82 2.02 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.874 1.702 . . . . 0.0 114.63 175.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.3 pt -112.53 156.58 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 CA-C-N 118.417 1.109 . . . . 0.0 111.994 177.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -131.39 132.52 44.46 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.115 -1.615 . . . . 0.0 109.258 149.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.5 m -114.75 160.2 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.478 1.511 . . . . 0.0 110.882 -175.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 t -148.8 -178.96 6.64 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.541 -1.349 . . . . 0.0 110.651 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.4 -123.97 7.07 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 120.763 -1.21 . . . . 0.0 114.463 167.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.47 171.27 26.9 Favored Glycine 0 N--CA 1.43 -1.75 0 CA-C-O 122.671 1.151 . . . . 0.0 113.208 178.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.8 p -77.62 -28.26 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -172.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -74.96 -46.29 36.45 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 120.391 -1.443 . . . . 0.0 114.209 -171.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 3.8 t -87.67 175.75 7.74 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.716 -1.24 . . . . 0.0 113.491 -172.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 78.4 p -83.28 46.09 1.1 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.345 1.858 . . . . 0.0 115.34 -171.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.49 -177.11 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 O-C-N 119.749 -1.844 . . . . 0.0 110.018 170.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -71.63 102.43 2.76 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.901 -1.749 . . . . 0.0 111.532 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 56.69 19.21 4.16 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 128.975 2.91 . . . . 0.0 118.636 174.38 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.24 69.33 1.41 Allowed Glycine 0 N--CA 1.43 -1.745 0 O-C-N 120.729 -1.232 . . . . 0.0 114.728 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.98 175.55 21.48 Favored Glycine 0 N--CA 1.43 -1.73 0 O-C-N 121.467 -1.019 . . . . 0.0 113.55 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.1 mm -102.81 117.18 47.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 125.798 1.639 . . . . 0.0 108.222 -176.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.23 149.81 44.23 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.166 -0.958 . . . . 0.0 109.947 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -78.12 122.59 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.506 -1.371 . . . . 0.0 113.14 177.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.52 -39.26 10.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.614 -1.304 . . . . 0.0 112.799 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.26 158.86 42.28 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.441 -1.412 . . . . 0.0 111.466 -177.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -122.46 120.8 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-O 122.965 1.364 . . . . 0.0 110.824 176.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.75 121.66 85.18 Favored Pre-proline 0 N--CA 1.43 -1.468 0 C-N-CA 125.802 1.641 . . . . 0.0 113.189 -171.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.42 134.37 41.39 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 CA-C-N 123.98 2.457 . . . . 0.0 112.689 179.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 56.7 mttm 82.29 20.35 0.29 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 129.173 2.989 . . . . 0.0 113.785 -172.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.51 154.85 30.23 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 119.966 -1.709 . . . . 0.0 115.938 169.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.47 -58.72 5.1 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.986 2.115 . . . . 0.0 115.562 158.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.06 -46.54 86.98 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.99 2.916 . . . . 0.0 111.612 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 tm-20 -41.73 -59.58 1.62 Allowed 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 169.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.0 t -69.54 -34.6 74.46 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -62.08 -46.81 87.44 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.015 -1.678 . . . . 0.0 113.542 -171.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 108.07 -6.69 34.86 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.359 -1.463 . . . . 0.0 116.08 155.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.4 mmp_? -70.23 -35.48 73.87 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.918 -1.342 . . . . 0.0 111.131 169.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.5 mt -87.22 128.94 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 126.396 1.878 . . . . 0.0 108.766 176.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -164.28 123.21 1.89 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.6 -1.312 . . . . 0.0 107.798 -176.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.17 112.92 0.31 Allowed 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 116.846 2.165 . . . . 0.0 116.846 -167.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.15 -8.66 12.32 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 118.552 -1.138 . . . . 0.0 113.616 -164.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -79.84 164.34 23.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 120.799 2.299 . . . . 0.0 113.019 175.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.1 ttt180 -125.57 124.79 42.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.153 -0.967 . . . . 0.0 110.877 -171.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.5 t -87.74 135.49 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 O-C-N 120.106 -1.621 . . . . 0.0 109.815 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.4 mp -106.24 -44.06 4.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.721 1.208 . . . . 0.0 111.111 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.96 132.54 15.79 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.705 -1.247 . . . . 0.0 111.255 -177.064 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 t -109.97 119.39 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.524 1.13 . . . . 0.0 108.518 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.87 24.6 9.7 Favored 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 126.146 1.778 . . . . 0.0 114.125 173.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 90.48 -9.9 76.15 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 120.147 -1.596 . . . . 0.0 114.182 -173.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.66 119.99 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.552 1.141 . . . . 0.0 108.098 -176.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.7 t -76.04 145.93 39.81 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.444 -1.41 . . . . 0.0 112.476 -174.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 95.9 mt -91.49 8.13 37.91 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.516 -1.365 . . . . 0.0 113.251 -175.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 77.1 mt-10 -68.27 107.73 2.92 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 119.535 -1.978 . . . . 0.0 113.934 -176.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.27 4.3 68.68 Favored Glycine 0 N--CA 1.429 -1.782 0 O-C-N 120.773 -1.205 . . . . 0.0 113.715 -175.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.52 148.11 45.34 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 121.139 -1.213 . . . . 0.0 113.79 168.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.3 p -80.51 173.92 12.12 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.852 -1.155 . . . . 0.0 111.845 169.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -55.54 -52.29 64.21 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.364 1.865 . . . . 0.0 112.368 168.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -57.14 -43.12 82.14 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 115.043 1.498 . . . . 0.0 115.043 173.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -56.27 -42.72 77.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.806 1.78 . . . . 0.0 115.806 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.6 -36.12 83.2 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.804 -1.185 . . . . 0.0 112.904 175.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.9 -44.36 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 O-C-N 120.662 -1.274 . . . . 0.0 111.191 177.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -54.04 -37.91 64.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.977 1.711 . . . . 0.0 113.247 171.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -73.36 -52.21 14.64 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.901 2.08 . . . . 0.0 112.224 177.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 48.3 mt -64.41 -31.47 72.7 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -70.05 -26.46 64.03 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.18 -1.575 . . . . 0.0 112.982 174.336 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.3 t30 -91.6 39.71 1.01 Allowed 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.563 1.545 . . . . 0.0 112.887 178.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 p -94.28 155.47 17.0 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 126.29 1.836 . . . . 0.0 111.786 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -146.59 20.65 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.038 -1.039 . . . . 0.0 112.587 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -69.68 -56.27 7.68 Favored 'General case' 0 N--CA 1.429 -1.523 0 O-C-N 121.2 -1.176 . . . . 0.0 112.38 173.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.1 t -98.54 128.47 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.826 1.298 . . . . 0.0 108.418 178.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.7 t -114.46 109.41 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 128.385 2.674 . . . . 0.0 109.024 -171.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -88.84 109.37 20.14 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 120.634 -1.291 . . . . 0.0 110.597 174.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -101.23 153.66 19.43 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.641 -1.287 . . . . 0.0 111.136 161.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -123.02 128.2 49.85 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 157.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -142.46 163.44 32.84 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 121.473 -0.767 . . . . 0.0 111.779 -171.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.51 136.02 53.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.399 1.88 . . . . 0.0 109.145 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -77.66 148.03 35.22 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.766 -1.834 . . . . 0.0 112.707 176.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.76 119.43 5.29 Favored Glycine 0 N--CA 1.43 -1.735 0 C-N-CA 125.106 1.336 . . . . 0.0 112.327 176.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -77.91 178.62 7.3 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 -172.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.3 m -114.45 161.98 25.74 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 124.606 1.162 . . . . 0.0 110.459 -176.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo . . . . . 0 N--CA 1.434 -2.014 0 C-N-CA 122.174 1.916 . . . . 0.0 115.215 168.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 97.8 mttt . . . . . 0 N--CA 1.43 -1.444 0 CA-C-O 118.062 -0.97 . . . . 0.0 108.901 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -77.85 62.55 7.91 Favored 'Trans proline' 0 N--CA 1.433 -2.034 0 C-N-CA 124.174 3.249 . . . . 0.0 113.425 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.49 48.55 0.26 Allowed Glycine 0 N--CA 1.429 -1.778 0 C-N-CA 124.893 1.235 . . . . 0.0 114.158 177.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -89.55 167.52 12.89 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 160.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -104.96 160.75 14.78 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 121.02 -1.05 . . . . 0.0 110.593 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.86 139.12 26.09 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 170.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.34 131.71 37.31 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.964 1.306 . . . . 0.0 109.412 165.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.1 t -119.73 115.04 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -177.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 -107.53 91.17 3.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.227 1.411 . . . . 0.0 107.81 177.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.23 132.77 54.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.593 1.157 . . . . 0.0 112.241 -162.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.15 137.96 33.5 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.14 -1.6 . . . . 0.0 111.871 176.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 27.9 mttp -70.13 148.42 48.73 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 115.214 1.561 . . . . 0.0 115.214 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 37.3 p -113.59 118.78 35.37 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.965 1.306 . . . . 0.0 109.76 173.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.7 t0 59.49 32.51 21.74 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.532 1.933 . . . . 0.0 114.172 -176.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.62 79.03 Favored Glycine 0 N--CA 1.429 -1.832 0 O-C-N 119.763 -1.835 . . . . 0.0 114.869 -173.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.4 p -121.5 144.56 48.63 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.72 -1.459 . . . . 0.0 112.151 178.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 74.2 mt -85.62 -60.42 2.03 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.923 -1.11 . . . . 0.0 109.943 165.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.04 46.87 0.5 Allowed Glycine 0 N--CA 1.43 -1.708 0 O-C-N 119.983 -1.698 . . . . 0.0 109.749 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.2 tt -140.73 144.71 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 123.337 1.541 . . . . 0.0 110.296 -175.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.6 t -118.83 133.3 55.93 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 166.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 m -108.44 164.67 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.49 1.116 . . . . 0.0 110.449 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 t -147.85 178.36 8.57 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.554 1.142 . . . . 0.0 108.481 176.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.99 -162.41 27.42 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.515 -1.366 . . . . 0.0 113.548 176.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.56 165.93 22.67 Favored Glycine 0 N--CA 1.431 -1.665 0 C-N-CA 124.753 1.168 . . . . 0.0 110.707 -173.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.62 -20.34 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.073 -1.251 . . . . 0.0 113.941 -176.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -66.49 -30.4 70.73 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.055 1.742 . . . . 0.0 113.784 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.6 t -114.63 166.88 11.25 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.982 -1.074 . . . . 0.0 110.089 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.3 m -84.12 36.38 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.577 -1.952 . . . . 0.0 115.903 -165.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.84 175.98 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 119.97 -1.706 . . . . 0.0 112.328 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -72.09 104.75 3.69 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.561 -1.337 . . . . 0.0 113.847 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 8.6 t60 48.35 51.88 14.4 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.138 2.575 . . . . 0.0 117.853 169.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 70.82 45.77 49.93 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.632 -1.293 . . . . 0.0 115.768 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -104.64 140.23 14.91 Favored Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.963 -1.316 . . . . 0.0 113.272 -178.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.64 127.8 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 170.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -128.03 157.64 40.1 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.465 -1.397 . . . . 0.0 111.218 -169.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.3 t -75.44 120.65 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 O-C-N 121.02 -1.05 . . . . 0.0 111.044 169.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -90.84 -52.09 5.04 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.626 1.571 . . . . 0.0 110.542 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.08 154.72 36.48 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.15 124.16 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 174.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.72 121.31 84.59 Favored Pre-proline 0 N--CA 1.429 -1.523 0 C-N-CA 126.671 1.989 . . . . 0.0 113.956 -167.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -57.7 123.41 13.67 Favored 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 124.448 2.624 . . . . 0.0 116.408 -172.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.268 3.9 mtpm? 76.84 25.99 0.82 Allowed 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 128.137 2.575 . . . . 0.0 114.855 -178.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.42 169.18 47.14 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.175 -1.578 . . . . 0.0 113.495 168.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.5 -58.76 5.01 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.084 2.154 . . . . 0.0 114.668 165.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.59 -47.71 77.63 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 128.861 2.864 . . . . 0.0 112.762 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -46.1 -59.03 3.12 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 116.845 2.165 . . . . 0.0 116.845 172.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 t -69.82 -27.71 65.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 124.848 1.259 . . . . 0.0 113.556 -175.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -50.79 -62.6 1.51 Allowed 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.838 2.055 . . . . 0.0 113.305 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.28 -45.36 1.16 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.969 -0.457 . . . . 0.0 113.087 168.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.46 -19.01 65.68 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 115.079 1.511 . . . . 0.0 115.079 -172.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.8 mt -96.31 117.19 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.519 0 C-N-CA 124.967 1.307 . . . . 0.0 109.06 172.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.7 m80 -118.57 159.45 23.54 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.773 -1.204 . . . . 0.0 110.879 -178.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -62.29 129.26 39.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.015 -1.678 . . . . 0.0 113.099 173.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.14 -0.3 72.0 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.886 -1.134 . . . . 0.0 114.831 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -79.62 152.23 30.14 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.768 -1.43 . . . . 0.0 111.289 178.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.8 ttt-85 -105.28 131.13 53.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.031 -1.668 . . . . 0.0 111.261 -168.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 38.3 t -85.34 136.88 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.963 -1.71 . . . . 0.0 110.941 -174.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -105.97 -56.65 2.15 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.908 -1.12 . . . . 0.0 109.386 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.7 137.22 18.79 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.186 -0.946 . . . . 0.0 111.925 -173.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.55 125.8 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 67.73 14.72 9.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.078 -1.639 . . . . 0.0 115.263 169.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.13 -13.26 52.26 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 119.748 -1.845 . . . . 0.0 112.913 -175.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -92.85 104.87 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 124.369 1.068 . . . . 0.0 109.333 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.3 t -74.26 126.71 31.23 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.665 -1.272 . . . . 0.0 109.589 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 85.1 mt -83.51 55.18 3.09 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.019 1.118 . . . . 0.0 114.019 -158.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -71.43 122.16 19.89 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 119.543 -1.973 . . . . 0.0 114.342 -172.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.63 5.09 72.59 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.186 -1.571 . . . . 0.0 115.437 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.62 140.59 49.81 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.255 1.946 . . . . 0.0 116.255 -171.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.2 p -93.3 178.86 5.59 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.496 2.319 . . . . 0.0 111.747 172.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 20.9 t-160 -57.48 -48.16 79.98 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 126.656 1.982 . . . . 0.0 114.463 179.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.3 tptt -56.66 -42.92 79.81 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 174.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.4 -50.48 73.8 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.868 1.667 . . . . 0.0 114.515 178.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.25 -38.31 83.07 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.038 1.335 . . . . 0.0 113.518 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 70.4 t -66.42 -46.92 85.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 O-C-N 120.792 -1.192 . . . . 0.0 111.851 173.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -54.65 -48.5 72.23 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.689 1.596 . . . . 0.0 112.359 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 13.6 m -64.84 -45.97 83.87 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.856 2.463 . . . . 0.0 114.048 175.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.1 mt -64.04 -34.1 77.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 119.29 -2.131 . . . . 0.0 114.675 174.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 17.6 mtp-105 -65.21 -36.58 84.63 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 112.851 172.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -86.52 46.22 1.33 Allowed 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 125.62 1.568 . . . . 0.0 112.712 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.1 p -107.12 155.99 19.27 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.65 1.58 . . . . 0.0 109.657 173.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.33 -156.4 32.29 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.647 -1.283 . . . . 0.0 112.53 178.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -68.88 -54.94 12.77 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.175 -1.191 . . . . 0.0 111.772 176.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 130.8 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 CA-C-O 122.497 1.141 . . . . 0.0 108.314 170.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 63.6 t -118.47 121.27 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 127.029 2.132 . . . . 0.0 109.743 -168.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -97.28 113.68 25.34 Favored 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 121.314 -0.866 . . . . 0.0 111.244 173.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.2 155.76 19.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.581 1.152 . . . . 0.0 112.639 169.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 40.3 tp -127.11 128.79 46.77 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 158.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.7 pp -142.3 170.15 16.25 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.671 -1.268 . . . . 0.0 111.213 175.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -114.7 145.74 41.71 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.267 1.827 . . . . 0.0 109.165 178.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.2 tptt -75.89 138.67 41.2 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.804 1.241 . . . . 0.0 111.308 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.16 130.28 38.37 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.822 -1.174 . . . . 0.0 114.135 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -83.89 -61.46 1.82 Allowed 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.654 -0.909 . . . . 0.0 112.063 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.2 m -98.49 144.14 27.57 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 124.288 1.035 . . . . 0.0 112.572 -177.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo . . . . . 0 N--CA 1.434 -2.026 0 C-N-CA 122.917 2.411 . . . . 0.0 114.005 166.975 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.269 32.4 ttmt . . . . . 0 N--CA 1.431 -1.423 0 CA-C-O 115.4 -2.238 . . . . 0.0 114.338 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -62.34 63.84 0.13 Allowed 'Trans proline' 0 N--CA 1.434 -2.007 0 C-N-CA 125.039 3.826 . . . . 0.0 117.538 168.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.06 27.43 1.7 Allowed Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 126.193 1.854 . . . . 0.0 112.622 -175.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -82.07 156.44 24.58 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 118.294 1.047 . . . . 0.0 109.171 167.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -114.01 149.8 34.84 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.805 1.242 . . . . 0.0 109.451 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -145.85 127.79 15.48 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -87.88 113.55 23.65 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 164.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 t -99.05 110.38 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 124.512 1.125 . . . . 0.0 109.702 -169.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.7 mt-10 -104.94 87.25 2.61 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.381 1.086 . . . . 0.0 110.242 -177.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.21 147.6 23.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.073 -1.017 . . . . 0.0 110.593 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.88 112.79 25.91 Favored 'General case' 0 N--CA 1.428 -1.544 0 C-N-CA 124.107 0.963 . . . . 0.0 108.593 160.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.6 ttmt -70.16 126.12 28.74 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.442 1.497 . . . . 0.0 112.608 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.8 p -104.27 123.35 47.21 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.045 -1.659 . . . . 0.0 110.894 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.8 t70 63.61 24.7 14.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.591 1.557 . . . . 0.0 113.861 170.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.6 4.81 89.95 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 119.51 -1.994 . . . . 0.0 115.189 -175.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.5 m -105.35 104.21 13.89 Favored 'General case' 0 N--CA 1.429 -1.477 0 CA-C-N 119.195 1.497 . . . . 0.0 111.629 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 11.9 tp -80.81 -45.51 16.81 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 120.563 -1.336 . . . . 0.0 111.475 173.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.06 28.08 3.23 Favored Glycine 0 N--CA 1.429 -1.773 0 C-N-CA 125.574 1.559 . . . . 0.0 113.547 170.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.9 tt -148.99 136.02 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 120.014 1.907 . . . . 0.0 114.694 -168.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.3 m -110.83 126.6 54.82 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.847 1.659 . . . . 0.0 108.48 167.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -104.24 172.01 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.219 1.007 . . . . 0.0 111.905 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.4 t -157.3 176.96 12.0 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.504 -1.372 . . . . 0.0 110.803 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 115.35 -128.33 8.03 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.457 1.027 . . . . 0.0 112.276 169.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.32 134.84 8.16 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.163 0.887 . . . . 0.0 111.279 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.7 m -66.95 -23.09 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 N-CA-C 115.702 1.741 . . . . 0.0 115.702 -170.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -99.17 4.49 46.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.779 1.632 . . . . 0.0 112.488 -176.018 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.6 m -87.57 -135.62 0.09 Allowed 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.118 -1.614 . . . . 0.0 110.908 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.5 m -80.24 -32.26 38.39 Favored 'General case' 0 N--CA 1.431 -1.377 0 O-C-N 118.39 -2.694 . . . . 0.0 110.036 177.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -83.74 92.13 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 126.135 1.774 . . . . 0.0 110.181 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.8 ttt-85 -70.03 109.99 4.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.582 -1.949 . . . . 0.0 111.706 -174.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 m170 58.8 45.66 15.19 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 125.818 1.647 . . . . 0.0 112.893 -167.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.53 -58.48 5.4 Favored Glycine 0 N--CA 1.429 -1.787 0 N-CA-C 115.66 1.024 . . . . 0.0 115.66 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.91 -177.92 20.62 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 124.917 1.246 . . . . 0.0 112.166 -165.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.7 mm -104.13 125.59 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.945 1.298 . . . . 0.0 109.664 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -126.84 158.81 35.68 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 120.276 -1.515 . . . . 0.0 112.182 -172.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.2 t -76.23 120.35 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 125.135 1.374 . . . . 0.0 112.689 175.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -93.93 -47.05 6.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.586 -1.321 . . . . 0.0 112.109 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.71 152.25 24.99 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 121.113 -0.992 . . . . 0.0 111.435 178.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.39 122.29 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 C-N-CA 126.136 1.774 . . . . 0.0 109.378 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 9.3 mm -77.58 123.93 86.66 Favored Pre-proline 0 N--CA 1.429 -1.495 0 C-N-CA 127.014 2.126 . . . . 0.0 114.352 -175.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -57.55 125.74 19.71 Favored 'Trans proline' 0 N--CA 1.434 -1.998 0 CA-C-N 124.607 2.681 . . . . 0.0 116.526 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.313 63.1 mttm 83.01 16.34 0.32 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 128.46 2.704 . . . . 0.0 113.72 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.06 162.48 38.83 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.116 -1.615 . . . . 0.0 114.128 169.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.41 -55.78 11.89 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.02 1.728 . . . . 0.0 114.977 170.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.89 -47.78 81.8 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.735 2.814 . . . . 0.0 112.59 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -48.44 -61.08 2.19 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 173.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.7 m -69.1 -32.59 72.11 Favored 'General case' 0 N--CA 1.429 -1.507 0 CA-C-N 115.499 -0.773 . . . . 0.0 112.859 -173.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -58.91 -70.28 0.16 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.947 1.699 . . . . 0.0 113.411 175.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.27 14.76 43.75 Favored Glycine 0 N--CA 1.43 -1.712 0 O-C-N 120.38 -1.45 . . . . 0.0 114.9 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -65.27 -26.47 68.1 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.707 -1.467 . . . . 0.0 111.691 159.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 71.6 mt -106.55 130.75 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 C-N-CA 126.686 1.994 . . . . 0.0 109.223 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -126.95 170.01 12.72 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-O 123.062 1.411 . . . . 0.0 110.835 169.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -60.59 129.69 42.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.01 -1.681 . . . . 0.0 113.388 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.31 4.15 86.44 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.291 -1.506 . . . . 0.0 115.608 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -75.46 161.98 28.74 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-N 119.835 1.817 . . . . 0.0 111.665 175.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.1 tpt85 -108.57 116.83 32.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.892 -1.13 . . . . 0.0 110.945 -170.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.6 t -84.66 130.6 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 O-C-N 120.511 -1.368 . . . . 0.0 108.283 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.31 -36.58 5.53 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.824 1.25 . . . . 0.0 112.401 -166.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 152.36 33.53 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.234 -1.541 . . . . 0.0 110.11 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.1 t -120.79 114.64 44.31 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 170.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 54.04 48.53 20.88 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.906 2.083 . . . . 0.0 115.535 170.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.06 -18.45 44.61 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 120.834 -1.166 . . . . 0.0 114.571 -177.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.6 t -94.21 105.8 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 O-C-N 120.82 -1.4 . . . . 0.0 109.004 -178.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.8 p -72.23 138.8 47.77 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.688 -1.257 . . . . 0.0 111.761 178.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 53.7 mt -87.15 32.62 0.68 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.636 -1.29 . . . . 0.0 112.777 -169.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -69.61 130.21 41.78 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.189 -2.195 . . . . 0.0 112.66 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.03 8.73 44.12 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 125.645 1.593 . . . . 0.0 116.253 -176.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.33 142.08 50.43 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -171.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 40.6 p -87.32 175.25 8.1 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.051 1.34 . . . . 0.0 110.312 173.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.1 t-160 -61.82 -40.22 94.5 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.644 -1.285 . . . . 0.0 111.757 174.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -54.93 -47.16 74.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.355 1.862 . . . . 0.0 114.928 173.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -56.6 -51.81 67.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 -179.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.32 -42.38 95.45 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.233 1.013 . . . . 0.0 113.28 177.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.08 -48.07 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.984 -1.073 . . . . 0.0 111.137 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -63.97 -41.31 97.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 3.5 m -61.0 -47.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 126.225 1.81 . . . . 0.0 112.874 175.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.7 mt -68.43 -29.67 68.38 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 175.33 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.4 ttt180 -62.76 -36.26 82.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.382 -1.449 . . . . 0.0 113.039 173.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -94.83 49.82 1.27 Allowed 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.643 -1.286 . . . . 0.0 111.76 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 37.0 p -107.34 139.68 41.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.325 1.45 . . . . 0.0 110.256 170.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.26 -142.95 12.25 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 123.564 0.602 . . . . 0.0 112.654 173.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -69.38 -60.98 1.98 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.303 -1.116 . . . . 0.0 113.401 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 t -92.02 118.24 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 122.701 1.239 . . . . 0.0 109.773 -176.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.6 t -117.93 111.1 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 126.122 1.769 . . . . 0.0 109.525 -166.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.8 m170 -99.71 103.01 14.65 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.092 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.5 mt -92.85 168.16 11.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.75 -1.844 . . . . 0.0 112.153 171.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.6 tp -129.05 137.67 51.43 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.016 1.326 . . . . 0.0 107.63 157.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.7 161.2 39.78 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.732 -1.23 . . . . 0.0 112.845 174.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -96.46 144.89 26.15 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 164.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.9 tmtt? -77.17 127.5 32.74 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.859 -1.151 . . . . 0.0 108.279 162.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.9 103.85 0.19 Allowed Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 125.735 1.636 . . . . 0.0 116.223 -166.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -65.49 -67.89 0.41 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -164.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 10.9 p -108.91 136.81 20.0 Favored Pre-proline 0 N--CA 1.429 -1.51 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.06 175.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo . . . . . 0 N--CA 1.434 -2.016 0 C-N-CA 122.438 2.092 . . . . 0.0 114.317 176.109 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 pttm . . . . . 0 N--CA 1.43 -1.438 0 CA-C-O 119.028 -0.511 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -69.82 -177.26 1.81 Allowed 'Trans proline' 0 N--CA 1.433 -2.031 0 C-N-CA 123.302 2.668 . . . . 0.0 115.631 -177.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.15 24.75 28.46 Favored Glycine 0 N--CA 1.43 -1.729 0 O-C-N 121.848 -0.533 . . . . 0.0 113.039 172.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -85.88 117.52 24.8 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.353 1.061 . . . . 0.0 108.982 -178.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -88.94 139.22 30.68 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.368 -1.458 . . . . 0.0 110.837 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.27 0.0 OUTLIER -147.4 140.48 25.12 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.277 1.513 . . . . 0.0 110.637 175.155 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -90.32 146.51 24.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.483 1.913 . . . . 0.0 109.323 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.5 t -122.81 110.46 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 125.008 1.323 . . . . 0.0 107.488 -174.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -105.83 84.2 2.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 CA-C-O 122.214 1.007 . . . . 0.0 108.458 174.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.3 tp -110.84 145.1 38.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.01 1.324 . . . . 0.0 110.283 -167.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.31 138.38 40.16 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 119.842 -1.786 . . . . 0.0 110.109 168.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -70.86 149.02 47.21 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 169.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.9 t -109.72 111.56 23.1 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.733 -1.229 . . . . 0.0 109.225 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.9 t0 43.34 50.27 5.98 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.923 2.489 . . . . 0.0 114.778 -178.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.97 -39.42 2.79 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.452 1.025 . . . . 0.0 115.043 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 m -102.03 148.72 25.03 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.731 -1.452 . . . . 0.0 114.793 -161.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -106.65 -61.37 1.54 Allowed 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.161 -0.962 . . . . 0.0 112.041 176.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.91 32.32 1.58 Allowed Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.669 -1.895 . . . . 0.0 112.798 175.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 pt -124.09 139.71 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 C-N-CA 125.105 1.362 . . . . 0.0 108.693 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.1 t -129.28 125.64 37.27 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 36.0 m -108.38 168.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.986 0.898 . . . . 0.0 112.63 -172.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.8 160.08 43.55 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.853 1.661 . . . . 0.0 109.095 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.86 -142.9 15.44 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.729 -1.232 . . . . 0.0 113.614 169.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.37 166.42 13.68 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 116.039 1.176 . . . . 0.0 116.039 174.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p -88.93 -28.32 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 O-C-N 120.757 -1.437 . . . . 0.0 114.64 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -83.94 -17.0 42.13 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.004 -1.685 . . . . 0.0 111.589 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.54 146.76 23.88 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.804 2.041 . . . . 0.0 109.677 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.5 m -86.31 60.58 6.32 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 120.71 -1.244 . . . . 0.0 112.004 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.9 m -100.34 -128.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 126.338 1.855 . . . . 0.0 111.321 -177.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -62.78 -61.13 2.62 Favored 'General case' 0 N--CA 1.432 -1.366 0 O-C-N 120.165 -1.584 . . . . 0.0 113.614 -177.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.0 t-160 151.34 65.43 0.0 OUTLIER 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 128.978 2.911 . . . . 0.0 106.174 -167.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 64.69 49.18 65.45 Favored Glycine 0 N--CA 1.429 -1.819 0 O-C-N 120.318 -1.489 . . . . 0.0 115.936 178.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -119.7 137.8 12.73 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.171 -1.194 . . . . 0.0 111.136 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 31.7 mm -103.41 120.85 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 172.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -124.57 160.98 27.17 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.788 -1.195 . . . . 0.0 109.119 -175.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.37 128.3 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.731 -1.231 . . . . 0.0 110.475 171.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 29.1 ttmt -89.94 -50.45 6.02 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.87 -1.144 . . . . 0.0 110.325 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.58 150.79 33.92 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 123.396 0.678 . . . . 0.0 109.873 -174.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -110.31 121.82 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 170.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 20.9 mm -76.64 121.0 84.08 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 126.219 1.808 . . . . 0.0 113.256 -171.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -58.31 122.93 12.52 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.83 2.353 . . . . 0.0 116.184 -175.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.321 64.7 mttt 82.5 20.16 0.27 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.367 2.267 . . . . 0.0 113.801 176.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.07 161.89 40.07 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.227 -0.921 . . . . 0.0 114.832 170.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.81 -57.04 7.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.131 2.172 . . . . 0.0 114.396 170.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.87 -52.55 62.67 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.58 2.352 . . . . 0.0 112.278 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -42.56 -64.86 0.54 Allowed 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.553 2.057 . . . . 0.0 116.553 174.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.9 m -69.94 -14.21 62.61 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -175.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.84 -64.32 1.03 Allowed 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.712 -1.243 . . . . 0.0 110.353 174.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.33 48.01 7.1 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 117.292 1.677 . . . . 0.0 117.292 170.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.7 mtt180 -84.56 -39.87 18.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 146.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 55.8 mt -83.42 121.47 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 126.162 1.785 . . . . 0.0 111.45 176.509 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 46.7 m-70 -122.08 171.75 8.75 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.243 1.497 . . . . 0.0 111.398 170.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -60.62 127.79 33.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.555 -1.34 . . . . 0.0 112.428 175.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.73 0.91 71.53 Favored Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 115.684 1.034 . . . . 0.0 115.684 -178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -82.17 150.05 27.61 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.83 1.815 . . . . 0.0 112.505 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -90.17 127.82 36.2 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.126 -1.609 . . . . 0.0 113.548 -177.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 30.4 t -83.12 132.79 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.787 177.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.93 -51.86 2.86 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.124 -0.985 . . . . 0.0 111.775 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.27 141.33 22.13 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.096 -1.627 . . . . 0.0 112.799 -175.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.8 t -114.94 120.28 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.343 1.057 . . . . 0.0 108.963 177.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 74.35 16.49 3.35 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.931 1.692 . . . . 0.0 114.558 169.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.54 -1.48 81.74 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.622 -1.299 . . . . 0.0 112.745 -170.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -98.28 117.36 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 125.353 1.461 . . . . 0.0 108.114 176.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t -74.21 125.86 29.34 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.3 -1.5 . . . . 0.0 109.346 178.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . 0.327 0.7 OUTLIER -92.27 39.32 1.02 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.314 1.531 . . . . 0.0 112.183 -176.251 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -76.36 121.37 22.91 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.135 -1.603 . . . . 0.0 110.753 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 81.5 17.79 70.2 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.757 1.17 . . . . 0.0 113.731 -172.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.25 154.26 41.09 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 123.226 1.489 . . . . 0.0 115.001 171.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.2 p -91.57 173.6 7.8 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.337 -1.477 . . . . 0.0 110.892 171.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -51.68 -51.93 52.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.439 1.896 . . . . 0.0 112.416 168.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.27 -53.19 61.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 115.446 1.647 . . . . 0.0 115.446 172.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -60.62 -42.74 97.46 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 -170.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.24 -29.65 68.91 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.168 1.387 . . . . 0.0 114.162 171.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.4 t -79.74 -44.28 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 125.033 1.333 . . . . 0.0 111.49 174.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -58.2 -37.24 74.4 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.335 -1.478 . . . . 0.0 112.745 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.7 m -65.83 -41.23 92.06 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 127.176 2.191 . . . . 0.0 113.54 172.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.9 mt -71.23 -40.14 71.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 175.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -72.08 -20.05 61.72 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.544 -1.973 . . . . 0.0 112.453 178.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -94.39 53.48 1.7 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.511 -1.368 . . . . 0.0 112.019 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.0 p -107.05 143.34 35.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.135 -1.603 . . . . 0.0 110.9 176.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.34 -154.97 18.49 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.76 -1.212 . . . . 0.0 111.242 171.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -66.5 -52.96 40.43 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.604 -1.527 . . . . 0.0 114.009 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.3 t -95.74 126.23 48.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 123.138 1.447 . . . . 0.0 109.567 177.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -109.82 109.36 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 127.298 2.239 . . . . 0.0 107.833 -175.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -93.73 111.44 23.13 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.091 -1.006 . . . . 0.0 108.988 172.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.9 mt -110.14 160.71 16.25 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.182 0.993 . . . . 0.0 112.457 170.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.95 133.11 49.2 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.413 1.485 . . . . 0.0 108.157 164.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.83 166.12 29.46 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.469 0.652 . . . . 0.0 112.536 178.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -101.86 144.74 30.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 121.046 -1.033 . . . . 0.0 111.179 173.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.6 tttt -75.86 126.82 31.73 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.615 1.566 . . . . 0.0 112.48 167.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.08 -166.88 32.25 Favored Glycine 0 N--CA 1.431 -1.656 0 CA-C-O 123.405 1.559 . . . . 0.0 116.883 178.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -94.95 -171.46 2.44 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 126.006 1.723 . . . . 0.0 111.288 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.0 t -80.16 117.84 69.53 Favored Pre-proline 0 N--CA 1.43 -1.43 0 CA-C-O 117.951 -1.023 . . . . 0.0 109.363 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo . . . . . 0 N--CA 1.434 -2.024 0 C-N-CA 122.41 2.073 . . . . 0.0 113.234 -174.912 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mmtt . . . . . 0 N--CA 1.431 -1.408 0 CA-C-O 116.372 -1.775 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -75.77 -179.56 5.28 Favored 'Trans proline' 0 N--CA 1.433 -2.041 0 CA-C-N 126.464 3.344 . . . . 0.0 112.408 175.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.92 6.89 66.69 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 120.951 -1.093 . . . . 0.0 114.017 178.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -78.41 157.7 28.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 O-C-N 121.123 -1.222 . . . . 0.0 110.745 175.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -119.93 137.72 53.88 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.42 1.488 . . . . 0.0 108.993 -174.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.08 140.76 28.28 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-O 122.827 1.298 . . . . 0.0 109.739 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -100.52 112.53 24.91 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.297 1.839 . . . . 0.0 108.039 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.8 t -103.81 102.08 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 O-C-N 120.608 -1.307 . . . . 0.0 108.769 -172.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.73 102.1 14.85 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 167.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.8 tp -120.03 138.02 53.76 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.701 1.201 . . . . 0.0 110.002 -172.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.17 122.3 43.37 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.27 -1.519 . . . . 0.0 109.486 173.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -71.42 171.51 11.14 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.289 -1.507 . . . . 0.0 114.408 177.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.2 t -97.03 -149.81 0.33 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.711 -1.243 . . . . 0.0 108.287 169.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.39 74.67 3.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.03 -2.294 . . . . 0.0 112.571 -175.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.36 -4.8 77.38 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.531 1.539 . . . . 0.0 115.509 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.2 t -121.57 135.83 54.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.104 -1.233 . . . . 0.0 112.015 -173.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.3 mt -103.92 -55.31 2.4 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.851 1.66 . . . . 0.0 110.113 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.0 30.03 0.59 Allowed Glycine 0 N--CA 1.431 -1.693 0 C-N-CA 125.369 1.462 . . . . 0.0 112.56 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.1 pt -125.95 141.44 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 CA-C-N 118.586 1.193 . . . . 0.0 113.477 -163.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.2 m -129.47 138.13 51.23 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.375 1.07 . . . . 0.0 109.005 158.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.4 m -118.34 169.58 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.525 0 C-N-CA 124.949 1.299 . . . . 0.0 112.49 -174.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.25 169.84 18.53 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 172.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 133.41 -147.94 19.19 Favored Glycine 0 N--CA 1.428 -1.836 0 O-C-N 120.572 -1.33 . . . . 0.0 115.53 165.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.17 172.26 24.17 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.43 1.014 . . . . 0.0 112.998 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.1 t -90.79 -51.88 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 C-N-CA 124.828 1.251 . . . . 0.0 112.917 -172.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -92.82 5.15 52.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.431 -1.418 . . . . 0.0 111.936 -169.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.7 m -78.14 170.18 17.04 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.461 2.304 . . . . 0.0 108.082 175.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.6 m -67.78 -6.74 22.67 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.16 -2.212 . . . . 0.0 115.921 177.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 3.3 m -78.12 89.83 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.548 1.166 . . . . 0.0 110.631 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 64.2 mtt85 -73.21 54.3 0.41 Allowed 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.849 -1.782 . . . . 0.0 115.123 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -123.98 -68.99 0.83 Allowed 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 126.052 1.741 . . . . 0.0 108.946 -177.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.69 -51.09 0.56 Allowed Glycine 0 N--CA 1.429 -1.803 0 O-C-N 120.729 -1.232 . . . . 0.0 112.352 176.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -83.64 176.47 52.38 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 115.932 1.133 . . . . 0.0 115.932 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 mm -99.17 129.18 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.833 2.053 . . . . 0.0 107.819 175.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -126.71 158.07 37.42 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.903 -1.123 . . . . 0.0 109.521 -174.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.9 t -75.95 117.36 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 O-C-N 121.023 -1.048 . . . . 0.0 111.377 174.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.8 tttp -88.33 -45.12 10.28 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.871 1.268 . . . . 0.0 110.83 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.0 163.19 39.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 121.252 -0.905 . . . . 0.0 108.995 173.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 tp -117.95 121.73 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 170.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.64 124.08 87.73 Favored Pre-proline 0 N--CA 1.429 -1.482 0 C-N-CA 126.076 1.75 . . . . 0.0 113.749 -165.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -59.26 127.42 23.93 Favored 'Trans proline' 0 C--N 1.299 -2.057 0 C-N-CA 122.778 2.319 . . . . 0.0 114.904 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.281 11.7 mptt 82.07 21.76 0.27 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 128.538 2.735 . . . . 0.0 112.649 -177.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.91 153.39 29.57 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.962 -1.711 . . . . 0.0 113.711 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.93 -54.87 13.69 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 126.464 1.906 . . . . 0.0 113.877 166.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -54.08 45.97 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 127.576 2.35 . . . . 0.0 112.265 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -40.95 -59.58 1.41 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 177.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.0 t -70.2 -29.99 66.98 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -66.2 -52.5 47.39 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.751 -1.218 . . . . 0.0 113.44 -172.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.11 21.7 9.86 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 120.663 -1.273 . . . . 0.0 115.946 158.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -85.15 -36.87 20.79 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.716 -1.461 . . . . 0.0 109.557 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.9 mt -100.48 124.73 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 125.781 1.632 . . . . 0.0 109.098 -176.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.516 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 3.4 t-80 -142.36 -175.39 4.43 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.117 1.437 . . . . 0.0 112.274 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.516 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.4 ttpp -68.95 123.56 21.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.027 -1.67 . . . . 0.0 113.307 -170.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.71 3.7 62.37 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.418 -0.801 . . . . 0.0 114.492 -178.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -78.72 156.38 28.94 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 119.423 1.612 . . . . 0.0 111.743 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -102.5 123.36 46.11 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.208 -1.558 . . . . 0.0 110.446 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 7.4 t -88.86 119.23 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 O-C-N 120.371 -1.456 . . . . 0.0 110.814 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 98.2 mt -94.09 -46.32 7.17 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.01 -1.056 . . . . 0.0 112.118 -175.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.37 144.01 25.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.855 -1.153 . . . . 0.0 112.484 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 2.9 p -113.42 111.71 37.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 C-N-CA 125.938 1.695 . . . . 0.0 112.504 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.9 t30 57.23 34.75 25.25 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.771 -1.83 . . . . 0.0 113.674 170.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.19 -28.56 13.32 Favored Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.314 1.435 . . . . 0.0 114.336 -172.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -98.07 129.45 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.235 2.017 . . . . 0.0 110.627 -163.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 26.6 p -71.37 132.33 44.68 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.164 -1.585 . . . . 0.0 112.607 -177.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 47.9 mt -99.45 35.96 1.86 Allowed 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.498 -1.376 . . . . 0.0 111.912 -178.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -89.67 144.26 26.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.714 -1.241 . . . . 0.0 109.486 167.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.26 -32.07 2.31 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.914 -1.117 . . . . 0.0 114.778 -176.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.66 152.28 44.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -175.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.8 p -91.76 175.36 6.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.985 -1.072 . . . . 0.0 112.012 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -58.64 -46.8 86.32 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.514 1.525 . . . . 0.0 112.249 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 30.0 tttp -54.69 -47.93 73.07 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 115.574 1.694 . . . . 0.0 115.574 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -58.67 -47.5 84.29 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.667 1.187 . . . . 0.0 113.652 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -61.67 -38.74 88.89 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.613 1.565 . . . . 0.0 114.22 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.22 -49.03 76.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 C-N-CA 124.866 1.266 . . . . 0.0 111.251 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -68.32 -30.13 69.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.771 -1.205 . . . . 0.0 112.168 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 38.8 m -64.33 -43.41 94.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.199 1.4 . . . . 0.0 114.691 167.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 67.3 mt -63.63 -37.03 85.8 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.074 -1.641 . . . . 0.0 114.171 173.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -67.09 -31.79 72.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.552 -1.342 . . . . 0.0 113.401 170.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -85.26 51.09 2.09 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.852 1.661 . . . . 0.0 112.1 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 p -106.59 148.48 28.24 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.442 -1.411 . . . . 0.0 109.867 171.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.66 -164.22 36.37 Favored Glycine 0 N--CA 1.43 -1.737 0 C-N-CA 123.778 0.704 . . . . 0.0 111.75 168.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -69.7 -46.27 66.38 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.732 -1.452 . . . . 0.0 114.65 -177.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 47.3 t -103.95 118.7 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 CA-C-O 122.437 1.113 . . . . 0.0 108.761 176.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.2 t -111.6 119.17 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 127.928 2.491 . . . . 0.0 109.926 -164.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -104.3 91.89 4.11 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.772 -1.205 . . . . 0.0 113.308 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -91.5 160.78 15.26 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.046 -2.284 . . . . 0.0 113.694 179.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.8 tp -127.0 128.06 45.77 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 161.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.32 158.48 44.32 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.989 -1.069 . . . . 0.0 112.213 176.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -110.07 140.71 43.83 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.047 1.339 . . . . 0.0 108.7 172.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.8 tptm -76.27 127.57 33.16 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.832 1.253 . . . . 0.0 111.476 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -72.45 147.99 41.46 Favored Glycine 0 N--CA 1.43 -1.751 0 C-N-CA 125.541 1.543 . . . . 0.0 113.415 -174.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 -78.26 177.13 8.65 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -170.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.5 p -147.73 128.0 6.78 Favored Pre-proline 0 N--CA 1.43 -1.428 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo . . . . . 0 C--N 1.3 -1.993 0 CA-C-N 122.417 1.899 . . . . 0.0 113.8 172.943 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? . . . . . 0 N--CA 1.429 -1.483 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -86.3 -173.94 1.36 Allowed 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.777 2.318 . . . . 0.0 112.777 -173.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.69 41.32 0.42 Allowed Glycine 0 N--CA 1.429 -1.771 0 C-N-CA 124.874 1.226 . . . . 0.0 115.643 172.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -87.81 153.95 20.93 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 124.914 1.286 . . . . 0.0 108.881 164.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.3 p -120.83 150.14 41.48 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.48 -1.388 . . . . 0.0 110.985 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 p90 -147.4 136.26 22.11 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.307 1.527 . . . . 0.0 109.412 172.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 21.4 mp0 -89.13 128.01 35.75 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 126.899 2.08 . . . . 0.0 108.581 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.404 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 74.6 t -109.82 94.87 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.497 0 O-C-N 121.036 -1.04 . . . . 0.0 108.252 -174.071 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -90.54 102.78 15.52 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-O 123.399 1.571 . . . . 0.0 109.61 169.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.6 tp -124.75 143.41 50.8 Favored 'General case' 0 N--CA 1.431 -1.395 0 C-N-CA 124.597 1.159 . . . . 0.0 110.678 -169.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.95 39.53 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.061 -1.649 . . . . 0.0 109.642 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -69.68 153.21 43.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.537 -1.352 . . . . 0.0 112.231 172.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.0 t -141.28 133.95 28.64 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 174.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 33.6 t0 50.93 39.48 22.83 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.959 2.104 . . . . 0.0 113.142 -172.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.13 3.05 55.52 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 120.11 -1.619 . . . . 0.0 116.898 -176.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 84.7 p -112.82 144.49 42.27 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 118.895 1.348 . . . . 0.0 114.03 -167.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 54.0 mt -102.84 -63.15 1.19 Allowed 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.92 1.288 . . . . 0.0 109.598 169.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.03 11.21 10.2 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 119.371 -2.081 . . . . 0.0 115.208 172.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 pt -100.56 131.58 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 CA-C-N 118.922 1.361 . . . . 0.0 111.188 174.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -110.8 121.61 45.76 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.055 -1.028 . . . . 0.0 108.7 168.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.9 m -105.49 165.68 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.702 1.201 . . . . 0.0 113.02 -173.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -149.25 162.53 39.83 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.328 1.451 . . . . 0.0 109.737 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.77 -135.14 12.45 Favored Glycine 0 N--CA 1.431 -1.698 0 CA-C-O 122.658 1.143 . . . . 0.0 115.853 163.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.55 172.6 44.27 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 121.253 -1.145 . . . . 0.0 113.407 -176.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m -73.2 -24.39 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 115.973 1.842 . . . . 0.0 115.973 -174.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -100.43 19.88 15.91 Favored 'General case' 0 N--CA 1.428 -1.535 0 O-C-N 120.573 -1.33 . . . . 0.0 113.025 -170.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . 0.254 12.5 t -116.35 -155.94 0.6 Allowed 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.428 -1.42 . . . . 0.0 109.975 170.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 29.4 p -71.73 -28.54 63.75 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 126.169 1.788 . . . . 0.0 115.048 -172.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 5.7 m -73.82 94.79 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 CA-C-O 123.422 1.582 . . . . 0.0 112.837 176.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 12.4 ptt180 -71.17 -13.6 61.99 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.112 -1.618 . . . . 0.0 114.655 -174.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 33.8 m-70 -71.38 -38.34 71.51 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.28 -1.512 . . . . 0.0 112.91 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.19 105.11 0.66 Allowed Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 124.44 1.019 . . . . 0.0 113.946 179.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.08 155.11 25.98 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.754 -1.439 . . . . 0.0 110.221 173.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -100.22 123.24 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.5 m-85 -123.59 157.21 34.24 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 121.059 -1.026 . . . . 0.0 110.667 -175.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.44 125.53 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 O-C-N 120.573 -1.329 . . . . 0.0 112.038 168.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -95.75 -35.62 11.47 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 120.397 -1.44 . . . . 0.0 112.457 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.51 158.03 36.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.854 -1.154 . . . . 0.0 112.221 -176.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -116.69 123.05 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.59 1.556 . . . . 0.0 109.881 175.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.2 mm -77.01 119.49 77.72 Favored Pre-proline 0 N--CA 1.43 -1.431 0 C-N-CA 125.93 1.692 . . . . 0.0 113.714 -176.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.74 124.39 12.27 Favored 'Trans proline' 0 C--N 1.299 -2.06 0 CA-C-N 124.744 2.73 . . . . 0.0 113.981 -172.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 10.5 mmmm 79.07 29.67 0.35 Allowed 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 129.334 3.054 . . . . 0.0 113.587 -175.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 162.66 38.14 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.507 -1.37 . . . . 0.0 113.102 162.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.08 -60.01 3.15 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 126.947 2.099 . . . . 0.0 114.911 166.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.32 -46.09 88.27 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 129.517 3.127 . . . . 0.0 112.391 -179.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -43.31 -65.67 0.46 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 171.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.5 t -67.72 -26.99 66.43 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -175.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.89 -56.82 16.99 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.265 -1.522 . . . . 0.0 111.8 174.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.19 2.57 64.03 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.72 -1.238 . . . . 0.0 114.733 157.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 65.0 mtt85 -56.04 -44.11 78.47 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.025 1.33 . . . . 0.0 110.793 159.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.5 mt -82.03 131.09 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 127.698 2.399 . . . . 0.0 111.759 -176.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 11.6 m-70 -122.72 155.44 36.45 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 128.314 2.646 . . . . 0.0 109.228 174.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 pttt -73.15 106.81 5.16 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.931 -1.73 . . . . 0.0 111.631 173.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.29 -31.35 2.06 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-O 119.16 -0.8 . . . . 0.0 113.733 -165.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.371 4.0 p30 -80.24 159.44 25.9 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 120.109 1.955 . . . . 0.0 116.112 -166.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.4 ttt85 -110.02 125.85 53.34 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.562 -1.336 . . . . 0.0 112.151 -162.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.5 t -82.11 135.07 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.488 -1.383 . . . . 0.0 111.173 -173.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 95.9 mt -103.83 -54.01 2.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.126 -0.983 . . . . 0.0 111.213 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.78 146.06 26.14 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.189 -1.569 . . . . 0.0 111.927 -174.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.0 t -114.04 107.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 123.704 0.802 . . . . 0.0 108.964 175.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.5 t30 61.81 45.17 7.93 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.967 2.107 . . . . 0.0 113.86 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.35 -24.25 14.89 Favored Glycine 0 N--CA 1.431 -1.68 0 O-C-N 121.136 -0.977 . . . . 0.0 113.571 -174.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.3 t -87.08 111.66 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.482 -1.599 . . . . 0.0 109.981 -175.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 p -69.31 128.62 37.24 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.721 1.209 . . . . 0.0 111.837 178.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 50.5 mt -86.03 52.18 2.41 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.168 -1.583 . . . . 0.0 111.869 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -78.9 121.16 24.51 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.592 -1.942 . . . . 0.0 113.48 -169.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.64 24.0 65.72 Favored Glycine 0 N--CA 1.431 -1.679 0 C-N-CA 124.873 1.225 . . . . 0.0 114.753 -176.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.96 42.34 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -170.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 74.6 p -91.65 170.5 9.87 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 124.688 1.195 . . . . 0.0 111.096 171.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 7.3 t-160 -58.44 -58.14 9.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.357 1.463 . . . . 0.0 114.41 -175.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -58.02 -29.74 65.55 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 116.169 1.914 . . . . 0.0 116.169 176.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.52 -52.18 66.46 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.411 1.484 . . . . 0.0 113.017 178.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.64 -45.13 89.93 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.066 1.746 . . . . 0.0 113.624 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.8 t -64.53 -48.73 83.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.146 1.378 . . . . 0.0 111.27 -179.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.3 mm-40 -65.75 -33.02 74.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.0 m -67.52 -45.37 75.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.525 1.93 . . . . 0.0 112.413 174.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.4 mt -58.89 -42.85 90.53 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 124.791 1.236 . . . . 0.0 113.508 172.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -69.97 -14.72 62.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 115.26 1.578 . . . . 0.0 115.26 178.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -95.65 36.63 1.26 Allowed 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.478 -2.014 . . . . 0.0 112.023 172.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 77.4 p -107.27 144.8 33.56 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.249 -1.532 . . . . 0.0 110.651 172.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.53 23.66 Favored Glycine 0 N--CA 1.429 -1.774 0 C-N-CA 123.965 0.793 . . . . 0.0 112.514 -177.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -60.9 -56.2 23.94 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.3 t -101.49 126.29 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 CA-C-O 122.282 1.039 . . . . 0.0 109.561 172.117 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 67.4 t -115.45 137.33 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 129.664 3.186 . . . . 0.0 108.662 -166.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 13.5 t-160 -124.22 106.33 10.21 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.505 -1.372 . . . . 0.0 111.394 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.404 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 18.7 mt -97.06 160.17 14.5 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 119.356 -2.09 . . . . 0.0 113.239 170.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 64.9 tp -127.96 131.87 49.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 161.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.0 pp -148.19 169.03 20.94 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.933 -1.104 . . . . 0.0 112.833 178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -117.01 143.46 45.71 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.576 1.55 . . . . 0.0 111.371 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -76.19 151.7 36.83 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 126.921 2.088 . . . . 0.0 113.386 -175.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -99.71 -161.11 28.85 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 125.777 1.656 . . . . 0.0 113.023 178.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -70.39 177.78 3.22 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 -167.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.12 124.4 35.38 Favored Pre-proline 0 N--CA 1.43 -1.455 0 O-C-N 120.586 -1.321 . . . . 0.0 109.696 -174.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_exo . . . . . 0 N--CA 1.434 -1.981 0 C-N-CA 123.238 2.625 . . . . 0.0 115.601 174.775 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.8 pttp . . . . . 0 N--CA 1.43 -1.467 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -71.44 177.68 6.45 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 122.025 1.817 . . . . 0.0 115.983 175.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.28 2.26 74.1 Favored Glycine 0 N--CA 1.43 -1.729 0 O-C-N 121.704 -0.623 . . . . 0.0 111.796 -178.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -93.96 139.0 31.45 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.635 1.974 . . . . 0.0 109.496 -171.226 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 p -106.96 149.53 27.41 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.13 -0.982 . . . . 0.0 112.524 -177.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -145.01 132.78 21.09 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.914 -1.116 . . . . 0.0 108.178 -176.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.87 120.01 28.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.39 1.476 . . . . 0.0 108.255 169.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.424 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 84.6 t -116.44 100.87 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 124.627 1.171 . . . . 0.0 109.328 -168.149 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -90.18 104.92 17.44 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.352 -1.468 . . . . 0.0 108.999 170.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.2 tp -119.95 130.67 54.89 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 124.91 1.284 . . . . 0.0 110.543 -169.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 146.12 28.54 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.722 -1.861 . . . . 0.0 109.64 173.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -67.93 166.02 16.55 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.933 1.827 . . . . 0.0 115.933 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 28.6 p -132.23 130.73 41.35 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.681 1.592 . . . . 0.0 108.163 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 46.6 44.43 13.5 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.925 2.09 . . . . 0.0 114.905 -175.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.88 -14.63 30.77 Favored Glycine 0 N--CA 1.429 -1.818 0 O-C-N 119.855 -1.778 . . . . 0.0 117.041 178.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 t -121.84 175.18 6.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 119.716 1.758 . . . . 0.0 112.113 -174.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 94.2 mt -99.96 -60.58 1.5 Allowed 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.702 1.201 . . . . 0.0 110.46 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.15 44.04 0.38 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.15 -1.594 . . . . 0.0 111.222 174.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 tt -144.06 147.86 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.068 1.413 . . . . 0.0 110.985 -172.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -124.57 117.69 24.89 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 125.071 1.348 . . . . 0.0 108.532 170.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 m -95.93 166.17 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 124.496 1.118 . . . . 0.0 112.726 -178.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.1 t -151.85 172.43 16.2 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.472 1.509 . . . . 0.0 110.247 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.47 -144.3 16.98 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.256 -0.902 . . . . 0.0 113.74 172.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.82 162.52 23.11 Favored Glycine 0 N--CA 1.43 -1.722 0 CA-C-O 122.489 1.049 . . . . 0.0 112.677 -177.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.5 p -66.07 -21.21 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.497 1.519 . . . . 0.0 114.508 -174.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -69.82 -27.26 64.73 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.902 1.681 . . . . 0.0 114.486 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 20.5 m -107.69 148.05 29.91 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.25 -1.531 . . . . 0.0 108.774 -174.18 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.7 t -78.56 58.66 2.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 119.434 -2.041 . . . . 0.0 113.944 -177.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 22.5 m -99.56 21.98 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 126.022 1.729 . . . . 0.0 114.561 -172.673 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.262 75.7 mtt180 82.44 98.02 0.05 OUTLIER 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.19 2.196 . . . . 0.0 110.494 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 42.5 m170 66.55 -73.43 0.07 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.953 2.101 . . . . 0.0 113.142 -166.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 158.6 40.62 0.02 OUTLIER Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.725 -1.234 . . . . 0.0 111.377 178.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -75.86 151.83 41.5 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.639 -0.918 . . . . 0.0 113.564 -173.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.5 mm -90.98 114.22 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.511 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 171.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -113.93 151.84 31.68 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.315 1.055 . . . . 0.0 110.012 -171.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.9 t -76.18 120.58 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.625 -1.297 . . . . 0.0 110.357 169.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -93.72 -48.59 6.25 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.707 -1.246 . . . . 0.0 110.587 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.43 157.99 43.92 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.491 -0.755 . . . . 0.0 109.51 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -124.47 123.92 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -77.33 122.46 86.12 Favored Pre-proline 0 N--CA 1.43 -1.446 0 CA-C-O 116.454 -1.736 . . . . 0.0 112.817 -170.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -58.11 128.6 29.39 Favored 'Trans proline' 0 N--CA 1.434 -1.991 0 CA-C-N 124.39 2.604 . . . . 0.0 115.797 -174.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.296 52.1 mtmt 76.07 17.52 2.12 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.283 2.233 . . . . 0.0 113.629 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.96 160.25 38.62 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.386 -1.446 . . . . 0.0 111.705 170.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.58 -56.47 8.32 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.14 -1.8 . . . . 0.0 115.837 168.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.0 -44.51 95.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.567 1.947 . . . . 0.0 112.399 -177.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -51.06 -65.21 0.6 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.297 1.592 . . . . 0.0 115.297 167.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 94.1 p -65.66 -26.94 68.02 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -169.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -55.47 -57.77 10.52 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.977 1.711 . . . . 0.0 113.228 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.63 -9.91 25.89 Favored Glycine 0 N--CA 1.43 -1.741 0 O-C-N 120.822 -1.174 . . . . 0.0 114.643 159.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.4 mtt180 -64.61 -32.4 74.05 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.763 1.225 . . . . 0.0 111.454 167.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 mt -96.91 124.76 49.89 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 C-N-CA 125.932 1.693 . . . . 0.0 110.762 -177.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 10.0 m80 -128.77 166.85 18.21 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.391 1.477 . . . . 0.0 109.487 170.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.0 ptpt -68.06 132.99 48.24 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.125 -1.609 . . . . 0.0 111.661 174.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 99.36 -7.9 60.19 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.026 -1.046 . . . . 0.0 114.524 -171.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -78.89 156.27 28.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-N 119.58 1.69 . . . . 0.0 112.41 -178.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -114.36 124.27 51.54 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.743 -1.223 . . . . 0.0 110.725 -168.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 10.7 t -87.67 131.29 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.296 -1.502 . . . . 0.0 110.162 -174.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.64 -44.8 5.46 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.684 -1.26 . . . . 0.0 110.307 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.32 143.22 25.67 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.598 -0.689 . . . . 0.0 110.814 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 39.9 t -124.93 124.06 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 173.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 63.82 33.79 12.42 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.966 1.707 . . . . 0.0 114.214 170.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.99 -15.76 62.75 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 120.693 -1.254 . . . . 0.0 113.698 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.38 116.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 121.554 -0.968 . . . . 0.0 110.202 -173.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -73.98 130.71 40.41 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.778 -1.202 . . . . 0.0 110.831 176.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.5 mt -85.48 44.2 1.08 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.866 -1.147 . . . . 0.0 114.065 -165.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -80.85 133.04 35.52 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.996 -2.315 . . . . 0.0 112.046 -177.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.53 13.07 67.78 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.488 -1.382 . . . . 0.0 114.793 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.31 142.72 48.85 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.767 1.395 . . . . 0.0 114.767 -178.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 36.0 p -90.56 178.18 6.16 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.013 1.725 . . . . 0.0 110.061 171.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -60.31 -48.98 79.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.837 -1.164 . . . . 0.0 112.971 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.0 mmtt -54.58 -38.51 66.78 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 126.365 1.866 . . . . 0.0 115.523 175.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -51.05 71.34 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.223 1.809 . . . . 0.0 113.187 -177.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.58 -34.05 73.6 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.516 1.527 . . . . 0.0 113.386 176.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.05 -53.44 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.375 0 C-N-CA 124.768 1.227 . . . . 0.0 110.127 178.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -60.79 -39.27 88.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 121.22 -0.925 . . . . 0.0 112.947 178.132 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 69.7 m -63.65 -40.64 97.37 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 124.828 1.251 . . . . 0.0 113.605 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 64.6 mt -72.0 -37.09 69.9 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.764 -1.21 . . . . 0.0 113.748 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 27.3 mtp180 -64.02 -47.35 80.59 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.188 -1.57 . . . . 0.0 112.793 176.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -88.14 58.97 5.05 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.716 1.246 . . . . 0.0 111.712 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.8 p -105.11 157.02 17.54 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.895 2.078 . . . . 0.0 110.052 176.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.26 -146.21 9.35 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.509 -1.37 . . . . 0.0 111.741 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.2 tt0 -71.85 -56.64 5.36 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.604 -1.527 . . . . 0.0 113.139 170.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 14.2 p -100.53 140.02 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.961 1.304 . . . . 0.0 109.316 179.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 72.5 t -124.22 122.85 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 127.496 2.318 . . . . 0.0 108.273 -170.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.8 m170 -100.52 101.36 12.27 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.058 -1.651 . . . . 0.0 110.561 177.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.424 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 8.7 mt -92.87 160.39 14.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.862 -1.774 . . . . 0.0 111.655 172.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.29 131.21 46.92 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 157.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.7 pp -143.4 166.85 23.62 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.993 -1.692 . . . . 0.0 112.312 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -112.73 146.24 39.11 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.406 1.882 . . . . 0.0 108.589 175.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.79 127.25 32.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.784 -1.197 . . . . 0.0 110.57 176.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.06 133.5 39.95 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.677 1.608 . . . . 0.0 113.379 -175.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -69.47 -34.71 74.77 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 115.435 1.643 . . . . 0.0 115.435 -166.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 m -132.58 160.52 67.97 Favored Pre-proline 0 N--CA 1.429 -1.484 0 O-C-N 121.469 -0.769 . . . . 0.0 109.435 -175.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo . . . . . 0 N--CA 1.434 -1.98 0 C-N-CA 122.697 2.264 . . . . 0.0 111.627 170.308 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.442 0 CA-C-O 115.739 -2.077 . . . . 0.0 112.142 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -73.69 178.94 6.12 Favored 'Trans proline' 0 N--CA 1.434 -1.997 0 CA-C-N 126.363 3.308 . . . . 0.0 113.007 173.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.91 7.69 68.08 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 121.105 -0.997 . . . . 0.0 114.358 174.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -95.92 152.21 18.72 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.197 0.999 . . . . 0.0 108.872 177.27 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.7 p -97.43 162.32 13.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 122.11 0.957 . . . . 0.0 112.534 -176.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -144.82 138.19 26.9 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -93.66 115.38 27.83 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 126.301 1.84 . . . . 0.0 107.149 166.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.435 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 32.7 t -111.87 99.78 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -175.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -90.05 100.09 12.98 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.351 -1.468 . . . . 0.0 109.593 176.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.0 tp -116.59 136.91 52.59 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.744 1.218 . . . . 0.0 111.032 -162.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.66 145.81 29.51 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.443 -1.41 . . . . 0.0 109.006 169.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -70.81 141.66 51.34 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.924 -1.11 . . . . 0.0 113.677 174.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.9 t -137.95 142.7 40.53 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.426 -1.421 . . . . 0.0 109.619 174.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.1 t0 54.55 34.71 21.84 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.107 2.163 . . . . 0.0 113.906 -177.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.55 63.26 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 124.877 1.227 . . . . 0.0 115.948 -174.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 71.7 p -121.32 142.41 49.99 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-N 118.886 1.343 . . . . 0.0 114.033 -171.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.4 mt -89.72 -61.61 1.65 Allowed 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 159.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.79 48.19 0.55 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 118.98 -2.325 . . . . 0.0 112.711 163.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.3 tt -145.94 150.11 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.334 1.064 . . . . 0.0 110.006 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.4 t -122.94 125.66 45.74 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 164.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 m -106.15 157.74 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 125.338 1.455 . . . . 0.0 110.025 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.9 t -141.95 170.34 15.9 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.094 0.958 . . . . 0.0 109.71 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -132.09 10.96 Favored Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 123.885 0.755 . . . . 0.0 113.228 173.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.45 -179.83 42.07 Favored Glycine 0 N--CA 1.431 -1.696 0 CA-C-O 122.46 1.033 . . . . 0.0 111.747 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.36 -8.68 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.499 0 O-C-N 120.923 -1.339 . . . . 0.0 113.274 -169.243 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -71.95 -51.36 22.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.341 -1.474 . . . . 0.0 113.082 -178.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.7 p -92.3 169.92 10.2 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.341 1.056 . . . . 0.0 110.662 178.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 67.3 m -92.09 60.97 3.89 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.935 -1.728 . . . . 0.0 111.47 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 6.2 p -83.17 160.83 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.435 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 166.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.64 104.74 0.11 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.202 1.401 . . . . 0.0 114.742 -172.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.5 t60 58.78 13.87 2.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 128.131 2.573 . . . . 0.0 117.474 -174.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.17 23.29 61.48 Favored Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.158 -1.589 . . . . 0.0 115.135 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.03 174.49 54.78 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 121.396 -1.061 . . . . 0.0 115.401 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.2 mm -103.7 117.56 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.716 1.607 . . . . 0.0 107.373 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -124.98 150.0 47.13 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.795 -1.19 . . . . 0.0 110.171 -168.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 32.2 t -75.66 122.31 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.456 -1.402 . . . . 0.0 113.201 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -89.3 -56.48 3.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.363 1.065 . . . . 0.0 109.686 173.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.46 156.19 43.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.117 -0.989 . . . . 0.0 111.454 -173.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.437 HG22 ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -119.2 117.97 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.06 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 28.7 mm -76.89 125.06 87.49 Favored Pre-proline 0 N--CA 1.43 -1.451 0 CA-C-O 115.391 -2.242 . . . . 0.0 113.0 -165.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -53.33 136.95 64.08 Favored 'Trans proline' 0 C--N 1.3 -1.979 0 C-N-CA 123.628 2.886 . . . . 0.0 116.899 -171.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.277 6.6 mtpm? 51.67 26.1 3.21 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 119.168 3.025 . . . . 0.0 119.168 -169.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.31 169.65 54.91 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 118.995 -2.316 . . . . 0.0 113.201 170.083 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.21 -60.86 2.55 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.121 1.768 . . . . 0.0 114.136 165.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.9 -45.48 92.33 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 129.01 2.924 . . . . 0.0 112.646 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.437 ' HG2' HG22 ' A' ' 47' ' ' ILE . 1.5 tm-20 -43.66 -68.25 0.21 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.826 1.65 . . . . 0.0 114.818 166.143 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 74.9 m -69.89 -14.84 62.93 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 116.367 1.988 . . . . 0.0 116.367 -174.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -61.38 -55.72 28.4 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.82 1.248 . . . . 0.0 111.751 170.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.29 4.7 77.1 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 120.301 -1.5 . . . . 0.0 115.699 167.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -75.17 -38.3 60.91 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.243 -1.739 . . . . 0.0 110.326 163.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.5 mt -77.59 120.63 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 126.352 1.861 . . . . 0.0 111.122 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -117.99 166.09 12.94 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 125.895 1.678 . . . . 0.0 111.153 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 48.0 tttm -63.98 127.3 30.81 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 119.966 -1.709 . . . . 0.0 111.936 171.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.59 0.94 68.98 Favored Glycine 0 N--CA 1.431 -1.662 0 O-C-N 121.29 -0.882 . . . . 0.0 113.992 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.06 153.47 43.59 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 119.178 1.489 . . . . 0.0 112.792 179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 65.1 ttt-85 -105.46 122.06 45.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.832 0.825 . . . . 0.0 109.299 -176.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.4 t -82.89 134.95 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.751 -1.218 . . . . 0.0 109.81 -177.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.2 mp -105.64 -50.08 3.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.856 -1.152 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.15 151.2 32.74 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.369 -1.457 . . . . 0.0 111.88 -175.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 3.4 p -118.06 110.21 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 122.379 1.085 . . . . 0.0 112.393 172.058 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 55.26 39.68 31.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.943 -1.723 . . . . 0.0 114.913 164.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.96 -13.42 60.55 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-O 119.324 -0.709 . . . . 0.0 114.5 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.9 t -102.17 111.12 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.614 2.207 . . . . 0.0 109.302 -176.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 43.6 m -76.27 119.73 20.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.213 -1.554 . . . . 0.0 110.625 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 87.2 mt -92.41 35.47 1.01 Allowed 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.66 -1.275 . . . . 0.0 112.223 -167.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -88.61 91.19 8.71 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 119.619 -1.926 . . . . 0.0 112.52 -168.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 96.93 10.55 54.99 Favored Glycine 0 N--CA 1.429 -1.812 0 C-N-CA 125.202 1.382 . . . . 0.0 112.157 -171.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.85 157.7 37.4 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-O 122.532 1.158 . . . . 0.0 113.535 171.356 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 41.5 p -83.49 172.91 11.94 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.255 -1.528 . . . . 0.0 113.169 -175.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-80 -58.41 -46.17 86.96 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.386 1.474 . . . . 0.0 113.613 170.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -57.96 -43.06 86.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 172.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.91 -55.15 36.04 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 114.432 1.271 . . . . 0.0 114.432 -175.136 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.3 -43.3 64.41 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 116.284 1.957 . . . . 0.0 116.284 171.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.57 -52.04 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.756 -1.215 . . . . 0.0 111.461 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -64.64 -30.63 71.65 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.19 -0.944 . . . . 0.0 111.886 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.4 m -63.87 -51.41 64.7 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.186 1.394 . . . . 0.0 113.509 170.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.6 mt -60.42 -37.01 79.51 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 120.565 1.53 . . . . 0.0 113.789 176.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -61.93 -44.41 96.83 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.493 1.517 . . . . 0.0 113.763 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -94.54 55.91 2.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.539 1.536 . . . . 0.0 112.682 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.45 145.36 31.87 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.533 -1.355 . . . . 0.0 109.983 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.02 -141.32 4.8 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.658 -1.276 . . . . 0.0 111.889 176.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -70.69 -58.31 3.78 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.383 -1.657 . . . . 0.0 113.791 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 t -109.57 137.76 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.533 1.133 . . . . 0.0 110.947 -176.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.6 t -125.13 122.56 63.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 C-N-CA 128.924 2.89 . . . . 0.0 110.911 -173.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.0 t-160 -100.81 95.9 6.94 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.139 -2.226 . . . . 0.0 113.085 176.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.435 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 23.5 mt -88.2 154.83 20.12 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 118.92 -2.363 . . . . 0.0 113.328 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 39.0 tp -127.25 135.46 50.64 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 163.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -150.63 168.91 22.89 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.889 -1.132 . . . . 0.0 111.942 175.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.92 141.68 47.63 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.078 2.151 . . . . 0.0 109.142 172.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.14 121.25 22.57 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.13 1.372 . . . . 0.0 112.305 179.269 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -86.0 138.44 16.07 Favored Glycine 0 N--CA 1.429 -1.77 0 C-N-CA 126.894 2.188 . . . . 0.0 114.307 -169.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -90.71 -176.26 4.65 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.368 -1.078 . . . . 0.0 113.89 -175.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.2 m -113.45 151.79 44.74 Favored Pre-proline 0 CA--C 1.489 -1.399 0 O-C-N 120.767 -1.208 . . . . 0.0 110.389 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 N--CA 1.434 -2.015 0 C-N-CA 122.322 2.015 . . . . 0.0 112.903 179.825 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.2 mtmt . . . . . 0 N--CA 1.429 -1.485 0 CA-C-O 116.222 -1.847 . . . . 0.0 115.126 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -77.07 -178.56 4.67 Favored 'Trans proline' 0 N--CA 1.434 -1.997 0 CA-C-N 125.962 3.165 . . . . 0.0 113.432 -176.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.44 3.75 55.22 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.46 -0.775 . . . . 0.0 112.928 -176.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -75.68 152.46 37.52 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.168 1.387 . . . . 0.0 111.183 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.86 139.61 44.73 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.364 -1.46 . . . . 0.0 110.325 -176.48 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -146.52 154.99 42.18 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-O 123.037 1.398 . . . . 0.0 110.298 174.172 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -108.6 142.24 39.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.893 1.677 . . . . 0.0 107.362 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.5 t -122.63 106.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.684 1.193 . . . . 0.0 108.648 -171.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -95.16 97.78 10.15 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 121.002 -1.061 . . . . 0.0 109.275 169.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.9 tp -119.79 129.93 54.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 123.787 0.835 . . . . 0.0 112.601 -168.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.71 123.55 44.08 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.365 -1.46 . . . . 0.0 109.452 171.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -69.61 114.83 8.19 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.507 1.523 . . . . 0.0 113.183 -177.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.3 t -96.53 129.67 43.86 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.323 -1.486 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.6 t70 41.48 49.41 3.55 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.337 2.655 . . . . 0.0 114.917 -175.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.29 10.61 70.01 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 117.336 1.695 . . . . 0.0 117.336 -178.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 85.3 p -120.97 129.12 53.3 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 119.86 1.83 . . . . 0.0 113.977 -175.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 82.5 mt -85.8 -58.31 2.7 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.823 -1.173 . . . . 0.0 111.077 168.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.37 23.05 4.25 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 119.4 -2.062 . . . . 0.0 113.598 176.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 pt -122.41 141.28 43.44 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 CA-C-O 123.092 1.425 . . . . 0.0 113.348 -174.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.9 t -113.45 126.61 55.53 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 159.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 m -115.59 159.54 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.03 1.332 . . . . 0.0 110.749 -177.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.21 166.11 28.01 Favored 'General case' 0 N--CA 1.428 -1.532 0 C-N-CA 124.862 1.265 . . . . 0.0 109.424 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.35 -143.0 16.79 Favored Glycine 0 N--CA 1.429 -1.815 0 O-C-N 120.155 -1.591 . . . . 0.0 114.674 160.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 103.56 161.63 25.09 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.548 1.07 . . . . 0.0 111.514 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.3 p -71.43 -25.78 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.547 -1.56 . . . . 0.0 114.068 -171.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.2 t-20 -91.4 1.48 57.09 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.433 1.493 . . . . 0.0 111.521 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 24.3 m -102.39 179.94 4.16 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.144 -2.169 . . . . 0.0 105.144 176.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 32.7 p -76.53 34.67 0.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 118.932 -2.355 . . . . 0.0 115.999 -172.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.1 t -96.46 110.32 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.456 -1.402 . . . . 0.0 110.118 -174.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.6 ptt85 -71.83 -31.47 66.56 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.282 -1.511 . . . . 0.0 112.61 -178.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 4.0 t-160 -85.86 -3.0 58.81 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.651 1.18 . . . . 0.0 113.07 178.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 64.92 72.69 0.68 Allowed Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 125.578 1.561 . . . . 0.0 116.866 170.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 172.72 45.71 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 118.891 -1.623 . . . . 0.0 114.128 177.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.0 mm -84.97 129.87 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.923 1.689 . . . . 0.0 109.104 174.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -122.89 150.37 43.0 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.166 -0.959 . . . . 0.0 109.271 -175.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -77.77 127.7 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.433 -1.417 . . . . 0.0 112.019 170.106 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.7 ttpp -94.91 -44.1 7.88 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.704 -1.247 . . . . 0.0 111.747 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.91 153.85 33.86 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.878 -1.139 . . . . 0.0 112.926 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.271 1.0 OUTLIER -102.94 118.14 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 CA-C-O 122.644 1.211 . . . . 0.0 110.038 168.822 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.9 mm -76.38 124.11 87.98 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 126.436 1.894 . . . . 0.0 112.366 -173.18 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -56.29 129.96 37.62 Favored 'Trans proline' 0 N--CA 1.434 -1.992 0 C-N-CA 122.835 2.357 . . . . 0.0 115.166 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.8 mtmt 75.4 22.34 1.67 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.265 1.826 . . . . 0.0 114.771 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.44 167.17 42.65 Favored Glycine 0 N--CA 1.43 -1.743 0 O-C-N 119.722 -1.861 . . . . 0.0 115.26 169.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.63 -63.35 1.15 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.3 98.09 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 129.087 2.955 . . . . 0.0 112.824 -176.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -42.21 -55.72 3.18 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 168.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.0 t -68.53 -38.15 80.61 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.74 -51.66 68.01 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 126.067 1.747 . . . . 0.0 112.171 177.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.31 1.02 72.6 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.606 -1.309 . . . . 0.0 114.421 159.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -67.87 -44.11 77.82 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.315 1.446 . . . . 0.0 110.498 166.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 36.0 mt -85.64 129.66 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 125.532 1.533 . . . . 0.0 109.8 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.38 167.33 29.09 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.288 1.035 . . . . 0.0 110.961 -171.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.0 tttm -50.72 121.41 5.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -178.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.07 7.6 67.83 Favored Glycine 0 N--CA 1.429 -1.804 0 CA-C-O 117.904 -1.498 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.296 1.7 p30 -77.51 152.64 34.02 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-N 120.786 2.293 . . . . 0.0 112.767 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -102.17 120.59 40.7 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -176.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.11 128.74 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.077 -1.015 . . . . 0.0 109.768 -176.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.1 mt -99.26 -45.29 5.93 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.435 -1.416 . . . . 0.0 111.446 -175.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.67 145.17 25.67 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.673 -1.267 . . . . 0.0 111.658 -178.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.1 t -112.31 108.52 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.051 0.94 . . . . 0.0 109.445 173.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.0 t30 60.08 38.82 20.32 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.879 1.672 . . . . 0.0 114.547 166.243 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -16.21 60.14 Favored Glycine 0 N--CA 1.43 -1.718 0 C-N-CA 125.307 1.432 . . . . 0.0 114.214 -177.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.4 t -97.14 120.68 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 121.008 -1.29 . . . . 0.0 110.58 -176.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.9 t -75.33 133.89 41.15 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.486 -1.384 . . . . 0.0 111.956 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 88.2 mt -88.21 12.62 13.34 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.908 -1.12 . . . . 0.0 113.628 -176.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 39.2 mm-40 -64.96 128.43 35.74 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 119.934 -1.729 . . . . 0.0 112.414 173.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.25 -6.57 67.29 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 125.314 1.435 . . . . 0.0 116.115 -176.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.6 149.71 45.37 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 116.953 2.205 . . . . 0.0 116.953 -174.524 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 30.5 p -93.19 -179.61 5.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 125.704 1.602 . . . . 0.0 110.943 171.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -63.91 -50.35 69.07 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.541 -1.349 . . . . 0.0 111.765 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 38.0 mttp -56.46 -39.35 73.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.915 1.45 . . . . 0.0 114.915 175.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -57.37 -54.3 48.41 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 114.51 1.3 . . . . 0.0 114.51 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.51 -36.13 81.97 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 124.63 1.172 . . . . 0.0 113.124 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.6 t -64.18 -51.27 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 120.949 -1.094 . . . . 0.0 110.706 174.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.581 -1.324 . . . . 0.0 113.608 178.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 87.8 m -62.87 -51.14 68.14 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.702 2.001 . . . . 0.0 112.874 173.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 74.3 mt -65.84 -32.05 73.35 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.95 -1.719 . . . . 0.0 114.988 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -68.18 -28.46 67.29 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.497 -1.377 . . . . 0.0 111.667 173.062 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -93.25 41.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.215 -1.553 . . . . 0.0 112.543 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -98.88 153.96 18.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.147 -1.596 . . . . 0.0 110.907 172.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -106.78 -138.33 8.93 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 124.777 1.18 . . . . 0.0 110.81 174.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -70.05 -66.9 0.54 Allowed 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -177.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.3 120.65 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 122.287 1.041 . . . . 0.0 109.256 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 71.3 t -114.54 119.53 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 128.51 2.724 . . . . 0.0 108.966 -167.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.1 t-160 -107.38 88.87 2.83 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.733 -1.229 . . . . 0.0 113.298 -174.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.1 mt -92.37 157.13 16.78 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.82 -1.8 . . . . 0.0 113.868 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 55.4 tp -127.47 129.09 46.82 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.743 1.217 . . . . 0.0 108.177 170.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.43 161.52 37.83 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-O 122.307 1.051 . . . . 0.0 113.715 179.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -120.35 132.07 55.12 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.108 1.363 . . . . 0.0 109.645 175.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.2 tptm -77.2 134.32 38.66 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.803 -1.186 . . . . 0.0 113.758 -164.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.29 162.41 32.12 Favored Glycine 0 N--CA 1.429 -1.784 0 CA-C-O 122.144 0.858 . . . . 0.0 114.553 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -87.03 176.23 7.73 Favored 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 124.411 1.084 . . . . 0.0 111.903 -178.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.5 p -135.63 117.18 11.99 Favored Pre-proline 0 N--CA 1.429 -1.479 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 166.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.434 -2.008 0 CA-C-N 123.391 2.247 . . . . 0.0 113.061 -170.962 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.262 1.3 mptp? . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 116.252 -1.832 . . . . 0.0 112.527 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.93 178.65 7.17 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 CA-C-N 125.829 3.117 . . . . 0.0 112.967 175.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.15 -30.09 10.1 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 121.241 -0.912 . . . . 0.0 113.963 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -80.79 167.91 19.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 118.373 1.087 . . . . 0.0 112.661 -176.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 45.0 p -105.41 161.45 14.31 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.211 1.405 . . . . 0.0 113.181 -175.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.22 140.66 25.46 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 167.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -88.54 132.96 34.3 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-O 122.264 1.031 . . . . 0.0 109.471 163.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 t -120.8 98.18 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 126.053 1.741 . . . . 0.0 109.727 -169.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.411 ' HG2' ' CD2' ' A' ' 93' ' ' HIS . 42.8 mt-10 -91.09 102.29 15.04 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.355 -1.466 . . . . 0.0 109.972 174.026 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -123.1 128.64 50.38 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.85 -1.156 . . . . 0.0 111.33 -166.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.23 125.19 47.83 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 119.967 -1.708 . . . . 0.0 110.354 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 47.9 mtpt -69.69 150.17 47.26 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.517 1.673 . . . . 0.0 115.517 -173.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.8 p -102.91 87.39 2.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.852 1.261 . . . . 0.0 109.407 178.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.2 t0 45.92 64.83 1.32 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.348 2.659 . . . . 0.0 116.127 -175.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.74 -29.54 9.04 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 121.06 -1.025 . . . . 0.0 113.549 -178.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.9 m -97.42 136.19 38.21 Favored 'General case' 0 N--CA 1.43 -1.445 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -169.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.2 mt -85.26 -60.5 2.02 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.23 1.412 . . . . 0.0 110.691 171.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.35 27.58 1.79 Allowed Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.404 -2.06 . . . . 0.0 111.292 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 pt -124.88 155.96 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.555 1.142 . . . . 0.0 110.961 -170.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.6 t -129.8 130.38 45.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 152.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -104.82 157.93 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.914 1.286 . . . . 0.0 109.617 -177.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -140.33 169.71 17.17 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.717 -1.24 . . . . 0.0 109.111 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.52 -140.29 15.32 Favored Glycine 0 N--CA 1.43 -1.734 0 CA-C-O 122.372 0.984 . . . . 0.0 114.876 164.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.23 157.53 32.23 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 122.235 0.908 . . . . 0.0 112.838 -174.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.5 m -66.34 -39.22 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 116.951 2.204 . . . . 0.0 116.951 -166.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -100.17 23.04 10.53 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.208 -1.558 . . . . 0.0 114.994 -167.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . 0.252 14.8 t -107.5 -145.18 0.39 Allowed 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.731 -1.231 . . . . 0.0 109.481 173.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 63.7 p -77.83 -24.74 48.58 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 118.875 -2.391 . . . . 0.0 114.502 -177.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.8 m -79.77 108.12 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 123.769 1.747 . . . . 0.0 111.748 175.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.9 ttm105 -73.04 120.29 18.46 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.23 -1.544 . . . . 0.0 111.727 -178.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.7 m170 61.44 38.88 15.64 Favored 'General case' 0 CA--C 1.489 -1.372 0 C-N-CA 126.431 1.892 . . . . 0.0 113.322 -167.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 126.01 25.44 Favored Glycine 0 N--CA 1.43 -1.76 0 CA-C-O 122.455 1.031 . . . . 0.0 114.974 -176.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -79.81 -176.18 49.02 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 121.27 -1.135 . . . . 0.0 111.125 158.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.8 mm -99.67 119.27 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -120.36 149.79 41.79 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.898 -1.126 . . . . 0.0 110.366 -171.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.8 t -76.75 112.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 O-C-N 121.022 -1.049 . . . . 0.0 111.67 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.36 -41.92 11.22 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 120.804 -1.185 . . . . 0.0 112.109 -174.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.61 151.99 35.97 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.82 -1.175 . . . . 0.0 110.411 176.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.98 119.91 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.5 1.143 . . . . 0.0 108.819 173.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.21 125.61 86.3 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 117.042 2.238 . . . . 0.0 117.042 -166.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -53.84 119.08 5.68 Favored 'Trans proline' 0 N--CA 1.434 -2.011 0 C-N-CA 123.645 2.897 . . . . 0.0 116.512 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.255 67.2 mmtt 76.16 30.0 0.73 Allowed 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 128.267 2.627 . . . . 0.0 112.421 -177.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 158.07 33.7 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.617 -1.302 . . . . 0.0 111.119 168.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -59.23 3.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.794 -1.416 . . . . 0.0 113.346 166.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.24 -46.69 85.77 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 128.553 2.741 . . . . 0.0 113.914 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -42.78 -60.62 1.51 Allowed 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 172.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.17 -30.96 69.29 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -60.93 -62.79 1.6 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 125.655 1.582 . . . . 0.0 113.336 -178.079 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.94 6.17 49.42 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 116.987 1.555 . . . . 0.0 116.987 166.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.7 mmt85 -72.33 -37.22 68.93 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-N 119.541 1.67 . . . . 0.0 110.805 164.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.9 mt -92.27 124.28 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.922 1.289 . . . . 0.0 108.11 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -145.6 176.86 9.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.387 -1.446 . . . . 0.0 111.619 175.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -65.59 126.4 28.23 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.298 1.039 . . . . 0.0 113.023 -170.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.24 80.65 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 121.128 -0.983 . . . . 0.0 115.533 -179.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.51 157.97 25.97 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 119.117 1.458 . . . . 0.0 111.911 -177.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -105.12 121.66 44.28 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.088 -1.008 . . . . 0.0 111.212 -172.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 58.9 t -82.31 134.39 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.406 0 C-N-CA 125.727 1.611 . . . . 0.0 107.895 -176.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -119.42 -52.14 2.27 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.96 -1.087 . . . . 0.0 113.715 -167.237 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.85 113.28 4.96 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.626 -1.296 . . . . 0.0 111.138 -173.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -93.59 111.64 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.164 -0.96 . . . . 0.0 108.945 -175.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 61.68 36.15 16.66 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.901 2.08 . . . . 0.0 113.407 177.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.39 -9.89 75.34 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 125.001 1.286 . . . . 0.0 113.669 -176.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.4 t -90.94 101.96 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.11 -1.818 . . . . 0.0 109.019 -176.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.3 m -66.79 133.21 49.67 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.707 -1.246 . . . . 0.0 112.125 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.2 mt -85.97 45.95 1.27 Allowed 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.293 1.037 . . . . 0.0 112.262 -171.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -74.82 118.99 18.4 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.93 -1.731 . . . . 0.0 112.295 -171.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.52 22.88 75.23 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 124.031 0.824 . . . . 0.0 114.825 -175.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.92 145.34 50.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -176.022 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.3 p -90.13 170.84 9.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.872 1.269 . . . . 0.0 110.835 168.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.3 t-160 -53.04 -50.58 64.01 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.324 1.85 . . . . 0.0 113.563 175.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -56.42 -43.25 79.23 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.436 1.494 . . . . 0.0 113.776 175.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.75 -47.04 77.67 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.302 1.841 . . . . 0.0 114.198 -175.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.31 -45.51 93.15 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.791 1.636 . . . . 0.0 113.176 174.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.1 t -66.29 -43.34 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 125.166 1.386 . . . . 0.0 111.717 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -59.37 -43.69 92.85 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.971 -1.08 . . . . 0.0 113.027 177.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -72.04 -36.54 69.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.3 1.04 . . . . 0.0 113.724 176.535 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.9 mt -63.81 -35.62 81.21 Favored 'General case' 0 CA--C 1.489 -1.393 0 O-C-N 120.056 -1.653 . . . . 0.0 114.832 171.181 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -71.57 -30.9 66.38 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.134 -1.604 . . . . 0.0 112.308 173.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -84.85 50.31 1.9 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.968 1.707 . . . . 0.0 112.628 174.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.3 p -106.3 164.28 12.14 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 125.512 1.525 . . . . 0.0 110.923 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -100.6 -168.99 28.81 Favored Glycine 0 N--CA 1.429 -1.786 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 164.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -68.56 -46.76 68.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-N 118.348 1.074 . . . . 0.0 113.71 -175.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.7 t -95.99 118.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 122.864 1.316 . . . . 0.0 109.843 172.01 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.6 t -109.74 118.88 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 127.09 2.156 . . . . 0.0 110.143 -169.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . 0.411 ' CD2' ' HG2' ' A' ' 17' ' ' GLU . 33.2 m170 -101.7 94.61 5.94 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.505 -1.372 . . . . 0.0 112.249 -179.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 tp -96.92 141.47 30.06 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 119.353 -2.092 . . . . 0.0 110.375 173.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 9.0 tt -104.98 130.45 53.18 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.97 -1.706 . . . . 0.0 108.823 162.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.9 pp -134.74 165.71 24.63 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.911 -1.118 . . . . 0.0 112.58 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -112.92 142.2 45.87 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.172 1.789 . . . . 0.0 109.44 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.27 123.03 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.64 -1.288 . . . . 0.0 111.056 178.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.33 145.29 24.09 Favored Glycine 0 N--CA 1.429 -1.779 0 C-N-CA 124.664 1.126 . . . . 0.0 112.003 178.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -96.86 -34.76 11.15 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.376 -1.073 . . . . 0.0 112.728 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -81.93 143.24 49.48 Favored Pre-proline 0 N--CA 1.43 -1.449 0 CA-C-O 117.372 -1.299 . . . . 0.0 108.986 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 N--CA 1.433 -2.064 0 CA-C-N 123.901 2.429 . . . . 0.0 113.398 167.639 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 43.3 pttt . . . . . 0 N--CA 1.43 -1.448 0 N-CA-C 110.616 -0.142 . . . . 0.0 110.616 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -80.54 62.39 8.52 Favored 'Trans proline' 0 C--N 1.3 -2.025 0 C-N-CA 125.066 3.844 . . . . 0.0 114.969 -166.091 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.43 61.33 0.19 Allowed Glycine 0 N--CA 1.43 -1.719 0 O-C-N 120.764 -1.21 . . . . 0.0 110.962 -176.387 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -91.23 166.85 12.72 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 124.642 1.177 . . . . 0.0 109.173 175.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.19 146.99 33.25 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.842 1.257 . . . . 0.0 108.758 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.19 140.67 26.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.998 0.904 . . . . 0.0 108.875 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -88.92 136.87 32.78 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-O 122.615 1.198 . . . . 0.0 107.901 161.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.3 t -117.98 114.06 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -104.31 88.76 3.05 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 169.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.9 tp -105.18 139.42 39.86 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 121.408 -0.808 . . . . 0.0 109.4 -173.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.64 123.63 45.96 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.495 -1.378 . . . . 0.0 107.85 167.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -68.22 128.91 38.27 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.885 2.474 . . . . 0.0 112.427 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.3 p -101.24 125.93 47.92 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.702 -1.248 . . . . 0.0 110.952 -178.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.4 t70 56.96 32.66 21.98 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.105 1.762 . . . . 0.0 114.837 177.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.57 -5.83 67.45 Favored Glycine 0 N--CA 1.431 -1.675 0 O-C-N 119.744 -1.848 . . . . 0.0 116.269 -179.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 74.3 m -112.04 135.23 52.94 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 118.77 1.285 . . . . 0.0 111.549 -171.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.6 mt -86.47 -62.86 1.42 Allowed 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.634 -1.292 . . . . 0.0 109.481 167.134 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.15 51.71 0.43 Allowed Glycine 0 N--CA 1.43 -1.764 0 O-C-N 119.291 -2.131 . . . . 0.0 111.52 170.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tt -142.69 142.7 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.505 0 CA-C-O 122.601 1.191 . . . . 0.0 111.008 -176.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.9 t -117.7 132.53 56.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 124.983 1.313 . . . . 0.0 107.667 167.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.4 m -113.15 164.5 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.681 1.192 . . . . 0.0 111.965 -176.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -144.09 172.53 12.76 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.119 1.368 . . . . 0.0 109.435 174.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.72 -143.12 16.54 Favored Glycine 0 N--CA 1.429 -1.828 0 C-N-CA 124.541 1.067 . . . . 0.0 115.243 171.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.7 -149.67 18.07 Favored Glycine 0 N--CA 1.429 -1.813 0 C-N-CA 124.823 1.201 . . . . 0.0 112.502 178.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.6 p -97.2 12.53 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.578 -1.542 . . . . 0.0 112.57 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -83.3 -61.77 1.76 Allowed 'General case' 0 N--CA 1.429 -1.51 0 O-C-N 118.872 -2.393 . . . . 0.0 111.963 -178.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 21.2 p -94.81 174.85 6.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.535 1.134 . . . . 0.0 110.979 -175.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.4 m -83.14 56.55 3.55 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.895 -1.753 . . . . 0.0 113.259 -175.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.8 m -100.54 4.22 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 O-C-N 120.493 -1.379 . . . . 0.0 113.716 -176.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.307 33.5 mmt180 93.03 123.0 0.02 OUTLIER 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.818 2.447 . . . . 0.0 108.894 -162.318 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.5 m170 -60.48 100.37 0.1 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.66 1.356 . . . . 0.0 114.66 -166.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.14 15.7 29.85 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 121.02 -1.05 . . . . 0.0 112.867 -177.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -80.35 92.66 1.4 Allowed Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.416 1.007 . . . . 0.0 112.048 177.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 15.0 mm -86.6 126.03 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 172.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -122.42 154.02 38.31 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.996 -1.065 . . . . 0.0 109.461 -174.008 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.6 t -76.16 118.86 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.967 -1.083 . . . . 0.0 111.524 175.048 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -88.53 -43.01 11.72 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.919 1.288 . . . . 0.0 110.123 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.66 150.82 23.36 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 121.105 -0.997 . . . . 0.0 109.123 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.438 HG22 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.2 117.66 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 170.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.04 117.67 65.67 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 115.296 -2.287 . . . . 0.0 113.369 -161.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -53.74 129.59 34.76 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 124.025 3.15 . . . . 0.0 116.387 -169.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 34.9 mttt 77.56 14.71 1.72 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.374 1.87 . . . . 0.0 114.474 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.85 165.81 46.16 Favored Glycine 0 N--CA 1.429 -1.794 0 O-C-N 119.658 -1.901 . . . . 0.0 113.421 173.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.31 -58.9 4.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 167.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.01 -50.18 71.74 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 128.935 2.894 . . . . 0.0 112.175 -178.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.438 ' HG2' HG22 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -41.78 -71.04 0.09 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.782 2.033 . . . . 0.0 114.997 166.515 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.9 t -70.02 -14.96 62.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -170.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -64.9 -59.25 4.4 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.743 -1.848 . . . . 0.0 111.946 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 97.78 29.46 7.71 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.046 -1.659 . . . . 0.0 116.682 165.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -92.92 -41.57 9.96 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.392 -1.064 . . . . 0.0 108.864 160.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.0 mt -97.88 118.76 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.399 1.88 . . . . 0.0 110.811 -170.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -128.59 174.77 9.1 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-O 123.085 1.421 . . . . 0.0 111.438 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -62.41 130.44 45.22 Favored 'General case' 0 N--CA 1.431 -1.387 0 O-C-N 119.579 -1.951 . . . . 0.0 112.583 176.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.8 -5.35 61.84 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.712 -0.618 . . . . 0.0 113.697 -177.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -77.54 156.37 30.99 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 118.661 1.23 . . . . 0.0 111.641 -176.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -106.93 123.0 47.55 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.579 1.181 . . . . 0.0 110.185 -172.479 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.5 t -85.64 133.68 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 O-C-N 120.217 -1.552 . . . . 0.0 111.089 -175.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.47 -51.62 2.88 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.025 -1.047 . . . . 0.0 111.073 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.76 148.26 28.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.958 -1.089 . . . . 0.0 113.137 -176.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.97 111.04 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.096 0.958 . . . . 0.0 110.303 173.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.6 t30 61.01 39.9 15.87 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.78 2.032 . . . . 0.0 113.323 172.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.07 -27.34 19.66 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 125.309 1.433 . . . . 0.0 113.459 -178.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.2 t -84.64 119.8 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 124.95 1.3 . . . . 0.0 110.817 -172.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.2 p -72.23 136.5 46.37 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.462 -1.399 . . . . 0.0 112.296 177.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 35.9 mt -87.95 -6.16 58.17 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.475 -1.391 . . . . 0.0 113.896 -175.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -68.71 95.26 0.65 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 119.581 -1.949 . . . . 0.0 115.878 -174.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.96 -15.13 5.14 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.819 1.2 . . . . 0.0 111.151 -177.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.4 158.88 35.52 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.8 p -87.52 179.12 6.61 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.712 -1.242 . . . . 0.0 111.115 172.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -67.21 -46.75 72.91 Favored 'General case' 0 N--CA 1.431 -1.393 0 O-C-N 120.703 -1.248 . . . . 0.0 110.755 173.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.7 tppt? -57.4 -40.93 79.28 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.201 1.401 . . . . 0.0 113.972 174.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.8 mm100 -56.93 -51.39 69.32 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.555 1.142 . . . . 0.0 114.076 176.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.99 -40.52 96.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.255 1.422 . . . . 0.0 113.519 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -66.17 -45.98 88.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.846 -1.159 . . . . 0.0 111.329 176.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -58.81 -40.07 83.04 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.629 -1.294 . . . . 0.0 112.95 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 84.2 m -68.2 -42.63 79.59 Favored 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 125.963 1.705 . . . . 0.0 113.569 178.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 72.9 mt -68.99 -33.55 73.86 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.987 -1.696 . . . . 0.0 114.391 176.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -72.35 -33.04 66.99 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 119.644 -1.91 . . . . 0.0 112.675 171.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -78.58 44.73 0.54 Allowed 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.854 2.061 . . . . 0.0 114.25 170.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -105.79 154.88 19.89 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.224 -2.172 . . . . 0.0 108.842 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.23 -146.56 17.64 Favored Glycine 0 N--CA 1.429 -1.776 0 O-C-N 120.916 -1.115 . . . . 0.0 112.921 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -70.85 -61.06 1.9 Allowed 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.402 1.081 . . . . 0.0 112.312 169.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.72 127.5 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 123.567 1.651 . . . . 0.0 110.244 177.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 73.3 t -120.61 114.17 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.398 1.879 . . . . 0.0 108.772 -162.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 m170 -101.86 94.1 5.64 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.044 0.938 . . . . 0.0 112.144 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -102.37 160.07 14.86 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.638 -1.914 . . . . 0.0 114.297 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.2 tp -128.35 132.8 48.59 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 124.869 1.268 . . . . 0.0 108.505 163.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.08 164.5 31.93 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.929 -1.107 . . . . 0.0 113.371 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -116.97 134.84 54.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 127.021 2.129 . . . . 0.0 107.773 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -77.58 144.94 37.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.355 -1.466 . . . . 0.0 112.671 -175.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -61.61 112.52 4.85 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 125.769 1.652 . . . . 0.0 114.423 174.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -70.3 -28.98 65.61 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.876 1.27 . . . . 0.0 113.545 -178.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.2 p -116.66 112.15 41.05 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 120.914 -1.116 . . . . 0.0 108.427 163.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo . . . . . 0 C--N 1.3 -2.014 0 C-N-CA 122.696 2.264 . . . . 0.0 113.63 -177.697 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt . . . . . 0 N--CA 1.43 -1.438 0 CA-C-O 115.212 -2.328 . . . . 0.0 112.866 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -74.64 -178.64 4.2 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 126.533 3.369 . . . . 0.0 113.073 163.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 121.92 95.7 1.35 Allowed Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -164.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -53.12 -60.69 2.97 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 129.924 3.29 . . . . 0.0 113.159 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.8 p -105.62 150.63 25.24 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-N 120.166 1.348 . . . . 0.0 110.206 166.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE1' ' HB3' ' A' ' 58' ' ' ARG . 27.1 p90 -147.69 164.43 33.58 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.635 1.207 . . . . 0.0 108.918 161.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -126.19 143.0 51.3 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.205 1.802 . . . . 0.0 106.858 -168.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.69 111.91 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 O-C-N 120.848 -1.157 . . . . 0.0 109.118 -173.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -103.1 94.16 5.39 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 125.762 1.625 . . . . 0.0 107.998 169.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.1 tp -123.86 134.36 53.59 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-O 122.208 1.004 . . . . 0.0 113.521 -167.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.62 137.37 39.11 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 125.67 1.588 . . . . 0.0 110.352 177.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -69.11 162.12 27.63 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 115.19 1.552 . . . . 0.0 115.19 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 39.5 p -130.97 114.91 15.8 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 26.9 t70 50.65 59.49 4.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.461 1.904 . . . . 0.0 113.844 -177.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.65 -36.05 2.83 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.13 -1.606 . . . . 0.0 115.663 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 61.5 m -106.38 149.31 27.12 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.346 1.458 . . . . 0.0 112.059 -162.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -96.22 -57.12 2.42 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 172.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.61 23.46 1.88 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 120.153 -1.592 . . . . 0.0 113.075 172.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 pt -115.21 125.53 72.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.085 1.354 . . . . 0.0 110.178 -176.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 t -112.39 128.49 56.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.302 -0.874 . . . . 0.0 108.796 170.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 163.55 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 111.896 -174.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.6 t -133.51 164.78 26.38 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.677 1.191 . . . . 0.0 108.015 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.39 -154.92 20.17 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.899 -1.125 . . . . 0.0 112.913 171.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.94 145.83 18.6 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.192 1.377 . . . . 0.0 110.445 -169.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -58.68 -34.17 50.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.57 -19.84 59.02 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -172.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.0 t -94.29 162.29 13.9 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.477 -1.389 . . . . 0.0 107.585 174.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 12.4 p -81.86 46.81 1.03 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.045 -1.659 . . . . 0.0 113.973 -168.555 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.1 m -92.13 133.77 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 120.403 -1.436 . . . . 0.0 110.154 173.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -73.28 -29.53 62.79 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.185 . . . . 0.0 110.451 167.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -43.44 -42.0 4.55 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 128.473 2.709 . . . . 0.0 116.744 178.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.71 61.17 7.05 Favored Glycine 0 N--CA 1.43 -1.71 0 N-CA-C 115.948 1.139 . . . . 0.0 115.948 169.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 172.33 178.52 42.57 Favored Glycine 0 N--CA 1.43 -1.759 0 N-CA-C 107.959 -2.057 . . . . 0.0 107.959 -177.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.8 mm -103.3 120.15 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -128.0 153.76 46.38 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.924 -1.11 . . . . 0.0 110.496 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 20.5 t -76.0 121.96 29.04 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.577 -1.327 . . . . 0.0 112.687 178.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmt? -97.84 -45.94 6.13 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.741 1.216 . . . . 0.0 112.503 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.51 154.79 27.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.104 -0.998 . . . . 0.0 110.466 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -111.3 126.14 68.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 CA-C-O 122.235 1.017 . . . . 0.0 109.742 175.461 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 14.1 mm -77.09 118.78 74.24 Favored Pre-proline 0 N--CA 1.43 -1.467 0 CA-C-O 116.043 -1.932 . . . . 0.0 113.761 -174.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -60.19 123.79 13.88 Favored 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 125.003 2.822 . . . . 0.0 115.763 -176.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.378 39.8 mtmt 75.59 31.76 0.73 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 127.372 2.269 . . . . 0.0 114.426 -175.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.09 162.39 36.89 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.819 -1.176 . . . . 0.0 112.96 159.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.07 -56.23 11.67 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 126.715 2.006 . . . . 0.0 114.489 165.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.22 -48.79 74.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 128.33 2.652 . . . . 0.0 111.813 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.4 tm-20 -41.84 -59.21 1.76 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 116.22 1.933 . . . . 0.0 116.22 176.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -69.86 -28.32 65.57 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.535 1.534 . . . . 0.0 114.359 -172.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.32 -56.57 20.15 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.981 1.712 . . . . 0.0 113.687 -173.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.54 -4.88 26.34 Favored Glycine 0 N--CA 1.429 -1.801 0 O-C-N 120.587 -1.32 . . . . 0.0 115.42 164.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.467 ' HB3' ' CE1' ' A' ' 14' ' ' PHE . 95.1 mtt180 -74.84 -61.86 1.74 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.628 -1.513 . . . . 0.0 110.605 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.69 125.69 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.886 1.674 . . . . 0.0 113.527 -177.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -141.7 159.49 42.11 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.49 1.614 . . . . 0.0 114.089 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 ttpt -52.55 127.21 22.0 Favored 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.521 2.328 . . . . 0.0 114.918 177.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 98.06 -7.31 62.43 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.031 0.824 . . . . 0.0 114.571 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.72 160.6 24.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 119.363 1.581 . . . . 0.0 112.508 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.7 ttt-85 -105.23 132.92 50.82 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.943 1.697 . . . . 0.0 111.192 -174.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.77 136.21 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 119.85 -1.781 . . . . 0.0 111.231 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -100.83 -60.66 1.48 Allowed 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.37 -1.457 . . . . 0.0 110.945 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.81 125.94 10.66 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.907 -1.12 . . . . 0.0 112.366 -171.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.9 t -99.04 114.33 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 123.837 0.855 . . . . 0.0 109.367 177.534 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.7 t30 59.52 35.28 22.7 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.042 1.737 . . . . 0.0 115.1 168.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.51 -10.74 66.98 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 124.971 1.272 . . . . 0.0 114.186 -177.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.31 107.88 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.782 -1.422 . . . . 0.0 109.659 -176.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.5 t -73.04 126.33 29.72 Favored 'General case' 0 N--CA 1.431 -1.391 0 O-C-N 120.777 -1.202 . . . . 0.0 111.177 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.4 mt -84.95 37.74 0.68 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -169.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -74.77 120.54 20.46 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.929 1.691 . . . . 0.0 110.656 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.11 11.95 79.3 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 120.49 -1.381 . . . . 0.0 114.412 -175.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.89 140.64 51.12 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 114.652 1.353 . . . . 0.0 114.652 -175.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.8 p -90.86 -179.28 5.45 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.689 1.195 . . . . 0.0 111.19 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -69.23 -45.43 69.81 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.752 -1.217 . . . . 0.0 110.317 179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -56.89 -41.63 78.4 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 170.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -53.1 62.05 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.671 -1.268 . . . . 0.0 113.915 178.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.95 -44.02 73.86 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.82 1.248 . . . . 0.0 113.575 178.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.4 -49.07 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.64 -1.288 . . . . 0.0 111.806 -177.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -65.73 -32.42 73.96 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.744 -1.222 . . . . 0.0 112.087 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 36.0 m -66.98 -45.06 78.79 Favored 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 125.774 1.63 . . . . 0.0 113.101 173.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 54.3 mt -68.64 -29.31 67.77 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.123 -1.611 . . . . 0.0 114.293 174.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.6 mtp180 -73.68 -47.46 39.5 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.227 -1.546 . . . . 0.0 113.159 171.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -89.18 55.67 3.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.148 -1.595 . . . . 0.0 113.543 -176.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.4 p -84.5 177.91 7.92 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.126 1.771 . . . . 0.0 111.531 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.8 -157.66 27.67 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 120.123 -1.61 . . . . 0.0 110.375 164.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.5 tm0? -71.33 -50.52 31.53 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.819 -1.989 . . . . 0.0 110.861 169.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.51 135.99 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.309 1.444 . . . . 0.0 109.844 174.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.7 t -107.72 126.16 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 C-N-CA 129.047 2.939 . . . . 0.0 108.448 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.9 t-160 -105.21 110.07 22.3 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.389 4.0 pp -125.1 151.24 45.97 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 117.032 2.234 . . . . 0.0 117.032 166.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.8 tp -114.97 134.23 55.36 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.839 2.056 . . . . 0.0 107.527 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -152.75 174.37 14.12 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.035 -1.041 . . . . 0.0 113.639 -179.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -119.39 132.47 55.84 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 125.712 1.605 . . . . 0.0 111.146 -175.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 145.95 34.37 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.112 -1.617 . . . . 0.0 113.644 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.25 78.77 1.97 Allowed Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.168 -1.582 . . . . 0.0 111.03 170.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -84.38 176.95 8.35 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 116.122 1.897 . . . . 0.0 116.122 -159.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 88.4 t -108.37 118.51 52.07 Favored Pre-proline 0 N--CA 1.43 -1.455 0 O-C-N 120.921 -1.112 . . . . 0.0 110.104 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.434 -2.007 0 C-N-CA 122.866 2.378 . . . . 0.0 113.164 166.527 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.43 -1.455 0 CA-C-O 115.45 -2.214 . . . . 0.0 114.421 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -67.54 177.5 3.95 Favored 'Trans proline' 0 C--N 1.299 -2.036 0 CA-C-N 126.255 3.269 . . . . 0.0 116.738 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.39 33.08 8.25 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -161.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -96.99 136.29 37.77 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.419 1.887 . . . . 0.0 109.752 -176.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.7 p -95.97 153.67 17.64 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.869 -1.769 . . . . 0.0 111.863 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -146.6 137.51 24.11 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 173.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -94.72 128.06 41.15 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.593 -1.317 . . . . 0.0 109.942 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.41 88.85 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -178.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.442 ' HG2' ' CD2' ' A' ' 93' ' ' HIS . 61.0 mt-10 -93.85 83.33 4.37 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 169.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.288 1.8 pp -109.2 162.75 13.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.771 1.272 . . . . 0.0 111.233 -178.035 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 133.73 46.88 Favored 'General case' 0 N--CA 1.428 -1.527 0 C-N-CA 124.728 1.211 . . . . 0.0 107.924 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -70.6 121.87 18.69 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.458 -1.401 . . . . 0.0 112.32 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 29.2 p -94.7 119.61 33.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.669 -1.269 . . . . 0.0 110.039 -174.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 t70 61.13 7.7 1.7 Allowed 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.056 2.142 . . . . 0.0 116.416 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 107.41 2.27 35.34 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.984 -1.698 . . . . 0.0 114.846 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 63.2 m -121.93 132.02 54.33 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.911 1.855 . . . . 0.0 113.306 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 85.5 mt -73.7 -44.24 57.03 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.712 -1.242 . . . . 0.0 111.425 164.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.5 29.74 3.31 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 119.767 -1.833 . . . . 0.0 111.719 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 pt -107.31 135.22 46.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.625 1.202 . . . . 0.0 114.215 -162.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 17.7 m -131.3 109.68 10.54 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.758 -1.839 . . . . 0.0 108.969 155.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.03 163.82 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-O 122.153 0.978 . . . . 0.0 112.145 -177.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.6 t -145.81 172.6 13.07 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.13 1.372 . . . . 0.0 108.28 175.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 -175.61 33.68 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.734 -1.229 . . . . 0.0 114.125 176.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 149.6 177.61 23.83 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -171.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.2 p -78.35 -41.61 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.434 1.272 . . . . 0.0 114.434 -173.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -98.65 7.77 45.72 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.021 -1.675 . . . . 0.0 111.219 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 10.6 m -84.02 158.23 21.55 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.035 1.734 . . . . 0.0 109.022 -177.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 34.3 p -74.48 47.74 0.32 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 126.247 1.819 . . . . 0.0 115.838 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.3 m -92.25 -178.25 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 126.758 2.023 . . . . 0.0 106.885 161.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.4 mtm180 -69.74 -53.67 17.36 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.766 -1.834 . . . . 0.0 113.746 -175.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.4 t60 -128.69 -45.39 1.31 Allowed 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.14 85.69 0.05 OUTLIER Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.858 -1.151 . . . . 0.0 111.54 -177.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -144.32 155.74 26.44 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.459 -1.024 . . . . 0.0 111.461 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.7 mm -102.39 123.34 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.894 1.678 . . . . 0.0 107.464 175.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -124.4 155.16 39.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.935 -1.103 . . . . 0.0 111.307 -170.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.1 t -76.05 119.31 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.883 -1.136 . . . . 0.0 110.789 169.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.9 pttt -95.51 -36.59 11.24 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.471 -1.393 . . . . 0.0 112.445 173.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -155.88 160.95 40.6 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.921 -1.112 . . . . 0.0 110.539 177.1 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -120.15 125.88 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 124.404 1.082 . . . . 0.0 109.216 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.8 mm -77.42 124.93 86.85 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.623 1.969 . . . . 0.0 114.265 -176.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_exo -56.57 133.87 60.73 Favored 'Trans proline' 0 N--CA 1.435 -1.968 0 CA-C-N 124.034 2.476 . . . . 0.0 116.237 176.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt 83.53 0.77 1.06 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 129.012 2.925 . . . . 0.0 114.71 -177.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.05 156.08 46.88 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.121 -1.612 . . . . 0.0 113.104 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.35 -53.14 23.78 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 172.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.2 -45.76 86.91 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 128.951 2.901 . . . . 0.0 112.622 177.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -50.21 -57.99 6.57 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 123.101 1.429 . . . . 0.0 114.656 171.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.4 t -68.02 -25.39 65.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.193 1.397 . . . . 0.0 113.717 -171.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -61.56 -71.94 0.13 Allowed 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.695 1.598 . . . . 0.0 112.501 173.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.76 -6.52 37.98 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 121.108 -0.995 . . . . 0.0 115.284 177.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.1 mtm180 -65.22 -35.47 81.15 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.867 -1.961 . . . . 0.0 111.893 165.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 73.3 mt -85.36 134.21 27.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 124.884 1.273 . . . . 0.0 109.683 176.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -139.17 161.31 37.73 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.807 -1.183 . . . . 0.0 108.922 177.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -54.71 125.05 18.37 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.985 1.714 . . . . 0.0 113.934 172.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.84 -2.25 66.41 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 124.286 0.946 . . . . 0.0 114.802 -178.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -82.12 160.18 23.19 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-N 119.614 1.707 . . . . 0.0 110.535 178.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -112.37 132.48 54.98 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.619 -1.3 . . . . 0.0 112.151 -168.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.7 t -87.14 127.68 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.319 -1.488 . . . . 0.0 110.657 178.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 88.1 mt -98.15 -48.1 5.23 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 121.132 -0.98 . . . . 0.0 111.253 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.44 134.6 18.16 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.995 -1.065 . . . . 0.0 109.787 -176.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.7 t -114.23 125.85 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 67.25 30.06 7.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.259 1.424 . . . . 0.0 111.721 175.28 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 85.19 -18.84 25.84 Favored Glycine 0 N--CA 1.431 -1.682 0 C-N-CA 125.058 1.313 . . . . 0.0 114.802 -173.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.85 123.27 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 O-C-N 120.776 -1.426 . . . . 0.0 110.521 -171.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.5 m -63.88 135.27 56.42 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.776 -1.202 . . . . 0.0 113.956 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 78.1 mt -86.17 56.52 4.02 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.754 -1.216 . . . . 0.0 111.65 177.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -78.85 123.11 26.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.571 -1.331 . . . . 0.0 112.508 -175.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 58.59 20.87 48.03 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 125.349 1.452 . . . . 0.0 115.139 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.64 144.66 51.04 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -164.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -76.58 178.45 6.67 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.611 1.164 . . . . 0.0 110.511 169.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -68.25 -48.84 63.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.427 -1.421 . . . . 0.0 111.738 172.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 41.2 mmtm -58.48 -31.67 68.05 Favored 'General case' 0 N--CA 1.429 -1.512 0 N-CA-C 116.012 1.856 . . . . 0.0 116.012 174.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 mm100 -56.35 -55.74 29.76 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 120.324 1.42 . . . . 0.0 114.181 175.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.53 87.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.198 0.999 . . . . 0.0 113.195 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -68.35 -48.39 73.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.028 1.331 . . . . 0.0 111.208 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -62.94 -36.82 84.68 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.482 -1.386 . . . . 0.0 112.791 177.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.1 m -67.26 -45.88 75.38 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.646 1.578 . . . . 0.0 113.188 175.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 20.8 mt -66.28 -34.74 78.68 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.399 -1.438 . . . . 0.0 114.031 175.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.51 -31.64 65.51 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.32 -1.488 . . . . 0.0 113.684 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -88.68 48.93 1.7 Allowed 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 122.185 0.993 . . . . 0.0 112.066 173.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 p -107.17 154.33 21.35 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.102 -1.624 . . . . 0.0 109.14 170.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -108.83 -132.5 6.61 Favored Glycine 0 N--CA 1.43 -1.718 0 CA-C-O 121.964 0.758 . . . . 0.0 113.823 -172.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.0 tm0? -70.82 -68.84 0.4 Allowed 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 121.308 -1.113 . . . . 0.0 113.54 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 9.2 p -98.33 131.98 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.873 1.32 . . . . 0.0 109.882 174.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.6 t -125.23 111.96 29.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 126.139 1.776 . . . . 0.0 110.209 -162.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . 0.442 ' CD2' ' HG2' ' A' ' 17' ' ' GLU . 30.4 m170 -93.14 101.15 13.44 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -178.243 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -92.73 146.19 23.84 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 120.113 -1.617 . . . . 0.0 112.602 168.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 60.5 tp -113.87 127.54 56.03 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 155.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -136.22 151.69 49.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 121.098 -1.001 . . . . 0.0 111.356 -171.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -117.34 131.63 56.75 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 123.404 1.573 . . . . 0.0 111.622 176.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -75.86 128.56 35.36 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.133 2.173 . . . . 0.0 110.798 177.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.05 -160.86 36.92 Favored Glycine 0 N--CA 1.431 -1.658 0 O-C-N 121.351 -0.843 . . . . 0.0 111.221 177.508 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -73.64 177.4 5.43 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.706 -1.467 . . . . 0.0 114.349 -175.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 58.6 t -98.85 133.68 22.15 Favored Pre-proline 0 N--CA 1.431 -1.423 0 CA-C-O 117.468 -1.253 . . . . 0.0 108.796 -176.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo . . . . . 0 N--CA 1.433 -2.085 0 C-N-CA 122.619 2.213 . . . . 0.0 113.414 177.398 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.1 mtpp . . . . . 0 N--CA 1.43 -1.454 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.42 178.77 5.45 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 CA-C-N 124.214 2.541 . . . . 0.0 111.587 171.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 96.76 17.73 32.12 Favored Glycine 0 N--CA 1.431 -1.677 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.3 t0 -87.4 164.4 16.23 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 120.097 1.949 . . . . 0.0 110.851 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 p -100.1 158.43 15.85 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.884 1.674 . . . . 0.0 112.541 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -144.67 146.71 32.37 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 171.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -89.57 113.19 24.58 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 165.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 t -98.77 99.66 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -90.38 94.36 9.7 Favored 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 174.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -105.14 126.48 52.12 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-O 122.464 1.126 . . . . 0.0 110.045 -174.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.82 139.25 38.64 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.133 -1.604 . . . . 0.0 110.225 176.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -66.18 130.86 44.66 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.002 -1.061 . . . . 0.0 113.075 175.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.9 p -91.09 84.72 5.75 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.228 -1.545 . . . . 0.0 110.378 177.161 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.1 t70 59.27 53.43 5.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.457 1.903 . . . . 0.0 113.487 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.96 -11.31 72.47 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.746 -1.221 . . . . 0.0 115.295 -176.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.5 t -94.53 112.92 24.69 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.419 -1.636 . . . . 0.0 113.519 -173.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 7.5 tp -125.84 63.03 1.22 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.662 1.585 . . . . 0.0 109.985 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -85.64 62.21 4.46 Favored Glycine 0 N--CA 1.43 -1.717 0 O-C-N 119.43 -2.043 . . . . 0.0 113.462 -164.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.93 127.34 55.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 124.74 1.216 . . . . 0.0 107.975 168.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.43 121.79 45.85 Favored 'General case' 0 CA--C 1.489 -1.371 0 C-N-CA 123.626 0.77 . . . . 0.0 109.442 177.438 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.0 m -104.46 170.42 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.724 1.209 . . . . 0.0 112.736 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -150.24 173.79 13.55 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.198 1.399 . . . . 0.0 108.51 173.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.83 -138.03 14.67 Favored Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 167.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.87 162.31 27.79 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.52 1.533 . . . . 0.0 113.023 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -63.0 -20.42 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.603 1.561 . . . . 0.0 114.988 177.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -81.7 -10.33 59.41 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.611 1.965 . . . . 0.0 112.152 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.2 m -115.18 143.95 44.44 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.148 1.379 . . . . 0.0 108.864 -176.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.7 t -87.43 61.81 6.8 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 119.597 -1.94 . . . . 0.0 110.783 177.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.02 41.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.075 1.75 . . . . 0.0 113.064 -165.107 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 59.73 64.85 1.22 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 119.672 -1.892 . . . . 0.0 111.863 -166.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.31 38.2 m80 75.01 157.57 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 127.647 2.379 . . . . 0.0 113.812 -173.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -80.14 86.33 1.29 Allowed Glycine 0 N--CA 1.431 -1.647 0 O-C-N 120.212 -1.555 . . . . 0.0 115.167 -167.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -146.46 171.07 27.39 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.144 0.878 . . . . 0.0 110.962 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.9 mm -97.85 131.98 43.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.69 1.196 . . . . 0.0 108.577 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.84 159.4 33.99 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.777 -1.202 . . . . 0.0 110.305 -175.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.68 119.53 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.694 -1.253 . . . . 0.0 111.023 174.28 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 57.2 tttm -91.43 -50.85 5.57 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 124.11 0.964 . . . . 0.0 111.85 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.09 155.83 31.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.038 -1.039 . . . . 0.0 110.904 -177.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.09 120.63 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-O 122.611 1.196 . . . . 0.0 109.643 172.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 34.6 mm -76.06 128.22 83.52 Favored Pre-proline 0 N--CA 1.43 -1.447 0 CA-C-O 116.09 -1.909 . . . . 0.0 113.252 -170.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -55.0 133.85 60.42 Favored 'Trans proline' 0 N--CA 1.434 -2.002 0 C-N-CA 124.416 3.411 . . . . 0.0 115.65 178.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? 67.76 13.76 9.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.526 1.53 . . . . 0.0 114.478 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.31 173.13 47.9 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 119.592 -1.942 . . . . 0.0 112.517 172.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.87 9.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 169.32 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.81 -40.1 95.83 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 126.595 1.958 . . . . 0.0 115.273 -173.022 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -41.35 -60.08 1.37 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 129.423 3.089 . . . . 0.0 113.607 178.02 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.5 t -70.2 -33.84 72.21 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 111.693 -2.503 . . . . 0.0 115.847 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -62.43 -48.57 79.1 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.272 1.429 . . . . 0.0 113.129 -165.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.64 -19.92 45.9 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.506 -1.371 . . . . 0.0 115.421 162.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.2 mmt-85 -75.74 -4.34 39.89 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 118.429 1.115 . . . . 0.0 112.764 172.308 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.5 mt -117.91 126.97 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.525 0 C-N-CA 125.259 1.423 . . . . 0.0 107.981 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -132.25 163.83 27.73 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.617 -1.302 . . . . 0.0 109.797 170.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -67.91 123.29 20.17 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.215 -1.553 . . . . 0.0 112.773 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 100.01 0.83 56.09 Favored Glycine 0 N--CA 1.431 -1.7 0 O-C-N 121.678 -0.639 . . . . 0.0 114.099 -174.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -80.17 164.86 22.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-N 119.555 1.678 . . . . 0.0 110.455 173.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.18 136.68 51.29 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.602 1.192 . . . . 0.0 111.722 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -91.15 125.12 43.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 126.113 1.765 . . . . 0.0 109.76 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 49.1 mt -103.89 -56.89 2.12 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.42 -1.425 . . . . 0.0 110.589 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.74 118.62 6.66 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 121.165 -0.959 . . . . 0.0 111.163 -176.157 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.47 115.79 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -176.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.9 t30 60.84 42.41 13.23 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 124.796 1.238 . . . . 0.0 114.321 165.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.17 -18.35 57.01 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.53 1.062 . . . . 0.0 114.05 -177.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.66 117.93 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.851 -1.381 . . . . 0.0 109.331 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 54.9 m -72.79 105.89 4.53 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 121.138 -0.976 . . . . 0.0 110.959 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 33.8 mt -89.8 25.67 2.0 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.695 -1.253 . . . . 0.0 112.092 -175.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -77.83 122.55 25.59 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.088 -1.632 . . . . 0.0 109.563 173.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 76.11 15.08 81.66 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 120.657 -1.277 . . . . 0.0 115.672 -170.369 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.28 163.11 28.28 Favored 'General case' 0 N--CA 1.429 -1.492 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 178.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.6 p -93.5 171.13 9.1 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.128 1.371 . . . . 0.0 111.196 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 64.8 t-80 -62.47 -51.06 68.95 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.476 -1.39 . . . . 0.0 114.185 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 mtmt -57.12 -42.58 81.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 174.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -56.58 -45.91 81.09 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.355 1.862 . . . . 0.0 114.241 -173.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.69 -39.63 94.59 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.902 1.681 . . . . 0.0 114.732 172.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.2 t -68.7 -49.26 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.011 1.324 . . . . 0.0 110.415 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 82.3 mt-10 -66.41 -33.33 75.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.341 -1.474 . . . . 0.0 113.552 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.8 m -61.2 -41.6 97.11 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.744 1.618 . . . . 0.0 113.072 169.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 76.0 mt -71.7 -30.69 65.94 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.361 -1.462 . . . . 0.0 114.276 173.126 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -67.28 -46.51 73.41 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.073 -1.642 . . . . 0.0 112.587 173.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -93.74 64.75 3.53 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.644 -1.285 . . . . 0.0 110.653 177.544 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 p -101.46 164.42 11.77 Favored 'General case' 0 N--CA 1.429 -1.512 0 C-N-CA 128.043 2.537 . . . . 0.0 109.329 173.16 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -92.8 -139.75 9.38 Favored Glycine 0 N--CA 1.431 -1.678 0 O-C-N 121.043 -1.035 . . . . 0.0 110.689 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -71.14 -68.47 0.44 Allowed 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.189 -1.183 . . . . 0.0 114.039 170.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.4 t -105.51 128.77 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 CA-C-O 122.509 1.147 . . . . 0.0 108.619 -176.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.04 117.99 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 128.409 2.683 . . . . 0.0 108.996 -170.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -98.2 102.13 13.79 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.486 -1.383 . . . . 0.0 111.192 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.7 tp -99.93 132.88 45.01 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.207 -1.558 . . . . 0.0 111.388 175.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -87.44 121.55 30.02 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.163 -1.792 . . . . 0.0 106.163 163.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.0 tt -123.45 143.63 50.02 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 123.689 0.796 . . . . 0.0 109.804 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -111.22 136.33 50.45 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 109.22 174.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -77.89 126.97 31.65 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 121.196 -0.94 . . . . 0.0 111.851 175.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.06 -140.22 6.19 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-O 122.418 1.01 . . . . 0.0 114.18 177.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 1.4 pm0 -80.71 -155.71 0.12 Allowed 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.796 1.638 . . . . 0.0 114.242 -172.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.4 m -80.2 146.37 62.48 Favored Pre-proline 0 N--CA 1.43 -1.435 0 O-C-N 119.336 -2.102 . . . . 0.0 109.842 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo . . . . . 0 C--N 1.299 -2.043 0 C-N-CA 122.254 1.969 . . . . 0.0 114.606 -155.721 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 41.8 mtmt . . . . . 0 N--CA 1.43 -1.468 0 CA-C-O 116.384 -1.77 . . . . 0.0 113.494 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -78.38 -161.59 0.15 Allowed 'Trans proline' 0 C--N 1.3 -1.996 0 CA-C-N 125.704 3.073 . . . . 0.0 112.853 174.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.82 77.61 0.4 Allowed Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 108.022 -2.031 . . . . 0.0 108.022 -155.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -53.12 -58.76 5.91 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.75 2.82 . . . . 0.0 111.777 -172.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.31 135.16 43.26 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.338 -0.851 . . . . 0.0 109.653 158.431 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.251 0.0 OUTLIER -146.77 146.51 30.3 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 122.458 1.123 . . . . 0.0 109.454 159.235 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.34 145.89 24.27 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.405 -1.434 . . . . 0.0 109.035 174.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 47.9 t -106.01 93.44 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 74.9 mt-10 -92.2 89.77 7.03 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.978 1.711 . . . . 0.0 108.426 175.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 65.6 tp -124.91 148.39 48.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 121.304 -0.873 . . . . 0.0 110.629 -171.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.66 48.48 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.219 1.408 . . . . 0.0 109.015 171.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -71.17 154.86 41.37 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 115.871 1.804 . . . . 0.0 115.871 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 77.5 p -121.08 131.55 54.34 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.849 -1.157 . . . . 0.0 109.482 171.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.1 t70 57.78 38.83 27.43 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 176.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.65 -16.14 16.06 Favored Glycine 0 N--CA 1.431 -1.656 0 O-C-N 119.477 -2.015 . . . . 0.0 114.985 -176.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.8 p -115.14 157.93 22.92 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.779 2.032 . . . . 0.0 112.551 -164.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -102.06 -60.64 1.5 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.677 -1.264 . . . . 0.0 108.957 173.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.86 56.64 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.555 -1.966 . . . . 0.0 110.838 169.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tt -147.24 145.29 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 CA-C-O 122.43 1.11 . . . . 0.0 110.784 -171.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.6 t -108.94 132.36 54.15 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 166.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.1 m -112.92 155.92 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 O-C-N 121.14 -0.975 . . . . 0.0 111.344 -175.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 t -129.0 168.02 16.63 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 124.084 0.954 . . . . 0.0 109.33 174.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.09 -151.68 18.31 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.418 -0.801 . . . . 0.0 113.928 167.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.48 139.63 10.65 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 123.975 0.798 . . . . 0.0 112.481 -176.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -71.18 -11.28 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 O-C-N 120.829 -1.395 . . . . 0.0 113.933 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -69.66 -33.98 73.33 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.181 -1.575 . . . . 0.0 113.764 178.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.5 t -107.53 169.32 8.65 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 120.898 -1.126 . . . . 0.0 111.563 -173.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.3 m -82.85 62.54 6.49 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.259 -1.525 . . . . 0.0 113.647 -174.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.8 t -72.44 -43.51 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 C-N-CA 125.679 1.592 . . . . 0.0 110.79 171.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 74.8 mtt85 67.94 37.89 2.95 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 128.297 2.639 . . . . 0.0 112.122 -169.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 21.0 t-160 -150.61 -52.35 0.14 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.501 -0.749 . . . . 0.0 110.583 -179.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.62 66.13 1.62 Allowed Glycine 0 N--CA 1.43 -1.729 0 O-C-N 120.59 -1.319 . . . . 0.0 115.253 169.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.77 171.09 34.27 Favored Glycine 0 N--CA 1.429 -1.772 0 N-CA-C 107.133 -2.387 . . . . 0.0 107.133 175.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.4 mm -103.78 114.79 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.286 1.434 . . . . 0.0 107.573 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.1 m-85 -123.58 157.05 34.57 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.206 1.003 . . . . 0.0 110.52 -171.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -75.03 122.5 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 C-N-CA 124.542 1.137 . . . . 0.0 110.713 175.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -93.18 -51.83 4.84 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.846 -1.159 . . . . 0.0 111.574 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.86 158.9 41.48 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -113.56 125.27 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 CA-C-O 122.565 1.174 . . . . 0.0 109.057 179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -76.58 124.19 87.8 Favored Pre-proline 0 N--CA 1.429 -1.487 0 CA-C-O 116.344 -1.788 . . . . 0.0 113.679 -167.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_exo -58.9 124.64 16.16 Favored 'Trans proline' 0 N--CA 1.433 -2.036 0 CA-C-N 124.566 2.667 . . . . 0.0 115.396 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 47.9 mtpt 74.88 30.74 0.93 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 127.101 2.16 . . . . 0.0 114.069 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.33 160.72 33.49 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.204 -0.935 . . . . 0.0 114.097 161.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.07 -54.03 14.48 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.982 2.113 . . . . 0.0 114.444 160.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.93 -46.48 87.56 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 127.586 2.354 . . . . 0.0 113.416 179.095 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.2 tm-20 -41.6 -64.57 0.55 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 116.415 2.005 . . . . 0.0 116.415 173.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 57.8 m -68.51 -18.46 64.38 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.557 1.943 . . . . 0.0 115.843 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.16 -56.84 16.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 CA-C-N 119.657 1.117 . . . . 0.0 112.52 -174.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 107.04 -25.81 21.06 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 115.151 0.82 . . . . 0.0 115.151 176.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -72.36 -29.17 63.54 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.951 1.875 . . . . 0.0 112.221 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.0 mt -90.34 120.71 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 120.591 -1.318 . . . . 0.0 111.024 174.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -124.32 168.67 12.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.937 1.351 . . . . 0.0 111.435 173.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -65.72 117.54 8.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.726 1.61 . . . . 0.0 113.43 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.13 11.21 57.75 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.744 -1.222 . . . . 0.0 114.563 -176.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -81.22 159.45 24.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.22 1.51 . . . . 0.0 111.909 173.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -112.97 124.49 52.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.109 1.363 . . . . 0.0 111.163 -166.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 39.0 t -92.08 121.31 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.381 0 O-C-N 120.288 -1.508 . . . . 0.0 110.716 179.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 78.3 mt -89.11 -45.52 9.54 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.102 -0.999 . . . . 0.0 110.749 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.63 143.47 24.62 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 121.378 -0.826 . . . . 0.0 110.709 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 44.9 t -111.14 114.45 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.053 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.7 t30 63.88 34.04 12.06 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 165.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.16 -17.35 59.45 Favored Glycine 0 N--CA 1.431 -1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 113.83 -175.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.6 t -99.03 121.34 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.41 . . . . 0.0 109.983 -175.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 20.3 t -75.32 138.69 41.97 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.255 -1.528 . . . . 0.0 112.03 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 76.8 mt -90.4 13.56 15.25 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.223 -0.923 . . . . 0.0 113.447 -176.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -61.15 111.99 1.93 Allowed 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 119.94 -1.725 . . . . 0.0 114.348 -177.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.95 0.29 83.53 Favored Glycine 0 N--CA 1.43 -1.704 0 C-N-CA 124.903 1.239 . . . . 0.0 115.463 -178.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.63 147.41 47.56 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 115.68 1.733 . . . . 0.0 115.68 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.9 p -92.79 178.68 5.7 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.797 1.239 . . . . 0.0 112.529 176.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -56.33 -56.61 18.93 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.977 1.711 . . . . 0.0 114.673 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 tppt? -57.39 -39.79 76.85 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.812 1.245 . . . . 0.0 113.317 -178.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.58 -50.4 72.03 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 126.634 1.974 . . . . 0.0 113.852 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.21 -41.45 99.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.862 1.665 . . . . 0.0 114.165 174.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.02 -49.03 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.215 1.406 . . . . 0.0 111.051 177.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -60.82 -39.17 88.0 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 124.691 1.196 . . . . 0.0 112.85 177.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.1 m -63.41 -49.79 72.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 126.998 2.119 . . . . 0.0 113.033 173.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 63.8 mt -66.66 -29.57 69.62 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.196 -1.565 . . . . 0.0 114.405 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -68.8 -49.25 60.12 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.598 -1.314 . . . . 0.0 112.274 169.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -85.02 64.65 8.82 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.414 -1.429 . . . . 0.0 111.641 177.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 p -106.18 160.08 15.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 128.792 2.837 . . . . 0.0 109.258 173.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.69 -163.61 39.08 Favored Glycine 0 N--CA 1.429 -1.77 0 O-C-N 121.046 -1.033 . . . . 0.0 111.584 176.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -66.69 -52.55 43.46 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.757 -1.437 . . . . 0.0 113.152 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.34 130.07 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 CA-C-O 122.695 1.236 . . . . 0.0 108.054 170.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.0 t -117.92 128.54 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 127.597 2.359 . . . . 0.0 108.029 -166.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.2 m80 -120.67 92.54 3.79 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -170.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.18 146.55 25.32 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 119.398 -2.064 . . . . 0.0 112.068 175.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 24.9 tp -104.6 116.56 32.28 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 162.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.4 tt -132.44 137.14 47.16 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.564 0.697 . . . . 0.0 111.927 -164.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.5 tt0 -108.87 126.65 53.29 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.866 -1.146 . . . . 0.0 109.267 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.5 tmtt? -79.98 140.03 36.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.674 -1.266 . . . . 0.0 112.433 -174.027 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.47 74.97 2.28 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.197 -1.565 . . . . 0.0 111.133 173.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.79 -50.09 74.87 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.221 1.408 . . . . 0.0 114.307 -170.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.5 t -106.67 113.58 62.76 Favored Pre-proline 0 N--CA 1.429 -1.501 0 C-N-CA 124.351 1.061 . . . . 0.0 108.554 172.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--N 1.299 -2.071 0 C-N-CA 122.65 2.234 . . . . 0.0 112.419 165.46 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt . . . . . 0 N--CA 1.429 -1.492 0 CA-C-O 115.458 -2.21 . . . . 0.0 113.009 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -71.91 -173.48 1.06 Allowed 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 126.345 3.302 . . . . 0.0 115.008 176.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.41 81.59 0.54 Allowed Glycine 0 N--CA 1.429 -1.784 0 C-N-CA 124.903 1.24 . . . . 0.0 110.293 -165.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -53.03 -50.02 65.1 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 129.543 3.137 . . . . 0.0 115.655 -163.119 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -119.35 148.2 43.47 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 121.121 1.782 . . . . 0.0 109.618 164.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 11.1 p90 -146.8 147.02 30.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 123.21 1.481 . . . . 0.0 109.23 171.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -104.1 120.5 41.22 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.317 2.247 . . . . 0.0 107.738 -178.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.3 t -114.04 103.69 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 119.975 -1.703 . . . . 0.0 109.83 -171.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -90.08 88.67 7.37 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.306 -1.496 . . . . 0.0 109.239 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 tp -100.92 130.39 46.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.761 -1.212 . . . . 0.0 112.702 -167.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.47 128.23 49.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.279 -1.513 . . . . 0.0 109.456 170.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -69.73 132.66 46.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.217 1.562 . . . . 0.0 115.217 -172.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 47.6 p -107.48 114.89 29.19 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.503 -1.373 . . . . 0.0 111.498 -176.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.4 t70 55.66 39.35 30.88 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.214 2.205 . . . . 0.0 113.12 172.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.73 4.5 90.29 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 119.514 -1.991 . . . . 0.0 115.583 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.6 t -121.48 134.59 55.07 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-N 118.549 1.175 . . . . 0.0 111.345 -176.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 86.2 mt -89.65 -42.52 11.32 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.826 -1.171 . . . . 0.0 109.99 173.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.28 9.27 22.2 Favored Glycine 0 N--CA 1.43 -1.731 0 O-C-N 120.833 -1.167 . . . . 0.0 114.503 175.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.8 pt -129.42 125.65 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 CA-C-N 118.466 1.133 . . . . 0.0 112.555 -166.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -110.15 139.83 44.88 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.974 -1.079 . . . . 0.0 109.233 166.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 m -111.05 170.71 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.81 1.244 . . . . 0.0 112.725 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -150.96 172.26 15.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.559 1.943 . . . . 0.0 108.2 174.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.1 -131.37 10.58 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 121.052 -1.03 . . . . 0.0 113.731 169.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 72.22 -175.36 42.75 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.936 1.255 . . . . 0.0 113.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.1 t -68.32 -9.71 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 126.4 1.88 . . . . 0.0 113.325 177.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -75.25 -24.65 57.67 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 118.658 -2.526 . . . . 0.0 112.113 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.1 m -115.56 152.25 33.38 Favored 'General case' 0 N--CA 1.428 -1.549 0 C-N-CA 125.64 1.576 . . . . 0.0 109.014 -173.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.9 p -81.7 60.72 4.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.09 -2.256 . . . . 0.0 115.031 -175.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 1.5 t -92.25 47.48 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 O-C-N 119.605 -1.934 . . . . 0.0 111.937 -175.482 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.252 26.7 ttt-85 36.61 41.91 0.18 Allowed 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 129.495 3.118 . . . . 0.0 117.974 -174.088 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.6 t60 151.4 -67.35 0.0 OUTLIER 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 129.729 3.212 . . . . 0.0 105.513 -172.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 120.92 97.1 1.54 Allowed Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 123.881 0.753 . . . . 0.0 111.65 -177.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -126.0 156.31 19.55 Favored Glycine 0 N--CA 1.43 -1.745 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 178.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.79 114.74 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.507 1.123 . . . . 0.0 109.238 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -111.9 153.62 26.41 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.261 -0.899 . . . . 0.0 110.225 -173.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.5 t -76.57 116.85 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 124.924 1.289 . . . . 0.0 112.473 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.2 ttpp -92.26 -40.88 10.71 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.272 1.029 . . . . 0.0 112.36 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.68 153.75 31.81 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.165 -1.584 . . . . 0.0 112.687 -177.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.265 1.0 OUTLIER -109.33 115.89 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-O 123.123 1.44 . . . . 0.0 109.988 171.776 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.1 mm -77.36 125.23 86.59 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 127.111 2.164 . . . . 0.0 113.79 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -55.69 124.34 16.03 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 C-N-CA 123.625 2.883 . . . . 0.0 116.115 -177.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.3 4.5 mptp? 74.38 24.59 1.81 Allowed 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.692 1.997 . . . . 0.0 113.22 176.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.01 159.11 35.54 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.439 -1.413 . . . . 0.0 111.785 165.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.6 -55.44 11.17 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.62 1.711 . . . . 0.0 115.62 175.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.53 -46.44 86.01 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 128.065 2.546 . . . . 0.0 112.561 179.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -48.9 -60.63 2.6 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.317 1.447 . . . . 0.0 113.944 174.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.2 m -69.39 -20.05 63.82 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -69.43 -64.03 0.95 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.511 -1.368 . . . . 0.0 110.996 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.72 11.09 41.74 Favored Glycine 0 N--CA 1.429 -1.771 0 O-C-N 119.862 -1.774 . . . . 0.0 114.849 164.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 71.9 mtt85 -62.45 -51.68 66.56 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.88 1.272 . . . . 0.0 109.905 159.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 2.8 mt -79.17 128.13 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 126.104 1.762 . . . . 0.0 112.132 -176.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.93 169.65 16.0 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 123.561 1.648 . . . . 0.0 111.641 174.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 14.7 ttpp -66.23 132.06 47.57 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.675 -1.891 . . . . 0.0 112.115 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.03 5.37 68.01 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 120.971 -1.08 . . . . 0.0 114.156 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -79.59 166.36 21.97 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 118.889 1.344 . . . . 0.0 109.586 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -134.08 148.34 51.01 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.172 -1.58 . . . . 0.0 112.772 176.539 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.0 t -102.82 134.0 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 C-N-CA 124.769 1.228 . . . . 0.0 111.171 -166.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.9 mp -99.07 -50.65 4.09 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.5 1.12 . . . . 0.0 110.662 -177.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.84 136.54 18.07 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.314 -0.866 . . . . 0.0 112.677 -175.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.2 t -113.36 125.77 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 124.671 1.189 . . . . 0.0 108.424 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 65.86 30.91 9.73 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.645 1.178 . . . . 0.0 112.521 168.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 91.96 -22.74 29.95 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.897 -1.127 . . . . 0.0 113.899 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.53 121.75 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 125.633 1.573 . . . . 0.0 110.666 -167.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.9 p -71.23 131.62 43.77 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.746 -1.221 . . . . 0.0 112.433 178.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.9 mt -84.23 64.65 8.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.089 -1.632 . . . . 0.0 112.083 -175.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -89.34 116.3 27.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.466 -1.396 . . . . 0.0 112.723 -173.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.83 17.79 79.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.004 -1.06 . . . . 0.0 113.256 179.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.97 143.21 50.92 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -168.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 70.6 p -93.71 179.69 5.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.248 1.819 . . . . 0.0 110.597 173.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 49.3 t-80 -68.35 -42.7 78.86 Favored 'General case' 0 N--CA 1.428 -1.53 0 O-C-N 119.775 -1.828 . . . . 0.0 110.001 173.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.2 tppm? -53.64 -46.34 70.5 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 125.389 1.476 . . . . 0.0 113.781 172.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.65 -51.28 67.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.208 1.403 . . . . 0.0 113.674 176.686 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.926 1.691 . . . . 0.0 113.686 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.7 t -66.35 -49.09 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 O-C-N 120.835 -1.165 . . . . 0.0 110.676 178.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.2 mm-40 -64.04 -31.22 72.33 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.669 -1.269 . . . . 0.0 114.03 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.3 m -69.47 -44.3 71.47 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.486 1.514 . . . . 0.0 112.234 175.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 82.6 mt -69.51 -32.31 71.08 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 172.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.61 -46.34 79.69 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.245 -1.534 . . . . 0.0 112.426 176.625 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.7 t30 -86.06 45.68 1.25 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.83 1.252 . . . . 0.0 112.648 -178.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.0 p -101.6 171.71 7.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.303 1.841 . . . . 0.0 108.658 172.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -125.38 -119.35 2.35 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.594 -1.316 . . . . 0.0 110.737 172.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -70.84 -70.25 0.32 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 124.288 1.035 . . . . 0.0 113.7 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 40.1 t -100.66 129.45 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 CA-C-O 123.136 1.446 . . . . 0.0 111.223 -175.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 96.9 t -122.6 104.61 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 128.466 2.706 . . . . 0.0 108.944 -174.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.0 t-160 -88.56 107.37 18.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.624 -1.923 . . . . 0.0 110.802 176.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.7 mt -94.04 144.23 25.66 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.775 -1.203 . . . . 0.0 111.242 169.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 31.6 tp -119.65 124.91 47.44 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 164.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.0 pp -150.58 168.29 24.7 Favored 'General case' 0 N--CA 1.429 -1.501 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -176.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -113.52 129.4 56.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.137 1.775 . . . . 0.0 111.041 -175.089 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? -78.41 137.14 37.84 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.455 1.502 . . . . 0.0 112.691 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -77.41 76.8 1.64 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 121.108 -0.995 . . . . 0.0 113.265 172.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -74.29 -15.98 60.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.59 170.08 17.07 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.652 1.981 . . . . 0.0 111.3 -174.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo . . . . . 0 N--CA 1.434 -2.012 0 CA-C-N 122.517 1.934 . . . . 0.0 116.869 -179.7 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 18.1 tptm . . . . . 0 N--CA 1.43 -1.428 0 CA-C-O 116.55 -1.691 . . . . 0.0 111.529 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -72.31 178.75 5.72 Favored 'Trans proline' 0 N--CA 1.433 -2.031 0 CA-C-N 126.337 3.299 . . . . 0.0 113.058 165.244 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 92.44 18.76 40.69 Favored Glycine 0 N--CA 1.43 -1.715 0 N-CA-C 115.563 0.985 . . . . 0.0 115.563 -179.362 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -94.8 151.8 18.94 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.085 1.354 . . . . 0.0 110.952 -179.537 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 2.1 p -93.07 156.43 16.88 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.748 1.619 . . . . 0.0 113.433 -177.634 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -147.48 134.23 20.02 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 173.361 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -90.98 137.26 32.5 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 162.46 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.7 t -124.6 93.47 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.9 -1.125 . . . . 0.0 109.011 -175.226 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.47 85.43 5.75 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.544 1.537 . . . . 0.0 110.906 173.286 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.292 1.7 pp -117.88 156.6 28.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 122.668 1.223 . . . . 0.0 112.554 -176.859 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.85 133.43 46.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.074 1.75 . . . . 0.0 112.074 -177.188 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -70.6 134.41 47.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.679 1.592 . . . . 0.0 115.228 -178.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.3 p -107.21 118.45 36.74 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.525 -1.359 . . . . 0.0 111.592 -178.086 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.3 t70 47.83 43.96 17.66 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.329 2.252 . . . . 0.0 115.678 175.777 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.41 -5.05 85.71 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.447 -1.408 . . . . 0.0 114.956 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 80.6 p -121.59 137.68 54.63 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.176 1.488 . . . . 0.0 114.072 -172.713 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 89.8 mt -90.61 -61.84 1.59 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.804 -1.185 . . . . 0.0 110.219 167.298 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.82 36.05 1.2 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.625 -1.922 . . . . 0.0 113.189 169.836 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -123.79 124.17 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.031 1.333 . . . . 0.0 109.986 -176.208 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.0 t -101.73 112.49 25.1 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.817 -1.177 . . . . 0.0 107.867 170.349 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.0 m -104.19 161.79 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.934 1.293 . . . . 0.0 111.664 -178.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -149.72 174.11 12.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.677 -1.264 . . . . 0.0 109.767 -175.172 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.42 -131.87 10.66 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 124.355 0.979 . . . . 0.0 113.519 168.334 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.83 176.89 51.04 Favored Glycine 0 N--CA 1.43 -1.758 0 N-CA-C 115.787 1.075 . . . . 0.0 115.787 174.659 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m -73.07 -6.53 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 117.356 2.354 . . . . 0.0 117.356 -170.127 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -86.05 -11.15 53.59 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.563 -1.961 . . . . 0.0 110.197 171.087 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.1 m -105.97 151.93 23.98 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.708 1.603 . . . . 0.0 106.776 -177.286 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 29.5 m -81.22 32.33 0.33 Allowed 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 118.533 -2.605 . . . . 0.0 114.587 -177.395 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.7 p -99.79 84.47 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.2 -1.562 . . . . 0.0 113.738 -165.984 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 47.9 70.21 0.45 Allowed 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.062 2.145 . . . . 0.0 114.229 176.748 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.3 m-70 69.33 -66.37 0.26 Allowed 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 127.281 2.233 . . . . 0.0 112.686 -164.682 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.18 66.96 0.04 OUTLIER Glycine 0 N--CA 1.429 -1.803 0 O-C-N 121.589 -0.694 . . . . 0.0 111.587 175.153 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -82.69 144.95 23.42 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.304 -1.115 . . . . 0.0 113.354 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 35.4 mm -93.71 123.44 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.498 -1.001 . . . . 0.0 109.16 174.501 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -123.33 154.25 39.17 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.889 -1.132 . . . . 0.0 110.215 -175.315 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.0 t -76.72 129.87 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.765 -1.21 . . . . 0.0 111.562 168.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -100.32 -50.11 4.04 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.374 1.47 . . . . 0.0 111.449 176.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.24 161.05 43.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.686 -1.259 . . . . 0.0 111.401 -175.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.76 125.78 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.431 1.092 . . . . 0.0 110.01 179.766 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.3 mm -77.13 115.99 53.57 Favored Pre-proline 0 N--CA 1.43 -1.455 0 C-N-CA 125.748 1.619 . . . . 0.0 112.816 -177.389 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -64.91 136.37 48.47 Favored 'Trans proline' 0 C--N 1.3 -1.988 0 CA-C-N 124.074 2.491 . . . . 0.0 113.044 -175.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.251 45.4 mtmt 83.94 7.0 0.63 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.852 2.861 . . . . 0.0 114.42 -175.318 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 160.22 35.93 Favored Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.97 -1.706 . . . . 0.0 114.983 176.142 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.34 -56.65 8.84 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.009 2.123 . . . . 0.0 115.994 169.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -45.98 83.66 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 128.231 2.612 . . . . 0.0 111.697 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -47.62 -64.61 0.74 Allowed 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.968 1.84 . . . . 0.0 115.968 169.492 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.0 m -70.13 -21.45 63.09 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 115.448 1.647 . . . . 0.0 115.448 -173.01 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.0 -65.8 0.56 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.295 1.438 . . . . 0.0 112.361 173.189 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.58 0.04 42.96 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 114.847 170.557 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -66.32 -51.73 54.32 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 118.766 1.283 . . . . 0.0 110.32 162.294 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.7 mt -78.26 134.96 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 124.902 1.281 . . . . 0.0 111.053 179.322 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.6 t-80 -147.59 156.78 43.15 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 122.063 0.935 . . . . 0.0 109.46 -178.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -65.61 126.02 27.05 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 119.501 -2.0 . . . . 0.0 114.37 -174.23 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.03 -4.86 35.98 Favored Glycine 0 N--CA 1.43 -1.758 0 CA-C-O 118.244 -1.309 . . . . 0.0 115.665 -173.229 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.363 3.1 p30 -81.58 163.41 22.63 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 121.207 2.503 . . . . 0.0 114.565 178.464 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.4 tpt85 -112.21 121.92 46.29 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.343 -1.473 . . . . 0.0 111.018 -167.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.6 t -87.94 136.24 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.105 -1.622 . . . . 0.0 110.277 -173.434 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 9.6 mp -102.3 -53.03 3.0 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 124.583 1.153 . . . . 0.0 110.494 175.776 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.93 147.43 27.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.825 -1.172 . . . . 0.0 112.209 -168.865 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.28 116.14 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 176.594 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 61.63 37.35 16.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.572 1.949 . . . . 0.0 115.073 167.723 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.18 59.62 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.522 1.058 . . . . 0.0 113.906 -175.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.6 t -95.44 112.62 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-N 118.546 1.173 . . . . 0.0 111.029 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.1 m -70.13 121.76 18.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.98 -1.075 . . . . 0.0 110.083 171.091 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.0 mt -72.85 -34.16 66.58 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -169.069 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -8.85 93.53 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 121.114 3.746 . . . . 0.0 121.114 -173.704 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.48 20.87 12.3 Favored Glycine 0 N--CA 1.43 -1.763 0 C-N-CA 125.134 1.35 . . . . 0.0 111.608 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.33 164.45 26.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 175.018 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -92.74 170.32 9.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.358 -1.464 . . . . 0.0 111.121 161.776 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -51.36 -56.7 11.71 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.293 1.837 . . . . 0.0 113.146 169.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -56.67 -36.19 69.3 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 174.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.7 mm-40 -55.59 -48.39 74.91 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 121.102 1.774 . . . . 0.0 113.79 175.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.95 -42.37 94.67 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.195 0.998 . . . . 0.0 113.26 177.889 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.4 t -65.43 -45.68 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 124.603 1.161 . . . . 0.0 111.266 178.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -62.38 -40.23 95.78 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.724 -1.235 . . . . 0.0 112.83 177.712 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.0 m -65.79 -42.27 90.95 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.435 2.294 . . . . 0.0 113.295 175.575 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.12 -36.85 84.26 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.303 1.441 . . . . 0.0 113.299 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -68.76 -30.14 68.68 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.245 -1.534 . . . . 0.0 113.133 172.032 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -84.81 45.96 1.21 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.02 1.728 . . . . 0.0 112.777 175.495 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 p -105.55 163.58 12.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 126.696 1.998 . . . . 0.0 110.214 177.793 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.92 -144.2 15.73 Favored Glycine 0 N--CA 1.43 -1.732 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 168.411 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -70.95 -60.71 2.09 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 121.191 -1.181 . . . . 0.0 113.666 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 29.5 t -98.42 119.85 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.948 1.356 . . . . 0.0 109.293 -175.345 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.1 t -112.78 114.87 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 C-N-CA 126.305 1.842 . . . . 0.0 109.306 -165.79 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -97.69 99.03 10.38 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.961 -1.087 . . . . 0.0 110.617 -177.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.0 mt -92.93 160.24 14.98 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 119.797 -1.814 . . . . 0.0 112.711 173.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.46 131.99 48.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.417 1.087 . . . . 0.0 108.09 165.814 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -147.86 172.98 13.3 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.395 -1.44 . . . . 0.0 112.415 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -127.49 148.63 50.31 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.162 1.785 . . . . 0.0 109.258 174.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -76.0 137.89 40.56 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 120.34 -1.475 . . . . 0.0 111.312 175.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.88 -158.93 34.96 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 121.316 -0.865 . . . . 0.0 111.392 173.069 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -73.75 177.82 5.22 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.849 -1.383 . . . . 0.0 113.714 -178.15 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -120.58 127.34 26.33 Favored Pre-proline 0 N--CA 1.43 -1.426 0 O-C-N 120.703 -1.248 . . . . 0.0 110.492 -171.178 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo . . . . . 0 N--CA 1.434 -2.013 0 CA-C-N 122.467 1.917 . . . . 0.0 112.657 169.218 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.0 pttm . . . . . 0 N--CA 1.43 -1.429 0 CA-C-O 119.531 -0.271 . . . . 0.0 111.597 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -78.18 177.4 8.82 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 121.84 1.693 . . . . 0.0 112.101 172.09 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.32 23.55 28.89 Favored Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 125.048 1.309 . . . . 0.0 112.351 -178.689 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -96.58 133.07 41.53 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.036 1.334 . . . . 0.0 109.206 -172.306 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.8 p -106.07 154.41 20.68 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 124.725 1.21 . . . . 0.0 112.184 178.414 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.46 143.9 29.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.694 -1.254 . . . . 0.0 108.567 -177.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -99.43 105.35 17.29 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.2 1.0 . . . . 0.0 109.636 -179.186 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.72 99.54 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.3 1.44 . . . . 0.0 109.457 -169.809 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -90.09 95.76 10.36 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.379 -1.451 . . . . 0.0 107.749 173.721 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -111.02 130.04 55.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.171 0.988 . . . . 0.0 110.467 -169.862 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.89 141.25 35.04 Favored 'General case' 0 CA--C 1.489 -1.372 0 O-C-N 120.471 -1.393 . . . . 0.0 109.727 172.937 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -64.42 147.22 53.13 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 178.699 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 31.3 p -116.15 122.87 46.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 167.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.2 t0 43.3 46.22 5.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 128.577 2.751 . . . . 0.0 114.422 -176.726 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.14 11.58 75.18 Favored Glycine 0 N--CA 1.431 -1.65 0 N-CA-C 117.891 1.917 . . . . 0.0 117.891 -178.357 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.0 m -117.32 153.67 32.58 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 119.473 1.637 . . . . 0.0 111.898 178.438 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 72.2 mt -96.11 -60.56 1.6 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.435 1.094 . . . . 0.0 108.9 165.429 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 119.14 37.58 0.8 Allowed Glycine 0 N--CA 1.43 -1.765 0 O-C-N 119.829 -1.794 . . . . 0.0 113.142 174.639 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 pt -129.5 139.17 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.173 1.389 . . . . 0.0 108.742 -175.493 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.5 m -111.79 117.7 33.56 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 157.668 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.5 m -99.05 162.59 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 124.351 1.061 . . . . 0.0 112.017 -174.631 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -150.11 -177.72 6.09 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.842 1.257 . . . . 0.0 110.001 178.168 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.53 -149.55 19.27 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.985 -1.072 . . . . 0.0 113.745 174.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.43 168.03 30.07 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 124.513 1.054 . . . . 0.0 112.924 -177.449 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -69.15 -17.89 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -172.218 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -82.59 -26.69 32.08 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.4 -1.438 . . . . 0.0 112.672 -171.479 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.4 p -103.46 165.57 10.95 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 120.339 -1.476 . . . . 0.0 112.054 -174.699 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.9 m -82.45 61.67 5.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.973 -1.704 . . . . 0.0 113.337 -174.878 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.6 m -100.64 -4.6 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.458 -1.401 . . . . 0.0 112.223 176.331 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.343 78.4 mtt180 72.41 117.28 0.05 OUTLIER 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.341 2.656 . . . . 0.0 114.674 -169.008 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.284 87.9 m-70 68.75 -61.29 0.42 Allowed 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 127.435 2.294 . . . . 0.0 115.314 -174.095 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.19 52.39 0.16 Allowed Glycine 0 N--CA 1.43 -1.716 0 N-CA-C 116.615 1.406 . . . . 0.0 116.615 170.623 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -75.15 156.19 48.55 Favored Glycine 0 N--CA 1.429 -1.769 0 CA-C-N 118.872 1.336 . . . . 0.0 113.429 170.8 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -96.93 121.88 47.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 175.591 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -126.71 154.26 44.36 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.854 -1.154 . . . . 0.0 110.522 -168.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.8 t -75.88 125.57 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.603 -1.31 . . . . 0.0 110.757 169.223 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.1 tttm -91.88 -44.92 8.65 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.738 -1.226 . . . . 0.0 110.671 178.662 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.44 148.11 29.93 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 123.129 0.572 . . . . 0.0 110.694 178.432 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -102.89 121.36 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.612 1.196 . . . . 0.0 110.121 173.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.4 mm -77.1 120.27 80.92 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 125.893 1.677 . . . . 0.0 114.219 -171.902 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -59.72 126.35 20.3 Favored 'Trans proline' 0 C--N 1.3 -2.013 0 CA-C-N 124.451 2.625 . . . . 0.0 115.325 -177.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.265 7.3 mtpm? 78.29 28.02 0.5 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.454 2.302 . . . . 0.0 112.598 -178.04 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.14 159.72 34.26 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.531 -1.356 . . . . 0.0 113.646 162.472 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.06 -60.83 2.45 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.054 2.142 . . . . 0.0 114.847 164.464 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.16 -49.19 78.63 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.191 2.996 . . . . 0.0 111.96 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -46.76 -61.58 1.78 Allowed 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 115.55 1.685 . . . . 0.0 115.55 171.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.8 m -68.27 -32.97 73.51 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 -173.594 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -51.01 -66.96 0.29 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.093 1.757 . . . . 0.0 113.323 176.368 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.25 -17.59 10.48 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 115.051 0.78 . . . . 0.0 115.051 174.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 56.9 mtt85 -71.27 -33.62 69.94 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 120.081 1.941 . . . . 0.0 112.491 170.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.8 mt -95.12 113.5 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.228 1.011 . . . . 0.0 109.628 176.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.675 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 79.9 t60 -143.65 -174.04 4.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.165 -1.584 . . . . 0.0 110.508 174.943 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.675 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.3 ttpt -60.15 127.65 32.89 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.32 1.848 . . . . 0.0 113.853 -174.753 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.95 -6.35 83.75 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 120.659 -1.275 . . . . 0.0 114.793 178.792 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -81.65 149.27 28.62 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.638 1.719 . . . . 0.0 112.893 -173.685 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -92.29 141.01 29.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.907 -1.745 . . . . 0.0 112.049 -170.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.38 119.11 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.63 1.172 . . . . 0.0 108.322 176.491 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.54 -52.46 2.99 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.355 -1.466 . . . . 0.0 111.072 -166.078 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.47 117.18 5.82 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 109.006 175.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.6 t -90.91 115.18 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.718 -173.134 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.0 t30 64.13 32.39 12.69 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.139 1.376 . . . . 0.0 111.853 174.909 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.42 -23.94 33.67 Favored Glycine 0 N--CA 1.429 -1.804 0 C-N-CA 124.764 1.173 . . . . 0.0 114.663 -173.495 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.5 t -87.03 111.9 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.689 -1.477 . . . . 0.0 111.698 -167.817 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.4 m -61.63 120.55 10.81 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.729 -1.232 . . . . 0.0 114.118 -179.013 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 38.9 mt -87.57 42.9 1.07 Allowed 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 112.371 -178.203 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -85.29 110.49 19.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 119.193 -2.192 . . . . 0.0 112.169 -174.335 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.3 -0.6 71.89 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 124.782 1.182 . . . . 0.0 114.228 179.412 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.03 155.09 41.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.3 1.963 . . . . 0.0 116.3 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.3 p -81.04 175.36 10.75 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.147 1.379 . . . . 0.0 112.428 174.253 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -67.28 -39.89 86.08 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.401 -1.437 . . . . 0.0 111.712 174.105 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -57.3 -48.53 78.69 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 113.607 174.953 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -56.46 -46.35 80.42 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.225 1.41 . . . . 0.0 114.503 179.044 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.08 -39.4 94.61 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.862 1.665 . . . . 0.0 114.364 175.577 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.5 t -76.19 -45.24 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.052 1.341 . . . . 0.0 111.388 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -58.99 -33.03 70.22 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 127.691 2.396 . . . . 0.0 112.19 175.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.6 m -72.53 -49.32 33.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.334 1.854 . . . . 0.0 113.752 170.662 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.8 mt -58.43 -45.36 88.62 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 120.641 1.564 . . . . 0.0 115.149 176.938 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 37.5 ptt85 -66.57 -28.23 68.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.831 -1.168 . . . . 0.0 113.798 -177.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -93.18 32.94 1.24 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.8 1.24 . . . . 0.0 113.616 -179.369 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 22.4 p -92.02 148.48 22.15 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.981 1.712 . . . . 0.0 111.384 174.142 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.25 -143.56 9.03 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.819 -1.176 . . . . 0.0 112.59 174.516 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -68.61 -59.79 2.88 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 114.871 1.434 . . . . 0.0 114.871 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.9 p -98.39 134.77 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.384 0 CA-C-O 122.919 1.342 . . . . 0.0 110.648 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.1 t -124.08 115.95 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 C-N-CA 127.525 2.33 . . . . 0.0 107.993 -171.414 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -97.19 89.09 4.65 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.366 -1.459 . . . . 0.0 112.229 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.6 tp -93.46 130.09 39.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.376 -2.077 . . . . 0.0 110.935 -178.134 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.3 tp -87.75 126.09 34.79 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 161.474 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 6.5 tt -122.32 148.54 44.92 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.543 1.137 . . . . 0.0 109.084 -170.106 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -125.3 142.79 51.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 171.608 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -77.25 160.36 28.96 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.517 -1.365 . . . . 0.0 111.916 -177.29 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.92 -147.17 8.66 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 120.382 -1.449 . . . . 0.0 112.937 168.119 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -72.68 177.76 4.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.924 -1.927 . . . . 0.0 113.428 178.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 45.4 t -90.59 122.45 67.09 Favored Pre-proline 0 N--CA 1.43 -1.47 0 O-C-N 119.926 -1.734 . . . . 0.0 109.431 178.61 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo . . . . . 0 C--N 1.3 -1.974 0 CA-C-N 123.481 2.279 . . . . 0.0 111.748 173.321 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 55.4 tptt . . . . . 0 N--CA 1.43 -1.432 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -88.94 179.25 2.47 Favored 'Trans proline' 0 N--CA 1.434 -2.025 0 C-N-CA 122.184 1.923 . . . . 0.0 113.063 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.94 41.74 2.58 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.502 1.049 . . . . 0.0 113.105 167.353 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -82.23 143.31 31.45 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 121.595 -0.944 . . . . 0.0 110.107 174.436 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -98.52 155.85 17.07 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.575 -1.328 . . . . 0.0 111.638 176.599 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 133.6 21.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 122.231 1.015 . . . . 0.0 108.839 177.329 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -87.49 133.55 33.74 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.326 1.45 . . . . 0.0 109.347 169.97 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.4 t -126.3 107.15 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.853 1.261 . . . . 0.0 108.4 -169.438 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -91.38 102.05 14.73 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 120.383 -1.448 . . . . 0.0 108.393 166.376 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.2 tp -113.32 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.945 0.878 . . . . 0.0 110.509 -171.608 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 139.85 36.99 Favored 'General case' 0 N--CA 1.428 -1.527 0 O-C-N 120.223 -1.548 . . . . 0.0 107.549 170.203 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -65.23 152.75 42.9 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 115.131 1.53 . . . . 0.0 115.131 -178.487 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 30.5 p -102.48 75.57 1.47 Allowed 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.19 -1.569 . . . . 0.0 108.542 175.313 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.3 t0 61.26 61.53 1.53 Allowed 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.126 1.77 . . . . 0.0 112.321 -177.055 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.41 -30.0 5.45 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.249 -1.532 . . . . 0.0 115.191 -175.291 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.7 m -92.27 136.14 33.43 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.256 -1.732 . . . . 0.0 112.802 -167.112 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 51.9 mt -102.0 -49.17 4.02 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.627 1.571 . . . . 0.0 110.539 177.413 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 -15.87 39.3 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 120.228 -1.545 . . . . 0.0 113.967 -179.087 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.8 pt -96.39 121.83 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 CA-C-N 119.355 1.578 . . . . 0.0 112.959 -176.579 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.3 m -114.06 137.77 51.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 166.228 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.5 m -124.85 165.3 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.307 1.043 . . . . 0.0 112.946 -165.619 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.7 t -144.91 177.89 8.42 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.572 1.549 . . . . 0.0 110.567 -179.346 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.16 -136.68 12.82 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 115.945 1.138 . . . . 0.0 115.945 166.894 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' A' ' 34' ' ' ASN . . . 74.48 176.21 35.58 Favored Glycine 0 N--CA 1.43 -1.715 0 C-N-CA 126.351 1.929 . . . . 0.0 113.85 -179.025 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -77.43 25.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 O-C-N 120.437 -1.625 . . . . 0.0 113.481 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.403 ' H ' ' C ' ' A' ' 32' ' ' GLY . 0.1 OUTLIER -98.88 -29.39 12.98 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.577 -1.952 . . . . 0.0 110.119 175.584 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 44.4 p -115.58 171.31 7.81 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 125.365 1.466 . . . . 0.0 108.568 -174.091 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 m -92.47 50.78 1.65 Allowed 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.136 -1.603 . . . . 0.0 111.531 176.352 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.94 153.05 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.958 1.303 . . . . 0.0 110.955 -177.472 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.5 mmt180 -62.08 121.72 13.74 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.756 -1.215 . . . . 0.0 112.913 179.49 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 72.16 -9.53 1.0 Allowed 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.894 2.478 . . . . 0.0 117.191 -176.443 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.7 61.75 4.79 Favored Glycine 0 N--CA 1.43 -1.719 0 O-C-N 119.804 -1.81 . . . . 0.0 114.685 179.439 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -143.52 172.17 24.96 Favored Glycine 0 N--CA 1.43 -1.746 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -177.406 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 mm -93.74 122.06 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 124.823 1.249 . . . . 0.0 108.367 -175.498 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -121.36 152.58 38.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.79 -1.194 . . . . 0.0 109.6 -175.096 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.9 129.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 O-C-N 120.455 -1.403 . . . . 0.0 111.739 174.211 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -96.21 -46.32 6.49 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 126.031 1.733 . . . . 0.0 111.761 -176.507 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.3 152.8 32.58 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.89 -1.131 . . . . 0.0 109.673 -176.846 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.27 1.0 OUTLIER -112.61 116.02 51.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 CA-C-O 122.72 1.247 . . . . 0.0 109.457 170.885 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.5 mm -76.43 127.59 84.26 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 116.218 -1.849 . . . . 0.0 114.161 -173.789 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -58.08 132.54 49.97 Favored 'Trans proline' 0 N--CA 1.433 -2.052 0 CA-C-N 124.474 2.634 . . . . 0.0 116.725 -179.035 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.278 53.8 mttp 72.15 18.97 4.66 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.35 2.26 . . . . 0.0 114.551 -174.087 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.84 157.17 45.07 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 119.394 -2.067 . . . . 0.0 112.227 170.863 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.36 -59.91 3.3 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.573 -1.545 . . . . 0.0 114.679 169.143 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.94 93.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.915 2.486 . . . . 0.0 112.263 -179.717 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -45.0 -61.75 1.5 Allowed 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.111 1.764 . . . . 0.0 114.15 173.001 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.5 t -67.75 -43.18 80.51 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -175.419 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.58 -58.08 6.65 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 127.202 2.201 . . . . 0.0 114.081 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.58 31.6 7.38 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.299 -1.5 . . . . 0.0 115.037 163.146 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 53.4 mtt180 -96.98 -29.98 13.35 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 125.291 1.436 . . . . 0.0 109.151 162.786 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.7 mt -108.54 130.01 62.0 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 125.361 1.464 . . . . 0.0 111.076 -179.486 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -141.58 170.55 15.5 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.894 -1.129 . . . . 0.0 109.579 172.842 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.8 pttm -66.59 140.96 57.98 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 118.604 -2.56 . . . . 0.0 113.74 178.119 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.5 -11.21 65.05 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.602 -0.686 . . . . 0.0 113.163 -171.535 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -79.71 154.37 28.62 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 119.162 1.481 . . . . 0.0 112.27 -177.316 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -97.73 123.75 41.79 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.241 1.416 . . . . 0.0 109.698 -174.895 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.8 t -88.11 130.63 37.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 O-C-N 120.053 -1.655 . . . . 0.0 110.17 -178.398 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -99.06 -52.29 3.59 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.079 -1.013 . . . . 0.0 111.001 -178.036 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.96 144.28 24.83 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.13 -0.981 . . . . 0.0 112.862 -172.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.3 t -113.51 111.72 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 66.44 35.78 5.46 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.433 1.893 . . . . 0.0 113.353 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.93 60.01 Favored Glycine 0 N--CA 1.431 -1.659 0 O-C-N 119.931 -1.73 . . . . 0.0 114.238 -175.03 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.35 104.42 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 125.308 1.443 . . . . 0.0 108.508 178.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.2 m -72.45 139.87 47.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.628 -1.295 . . . . 0.0 112.552 -175.29 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 98.9 mt -90.24 -2.4 58.03 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -169.297 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -67.81 105.2 1.88 Allowed 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.219 -1.551 . . . . 0.0 113.927 -176.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 115.1 -20.99 13.72 Favored Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 125.454 1.502 . . . . 0.0 112.969 -174.698 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.04 153.92 40.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 179.237 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 80.4 p -92.16 176.93 6.31 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.558 -1.339 . . . . 0.0 112.843 -179.914 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.9 t-80 -56.21 -53.01 62.25 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.162 1.785 . . . . 0.0 112.359 172.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -55.45 -46.97 76.74 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.622 1.169 . . . . 0.0 113.548 177.55 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.87 -51.59 68.98 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.896 1.443 . . . . 0.0 114.896 177.772 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.22 -36.69 84.95 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.448 -1.408 . . . . 0.0 114.563 176.759 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 95.6 t -72.82 -40.62 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.383 -1.448 . . . . 0.0 111.618 178.186 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -57.63 -44.98 85.96 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.258 -1.526 . . . . 0.0 111.879 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 63.7 m -61.64 -46.71 88.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.718 2.007 . . . . 0.0 114.643 178.157 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . 0.258 0.1 OUTLIER -73.15 -30.85 63.88 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 121.723 2.056 . . . . 0.0 113.893 -178.673 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.36 -39.48 92.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.795 -1.19 . . . . 0.0 111.437 169.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -88.94 55.68 3.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 123.02 1.39 . . . . 0.0 111.233 177.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.4 p -106.32 156.95 17.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.615 1.566 . . . . 0.0 109.624 174.184 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.15 -162.63 32.96 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 121.374 -0.828 . . . . 0.0 111.987 176.294 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -70.79 -48.96 51.49 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.213 1.405 . . . . 0.0 111.551 175.335 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.4 134.03 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.512 1.149 . . . . 0.0 108.044 167.515 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 82.8 t -124.4 134.95 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 128.562 2.745 . . . . 0.0 107.778 -170.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 23.2 t-160 -122.73 95.23 4.54 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.856 -1.778 . . . . 0.0 110.497 -173.009 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.6 mt -99.58 157.3 16.55 Favored 'General case' 0 N--CA 1.429 -1.517 0 O-C-N 120.02 -1.675 . . . . 0.0 114.023 -177.122 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.4 tp -127.2 131.64 50.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 162.335 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.14 163.48 32.75 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.889 -1.132 . . . . 0.0 111.165 176.251 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -117.17 144.73 44.43 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.535 1.934 . . . . 0.0 108.181 176.918 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.4 tptt -76.16 137.97 40.4 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.623 -1.298 . . . . 0.0 112.407 -177.201 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.78 123.13 25.45 Favored Glycine 0 N--CA 1.429 -1.811 0 C-N-CA 126.406 1.955 . . . . 0.0 116.209 -175.953 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -82.13 179.56 7.76 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -172.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.3 m -98.29 178.61 1.27 Allowed Pre-proline 0 N--CA 1.43 -1.442 0 C-N-CA 126.315 1.846 . . . . 0.0 110.739 -175.699 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 N--CA 1.434 -2.008 0 C-N-CA 122.042 1.828 . . . . 0.0 115.562 168.182 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 79.1 mttt . . . . . 0 N--CA 1.43 -1.468 0 CA-C-O 116.45 -1.738 . . . . 0.0 112.895 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -66.14 -174.22 0.39 Allowed 'Trans proline' 0 N--CA 1.433 -2.041 0 CA-C-N 125.31 2.932 . . . . 0.0 114.71 164.465 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.61 28.68 15.66 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 120.464 -1.398 . . . . 0.0 114.826 176.986 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -90.66 172.84 8.38 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 164.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 36.3 p -120.7 165.08 15.59 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.069 -1.644 . . . . 0.0 111.76 -178.725 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.51 144.36 28.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 121.889 0.852 . . . . 0.0 109.677 165.018 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.97 130.2 35.5 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 125.643 1.577 . . . . 0.0 109.835 168.929 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.2 t -118.49 113.12 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 124.819 1.248 . . . . 0.0 108.461 -177.283 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -94.94 108.46 20.52 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 165.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 21.7 tp -123.65 128.69 50.03 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.693 1.235 . . . . 0.0 110.394 -176.162 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.99 137.45 39.34 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.757 -1.839 . . . . 0.0 109.569 169.326 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -69.41 136.17 51.26 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.122 -0.986 . . . . 0.0 113.101 177.006 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.9 p -90.02 93.1 9.26 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.41 -1.431 . . . . 0.0 111.448 -171.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.7 t70 56.29 41.92 28.53 Favored 'General case' 0 N--CA 1.429 -1.523 0 C-N-CA 125.812 1.645 . . . . 0.0 113.26 178.023 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.03 -20.43 40.81 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.766 1.174 . . . . 0.0 115.372 -174.707 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -94.11 110.68 22.38 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.254 1.527 . . . . 0.0 114.163 -170.535 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.5 tt -125.53 64.79 1.17 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 169.856 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -82.16 74.99 2.4 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 126.754 2.121 . . . . 0.0 111.259 -164.72 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.2 pt -100.65 156.49 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 125.332 1.453 . . . . 0.0 111.149 169.774 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 46.7 t -129.05 127.6 41.89 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.138 -1.601 . . . . 0.0 107.318 158.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 m -120.49 168.2 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 124.676 1.19 . . . . 0.0 110.141 -178.525 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -149.97 -175.31 5.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.614 -1.304 . . . . 0.0 107.566 176.031 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.89 -168.7 12.62 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.888 -1.132 . . . . 0.0 114.631 168.608 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.1 161.76 18.65 Favored Glycine 0 N--CA 1.431 -1.652 0 CA-C-O 122.901 1.278 . . . . 0.0 115.039 173.076 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t -59.96 -34.66 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 127.405 2.282 . . . . 0.0 115.646 -178.151 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -78.05 -27.99 48.83 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 119.707 -1.87 . . . . 0.0 112.471 -175.569 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.3 p -99.26 156.11 17.15 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.042 1.337 . . . . 0.0 111.175 -172.296 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 16.1 m -82.27 49.63 1.46 Allowed 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.991 -1.693 . . . . 0.0 114.089 -169.754 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.2 m -93.31 10.64 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 O-C-N 119.591 -1.943 . . . . 0.0 114.309 -168.524 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.261 25.9 ttt-85 87.59 73.46 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 127.761 2.424 . . . . 0.0 111.146 -177.237 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.9 t60 90.22 -62.62 0.02 OUTLIER 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 129.474 3.11 . . . . 0.0 112.519 -176.818 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 158.87 -160.59 31.25 Favored Glycine 0 N--CA 1.431 -1.691 0 N-CA-C 106.117 -2.793 . . . . 0.0 106.117 -166.053 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.11 146.15 14.69 Favored Glycine 0 N--CA 1.43 -1.701 0 C-N-CA 125.428 1.489 . . . . 0.0 111.114 -169.298 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.9 mm -99.47 126.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 177.339 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -127.11 152.63 47.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 119.657 1.117 . . . . 0.0 111.3 -170.322 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.42 126.18 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 O-C-N 120.555 -1.34 . . . . 0.0 112.964 172.674 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 39.6 tttp -97.93 -39.5 8.94 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.191 1.396 . . . . 0.0 111.81 -175.483 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -161.29 154.69 21.55 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.226 -0.921 . . . . 0.0 110.291 173.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.23 120.72 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 124.252 1.021 . . . . 0.0 108.436 168.59 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.2 mm -76.62 127.1 85.1 Favored Pre-proline 0 N--CA 1.43 -1.437 0 CA-C-O 116.752 -1.594 . . . . 0.0 113.993 -169.666 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -55.26 119.89 7.28 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 123.737 2.958 . . . . 0.0 115.942 177.3 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.37 5.3 mmmp? 78.92 23.14 0.59 Allowed 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.562 2.745 . . . . 0.0 116.059 -175.155 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.04 164.46 40.66 Favored Glycine 0 N--CA 1.431 -1.673 0 O-C-N 120.544 -1.347 . . . . 0.0 112.14 163.303 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -58.71 4.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.857 1.428 . . . . 0.0 114.857 168.323 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.39 -26.85 68.64 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.376 1.871 . . . . 0.0 114.576 -177.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.66 -54.26 45.07 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.688 1.709 . . . . 0.0 113.057 177.156 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 t -65.88 -44.01 86.62 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 125.511 1.524 . . . . 0.0 112.985 -176.167 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -45.01 -55.79 5.23 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.232 2.613 . . . . 0.0 116.272 -172.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.49 6.93 35.26 Favored Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 116.965 1.546 . . . . 0.0 116.965 162.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -90.17 -49.42 6.57 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.804 -1.41 . . . . 0.0 109.354 167.75 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 87.3 mt -79.31 128.99 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.351 1.46 . . . . 0.0 112.242 -171.647 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -132.94 153.55 51.31 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.876 1.67 . . . . 0.0 111.047 -178.418 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -51.49 123.19 9.28 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.134 1.774 . . . . 0.0 113.763 170.436 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 93.04 0.11 68.61 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 120.868 -1.145 . . . . 0.0 115.906 -178.429 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 1.7 p30 -82.05 159.07 23.54 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 120.119 1.959 . . . . 0.0 113.936 176.006 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -100.32 130.03 46.38 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.592 -1.318 . . . . 0.0 112.788 -177.004 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -85.7 125.37 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.934 1.294 . . . . 0.0 110.014 176.112 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.36 -42.7 6.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.777 -1.202 . . . . 0.0 111.825 -174.464 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 148.9 29.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.716 -1.24 . . . . 0.0 111.647 179.795 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 t -118.73 109.4 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 171.093 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.3 t30 45.13 67.47 0.71 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.297 2.639 . . . . 0.0 116.11 173.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 88.48 -29.38 5.75 Favored Glycine 0 N--CA 1.43 -1.725 0 C-N-CA 124.098 0.856 . . . . 0.0 113.555 -179.476 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -94.5 111.27 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 121.084 -1.245 . . . . 0.0 109.109 -171.771 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 73.6 m -69.99 133.49 47.31 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 176.677 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.1 mt -86.5 50.06 1.92 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.847 -1.158 . . . . 0.0 111.064 -178.411 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -89.7 133.23 34.77 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.599 2.36 . . . . 0.0 109.715 178.133 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.67 3.83 22.82 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 117.232 1.653 . . . . 0.0 117.232 -179.543 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.84 148.7 45.94 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 115.645 1.72 . . . . 0.0 115.645 -170.763 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 69.2 p -90.01 174.51 7.62 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.838 -1.164 . . . . 0.0 110.481 165.063 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -52.92 -52.71 56.82 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.172 1.789 . . . . 0.0 113.715 174.758 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -55.64 -40.4 72.14 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 126.074 1.75 . . . . 0.0 114.598 -179.503 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -54.95 -57.23 12.5 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 126.883 2.073 . . . . 0.0 113.146 177.654 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.61 -37.8 83.03 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.57 1.148 . . . . 0.0 113.815 178.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.5 t -68.35 -48.18 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.653 -1.279 . . . . 0.0 110.722 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 53.2 mm-40 -66.52 -26.86 67.36 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.249 -1.532 . . . . 0.0 112.855 178.316 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 66.5 m -69.68 -46.19 66.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.814 1.646 . . . . 0.0 113.085 170.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 47.7 mt -72.23 -22.35 61.26 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 119.779 -1.826 . . . . 0.0 114.822 176.475 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -68.3 -50.72 51.62 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.137 -1.602 . . . . 0.0 111.057 166.217 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.52 60.01 5.43 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.273 1.429 . . . . 0.0 113.281 -174.071 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 44.0 p -92.23 -175.9 4.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.422 -1.424 . . . . 0.0 110.73 171.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.22 -150.95 23.51 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 157.759 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -71.25 -52.57 18.24 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.771 1.228 . . . . 0.0 113.358 174.596 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 17.3 t -104.74 120.48 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 122.338 1.066 . . . . 0.0 110.613 -176.915 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.8 t -109.29 139.6 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 127.623 2.369 . . . . 0.0 109.676 -169.668 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -115.49 112.97 23.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.248 -1.533 . . . . 0.0 109.325 174.178 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -107.03 158.55 16.96 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.279 1.432 . . . . 0.0 113.034 176.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 67.2 tp -126.29 130.8 51.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 164.119 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.78 159.23 41.98 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 121.084 -1.01 . . . . 0.0 112.713 174.528 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -101.58 137.16 40.27 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 126.137 1.775 . . . . 0.0 108.443 175.029 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -75.38 113.95 13.37 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.607 -1.308 . . . . 0.0 111.071 -171.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.95 137.03 40.99 Favored Glycine 0 N--CA 1.431 -1.649 0 C-N-CA 127.635 2.54 . . . . 0.0 117.539 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 29.2 mt-30 -86.36 -57.43 3.01 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.406 1.482 . . . . 0.0 110.281 -170.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.7 m -111.7 132.99 21.64 Favored Pre-proline 0 N--CA 1.43 -1.471 0 C-N-CA 124.287 1.035 . . . . 0.0 109.986 -178.145 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo . . . . . 0 N--CA 1.434 -2.022 0 C-N-CA 122.716 2.277 . . . . 0.0 110.767 167.928 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.433 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -79.02 179.6 6.33 Favored 'Trans proline' 0 C--N 1.299 -2.036 0 C-N-CA 122.317 2.011 . . . . 0.0 112.481 171.748 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.29 42.52 1.74 Allowed Glycine 0 N--CA 1.431 -1.649 0 N-CA-C 116.471 1.348 . . . . 0.0 116.471 168.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -89.42 115.6 26.98 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.797 1.239 . . . . 0.0 108.937 169.762 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -92.5 146.23 23.84 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.261 -1.524 . . . . 0.0 109.934 176.967 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -146.41 137.36 24.27 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 123.048 1.404 . . . . 0.0 109.192 179.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.15 141.25 34.3 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.703 1.601 . . . . 0.0 109.128 -178.795 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.5 t -130.66 113.18 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -171.824 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -107.39 75.16 1.0 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.879 1.324 . . . . 0.0 107.845 173.411 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.7 tp -94.8 135.11 36.68 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.357 1.463 . . . . 0.0 111.864 -168.552 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.49 146.08 28.63 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.269 -1.519 . . . . 0.0 111.796 173.373 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -70.27 157.97 36.74 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 115.192 1.552 . . . . 0.0 115.192 176.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.4 t -134.57 125.77 27.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.77 -1.206 . . . . 0.0 108.578 168.758 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 1.2 t70 50.55 40.82 24.43 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.985 2.514 . . . . 0.0 114.25 -170.49 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.1 -9.98 50.8 Favored Glycine 0 N--CA 1.431 -1.688 0 O-C-N 120.224 -1.547 . . . . 0.0 116.302 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.01 144.19 34.01 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.693 -1.475 . . . . 0.0 113.146 -166.849 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 49.8 mt -99.78 -62.28 1.26 Allowed 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.287 -0.883 . . . . 0.0 110.458 173.8 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.71 47.52 0.73 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 119.574 -1.954 . . . . 0.0 112.923 168.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.6 tt -147.53 137.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.666 1.222 . . . . 0.0 112.016 -178.741 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.7 m -105.42 133.89 49.43 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.928 1.291 . . . . 0.0 108.855 168.162 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.8 m -107.7 170.68 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.39 1.09 . . . . 0.0 110.766 178.806 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -150.41 -172.49 4.19 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.458 -1.401 . . . . 0.0 108.508 174.775 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.98 -144.84 18.56 Favored Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 124.893 1.235 . . . . 0.0 111.309 179.316 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.36 146.44 13.7 Favored Glycine 0 N--CA 1.43 -1.757 0 C-N-CA 124.098 0.856 . . . . 0.0 112.367 177.434 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t -70.02 -31.1 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.929 -1.336 . . . . 0.0 114.126 -170.154 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -91.82 -8.15 47.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.559 -1.338 . . . . 0.0 112.273 -178.666 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 25.3 m -77.86 147.12 35.28 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.328 -1.482 . . . . 0.0 108.585 178.672 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m -83.29 58.91 4.73 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 119.298 -2.126 . . . . 0.0 111.721 178.167 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.5 p -99.67 147.68 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 128.416 2.686 . . . . 0.0 108.377 178.496 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 65.8 mmt-85 -68.76 109.19 3.73 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.511 -1.368 . . . . 0.0 112.131 177.546 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.313 3.1 t60 51.96 104.94 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 129.322 3.049 . . . . 0.0 116.588 -170.28 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.15 92.3 0.03 OUTLIER Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 126.755 2.122 . . . . 0.0 117.541 -169.086 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.42 -176.35 14.5 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 173.595 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.6 mm -101.9 129.0 53.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.832 1.253 . . . . 0.0 109.091 -179.243 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -125.55 156.96 38.24 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.632 -1.293 . . . . 0.0 109.952 -170.823 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -75.31 121.07 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.398 -1.439 . . . . 0.0 111.929 173.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -88.33 -59.42 2.24 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.092 -1.63 . . . . 0.0 110.793 179.2 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.58 154.55 34.46 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.633 -0.667 . . . . 0.0 110.187 -172.193 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.53 125.88 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 CA-C-O 121.848 0.832 . . . . 0.0 109.541 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 16.5 mm -77.67 125.18 86.21 Favored Pre-proline 0 N--CA 1.429 -1.497 0 C-N-CA 126.259 1.823 . . . . 0.0 113.473 -173.594 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.58 130.32 39.35 Favored 'Trans proline' 0 N--CA 1.434 -1.996 0 CA-C-N 124.356 2.591 . . . . 0.0 116.568 -175.492 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.275 1.8 mptp? 73.59 13.95 4.35 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 127.592 2.357 . . . . 0.0 115.004 178.916 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.12 164.21 52.64 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 119.615 -1.928 . . . . 0.0 113.767 174.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.43 -56.76 10.05 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 126.325 1.85 . . . . 0.0 114.733 168.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.28 -46.68 82.6 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 128.673 2.789 . . . . 0.0 112.351 178.522 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.1 tm-20 -47.71 -61.97 1.68 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.996 1.851 . . . . 0.0 115.996 170.696 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 65.4 m -69.0 -26.71 65.15 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -175.654 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -55.61 -68.05 0.23 Allowed 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.942 1.697 . . . . 0.0 111.651 174.349 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.48 30.33 33.63 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.043 -1.036 . . . . 0.0 114.925 171.798 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -78.48 -47.76 16.75 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 120.727 -1.455 . . . . 0.0 108.48 147.84 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.3 111.85 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 C-N-CA 125.956 1.703 . . . . 0.0 112.636 -175.099 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -117.21 160.35 21.21 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 123.922 1.82 . . . . 0.0 113.151 -178.503 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -60.94 129.49 41.68 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.259 1.423 . . . . 0.0 113.949 -174.42 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 87.54 -4.85 85.77 Favored Glycine 0 N--CA 1.431 -1.675 0 CA-C-O 118.91 -0.939 . . . . 0.0 114.06 176.108 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -80.96 162.69 23.76 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 119.508 1.654 . . . . 0.0 112.3 -173.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 14.9 ttt180 -106.19 123.97 48.86 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.535 -1.353 . . . . 0.0 111.87 -159.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.1 123.28 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.976 -1.077 . . . . 0.0 110.099 -175.2 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -94.47 -44.05 8.06 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.876 -1.14 . . . . 0.0 110.625 -177.563 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.89 137.93 19.18 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.577 -0.702 . . . . 0.0 112.205 -173.043 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -111.42 126.71 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 174.422 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 71.02 14.81 6.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.267 1.827 . . . . 0.0 111.424 -179.623 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.21 89.62 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 125.956 1.741 . . . . 0.0 114.156 -170.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -91.77 124.62 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-N 118.868 1.334 . . . . 0.0 109.568 -179.83 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 25.4 m -72.92 135.02 45.01 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.767 -1.208 . . . . 0.0 112.817 -172.127 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.5 mt -87.34 36.34 0.74 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.684 -1.26 . . . . 0.0 114.364 -174.118 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -72.71 116.91 13.76 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.143 -2.223 . . . . 0.0 113.572 -170.933 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.23 13.09 79.78 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.13 -0.981 . . . . 0.0 114.26 -177.643 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.32 144.33 51.74 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -177.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 64.7 p -81.73 173.33 12.41 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.252 -1.53 . . . . 0.0 110.493 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -59.52 -48.14 82.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.874 -1.141 . . . . 0.0 111.648 172.182 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.12 -47.96 77.14 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.119 1.368 . . . . 0.0 114.23 174.145 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -58.86 -47.16 85.88 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.235 1.939 . . . . 0.0 116.235 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.35 -35.43 80.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.723 -1.235 . . . . 0.0 112.215 173.166 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.62 -45.02 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.012 -1.055 . . . . 0.0 111.077 178.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -58.65 -40.77 84.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.625 -1.297 . . . . 0.0 113.232 173.545 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.7 m -66.43 -38.81 88.27 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.702 1.601 . . . . 0.0 113.017 178.668 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 38.9 mt -72.61 -31.73 65.39 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.353 -1.467 . . . . 0.0 113.945 172.569 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.1 -42.16 76.49 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.485 -1.385 . . . . 0.0 112.876 173.692 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -79.04 58.17 2.38 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 124.086 1.898 . . . . 0.0 111.415 174.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 p -107.7 143.9 35.56 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.898 2.479 . . . . 0.0 108.88 170.951 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.77 -141.85 8.23 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 121.154 -0.966 . . . . 0.0 112.063 172.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.5 tt0 -62.44 -57.56 10.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.581 1.552 . . . . 0.0 113.118 174.304 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.21 142.54 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 CA-C-O 122.695 1.236 . . . . 0.0 110.487 178.231 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 64.8 t -124.23 112.35 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 128.268 2.627 . . . . 0.0 109.16 -170.834 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -97.47 108.1 20.75 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.783 -1.198 . . . . 0.0 111.637 176.744 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.1 mt -105.38 146.52 29.32 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.904 -1.122 . . . . 0.0 113.251 172.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.9 tp -116.33 126.59 53.74 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 162.864 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.1 pp -146.81 163.95 34.37 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.246 -0.909 . . . . 0.0 110.949 179.556 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -123.31 143.08 50.31 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.252 1.021 . . . . 0.0 112.151 -176.855 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -74.71 112.63 11.11 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.662 1.585 . . . . 0.0 109.177 174.199 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -43.03 137.68 3.57 Favored Glycine 0 N--CA 1.431 -1.683 0 C-N-CA 128.389 2.9 . . . . 0.0 119.964 -157.163 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -61.25 -165.32 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 129.424 3.089 . . . . 0.0 115.948 177.356 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 12.9 p -130.16 135.8 28.02 Favored Pre-proline 0 N--CA 1.43 -1.47 0 O-C-N 118.972 -2.33 . . . . 0.0 105.176 169.878 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo . . . . . 0 N--CA 1.434 -1.985 0 CA-C-N 124.524 2.651 . . . . 0.0 113.088 -177.344 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.2 pttp . . . . . 0 N--CA 1.43 -1.443 0 CA-C-O 117.676 -1.154 . . . . 0.0 108.336 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -70.82 -172.99 0.76 Allowed 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 123.274 2.205 . . . . 0.0 115.041 178.757 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.65 39.99 5.76 Favored Glycine 0 N--CA 1.429 -1.791 0 O-C-N 120.965 -1.085 . . . . 0.0 114.85 169.259 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -97.89 149.65 22.16 Favored 'General case' 0 CA--C 1.489 -1.394 0 CA-C-N 118.381 1.091 . . . . 0.0 109.944 173.146 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.0 p -91.01 159.67 16.02 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.328 1.051 . . . . 0.0 113.812 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -144.32 138.95 28.23 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -87.78 122.73 31.79 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.649 -1.282 . . . . 0.0 108.988 164.673 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.457 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 53.7 t -107.18 88.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -96.54 89.19 4.91 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.039 1.736 . . . . 0.0 108.034 177.949 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.0 tp -125.48 151.74 45.87 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.513 1.525 . . . . 0.0 109.758 -171.309 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.04 153.74 19.96 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.194 -1.566 . . . . 0.0 110.76 167.816 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -67.22 156.25 36.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 115.364 1.616 . . . . 0.0 115.364 -179.552 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 63.1 p -116.18 114.42 24.42 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.834 -1.166 . . . . 0.0 108.657 169.487 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.6 t0 40.56 56.91 2.69 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.843 2.457 . . . . 0.0 115.293 -176.701 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.75 -30.32 5.43 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 125.015 1.293 . . . . 0.0 115.488 -177.003 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.49 142.76 33.16 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.729 -1.454 . . . . 0.0 114.783 -162.749 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 95.9 mt -94.54 -60.55 1.69 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.223 1.409 . . . . 0.0 107.98 164.645 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.9 36.38 0.89 Allowed Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.873 -1.767 . . . . 0.0 112.504 167.885 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 pt -118.78 124.42 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 122.577 1.179 . . . . 0.0 111.179 -174.7 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.2 m -100.05 125.24 46.09 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 164.165 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -107.48 170.1 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 124.192 0.997 . . . . 0.0 111.438 -175.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -153.34 178.78 9.41 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.467 -1.396 . . . . 0.0 108.146 177.005 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.22 13.73 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.627 1.108 . . . . 0.0 114.139 175.537 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.68 152.73 10.93 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 126.239 1.876 . . . . 0.0 111.527 -177.222 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p -71.97 -33.13 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.592 -1.534 . . . . 0.0 114.755 -175.325 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 26.1 m120 -98.51 8.19 45.2 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.447 -1.408 . . . . 0.0 111.683 -175.849 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.34 -157.45 0.35 Allowed 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 124.467 1.107 . . . . 0.0 109.443 -176.445 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 73.1 m -96.46 9.56 40.96 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 118.933 -2.354 . . . . 0.0 112.403 -174.692 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.14 125.92 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.57 -1.331 . . . . 0.0 108.712 169.316 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -72.16 -40.94 67.64 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.59 -1.944 . . . . 0.0 113.07 -177.96 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 55.0 m80 -60.92 -34.65 75.02 Favored 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 114.92 1.452 . . . . 0.0 114.92 -175.637 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.0 93.01 0.69 Allowed Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 123.895 0.76 . . . . 0.0 113.014 173.577 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -172.35 169.29 42.41 Favored Glycine 0 N--CA 1.43 -1.713 0 O-C-N 120.366 -1.667 . . . . 0.0 111.622 -178.709 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.65 131.25 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 174.751 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -128.14 154.81 45.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 120.964 -1.085 . . . . 0.0 109.466 -173.141 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.6 t -77.06 122.74 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 O-C-N 120.348 -1.47 . . . . 0.0 112.656 175.029 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -92.0 -47.47 7.27 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.803 1.241 . . . . 0.0 112.18 178.862 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.69 161.83 37.14 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.174 -0.954 . . . . 0.0 110.786 -179.753 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -118.03 124.57 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.742 1.217 . . . . 0.0 109.487 -178.384 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.5 mm -77.19 121.02 83.94 Favored Pre-proline 0 N--CA 1.43 -1.454 0 CA-C-O 116.45 -1.738 . . . . 0.0 114.454 -175.214 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_exo -58.2 122.86 12.41 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 123.275 2.65 . . . . 0.0 116.202 -178.985 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.323 72.0 mmtt 76.73 31.36 0.56 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 127.064 2.146 . . . . 0.0 113.812 -177.57 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.5 162.68 38.21 Favored Glycine 0 N--CA 1.431 -1.685 0 CA-C-O 122.262 0.923 . . . . 0.0 112.117 159.107 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.98 -59.44 4.15 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.253 1.821 . . . . 0.0 114.653 166.585 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.73 -49.37 76.69 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 129.395 3.078 . . . . 0.0 111.705 -176.676 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -41.74 -66.53 0.34 Allowed 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 172.179 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.3 m -70.04 -10.82 59.96 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -176.35 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -75.55 -57.19 4.03 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 119.374 -2.079 . . . . 0.0 111.313 177.37 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.18 0.79 54.37 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.909 -1.12 . . . . 0.0 115.411 170.236 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.3 mmt-85 -66.88 -33.69 76.15 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.68 -1.482 . . . . 0.0 110.941 162.97 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 81.6 mt -90.67 113.14 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 C-N-CA 126.066 1.746 . . . . 0.0 110.727 -178.696 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -113.11 156.46 23.13 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-O 123.625 1.679 . . . . 0.0 112.698 179.352 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -69.57 128.08 35.23 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 119.999 -1.688 . . . . 0.0 111.994 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 89.14 8.01 69.36 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.628 -1.295 . . . . 0.0 114.567 -177.137 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -79.83 173.42 12.61 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 119.672 1.736 . . . . 0.0 113.34 175.617 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.8 ttt-85 -101.55 140.74 35.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 123.104 1.431 . . . . 0.0 110.644 174.956 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -99.69 136.11 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.172 -1.58 . . . . 0.0 107.507 178.768 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -100.71 -57.4 2.11 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.931 -1.73 . . . . 0.0 113.063 -176.988 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.57 139.19 20.64 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.762 -1.211 . . . . 0.0 109.596 -174.678 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.29 113.28 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-O 121.884 0.85 . . . . 0.0 109.153 179.022 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 6.7 t30 67.35 21.7 9.7 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.31 1.844 . . . . 0.0 114.648 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.81 -13.64 41.77 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 120.897 -1.127 . . . . 0.0 112.777 -175.219 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.0 t -94.14 116.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 121.218 -1.166 . . . . 0.0 109.257 -176.796 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.6 p -74.51 133.99 42.28 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.628 -1.295 . . . . 0.0 111.615 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.0 mt -86.67 22.12 2.01 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.729 -1.232 . . . . 0.0 113.531 -172.813 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.0 mm-40 -68.08 119.69 13.09 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.87 -1.769 . . . . 0.0 111.982 174.085 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.33 8.65 83.89 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 121.214 -0.929 . . . . 0.0 115.369 -176.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.16 144.56 46.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.796 1.776 . . . . 0.0 115.796 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 73.0 p -87.1 178.3 6.95 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.566 -1.333 . . . . 0.0 109.717 168.451 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -62.98 -46.95 85.27 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.823 -1.798 . . . . 0.0 112.12 171.477 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 4.7 tmtm? -55.0 -39.53 69.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.612 1.965 . . . . 0.0 115.436 174.686 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -58.61 -51.12 71.27 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 173.573 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.07 -35.29 79.52 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 124.651 1.18 . . . . 0.0 112.985 -178.765 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.9 t -64.89 -48.57 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 124.653 1.181 . . . . 0.0 110.846 173.94 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 75.6 mt-10 -58.81 -45.42 89.98 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.923 -1.111 . . . . 0.0 113.286 176.882 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 94.5 m -62.59 -43.75 98.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.765 2.026 . . . . 0.0 112.741 178.386 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 22.8 mt -61.48 -45.55 93.79 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.702 -1.249 . . . . 0.0 114.326 172.148 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 55.7 mtp85 -73.2 -27.56 61.69 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.444 -1.41 . . . . 0.0 113.934 -177.467 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -84.32 50.56 1.89 Allowed 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.121 -1.612 . . . . 0.0 112.039 172.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.7 149.88 26.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.409 1.884 . . . . 0.0 109.966 174.911 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.41 -153.46 20.79 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.959 -1.088 . . . . 0.0 112.496 173.478 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -68.34 -53.48 23.86 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.384 -1.657 . . . . 0.0 113.62 178.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 54.1 t -93.07 136.51 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.502 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 173.837 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.7 t -124.39 126.56 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 C-N-CA 125.633 1.573 . . . . 0.0 109.239 -170.183 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -105.38 95.5 5.87 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.904 -1.748 . . . . 0.0 113.329 -178.128 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.457 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 34.8 mt -94.22 153.4 18.08 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 118.581 -2.574 . . . . 0.0 113.305 176.7 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 25.3 tp -116.43 138.79 51.09 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 158.86 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -137.89 153.67 49.52 Favored 'General case' 0 N--CA 1.429 -1.522 0 C-N-CA 124.941 1.297 . . . . 0.0 109.878 -164.959 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -133.13 136.06 45.56 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 119.938 1.245 . . . . 0.0 111.053 169.441 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -75.9 128.43 35.09 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.328 -1.483 . . . . 0.0 111.553 -178.196 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -66.53 151.91 52.3 Favored Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 115.965 1.146 . . . . 0.0 115.965 -172.002 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.98 -50.82 4.93 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.008 1.323 . . . . 0.0 112.876 -176.165 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 9.6 m -120.91 143.79 37.59 Favored Pre-proline 0 N--CA 1.429 -1.489 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 166.852 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo . . . . . 0 N--CA 1.434 -1.99 0 CA-C-N 122.845 2.052 . . . . 0.0 111.89 179.587 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.0 pttm . . . . . 0 N--CA 1.43 -1.445 0 CA-C-O 119.54 -0.267 . . . . 0.0 111.427 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -67.55 178.27 3.37 Favored 'Trans proline' 0 N--CA 1.434 -1.99 0 C-N-CA 122.372 2.048 . . . . 0.0 114.279 167.034 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.49 25.72 7.61 Favored Glycine 0 N--CA 1.43 -1.751 0 C-N-CA 125.357 1.456 . . . . 0.0 111.892 179.912 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -84.55 112.22 20.22 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 121.171 -1.194 . . . . 0.0 109.671 -177.929 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 p -109.98 150.21 28.83 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.743 1.217 . . . . 0.0 111.69 -175.304 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.79 131.14 18.59 Favored 'General case' 0 N--CA 1.431 -1.425 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.907 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -88.51 113.55 24.21 Favored 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.4 t -99.82 100.82 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 O-C-N 120.637 -1.289 . . . . 0.0 108.964 -171.217 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.67 95.96 8.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.88 1.672 . . . . 0.0 108.559 177.427 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 51.6 tp -124.74 145.09 49.89 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.751 1.22 . . . . 0.0 111.315 -166.885 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.08 137.68 40.93 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.427 -1.421 . . . . 0.0 111.052 173.165 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -70.64 149.42 47.04 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 117.414 2.375 . . . . 0.0 117.414 -177.715 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 72.0 p -127.14 132.62 50.51 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.355 -1.466 . . . . 0.0 109.695 176.403 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 13.1 t70 64.73 16.12 10.2 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.883 2.073 . . . . 0.0 114.352 -177.981 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.37 6.93 89.0 Favored Glycine 0 N--CA 1.43 -1.734 0 O-C-N 119.647 -1.908 . . . . 0.0 114.63 -174.259 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -123.24 173.63 7.8 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 121.27 -1.135 . . . . 0.0 110.774 176.121 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -109.71 -57.57 2.17 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.534 1.134 . . . . 0.0 108.173 171.45 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.4 50.24 0.11 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 119.841 -1.787 . . . . 0.0 111.861 163.297 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.7 tt -137.51 140.63 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.102 0.953 . . . . 0.0 111.191 -171.304 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.3 t -121.81 139.08 54.06 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.11 1.364 . . . . 0.0 108.284 170.39 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.6 m -116.95 170.31 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.929 -1.107 . . . . 0.0 113.74 -167.597 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -152.59 160.06 43.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.613 -1.304 . . . . 0.0 109.776 175.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.29 -148.25 19.58 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.909 -1.12 . . . . 0.0 115.02 172.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.45 -174.23 20.96 Favored Glycine 0 N--CA 1.43 -1.719 0 C-N-CA 125.443 1.497 . . . . 0.0 109.474 -169.604 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.5 m -80.42 49.04 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 O-C-N 120.539 -1.565 . . . . 0.0 113.753 -178.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -98.45 -70.89 0.71 Allowed 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.415 -1.428 . . . . 0.0 108.622 174.91 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 26.7 p -102.31 177.01 5.0 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.133 1.773 . . . . 0.0 109.997 -175.232 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 75.4 m -87.16 53.14 2.71 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 119.869 -1.769 . . . . 0.0 111.54 -179.267 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.3 p -87.35 85.79 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.499 0 C-N-CA 125.545 1.538 . . . . 0.0 109.984 177.89 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 39.78 79.15 0.04 OUTLIER 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 128.336 2.654 . . . . 0.0 116.015 -172.179 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.264 97.5 m-70 72.16 -45.11 0.61 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.776 2.031 . . . . 0.0 115.004 -165.079 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.88 78.77 0.57 Allowed Glycine 0 N--CA 1.431 -1.643 0 C-N-CA 125.03 1.3 . . . . 0.0 110.721 -177.901 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -134.72 166.96 24.14 Favored Glycine 0 N--CA 1.429 -1.816 0 O-C-N 121.667 -0.902 . . . . 0.0 112.236 -176.769 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.1 mm -85.53 116.83 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 C-N-CA 124.97 1.308 . . . . 0.0 110.615 -176.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -114.78 156.36 25.0 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.536 -1.353 . . . . 0.0 109.68 -177.822 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -76.99 123.14 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.214 -1.554 . . . . 0.0 111.029 170.599 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 12.7 ttmm -91.15 -45.41 8.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.198 -1.564 . . . . 0.0 111.084 175.788 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.17 156.49 42.25 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 120.172 -1.58 . . . . 0.0 111.414 -179.734 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -119.32 128.13 75.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 124.485 1.114 . . . . 0.0 108.642 177.392 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.91 121.27 84.49 Favored Pre-proline 0 N--CA 1.429 -1.513 0 N-CA-C 117.004 2.224 . . . . 0.0 117.004 -171.086 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -56.01 122.95 12.67 Favored 'Trans proline' 0 N--CA 1.434 -2.017 0 C-N-CA 123.44 2.76 . . . . 0.0 116.549 -177.288 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.4 mtmm 78.43 13.0 1.52 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 128.367 2.667 . . . . 0.0 114.465 -176.168 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.95 157.77 47.45 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 120.007 -1.683 . . . . 0.0 111.682 172.852 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.21 -55.81 7.88 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.873 1.669 . . . . 0.0 114.735 170.166 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.9 -47.76 79.32 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 127.659 2.384 . . . . 0.0 113.327 178.82 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -47.48 -61.97 1.66 Allowed 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.219 1.563 . . . . 0.0 115.219 170.299 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -65.39 -31.64 72.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.993 1.317 . . . . 0.0 113.62 -171.853 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -54.89 -63.56 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.186 2.194 . . . . 0.0 113.097 174.388 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.53 47.49 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.972 -1.08 . . . . 0.0 115.344 171.76 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.408 ' HE ' ' HA ' ' A' ' 58' ' ' ARG . 2.0 mmp_? -76.64 -22.05 54.64 Favored 'General case' 0 N--CA 1.429 -1.481 0 CA-C-N 119.817 1.809 . . . . 0.0 112.438 171.368 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.3 mt -103.26 123.58 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.537 1.135 . . . . 0.0 108.252 171.656 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.738 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 25.9 t-80 -146.67 -171.25 3.71 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.63 1.681 . . . . 0.0 111.717 176.692 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.738 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 44.4 tttp -72.2 123.87 23.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.015 1.726 . . . . 0.0 113.785 -166.105 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.12 76.59 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.721 -1.237 . . . . 0.0 113.935 -176.266 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . 0.406 ' CG ' ' HZ3' ' A' ' 98' ' ' LYS . 86.5 m-20 -80.62 155.53 26.83 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 119.313 1.556 . . . . 0.0 112.309 173.114 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.1 tpt85 -106.07 118.73 37.37 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.681 -1.262 . . . . 0.0 109.034 -174.01 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 59.2 t -91.46 122.63 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.451 -1.405 . . . . 0.0 108.522 -178.24 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -87.08 -45.0 11.12 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.157 0.983 . . . . 0.0 110.287 -177.099 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.45 139.73 21.29 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.885 0.85 . . . . 0.0 110.621 -173.829 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.8 t -118.2 122.41 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 177.845 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 64.11 25.66 13.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.582 -1.323 . . . . 0.0 114.152 172.754 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.03 -5.44 84.49 Favored Glycine 0 N--CA 1.429 -1.787 0 O-C-N 120.191 -1.568 . . . . 0.0 114.102 -175.719 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.5 t -95.41 126.08 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 C-N-CA 125.031 1.332 . . . . 0.0 109.547 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.1 t -76.8 127.57 33.0 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.52 -1.363 . . . . 0.0 110.634 -178.866 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.4 mt -82.82 2.62 33.22 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.28 -1.513 . . . . 0.0 114.227 -175.793 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -65.07 126.05 26.84 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.105 -2.247 . . . . 0.0 112.668 -178.857 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.65 -8.36 77.78 Favored Glycine 0 N--CA 1.429 -1.79 0 O-C-N 121.013 -1.054 . . . . 0.0 114.839 -175.776 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.09 146.0 46.08 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 177.216 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 24.1 p -92.37 -179.38 5.2 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.041 1.736 . . . . 0.0 111.441 171.227 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-160 -57.08 -52.93 63.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.817 1.647 . . . . 0.0 114.693 -177.881 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.3 tmtp? -56.73 -38.23 72.08 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -58.95 -53.27 60.27 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.886 1.674 . . . . 0.0 115.127 177.767 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.76 -37.26 86.69 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.255 1.422 . . . . 0.0 112.464 178.711 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.22 -51.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.577 1.151 . . . . 0.0 111.047 175.202 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -64.84 -33.53 76.22 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 178.959 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 35.3 m -75.37 -43.2 51.6 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.682 1.593 . . . . 0.0 113.252 179.568 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 27.5 mt -66.2 -42.09 89.29 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.623 -1.298 . . . . 0.0 113.062 173.03 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.9 ptt85 -72.71 -37.41 67.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.898 -1.127 . . . . 0.0 113.869 -176.854 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -85.71 59.78 5.84 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 123.412 1.577 . . . . 0.0 111.5 176.41 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.9 p -107.61 153.69 22.52 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.545 1.938 . . . . 0.0 108.916 173.781 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.35 -151.89 21.87 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.846 -1.159 . . . . 0.0 112.624 -174.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -50.73 38.73 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.873 -1.369 . . . . 0.0 113.332 -179.572 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.14 137.09 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.511 1.148 . . . . 0.0 109.177 169.129 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 40.3 t -125.3 127.1 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 127.023 2.129 . . . . 0.0 110.293 -166.917 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 18.3 m170 -105.11 114.52 28.77 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.669 -1.27 . . . . 0.0 112.432 172.623 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 9.5 mt -103.26 164.96 11.31 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.087 -1.633 . . . . 0.0 112.261 163.02 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 58.7 tp -127.28 124.63 39.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.65 1.18 . . . . 0.0 107.838 158.407 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.99 162.16 32.84 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.257 -0.902 . . . . 0.0 112.387 175.677 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -117.51 144.69 44.82 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.407 1.883 . . . . 0.0 109.64 175.108 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.406 ' HZ3' ' CG ' ' A' ' 63' ' ' ASP . 0.0 OUTLIER -77.09 70.33 3.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 127.458 2.303 . . . . 0.0 113.223 -174.174 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.12 -163.94 44.61 Favored Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 125.873 1.701 . . . . 0.0 114.854 178.104 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -97.51 -33.77 11.24 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.585 -1.538 . . . . 0.0 110.947 158.258 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 11.0 p -136.12 142.68 40.96 Favored Pre-proline 0 N--CA 1.43 -1.444 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 174.051 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--N 1.3 -2.014 0 CA-C-N 122.434 1.905 . . . . 0.0 115.184 173.445 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.5 mtpt . . . . . 0 N--CA 1.43 -1.455 0 CA-C-O 116.731 -1.604 . . . . 0.0 112.687 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -97.66 -164.83 0.08 OUTLIER 'Trans proline' 0 N--CA 1.433 -2.039 0 CA-C-N 125.093 2.855 . . . . 0.0 109.933 153.615 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.94 76.8 0.82 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 177.89 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -52.7 -52.7 54.9 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 126.907 2.083 . . . . 0.0 116.007 -161.387 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.7 p -123.11 149.35 44.61 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 121.827 2.103 . . . . 0.0 111.585 168.372 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.3 p90 -147.84 148.87 31.35 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.037 1.399 . . . . 0.0 109.592 171.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -92.88 141.62 28.22 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.334 1.854 . . . . 0.0 109.346 176.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.423 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 55.3 t -125.74 90.31 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.63 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.2 84.63 4.47 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.401 -1.437 . . . . 0.0 108.22 177.073 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.9 tp -113.73 145.16 41.77 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.113 1.365 . . . . 0.0 111.424 -162.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.58 122.43 44.37 Favored 'General case' 0 N--CA 1.429 -1.501 0 O-C-N 120.257 -1.527 . . . . 0.0 108.981 171.291 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -71.68 165.99 22.84 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 179.264 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.4 p -134.23 139.95 46.13 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 124.724 1.21 . . . . 0.0 108.53 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.6 t70 66.77 8.55 6.05 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.944 1.698 . . . . 0.0 115.081 174.205 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.99 -8.47 63.2 Favored Glycine 0 N--CA 1.431 -1.69 0 O-C-N 120.097 -1.627 . . . . 0.0 113.762 -176.279 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 66.8 m -119.47 152.06 37.54 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 118.729 1.264 . . . . 0.0 111.814 -172.346 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.6 mt -86.95 -55.24 3.92 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.259 -1.525 . . . . 0.0 111.734 176.397 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 20.05 1.78 Allowed Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.414 -1.428 . . . . 0.0 112.107 177.25 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.6 pt -115.25 150.21 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 124.941 1.296 . . . . 0.0 110.18 -177.358 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 7.7 t -127.82 123.45 35.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 163.356 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.91 163.54 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.544 1.138 . . . . 0.0 111.683 -172.207 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -150.05 173.9 13.34 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.882 1.273 . . . . 0.0 109.409 -175.441 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.86 -136.11 13.2 Favored Glycine 0 N--CA 1.43 -1.761 0 O-C-N 120.872 -1.142 . . . . 0.0 113.761 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.54 167.73 43.47 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.246 0.927 . . . . 0.0 114.41 177.258 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m -66.39 -21.08 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 115.548 1.685 . . . . 0.0 115.548 -175.17 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.8 p-10 -77.99 -15.67 58.76 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.408 -1.432 . . . . 0.0 113.004 177.062 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.3 m -106.38 151.82 24.39 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.772 1.629 . . . . 0.0 108.29 -174.576 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 22.2 p -79.11 39.68 0.39 Allowed 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.64 -1.913 . . . . 0.0 115.233 -174.035 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.2 m -92.1 169.04 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.979 1.712 . . . . 0.0 111.963 -179.488 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -70.71 119.41 14.81 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.428 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 57.49 21.87 7.47 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.533 2.333 . . . . 0.0 116.602 178.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.73 29.02 73.48 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.314 -1.491 . . . . 0.0 115.68 -178.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -77.71 155.77 43.53 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 121.78 -0.835 . . . . 0.0 114.829 -175.121 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.8 mm -100.41 125.4 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 C-N-CA 125.2 1.4 . . . . 0.0 107.38 175.18 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.1 m-85 -126.48 153.52 44.99 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.566 -1.334 . . . . 0.0 111.319 -171.562 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.5 t -75.86 122.83 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.861 -1.149 . . . . 0.0 111.987 172.195 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -91.1 -47.17 7.69 Favored 'General case' 0 N--CA 1.429 -1.498 0 C-N-CA 125.639 1.576 . . . . 0.0 110.857 177.419 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.15 165.19 37.12 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.651 -0.656 . . . . 0.0 110.402 -176.702 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -116.13 132.73 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.309 1.043 . . . . 0.0 108.342 175.021 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.5 mm -77.8 121.49 84.25 Favored Pre-proline 0 N--CA 1.429 -1.491 0 C-N-CA 126.137 1.775 . . . . 0.0 114.37 -174.854 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -59.32 123.76 14.1 Favored 'Trans proline' 0 N--CA 1.434 -2.007 0 CA-C-N 124.97 2.811 . . . . 0.0 116.795 -176.104 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.314 59.9 mmtt 68.98 30.9 4.36 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 127.773 2.429 . . . . 0.0 114.534 -176.144 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.02 163.33 39.69 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.31 -1.494 . . . . 0.0 112.8 167.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.36 -58.49 5.57 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.479 1.912 . . . . 0.0 114.593 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.83 -46.94 79.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.775 2.03 . . . . 0.0 112.433 -177.107 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -45.44 -62.32 1.32 Allowed 'General case' 0 N--CA 1.429 -1.506 0 C-N-CA 126.87 2.068 . . . . 0.0 115.842 170.657 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.4 m -69.55 -32.07 70.64 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -176.02 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -56.6 -56.4 21.84 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.16 1.784 . . . . 0.0 113.703 173.92 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.88 25.25 32.63 Favored Glycine 0 N--CA 1.431 -1.698 0 O-C-N 120.602 -1.311 . . . . 0.0 116.232 164.49 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.6 mmt-85 -78.89 -52.48 8.24 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.775 -1.426 . . . . 0.0 107.675 160.723 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 74.9 mt -77.82 122.08 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.1 1.36 . . . . 0.0 110.873 178.282 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.477 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 9.4 t-160 -131.27 -176.47 4.03 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.033 1.397 . . . . 0.0 112.019 174.95 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 81.4 tttt -69.07 128.32 36.26 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 119.816 -1.803 . . . . 0.0 112.083 -172.295 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.91 1.8 79.26 Favored Glycine 0 N--CA 1.429 -1.772 0 CA-C-O 118.507 -1.163 . . . . 0.0 114.849 -179.408 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.16 158.61 31.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 120.092 1.946 . . . . 0.0 112.057 178.426 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.23 119.59 39.92 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.656 -1.278 . . . . 0.0 110.305 -169.286 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.4 t -85.35 124.8 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 125.985 1.714 . . . . 0.0 110.764 -169.773 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 74.0 mt -106.44 -51.45 2.95 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.319 -1.488 . . . . 0.0 113.888 -173.626 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.16 138.32 20.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.069 -1.644 . . . . 0.0 112.606 -172.042 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 2.2 p -108.77 108.71 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.387 1.475 . . . . 0.0 112.204 -178.877 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.4 t30 58.46 36.94 25.66 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.17 1.788 . . . . 0.0 113.376 168.853 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.95 -9.39 68.09 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 125.829 1.681 . . . . 0.0 115.473 -172.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.4 t -103.0 116.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-N 120.808 2.304 . . . . 0.0 111.085 -174.895 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.3 p -69.07 126.05 28.58 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 120.355 -1.466 . . . . 0.0 113.571 179.852 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.5 mt -87.97 46.94 1.43 Allowed 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.633 -1.292 . . . . 0.0 112.852 -176.421 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -89.46 123.02 33.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.326 -2.109 . . . . 0.0 111.189 -178.448 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.58 1.97 89.36 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 121.058 -1.027 . . . . 0.0 114.798 175.041 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.86 162.9 28.77 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.737 1.754 . . . . 0.0 115.737 -178.288 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 p -83.63 173.72 11.14 Favored 'General case' 0 N--CA 1.431 -1.395 0 O-C-N 120.525 -1.359 . . . . 0.0 111.723 176.906 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-160 -56.43 -53.57 55.91 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.755 1.222 . . . . 0.0 112.798 168.298 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.35 -46.26 89.11 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.744 1.387 . . . . 0.0 114.744 179.259 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.99 -48.24 76.23 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.059 1.344 . . . . 0.0 114.505 -173.92 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.85 -42.02 96.98 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 124.833 1.253 . . . . 0.0 113.561 174.366 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.7 t -66.27 -48.84 79.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 125.126 1.371 . . . . 0.0 111.121 179.101 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -60.39 -46.32 90.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.736 1.214 . . . . 0.0 112.775 179.062 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.3 m -60.03 -43.99 94.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.372 1.469 . . . . 0.0 113.844 172.62 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 37.2 mt -69.72 -34.36 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.119 -1.613 . . . . 0.0 114.725 178.09 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . 0.271 42.9 ptt85 -71.95 -38.93 69.7 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.035 -1.665 . . . . 0.0 113.19 172.801 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.9 t30 -84.34 48.4 1.49 Allowed 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.787 -1.195 . . . . 0.0 113.722 175.936 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 p -99.58 150.46 22.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.032 2.133 . . . . 0.0 109.97 174.311 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.79 -163.46 17.29 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.579 1.085 . . . . 0.0 113.34 177.099 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -68.99 -47.63 65.06 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.522 -1.575 . . . . 0.0 113.799 -178.465 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.25 118.74 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 CA-C-O 122.091 0.948 . . . . 0.0 108.721 179.836 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 65.4 t -124.11 119.26 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 126.457 1.903 . . . . 0.0 110.395 -161.283 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -103.32 97.57 7.61 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.076 -1.64 . . . . 0.0 113.845 -178.433 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.423 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 15.8 mt -93.39 148.58 21.94 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.703 -1.873 . . . . 0.0 111.342 176.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -127.75 127.97 44.53 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 171.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . 0.273 0.0 OUTLIER -146.13 169.59 18.41 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.349 -1.469 . . . . 0.0 113.739 -177.07 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.54 131.6 56.88 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.362 1.865 . . . . 0.0 110.493 -173.414 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.6 153.92 30.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.304 -1.498 . . . . 0.0 113.467 179.182 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.41 84.03 1.55 Allowed Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.242 0.925 . . . . 0.0 111.893 165.156 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -78.25 -49.49 13.63 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 127.614 2.366 . . . . 0.0 112.03 -176.4 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 1.4 p -130.21 126.16 22.14 Favored Pre-proline 0 N--CA 1.43 -1.474 0 C-N-CA 124.96 1.304 . . . . 0.0 109.101 -176.634 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.433 -2.073 0 C-N-CA 122.985 2.457 . . . . 0.0 114.85 -171.367 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? . . . . . 0 N--CA 1.43 -1.458 0 CA-C-O 119.106 -0.474 . . . . 0.0 109.731 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -74.19 -179.94 5.19 Favored 'Trans proline' 0 C--N 1.3 -1.993 0 C-N-CA 122.751 2.301 . . . . 0.0 112.648 -178.452 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.58 34.58 7.81 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 121.266 -0.896 . . . . 0.0 111.856 -170.107 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.77 129.52 41.68 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.711 1.605 . . . . 0.0 108.722 -176.554 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.3 p -94.29 144.52 25.46 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.473 -1.392 . . . . 0.0 112.379 -177.203 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -147.29 140.45 25.23 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 122.74 1.257 . . . . 0.0 107.974 177.337 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -99.43 127.05 45.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.367 1.067 . . . . 0.0 109.765 178.017 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.9 t -116.44 93.32 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.717 1.207 . . . . 0.0 108.364 -170.591 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -89.63 103.82 16.43 Favored 'General case' 0 N--CA 1.429 -1.5 0 CA-C-O 123.221 1.486 . . . . 0.0 107.831 168.668 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.7 tp -121.59 144.52 48.69 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.24 1.416 . . . . 0.0 109.047 -165.55 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.41 120.26 40.02 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 124.672 1.189 . . . . 0.0 109.333 172.059 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -69.43 129.01 38.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.202 1.401 . . . . 0.0 112.412 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.9 t -92.7 104.74 16.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.641 1.21 . . . . 0.0 110.737 -172.31 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.4 t70 33.04 60.29 0.43 Allowed 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 129.339 3.056 . . . . 0.0 116.85 -173.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.67 -10.27 74.21 Favored Glycine 0 N--CA 1.43 -1.767 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 178.357 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -111.64 127.11 55.65 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 120.494 2.147 . . . . 0.0 111.519 -179.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.0 tp -92.32 -61.49 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.05 -1.031 . . . . 0.0 111.921 -178.844 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.92 -11.8 3.12 Favored Glycine 0 N--CA 1.429 -1.78 0 O-C-N 119.663 -1.898 . . . . 0.0 115.209 170.617 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.0 pt -105.9 141.03 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 119.321 1.561 . . . . 0.0 113.29 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 m -113.23 122.74 48.38 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 159.856 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.72 170.04 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.696 1.236 . . . . 0.0 112.622 -172.933 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 t -152.52 172.35 16.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.755 -1.215 . . . . 0.0 109.602 176.354 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.71 -142.26 15.64 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 113.67 171.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.57 150.7 27.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.56 1.076 . . . . 0.0 112.834 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.9 p -61.6 -31.47 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -174.272 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -79.76 -16.57 55.33 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.596 1.558 . . . . 0.0 114.369 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.5 m -88.92 152.43 21.73 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 179.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.7 t -82.52 50.21 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.237 -2.164 . . . . 0.0 113.483 -173.222 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 15.6 m -100.4 51.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.674 -1.892 . . . . 0.0 112.452 -172.482 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 73.25 -43.52 0.56 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.604 1.961 . . . . 0.0 116.228 173.652 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 53.7 t60 -144.6 -60.93 0.37 Allowed 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.677 -1.265 . . . . 0.0 108.87 170.235 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.75 -143.66 7.21 Favored Glycine 0 N--CA 1.43 -1.756 0 N-CA-C 106.659 -2.576 . . . . 0.0 106.659 -173.797 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.58 136.91 4.66 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.312 0.958 . . . . 0.0 113.31 176.501 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.1 mm -101.69 122.04 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 124.824 1.249 . . . . 0.0 108.412 179.859 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 75.3 m-85 -127.34 152.64 47.21 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.202 -0.936 . . . . 0.0 109.706 -173.552 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -75.82 125.84 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 O-C-N 120.483 -1.386 . . . . 0.0 111.341 171.661 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -98.93 -40.69 7.95 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.634 -1.292 . . . . 0.0 112.316 -179.399 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.61 155.33 40.1 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 121.453 -0.779 . . . . 0.0 111.222 179.699 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.95 124.87 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 CA-C-O 122.465 1.126 . . . . 0.0 111.28 -179.827 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp -76.33 122.97 87.72 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.848 2.059 . . . . 0.0 116.136 -169.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -58.25 112.9 1.32 Allowed 'Trans proline' 0 N--CA 1.434 -1.997 0 C-N-CA 123.767 2.978 . . . . 0.0 117.232 -175.588 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.305 48.5 mtmt 79.06 32.27 0.27 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.875 2.87 . . . . 0.0 113.8 -178.124 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.8 159.99 35.08 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 121.418 -0.801 . . . . 0.0 112.026 167.234 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.45 -60.39 2.88 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.519 1.528 . . . . 0.0 114.426 169.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.75 99.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 127.396 2.278 . . . . 0.0 112.677 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.8 tm-20 -51.49 -65.36 0.57 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 125.771 1.628 . . . . 0.0 114.626 174.678 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.0 t -69.15 -23.22 63.93 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -174.345 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -51.5 -63.94 0.97 Allowed 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.079 1.752 . . . . 0.0 113.019 172.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.24 -12.64 28.66 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 121.288 -0.883 . . . . 0.0 114.647 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 -64.22 -56.02 17.58 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 124.409 1.084 . . . . 0.0 111.002 168.614 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.8 mt -78.55 128.73 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 124.957 1.303 . . . . 0.0 110.839 179.074 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -145.7 171.11 15.21 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.132 -0.98 . . . . 0.0 110.113 177.862 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . 0.264 0.0 OUTLIER -64.45 139.67 58.79 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 119.398 -2.064 . . . . 0.0 113.829 179.445 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.78 -7.8 67.99 Favored Glycine 0 N--CA 1.43 -1.709 0 CA-C-O 118.509 -1.162 . . . . 0.0 114.278 -172.67 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -80.75 138.65 36.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 119.8 1.8 . . . . 0.0 113.363 -176.269 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -98.2 133.43 42.63 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.57 -1.331 . . . . 0.0 111.668 -174.408 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -82.89 148.73 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.494 -1.379 . . . . 0.0 112.942 -179.384 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -109.39 -51.37 2.88 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.752 1.221 . . . . 0.0 109.689 171.028 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 143.77 25.24 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.801 -1.187 . . . . 0.0 110.925 -175.35 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 58.8 t -117.6 129.09 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.39 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 77.18 -30.46 0.17 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.407 2.683 . . . . 0.0 113.983 173.236 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.09 -17.11 1.54 Allowed Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 126.316 1.913 . . . . 0.0 109.265 -169.937 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.72 116.53 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 125.379 1.472 . . . . 0.0 109.275 -176.196 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.3 m -71.12 127.42 32.53 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.807 -1.183 . . . . 0.0 111.104 176.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 22.9 mt -93.88 43.02 1.1 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.027 -1.046 . . . . 0.0 112.699 -171.057 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -75.79 119.93 20.46 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.19 -2.194 . . . . 0.0 112.21 -178.344 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.23 13.2 82.26 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.117 -1.615 . . . . 0.0 115.306 -178.33 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.94 151.42 44.69 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -82.09 172.83 12.76 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.207 1.003 . . . . 0.0 111.148 176.345 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -61.08 -50.0 75.05 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.909 1.284 . . . . 0.0 113.118 175.057 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.3 -42.01 80.93 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 171.695 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -55.36 -48.78 73.72 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 114.499 1.296 . . . . 0.0 114.499 -175.428 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.96 98.38 Favored 'General case' 0 N--CA 1.431 -1.4 0 C-N-CA 125.126 1.37 . . . . 0.0 113.855 177.2 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.1 -49.87 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 C-N-CA 125.112 1.365 . . . . 0.0 110.451 177.609 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -64.26 -32.26 73.78 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.692 -1.255 . . . . 0.0 113.96 179.632 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 53.0 m -67.65 -46.48 72.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.61 1.964 . . . . 0.0 112.236 173.501 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 70.1 mt -64.02 -38.94 92.89 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.98 -1.075 . . . . 0.0 113.727 173.531 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.12 -45.22 83.67 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.967 1.707 . . . . 0.0 112.444 175.39 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -85.39 44.58 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.265 1.426 . . . . 0.0 113.224 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.3 p -106.81 160.27 15.61 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.075 -1.641 . . . . 0.0 108.739 170.02 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.82 -131.05 4.79 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.474 1.035 . . . . 0.0 110.856 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -69.77 -69.01 0.37 Allowed 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 114.729 1.381 . . . . 0.0 114.729 178.029 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 52.8 t -92.25 124.65 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 CA-C-O 122.853 1.311 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.8 t -124.15 120.82 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 127.574 2.349 . . . . 0.0 109.272 -169.622 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -100.46 113.02 25.46 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.796 -1.815 . . . . 0.0 112.212 173.683 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -97.57 149.32 22.34 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.747 -1.845 . . . . 0.0 111.672 163.336 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.9 124.64 48.77 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 161.773 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -150.28 168.46 23.98 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.874 -1.141 . . . . 0.0 113.149 -178.423 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -119.34 144.96 46.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.478 1.511 . . . . 0.0 111.503 -177.905 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.6 tppt? -75.28 128.1 34.66 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.487 1.515 . . . . 0.0 112.755 -179.687 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.34 136.41 32.16 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.798 1.19 . . . . 0.0 115.393 -177.256 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -68.58 -34.54 75.99 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 115.752 1.76 . . . . 0.0 115.752 -175.306 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.6 p -112.11 132.25 22.14 Favored Pre-proline 0 N--CA 1.43 -1.444 0 C-N-CA 124.838 1.255 . . . . 0.0 108.442 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo . . . . . 0 C--N 1.3 -1.989 0 C-N-CA 122.699 2.266 . . . . 0.0 114.173 -177.607 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.6 mtmm . . . . . 0 N--CA 1.43 -1.442 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -78.18 179.69 6.27 Favored 'Trans proline' 0 C--N 1.3 -2.01 0 C-N-CA 122.767 2.311 . . . . 0.0 109.895 157.237 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.19 -2.02 83.21 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.596 -1.315 . . . . 0.0 113.849 175.901 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 t0 -80.96 150.79 28.81 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.303 -1.116 . . . . 0.0 110.055 179.455 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.0 p -102.55 157.57 16.84 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.339 1.055 . . . . 0.0 110.972 -178.857 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -146.16 124.35 12.2 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.713 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -88.94 108.6 19.65 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 122.69 1.233 . . . . 0.0 109.287 162.77 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.2 t -99.06 108.9 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 128.287 2.635 . . . . 0.0 109.303 -168.766 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.4 101.14 13.82 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.845 -1.159 . . . . 0.0 109.737 173.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -108.64 158.06 17.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.872 1.32 . . . . 0.0 108.849 172.979 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.41 145.84 29.38 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 104.406 -2.442 . . . . 0.0 104.406 152.609 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -70.03 146.82 50.75 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.899 -1.126 . . . . 0.0 112.501 171.384 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.7 p -106.07 94.72 5.32 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.47 1.129 . . . . 0.0 108.876 178.683 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.0 t0 54.75 60.07 3.72 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.339 1.856 . . . . 0.0 114.023 -178.998 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.63 -34.66 3.64 Favored Glycine 0 N--CA 1.43 -1.739 0 O-C-N 120.701 -1.25 . . . . 0.0 115.693 -176.865 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -94.19 145.63 24.57 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.191 -1.182 . . . . 0.0 113.435 -167.513 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.04 -18.49 13.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.986 -1.071 . . . . 0.0 111.714 176.648 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.63 4.73 54.57 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.483 -2.011 . . . . 0.0 114.756 175.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.4 pt -120.06 133.02 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 124.862 1.265 . . . . 0.0 111.293 -171.87 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -113.51 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 126.194 1.798 . . . . 0.0 107.165 168.639 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.69 162.7 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.467 1.127 . . . . 0.0 113.777 -169.014 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.2 t -144.1 178.48 7.84 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.562 1.545 . . . . 0.0 110.055 176.424 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.46 -143.22 16.6 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.979 1.276 . . . . 0.0 113.85 171.487 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.46 158.97 19.31 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 124.488 1.042 . . . . 0.0 113.028 -177.638 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m -63.25 -15.11 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 116.353 1.983 . . . . 0.0 116.353 -171.744 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -83.82 -25.06 30.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 119.903 -1.748 . . . . 0.0 113.78 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.5 p -91.64 167.92 11.86 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 121.082 -1.011 . . . . 0.0 111.2 -177.01 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.0 t -80.6 60.94 4.12 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.12 -1.613 . . . . 0.0 114.109 -176.767 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -101.45 176.12 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 127.188 2.195 . . . . 0.0 109.496 167.9 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -73.69 -61.19 1.92 Allowed 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 115.293 1.59 . . . . 0.0 115.293 -176.817 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 6.2 p80 -133.78 54.14 1.97 Allowed 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 122.058 0.932 . . . . 0.0 109.896 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.39 -121.43 26.17 Favored Glycine 0 N--CA 1.43 -1.71 0 O-C-N 120.803 -1.186 . . . . 0.0 113.78 -175.217 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.8 137.0 0.25 Allowed Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.476 1.036 . . . . 0.0 115.093 -174.994 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.6 mm -94.67 129.22 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.034 -1.862 . . . . 0.0 107.721 174.387 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.37 157.19 40.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.314 -1.491 . . . . 0.0 109.165 -176.223 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.6 130.27 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 O-C-N 121.179 -0.95 . . . . 0.0 111.066 171.202 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -99.66 -59.82 1.65 Allowed 'General case' 0 N--CA 1.431 -1.392 0 O-C-N 120.313 -1.492 . . . . 0.0 111.398 177.564 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.17 153.69 47.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 -174.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.43 122.78 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.383 1.087 . . . . 0.0 108.917 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.4 117.92 67.81 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 116.244 -1.836 . . . . 0.0 112.596 -173.23 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -64.72 124.47 13.23 Favored 'Trans proline' 0 N--CA 1.433 -2.043 0 C-N-CA 123.577 2.851 . . . . 0.0 114.131 -171.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.262 91.7 mttt 70.15 37.47 1.66 Allowed 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.379 2.672 . . . . 0.0 112.473 -170.989 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.54 164.54 36.27 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.018 -1.051 . . . . 0.0 113.073 163.726 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.83 -63.02 1.21 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.523 1.529 . . . . 0.0 114.68 170.415 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.82 -48.5 76.57 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 127.69 2.396 . . . . 0.0 113.738 178.543 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.6 tm-20 -43.7 -55.07 4.62 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.975 1.842 . . . . 0.0 115.975 -177.695 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.8 t -67.55 -28.01 67.43 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 114.472 -1.24 . . . . 0.0 113.785 -174.272 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -73.45 -65.54 0.8 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.499 1.12 . . . . 0.0 111.559 -178.808 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.18 10.19 34.8 Favored Glycine 0 N--CA 1.43 -1.755 0 N-CA-C 116.527 1.371 . . . . 0.0 116.527 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 67.2 mtt85 -64.3 -36.2 83.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.945 1.372 . . . . 0.0 111.022 162.265 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.6 mt -94.78 129.45 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.336 1.454 . . . . 0.0 108.82 177.326 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.0 170.07 16.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.81 1.767 . . . . 0.0 110.685 176.737 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 51.2 mtpt -61.6 123.88 19.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.605 1.562 . . . . 0.0 112.001 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 0.3 62.74 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 120.303 -1.498 . . . . 0.0 115.26 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -74.0 157.11 36.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.175 1.487 . . . . 0.0 112.339 178.089 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.5 ttt180 -88.14 125.81 34.8 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.248 1.419 . . . . 0.0 111.101 178.128 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 50.0 t -91.6 128.72 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 124.223 1.009 . . . . 0.0 109.13 178.681 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -105.41 -57.4 2.04 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.684 -1.26 . . . . 0.0 111.305 -179.305 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.95 138.0 20.32 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.857 -1.152 . . . . 0.0 111.663 -170.825 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.8 t -107.45 107.43 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.417 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 27.1 t30 57.73 52.07 8.59 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.785 1.634 . . . . 0.0 114.311 167.832 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.43 -29.4 10.33 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.95 1.262 . . . . 0.0 114.095 -176.541 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.7 118.18 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-N 118.805 1.303 . . . . 0.0 111.235 -170.443 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 57.7 m -69.76 131.67 44.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.493 -1.38 . . . . 0.0 112.413 176.196 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 25.7 mt -93.36 -6.03 48.18 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 121.026 -1.046 . . . . 0.0 112.433 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -55.22 127.52 29.68 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.576 1.55 . . . . 0.0 114.831 -179.084 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.67 -10.82 70.61 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 115.888 1.115 . . . . 0.0 115.888 -178.005 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.5 178.39 4.07 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 116.989 2.218 . . . . 0.0 116.989 -177.556 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 47.1 p -92.19 171.22 9.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.282 -1.511 . . . . 0.0 110.835 165.678 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -54.2 -42.07 69.33 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.261 1.824 . . . . 0.0 112.883 168.594 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 43.5 tptt -57.54 -42.4 82.87 Favored 'General case' 0 N--CA 1.429 -1.506 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -58.93 -49.43 77.87 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.537 -1.352 . . . . 0.0 114.102 175.109 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.43 -44.29 84.53 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.441 1.497 . . . . 0.0 114.052 174.276 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.01 -45.54 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 124.987 1.315 . . . . 0.0 111.886 177.278 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 -64.43 -37.71 88.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 123.811 0.844 . . . . 0.0 112.586 176.602 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.8 m -63.4 -45.6 90.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.788 2.035 . . . . 0.0 113.018 174.204 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.7 mt -69.21 -21.64 63.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.031 -1.668 . . . . 0.0 114.269 174.193 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -72.15 -53.34 13.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.228 -1.545 . . . . 0.0 111.328 168.684 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -92.68 43.37 1.12 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.946 1.698 . . . . 0.0 112.842 -174.409 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . 0.287 6.2 t -106.39 160.01 15.71 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.48 -1.387 . . . . 0.0 110.905 173.164 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.75 -164.8 38.79 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.929 1.252 . . . . 0.0 113.317 -166.052 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -69.8 -49.84 48.86 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.732 -1.452 . . . . 0.0 112.66 174.095 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 59.0 t -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.907 0.86 . . . . 0.0 108.78 179.611 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -123.97 120.39 59.43 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.568 1.547 . . . . 0.0 109.725 -163.065 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 11.8 t-160 -104.82 95.48 5.9 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.633 -1.292 . . . . 0.0 112.435 -175.867 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 27.1 mt -89.99 134.58 34.15 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.762 -1.836 . . . . 0.0 113.397 -176.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 66.1 tp -104.89 123.0 46.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.613 -1.304 . . . . 0.0 109.114 167.748 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.37 163.9 30.69 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.47 -0.769 . . . . 0.0 111.54 175.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -127.38 140.07 52.43 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.642 1.577 . . . . 0.0 109.629 -178.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 125.46 29.37 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.762 -1.211 . . . . 0.0 114.033 -170.344 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.39 174.33 54.94 Favored Glycine 0 N--CA 1.43 -1.732 0 C-N-CA 125.69 1.614 . . . . 0.0 115.013 177.597 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -94.72 -68.37 0.8 Allowed 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.909 1.284 . . . . 0.0 113.146 -168.263 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.5 m -80.17 126.27 79.7 Favored Pre-proline 0 N--CA 1.431 -1.412 0 O-C-N 120.529 -1.357 . . . . 0.0 113.663 -166.474 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo . . . . . 0 N--CA 1.434 -2.021 0 C-N-CA 122.355 2.036 . . . . 0.0 112.762 173.762 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 mmmp? . . . . . 0 N--CA 1.429 -1.476 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -74.66 179.64 5.77 Favored 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 122.908 2.405 . . . . 0.0 112.287 159.451 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.67 37.79 2.0 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.54 -0.725 . . . . 0.0 114.409 165.513 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -77.89 150.93 34.04 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.947 1.299 . . . . 0.0 110.897 173.916 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -114.58 148.09 38.54 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.654 -1.278 . . . . 0.0 111.22 -176.479 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.69 149.39 32.36 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-O 121.982 0.896 . . . . 0.0 108.963 178.664 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -90.82 145.11 25.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.409 -0.807 . . . . 0.0 109.249 160.811 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.0 t -120.53 94.44 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.086 1.354 . . . . 0.0 107.613 -178.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 -90.47 95.66 10.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.929 1.347 . . . . 0.0 107.92 171.669 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 29.2 tp -123.99 138.36 54.47 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 125.315 1.446 . . . . 0.0 110.594 -164.136 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.62 138.59 39.33 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.699 -1.251 . . . . 0.0 108.658 173.857 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -69.48 145.55 52.63 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.22 1.563 . . . . 0.0 115.22 -178.283 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.6 p -100.09 102.21 13.48 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.962 -1.086 . . . . 0.0 109.157 176.192 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.5 t0 55.8 38.46 30.09 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.551 1.54 . . . . 0.0 114.166 179.314 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.48 -20.51 47.86 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.471 -1.393 . . . . 0.0 114.944 -176.699 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -93.56 137.95 32.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.7 -1.47 . . . . 0.0 112.248 -173.182 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.3 mt -87.58 -60.66 1.91 Allowed 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.249 -0.907 . . . . 0.0 110.306 172.21 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.6 8.93 2.69 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.365 -1.46 . . . . 0.0 113.158 175.29 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 pt -123.59 142.53 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-N 119.325 1.563 . . . . 0.0 112.052 -176.177 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.3 t -116.67 139.17 50.84 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 155.486 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.87 169.46 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 124.828 1.251 . . . . 0.0 112.293 -174.321 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -150.3 -179.22 7.02 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 126.053 1.741 . . . . 0.0 109.0 -177.999 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.65 -144.36 17.17 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.611 -1.306 . . . . 0.0 112.301 177.174 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 108.23 150.35 15.08 Favored Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 124.728 1.156 . . . . 0.0 112.937 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.21 -30.22 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -174.805 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 38.2 t30 -91.93 0.38 57.48 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.891 -1.756 . . . . 0.0 111.431 -177.409 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 26.2 m -83.55 177.5 8.4 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.819 2.048 . . . . 0.0 108.066 -179.999 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.3 m -70.48 -3.29 17.13 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 118.877 -2.389 . . . . 0.0 116.374 -176.483 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 14.1 m -78.87 123.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 122.472 1.129 . . . . 0.0 110.352 172.949 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 91.4 mtt180 -72.44 -34.72 67.98 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.368 -1.458 . . . . 0.0 114.867 -170.916 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 63.6 m170 -76.79 -55.42 5.51 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.6 -1.312 . . . . 0.0 112.822 178.412 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.04 102.25 2.69 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.823 -1.173 . . . . 0.0 112.534 168.705 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.48 168.62 37.49 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 177.089 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.99 136.61 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.899 1.28 . . . . 0.0 108.408 178.46 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -133.89 157.45 45.93 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 121.246 -0.908 . . . . 0.0 108.869 -175.313 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.1 t -76.48 129.73 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 119.872 -1.767 . . . . 0.0 112.338 175.504 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -93.91 -48.88 6.07 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.375 -1.453 . . . . 0.0 112.542 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.92 152.93 32.03 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 123.111 0.565 . . . . 0.0 110.572 -174.849 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -103.43 120.55 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 CA-C-O 122.841 1.305 . . . . 0.0 110.243 174.09 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.81 127.85 83.03 Favored Pre-proline 0 N--CA 1.431 -1.402 0 C-N-CA 126.331 1.852 . . . . 0.0 113.604 -172.002 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -55.73 126.3 21.97 Favored 'Trans proline' 0 N--CA 1.433 -2.042 0 C-N-CA 122.916 2.411 . . . . 0.0 117.034 -177.869 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? 77.22 13.58 2.01 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 128.864 2.866 . . . . 0.0 114.166 176.143 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.48 161.42 51.55 Favored Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.618 -1.301 . . . . 0.0 114.805 179.073 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.21 -57.67 6.34 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 126.843 2.057 . . . . 0.0 114.808 171.505 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.55 -48.53 77.09 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 128.399 2.68 . . . . 0.0 112.233 179.54 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -41.97 -63.07 0.79 Allowed 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 126.836 2.055 . . . . 0.0 114.386 173.497 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.7 m -70.22 -35.05 73.6 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.029 1.492 . . . . 0.0 115.029 -172.044 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -56.43 -68.66 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.238 1.815 . . . . 0.0 113.213 176.536 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.73 6.17 23.34 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 168.575 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -65.94 -49.52 67.64 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 119.09 1.445 . . . . 0.0 110.461 165.046 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.85 134.01 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.506 0 C-N-CA 125.58 1.552 . . . . 0.0 110.032 177.911 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 -145.61 142.36 29.03 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.409 1.084 . . . . 0.0 109.889 -174.862 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -43.74 116.02 0.9 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.231 1.812 . . . . 0.0 115.739 -178.883 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 103.99 -2.95 44.53 Favored Glycine 0 N--CA 1.428 -1.834 0 O-C-N 120.652 -1.28 . . . . 0.0 115.946 179.731 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.276 1.4 p30 -76.95 175.26 9.71 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 120.099 1.949 . . . . 0.0 115.549 -175.166 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -101.94 121.32 41.91 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.677 -1.264 . . . . 0.0 112.564 -175.395 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.12 114.75 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 123.868 0.867 . . . . 0.0 110.288 179.125 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 mp -93.75 -43.93 8.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.321 -1.487 . . . . 0.0 111.17 -176.585 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.6 142.34 24.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.864 -1.147 . . . . 0.0 111.625 -175.256 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.5 t -118.12 117.67 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 124.02 0.928 . . . . 0.0 109.01 175.763 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.3 37.31 14.07 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.985 2.114 . . . . 0.0 113.072 170.515 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.81 -33.23 6.67 Favored Glycine 0 N--CA 1.43 -1.75 0 C-N-CA 124.852 1.215 . . . . 0.0 113.444 -174.73 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -91.58 119.67 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 C-N-CA 124.974 1.309 . . . . 0.0 112.501 -165.292 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.9 m -65.81 130.3 42.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.881 -1.137 . . . . 0.0 112.88 177.796 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 44.2 mt -90.11 62.05 5.39 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.526 -1.359 . . . . 0.0 112.46 -174.892 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -90.09 136.09 33.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.642 -1.286 . . . . 0.0 111.71 174.365 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 71.32 11.47 71.5 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 121.024 -1.047 . . . . 0.0 115.454 175.366 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.0 143.03 49.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -176.236 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 48.1 p -82.35 173.64 11.86 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.995 -1.066 . . . . 0.0 111.118 167.443 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -62.26 -41.65 98.64 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.724 -1.235 . . . . 0.0 112.754 174.496 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -58.74 -47.01 86.08 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 126.069 1.748 . . . . 0.0 114.2 170.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -56.07 -47.82 77.24 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 126.524 1.93 . . . . 0.0 114.335 -176.447 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -56.83 -39.73 74.77 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.222 1.809 . . . . 0.0 115.025 173.192 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 79.1 t -69.01 -53.38 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 124.941 1.296 . . . . 0.0 110.862 177.947 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -59.95 -44.18 94.55 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 114.757 1.391 . . . . 0.0 114.757 -176.815 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.7 m -57.67 -40.9 80.44 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.013 2.525 . . . . 0.0 114.545 170.656 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 28.3 mt -68.77 -42.34 77.59 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 119.652 -1.905 . . . . 0.0 113.805 170.956 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 85.8 mmt-85 -60.7 -39.24 87.78 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.698 -1.251 . . . . 0.0 113.501 178.652 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -85.93 48.49 1.61 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.479 -1.388 . . . . 0.0 113.156 178.873 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.9 p -106.86 158.03 17.31 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.281 1.832 . . . . 0.0 109.657 173.293 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -98.75 -141.1 11.9 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 121.12 -0.988 . . . . 0.0 112.821 -176.383 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -69.09 -65.26 0.73 Allowed 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 121.058 -1.26 . . . . 0.0 113.251 175.727 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.2 p -98.66 133.66 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 123.14 1.448 . . . . 0.0 110.173 176.523 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.0 t -124.62 128.78 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 128.297 2.639 . . . . 0.0 108.745 -162.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -108.9 93.93 4.78 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.752 -1.218 . . . . 0.0 112.578 -176.537 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 mt -95.27 162.14 13.81 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 119.538 -1.976 . . . . 0.0 112.411 178.002 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.9 tt -130.27 133.04 46.2 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.825 -1.172 . . . . 0.0 110.641 165.917 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.04 162.56 35.18 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 113.609 0.966 . . . . 0.0 113.609 178.527 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -113.54 138.58 49.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 125.712 1.605 . . . . 0.0 107.647 172.249 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.2 tppp? -75.76 134.65 40.4 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 122.216 1.007 . . . . 0.0 111.214 -173.209 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -72.09 149.52 44.41 Favored Glycine 0 N--CA 1.431 -1.691 0 C-N-CA 124.586 1.089 . . . . 0.0 114.638 -177.114 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -81.77 179.04 7.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -173.401 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.7 m -84.31 148.48 52.87 Favored Pre-proline 0 N--CA 1.43 -1.457 0 O-C-N 120.393 -1.442 . . . . 0.0 111.123 176.557 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 C--N 1.299 -2.028 0 C-N-CA 122.153 1.902 . . . . 0.0 112.422 175.827 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 74.8 mttt . . . . . 0 N--CA 1.431 -1.424 0 CA-C-O 115.376 -2.25 . . . . 0.0 114.421 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.11 179.51 6.25 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 CA-C-N 127.29 3.639 . . . . 0.0 111.569 155.961 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.71 -119.88 4.09 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -165.225 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -99.86 -63.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 118.492 1.146 . . . . 0.0 113.695 -174.134 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.0 p -125.98 155.42 41.42 Favored 'General case' 0 N--CA 1.431 -1.384 0 O-C-N 120.126 -1.609 . . . . 0.0 113.011 -179.107 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -145.52 142.42 29.19 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 122.943 1.354 . . . . 0.0 109.182 170.324 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -95.45 126.59 40.85 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.413 1.485 . . . . 0.0 107.955 171.22 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.3 t -118.49 117.77 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.295 1.038 . . . . 0.0 108.488 -174.722 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -100.79 88.08 3.49 Favored 'General case' 0 N--CA 1.432 -1.369 0 O-C-N 120.62 -1.3 . . . . 0.0 108.703 168.976 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 63.2 tp -95.7 137.69 34.4 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.593 1.157 . . . . 0.0 110.214 -174.226 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.32 128.95 47.25 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.185 -1.572 . . . . 0.0 108.566 172.012 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -70.42 136.43 49.55 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 121.344 -0.848 . . . . 0.0 113.123 178.416 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.0 p -107.2 121.03 43.71 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 174.376 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.9 t70 55.17 49.0 18.27 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.982 1.713 . . . . 0.0 113.753 -176.019 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.21 -9.64 6.94 Favored Glycine 0 N--CA 1.429 -1.789 0 N-CA-C 117.739 1.856 . . . . 0.0 117.739 174.315 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -121.43 156.18 33.27 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 119.207 1.503 . . . . 0.0 111.131 -168.531 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 16.4 mt -93.91 -60.4 1.76 Allowed 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.54 1.136 . . . . 0.0 110.925 -177.268 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.03 38.78 0.48 Allowed Glycine 0 N--CA 1.431 -1.657 0 O-C-N 119.373 -2.079 . . . . 0.0 110.54 174.588 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.3 pt -128.93 141.12 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 CA-C-O 121.871 0.843 . . . . 0.0 112.146 -163.208 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 29.7 t -117.77 117.36 29.1 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 166.33 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.47 160.64 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 124.529 1.132 . . . . 0.0 111.158 179.398 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.0 t -150.61 155.63 39.77 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.121 -0.987 . . . . 0.0 111.621 -178.527 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 124.03 -130.13 7.48 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 121.129 -0.982 . . . . 0.0 113.219 168.8 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 124.01 -148.81 16.83 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.182 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.6 t -125.17 -44.95 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.496 0 CA-C-O 123.451 1.596 . . . . 0.0 107.332 171.418 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -74.21 -14.85 61.0 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 126.85 2.06 . . . . 0.0 115.464 -171.239 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.1 p -84.97 -119.51 0.03 OUTLIER 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.466 1.907 . . . . 0.0 112.068 -173.487 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 40.1 p -91.49 -38.5 12.5 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.574 -1.954 . . . . 0.0 111.52 177.057 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 5.6 p -81.46 81.24 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 123.945 1.831 . . . . 0.0 112.03 -177.853 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -62.17 -26.94 68.62 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.826 1.65 . . . . 0.0 114.757 -175.697 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -66.33 -37.16 84.71 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.677 -1.264 . . . . 0.0 113.591 176.506 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.4 106.32 3.09 Favored Glycine 0 N--CA 1.429 -1.789 0 C-N-CA 124.198 0.904 . . . . 0.0 113.139 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -166.52 128.42 1.75 Allowed Glycine 0 N--CA 1.43 -1.759 0 O-C-N 122.002 -0.705 . . . . 0.0 113.887 173.783 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.7 mm -95.99 119.76 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 C-N-CA 125.851 1.66 . . . . 0.0 107.526 171.476 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -123.06 154.4 38.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.145 -0.972 . . . . 0.0 110.303 -174.528 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.6 t -76.8 119.38 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 124.387 1.075 . . . . 0.0 110.555 169.919 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -88.5 -46.83 8.79 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 124.858 1.263 . . . . 0.0 110.38 -176.471 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.75 161.39 37.01 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 123.316 0.647 . . . . 0.0 110.37 177.599 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.53 127.08 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.469 1.107 . . . . 0.0 110.303 176.329 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.1 mp -77.43 122.28 85.75 Favored Pre-proline 0 N--CA 1.43 -1.47 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -169.971 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_exo -55.29 122.13 11.16 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 C-N-CA 123.551 2.834 . . . . 0.0 116.6 179.952 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 17.6 mmtt 80.89 18.82 0.49 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 129.253 3.021 . . . . 0.0 113.488 -177.682 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.76 156.8 33.46 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.127 -1.608 . . . . 0.0 111.942 172.877 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.61 -56.28 7.53 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 125.949 1.699 . . . . 0.0 114.468 171.293 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.31 -51.14 67.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 128.308 2.643 . . . . 0.0 112.832 178.059 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.9 tm-20 -44.92 -59.65 2.46 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 172.441 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.3 t -68.1 -30.36 69.51 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.832 1.253 . . . . 0.0 113.436 -174.078 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -61.36 -55.61 29.62 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.857 1.263 . . . . 0.0 113.869 -177.141 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.59 1.43 29.18 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.516 1.367 . . . . 0.0 116.516 162.108 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.2 mmp_? -74.67 -54.6 7.09 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.5 -1.588 . . . . 0.0 110.367 164.475 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mt -78.25 128.04 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.339 1.456 . . . . 0.0 112.648 -173.607 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.01 172.64 12.71 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-O 124.14 1.924 . . . . 0.0 112.629 177.298 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -56.14 124.04 16.51 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.031 1.732 . . . . 0.0 113.822 172.136 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.88 4.2 61.79 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 113.903 178.759 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -79.11 162.31 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 119.054 1.427 . . . . 0.0 111.794 174.406 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -120.57 123.46 42.92 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.233 -1.542 . . . . 0.0 111.02 -172.978 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.6 t -83.06 125.48 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 O-C-N 120.278 -1.514 . . . . 0.0 111.83 -171.872 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 80.5 mt -103.3 -44.57 5.13 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.743 -1.223 . . . . 0.0 112.324 -177.005 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.97 140.9 22.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.504 -1.373 . . . . 0.0 112.329 -177.874 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -112.75 115.49 49.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 174.72 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 57.86 41.97 23.92 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.641 1.976 . . . . 0.0 114.993 170.606 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.45 -25.62 26.42 Favored Glycine 0 N--CA 1.431 -1.655 0 O-C-N 120.964 -1.085 . . . . 0.0 113.563 -177.008 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 t -94.06 112.25 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.926 -1.338 . . . . 0.0 110.412 -172.947 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . 0.25 81.1 p -76.36 140.66 41.51 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.212 -1.555 . . . . 0.0 112.998 176.851 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.0 mt -85.44 41.68 0.91 Allowed 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.426 1.09 . . . . 0.0 112.29 -168.9 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -72.72 121.53 19.99 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.101 -1.624 . . . . 0.0 112.047 -178.413 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 70.37 11.58 68.17 Favored Glycine 0 N--CA 1.429 -1.821 0 C-N-CA 125.191 1.377 . . . . 0.0 115.764 179.374 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.94 143.57 47.62 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -178.138 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.1 p -91.82 178.81 5.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.644 1.578 . . . . 0.0 111.728 174.34 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 30.8 t-80 -57.3 -52.73 64.16 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 115.873 1.805 . . . . 0.0 115.873 -169.6 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.6 -40.66 79.57 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 178.124 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.4 mp0 -56.92 -51.33 69.54 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.792 2.037 . . . . 0.0 113.209 -172.229 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.49 -39.09 79.06 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.556 1.942 . . . . 0.0 113.823 175.453 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 87.7 t -67.55 -53.04 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.044 1.337 . . . . 0.0 110.727 177.467 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -61.69 -38.69 88.76 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 121.009 -1.057 . . . . 0.0 113.78 -178.609 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.5 m -66.53 -40.42 89.11 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 127.032 2.133 . . . . 0.0 112.682 177.213 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.49 -42.24 87.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.431 -1.418 . . . . 0.0 113.231 171.139 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -68.2 -42.76 79.39 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.523 -1.361 . . . . 0.0 114.605 179.846 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 38.9 t-20 -86.32 57.2 4.35 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 123.036 1.398 . . . . 0.0 111.712 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -98.12 163.59 12.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.017 2.527 . . . . 0.0 109.617 175.115 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.46 -160.11 33.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.422 1.011 . . . . 0.0 110.923 168.931 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 60.1 tt0 -68.74 -52.07 34.53 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.75 -1.441 . . . . 0.0 112.998 -174.234 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.81 119.9 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 C-N-CA 124.894 1.278 . . . . 0.0 109.63 177.008 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 84.5 t -112.18 110.26 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 128.066 2.547 . . . . 0.0 110.153 -167.216 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.1 t-160 -92.8 96.7 10.3 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.7 -1.25 . . . . 0.0 112.779 -178.205 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.3 mt -89.11 156.71 18.65 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.217 -2.177 . . . . 0.0 112.677 175.773 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 57.9 tp -127.01 129.41 48.02 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 157.611 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.0 pp -150.86 167.34 27.8 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.715 -1.24 . . . . 0.0 111.745 177.784 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -108.89 123.16 48.63 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.17 1.388 . . . . 0.0 110.345 -173.541 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.1 tptm -78.47 139.02 38.73 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.365 1.466 . . . . 0.0 111.37 -178.681 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -93.41 96.03 2.05 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 108.209 -1.956 . . . . 0.0 108.209 163.236 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 28.2 pt20 -65.62 -31.84 73.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 116.266 1.951 . . . . 0.0 116.266 -165.44 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.6 m -104.31 154.15 38.51 Favored Pre-proline 0 N--CA 1.43 -1.473 0 C-N-CA 125.803 1.641 . . . . 0.0 110.283 176.089 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo . . . . . 0 N--CA 1.434 -2.004 0 C-N-CA 122.746 2.298 . . . . 0.0 112.712 169.892 . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? . . . . . 0 N--CA 1.43 -1.432 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 . . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 178.88 6.65 Favored 'Trans proline' 0 N--CA 1.434 -2.006 0 C-N-CA 122.503 2.135 . . . . 0.0 111.992 165.125 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 112.62 38.24 1.34 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 124.085 0.85 . . . . 0.0 111.838 179.175 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -95.66 157.57 15.84 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 124.246 1.018 . . . . 0.0 109.986 177.799 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -96.96 149.24 22.13 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.689 -1.257 . . . . 0.0 111.256 177.102 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -147.8 143.52 27.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 122.923 1.344 . . . . 0.0 109.186 -179.087 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.6 mp0 -102.53 129.53 49.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.536 1.934 . . . . 0.0 108.12 179.12 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.7 t -125.0 97.69 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.825 -1.172 . . . . 0.0 109.753 -170.429 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -97.81 77.24 2.5 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 119.938 -1.726 . . . . 0.0 108.899 173.906 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.4 130.47 52.75 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 125.372 1.469 . . . . 0.0 109.992 -170.159 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.7 154.79 17.04 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 127.074 2.15 . . . . 0.0 112.336 176.656 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -69.12 152.03 45.66 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -175.484 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.2 p -98.77 100.48 11.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.855 -1.153 . . . . 0.0 108.689 171.114 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.3 t0 52.41 52.99 13.08 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.636 1.574 . . . . 0.0 113.798 176.19 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.14 -27.32 10.48 Favored Glycine 0 N--CA 1.429 -1.779 0 O-C-N 120.859 -1.151 . . . . 0.0 115.71 -176.122 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.0 m -98.47 128.18 44.72 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-N 119.64 1.72 . . . . 0.0 113.106 -169.849 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.6 tp -84.63 -56.3 3.67 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.487 -1.383 . . . . 0.0 109.537 175.717 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.93 28.76 0.85 Allowed Glycine 0 N--CA 1.43 -1.764 0 C-N-CA 125.205 1.383 . . . . 0.0 113.249 168.091 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.1 tt -147.19 143.94 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 CA-C-N 119.619 1.709 . . . . 0.0 112.645 -166.26 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.6 t -123.76 138.21 54.55 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.041 1.336 . . . . 0.0 108.889 165.106 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 m -113.74 163.28 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 126.153 1.781 . . . . 0.0 112.313 -177.308 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -145.35 178.15 8.31 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 126.917 2.087 . . . . 0.0 109.556 -179.255 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.97 -145.19 16.22 Favored Glycine 0 N--CA 1.431 -1.669 0 O-C-N 120.562 -1.336 . . . . 0.0 114.65 173.978 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.09 156.51 31.33 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 125.539 1.542 . . . . 0.0 114.622 176.156 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t -48.68 -47.05 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -178.586 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -88.94 18.08 5.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 119.791 -1.818 . . . . 0.0 112.306 -177.38 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 40.5 m -110.53 148.82 31.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 169.592 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.3 m -83.72 56.15 3.52 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.731 -1.856 . . . . 0.0 111.974 -176.317 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.3 p -99.37 153.2 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 127.488 2.315 . . . . 0.0 108.043 174.173 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tpt180 -56.72 116.97 3.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 125.594 1.558 . . . . 0.0 113.57 -179.609 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.4 m80 70.18 -58.15 0.55 Allowed 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.429 2.292 . . . . 0.0 115.561 -174.188 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 142.5 41.22 0.06 OUTLIER Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 124.62 1.105 . . . . 0.0 113.794 178.773 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.89 161.52 28.19 Favored Glycine 0 N--CA 1.431 -1.679 0 O-C-N 120.681 -1.481 . . . . 0.0 114.534 -173.721 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.9 mm -102.91 125.18 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 124.932 1.293 . . . . 0.0 108.255 179.884 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -128.42 155.33 44.93 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.928 -1.107 . . . . 0.0 111.341 -170.724 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.41 125.83 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.358 -1.464 . . . . 0.0 111.8 173.452 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.6 ttmt -89.02 -55.6 3.62 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.005 1.322 . . . . 0.0 110.115 177.203 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.73 150.09 30.61 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 121.502 -0.749 . . . . 0.0 110.607 -171.017 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -106.89 123.66 62.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.406 1.098 . . . . 0.0 108.306 172.373 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.3 mm -77.49 121.92 85.15 Favored Pre-proline 0 CA--C 1.489 -1.395 0 CA-C-O 115.755 -2.069 . . . . 0.0 114.346 -172.143 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -57.55 115.01 2.2 Favored 'Trans proline' 0 C--N 1.3 -1.996 0 C-N-CA 123.866 3.044 . . . . 0.0 117.151 -174.153 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.382 26.7 mtpp 71.07 41.81 0.78 Allowed 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.157 2.583 . . . . 0.0 114.913 -172.813 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.9 168.21 42.99 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.167 -1.583 . . . . 0.0 112.177 153.294 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.14 -60.02 3.55 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.23 1.812 . . . . 0.0 114.844 165.576 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.83 -42.71 97.56 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.31 2.244 . . . . 0.0 112.904 -178.026 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.8 tm-20 -47.91 -61.98 1.69 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.833 1.79 . . . . 0.0 115.833 171.376 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.5 t -68.03 -31.25 70.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.759 1.224 . . . . 0.0 112.515 -173.168 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -64.41 -65.94 0.61 Allowed 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.889 -1.132 . . . . 0.0 111.201 171.548 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 20.6 33.56 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 119.228 -2.17 . . . . 0.0 114.421 162.582 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -63.01 -44.37 96.19 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 121.341 -1.093 . . . . 0.0 109.866 157.442 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 52.0 mt -92.57 131.81 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.233 1.813 . . . . 0.0 110.495 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . 0.666 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 6.9 t-80 -145.24 -169.99 3.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-O 123.172 1.463 . . . . 0.0 112.727 167.828 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.666 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 40.4 ttpt -61.99 122.83 16.45 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 126.217 1.807 . . . . 0.0 113.378 -176.551 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 101.83 -4.74 53.32 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.384 -0.823 . . . . 0.0 114.073 179.725 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -74.66 161.61 29.51 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 118.925 1.363 . . . . 0.0 112.868 -177.28 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -122.09 121.3 36.63 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.771 -1.205 . . . . 0.0 111.047 -165.194 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 8.4 t -89.35 125.73 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 120.78 -1.2 . . . . 0.0 111.772 -169.103 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -102.27 -44.57 5.37 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.113 -0.992 . . . . 0.0 111.466 -177.231 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 139.36 21.21 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.681 -1.262 . . . . 0.0 111.67 -178.079 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.7 t -114.34 117.96 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.214 1.006 . . . . 0.0 109.877 177.729 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.3 t30 62.18 29.05 17.41 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 128.274 2.63 . . . . 0.0 114.24 168.808 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.01 -17.99 40.53 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.422 1.487 . . . . 0.0 113.58 -177.386 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.3 t -101.78 123.78 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 O-C-N 120.854 -1.38 . . . . 0.0 110.401 -172.97 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 m -71.27 138.15 49.16 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.105 -1.622 . . . . 0.0 112.825 179.457 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.2 mt -88.41 62.54 6.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.286 -1.509 . . . . 0.0 111.067 179.194 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -89.62 118.12 29.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.35 -1.469 . . . . 0.0 112.039 -178.18 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.34 6.72 70.65 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 125.121 1.343 . . . . 0.0 115.239 177.808 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 150.62 44.4 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 116.157 1.91 . . . . 0.0 116.157 -172.557 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 55.9 p -88.77 174.15 8.16 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.556 1.942 . . . . 0.0 111.235 175.968 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 -58.84 -48.58 80.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.646 -1.284 . . . . 0.0 113.238 177.319 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -53.55 -46.93 70.41 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.691 1.597 . . . . 0.0 114.21 176.572 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -54.89 -49.93 69.99 Favored 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 125.57 1.548 . . . . 0.0 113.633 -179.059 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.25 -38.79 88.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 176.346 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.8 t -67.71 -51.16 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.434 -1.416 . . . . 0.0 111.18 -179.058 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -33.01 74.72 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.35 1.06 . . . . 0.0 112.929 179.799 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 64.0 m -65.31 -49.65 68.66 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.459 1.904 . . . . 0.0 112.671 171.174 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -62.91 -32.48 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.168 -1.583 . . . . 0.0 114.145 174.427 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -65.07 -45.29 85.9 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.383 -1.448 . . . . 0.0 112.925 168.658 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -82.86 45.71 1.02 Allowed 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.218 -1.551 . . . . 0.0 113.755 -179.143 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 p -100.94 160.67 14.17 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 126.819 2.048 . . . . 0.0 109.251 175.485 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.71 -142.37 10.7 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.561 -1.337 . . . . 0.0 112.376 172.919 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -71.21 -59.86 2.54 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 126.294 1.838 . . . . 0.0 111.34 172.319 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 11.0 p -94.46 134.16 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.078 1.351 . . . . 0.0 111.465 -179.868 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 87.5 t -125.65 123.23 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.857 -1.152 . . . . 0.0 109.986 -169.685 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -103.61 89.79 3.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.122 -1.611 . . . . 0.0 114.204 -176.035 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.7 mt -89.0 155.91 19.19 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.665 -2.522 . . . . 0.0 112.934 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.7 tt -129.98 128.28 41.73 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 161.297 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -154.04 170.69 20.51 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.892 -1.13 . . . . 0.0 112.934 -174.963 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -119.23 144.3 46.82 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.815 1.646 . . . . 0.0 110.461 -178.691 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? -75.31 140.78 43.33 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.626 -1.297 . . . . 0.0 111.132 174.977 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -66.23 121.1 17.39 Favored Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 125.353 1.454 . . . . 0.0 114.302 176.534 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -83.42 178.56 7.98 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 121.262 -1.14 . . . . 0.0 113.661 -177.349 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 2.9 m -98.12 114.03 64.63 Favored Pre-proline 0 N--CA 1.429 -1.491 0 O-C-N 120.821 -1.174 . . . . 0.0 110.272 175.469 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo . . . . . 0 C--N 1.3 -1.994 0 CA-C-N 123.431 2.261 . . . . 0.0 114.428 178.277 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.429 -1.494 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -81.06 -179.91 5.44 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.681 2.254 . . . . 0.0 111.906 174.597 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 92.65 23.04 27.05 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 115.54 0.976 . . . . 0.0 115.54 174.998 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -91.77 157.41 16.92 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 118.741 1.271 . . . . 0.0 110.346 174.155 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -108.04 155.3 20.52 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.76 1.224 . . . . 0.0 112.855 -177.933 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -144.83 143.31 30.56 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.492 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -93.5 137.89 32.33 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 168.114 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.442 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 26.4 t -126.07 99.53 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -175.407 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -99.39 89.79 4.31 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-O 123.049 1.404 . . . . 0.0 109.046 176.527 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.0 tp -118.11 141.14 48.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.983 1.713 . . . . 0.0 110.844 -160.499 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.59 136.85 42.53 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.509 -1.37 . . . . 0.0 111.057 175.916 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -66.84 161.46 23.81 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 117.035 2.235 . . . . 0.0 117.035 -173.267 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.5 p -113.2 99.4 7.79 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 126.532 1.933 . . . . 0.0 109.333 174.675 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.9 t70 50.14 49.91 19.57 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.726 1.61 . . . . 0.0 114.92 171.643 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.05 -18.95 55.72 Favored Glycine 0 N--CA 1.431 -1.682 0 O-C-N 120.05 -1.656 . . . . 0.0 116.345 179.873 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.7 p -113.16 161.23 17.38 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 119.312 1.556 . . . . 0.0 113.239 -177.079 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 mt -97.05 -54.97 3.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 166.508 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.22 50.34 0.34 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.005 -1.684 . . . . 0.0 110.438 171.722 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tt -146.13 142.83 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 CA-C-O 122.618 1.199 . . . . 0.0 109.751 -174.147 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.0 t -111.17 129.77 55.84 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 168.571 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 m -111.07 165.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 C-N-CA 124.642 1.177 . . . . 0.0 110.547 -178.794 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 t -151.19 170.14 20.19 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.768 -1.207 . . . . 0.0 109.865 177.996 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.72 -154.68 20.35 Favored Glycine 0 N--CA 1.431 -1.696 0 O-C-N 121.337 -0.852 . . . . 0.0 112.73 178.069 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.63 147.85 23.28 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 121.698 -0.883 . . . . 0.0 113.008 -178.068 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m -63.05 -15.9 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 N-CA-C 116.728 2.122 . . . . 0.0 116.728 -167.678 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -80.48 -23.26 40.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.35 -1.469 . . . . 0.0 113.638 -179.909 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.1 p -81.27 -136.12 0.03 OUTLIER 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.618 1.167 . . . . 0.0 113.481 -164.697 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.9 m -77.09 -39.53 49.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 119.086 -2.259 . . . . 0.0 110.96 174.642 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -78.15 123.99 35.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.511 1.124 . . . . 0.0 112.312 -175.523 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -67.75 -60.53 2.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.288 -1.508 . . . . 0.0 113.257 -177.94 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -88.97 80.46 7.06 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.372 -1.455 . . . . 0.0 109.58 169.06 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -82.86 115.54 4.04 Favored Glycine 0 N--CA 1.429 -1.779 0 CA-C-O 122.364 0.98 . . . . 0.0 114.868 -173.286 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.08 163.98 34.95 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 157.875 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.6 mm -99.97 128.51 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 177.338 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -127.12 159.06 35.35 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.795 -1.191 . . . . 0.0 109.684 -173.674 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.26 125.53 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 O-C-N 121.089 -1.007 . . . . 0.0 111.897 176.493 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -91.9 -49.11 6.41 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.381 177.879 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -159.12 157.76 31.59 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.412 -1.43 . . . . 0.0 111.33 177.602 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.39 121.38 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.656 1.217 . . . . 0.0 110.056 174.404 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 22.0 mm -77.47 133.28 67.66 Favored Pre-proline 0 N--CA 1.429 -1.477 0 C-N-CA 127.527 2.331 . . . . 0.0 115.671 -165.901 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -54.07 118.19 4.71 Favored 'Trans proline' 0 N--CA 1.434 -1.973 0 C-N-CA 123.864 3.043 . . . . 0.0 118.335 -178.704 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 61.85 40.74 12.37 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 128.949 2.9 . . . . 0.0 113.646 -177.274 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.29 164.23 36.45 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.114 -1.616 . . . . 0.0 112.86 162.785 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.62 -57.37 7.29 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.359 1.864 . . . . 0.0 114.87 164.472 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.6 -43.32 97.26 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 127.341 2.256 . . . . 0.0 112.517 -179.03 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.96 -62.38 1.56 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 167.143 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.4 t -69.52 -23.21 63.57 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.244 1.418 . . . . 0.0 114.719 -170.781 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -59.54 -58.32 9.11 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 125.837 1.655 . . . . 0.0 113.495 178.81 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.9 -13.02 10.68 Favored Glycine 0 N--CA 1.43 -1.729 0 CA-C-N 120.419 1.463 . . . . 0.0 115.651 168.347 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.5 mmt180 -75.16 -52.64 10.47 Favored 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 120.515 -1.58 . . . . 0.0 111.258 177.034 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 57.3 mt -81.06 116.38 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 126.231 1.812 . . . . 0.0 112.789 -168.738 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -117.88 164.91 14.34 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.37 1.868 . . . . 0.0 112.039 -179.262 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.76 124.34 20.46 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.551 -1.968 . . . . 0.0 114.019 176.459 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.12 6.8 68.67 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.686 -1.259 . . . . 0.0 114.736 -176.25 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -75.56 160.65 29.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.341 1.57 . . . . 0.0 111.273 174.024 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.7 ttt180 -101.44 126.71 48.26 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.794 -1.191 . . . . 0.0 110.29 -175.503 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.8 t -86.66 111.64 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.429 1.092 . . . . 0.0 108.494 -177.087 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.3 mt -91.14 -53.95 4.15 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.005 -1.684 . . . . 0.0 111.996 -171.571 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.11 146.99 27.96 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.807 -1.183 . . . . 0.0 108.881 -176.774 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.54 110.34 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 177.02 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.0 t30 63.17 34.99 13.09 Favored 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 126.424 1.89 . . . . 0.0 114.989 167.026 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 92.97 -6.01 76.24 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 121.083 -1.011 . . . . 0.0 113.884 -174.93 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.4 t -96.94 113.31 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-N 118.909 1.354 . . . . 0.0 109.719 179.057 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.3 m -70.94 123.89 23.07 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 124.551 1.14 . . . . 0.0 111.047 176.642 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 23.8 mt -84.23 0.76 47.62 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.306 -1.496 . . . . 0.0 114.381 -172.613 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.31 111.98 0.99 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.277 -1.514 . . . . 0.0 114.135 179.263 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.28 12.97 79.84 Favored Glycine 0 N--CA 1.429 -1.78 0 C-N-CA 124.499 1.047 . . . . 0.0 114.473 -179.081 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.72 160.69 31.8 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.208 -1.76 . . . . 0.0 115.742 173.085 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.9 p -89.87 173.88 8.0 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.488 -1.382 . . . . 0.0 111.131 171.505 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -59.59 -49.42 77.83 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.347 1.459 . . . . 0.0 112.186 170.179 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -55.35 -46.15 76.43 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 125.067 1.347 . . . . 0.0 114.102 173.716 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -55.92 -54.06 49.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 178.202 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.62 87.43 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 178.343 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.9 t -66.11 -49.51 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.859 -1.151 . . . . 0.0 111.372 176.377 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -66.99 -31.47 72.06 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.5 -1.375 . . . . 0.0 113.624 -179.083 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 100.0 m -65.82 -49.93 66.47 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 127.315 2.246 . . . . 0.0 111.667 171.525 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.8 mt -59.89 -41.15 90.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.466 -1.396 . . . . 0.0 113.97 174.083 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -60.33 -41.04 92.7 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.749 -1.22 . . . . 0.0 113.515 172.628 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -83.23 25.68 0.7 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.487 -1.383 . . . . 0.0 114.584 -179.618 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 59.0 p -87.23 150.9 23.6 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.13 -1.606 . . . . 0.0 109.056 168.783 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.74 -152.31 21.4 Favored Glycine 0 N--CA 1.429 -1.788 0 O-C-N 121.243 -0.911 . . . . 0.0 112.854 -179.667 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -69.59 -50.94 39.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.972 -1.31 . . . . 0.0 112.955 -177.409 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.0 p -97.79 134.25 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 123.094 1.426 . . . . 0.0 109.625 166.19 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.4 t -122.89 123.37 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 126.735 2.014 . . . . 0.0 109.027 -164.897 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -100.59 103.05 14.33 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.53 -1.357 . . . . 0.0 111.242 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 28.8 mt -100.45 158.61 15.78 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.608 -1.932 . . . . 0.0 112.554 175.87 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 45.9 tp -127.57 130.68 49.5 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 161.278 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -141.84 167.25 22.6 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.469 -1.395 . . . . 0.0 112.814 176.168 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -122.26 147.71 45.88 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 124.671 1.188 . . . . 0.0 110.099 179.28 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? -75.02 127.45 33.27 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.371 1.868 . . . . 0.0 110.559 179.803 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -73.69 156.43 50.78 Favored Glycine 0 N--CA 1.429 -1.768 0 C-N-CA 125.048 1.309 . . . . 0.0 116.266 -174.591 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -79.51 -82.62 0.1 Allowed 'General case' 0 N--CA 1.431 -1.398 0 C-N-CA 125.169 1.388 . . . . 0.0 113.056 -173.51 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 30.9 m -101.63 158.1 32.41 Favored Pre-proline 0 N--CA 1.43 -1.461 0 C-N-CA 125.28 1.432 . . . . 0.0 111.875 -175.824 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo . . . . . 0 N--CA 1.434 -2.002 0 C-N-CA 122.504 2.136 . . . . 0.0 112.436 167.857 . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 76.4 mttt . . . . . 0 N--CA 1.431 -1.417 0 CA-C-O 118.57 -0.729 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -77.74 178.67 7.33 Favored 'Trans proline' 0 N--CA 1.434 -2.021 0 C-N-CA 122.554 2.169 . . . . 0.0 113.024 179.633 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 96.29 -22.72 38.34 Favored Glycine 0 N--CA 1.431 -1.68 0 N-CA-C 116.267 1.267 . . . . 0.0 116.267 165.856 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.1 t0 -77.17 143.23 39.22 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 121.053 -1.263 . . . . 0.0 112.13 -178.691 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.6 p -103.45 146.13 28.98 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.796 -1.19 . . . . 0.0 111.592 -179.445 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -148.29 144.97 27.96 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-O 122.552 1.167 . . . . 0.0 109.244 171.683 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -89.8 146.16 24.66 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.99 1.716 . . . . 0.0 108.799 172.728 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 20.0 t -124.89 102.55 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.106 -1.621 . . . . 0.0 107.92 177.636 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -96.18 99.13 10.89 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 168.179 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 54.0 tp -123.44 138.51 54.57 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.279 1.432 . . . . 0.0 110.905 -167.374 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 133.84 45.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.44 -1.413 . . . . 0.0 109.763 172.151 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -65.77 153.3 42.19 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 177.627 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 62.3 p -119.88 116.47 25.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 172.236 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.1 t0 56.98 48.74 15.17 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.855 1.662 . . . . 0.0 113.723 178.598 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 -7.37 30.19 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 125.744 1.64 . . . . 0.0 116.55 177.722 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.9 m -121.19 150.23 41.62 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.266 -1.138 . . . . 0.0 111.25 -162.287 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.8 mt -97.16 -62.67 1.22 Allowed 'General case' 0 N--CA 1.429 -1.521 0 O-C-N 120.665 -1.272 . . . . 0.0 111.447 178.52 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.02 46.88 0.32 Allowed Glycine 0 N--CA 1.43 -1.755 0 O-C-N 120.4 -1.438 . . . . 0.0 111.979 171.573 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.4 tt -147.49 150.4 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 CA-C-O 122.578 1.18 . . . . 0.0 111.217 -172.883 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -123.84 132.73 53.82 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.639 1.176 . . . . 0.0 108.699 168.943 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -102.61 163.81 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.812 1.245 . . . . 0.0 113.179 -179.604 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 t -147.5 169.98 18.41 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 126.095 1.758 . . . . 0.0 109.3 -177.363 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.57 -139.31 14.34 Favored Glycine 0 N--CA 1.43 -1.708 0 O-C-N 120.707 -1.246 . . . . 0.0 113.833 171.154 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.3 -177.36 34.89 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 121.415 -1.05 . . . . 0.0 113.206 -178.656 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.1 m -65.08 -24.16 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 N-CA-C 116.695 2.109 . . . . 0.0 116.695 -172.078 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -99.07 16.05 23.89 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.85 -1.156 . . . . 0.0 111.645 -175.014 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 72.0 p -115.28 158.93 21.66 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 124.72 1.208 . . . . 0.0 109.648 168.551 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.8 t -92.37 60.42 3.62 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.261 -1.525 . . . . 0.0 112.518 -176.119 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.8 m -97.48 -2.82 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 120.428 -1.42 . . . . 0.0 112.754 -177.99 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.283 8.0 mpt_? 84.21 119.28 0.04 OUTLIER 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 129.843 3.257 . . . . 0.0 110.269 -169.418 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 68.59 -61.4 0.41 Allowed 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 127.133 2.173 . . . . 0.0 115.58 -179.794 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.5 95.47 0.27 Allowed Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.008 1.29 . . . . 0.0 110.848 179.486 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -128.95 148.24 18.02 Favored Glycine 0 N--CA 1.43 -1.758 0 C-N-CA 123.964 0.792 . . . . 0.0 114.115 -176.675 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.2 mm -93.92 130.26 43.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 126.485 1.914 . . . . 0.0 109.477 -178.882 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -126.44 163.03 24.21 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.807 -1.183 . . . . 0.0 110.222 -178.37 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.6 t -76.69 126.55 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.765 -1.209 . . . . 0.0 112.016 169.559 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -91.91 -52.05 4.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.943 -1.098 . . . . 0.0 111.875 176.937 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.6 155.57 39.67 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.079 -1.013 . . . . 0.0 109.977 -177.762 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.68 123.58 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.156 0.979 . . . . 0.0 108.484 175.455 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 23.2 mm -77.76 121.86 84.83 Favored Pre-proline 0 N--CA 1.43 -1.459 0 C-N-CA 125.866 1.666 . . . . 0.0 113.399 -172.399 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -59.19 131.51 41.66 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 CA-C-N 124.323 2.58 . . . . 0.0 115.821 -176.547 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 92.5 mttt 77.39 17.33 1.51 Allowed 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 127.331 2.252 . . . . 0.0 112.822 -178.613 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.1 158.78 42.66 Favored Glycine 0 N--CA 1.429 -1.8 0 O-C-N 119.864 -1.772 . . . . 0.0 113.048 173.462 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.83 -59.38 3.89 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.625 1.97 . . . . 0.0 114.193 166.674 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.5 -48.0 81.5 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.271 2.228 . . . . 0.0 112.136 179.854 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 tm-20 -44.7 -66.0 0.45 Allowed 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 116.318 1.97 . . . . 0.0 116.318 170.442 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 44.8 t -63.32 -25.96 68.54 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -172.895 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -54.33 -53.19 57.19 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 124.983 1.313 . . . . 0.0 113.602 179.319 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.46 -8.16 54.67 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.507 -0.746 . . . . 0.0 113.204 167.234 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -68.12 -44.84 75.22 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.229 -1.16 . . . . 0.0 111.153 168.605 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.0 mt -91.56 131.56 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.927 1.691 . . . . 0.0 112.47 -175.65 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.22 179.47 7.75 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.245 -1.534 . . . . 0.0 112.922 170.579 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -60.09 129.44 41.78 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.761 -1.837 . . . . 0.0 114.956 -175.005 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.51 3.12 78.43 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.919 -1.113 . . . . 0.0 115.07 -179.693 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -76.03 145.75 39.95 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 119.617 1.708 . . . . 0.0 111.739 176.266 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -95.3 125.5 39.97 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.252 -1.53 . . . . 0.0 110.384 -173.711 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 54.1 t -81.43 132.3 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.243 -1.535 . . . . 0.0 109.107 -178.884 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -103.24 -52.96 2.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.079 -1.013 . . . . 0.0 109.299 177.406 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.88 134.77 17.79 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 111.638 -171.799 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.1 t -110.36 120.2 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.532 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 67.81 18.54 9.7 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.51 1.924 . . . . 0.0 113.525 174.9 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.39 -17.22 54.09 Favored Glycine 0 N--CA 1.428 -1.839 0 O-C-N 120.771 -1.206 . . . . 0.0 112.981 -175.719 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.5 t -88.66 114.03 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 O-C-N 120.657 -1.496 . . . . 0.0 109.833 -178.372 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.2 m -75.65 127.85 33.95 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 120.727 -1.233 . . . . 0.0 111.279 -179.947 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.26 51.27 2.19 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.847 -1.158 . . . . 0.0 113.583 -165.302 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -74.49 111.32 9.57 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 119.162 -2.212 . . . . 0.0 115.182 -170.42 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.45 13.24 83.07 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.634 -1.291 . . . . 0.0 114.14 -179.751 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.34 159.44 34.56 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.715 1.245 . . . . 0.0 113.991 -179.133 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 45.6 p -84.68 169.77 13.97 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.512 -1.368 . . . . 0.0 111.448 172.288 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -56.25 -47.12 79.15 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.437 1.495 . . . . 0.0 112.176 168.452 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.6 tptp -50.72 -50.03 56.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.976 1.71 . . . . 0.0 113.973 174.501 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -56.27 -49.04 75.36 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 174.92 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.41 88.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.726 1.21 . . . . 0.0 114.182 174.951 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.31 -46.8 86.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 O-C-N 120.732 -1.23 . . . . 0.0 111.62 175.638 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -61.47 -34.45 75.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.557 -1.34 . . . . 0.0 114.094 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 1.5 m -77.82 -35.39 51.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.525 1.53 . . . . 0.0 113.091 174.832 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 53.1 mt -70.2 -24.29 63.09 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 119.694 -1.879 . . . . 0.0 114.783 168.997 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -69.64 -48.65 59.18 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 119.68 -1.888 . . . . 0.0 111.984 168.064 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -85.44 52.58 2.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 114.394 1.257 . . . . 0.0 114.394 -176.402 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 56.6 p -88.99 178.78 6.31 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.112 -1.617 . . . . 0.0 109.941 170.691 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.89 -165.31 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 160.836 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -70.56 -42.7 70.77 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.52 -0.988 . . . . 0.0 112.714 175.067 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 41.8 t -94.83 126.59 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 166.5 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 53.0 t -114.45 132.29 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 129.22 3.008 . . . . 0.0 108.653 -168.148 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -120.73 91.25 3.49 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 111.557 -170.845 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.9 mt -94.51 155.01 17.13 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.619 -1.926 . . . . 0.0 112.637 177.786 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.0 tt -129.62 133.13 46.98 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.456 -0.777 . . . . 0.0 109.103 161.984 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -152.63 170.41 20.3 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 120.143 -1.598 . . . . 0.0 112.669 -175.083 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -116.53 145.51 43.28 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 125.576 1.55 . . . . 0.0 110.235 179.647 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 18.4 tptt -75.45 137.98 41.32 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 125.955 1.702 . . . . 0.0 112.524 -177.446 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -98.82 165.6 21.12 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 125.359 1.457 . . . . 0.0 112.77 176.546 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -77.18 179.75 6.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -176.766 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.2 m -111.05 154.32 43.52 Favored Pre-proline 0 N--CA 1.43 -1.456 0 O-C-N 120.404 -1.435 . . . . 0.0 111.736 -170.788 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_exo . . . . . 0 N--CA 1.434 -2.015 0 C-N-CA 123.073 2.515 . . . . 0.0 115.638 168.836 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 12.6 t70 . . . . . 0 N--CA 1.43 -1.428 0 CA-C-O 120.539 0.209 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.84 154.26 20.39 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.648 -1.907 . . . . 0.0 112.467 -175.421 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -146.15 141.38 27.45 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.131 0.967 . . . . 0.0 109.505 167.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -92.7 119.73 32.4 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.776 1.63 . . . . 0.0 107.276 163.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 10.9 t -107.65 101.57 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 122.485 1.136 . . . . 0.0 108.029 -174.053 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -92.43 79.6 4.94 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.461 1.505 . . . . 0.0 108.749 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.9 tp -104.64 133.52 49.36 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-O 122.643 1.211 . . . . 0.0 111.264 -166.325 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.7 146.32 27.9 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.167 -1.583 . . . . 0.0 108.848 170.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.76 158.67 34.99 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.205 -1.559 . . . . 0.0 114.558 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.2 t -112.05 105.33 13.69 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 170.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . 0.256 22.9 t70 29.64 63.29 0.15 Allowed 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.94 2.896 . . . . 0.0 117.37 -165.435 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.74 10.09 85.56 Favored Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 117.244 1.658 . . . . 0.0 117.244 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.6 m -121.1 134.15 55.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 119.586 1.693 . . . . 0.0 113.499 176.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.6 mt -89.98 -63.01 1.34 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.552 1.141 . . . . 0.0 111.857 167.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.35 34.35 2.51 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 119.684 -1.885 . . . . 0.0 114.378 173.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.9 pt -125.92 131.47 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.686 1.594 . . . . 0.0 110.769 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 22.4 t -105.63 106.9 17.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 166.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.7 m -110.02 152.77 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 C-N-CA 124.548 1.139 . . . . 0.0 111.414 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.1 t -150.7 175.61 11.8 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.167 -0.958 . . . . 0.0 110.974 -172.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.01 -127.5 7.13 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 121.054 -1.029 . . . . 0.0 113.527 170.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.61 -170.52 20.27 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.36 1.457 . . . . 0.0 112.174 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.43 -1.456 0 C-N-CA 124.896 1.278 . . . . 0.0 114.343 -177.968 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.704 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.4 mm -103.75 129.08 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.842 1.257 . . . . 0.0 108.155 -178.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -127.68 149.47 50.19 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 121.312 -0.868 . . . . 0.0 109.574 -171.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.5 t -77.09 122.62 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 O-C-N 120.845 -1.159 . . . . 0.0 111.684 172.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -88.33 -50.44 6.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.827 -1.171 . . . . 0.0 110.816 176.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.51 158.65 44.4 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 122.162 -0.337 . . . . 0.0 111.829 -175.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.41 120.47 64.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.706 1.202 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.68 119.55 77.9 Favored Pre-proline 0 N--CA 1.429 -1.477 0 CA-C-O 116.794 -1.574 . . . . 0.0 113.37 -169.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -63.66 128.18 21.58 Favored 'Trans proline' 0 N--CA 1.434 -2.018 0 C-N-CA 123.207 2.605 . . . . 0.0 113.931 -173.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.264 54.3 mttm 82.47 21.33 0.25 Allowed 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 128.063 2.545 . . . . 0.0 113.642 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.1 160.83 37.18 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 119.897 -1.752 . . . . 0.0 114.428 170.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -52.44 -59.78 4.02 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.341 1.856 . . . . 0.0 115.402 164.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.49 -45.23 88.23 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 128.823 2.849 . . . . 0.0 111.225 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -44.42 -64.2 0.73 Allowed 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 170.025 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 m -70.2 -22.37 62.94 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.565 1.691 . . . . 0.0 115.565 -177.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.45 -61.61 2.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.829 1.652 . . . . 0.0 112.603 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.88 5.0 64.71 Favored Glycine 0 N--CA 1.43 -1.717 0 N-CA-C 116.14 1.216 . . . . 0.0 116.14 169.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -77.17 -32.92 56.53 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 118.767 1.283 . . . . 0.0 109.635 160.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.7 mt -92.27 135.91 26.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.966 1.306 . . . . 0.0 109.161 170.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -159.47 160.97 35.33 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.589 -1.319 . . . . 0.0 110.014 178.144 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.5 pttt -64.87 135.49 55.79 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.383 -2.073 . . . . 0.0 114.628 -171.157 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.46 4.93 67.62 Favored Glycine 0 N--CA 1.43 -1.744 0 CA-C-O 118.295 -1.28 . . . . 0.0 115.436 -172.439 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.344 1.6 p30 -80.15 166.13 21.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 121.468 2.634 . . . . 0.0 114.375 171.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 9.9 tpt85 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.496 1.118 . . . . 0.0 109.186 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 5.0 t -85.68 139.27 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 123.748 0.819 . . . . 0.0 109.805 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.17 -53.23 2.7 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.862 -1.149 . . . . 0.0 109.291 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.69 150.62 31.31 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 112.744 -175.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.917 HG11 HG21 ' A' ' 84' ' ' THR . 2.5 p -119.38 107.74 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 125.45 1.5 . . . . 0.0 110.266 177.144 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.1 t30 58.93 37.05 24.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.672 -1.893 . . . . 0.0 113.282 173.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.07 -29.69 11.59 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.891 1.234 . . . . 0.0 114.023 -172.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 44.5 t -87.98 119.55 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 119.734 1.767 . . . . 0.0 110.777 -163.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.8 m -69.87 117.63 11.71 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.1 -1.0 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 18.2 mt -83.84 -4.65 58.83 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.573 -1.329 . . . . 0.0 113.873 -169.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -74.05 116.37 14.6 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.217 -1.552 . . . . 0.0 112.044 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 107.93 -20.87 30.62 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 124.175 0.893 . . . . 0.0 112.064 -175.105 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.35 148.79 46.68 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.772 -1.428 . . . . 0.0 112.902 172.476 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.414 HG22 ' H ' ' A' ' 78' ' ' HIS . 0.2 OUTLIER -90.21 -179.14 5.58 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.301 -1.499 . . . . 0.0 112.008 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 78' ' ' HIS . . . . . 0.414 ' H ' HG22 ' A' ' 77' ' ' THR . 10.4 t-160 -61.23 -47.6 85.35 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.463 1.905 . . . . 0.0 112.765 -174.26 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.68 -46.96 80.85 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 115.173 1.546 . . . . 0.0 115.173 173.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 15.9 mp0 -55.88 -51.13 68.65 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.681 1.593 . . . . 0.0 113.822 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.05 -36.42 83.51 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.1 t -67.29 -49.39 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 O-C-N 120.661 -1.274 . . . . 0.0 110.941 176.037 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -62.5 -37.12 84.78 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.126 0.97 . . . . 0.0 113.285 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' THR . . . . . 0.917 HG21 HG11 ' A' ' 68' ' ' VAL . 54.0 m -58.59 -52.28 66.32 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.261 1.824 . . . . 0.0 112.57 173.298 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -63.27 -37.02 85.61 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 175.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.44 -42.88 99.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.108 1.363 . . . . 0.0 111.608 175.111 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -88.97 43.16 1.13 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.716 1.606 . . . . 0.0 112.663 177.359 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.6 p -100.53 156.19 17.43 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.203 -1.56 . . . . 0.0 110.184 169.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.32 -146.42 20.32 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.656 1.122 . . . . 0.0 113.141 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -69.97 -57.41 5.04 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.757 -1.437 . . . . 0.0 114.331 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.38 131.91 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 CA-C-O 122.454 1.121 . . . . 0.0 108.534 176.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -124.57 120.73 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 127.611 2.364 . . . . 0.0 108.977 -167.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -107.2 93.41 4.54 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 119.878 -1.764 . . . . 0.0 112.523 -171.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 1.1 mm? -91.54 160.04 15.62 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 118.782 -2.448 . . . . 0.0 113.794 -177.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 38.8 tp -127.87 128.92 46.03 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.289 1.436 . . . . 0.0 108.867 162.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.72 169.89 18.11 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.292 -1.505 . . . . 0.0 113.041 177.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -126.96 134.94 50.28 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.149 0.979 . . . . 0.0 112.873 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.47 0 C-N-CA 126.415 1.886 . . . . 0.0 113.444 -177.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.429 -1.478 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 48.4 p -100.14 162.59 12.87 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.416 -1.427 . . . . 0.0 113.276 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.62 149.86 34.34 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 168.102 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -104.03 119.11 38.23 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-O 122.719 1.247 . . . . 0.0 109.242 167.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.8 t -98.07 108.48 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.588 1.955 . . . . 0.0 108.344 -175.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -104.42 86.47 2.53 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.196 1.398 . . . . 0.0 108.443 173.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 52.5 tp -120.38 142.29 49.31 Favored 'General case' 0 N--CA 1.431 -1.379 0 C-N-CA 125.111 1.364 . . . . 0.0 110.609 -165.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 140.59 35.9 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.651 1.58 . . . . 0.0 110.585 173.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -69.71 158.79 34.72 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.9 p -112.61 105.7 13.95 Favored 'General case' 0 N--CA 1.429 -1.518 0 C-N-CA 125.076 1.35 . . . . 0.0 108.761 172.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.2 t70 55.34 45.38 25.62 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.437 1.895 . . . . 0.0 113.656 -176.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.44 -5.26 64.61 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.349 -1.47 . . . . 0.0 115.563 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 60.5 p -107.92 149.78 27.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -174.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.0 mt -100.83 -56.25 2.37 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.229 1.411 . . . . 0.0 108.278 172.06 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 51' ' ' GLY . . . 106.06 55.71 0.68 Allowed Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.324 -1.485 . . . . 0.0 111.863 173.034 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.5 tt -143.39 142.26 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 CA-C-O 122.295 1.045 . . . . 0.0 110.401 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 44.3 t -112.79 115.09 27.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.435 1.894 . . . . 0.0 107.441 171.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.6 m -101.4 160.1 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 122.43 1.11 . . . . 0.0 111.84 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.5 t -144.05 -179.46 6.51 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 125.253 1.421 . . . . 0.0 107.906 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.1 -155.43 16.3 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 121.085 -1.009 . . . . 0.0 113.722 173.172 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.2 152.68 22.55 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.692 1.139 . . . . 0.0 114.173 176.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.43 -1.456 0 N-CA-C 115.208 1.559 . . . . 0.0 115.208 -170.247 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.752 0 CA-C-O 121.661 0.59 . . . . 0.0 114.313 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 46.7 mm -103.69 127.72 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 125.487 1.515 . . . . 0.0 108.082 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -130.92 157.01 44.08 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 121.07 -1.019 . . . . 0.0 112.6 -168.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.4 t -75.87 124.4 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.97 -1.081 . . . . 0.0 111.168 169.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -93.15 -46.43 7.43 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.246 -0.909 . . . . 0.0 110.61 170.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.53 153.5 34.68 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 111.121 177.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.16 121.68 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-O 123.016 1.389 . . . . 0.0 109.052 176.008 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 33.2 mm -76.53 126.27 86.37 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 127.028 2.131 . . . . 0.0 113.157 -166.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -60.63 138.42 79.83 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 124.722 2.722 . . . . 0.0 113.976 -173.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm 53.43 37.08 24.73 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 116.822 2.156 . . . . 0.0 116.822 -169.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 26' ' ' GLY . . . -84.72 160.74 35.97 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.078 -1.639 . . . . 0.0 113.225 159.443 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.75 -56.37 12.34 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.252 -1.734 . . . . 0.0 115.658 163.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.71 -47.65 77.57 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.196 2.999 . . . . 0.0 112.517 -179.272 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -40.81 -64.88 0.48 Allowed 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.656 1.582 . . . . 0.0 113.975 164.696 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 12.9 t -67.65 -34.89 77.84 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.456 1.102 . . . . 0.0 113.887 -170.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -53.46 -65.43 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.616 1.966 . . . . 0.0 113.906 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.22 -10.78 24.45 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 115.496 0.959 . . . . 0.0 115.496 172.006 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -72.72 -24.75 61.03 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 119.634 1.717 . . . . 0.0 113.194 172.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 67.5 mt -105.4 135.93 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.542 1.537 . . . . 0.0 108.452 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -154.15 158.25 40.1 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.844 -1.16 . . . . 0.0 112.169 -170.241 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -51.83 122.78 8.85 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.007 -1.683 . . . . 0.0 115.49 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.59 -5.51 64.63 Favored Glycine 0 N--CA 1.429 -1.771 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 0.3 OUTLIER -80.19 171.83 14.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.923 1.861 . . . . 0.0 114.343 -175.823 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -119.74 125.73 49.35 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.402 -1.436 . . . . 0.0 112.709 -169.101 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.0 t -82.61 127.85 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.734 -1.229 . . . . 0.0 110.027 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.41 -46.45 5.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 110.525 176.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.79 136.57 17.13 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.556 -1.34 . . . . 0.0 114.003 -177.529 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -104.37 116.93 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 124.536 1.135 . . . . 0.0 108.525 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.5 t30 59.38 39.47 22.13 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.137 -1.602 . . . . 0.0 113.767 175.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.09 -33.5 5.21 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 121.209 -0.932 . . . . 0.0 113.889 -174.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -87.03 117.75 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 C-N-CA 124.725 1.21 . . . . 0.0 111.471 -167.12 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 t -76.55 139.32 40.68 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.318 -1.489 . . . . 0.0 112.628 -174.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.2 mt -89.69 20.86 3.79 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -171.288 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -62.17 117.71 6.4 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 119.829 -1.794 . . . . 0.0 114.591 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 84.94 10.8 78.02 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 124.483 1.039 . . . . 0.0 113.65 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.72 157.14 38.46 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.3 p -91.22 170.03 10.34 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.863 -1.148 . . . . 0.0 109.677 170.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -53.91 -55.2 29.09 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.889 1.276 . . . . 0.0 113.322 170.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -56.44 -44.34 80.34 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.049 1.499 . . . . 0.0 115.049 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -61.06 -46.05 92.25 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -175.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.98 -33.43 75.71 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.809 1.244 . . . . 0.0 112.669 172.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.06 -48.34 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.463 1.105 . . . . 0.0 110.381 178.245 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -59.05 -42.24 89.81 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.714 -1.241 . . . . 0.0 113.043 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.6 m -62.03 -48.06 81.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.036 2.134 . . . . 0.0 112.858 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 33.4 mt -65.54 -37.12 85.82 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.109 1.364 . . . . 0.0 114.246 175.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -68.69 -31.54 70.71 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.337 -1.477 . . . . 0.0 112.474 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -88.51 48.58 1.66 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 124.828 1.251 . . . . 0.0 112.139 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.6 p -98.82 154.48 17.98 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.132 1.773 . . . . 0.0 107.894 166.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.66 -157.76 30.82 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.803 -1.186 . . . . 0.0 112.007 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? -69.43 -49.08 58.46 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 121.099 -1.236 . . . . 0.0 112.6 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 56.4 t -99.16 132.72 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.43 1.092 . . . . 0.0 108.325 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 74.4 t -120.3 124.8 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 126.556 1.943 . . . . 0.0 109.649 -165.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -113.58 87.46 2.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.627 1.171 . . . . 0.0 112.196 -174.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.279 3.1 pp -123.5 148.28 46.4 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 117.794 2.516 . . . . 0.0 117.794 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 49.9 tp -105.82 128.31 53.65 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.878 1.671 . . . . 0.0 108.433 -176.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.34 158.68 43.65 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 121.999 0.904 . . . . 0.0 110.822 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -95.52 150.98 19.72 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 165.214 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 122.221 1.01 . . . . 0.0 109.791 165.393 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t70 . . . . . 0 N--CA 1.43 -1.474 0 N-CA-C 113.113 0.782 . . . . 0.0 113.113 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 38.5 p -121.86 154.42 37.09 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 121.077 -1.014 . . . . 0.0 112.79 -174.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.2 139.65 27.36 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.072 -1.017 . . . . 0.0 109.082 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -92.72 131.0 38.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.86 -1.15 . . . . 0.0 109.899 168.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.8 t -116.71 111.83 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.057 1.343 . . . . 0.0 108.656 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -102.55 78.06 1.68 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.419 -1.425 . . . . 0.0 109.288 172.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.5 tp -94.74 146.83 23.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 124.297 1.039 . . . . 0.0 111.063 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.48 127.59 50.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.085 -1.634 . . . . 0.0 108.932 167.151 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.1 ptmt -70.15 149.55 47.44 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 p -106.55 111.44 23.99 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.272 -1.517 . . . . 0.0 111.635 -174.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.0 t0 54.26 39.46 30.85 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.424 2.29 . . . . 0.0 113.522 -175.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.02 -7.22 78.71 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.281 -1.512 . . . . 0.0 115.713 -176.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.8 t -109.39 150.38 28.14 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-N 119.15 1.475 . . . . 0.0 112.005 -172.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.4 mt -100.71 -61.59 1.35 Allowed 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.237 -1.539 . . . . 0.0 112.151 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.53 33.81 0.91 Allowed Glycine 0 N--CA 1.43 -1.746 0 O-C-N 119.914 -1.741 . . . . 0.0 111.497 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 pt -124.38 150.36 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.429 1.092 . . . . 0.0 111.261 -174.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 35.4 m -126.67 134.33 50.74 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 156.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 m -117.84 161.58 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 CA-C-O 122.346 1.07 . . . . 0.0 112.102 -170.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.64 -173.35 4.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 124.2 1.0 . . . . 0.0 109.595 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.06 -152.41 20.25 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.994 -1.067 . . . . 0.0 115.437 171.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.67 172.66 30.62 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 125.593 1.568 . . . . 0.0 111.621 -176.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.43 -1.463 0 C-N-CA 125.065 1.346 . . . . 0.0 113.065 176.169 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.682 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.2 mm -95.32 127.72 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.239 1.416 . . . . 0.0 108.584 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -125.7 155.58 40.69 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 120.757 -1.214 . . . . 0.0 111.404 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.5 t -75.96 122.26 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.999 -1.063 . . . . 0.0 110.945 169.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.0 ttmm -87.9 -42.06 12.76 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.376 1.47 . . . . 0.0 109.703 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.24 160.0 38.2 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.77 -0.581 . . . . 0.0 109.946 175.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -119.17 121.36 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 C-N-CA 124.348 1.059 . . . . 0.0 108.841 174.315 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.46 119.38 77.22 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 115.872 -2.013 . . . . 0.0 116.144 -169.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -59.86 123.24 12.83 Favored 'Trans proline' 0 N--CA 1.434 -2.024 0 CA-C-N 124.659 2.7 . . . . 0.0 114.916 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.254 83.7 mttt 81.74 26.53 0.19 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 128.229 2.612 . . . . 0.0 111.921 -172.172 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.61 157.49 31.39 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 119.768 -1.833 . . . . 0.0 111.812 164.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.57 -58.74 5.47 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.59 -2.123 . . . . 0.0 114.287 160.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.1 -40.12 95.54 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 127.45 2.3 . . . . 0.0 112.826 -177.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 -52.07 -59.74 4.01 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 166.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.5 t -68.82 -25.21 64.56 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 125.837 1.655 . . . . 0.0 114.905 -167.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -46.48 -63.15 1.08 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.1 1.76 . . . . 0.0 113.964 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 114.48 -2.51 23.5 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.217 -0.927 . . . . 0.0 114.324 171.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.6 mtm180 -85.81 -28.64 24.36 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.006 -1.29 . . . . 0.0 113.095 171.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.1 mt -108.61 132.07 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 C-N-CA 126.445 1.898 . . . . 0.0 110.664 -170.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.12 -176.71 4.91 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.356 -1.465 . . . . 0.0 112.424 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -68.43 121.19 15.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.416 -1.428 . . . . 0.0 112.738 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 105.41 -2.52 39.88 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 121.418 -0.801 . . . . 0.0 114.393 -175.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -80.35 147.8 30.91 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 119.419 1.609 . . . . 0.0 112.393 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 23.5 ttm180 -97.07 134.34 40.56 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.838 -1.164 . . . . 0.0 110.452 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.1 t -86.45 127.39 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.96 -1.087 . . . . 0.0 109.196 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.47 -45.94 4.71 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.496 -1.377 . . . . 0.0 111.253 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.0 128.69 12.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.489 -1.382 . . . . 0.0 111.584 -176.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 t -108.9 124.04 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 66.55 28.1 9.47 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.521 -1.362 . . . . 0.0 113.666 170.5 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.74 -12.53 66.92 Favored Glycine 0 N--CA 1.429 -1.809 0 O-C-N 119.962 -1.712 . . . . 0.0 113.773 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.9 t -96.14 116.09 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.155 -1.203 . . . . 0.0 109.026 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 92.7 p -75.36 140.83 43.27 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.357 -1.464 . . . . 0.0 111.592 177.541 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.2 mt -88.29 50.93 2.06 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.652 -1.28 . . . . 0.0 112.744 -166.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -73.67 125.07 27.21 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.977 -1.702 . . . . 0.0 112.19 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.79 10.64 61.51 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.237 1.399 . . . . 0.0 115.453 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.26 139.4 50.0 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 115.898 1.814 . . . . 0.0 115.898 -170.482 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.8 p -91.64 173.26 7.98 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 124.868 1.267 . . . . 0.0 110.27 176.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -58.96 -49.41 77.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.962 -1.086 . . . . 0.0 113.531 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -56.33 -40.29 74.2 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 175.089 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -53.9 51.56 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.565 1.546 . . . . 0.0 113.766 179.069 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.5 87.73 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.472 1.509 . . . . 0.0 113.86 177.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.62 -48.15 88.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.772 1.229 . . . . 0.0 110.894 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -63.21 -41.27 99.11 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 175.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.3 m -61.48 -45.95 92.08 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 125.96 1.704 . . . . 0.0 113.277 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.64 -30.4 67.02 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.269 -1.519 . . . . 0.0 113.91 176.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.58 -45.03 92.29 Favored 'General case' 0 CA--C 1.488 -1.419 0 O-C-N 120.453 -1.405 . . . . 0.0 112.025 167.813 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -78.02 48.81 0.75 Allowed 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 128.116 2.567 . . . . 0.0 113.679 176.331 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 35.3 p -106.03 156.0 18.84 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.268 -1.52 . . . . 0.0 110.218 174.494 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.21 -164.19 38.35 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.778 -1.201 . . . . 0.0 111.036 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -69.78 -47.81 61.52 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 118.922 1.361 . . . . 0.0 112.236 172.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.27 123.82 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-O 123.171 1.463 . . . . 0.0 107.505 169.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.4 t -113.2 103.59 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 126.956 2.103 . . . . 0.0 109.019 -168.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.6 t-160 -89.2 101.57 14.23 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 123.784 0.834 . . . . 0.0 111.523 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.6 mt -102.97 162.12 13.2 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-O 122.665 1.221 . . . . 0.0 113.822 172.292 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.5 tt -129.04 132.19 47.44 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.036 1.335 . . . . 0.0 108.021 159.311 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.01 164.64 28.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.012 -1.055 . . . . 0.0 113.23 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -113.88 142.47 46.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.405 1.882 . . . . 0.0 109.918 177.014 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 19.7 tptt . . . . . 0 N--CA 1.43 -1.442 0 C-N-CA 125.818 1.647 . . . . 0.0 112.794 177.58 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.6 t0 . . . . . 0 N--CA 1.431 -1.423 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.0 p -101.83 150.47 23.14 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.375 -1.453 . . . . 0.0 112.532 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.76 134.88 22.76 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.903 -1.123 . . . . 0.0 108.72 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -91.04 121.4 32.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.334 1.454 . . . . 0.0 109.615 174.156 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.19 102.77 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.803 -1.186 . . . . 0.0 108.236 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -104.46 81.88 1.85 Allowed 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.123 1.369 . . . . 0.0 108.226 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.6 tp -111.78 149.27 31.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.694 1.198 . . . . 0.0 110.325 -165.355 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.89 144.81 30.72 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.347 -1.471 . . . . 0.0 108.869 170.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -70.12 154.64 41.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.609 -1.307 . . . . 0.0 112.638 173.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.6 p -112.92 100.79 8.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.836 -1.165 . . . . 0.0 109.066 175.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 22.0 t0 58.01 45.42 18.01 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 126.014 1.726 . . . . 0.0 113.248 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.54 -10.99 67.4 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 125.049 1.309 . . . . 0.0 115.226 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 62.1 m -104.04 148.78 25.83 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.787 1.293 . . . . 0.0 113.561 -169.056 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.0 mt -119.31 -54.03 2.21 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.999 1.32 . . . . 0.0 109.354 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.5 43.32 1.86 Allowed Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 127.036 2.255 . . . . 0.0 113.877 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 pt -121.52 121.15 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 CA-C-N 119.394 1.597 . . . . 0.0 115.031 -167.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.4 m -116.72 123.83 48.16 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.549 -1.345 . . . . 0.0 109.202 165.388 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.46 173.91 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.072 1.349 . . . . 0.0 111.709 -171.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.7 t -146.31 168.47 21.01 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.059 1.344 . . . . 0.0 108.515 174.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.67 -154.18 17.15 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.842 -1.161 . . . . 0.0 115.149 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 101.5 165.99 27.43 Favored Glycine 0 N--CA 1.429 -1.785 0 C-N-CA 125.247 1.403 . . . . 0.0 112.379 -179.003 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 N--CA 1.43 -1.467 0 N-CA-C 115.937 1.829 . . . . 0.0 115.937 -171.173 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.714 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.72 125.76 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.876 1.271 . . . . 0.0 107.972 178.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -128.88 157.49 41.42 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.602 -1.312 . . . . 0.0 111.398 -172.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.8 t -76.39 126.54 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.495 1.518 . . . . 0.0 111.181 172.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -109.79 -51.67 2.85 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.338 -1.477 . . . . 0.0 113.164 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.0 157.01 43.49 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 121.226 -0.921 . . . . 0.0 109.975 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -125.77 126.09 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 C-N-CA 123.988 0.915 . . . . 0.0 109.195 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.6 mm -77.26 122.45 86.16 Favored Pre-proline 0 N--CA 1.429 -1.493 0 CA-C-O 116.238 -1.839 . . . . 0.0 114.507 -173.193 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -57.28 127.6 26.24 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 CA-C-N 124.506 2.645 . . . . 0.0 116.18 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.292 50.8 mttp 79.36 22.64 0.56 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 127.545 2.338 . . . . 0.0 113.385 -177.27 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.17 156.3 30.76 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.9 -1.75 . . . . 0.0 112.16 165.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.09 -55.33 12.53 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.824 1.65 . . . . 0.0 115.268 170.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.36 -48.51 75.25 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.89 2.476 . . . . 0.0 111.448 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 tm-20 -47.49 -59.15 3.44 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 173.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.0 t -68.37 -30.37 69.29 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.647 1.179 . . . . 0.0 113.387 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -65.02 -60.43 3.05 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.963 1.305 . . . . 0.0 111.199 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.96 31.07 15.73 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.45 -1.406 . . . . 0.0 116.431 167.062 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -83.3 -39.82 20.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 121.458 -1.025 . . . . 0.0 108.747 159.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mt -79.17 99.81 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 123.933 0.893 . . . . 0.0 110.313 175.188 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -122.81 156.77 33.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.82 1.295 . . . . 0.0 109.627 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.1 pttt -67.78 131.27 45.24 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.136 -1.602 . . . . 0.0 113.379 -171.02 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.87 -19.52 32.84 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.164 -0.96 . . . . 0.0 114.1 -172.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -79.51 157.1 27.51 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 120.152 1.976 . . . . 0.0 113.312 -173.412 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 70.6 ttt-85 -108.88 134.93 50.9 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.154 -1.591 . . . . 0.0 111.289 -173.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.11 132.75 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 119.945 -1.722 . . . . 0.0 110.986 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.72 -52.4 4.9 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.914 -1.116 . . . . 0.0 111.788 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.96 140.14 20.3 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.907 -0.496 . . . . 0.0 112.016 -165.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.1 t -109.22 118.24 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 171.012 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 63.18 20.89 12.55 Favored 'General case' 0 N--CA 1.429 -1.514 0 C-N-CA 125.968 1.707 . . . . 0.0 113.974 -178.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 86.52 -0.55 86.94 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.279 -1.513 . . . . 0.0 114.069 -174.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -86.05 117.56 30.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.853 1.261 . . . . 0.0 109.045 176.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.0 p -75.63 132.36 40.55 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.774 -1.204 . . . . 0.0 113.702 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 67.6 mt -84.77 -13.19 51.95 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -168.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -63.63 131.74 48.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.595 -1.941 . . . . 0.0 112.72 174.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.18 -30.35 9.22 Favored Glycine 0 N--CA 1.431 -1.697 0 C-N-CA 124.518 1.056 . . . . 0.0 113.674 -171.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.23 156.87 39.04 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -88.23 172.61 9.34 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.244 1.018 . . . . 0.0 111.681 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -63.82 -43.35 96.48 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.554 -1.341 . . . . 0.0 112.151 175.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -54.8 -44.87 74.18 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 126.646 1.978 . . . . 0.0 114.416 171.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -56.03 -55.05 37.48 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.93 -34.85 78.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.61 -53.76 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.33 1.052 . . . . 0.0 110.566 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -61.92 -39.43 92.01 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.011 0.91 . . . . 0.0 113.036 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 97.0 m -66.86 -42.38 85.78 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.452 1.901 . . . . 0.0 113.219 179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 65.5 mt -69.54 -36.92 76.83 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.068 -1.02 . . . . 0.0 113.082 173.214 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -53.55 56.4 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.789 -1.195 . . . . 0.0 113.03 173.39 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -81.04 43.06 0.68 Allowed 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.863 1.665 . . . . 0.0 112.748 -177.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.416 ' HB ' HG22 ' A' ' 92' ' ' VAL . 26.1 p -91.76 155.37 18.3 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 127.425 2.29 . . . . 0.0 108.814 168.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.98 -140.7 7.01 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.973 -1.079 . . . . 0.0 114.078 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 2.1 tm0? -71.02 -53.48 14.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.329 -1.101 . . . . 0.0 111.993 177.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 95.0 t -97.89 135.89 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.397 1.57 . . . . 0.0 109.17 169.382 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 88' ' ' THR . 48.2 t -111.43 117.66 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 128.574 2.75 . . . . 0.0 108.131 -176.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 52.9 m170 -105.23 104.41 14.14 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.872 -1.143 . . . . 0.0 111.244 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -106.73 163.75 12.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.884 -1.135 . . . . 0.0 113.799 171.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.3 tp -128.2 134.11 48.97 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 124.856 1.263 . . . . 0.0 108.36 158.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.8 pp -145.17 164.87 29.98 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.637 -1.29 . . . . 0.0 111.285 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -121.42 149.72 42.59 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.023 1.729 . . . . 0.0 110.894 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.463 0 C-N-CA 125.482 1.513 . . . . 0.0 110.761 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.7 t70 . . . . . 0 N--CA 1.43 -1.453 0 N-CA-C 114.867 1.432 . . . . 0.0 114.867 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -123.56 154.73 38.82 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-N 119.419 1.009 . . . . 0.0 110.596 163.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -144.43 149.92 36.83 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 123.882 0.873 . . . . 0.0 109.438 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -99.63 125.85 45.53 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.123 1.369 . . . . 0.0 109.275 167.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.46 94.88 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 O-C-N 120.481 -1.387 . . . . 0.0 107.954 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -90.62 81.54 5.87 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.658 -1.276 . . . . 0.0 109.387 169.591 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 49.2 tp -96.39 133.6 40.6 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.652 1.181 . . . . 0.0 111.642 -171.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.16 138.72 38.73 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 119.878 -1.764 . . . . 0.0 110.147 172.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -68.25 156.51 37.49 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.726 1.21 . . . . 0.0 113.721 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.4 t -129.25 135.8 49.27 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 172.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.0 t70 33.34 52.12 0.35 Allowed 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 128.248 2.619 . . . . 0.0 116.57 -173.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.68 -5.45 69.49 Favored Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 117.678 1.831 . . . . 0.0 117.678 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.7 m -121.57 150.63 41.38 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.535 1.668 . . . . 0.0 113.988 -169.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 46.9 mt -101.28 -60.24 1.56 Allowed 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.232 1.413 . . . . 0.0 109.606 168.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.18 41.82 2.02 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.874 1.702 . . . . 0.0 114.63 175.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.3 pt -112.53 156.58 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 CA-C-N 118.417 1.109 . . . . 0.0 111.994 177.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -131.39 132.52 44.46 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.115 -1.615 . . . . 0.0 109.258 149.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.5 m -114.75 160.2 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.478 1.511 . . . . 0.0 110.882 -175.126 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 t -148.8 -178.96 6.64 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.541 -1.349 . . . . 0.0 110.651 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.4 -123.97 7.07 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 120.763 -1.21 . . . . 0.0 114.463 167.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.47 171.27 26.9 Favored Glycine 0 N--CA 1.43 -1.75 0 CA-C-O 122.671 1.151 . . . . 0.0 113.208 178.361 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -172.977 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.73 0 CA-C-O 122.067 0.815 . . . . 0.0 113.55 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.1 mm -102.81 117.18 47.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 125.798 1.639 . . . . 0.0 108.222 -176.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.23 149.81 44.23 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.166 -0.958 . . . . 0.0 109.947 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -78.12 122.59 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.506 -1.371 . . . . 0.0 113.14 177.26 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.52 -39.26 10.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.614 -1.304 . . . . 0.0 112.799 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.26 158.86 42.28 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.441 -1.412 . . . . 0.0 111.466 -177.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.412 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -122.46 120.8 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-O 122.965 1.364 . . . . 0.0 110.824 176.627 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.75 121.66 85.18 Favored Pre-proline 0 N--CA 1.43 -1.468 0 C-N-CA 125.802 1.641 . . . . 0.0 113.189 -171.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.42 134.37 41.39 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 CA-C-N 123.98 2.457 . . . . 0.0 112.689 179.287 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 56.7 mttm 82.29 20.35 0.29 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 129.173 2.989 . . . . 0.0 113.785 -172.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.51 154.85 30.23 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 119.966 -1.709 . . . . 0.0 115.938 169.274 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.47 -58.72 5.1 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.986 2.115 . . . . 0.0 115.562 158.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.06 -46.54 86.98 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.99 2.916 . . . . 0.0 111.612 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.412 ' HA ' HG12 ' A' ' 47' ' ' ILE . 2.6 tm-20 -41.73 -59.58 1.62 Allowed 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 169.397 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.0 t -69.54 -34.6 74.46 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -62.08 -46.81 87.44 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.015 -1.678 . . . . 0.0 113.542 -171.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 108.07 -6.69 34.86 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.359 -1.463 . . . . 0.0 116.08 155.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.482 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.4 mmp_? -70.23 -35.48 73.87 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.918 -1.342 . . . . 0.0 111.131 169.138 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.5 mt -87.22 128.94 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 126.396 1.878 . . . . 0.0 108.766 176.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -164.28 123.21 1.89 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.6 -1.312 . . . . 0.0 107.798 -176.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.17 112.92 0.31 Allowed 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 116.846 2.165 . . . . 0.0 116.846 -167.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.15 -8.66 12.32 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 118.552 -1.138 . . . . 0.0 113.616 -164.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -79.84 164.34 23.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 120.799 2.299 . . . . 0.0 113.019 175.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.1 ttt180 -125.57 124.79 42.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.153 -0.967 . . . . 0.0 110.877 -171.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.5 t -87.74 135.49 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 O-C-N 120.106 -1.621 . . . . 0.0 109.815 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.4 mp -106.24 -44.06 4.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.721 1.208 . . . . 0.0 111.111 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.96 132.54 15.79 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.705 -1.247 . . . . 0.0 111.255 -177.064 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 t -109.97 119.39 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.524 1.13 . . . . 0.0 108.518 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.87 24.6 9.7 Favored 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 126.146 1.778 . . . . 0.0 114.125 173.02 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 90.48 -9.9 76.15 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 120.147 -1.596 . . . . 0.0 114.182 -173.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.66 119.99 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.552 1.141 . . . . 0.0 108.098 -176.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.7 t -76.04 145.93 39.81 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.444 -1.41 . . . . 0.0 112.476 -174.25 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 95.9 mt -91.49 8.13 37.91 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.516 -1.365 . . . . 0.0 113.251 -175.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 77.1 mt-10 -68.27 107.73 2.92 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 119.535 -1.978 . . . . 0.0 113.934 -176.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.27 4.3 68.68 Favored Glycine 0 N--CA 1.429 -1.782 0 O-C-N 120.773 -1.205 . . . . 0.0 113.715 -175.176 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.52 148.11 45.34 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 121.139 -1.213 . . . . 0.0 113.79 168.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.3 p -80.51 173.92 12.12 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.852 -1.155 . . . . 0.0 111.845 169.228 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -55.54 -52.29 64.21 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.364 1.865 . . . . 0.0 112.368 168.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -57.14 -43.12 82.14 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 115.043 1.498 . . . . 0.0 115.043 173.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -56.27 -42.72 77.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.806 1.78 . . . . 0.0 115.806 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.6 -36.12 83.2 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.804 -1.185 . . . . 0.0 112.904 175.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.9 -44.36 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 O-C-N 120.662 -1.274 . . . . 0.0 111.191 177.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -54.04 -37.91 64.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.977 1.711 . . . . 0.0 113.247 171.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -73.36 -52.21 14.64 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.901 2.08 . . . . 0.0 112.224 177.196 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 48.3 mt -64.41 -31.47 72.7 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -70.05 -26.46 64.03 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.18 -1.575 . . . . 0.0 112.982 174.336 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.3 t30 -91.6 39.71 1.01 Allowed 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.563 1.545 . . . . 0.0 112.887 178.27 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 p -94.28 155.47 17.0 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 126.29 1.836 . . . . 0.0 111.786 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -146.59 20.65 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.038 -1.039 . . . . 0.0 112.587 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -69.68 -56.27 7.68 Favored 'General case' 0 N--CA 1.429 -1.523 0 O-C-N 121.2 -1.176 . . . . 0.0 112.38 173.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.1 t -98.54 128.47 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.826 1.298 . . . . 0.0 108.418 178.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.7 t -114.46 109.41 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 128.385 2.674 . . . . 0.0 109.024 -171.292 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -88.84 109.37 20.14 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 120.634 -1.291 . . . . 0.0 110.597 174.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -101.23 153.66 19.43 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.641 -1.287 . . . . 0.0 111.136 161.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -123.02 128.2 49.85 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 157.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -142.46 163.44 32.84 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 121.473 -0.767 . . . . 0.0 111.779 -171.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.51 136.02 53.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.399 1.88 . . . . 0.0 109.145 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.1 tptm . . . . . 0 N--CA 1.43 -1.452 0 O-C-N 119.766 -1.834 . . . . 0.0 112.707 176.3 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 44.0 t0 . . . . . 0 N--CA 1.43 -1.451 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -104.96 160.75 14.78 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 121.02 -1.05 . . . . 0.0 110.593 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.86 139.12 26.09 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 170.614 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.34 131.71 37.31 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.964 1.306 . . . . 0.0 109.412 165.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.1 t -119.73 115.04 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -177.371 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 -107.53 91.17 3.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.227 1.411 . . . . 0.0 107.81 177.318 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.23 132.77 54.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.593 1.157 . . . . 0.0 112.241 -162.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.15 137.96 33.5 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.14 -1.6 . . . . 0.0 111.871 176.213 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 27.9 mttp -70.13 148.42 48.73 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 115.214 1.561 . . . . 0.0 115.214 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 37.3 p -113.59 118.78 35.37 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.965 1.306 . . . . 0.0 109.76 173.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.7 t0 59.49 32.51 21.74 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.532 1.933 . . . . 0.0 114.172 -176.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.62 79.03 Favored Glycine 0 N--CA 1.429 -1.832 0 O-C-N 119.763 -1.835 . . . . 0.0 114.869 -173.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.4 p -121.5 144.56 48.63 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.72 -1.459 . . . . 0.0 112.151 178.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 74.2 mt -85.62 -60.42 2.03 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.923 -1.11 . . . . 0.0 109.943 165.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.04 46.87 0.5 Allowed Glycine 0 N--CA 1.43 -1.708 0 O-C-N 119.983 -1.698 . . . . 0.0 109.749 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.2 tt -140.73 144.71 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 123.337 1.541 . . . . 0.0 110.296 -175.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.6 t -118.83 133.3 55.93 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 166.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 m -108.44 164.67 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.49 1.116 . . . . 0.0 110.449 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 t -147.85 178.36 8.57 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.554 1.142 . . . . 0.0 108.481 176.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.99 -162.41 27.42 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.515 -1.366 . . . . 0.0 113.548 176.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.56 165.93 22.67 Favored Glycine 0 N--CA 1.431 -1.665 0 C-N-CA 124.753 1.168 . . . . 0.0 110.707 -173.452 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.2 t . . . . . 0 N--CA 1.43 -1.45 0 O-C-N 121.073 -1.251 . . . . 0.0 113.941 -176.231 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.73 0 CA-C-O 121.118 0.288 . . . . 0.0 113.272 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.64 127.8 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 170.159 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -128.03 157.64 40.1 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.465 -1.397 . . . . 0.0 111.218 -169.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.3 t -75.44 120.65 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 O-C-N 121.02 -1.05 . . . . 0.0 111.044 169.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -90.84 -52.09 5.04 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.626 1.571 . . . . 0.0 110.542 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.08 154.72 36.48 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.15 124.16 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 174.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.72 121.31 84.59 Favored Pre-proline 0 N--CA 1.429 -1.523 0 C-N-CA 126.671 1.989 . . . . 0.0 113.956 -167.222 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -57.7 123.41 13.67 Favored 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 124.448 2.624 . . . . 0.0 116.408 -172.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.268 3.9 mtpm? 76.84 25.99 0.82 Allowed 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 128.137 2.575 . . . . 0.0 114.855 -178.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.42 169.18 47.14 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.175 -1.578 . . . . 0.0 113.495 168.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.5 -58.76 5.01 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.084 2.154 . . . . 0.0 114.668 165.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.59 -47.71 77.63 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 128.861 2.864 . . . . 0.0 112.762 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -46.1 -59.03 3.12 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 116.845 2.165 . . . . 0.0 116.845 172.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 t -69.82 -27.71 65.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 124.848 1.259 . . . . 0.0 113.556 -175.414 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -50.79 -62.6 1.51 Allowed 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.838 2.055 . . . . 0.0 113.305 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.28 -45.36 1.16 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.969 -0.457 . . . . 0.0 113.087 168.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.46 -19.01 65.68 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 115.079 1.511 . . . . 0.0 115.079 -172.589 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.8 mt -96.31 117.19 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.519 0 C-N-CA 124.967 1.307 . . . . 0.0 109.06 172.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.7 m80 -118.57 159.45 23.54 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.773 -1.204 . . . . 0.0 110.879 -178.102 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -62.29 129.26 39.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.015 -1.678 . . . . 0.0 113.099 173.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.14 -0.3 72.0 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.886 -1.134 . . . . 0.0 114.831 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -79.62 152.23 30.14 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.768 -1.43 . . . . 0.0 111.289 178.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.8 ttt-85 -105.28 131.13 53.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.031 -1.668 . . . . 0.0 111.261 -168.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 38.3 t -85.34 136.88 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.963 -1.71 . . . . 0.0 110.941 -174.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -105.97 -56.65 2.15 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.908 -1.12 . . . . 0.0 109.386 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.7 137.22 18.79 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.186 -0.946 . . . . 0.0 111.925 -173.344 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.55 125.8 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 67.73 14.72 9.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.078 -1.639 . . . . 0.0 115.263 169.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.13 -13.26 52.26 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 119.748 -1.845 . . . . 0.0 112.913 -175.318 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -92.85 104.87 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 124.369 1.068 . . . . 0.0 109.333 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.3 t -74.26 126.71 31.23 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.665 -1.272 . . . . 0.0 109.589 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 85.1 mt -83.51 55.18 3.09 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.019 1.118 . . . . 0.0 114.019 -158.406 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -71.43 122.16 19.89 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 119.543 -1.973 . . . . 0.0 114.342 -172.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.63 5.09 72.59 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.186 -1.571 . . . . 0.0 115.437 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.62 140.59 49.81 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.255 1.946 . . . . 0.0 116.255 -171.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.2 p -93.3 178.86 5.59 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.496 2.319 . . . . 0.0 111.747 172.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 20.9 t-160 -57.48 -48.16 79.98 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 126.656 1.982 . . . . 0.0 114.463 179.112 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.3 tptt -56.66 -42.92 79.81 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 174.281 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.4 -50.48 73.8 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.868 1.667 . . . . 0.0 114.515 178.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.25 -38.31 83.07 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.038 1.335 . . . . 0.0 113.518 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 70.4 t -66.42 -46.92 85.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 O-C-N 120.792 -1.192 . . . . 0.0 111.851 173.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -54.65 -48.5 72.23 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.689 1.596 . . . . 0.0 112.359 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 13.6 m -64.84 -45.97 83.87 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.856 2.463 . . . . 0.0 114.048 175.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.1 mt -64.04 -34.1 77.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 119.29 -2.131 . . . . 0.0 114.675 174.453 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 17.6 mtp-105 -65.21 -36.58 84.63 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 112.851 172.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -86.52 46.22 1.33 Allowed 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 125.62 1.568 . . . . 0.0 112.712 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.418 ' HB ' HG22 ' A' ' 92' ' ' VAL . 25.1 p -107.12 155.99 19.27 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.65 1.58 . . . . 0.0 109.657 173.546 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.33 -156.4 32.29 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.647 -1.283 . . . . 0.0 112.53 178.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -68.88 -54.94 12.77 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.175 -1.191 . . . . 0.0 111.772 176.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 130.8 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 CA-C-O 122.497 1.141 . . . . 0.0 108.314 170.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.418 HG22 ' HB ' ' A' ' 88' ' ' THR . 63.6 t -118.47 121.27 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 127.029 2.132 . . . . 0.0 109.743 -168.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -97.28 113.68 25.34 Favored 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 121.314 -0.866 . . . . 0.0 111.244 173.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.2 155.76 19.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.581 1.152 . . . . 0.0 112.639 169.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 40.3 tp -127.11 128.79 46.77 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 158.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.7 pp -142.3 170.15 16.25 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.671 -1.268 . . . . 0.0 111.213 175.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -114.7 145.74 41.71 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.267 1.827 . . . . 0.0 109.165 178.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.2 tptt . . . . . 0 N--CA 1.43 -1.454 0 C-N-CA 124.804 1.241 . . . . 0.0 111.308 -179.944 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.7 t0 . . . . . 0 N--CA 1.431 -1.391 0 CA-C-O 121.77 0.795 . . . . 0.0 109.171 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -114.01 149.8 34.84 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.805 1.242 . . . . 0.0 109.451 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -145.85 127.79 15.48 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -87.88 113.55 23.65 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 164.084 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 t -99.05 110.38 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 124.512 1.125 . . . . 0.0 109.702 -169.579 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.7 mt-10 -104.94 87.25 2.61 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.381 1.086 . . . . 0.0 110.242 -177.008 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.21 147.6 23.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.073 -1.017 . . . . 0.0 110.593 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.88 112.79 25.91 Favored 'General case' 0 N--CA 1.428 -1.544 0 C-N-CA 124.107 0.963 . . . . 0.0 108.593 160.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.6 ttmt -70.16 126.12 28.74 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.442 1.497 . . . . 0.0 112.608 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.8 p -104.27 123.35 47.21 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.045 -1.659 . . . . 0.0 110.894 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.8 t70 63.61 24.7 14.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.591 1.557 . . . . 0.0 113.861 170.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.6 4.81 89.95 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 119.51 -1.994 . . . . 0.0 115.189 -175.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.5 m -105.35 104.21 13.89 Favored 'General case' 0 N--CA 1.429 -1.477 0 CA-C-N 119.195 1.497 . . . . 0.0 111.629 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 11.9 tp -80.81 -45.51 16.81 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 120.563 -1.336 . . . . 0.0 111.475 173.363 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.06 28.08 3.23 Favored Glycine 0 N--CA 1.429 -1.773 0 C-N-CA 125.574 1.559 . . . . 0.0 113.547 170.13 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.9 tt -148.99 136.02 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 120.014 1.907 . . . . 0.0 114.694 -168.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.3 m -110.83 126.6 54.82 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.847 1.659 . . . . 0.0 108.48 167.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -104.24 172.01 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.219 1.007 . . . . 0.0 111.905 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.4 t -157.3 176.96 12.0 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.504 -1.372 . . . . 0.0 110.803 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 115.35 -128.33 8.03 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.457 1.027 . . . . 0.0 112.276 169.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.32 134.84 8.16 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.163 0.887 . . . . 0.0 111.279 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.7 m . . . . . 0 N--CA 1.43 -1.438 0 N-CA-C 115.702 1.741 . . . . 0.0 115.702 -170.244 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.702 0 N-CA-C 112.166 -0.374 . . . . 0.0 112.166 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.7 mm -104.13 125.59 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.945 1.298 . . . . 0.0 109.664 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -126.84 158.81 35.68 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 120.276 -1.515 . . . . 0.0 112.182 -172.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.2 t -76.23 120.35 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 125.135 1.374 . . . . 0.0 112.689 175.035 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -93.93 -47.05 6.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.586 -1.321 . . . . 0.0 112.109 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.71 152.25 24.99 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 121.113 -0.992 . . . . 0.0 111.435 178.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.39 122.29 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 C-N-CA 126.136 1.774 . . . . 0.0 109.378 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 9.3 mm -77.58 123.93 86.66 Favored Pre-proline 0 N--CA 1.429 -1.495 0 C-N-CA 127.014 2.126 . . . . 0.0 114.352 -175.429 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -57.55 125.74 19.71 Favored 'Trans proline' 0 N--CA 1.434 -1.998 0 CA-C-N 124.607 2.681 . . . . 0.0 116.526 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.313 63.1 mttm 83.01 16.34 0.32 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 128.46 2.704 . . . . 0.0 113.72 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.06 162.48 38.83 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.116 -1.615 . . . . 0.0 114.128 169.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.41 -55.78 11.89 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.02 1.728 . . . . 0.0 114.977 170.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.89 -47.78 81.8 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.735 2.814 . . . . 0.0 112.59 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -48.44 -61.08 2.19 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 173.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.7 m -69.1 -32.59 72.11 Favored 'General case' 0 N--CA 1.429 -1.507 0 CA-C-N 115.499 -0.773 . . . . 0.0 112.859 -173.035 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -58.91 -70.28 0.16 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.947 1.699 . . . . 0.0 113.411 175.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.27 14.76 43.75 Favored Glycine 0 N--CA 1.43 -1.712 0 O-C-N 120.38 -1.45 . . . . 0.0 114.9 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -65.27 -26.47 68.1 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.707 -1.467 . . . . 0.0 111.691 159.231 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 71.6 mt -106.55 130.75 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 C-N-CA 126.686 1.994 . . . . 0.0 109.223 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -126.95 170.01 12.72 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-O 123.062 1.411 . . . . 0.0 110.835 169.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -60.59 129.69 42.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.01 -1.681 . . . . 0.0 113.388 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.31 4.15 86.44 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.291 -1.506 . . . . 0.0 115.608 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -75.46 161.98 28.74 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-N 119.835 1.817 . . . . 0.0 111.665 175.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.1 tpt85 -108.57 116.83 32.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.892 -1.13 . . . . 0.0 110.945 -170.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.6 t -84.66 130.6 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 O-C-N 120.511 -1.368 . . . . 0.0 108.283 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.31 -36.58 5.53 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.824 1.25 . . . . 0.0 112.401 -166.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 152.36 33.53 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.234 -1.541 . . . . 0.0 110.11 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.1 t -120.79 114.64 44.31 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 170.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 54.04 48.53 20.88 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.906 2.083 . . . . 0.0 115.535 170.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.06 -18.45 44.61 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 120.834 -1.166 . . . . 0.0 114.571 -177.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.6 t -94.21 105.8 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 O-C-N 120.82 -1.4 . . . . 0.0 109.004 -178.238 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.8 p -72.23 138.8 47.77 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.688 -1.257 . . . . 0.0 111.761 178.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 53.7 mt -87.15 32.62 0.68 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.636 -1.29 . . . . 0.0 112.777 -169.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -69.61 130.21 41.78 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.189 -2.195 . . . . 0.0 112.66 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.03 8.73 44.12 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 125.645 1.593 . . . . 0.0 116.253 -176.098 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.33 142.08 50.43 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -171.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 40.6 p -87.32 175.25 8.1 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.051 1.34 . . . . 0.0 110.312 173.437 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.1 t-160 -61.82 -40.22 94.5 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.644 -1.285 . . . . 0.0 111.757 174.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -54.93 -47.16 74.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.355 1.862 . . . . 0.0 114.928 173.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -56.6 -51.81 67.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 -179.079 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.32 -42.38 95.45 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.233 1.013 . . . . 0.0 113.28 177.23 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.08 -48.07 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.984 -1.073 . . . . 0.0 111.137 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -63.97 -41.31 97.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 3.5 m -61.0 -47.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 126.225 1.81 . . . . 0.0 112.874 175.226 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.7 mt -68.43 -29.67 68.38 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 175.33 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.4 ttt180 -62.76 -36.26 82.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.382 -1.449 . . . . 0.0 113.039 173.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -94.83 49.82 1.27 Allowed 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.643 -1.286 . . . . 0.0 111.76 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 37.0 p -107.34 139.68 41.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.325 1.45 . . . . 0.0 110.256 170.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.26 -142.95 12.25 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 123.564 0.602 . . . . 0.0 112.654 173.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -69.38 -60.98 1.98 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.303 -1.116 . . . . 0.0 113.401 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 t -92.02 118.24 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 122.701 1.239 . . . . 0.0 109.773 -176.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.6 t -117.93 111.1 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 126.122 1.769 . . . . 0.0 109.525 -166.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.8 m170 -99.71 103.01 14.65 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.092 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.5 mt -92.85 168.16 11.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.75 -1.844 . . . . 0.0 112.153 171.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.6 tp -129.05 137.67 51.43 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.016 1.326 . . . . 0.0 107.63 157.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.7 161.2 39.78 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.732 -1.23 . . . . 0.0 112.845 174.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -96.46 144.89 26.15 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 164.546 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.9 tmtt? . . . . . 0 N--CA 1.43 -1.451 0 O-C-N 120.859 -1.151 . . . . 0.0 108.279 162.913 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.9 t0 . . . . . 0 N--CA 1.429 -1.496 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -88.94 139.22 30.68 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.368 -1.458 . . . . 0.0 110.837 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.27 0.0 OUTLIER -147.4 140.48 25.12 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.277 1.513 . . . . 0.0 110.637 175.155 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -90.32 146.51 24.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.483 1.913 . . . . 0.0 109.323 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.5 t -122.81 110.46 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 125.008 1.323 . . . . 0.0 107.488 -174.37 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -105.83 84.2 2.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 CA-C-O 122.214 1.007 . . . . 0.0 108.458 174.006 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.3 tp -110.84 145.1 38.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.01 1.324 . . . . 0.0 110.283 -167.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.31 138.38 40.16 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 119.842 -1.786 . . . . 0.0 110.109 168.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -70.86 149.02 47.21 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 169.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.9 t -109.72 111.56 23.1 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.733 -1.229 . . . . 0.0 109.225 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.9 t0 43.34 50.27 5.98 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.923 2.489 . . . . 0.0 114.778 -178.609 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.97 -39.42 2.79 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.452 1.025 . . . . 0.0 115.043 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 m -102.03 148.72 25.03 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.731 -1.452 . . . . 0.0 114.793 -161.377 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -106.65 -61.37 1.54 Allowed 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.161 -0.962 . . . . 0.0 112.041 176.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.91 32.32 1.58 Allowed Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.669 -1.895 . . . . 0.0 112.798 175.126 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 pt -124.09 139.71 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 C-N-CA 125.105 1.362 . . . . 0.0 108.693 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.1 t -129.28 125.64 37.27 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 36.0 m -108.38 168.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.986 0.898 . . . . 0.0 112.63 -172.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.8 160.08 43.55 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.853 1.661 . . . . 0.0 109.095 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.86 -142.9 15.44 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.729 -1.232 . . . . 0.0 113.614 169.161 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.37 166.42 13.68 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 116.039 1.176 . . . . 0.0 116.039 174.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.431 -1.401 0 O-C-N 120.757 -1.437 . . . . 0.0 114.64 -179.015 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 31.7 mm -103.41 120.85 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 172.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -124.57 160.98 27.17 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.788 -1.195 . . . . 0.0 109.119 -175.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.37 128.3 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.731 -1.231 . . . . 0.0 110.475 171.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 29.1 ttmt -89.94 -50.45 6.02 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.87 -1.144 . . . . 0.0 110.325 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.58 150.79 33.92 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 123.396 0.678 . . . . 0.0 109.873 -174.44 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -110.31 121.82 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 170.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 20.9 mm -76.64 121.0 84.08 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 126.219 1.808 . . . . 0.0 113.256 -171.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -58.31 122.93 12.52 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.83 2.353 . . . . 0.0 116.184 -175.027 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.321 64.7 mttt 82.5 20.16 0.27 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.367 2.267 . . . . 0.0 113.801 176.196 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.07 161.89 40.07 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.227 -0.921 . . . . 0.0 114.832 170.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.81 -57.04 7.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.131 2.172 . . . . 0.0 114.396 170.487 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.87 -52.55 62.67 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.58 2.352 . . . . 0.0 112.278 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -42.56 -64.86 0.54 Allowed 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.553 2.057 . . . . 0.0 116.553 174.472 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.9 m -69.94 -14.21 62.61 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -175.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.84 -64.32 1.03 Allowed 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.712 -1.243 . . . . 0.0 110.353 174.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.33 48.01 7.1 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 117.292 1.677 . . . . 0.0 117.292 170.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.7 mtt180 -84.56 -39.87 18.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 146.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 55.8 mt -83.42 121.47 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 126.162 1.785 . . . . 0.0 111.45 176.509 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 46.7 m-70 -122.08 171.75 8.75 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.243 1.497 . . . . 0.0 111.398 170.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -60.62 127.79 33.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.555 -1.34 . . . . 0.0 112.428 175.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.73 0.91 71.53 Favored Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 115.684 1.034 . . . . 0.0 115.684 -178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -82.17 150.05 27.61 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.83 1.815 . . . . 0.0 112.505 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -90.17 127.82 36.2 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.126 -1.609 . . . . 0.0 113.548 -177.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 30.4 t -83.12 132.79 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.787 177.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.93 -51.86 2.86 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.124 -0.985 . . . . 0.0 111.775 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.27 141.33 22.13 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.096 -1.627 . . . . 0.0 112.799 -175.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.8 t -114.94 120.28 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.343 1.057 . . . . 0.0 108.963 177.407 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 74.35 16.49 3.35 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.931 1.692 . . . . 0.0 114.558 169.595 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.54 -1.48 81.74 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.622 -1.299 . . . . 0.0 112.745 -170.219 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -98.28 117.36 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 125.353 1.461 . . . . 0.0 108.114 176.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t -74.21 125.86 29.34 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.3 -1.5 . . . . 0.0 109.346 178.083 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . 0.327 0.7 OUTLIER -92.27 39.32 1.02 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.314 1.531 . . . . 0.0 112.183 -176.251 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -76.36 121.37 22.91 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.135 -1.603 . . . . 0.0 110.753 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 81.5 17.79 70.2 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.757 1.17 . . . . 0.0 113.731 -172.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.25 154.26 41.09 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 123.226 1.489 . . . . 0.0 115.001 171.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.2 p -91.57 173.6 7.8 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.337 -1.477 . . . . 0.0 110.892 171.279 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -51.68 -51.93 52.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.439 1.896 . . . . 0.0 112.416 168.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.27 -53.19 61.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 115.446 1.647 . . . . 0.0 115.446 172.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -60.62 -42.74 97.46 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 -170.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.24 -29.65 68.91 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.168 1.387 . . . . 0.0 114.162 171.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.4 t -79.74 -44.28 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 125.033 1.333 . . . . 0.0 111.49 174.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -58.2 -37.24 74.4 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.335 -1.478 . . . . 0.0 112.745 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.7 m -65.83 -41.23 92.06 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 127.176 2.191 . . . . 0.0 113.54 172.556 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.9 mt -71.23 -40.14 71.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 175.182 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -72.08 -20.05 61.72 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.544 -1.973 . . . . 0.0 112.453 178.135 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -94.39 53.48 1.7 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.511 -1.368 . . . . 0.0 112.019 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.0 p -107.05 143.34 35.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.135 -1.603 . . . . 0.0 110.9 176.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.34 -154.97 18.49 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.76 -1.212 . . . . 0.0 111.242 171.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -66.5 -52.96 40.43 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.604 -1.527 . . . . 0.0 114.009 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.3 t -95.74 126.23 48.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 123.138 1.447 . . . . 0.0 109.567 177.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -109.82 109.36 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 127.298 2.239 . . . . 0.0 107.833 -175.597 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -93.73 111.44 23.13 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.091 -1.006 . . . . 0.0 108.988 172.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.9 mt -110.14 160.71 16.25 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.182 0.993 . . . . 0.0 112.457 170.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.95 133.11 49.2 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.413 1.485 . . . . 0.0 108.157 164.704 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.83 166.12 29.46 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.469 0.652 . . . . 0.0 112.536 178.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -101.86 144.74 30.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 121.046 -1.033 . . . . 0.0 111.179 173.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.6 tttt . . . . . 0 N--CA 1.43 -1.47 0 C-N-CA 125.615 1.566 . . . . 0.0 112.48 167.013 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.9 t0 . . . . . 0 N--CA 1.429 -1.503 0 CA-C-O 121.134 0.493 . . . . 0.0 110.745 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -119.93 137.72 53.88 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.42 1.488 . . . . 0.0 108.993 -174.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.08 140.76 28.28 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-O 122.827 1.298 . . . . 0.0 109.739 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -100.52 112.53 24.91 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.297 1.839 . . . . 0.0 108.039 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.8 t -103.81 102.08 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 O-C-N 120.608 -1.307 . . . . 0.0 108.769 -172.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.73 102.1 14.85 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 167.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.8 tp -120.03 138.02 53.76 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.701 1.201 . . . . 0.0 110.002 -172.69 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.17 122.3 43.37 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.27 -1.519 . . . . 0.0 109.486 173.429 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -71.42 171.51 11.14 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.289 -1.507 . . . . 0.0 114.408 177.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.2 t -97.03 -149.81 0.33 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.711 -1.243 . . . . 0.0 108.287 169.381 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.39 74.67 3.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.03 -2.294 . . . . 0.0 112.571 -175.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.36 -4.8 77.38 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.531 1.539 . . . . 0.0 115.509 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.2 t -121.57 135.83 54.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.104 -1.233 . . . . 0.0 112.015 -173.472 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.3 mt -103.92 -55.31 2.4 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.851 1.66 . . . . 0.0 110.113 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.0 30.03 0.59 Allowed Glycine 0 N--CA 1.431 -1.693 0 C-N-CA 125.369 1.462 . . . . 0.0 112.56 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.454 HD12 HD13 ' A' ' 85' ' ' LEU . 11.1 pt -125.95 141.44 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 CA-C-N 118.586 1.193 . . . . 0.0 113.477 -163.401 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.2 m -129.47 138.13 51.23 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.375 1.07 . . . . 0.0 109.005 158.24 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.4 m -118.34 169.58 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.525 0 C-N-CA 124.949 1.299 . . . . 0.0 112.49 -174.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.25 169.84 18.53 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 172.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 133.41 -147.94 19.19 Favored Glycine 0 N--CA 1.428 -1.836 0 O-C-N 120.572 -1.33 . . . . 0.0 115.53 165.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.17 172.26 24.17 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.43 1.014 . . . . 0.0 112.998 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.1 t . . . . . 0 N--CA 1.429 -1.501 0 C-N-CA 124.828 1.251 . . . . 0.0 112.917 -172.454 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.751 0 N-CA-C 115.932 1.133 . . . . 0.0 115.932 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 mm -99.17 129.18 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.833 2.053 . . . . 0.0 107.819 175.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -126.71 158.07 37.42 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.903 -1.123 . . . . 0.0 109.521 -174.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.9 t -75.95 117.36 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 O-C-N 121.023 -1.048 . . . . 0.0 111.377 174.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.8 tttp -88.33 -45.12 10.28 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.871 1.268 . . . . 0.0 110.83 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.0 163.19 39.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 121.252 -0.905 . . . . 0.0 108.995 173.245 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 tp -117.95 121.73 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 170.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.64 124.08 87.73 Favored Pre-proline 0 N--CA 1.429 -1.482 0 C-N-CA 126.076 1.75 . . . . 0.0 113.749 -165.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -59.26 127.42 23.93 Favored 'Trans proline' 0 C--N 1.299 -2.057 0 C-N-CA 122.778 2.319 . . . . 0.0 114.904 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.281 11.7 mptt 82.07 21.76 0.27 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 128.538 2.735 . . . . 0.0 112.649 -177.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.91 153.39 29.57 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.962 -1.711 . . . . 0.0 113.711 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.93 -54.87 13.69 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 126.464 1.906 . . . . 0.0 113.877 166.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -54.08 45.97 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 127.576 2.35 . . . . 0.0 112.265 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -40.95 -59.58 1.41 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 177.172 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.0 t -70.2 -29.99 66.98 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -66.2 -52.5 47.39 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.751 -1.218 . . . . 0.0 113.44 -172.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.11 21.7 9.86 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 120.663 -1.273 . . . . 0.0 115.946 158.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -85.15 -36.87 20.79 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.716 -1.461 . . . . 0.0 109.557 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.9 mt -100.48 124.73 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 125.781 1.632 . . . . 0.0 109.098 -176.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.497 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 3.4 t-80 -142.36 -175.39 4.43 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.117 1.437 . . . . 0.0 112.274 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.4 ttpp -68.95 123.56 21.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.027 -1.67 . . . . 0.0 113.307 -170.356 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.71 3.7 62.37 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.418 -0.801 . . . . 0.0 114.492 -178.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -78.72 156.38 28.94 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 119.423 1.612 . . . . 0.0 111.743 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -102.5 123.36 46.11 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.208 -1.558 . . . . 0.0 110.446 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 7.4 t -88.86 119.23 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 O-C-N 120.371 -1.456 . . . . 0.0 110.814 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 98.2 mt -94.09 -46.32 7.17 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.01 -1.056 . . . . 0.0 112.118 -175.286 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.37 144.01 25.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.855 -1.153 . . . . 0.0 112.484 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.816 HG11 HG21 ' A' ' 84' ' ' THR . 2.9 p -113.42 111.71 37.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 C-N-CA 125.938 1.695 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.9 t30 57.23 34.75 25.25 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.771 -1.83 . . . . 0.0 113.674 170.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.19 -28.56 13.32 Favored Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.314 1.435 . . . . 0.0 114.336 -172.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -98.07 129.45 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.235 2.017 . . . . 0.0 110.627 -163.201 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 26.6 p -71.37 132.33 44.68 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.164 -1.585 . . . . 0.0 112.607 -177.224 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 47.9 mt -99.45 35.96 1.86 Allowed 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.498 -1.376 . . . . 0.0 111.912 -178.216 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -89.67 144.26 26.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.714 -1.241 . . . . 0.0 109.486 167.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.26 -32.07 2.31 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.914 -1.117 . . . . 0.0 114.778 -176.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.66 152.28 44.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -175.364 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.8 p -91.76 175.36 6.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.985 -1.072 . . . . 0.0 112.012 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -58.64 -46.8 86.32 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.514 1.525 . . . . 0.0 112.249 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 30.0 tttp -54.69 -47.93 73.07 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 115.574 1.694 . . . . 0.0 115.574 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -58.67 -47.5 84.29 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.667 1.187 . . . . 0.0 113.652 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -61.67 -38.74 88.89 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.613 1.565 . . . . 0.0 114.22 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.22 -49.03 76.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 C-N-CA 124.866 1.266 . . . . 0.0 111.251 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -68.32 -30.13 69.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.771 -1.205 . . . . 0.0 112.168 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' THR . . . . . 0.816 HG21 HG11 ' A' ' 68' ' ' VAL . 38.8 m -64.33 -43.41 94.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.199 1.4 . . . . 0.0 114.691 167.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.454 HD13 HD12 ' A' ' 27' ' ' ILE . 67.3 mt -63.63 -37.03 85.8 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.074 -1.641 . . . . 0.0 114.171 173.522 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -67.09 -31.79 72.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.552 -1.342 . . . . 0.0 113.401 170.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -85.26 51.09 2.09 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.852 1.661 . . . . 0.0 112.1 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 p -106.59 148.48 28.24 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.442 -1.411 . . . . 0.0 109.867 171.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.66 -164.22 36.37 Favored Glycine 0 N--CA 1.43 -1.737 0 C-N-CA 123.778 0.704 . . . . 0.0 111.75 168.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -69.7 -46.27 66.38 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.732 -1.452 . . . . 0.0 114.65 -177.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 47.3 t -103.95 118.7 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 CA-C-O 122.437 1.113 . . . . 0.0 108.761 176.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.2 t -111.6 119.17 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 127.928 2.491 . . . . 0.0 109.926 -164.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -104.3 91.89 4.11 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.772 -1.205 . . . . 0.0 113.308 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -91.5 160.78 15.26 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.046 -2.284 . . . . 0.0 113.694 179.035 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.8 tp -127.0 128.06 45.77 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 161.324 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.32 158.48 44.32 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.989 -1.069 . . . . 0.0 112.213 176.72 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -110.07 140.71 43.83 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.047 1.339 . . . . 0.0 108.7 172.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.8 tptm . . . . . 0 N--CA 1.43 -1.434 0 C-N-CA 124.832 1.253 . . . . 0.0 111.476 -177.31 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 42.7 t0 . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.3 p -120.83 150.14 41.48 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.48 -1.388 . . . . 0.0 110.985 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' A' ' 96' ' ' LEU . 2.2 p90 -147.4 136.26 22.11 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.307 1.527 . . . . 0.0 109.412 172.679 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 21.4 mp0 -89.13 128.01 35.75 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 126.899 2.08 . . . . 0.0 108.581 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 74.6 t -109.82 94.87 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.497 0 O-C-N 121.036 -1.04 . . . . 0.0 108.252 -174.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -90.54 102.78 15.52 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-O 123.399 1.571 . . . . 0.0 109.61 169.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.6 tp -124.75 143.41 50.8 Favored 'General case' 0 N--CA 1.431 -1.395 0 C-N-CA 124.597 1.159 . . . . 0.0 110.678 -169.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.95 39.53 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.061 -1.649 . . . . 0.0 109.642 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -69.68 153.21 43.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.537 -1.352 . . . . 0.0 112.231 172.043 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.0 t -141.28 133.95 28.64 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 174.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 33.6 t0 50.93 39.48 22.83 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.959 2.104 . . . . 0.0 113.142 -172.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.13 3.05 55.52 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 120.11 -1.619 . . . . 0.0 116.898 -176.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 84.7 p -112.82 144.49 42.27 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 118.895 1.348 . . . . 0.0 114.03 -167.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 54.0 mt -102.84 -63.15 1.19 Allowed 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.92 1.288 . . . . 0.0 109.598 169.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.03 11.21 10.2 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 119.371 -2.081 . . . . 0.0 115.208 172.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 pt -100.56 131.58 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 CA-C-N 118.922 1.361 . . . . 0.0 111.188 174.179 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -110.8 121.61 45.76 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.055 -1.028 . . . . 0.0 108.7 168.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.9 m -105.49 165.68 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.702 1.201 . . . . 0.0 113.02 -173.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -149.25 162.53 39.83 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.328 1.451 . . . . 0.0 109.737 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.77 -135.14 12.45 Favored Glycine 0 N--CA 1.431 -1.698 0 CA-C-O 122.658 1.143 . . . . 0.0 115.853 163.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.55 172.6 44.27 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 121.253 -1.145 . . . . 0.0 113.407 -176.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.43 -1.443 0 N-CA-C 115.973 1.842 . . . . 0.0 115.973 -174.391 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.728 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -100.22 123.24 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.5 m-85 -123.59 157.21 34.24 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 121.059 -1.026 . . . . 0.0 110.667 -175.643 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.44 125.53 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 O-C-N 120.573 -1.329 . . . . 0.0 112.038 168.481 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -95.75 -35.62 11.47 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 120.397 -1.44 . . . . 0.0 112.457 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.51 158.03 36.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.854 -1.154 . . . . 0.0 112.221 -176.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -116.69 123.05 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.59 1.556 . . . . 0.0 109.881 175.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.2 mm -77.01 119.49 77.72 Favored Pre-proline 0 N--CA 1.43 -1.431 0 C-N-CA 125.93 1.692 . . . . 0.0 113.714 -176.227 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.74 124.39 12.27 Favored 'Trans proline' 0 C--N 1.299 -2.06 0 CA-C-N 124.744 2.73 . . . . 0.0 113.981 -172.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 10.5 mmmm 79.07 29.67 0.35 Allowed 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 129.334 3.054 . . . . 0.0 113.587 -175.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 162.66 38.14 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.507 -1.37 . . . . 0.0 113.102 162.266 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.08 -60.01 3.15 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 126.947 2.099 . . . . 0.0 114.911 166.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.32 -46.09 88.27 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 129.517 3.127 . . . . 0.0 112.391 -179.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -43.31 -65.67 0.46 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 171.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.5 t -67.72 -26.99 66.43 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -175.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.89 -56.82 16.99 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.265 -1.522 . . . . 0.0 111.8 174.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.19 2.57 64.03 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.72 -1.238 . . . . 0.0 114.733 157.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 65.0 mtt85 -56.04 -44.11 78.47 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.025 1.33 . . . . 0.0 110.793 159.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.5 mt -82.03 131.09 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 127.698 2.399 . . . . 0.0 111.759 -176.193 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 11.6 m-70 -122.72 155.44 36.45 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 128.314 2.646 . . . . 0.0 109.228 174.724 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 pttt -73.15 106.81 5.16 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.931 -1.73 . . . . 0.0 111.631 173.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.29 -31.35 2.06 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-O 119.16 -0.8 . . . . 0.0 113.733 -165.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.371 4.0 p30 -80.24 159.44 25.9 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 120.109 1.955 . . . . 0.0 116.112 -166.449 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.4 ttt85 -110.02 125.85 53.34 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.562 -1.336 . . . . 0.0 112.151 -162.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.5 t -82.11 135.07 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.488 -1.383 . . . . 0.0 111.173 -173.292 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 95.9 mt -103.83 -54.01 2.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.126 -0.983 . . . . 0.0 111.213 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.78 146.06 26.14 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.189 -1.569 . . . . 0.0 111.927 -174.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.0 t -114.04 107.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 123.704 0.802 . . . . 0.0 108.964 175.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.5 t30 61.81 45.17 7.93 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.967 2.107 . . . . 0.0 113.86 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.35 -24.25 14.89 Favored Glycine 0 N--CA 1.431 -1.68 0 O-C-N 121.136 -0.977 . . . . 0.0 113.571 -174.49 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.3 t -87.08 111.66 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.482 -1.599 . . . . 0.0 109.981 -175.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 p -69.31 128.62 37.24 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.721 1.209 . . . . 0.0 111.837 178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 50.5 mt -86.03 52.18 2.41 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.168 -1.583 . . . . 0.0 111.869 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -78.9 121.16 24.51 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.592 -1.942 . . . . 0.0 113.48 -169.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.64 24.0 65.72 Favored Glycine 0 N--CA 1.431 -1.679 0 C-N-CA 124.873 1.225 . . . . 0.0 114.753 -176.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.96 42.34 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -170.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 74.6 p -91.65 170.5 9.87 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 124.688 1.195 . . . . 0.0 111.096 171.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 7.3 t-160 -58.44 -58.14 9.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.357 1.463 . . . . 0.0 114.41 -175.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -58.02 -29.74 65.55 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 116.169 1.914 . . . . 0.0 116.169 176.386 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.52 -52.18 66.46 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.411 1.484 . . . . 0.0 113.017 178.587 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.64 -45.13 89.93 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.066 1.746 . . . . 0.0 113.624 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.8 t -64.53 -48.73 83.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.146 1.378 . . . . 0.0 111.27 -179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.3 mm-40 -65.75 -33.02 74.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.0 m -67.52 -45.37 75.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.525 1.93 . . . . 0.0 112.413 174.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.4 mt -58.89 -42.85 90.53 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 124.791 1.236 . . . . 0.0 113.508 172.216 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -69.97 -14.72 62.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 115.26 1.578 . . . . 0.0 115.26 178.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -95.65 36.63 1.26 Allowed 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.478 -2.014 . . . . 0.0 112.023 172.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 77.4 p -107.27 144.8 33.56 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.249 -1.532 . . . . 0.0 110.651 172.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.53 23.66 Favored Glycine 0 N--CA 1.429 -1.774 0 C-N-CA 123.965 0.793 . . . . 0.0 112.514 -177.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -56.2 23.94 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.3 t -101.49 126.29 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 CA-C-O 122.282 1.039 . . . . 0.0 109.561 172.117 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 67.4 t -115.45 137.33 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 129.664 3.186 . . . . 0.0 108.662 -166.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 13.5 t-160 -124.22 106.33 10.21 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.505 -1.372 . . . . 0.0 111.394 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 18.7 mt -97.06 160.17 14.5 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 119.356 -2.09 . . . . 0.0 113.239 170.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 64.9 tp -127.96 131.87 49.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 161.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.567 HD11 ' CE2' ' A' ' 14' ' ' PHE . 2.0 pp -148.19 169.03 20.94 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.933 -1.104 . . . . 0.0 112.833 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -117.01 143.46 45.71 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.576 1.55 . . . . 0.0 111.371 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.3 tptm . . . . . 0 N--CA 1.429 -1.52 0 C-N-CA 126.921 2.088 . . . . 0.0 113.386 -175.883 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.8 t0 . . . . . 0 N--CA 1.43 -1.454 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 p -106.96 149.53 27.41 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.13 -0.982 . . . . 0.0 112.524 -177.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -145.01 132.78 21.09 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.914 -1.116 . . . . 0.0 108.178 -176.044 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.87 120.01 28.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.39 1.476 . . . . 0.0 108.255 169.175 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 84.6 t -116.44 100.87 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 124.627 1.171 . . . . 0.0 109.328 -168.149 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -90.18 104.92 17.44 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.352 -1.468 . . . . 0.0 108.999 170.299 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.2 tp -119.95 130.67 54.89 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 124.91 1.284 . . . . 0.0 110.543 -169.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 146.12 28.54 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.722 -1.861 . . . . 0.0 109.64 173.103 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -67.93 166.02 16.55 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.933 1.827 . . . . 0.0 115.933 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 28.6 p -132.23 130.73 41.35 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.681 1.592 . . . . 0.0 108.163 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 46.6 44.43 13.5 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.925 2.09 . . . . 0.0 114.905 -175.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.88 -14.63 30.77 Favored Glycine 0 N--CA 1.429 -1.818 0 O-C-N 119.855 -1.778 . . . . 0.0 117.041 178.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 t -121.84 175.18 6.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 119.716 1.758 . . . . 0.0 112.113 -174.489 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 94.2 mt -99.96 -60.58 1.5 Allowed 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.702 1.201 . . . . 0.0 110.46 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.15 44.04 0.38 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.15 -1.594 . . . . 0.0 111.222 174.243 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 tt -144.06 147.86 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.068 1.413 . . . . 0.0 110.985 -172.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -124.57 117.69 24.89 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 125.071 1.348 . . . . 0.0 108.532 170.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 m -95.93 166.17 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 124.496 1.118 . . . . 0.0 112.726 -178.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.1 t -151.85 172.43 16.2 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.472 1.509 . . . . 0.0 110.247 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.47 -144.3 16.98 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.256 -0.902 . . . . 0.0 113.74 172.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.82 162.52 23.11 Favored Glycine 0 N--CA 1.43 -1.722 0 CA-C-O 122.489 1.049 . . . . 0.0 112.677 -177.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.43 -1.474 0 C-N-CA 125.497 1.519 . . . . 0.0 114.508 -174.84 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.711 0 CA-C-O 121.426 0.459 . . . . 0.0 113.564 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.5 mm -90.98 114.22 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.511 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 171.09 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -113.93 151.84 31.68 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.315 1.055 . . . . 0.0 110.012 -171.069 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.9 t -76.18 120.58 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.625 -1.297 . . . . 0.0 110.357 169.472 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -93.72 -48.59 6.25 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.707 -1.246 . . . . 0.0 110.587 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.43 157.99 43.92 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.491 -0.755 . . . . 0.0 109.51 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.533 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.5 tp -124.47 123.92 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.4 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -77.33 122.46 86.12 Favored Pre-proline 0 N--CA 1.43 -1.446 0 CA-C-O 116.454 -1.736 . . . . 0.0 112.817 -170.304 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -58.11 128.6 29.39 Favored 'Trans proline' 0 N--CA 1.434 -1.991 0 CA-C-N 124.39 2.604 . . . . 0.0 115.797 -174.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.296 52.1 mtmt 76.07 17.52 2.12 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.283 2.233 . . . . 0.0 113.629 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.96 160.25 38.62 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.386 -1.446 . . . . 0.0 111.705 170.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.58 -56.47 8.32 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.14 -1.8 . . . . 0.0 115.837 168.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.0 -44.51 95.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.567 1.947 . . . . 0.0 112.399 -177.661 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.533 ' HG2' HG23 ' A' ' 47' ' ' ILE . 7.4 tm-20 -51.06 -65.21 0.6 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.297 1.592 . . . . 0.0 115.297 167.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 94.1 p -65.66 -26.94 68.02 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -169.269 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -55.47 -57.77 10.52 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.977 1.711 . . . . 0.0 113.228 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.63 -9.91 25.89 Favored Glycine 0 N--CA 1.43 -1.741 0 O-C-N 120.822 -1.174 . . . . 0.0 114.643 159.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.4 mtt180 -64.61 -32.4 74.05 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.763 1.225 . . . . 0.0 111.454 167.79 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 mt -96.91 124.76 49.89 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 C-N-CA 125.932 1.693 . . . . 0.0 110.762 -177.053 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 10.0 m80 -128.77 166.85 18.21 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.391 1.477 . . . . 0.0 109.487 170.168 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.0 ptpt -68.06 132.99 48.24 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.125 -1.609 . . . . 0.0 111.661 174.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 99.36 -7.9 60.19 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.026 -1.046 . . . . 0.0 114.524 -171.145 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -78.89 156.27 28.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-N 119.58 1.69 . . . . 0.0 112.41 -178.027 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -114.36 124.27 51.54 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.743 -1.223 . . . . 0.0 110.725 -168.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 10.7 t -87.67 131.29 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.296 -1.502 . . . . 0.0 110.162 -174.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.64 -44.8 5.46 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.684 -1.26 . . . . 0.0 110.307 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.32 143.22 25.67 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.598 -0.689 . . . . 0.0 110.814 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 39.9 t -124.93 124.06 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 173.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 63.82 33.79 12.42 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.966 1.707 . . . . 0.0 114.214 170.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.99 -15.76 62.75 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 120.693 -1.254 . . . . 0.0 113.698 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.38 116.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 121.554 -0.968 . . . . 0.0 110.202 -173.349 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -73.98 130.71 40.41 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.778 -1.202 . . . . 0.0 110.831 176.579 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.5 mt -85.48 44.2 1.08 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.866 -1.147 . . . . 0.0 114.065 -165.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -80.85 133.04 35.52 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.996 -2.315 . . . . 0.0 112.046 -177.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.53 13.07 67.78 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.488 -1.382 . . . . 0.0 114.793 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.31 142.72 48.85 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.767 1.395 . . . . 0.0 114.767 -178.553 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 36.0 p -90.56 178.18 6.16 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.013 1.725 . . . . 0.0 110.061 171.367 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -60.31 -48.98 79.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.837 -1.164 . . . . 0.0 112.971 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.0 mmtt -54.58 -38.51 66.78 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 126.365 1.866 . . . . 0.0 115.523 175.689 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -51.05 71.34 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.223 1.809 . . . . 0.0 113.187 -177.751 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.58 -34.05 73.6 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.516 1.527 . . . . 0.0 113.386 176.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.05 -53.44 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.375 0 C-N-CA 124.768 1.227 . . . . 0.0 110.127 178.45 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -60.79 -39.27 88.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 121.22 -0.925 . . . . 0.0 112.947 178.132 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 69.7 m -63.65 -40.64 97.37 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 124.828 1.251 . . . . 0.0 113.605 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 64.6 mt -72.0 -37.09 69.9 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.764 -1.21 . . . . 0.0 113.748 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 27.3 mtp180 -64.02 -47.35 80.59 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.188 -1.57 . . . . 0.0 112.793 176.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -88.14 58.97 5.05 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.716 1.246 . . . . 0.0 111.712 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.8 p -105.11 157.02 17.54 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.895 2.078 . . . . 0.0 110.052 176.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.26 -146.21 9.35 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.509 -1.37 . . . . 0.0 111.741 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.2 tt0 -71.85 -56.64 5.36 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.604 -1.527 . . . . 0.0 113.139 170.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 14.2 p -100.53 140.02 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.961 1.304 . . . . 0.0 109.316 179.26 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 72.5 t -124.22 122.85 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 127.496 2.318 . . . . 0.0 108.273 -170.186 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.8 m170 -100.52 101.36 12.27 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.058 -1.651 . . . . 0.0 110.561 177.179 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 8.7 mt -92.87 160.39 14.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.862 -1.774 . . . . 0.0 111.655 172.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.29 131.21 46.92 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 157.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.7 pp -143.4 166.85 23.62 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.993 -1.692 . . . . 0.0 112.312 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -112.73 146.24 39.11 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.406 1.882 . . . . 0.0 108.589 175.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.43 -1.427 0 O-C-N 120.784 -1.197 . . . . 0.0 110.57 176.524 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.6 t0 . . . . . 0 N--CA 1.43 -1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.7 p -97.43 162.32 13.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 122.11 0.957 . . . . 0.0 112.534 -176.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -144.82 138.19 26.9 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -93.66 115.38 27.83 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 126.301 1.84 . . . . 0.0 107.149 166.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.403 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 32.7 t -111.87 99.78 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -175.683 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -90.05 100.09 12.98 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.351 -1.468 . . . . 0.0 109.593 176.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.0 tp -116.59 136.91 52.59 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.744 1.218 . . . . 0.0 111.032 -162.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.66 145.81 29.51 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.443 -1.41 . . . . 0.0 109.006 169.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -70.81 141.66 51.34 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.924 -1.11 . . . . 0.0 113.677 174.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.9 t -137.95 142.7 40.53 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.426 -1.421 . . . . 0.0 109.619 174.164 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.1 t0 54.55 34.71 21.84 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.107 2.163 . . . . 0.0 113.906 -177.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.55 63.26 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 124.877 1.227 . . . . 0.0 115.948 -174.869 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 71.7 p -121.32 142.41 49.99 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-N 118.886 1.343 . . . . 0.0 114.033 -171.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.4 mt -89.72 -61.61 1.65 Allowed 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 159.087 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.79 48.19 0.55 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 118.98 -2.325 . . . . 0.0 112.711 163.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.3 tt -145.94 150.11 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.334 1.064 . . . . 0.0 110.006 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.4 t -122.94 125.66 45.74 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 164.28 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 m -106.15 157.74 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 125.338 1.455 . . . . 0.0 110.025 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.9 t -141.95 170.34 15.9 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.094 0.958 . . . . 0.0 109.71 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -132.09 10.96 Favored Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 123.885 0.755 . . . . 0.0 113.228 173.448 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.45 -179.83 42.07 Favored Glycine 0 N--CA 1.431 -1.696 0 CA-C-O 122.46 1.033 . . . . 0.0 111.747 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.429 -1.499 0 O-C-N 120.923 -1.339 . . . . 0.0 113.274 -169.243 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.784 0 N-CA-C 115.401 0.92 . . . . 0.0 115.401 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.2 mm -103.7 117.56 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.716 1.607 . . . . 0.0 107.373 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -124.98 150.0 47.13 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.795 -1.19 . . . . 0.0 110.171 -168.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 32.2 t -75.66 122.31 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.456 -1.402 . . . . 0.0 113.201 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -89.3 -56.48 3.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.363 1.065 . . . . 0.0 109.686 173.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.46 156.19 43.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.117 -0.989 . . . . 0.0 111.454 -173.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.63 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -119.2 117.97 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.06 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 28.7 mm -76.89 125.06 87.49 Favored Pre-proline 0 N--CA 1.43 -1.451 0 CA-C-O 115.391 -2.242 . . . . 0.0 113.0 -165.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -53.33 136.95 64.08 Favored 'Trans proline' 0 C--N 1.3 -1.979 0 C-N-CA 123.628 2.886 . . . . 0.0 116.899 -171.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.277 6.6 mtpm? 51.67 26.1 3.21 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 119.168 3.025 . . . . 0.0 119.168 -169.61 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.31 169.65 54.91 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 118.995 -2.316 . . . . 0.0 113.201 170.083 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.21 -60.86 2.55 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.121 1.768 . . . . 0.0 114.136 165.228 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.9 -45.48 92.33 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 129.01 2.924 . . . . 0.0 112.646 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.5 tm-20 -43.66 -68.25 0.21 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.826 1.65 . . . . 0.0 114.818 166.143 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 74.9 m -69.89 -14.84 62.93 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 116.367 1.988 . . . . 0.0 116.367 -174.136 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -61.38 -55.72 28.4 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.82 1.248 . . . . 0.0 111.751 170.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.29 4.7 77.1 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 120.301 -1.5 . . . . 0.0 115.699 167.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -75.17 -38.3 60.91 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.243 -1.739 . . . . 0.0 110.326 163.203 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.5 mt -77.59 120.63 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 126.352 1.861 . . . . 0.0 111.122 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -117.99 166.09 12.94 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 125.895 1.678 . . . . 0.0 111.153 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 48.0 tttm -63.98 127.3 30.81 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 119.966 -1.709 . . . . 0.0 111.936 171.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.59 0.94 68.98 Favored Glycine 0 N--CA 1.431 -1.662 0 O-C-N 121.29 -0.882 . . . . 0.0 113.992 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.06 153.47 43.59 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 119.178 1.489 . . . . 0.0 112.792 179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 65.1 ttt-85 -105.46 122.06 45.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.832 0.825 . . . . 0.0 109.299 -176.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.4 t -82.89 134.95 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.751 -1.218 . . . . 0.0 109.81 -177.194 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.2 mp -105.64 -50.08 3.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.856 -1.152 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.15 151.2 32.74 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.369 -1.457 . . . . 0.0 111.88 -175.696 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.97 HG11 HG21 ' A' ' 84' ' ' THR . 3.4 p -118.06 110.21 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 122.379 1.085 . . . . 0.0 112.393 172.058 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 55.26 39.68 31.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.943 -1.723 . . . . 0.0 114.913 164.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.96 -13.42 60.55 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-O 119.324 -0.709 . . . . 0.0 114.5 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.9 t -102.17 111.12 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.614 2.207 . . . . 0.0 109.302 -176.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 43.6 m -76.27 119.73 20.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.213 -1.554 . . . . 0.0 110.625 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 87.2 mt -92.41 35.47 1.01 Allowed 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.66 -1.275 . . . . 0.0 112.223 -167.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -88.61 91.19 8.71 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 119.619 -1.926 . . . . 0.0 112.52 -168.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 96.93 10.55 54.99 Favored Glycine 0 N--CA 1.429 -1.812 0 C-N-CA 125.202 1.382 . . . . 0.0 112.157 -171.172 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.85 157.7 37.4 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-O 122.532 1.158 . . . . 0.0 113.535 171.356 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 41.5 p -83.49 172.91 11.94 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.255 -1.528 . . . . 0.0 113.169 -175.173 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-80 -58.41 -46.17 86.96 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.386 1.474 . . . . 0.0 113.613 170.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -57.96 -43.06 86.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 172.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.91 -55.15 36.04 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 114.432 1.271 . . . . 0.0 114.432 -175.136 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.3 -43.3 64.41 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 116.284 1.957 . . . . 0.0 116.284 171.522 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.57 -52.04 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.756 -1.215 . . . . 0.0 111.461 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -64.64 -30.63 71.65 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.19 -0.944 . . . . 0.0 111.886 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' THR . . . . . 0.97 HG21 HG11 ' A' ' 68' ' ' VAL . 39.4 m -63.87 -51.41 64.7 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.186 1.394 . . . . 0.0 113.509 170.582 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.6 mt -60.42 -37.01 79.51 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 120.565 1.53 . . . . 0.0 113.789 176.275 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -61.93 -44.41 96.83 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.493 1.517 . . . . 0.0 113.763 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -94.54 55.91 2.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.539 1.536 . . . . 0.0 112.682 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.45 145.36 31.87 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.533 -1.355 . . . . 0.0 109.983 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.02 -141.32 4.8 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.658 -1.276 . . . . 0.0 111.889 176.579 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -70.69 -58.31 3.78 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.383 -1.657 . . . . 0.0 113.791 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 t -109.57 137.76 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.533 1.133 . . . . 0.0 110.947 -176.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.6 t -125.13 122.56 63.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 C-N-CA 128.924 2.89 . . . . 0.0 110.911 -173.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.0 t-160 -100.81 95.9 6.94 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.139 -2.226 . . . . 0.0 113.085 176.33 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.403 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 23.5 mt -88.2 154.83 20.12 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 118.92 -2.363 . . . . 0.0 113.328 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 39.0 tp -127.25 135.46 50.64 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 163.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -150.63 168.91 22.89 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.889 -1.132 . . . . 0.0 111.942 175.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.92 141.68 47.63 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.078 2.151 . . . . 0.0 109.142 172.487 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.453 0 C-N-CA 125.13 1.372 . . . . 0.0 112.305 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.5 t0 . . . . . 0 N--CA 1.431 -1.404 0 CA-C-O 121.276 0.56 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.86 139.61 44.73 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.364 -1.46 . . . . 0.0 110.325 -176.48 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -146.52 154.99 42.18 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-O 123.037 1.398 . . . . 0.0 110.298 174.172 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -108.6 142.24 39.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.893 1.677 . . . . 0.0 107.362 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.5 t -122.63 106.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.684 1.193 . . . . 0.0 108.648 -171.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -95.16 97.78 10.15 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 121.002 -1.061 . . . . 0.0 109.275 169.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.9 tp -119.79 129.93 54.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 123.787 0.835 . . . . 0.0 112.601 -168.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.71 123.55 44.08 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.365 -1.46 . . . . 0.0 109.452 171.259 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -69.61 114.83 8.19 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.507 1.523 . . . . 0.0 113.183 -177.06 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.3 t -96.53 129.67 43.86 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.323 -1.486 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.6 t70 41.48 49.41 3.55 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.337 2.655 . . . . 0.0 114.917 -175.303 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.29 10.61 70.01 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 117.336 1.695 . . . . 0.0 117.336 -178.34 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 85.3 p -120.97 129.12 53.3 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 119.86 1.83 . . . . 0.0 113.977 -175.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 82.5 mt -85.8 -58.31 2.7 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.823 -1.173 . . . . 0.0 111.077 168.184 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.37 23.05 4.25 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 119.4 -2.062 . . . . 0.0 113.598 176.109 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 pt -122.41 141.28 43.44 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 CA-C-O 123.092 1.425 . . . . 0.0 113.348 -174.299 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.9 t -113.45 126.61 55.53 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 159.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 m -115.59 159.54 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.03 1.332 . . . . 0.0 110.749 -177.537 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.21 166.11 28.01 Favored 'General case' 0 N--CA 1.428 -1.532 0 C-N-CA 124.862 1.265 . . . . 0.0 109.424 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.35 -143.0 16.79 Favored Glycine 0 N--CA 1.429 -1.815 0 O-C-N 120.155 -1.591 . . . . 0.0 114.674 160.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 103.56 161.63 25.09 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.548 1.07 . . . . 0.0 111.514 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.43 -1.45 0 O-C-N 120.547 -1.56 . . . . 0.0 114.068 -171.405 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.748 0 CA-C-O 121.639 0.577 . . . . 0.0 114.128 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.0 mm -84.97 129.87 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.923 1.689 . . . . 0.0 109.104 174.684 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -122.89 150.37 43.0 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.166 -0.959 . . . . 0.0 109.271 -175.683 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -77.77 127.7 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.433 -1.417 . . . . 0.0 112.019 170.106 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.7 ttpp -94.91 -44.1 7.88 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.704 -1.247 . . . . 0.0 111.747 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.91 153.85 33.86 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.878 -1.139 . . . . 0.0 112.926 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.271 1.0 OUTLIER -102.94 118.14 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 CA-C-O 122.644 1.211 . . . . 0.0 110.038 168.822 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.9 mm -76.38 124.11 87.98 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 126.436 1.894 . . . . 0.0 112.366 -173.18 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -56.29 129.96 37.62 Favored 'Trans proline' 0 N--CA 1.434 -1.992 0 C-N-CA 122.835 2.357 . . . . 0.0 115.166 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.8 mtmt 75.4 22.34 1.67 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.265 1.826 . . . . 0.0 114.771 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.44 167.17 42.65 Favored Glycine 0 N--CA 1.43 -1.743 0 O-C-N 119.722 -1.861 . . . . 0.0 115.26 169.717 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.63 -63.35 1.15 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.3 98.09 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 129.087 2.955 . . . . 0.0 112.824 -176.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -42.21 -55.72 3.18 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 168.078 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.0 t -68.53 -38.15 80.61 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.74 -51.66 68.01 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 126.067 1.747 . . . . 0.0 112.171 177.458 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.31 1.02 72.6 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.606 -1.309 . . . . 0.0 114.421 159.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -67.87 -44.11 77.82 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.315 1.446 . . . . 0.0 110.498 166.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 36.0 mt -85.64 129.66 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 125.532 1.533 . . . . 0.0 109.8 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.38 167.33 29.09 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.288 1.035 . . . . 0.0 110.961 -171.555 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.0 tttm -50.72 121.41 5.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -178.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.07 7.6 67.83 Favored Glycine 0 N--CA 1.429 -1.804 0 CA-C-O 117.904 -1.498 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.296 1.7 p30 -77.51 152.64 34.02 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-N 120.786 2.293 . . . . 0.0 112.767 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -102.17 120.59 40.7 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -176.323 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.11 128.74 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.077 -1.015 . . . . 0.0 109.768 -176.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.1 mt -99.26 -45.29 5.93 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.435 -1.416 . . . . 0.0 111.446 -175.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.67 145.17 25.67 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.673 -1.267 . . . . 0.0 111.658 -178.449 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.1 t -112.31 108.52 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.051 0.94 . . . . 0.0 109.445 173.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.0 t30 60.08 38.82 20.32 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.879 1.672 . . . . 0.0 114.547 166.243 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -16.21 60.14 Favored Glycine 0 N--CA 1.43 -1.718 0 C-N-CA 125.307 1.432 . . . . 0.0 114.214 -177.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.4 t -97.14 120.68 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 121.008 -1.29 . . . . 0.0 110.58 -176.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.9 t -75.33 133.89 41.15 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.486 -1.384 . . . . 0.0 111.956 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 88.2 mt -88.21 12.62 13.34 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.908 -1.12 . . . . 0.0 113.628 -176.52 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 39.2 mm-40 -64.96 128.43 35.74 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 119.934 -1.729 . . . . 0.0 112.414 173.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.25 -6.57 67.29 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 125.314 1.435 . . . . 0.0 116.115 -176.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.6 149.71 45.37 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 116.953 2.205 . . . . 0.0 116.953 -174.524 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 30.5 p -93.19 -179.61 5.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 125.704 1.602 . . . . 0.0 110.943 171.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -63.91 -50.35 69.07 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.541 -1.349 . . . . 0.0 111.765 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 38.0 mttp -56.46 -39.35 73.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.915 1.45 . . . . 0.0 114.915 175.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -57.37 -54.3 48.41 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 114.51 1.3 . . . . 0.0 114.51 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.51 -36.13 81.97 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 124.63 1.172 . . . . 0.0 113.124 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.6 t -64.18 -51.27 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 120.949 -1.094 . . . . 0.0 110.706 174.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.581 -1.324 . . . . 0.0 113.608 178.113 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 87.8 m -62.87 -51.14 68.14 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.702 2.001 . . . . 0.0 112.874 173.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 74.3 mt -65.84 -32.05 73.35 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.95 -1.719 . . . . 0.0 114.988 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -68.18 -28.46 67.29 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.497 -1.377 . . . . 0.0 111.667 173.062 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -93.25 41.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.215 -1.553 . . . . 0.0 112.543 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -98.88 153.96 18.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.147 -1.596 . . . . 0.0 110.907 172.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -106.78 -138.33 8.93 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 124.777 1.18 . . . . 0.0 110.81 174.028 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -70.05 -66.9 0.54 Allowed 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -177.262 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.3 120.65 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 122.287 1.041 . . . . 0.0 109.256 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 71.3 t -114.54 119.53 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 128.51 2.724 . . . . 0.0 108.966 -167.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.1 t-160 -107.38 88.87 2.83 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.733 -1.229 . . . . 0.0 113.298 -174.204 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.1 mt -92.37 157.13 16.78 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.82 -1.8 . . . . 0.0 113.868 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 55.4 tp -127.47 129.09 46.82 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.743 1.217 . . . . 0.0 108.177 170.21 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.43 161.52 37.83 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-O 122.307 1.051 . . . . 0.0 113.715 179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -120.35 132.07 55.12 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.108 1.363 . . . . 0.0 109.645 175.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.2 tptm . . . . . 0 N--CA 1.43 -1.426 0 O-C-N 120.803 -1.186 . . . . 0.0 113.758 -164.773 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.7 t0 . . . . . 0 N--CA 1.431 -1.417 0 CA-C-O 122.063 0.935 . . . . 0.0 112.661 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 45.0 p -105.41 161.45 14.31 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.211 1.405 . . . . 0.0 113.181 -175.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.22 140.66 25.46 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 167.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -88.54 132.96 34.3 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-O 122.264 1.031 . . . . 0.0 109.471 163.166 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 t -120.8 98.18 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 126.053 1.741 . . . . 0.0 109.727 -169.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.09 102.29 15.04 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.355 -1.466 . . . . 0.0 109.972 174.026 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.519 HD11 ' HA ' ' A' ' 53' ' ' ALA . 0.4 OUTLIER -123.1 128.64 50.38 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.85 -1.156 . . . . 0.0 111.33 -166.805 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.23 125.19 47.83 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 119.967 -1.708 . . . . 0.0 110.354 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 47.9 mtpt -69.69 150.17 47.26 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.517 1.673 . . . . 0.0 115.517 -173.829 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.8 p -102.91 87.39 2.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.852 1.261 . . . . 0.0 109.407 178.466 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.2 t0 45.92 64.83 1.32 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.348 2.659 . . . . 0.0 116.127 -175.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.74 -29.54 9.04 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 121.06 -1.025 . . . . 0.0 113.549 -178.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.9 m -97.42 136.19 38.21 Favored 'General case' 0 N--CA 1.43 -1.445 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -169.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.2 mt -85.26 -60.5 2.02 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.23 1.412 . . . . 0.0 110.691 171.096 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.35 27.58 1.79 Allowed Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.404 -2.06 . . . . 0.0 111.292 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 pt -124.88 155.96 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.555 1.142 . . . . 0.0 110.961 -170.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.6 t -129.8 130.38 45.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 152.575 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -104.82 157.93 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.914 1.286 . . . . 0.0 109.617 -177.52 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -140.33 169.71 17.17 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.717 -1.24 . . . . 0.0 109.111 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.52 -140.29 15.32 Favored Glycine 0 N--CA 1.43 -1.734 0 CA-C-O 122.372 0.984 . . . . 0.0 114.876 164.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.23 157.53 32.23 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 122.235 0.908 . . . . 0.0 112.838 -174.848 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 N--CA 1.431 -1.408 0 N-CA-C 116.951 2.204 . . . . 0.0 116.951 -166.179 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.726 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.8 mm -99.67 119.27 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -120.36 149.79 41.79 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.898 -1.126 . . . . 0.0 110.366 -171.221 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.8 t -76.75 112.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 O-C-N 121.022 -1.049 . . . . 0.0 111.67 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.36 -41.92 11.22 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 120.804 -1.185 . . . . 0.0 112.109 -174.588 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.61 151.99 35.97 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.82 -1.175 . . . . 0.0 110.411 176.734 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.98 119.91 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.5 1.143 . . . . 0.0 108.819 173.136 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.21 125.61 86.3 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 117.042 2.238 . . . . 0.0 117.042 -166.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -53.84 119.08 5.68 Favored 'Trans proline' 0 N--CA 1.434 -2.011 0 C-N-CA 123.645 2.897 . . . . 0.0 116.512 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.255 67.2 mmtt 76.16 30.0 0.73 Allowed 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 128.267 2.627 . . . . 0.0 112.421 -177.231 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 158.07 33.7 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.617 -1.302 . . . . 0.0 111.119 168.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -59.23 3.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.794 -1.416 . . . . 0.0 113.346 166.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.519 ' HA ' HD11 ' A' ' 18' ' ' LEU . . . -63.24 -46.69 85.77 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 128.553 2.741 . . . . 0.0 113.914 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -42.78 -60.62 1.51 Allowed 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 172.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.17 -30.96 69.29 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -60.93 -62.79 1.6 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 125.655 1.582 . . . . 0.0 113.336 -178.079 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.94 6.17 49.42 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 116.987 1.555 . . . . 0.0 116.987 166.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.7 mmt85 -72.33 -37.22 68.93 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-N 119.541 1.67 . . . . 0.0 110.805 164.123 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.9 mt -92.27 124.28 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.922 1.289 . . . . 0.0 108.11 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -145.6 176.86 9.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.387 -1.446 . . . . 0.0 111.619 175.036 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -65.59 126.4 28.23 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.298 1.039 . . . . 0.0 113.023 -170.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.24 80.65 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 121.128 -0.983 . . . . 0.0 115.533 -179.096 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.51 157.97 25.97 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 119.117 1.458 . . . . 0.0 111.911 -177.065 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -105.12 121.66 44.28 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.088 -1.008 . . . . 0.0 111.212 -172.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.43 HG13 HD11 ' A' ' 94' ' ' LEU . 58.9 t -82.31 134.39 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.406 0 C-N-CA 125.727 1.611 . . . . 0.0 107.895 -176.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -119.42 -52.14 2.27 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.96 -1.087 . . . . 0.0 113.715 -167.237 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.85 113.28 4.96 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.626 -1.296 . . . . 0.0 111.138 -173.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -93.59 111.64 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.164 -0.96 . . . . 0.0 108.945 -175.417 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 61.68 36.15 16.66 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.901 2.08 . . . . 0.0 113.407 177.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.39 -9.89 75.34 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 125.001 1.286 . . . . 0.0 113.669 -176.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.4 t -90.94 101.96 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.11 -1.818 . . . . 0.0 109.019 -176.734 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.3 m -66.79 133.21 49.67 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.707 -1.246 . . . . 0.0 112.125 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.2 mt -85.97 45.95 1.27 Allowed 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.293 1.037 . . . . 0.0 112.262 -171.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -74.82 118.99 18.4 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.93 -1.731 . . . . 0.0 112.295 -171.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.52 22.88 75.23 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 124.031 0.824 . . . . 0.0 114.825 -175.143 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.92 145.34 50.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -176.022 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.3 p -90.13 170.84 9.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.872 1.269 . . . . 0.0 110.835 168.177 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.3 t-160 -53.04 -50.58 64.01 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.324 1.85 . . . . 0.0 113.563 175.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -56.42 -43.25 79.23 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.436 1.494 . . . . 0.0 113.776 175.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.75 -47.04 77.67 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.302 1.841 . . . . 0.0 114.198 -175.7 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.31 -45.51 93.15 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.791 1.636 . . . . 0.0 113.176 174.332 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.1 t -66.29 -43.34 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 125.166 1.386 . . . . 0.0 111.717 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -59.37 -43.69 92.85 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.971 -1.08 . . . . 0.0 113.027 177.221 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -72.04 -36.54 69.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.3 1.04 . . . . 0.0 113.724 176.535 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.9 mt -63.81 -35.62 81.21 Favored 'General case' 0 CA--C 1.489 -1.393 0 O-C-N 120.056 -1.653 . . . . 0.0 114.832 171.181 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -71.57 -30.9 66.38 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.134 -1.604 . . . . 0.0 112.308 173.158 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -84.85 50.31 1.9 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.968 1.707 . . . . 0.0 112.628 174.514 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.3 p -106.3 164.28 12.14 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 125.512 1.525 . . . . 0.0 110.923 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -100.6 -168.99 28.81 Favored Glycine 0 N--CA 1.429 -1.786 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 164.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -68.56 -46.76 68.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-N 118.348 1.074 . . . . 0.0 113.71 -175.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.7 t -95.99 118.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 122.864 1.316 . . . . 0.0 109.843 172.01 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.6 t -109.74 118.88 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 127.09 2.156 . . . . 0.0 110.143 -169.269 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -101.7 94.61 5.94 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.505 -1.372 . . . . 0.0 112.249 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.43 HD11 HG13 ' A' ' 65' ' ' VAL . 19.9 tp -96.92 141.47 30.06 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 119.353 -2.092 . . . . 0.0 110.375 173.537 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 9.0 tt -104.98 130.45 53.18 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.97 -1.706 . . . . 0.0 108.823 162.226 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.9 pp -134.74 165.71 24.63 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.911 -1.118 . . . . 0.0 112.58 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -112.92 142.2 45.87 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.172 1.789 . . . . 0.0 109.44 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.429 -1.498 0 O-C-N 120.64 -1.288 . . . . 0.0 111.056 178.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.0 t0 . . . . . 0 N--CA 1.429 -1.51 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.19 146.99 33.25 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.842 1.257 . . . . 0.0 108.758 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.19 140.67 26.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.998 0.904 . . . . 0.0 108.875 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -88.92 136.87 32.78 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-O 122.615 1.198 . . . . 0.0 107.901 161.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.3 t -117.98 114.06 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -104.31 88.76 3.05 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 169.395 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.9 tp -105.18 139.42 39.86 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 121.408 -0.808 . . . . 0.0 109.4 -173.579 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.64 123.63 45.96 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.495 -1.378 . . . . 0.0 107.85 167.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -68.22 128.91 38.27 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.885 2.474 . . . . 0.0 112.427 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.3 p -101.24 125.93 47.92 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.702 -1.248 . . . . 0.0 110.952 -178.113 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.4 t70 56.96 32.66 21.98 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.105 1.762 . . . . 0.0 114.837 177.267 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.57 -5.83 67.45 Favored Glycine 0 N--CA 1.431 -1.675 0 O-C-N 119.744 -1.848 . . . . 0.0 116.269 -179.454 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 74.3 m -112.04 135.23 52.94 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 118.77 1.285 . . . . 0.0 111.549 -171.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.6 mt -86.47 -62.86 1.42 Allowed 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.634 -1.292 . . . . 0.0 109.481 167.134 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.15 51.71 0.43 Allowed Glycine 0 N--CA 1.43 -1.764 0 O-C-N 119.291 -2.131 . . . . 0.0 111.52 170.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tt -142.69 142.7 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.505 0 CA-C-O 122.601 1.191 . . . . 0.0 111.008 -176.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.9 t -117.7 132.53 56.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 124.983 1.313 . . . . 0.0 107.667 167.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.4 m -113.15 164.5 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.681 1.192 . . . . 0.0 111.965 -176.402 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -144.09 172.53 12.76 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.119 1.368 . . . . 0.0 109.435 174.399 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.72 -143.12 16.54 Favored Glycine 0 N--CA 1.429 -1.828 0 C-N-CA 124.541 1.067 . . . . 0.0 115.243 171.188 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.7 -149.67 18.07 Favored Glycine 0 N--CA 1.429 -1.813 0 C-N-CA 124.823 1.201 . . . . 0.0 112.502 178.164 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 N--CA 1.43 -1.426 0 O-C-N 120.578 -1.542 . . . . 0.0 112.57 178.424 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.724 0 CA-C-O 121.386 0.437 . . . . 0.0 112.048 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 15.0 mm -86.6 126.03 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 172.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -122.42 154.02 38.31 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.996 -1.065 . . . . 0.0 109.461 -174.008 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.6 t -76.16 118.86 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.967 -1.083 . . . . 0.0 111.524 175.048 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -88.53 -43.01 11.72 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.919 1.288 . . . . 0.0 110.123 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.66 150.82 23.36 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 121.105 -0.997 . . . . 0.0 109.123 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.551 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.2 117.66 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 170.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.04 117.67 65.67 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 115.296 -2.287 . . . . 0.0 113.369 -161.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -53.74 129.59 34.76 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 124.025 3.15 . . . . 0.0 116.387 -169.401 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 34.9 mttt 77.56 14.71 1.72 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.374 1.87 . . . . 0.0 114.474 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.85 165.81 46.16 Favored Glycine 0 N--CA 1.429 -1.794 0 O-C-N 119.658 -1.901 . . . . 0.0 113.421 173.663 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.31 -58.9 4.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 167.247 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.01 -50.18 71.74 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 128.935 2.894 . . . . 0.0 112.175 -178.6 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.551 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -41.78 -71.04 0.09 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.782 2.033 . . . . 0.0 114.997 166.515 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.9 t -70.02 -14.96 62.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -170.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -64.9 -59.25 4.4 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.743 -1.848 . . . . 0.0 111.946 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 97.78 29.46 7.71 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.046 -1.659 . . . . 0.0 116.682 165.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -92.92 -41.57 9.96 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.392 -1.064 . . . . 0.0 108.864 160.266 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.0 mt -97.88 118.76 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.399 1.88 . . . . 0.0 110.811 -170.141 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -128.59 174.77 9.1 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-O 123.085 1.421 . . . . 0.0 111.438 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -62.41 130.44 45.22 Favored 'General case' 0 N--CA 1.431 -1.387 0 O-C-N 119.579 -1.951 . . . . 0.0 112.583 176.012 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.8 -5.35 61.84 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.712 -0.618 . . . . 0.0 113.697 -177.094 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -77.54 156.37 30.99 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 118.661 1.23 . . . . 0.0 111.641 -176.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -106.93 123.0 47.55 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.579 1.181 . . . . 0.0 110.185 -172.479 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.5 t -85.64 133.68 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 O-C-N 120.217 -1.552 . . . . 0.0 111.089 -175.749 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.47 -51.62 2.88 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.025 -1.047 . . . . 0.0 111.073 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.76 148.26 28.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.958 -1.089 . . . . 0.0 113.137 -176.144 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.97 111.04 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.096 0.958 . . . . 0.0 110.303 173.115 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.6 t30 61.01 39.9 15.87 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.78 2.032 . . . . 0.0 113.323 172.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.07 -27.34 19.66 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 125.309 1.433 . . . . 0.0 113.459 -178.145 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.2 t -84.64 119.8 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 124.95 1.3 . . . . 0.0 110.817 -172.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.2 p -72.23 136.5 46.37 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.462 -1.399 . . . . 0.0 112.296 177.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 35.9 mt -87.95 -6.16 58.17 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.475 -1.391 . . . . 0.0 113.896 -175.213 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -68.71 95.26 0.65 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 119.581 -1.949 . . . . 0.0 115.878 -174.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.96 -15.13 5.14 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.819 1.2 . . . . 0.0 111.151 -177.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.4 158.88 35.52 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.8 p -87.52 179.12 6.61 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.712 -1.242 . . . . 0.0 111.115 172.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -67.21 -46.75 72.91 Favored 'General case' 0 N--CA 1.431 -1.393 0 O-C-N 120.703 -1.248 . . . . 0.0 110.755 173.412 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.7 tppt? -57.4 -40.93 79.28 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.201 1.401 . . . . 0.0 113.972 174.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.8 mm100 -56.93 -51.39 69.32 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.555 1.142 . . . . 0.0 114.076 176.06 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.99 -40.52 96.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.255 1.422 . . . . 0.0 113.519 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -66.17 -45.98 88.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.846 -1.159 . . . . 0.0 111.329 176.002 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -58.81 -40.07 83.04 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.629 -1.294 . . . . 0.0 112.95 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 84.2 m -68.2 -42.63 79.59 Favored 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 125.963 1.705 . . . . 0.0 113.569 178.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 72.9 mt -68.99 -33.55 73.86 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.987 -1.696 . . . . 0.0 114.391 176.724 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -72.35 -33.04 66.99 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 119.644 -1.91 . . . . 0.0 112.675 171.119 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -78.58 44.73 0.54 Allowed 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.854 2.061 . . . . 0.0 114.25 170.402 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -105.79 154.88 19.89 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.224 -2.172 . . . . 0.0 108.842 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.23 -146.56 17.64 Favored Glycine 0 N--CA 1.429 -1.776 0 O-C-N 120.916 -1.115 . . . . 0.0 112.921 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -70.85 -61.06 1.9 Allowed 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.402 1.081 . . . . 0.0 112.312 169.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.72 127.5 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 123.567 1.651 . . . . 0.0 110.244 177.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 73.3 t -120.61 114.17 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.398 1.879 . . . . 0.0 108.772 -162.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 m170 -101.86 94.1 5.64 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.044 0.938 . . . . 0.0 112.144 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -102.37 160.07 14.86 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.638 -1.914 . . . . 0.0 114.297 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.2 tp -128.35 132.8 48.59 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 124.869 1.268 . . . . 0.0 108.505 163.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.08 164.5 31.93 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.929 -1.107 . . . . 0.0 113.371 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -116.97 134.84 54.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 127.021 2.129 . . . . 0.0 107.773 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? . . . . . 0 N--CA 1.43 -1.463 0 O-C-N 120.355 -1.466 . . . . 0.0 112.671 -175.237 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.5 t70 . . . . . 0 N--CA 1.43 -1.462 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.8 p -105.62 150.63 25.24 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-N 120.166 1.348 . . . . 0.0 110.206 166.216 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.611 ' CE1' HD21 ' A' ' 96' ' ' LEU . 27.1 p90 -147.69 164.43 33.58 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.635 1.207 . . . . 0.0 108.918 161.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -126.19 143.0 51.3 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.205 1.802 . . . . 0.0 106.858 -168.074 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.69 111.91 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 O-C-N 120.848 -1.157 . . . . 0.0 109.118 -173.233 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -103.1 94.16 5.39 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 125.762 1.625 . . . . 0.0 107.998 169.447 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.1 tp -123.86 134.36 53.59 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-O 122.208 1.004 . . . . 0.0 113.521 -167.207 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.62 137.37 39.11 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 125.67 1.588 . . . . 0.0 110.352 177.141 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -69.11 162.12 27.63 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 115.19 1.552 . . . . 0.0 115.19 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 39.5 p -130.97 114.91 15.8 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.059 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 26.9 t70 50.65 59.49 4.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.461 1.904 . . . . 0.0 113.844 -177.548 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.65 -36.05 2.83 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.13 -1.606 . . . . 0.0 115.663 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 61.5 m -106.38 149.31 27.12 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.346 1.458 . . . . 0.0 112.059 -162.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -96.22 -57.12 2.42 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 172.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.61 23.46 1.88 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 120.153 -1.592 . . . . 0.0 113.075 172.549 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 pt -115.21 125.53 72.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.085 1.354 . . . . 0.0 110.178 -176.631 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 t -112.39 128.49 56.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.302 -0.874 . . . . 0.0 108.796 170.233 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 163.55 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 111.896 -174.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.6 t -133.51 164.78 26.38 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.677 1.191 . . . . 0.0 108.015 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.39 -154.92 20.17 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.899 -1.125 . . . . 0.0 112.913 171.403 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.94 145.83 18.6 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.192 1.377 . . . . 0.0 110.445 -169.65 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.43 -1.447 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -172.634 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 107.959 -2.057 . . . . 0.0 107.959 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.8 mm -103.3 120.15 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.205 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -128.0 153.76 46.38 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.924 -1.11 . . . . 0.0 110.496 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 20.5 t -76.0 121.96 29.04 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.577 -1.327 . . . . 0.0 112.687 178.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmt? -97.84 -45.94 6.13 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.741 1.216 . . . . 0.0 112.503 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.51 154.79 27.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.104 -0.998 . . . . 0.0 110.466 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.417 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -111.3 126.14 68.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 CA-C-O 122.235 1.017 . . . . 0.0 109.742 175.461 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 14.1 mm -77.09 118.78 74.24 Favored Pre-proline 0 N--CA 1.43 -1.467 0 CA-C-O 116.043 -1.932 . . . . 0.0 113.761 -174.415 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -60.19 123.79 13.88 Favored 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 125.003 2.822 . . . . 0.0 115.763 -176.356 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.378 39.8 mtmt 75.59 31.76 0.73 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 127.372 2.269 . . . . 0.0 114.426 -175.745 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.09 162.39 36.89 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.819 -1.176 . . . . 0.0 112.96 159.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.07 -56.23 11.67 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 126.715 2.006 . . . . 0.0 114.489 165.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.22 -48.79 74.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 128.33 2.652 . . . . 0.0 111.813 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.417 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.4 tm-20 -41.84 -59.21 1.76 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 116.22 1.933 . . . . 0.0 116.22 176.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -69.86 -28.32 65.57 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.535 1.534 . . . . 0.0 114.359 -172.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.32 -56.57 20.15 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.981 1.712 . . . . 0.0 113.687 -173.449 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.54 -4.88 26.34 Favored Glycine 0 N--CA 1.429 -1.801 0 O-C-N 120.587 -1.32 . . . . 0.0 115.42 164.566 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 14' ' ' PHE . 95.1 mtt180 -74.84 -61.86 1.74 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.628 -1.513 . . . . 0.0 110.605 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 94' ' ' LEU . 97.0 mt -67.69 125.69 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.886 1.674 . . . . 0.0 113.527 -177.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -141.7 159.49 42.11 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.49 1.614 . . . . 0.0 114.089 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 ttpt -52.55 127.21 22.0 Favored 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.521 2.328 . . . . 0.0 114.918 177.259 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 98.06 -7.31 62.43 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.031 0.824 . . . . 0.0 114.571 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.72 160.6 24.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 119.363 1.581 . . . . 0.0 112.508 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.7 ttt-85 -105.23 132.92 50.82 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.943 1.697 . . . . 0.0 111.192 -174.464 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.77 136.21 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 119.85 -1.781 . . . . 0.0 111.231 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -100.83 -60.66 1.48 Allowed 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.37 -1.457 . . . . 0.0 110.945 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.81 125.94 10.66 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.907 -1.12 . . . . 0.0 112.366 -171.078 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.9 t -99.04 114.33 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 123.837 0.855 . . . . 0.0 109.367 177.534 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.7 t30 59.52 35.28 22.7 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.042 1.737 . . . . 0.0 115.1 168.416 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.51 -10.74 66.98 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 124.971 1.272 . . . . 0.0 114.186 -177.155 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.31 107.88 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.782 -1.422 . . . . 0.0 109.659 -176.34 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.5 t -73.04 126.33 29.72 Favored 'General case' 0 N--CA 1.431 -1.391 0 O-C-N 120.777 -1.202 . . . . 0.0 111.177 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.4 mt -84.95 37.74 0.68 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -169.42 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -74.77 120.54 20.46 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.929 1.691 . . . . 0.0 110.656 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.11 11.95 79.3 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 120.49 -1.381 . . . . 0.0 114.412 -175.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.89 140.64 51.12 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 114.652 1.353 . . . . 0.0 114.652 -175.028 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.8 p -90.86 -179.28 5.45 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.689 1.195 . . . . 0.0 111.19 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -69.23 -45.43 69.81 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.752 -1.217 . . . . 0.0 110.317 179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -56.89 -41.63 78.4 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 170.274 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -53.1 62.05 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.671 -1.268 . . . . 0.0 113.915 178.764 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.95 -44.02 73.86 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.82 1.248 . . . . 0.0 113.575 178.271 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.4 -49.07 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.64 -1.288 . . . . 0.0 111.806 -177.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -65.73 -32.42 73.96 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.744 -1.222 . . . . 0.0 112.087 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 36.0 m -66.98 -45.06 78.79 Favored 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 125.774 1.63 . . . . 0.0 113.101 173.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 54.3 mt -68.64 -29.31 67.77 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.123 -1.611 . . . . 0.0 114.293 174.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.6 mtp180 -73.68 -47.46 39.5 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.227 -1.546 . . . . 0.0 113.159 171.746 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -89.18 55.67 3.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.148 -1.595 . . . . 0.0 113.543 -176.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.4 p -84.5 177.91 7.92 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.126 1.771 . . . . 0.0 111.531 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.8 -157.66 27.67 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 120.123 -1.61 . . . . 0.0 110.375 164.58 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.5 tm0? -71.33 -50.52 31.53 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.819 -1.989 . . . . 0.0 110.861 169.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.51 135.99 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.309 1.444 . . . . 0.0 109.844 174.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.7 t -107.72 126.16 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 C-N-CA 129.047 2.939 . . . . 0.0 108.448 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.9 t-160 -105.21 110.07 22.3 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.258 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.434 HD11 HD11 ' A' ' 59' ' ' ILE 0.389 4.0 pp -125.1 151.24 45.97 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 117.032 2.234 . . . . 0.0 117.032 166.867 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.8 tp -114.97 134.23 55.36 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.839 2.056 . . . . 0.0 107.527 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.611 HD21 ' CE1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -152.75 174.37 14.12 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.035 -1.041 . . . . 0.0 113.639 -179.21 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -119.39 132.47 55.84 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 125.712 1.605 . . . . 0.0 111.146 -175.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.435 0 O-C-N 120.112 -1.617 . . . . 0.0 113.644 -179.639 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.6 t0 . . . . . 0 N--CA 1.43 -1.462 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.7 p -95.97 153.67 17.64 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.869 -1.769 . . . . 0.0 111.863 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.68 ' CZ ' HD22 ' A' ' 96' ' ' LEU . 37.4 p90 -146.6 137.51 24.11 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 173.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -94.72 128.06 41.15 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.593 -1.317 . . . . 0.0 109.942 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.41 88.85 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -178.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -93.85 83.33 4.37 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 169.014 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.419 HD13 ' HB1' ' A' ' 52' ' ' ALA 0.288 1.8 pp -109.2 162.75 13.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.771 1.272 . . . . 0.0 111.233 -178.035 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 133.73 46.88 Favored 'General case' 0 N--CA 1.428 -1.527 0 C-N-CA 124.728 1.211 . . . . 0.0 107.924 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -70.6 121.87 18.69 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.458 -1.401 . . . . 0.0 112.32 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 29.2 p -94.7 119.61 33.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.669 -1.269 . . . . 0.0 110.039 -174.136 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 t70 61.13 7.7 1.7 Allowed 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.056 2.142 . . . . 0.0 116.416 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 107.41 2.27 35.34 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.984 -1.698 . . . . 0.0 114.846 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 63.2 m -121.93 132.02 54.33 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.911 1.855 . . . . 0.0 113.306 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 85.5 mt -73.7 -44.24 57.03 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.712 -1.242 . . . . 0.0 111.425 164.547 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.5 29.74 3.31 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 119.767 -1.833 . . . . 0.0 111.719 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 pt -107.31 135.22 46.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.625 1.202 . . . . 0.0 114.215 -162.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 17.7 m -131.3 109.68 10.54 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.758 -1.839 . . . . 0.0 108.969 155.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.03 163.82 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-O 122.153 0.978 . . . . 0.0 112.145 -177.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.6 t -145.81 172.6 13.07 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.13 1.372 . . . . 0.0 108.28 175.104 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 -175.61 33.68 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.734 -1.229 . . . . 0.0 114.125 176.705 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 149.6 177.61 23.83 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -171.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.434 1.272 . . . . 0.0 114.434 -173.828 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.691 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.7 mm -102.39 123.34 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.894 1.678 . . . . 0.0 107.464 175.172 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -124.4 155.16 39.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.935 -1.103 . . . . 0.0 111.307 -170.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.1 t -76.05 119.31 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.883 -1.136 . . . . 0.0 110.789 169.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.9 pttt -95.51 -36.59 11.24 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.471 -1.393 . . . . 0.0 112.445 173.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -155.88 160.95 40.6 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.921 -1.112 . . . . 0.0 110.539 177.1 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.436 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -120.15 125.88 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 124.404 1.082 . . . . 0.0 109.216 177.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.8 mm -77.42 124.93 86.85 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.623 1.969 . . . . 0.0 114.265 -176.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_exo -56.57 133.87 60.73 Favored 'Trans proline' 0 N--CA 1.435 -1.968 0 CA-C-N 124.034 2.476 . . . . 0.0 116.237 176.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt 83.53 0.77 1.06 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 129.012 2.925 . . . . 0.0 114.71 -177.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.05 156.08 46.88 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.121 -1.612 . . . . 0.0 113.104 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HB1' HD13 ' A' ' 18' ' ' LEU . . . -49.35 -53.14 23.78 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 172.495 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.2 -45.76 86.91 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 128.951 2.901 . . . . 0.0 112.622 177.523 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.436 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.6 tm-20 -50.21 -57.99 6.57 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 123.101 1.429 . . . . 0.0 114.656 171.144 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.4 t -68.02 -25.39 65.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.193 1.397 . . . . 0.0 113.717 -171.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -61.56 -71.94 0.13 Allowed 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.695 1.598 . . . . 0.0 112.501 173.661 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.76 -6.52 37.98 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 121.108 -0.995 . . . . 0.0 115.284 177.171 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.1 mtm180 -65.22 -35.47 81.15 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.867 -1.961 . . . . 0.0 111.893 165.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 73.3 mt -85.36 134.21 27.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 124.884 1.273 . . . . 0.0 109.683 176.657 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -139.17 161.31 37.73 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.807 -1.183 . . . . 0.0 108.922 177.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -54.71 125.05 18.37 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.985 1.714 . . . . 0.0 113.934 172.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.84 -2.25 66.41 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 124.286 0.946 . . . . 0.0 114.802 -178.192 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -82.12 160.18 23.19 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-N 119.614 1.707 . . . . 0.0 110.535 178.793 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -112.37 132.48 54.98 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.619 -1.3 . . . . 0.0 112.151 -168.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.7 t -87.14 127.68 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.319 -1.488 . . . . 0.0 110.657 178.588 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 88.1 mt -98.15 -48.1 5.23 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 121.132 -0.98 . . . . 0.0 111.253 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.44 134.6 18.16 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.995 -1.065 . . . . 0.0 109.787 -176.506 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.7 t -114.23 125.85 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 67.25 30.06 7.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.259 1.424 . . . . 0.0 111.721 175.28 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 85.19 -18.84 25.84 Favored Glycine 0 N--CA 1.431 -1.682 0 C-N-CA 125.058 1.313 . . . . 0.0 114.802 -173.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.85 123.27 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 O-C-N 120.776 -1.426 . . . . 0.0 110.521 -171.195 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.5 m -63.88 135.27 56.42 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.776 -1.202 . . . . 0.0 113.956 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 78.1 mt -86.17 56.52 4.02 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.754 -1.216 . . . . 0.0 111.65 177.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -78.85 123.11 26.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.571 -1.331 . . . . 0.0 112.508 -175.073 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 58.59 20.87 48.03 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 125.349 1.452 . . . . 0.0 115.139 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.64 144.66 51.04 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -164.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -76.58 178.45 6.67 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.611 1.164 . . . . 0.0 110.511 169.149 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -68.25 -48.84 63.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.427 -1.421 . . . . 0.0 111.738 172.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 41.2 mmtm -58.48 -31.67 68.05 Favored 'General case' 0 N--CA 1.429 -1.512 0 N-CA-C 116.012 1.856 . . . . 0.0 116.012 174.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 mm100 -56.35 -55.74 29.76 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 120.324 1.42 . . . . 0.0 114.181 175.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.53 87.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.198 0.999 . . . . 0.0 113.195 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -68.35 -48.39 73.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.028 1.331 . . . . 0.0 111.208 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -62.94 -36.82 84.68 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.482 -1.386 . . . . 0.0 112.791 177.362 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.1 m -67.26 -45.88 75.38 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.646 1.578 . . . . 0.0 113.188 175.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 20.8 mt -66.28 -34.74 78.68 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.399 -1.438 . . . . 0.0 114.031 175.055 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.51 -31.64 65.51 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.32 -1.488 . . . . 0.0 113.684 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -88.68 48.93 1.7 Allowed 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 122.185 0.993 . . . . 0.0 112.066 173.302 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 p -107.17 154.33 21.35 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.102 -1.624 . . . . 0.0 109.14 170.63 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -108.83 -132.5 6.61 Favored Glycine 0 N--CA 1.43 -1.718 0 CA-C-O 121.964 0.758 . . . . 0.0 113.823 -172.383 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.0 tm0? -70.82 -68.84 0.4 Allowed 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 121.308 -1.113 . . . . 0.0 113.54 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 9.2 p -98.33 131.98 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.873 1.32 . . . . 0.0 109.882 174.094 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.6 t -125.23 111.96 29.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 126.139 1.776 . . . . 0.0 110.209 -162.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -93.14 101.15 13.44 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -178.243 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -92.73 146.19 23.84 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 120.113 -1.617 . . . . 0.0 112.602 168.072 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 60.5 tp -113.87 127.54 56.03 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 155.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.68 HD22 ' CZ ' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -136.22 151.69 49.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 121.098 -1.001 . . . . 0.0 111.356 -171.172 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -117.34 131.63 56.75 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 123.404 1.573 . . . . 0.0 111.622 176.401 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? . . . . . 0 N--CA 1.43 -1.445 0 C-N-CA 127.133 2.173 . . . . 0.0 110.798 177.318 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.3 t0 . . . . . 0 N--CA 1.43 -1.443 0 CA-C-O 121.585 0.707 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 p -100.1 158.43 15.85 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.884 1.674 . . . . 0.0 112.541 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -144.67 146.71 32.37 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 171.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -89.57 113.19 24.58 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 165.108 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 t -98.77 99.66 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -90.38 94.36 9.7 Favored 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 174.287 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -105.14 126.48 52.12 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-O 122.464 1.126 . . . . 0.0 110.045 -174.7 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.82 139.25 38.64 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.133 -1.604 . . . . 0.0 110.225 176.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -66.18 130.86 44.66 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.002 -1.061 . . . . 0.0 113.075 175.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.9 p -91.09 84.72 5.75 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.228 -1.545 . . . . 0.0 110.378 177.161 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.1 t70 59.27 53.43 5.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.457 1.903 . . . . 0.0 113.487 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.96 -11.31 72.47 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.746 -1.221 . . . . 0.0 115.295 -176.37 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.5 t -94.53 112.92 24.69 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.419 -1.636 . . . . 0.0 113.519 -173.099 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 7.5 tp -125.84 63.03 1.22 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.662 1.585 . . . . 0.0 109.985 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -85.64 62.21 4.46 Favored Glycine 0 N--CA 1.43 -1.717 0 O-C-N 119.43 -2.043 . . . . 0.0 113.462 -164.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.93 127.34 55.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 124.74 1.216 . . . . 0.0 107.975 168.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.43 121.79 45.85 Favored 'General case' 0 CA--C 1.489 -1.371 0 C-N-CA 123.626 0.77 . . . . 0.0 109.442 177.438 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.0 m -104.46 170.42 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.724 1.209 . . . . 0.0 112.736 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -150.24 173.79 13.55 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.198 1.399 . . . . 0.0 108.51 173.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.83 -138.03 14.67 Favored Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 167.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.87 162.31 27.79 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.52 1.533 . . . . 0.0 113.023 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 N--CA 1.43 -1.445 0 C-N-CA 125.603 1.561 . . . . 0.0 114.988 177.453 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.742 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.9 mm -97.85 131.98 43.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.69 1.196 . . . . 0.0 108.577 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.84 159.4 33.99 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.777 -1.202 . . . . 0.0 110.305 -175.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.68 119.53 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.694 -1.253 . . . . 0.0 111.023 174.28 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 57.2 tttm -91.43 -50.85 5.57 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 124.11 0.964 . . . . 0.0 111.85 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.09 155.83 31.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.038 -1.039 . . . . 0.0 110.904 -177.505 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.41 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -114.09 120.63 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-O 122.611 1.196 . . . . 0.0 109.643 172.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 34.6 mm -76.06 128.22 83.52 Favored Pre-proline 0 N--CA 1.43 -1.447 0 CA-C-O 116.09 -1.909 . . . . 0.0 113.252 -170.477 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -55.0 133.85 60.42 Favored 'Trans proline' 0 N--CA 1.434 -2.002 0 C-N-CA 124.416 3.411 . . . . 0.0 115.65 178.569 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? 67.76 13.76 9.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.526 1.53 . . . . 0.0 114.478 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.31 173.13 47.9 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 119.592 -1.942 . . . . 0.0 112.517 172.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.87 9.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 169.32 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.81 -40.1 95.83 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 126.595 1.958 . . . . 0.0 115.273 -173.022 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.41 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.0 OUTLIER -41.35 -60.08 1.37 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 129.423 3.089 . . . . 0.0 113.607 178.02 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.5 t -70.2 -33.84 72.21 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 111.693 -2.503 . . . . 0.0 115.847 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -62.43 -48.57 79.1 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.272 1.429 . . . . 0.0 113.129 -165.802 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.64 -19.92 45.9 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.506 -1.371 . . . . 0.0 115.421 162.491 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.2 mmt-85 -75.74 -4.34 39.89 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 118.429 1.115 . . . . 0.0 112.764 172.308 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.5 mt -117.91 126.97 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.525 0 C-N-CA 125.259 1.423 . . . . 0.0 107.981 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -132.25 163.83 27.73 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.617 -1.302 . . . . 0.0 109.797 170.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -67.91 123.29 20.17 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.215 -1.553 . . . . 0.0 112.773 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 100.01 0.83 56.09 Favored Glycine 0 N--CA 1.431 -1.7 0 O-C-N 121.678 -0.639 . . . . 0.0 114.099 -174.728 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -80.17 164.86 22.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-N 119.555 1.678 . . . . 0.0 110.455 173.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.18 136.68 51.29 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.602 1.192 . . . . 0.0 111.722 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -91.15 125.12 43.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 126.113 1.765 . . . . 0.0 109.76 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 49.1 mt -103.89 -56.89 2.12 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.42 -1.425 . . . . 0.0 110.589 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.74 118.62 6.66 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 121.165 -0.959 . . . . 0.0 111.163 -176.157 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.45 HG22 HD13 ' A' ' 94' ' ' LEU . 57.7 t -98.47 115.79 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -176.644 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.9 t30 60.84 42.41 13.23 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 124.796 1.238 . . . . 0.0 114.321 165.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.17 -18.35 57.01 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.53 1.062 . . . . 0.0 114.05 -177.575 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.66 117.93 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.851 -1.381 . . . . 0.0 109.331 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 54.9 m -72.79 105.89 4.53 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 121.138 -0.976 . . . . 0.0 110.959 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 33.8 mt -89.8 25.67 2.0 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.695 -1.253 . . . . 0.0 112.092 -175.716 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -77.83 122.55 25.59 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.088 -1.632 . . . . 0.0 109.563 173.12 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 76.11 15.08 81.66 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 120.657 -1.277 . . . . 0.0 115.672 -170.369 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.28 163.11 28.28 Favored 'General case' 0 N--CA 1.429 -1.492 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 178.318 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.6 p -93.5 171.13 9.1 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.128 1.371 . . . . 0.0 111.196 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 64.8 t-80 -62.47 -51.06 68.95 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.476 -1.39 . . . . 0.0 114.185 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 mtmt -57.12 -42.58 81.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 174.24 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 55.8 tt0 -56.58 -45.91 81.09 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.355 1.862 . . . . 0.0 114.241 -173.736 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.69 -39.63 94.59 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.902 1.681 . . . . 0.0 114.732 172.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.2 t -68.7 -49.26 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.011 1.324 . . . . 0.0 110.415 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 82.3 mt-10 -66.41 -33.33 75.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.341 -1.474 . . . . 0.0 113.552 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.8 m -61.2 -41.6 97.11 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.744 1.618 . . . . 0.0 113.072 169.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 76.0 mt -71.7 -30.69 65.94 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.361 -1.462 . . . . 0.0 114.276 173.126 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -67.28 -46.51 73.41 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.073 -1.642 . . . . 0.0 112.587 173.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -93.74 64.75 3.53 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.644 -1.285 . . . . 0.0 110.653 177.544 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 p -101.46 164.42 11.77 Favored 'General case' 0 N--CA 1.429 -1.512 0 C-N-CA 128.043 2.537 . . . . 0.0 109.329 173.16 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -92.8 -139.75 9.38 Favored Glycine 0 N--CA 1.431 -1.678 0 O-C-N 121.043 -1.035 . . . . 0.0 110.689 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -71.14 -68.47 0.44 Allowed 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.189 -1.183 . . . . 0.0 114.039 170.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.4 t -105.51 128.77 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 CA-C-O 122.509 1.147 . . . . 0.0 108.619 -176.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.04 117.99 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 128.409 2.683 . . . . 0.0 108.996 -170.519 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -98.2 102.13 13.79 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.486 -1.383 . . . . 0.0 111.192 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.45 HD13 HG22 ' A' ' 68' ' ' VAL . 31.7 tp -99.93 132.88 45.01 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.207 -1.558 . . . . 0.0 111.388 175.202 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -87.44 121.55 30.02 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.163 -1.792 . . . . 0.0 106.163 163.015 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.0 tt -123.45 143.63 50.02 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 123.689 0.796 . . . . 0.0 109.804 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -111.22 136.33 50.45 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 109.22 174.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? . . . . . 0 N--CA 1.43 -1.433 0 O-C-N 121.196 -0.94 . . . . 0.0 111.851 175.366 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 35.5 t70 . . . . . 0 N--CA 1.43 -1.463 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.31 135.16 43.26 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.338 -0.851 . . . . 0.0 109.653 158.431 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.251 0.0 OUTLIER -146.77 146.51 30.3 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 122.458 1.123 . . . . 0.0 109.454 159.235 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.34 145.89 24.27 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.405 -1.434 . . . . 0.0 109.035 174.612 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 47.9 t -106.01 93.44 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 74.9 mt-10 -92.2 89.77 7.03 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.978 1.711 . . . . 0.0 108.426 175.223 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 65.6 tp -124.91 148.39 48.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 121.304 -0.873 . . . . 0.0 110.629 -171.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.66 48.48 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.219 1.408 . . . . 0.0 109.015 171.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -71.17 154.86 41.37 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 115.871 1.804 . . . . 0.0 115.871 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 77.5 p -121.08 131.55 54.34 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.849 -1.157 . . . . 0.0 109.482 171.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.1 t70 57.78 38.83 27.43 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 176.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.65 -16.14 16.06 Favored Glycine 0 N--CA 1.431 -1.656 0 O-C-N 119.477 -2.015 . . . . 0.0 114.985 -176.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.8 p -115.14 157.93 22.92 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.779 2.032 . . . . 0.0 112.551 -164.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.404 HD13 ' HA ' ' A' ' 25' ' ' LEU . 3.7 mm? -102.06 -60.64 1.5 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.677 -1.264 . . . . 0.0 108.957 173.502 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.86 56.64 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.555 -1.966 . . . . 0.0 110.838 169.464 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tt -147.24 145.29 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 CA-C-O 122.43 1.11 . . . . 0.0 110.784 -171.498 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.6 t -108.94 132.36 54.15 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 166.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.1 m -112.92 155.92 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 O-C-N 121.14 -0.975 . . . . 0.0 111.344 -175.503 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 t -129.0 168.02 16.63 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 124.084 0.954 . . . . 0.0 109.33 174.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.09 -151.68 18.31 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.418 -0.801 . . . . 0.0 113.928 167.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.48 139.63 10.65 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 123.975 0.798 . . . . 0.0 112.481 -176.295 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.43 -1.465 0 O-C-N 120.829 -1.395 . . . . 0.0 113.933 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.772 0 N-CA-C 107.133 -2.387 . . . . 0.0 107.133 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.4 mm -103.78 114.79 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.286 1.434 . . . . 0.0 107.573 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.1 m-85 -123.58 157.05 34.57 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.206 1.003 . . . . 0.0 110.52 -171.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -75.03 122.5 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 C-N-CA 124.542 1.137 . . . . 0.0 110.713 175.239 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -93.18 -51.83 4.84 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.846 -1.159 . . . . 0.0 111.574 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.86 158.9 41.48 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.041 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.413 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -113.56 125.27 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 CA-C-O 122.565 1.174 . . . . 0.0 109.057 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -76.58 124.19 87.8 Favored Pre-proline 0 N--CA 1.429 -1.487 0 CA-C-O 116.344 -1.788 . . . . 0.0 113.679 -167.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_exo -58.9 124.64 16.16 Favored 'Trans proline' 0 N--CA 1.433 -2.036 0 CA-C-N 124.566 2.667 . . . . 0.0 115.396 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 47.9 mtpt 74.88 30.74 0.93 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 127.101 2.16 . . . . 0.0 114.069 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.33 160.72 33.49 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.204 -0.935 . . . . 0.0 114.097 161.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.07 -54.03 14.48 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.982 2.113 . . . . 0.0 114.444 160.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.93 -46.48 87.56 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 127.586 2.354 . . . . 0.0 113.416 179.095 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.2 tm-20 -41.6 -64.57 0.55 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 116.415 2.005 . . . . 0.0 116.415 173.441 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 57.8 m -68.51 -18.46 64.38 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.557 1.943 . . . . 0.0 115.843 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.16 -56.84 16.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 CA-C-N 119.657 1.117 . . . . 0.0 112.52 -174.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 107.04 -25.81 21.06 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 115.151 0.82 . . . . 0.0 115.151 176.109 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -72.36 -29.17 63.54 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.951 1.875 . . . . 0.0 112.221 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.0 mt -90.34 120.71 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 120.591 -1.318 . . . . 0.0 111.024 174.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -124.32 168.67 12.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.937 1.351 . . . . 0.0 111.435 173.112 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -65.72 117.54 8.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.726 1.61 . . . . 0.0 113.43 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.13 11.21 57.75 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.744 -1.222 . . . . 0.0 114.563 -176.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -81.22 159.45 24.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.22 1.51 . . . . 0.0 111.909 173.619 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -112.97 124.49 52.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.109 1.363 . . . . 0.0 111.163 -166.741 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 39.0 t -92.08 121.31 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.381 0 O-C-N 120.288 -1.508 . . . . 0.0 110.716 179.54 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 78.3 mt -89.11 -45.52 9.54 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.102 -0.999 . . . . 0.0 110.749 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.63 143.47 24.62 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 121.378 -0.826 . . . . 0.0 110.709 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 44.9 t -111.14 114.45 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.053 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.7 t30 63.88 34.04 12.06 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 165.814 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.16 -17.35 59.45 Favored Glycine 0 N--CA 1.431 -1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 113.83 -175.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.6 t -99.03 121.34 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.41 . . . . 0.0 109.983 -175.472 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 20.3 t -75.32 138.69 41.97 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.255 -1.528 . . . . 0.0 112.03 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 76.8 mt -90.4 13.56 15.25 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.223 -0.923 . . . . 0.0 113.447 -176.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -61.15 111.99 1.93 Allowed 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 119.94 -1.725 . . . . 0.0 114.348 -177.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.95 0.29 83.53 Favored Glycine 0 N--CA 1.43 -1.704 0 C-N-CA 124.903 1.239 . . . . 0.0 115.463 -178.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.63 147.41 47.56 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 115.68 1.733 . . . . 0.0 115.68 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.9 p -92.79 178.68 5.7 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.797 1.239 . . . . 0.0 112.529 176.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -56.33 -56.61 18.93 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.977 1.711 . . . . 0.0 114.673 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 tppt? -57.39 -39.79 76.85 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.812 1.245 . . . . 0.0 113.317 -178.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.58 -50.4 72.03 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 126.634 1.974 . . . . 0.0 113.852 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.21 -41.45 99.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.862 1.665 . . . . 0.0 114.165 174.327 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.02 -49.03 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.215 1.406 . . . . 0.0 111.051 177.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -60.82 -39.17 88.0 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 124.691 1.196 . . . . 0.0 112.85 177.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.1 m -63.41 -49.79 72.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 126.998 2.119 . . . . 0.0 113.033 173.496 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 63.8 mt -66.66 -29.57 69.62 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.196 -1.565 . . . . 0.0 114.405 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -68.8 -49.25 60.12 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.598 -1.314 . . . . 0.0 112.274 169.325 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -85.02 64.65 8.82 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.414 -1.429 . . . . 0.0 111.641 177.702 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 p -106.18 160.08 15.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 128.792 2.837 . . . . 0.0 109.258 173.045 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.69 -163.61 39.08 Favored Glycine 0 N--CA 1.429 -1.77 0 O-C-N 121.046 -1.033 . . . . 0.0 111.584 176.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -66.69 -52.55 43.46 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.757 -1.437 . . . . 0.0 113.152 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.34 130.07 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 CA-C-O 122.695 1.236 . . . . 0.0 108.054 170.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.0 t -117.92 128.54 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 127.597 2.359 . . . . 0.0 108.029 -166.121 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.2 m80 -120.67 92.54 3.79 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -170.498 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.18 146.55 25.32 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 119.398 -2.064 . . . . 0.0 112.068 175.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 24.9 tp -104.6 116.56 32.28 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 162.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.4 tt -132.44 137.14 47.16 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.564 0.697 . . . . 0.0 111.927 -164.07 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.5 tt0 -108.87 126.65 53.29 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.866 -1.146 . . . . 0.0 109.267 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.5 tmtt? . . . . . 0 N--CA 1.43 -1.436 0 O-C-N 120.674 -1.266 . . . . 0.0 112.433 -174.027 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 N--CA 1.429 -1.479 0 N-CA-C 115.655 1.724 . . . . 0.0 115.655 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -119.35 148.2 43.47 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 121.121 1.782 . . . . 0.0 109.618 164.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 11.1 p90 -146.8 147.02 30.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 123.21 1.481 . . . . 0.0 109.23 171.768 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -104.1 120.5 41.22 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.317 2.247 . . . . 0.0 107.738 -178.752 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.3 t -114.04 103.69 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 119.975 -1.703 . . . . 0.0 109.83 -171.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -90.08 88.67 7.37 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.306 -1.496 . . . . 0.0 109.239 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 tp -100.92 130.39 46.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.761 -1.212 . . . . 0.0 112.702 -167.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.47 128.23 49.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.279 -1.513 . . . . 0.0 109.456 170.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -69.73 132.66 46.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.217 1.562 . . . . 0.0 115.217 -172.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 47.6 p -107.48 114.89 29.19 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.503 -1.373 . . . . 0.0 111.498 -176.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.4 t70 55.66 39.35 30.88 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.214 2.205 . . . . 0.0 113.12 172.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.73 4.5 90.29 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 119.514 -1.991 . . . . 0.0 115.583 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.6 t -121.48 134.59 55.07 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-N 118.549 1.175 . . . . 0.0 111.345 -176.541 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 86.2 mt -89.65 -42.52 11.32 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.826 -1.171 . . . . 0.0 109.99 173.305 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.28 9.27 22.2 Favored Glycine 0 N--CA 1.43 -1.731 0 O-C-N 120.833 -1.167 . . . . 0.0 114.503 175.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.8 pt -129.42 125.65 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 CA-C-N 118.466 1.133 . . . . 0.0 112.555 -166.051 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -110.15 139.83 44.88 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.974 -1.079 . . . . 0.0 109.233 166.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 m -111.05 170.71 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.81 1.244 . . . . 0.0 112.725 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -150.96 172.26 15.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.559 1.943 . . . . 0.0 108.2 174.651 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.1 -131.37 10.58 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 121.052 -1.03 . . . . 0.0 113.731 169.76 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 72.22 -175.36 42.75 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.936 1.255 . . . . 0.0 113.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.1 t . . . . . 0 N--CA 1.43 -1.447 0 C-N-CA 126.4 1.88 . . . . 0.0 113.325 177.937 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.745 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.79 114.74 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.507 1.123 . . . . 0.0 109.238 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -111.9 153.62 26.41 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.261 -0.899 . . . . 0.0 110.225 -173.765 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.5 t -76.57 116.85 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 124.924 1.289 . . . . 0.0 112.473 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.2 ttpp -92.26 -40.88 10.71 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.272 1.029 . . . . 0.0 112.36 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.68 153.75 31.81 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.165 -1.584 . . . . 0.0 112.687 -177.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.265 1.0 OUTLIER -109.33 115.89 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-O 123.123 1.44 . . . . 0.0 109.988 171.776 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.1 mm -77.36 125.23 86.59 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 127.111 2.164 . . . . 0.0 113.79 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -55.69 124.34 16.03 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 C-N-CA 123.625 2.883 . . . . 0.0 116.115 -177.49 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.3 4.5 mptp? 74.38 24.59 1.81 Allowed 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.692 1.997 . . . . 0.0 113.22 176.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.01 159.11 35.54 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.439 -1.413 . . . . 0.0 111.785 165.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.6 -55.44 11.17 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.62 1.711 . . . . 0.0 115.62 175.291 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.443 ' HB1' HD12 ' A' ' 59' ' ' ILE . . . -63.53 -46.44 86.01 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 128.065 2.546 . . . . 0.0 112.561 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -48.9 -60.63 2.6 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.317 1.447 . . . . 0.0 113.944 174.489 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.2 m -69.39 -20.05 63.82 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -69.43 -64.03 0.95 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.511 -1.368 . . . . 0.0 110.996 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.72 11.09 41.74 Favored Glycine 0 N--CA 1.429 -1.771 0 O-C-N 119.862 -1.774 . . . . 0.0 114.849 164.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 71.9 mtt85 -62.45 -51.68 66.56 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.88 1.272 . . . . 0.0 109.905 159.473 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.443 HD12 ' HB1' ' A' ' 53' ' ' ALA . 2.8 mt -79.17 128.13 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 126.104 1.762 . . . . 0.0 112.132 -176.515 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.93 169.65 16.0 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 123.561 1.648 . . . . 0.0 111.641 174.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 14.7 ttpp -66.23 132.06 47.57 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.675 -1.891 . . . . 0.0 112.115 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.03 5.37 68.01 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 120.971 -1.08 . . . . 0.0 114.156 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -79.59 166.36 21.97 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 118.889 1.344 . . . . 0.0 109.586 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -134.08 148.34 51.01 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.172 -1.58 . . . . 0.0 112.772 176.539 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.0 t -102.82 134.0 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 C-N-CA 124.769 1.228 . . . . 0.0 111.171 -166.425 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.9 mp -99.07 -50.65 4.09 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.5 1.12 . . . . 0.0 110.662 -177.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.84 136.54 18.07 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.314 -0.866 . . . . 0.0 112.677 -175.197 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.2 t -113.36 125.77 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 124.671 1.189 . . . . 0.0 108.424 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 65.86 30.91 9.73 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.645 1.178 . . . . 0.0 112.521 168.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 91.96 -22.74 29.95 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.897 -1.127 . . . . 0.0 113.899 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.53 121.75 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 125.633 1.573 . . . . 0.0 110.666 -167.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.9 p -71.23 131.62 43.77 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.746 -1.221 . . . . 0.0 112.433 178.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.9 mt -84.23 64.65 8.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.089 -1.632 . . . . 0.0 112.083 -175.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -89.34 116.3 27.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.466 -1.396 . . . . 0.0 112.723 -173.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.83 17.79 79.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.004 -1.06 . . . . 0.0 113.256 179.579 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.97 143.21 50.92 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -168.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 70.6 p -93.71 179.69 5.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.248 1.819 . . . . 0.0 110.597 173.129 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 28.8 t60 -68.35 -42.7 78.86 Favored 'General case' 0 N--CA 1.428 -1.53 0 O-C-N 119.775 -1.828 . . . . 0.0 110.001 173.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.2 tppm? -53.64 -46.34 70.5 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 125.389 1.476 . . . . 0.0 113.781 172.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -55.65 -51.28 67.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.208 1.403 . . . . 0.0 113.674 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.926 1.691 . . . . 0.0 113.686 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.7 t -66.35 -49.09 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 O-C-N 120.835 -1.165 . . . . 0.0 110.676 178.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.2 mm-40 -64.04 -31.22 72.33 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.669 -1.269 . . . . 0.0 114.03 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.3 m -69.47 -44.3 71.47 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.486 1.514 . . . . 0.0 112.234 175.421 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 82.6 mt -69.51 -32.31 71.08 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 172.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.61 -46.34 79.69 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.245 -1.534 . . . . 0.0 112.426 176.625 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.7 t30 -86.06 45.68 1.25 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.83 1.252 . . . . 0.0 112.648 -178.454 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.0 p -101.6 171.71 7.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.303 1.841 . . . . 0.0 108.658 172.868 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -125.38 -119.35 2.35 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.594 -1.316 . . . . 0.0 110.737 172.449 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -70.84 -70.25 0.32 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 124.288 1.035 . . . . 0.0 113.7 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 40.1 t -100.66 129.45 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 CA-C-O 123.136 1.446 . . . . 0.0 111.223 -175.2 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 96.9 t -122.6 104.61 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 128.466 2.706 . . . . 0.0 108.944 -174.276 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.0 t-160 -88.56 107.37 18.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.624 -1.923 . . . . 0.0 110.802 176.375 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.7 mt -94.04 144.23 25.66 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.775 -1.203 . . . . 0.0 111.242 169.238 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 31.6 tp -119.65 124.91 47.44 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 164.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.422 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.0 pp -150.58 168.29 24.7 Favored 'General case' 0 N--CA 1.429 -1.501 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -176.325 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -113.52 129.4 56.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.137 1.775 . . . . 0.0 111.041 -175.089 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? . . . . . 0 N--CA 1.431 -1.401 0 C-N-CA 125.455 1.502 . . . . 0.0 112.691 179.233 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.7 t0 . . . . . 0 N--CA 1.431 -1.414 0 CA-C-O 121.152 0.501 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 2.1 p -93.07 156.43 16.88 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.748 1.619 . . . . 0.0 113.433 -177.634 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -147.48 134.23 20.02 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 173.361 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -90.98 137.26 32.5 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 162.46 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.7 t -124.6 93.47 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.9 -1.125 . . . . 0.0 109.011 -175.226 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.47 85.43 5.75 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.544 1.537 . . . . 0.0 110.906 173.286 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.292 1.7 pp -117.88 156.6 28.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 122.668 1.223 . . . . 0.0 112.554 -176.859 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.85 133.43 46.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.074 1.75 . . . . 0.0 112.074 -177.188 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -70.6 134.41 47.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.679 1.592 . . . . 0.0 115.228 -178.993 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.3 p -107.21 118.45 36.74 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.525 -1.359 . . . . 0.0 111.592 -178.086 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.3 t70 47.83 43.96 17.66 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.329 2.252 . . . . 0.0 115.678 175.777 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.41 -5.05 85.71 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.447 -1.408 . . . . 0.0 114.956 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 80.6 p -121.59 137.68 54.63 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.176 1.488 . . . . 0.0 114.072 -172.713 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.404 HD21 HG21 ' A' ' 92' ' ' VAL . 89.8 mt -90.61 -61.84 1.59 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.804 -1.185 . . . . 0.0 110.219 167.298 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.82 36.05 1.2 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.625 -1.922 . . . . 0.0 113.189 169.836 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -123.79 124.17 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.031 1.333 . . . . 0.0 109.986 -176.208 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.0 t -101.73 112.49 25.1 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.817 -1.177 . . . . 0.0 107.867 170.349 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.0 m -104.19 161.79 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.934 1.293 . . . . 0.0 111.664 -178.773 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -149.72 174.11 12.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.677 -1.264 . . . . 0.0 109.767 -175.172 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.42 -131.87 10.66 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 124.355 0.979 . . . . 0.0 113.519 168.334 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.83 176.89 51.04 Favored Glycine 0 N--CA 1.43 -1.758 0 N-CA-C 115.787 1.075 . . . . 0.0 115.787 174.659 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.43 -1.468 0 N-CA-C 117.356 2.354 . . . . 0.0 117.356 -170.127 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.762 0 CA-C-O 120.932 0.185 . . . . 0.0 113.354 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 35.4 mm -93.71 123.44 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.498 -1.001 . . . . 0.0 109.16 174.501 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -123.33 154.25 39.17 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.889 -1.132 . . . . 0.0 110.215 -175.315 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.0 t -76.72 129.87 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.765 -1.21 . . . . 0.0 111.562 168.967 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -100.32 -50.11 4.04 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.374 1.47 . . . . 0.0 111.449 176.925 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.24 161.05 43.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.686 -1.259 . . . . 0.0 111.401 -175.793 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -115.76 125.78 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.431 1.092 . . . . 0.0 110.01 179.766 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.3 mm -77.13 115.99 53.57 Favored Pre-proline 0 N--CA 1.43 -1.455 0 C-N-CA 125.748 1.619 . . . . 0.0 112.816 -177.389 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -64.91 136.37 48.47 Favored 'Trans proline' 0 C--N 1.3 -1.988 0 CA-C-N 124.074 2.491 . . . . 0.0 113.044 -175.95 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.251 45.4 mtmt 83.94 7.0 0.63 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.852 2.861 . . . . 0.0 114.42 -175.318 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 160.22 35.93 Favored Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.97 -1.706 . . . . 0.0 114.983 176.142 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.34 -56.65 8.84 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.009 2.123 . . . . 0.0 115.994 169.542 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -45.98 83.66 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 128.231 2.612 . . . . 0.0 111.697 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.409 ' HA ' HG12 ' A' ' 47' ' ' ILE . 7.1 tm-20 -47.62 -64.61 0.74 Allowed 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.968 1.84 . . . . 0.0 115.968 169.492 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.0 m -70.13 -21.45 63.09 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 115.448 1.647 . . . . 0.0 115.448 -173.01 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.0 -65.8 0.56 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.295 1.438 . . . . 0.0 112.361 173.189 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.58 0.04 42.96 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 114.847 170.557 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -66.32 -51.73 54.32 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 118.766 1.283 . . . . 0.0 110.32 162.294 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.51 HD11 HD12 ' A' ' 94' ' ' LEU . 51.7 mt -78.26 134.96 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 124.902 1.281 . . . . 0.0 111.053 179.322 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.6 t-80 -147.59 156.78 43.15 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 122.063 0.935 . . . . 0.0 109.46 -178.78 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -65.61 126.02 27.05 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 119.501 -2.0 . . . . 0.0 114.37 -174.23 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.03 -4.86 35.98 Favored Glycine 0 N--CA 1.43 -1.758 0 CA-C-O 118.244 -1.309 . . . . 0.0 115.665 -173.229 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.363 3.1 p30 -81.58 163.41 22.63 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 121.207 2.503 . . . . 0.0 114.565 178.464 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.4 tpt85 -112.21 121.92 46.29 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.343 -1.473 . . . . 0.0 111.018 -167.931 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.6 t -87.94 136.24 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.105 -1.622 . . . . 0.0 110.277 -173.434 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 9.6 mp -102.3 -53.03 3.0 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 124.583 1.153 . . . . 0.0 110.494 175.776 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.93 147.43 27.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.825 -1.172 . . . . 0.0 112.209 -168.865 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.28 116.14 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 176.594 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 61.63 37.35 16.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.572 1.949 . . . . 0.0 115.073 167.723 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.18 59.62 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.522 1.058 . . . . 0.0 113.906 -175.765 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.6 t -95.44 112.62 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-N 118.546 1.173 . . . . 0.0 111.029 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.1 m -70.13 121.76 18.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.98 -1.075 . . . . 0.0 110.083 171.091 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.0 mt -72.85 -34.16 66.58 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -169.069 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -8.85 93.53 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 121.114 3.746 . . . . 0.0 121.114 -173.704 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.48 20.87 12.3 Favored Glycine 0 N--CA 1.43 -1.763 0 C-N-CA 125.134 1.35 . . . . 0.0 111.608 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.33 164.45 26.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 175.018 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -92.74 170.32 9.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.358 -1.464 . . . . 0.0 111.121 161.776 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -51.36 -56.7 11.71 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.293 1.837 . . . . 0.0 113.146 169.905 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -56.67 -36.19 69.3 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 174.231 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.7 mm-40 -55.59 -48.39 74.91 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 121.102 1.774 . . . . 0.0 113.79 175.931 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.95 -42.37 94.67 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.195 0.998 . . . . 0.0 113.26 177.889 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.4 t -65.43 -45.68 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 124.603 1.161 . . . . 0.0 111.266 178.489 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -62.38 -40.23 95.78 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.724 -1.235 . . . . 0.0 112.83 177.712 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.0 m -65.79 -42.27 90.95 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.435 2.294 . . . . 0.0 113.295 175.575 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.12 -36.85 84.26 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.303 1.441 . . . . 0.0 113.299 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -68.76 -30.14 68.68 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.245 -1.534 . . . . 0.0 113.133 172.032 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -84.81 45.96 1.21 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.02 1.728 . . . . 0.0 112.777 175.495 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 p -105.55 163.58 12.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 126.696 1.998 . . . . 0.0 110.214 177.793 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.92 -144.2 15.73 Favored Glycine 0 N--CA 1.43 -1.732 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 168.411 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -70.95 -60.71 2.09 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 121.191 -1.181 . . . . 0.0 113.666 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 29.5 t -98.42 119.85 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.948 1.356 . . . . 0.0 109.293 -175.345 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.404 HG21 HD21 ' A' ' 25' ' ' LEU . 88.1 t -112.78 114.87 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 C-N-CA 126.305 1.842 . . . . 0.0 109.306 -165.79 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -97.69 99.03 10.38 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.961 -1.087 . . . . 0.0 110.617 -177.932 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.51 HD12 HD11 ' A' ' 59' ' ' ILE . 21.0 mt -92.93 160.24 14.98 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 119.797 -1.814 . . . . 0.0 112.711 173.996 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.46 131.99 48.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.417 1.087 . . . . 0.0 108.09 165.814 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -147.86 172.98 13.3 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.395 -1.44 . . . . 0.0 112.415 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -127.49 148.63 50.31 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.162 1.785 . . . . 0.0 109.258 174.938 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 27.5 tptt . . . . . 0 N--CA 1.429 -1.492 0 O-C-N 120.34 -1.475 . . . . 0.0 111.312 175.716 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 t0 . . . . . 0 N--CA 1.43 -1.46 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.8 p -106.07 154.41 20.68 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 124.725 1.21 . . . . 0.0 112.184 178.414 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.46 143.9 29.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.694 -1.254 . . . . 0.0 108.567 -177.944 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -99.43 105.35 17.29 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.2 1.0 . . . . 0.0 109.636 -179.186 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.72 99.54 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.3 1.44 . . . . 0.0 109.457 -169.809 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -90.09 95.76 10.36 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.379 -1.451 . . . . 0.0 107.749 173.721 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -111.02 130.04 55.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.171 0.988 . . . . 0.0 110.467 -169.862 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.89 141.25 35.04 Favored 'General case' 0 CA--C 1.489 -1.372 0 O-C-N 120.471 -1.393 . . . . 0.0 109.727 172.937 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -64.42 147.22 53.13 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 178.699 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 31.3 p -116.15 122.87 46.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 167.624 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.2 t0 43.3 46.22 5.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 128.577 2.751 . . . . 0.0 114.422 -176.726 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.14 11.58 75.18 Favored Glycine 0 N--CA 1.431 -1.65 0 N-CA-C 117.891 1.917 . . . . 0.0 117.891 -178.357 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.0 m -117.32 153.67 32.58 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 119.473 1.637 . . . . 0.0 111.898 178.438 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 72.2 mt -96.11 -60.56 1.6 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.435 1.094 . . . . 0.0 108.9 165.429 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 119.14 37.58 0.8 Allowed Glycine 0 N--CA 1.43 -1.765 0 O-C-N 119.829 -1.794 . . . . 0.0 113.142 174.639 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 pt -129.5 139.17 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.173 1.389 . . . . 0.0 108.742 -175.493 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.5 m -111.79 117.7 33.56 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 157.668 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.5 m -99.05 162.59 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 124.351 1.061 . . . . 0.0 112.017 -174.631 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -150.11 -177.72 6.09 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.842 1.257 . . . . 0.0 110.001 178.168 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.53 -149.55 19.27 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.985 -1.072 . . . . 0.0 113.745 174.752 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.43 168.03 30.07 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 124.513 1.054 . . . . 0.0 112.924 -177.449 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.431 -1.419 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -172.218 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.769 0 CA-C-O 121.42 0.456 . . . . 0.0 113.429 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -96.93 121.88 47.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 175.591 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -126.71 154.26 44.36 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.854 -1.154 . . . . 0.0 110.522 -168.426 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.8 t -75.88 125.57 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.603 -1.31 . . . . 0.0 110.757 169.223 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.1 tttm -91.88 -44.92 8.65 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.738 -1.226 . . . . 0.0 110.671 178.662 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.44 148.11 29.93 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 123.129 0.572 . . . . 0.0 110.694 178.432 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -102.89 121.36 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.612 1.196 . . . . 0.0 110.121 173.962 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.4 mm -77.1 120.27 80.92 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 125.893 1.677 . . . . 0.0 114.219 -171.902 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -59.72 126.35 20.3 Favored 'Trans proline' 0 C--N 1.3 -2.013 0 CA-C-N 124.451 2.625 . . . . 0.0 115.325 -177.587 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.265 7.3 mtpm? 78.29 28.02 0.5 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.454 2.302 . . . . 0.0 112.598 -178.04 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.14 159.72 34.26 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.531 -1.356 . . . . 0.0 113.646 162.472 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.06 -60.83 2.45 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.054 2.142 . . . . 0.0 114.847 164.464 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.16 -49.19 78.63 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.191 2.996 . . . . 0.0 111.96 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -46.76 -61.58 1.78 Allowed 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 115.55 1.685 . . . . 0.0 115.55 171.089 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.8 m -68.27 -32.97 73.51 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 -173.594 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -51.01 -66.96 0.29 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.093 1.757 . . . . 0.0 113.323 176.368 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.25 -17.59 10.48 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 115.051 0.78 . . . . 0.0 115.051 174.601 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 56.9 mtt85 -71.27 -33.62 69.94 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 120.081 1.941 . . . . 0.0 112.491 170.981 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.8 mt -95.12 113.5 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.228 1.011 . . . . 0.0 109.628 176.929 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.657 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 79.9 t60 -143.65 -174.04 4.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.165 -1.584 . . . . 0.0 110.508 174.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.657 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.3 ttpt -60.15 127.65 32.89 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.32 1.848 . . . . 0.0 113.853 -174.753 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.95 -6.35 83.75 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 120.659 -1.275 . . . . 0.0 114.793 178.792 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -81.65 149.27 28.62 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.638 1.719 . . . . 0.0 112.893 -173.685 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -92.29 141.01 29.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.907 -1.745 . . . . 0.0 112.049 -170.711 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.38 119.11 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.63 1.172 . . . . 0.0 108.322 176.491 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.54 -52.46 2.99 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.355 -1.466 . . . . 0.0 111.072 -166.078 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.47 117.18 5.82 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 109.006 175.95 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.6 t -90.91 115.18 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.718 -173.134 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.0 t30 64.13 32.39 12.69 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.139 1.376 . . . . 0.0 111.853 174.909 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.42 -23.94 33.67 Favored Glycine 0 N--CA 1.429 -1.804 0 C-N-CA 124.764 1.173 . . . . 0.0 114.663 -173.495 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.5 t -87.03 111.9 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.689 -1.477 . . . . 0.0 111.698 -167.817 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.4 m -61.63 120.55 10.81 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.729 -1.232 . . . . 0.0 114.118 -179.013 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 38.9 mt -87.57 42.9 1.07 Allowed 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 112.371 -178.203 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -85.29 110.49 19.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 119.193 -2.192 . . . . 0.0 112.169 -174.335 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.3 -0.6 71.89 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 124.782 1.182 . . . . 0.0 114.228 179.412 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.03 155.09 41.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.3 1.963 . . . . 0.0 116.3 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.3 p -81.04 175.36 10.75 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.147 1.379 . . . . 0.0 112.428 174.253 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -67.28 -39.89 86.08 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.401 -1.437 . . . . 0.0 111.712 174.105 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -57.3 -48.53 78.69 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 113.607 174.953 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -56.46 -46.35 80.42 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.225 1.41 . . . . 0.0 114.503 179.044 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.08 -39.4 94.61 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.862 1.665 . . . . 0.0 114.364 175.577 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.5 t -76.19 -45.24 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.052 1.341 . . . . 0.0 111.388 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -58.99 -33.03 70.22 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 127.691 2.396 . . . . 0.0 112.19 175.761 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.6 m -72.53 -49.32 33.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.334 1.854 . . . . 0.0 113.752 170.662 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.8 mt -58.43 -45.36 88.62 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 120.641 1.564 . . . . 0.0 115.149 176.938 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 37.5 ptt85 -66.57 -28.23 68.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.831 -1.168 . . . . 0.0 113.798 -177.906 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -93.18 32.94 1.24 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.8 1.24 . . . . 0.0 113.616 -179.369 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 22.4 p -92.02 148.48 22.15 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.981 1.712 . . . . 0.0 111.384 174.142 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.25 -143.56 9.03 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.819 -1.176 . . . . 0.0 112.59 174.516 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -68.61 -59.79 2.88 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 114.871 1.434 . . . . 0.0 114.871 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.9 p -98.39 134.77 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.384 0 CA-C-O 122.919 1.342 . . . . 0.0 110.648 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.1 t -124.08 115.95 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 C-N-CA 127.525 2.33 . . . . 0.0 107.993 -171.414 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 7.3 m-70 -97.19 89.09 4.65 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.366 -1.459 . . . . 0.0 112.229 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.6 tp -93.46 130.09 39.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.376 -2.077 . . . . 0.0 110.935 -178.134 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.3 tp -87.75 126.09 34.79 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 161.474 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 6.5 tt -122.32 148.54 44.92 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.543 1.137 . . . . 0.0 109.084 -170.106 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -125.3 142.79 51.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 171.608 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.6 tptm . . . . . 0 N--CA 1.43 -1.463 0 O-C-N 120.517 -1.365 . . . . 0.0 111.916 -177.29 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t0 . . . . . 0 N--CA 1.43 -1.442 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -98.52 155.85 17.07 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.575 -1.328 . . . . 0.0 111.638 176.599 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 133.6 21.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 122.231 1.015 . . . . 0.0 108.839 177.329 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -87.49 133.55 33.74 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.326 1.45 . . . . 0.0 109.347 169.97 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.4 t -126.3 107.15 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.853 1.261 . . . . 0.0 108.4 -169.438 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -91.38 102.05 14.73 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 120.383 -1.448 . . . . 0.0 108.393 166.376 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.2 tp -113.32 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.945 0.878 . . . . 0.0 110.509 -171.608 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 139.85 36.99 Favored 'General case' 0 N--CA 1.428 -1.527 0 O-C-N 120.223 -1.548 . . . . 0.0 107.549 170.203 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -65.23 152.75 42.9 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 115.131 1.53 . . . . 0.0 115.131 -178.487 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 30.5 p -102.48 75.57 1.47 Allowed 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.19 -1.569 . . . . 0.0 108.542 175.313 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.3 t0 61.26 61.53 1.53 Allowed 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.126 1.77 . . . . 0.0 112.321 -177.055 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.41 -30.0 5.45 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.249 -1.532 . . . . 0.0 115.191 -175.291 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.7 m -92.27 136.14 33.43 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.256 -1.732 . . . . 0.0 112.802 -167.112 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.551 HD21 HG21 ' A' ' 92' ' ' VAL . 51.9 mt -102.0 -49.17 4.02 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.627 1.571 . . . . 0.0 110.539 177.413 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 -15.87 39.3 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 120.228 -1.545 . . . . 0.0 113.967 -179.087 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.8 pt -96.39 121.83 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 CA-C-N 119.355 1.578 . . . . 0.0 112.959 -176.579 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.3 m -114.06 137.77 51.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 166.228 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.5 m -124.85 165.3 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.307 1.043 . . . . 0.0 112.946 -165.619 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.7 t -144.91 177.89 8.42 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.572 1.549 . . . . 0.0 110.567 -179.346 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.16 -136.68 12.82 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 115.945 1.138 . . . . 0.0 115.945 166.894 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.48 176.21 35.58 Favored Glycine 0 N--CA 1.43 -1.715 0 C-N-CA 126.351 1.929 . . . . 0.0 113.85 -179.025 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.43 -1.43 0 O-C-N 120.437 -1.625 . . . . 0.0 113.481 179.813 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.746 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 mm -93.74 122.06 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 124.823 1.249 . . . . 0.0 108.367 -175.498 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -121.36 152.58 38.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.79 -1.194 . . . . 0.0 109.6 -175.096 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.9 129.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 O-C-N 120.455 -1.403 . . . . 0.0 111.739 174.211 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -96.21 -46.32 6.49 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 126.031 1.733 . . . . 0.0 111.761 -176.507 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.3 152.8 32.58 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.89 -1.131 . . . . 0.0 109.673 -176.846 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.27 1.0 OUTLIER -112.61 116.02 51.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 CA-C-O 122.72 1.247 . . . . 0.0 109.457 170.885 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.5 mm -76.43 127.59 84.26 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 116.218 -1.849 . . . . 0.0 114.161 -173.789 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -58.08 132.54 49.97 Favored 'Trans proline' 0 N--CA 1.433 -2.052 0 CA-C-N 124.474 2.634 . . . . 0.0 116.725 -179.035 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.278 53.8 mttp 72.15 18.97 4.66 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.35 2.26 . . . . 0.0 114.551 -174.087 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.84 157.17 45.07 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 119.394 -2.067 . . . . 0.0 112.227 170.863 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.36 -59.91 3.3 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.573 -1.545 . . . . 0.0 114.679 169.143 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.94 93.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.915 2.486 . . . . 0.0 112.263 -179.717 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -45.0 -61.75 1.5 Allowed 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.111 1.764 . . . . 0.0 114.15 173.001 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.5 t -67.75 -43.18 80.51 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -175.419 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.58 -58.08 6.65 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 127.202 2.201 . . . . 0.0 114.081 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.58 31.6 7.38 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.299 -1.5 . . . . 0.0 115.037 163.146 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 53.4 mtt180 -96.98 -29.98 13.35 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 125.291 1.436 . . . . 0.0 109.151 162.786 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.7 mt -108.54 130.01 62.0 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 125.361 1.464 . . . . 0.0 111.076 -179.486 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -141.58 170.55 15.5 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.894 -1.129 . . . . 0.0 109.579 172.842 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.8 pttm -66.59 140.96 57.98 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 118.604 -2.56 . . . . 0.0 113.74 178.119 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.5 -11.21 65.05 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.602 -0.686 . . . . 0.0 113.163 -171.535 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -79.71 154.37 28.62 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 119.162 1.481 . . . . 0.0 112.27 -177.316 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -97.73 123.75 41.79 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.241 1.416 . . . . 0.0 109.698 -174.895 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.8 t -88.11 130.63 37.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 O-C-N 120.053 -1.655 . . . . 0.0 110.17 -178.398 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -99.06 -52.29 3.59 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.079 -1.013 . . . . 0.0 111.001 -178.036 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.96 144.28 24.83 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.13 -0.981 . . . . 0.0 112.862 -172.828 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.3 t -113.51 111.72 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 66.44 35.78 5.46 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.433 1.893 . . . . 0.0 113.353 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.93 60.01 Favored Glycine 0 N--CA 1.431 -1.659 0 O-C-N 119.931 -1.73 . . . . 0.0 114.238 -175.03 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.35 104.42 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 125.308 1.443 . . . . 0.0 108.508 178.907 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.2 m -72.45 139.87 47.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.628 -1.295 . . . . 0.0 112.552 -175.29 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 98.9 mt -90.24 -2.4 58.03 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -169.297 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -67.81 105.2 1.88 Allowed 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.219 -1.551 . . . . 0.0 113.927 -176.068 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 115.1 -20.99 13.72 Favored Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 125.454 1.502 . . . . 0.0 112.969 -174.698 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.04 153.92 40.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 179.237 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 80.4 p -92.16 176.93 6.31 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.558 -1.339 . . . . 0.0 112.843 -179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.9 t-80 -56.21 -53.01 62.25 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.162 1.785 . . . . 0.0 112.359 172.954 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -55.45 -46.97 76.74 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.622 1.169 . . . . 0.0 113.548 177.55 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.87 -51.59 68.98 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.896 1.443 . . . . 0.0 114.896 177.772 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.22 -36.69 84.95 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.448 -1.408 . . . . 0.0 114.563 176.759 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 95.6 t -72.82 -40.62 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.383 -1.448 . . . . 0.0 111.618 178.186 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -57.63 -44.98 85.96 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.258 -1.526 . . . . 0.0 111.879 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 63.7 m -61.64 -46.71 88.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.718 2.007 . . . . 0.0 114.643 178.157 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . 0.258 0.1 OUTLIER -73.15 -30.85 63.88 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 121.723 2.056 . . . . 0.0 113.893 -178.673 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.36 -39.48 92.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.795 -1.19 . . . . 0.0 111.437 169.729 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -88.94 55.68 3.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 123.02 1.39 . . . . 0.0 111.233 177.825 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.466 ' HB ' HG22 ' A' ' 92' ' ' VAL . 17.4 p -106.32 156.95 17.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.615 1.566 . . . . 0.0 109.624 174.184 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.15 -162.63 32.96 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 121.374 -0.828 . . . . 0.0 111.987 176.294 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -70.79 -48.96 51.49 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.213 1.405 . . . . 0.0 111.551 175.335 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.4 134.03 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.512 1.149 . . . . 0.0 108.044 167.515 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.551 HG21 HD21 ' A' ' 25' ' ' LEU . 82.8 t -124.4 134.95 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 128.562 2.745 . . . . 0.0 107.778 -170.976 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 23.2 t-160 -122.73 95.23 4.54 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.856 -1.778 . . . . 0.0 110.497 -173.009 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.6 mt -99.58 157.3 16.55 Favored 'General case' 0 N--CA 1.429 -1.517 0 O-C-N 120.02 -1.675 . . . . 0.0 114.023 -177.122 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.4 tp -127.2 131.64 50.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 162.335 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.14 163.48 32.75 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.889 -1.132 . . . . 0.0 111.165 176.251 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -117.17 144.73 44.43 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.535 1.934 . . . . 0.0 108.181 176.918 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.4 tptt . . . . . 0 N--CA 1.431 -1.419 0 O-C-N 120.623 -1.298 . . . . 0.0 112.407 -177.201 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 46.4 t0 . . . . . 0 N--CA 1.429 -1.484 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 36.3 p -120.7 165.08 15.59 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.069 -1.644 . . . . 0.0 111.76 -178.725 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.51 144.36 28.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 121.889 0.852 . . . . 0.0 109.677 165.018 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.97 130.2 35.5 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 125.643 1.577 . . . . 0.0 109.835 168.929 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.2 t -118.49 113.12 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 124.819 1.248 . . . . 0.0 108.461 -177.283 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -94.94 108.46 20.52 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 165.934 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 21.7 tp -123.65 128.69 50.03 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.693 1.235 . . . . 0.0 110.394 -176.162 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.99 137.45 39.34 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.757 -1.839 . . . . 0.0 109.569 169.326 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -69.41 136.17 51.26 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.122 -0.986 . . . . 0.0 113.101 177.006 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.9 p -90.02 93.1 9.26 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.41 -1.431 . . . . 0.0 111.448 -171.975 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.7 t70 56.29 41.92 28.53 Favored 'General case' 0 N--CA 1.429 -1.523 0 C-N-CA 125.812 1.645 . . . . 0.0 113.26 178.023 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.03 -20.43 40.81 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.766 1.174 . . . . 0.0 115.372 -174.707 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -94.11 110.68 22.38 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.254 1.527 . . . . 0.0 114.163 -170.535 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.5 tt -125.53 64.79 1.17 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 169.856 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -82.16 74.99 2.4 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 126.754 2.121 . . . . 0.0 111.259 -164.72 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.2 pt -100.65 156.49 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 125.332 1.453 . . . . 0.0 111.149 169.774 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 46.7 t -129.05 127.6 41.89 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.138 -1.601 . . . . 0.0 107.318 158.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 m -120.49 168.2 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 124.676 1.19 . . . . 0.0 110.141 -178.525 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -149.97 -175.31 5.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.614 -1.304 . . . . 0.0 107.566 176.031 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.89 -168.7 12.62 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.888 -1.132 . . . . 0.0 114.631 168.608 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.1 161.76 18.65 Favored Glycine 0 N--CA 1.431 -1.652 0 CA-C-O 122.901 1.278 . . . . 0.0 115.039 173.076 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.43 -1.438 0 C-N-CA 127.405 2.282 . . . . 0.0 115.646 -178.151 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.701 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.9 mm -99.47 126.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 177.339 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -127.11 152.63 47.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 119.657 1.117 . . . . 0.0 111.3 -170.322 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.42 126.18 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 O-C-N 120.555 -1.34 . . . . 0.0 112.964 172.674 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 39.6 tttp -97.93 -39.5 8.94 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.191 1.396 . . . . 0.0 111.81 -175.483 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -161.29 154.69 21.55 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.226 -0.921 . . . . 0.0 110.291 173.759 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.23 120.72 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 124.252 1.021 . . . . 0.0 108.436 168.59 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.2 mm -76.62 127.1 85.1 Favored Pre-proline 0 N--CA 1.43 -1.437 0 CA-C-O 116.752 -1.594 . . . . 0.0 113.993 -169.666 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -55.26 119.89 7.28 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 123.737 2.958 . . . . 0.0 115.942 177.3 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.37 5.3 mmmp? 78.92 23.14 0.59 Allowed 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.562 2.745 . . . . 0.0 116.059 -175.155 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.04 164.46 40.66 Favored Glycine 0 N--CA 1.431 -1.673 0 O-C-N 120.544 -1.347 . . . . 0.0 112.14 163.303 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -58.71 4.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.857 1.428 . . . . 0.0 114.857 168.323 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.39 -26.85 68.64 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.376 1.871 . . . . 0.0 114.576 -177.772 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.66 -54.26 45.07 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.688 1.709 . . . . 0.0 113.057 177.156 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 t -65.88 -44.01 86.62 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 125.511 1.524 . . . . 0.0 112.985 -176.167 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -45.01 -55.79 5.23 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.232 2.613 . . . . 0.0 116.272 -172.637 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.49 6.93 35.26 Favored Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 116.965 1.546 . . . . 0.0 116.965 162.29 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -90.17 -49.42 6.57 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.804 -1.41 . . . . 0.0 109.354 167.75 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 87.3 mt -79.31 128.99 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.351 1.46 . . . . 0.0 112.242 -171.647 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -132.94 153.55 51.31 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.876 1.67 . . . . 0.0 111.047 -178.418 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -51.49 123.19 9.28 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.134 1.774 . . . . 0.0 113.763 170.436 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 93.04 0.11 68.61 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 120.868 -1.145 . . . . 0.0 115.906 -178.429 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 1.7 p30 -82.05 159.07 23.54 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 120.119 1.959 . . . . 0.0 113.936 176.006 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -100.32 130.03 46.38 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.592 -1.318 . . . . 0.0 112.788 -177.004 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -85.7 125.37 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.934 1.294 . . . . 0.0 110.014 176.112 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.36 -42.7 6.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.777 -1.202 . . . . 0.0 111.825 -174.464 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 148.9 29.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.716 -1.24 . . . . 0.0 111.647 179.795 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 t -118.73 109.4 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 171.093 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.3 t30 45.13 67.47 0.71 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.297 2.639 . . . . 0.0 116.11 173.847 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 88.48 -29.38 5.75 Favored Glycine 0 N--CA 1.43 -1.725 0 C-N-CA 124.098 0.856 . . . . 0.0 113.555 -179.476 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -94.5 111.27 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 121.084 -1.245 . . . . 0.0 109.109 -171.771 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 73.6 m -69.99 133.49 47.31 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 176.677 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.1 mt -86.5 50.06 1.92 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.847 -1.158 . . . . 0.0 111.064 -178.411 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -89.7 133.23 34.77 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.599 2.36 . . . . 0.0 109.715 178.133 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.67 3.83 22.82 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 117.232 1.653 . . . . 0.0 117.232 -179.543 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.84 148.7 45.94 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 115.645 1.72 . . . . 0.0 115.645 -170.763 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 69.2 p -90.01 174.51 7.62 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.838 -1.164 . . . . 0.0 110.481 165.063 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -52.92 -52.71 56.82 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.172 1.789 . . . . 0.0 113.715 174.758 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -55.64 -40.4 72.14 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 126.074 1.75 . . . . 0.0 114.598 -179.503 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -54.95 -57.23 12.5 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 126.883 2.073 . . . . 0.0 113.146 177.654 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.61 -37.8 83.03 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.57 1.148 . . . . 0.0 113.815 178.794 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.5 t -68.35 -48.18 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.653 -1.279 . . . . 0.0 110.722 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 53.2 mm-40 -66.52 -26.86 67.36 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.249 -1.532 . . . . 0.0 112.855 178.316 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 66.5 m -69.68 -46.19 66.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.814 1.646 . . . . 0.0 113.085 170.887 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 47.7 mt -72.23 -22.35 61.26 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 119.779 -1.826 . . . . 0.0 114.822 176.475 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -68.3 -50.72 51.62 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.137 -1.602 . . . . 0.0 111.057 166.217 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.52 60.01 5.43 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.273 1.429 . . . . 0.0 113.281 -174.071 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 44.0 p -92.23 -175.9 4.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.422 -1.424 . . . . 0.0 110.73 171.541 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.22 -150.95 23.51 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 157.759 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -71.25 -52.57 18.24 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.771 1.228 . . . . 0.0 113.358 174.596 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 17.3 t -104.74 120.48 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 122.338 1.066 . . . . 0.0 110.613 -176.915 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.8 t -109.29 139.6 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 127.623 2.369 . . . . 0.0 109.676 -169.668 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -115.49 112.97 23.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.248 -1.533 . . . . 0.0 109.325 174.178 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -107.03 158.55 16.96 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.279 1.432 . . . . 0.0 113.034 176.612 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 67.2 tp -126.29 130.8 51.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 164.119 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.78 159.23 41.98 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 121.084 -1.01 . . . . 0.0 112.713 174.528 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -101.58 137.16 40.27 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 126.137 1.775 . . . . 0.0 108.443 175.029 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.431 -1.41 0 O-C-N 120.607 -1.308 . . . . 0.0 111.071 -171.746 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.6 t0 . . . . . 0 N--CA 1.43 -1.436 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -92.5 146.23 23.84 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.261 -1.524 . . . . 0.0 109.934 176.967 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 16.8 p90 -146.41 137.36 24.27 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 123.048 1.404 . . . . 0.0 109.192 179.837 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.15 141.25 34.3 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.703 1.601 . . . . 0.0 109.128 -178.795 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.5 t -130.66 113.18 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -171.824 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -107.39 75.16 1.0 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.879 1.324 . . . . 0.0 107.845 173.411 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.7 tp -94.8 135.11 36.68 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.357 1.463 . . . . 0.0 111.864 -168.552 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.49 146.08 28.63 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.269 -1.519 . . . . 0.0 111.796 173.373 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -70.27 157.97 36.74 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 115.192 1.552 . . . . 0.0 115.192 176.494 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.4 t -134.57 125.77 27.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.77 -1.206 . . . . 0.0 108.578 168.758 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 1.2 t70 50.55 40.82 24.43 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.985 2.514 . . . . 0.0 114.25 -170.49 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.1 -9.98 50.8 Favored Glycine 0 N--CA 1.431 -1.688 0 O-C-N 120.224 -1.547 . . . . 0.0 116.302 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.01 144.19 34.01 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.693 -1.475 . . . . 0.0 113.146 -166.849 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.461 HD21 HG21 ' A' ' 92' ' ' VAL . 49.8 mt -99.78 -62.28 1.26 Allowed 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.287 -0.883 . . . . 0.0 110.458 173.8 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.71 47.52 0.73 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 119.574 -1.954 . . . . 0.0 112.923 168.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.6 tt -147.53 137.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.666 1.222 . . . . 0.0 112.016 -178.741 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.7 m -105.42 133.89 49.43 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.928 1.291 . . . . 0.0 108.855 168.162 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.8 m -107.7 170.68 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.39 1.09 . . . . 0.0 110.766 178.806 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -150.41 -172.49 4.19 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.458 -1.401 . . . . 0.0 108.508 174.775 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.98 -144.84 18.56 Favored Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 124.893 1.235 . . . . 0.0 111.309 179.316 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.36 146.44 13.7 Favored Glycine 0 N--CA 1.43 -1.757 0 C-N-CA 124.098 0.856 . . . . 0.0 112.367 177.434 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t . . . . . 0 N--CA 1.43 -1.441 0 O-C-N 120.929 -1.336 . . . . 0.0 114.126 -170.154 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.797 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.6 mm -101.9 129.0 53.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.832 1.253 . . . . 0.0 109.091 -179.243 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -125.55 156.96 38.24 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.632 -1.293 . . . . 0.0 109.952 -170.823 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -75.31 121.07 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.398 -1.439 . . . . 0.0 111.929 173.203 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -88.33 -59.42 2.24 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.092 -1.63 . . . . 0.0 110.793 179.2 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.58 154.55 34.46 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.633 -0.667 . . . . 0.0 110.187 -172.193 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.429 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.1 tp -111.53 125.88 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 CA-C-O 121.848 0.832 . . . . 0.0 109.541 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 16.5 mm -77.67 125.18 86.21 Favored Pre-proline 0 N--CA 1.429 -1.497 0 C-N-CA 126.259 1.823 . . . . 0.0 113.473 -173.594 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.58 130.32 39.35 Favored 'Trans proline' 0 N--CA 1.434 -1.996 0 CA-C-N 124.356 2.591 . . . . 0.0 116.568 -175.492 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.275 1.8 mptp? 73.59 13.95 4.35 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 127.592 2.357 . . . . 0.0 115.004 178.916 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.12 164.21 52.64 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 119.615 -1.928 . . . . 0.0 113.767 174.997 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.43 -56.76 10.05 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 126.325 1.85 . . . . 0.0 114.733 168.831 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.28 -46.68 82.6 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 128.673 2.789 . . . . 0.0 112.351 178.522 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HA ' HG12 ' A' ' 47' ' ' ILE . 3.1 tm-20 -47.71 -61.97 1.68 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.996 1.851 . . . . 0.0 115.996 170.696 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 65.4 m -69.0 -26.71 65.15 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -175.654 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -55.61 -68.05 0.23 Allowed 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.942 1.697 . . . . 0.0 111.651 174.349 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.48 30.33 33.63 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.043 -1.036 . . . . 0.0 114.925 171.798 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -78.48 -47.76 16.75 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 120.727 -1.455 . . . . 0.0 108.48 147.84 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.3 111.85 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 C-N-CA 125.956 1.703 . . . . 0.0 112.636 -175.099 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -117.21 160.35 21.21 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 123.922 1.82 . . . . 0.0 113.151 -178.503 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -60.94 129.49 41.68 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.259 1.423 . . . . 0.0 113.949 -174.42 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 87.54 -4.85 85.77 Favored Glycine 0 N--CA 1.431 -1.675 0 CA-C-O 118.91 -0.939 . . . . 0.0 114.06 176.108 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -80.96 162.69 23.76 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 119.508 1.654 . . . . 0.0 112.3 -173.866 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 14.9 ttt180 -106.19 123.97 48.86 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.535 -1.353 . . . . 0.0 111.87 -159.897 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.1 123.28 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.976 -1.077 . . . . 0.0 110.099 -175.2 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -94.47 -44.05 8.06 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.876 -1.14 . . . . 0.0 110.625 -177.563 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.89 137.93 19.18 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.577 -0.702 . . . . 0.0 112.205 -173.043 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -111.42 126.71 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 174.422 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 71.02 14.81 6.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.267 1.827 . . . . 0.0 111.424 -179.623 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.21 89.62 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 125.956 1.741 . . . . 0.0 114.156 -170.347 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -91.77 124.62 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-N 118.868 1.334 . . . . 0.0 109.568 -179.83 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 25.4 m -72.92 135.02 45.01 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.767 -1.208 . . . . 0.0 112.817 -172.127 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.5 mt -87.34 36.34 0.74 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.684 -1.26 . . . . 0.0 114.364 -174.118 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -72.71 116.91 13.76 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.143 -2.223 . . . . 0.0 113.572 -170.933 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.23 13.09 79.78 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.13 -0.981 . . . . 0.0 114.26 -177.643 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.32 144.33 51.74 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -177.996 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 64.7 p -81.73 173.33 12.41 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.252 -1.53 . . . . 0.0 110.493 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -59.52 -48.14 82.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.874 -1.141 . . . . 0.0 111.648 172.182 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.12 -47.96 77.14 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.119 1.368 . . . . 0.0 114.23 174.145 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -58.86 -47.16 85.88 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.235 1.939 . . . . 0.0 116.235 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.35 -35.43 80.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.723 -1.235 . . . . 0.0 112.215 173.166 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.62 -45.02 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.012 -1.055 . . . . 0.0 111.077 178.951 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -58.65 -40.77 84.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.625 -1.297 . . . . 0.0 113.232 173.545 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.7 m -66.43 -38.81 88.27 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.702 1.601 . . . . 0.0 113.017 178.668 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 38.9 mt -72.61 -31.73 65.39 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.353 -1.467 . . . . 0.0 113.945 172.569 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.1 -42.16 76.49 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.485 -1.385 . . . . 0.0 112.876 173.692 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -79.04 58.17 2.38 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 124.086 1.898 . . . . 0.0 111.415 174.272 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 p -107.7 143.9 35.56 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.898 2.479 . . . . 0.0 108.88 170.951 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.77 -141.85 8.23 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 121.154 -0.966 . . . . 0.0 112.063 172.953 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.5 tt0 -62.44 -57.56 10.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.581 1.552 . . . . 0.0 113.118 174.304 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.21 142.54 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 CA-C-O 122.695 1.236 . . . . 0.0 110.487 178.231 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG21 HD21 ' A' ' 25' ' ' LEU . 64.8 t -124.23 112.35 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 128.268 2.627 . . . . 0.0 109.16 -170.834 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -97.47 108.1 20.75 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.783 -1.198 . . . . 0.0 111.637 176.744 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.1 mt -105.38 146.52 29.32 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.904 -1.122 . . . . 0.0 113.251 172.94 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.9 tp -116.33 126.59 53.74 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 162.864 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.508 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 1.1 pp -146.81 163.95 34.37 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.246 -0.909 . . . . 0.0 110.949 179.556 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -123.31 143.08 50.31 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.252 1.021 . . . . 0.0 112.151 -176.855 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.4 tptm . . . . . 0 N--CA 1.43 -1.43 0 C-N-CA 125.662 1.585 . . . . 0.0 109.177 174.199 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.2 t70 . . . . . 0 CA--C 1.489 -1.394 0 CA-C-O 121.489 0.661 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.0 p -91.01 159.67 16.02 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.328 1.051 . . . . 0.0 113.812 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -144.32 138.95 28.23 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.835 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -87.78 122.73 31.79 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.649 -1.282 . . . . 0.0 108.988 164.673 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 53.7 t -107.18 88.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.986 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -96.54 89.19 4.91 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.039 1.736 . . . . 0.0 108.034 177.949 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.0 tp -125.48 151.74 45.87 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.513 1.525 . . . . 0.0 109.758 -171.309 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.04 153.74 19.96 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.194 -1.566 . . . . 0.0 110.76 167.816 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -67.22 156.25 36.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 115.364 1.616 . . . . 0.0 115.364 -179.552 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 63.1 p -116.18 114.42 24.42 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.834 -1.166 . . . . 0.0 108.657 169.487 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.6 t0 40.56 56.91 2.69 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.843 2.457 . . . . 0.0 115.293 -176.701 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.75 -30.32 5.43 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 125.015 1.293 . . . . 0.0 115.488 -177.003 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.49 142.76 33.16 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.729 -1.454 . . . . 0.0 114.783 -162.749 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 95.9 mt -94.54 -60.55 1.69 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.223 1.409 . . . . 0.0 107.98 164.645 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.9 36.38 0.89 Allowed Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.873 -1.767 . . . . 0.0 112.504 167.885 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 pt -118.78 124.42 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 122.577 1.179 . . . . 0.0 111.179 -174.7 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.2 m -100.05 125.24 46.09 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 164.165 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -107.48 170.1 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 124.192 0.997 . . . . 0.0 111.438 -175.497 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -153.34 178.78 9.41 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.467 -1.396 . . . . 0.0 108.146 177.005 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.22 13.73 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.627 1.108 . . . . 0.0 114.139 175.537 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.68 152.73 10.93 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 126.239 1.876 . . . . 0.0 111.527 -177.222 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.43 -1.441 0 O-C-N 120.592 -1.534 . . . . 0.0 114.755 -175.325 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.713 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.65 131.25 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 174.751 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -128.14 154.81 45.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 120.964 -1.085 . . . . 0.0 109.466 -173.141 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.6 t -77.06 122.74 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 O-C-N 120.348 -1.47 . . . . 0.0 112.656 175.029 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -92.0 -47.47 7.27 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.803 1.241 . . . . 0.0 112.18 178.862 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.69 161.83 37.14 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.174 -0.954 . . . . 0.0 110.786 -179.753 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -118.03 124.57 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.742 1.217 . . . . 0.0 109.487 -178.384 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.5 mm -77.19 121.02 83.94 Favored Pre-proline 0 N--CA 1.43 -1.454 0 CA-C-O 116.45 -1.738 . . . . 0.0 114.454 -175.214 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_exo -58.2 122.86 12.41 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 123.275 2.65 . . . . 0.0 116.202 -178.985 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.323 72.0 mmtt 76.73 31.36 0.56 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 127.064 2.146 . . . . 0.0 113.812 -177.57 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.5 162.68 38.21 Favored Glycine 0 N--CA 1.431 -1.685 0 CA-C-O 122.262 0.923 . . . . 0.0 112.117 159.107 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.98 -59.44 4.15 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.253 1.821 . . . . 0.0 114.653 166.585 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.73 -49.37 76.69 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 129.395 3.078 . . . . 0.0 111.705 -176.676 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -41.74 -66.53 0.34 Allowed 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 172.179 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.3 m -70.04 -10.82 59.96 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -176.35 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -75.55 -57.19 4.03 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 119.374 -2.079 . . . . 0.0 111.313 177.37 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.18 0.79 54.37 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.909 -1.12 . . . . 0.0 115.411 170.236 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.3 mmt-85 -66.88 -33.69 76.15 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.68 -1.482 . . . . 0.0 110.941 162.97 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 81.6 mt -90.67 113.14 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 C-N-CA 126.066 1.746 . . . . 0.0 110.727 -178.696 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -113.11 156.46 23.13 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-O 123.625 1.679 . . . . 0.0 112.698 179.352 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -69.57 128.08 35.23 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 119.999 -1.688 . . . . 0.0 111.994 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 89.14 8.01 69.36 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.628 -1.295 . . . . 0.0 114.567 -177.137 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -79.83 173.42 12.61 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 119.672 1.736 . . . . 0.0 113.34 175.617 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.8 ttt-85 -101.55 140.74 35.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 123.104 1.431 . . . . 0.0 110.644 174.956 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -99.69 136.11 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.172 -1.58 . . . . 0.0 107.507 178.768 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -100.71 -57.4 2.11 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.931 -1.73 . . . . 0.0 113.063 -176.988 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.57 139.19 20.64 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.762 -1.211 . . . . 0.0 109.596 -174.678 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.29 113.28 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-O 121.884 0.85 . . . . 0.0 109.153 179.022 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 6.7 t30 67.35 21.7 9.7 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.31 1.844 . . . . 0.0 114.648 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.81 -13.64 41.77 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 120.897 -1.127 . . . . 0.0 112.777 -175.219 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.0 t -94.14 116.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 121.218 -1.166 . . . . 0.0 109.257 -176.796 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.6 p -74.51 133.99 42.28 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.628 -1.295 . . . . 0.0 111.615 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.0 mt -86.67 22.12 2.01 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.729 -1.232 . . . . 0.0 113.531 -172.813 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.0 mm-40 -68.08 119.69 13.09 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.87 -1.769 . . . . 0.0 111.982 174.085 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.33 8.65 83.89 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 121.214 -0.929 . . . . 0.0 115.369 -176.724 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.16 144.56 46.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.796 1.776 . . . . 0.0 115.796 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 73.0 p -87.1 178.3 6.95 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.566 -1.333 . . . . 0.0 109.717 168.451 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -62.98 -46.95 85.27 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.823 -1.798 . . . . 0.0 112.12 171.477 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 4.7 tmtm? -55.0 -39.53 69.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.612 1.965 . . . . 0.0 115.436 174.686 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -58.61 -51.12 71.27 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 173.573 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.07 -35.29 79.52 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 124.651 1.18 . . . . 0.0 112.985 -178.765 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.9 t -64.89 -48.57 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 124.653 1.181 . . . . 0.0 110.846 173.94 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 75.6 mt-10 -58.81 -45.42 89.98 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.923 -1.111 . . . . 0.0 113.286 176.882 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 94.5 m -62.59 -43.75 98.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.765 2.026 . . . . 0.0 112.741 178.386 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 22.8 mt -61.48 -45.55 93.79 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.702 -1.249 . . . . 0.0 114.326 172.148 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 55.7 mtp85 -73.2 -27.56 61.69 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.444 -1.41 . . . . 0.0 113.934 -177.467 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -84.32 50.56 1.89 Allowed 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.121 -1.612 . . . . 0.0 112.039 172.006 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.412 ' HB ' HG22 ' A' ' 92' ' ' VAL . 7.4 p -106.7 149.88 26.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.409 1.884 . . . . 0.0 109.966 174.911 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.41 -153.46 20.79 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.959 -1.088 . . . . 0.0 112.496 173.478 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -68.34 -53.48 23.86 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.384 -1.657 . . . . 0.0 113.62 178.677 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 54.1 t -93.07 136.51 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.502 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 173.837 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 88' ' ' THR . 90.7 t -124.39 126.56 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 C-N-CA 125.633 1.573 . . . . 0.0 109.239 -170.183 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -105.38 95.5 5.87 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.904 -1.748 . . . . 0.0 113.329 -178.128 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.485 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 34.8 mt -94.22 153.4 18.08 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 118.581 -2.574 . . . . 0.0 113.305 176.7 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 25.3 tp -116.43 138.79 51.09 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 158.86 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.436 HD13 ' N ' ' A' ' 97' ' ' GLU . 0.4 OUTLIER -137.89 153.67 49.52 Favored 'General case' 0 N--CA 1.429 -1.522 0 C-N-CA 124.941 1.297 . . . . 0.0 109.878 -164.959 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.436 ' N ' HD13 ' A' ' 96' ' ' LEU . 41.7 tt0 -133.13 136.06 45.56 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 119.938 1.245 . . . . 0.0 111.053 169.441 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? . . . . . 0 N--CA 1.43 -1.472 0 O-C-N 120.328 -1.483 . . . . 0.0 111.553 -178.196 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.6 t0 . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 p -109.98 150.21 28.83 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.743 1.217 . . . . 0.0 111.69 -175.304 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.79 131.14 18.59 Favored 'General case' 0 N--CA 1.431 -1.425 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.907 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -88.51 113.55 24.21 Favored 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.825 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.4 t -99.82 100.82 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 O-C-N 120.637 -1.289 . . . . 0.0 108.964 -171.217 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.67 95.96 8.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.88 1.672 . . . . 0.0 108.559 177.427 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 51.6 tp -124.74 145.09 49.89 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.751 1.22 . . . . 0.0 111.315 -166.885 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.08 137.68 40.93 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.427 -1.421 . . . . 0.0 111.052 173.165 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -70.64 149.42 47.04 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 117.414 2.375 . . . . 0.0 117.414 -177.715 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 72.0 p -127.14 132.62 50.51 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.355 -1.466 . . . . 0.0 109.695 176.403 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 13.1 t70 64.73 16.12 10.2 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.883 2.073 . . . . 0.0 114.352 -177.981 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.37 6.93 89.0 Favored Glycine 0 N--CA 1.43 -1.734 0 O-C-N 119.647 -1.908 . . . . 0.0 114.63 -174.259 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -123.24 173.63 7.8 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 121.27 -1.135 . . . . 0.0 110.774 176.121 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -109.71 -57.57 2.17 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.534 1.134 . . . . 0.0 108.173 171.45 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.4 50.24 0.11 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 119.841 -1.787 . . . . 0.0 111.861 163.297 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.7 tt -137.51 140.63 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.102 0.953 . . . . 0.0 111.191 -171.304 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.3 t -121.81 139.08 54.06 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.11 1.364 . . . . 0.0 108.284 170.39 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.6 m -116.95 170.31 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.929 -1.107 . . . . 0.0 113.74 -167.597 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -152.59 160.06 43.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.613 -1.304 . . . . 0.0 109.776 175.969 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.29 -148.25 19.58 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.909 -1.12 . . . . 0.0 115.02 172.126 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.45 -174.23 20.96 Favored Glycine 0 N--CA 1.43 -1.719 0 C-N-CA 125.443 1.497 . . . . 0.0 109.474 -169.604 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 N--CA 1.431 -1.422 0 O-C-N 120.539 -1.565 . . . . 0.0 113.753 -178.683 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.816 0 N-CA-C 112.236 -0.346 . . . . 0.0 112.236 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.1 mm -85.53 116.83 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 C-N-CA 124.97 1.308 . . . . 0.0 110.615 -176.978 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -114.78 156.36 25.0 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.536 -1.353 . . . . 0.0 109.68 -177.822 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -76.99 123.14 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.214 -1.554 . . . . 0.0 111.029 170.599 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 12.7 ttmm -91.15 -45.41 8.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.198 -1.564 . . . . 0.0 111.084 175.788 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.17 156.49 42.25 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 120.172 -1.58 . . . . 0.0 111.414 -179.734 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -119.32 128.13 75.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 124.485 1.114 . . . . 0.0 108.642 177.392 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.91 121.27 84.49 Favored Pre-proline 0 N--CA 1.429 -1.513 0 N-CA-C 117.004 2.224 . . . . 0.0 117.004 -171.086 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -56.01 122.95 12.67 Favored 'Trans proline' 0 N--CA 1.434 -2.017 0 C-N-CA 123.44 2.76 . . . . 0.0 116.549 -177.288 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.4 mtmm 78.43 13.0 1.52 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 128.367 2.667 . . . . 0.0 114.465 -176.168 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.95 157.77 47.45 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 120.007 -1.683 . . . . 0.0 111.682 172.852 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.21 -55.81 7.88 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.873 1.669 . . . . 0.0 114.735 170.166 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.9 -47.76 79.32 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 127.659 2.384 . . . . 0.0 113.327 178.82 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -47.48 -61.97 1.66 Allowed 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.219 1.563 . . . . 0.0 115.219 170.299 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -65.39 -31.64 72.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.993 1.317 . . . . 0.0 113.62 -171.853 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -54.89 -63.56 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.186 2.194 . . . . 0.0 113.097 174.388 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.53 47.49 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.972 -1.08 . . . . 0.0 115.344 171.76 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 58' ' ' ARG . . . . . 0.437 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.0 mmp_? -76.64 -22.05 54.64 Favored 'General case' 0 N--CA 1.429 -1.481 0 CA-C-N 119.817 1.809 . . . . 0.0 112.438 171.368 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.3 mt -103.26 123.58 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.537 1.135 . . . . 0.0 108.252 171.656 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.733 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 25.9 t-80 -146.67 -171.25 3.71 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.63 1.681 . . . . 0.0 111.717 176.692 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.733 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 44.4 tttp -72.2 123.87 23.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.015 1.726 . . . . 0.0 113.785 -166.105 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.12 76.59 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.721 -1.237 . . . . 0.0 113.935 -176.266 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -80.62 155.53 26.83 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 119.313 1.556 . . . . 0.0 112.309 173.114 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.1 tpt85 -106.07 118.73 37.37 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.681 -1.262 . . . . 0.0 109.034 -174.01 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 59.2 t -91.46 122.63 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.451 -1.405 . . . . 0.0 108.522 -178.24 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -87.08 -45.0 11.12 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.157 0.983 . . . . 0.0 110.287 -177.099 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.45 139.73 21.29 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.885 0.85 . . . . 0.0 110.621 -173.829 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.8 t -118.2 122.41 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 177.845 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 64.11 25.66 13.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.582 -1.323 . . . . 0.0 114.152 172.754 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.03 -5.44 84.49 Favored Glycine 0 N--CA 1.429 -1.787 0 O-C-N 120.191 -1.568 . . . . 0.0 114.102 -175.719 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.5 t -95.41 126.08 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 C-N-CA 125.031 1.332 . . . . 0.0 109.547 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.1 t -76.8 127.57 33.0 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.52 -1.363 . . . . 0.0 110.634 -178.866 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.4 mt -82.82 2.62 33.22 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.28 -1.513 . . . . 0.0 114.227 -175.793 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -65.07 126.05 26.84 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.105 -2.247 . . . . 0.0 112.668 -178.857 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.65 -8.36 77.78 Favored Glycine 0 N--CA 1.429 -1.79 0 O-C-N 121.013 -1.054 . . . . 0.0 114.839 -175.776 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.09 146.0 46.08 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 177.216 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 24.1 p -92.37 -179.38 5.2 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.041 1.736 . . . . 0.0 111.441 171.227 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-160 -57.08 -52.93 63.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.817 1.647 . . . . 0.0 114.693 -177.881 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.3 tmtp? -56.73 -38.23 72.08 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -58.95 -53.27 60.27 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.886 1.674 . . . . 0.0 115.127 177.767 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.76 -37.26 86.69 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.255 1.422 . . . . 0.0 112.464 178.711 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.22 -51.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.577 1.151 . . . . 0.0 111.047 175.202 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -64.84 -33.53 76.22 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 178.959 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 35.3 m -75.37 -43.2 51.6 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.682 1.593 . . . . 0.0 113.252 179.568 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 27.5 mt -66.2 -42.09 89.29 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.623 -1.298 . . . . 0.0 113.062 173.03 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.9 ptt85 -72.71 -37.41 67.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.898 -1.127 . . . . 0.0 113.869 -176.854 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -85.71 59.78 5.84 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 123.412 1.577 . . . . 0.0 111.5 176.41 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' VAL . 4.9 p -107.61 153.69 22.52 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.545 1.938 . . . . 0.0 108.916 173.781 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.35 -151.89 21.87 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.846 -1.159 . . . . 0.0 112.624 -174.924 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -50.73 38.73 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.873 -1.369 . . . . 0.0 113.332 -179.572 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.14 137.09 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.511 1.148 . . . . 0.0 109.177 169.129 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.449 HG22 ' HB ' ' A' ' 88' ' ' THR . 40.3 t -125.3 127.1 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 127.023 2.129 . . . . 0.0 110.293 -166.917 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 18.3 m170 -105.11 114.52 28.77 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.669 -1.27 . . . . 0.0 112.432 172.623 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 9.5 mt -103.26 164.96 11.31 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.087 -1.633 . . . . 0.0 112.261 163.02 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 58.7 tp -127.28 124.63 39.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.65 1.18 . . . . 0.0 107.838 158.407 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.99 162.16 32.84 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.257 -0.902 . . . . 0.0 112.387 175.677 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -117.51 144.69 44.82 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.407 1.883 . . . . 0.0 109.64 175.108 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.431 -1.408 0 C-N-CA 127.458 2.303 . . . . 0.0 113.223 -174.174 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 36.3 t70 . . . . . 0 N--CA 1.431 -1.391 0 N-CA-C 116.007 1.855 . . . . 0.0 116.007 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.7 p -123.11 149.35 44.61 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 121.827 2.103 . . . . 0.0 111.585 168.372 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.3 p90 -147.84 148.87 31.35 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.037 1.399 . . . . 0.0 109.592 171.237 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -92.88 141.62 28.22 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.334 1.854 . . . . 0.0 109.346 176.938 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.74 90.31 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.63 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.2 84.63 4.47 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.401 -1.437 . . . . 0.0 108.22 177.073 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.9 tp -113.73 145.16 41.77 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.113 1.365 . . . . 0.0 111.424 -162.716 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.58 122.43 44.37 Favored 'General case' 0 N--CA 1.429 -1.501 0 O-C-N 120.257 -1.527 . . . . 0.0 108.981 171.291 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -71.68 165.99 22.84 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 179.264 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.4 p -134.23 139.95 46.13 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 124.724 1.21 . . . . 0.0 108.53 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.6 t70 66.77 8.55 6.05 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.944 1.698 . . . . 0.0 115.081 174.205 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.99 -8.47 63.2 Favored Glycine 0 N--CA 1.431 -1.69 0 O-C-N 120.097 -1.627 . . . . 0.0 113.762 -176.279 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 66.8 m -119.47 152.06 37.54 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 118.729 1.264 . . . . 0.0 111.814 -172.346 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.6 mt -86.95 -55.24 3.92 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.259 -1.525 . . . . 0.0 111.734 176.397 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 20.05 1.78 Allowed Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.414 -1.428 . . . . 0.0 112.107 177.25 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.6 pt -115.25 150.21 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 124.941 1.296 . . . . 0.0 110.18 -177.358 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 7.7 t -127.82 123.45 35.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 163.356 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.91 163.54 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.544 1.138 . . . . 0.0 111.683 -172.207 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -150.05 173.9 13.34 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.882 1.273 . . . . 0.0 109.409 -175.441 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.86 -136.11 13.2 Favored Glycine 0 N--CA 1.43 -1.761 0 O-C-N 120.872 -1.142 . . . . 0.0 113.761 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.54 167.73 43.47 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.246 0.927 . . . . 0.0 114.41 177.258 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.43 -1.442 0 N-CA-C 115.548 1.685 . . . . 0.0 115.548 -175.17 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.778 0 CA-C-O 121.924 0.736 . . . . 0.0 114.829 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.8 mm -100.41 125.4 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 C-N-CA 125.2 1.4 . . . . 0.0 107.38 175.18 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.1 m-85 -126.48 153.52 44.99 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.566 -1.334 . . . . 0.0 111.319 -171.562 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.5 t -75.86 122.83 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.861 -1.149 . . . . 0.0 111.987 172.195 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -91.1 -47.17 7.69 Favored 'General case' 0 N--CA 1.429 -1.498 0 C-N-CA 125.639 1.576 . . . . 0.0 110.857 177.419 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.15 165.19 37.12 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.651 -0.656 . . . . 0.0 110.402 -176.702 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -116.13 132.73 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.309 1.043 . . . . 0.0 108.342 175.021 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.5 mm -77.8 121.49 84.25 Favored Pre-proline 0 N--CA 1.429 -1.491 0 C-N-CA 126.137 1.775 . . . . 0.0 114.37 -174.854 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -59.32 123.76 14.1 Favored 'Trans proline' 0 N--CA 1.434 -2.007 0 CA-C-N 124.97 2.811 . . . . 0.0 116.795 -176.104 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.314 59.9 mmtt 68.98 30.9 4.36 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 127.773 2.429 . . . . 0.0 114.534 -176.144 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.02 163.33 39.69 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.31 -1.494 . . . . 0.0 112.8 167.899 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.36 -58.49 5.57 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.479 1.912 . . . . 0.0 114.593 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.83 -46.94 79.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.775 2.03 . . . . 0.0 112.433 -177.107 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -45.44 -62.32 1.32 Allowed 'General case' 0 N--CA 1.429 -1.506 0 C-N-CA 126.87 2.068 . . . . 0.0 115.842 170.657 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.4 m -69.55 -32.07 70.64 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -176.02 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -56.6 -56.4 21.84 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.16 1.784 . . . . 0.0 113.703 173.92 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.88 25.25 32.63 Favored Glycine 0 N--CA 1.431 -1.698 0 O-C-N 120.602 -1.311 . . . . 0.0 116.232 164.49 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.6 mmt-85 -78.89 -52.48 8.24 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.775 -1.426 . . . . 0.0 107.675 160.723 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 74.9 mt -77.82 122.08 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.1 1.36 . . . . 0.0 110.873 178.282 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.454 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 1.9 t60 -131.27 -176.47 4.03 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.033 1.397 . . . . 0.0 112.019 174.95 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 81.4 tttt -69.07 128.32 36.26 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 119.816 -1.803 . . . . 0.0 112.083 -172.295 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.91 1.8 79.26 Favored Glycine 0 N--CA 1.429 -1.772 0 CA-C-O 118.507 -1.163 . . . . 0.0 114.849 -179.408 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.16 158.61 31.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 120.092 1.946 . . . . 0.0 112.057 178.426 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.23 119.59 39.92 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.656 -1.278 . . . . 0.0 110.305 -169.286 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.4 t -85.35 124.8 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 125.985 1.714 . . . . 0.0 110.764 -169.773 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 74.0 mt -106.44 -51.45 2.95 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.319 -1.488 . . . . 0.0 113.888 -173.626 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.16 138.32 20.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.069 -1.644 . . . . 0.0 112.606 -172.042 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.706 HG11 HG21 ' A' ' 84' ' ' THR . 2.2 p -108.77 108.71 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.387 1.475 . . . . 0.0 112.204 -178.877 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.4 t30 58.46 36.94 25.66 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.17 1.788 . . . . 0.0 113.376 168.853 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.95 -9.39 68.09 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 125.829 1.681 . . . . 0.0 115.473 -172.971 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.4 t -103.0 116.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-N 120.808 2.304 . . . . 0.0 111.085 -174.895 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.3 p -69.07 126.05 28.58 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 120.355 -1.466 . . . . 0.0 113.571 179.852 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.5 mt -87.97 46.94 1.43 Allowed 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.633 -1.292 . . . . 0.0 112.852 -176.421 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -89.46 123.02 33.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.326 -2.109 . . . . 0.0 111.189 -178.448 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.58 1.97 89.36 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 121.058 -1.027 . . . . 0.0 114.798 175.041 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.86 162.9 28.77 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.737 1.754 . . . . 0.0 115.737 -178.288 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 p -83.63 173.72 11.14 Favored 'General case' 0 N--CA 1.431 -1.395 0 O-C-N 120.525 -1.359 . . . . 0.0 111.723 176.906 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-160 -56.43 -53.57 55.91 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.755 1.222 . . . . 0.0 112.798 168.298 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.35 -46.26 89.11 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.744 1.387 . . . . 0.0 114.744 179.259 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.99 -48.24 76.23 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.059 1.344 . . . . 0.0 114.505 -173.92 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.85 -42.02 96.98 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 124.833 1.253 . . . . 0.0 113.561 174.366 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.7 t -66.27 -48.84 79.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 125.126 1.371 . . . . 0.0 111.121 179.101 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -60.39 -46.32 90.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.736 1.214 . . . . 0.0 112.775 179.062 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 84' ' ' THR . . . . . 0.706 HG21 HG11 ' A' ' 68' ' ' VAL . 2.3 m -60.03 -43.99 94.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.372 1.469 . . . . 0.0 113.844 172.62 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 37.2 mt -69.72 -34.36 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.119 -1.613 . . . . 0.0 114.725 178.09 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . 0.271 42.9 ptt85 -71.95 -38.93 69.7 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.035 -1.665 . . . . 0.0 113.19 172.801 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.9 t30 -84.34 48.4 1.49 Allowed 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.787 -1.195 . . . . 0.0 113.722 175.936 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 p -99.58 150.46 22.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.032 2.133 . . . . 0.0 109.97 174.311 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.79 -163.46 17.29 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.579 1.085 . . . . 0.0 113.34 177.099 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -68.99 -47.63 65.06 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.522 -1.575 . . . . 0.0 113.799 -178.465 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.25 118.74 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 CA-C-O 122.091 0.948 . . . . 0.0 108.721 179.836 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 65.4 t -124.11 119.26 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 126.457 1.903 . . . . 0.0 110.395 -161.283 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -103.32 97.57 7.61 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.076 -1.64 . . . . 0.0 113.845 -178.433 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.39 148.58 21.94 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.703 -1.873 . . . . 0.0 111.342 176.749 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -127.75 127.97 44.53 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 171.849 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . 0.273 0.0 OUTLIER -146.13 169.59 18.41 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.349 -1.469 . . . . 0.0 113.739 -177.07 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.54 131.6 56.88 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.362 1.865 . . . . 0.0 110.493 -173.414 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.485 0 O-C-N 120.304 -1.498 . . . . 0.0 113.467 179.182 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.431 -1.419 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.3 p -94.29 144.52 25.46 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.473 -1.392 . . . . 0.0 112.379 -177.203 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.432 ' CE1' HD21 ' A' ' 96' ' ' LEU . 5.9 p90 -147.29 140.45 25.23 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 122.74 1.257 . . . . 0.0 107.974 177.337 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -99.43 127.05 45.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.367 1.067 . . . . 0.0 109.765 178.017 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.9 t -116.44 93.32 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.717 1.207 . . . . 0.0 108.364 -170.591 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -89.63 103.82 16.43 Favored 'General case' 0 N--CA 1.429 -1.5 0 CA-C-O 123.221 1.486 . . . . 0.0 107.831 168.668 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.7 tp -121.59 144.52 48.69 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.24 1.416 . . . . 0.0 109.047 -165.55 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.41 120.26 40.02 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 124.672 1.189 . . . . 0.0 109.333 172.059 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -69.43 129.01 38.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.202 1.401 . . . . 0.0 112.412 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.9 t -92.7 104.74 16.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.641 1.21 . . . . 0.0 110.737 -172.31 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.4 t70 33.04 60.29 0.43 Allowed 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 129.339 3.056 . . . . 0.0 116.85 -173.961 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.67 -10.27 74.21 Favored Glycine 0 N--CA 1.43 -1.767 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 178.357 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -111.64 127.11 55.65 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 120.494 2.147 . . . . 0.0 111.519 -179.748 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.0 tp -92.32 -61.49 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.05 -1.031 . . . . 0.0 111.921 -178.844 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.92 -11.8 3.12 Favored Glycine 0 N--CA 1.429 -1.78 0 O-C-N 119.663 -1.898 . . . . 0.0 115.209 170.617 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.0 pt -105.9 141.03 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 119.321 1.561 . . . . 0.0 113.29 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 m -113.23 122.74 48.38 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 159.856 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.72 170.04 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.696 1.236 . . . . 0.0 112.622 -172.933 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 t -152.52 172.35 16.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.755 -1.215 . . . . 0.0 109.602 176.354 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.71 -142.26 15.64 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 113.67 171.415 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.57 150.7 27.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.56 1.076 . . . . 0.0 112.834 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.9 p . . . . . 0 N--CA 1.429 -1.485 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -174.272 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.801 0 CA-C-O 121.259 0.366 . . . . 0.0 113.31 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.486 ' HB ' HG12 ' A' ' 65' ' ' VAL . 25.1 mm -101.69 122.04 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 124.824 1.249 . . . . 0.0 108.412 179.859 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 75.3 m-85 -127.34 152.64 47.21 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.202 -0.936 . . . . 0.0 109.706 -173.552 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -75.82 125.84 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 O-C-N 120.483 -1.386 . . . . 0.0 111.341 171.661 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -98.93 -40.69 7.95 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.634 -1.292 . . . . 0.0 112.316 -179.399 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.61 155.33 40.1 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 121.453 -0.779 . . . . 0.0 111.222 179.699 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.448 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -115.95 124.87 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 CA-C-O 122.465 1.126 . . . . 0.0 111.28 -179.827 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp -76.33 122.97 87.72 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.848 2.059 . . . . 0.0 116.136 -169.176 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -58.25 112.9 1.32 Allowed 'Trans proline' 0 N--CA 1.434 -1.997 0 C-N-CA 123.767 2.978 . . . . 0.0 117.232 -175.588 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.305 48.5 mtmt 79.06 32.27 0.27 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.875 2.87 . . . . 0.0 113.8 -178.124 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.8 159.99 35.08 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 121.418 -0.801 . . . . 0.0 112.026 167.234 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.45 -60.39 2.88 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.519 1.528 . . . . 0.0 114.426 169.46 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.75 99.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 127.396 2.278 . . . . 0.0 112.677 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.448 ' CG ' HG23 ' A' ' 47' ' ' ILE . 2.8 tm-20 -51.49 -65.36 0.57 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 125.771 1.628 . . . . 0.0 114.626 174.678 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.0 t -69.15 -23.22 63.93 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -174.345 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -51.5 -63.94 0.97 Allowed 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.079 1.752 . . . . 0.0 113.019 172.971 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.24 -12.64 28.66 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 121.288 -0.883 . . . . 0.0 114.647 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 -64.22 -56.02 17.58 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 124.409 1.084 . . . . 0.0 111.002 168.614 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.8 mt -78.55 128.73 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 124.957 1.303 . . . . 0.0 110.839 179.074 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -145.7 171.11 15.21 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.132 -0.98 . . . . 0.0 110.113 177.862 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . 0.264 0.0 OUTLIER -64.45 139.67 58.79 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 119.398 -2.064 . . . . 0.0 113.829 179.445 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.78 -7.8 67.99 Favored Glycine 0 N--CA 1.43 -1.709 0 CA-C-O 118.509 -1.162 . . . . 0.0 114.278 -172.67 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.487 ' HB3' HD23 ' A' ' 96' ' ' LEU . 97.7 m-20 -80.75 138.65 36.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 119.8 1.8 . . . . 0.0 113.363 -176.269 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -98.2 133.43 42.63 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.57 -1.331 . . . . 0.0 111.668 -174.408 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.486 HG12 ' HB ' ' A' ' 42' ' ' ILE . 0.4 OUTLIER -82.89 148.73 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.494 -1.379 . . . . 0.0 112.942 -179.384 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -109.39 -51.37 2.88 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.752 1.221 . . . . 0.0 109.689 171.028 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 143.77 25.24 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.801 -1.187 . . . . 0.0 110.925 -175.35 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 58.8 t -117.6 129.09 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.39 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 77.18 -30.46 0.17 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.407 2.683 . . . . 0.0 113.983 173.236 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.09 -17.11 1.54 Allowed Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 126.316 1.913 . . . . 0.0 109.265 -169.937 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.72 116.53 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 125.379 1.472 . . . . 0.0 109.275 -176.196 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.3 m -71.12 127.42 32.53 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.807 -1.183 . . . . 0.0 111.104 176.991 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 22.9 mt -93.88 43.02 1.1 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.027 -1.046 . . . . 0.0 112.699 -171.057 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -75.79 119.93 20.46 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.19 -2.194 . . . . 0.0 112.21 -178.344 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.23 13.2 82.26 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.117 -1.615 . . . . 0.0 115.306 -178.33 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.94 151.42 44.69 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.415 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -82.09 172.83 12.76 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.207 1.003 . . . . 0.0 111.148 176.345 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -61.08 -50.0 75.05 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.909 1.284 . . . . 0.0 113.118 175.057 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.3 -42.01 80.93 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 171.695 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -55.36 -48.78 73.72 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 114.499 1.296 . . . . 0.0 114.499 -175.428 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.96 98.38 Favored 'General case' 0 N--CA 1.431 -1.4 0 C-N-CA 125.126 1.37 . . . . 0.0 113.855 177.2 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.1 -49.87 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 C-N-CA 125.112 1.365 . . . . 0.0 110.451 177.609 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -64.26 -32.26 73.78 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.692 -1.255 . . . . 0.0 113.96 179.632 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 53.0 m -67.65 -46.48 72.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.61 1.964 . . . . 0.0 112.236 173.501 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 70.1 mt -64.02 -38.94 92.89 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.98 -1.075 . . . . 0.0 113.727 173.531 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.12 -45.22 83.67 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.967 1.707 . . . . 0.0 112.444 175.39 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -85.39 44.58 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.265 1.426 . . . . 0.0 113.224 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.3 p -106.81 160.27 15.61 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.075 -1.641 . . . . 0.0 108.739 170.02 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.82 -131.05 4.79 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.474 1.035 . . . . 0.0 110.856 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -69.77 -69.01 0.37 Allowed 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 114.729 1.381 . . . . 0.0 114.729 178.029 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 52.8 t -92.25 124.65 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 CA-C-O 122.853 1.311 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.8 t -124.15 120.82 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 127.574 2.349 . . . . 0.0 109.272 -169.622 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -100.46 113.02 25.46 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.796 -1.815 . . . . 0.0 112.212 173.683 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -97.57 149.32 22.34 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.747 -1.845 . . . . 0.0 111.672 163.336 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.9 124.64 48.77 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 161.773 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.487 HD23 ' HB3' ' A' ' 63' ' ' ASP . 0.0 OUTLIER -150.28 168.46 23.98 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.874 -1.141 . . . . 0.0 113.149 -178.423 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -119.34 144.96 46.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.478 1.511 . . . . 0.0 111.503 -177.905 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.6 tppt? . . . . . 0 N--CA 1.43 -1.459 0 C-N-CA 125.487 1.515 . . . . 0.0 112.755 -179.687 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 t0 . . . . . 0 N--CA 1.43 -1.431 0 CA-C-O 121.296 0.569 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.0 p -102.55 157.57 16.84 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.339 1.055 . . . . 0.0 110.972 -178.857 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -146.16 124.35 12.2 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.713 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -88.94 108.6 19.65 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 122.69 1.233 . . . . 0.0 109.287 162.77 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.2 t -99.06 108.9 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 128.287 2.635 . . . . 0.0 109.303 -168.766 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.4 101.14 13.82 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.845 -1.159 . . . . 0.0 109.737 173.804 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -108.64 158.06 17.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.872 1.32 . . . . 0.0 108.849 172.979 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.41 145.84 29.38 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 104.406 -2.442 . . . . 0.0 104.406 152.609 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -70.03 146.82 50.75 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.899 -1.126 . . . . 0.0 112.501 171.384 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.7 p -106.07 94.72 5.32 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.47 1.129 . . . . 0.0 108.876 178.683 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.0 t0 54.75 60.07 3.72 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.339 1.856 . . . . 0.0 114.023 -178.998 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.63 -34.66 3.64 Favored Glycine 0 N--CA 1.43 -1.739 0 O-C-N 120.701 -1.25 . . . . 0.0 115.693 -176.865 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -94.19 145.63 24.57 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.191 -1.182 . . . . 0.0 113.435 -167.513 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.04 -18.49 13.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.986 -1.071 . . . . 0.0 111.714 176.648 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.63 4.73 54.57 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.483 -2.011 . . . . 0.0 114.756 175.736 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.4 pt -120.06 133.02 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 124.862 1.265 . . . . 0.0 111.293 -171.87 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -113.51 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 126.194 1.798 . . . . 0.0 107.165 168.639 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.69 162.7 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.467 1.127 . . . . 0.0 113.777 -169.014 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.2 t -144.1 178.48 7.84 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.562 1.545 . . . . 0.0 110.055 176.424 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.46 -143.22 16.6 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.979 1.276 . . . . 0.0 113.85 171.487 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.46 158.97 19.31 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 124.488 1.042 . . . . 0.0 113.028 -177.638 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m . . . . . 0 N--CA 1.43 -1.44 0 N-CA-C 116.353 1.983 . . . . 0.0 116.353 -171.744 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.747 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.6 mm -94.67 129.22 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.034 -1.862 . . . . 0.0 107.721 174.387 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.37 157.19 40.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.314 -1.491 . . . . 0.0 109.165 -176.223 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.6 130.27 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 O-C-N 121.179 -0.95 . . . . 0.0 111.066 171.202 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -99.66 -59.82 1.65 Allowed 'General case' 0 N--CA 1.431 -1.392 0 O-C-N 120.313 -1.492 . . . . 0.0 111.398 177.564 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.17 153.69 47.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 -174.947 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.428 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -108.43 122.78 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.383 1.087 . . . . 0.0 108.917 178.364 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.4 117.92 67.81 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 116.244 -1.836 . . . . 0.0 112.596 -173.23 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -64.72 124.47 13.23 Favored 'Trans proline' 0 N--CA 1.433 -2.043 0 C-N-CA 123.577 2.851 . . . . 0.0 114.131 -171.726 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.262 91.7 mttt 70.15 37.47 1.66 Allowed 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.379 2.672 . . . . 0.0 112.473 -170.989 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.54 164.54 36.27 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.018 -1.051 . . . . 0.0 113.073 163.726 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.83 -63.02 1.21 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.523 1.529 . . . . 0.0 114.68 170.415 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.82 -48.5 76.57 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 127.69 2.396 . . . . 0.0 113.738 178.543 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.428 ' HG2' HG23 ' A' ' 47' ' ' ILE . 9.6 tm-20 -43.7 -55.07 4.62 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.975 1.842 . . . . 0.0 115.975 -177.695 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.8 t -67.55 -28.01 67.43 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 114.472 -1.24 . . . . 0.0 113.785 -174.272 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -73.45 -65.54 0.8 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.499 1.12 . . . . 0.0 111.559 -178.808 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.18 10.19 34.8 Favored Glycine 0 N--CA 1.43 -1.755 0 N-CA-C 116.527 1.371 . . . . 0.0 116.527 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 67.2 mtt85 -64.3 -36.2 83.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.945 1.372 . . . . 0.0 111.022 162.265 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.6 mt -94.78 129.45 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.336 1.454 . . . . 0.0 108.82 177.326 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.0 170.07 16.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.81 1.767 . . . . 0.0 110.685 176.737 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 51.2 mtpt -61.6 123.88 19.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.605 1.562 . . . . 0.0 112.001 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 0.3 62.74 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 120.303 -1.498 . . . . 0.0 115.26 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -74.0 157.11 36.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.175 1.487 . . . . 0.0 112.339 178.089 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.5 ttt180 -88.14 125.81 34.8 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.248 1.419 . . . . 0.0 111.101 178.128 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 50.0 t -91.6 128.72 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 124.223 1.009 . . . . 0.0 109.13 178.681 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -105.41 -57.4 2.04 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.684 -1.26 . . . . 0.0 111.305 -179.305 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.95 138.0 20.32 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.857 -1.152 . . . . 0.0 111.663 -170.825 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.8 t -107.45 107.43 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.417 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 27.1 t30 57.73 52.07 8.59 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.785 1.634 . . . . 0.0 114.311 167.832 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.43 -29.4 10.33 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.95 1.262 . . . . 0.0 114.095 -176.541 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.7 118.18 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-N 118.805 1.303 . . . . 0.0 111.235 -170.443 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 57.7 m -69.76 131.67 44.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.493 -1.38 . . . . 0.0 112.413 176.196 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 25.7 mt -93.36 -6.03 48.18 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 121.026 -1.046 . . . . 0.0 112.433 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -55.22 127.52 29.68 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.576 1.55 . . . . 0.0 114.831 -179.084 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.67 -10.82 70.61 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 115.888 1.115 . . . . 0.0 115.888 -178.005 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 76' ' ' ALA . . . . . 0.411 ' HB1' ' HB2' ' A' ' 80' ' ' GLN . . . -72.5 178.39 4.07 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 116.989 2.218 . . . . 0.0 116.989 -177.556 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 47.1 p -92.19 171.22 9.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.282 -1.511 . . . . 0.0 110.835 165.678 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -54.2 -42.07 69.33 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.261 1.824 . . . . 0.0 112.883 168.594 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 43.5 tptt -57.54 -42.4 82.87 Favored 'General case' 0 N--CA 1.429 -1.506 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.411 ' HB2' ' HB1' ' A' ' 76' ' ' ALA . 4.3 mp0 -58.93 -49.43 77.87 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.537 -1.352 . . . . 0.0 114.102 175.109 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.43 -44.29 84.53 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.441 1.497 . . . . 0.0 114.052 174.276 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.01 -45.54 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 124.987 1.315 . . . . 0.0 111.886 177.278 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 -64.43 -37.71 88.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 123.811 0.844 . . . . 0.0 112.586 176.602 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.8 m -63.4 -45.6 90.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.788 2.035 . . . . 0.0 113.018 174.204 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.7 mt -69.21 -21.64 63.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.031 -1.668 . . . . 0.0 114.269 174.193 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -72.15 -53.34 13.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.228 -1.545 . . . . 0.0 111.328 168.684 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -92.68 43.37 1.12 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.946 1.698 . . . . 0.0 112.842 -174.409 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . 0.287 6.2 t -106.39 160.01 15.71 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.48 -1.387 . . . . 0.0 110.905 173.164 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.75 -164.8 38.79 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.929 1.252 . . . . 0.0 113.317 -166.052 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -69.8 -49.84 48.86 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.732 -1.452 . . . . 0.0 112.66 174.095 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 59.0 t -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.907 0.86 . . . . 0.0 108.78 179.611 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -123.97 120.39 59.43 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.568 1.547 . . . . 0.0 109.725 -163.065 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 11.8 t-160 -104.82 95.48 5.9 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.633 -1.292 . . . . 0.0 112.435 -175.867 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 27.1 mt -89.99 134.58 34.15 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.762 -1.836 . . . . 0.0 113.397 -176.922 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 66.1 tp -104.89 123.0 46.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.613 -1.304 . . . . 0.0 109.114 167.748 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.37 163.9 30.69 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.47 -0.769 . . . . 0.0 111.54 175.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -127.38 140.07 52.43 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.642 1.577 . . . . 0.0 109.629 -178.892 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.476 0 O-C-N 120.762 -1.211 . . . . 0.0 114.033 -170.344 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.7 t0 . . . . . 0 N--CA 1.431 -1.421 0 CA-C-O 120.567 0.222 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -114.58 148.09 38.54 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.654 -1.278 . . . . 0.0 111.22 -176.479 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.69 149.39 32.36 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-O 121.982 0.896 . . . . 0.0 108.963 178.664 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -90.82 145.11 25.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.409 -0.807 . . . . 0.0 109.249 160.811 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.0 t -120.53 94.44 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.086 1.354 . . . . 0.0 107.613 -178.849 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 -90.47 95.66 10.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.929 1.347 . . . . 0.0 107.92 171.669 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 29.2 tp -123.99 138.36 54.47 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 125.315 1.446 . . . . 0.0 110.594 -164.136 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.62 138.59 39.33 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.699 -1.251 . . . . 0.0 108.658 173.857 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -69.48 145.55 52.63 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.22 1.563 . . . . 0.0 115.22 -178.283 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.6 p -100.09 102.21 13.48 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.962 -1.086 . . . . 0.0 109.157 176.192 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.5 t0 55.8 38.46 30.09 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.551 1.54 . . . . 0.0 114.166 179.314 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.48 -20.51 47.86 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.471 -1.393 . . . . 0.0 114.944 -176.699 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -93.56 137.95 32.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.7 -1.47 . . . . 0.0 112.248 -173.182 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.3 mt -87.58 -60.66 1.91 Allowed 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.249 -0.907 . . . . 0.0 110.306 172.21 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.6 8.93 2.69 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.365 -1.46 . . . . 0.0 113.158 175.29 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 pt -123.59 142.53 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-N 119.325 1.563 . . . . 0.0 112.052 -176.177 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.3 t -116.67 139.17 50.84 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 155.486 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.87 169.46 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 124.828 1.251 . . . . 0.0 112.293 -174.321 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -150.3 -179.22 7.02 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 126.053 1.741 . . . . 0.0 109.0 -177.999 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.65 -144.36 17.17 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.611 -1.306 . . . . 0.0 112.301 177.174 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 108.23 150.35 15.08 Favored Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 124.728 1.156 . . . . 0.0 112.937 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -174.805 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.737 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.99 136.61 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.899 1.28 . . . . 0.0 108.408 178.46 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -133.89 157.45 45.93 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 121.246 -0.908 . . . . 0.0 108.869 -175.313 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.1 t -76.48 129.73 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 119.872 -1.767 . . . . 0.0 112.338 175.504 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -93.91 -48.88 6.07 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.375 -1.453 . . . . 0.0 112.542 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.92 152.93 32.03 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 123.111 0.565 . . . . 0.0 110.572 -174.849 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -103.43 120.55 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 CA-C-O 122.841 1.305 . . . . 0.0 110.243 174.09 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.81 127.85 83.03 Favored Pre-proline 0 N--CA 1.431 -1.402 0 C-N-CA 126.331 1.852 . . . . 0.0 113.604 -172.002 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -55.73 126.3 21.97 Favored 'Trans proline' 0 N--CA 1.433 -2.042 0 C-N-CA 122.916 2.411 . . . . 0.0 117.034 -177.869 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? 77.22 13.58 2.01 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 128.864 2.866 . . . . 0.0 114.166 176.143 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.48 161.42 51.55 Favored Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.618 -1.301 . . . . 0.0 114.805 179.073 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.21 -57.67 6.34 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 126.843 2.057 . . . . 0.0 114.808 171.505 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.55 -48.53 77.09 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 128.399 2.68 . . . . 0.0 112.233 179.54 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -41.97 -63.07 0.79 Allowed 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 126.836 2.055 . . . . 0.0 114.386 173.497 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.7 m -70.22 -35.05 73.6 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.029 1.492 . . . . 0.0 115.029 -172.044 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -56.43 -68.66 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.238 1.815 . . . . 0.0 113.213 176.536 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.73 6.17 23.34 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 168.575 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -65.94 -49.52 67.64 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 119.09 1.445 . . . . 0.0 110.461 165.046 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.85 134.01 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.506 0 C-N-CA 125.58 1.552 . . . . 0.0 110.032 177.911 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 -145.61 142.36 29.03 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.409 1.084 . . . . 0.0 109.889 -174.862 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -43.74 116.02 0.9 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.231 1.812 . . . . 0.0 115.739 -178.883 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 103.99 -2.95 44.53 Favored Glycine 0 N--CA 1.428 -1.834 0 O-C-N 120.652 -1.28 . . . . 0.0 115.946 179.731 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.276 1.4 p30 -76.95 175.26 9.71 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 120.099 1.949 . . . . 0.0 115.549 -175.166 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -101.94 121.32 41.91 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.677 -1.264 . . . . 0.0 112.564 -175.395 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.12 114.75 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 123.868 0.867 . . . . 0.0 110.288 179.125 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 mp -93.75 -43.93 8.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.321 -1.487 . . . . 0.0 111.17 -176.585 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.6 142.34 24.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.864 -1.147 . . . . 0.0 111.625 -175.256 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.5 t -118.12 117.67 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 124.02 0.928 . . . . 0.0 109.01 175.763 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.3 37.31 14.07 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.985 2.114 . . . . 0.0 113.072 170.515 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.81 -33.23 6.67 Favored Glycine 0 N--CA 1.43 -1.75 0 C-N-CA 124.852 1.215 . . . . 0.0 113.444 -174.73 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -91.58 119.67 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 C-N-CA 124.974 1.309 . . . . 0.0 112.501 -165.292 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.9 m -65.81 130.3 42.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.881 -1.137 . . . . 0.0 112.88 177.796 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 44.2 mt -90.11 62.05 5.39 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.526 -1.359 . . . . 0.0 112.46 -174.892 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -90.09 136.09 33.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.642 -1.286 . . . . 0.0 111.71 174.365 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 71.32 11.47 71.5 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 121.024 -1.047 . . . . 0.0 115.454 175.366 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.0 143.03 49.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -176.236 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 48.1 p -82.35 173.64 11.86 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.995 -1.066 . . . . 0.0 111.118 167.443 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -62.26 -41.65 98.64 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.724 -1.235 . . . . 0.0 112.754 174.496 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -58.74 -47.01 86.08 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 126.069 1.748 . . . . 0.0 114.2 170.94 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -56.07 -47.82 77.24 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 126.524 1.93 . . . . 0.0 114.335 -176.447 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -56.83 -39.73 74.77 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.222 1.809 . . . . 0.0 115.025 173.192 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 79.1 t -69.01 -53.38 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 124.941 1.296 . . . . 0.0 110.862 177.947 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -59.95 -44.18 94.55 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 114.757 1.391 . . . . 0.0 114.757 -176.815 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.7 m -57.67 -40.9 80.44 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.013 2.525 . . . . 0.0 114.545 170.656 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 28.3 mt -68.77 -42.34 77.59 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 119.652 -1.905 . . . . 0.0 113.805 170.956 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 85.8 mmt-85 -60.7 -39.24 87.78 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.698 -1.251 . . . . 0.0 113.501 178.652 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -85.93 48.49 1.61 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.479 -1.388 . . . . 0.0 113.156 178.873 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.435 ' HB ' HG22 ' A' ' 92' ' ' VAL . 21.9 p -106.86 158.03 17.31 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.281 1.832 . . . . 0.0 109.657 173.293 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -98.75 -141.1 11.9 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 121.12 -0.988 . . . . 0.0 112.821 -176.383 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -69.09 -65.26 0.73 Allowed 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 121.058 -1.26 . . . . 0.0 113.251 175.727 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.2 p -98.66 133.66 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 123.14 1.448 . . . . 0.0 110.173 176.523 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.435 HG22 ' HB ' ' A' ' 88' ' ' THR . 99.0 t -124.62 128.78 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 128.297 2.639 . . . . 0.0 108.745 -162.94 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -108.9 93.93 4.78 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.752 -1.218 . . . . 0.0 112.578 -176.537 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 mt -95.27 162.14 13.81 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 119.538 -1.976 . . . . 0.0 112.411 178.002 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.9 tt -130.27 133.04 46.2 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.825 -1.172 . . . . 0.0 110.641 165.917 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.04 162.56 35.18 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 113.609 0.966 . . . . 0.0 113.609 178.527 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -113.54 138.58 49.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 125.712 1.605 . . . . 0.0 107.647 172.249 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.2 tppp? . . . . . 0 N--CA 1.429 -1.495 0 CA-C-O 122.216 1.007 . . . . 0.0 111.214 -173.209 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t70 . . . . . 0 N--CA 1.43 -1.439 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.0 p -125.98 155.42 41.42 Favored 'General case' 0 N--CA 1.431 -1.384 0 O-C-N 120.126 -1.609 . . . . 0.0 113.011 -179.107 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.475 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 12.4 p90 -145.52 142.42 29.19 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 122.943 1.354 . . . . 0.0 109.182 170.324 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -95.45 126.59 40.85 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.413 1.485 . . . . 0.0 107.955 171.22 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.3 t -118.49 117.77 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.295 1.038 . . . . 0.0 108.488 -174.722 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -100.79 88.08 3.49 Favored 'General case' 0 N--CA 1.432 -1.369 0 O-C-N 120.62 -1.3 . . . . 0.0 108.703 168.976 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 63.2 tp -95.7 137.69 34.4 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.593 1.157 . . . . 0.0 110.214 -174.226 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.32 128.95 47.25 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.185 -1.572 . . . . 0.0 108.566 172.012 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -70.42 136.43 49.55 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 121.344 -0.848 . . . . 0.0 113.123 178.416 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.0 p -107.2 121.03 43.71 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 174.376 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.9 t70 55.17 49.0 18.27 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.982 1.713 . . . . 0.0 113.753 -176.019 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.21 -9.64 6.94 Favored Glycine 0 N--CA 1.429 -1.789 0 N-CA-C 117.739 1.856 . . . . 0.0 117.739 174.315 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -121.43 156.18 33.27 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 119.207 1.503 . . . . 0.0 111.131 -168.531 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 16.4 mt -93.91 -60.4 1.76 Allowed 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.54 1.136 . . . . 0.0 110.925 -177.268 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.03 38.78 0.48 Allowed Glycine 0 N--CA 1.431 -1.657 0 O-C-N 119.373 -2.079 . . . . 0.0 110.54 174.588 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.3 pt -128.93 141.12 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 CA-C-O 121.871 0.843 . . . . 0.0 112.146 -163.208 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 29.7 t -117.77 117.36 29.1 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 166.33 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.47 160.64 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 124.529 1.132 . . . . 0.0 111.158 179.398 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.0 t -150.61 155.63 39.77 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.121 -0.987 . . . . 0.0 111.621 -178.527 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 124.03 -130.13 7.48 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 121.129 -0.982 . . . . 0.0 113.219 168.8 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 124.01 -148.81 16.83 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.182 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.6 t . . . . . 0 N--CA 1.429 -1.496 0 CA-C-O 123.451 1.596 . . . . 0.0 107.332 171.418 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 113.887 0.315 . . . . 0.0 113.887 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.7 mm -95.99 119.76 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 C-N-CA 125.851 1.66 . . . . 0.0 107.526 171.476 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -123.06 154.4 38.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.145 -0.972 . . . . 0.0 110.303 -174.528 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.6 t -76.8 119.38 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 124.387 1.075 . . . . 0.0 110.555 169.919 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -88.5 -46.83 8.79 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 124.858 1.263 . . . . 0.0 110.38 -176.471 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.75 161.39 37.01 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 123.316 0.647 . . . . 0.0 110.37 177.599 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.53 127.08 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.469 1.107 . . . . 0.0 110.303 176.329 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.1 mp -77.43 122.28 85.75 Favored Pre-proline 0 N--CA 1.43 -1.47 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -169.971 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_exo -55.29 122.13 11.16 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 C-N-CA 123.551 2.834 . . . . 0.0 116.6 179.952 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 17.6 mmtt 80.89 18.82 0.49 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 129.253 3.021 . . . . 0.0 113.488 -177.682 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.76 156.8 33.46 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.127 -1.608 . . . . 0.0 111.942 172.877 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.61 -56.28 7.53 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 125.949 1.699 . . . . 0.0 114.468 171.293 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.31 -51.14 67.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 128.308 2.643 . . . . 0.0 112.832 178.059 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.9 tm-20 -44.92 -59.65 2.46 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 172.441 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.3 t -68.1 -30.36 69.51 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.832 1.253 . . . . 0.0 113.436 -174.078 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -61.36 -55.61 29.62 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.857 1.263 . . . . 0.0 113.869 -177.141 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.59 1.43 29.18 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.516 1.367 . . . . 0.0 116.516 162.108 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.2 mmp_? -74.67 -54.6 7.09 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.5 -1.588 . . . . 0.0 110.367 164.475 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mt -78.25 128.04 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.339 1.456 . . . . 0.0 112.648 -173.607 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.01 172.64 12.71 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-O 124.14 1.924 . . . . 0.0 112.629 177.298 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -56.14 124.04 16.51 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.031 1.732 . . . . 0.0 113.822 172.136 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.88 4.2 61.79 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 113.903 178.759 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -79.11 162.31 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 119.054 1.427 . . . . 0.0 111.794 174.406 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -120.57 123.46 42.92 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.233 -1.542 . . . . 0.0 111.02 -172.978 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.6 t -83.06 125.48 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 O-C-N 120.278 -1.514 . . . . 0.0 111.83 -171.872 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 80.5 mt -103.3 -44.57 5.13 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.743 -1.223 . . . . 0.0 112.324 -177.005 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.4 ' HB3' ' HB3' ' A' ' 95' ' ' LEU . . . -149.97 140.9 22.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.504 -1.373 . . . . 0.0 112.329 -177.874 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -112.75 115.49 49.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 174.72 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 57.86 41.97 23.92 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.641 1.976 . . . . 0.0 114.993 170.606 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.45 -25.62 26.42 Favored Glycine 0 N--CA 1.431 -1.655 0 O-C-N 120.964 -1.085 . . . . 0.0 113.563 -177.008 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 t -94.06 112.25 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.926 -1.338 . . . . 0.0 110.412 -172.947 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . 0.25 81.1 p -76.36 140.66 41.51 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.212 -1.555 . . . . 0.0 112.998 176.851 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.0 mt -85.44 41.68 0.91 Allowed 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.426 1.09 . . . . 0.0 112.29 -168.9 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -72.72 121.53 19.99 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.101 -1.624 . . . . 0.0 112.047 -178.413 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 70.37 11.58 68.17 Favored Glycine 0 N--CA 1.429 -1.821 0 C-N-CA 125.191 1.377 . . . . 0.0 115.764 179.374 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.94 143.57 47.62 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -178.138 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.1 p -91.82 178.81 5.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.644 1.578 . . . . 0.0 111.728 174.34 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 30.8 t-80 -57.3 -52.73 64.16 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 115.873 1.805 . . . . 0.0 115.873 -169.6 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.6 -40.66 79.57 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 178.124 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.4 mp0 -56.92 -51.33 69.54 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.792 2.037 . . . . 0.0 113.209 -172.229 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.49 -39.09 79.06 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.556 1.942 . . . . 0.0 113.823 175.453 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 87.7 t -67.55 -53.04 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.044 1.337 . . . . 0.0 110.727 177.467 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -61.69 -38.69 88.76 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 121.009 -1.057 . . . . 0.0 113.78 -178.609 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.5 m -66.53 -40.42 89.11 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 127.032 2.133 . . . . 0.0 112.682 177.213 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.49 -42.24 87.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.431 -1.418 . . . . 0.0 113.231 171.139 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -68.2 -42.76 79.39 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.523 -1.361 . . . . 0.0 114.605 179.846 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 38.9 t-20 -86.32 57.2 4.35 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 123.036 1.398 . . . . 0.0 111.712 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -98.12 163.59 12.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.017 2.527 . . . . 0.0 109.617 175.115 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.46 -160.11 33.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.422 1.011 . . . . 0.0 110.923 168.931 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 60.1 tt0 -68.74 -52.07 34.53 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.75 -1.441 . . . . 0.0 112.998 -174.234 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.81 119.9 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 C-N-CA 124.894 1.278 . . . . 0.0 109.63 177.008 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 84.5 t -112.18 110.26 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 128.066 2.547 . . . . 0.0 110.153 -167.216 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.1 t-160 -92.8 96.7 10.3 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.7 -1.25 . . . . 0.0 112.779 -178.205 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.3 mt -89.11 156.71 18.65 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.217 -2.177 . . . . 0.0 112.677 175.773 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 95' ' ' LEU . . . . . 0.4 ' HB3' ' HB3' ' A' ' 67' ' ' ALA . 57.9 tp -127.01 129.41 48.02 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 157.611 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.475 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 3.0 pp -150.86 167.34 27.8 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.715 -1.24 . . . . 0.0 111.745 177.784 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -108.89 123.16 48.63 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.17 1.388 . . . . 0.0 110.345 -173.541 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.1 tptm . . . . . 0 N--CA 1.429 -1.484 0 C-N-CA 125.365 1.466 . . . . 0.0 111.37 -178.681 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.3 t70 . . . . . 0 N--CA 1.429 -1.49 0 CA-C-O 121.306 0.574 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -96.96 149.24 22.13 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.689 -1.257 . . . . 0.0 111.256 177.102 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -147.8 143.52 27.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 122.923 1.344 . . . . 0.0 109.186 -179.087 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.6 mp0 -102.53 129.53 49.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.536 1.934 . . . . 0.0 108.12 179.12 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.7 t -125.0 97.69 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.825 -1.172 . . . . 0.0 109.753 -170.429 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -97.81 77.24 2.5 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 119.938 -1.726 . . . . 0.0 108.899 173.906 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.4 130.47 52.75 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 125.372 1.469 . . . . 0.0 109.992 -170.159 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.7 154.79 17.04 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 127.074 2.15 . . . . 0.0 112.336 176.656 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -69.12 152.03 45.66 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -175.484 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.2 p -98.77 100.48 11.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.855 -1.153 . . . . 0.0 108.689 171.114 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.3 t0 52.41 52.99 13.08 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.636 1.574 . . . . 0.0 113.798 176.19 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.14 -27.32 10.48 Favored Glycine 0 N--CA 1.429 -1.779 0 O-C-N 120.859 -1.151 . . . . 0.0 115.71 -176.122 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.0 m -98.47 128.18 44.72 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-N 119.64 1.72 . . . . 0.0 113.106 -169.849 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.6 tp -84.63 -56.3 3.67 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.487 -1.383 . . . . 0.0 109.537 175.717 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.93 28.76 0.85 Allowed Glycine 0 N--CA 1.43 -1.764 0 C-N-CA 125.205 1.383 . . . . 0.0 113.249 168.091 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.1 tt -147.19 143.94 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 CA-C-N 119.619 1.709 . . . . 0.0 112.645 -166.26 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.6 t -123.76 138.21 54.55 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.041 1.336 . . . . 0.0 108.889 165.106 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 m -113.74 163.28 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 126.153 1.781 . . . . 0.0 112.313 -177.308 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -145.35 178.15 8.31 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 126.917 2.087 . . . . 0.0 109.556 -179.255 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.97 -145.19 16.22 Favored Glycine 0 N--CA 1.431 -1.669 0 O-C-N 120.562 -1.336 . . . . 0.0 114.65 173.978 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.09 156.51 31.33 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 125.539 1.542 . . . . 0.0 114.622 176.156 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.429 -1.487 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -178.586 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.679 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.9 mm -102.91 125.18 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 124.932 1.293 . . . . 0.0 108.255 179.884 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -128.42 155.33 44.93 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.928 -1.107 . . . . 0.0 111.341 -170.724 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.41 125.83 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.358 -1.464 . . . . 0.0 111.8 173.452 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.6 ttmt -89.02 -55.6 3.62 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.005 1.322 . . . . 0.0 110.115 177.203 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.73 150.09 30.61 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 121.502 -0.749 . . . . 0.0 110.607 -171.017 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.415 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -106.89 123.66 62.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.406 1.098 . . . . 0.0 108.306 172.373 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.3 mm -77.49 121.92 85.15 Favored Pre-proline 0 CA--C 1.489 -1.395 0 CA-C-O 115.755 -2.069 . . . . 0.0 114.346 -172.143 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -57.55 115.01 2.2 Favored 'Trans proline' 0 C--N 1.3 -1.996 0 C-N-CA 123.866 3.044 . . . . 0.0 117.151 -174.153 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.382 26.7 mtpp 71.07 41.81 0.78 Allowed 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.157 2.583 . . . . 0.0 114.913 -172.813 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.9 168.21 42.99 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.167 -1.583 . . . . 0.0 112.177 153.294 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.14 -60.02 3.55 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.23 1.812 . . . . 0.0 114.844 165.576 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.83 -42.71 97.56 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.31 2.244 . . . . 0.0 112.904 -178.026 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.415 ' CG ' HG23 ' A' ' 47' ' ' ILE . 4.8 tm-20 -47.91 -61.98 1.69 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.833 1.79 . . . . 0.0 115.833 171.376 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.5 t -68.03 -31.25 70.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.759 1.224 . . . . 0.0 112.515 -173.168 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -64.41 -65.94 0.61 Allowed 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.889 -1.132 . . . . 0.0 111.201 171.548 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 20.6 33.56 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 119.228 -2.17 . . . . 0.0 114.421 162.582 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -63.01 -44.37 96.19 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 121.341 -1.093 . . . . 0.0 109.866 157.442 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 52.0 mt -92.57 131.81 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.233 1.813 . . . . 0.0 110.495 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 60' ' ' HIS . . . . . 0.638 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 6.9 t-80 -145.24 -169.99 3.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-O 123.172 1.463 . . . . 0.0 112.727 167.828 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.638 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 40.4 ttpt -61.99 122.83 16.45 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 126.217 1.807 . . . . 0.0 113.378 -176.551 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 101.83 -4.74 53.32 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.384 -0.823 . . . . 0.0 114.073 179.725 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -74.66 161.61 29.51 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 118.925 1.363 . . . . 0.0 112.868 -177.28 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -122.09 121.3 36.63 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.771 -1.205 . . . . 0.0 111.047 -165.194 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 8.4 t -89.35 125.73 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 120.78 -1.2 . . . . 0.0 111.772 -169.103 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -102.27 -44.57 5.37 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.113 -0.992 . . . . 0.0 111.466 -177.231 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 139.36 21.21 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.681 -1.262 . . . . 0.0 111.67 -178.079 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.7 t -114.34 117.96 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.214 1.006 . . . . 0.0 109.877 177.729 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.3 t30 62.18 29.05 17.41 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 128.274 2.63 . . . . 0.0 114.24 168.808 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.01 -17.99 40.53 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.422 1.487 . . . . 0.0 113.58 -177.386 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.3 t -101.78 123.78 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 O-C-N 120.854 -1.38 . . . . 0.0 110.401 -172.97 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 m -71.27 138.15 49.16 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.105 -1.622 . . . . 0.0 112.825 179.457 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.2 mt -88.41 62.54 6.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.286 -1.509 . . . . 0.0 111.067 179.194 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -89.62 118.12 29.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.35 -1.469 . . . . 0.0 112.039 -178.18 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.34 6.72 70.65 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 125.121 1.343 . . . . 0.0 115.239 177.808 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 150.62 44.4 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 116.157 1.91 . . . . 0.0 116.157 -172.557 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 55.9 p -88.77 174.15 8.16 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.556 1.942 . . . . 0.0 111.235 175.968 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 -58.84 -48.58 80.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.646 -1.284 . . . . 0.0 113.238 177.319 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -53.55 -46.93 70.41 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.691 1.597 . . . . 0.0 114.21 176.572 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -54.89 -49.93 69.99 Favored 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 125.57 1.548 . . . . 0.0 113.633 -179.059 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.25 -38.79 88.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 176.346 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.8 t -67.71 -51.16 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.434 -1.416 . . . . 0.0 111.18 -179.058 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -33.01 74.72 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.35 1.06 . . . . 0.0 112.929 179.799 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 64.0 m -65.31 -49.65 68.66 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.459 1.904 . . . . 0.0 112.671 171.174 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -62.91 -32.48 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.168 -1.583 . . . . 0.0 114.145 174.427 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -65.07 -45.29 85.9 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.383 -1.448 . . . . 0.0 112.925 168.658 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -82.86 45.71 1.02 Allowed 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.218 -1.551 . . . . 0.0 113.755 -179.143 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 p -100.94 160.67 14.17 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 126.819 2.048 . . . . 0.0 109.251 175.485 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.71 -142.37 10.7 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.561 -1.337 . . . . 0.0 112.376 172.919 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -71.21 -59.86 2.54 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 126.294 1.838 . . . . 0.0 111.34 172.319 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 11.0 p -94.46 134.16 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.078 1.351 . . . . 0.0 111.465 -179.868 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 87.5 t -125.65 123.23 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.857 -1.152 . . . . 0.0 109.986 -169.685 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -103.61 89.79 3.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.122 -1.611 . . . . 0.0 114.204 -176.035 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.7 mt -89.0 155.91 19.19 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.665 -2.522 . . . . 0.0 112.934 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.7 tt -129.98 128.28 41.73 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 161.297 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -154.04 170.69 20.51 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.892 -1.13 . . . . 0.0 112.934 -174.963 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -119.23 144.3 46.82 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.815 1.646 . . . . 0.0 110.461 -178.691 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? . . . . . 0 N--CA 1.43 -1.447 0 O-C-N 120.626 -1.297 . . . . 0.0 111.132 174.977 . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.4 t0 . . . . . 0 N--CA 1.429 -1.478 0 CA-C-O 121.187 0.518 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -108.04 155.3 20.52 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.76 1.224 . . . . 0.0 112.855 -177.933 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -144.83 143.31 30.56 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.492 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -93.5 137.89 32.33 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 168.114 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.421 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 26.4 t -126.07 99.53 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -175.407 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -99.39 89.79 4.31 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-O 123.049 1.404 . . . . 0.0 109.046 176.527 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.0 tp -118.11 141.14 48.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.983 1.713 . . . . 0.0 110.844 -160.499 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.59 136.85 42.53 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.509 -1.37 . . . . 0.0 111.057 175.916 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -66.84 161.46 23.81 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 117.035 2.235 . . . . 0.0 117.035 -173.267 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.5 p -113.2 99.4 7.79 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 126.532 1.933 . . . . 0.0 109.333 174.675 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.9 t70 50.14 49.91 19.57 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.726 1.61 . . . . 0.0 114.92 171.643 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.05 -18.95 55.72 Favored Glycine 0 N--CA 1.431 -1.682 0 O-C-N 120.05 -1.656 . . . . 0.0 116.345 179.873 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.7 p -113.16 161.23 17.38 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 119.312 1.556 . . . . 0.0 113.239 -177.079 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 mt -97.05 -54.97 3.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 166.508 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.22 50.34 0.34 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.005 -1.684 . . . . 0.0 110.438 171.722 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tt -146.13 142.83 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 CA-C-O 122.618 1.199 . . . . 0.0 109.751 -174.147 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.0 t -111.17 129.77 55.84 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 168.571 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 m -111.07 165.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 C-N-CA 124.642 1.177 . . . . 0.0 110.547 -178.794 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 t -151.19 170.14 20.19 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.768 -1.207 . . . . 0.0 109.865 177.996 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.72 -154.68 20.35 Favored Glycine 0 N--CA 1.431 -1.696 0 O-C-N 121.337 -0.852 . . . . 0.0 112.73 178.069 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.63 147.85 23.28 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 121.698 -0.883 . . . . 0.0 113.008 -178.068 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 N--CA 1.431 -1.421 0 N-CA-C 116.728 2.122 . . . . 0.0 116.728 -167.678 . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.689 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.6 mm -99.97 128.51 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 177.338 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -127.12 159.06 35.35 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.795 -1.191 . . . . 0.0 109.684 -173.674 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.26 125.53 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 O-C-N 121.089 -1.007 . . . . 0.0 111.897 176.493 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -91.9 -49.11 6.41 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.381 177.879 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -159.12 157.76 31.59 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.412 -1.43 . . . . 0.0 111.33 177.602 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.39 121.38 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.656 1.217 . . . . 0.0 110.056 174.404 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 22.0 mm -77.47 133.28 67.66 Favored Pre-proline 0 N--CA 1.429 -1.477 0 C-N-CA 127.527 2.331 . . . . 0.0 115.671 -165.901 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -54.07 118.19 4.71 Favored 'Trans proline' 0 N--CA 1.434 -1.973 0 C-N-CA 123.864 3.043 . . . . 0.0 118.335 -178.704 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 61.85 40.74 12.37 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 128.949 2.9 . . . . 0.0 113.646 -177.274 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.29 164.23 36.45 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.114 -1.616 . . . . 0.0 112.86 162.785 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.62 -57.37 7.29 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.359 1.864 . . . . 0.0 114.87 164.472 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.6 -43.32 97.26 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 127.341 2.256 . . . . 0.0 112.517 -179.03 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.96 -62.38 1.56 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 167.143 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.4 t -69.52 -23.21 63.57 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.244 1.418 . . . . 0.0 114.719 -170.781 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -59.54 -58.32 9.11 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 125.837 1.655 . . . . 0.0 113.495 178.81 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.9 -13.02 10.68 Favored Glycine 0 N--CA 1.43 -1.729 0 CA-C-N 120.419 1.463 . . . . 0.0 115.651 168.347 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.5 mmt180 -75.16 -52.64 10.47 Favored 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 120.515 -1.58 . . . . 0.0 111.258 177.034 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 57.3 mt -81.06 116.38 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 126.231 1.812 . . . . 0.0 112.789 -168.738 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -117.88 164.91 14.34 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.37 1.868 . . . . 0.0 112.039 -179.262 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.76 124.34 20.46 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.551 -1.968 . . . . 0.0 114.019 176.459 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.12 6.8 68.67 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.686 -1.259 . . . . 0.0 114.736 -176.25 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -75.56 160.65 29.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.341 1.57 . . . . 0.0 111.273 174.024 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.7 ttt180 -101.44 126.71 48.26 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.794 -1.191 . . . . 0.0 110.29 -175.503 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.8 t -86.66 111.64 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.429 1.092 . . . . 0.0 108.494 -177.087 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.3 mt -91.14 -53.95 4.15 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.005 -1.684 . . . . 0.0 111.996 -171.571 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.11 146.99 27.96 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.807 -1.183 . . . . 0.0 108.881 -176.774 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.54 110.34 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 177.02 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.0 t30 63.17 34.99 13.09 Favored 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 126.424 1.89 . . . . 0.0 114.989 167.026 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 92.97 -6.01 76.24 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 121.083 -1.011 . . . . 0.0 113.884 -174.93 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.4 t -96.94 113.31 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-N 118.909 1.354 . . . . 0.0 109.719 179.057 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.3 m -70.94 123.89 23.07 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 124.551 1.14 . . . . 0.0 111.047 176.642 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 23.8 mt -84.23 0.76 47.62 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.306 -1.496 . . . . 0.0 114.381 -172.613 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.31 111.98 0.99 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.277 -1.514 . . . . 0.0 114.135 179.263 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.28 12.97 79.84 Favored Glycine 0 N--CA 1.429 -1.78 0 C-N-CA 124.499 1.047 . . . . 0.0 114.473 -179.081 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.72 160.69 31.8 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.208 -1.76 . . . . 0.0 115.742 173.085 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.9 p -89.87 173.88 8.0 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.488 -1.382 . . . . 0.0 111.131 171.505 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -59.59 -49.42 77.83 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.347 1.459 . . . . 0.0 112.186 170.179 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -55.35 -46.15 76.43 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 125.067 1.347 . . . . 0.0 114.102 173.716 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -55.92 -54.06 49.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 178.202 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.62 87.43 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 178.343 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.9 t -66.11 -49.51 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.859 -1.151 . . . . 0.0 111.372 176.377 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -66.99 -31.47 72.06 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.5 -1.375 . . . . 0.0 113.624 -179.083 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 100.0 m -65.82 -49.93 66.47 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 127.315 2.246 . . . . 0.0 111.667 171.525 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.8 mt -59.89 -41.15 90.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.466 -1.396 . . . . 0.0 113.97 174.083 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -60.33 -41.04 92.7 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.749 -1.22 . . . . 0.0 113.515 172.628 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -83.23 25.68 0.7 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.487 -1.383 . . . . 0.0 114.584 -179.618 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.442 ' HB ' HG22 ' A' ' 92' ' ' VAL . 59.0 p -87.23 150.9 23.6 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.13 -1.606 . . . . 0.0 109.056 168.783 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.74 -152.31 21.4 Favored Glycine 0 N--CA 1.429 -1.788 0 O-C-N 121.243 -0.911 . . . . 0.0 112.854 -179.667 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -69.59 -50.94 39.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.972 -1.31 . . . . 0.0 112.955 -177.409 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.0 p -97.79 134.25 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 123.094 1.426 . . . . 0.0 109.625 166.19 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.442 HG22 ' HB ' ' A' ' 88' ' ' THR . 97.4 t -122.89 123.37 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 126.735 2.014 . . . . 0.0 109.027 -164.897 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 1.2 m-70 -100.59 103.05 14.33 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.53 -1.357 . . . . 0.0 111.242 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.421 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 28.8 mt -100.45 158.61 15.78 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.608 -1.932 . . . . 0.0 112.554 175.87 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 45.9 tp -127.57 130.68 49.5 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 161.278 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -141.84 167.25 22.6 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.469 -1.395 . . . . 0.0 112.814 176.168 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -122.26 147.71 45.88 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 124.671 1.188 . . . . 0.0 110.099 179.28 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? . . . . . 0 N--CA 1.43 -1.448 0 C-N-CA 126.371 1.868 . . . . 0.0 110.559 179.803 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.1 t0 . . . . . 0 N--CA 1.43 -1.475 0 CA-C-O 121.073 0.463 . . . . 0.0 112.13 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.6 p -103.45 146.13 28.98 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.796 -1.19 . . . . 0.0 111.592 -179.445 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.463 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 8.3 p90 -148.29 144.97 27.96 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-O 122.552 1.167 . . . . 0.0 109.244 171.683 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -89.8 146.16 24.66 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.99 1.716 . . . . 0.0 108.799 172.728 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 20.0 t -124.89 102.55 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.106 -1.621 . . . . 0.0 107.92 177.636 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -96.18 99.13 10.89 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 168.179 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 54.0 tp -123.44 138.51 54.57 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.279 1.432 . . . . 0.0 110.905 -167.374 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 133.84 45.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.44 -1.413 . . . . 0.0 109.763 172.151 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -65.77 153.3 42.19 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 177.627 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 62.3 p -119.88 116.47 25.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 172.236 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.1 t0 56.98 48.74 15.17 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.855 1.662 . . . . 0.0 113.723 178.598 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 -7.37 30.19 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 125.744 1.64 . . . . 0.0 116.55 177.722 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.9 m -121.19 150.23 41.62 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.266 -1.138 . . . . 0.0 111.25 -162.287 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.8 mt -97.16 -62.67 1.22 Allowed 'General case' 0 N--CA 1.429 -1.521 0 O-C-N 120.665 -1.272 . . . . 0.0 111.447 178.52 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.02 46.88 0.32 Allowed Glycine 0 N--CA 1.43 -1.755 0 O-C-N 120.4 -1.438 . . . . 0.0 111.979 171.573 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.4 tt -147.49 150.4 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 CA-C-O 122.578 1.18 . . . . 0.0 111.217 -172.883 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -123.84 132.73 53.82 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.639 1.176 . . . . 0.0 108.699 168.943 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -102.61 163.81 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.812 1.245 . . . . 0.0 113.179 -179.604 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 t -147.5 169.98 18.41 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 126.095 1.758 . . . . 0.0 109.3 -177.363 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.57 -139.31 14.34 Favored Glycine 0 N--CA 1.43 -1.708 0 O-C-N 120.707 -1.246 . . . . 0.0 113.833 171.154 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.3 -177.36 34.89 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 121.415 -1.05 . . . . 0.0 113.206 -178.656 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.43 -1.465 0 N-CA-C 116.695 2.109 . . . . 0.0 116.695 -172.078 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.758 0 N-CA-C 114.115 0.406 . . . . 0.0 114.115 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.2 mm -93.92 130.26 43.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 126.485 1.914 . . . . 0.0 109.477 -178.882 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -126.44 163.03 24.21 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.807 -1.183 . . . . 0.0 110.222 -178.37 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.6 t -76.69 126.55 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.765 -1.209 . . . . 0.0 112.016 169.559 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -91.91 -52.05 4.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.943 -1.098 . . . . 0.0 111.875 176.937 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.6 155.57 39.67 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.079 -1.013 . . . . 0.0 109.977 -177.762 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.477 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -116.68 123.58 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.156 0.979 . . . . 0.0 108.484 175.455 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 23.2 mm -77.76 121.86 84.83 Favored Pre-proline 0 N--CA 1.43 -1.459 0 C-N-CA 125.866 1.666 . . . . 0.0 113.399 -172.399 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -59.19 131.51 41.66 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 CA-C-N 124.323 2.58 . . . . 0.0 115.821 -176.547 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 92.5 mttt 77.39 17.33 1.51 Allowed 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 127.331 2.252 . . . . 0.0 112.822 -178.613 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.1 158.78 42.66 Favored Glycine 0 N--CA 1.429 -1.8 0 O-C-N 119.864 -1.772 . . . . 0.0 113.048 173.462 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.83 -59.38 3.89 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.625 1.97 . . . . 0.0 114.193 166.674 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.5 -48.0 81.5 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.271 2.228 . . . . 0.0 112.136 179.854 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.477 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.7 tm-20 -44.7 -66.0 0.45 Allowed 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 116.318 1.97 . . . . 0.0 116.318 170.442 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 44.8 t -63.32 -25.96 68.54 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -172.895 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -54.33 -53.19 57.19 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 124.983 1.313 . . . . 0.0 113.602 179.319 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.46 -8.16 54.67 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.507 -0.746 . . . . 0.0 113.204 167.234 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -68.12 -44.84 75.22 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.229 -1.16 . . . . 0.0 111.153 168.605 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.0 mt -91.56 131.56 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.927 1.691 . . . . 0.0 112.47 -175.65 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.22 179.47 7.75 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.245 -1.534 . . . . 0.0 112.922 170.579 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -60.09 129.44 41.78 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.761 -1.837 . . . . 0.0 114.956 -175.005 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.51 3.12 78.43 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.919 -1.113 . . . . 0.0 115.07 -179.693 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 63' ' ' ASP . . . . . 0.43 ' HB3' HD13 ' A' ' 96' ' ' LEU . 86.7 m-20 -76.03 145.75 39.95 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 119.617 1.708 . . . . 0.0 111.739 176.266 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -95.3 125.5 39.97 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.252 -1.53 . . . . 0.0 110.384 -173.711 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 54.1 t -81.43 132.3 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.243 -1.535 . . . . 0.0 109.107 -178.884 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -103.24 -52.96 2.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.079 -1.013 . . . . 0.0 109.299 177.406 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.88 134.77 17.79 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 111.638 -171.799 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 84' ' ' THR . 61.1 t -110.36 120.2 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.532 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 67.81 18.54 9.7 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.51 1.924 . . . . 0.0 113.525 174.9 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.39 -17.22 54.09 Favored Glycine 0 N--CA 1.428 -1.839 0 O-C-N 120.771 -1.206 . . . . 0.0 112.981 -175.719 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.5 t -88.66 114.03 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 O-C-N 120.657 -1.496 . . . . 0.0 109.833 -178.372 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.2 m -75.65 127.85 33.95 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 120.727 -1.233 . . . . 0.0 111.279 -179.947 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.26 51.27 2.19 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.847 -1.158 . . . . 0.0 113.583 -165.302 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -74.49 111.32 9.57 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 119.162 -2.212 . . . . 0.0 115.182 -170.42 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.45 13.24 83.07 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.634 -1.291 . . . . 0.0 114.14 -179.751 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.34 159.44 34.56 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.715 1.245 . . . . 0.0 113.991 -179.133 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 45.6 p -84.68 169.77 13.97 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.512 -1.368 . . . . 0.0 111.448 172.288 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -56.25 -47.12 79.15 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.437 1.495 . . . . 0.0 112.176 168.452 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.6 tptp -50.72 -50.03 56.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.976 1.71 . . . . 0.0 113.973 174.501 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -56.27 -49.04 75.36 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 174.92 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.41 88.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.726 1.21 . . . . 0.0 114.182 174.951 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.31 -46.8 86.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 O-C-N 120.732 -1.23 . . . . 0.0 111.62 175.638 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -61.47 -34.45 75.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.557 -1.34 . . . . 0.0 114.094 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 84' ' ' THR . . . . . 0.403 HG22 HG11 ' A' ' 68' ' ' VAL . 1.5 m -77.82 -35.39 51.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.525 1.53 . . . . 0.0 113.091 174.832 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 53.1 mt -70.2 -24.29 63.09 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 119.694 -1.879 . . . . 0.0 114.783 168.997 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -69.64 -48.65 59.18 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 119.68 -1.888 . . . . 0.0 111.984 168.064 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -85.44 52.58 2.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 114.394 1.257 . . . . 0.0 114.394 -176.402 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 56.6 p -88.99 178.78 6.31 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.112 -1.617 . . . . 0.0 109.941 170.691 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.89 -165.31 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 160.836 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -70.56 -42.7 70.77 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.52 -0.988 . . . . 0.0 112.714 175.067 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 41.8 t -94.83 126.59 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 166.5 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 53.0 t -114.45 132.29 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 129.22 3.008 . . . . 0.0 108.653 -168.148 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -120.73 91.25 3.49 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 111.557 -170.845 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.9 mt -94.51 155.01 17.13 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.619 -1.926 . . . . 0.0 112.637 177.786 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.0 tt -129.62 133.13 46.98 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.456 -0.777 . . . . 0.0 109.103 161.984 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.463 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.6 pp -152.63 170.41 20.3 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 120.143 -1.598 . . . . 0.0 112.669 -175.083 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -116.53 145.51 43.28 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 125.576 1.55 . . . . 0.0 110.235 179.647 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 18.4 tptt . . . . . 0 N--CA 1.43 -1.441 0 C-N-CA 125.955 1.702 . . . . 0.0 112.524 -177.446 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 pttp . . . . . 0 N--CA 1.43 -1.469 0 CA-C-O 119.204 -0.427 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -84.05 178.5 5.28 Favored 'Trans proline' 0 N--CA 1.434 -2.019 0 C-N-CA 122.639 2.226 . . . . 0.0 111.908 163.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.47 49.87 3.11 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 116.593 1.397 . . . . 0.0 116.593 163.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -96.14 135.07 38.43 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-N 119.104 1.452 . . . . 0.0 110.484 173.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.84 154.26 20.39 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.648 -1.907 . . . . 0.0 112.467 -175.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -146.15 141.38 27.45 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.131 0.967 . . . . 0.0 109.505 167.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -92.7 119.73 32.4 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.776 1.63 . . . . 0.0 107.276 163.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 10.9 t -107.65 101.57 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 122.485 1.136 . . . . 0.0 108.029 -174.053 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -92.43 79.6 4.94 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.461 1.505 . . . . 0.0 108.749 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.9 tp -104.64 133.52 49.36 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-O 122.643 1.211 . . . . 0.0 111.264 -166.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.7 146.32 27.9 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.167 -1.583 . . . . 0.0 108.848 170.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.76 158.67 34.99 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.205 -1.559 . . . . 0.0 114.558 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.2 t -112.05 105.33 13.69 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 170.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . 0.256 22.9 t70 29.64 63.29 0.15 Allowed 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.94 2.896 . . . . 0.0 117.37 -165.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.74 10.09 85.56 Favored Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 117.244 1.658 . . . . 0.0 117.244 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.6 m -121.1 134.15 55.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 119.586 1.693 . . . . 0.0 113.499 176.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.6 mt -89.98 -63.01 1.34 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.552 1.141 . . . . 0.0 111.857 167.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.35 34.35 2.51 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 119.684 -1.885 . . . . 0.0 114.378 173.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.9 pt -125.92 131.47 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.686 1.594 . . . . 0.0 110.769 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 22.4 t -105.63 106.9 17.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 166.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.7 m -110.02 152.77 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 C-N-CA 124.548 1.139 . . . . 0.0 111.414 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.1 t -150.7 175.61 11.8 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.167 -0.958 . . . . 0.0 110.974 -172.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.01 -127.5 7.13 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 121.054 -1.029 . . . . 0.0 113.527 170.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.61 -170.52 20.27 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.36 1.457 . . . . 0.0 112.174 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.7 p -104.5 -34.16 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.896 1.278 . . . . 0.0 114.343 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -94.06 -4.2 49.87 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.437 -2.039 . . . . 0.0 113.959 -166.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 30.2 p -94.76 -139.97 0.24 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.49 1.116 . . . . 0.0 110.866 -167.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 27.2 t -74.19 -39.89 62.87 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.749 -1.844 . . . . 0.0 112.821 177.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.8 m -77.24 129.08 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.786 -1.196 . . . . 0.0 114.098 -172.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -72.6 -29.44 63.51 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 126.119 1.768 . . . . 0.0 113.237 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -63.48 -25.98 68.51 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 116.955 2.205 . . . . 0.0 116.955 -166.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.85 68.05 1.68 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.016 -1.052 . . . . 0.0 114.748 171.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 179.05 171.12 41.88 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 121.113 -1.228 . . . . 0.0 110.772 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.4 mm -103.75 129.08 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.842 1.257 . . . . 0.0 108.155 -178.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -127.68 149.47 50.19 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 121.312 -0.868 . . . . 0.0 109.574 -171.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.5 t -77.09 122.62 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 O-C-N 120.845 -1.159 . . . . 0.0 111.684 172.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -88.33 -50.44 6.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.827 -1.171 . . . . 0.0 110.816 176.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.51 158.65 44.4 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 122.162 -0.337 . . . . 0.0 111.829 -175.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.41 120.47 64.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.706 1.202 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.68 119.55 77.9 Favored Pre-proline 0 N--CA 1.429 -1.477 0 CA-C-O 116.794 -1.574 . . . . 0.0 113.37 -169.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -63.66 128.18 21.58 Favored 'Trans proline' 0 N--CA 1.434 -2.018 0 C-N-CA 123.207 2.605 . . . . 0.0 113.931 -173.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.264 54.3 mttm 82.47 21.33 0.25 Allowed 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 128.063 2.545 . . . . 0.0 113.642 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.1 160.83 37.18 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 119.897 -1.752 . . . . 0.0 114.428 170.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -52.44 -59.78 4.02 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.341 1.856 . . . . 0.0 115.402 164.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.49 -45.23 88.23 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 128.823 2.849 . . . . 0.0 111.225 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -44.42 -64.2 0.73 Allowed 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 170.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 m -70.2 -22.37 62.94 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.565 1.691 . . . . 0.0 115.565 -177.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.45 -61.61 2.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.829 1.652 . . . . 0.0 112.603 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.88 5.0 64.71 Favored Glycine 0 N--CA 1.43 -1.717 0 N-CA-C 116.14 1.216 . . . . 0.0 116.14 169.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -77.17 -32.92 56.53 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 118.767 1.283 . . . . 0.0 109.635 160.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.7 mt -92.27 135.91 26.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.966 1.306 . . . . 0.0 109.161 170.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -159.47 160.97 35.33 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.589 -1.319 . . . . 0.0 110.014 178.144 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.5 pttt -64.87 135.49 55.79 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.383 -2.073 . . . . 0.0 114.628 -171.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.46 4.93 67.62 Favored Glycine 0 N--CA 1.43 -1.744 0 CA-C-O 118.295 -1.28 . . . . 0.0 115.436 -172.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.344 1.6 p30 -80.15 166.13 21.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 121.468 2.634 . . . . 0.0 114.375 171.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 9.9 tpt85 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.496 1.118 . . . . 0.0 109.186 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 5.0 t -85.68 139.27 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 123.748 0.819 . . . . 0.0 109.805 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.17 -53.23 2.7 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.862 -1.149 . . . . 0.0 109.291 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.69 150.62 31.31 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 112.744 -175.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.917 HG11 HG21 ' A' ' 84' ' ' THR . 2.5 p -119.38 107.74 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 125.45 1.5 . . . . 0.0 110.266 177.144 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.1 t30 58.93 37.05 24.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.672 -1.893 . . . . 0.0 113.282 173.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.07 -29.69 11.59 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.891 1.234 . . . . 0.0 114.023 -172.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 44.5 t -87.98 119.55 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 119.734 1.767 . . . . 0.0 110.777 -163.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.8 m -69.87 117.63 11.71 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.1 -1.0 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 18.2 mt -83.84 -4.65 58.83 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.573 -1.329 . . . . 0.0 113.873 -169.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -74.05 116.37 14.6 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.217 -1.552 . . . . 0.0 112.044 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 107.93 -20.87 30.62 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 124.175 0.893 . . . . 0.0 112.064 -175.105 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.35 148.79 46.68 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.772 -1.428 . . . . 0.0 112.902 172.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.414 HG22 ' H ' ' A' ' 78' ' ' HIS . 0.2 OUTLIER -90.21 -179.14 5.58 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.301 -1.499 . . . . 0.0 112.008 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 78' ' ' HIS . . . . . 0.414 ' H ' HG22 ' A' ' 77' ' ' THR . 10.4 t-160 -61.23 -47.6 85.35 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.463 1.905 . . . . 0.0 112.765 -174.26 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.68 -46.96 80.85 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 115.173 1.546 . . . . 0.0 115.173 173.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 15.9 mp0 -55.88 -51.13 68.65 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.681 1.593 . . . . 0.0 113.822 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.05 -36.42 83.51 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.1 t -67.29 -49.39 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 O-C-N 120.661 -1.274 . . . . 0.0 110.941 176.037 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -62.5 -37.12 84.78 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.126 0.97 . . . . 0.0 113.285 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' THR . . . . . 0.917 HG21 HG11 ' A' ' 68' ' ' VAL . 54.0 m -58.59 -52.28 66.32 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.261 1.824 . . . . 0.0 112.57 173.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -63.27 -37.02 85.61 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 175.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.44 -42.88 99.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.108 1.363 . . . . 0.0 111.608 175.111 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -88.97 43.16 1.13 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.716 1.606 . . . . 0.0 112.663 177.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.6 p -100.53 156.19 17.43 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.203 -1.56 . . . . 0.0 110.184 169.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.32 -146.42 20.32 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.656 1.122 . . . . 0.0 113.141 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -69.97 -57.41 5.04 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.757 -1.437 . . . . 0.0 114.331 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.38 131.91 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 CA-C-O 122.454 1.121 . . . . 0.0 108.534 176.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -124.57 120.73 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 127.611 2.364 . . . . 0.0 108.977 -167.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -107.2 93.41 4.54 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 119.878 -1.764 . . . . 0.0 112.523 -171.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 1.1 mm? -91.54 160.04 15.62 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 118.782 -2.448 . . . . 0.0 113.794 -177.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 38.8 tp -127.87 128.92 46.03 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.289 1.436 . . . . 0.0 108.867 162.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.72 169.89 18.11 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.292 -1.505 . . . . 0.0 113.041 177.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -126.96 134.94 50.28 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.149 0.979 . . . . 0.0 112.873 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 76.71 4.16 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 126.415 1.886 . . . . 0.0 113.444 -177.16 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 84.5 145.35 7.06 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 125.146 1.355 . . . . 0.0 115.368 168.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -97.01 -62.01 1.32 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.744 1.259 . . . . 0.0 110.024 164.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.6 m -102.75 134.08 20.07 Favored Pre-proline 0 N--CA 1.43 -1.446 0 C-N-CA 125.345 1.458 . . . . 0.0 110.029 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo . . . . . 0 C--N 1.3 -1.995 0 C-N-CA 122.241 1.96 . . . . 0.0 114.691 173.891 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.479 0 CA-C-O 119.809 -0.138 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -82.07 61.78 7.9 Favored 'Trans proline' 0 N--CA 1.435 -1.969 0 C-N-CA 124.005 3.137 . . . . 0.0 114.439 -168.185 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.38 61.41 0.18 Allowed Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.707 -1.246 . . . . 0.0 116.037 176.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -98.34 -179.02 4.22 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 155.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 48.4 p -100.14 162.59 12.87 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.416 -1.427 . . . . 0.0 113.276 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.62 149.86 34.34 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 168.102 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -104.03 119.11 38.23 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-O 122.719 1.247 . . . . 0.0 109.242 167.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.8 t -98.07 108.48 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.588 1.955 . . . . 0.0 108.344 -175.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -104.42 86.47 2.53 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.196 1.398 . . . . 0.0 108.443 173.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 52.5 tp -120.38 142.29 49.31 Favored 'General case' 0 N--CA 1.431 -1.379 0 C-N-CA 125.111 1.364 . . . . 0.0 110.609 -165.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 140.59 35.9 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.651 1.58 . . . . 0.0 110.585 173.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -69.71 158.79 34.72 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.9 p -112.61 105.7 13.95 Favored 'General case' 0 N--CA 1.429 -1.518 0 C-N-CA 125.076 1.35 . . . . 0.0 108.761 172.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.2 t70 55.34 45.38 25.62 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.437 1.895 . . . . 0.0 113.656 -176.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.44 -5.26 64.61 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.349 -1.47 . . . . 0.0 115.563 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 60.5 p -107.92 149.78 27.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -174.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.0 mt -100.83 -56.25 2.37 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.229 1.411 . . . . 0.0 108.278 172.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 51' ' ' GLY . . . 106.06 55.71 0.68 Allowed Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.324 -1.485 . . . . 0.0 111.863 173.034 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.5 tt -143.39 142.26 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 CA-C-O 122.295 1.045 . . . . 0.0 110.401 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 44.3 t -112.79 115.09 27.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.435 1.894 . . . . 0.0 107.441 171.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.6 m -101.4 160.1 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 122.43 1.11 . . . . 0.0 111.84 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.5 t -144.05 -179.46 6.51 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 125.253 1.421 . . . . 0.0 107.906 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.1 -155.43 16.3 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 121.085 -1.009 . . . . 0.0 113.722 173.172 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.2 152.68 22.55 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.692 1.139 . . . . 0.0 114.173 176.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.1 p -79.06 -17.21 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 115.208 1.559 . . . . 0.0 115.208 -170.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.5 -21.7 44.97 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 119.391 -2.068 . . . . 0.0 111.202 -178.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.05 168.59 10.67 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 126.937 2.095 . . . . 0.0 109.541 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 79.1 p -81.1 53.6 2.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.99 -1.694 . . . . 0.0 112.68 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 75.6 t -94.3 134.92 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 O-C-N 119.871 -1.768 . . . . 0.0 109.185 -171.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -70.52 110.5 5.43 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.149 -0.969 . . . . 0.0 110.807 -177.182 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.278 1.8 t-80 72.81 2.75 4.48 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 127.405 2.282 . . . . 0.0 116.57 -170.106 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.86 63.85 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 118.873 2.309 . . . . 0.0 118.873 167.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -80.2 179.29 53.42 Favored Glycine 0 N--CA 1.43 -1.752 0 CA-C-N 118.944 1.372 . . . . 0.0 114.313 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 46.7 mm -103.69 127.72 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 125.487 1.515 . . . . 0.0 108.082 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -130.92 157.01 44.08 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 121.07 -1.019 . . . . 0.0 112.6 -168.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.4 t -75.87 124.4 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.97 -1.081 . . . . 0.0 111.168 169.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -93.15 -46.43 7.43 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.246 -0.909 . . . . 0.0 110.61 170.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.53 153.5 34.68 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 111.121 177.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.16 121.68 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-O 123.016 1.389 . . . . 0.0 109.052 176.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 33.2 mm -76.53 126.27 86.37 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 127.028 2.131 . . . . 0.0 113.157 -166.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -60.63 138.42 79.83 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 124.722 2.722 . . . . 0.0 113.976 -173.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm 53.43 37.08 24.73 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 116.822 2.156 . . . . 0.0 116.822 -169.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 26' ' ' GLY . . . -84.72 160.74 35.97 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.078 -1.639 . . . . 0.0 113.225 159.443 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.75 -56.37 12.34 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.252 -1.734 . . . . 0.0 115.658 163.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.71 -47.65 77.57 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.196 2.999 . . . . 0.0 112.517 -179.272 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -40.81 -64.88 0.48 Allowed 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.656 1.582 . . . . 0.0 113.975 164.696 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 12.9 t -67.65 -34.89 77.84 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.456 1.102 . . . . 0.0 113.887 -170.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -53.46 -65.43 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.616 1.966 . . . . 0.0 113.906 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.22 -10.78 24.45 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 115.496 0.959 . . . . 0.0 115.496 172.006 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -72.72 -24.75 61.03 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 119.634 1.717 . . . . 0.0 113.194 172.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 67.5 mt -105.4 135.93 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.542 1.537 . . . . 0.0 108.452 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -154.15 158.25 40.1 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.844 -1.16 . . . . 0.0 112.169 -170.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -51.83 122.78 8.85 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.007 -1.683 . . . . 0.0 115.49 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.59 -5.51 64.63 Favored Glycine 0 N--CA 1.429 -1.771 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 0.3 OUTLIER -80.19 171.83 14.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.923 1.861 . . . . 0.0 114.343 -175.823 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -119.74 125.73 49.35 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.402 -1.436 . . . . 0.0 112.709 -169.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.0 t -82.61 127.85 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.734 -1.229 . . . . 0.0 110.027 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.41 -46.45 5.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 110.525 176.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.79 136.57 17.13 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.556 -1.34 . . . . 0.0 114.003 -177.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -104.37 116.93 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 124.536 1.135 . . . . 0.0 108.525 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.5 t30 59.38 39.47 22.13 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.137 -1.602 . . . . 0.0 113.767 175.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.09 -33.5 5.21 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 121.209 -0.932 . . . . 0.0 113.889 -174.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -87.03 117.75 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 C-N-CA 124.725 1.21 . . . . 0.0 111.471 -167.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 t -76.55 139.32 40.68 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.318 -1.489 . . . . 0.0 112.628 -174.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.2 mt -89.69 20.86 3.79 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -171.288 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -62.17 117.71 6.4 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 119.829 -1.794 . . . . 0.0 114.591 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 84.94 10.8 78.02 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 124.483 1.039 . . . . 0.0 113.65 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.72 157.14 38.46 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.3 p -91.22 170.03 10.34 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.863 -1.148 . . . . 0.0 109.677 170.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -53.91 -55.2 29.09 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.889 1.276 . . . . 0.0 113.322 170.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -56.44 -44.34 80.34 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.049 1.499 . . . . 0.0 115.049 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -61.06 -46.05 92.25 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -175.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.98 -33.43 75.71 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.809 1.244 . . . . 0.0 112.669 172.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.06 -48.34 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.463 1.105 . . . . 0.0 110.381 178.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -59.05 -42.24 89.81 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.714 -1.241 . . . . 0.0 113.043 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.6 m -62.03 -48.06 81.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.036 2.134 . . . . 0.0 112.858 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 33.4 mt -65.54 -37.12 85.82 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.109 1.364 . . . . 0.0 114.246 175.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -68.69 -31.54 70.71 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.337 -1.477 . . . . 0.0 112.474 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -88.51 48.58 1.66 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 124.828 1.251 . . . . 0.0 112.139 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.6 p -98.82 154.48 17.98 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.132 1.773 . . . . 0.0 107.894 166.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.66 -157.76 30.82 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.803 -1.186 . . . . 0.0 112.007 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? -69.43 -49.08 58.46 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 121.099 -1.236 . . . . 0.0 112.6 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 56.4 t -99.16 132.72 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.43 1.092 . . . . 0.0 108.325 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 74.4 t -120.3 124.8 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 126.556 1.943 . . . . 0.0 109.649 -165.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 -113.58 87.46 2.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.627 1.171 . . . . 0.0 112.196 -174.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.279 3.1 pp -123.5 148.28 46.4 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 117.794 2.516 . . . . 0.0 117.794 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 49.9 tp -105.82 128.31 53.65 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.878 1.671 . . . . 0.0 108.433 -176.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.34 158.68 43.65 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 121.999 0.904 . . . . 0.0 110.822 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -95.52 150.98 19.72 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 165.214 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? -75.82 152.89 37.19 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.221 1.01 . . . . 0.0 109.791 165.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -115.72 164.75 12.17 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.94 1.257 . . . . 0.0 110.87 178.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -75.58 179.48 5.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 114.688 1.366 . . . . 0.0 114.688 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 30.9 m -87.47 143.61 34.39 Favored Pre-proline 0 N--CA 1.431 -1.409 0 O-C-N 120.545 -1.347 . . . . 0.0 112.682 -177.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo . . . . . 0 N--CA 1.434 -2.011 0 C-N-CA 123.309 2.672 . . . . 0.0 112.725 161.209 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.7 pttm . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 119.326 -0.368 . . . . 0.0 111.387 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.04 176.5 9.95 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 121.894 1.73 . . . . 0.0 112.173 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.95 12.18 62.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.859 -0.526 . . . . 0.0 112.759 -176.168 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -81.1 156.02 25.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.321 1.848 . . . . 0.0 113.113 -168.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 38.5 p -121.86 154.42 37.09 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 121.077 -1.014 . . . . 0.0 112.79 -174.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.2 139.65 27.36 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.072 -1.017 . . . . 0.0 109.082 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -92.72 131.0 38.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.86 -1.15 . . . . 0.0 109.899 168.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.8 t -116.71 111.83 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.057 1.343 . . . . 0.0 108.656 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -102.55 78.06 1.68 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.419 -1.425 . . . . 0.0 109.288 172.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.5 tp -94.74 146.83 23.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 124.297 1.039 . . . . 0.0 111.063 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.48 127.59 50.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.085 -1.634 . . . . 0.0 108.932 167.151 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.1 ptmt -70.15 149.55 47.44 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 p -106.55 111.44 23.99 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.272 -1.517 . . . . 0.0 111.635 -174.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.0 t0 54.26 39.46 30.85 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.424 2.29 . . . . 0.0 113.522 -175.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.02 -7.22 78.71 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.281 -1.512 . . . . 0.0 115.713 -176.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.8 t -109.39 150.38 28.14 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-N 119.15 1.475 . . . . 0.0 112.005 -172.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.4 mt -100.71 -61.59 1.35 Allowed 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.237 -1.539 . . . . 0.0 112.151 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.53 33.81 0.91 Allowed Glycine 0 N--CA 1.43 -1.746 0 O-C-N 119.914 -1.741 . . . . 0.0 111.497 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 pt -124.38 150.36 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.429 1.092 . . . . 0.0 111.261 -174.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 35.4 m -126.67 134.33 50.74 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 156.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 m -117.84 161.58 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 CA-C-O 122.346 1.07 . . . . 0.0 112.102 -170.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.64 -173.35 4.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 124.2 1.0 . . . . 0.0 109.595 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.06 -152.41 20.25 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.994 -1.067 . . . . 0.0 115.437 171.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.67 172.66 30.62 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 125.593 1.568 . . . . 0.0 111.621 -176.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t -60.24 -37.26 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 125.065 1.346 . . . . 0.0 113.065 176.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -73.88 -22.68 59.64 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 126.283 1.833 . . . . 0.0 113.809 -173.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 26.8 m -98.72 141.9 30.95 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 124.627 1.171 . . . . 0.0 108.444 -174.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 14.2 m -78.02 61.02 2.5 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 119.975 -1.703 . . . . 0.0 114.112 -176.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.4 m -100.58 7.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 127.1 2.16 . . . . 0.0 114.548 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 58.1 ttp85 78.71 120.62 0.05 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.556 2.342 . . . . 0.0 112.064 -171.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 39.6 t60 72.47 -69.77 0.18 Allowed 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.947 1.699 . . . . 0.0 115.512 172.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 144.97 95.57 0.19 Allowed Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -174.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.17 152.14 23.46 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.2 mm -95.32 127.72 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.239 1.416 . . . . 0.0 108.584 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -125.7 155.58 40.69 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 120.757 -1.214 . . . . 0.0 111.404 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.5 t -75.96 122.26 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.999 -1.063 . . . . 0.0 110.945 169.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.0 ttmm -87.9 -42.06 12.76 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.376 1.47 . . . . 0.0 109.703 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.24 160.0 38.2 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.77 -0.581 . . . . 0.0 109.946 175.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -119.17 121.36 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 C-N-CA 124.348 1.059 . . . . 0.0 108.841 174.315 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.46 119.38 77.22 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 115.872 -2.013 . . . . 0.0 116.144 -169.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -59.86 123.24 12.83 Favored 'Trans proline' 0 N--CA 1.434 -2.024 0 CA-C-N 124.659 2.7 . . . . 0.0 114.916 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.254 83.7 mttt 81.74 26.53 0.19 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 128.229 2.612 . . . . 0.0 111.921 -172.172 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.61 157.49 31.39 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 119.768 -1.833 . . . . 0.0 111.812 164.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.57 -58.74 5.47 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.59 -2.123 . . . . 0.0 114.287 160.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.1 -40.12 95.54 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 127.45 2.3 . . . . 0.0 112.826 -177.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 -52.07 -59.74 4.01 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 166.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.5 t -68.82 -25.21 64.56 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 125.837 1.655 . . . . 0.0 114.905 -167.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -46.48 -63.15 1.08 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.1 1.76 . . . . 0.0 113.964 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 114.48 -2.51 23.5 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.217 -0.927 . . . . 0.0 114.324 171.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.6 mtm180 -85.81 -28.64 24.36 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.006 -1.29 . . . . 0.0 113.095 171.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.1 mt -108.61 132.07 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 C-N-CA 126.445 1.898 . . . . 0.0 110.664 -170.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.12 -176.71 4.91 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.356 -1.465 . . . . 0.0 112.424 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -68.43 121.19 15.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.416 -1.428 . . . . 0.0 112.738 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 105.41 -2.52 39.88 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 121.418 -0.801 . . . . 0.0 114.393 -175.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -80.35 147.8 30.91 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 119.419 1.609 . . . . 0.0 112.393 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 23.5 ttm180 -97.07 134.34 40.56 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.838 -1.164 . . . . 0.0 110.452 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.1 t -86.45 127.39 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.96 -1.087 . . . . 0.0 109.196 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.47 -45.94 4.71 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.496 -1.377 . . . . 0.0 111.253 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.0 128.69 12.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.489 -1.382 . . . . 0.0 111.584 -176.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 t -108.9 124.04 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 66.55 28.1 9.47 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.521 -1.362 . . . . 0.0 113.666 170.5 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.74 -12.53 66.92 Favored Glycine 0 N--CA 1.429 -1.809 0 O-C-N 119.962 -1.712 . . . . 0.0 113.773 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.9 t -96.14 116.09 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.155 -1.203 . . . . 0.0 109.026 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 92.7 p -75.36 140.83 43.27 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.357 -1.464 . . . . 0.0 111.592 177.541 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.2 mt -88.29 50.93 2.06 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.652 -1.28 . . . . 0.0 112.744 -166.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -73.67 125.07 27.21 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.977 -1.702 . . . . 0.0 112.19 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.79 10.64 61.51 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.237 1.399 . . . . 0.0 115.453 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.26 139.4 50.0 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 115.898 1.814 . . . . 0.0 115.898 -170.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.8 p -91.64 173.26 7.98 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 124.868 1.267 . . . . 0.0 110.27 176.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -58.96 -49.41 77.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.962 -1.086 . . . . 0.0 113.531 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -56.33 -40.29 74.2 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 175.089 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -53.9 51.56 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.565 1.546 . . . . 0.0 113.766 179.069 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.5 87.73 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.472 1.509 . . . . 0.0 113.86 177.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.62 -48.15 88.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.772 1.229 . . . . 0.0 110.894 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -63.21 -41.27 99.11 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 175.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.3 m -61.48 -45.95 92.08 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 125.96 1.704 . . . . 0.0 113.277 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.64 -30.4 67.02 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.269 -1.519 . . . . 0.0 113.91 176.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.58 -45.03 92.29 Favored 'General case' 0 CA--C 1.488 -1.419 0 O-C-N 120.453 -1.405 . . . . 0.0 112.025 167.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -78.02 48.81 0.75 Allowed 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 128.116 2.567 . . . . 0.0 113.679 176.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 35.3 p -106.03 156.0 18.84 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.268 -1.52 . . . . 0.0 110.218 174.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.21 -164.19 38.35 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.778 -1.201 . . . . 0.0 111.036 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -69.78 -47.81 61.52 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 118.922 1.361 . . . . 0.0 112.236 172.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.27 123.82 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-O 123.171 1.463 . . . . 0.0 107.505 169.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.4 t -113.2 103.59 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 126.956 2.103 . . . . 0.0 109.019 -168.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.6 t-160 -89.2 101.57 14.23 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 123.784 0.834 . . . . 0.0 111.523 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.6 mt -102.97 162.12 13.2 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-O 122.665 1.221 . . . . 0.0 113.822 172.292 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.5 tt -129.04 132.19 47.44 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.036 1.335 . . . . 0.0 108.021 159.311 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.01 164.64 28.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.012 -1.055 . . . . 0.0 113.23 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -113.88 142.47 46.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.405 1.882 . . . . 0.0 109.918 177.014 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 19.7 tptt -75.31 133.14 41.35 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.818 1.647 . . . . 0.0 112.794 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.32 127.87 40.27 Favored Glycine 0 N--CA 1.43 -1.709 0 C-N-CA 127.519 2.485 . . . . 0.0 117.211 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -73.22 -39.97 65.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.652 2.381 . . . . 0.0 114.127 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.4 p -141.16 126.35 10.89 Favored Pre-proline 0 N--CA 1.429 -1.484 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 170.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo . . . . . 0 N--CA 1.434 -2.028 0 CA-C-N 122.853 2.055 . . . . 0.0 113.904 175.148 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 91.3 mttt . . . . . 0 N--CA 1.431 -1.406 0 CA-C-O 118.824 -0.608 . . . . 0.0 111.028 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_exo -67.07 179.11 2.49 Favored 'Trans proline' 0 N--CA 1.434 -1.999 0 C-N-CA 122.725 2.283 . . . . 0.0 115.592 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.44 24.04 5.49 Favored Glycine 0 N--CA 1.429 -1.777 0 C-N-CA 124.008 0.813 . . . . 0.0 114.585 -175.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -85.72 131.99 34.23 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.33 1.452 . . . . 0.0 109.342 175.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.0 p -101.83 150.47 23.14 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.375 -1.453 . . . . 0.0 112.532 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.76 134.88 22.76 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.903 -1.123 . . . . 0.0 108.72 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -91.04 121.4 32.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.334 1.454 . . . . 0.0 109.615 174.156 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.19 102.77 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.803 -1.186 . . . . 0.0 108.236 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -104.46 81.88 1.85 Allowed 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.123 1.369 . . . . 0.0 108.226 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.6 tp -111.78 149.27 31.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.694 1.198 . . . . 0.0 110.325 -165.355 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.89 144.81 30.72 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.347 -1.471 . . . . 0.0 108.869 170.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -70.12 154.64 41.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.609 -1.307 . . . . 0.0 112.638 173.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.6 p -112.92 100.79 8.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.836 -1.165 . . . . 0.0 109.066 175.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 22.0 t0 58.01 45.42 18.01 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 126.014 1.726 . . . . 0.0 113.248 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.54 -10.99 67.4 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 125.049 1.309 . . . . 0.0 115.226 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 62.1 m -104.04 148.78 25.83 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.787 1.293 . . . . 0.0 113.561 -169.056 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.0 mt -119.31 -54.03 2.21 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.999 1.32 . . . . 0.0 109.354 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.5 43.32 1.86 Allowed Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 127.036 2.255 . . . . 0.0 113.877 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 pt -121.52 121.15 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 CA-C-N 119.394 1.597 . . . . 0.0 115.031 -167.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.4 m -116.72 123.83 48.16 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.549 -1.345 . . . . 0.0 109.202 165.388 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.46 173.91 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.072 1.349 . . . . 0.0 111.709 -171.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.7 t -146.31 168.47 21.01 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.059 1.344 . . . . 0.0 108.515 174.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.67 -154.18 17.15 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.842 -1.161 . . . . 0.0 115.149 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 101.5 165.99 27.43 Favored Glycine 0 N--CA 1.429 -1.785 0 C-N-CA 125.247 1.403 . . . . 0.0 112.379 -179.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.7 m -84.28 17.13 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 115.937 1.829 . . . . 0.0 115.937 -171.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -97.88 -64.29 1.05 Allowed 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 119.421 -2.049 . . . . 0.0 110.507 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 51.9 m -79.75 155.91 27.73 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.545 1.538 . . . . 0.0 108.81 -176.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 65.6 p -75.09 60.99 1.06 Allowed 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.665 -1.897 . . . . 0.0 114.642 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 14.8 t -99.4 89.41 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.24 -1.537 . . . . 0.0 108.772 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? 38.75 67.24 0.44 Allowed 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 128.599 2.759 . . . . 0.0 115.961 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 69.27 -3.21 1.62 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.9 84.7 1.7 Allowed Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.577 -1.327 . . . . 0.0 111.417 -169.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -137.53 168.66 24.37 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 167.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.72 125.76 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.876 1.271 . . . . 0.0 107.972 178.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -128.88 157.49 41.42 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.602 -1.312 . . . . 0.0 111.398 -172.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.8 t -76.39 126.54 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.495 1.518 . . . . 0.0 111.181 172.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -109.79 -51.67 2.85 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.338 -1.477 . . . . 0.0 113.164 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.0 157.01 43.49 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 121.226 -0.921 . . . . 0.0 109.975 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -125.77 126.09 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 C-N-CA 123.988 0.915 . . . . 0.0 109.195 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.6 mm -77.26 122.45 86.16 Favored Pre-proline 0 N--CA 1.429 -1.493 0 CA-C-O 116.238 -1.839 . . . . 0.0 114.507 -173.193 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -57.28 127.6 26.24 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 CA-C-N 124.506 2.645 . . . . 0.0 116.18 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.292 50.8 mttp 79.36 22.64 0.56 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 127.545 2.338 . . . . 0.0 113.385 -177.27 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.17 156.3 30.76 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.9 -1.75 . . . . 0.0 112.16 165.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.09 -55.33 12.53 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.824 1.65 . . . . 0.0 115.268 170.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.36 -48.51 75.25 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.89 2.476 . . . . 0.0 111.448 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 tm-20 -47.49 -59.15 3.44 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 173.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.0 t -68.37 -30.37 69.29 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.647 1.179 . . . . 0.0 113.387 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -65.02 -60.43 3.05 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.963 1.305 . . . . 0.0 111.199 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.96 31.07 15.73 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.45 -1.406 . . . . 0.0 116.431 167.062 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -83.3 -39.82 20.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 121.458 -1.025 . . . . 0.0 108.747 159.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mt -79.17 99.81 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 123.933 0.893 . . . . 0.0 110.313 175.188 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -122.81 156.77 33.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.82 1.295 . . . . 0.0 109.627 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.1 pttt -67.78 131.27 45.24 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.136 -1.602 . . . . 0.0 113.379 -171.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.87 -19.52 32.84 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.164 -0.96 . . . . 0.0 114.1 -172.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -79.51 157.1 27.51 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 120.152 1.976 . . . . 0.0 113.312 -173.412 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 70.6 ttt-85 -108.88 134.93 50.9 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.154 -1.591 . . . . 0.0 111.289 -173.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.11 132.75 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 119.945 -1.722 . . . . 0.0 110.986 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.72 -52.4 4.9 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.914 -1.116 . . . . 0.0 111.788 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.96 140.14 20.3 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.907 -0.496 . . . . 0.0 112.016 -165.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.1 t -109.22 118.24 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 171.012 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 63.18 20.89 12.55 Favored 'General case' 0 N--CA 1.429 -1.514 0 C-N-CA 125.968 1.707 . . . . 0.0 113.974 -178.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 86.52 -0.55 86.94 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.279 -1.513 . . . . 0.0 114.069 -174.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -86.05 117.56 30.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.853 1.261 . . . . 0.0 109.045 176.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.0 p -75.63 132.36 40.55 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.774 -1.204 . . . . 0.0 113.702 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 67.6 mt -84.77 -13.19 51.95 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -168.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -63.63 131.74 48.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.595 -1.941 . . . . 0.0 112.72 174.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.18 -30.35 9.22 Favored Glycine 0 N--CA 1.431 -1.697 0 C-N-CA 124.518 1.056 . . . . 0.0 113.674 -171.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.23 156.87 39.04 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -88.23 172.61 9.34 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.244 1.018 . . . . 0.0 111.681 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -63.82 -43.35 96.48 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.554 -1.341 . . . . 0.0 112.151 175.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -54.8 -44.87 74.18 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 126.646 1.978 . . . . 0.0 114.416 171.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -56.03 -55.05 37.48 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.93 -34.85 78.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.61 -53.76 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.33 1.052 . . . . 0.0 110.566 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -61.92 -39.43 92.01 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.011 0.91 . . . . 0.0 113.036 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 97.0 m -66.86 -42.38 85.78 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.452 1.901 . . . . 0.0 113.219 179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 65.5 mt -69.54 -36.92 76.83 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.068 -1.02 . . . . 0.0 113.082 173.214 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -53.55 56.4 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.789 -1.195 . . . . 0.0 113.03 173.39 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -81.04 43.06 0.68 Allowed 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.863 1.665 . . . . 0.0 112.748 -177.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.416 ' HB ' HG22 ' A' ' 92' ' ' VAL . 26.1 p -91.76 155.37 18.3 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 127.425 2.29 . . . . 0.0 108.814 168.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.98 -140.7 7.01 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.973 -1.079 . . . . 0.0 114.078 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 2.1 tm0? -71.02 -53.48 14.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.329 -1.101 . . . . 0.0 111.993 177.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 95.0 t -97.89 135.89 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.397 1.57 . . . . 0.0 109.17 169.382 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 88' ' ' THR . 48.2 t -111.43 117.66 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 128.574 2.75 . . . . 0.0 108.131 -176.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 52.9 m170 -105.23 104.41 14.14 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.872 -1.143 . . . . 0.0 111.244 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -106.73 163.75 12.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.884 -1.135 . . . . 0.0 113.799 171.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.3 tp -128.2 134.11 48.97 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 124.856 1.263 . . . . 0.0 108.36 158.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.8 pp -145.17 164.87 29.98 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.637 -1.29 . . . . 0.0 111.285 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -121.42 149.72 42.59 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.023 1.729 . . . . 0.0 110.894 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.01 121.28 20.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.482 1.513 . . . . 0.0 110.761 176.178 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -76.39 -178.19 44.98 Favored Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 125.593 1.568 . . . . 0.0 114.22 -178.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -81.69 178.71 8.17 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.842 -1.387 . . . . 0.0 112.615 -175.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.2 t -113.26 102.57 54.97 Favored Pre-proline 0 N--CA 1.43 -1.472 0 O-C-N 120.793 -1.192 . . . . 0.0 110.377 -171.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 C--N 1.301 -1.97 0 C-N-CA 121.958 1.772 . . . . 0.0 110.591 155.664 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.7 tttt . . . . . 0 N--CA 1.43 -1.461 0 CA-C-O 117.451 -1.261 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -76.2 23.22 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.079 0 C-N-CA 122.853 2.369 . . . . 0.0 118.069 -170.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.13 59.8 1.45 Allowed Glycine 0 N--CA 1.431 -1.688 0 N-CA-C 108.965 -1.654 . . . . 0.0 108.965 -170.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -53.86 -58.47 7.14 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.867 1.432 . . . . 0.0 114.867 -163.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -123.56 154.73 38.82 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-N 119.419 1.009 . . . . 0.0 110.596 163.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -144.43 149.92 36.83 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 123.882 0.873 . . . . 0.0 109.438 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -99.63 125.85 45.53 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.123 1.369 . . . . 0.0 109.275 167.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.46 94.88 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 O-C-N 120.481 -1.387 . . . . 0.0 107.954 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -90.62 81.54 5.87 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.658 -1.276 . . . . 0.0 109.387 169.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 49.2 tp -96.39 133.6 40.6 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.652 1.181 . . . . 0.0 111.642 -171.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.16 138.72 38.73 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 119.878 -1.764 . . . . 0.0 110.147 172.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -68.25 156.51 37.49 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.726 1.21 . . . . 0.0 113.721 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.4 t -129.25 135.8 49.27 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 172.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.0 t70 33.34 52.12 0.35 Allowed 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 128.248 2.619 . . . . 0.0 116.57 -173.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.68 -5.45 69.49 Favored Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 117.678 1.831 . . . . 0.0 117.678 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.7 m -121.57 150.63 41.38 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.535 1.668 . . . . 0.0 113.988 -169.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 46.9 mt -101.28 -60.24 1.56 Allowed 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.232 1.413 . . . . 0.0 109.606 168.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.18 41.82 2.02 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.874 1.702 . . . . 0.0 114.63 175.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.3 pt -112.53 156.58 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 CA-C-N 118.417 1.109 . . . . 0.0 111.994 177.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -131.39 132.52 44.46 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.115 -1.615 . . . . 0.0 109.258 149.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.5 m -114.75 160.2 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.478 1.511 . . . . 0.0 110.882 -175.126 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 t -148.8 -178.96 6.64 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.541 -1.349 . . . . 0.0 110.651 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.4 -123.97 7.07 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 120.763 -1.21 . . . . 0.0 114.463 167.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.47 171.27 26.9 Favored Glycine 0 N--CA 1.43 -1.75 0 CA-C-O 122.671 1.151 . . . . 0.0 113.208 178.361 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.8 p -77.62 -28.26 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -172.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -74.96 -46.29 36.45 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 120.391 -1.443 . . . . 0.0 114.209 -171.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 3.8 t -87.67 175.75 7.74 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.716 -1.24 . . . . 0.0 113.491 -172.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 78.4 p -83.28 46.09 1.1 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.345 1.858 . . . . 0.0 115.34 -171.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.49 -177.11 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 O-C-N 119.749 -1.844 . . . . 0.0 110.018 170.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -71.63 102.43 2.76 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.901 -1.749 . . . . 0.0 111.532 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 56.69 19.21 4.16 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 128.975 2.91 . . . . 0.0 118.636 174.38 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.24 69.33 1.41 Allowed Glycine 0 N--CA 1.43 -1.745 0 O-C-N 120.729 -1.232 . . . . 0.0 114.728 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.98 175.55 21.48 Favored Glycine 0 N--CA 1.43 -1.73 0 O-C-N 121.467 -1.019 . . . . 0.0 113.55 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.1 mm -102.81 117.18 47.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 125.798 1.639 . . . . 0.0 108.222 -176.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.23 149.81 44.23 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.166 -0.958 . . . . 0.0 109.947 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -78.12 122.59 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.506 -1.371 . . . . 0.0 113.14 177.26 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.52 -39.26 10.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.614 -1.304 . . . . 0.0 112.799 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.26 158.86 42.28 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.441 -1.412 . . . . 0.0 111.466 -177.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.412 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -122.46 120.8 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-O 122.965 1.364 . . . . 0.0 110.824 176.627 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.75 121.66 85.18 Favored Pre-proline 0 N--CA 1.43 -1.468 0 C-N-CA 125.802 1.641 . . . . 0.0 113.189 -171.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.42 134.37 41.39 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 CA-C-N 123.98 2.457 . . . . 0.0 112.689 179.287 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 56.7 mttm 82.29 20.35 0.29 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 129.173 2.989 . . . . 0.0 113.785 -172.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.51 154.85 30.23 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 119.966 -1.709 . . . . 0.0 115.938 169.274 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.47 -58.72 5.1 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.986 2.115 . . . . 0.0 115.562 158.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.06 -46.54 86.98 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.99 2.916 . . . . 0.0 111.612 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.412 ' HA ' HG12 ' A' ' 47' ' ' ILE . 2.6 tm-20 -41.73 -59.58 1.62 Allowed 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 169.397 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.0 t -69.54 -34.6 74.46 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -62.08 -46.81 87.44 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.015 -1.678 . . . . 0.0 113.542 -171.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 108.07 -6.69 34.86 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.359 -1.463 . . . . 0.0 116.08 155.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.482 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.4 mmp_? -70.23 -35.48 73.87 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.918 -1.342 . . . . 0.0 111.131 169.138 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.5 mt -87.22 128.94 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 126.396 1.878 . . . . 0.0 108.766 176.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -164.28 123.21 1.89 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.6 -1.312 . . . . 0.0 107.798 -176.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.17 112.92 0.31 Allowed 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 116.846 2.165 . . . . 0.0 116.846 -167.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.15 -8.66 12.32 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 118.552 -1.138 . . . . 0.0 113.616 -164.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -79.84 164.34 23.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 120.799 2.299 . . . . 0.0 113.019 175.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.1 ttt180 -125.57 124.79 42.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.153 -0.967 . . . . 0.0 110.877 -171.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.5 t -87.74 135.49 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 O-C-N 120.106 -1.621 . . . . 0.0 109.815 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.4 mp -106.24 -44.06 4.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.721 1.208 . . . . 0.0 111.111 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.96 132.54 15.79 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.705 -1.247 . . . . 0.0 111.255 -177.064 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 t -109.97 119.39 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.524 1.13 . . . . 0.0 108.518 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.87 24.6 9.7 Favored 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 126.146 1.778 . . . . 0.0 114.125 173.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 90.48 -9.9 76.15 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 120.147 -1.596 . . . . 0.0 114.182 -173.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.66 119.99 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.552 1.141 . . . . 0.0 108.098 -176.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.7 t -76.04 145.93 39.81 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.444 -1.41 . . . . 0.0 112.476 -174.25 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 95.9 mt -91.49 8.13 37.91 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.516 -1.365 . . . . 0.0 113.251 -175.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 77.1 mt-10 -68.27 107.73 2.92 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 119.535 -1.978 . . . . 0.0 113.934 -176.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.27 4.3 68.68 Favored Glycine 0 N--CA 1.429 -1.782 0 O-C-N 120.773 -1.205 . . . . 0.0 113.715 -175.176 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.52 148.11 45.34 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 121.139 -1.213 . . . . 0.0 113.79 168.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.3 p -80.51 173.92 12.12 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.852 -1.155 . . . . 0.0 111.845 169.228 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -55.54 -52.29 64.21 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.364 1.865 . . . . 0.0 112.368 168.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -57.14 -43.12 82.14 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 115.043 1.498 . . . . 0.0 115.043 173.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -56.27 -42.72 77.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.806 1.78 . . . . 0.0 115.806 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.6 -36.12 83.2 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.804 -1.185 . . . . 0.0 112.904 175.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.9 -44.36 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 O-C-N 120.662 -1.274 . . . . 0.0 111.191 177.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -54.04 -37.91 64.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.977 1.711 . . . . 0.0 113.247 171.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -73.36 -52.21 14.64 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.901 2.08 . . . . 0.0 112.224 177.196 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 48.3 mt -64.41 -31.47 72.7 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -70.05 -26.46 64.03 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.18 -1.575 . . . . 0.0 112.982 174.336 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.3 t30 -91.6 39.71 1.01 Allowed 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.563 1.545 . . . . 0.0 112.887 178.27 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 p -94.28 155.47 17.0 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 126.29 1.836 . . . . 0.0 111.786 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -146.59 20.65 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.038 -1.039 . . . . 0.0 112.587 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -69.68 -56.27 7.68 Favored 'General case' 0 N--CA 1.429 -1.523 0 O-C-N 121.2 -1.176 . . . . 0.0 112.38 173.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.1 t -98.54 128.47 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.826 1.298 . . . . 0.0 108.418 178.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.7 t -114.46 109.41 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 128.385 2.674 . . . . 0.0 109.024 -171.292 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -88.84 109.37 20.14 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 120.634 -1.291 . . . . 0.0 110.597 174.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -101.23 153.66 19.43 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.641 -1.287 . . . . 0.0 111.136 161.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -123.02 128.2 49.85 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 157.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -142.46 163.44 32.84 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 121.473 -0.767 . . . . 0.0 111.779 -171.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.51 136.02 53.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.399 1.88 . . . . 0.0 109.145 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -77.66 148.03 35.22 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.766 -1.834 . . . . 0.0 112.707 176.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.76 119.43 5.29 Favored Glycine 0 N--CA 1.43 -1.735 0 C-N-CA 125.106 1.336 . . . . 0.0 112.327 176.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -77.91 178.62 7.3 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 -172.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.3 m -114.45 161.98 25.74 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 124.606 1.162 . . . . 0.0 110.459 -176.464 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo . . . . . 0 N--CA 1.434 -2.014 0 C-N-CA 122.174 1.916 . . . . 0.0 115.215 168.936 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 97.8 mttt . . . . . 0 N--CA 1.43 -1.444 0 CA-C-O 118.062 -0.97 . . . . 0.0 108.901 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -77.85 62.55 7.91 Favored 'Trans proline' 0 N--CA 1.433 -2.034 0 C-N-CA 124.174 3.249 . . . . 0.0 113.425 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.49 48.55 0.26 Allowed Glycine 0 N--CA 1.429 -1.778 0 C-N-CA 124.893 1.235 . . . . 0.0 114.158 177.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -89.55 167.52 12.89 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 160.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -104.96 160.75 14.78 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 121.02 -1.05 . . . . 0.0 110.593 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.86 139.12 26.09 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 170.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.34 131.71 37.31 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.964 1.306 . . . . 0.0 109.412 165.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.1 t -119.73 115.04 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -177.371 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 -107.53 91.17 3.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.227 1.411 . . . . 0.0 107.81 177.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.23 132.77 54.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.593 1.157 . . . . 0.0 112.241 -162.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.15 137.96 33.5 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.14 -1.6 . . . . 0.0 111.871 176.213 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 27.9 mttp -70.13 148.42 48.73 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 115.214 1.561 . . . . 0.0 115.214 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 37.3 p -113.59 118.78 35.37 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.965 1.306 . . . . 0.0 109.76 173.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.7 t0 59.49 32.51 21.74 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.532 1.933 . . . . 0.0 114.172 -176.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.62 79.03 Favored Glycine 0 N--CA 1.429 -1.832 0 O-C-N 119.763 -1.835 . . . . 0.0 114.869 -173.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.4 p -121.5 144.56 48.63 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.72 -1.459 . . . . 0.0 112.151 178.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 74.2 mt -85.62 -60.42 2.03 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.923 -1.11 . . . . 0.0 109.943 165.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.04 46.87 0.5 Allowed Glycine 0 N--CA 1.43 -1.708 0 O-C-N 119.983 -1.698 . . . . 0.0 109.749 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.2 tt -140.73 144.71 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 123.337 1.541 . . . . 0.0 110.296 -175.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.6 t -118.83 133.3 55.93 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 166.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 m -108.44 164.67 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.49 1.116 . . . . 0.0 110.449 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 t -147.85 178.36 8.57 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.554 1.142 . . . . 0.0 108.481 176.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.99 -162.41 27.42 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.515 -1.366 . . . . 0.0 113.548 176.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.56 165.93 22.67 Favored Glycine 0 N--CA 1.431 -1.665 0 C-N-CA 124.753 1.168 . . . . 0.0 110.707 -173.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.62 -20.34 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.073 -1.251 . . . . 0.0 113.941 -176.231 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -66.49 -30.4 70.73 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.055 1.742 . . . . 0.0 113.784 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.6 t -114.63 166.88 11.25 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.982 -1.074 . . . . 0.0 110.089 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.3 m -84.12 36.38 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.577 -1.952 . . . . 0.0 115.903 -165.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.84 175.98 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 119.97 -1.706 . . . . 0.0 112.328 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -72.09 104.75 3.69 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.561 -1.337 . . . . 0.0 113.847 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 8.6 t60 48.35 51.88 14.4 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.138 2.575 . . . . 0.0 117.853 169.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 70.82 45.77 49.93 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.632 -1.293 . . . . 0.0 115.768 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -104.64 140.23 14.91 Favored Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.963 -1.316 . . . . 0.0 113.272 -178.034 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.64 127.8 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 170.159 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -128.03 157.64 40.1 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.465 -1.397 . . . . 0.0 111.218 -169.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.3 t -75.44 120.65 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 O-C-N 121.02 -1.05 . . . . 0.0 111.044 169.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -90.84 -52.09 5.04 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.626 1.571 . . . . 0.0 110.542 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.08 154.72 36.48 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.15 124.16 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 174.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.72 121.31 84.59 Favored Pre-proline 0 N--CA 1.429 -1.523 0 C-N-CA 126.671 1.989 . . . . 0.0 113.956 -167.222 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -57.7 123.41 13.67 Favored 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 124.448 2.624 . . . . 0.0 116.408 -172.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.268 3.9 mtpm? 76.84 25.99 0.82 Allowed 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 128.137 2.575 . . . . 0.0 114.855 -178.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.42 169.18 47.14 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.175 -1.578 . . . . 0.0 113.495 168.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.5 -58.76 5.01 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.084 2.154 . . . . 0.0 114.668 165.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.59 -47.71 77.63 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 128.861 2.864 . . . . 0.0 112.762 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -46.1 -59.03 3.12 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 116.845 2.165 . . . . 0.0 116.845 172.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 t -69.82 -27.71 65.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 124.848 1.259 . . . . 0.0 113.556 -175.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -50.79 -62.6 1.51 Allowed 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.838 2.055 . . . . 0.0 113.305 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.28 -45.36 1.16 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.969 -0.457 . . . . 0.0 113.087 168.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.46 -19.01 65.68 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 115.079 1.511 . . . . 0.0 115.079 -172.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.8 mt -96.31 117.19 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.519 0 C-N-CA 124.967 1.307 . . . . 0.0 109.06 172.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.7 m80 -118.57 159.45 23.54 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.773 -1.204 . . . . 0.0 110.879 -178.102 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -62.29 129.26 39.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.015 -1.678 . . . . 0.0 113.099 173.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.14 -0.3 72.0 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.886 -1.134 . . . . 0.0 114.831 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -79.62 152.23 30.14 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.768 -1.43 . . . . 0.0 111.289 178.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.8 ttt-85 -105.28 131.13 53.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.031 -1.668 . . . . 0.0 111.261 -168.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 38.3 t -85.34 136.88 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.963 -1.71 . . . . 0.0 110.941 -174.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -105.97 -56.65 2.15 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.908 -1.12 . . . . 0.0 109.386 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.7 137.22 18.79 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.186 -0.946 . . . . 0.0 111.925 -173.344 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.55 125.8 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 67.73 14.72 9.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.078 -1.639 . . . . 0.0 115.263 169.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.13 -13.26 52.26 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 119.748 -1.845 . . . . 0.0 112.913 -175.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -92.85 104.87 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 124.369 1.068 . . . . 0.0 109.333 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.3 t -74.26 126.71 31.23 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.665 -1.272 . . . . 0.0 109.589 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 85.1 mt -83.51 55.18 3.09 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.019 1.118 . . . . 0.0 114.019 -158.406 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -71.43 122.16 19.89 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 119.543 -1.973 . . . . 0.0 114.342 -172.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.63 5.09 72.59 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.186 -1.571 . . . . 0.0 115.437 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.62 140.59 49.81 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.255 1.946 . . . . 0.0 116.255 -171.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.2 p -93.3 178.86 5.59 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.496 2.319 . . . . 0.0 111.747 172.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 20.9 t-160 -57.48 -48.16 79.98 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 126.656 1.982 . . . . 0.0 114.463 179.112 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.3 tptt -56.66 -42.92 79.81 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 174.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.4 -50.48 73.8 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.868 1.667 . . . . 0.0 114.515 178.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.25 -38.31 83.07 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.038 1.335 . . . . 0.0 113.518 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 70.4 t -66.42 -46.92 85.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 O-C-N 120.792 -1.192 . . . . 0.0 111.851 173.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -54.65 -48.5 72.23 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.689 1.596 . . . . 0.0 112.359 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 13.6 m -64.84 -45.97 83.87 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.856 2.463 . . . . 0.0 114.048 175.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.1 mt -64.04 -34.1 77.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 119.29 -2.131 . . . . 0.0 114.675 174.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 17.6 mtp-105 -65.21 -36.58 84.63 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 112.851 172.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -86.52 46.22 1.33 Allowed 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 125.62 1.568 . . . . 0.0 112.712 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.418 ' HB ' HG22 ' A' ' 92' ' ' VAL . 25.1 p -107.12 155.99 19.27 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.65 1.58 . . . . 0.0 109.657 173.546 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.33 -156.4 32.29 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.647 -1.283 . . . . 0.0 112.53 178.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -68.88 -54.94 12.77 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.175 -1.191 . . . . 0.0 111.772 176.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 130.8 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 CA-C-O 122.497 1.141 . . . . 0.0 108.314 170.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.418 HG22 ' HB ' ' A' ' 88' ' ' THR . 63.6 t -118.47 121.27 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 127.029 2.132 . . . . 0.0 109.743 -168.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -97.28 113.68 25.34 Favored 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 121.314 -0.866 . . . . 0.0 111.244 173.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.2 155.76 19.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.581 1.152 . . . . 0.0 112.639 169.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 40.3 tp -127.11 128.79 46.77 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 158.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.7 pp -142.3 170.15 16.25 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.671 -1.268 . . . . 0.0 111.213 175.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -114.7 145.74 41.71 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.267 1.827 . . . . 0.0 109.165 178.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.2 tptt -75.89 138.67 41.2 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.804 1.241 . . . . 0.0 111.308 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.16 130.28 38.37 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.822 -1.174 . . . . 0.0 114.135 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -83.89 -61.46 1.82 Allowed 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.654 -0.909 . . . . 0.0 112.063 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.2 m -98.49 144.14 27.57 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 124.288 1.035 . . . . 0.0 112.572 -177.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo . . . . . 0 N--CA 1.434 -2.026 0 C-N-CA 122.917 2.411 . . . . 0.0 114.005 166.975 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.269 32.4 ttmt . . . . . 0 N--CA 1.431 -1.423 0 CA-C-O 115.4 -2.238 . . . . 0.0 114.338 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -62.34 63.84 0.13 Allowed 'Trans proline' 0 N--CA 1.434 -2.007 0 C-N-CA 125.039 3.826 . . . . 0.0 117.538 168.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.06 27.43 1.7 Allowed Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 126.193 1.854 . . . . 0.0 112.622 -175.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -82.07 156.44 24.58 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 118.294 1.047 . . . . 0.0 109.171 167.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -114.01 149.8 34.84 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.805 1.242 . . . . 0.0 109.451 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -145.85 127.79 15.48 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -87.88 113.55 23.65 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 164.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 t -99.05 110.38 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 124.512 1.125 . . . . 0.0 109.702 -169.579 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.7 mt-10 -104.94 87.25 2.61 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.381 1.086 . . . . 0.0 110.242 -177.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.21 147.6 23.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.073 -1.017 . . . . 0.0 110.593 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.88 112.79 25.91 Favored 'General case' 0 N--CA 1.428 -1.544 0 C-N-CA 124.107 0.963 . . . . 0.0 108.593 160.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.6 ttmt -70.16 126.12 28.74 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.442 1.497 . . . . 0.0 112.608 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.8 p -104.27 123.35 47.21 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.045 -1.659 . . . . 0.0 110.894 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.8 t70 63.61 24.7 14.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.591 1.557 . . . . 0.0 113.861 170.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.6 4.81 89.95 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 119.51 -1.994 . . . . 0.0 115.189 -175.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.5 m -105.35 104.21 13.89 Favored 'General case' 0 N--CA 1.429 -1.477 0 CA-C-N 119.195 1.497 . . . . 0.0 111.629 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 11.9 tp -80.81 -45.51 16.81 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 120.563 -1.336 . . . . 0.0 111.475 173.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.06 28.08 3.23 Favored Glycine 0 N--CA 1.429 -1.773 0 C-N-CA 125.574 1.559 . . . . 0.0 113.547 170.13 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.9 tt -148.99 136.02 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 120.014 1.907 . . . . 0.0 114.694 -168.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.3 m -110.83 126.6 54.82 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.847 1.659 . . . . 0.0 108.48 167.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -104.24 172.01 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.219 1.007 . . . . 0.0 111.905 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.4 t -157.3 176.96 12.0 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.504 -1.372 . . . . 0.0 110.803 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 115.35 -128.33 8.03 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.457 1.027 . . . . 0.0 112.276 169.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.32 134.84 8.16 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.163 0.887 . . . . 0.0 111.279 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.7 m -66.95 -23.09 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 N-CA-C 115.702 1.741 . . . . 0.0 115.702 -170.244 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -99.17 4.49 46.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.779 1.632 . . . . 0.0 112.488 -176.018 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.6 m -87.57 -135.62 0.09 Allowed 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.118 -1.614 . . . . 0.0 110.908 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.5 m -80.24 -32.26 38.39 Favored 'General case' 0 N--CA 1.431 -1.377 0 O-C-N 118.39 -2.694 . . . . 0.0 110.036 177.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -83.74 92.13 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 126.135 1.774 . . . . 0.0 110.181 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.8 ttt-85 -70.03 109.99 4.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.582 -1.949 . . . . 0.0 111.706 -174.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 m170 58.8 45.66 15.19 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 125.818 1.647 . . . . 0.0 112.893 -167.384 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.53 -58.48 5.4 Favored Glycine 0 N--CA 1.429 -1.787 0 N-CA-C 115.66 1.024 . . . . 0.0 115.66 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.91 -177.92 20.62 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 124.917 1.246 . . . . 0.0 112.166 -165.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.7 mm -104.13 125.59 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.945 1.298 . . . . 0.0 109.664 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -126.84 158.81 35.68 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 120.276 -1.515 . . . . 0.0 112.182 -172.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.2 t -76.23 120.35 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 125.135 1.374 . . . . 0.0 112.689 175.035 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -93.93 -47.05 6.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.586 -1.321 . . . . 0.0 112.109 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.71 152.25 24.99 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 121.113 -0.992 . . . . 0.0 111.435 178.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.39 122.29 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 C-N-CA 126.136 1.774 . . . . 0.0 109.378 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 9.3 mm -77.58 123.93 86.66 Favored Pre-proline 0 N--CA 1.429 -1.495 0 C-N-CA 127.014 2.126 . . . . 0.0 114.352 -175.429 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -57.55 125.74 19.71 Favored 'Trans proline' 0 N--CA 1.434 -1.998 0 CA-C-N 124.607 2.681 . . . . 0.0 116.526 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.313 63.1 mttm 83.01 16.34 0.32 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 128.46 2.704 . . . . 0.0 113.72 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.06 162.48 38.83 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.116 -1.615 . . . . 0.0 114.128 169.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.41 -55.78 11.89 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.02 1.728 . . . . 0.0 114.977 170.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.89 -47.78 81.8 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.735 2.814 . . . . 0.0 112.59 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -48.44 -61.08 2.19 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 173.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.7 m -69.1 -32.59 72.11 Favored 'General case' 0 N--CA 1.429 -1.507 0 CA-C-N 115.499 -0.773 . . . . 0.0 112.859 -173.035 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -58.91 -70.28 0.16 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.947 1.699 . . . . 0.0 113.411 175.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.27 14.76 43.75 Favored Glycine 0 N--CA 1.43 -1.712 0 O-C-N 120.38 -1.45 . . . . 0.0 114.9 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -65.27 -26.47 68.1 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.707 -1.467 . . . . 0.0 111.691 159.231 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 71.6 mt -106.55 130.75 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 C-N-CA 126.686 1.994 . . . . 0.0 109.223 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -126.95 170.01 12.72 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-O 123.062 1.411 . . . . 0.0 110.835 169.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -60.59 129.69 42.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.01 -1.681 . . . . 0.0 113.388 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.31 4.15 86.44 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.291 -1.506 . . . . 0.0 115.608 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -75.46 161.98 28.74 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-N 119.835 1.817 . . . . 0.0 111.665 175.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.1 tpt85 -108.57 116.83 32.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.892 -1.13 . . . . 0.0 110.945 -170.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.6 t -84.66 130.6 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 O-C-N 120.511 -1.368 . . . . 0.0 108.283 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.31 -36.58 5.53 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.824 1.25 . . . . 0.0 112.401 -166.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 152.36 33.53 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.234 -1.541 . . . . 0.0 110.11 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.1 t -120.79 114.64 44.31 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 170.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 54.04 48.53 20.88 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.906 2.083 . . . . 0.0 115.535 170.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.06 -18.45 44.61 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 120.834 -1.166 . . . . 0.0 114.571 -177.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.6 t -94.21 105.8 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 O-C-N 120.82 -1.4 . . . . 0.0 109.004 -178.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.8 p -72.23 138.8 47.77 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.688 -1.257 . . . . 0.0 111.761 178.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 53.7 mt -87.15 32.62 0.68 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.636 -1.29 . . . . 0.0 112.777 -169.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -69.61 130.21 41.78 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.189 -2.195 . . . . 0.0 112.66 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.03 8.73 44.12 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 125.645 1.593 . . . . 0.0 116.253 -176.098 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.33 142.08 50.43 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -171.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 40.6 p -87.32 175.25 8.1 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.051 1.34 . . . . 0.0 110.312 173.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.1 t-160 -61.82 -40.22 94.5 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.644 -1.285 . . . . 0.0 111.757 174.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -54.93 -47.16 74.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.355 1.862 . . . . 0.0 114.928 173.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -56.6 -51.81 67.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 -179.079 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.32 -42.38 95.45 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.233 1.013 . . . . 0.0 113.28 177.23 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.08 -48.07 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.984 -1.073 . . . . 0.0 111.137 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -63.97 -41.31 97.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 3.5 m -61.0 -47.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 126.225 1.81 . . . . 0.0 112.874 175.226 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.7 mt -68.43 -29.67 68.38 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 175.33 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.4 ttt180 -62.76 -36.26 82.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.382 -1.449 . . . . 0.0 113.039 173.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -94.83 49.82 1.27 Allowed 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.643 -1.286 . . . . 0.0 111.76 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 37.0 p -107.34 139.68 41.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.325 1.45 . . . . 0.0 110.256 170.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.26 -142.95 12.25 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 123.564 0.602 . . . . 0.0 112.654 173.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -69.38 -60.98 1.98 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.303 -1.116 . . . . 0.0 113.401 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 t -92.02 118.24 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 122.701 1.239 . . . . 0.0 109.773 -176.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.6 t -117.93 111.1 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 126.122 1.769 . . . . 0.0 109.525 -166.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.8 m170 -99.71 103.01 14.65 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.092 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.5 mt -92.85 168.16 11.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.75 -1.844 . . . . 0.0 112.153 171.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.6 tp -129.05 137.67 51.43 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.016 1.326 . . . . 0.0 107.63 157.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.7 161.2 39.78 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.732 -1.23 . . . . 0.0 112.845 174.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -96.46 144.89 26.15 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 164.546 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.9 tmtt? -77.17 127.5 32.74 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.859 -1.151 . . . . 0.0 108.279 162.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.9 103.85 0.19 Allowed Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 125.735 1.636 . . . . 0.0 116.223 -166.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -65.49 -67.89 0.41 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -164.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 10.9 p -108.91 136.81 20.0 Favored Pre-proline 0 N--CA 1.429 -1.51 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.06 175.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo . . . . . 0 N--CA 1.434 -2.016 0 C-N-CA 122.438 2.092 . . . . 0.0 114.317 176.109 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 pttm . . . . . 0 N--CA 1.43 -1.438 0 CA-C-O 119.028 -0.511 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -69.82 -177.26 1.81 Allowed 'Trans proline' 0 N--CA 1.433 -2.031 0 C-N-CA 123.302 2.668 . . . . 0.0 115.631 -177.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.15 24.75 28.46 Favored Glycine 0 N--CA 1.43 -1.729 0 O-C-N 121.848 -0.533 . . . . 0.0 113.039 172.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -85.88 117.52 24.8 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.353 1.061 . . . . 0.0 108.982 -178.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -88.94 139.22 30.68 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.368 -1.458 . . . . 0.0 110.837 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.27 0.0 OUTLIER -147.4 140.48 25.12 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.277 1.513 . . . . 0.0 110.637 175.155 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -90.32 146.51 24.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.483 1.913 . . . . 0.0 109.323 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.5 t -122.81 110.46 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 125.008 1.323 . . . . 0.0 107.488 -174.37 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -105.83 84.2 2.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 CA-C-O 122.214 1.007 . . . . 0.0 108.458 174.006 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.3 tp -110.84 145.1 38.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.01 1.324 . . . . 0.0 110.283 -167.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.31 138.38 40.16 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 119.842 -1.786 . . . . 0.0 110.109 168.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -70.86 149.02 47.21 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 169.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.9 t -109.72 111.56 23.1 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.733 -1.229 . . . . 0.0 109.225 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.9 t0 43.34 50.27 5.98 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.923 2.489 . . . . 0.0 114.778 -178.609 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.97 -39.42 2.79 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.452 1.025 . . . . 0.0 115.043 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 m -102.03 148.72 25.03 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.731 -1.452 . . . . 0.0 114.793 -161.377 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -106.65 -61.37 1.54 Allowed 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.161 -0.962 . . . . 0.0 112.041 176.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.91 32.32 1.58 Allowed Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.669 -1.895 . . . . 0.0 112.798 175.126 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 pt -124.09 139.71 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 C-N-CA 125.105 1.362 . . . . 0.0 108.693 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.1 t -129.28 125.64 37.27 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 36.0 m -108.38 168.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.986 0.898 . . . . 0.0 112.63 -172.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.8 160.08 43.55 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.853 1.661 . . . . 0.0 109.095 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.86 -142.9 15.44 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.729 -1.232 . . . . 0.0 113.614 169.161 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.37 166.42 13.68 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 116.039 1.176 . . . . 0.0 116.039 174.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p -88.93 -28.32 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 O-C-N 120.757 -1.437 . . . . 0.0 114.64 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -83.94 -17.0 42.13 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.004 -1.685 . . . . 0.0 111.589 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.54 146.76 23.88 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.804 2.041 . . . . 0.0 109.677 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.5 m -86.31 60.58 6.32 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 120.71 -1.244 . . . . 0.0 112.004 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.9 m -100.34 -128.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 126.338 1.855 . . . . 0.0 111.321 -177.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -62.78 -61.13 2.62 Favored 'General case' 0 N--CA 1.432 -1.366 0 O-C-N 120.165 -1.584 . . . . 0.0 113.614 -177.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.0 t-160 151.34 65.43 0.0 OUTLIER 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 128.978 2.911 . . . . 0.0 106.174 -167.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 64.69 49.18 65.45 Favored Glycine 0 N--CA 1.429 -1.819 0 O-C-N 120.318 -1.489 . . . . 0.0 115.936 178.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -119.7 137.8 12.73 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.171 -1.194 . . . . 0.0 111.136 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 31.7 mm -103.41 120.85 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 172.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -124.57 160.98 27.17 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.788 -1.195 . . . . 0.0 109.119 -175.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.37 128.3 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.731 -1.231 . . . . 0.0 110.475 171.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 29.1 ttmt -89.94 -50.45 6.02 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.87 -1.144 . . . . 0.0 110.325 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.58 150.79 33.92 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 123.396 0.678 . . . . 0.0 109.873 -174.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -110.31 121.82 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 170.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 20.9 mm -76.64 121.0 84.08 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 126.219 1.808 . . . . 0.0 113.256 -171.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -58.31 122.93 12.52 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.83 2.353 . . . . 0.0 116.184 -175.027 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.321 64.7 mttt 82.5 20.16 0.27 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.367 2.267 . . . . 0.0 113.801 176.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.07 161.89 40.07 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.227 -0.921 . . . . 0.0 114.832 170.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.81 -57.04 7.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.131 2.172 . . . . 0.0 114.396 170.487 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.87 -52.55 62.67 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.58 2.352 . . . . 0.0 112.278 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -42.56 -64.86 0.54 Allowed 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.553 2.057 . . . . 0.0 116.553 174.472 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.9 m -69.94 -14.21 62.61 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -175.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.84 -64.32 1.03 Allowed 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.712 -1.243 . . . . 0.0 110.353 174.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.33 48.01 7.1 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 117.292 1.677 . . . . 0.0 117.292 170.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.7 mtt180 -84.56 -39.87 18.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 146.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 55.8 mt -83.42 121.47 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 126.162 1.785 . . . . 0.0 111.45 176.509 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 46.7 m-70 -122.08 171.75 8.75 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.243 1.497 . . . . 0.0 111.398 170.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -60.62 127.79 33.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.555 -1.34 . . . . 0.0 112.428 175.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.73 0.91 71.53 Favored Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 115.684 1.034 . . . . 0.0 115.684 -178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -82.17 150.05 27.61 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.83 1.815 . . . . 0.0 112.505 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -90.17 127.82 36.2 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.126 -1.609 . . . . 0.0 113.548 -177.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 30.4 t -83.12 132.79 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.787 177.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.93 -51.86 2.86 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.124 -0.985 . . . . 0.0 111.775 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.27 141.33 22.13 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.096 -1.627 . . . . 0.0 112.799 -175.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.8 t -114.94 120.28 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.343 1.057 . . . . 0.0 108.963 177.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 74.35 16.49 3.35 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.931 1.692 . . . . 0.0 114.558 169.595 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.54 -1.48 81.74 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.622 -1.299 . . . . 0.0 112.745 -170.219 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -98.28 117.36 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 125.353 1.461 . . . . 0.0 108.114 176.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t -74.21 125.86 29.34 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.3 -1.5 . . . . 0.0 109.346 178.083 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . 0.327 0.7 OUTLIER -92.27 39.32 1.02 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.314 1.531 . . . . 0.0 112.183 -176.251 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -76.36 121.37 22.91 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.135 -1.603 . . . . 0.0 110.753 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 81.5 17.79 70.2 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.757 1.17 . . . . 0.0 113.731 -172.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.25 154.26 41.09 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 123.226 1.489 . . . . 0.0 115.001 171.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.2 p -91.57 173.6 7.8 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.337 -1.477 . . . . 0.0 110.892 171.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -51.68 -51.93 52.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.439 1.896 . . . . 0.0 112.416 168.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.27 -53.19 61.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 115.446 1.647 . . . . 0.0 115.446 172.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -60.62 -42.74 97.46 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 -170.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.24 -29.65 68.91 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.168 1.387 . . . . 0.0 114.162 171.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.4 t -79.74 -44.28 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 125.033 1.333 . . . . 0.0 111.49 174.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -58.2 -37.24 74.4 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.335 -1.478 . . . . 0.0 112.745 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.7 m -65.83 -41.23 92.06 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 127.176 2.191 . . . . 0.0 113.54 172.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.9 mt -71.23 -40.14 71.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 175.182 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -72.08 -20.05 61.72 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.544 -1.973 . . . . 0.0 112.453 178.135 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -94.39 53.48 1.7 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.511 -1.368 . . . . 0.0 112.019 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.0 p -107.05 143.34 35.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.135 -1.603 . . . . 0.0 110.9 176.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.34 -154.97 18.49 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.76 -1.212 . . . . 0.0 111.242 171.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -66.5 -52.96 40.43 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.604 -1.527 . . . . 0.0 114.009 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.3 t -95.74 126.23 48.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 123.138 1.447 . . . . 0.0 109.567 177.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -109.82 109.36 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 127.298 2.239 . . . . 0.0 107.833 -175.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -93.73 111.44 23.13 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.091 -1.006 . . . . 0.0 108.988 172.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.9 mt -110.14 160.71 16.25 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.182 0.993 . . . . 0.0 112.457 170.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.95 133.11 49.2 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.413 1.485 . . . . 0.0 108.157 164.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.83 166.12 29.46 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.469 0.652 . . . . 0.0 112.536 178.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -101.86 144.74 30.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 121.046 -1.033 . . . . 0.0 111.179 173.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.6 tttt -75.86 126.82 31.73 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.615 1.566 . . . . 0.0 112.48 167.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.08 -166.88 32.25 Favored Glycine 0 N--CA 1.431 -1.656 0 CA-C-O 123.405 1.559 . . . . 0.0 116.883 178.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -94.95 -171.46 2.44 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 126.006 1.723 . . . . 0.0 111.288 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.0 t -80.16 117.84 69.53 Favored Pre-proline 0 N--CA 1.43 -1.43 0 CA-C-O 117.951 -1.023 . . . . 0.0 109.363 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo . . . . . 0 N--CA 1.434 -2.024 0 C-N-CA 122.41 2.073 . . . . 0.0 113.234 -174.912 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mmtt . . . . . 0 N--CA 1.431 -1.408 0 CA-C-O 116.372 -1.775 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -75.77 -179.56 5.28 Favored 'Trans proline' 0 N--CA 1.433 -2.041 0 CA-C-N 126.464 3.344 . . . . 0.0 112.408 175.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.92 6.89 66.69 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 120.951 -1.093 . . . . 0.0 114.017 178.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -78.41 157.7 28.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 O-C-N 121.123 -1.222 . . . . 0.0 110.745 175.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -119.93 137.72 53.88 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.42 1.488 . . . . 0.0 108.993 -174.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.08 140.76 28.28 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-O 122.827 1.298 . . . . 0.0 109.739 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -100.52 112.53 24.91 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.297 1.839 . . . . 0.0 108.039 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.8 t -103.81 102.08 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 O-C-N 120.608 -1.307 . . . . 0.0 108.769 -172.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.73 102.1 14.85 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 167.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.8 tp -120.03 138.02 53.76 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.701 1.201 . . . . 0.0 110.002 -172.69 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.17 122.3 43.37 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.27 -1.519 . . . . 0.0 109.486 173.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -71.42 171.51 11.14 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.289 -1.507 . . . . 0.0 114.408 177.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.2 t -97.03 -149.81 0.33 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.711 -1.243 . . . . 0.0 108.287 169.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.39 74.67 3.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.03 -2.294 . . . . 0.0 112.571 -175.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.36 -4.8 77.38 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.531 1.539 . . . . 0.0 115.509 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.2 t -121.57 135.83 54.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.104 -1.233 . . . . 0.0 112.015 -173.472 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.3 mt -103.92 -55.31 2.4 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.851 1.66 . . . . 0.0 110.113 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.0 30.03 0.59 Allowed Glycine 0 N--CA 1.431 -1.693 0 C-N-CA 125.369 1.462 . . . . 0.0 112.56 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.454 HD12 HD13 ' A' ' 85' ' ' LEU . 11.1 pt -125.95 141.44 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 CA-C-N 118.586 1.193 . . . . 0.0 113.477 -163.401 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.2 m -129.47 138.13 51.23 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.375 1.07 . . . . 0.0 109.005 158.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.4 m -118.34 169.58 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.525 0 C-N-CA 124.949 1.299 . . . . 0.0 112.49 -174.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.25 169.84 18.53 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 172.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 133.41 -147.94 19.19 Favored Glycine 0 N--CA 1.428 -1.836 0 O-C-N 120.572 -1.33 . . . . 0.0 115.53 165.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.17 172.26 24.17 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.43 1.014 . . . . 0.0 112.998 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.1 t -90.79 -51.88 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 C-N-CA 124.828 1.251 . . . . 0.0 112.917 -172.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -92.82 5.15 52.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.431 -1.418 . . . . 0.0 111.936 -169.184 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.7 m -78.14 170.18 17.04 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.461 2.304 . . . . 0.0 108.082 175.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.6 m -67.78 -6.74 22.67 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.16 -2.212 . . . . 0.0 115.921 177.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 3.3 m -78.12 89.83 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.548 1.166 . . . . 0.0 110.631 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 64.2 mtt85 -73.21 54.3 0.41 Allowed 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.849 -1.782 . . . . 0.0 115.123 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -123.98 -68.99 0.83 Allowed 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 126.052 1.741 . . . . 0.0 108.946 -177.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.69 -51.09 0.56 Allowed Glycine 0 N--CA 1.429 -1.803 0 O-C-N 120.729 -1.232 . . . . 0.0 112.352 176.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -83.64 176.47 52.38 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 115.932 1.133 . . . . 0.0 115.932 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 mm -99.17 129.18 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.833 2.053 . . . . 0.0 107.819 175.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -126.71 158.07 37.42 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.903 -1.123 . . . . 0.0 109.521 -174.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.9 t -75.95 117.36 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 O-C-N 121.023 -1.048 . . . . 0.0 111.377 174.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.8 tttp -88.33 -45.12 10.28 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.871 1.268 . . . . 0.0 110.83 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.0 163.19 39.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 121.252 -0.905 . . . . 0.0 108.995 173.245 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 tp -117.95 121.73 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 170.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.64 124.08 87.73 Favored Pre-proline 0 N--CA 1.429 -1.482 0 C-N-CA 126.076 1.75 . . . . 0.0 113.749 -165.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -59.26 127.42 23.93 Favored 'Trans proline' 0 C--N 1.299 -2.057 0 C-N-CA 122.778 2.319 . . . . 0.0 114.904 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.281 11.7 mptt 82.07 21.76 0.27 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 128.538 2.735 . . . . 0.0 112.649 -177.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.91 153.39 29.57 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.962 -1.711 . . . . 0.0 113.711 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.93 -54.87 13.69 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 126.464 1.906 . . . . 0.0 113.877 166.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -54.08 45.97 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 127.576 2.35 . . . . 0.0 112.265 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -40.95 -59.58 1.41 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 177.172 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.0 t -70.2 -29.99 66.98 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -66.2 -52.5 47.39 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.751 -1.218 . . . . 0.0 113.44 -172.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.11 21.7 9.86 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 120.663 -1.273 . . . . 0.0 115.946 158.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -85.15 -36.87 20.79 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.716 -1.461 . . . . 0.0 109.557 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.9 mt -100.48 124.73 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 125.781 1.632 . . . . 0.0 109.098 -176.578 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.497 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 3.4 t-80 -142.36 -175.39 4.43 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.117 1.437 . . . . 0.0 112.274 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.4 ttpp -68.95 123.56 21.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.027 -1.67 . . . . 0.0 113.307 -170.356 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.71 3.7 62.37 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.418 -0.801 . . . . 0.0 114.492 -178.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -78.72 156.38 28.94 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 119.423 1.612 . . . . 0.0 111.743 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -102.5 123.36 46.11 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.208 -1.558 . . . . 0.0 110.446 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 7.4 t -88.86 119.23 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 O-C-N 120.371 -1.456 . . . . 0.0 110.814 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 98.2 mt -94.09 -46.32 7.17 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.01 -1.056 . . . . 0.0 112.118 -175.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.37 144.01 25.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.855 -1.153 . . . . 0.0 112.484 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.816 HG11 HG21 ' A' ' 84' ' ' THR . 2.9 p -113.42 111.71 37.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 C-N-CA 125.938 1.695 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.9 t30 57.23 34.75 25.25 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.771 -1.83 . . . . 0.0 113.674 170.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.19 -28.56 13.32 Favored Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.314 1.435 . . . . 0.0 114.336 -172.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -98.07 129.45 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.235 2.017 . . . . 0.0 110.627 -163.201 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 26.6 p -71.37 132.33 44.68 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.164 -1.585 . . . . 0.0 112.607 -177.224 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 47.9 mt -99.45 35.96 1.86 Allowed 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.498 -1.376 . . . . 0.0 111.912 -178.216 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -89.67 144.26 26.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.714 -1.241 . . . . 0.0 109.486 167.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.26 -32.07 2.31 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.914 -1.117 . . . . 0.0 114.778 -176.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.66 152.28 44.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -175.364 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.8 p -91.76 175.36 6.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.985 -1.072 . . . . 0.0 112.012 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -58.64 -46.8 86.32 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.514 1.525 . . . . 0.0 112.249 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 30.0 tttp -54.69 -47.93 73.07 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 115.574 1.694 . . . . 0.0 115.574 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -58.67 -47.5 84.29 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.667 1.187 . . . . 0.0 113.652 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -61.67 -38.74 88.89 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.613 1.565 . . . . 0.0 114.22 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.22 -49.03 76.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 C-N-CA 124.866 1.266 . . . . 0.0 111.251 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -68.32 -30.13 69.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.771 -1.205 . . . . 0.0 112.168 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' THR . . . . . 0.816 HG21 HG11 ' A' ' 68' ' ' VAL . 38.8 m -64.33 -43.41 94.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.199 1.4 . . . . 0.0 114.691 167.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.454 HD13 HD12 ' A' ' 27' ' ' ILE . 67.3 mt -63.63 -37.03 85.8 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.074 -1.641 . . . . 0.0 114.171 173.522 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -67.09 -31.79 72.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.552 -1.342 . . . . 0.0 113.401 170.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -85.26 51.09 2.09 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.852 1.661 . . . . 0.0 112.1 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 p -106.59 148.48 28.24 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.442 -1.411 . . . . 0.0 109.867 171.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.66 -164.22 36.37 Favored Glycine 0 N--CA 1.43 -1.737 0 C-N-CA 123.778 0.704 . . . . 0.0 111.75 168.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -69.7 -46.27 66.38 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.732 -1.452 . . . . 0.0 114.65 -177.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 47.3 t -103.95 118.7 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 CA-C-O 122.437 1.113 . . . . 0.0 108.761 176.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.2 t -111.6 119.17 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 127.928 2.491 . . . . 0.0 109.926 -164.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -104.3 91.89 4.11 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.772 -1.205 . . . . 0.0 113.308 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -91.5 160.78 15.26 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.046 -2.284 . . . . 0.0 113.694 179.035 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.8 tp -127.0 128.06 45.77 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 161.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.32 158.48 44.32 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.989 -1.069 . . . . 0.0 112.213 176.72 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -110.07 140.71 43.83 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.047 1.339 . . . . 0.0 108.7 172.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.8 tptm -76.27 127.57 33.16 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.832 1.253 . . . . 0.0 111.476 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -72.45 147.99 41.46 Favored Glycine 0 N--CA 1.43 -1.751 0 C-N-CA 125.541 1.543 . . . . 0.0 113.415 -174.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 -78.26 177.13 8.65 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -170.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.5 p -147.73 128.0 6.78 Favored Pre-proline 0 N--CA 1.43 -1.428 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo . . . . . 0 C--N 1.3 -1.993 0 CA-C-N 122.417 1.899 . . . . 0.0 113.8 172.943 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? . . . . . 0 N--CA 1.429 -1.483 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -86.3 -173.94 1.36 Allowed 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.777 2.318 . . . . 0.0 112.777 -173.316 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.69 41.32 0.42 Allowed Glycine 0 N--CA 1.429 -1.771 0 C-N-CA 124.874 1.226 . . . . 0.0 115.643 172.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -87.81 153.95 20.93 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 124.914 1.286 . . . . 0.0 108.881 164.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.3 p -120.83 150.14 41.48 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.48 -1.388 . . . . 0.0 110.985 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' A' ' 96' ' ' LEU . 2.2 p90 -147.4 136.26 22.11 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.307 1.527 . . . . 0.0 109.412 172.679 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 21.4 mp0 -89.13 128.01 35.75 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 126.899 2.08 . . . . 0.0 108.581 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 74.6 t -109.82 94.87 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.497 0 O-C-N 121.036 -1.04 . . . . 0.0 108.252 -174.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -90.54 102.78 15.52 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-O 123.399 1.571 . . . . 0.0 109.61 169.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.6 tp -124.75 143.41 50.8 Favored 'General case' 0 N--CA 1.431 -1.395 0 C-N-CA 124.597 1.159 . . . . 0.0 110.678 -169.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.95 39.53 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.061 -1.649 . . . . 0.0 109.642 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -69.68 153.21 43.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.537 -1.352 . . . . 0.0 112.231 172.043 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.0 t -141.28 133.95 28.64 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 174.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 33.6 t0 50.93 39.48 22.83 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.959 2.104 . . . . 0.0 113.142 -172.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.13 3.05 55.52 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 120.11 -1.619 . . . . 0.0 116.898 -176.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 84.7 p -112.82 144.49 42.27 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 118.895 1.348 . . . . 0.0 114.03 -167.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 54.0 mt -102.84 -63.15 1.19 Allowed 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.92 1.288 . . . . 0.0 109.598 169.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.03 11.21 10.2 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 119.371 -2.081 . . . . 0.0 115.208 172.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 pt -100.56 131.58 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 CA-C-N 118.922 1.361 . . . . 0.0 111.188 174.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -110.8 121.61 45.76 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.055 -1.028 . . . . 0.0 108.7 168.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.9 m -105.49 165.68 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.702 1.201 . . . . 0.0 113.02 -173.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -149.25 162.53 39.83 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.328 1.451 . . . . 0.0 109.737 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.77 -135.14 12.45 Favored Glycine 0 N--CA 1.431 -1.698 0 CA-C-O 122.658 1.143 . . . . 0.0 115.853 163.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.55 172.6 44.27 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 121.253 -1.145 . . . . 0.0 113.407 -176.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m -73.2 -24.39 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 115.973 1.842 . . . . 0.0 115.973 -174.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -100.43 19.88 15.91 Favored 'General case' 0 N--CA 1.428 -1.535 0 O-C-N 120.573 -1.33 . . . . 0.0 113.025 -170.139 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . 0.254 12.5 t -116.35 -155.94 0.6 Allowed 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.428 -1.42 . . . . 0.0 109.975 170.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 29.4 p -71.73 -28.54 63.75 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 126.169 1.788 . . . . 0.0 115.048 -172.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 5.7 m -73.82 94.79 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 CA-C-O 123.422 1.582 . . . . 0.0 112.837 176.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 12.4 ptt180 -71.17 -13.6 61.99 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.112 -1.618 . . . . 0.0 114.655 -174.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 33.8 m-70 -71.38 -38.34 71.51 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.28 -1.512 . . . . 0.0 112.91 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.19 105.11 0.66 Allowed Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 124.44 1.019 . . . . 0.0 113.946 179.205 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.08 155.11 25.98 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.754 -1.439 . . . . 0.0 110.221 173.099 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -100.22 123.24 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.5 m-85 -123.59 157.21 34.24 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 121.059 -1.026 . . . . 0.0 110.667 -175.643 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.44 125.53 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 O-C-N 120.573 -1.329 . . . . 0.0 112.038 168.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -95.75 -35.62 11.47 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 120.397 -1.44 . . . . 0.0 112.457 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.51 158.03 36.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.854 -1.154 . . . . 0.0 112.221 -176.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -116.69 123.05 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.59 1.556 . . . . 0.0 109.881 175.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.2 mm -77.01 119.49 77.72 Favored Pre-proline 0 N--CA 1.43 -1.431 0 C-N-CA 125.93 1.692 . . . . 0.0 113.714 -176.227 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.74 124.39 12.27 Favored 'Trans proline' 0 C--N 1.299 -2.06 0 CA-C-N 124.744 2.73 . . . . 0.0 113.981 -172.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 10.5 mmmm 79.07 29.67 0.35 Allowed 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 129.334 3.054 . . . . 0.0 113.587 -175.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 162.66 38.14 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.507 -1.37 . . . . 0.0 113.102 162.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.08 -60.01 3.15 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 126.947 2.099 . . . . 0.0 114.911 166.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.32 -46.09 88.27 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 129.517 3.127 . . . . 0.0 112.391 -179.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -43.31 -65.67 0.46 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 171.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.5 t -67.72 -26.99 66.43 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -175.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.89 -56.82 16.99 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.265 -1.522 . . . . 0.0 111.8 174.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.19 2.57 64.03 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.72 -1.238 . . . . 0.0 114.733 157.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 65.0 mtt85 -56.04 -44.11 78.47 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.025 1.33 . . . . 0.0 110.793 159.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.5 mt -82.03 131.09 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 127.698 2.399 . . . . 0.0 111.759 -176.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 11.6 m-70 -122.72 155.44 36.45 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 128.314 2.646 . . . . 0.0 109.228 174.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 pttt -73.15 106.81 5.16 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.931 -1.73 . . . . 0.0 111.631 173.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.29 -31.35 2.06 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-O 119.16 -0.8 . . . . 0.0 113.733 -165.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.371 4.0 p30 -80.24 159.44 25.9 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 120.109 1.955 . . . . 0.0 116.112 -166.449 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.4 ttt85 -110.02 125.85 53.34 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.562 -1.336 . . . . 0.0 112.151 -162.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.5 t -82.11 135.07 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.488 -1.383 . . . . 0.0 111.173 -173.292 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 95.9 mt -103.83 -54.01 2.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.126 -0.983 . . . . 0.0 111.213 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.78 146.06 26.14 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.189 -1.569 . . . . 0.0 111.927 -174.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.0 t -114.04 107.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 123.704 0.802 . . . . 0.0 108.964 175.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.5 t30 61.81 45.17 7.93 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.967 2.107 . . . . 0.0 113.86 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.35 -24.25 14.89 Favored Glycine 0 N--CA 1.431 -1.68 0 O-C-N 121.136 -0.977 . . . . 0.0 113.571 -174.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.3 t -87.08 111.66 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.482 -1.599 . . . . 0.0 109.981 -175.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 p -69.31 128.62 37.24 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.721 1.209 . . . . 0.0 111.837 178.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 50.5 mt -86.03 52.18 2.41 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.168 -1.583 . . . . 0.0 111.869 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -78.9 121.16 24.51 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.592 -1.942 . . . . 0.0 113.48 -169.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.64 24.0 65.72 Favored Glycine 0 N--CA 1.431 -1.679 0 C-N-CA 124.873 1.225 . . . . 0.0 114.753 -176.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.96 42.34 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -170.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 74.6 p -91.65 170.5 9.87 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 124.688 1.195 . . . . 0.0 111.096 171.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 7.3 t-160 -58.44 -58.14 9.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.357 1.463 . . . . 0.0 114.41 -175.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -58.02 -29.74 65.55 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 116.169 1.914 . . . . 0.0 116.169 176.386 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.52 -52.18 66.46 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.411 1.484 . . . . 0.0 113.017 178.587 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.64 -45.13 89.93 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.066 1.746 . . . . 0.0 113.624 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.8 t -64.53 -48.73 83.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.146 1.378 . . . . 0.0 111.27 -179.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.3 mm-40 -65.75 -33.02 74.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.0 m -67.52 -45.37 75.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.525 1.93 . . . . 0.0 112.413 174.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.4 mt -58.89 -42.85 90.53 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 124.791 1.236 . . . . 0.0 113.508 172.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -69.97 -14.72 62.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 115.26 1.578 . . . . 0.0 115.26 178.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -95.65 36.63 1.26 Allowed 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.478 -2.014 . . . . 0.0 112.023 172.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 77.4 p -107.27 144.8 33.56 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.249 -1.532 . . . . 0.0 110.651 172.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.53 23.66 Favored Glycine 0 N--CA 1.429 -1.774 0 C-N-CA 123.965 0.793 . . . . 0.0 112.514 -177.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -56.2 23.94 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.3 t -101.49 126.29 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 CA-C-O 122.282 1.039 . . . . 0.0 109.561 172.117 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 67.4 t -115.45 137.33 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 129.664 3.186 . . . . 0.0 108.662 -166.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 13.5 t-160 -124.22 106.33 10.21 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.505 -1.372 . . . . 0.0 111.394 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 18.7 mt -97.06 160.17 14.5 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 119.356 -2.09 . . . . 0.0 113.239 170.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 64.9 tp -127.96 131.87 49.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 161.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.567 HD11 ' CE2' ' A' ' 14' ' ' PHE . 2.0 pp -148.19 169.03 20.94 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.933 -1.104 . . . . 0.0 112.833 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -117.01 143.46 45.71 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.576 1.55 . . . . 0.0 111.371 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -76.19 151.7 36.83 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 126.921 2.088 . . . . 0.0 113.386 -175.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -99.71 -161.11 28.85 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 125.777 1.656 . . . . 0.0 113.023 178.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -70.39 177.78 3.22 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 -167.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.12 124.4 35.38 Favored Pre-proline 0 N--CA 1.43 -1.455 0 O-C-N 120.586 -1.321 . . . . 0.0 109.696 -174.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_exo . . . . . 0 N--CA 1.434 -1.981 0 C-N-CA 123.238 2.625 . . . . 0.0 115.601 174.775 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.8 pttp . . . . . 0 N--CA 1.43 -1.467 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -71.44 177.68 6.45 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 122.025 1.817 . . . . 0.0 115.983 175.088 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.28 2.26 74.1 Favored Glycine 0 N--CA 1.43 -1.729 0 O-C-N 121.704 -0.623 . . . . 0.0 111.796 -178.799 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -93.96 139.0 31.45 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.635 1.974 . . . . 0.0 109.496 -171.226 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 p -106.96 149.53 27.41 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.13 -0.982 . . . . 0.0 112.524 -177.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -145.01 132.78 21.09 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.914 -1.116 . . . . 0.0 108.178 -176.044 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.87 120.01 28.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.39 1.476 . . . . 0.0 108.255 169.175 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 84.6 t -116.44 100.87 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 124.627 1.171 . . . . 0.0 109.328 -168.149 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -90.18 104.92 17.44 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.352 -1.468 . . . . 0.0 108.999 170.299 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.2 tp -119.95 130.67 54.89 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 124.91 1.284 . . . . 0.0 110.543 -169.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 146.12 28.54 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.722 -1.861 . . . . 0.0 109.64 173.103 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -67.93 166.02 16.55 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.933 1.827 . . . . 0.0 115.933 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 28.6 p -132.23 130.73 41.35 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.681 1.592 . . . . 0.0 108.163 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 46.6 44.43 13.5 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.925 2.09 . . . . 0.0 114.905 -175.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.88 -14.63 30.77 Favored Glycine 0 N--CA 1.429 -1.818 0 O-C-N 119.855 -1.778 . . . . 0.0 117.041 178.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 t -121.84 175.18 6.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 119.716 1.758 . . . . 0.0 112.113 -174.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 94.2 mt -99.96 -60.58 1.5 Allowed 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.702 1.201 . . . . 0.0 110.46 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.15 44.04 0.38 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.15 -1.594 . . . . 0.0 111.222 174.243 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 tt -144.06 147.86 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.068 1.413 . . . . 0.0 110.985 -172.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -124.57 117.69 24.89 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 125.071 1.348 . . . . 0.0 108.532 170.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 m -95.93 166.17 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 124.496 1.118 . . . . 0.0 112.726 -178.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.1 t -151.85 172.43 16.2 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.472 1.509 . . . . 0.0 110.247 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.47 -144.3 16.98 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.256 -0.902 . . . . 0.0 113.74 172.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.82 162.52 23.11 Favored Glycine 0 N--CA 1.43 -1.722 0 CA-C-O 122.489 1.049 . . . . 0.0 112.677 -177.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.5 p -66.07 -21.21 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.497 1.519 . . . . 0.0 114.508 -174.84 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -69.82 -27.26 64.73 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.902 1.681 . . . . 0.0 114.486 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 20.5 m -107.69 148.05 29.91 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.25 -1.531 . . . . 0.0 108.774 -174.18 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.7 t -78.56 58.66 2.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 119.434 -2.041 . . . . 0.0 113.944 -177.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 22.5 m -99.56 21.98 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 126.022 1.729 . . . . 0.0 114.561 -172.673 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.262 75.7 mtt180 82.44 98.02 0.05 OUTLIER 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.19 2.196 . . . . 0.0 110.494 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 42.5 m170 66.55 -73.43 0.07 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.953 2.101 . . . . 0.0 113.142 -166.178 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 158.6 40.62 0.02 OUTLIER Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.725 -1.234 . . . . 0.0 111.377 178.469 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -75.86 151.83 41.5 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.639 -0.918 . . . . 0.0 113.564 -173.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.5 mm -90.98 114.22 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.511 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 171.09 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -113.93 151.84 31.68 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.315 1.055 . . . . 0.0 110.012 -171.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.9 t -76.18 120.58 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.625 -1.297 . . . . 0.0 110.357 169.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -93.72 -48.59 6.25 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.707 -1.246 . . . . 0.0 110.587 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.43 157.99 43.92 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.491 -0.755 . . . . 0.0 109.51 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.533 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.5 tp -124.47 123.92 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.4 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -77.33 122.46 86.12 Favored Pre-proline 0 N--CA 1.43 -1.446 0 CA-C-O 116.454 -1.736 . . . . 0.0 112.817 -170.304 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -58.11 128.6 29.39 Favored 'Trans proline' 0 N--CA 1.434 -1.991 0 CA-C-N 124.39 2.604 . . . . 0.0 115.797 -174.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.296 52.1 mtmt 76.07 17.52 2.12 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.283 2.233 . . . . 0.0 113.629 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.96 160.25 38.62 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.386 -1.446 . . . . 0.0 111.705 170.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.58 -56.47 8.32 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.14 -1.8 . . . . 0.0 115.837 168.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.0 -44.51 95.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.567 1.947 . . . . 0.0 112.399 -177.661 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.533 ' HG2' HG23 ' A' ' 47' ' ' ILE . 7.4 tm-20 -51.06 -65.21 0.6 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.297 1.592 . . . . 0.0 115.297 167.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 94.1 p -65.66 -26.94 68.02 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -169.269 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -55.47 -57.77 10.52 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.977 1.711 . . . . 0.0 113.228 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.63 -9.91 25.89 Favored Glycine 0 N--CA 1.43 -1.741 0 O-C-N 120.822 -1.174 . . . . 0.0 114.643 159.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.4 mtt180 -64.61 -32.4 74.05 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.763 1.225 . . . . 0.0 111.454 167.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 mt -96.91 124.76 49.89 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 C-N-CA 125.932 1.693 . . . . 0.0 110.762 -177.053 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 10.0 m80 -128.77 166.85 18.21 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.391 1.477 . . . . 0.0 109.487 170.168 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.0 ptpt -68.06 132.99 48.24 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.125 -1.609 . . . . 0.0 111.661 174.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 99.36 -7.9 60.19 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.026 -1.046 . . . . 0.0 114.524 -171.145 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -78.89 156.27 28.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-N 119.58 1.69 . . . . 0.0 112.41 -178.027 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -114.36 124.27 51.54 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.743 -1.223 . . . . 0.0 110.725 -168.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 10.7 t -87.67 131.29 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.296 -1.502 . . . . 0.0 110.162 -174.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.64 -44.8 5.46 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.684 -1.26 . . . . 0.0 110.307 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.32 143.22 25.67 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.598 -0.689 . . . . 0.0 110.814 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 39.9 t -124.93 124.06 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 173.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 63.82 33.79 12.42 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.966 1.707 . . . . 0.0 114.214 170.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.99 -15.76 62.75 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 120.693 -1.254 . . . . 0.0 113.698 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.38 116.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 121.554 -0.968 . . . . 0.0 110.202 -173.349 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -73.98 130.71 40.41 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.778 -1.202 . . . . 0.0 110.831 176.579 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.5 mt -85.48 44.2 1.08 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.866 -1.147 . . . . 0.0 114.065 -165.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -80.85 133.04 35.52 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.996 -2.315 . . . . 0.0 112.046 -177.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.53 13.07 67.78 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.488 -1.382 . . . . 0.0 114.793 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.31 142.72 48.85 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.767 1.395 . . . . 0.0 114.767 -178.553 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 36.0 p -90.56 178.18 6.16 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.013 1.725 . . . . 0.0 110.061 171.367 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -60.31 -48.98 79.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.837 -1.164 . . . . 0.0 112.971 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.0 mmtt -54.58 -38.51 66.78 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 126.365 1.866 . . . . 0.0 115.523 175.689 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -51.05 71.34 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.223 1.809 . . . . 0.0 113.187 -177.751 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.58 -34.05 73.6 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.516 1.527 . . . . 0.0 113.386 176.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.05 -53.44 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.375 0 C-N-CA 124.768 1.227 . . . . 0.0 110.127 178.45 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -60.79 -39.27 88.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 121.22 -0.925 . . . . 0.0 112.947 178.132 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 69.7 m -63.65 -40.64 97.37 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 124.828 1.251 . . . . 0.0 113.605 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 64.6 mt -72.0 -37.09 69.9 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.764 -1.21 . . . . 0.0 113.748 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 27.3 mtp180 -64.02 -47.35 80.59 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.188 -1.57 . . . . 0.0 112.793 176.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -88.14 58.97 5.05 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.716 1.246 . . . . 0.0 111.712 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.8 p -105.11 157.02 17.54 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.895 2.078 . . . . 0.0 110.052 176.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.26 -146.21 9.35 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.509 -1.37 . . . . 0.0 111.741 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.2 tt0 -71.85 -56.64 5.36 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.604 -1.527 . . . . 0.0 113.139 170.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 14.2 p -100.53 140.02 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.961 1.304 . . . . 0.0 109.316 179.26 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 72.5 t -124.22 122.85 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 127.496 2.318 . . . . 0.0 108.273 -170.186 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.8 m170 -100.52 101.36 12.27 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.058 -1.651 . . . . 0.0 110.561 177.179 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 8.7 mt -92.87 160.39 14.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.862 -1.774 . . . . 0.0 111.655 172.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.29 131.21 46.92 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 157.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.7 pp -143.4 166.85 23.62 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.993 -1.692 . . . . 0.0 112.312 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -112.73 146.24 39.11 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.406 1.882 . . . . 0.0 108.589 175.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.79 127.25 32.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.784 -1.197 . . . . 0.0 110.57 176.524 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.06 133.5 39.95 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.677 1.608 . . . . 0.0 113.379 -175.25 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -69.47 -34.71 74.77 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 115.435 1.643 . . . . 0.0 115.435 -166.398 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 m -132.58 160.52 67.97 Favored Pre-proline 0 N--CA 1.429 -1.484 0 O-C-N 121.469 -0.769 . . . . 0.0 109.435 -175.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo . . . . . 0 N--CA 1.434 -1.98 0 C-N-CA 122.697 2.264 . . . . 0.0 111.627 170.308 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.442 0 CA-C-O 115.739 -2.077 . . . . 0.0 112.142 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -73.69 178.94 6.12 Favored 'Trans proline' 0 N--CA 1.434 -1.997 0 CA-C-N 126.363 3.308 . . . . 0.0 113.007 173.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.91 7.69 68.08 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 121.105 -0.997 . . . . 0.0 114.358 174.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -95.92 152.21 18.72 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.197 0.999 . . . . 0.0 108.872 177.27 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.7 p -97.43 162.32 13.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 122.11 0.957 . . . . 0.0 112.534 -176.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -144.82 138.19 26.9 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -93.66 115.38 27.83 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 126.301 1.84 . . . . 0.0 107.149 166.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.403 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 32.7 t -111.87 99.78 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -175.683 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -90.05 100.09 12.98 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.351 -1.468 . . . . 0.0 109.593 176.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.0 tp -116.59 136.91 52.59 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.744 1.218 . . . . 0.0 111.032 -162.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.66 145.81 29.51 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.443 -1.41 . . . . 0.0 109.006 169.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -70.81 141.66 51.34 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.924 -1.11 . . . . 0.0 113.677 174.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.9 t -137.95 142.7 40.53 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.426 -1.421 . . . . 0.0 109.619 174.164 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.1 t0 54.55 34.71 21.84 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.107 2.163 . . . . 0.0 113.906 -177.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.55 63.26 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 124.877 1.227 . . . . 0.0 115.948 -174.869 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 71.7 p -121.32 142.41 49.99 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-N 118.886 1.343 . . . . 0.0 114.033 -171.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.4 mt -89.72 -61.61 1.65 Allowed 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 159.087 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.79 48.19 0.55 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 118.98 -2.325 . . . . 0.0 112.711 163.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.3 tt -145.94 150.11 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.334 1.064 . . . . 0.0 110.006 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.4 t -122.94 125.66 45.74 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 164.28 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 m -106.15 157.74 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 125.338 1.455 . . . . 0.0 110.025 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.9 t -141.95 170.34 15.9 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.094 0.958 . . . . 0.0 109.71 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -132.09 10.96 Favored Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 123.885 0.755 . . . . 0.0 113.228 173.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.45 -179.83 42.07 Favored Glycine 0 N--CA 1.431 -1.696 0 CA-C-O 122.46 1.033 . . . . 0.0 111.747 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.36 -8.68 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.499 0 O-C-N 120.923 -1.339 . . . . 0.0 113.274 -169.243 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -71.95 -51.36 22.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.341 -1.474 . . . . 0.0 113.082 -178.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.7 p -92.3 169.92 10.2 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.341 1.056 . . . . 0.0 110.662 178.206 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 67.3 m -92.09 60.97 3.89 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.935 -1.728 . . . . 0.0 111.47 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 6.2 p -83.17 160.83 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.435 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 166.571 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.64 104.74 0.11 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.202 1.401 . . . . 0.0 114.742 -172.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.5 t60 58.78 13.87 2.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 128.131 2.573 . . . . 0.0 117.474 -174.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.17 23.29 61.48 Favored Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.158 -1.589 . . . . 0.0 115.135 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.03 174.49 54.78 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 121.396 -1.061 . . . . 0.0 115.401 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.2 mm -103.7 117.56 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.716 1.607 . . . . 0.0 107.373 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -124.98 150.0 47.13 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.795 -1.19 . . . . 0.0 110.171 -168.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 32.2 t -75.66 122.31 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.456 -1.402 . . . . 0.0 113.201 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -89.3 -56.48 3.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.363 1.065 . . . . 0.0 109.686 173.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.46 156.19 43.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.117 -0.989 . . . . 0.0 111.454 -173.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.63 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -119.2 117.97 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.06 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 28.7 mm -76.89 125.06 87.49 Favored Pre-proline 0 N--CA 1.43 -1.451 0 CA-C-O 115.391 -2.242 . . . . 0.0 113.0 -165.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -53.33 136.95 64.08 Favored 'Trans proline' 0 C--N 1.3 -1.979 0 C-N-CA 123.628 2.886 . . . . 0.0 116.899 -171.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.277 6.6 mtpm? 51.67 26.1 3.21 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 119.168 3.025 . . . . 0.0 119.168 -169.61 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.31 169.65 54.91 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 118.995 -2.316 . . . . 0.0 113.201 170.083 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.21 -60.86 2.55 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.121 1.768 . . . . 0.0 114.136 165.228 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.9 -45.48 92.33 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 129.01 2.924 . . . . 0.0 112.646 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.5 tm-20 -43.66 -68.25 0.21 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.826 1.65 . . . . 0.0 114.818 166.143 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 74.9 m -69.89 -14.84 62.93 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 116.367 1.988 . . . . 0.0 116.367 -174.136 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -61.38 -55.72 28.4 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.82 1.248 . . . . 0.0 111.751 170.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.29 4.7 77.1 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 120.301 -1.5 . . . . 0.0 115.699 167.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -75.17 -38.3 60.91 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.243 -1.739 . . . . 0.0 110.326 163.203 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.5 mt -77.59 120.63 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 126.352 1.861 . . . . 0.0 111.122 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -117.99 166.09 12.94 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 125.895 1.678 . . . . 0.0 111.153 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 48.0 tttm -63.98 127.3 30.81 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 119.966 -1.709 . . . . 0.0 111.936 171.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.59 0.94 68.98 Favored Glycine 0 N--CA 1.431 -1.662 0 O-C-N 121.29 -0.882 . . . . 0.0 113.992 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.06 153.47 43.59 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 119.178 1.489 . . . . 0.0 112.792 179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 65.1 ttt-85 -105.46 122.06 45.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.832 0.825 . . . . 0.0 109.299 -176.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.4 t -82.89 134.95 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.751 -1.218 . . . . 0.0 109.81 -177.194 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.2 mp -105.64 -50.08 3.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.856 -1.152 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.15 151.2 32.74 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.369 -1.457 . . . . 0.0 111.88 -175.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.97 HG11 HG21 ' A' ' 84' ' ' THR . 3.4 p -118.06 110.21 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 122.379 1.085 . . . . 0.0 112.393 172.058 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 55.26 39.68 31.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.943 -1.723 . . . . 0.0 114.913 164.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.96 -13.42 60.55 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-O 119.324 -0.709 . . . . 0.0 114.5 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.9 t -102.17 111.12 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.614 2.207 . . . . 0.0 109.302 -176.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 43.6 m -76.27 119.73 20.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.213 -1.554 . . . . 0.0 110.625 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 87.2 mt -92.41 35.47 1.01 Allowed 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.66 -1.275 . . . . 0.0 112.223 -167.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -88.61 91.19 8.71 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 119.619 -1.926 . . . . 0.0 112.52 -168.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 96.93 10.55 54.99 Favored Glycine 0 N--CA 1.429 -1.812 0 C-N-CA 125.202 1.382 . . . . 0.0 112.157 -171.172 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.85 157.7 37.4 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-O 122.532 1.158 . . . . 0.0 113.535 171.356 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 41.5 p -83.49 172.91 11.94 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.255 -1.528 . . . . 0.0 113.169 -175.173 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-80 -58.41 -46.17 86.96 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.386 1.474 . . . . 0.0 113.613 170.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -57.96 -43.06 86.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 172.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.91 -55.15 36.04 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 114.432 1.271 . . . . 0.0 114.432 -175.136 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.3 -43.3 64.41 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 116.284 1.957 . . . . 0.0 116.284 171.522 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.57 -52.04 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.756 -1.215 . . . . 0.0 111.461 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -64.64 -30.63 71.65 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.19 -0.944 . . . . 0.0 111.886 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' THR . . . . . 0.97 HG21 HG11 ' A' ' 68' ' ' VAL . 39.4 m -63.87 -51.41 64.7 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.186 1.394 . . . . 0.0 113.509 170.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.6 mt -60.42 -37.01 79.51 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 120.565 1.53 . . . . 0.0 113.789 176.275 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -61.93 -44.41 96.83 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.493 1.517 . . . . 0.0 113.763 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -94.54 55.91 2.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.539 1.536 . . . . 0.0 112.682 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.45 145.36 31.87 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.533 -1.355 . . . . 0.0 109.983 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.02 -141.32 4.8 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.658 -1.276 . . . . 0.0 111.889 176.579 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -70.69 -58.31 3.78 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.383 -1.657 . . . . 0.0 113.791 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 t -109.57 137.76 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.533 1.133 . . . . 0.0 110.947 -176.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.6 t -125.13 122.56 63.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 C-N-CA 128.924 2.89 . . . . 0.0 110.911 -173.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.0 t-160 -100.81 95.9 6.94 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.139 -2.226 . . . . 0.0 113.085 176.33 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.403 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 23.5 mt -88.2 154.83 20.12 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 118.92 -2.363 . . . . 0.0 113.328 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 39.0 tp -127.25 135.46 50.64 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 163.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -150.63 168.91 22.89 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.889 -1.132 . . . . 0.0 111.942 175.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.92 141.68 47.63 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.078 2.151 . . . . 0.0 109.142 172.487 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.14 121.25 22.57 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.13 1.372 . . . . 0.0 112.305 179.269 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -86.0 138.44 16.07 Favored Glycine 0 N--CA 1.429 -1.77 0 C-N-CA 126.894 2.188 . . . . 0.0 114.307 -169.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -90.71 -176.26 4.65 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.368 -1.078 . . . . 0.0 113.89 -175.431 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.2 m -113.45 151.79 44.74 Favored Pre-proline 0 CA--C 1.489 -1.399 0 O-C-N 120.767 -1.208 . . . . 0.0 110.389 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 N--CA 1.434 -2.015 0 C-N-CA 122.322 2.015 . . . . 0.0 112.903 179.825 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.2 mtmt . . . . . 0 N--CA 1.429 -1.485 0 CA-C-O 116.222 -1.847 . . . . 0.0 115.126 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -77.07 -178.56 4.67 Favored 'Trans proline' 0 N--CA 1.434 -1.997 0 CA-C-N 125.962 3.165 . . . . 0.0 113.432 -176.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.44 3.75 55.22 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.46 -0.775 . . . . 0.0 112.928 -176.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -75.68 152.46 37.52 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.168 1.387 . . . . 0.0 111.183 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.86 139.61 44.73 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.364 -1.46 . . . . 0.0 110.325 -176.48 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -146.52 154.99 42.18 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-O 123.037 1.398 . . . . 0.0 110.298 174.172 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -108.6 142.24 39.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.893 1.677 . . . . 0.0 107.362 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.5 t -122.63 106.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.684 1.193 . . . . 0.0 108.648 -171.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -95.16 97.78 10.15 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 121.002 -1.061 . . . . 0.0 109.275 169.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.9 tp -119.79 129.93 54.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 123.787 0.835 . . . . 0.0 112.601 -168.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.71 123.55 44.08 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.365 -1.46 . . . . 0.0 109.452 171.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -69.61 114.83 8.19 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.507 1.523 . . . . 0.0 113.183 -177.06 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.3 t -96.53 129.67 43.86 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.323 -1.486 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.6 t70 41.48 49.41 3.55 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.337 2.655 . . . . 0.0 114.917 -175.303 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.29 10.61 70.01 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 117.336 1.695 . . . . 0.0 117.336 -178.34 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 85.3 p -120.97 129.12 53.3 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 119.86 1.83 . . . . 0.0 113.977 -175.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 82.5 mt -85.8 -58.31 2.7 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.823 -1.173 . . . . 0.0 111.077 168.184 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.37 23.05 4.25 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 119.4 -2.062 . . . . 0.0 113.598 176.109 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 pt -122.41 141.28 43.44 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 CA-C-O 123.092 1.425 . . . . 0.0 113.348 -174.299 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.9 t -113.45 126.61 55.53 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 159.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 m -115.59 159.54 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.03 1.332 . . . . 0.0 110.749 -177.537 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.21 166.11 28.01 Favored 'General case' 0 N--CA 1.428 -1.532 0 C-N-CA 124.862 1.265 . . . . 0.0 109.424 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.35 -143.0 16.79 Favored Glycine 0 N--CA 1.429 -1.815 0 O-C-N 120.155 -1.591 . . . . 0.0 114.674 160.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 103.56 161.63 25.09 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.548 1.07 . . . . 0.0 111.514 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.3 p -71.43 -25.78 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.547 -1.56 . . . . 0.0 114.068 -171.405 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.2 t-20 -91.4 1.48 57.09 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.433 1.493 . . . . 0.0 111.521 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 36' ' ' SER . 24.3 m -102.39 179.94 4.16 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.144 -2.169 . . . . 0.0 105.144 176.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.611 ' H ' HG22 ' A' ' 35' ' ' THR . 32.7 p -76.53 34.67 0.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 118.932 -2.355 . . . . 0.0 115.999 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.1 t -96.46 110.32 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.456 -1.402 . . . . 0.0 110.118 -174.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.6 ptt85 -71.83 -31.47 66.56 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.282 -1.511 . . . . 0.0 112.61 -178.596 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 4.0 t-160 -85.86 -3.0 58.81 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.651 1.18 . . . . 0.0 113.07 178.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 64.92 72.69 0.68 Allowed Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 125.578 1.561 . . . . 0.0 116.866 170.644 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 172.72 45.71 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 118.891 -1.623 . . . . 0.0 114.128 177.317 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.0 mm -84.97 129.87 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.923 1.689 . . . . 0.0 109.104 174.684 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -122.89 150.37 43.0 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.166 -0.959 . . . . 0.0 109.271 -175.683 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -77.77 127.7 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.433 -1.417 . . . . 0.0 112.019 170.106 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.7 ttpp -94.91 -44.1 7.88 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.704 -1.247 . . . . 0.0 111.747 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.91 153.85 33.86 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.878 -1.139 . . . . 0.0 112.926 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.271 1.0 OUTLIER -102.94 118.14 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 CA-C-O 122.644 1.211 . . . . 0.0 110.038 168.822 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.9 mm -76.38 124.11 87.98 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 126.436 1.894 . . . . 0.0 112.366 -173.18 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -56.29 129.96 37.62 Favored 'Trans proline' 0 N--CA 1.434 -1.992 0 C-N-CA 122.835 2.357 . . . . 0.0 115.166 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.8 mtmt 75.4 22.34 1.67 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.265 1.826 . . . . 0.0 114.771 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.44 167.17 42.65 Favored Glycine 0 N--CA 1.43 -1.743 0 O-C-N 119.722 -1.861 . . . . 0.0 115.26 169.717 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.63 -63.35 1.15 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.3 98.09 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 129.087 2.955 . . . . 0.0 112.824 -176.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -42.21 -55.72 3.18 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 168.078 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.0 t -68.53 -38.15 80.61 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.74 -51.66 68.01 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 126.067 1.747 . . . . 0.0 112.171 177.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.31 1.02 72.6 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.606 -1.309 . . . . 0.0 114.421 159.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -67.87 -44.11 77.82 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.315 1.446 . . . . 0.0 110.498 166.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 36.0 mt -85.64 129.66 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 125.532 1.533 . . . . 0.0 109.8 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.38 167.33 29.09 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.288 1.035 . . . . 0.0 110.961 -171.555 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.0 tttm -50.72 121.41 5.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -178.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.07 7.6 67.83 Favored Glycine 0 N--CA 1.429 -1.804 0 CA-C-O 117.904 -1.498 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.296 1.7 p30 -77.51 152.64 34.02 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-N 120.786 2.293 . . . . 0.0 112.767 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -102.17 120.59 40.7 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -176.323 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.11 128.74 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.077 -1.015 . . . . 0.0 109.768 -176.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.1 mt -99.26 -45.29 5.93 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.435 -1.416 . . . . 0.0 111.446 -175.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.67 145.17 25.67 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.673 -1.267 . . . . 0.0 111.658 -178.449 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.1 t -112.31 108.52 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.051 0.94 . . . . 0.0 109.445 173.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.0 t30 60.08 38.82 20.32 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.879 1.672 . . . . 0.0 114.547 166.243 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -16.21 60.14 Favored Glycine 0 N--CA 1.43 -1.718 0 C-N-CA 125.307 1.432 . . . . 0.0 114.214 -177.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.4 t -97.14 120.68 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 121.008 -1.29 . . . . 0.0 110.58 -176.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.9 t -75.33 133.89 41.15 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.486 -1.384 . . . . 0.0 111.956 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 88.2 mt -88.21 12.62 13.34 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.908 -1.12 . . . . 0.0 113.628 -176.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 39.2 mm-40 -64.96 128.43 35.74 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 119.934 -1.729 . . . . 0.0 112.414 173.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.25 -6.57 67.29 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 125.314 1.435 . . . . 0.0 116.115 -176.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.6 149.71 45.37 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 116.953 2.205 . . . . 0.0 116.953 -174.524 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 30.5 p -93.19 -179.61 5.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 125.704 1.602 . . . . 0.0 110.943 171.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -63.91 -50.35 69.07 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.541 -1.349 . . . . 0.0 111.765 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 38.0 mttp -56.46 -39.35 73.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.915 1.45 . . . . 0.0 114.915 175.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -57.37 -54.3 48.41 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 114.51 1.3 . . . . 0.0 114.51 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.51 -36.13 81.97 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 124.63 1.172 . . . . 0.0 113.124 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.6 t -64.18 -51.27 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 120.949 -1.094 . . . . 0.0 110.706 174.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.581 -1.324 . . . . 0.0 113.608 178.113 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 87.8 m -62.87 -51.14 68.14 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.702 2.001 . . . . 0.0 112.874 173.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 74.3 mt -65.84 -32.05 73.35 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.95 -1.719 . . . . 0.0 114.988 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -68.18 -28.46 67.29 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.497 -1.377 . . . . 0.0 111.667 173.062 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -93.25 41.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.215 -1.553 . . . . 0.0 112.543 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -98.88 153.96 18.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.147 -1.596 . . . . 0.0 110.907 172.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -106.78 -138.33 8.93 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 124.777 1.18 . . . . 0.0 110.81 174.028 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -70.05 -66.9 0.54 Allowed 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -177.262 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.3 120.65 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 122.287 1.041 . . . . 0.0 109.256 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 71.3 t -114.54 119.53 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 128.51 2.724 . . . . 0.0 108.966 -167.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.1 t-160 -107.38 88.87 2.83 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.733 -1.229 . . . . 0.0 113.298 -174.204 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.1 mt -92.37 157.13 16.78 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.82 -1.8 . . . . 0.0 113.868 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 55.4 tp -127.47 129.09 46.82 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.743 1.217 . . . . 0.0 108.177 170.21 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.43 161.52 37.83 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-O 122.307 1.051 . . . . 0.0 113.715 179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -120.35 132.07 55.12 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.108 1.363 . . . . 0.0 109.645 175.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.2 tptm -77.2 134.32 38.66 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.803 -1.186 . . . . 0.0 113.758 -164.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.29 162.41 32.12 Favored Glycine 0 N--CA 1.429 -1.784 0 CA-C-O 122.144 0.858 . . . . 0.0 114.553 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -87.03 176.23 7.73 Favored 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 124.411 1.084 . . . . 0.0 111.903 -178.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.5 p -135.63 117.18 11.99 Favored Pre-proline 0 N--CA 1.429 -1.479 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 166.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.434 -2.008 0 CA-C-N 123.391 2.247 . . . . 0.0 113.061 -170.962 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.262 1.3 mptp? . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 116.252 -1.832 . . . . 0.0 112.527 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.93 178.65 7.17 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 CA-C-N 125.829 3.117 . . . . 0.0 112.967 175.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.15 -30.09 10.1 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 121.241 -0.912 . . . . 0.0 113.963 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -80.79 167.91 19.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 118.373 1.087 . . . . 0.0 112.661 -176.035 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 45.0 p -105.41 161.45 14.31 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.211 1.405 . . . . 0.0 113.181 -175.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.22 140.66 25.46 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 167.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -88.54 132.96 34.3 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-O 122.264 1.031 . . . . 0.0 109.471 163.166 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 t -120.8 98.18 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 126.053 1.741 . . . . 0.0 109.727 -169.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.09 102.29 15.04 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.355 -1.466 . . . . 0.0 109.972 174.026 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.519 HD11 ' HA ' ' A' ' 53' ' ' ALA . 0.4 OUTLIER -123.1 128.64 50.38 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.85 -1.156 . . . . 0.0 111.33 -166.805 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.23 125.19 47.83 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 119.967 -1.708 . . . . 0.0 110.354 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 47.9 mtpt -69.69 150.17 47.26 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.517 1.673 . . . . 0.0 115.517 -173.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.8 p -102.91 87.39 2.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.852 1.261 . . . . 0.0 109.407 178.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.2 t0 45.92 64.83 1.32 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.348 2.659 . . . . 0.0 116.127 -175.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.74 -29.54 9.04 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 121.06 -1.025 . . . . 0.0 113.549 -178.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.9 m -97.42 136.19 38.21 Favored 'General case' 0 N--CA 1.43 -1.445 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -169.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.2 mt -85.26 -60.5 2.02 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.23 1.412 . . . . 0.0 110.691 171.096 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.35 27.58 1.79 Allowed Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.404 -2.06 . . . . 0.0 111.292 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 pt -124.88 155.96 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.555 1.142 . . . . 0.0 110.961 -170.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.6 t -129.8 130.38 45.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 152.575 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -104.82 157.93 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.914 1.286 . . . . 0.0 109.617 -177.52 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -140.33 169.71 17.17 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.717 -1.24 . . . . 0.0 109.111 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.52 -140.29 15.32 Favored Glycine 0 N--CA 1.43 -1.734 0 CA-C-O 122.372 0.984 . . . . 0.0 114.876 164.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.23 157.53 32.23 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 122.235 0.908 . . . . 0.0 112.838 -174.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.5 m -66.34 -39.22 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 116.951 2.204 . . . . 0.0 116.951 -166.179 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -100.17 23.04 10.53 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.208 -1.558 . . . . 0.0 114.994 -167.495 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . 0.252 14.8 t -107.5 -145.18 0.39 Allowed 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.731 -1.231 . . . . 0.0 109.481 173.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 63.7 p -77.83 -24.74 48.58 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 118.875 -2.391 . . . . 0.0 114.502 -177.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.8 m -79.77 108.12 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 123.769 1.747 . . . . 0.0 111.748 175.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.9 ttm105 -73.04 120.29 18.46 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.23 -1.544 . . . . 0.0 111.727 -178.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.7 m170 61.44 38.88 15.64 Favored 'General case' 0 CA--C 1.489 -1.372 0 C-N-CA 126.431 1.892 . . . . 0.0 113.322 -167.191 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 126.01 25.44 Favored Glycine 0 N--CA 1.43 -1.76 0 CA-C-O 122.455 1.031 . . . . 0.0 114.974 -176.463 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -79.81 -176.18 49.02 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 121.27 -1.135 . . . . 0.0 111.125 158.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.8 mm -99.67 119.27 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -120.36 149.79 41.79 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.898 -1.126 . . . . 0.0 110.366 -171.221 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.8 t -76.75 112.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 O-C-N 121.022 -1.049 . . . . 0.0 111.67 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.36 -41.92 11.22 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 120.804 -1.185 . . . . 0.0 112.109 -174.588 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.61 151.99 35.97 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.82 -1.175 . . . . 0.0 110.411 176.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.98 119.91 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.5 1.143 . . . . 0.0 108.819 173.136 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.21 125.61 86.3 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 117.042 2.238 . . . . 0.0 117.042 -166.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -53.84 119.08 5.68 Favored 'Trans proline' 0 N--CA 1.434 -2.011 0 C-N-CA 123.645 2.897 . . . . 0.0 116.512 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.255 67.2 mmtt 76.16 30.0 0.73 Allowed 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 128.267 2.627 . . . . 0.0 112.421 -177.231 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 158.07 33.7 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.617 -1.302 . . . . 0.0 111.119 168.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -59.23 3.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.794 -1.416 . . . . 0.0 113.346 166.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.519 ' HA ' HD11 ' A' ' 18' ' ' LEU . . . -63.24 -46.69 85.77 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 128.553 2.741 . . . . 0.0 113.914 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -42.78 -60.62 1.51 Allowed 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 172.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.17 -30.96 69.29 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -60.93 -62.79 1.6 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 125.655 1.582 . . . . 0.0 113.336 -178.079 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.94 6.17 49.42 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 116.987 1.555 . . . . 0.0 116.987 166.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.7 mmt85 -72.33 -37.22 68.93 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-N 119.541 1.67 . . . . 0.0 110.805 164.123 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.9 mt -92.27 124.28 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.922 1.289 . . . . 0.0 108.11 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -145.6 176.86 9.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.387 -1.446 . . . . 0.0 111.619 175.036 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -65.59 126.4 28.23 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.298 1.039 . . . . 0.0 113.023 -170.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.24 80.65 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 121.128 -0.983 . . . . 0.0 115.533 -179.096 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.51 157.97 25.97 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 119.117 1.458 . . . . 0.0 111.911 -177.065 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -105.12 121.66 44.28 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.088 -1.008 . . . . 0.0 111.212 -172.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.43 HG13 HD11 ' A' ' 94' ' ' LEU . 58.9 t -82.31 134.39 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.406 0 C-N-CA 125.727 1.611 . . . . 0.0 107.895 -176.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -119.42 -52.14 2.27 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.96 -1.087 . . . . 0.0 113.715 -167.237 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.85 113.28 4.96 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.626 -1.296 . . . . 0.0 111.138 -173.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -93.59 111.64 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.164 -0.96 . . . . 0.0 108.945 -175.417 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 61.68 36.15 16.66 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.901 2.08 . . . . 0.0 113.407 177.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.39 -9.89 75.34 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 125.001 1.286 . . . . 0.0 113.669 -176.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.4 t -90.94 101.96 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.11 -1.818 . . . . 0.0 109.019 -176.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.3 m -66.79 133.21 49.67 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.707 -1.246 . . . . 0.0 112.125 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.2 mt -85.97 45.95 1.27 Allowed 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.293 1.037 . . . . 0.0 112.262 -171.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -74.82 118.99 18.4 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.93 -1.731 . . . . 0.0 112.295 -171.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.52 22.88 75.23 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 124.031 0.824 . . . . 0.0 114.825 -175.143 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.92 145.34 50.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -176.022 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.3 p -90.13 170.84 9.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.872 1.269 . . . . 0.0 110.835 168.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.3 t-160 -53.04 -50.58 64.01 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.324 1.85 . . . . 0.0 113.563 175.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -56.42 -43.25 79.23 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.436 1.494 . . . . 0.0 113.776 175.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.75 -47.04 77.67 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.302 1.841 . . . . 0.0 114.198 -175.7 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.31 -45.51 93.15 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.791 1.636 . . . . 0.0 113.176 174.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.1 t -66.29 -43.34 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 125.166 1.386 . . . . 0.0 111.717 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -59.37 -43.69 92.85 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.971 -1.08 . . . . 0.0 113.027 177.221 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -72.04 -36.54 69.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.3 1.04 . . . . 0.0 113.724 176.535 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.9 mt -63.81 -35.62 81.21 Favored 'General case' 0 CA--C 1.489 -1.393 0 O-C-N 120.056 -1.653 . . . . 0.0 114.832 171.181 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -71.57 -30.9 66.38 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.134 -1.604 . . . . 0.0 112.308 173.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -84.85 50.31 1.9 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.968 1.707 . . . . 0.0 112.628 174.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.3 p -106.3 164.28 12.14 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 125.512 1.525 . . . . 0.0 110.923 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -100.6 -168.99 28.81 Favored Glycine 0 N--CA 1.429 -1.786 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 164.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -68.56 -46.76 68.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-N 118.348 1.074 . . . . 0.0 113.71 -175.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.7 t -95.99 118.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 122.864 1.316 . . . . 0.0 109.843 172.01 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.6 t -109.74 118.88 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 127.09 2.156 . . . . 0.0 110.143 -169.269 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -101.7 94.61 5.94 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.505 -1.372 . . . . 0.0 112.249 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.43 HD11 HG13 ' A' ' 65' ' ' VAL . 19.9 tp -96.92 141.47 30.06 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 119.353 -2.092 . . . . 0.0 110.375 173.537 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 9.0 tt -104.98 130.45 53.18 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.97 -1.706 . . . . 0.0 108.823 162.226 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.9 pp -134.74 165.71 24.63 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.911 -1.118 . . . . 0.0 112.58 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -112.92 142.2 45.87 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.172 1.789 . . . . 0.0 109.44 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.27 123.03 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.64 -1.288 . . . . 0.0 111.056 178.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.33 145.29 24.09 Favored Glycine 0 N--CA 1.429 -1.779 0 C-N-CA 124.664 1.126 . . . . 0.0 112.003 178.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -96.86 -34.76 11.15 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.376 -1.073 . . . . 0.0 112.728 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -81.93 143.24 49.48 Favored Pre-proline 0 N--CA 1.43 -1.449 0 CA-C-O 117.372 -1.299 . . . . 0.0 108.986 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 N--CA 1.433 -2.064 0 CA-C-N 123.901 2.429 . . . . 0.0 113.398 167.639 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 43.3 pttt . . . . . 0 N--CA 1.43 -1.448 0 N-CA-C 110.616 -0.142 . . . . 0.0 110.616 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -80.54 62.39 8.52 Favored 'Trans proline' 0 C--N 1.3 -2.025 0 C-N-CA 125.066 3.844 . . . . 0.0 114.969 -166.091 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.43 61.33 0.19 Allowed Glycine 0 N--CA 1.43 -1.719 0 O-C-N 120.764 -1.21 . . . . 0.0 110.962 -176.387 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -91.23 166.85 12.72 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 124.642 1.177 . . . . 0.0 109.173 175.18 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.19 146.99 33.25 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.842 1.257 . . . . 0.0 108.758 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.19 140.67 26.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.998 0.904 . . . . 0.0 108.875 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -88.92 136.87 32.78 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-O 122.615 1.198 . . . . 0.0 107.901 161.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.3 t -117.98 114.06 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -104.31 88.76 3.05 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 169.395 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.9 tp -105.18 139.42 39.86 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 121.408 -0.808 . . . . 0.0 109.4 -173.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.64 123.63 45.96 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.495 -1.378 . . . . 0.0 107.85 167.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -68.22 128.91 38.27 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.885 2.474 . . . . 0.0 112.427 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.3 p -101.24 125.93 47.92 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.702 -1.248 . . . . 0.0 110.952 -178.113 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.4 t70 56.96 32.66 21.98 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.105 1.762 . . . . 0.0 114.837 177.267 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.57 -5.83 67.45 Favored Glycine 0 N--CA 1.431 -1.675 0 O-C-N 119.744 -1.848 . . . . 0.0 116.269 -179.454 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 74.3 m -112.04 135.23 52.94 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 118.77 1.285 . . . . 0.0 111.549 -171.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.6 mt -86.47 -62.86 1.42 Allowed 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.634 -1.292 . . . . 0.0 109.481 167.134 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.15 51.71 0.43 Allowed Glycine 0 N--CA 1.43 -1.764 0 O-C-N 119.291 -2.131 . . . . 0.0 111.52 170.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tt -142.69 142.7 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.505 0 CA-C-O 122.601 1.191 . . . . 0.0 111.008 -176.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.9 t -117.7 132.53 56.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 124.983 1.313 . . . . 0.0 107.667 167.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.4 m -113.15 164.5 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.681 1.192 . . . . 0.0 111.965 -176.402 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -144.09 172.53 12.76 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.119 1.368 . . . . 0.0 109.435 174.399 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.72 -143.12 16.54 Favored Glycine 0 N--CA 1.429 -1.828 0 C-N-CA 124.541 1.067 . . . . 0.0 115.243 171.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.7 -149.67 18.07 Favored Glycine 0 N--CA 1.429 -1.813 0 C-N-CA 124.823 1.201 . . . . 0.0 112.502 178.164 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.6 p -97.2 12.53 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.578 -1.542 . . . . 0.0 112.57 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -83.3 -61.77 1.76 Allowed 'General case' 0 N--CA 1.429 -1.51 0 O-C-N 118.872 -2.393 . . . . 0.0 111.963 -178.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 21.2 p -94.81 174.85 6.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.535 1.134 . . . . 0.0 110.979 -175.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.4 m -83.14 56.55 3.55 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.895 -1.753 . . . . 0.0 113.259 -175.184 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.8 m -100.54 4.22 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 O-C-N 120.493 -1.379 . . . . 0.0 113.716 -176.438 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.307 33.5 mmt180 93.03 123.0 0.02 OUTLIER 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.818 2.447 . . . . 0.0 108.894 -162.318 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.5 m170 -60.48 100.37 0.1 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.66 1.356 . . . . 0.0 114.66 -166.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.14 15.7 29.85 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 121.02 -1.05 . . . . 0.0 112.867 -177.612 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -80.35 92.66 1.4 Allowed Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.416 1.007 . . . . 0.0 112.048 177.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 15.0 mm -86.6 126.03 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 172.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -122.42 154.02 38.31 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.996 -1.065 . . . . 0.0 109.461 -174.008 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.6 t -76.16 118.86 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.967 -1.083 . . . . 0.0 111.524 175.048 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -88.53 -43.01 11.72 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.919 1.288 . . . . 0.0 110.123 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.66 150.82 23.36 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 121.105 -0.997 . . . . 0.0 109.123 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.551 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.2 117.66 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 170.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.04 117.67 65.67 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 115.296 -2.287 . . . . 0.0 113.369 -161.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -53.74 129.59 34.76 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 124.025 3.15 . . . . 0.0 116.387 -169.401 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 34.9 mttt 77.56 14.71 1.72 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.374 1.87 . . . . 0.0 114.474 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.85 165.81 46.16 Favored Glycine 0 N--CA 1.429 -1.794 0 O-C-N 119.658 -1.901 . . . . 0.0 113.421 173.663 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.31 -58.9 4.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 167.247 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.01 -50.18 71.74 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 128.935 2.894 . . . . 0.0 112.175 -178.6 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.551 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -41.78 -71.04 0.09 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.782 2.033 . . . . 0.0 114.997 166.515 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.9 t -70.02 -14.96 62.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -170.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -64.9 -59.25 4.4 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.743 -1.848 . . . . 0.0 111.946 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 97.78 29.46 7.71 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.046 -1.659 . . . . 0.0 116.682 165.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -92.92 -41.57 9.96 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.392 -1.064 . . . . 0.0 108.864 160.266 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.0 mt -97.88 118.76 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.399 1.88 . . . . 0.0 110.811 -170.141 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -128.59 174.77 9.1 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-O 123.085 1.421 . . . . 0.0 111.438 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -62.41 130.44 45.22 Favored 'General case' 0 N--CA 1.431 -1.387 0 O-C-N 119.579 -1.951 . . . . 0.0 112.583 176.012 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.8 -5.35 61.84 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.712 -0.618 . . . . 0.0 113.697 -177.094 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -77.54 156.37 30.99 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 118.661 1.23 . . . . 0.0 111.641 -176.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -106.93 123.0 47.55 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.579 1.181 . . . . 0.0 110.185 -172.479 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.5 t -85.64 133.68 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 O-C-N 120.217 -1.552 . . . . 0.0 111.089 -175.749 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.47 -51.62 2.88 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.025 -1.047 . . . . 0.0 111.073 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.76 148.26 28.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.958 -1.089 . . . . 0.0 113.137 -176.144 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.97 111.04 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.096 0.958 . . . . 0.0 110.303 173.115 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.6 t30 61.01 39.9 15.87 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.78 2.032 . . . . 0.0 113.323 172.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.07 -27.34 19.66 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 125.309 1.433 . . . . 0.0 113.459 -178.145 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.2 t -84.64 119.8 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 124.95 1.3 . . . . 0.0 110.817 -172.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.2 p -72.23 136.5 46.37 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.462 -1.399 . . . . 0.0 112.296 177.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 35.9 mt -87.95 -6.16 58.17 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.475 -1.391 . . . . 0.0 113.896 -175.213 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -68.71 95.26 0.65 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 119.581 -1.949 . . . . 0.0 115.878 -174.594 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.96 -15.13 5.14 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.819 1.2 . . . . 0.0 111.151 -177.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.4 158.88 35.52 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.8 p -87.52 179.12 6.61 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.712 -1.242 . . . . 0.0 111.115 172.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -67.21 -46.75 72.91 Favored 'General case' 0 N--CA 1.431 -1.393 0 O-C-N 120.703 -1.248 . . . . 0.0 110.755 173.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.7 tppt? -57.4 -40.93 79.28 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.201 1.401 . . . . 0.0 113.972 174.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.8 mm100 -56.93 -51.39 69.32 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.555 1.142 . . . . 0.0 114.076 176.06 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.99 -40.52 96.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.255 1.422 . . . . 0.0 113.519 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -66.17 -45.98 88.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.846 -1.159 . . . . 0.0 111.329 176.002 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -58.81 -40.07 83.04 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.629 -1.294 . . . . 0.0 112.95 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 84.2 m -68.2 -42.63 79.59 Favored 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 125.963 1.705 . . . . 0.0 113.569 178.664 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 72.9 mt -68.99 -33.55 73.86 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.987 -1.696 . . . . 0.0 114.391 176.724 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -72.35 -33.04 66.99 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 119.644 -1.91 . . . . 0.0 112.675 171.119 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -78.58 44.73 0.54 Allowed 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.854 2.061 . . . . 0.0 114.25 170.402 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -105.79 154.88 19.89 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.224 -2.172 . . . . 0.0 108.842 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.23 -146.56 17.64 Favored Glycine 0 N--CA 1.429 -1.776 0 O-C-N 120.916 -1.115 . . . . 0.0 112.921 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -70.85 -61.06 1.9 Allowed 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.402 1.081 . . . . 0.0 112.312 169.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.72 127.5 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 123.567 1.651 . . . . 0.0 110.244 177.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 73.3 t -120.61 114.17 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.398 1.879 . . . . 0.0 108.772 -162.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 m170 -101.86 94.1 5.64 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.044 0.938 . . . . 0.0 112.144 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -102.37 160.07 14.86 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.638 -1.914 . . . . 0.0 114.297 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.2 tp -128.35 132.8 48.59 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 124.869 1.268 . . . . 0.0 108.505 163.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.08 164.5 31.93 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.929 -1.107 . . . . 0.0 113.371 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -116.97 134.84 54.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 127.021 2.129 . . . . 0.0 107.773 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -77.58 144.94 37.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.355 -1.466 . . . . 0.0 112.671 -175.237 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -61.61 112.52 4.85 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 125.769 1.652 . . . . 0.0 114.423 174.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -70.3 -28.98 65.61 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.876 1.27 . . . . 0.0 113.545 -178.124 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.2 p -116.66 112.15 41.05 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 120.914 -1.116 . . . . 0.0 108.427 163.224 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo . . . . . 0 C--N 1.3 -2.014 0 C-N-CA 122.696 2.264 . . . . 0.0 113.63 -177.697 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt . . . . . 0 N--CA 1.43 -1.438 0 CA-C-O 115.212 -2.328 . . . . 0.0 112.866 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -74.64 -178.64 4.2 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 126.533 3.369 . . . . 0.0 113.073 163.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 121.92 95.7 1.35 Allowed Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -164.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -53.12 -60.69 2.97 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 129.924 3.29 . . . . 0.0 113.159 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.8 p -105.62 150.63 25.24 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-N 120.166 1.348 . . . . 0.0 110.206 166.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.611 ' CE1' HD21 ' A' ' 96' ' ' LEU . 27.1 p90 -147.69 164.43 33.58 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.635 1.207 . . . . 0.0 108.918 161.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -126.19 143.0 51.3 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.205 1.802 . . . . 0.0 106.858 -168.074 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.69 111.91 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 O-C-N 120.848 -1.157 . . . . 0.0 109.118 -173.233 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -103.1 94.16 5.39 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 125.762 1.625 . . . . 0.0 107.998 169.447 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.1 tp -123.86 134.36 53.59 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-O 122.208 1.004 . . . . 0.0 113.521 -167.207 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.62 137.37 39.11 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 125.67 1.588 . . . . 0.0 110.352 177.141 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -69.11 162.12 27.63 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 115.19 1.552 . . . . 0.0 115.19 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 39.5 p -130.97 114.91 15.8 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.059 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 26.9 t70 50.65 59.49 4.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.461 1.904 . . . . 0.0 113.844 -177.548 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.65 -36.05 2.83 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.13 -1.606 . . . . 0.0 115.663 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 61.5 m -106.38 149.31 27.12 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.346 1.458 . . . . 0.0 112.059 -162.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -96.22 -57.12 2.42 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 172.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.61 23.46 1.88 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 120.153 -1.592 . . . . 0.0 113.075 172.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 pt -115.21 125.53 72.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.085 1.354 . . . . 0.0 110.178 -176.631 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 t -112.39 128.49 56.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.302 -0.874 . . . . 0.0 108.796 170.233 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 163.55 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 111.896 -174.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.6 t -133.51 164.78 26.38 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.677 1.191 . . . . 0.0 108.015 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.39 -154.92 20.17 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.899 -1.125 . . . . 0.0 112.913 171.403 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.94 145.83 18.6 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.192 1.377 . . . . 0.0 110.445 -169.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -58.68 -34.17 50.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.57 -19.84 59.02 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -172.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.0 t -94.29 162.29 13.9 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.477 -1.389 . . . . 0.0 107.585 174.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 12.4 p -81.86 46.81 1.03 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.045 -1.659 . . . . 0.0 113.973 -168.555 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.1 m -92.13 133.77 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 120.403 -1.436 . . . . 0.0 110.154 173.152 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -73.28 -29.53 62.79 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.185 . . . . 0.0 110.451 167.534 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -43.44 -42.0 4.55 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 128.473 2.709 . . . . 0.0 116.744 178.063 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.71 61.17 7.05 Favored Glycine 0 N--CA 1.43 -1.71 0 N-CA-C 115.948 1.139 . . . . 0.0 115.948 169.616 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 172.33 178.52 42.57 Favored Glycine 0 N--CA 1.43 -1.759 0 N-CA-C 107.959 -2.057 . . . . 0.0 107.959 -177.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.8 mm -103.3 120.15 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.205 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -128.0 153.76 46.38 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.924 -1.11 . . . . 0.0 110.496 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 20.5 t -76.0 121.96 29.04 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.577 -1.327 . . . . 0.0 112.687 178.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmt? -97.84 -45.94 6.13 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.741 1.216 . . . . 0.0 112.503 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.51 154.79 27.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.104 -0.998 . . . . 0.0 110.466 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.417 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -111.3 126.14 68.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 CA-C-O 122.235 1.017 . . . . 0.0 109.742 175.461 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 14.1 mm -77.09 118.78 74.24 Favored Pre-proline 0 N--CA 1.43 -1.467 0 CA-C-O 116.043 -1.932 . . . . 0.0 113.761 -174.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -60.19 123.79 13.88 Favored 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 125.003 2.822 . . . . 0.0 115.763 -176.356 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.378 39.8 mtmt 75.59 31.76 0.73 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 127.372 2.269 . . . . 0.0 114.426 -175.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.09 162.39 36.89 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.819 -1.176 . . . . 0.0 112.96 159.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.07 -56.23 11.67 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 126.715 2.006 . . . . 0.0 114.489 165.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.22 -48.79 74.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 128.33 2.652 . . . . 0.0 111.813 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.417 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.4 tm-20 -41.84 -59.21 1.76 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 116.22 1.933 . . . . 0.0 116.22 176.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -69.86 -28.32 65.57 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.535 1.534 . . . . 0.0 114.359 -172.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.32 -56.57 20.15 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.981 1.712 . . . . 0.0 113.687 -173.449 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.54 -4.88 26.34 Favored Glycine 0 N--CA 1.429 -1.801 0 O-C-N 120.587 -1.32 . . . . 0.0 115.42 164.566 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 14' ' ' PHE . 95.1 mtt180 -74.84 -61.86 1.74 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.628 -1.513 . . . . 0.0 110.605 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 94' ' ' LEU . 97.0 mt -67.69 125.69 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.886 1.674 . . . . 0.0 113.527 -177.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -141.7 159.49 42.11 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.49 1.614 . . . . 0.0 114.089 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 ttpt -52.55 127.21 22.0 Favored 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.521 2.328 . . . . 0.0 114.918 177.259 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 98.06 -7.31 62.43 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.031 0.824 . . . . 0.0 114.571 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.72 160.6 24.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 119.363 1.581 . . . . 0.0 112.508 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.7 ttt-85 -105.23 132.92 50.82 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.943 1.697 . . . . 0.0 111.192 -174.464 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.77 136.21 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 119.85 -1.781 . . . . 0.0 111.231 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -100.83 -60.66 1.48 Allowed 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.37 -1.457 . . . . 0.0 110.945 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.81 125.94 10.66 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.907 -1.12 . . . . 0.0 112.366 -171.078 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.9 t -99.04 114.33 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 123.837 0.855 . . . . 0.0 109.367 177.534 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.7 t30 59.52 35.28 22.7 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.042 1.737 . . . . 0.0 115.1 168.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.51 -10.74 66.98 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 124.971 1.272 . . . . 0.0 114.186 -177.155 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.31 107.88 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.782 -1.422 . . . . 0.0 109.659 -176.34 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.5 t -73.04 126.33 29.72 Favored 'General case' 0 N--CA 1.431 -1.391 0 O-C-N 120.777 -1.202 . . . . 0.0 111.177 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.4 mt -84.95 37.74 0.68 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -169.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -74.77 120.54 20.46 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.929 1.691 . . . . 0.0 110.656 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.11 11.95 79.3 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 120.49 -1.381 . . . . 0.0 114.412 -175.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.89 140.64 51.12 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 114.652 1.353 . . . . 0.0 114.652 -175.028 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.8 p -90.86 -179.28 5.45 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.689 1.195 . . . . 0.0 111.19 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -69.23 -45.43 69.81 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.752 -1.217 . . . . 0.0 110.317 179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -56.89 -41.63 78.4 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 170.274 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -53.1 62.05 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.671 -1.268 . . . . 0.0 113.915 178.764 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.95 -44.02 73.86 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.82 1.248 . . . . 0.0 113.575 178.271 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.4 -49.07 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.64 -1.288 . . . . 0.0 111.806 -177.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -65.73 -32.42 73.96 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.744 -1.222 . . . . 0.0 112.087 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 36.0 m -66.98 -45.06 78.79 Favored 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 125.774 1.63 . . . . 0.0 113.101 173.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 54.3 mt -68.64 -29.31 67.77 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.123 -1.611 . . . . 0.0 114.293 174.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.6 mtp180 -73.68 -47.46 39.5 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.227 -1.546 . . . . 0.0 113.159 171.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -89.18 55.67 3.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.148 -1.595 . . . . 0.0 113.543 -176.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.4 p -84.5 177.91 7.92 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.126 1.771 . . . . 0.0 111.531 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.8 -157.66 27.67 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 120.123 -1.61 . . . . 0.0 110.375 164.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.5 tm0? -71.33 -50.52 31.53 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.819 -1.989 . . . . 0.0 110.861 169.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.51 135.99 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.309 1.444 . . . . 0.0 109.844 174.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.7 t -107.72 126.16 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 C-N-CA 129.047 2.939 . . . . 0.0 108.448 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.9 t-160 -105.21 110.07 22.3 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.434 HD11 HD11 ' A' ' 59' ' ' ILE 0.389 4.0 pp -125.1 151.24 45.97 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 117.032 2.234 . . . . 0.0 117.032 166.867 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.8 tp -114.97 134.23 55.36 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.839 2.056 . . . . 0.0 107.527 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.611 HD21 ' CE1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -152.75 174.37 14.12 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.035 -1.041 . . . . 0.0 113.639 -179.21 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -119.39 132.47 55.84 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 125.712 1.605 . . . . 0.0 111.146 -175.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 145.95 34.37 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.112 -1.617 . . . . 0.0 113.644 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.25 78.77 1.97 Allowed Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.168 -1.582 . . . . 0.0 111.03 170.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -84.38 176.95 8.35 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 116.122 1.897 . . . . 0.0 116.122 -159.138 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 88.4 t -108.37 118.51 52.07 Favored Pre-proline 0 N--CA 1.43 -1.455 0 O-C-N 120.921 -1.112 . . . . 0.0 110.104 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.434 -2.007 0 C-N-CA 122.866 2.378 . . . . 0.0 113.164 166.527 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.43 -1.455 0 CA-C-O 115.45 -2.214 . . . . 0.0 114.421 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -67.54 177.5 3.95 Favored 'Trans proline' 0 C--N 1.299 -2.036 0 CA-C-N 126.255 3.269 . . . . 0.0 116.738 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.39 33.08 8.25 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -161.61 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -96.99 136.29 37.77 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.419 1.887 . . . . 0.0 109.752 -176.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.7 p -95.97 153.67 17.64 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.869 -1.769 . . . . 0.0 111.863 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.68 ' CZ ' HD22 ' A' ' 96' ' ' LEU . 37.4 p90 -146.6 137.51 24.11 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 173.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -94.72 128.06 41.15 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.593 -1.317 . . . . 0.0 109.942 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.41 88.85 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -178.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 61.0 mt-10 -93.85 83.33 4.37 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 169.014 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.419 HD13 ' HB1' ' A' ' 52' ' ' ALA 0.288 1.8 pp -109.2 162.75 13.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.771 1.272 . . . . 0.0 111.233 -178.035 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 133.73 46.88 Favored 'General case' 0 N--CA 1.428 -1.527 0 C-N-CA 124.728 1.211 . . . . 0.0 107.924 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -70.6 121.87 18.69 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.458 -1.401 . . . . 0.0 112.32 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 29.2 p -94.7 119.61 33.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.669 -1.269 . . . . 0.0 110.039 -174.136 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 t70 61.13 7.7 1.7 Allowed 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.056 2.142 . . . . 0.0 116.416 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 107.41 2.27 35.34 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.984 -1.698 . . . . 0.0 114.846 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 63.2 m -121.93 132.02 54.33 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.911 1.855 . . . . 0.0 113.306 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 85.5 mt -73.7 -44.24 57.03 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.712 -1.242 . . . . 0.0 111.425 164.547 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.5 29.74 3.31 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 119.767 -1.833 . . . . 0.0 111.719 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 pt -107.31 135.22 46.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.625 1.202 . . . . 0.0 114.215 -162.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 17.7 m -131.3 109.68 10.54 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.758 -1.839 . . . . 0.0 108.969 155.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.03 163.82 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-O 122.153 0.978 . . . . 0.0 112.145 -177.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.6 t -145.81 172.6 13.07 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.13 1.372 . . . . 0.0 108.28 175.104 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 -175.61 33.68 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.734 -1.229 . . . . 0.0 114.125 176.705 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 149.6 177.61 23.83 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -171.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.2 p -78.35 -41.61 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.434 1.272 . . . . 0.0 114.434 -173.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -98.65 7.77 45.72 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.021 -1.675 . . . . 0.0 111.219 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 10.6 m -84.02 158.23 21.55 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.035 1.734 . . . . 0.0 109.022 -177.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 34.3 p -74.48 47.74 0.32 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 126.247 1.819 . . . . 0.0 115.838 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.3 m -92.25 -178.25 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 126.758 2.023 . . . . 0.0 106.885 161.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.4 mtm180 -69.74 -53.67 17.36 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.766 -1.834 . . . . 0.0 113.746 -175.503 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.4 t60 -128.69 -45.39 1.31 Allowed 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.14 85.69 0.05 OUTLIER Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.858 -1.151 . . . . 0.0 111.54 -177.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -144.32 155.74 26.44 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.459 -1.024 . . . . 0.0 111.461 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.7 mm -102.39 123.34 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.894 1.678 . . . . 0.0 107.464 175.172 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -124.4 155.16 39.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.935 -1.103 . . . . 0.0 111.307 -170.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.1 t -76.05 119.31 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.883 -1.136 . . . . 0.0 110.789 169.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.9 pttt -95.51 -36.59 11.24 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.471 -1.393 . . . . 0.0 112.445 173.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -155.88 160.95 40.6 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.921 -1.112 . . . . 0.0 110.539 177.1 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.436 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -120.15 125.88 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 124.404 1.082 . . . . 0.0 109.216 177.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.8 mm -77.42 124.93 86.85 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.623 1.969 . . . . 0.0 114.265 -176.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_exo -56.57 133.87 60.73 Favored 'Trans proline' 0 N--CA 1.435 -1.968 0 CA-C-N 124.034 2.476 . . . . 0.0 116.237 176.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt 83.53 0.77 1.06 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 129.012 2.925 . . . . 0.0 114.71 -177.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.05 156.08 46.88 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.121 -1.612 . . . . 0.0 113.104 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HB1' HD13 ' A' ' 18' ' ' LEU . . . -49.35 -53.14 23.78 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 172.495 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.2 -45.76 86.91 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 128.951 2.901 . . . . 0.0 112.622 177.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.436 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.6 tm-20 -50.21 -57.99 6.57 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 123.101 1.429 . . . . 0.0 114.656 171.144 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.4 t -68.02 -25.39 65.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.193 1.397 . . . . 0.0 113.717 -171.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -61.56 -71.94 0.13 Allowed 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.695 1.598 . . . . 0.0 112.501 173.661 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.76 -6.52 37.98 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 121.108 -0.995 . . . . 0.0 115.284 177.171 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.1 mtm180 -65.22 -35.47 81.15 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.867 -1.961 . . . . 0.0 111.893 165.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 73.3 mt -85.36 134.21 27.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 124.884 1.273 . . . . 0.0 109.683 176.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -139.17 161.31 37.73 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.807 -1.183 . . . . 0.0 108.922 177.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -54.71 125.05 18.37 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.985 1.714 . . . . 0.0 113.934 172.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.84 -2.25 66.41 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 124.286 0.946 . . . . 0.0 114.802 -178.192 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -82.12 160.18 23.19 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-N 119.614 1.707 . . . . 0.0 110.535 178.793 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -112.37 132.48 54.98 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.619 -1.3 . . . . 0.0 112.151 -168.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.7 t -87.14 127.68 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.319 -1.488 . . . . 0.0 110.657 178.588 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 88.1 mt -98.15 -48.1 5.23 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 121.132 -0.98 . . . . 0.0 111.253 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.44 134.6 18.16 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.995 -1.065 . . . . 0.0 109.787 -176.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.7 t -114.23 125.85 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 67.25 30.06 7.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.259 1.424 . . . . 0.0 111.721 175.28 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 85.19 -18.84 25.84 Favored Glycine 0 N--CA 1.431 -1.682 0 C-N-CA 125.058 1.313 . . . . 0.0 114.802 -173.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.85 123.27 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 O-C-N 120.776 -1.426 . . . . 0.0 110.521 -171.195 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.5 m -63.88 135.27 56.42 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.776 -1.202 . . . . 0.0 113.956 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 78.1 mt -86.17 56.52 4.02 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.754 -1.216 . . . . 0.0 111.65 177.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -78.85 123.11 26.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.571 -1.331 . . . . 0.0 112.508 -175.073 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 58.59 20.87 48.03 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 125.349 1.452 . . . . 0.0 115.139 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.64 144.66 51.04 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -164.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -76.58 178.45 6.67 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.611 1.164 . . . . 0.0 110.511 169.149 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -68.25 -48.84 63.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.427 -1.421 . . . . 0.0 111.738 172.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 41.2 mmtm -58.48 -31.67 68.05 Favored 'General case' 0 N--CA 1.429 -1.512 0 N-CA-C 116.012 1.856 . . . . 0.0 116.012 174.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 mm100 -56.35 -55.74 29.76 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 120.324 1.42 . . . . 0.0 114.181 175.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.53 87.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.198 0.999 . . . . 0.0 113.195 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -68.35 -48.39 73.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.028 1.331 . . . . 0.0 111.208 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -62.94 -36.82 84.68 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.482 -1.386 . . . . 0.0 112.791 177.362 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.1 m -67.26 -45.88 75.38 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.646 1.578 . . . . 0.0 113.188 175.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 20.8 mt -66.28 -34.74 78.68 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.399 -1.438 . . . . 0.0 114.031 175.055 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.51 -31.64 65.51 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.32 -1.488 . . . . 0.0 113.684 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -88.68 48.93 1.7 Allowed 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 122.185 0.993 . . . . 0.0 112.066 173.302 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 p -107.17 154.33 21.35 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.102 -1.624 . . . . 0.0 109.14 170.63 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -108.83 -132.5 6.61 Favored Glycine 0 N--CA 1.43 -1.718 0 CA-C-O 121.964 0.758 . . . . 0.0 113.823 -172.383 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.0 tm0? -70.82 -68.84 0.4 Allowed 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 121.308 -1.113 . . . . 0.0 113.54 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 9.2 p -98.33 131.98 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.873 1.32 . . . . 0.0 109.882 174.094 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.6 t -125.23 111.96 29.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 126.139 1.776 . . . . 0.0 110.209 -162.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -93.14 101.15 13.44 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -178.243 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -92.73 146.19 23.84 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 120.113 -1.617 . . . . 0.0 112.602 168.072 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 60.5 tp -113.87 127.54 56.03 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 155.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.68 HD22 ' CZ ' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -136.22 151.69 49.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 121.098 -1.001 . . . . 0.0 111.356 -171.172 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -117.34 131.63 56.75 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 123.404 1.573 . . . . 0.0 111.622 176.401 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -75.86 128.56 35.36 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.133 2.173 . . . . 0.0 110.798 177.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.05 -160.86 36.92 Favored Glycine 0 N--CA 1.431 -1.658 0 O-C-N 121.351 -0.843 . . . . 0.0 111.221 177.508 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -73.64 177.4 5.43 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.706 -1.467 . . . . 0.0 114.349 -175.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 58.6 t -98.85 133.68 22.15 Favored Pre-proline 0 N--CA 1.431 -1.423 0 CA-C-O 117.468 -1.253 . . . . 0.0 108.796 -176.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo . . . . . 0 N--CA 1.433 -2.085 0 C-N-CA 122.619 2.213 . . . . 0.0 113.414 177.398 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.1 mtpp . . . . . 0 N--CA 1.43 -1.454 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.42 178.77 5.45 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 CA-C-N 124.214 2.541 . . . . 0.0 111.587 171.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 96.76 17.73 32.12 Favored Glycine 0 N--CA 1.431 -1.677 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.3 t0 -87.4 164.4 16.23 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 120.097 1.949 . . . . 0.0 110.851 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 p -100.1 158.43 15.85 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.884 1.674 . . . . 0.0 112.541 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -144.67 146.71 32.37 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 171.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -89.57 113.19 24.58 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 165.108 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 t -98.77 99.66 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -90.38 94.36 9.7 Favored 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 174.287 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -105.14 126.48 52.12 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-O 122.464 1.126 . . . . 0.0 110.045 -174.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.82 139.25 38.64 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.133 -1.604 . . . . 0.0 110.225 176.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -66.18 130.86 44.66 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.002 -1.061 . . . . 0.0 113.075 175.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.9 p -91.09 84.72 5.75 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.228 -1.545 . . . . 0.0 110.378 177.161 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.1 t70 59.27 53.43 5.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.457 1.903 . . . . 0.0 113.487 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.96 -11.31 72.47 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.746 -1.221 . . . . 0.0 115.295 -176.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.5 t -94.53 112.92 24.69 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.419 -1.636 . . . . 0.0 113.519 -173.099 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 7.5 tp -125.84 63.03 1.22 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.662 1.585 . . . . 0.0 109.985 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -85.64 62.21 4.46 Favored Glycine 0 N--CA 1.43 -1.717 0 O-C-N 119.43 -2.043 . . . . 0.0 113.462 -164.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.93 127.34 55.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 124.74 1.216 . . . . 0.0 107.975 168.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.43 121.79 45.85 Favored 'General case' 0 CA--C 1.489 -1.371 0 C-N-CA 123.626 0.77 . . . . 0.0 109.442 177.438 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.0 m -104.46 170.42 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.724 1.209 . . . . 0.0 112.736 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -150.24 173.79 13.55 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.198 1.399 . . . . 0.0 108.51 173.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.83 -138.03 14.67 Favored Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 167.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.87 162.31 27.79 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.52 1.533 . . . . 0.0 113.023 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -63.0 -20.42 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.603 1.561 . . . . 0.0 114.988 177.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -81.7 -10.33 59.41 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.611 1.965 . . . . 0.0 112.152 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.2 m -115.18 143.95 44.44 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.148 1.379 . . . . 0.0 108.864 -176.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.7 t -87.43 61.81 6.8 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 119.597 -1.94 . . . . 0.0 110.783 177.24 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.02 41.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.075 1.75 . . . . 0.0 113.064 -165.107 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 59.73 64.85 1.22 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 119.672 -1.892 . . . . 0.0 111.863 -166.236 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.31 38.2 m80 75.01 157.57 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 127.647 2.379 . . . . 0.0 113.812 -173.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -80.14 86.33 1.29 Allowed Glycine 0 N--CA 1.431 -1.647 0 O-C-N 120.212 -1.555 . . . . 0.0 115.167 -167.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -146.46 171.07 27.39 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.144 0.878 . . . . 0.0 110.962 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.9 mm -97.85 131.98 43.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.69 1.196 . . . . 0.0 108.577 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.84 159.4 33.99 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.777 -1.202 . . . . 0.0 110.305 -175.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.68 119.53 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.694 -1.253 . . . . 0.0 111.023 174.28 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 57.2 tttm -91.43 -50.85 5.57 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 124.11 0.964 . . . . 0.0 111.85 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.09 155.83 31.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.038 -1.039 . . . . 0.0 110.904 -177.505 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.41 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -114.09 120.63 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-O 122.611 1.196 . . . . 0.0 109.643 172.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 34.6 mm -76.06 128.22 83.52 Favored Pre-proline 0 N--CA 1.43 -1.447 0 CA-C-O 116.09 -1.909 . . . . 0.0 113.252 -170.477 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -55.0 133.85 60.42 Favored 'Trans proline' 0 N--CA 1.434 -2.002 0 C-N-CA 124.416 3.411 . . . . 0.0 115.65 178.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? 67.76 13.76 9.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.526 1.53 . . . . 0.0 114.478 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.31 173.13 47.9 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 119.592 -1.942 . . . . 0.0 112.517 172.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.87 9.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 169.32 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.81 -40.1 95.83 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 126.595 1.958 . . . . 0.0 115.273 -173.022 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.41 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.0 OUTLIER -41.35 -60.08 1.37 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 129.423 3.089 . . . . 0.0 113.607 178.02 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.5 t -70.2 -33.84 72.21 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 111.693 -2.503 . . . . 0.0 115.847 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -62.43 -48.57 79.1 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.272 1.429 . . . . 0.0 113.129 -165.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.64 -19.92 45.9 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.506 -1.371 . . . . 0.0 115.421 162.491 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.2 mmt-85 -75.74 -4.34 39.89 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 118.429 1.115 . . . . 0.0 112.764 172.308 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.5 mt -117.91 126.97 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.525 0 C-N-CA 125.259 1.423 . . . . 0.0 107.981 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -132.25 163.83 27.73 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.617 -1.302 . . . . 0.0 109.797 170.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -67.91 123.29 20.17 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.215 -1.553 . . . . 0.0 112.773 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 100.01 0.83 56.09 Favored Glycine 0 N--CA 1.431 -1.7 0 O-C-N 121.678 -0.639 . . . . 0.0 114.099 -174.728 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -80.17 164.86 22.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-N 119.555 1.678 . . . . 0.0 110.455 173.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.18 136.68 51.29 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.602 1.192 . . . . 0.0 111.722 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -91.15 125.12 43.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 126.113 1.765 . . . . 0.0 109.76 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 49.1 mt -103.89 -56.89 2.12 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.42 -1.425 . . . . 0.0 110.589 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.74 118.62 6.66 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 121.165 -0.959 . . . . 0.0 111.163 -176.157 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.45 HG22 HD13 ' A' ' 94' ' ' LEU . 57.7 t -98.47 115.79 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -176.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.9 t30 60.84 42.41 13.23 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 124.796 1.238 . . . . 0.0 114.321 165.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.17 -18.35 57.01 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.53 1.062 . . . . 0.0 114.05 -177.575 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.66 117.93 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.851 -1.381 . . . . 0.0 109.331 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 54.9 m -72.79 105.89 4.53 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 121.138 -0.976 . . . . 0.0 110.959 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 33.8 mt -89.8 25.67 2.0 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.695 -1.253 . . . . 0.0 112.092 -175.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -77.83 122.55 25.59 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.088 -1.632 . . . . 0.0 109.563 173.12 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 76.11 15.08 81.66 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 120.657 -1.277 . . . . 0.0 115.672 -170.369 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.28 163.11 28.28 Favored 'General case' 0 N--CA 1.429 -1.492 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 178.318 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.6 p -93.5 171.13 9.1 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.128 1.371 . . . . 0.0 111.196 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 64.8 t-80 -62.47 -51.06 68.95 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.476 -1.39 . . . . 0.0 114.185 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 mtmt -57.12 -42.58 81.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 174.24 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 55.8 tt0 -56.58 -45.91 81.09 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.355 1.862 . . . . 0.0 114.241 -173.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.69 -39.63 94.59 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.902 1.681 . . . . 0.0 114.732 172.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.2 t -68.7 -49.26 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.011 1.324 . . . . 0.0 110.415 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 82.3 mt-10 -66.41 -33.33 75.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.341 -1.474 . . . . 0.0 113.552 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.8 m -61.2 -41.6 97.11 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.744 1.618 . . . . 0.0 113.072 169.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 76.0 mt -71.7 -30.69 65.94 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.361 -1.462 . . . . 0.0 114.276 173.126 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -67.28 -46.51 73.41 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.073 -1.642 . . . . 0.0 112.587 173.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -93.74 64.75 3.53 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.644 -1.285 . . . . 0.0 110.653 177.544 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 p -101.46 164.42 11.77 Favored 'General case' 0 N--CA 1.429 -1.512 0 C-N-CA 128.043 2.537 . . . . 0.0 109.329 173.16 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -92.8 -139.75 9.38 Favored Glycine 0 N--CA 1.431 -1.678 0 O-C-N 121.043 -1.035 . . . . 0.0 110.689 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -71.14 -68.47 0.44 Allowed 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.189 -1.183 . . . . 0.0 114.039 170.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.4 t -105.51 128.77 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 CA-C-O 122.509 1.147 . . . . 0.0 108.619 -176.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.04 117.99 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 128.409 2.683 . . . . 0.0 108.996 -170.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -98.2 102.13 13.79 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.486 -1.383 . . . . 0.0 111.192 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.45 HD13 HG22 ' A' ' 68' ' ' VAL . 31.7 tp -99.93 132.88 45.01 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.207 -1.558 . . . . 0.0 111.388 175.202 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -87.44 121.55 30.02 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.163 -1.792 . . . . 0.0 106.163 163.015 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.0 tt -123.45 143.63 50.02 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 123.689 0.796 . . . . 0.0 109.804 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -111.22 136.33 50.45 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 109.22 174.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -77.89 126.97 31.65 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 121.196 -0.94 . . . . 0.0 111.851 175.366 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.06 -140.22 6.19 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-O 122.418 1.01 . . . . 0.0 114.18 177.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -80.71 -155.71 0.12 Allowed 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.796 1.638 . . . . 0.0 114.242 -172.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.4 m -80.2 146.37 62.48 Favored Pre-proline 0 N--CA 1.43 -1.435 0 O-C-N 119.336 -2.102 . . . . 0.0 109.842 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo . . . . . 0 C--N 1.299 -2.043 0 C-N-CA 122.254 1.969 . . . . 0.0 114.606 -155.721 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 41.8 mtmt . . . . . 0 N--CA 1.43 -1.468 0 CA-C-O 116.384 -1.77 . . . . 0.0 113.494 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -78.38 -161.59 0.15 Allowed 'Trans proline' 0 C--N 1.3 -1.996 0 CA-C-N 125.704 3.073 . . . . 0.0 112.853 174.174 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.82 77.61 0.4 Allowed Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 108.022 -2.031 . . . . 0.0 108.022 -155.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -53.12 -58.76 5.91 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.75 2.82 . . . . 0.0 111.777 -172.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.31 135.16 43.26 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.338 -0.851 . . . . 0.0 109.653 158.431 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.251 0.0 OUTLIER -146.77 146.51 30.3 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 122.458 1.123 . . . . 0.0 109.454 159.235 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.34 145.89 24.27 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.405 -1.434 . . . . 0.0 109.035 174.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 47.9 t -106.01 93.44 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 74.9 mt-10 -92.2 89.77 7.03 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.978 1.711 . . . . 0.0 108.426 175.223 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 65.6 tp -124.91 148.39 48.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 121.304 -0.873 . . . . 0.0 110.629 -171.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.66 48.48 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.219 1.408 . . . . 0.0 109.015 171.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -71.17 154.86 41.37 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 115.871 1.804 . . . . 0.0 115.871 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 77.5 p -121.08 131.55 54.34 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.849 -1.157 . . . . 0.0 109.482 171.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.1 t70 57.78 38.83 27.43 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 176.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.65 -16.14 16.06 Favored Glycine 0 N--CA 1.431 -1.656 0 O-C-N 119.477 -2.015 . . . . 0.0 114.985 -176.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.8 p -115.14 157.93 22.92 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.779 2.032 . . . . 0.0 112.551 -164.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.404 HD13 ' HA ' ' A' ' 25' ' ' LEU . 3.7 mm? -102.06 -60.64 1.5 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.677 -1.264 . . . . 0.0 108.957 173.502 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.86 56.64 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.555 -1.966 . . . . 0.0 110.838 169.464 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tt -147.24 145.29 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 CA-C-O 122.43 1.11 . . . . 0.0 110.784 -171.498 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.6 t -108.94 132.36 54.15 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 166.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.1 m -112.92 155.92 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 O-C-N 121.14 -0.975 . . . . 0.0 111.344 -175.503 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 t -129.0 168.02 16.63 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 124.084 0.954 . . . . 0.0 109.33 174.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.09 -151.68 18.31 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.418 -0.801 . . . . 0.0 113.928 167.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.48 139.63 10.65 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 123.975 0.798 . . . . 0.0 112.481 -176.295 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -71.18 -11.28 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 O-C-N 120.829 -1.395 . . . . 0.0 113.933 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -69.66 -33.98 73.33 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.181 -1.575 . . . . 0.0 113.764 178.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.5 t -107.53 169.32 8.65 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 120.898 -1.126 . . . . 0.0 111.563 -173.348 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.3 m -82.85 62.54 6.49 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.259 -1.525 . . . . 0.0 113.647 -174.298 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.8 t -72.44 -43.51 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 C-N-CA 125.679 1.592 . . . . 0.0 110.79 171.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 74.8 mtt85 67.94 37.89 2.95 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 128.297 2.639 . . . . 0.0 112.122 -169.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -150.61 -52.35 0.14 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.501 -0.749 . . . . 0.0 110.583 -179.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.62 66.13 1.62 Allowed Glycine 0 N--CA 1.43 -1.729 0 O-C-N 120.59 -1.319 . . . . 0.0 115.253 169.603 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.77 171.09 34.27 Favored Glycine 0 N--CA 1.429 -1.772 0 N-CA-C 107.133 -2.387 . . . . 0.0 107.133 175.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.4 mm -103.78 114.79 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.286 1.434 . . . . 0.0 107.573 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.1 m-85 -123.58 157.05 34.57 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.206 1.003 . . . . 0.0 110.52 -171.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -75.03 122.5 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 C-N-CA 124.542 1.137 . . . . 0.0 110.713 175.239 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -93.18 -51.83 4.84 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.846 -1.159 . . . . 0.0 111.574 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.86 158.9 41.48 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.041 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.413 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -113.56 125.27 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 CA-C-O 122.565 1.174 . . . . 0.0 109.057 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -76.58 124.19 87.8 Favored Pre-proline 0 N--CA 1.429 -1.487 0 CA-C-O 116.344 -1.788 . . . . 0.0 113.679 -167.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_exo -58.9 124.64 16.16 Favored 'Trans proline' 0 N--CA 1.433 -2.036 0 CA-C-N 124.566 2.667 . . . . 0.0 115.396 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 47.9 mtpt 74.88 30.74 0.93 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 127.101 2.16 . . . . 0.0 114.069 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.33 160.72 33.49 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.204 -0.935 . . . . 0.0 114.097 161.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.07 -54.03 14.48 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.982 2.113 . . . . 0.0 114.444 160.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.93 -46.48 87.56 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 127.586 2.354 . . . . 0.0 113.416 179.095 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.2 tm-20 -41.6 -64.57 0.55 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 116.415 2.005 . . . . 0.0 116.415 173.441 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 57.8 m -68.51 -18.46 64.38 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.557 1.943 . . . . 0.0 115.843 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.16 -56.84 16.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 CA-C-N 119.657 1.117 . . . . 0.0 112.52 -174.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 107.04 -25.81 21.06 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 115.151 0.82 . . . . 0.0 115.151 176.109 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -72.36 -29.17 63.54 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.951 1.875 . . . . 0.0 112.221 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.0 mt -90.34 120.71 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 120.591 -1.318 . . . . 0.0 111.024 174.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -124.32 168.67 12.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.937 1.351 . . . . 0.0 111.435 173.112 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -65.72 117.54 8.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.726 1.61 . . . . 0.0 113.43 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.13 11.21 57.75 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.744 -1.222 . . . . 0.0 114.563 -176.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -81.22 159.45 24.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.22 1.51 . . . . 0.0 111.909 173.619 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -112.97 124.49 52.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.109 1.363 . . . . 0.0 111.163 -166.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 39.0 t -92.08 121.31 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.381 0 O-C-N 120.288 -1.508 . . . . 0.0 110.716 179.54 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 78.3 mt -89.11 -45.52 9.54 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.102 -0.999 . . . . 0.0 110.749 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.63 143.47 24.62 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 121.378 -0.826 . . . . 0.0 110.709 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 44.9 t -111.14 114.45 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.053 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.7 t30 63.88 34.04 12.06 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 165.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.16 -17.35 59.45 Favored Glycine 0 N--CA 1.431 -1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 113.83 -175.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.6 t -99.03 121.34 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.41 . . . . 0.0 109.983 -175.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 20.3 t -75.32 138.69 41.97 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.255 -1.528 . . . . 0.0 112.03 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 76.8 mt -90.4 13.56 15.25 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.223 -0.923 . . . . 0.0 113.447 -176.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -61.15 111.99 1.93 Allowed 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 119.94 -1.725 . . . . 0.0 114.348 -177.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.95 0.29 83.53 Favored Glycine 0 N--CA 1.43 -1.704 0 C-N-CA 124.903 1.239 . . . . 0.0 115.463 -178.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.63 147.41 47.56 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 115.68 1.733 . . . . 0.0 115.68 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.9 p -92.79 178.68 5.7 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.797 1.239 . . . . 0.0 112.529 176.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -56.33 -56.61 18.93 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.977 1.711 . . . . 0.0 114.673 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 tppt? -57.39 -39.79 76.85 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.812 1.245 . . . . 0.0 113.317 -178.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.58 -50.4 72.03 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 126.634 1.974 . . . . 0.0 113.852 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.21 -41.45 99.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.862 1.665 . . . . 0.0 114.165 174.327 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.02 -49.03 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.215 1.406 . . . . 0.0 111.051 177.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -60.82 -39.17 88.0 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 124.691 1.196 . . . . 0.0 112.85 177.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.1 m -63.41 -49.79 72.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 126.998 2.119 . . . . 0.0 113.033 173.496 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 63.8 mt -66.66 -29.57 69.62 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.196 -1.565 . . . . 0.0 114.405 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -68.8 -49.25 60.12 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.598 -1.314 . . . . 0.0 112.274 169.325 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -85.02 64.65 8.82 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.414 -1.429 . . . . 0.0 111.641 177.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 p -106.18 160.08 15.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 128.792 2.837 . . . . 0.0 109.258 173.045 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.69 -163.61 39.08 Favored Glycine 0 N--CA 1.429 -1.77 0 O-C-N 121.046 -1.033 . . . . 0.0 111.584 176.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -66.69 -52.55 43.46 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.757 -1.437 . . . . 0.0 113.152 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.34 130.07 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 CA-C-O 122.695 1.236 . . . . 0.0 108.054 170.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.0 t -117.92 128.54 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 127.597 2.359 . . . . 0.0 108.029 -166.121 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.2 m80 -120.67 92.54 3.79 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -170.498 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.18 146.55 25.32 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 119.398 -2.064 . . . . 0.0 112.068 175.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 24.9 tp -104.6 116.56 32.28 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 162.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.4 tt -132.44 137.14 47.16 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.564 0.697 . . . . 0.0 111.927 -164.07 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.5 tt0 -108.87 126.65 53.29 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.866 -1.146 . . . . 0.0 109.267 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.5 tmtt? -79.98 140.03 36.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.674 -1.266 . . . . 0.0 112.433 -174.027 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.47 74.97 2.28 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.197 -1.565 . . . . 0.0 111.133 173.441 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.79 -50.09 74.87 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.221 1.408 . . . . 0.0 114.307 -170.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.5 t -106.67 113.58 62.76 Favored Pre-proline 0 N--CA 1.429 -1.501 0 C-N-CA 124.351 1.061 . . . . 0.0 108.554 172.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--N 1.299 -2.071 0 C-N-CA 122.65 2.234 . . . . 0.0 112.419 165.46 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt . . . . . 0 N--CA 1.429 -1.492 0 CA-C-O 115.458 -2.21 . . . . 0.0 113.009 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -71.91 -173.48 1.06 Allowed 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 126.345 3.302 . . . . 0.0 115.008 176.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.41 81.59 0.54 Allowed Glycine 0 N--CA 1.429 -1.784 0 C-N-CA 124.903 1.24 . . . . 0.0 110.293 -165.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -53.03 -50.02 65.1 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 129.543 3.137 . . . . 0.0 115.655 -163.119 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -119.35 148.2 43.47 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 121.121 1.782 . . . . 0.0 109.618 164.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 11.1 p90 -146.8 147.02 30.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 123.21 1.481 . . . . 0.0 109.23 171.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -104.1 120.5 41.22 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.317 2.247 . . . . 0.0 107.738 -178.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.3 t -114.04 103.69 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 119.975 -1.703 . . . . 0.0 109.83 -171.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -90.08 88.67 7.37 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.306 -1.496 . . . . 0.0 109.239 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 tp -100.92 130.39 46.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.761 -1.212 . . . . 0.0 112.702 -167.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.47 128.23 49.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.279 -1.513 . . . . 0.0 109.456 170.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -69.73 132.66 46.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.217 1.562 . . . . 0.0 115.217 -172.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 47.6 p -107.48 114.89 29.19 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.503 -1.373 . . . . 0.0 111.498 -176.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.4 t70 55.66 39.35 30.88 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.214 2.205 . . . . 0.0 113.12 172.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.73 4.5 90.29 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 119.514 -1.991 . . . . 0.0 115.583 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.6 t -121.48 134.59 55.07 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-N 118.549 1.175 . . . . 0.0 111.345 -176.541 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 86.2 mt -89.65 -42.52 11.32 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.826 -1.171 . . . . 0.0 109.99 173.305 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.28 9.27 22.2 Favored Glycine 0 N--CA 1.43 -1.731 0 O-C-N 120.833 -1.167 . . . . 0.0 114.503 175.346 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.8 pt -129.42 125.65 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 CA-C-N 118.466 1.133 . . . . 0.0 112.555 -166.051 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -110.15 139.83 44.88 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.974 -1.079 . . . . 0.0 109.233 166.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 m -111.05 170.71 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.81 1.244 . . . . 0.0 112.725 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -150.96 172.26 15.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.559 1.943 . . . . 0.0 108.2 174.651 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.1 -131.37 10.58 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 121.052 -1.03 . . . . 0.0 113.731 169.76 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 72.22 -175.36 42.75 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.936 1.255 . . . . 0.0 113.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.1 t -68.32 -9.71 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 126.4 1.88 . . . . 0.0 113.325 177.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -75.25 -24.65 57.67 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 118.658 -2.526 . . . . 0.0 112.113 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.1 m -115.56 152.25 33.38 Favored 'General case' 0 N--CA 1.428 -1.549 0 C-N-CA 125.64 1.576 . . . . 0.0 109.014 -173.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.9 p -81.7 60.72 4.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.09 -2.256 . . . . 0.0 115.031 -175.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 1.5 t -92.25 47.48 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 O-C-N 119.605 -1.934 . . . . 0.0 111.937 -175.482 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.252 26.7 ttt-85 36.61 41.91 0.18 Allowed 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 129.495 3.118 . . . . 0.0 117.974 -174.088 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.6 t60 151.4 -67.35 0.0 OUTLIER 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 129.729 3.212 . . . . 0.0 105.513 -172.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 120.92 97.1 1.54 Allowed Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 123.881 0.753 . . . . 0.0 111.65 -177.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -126.0 156.31 19.55 Favored Glycine 0 N--CA 1.43 -1.745 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 178.719 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.79 114.74 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.507 1.123 . . . . 0.0 109.238 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -111.9 153.62 26.41 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.261 -0.899 . . . . 0.0 110.225 -173.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.5 t -76.57 116.85 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 124.924 1.289 . . . . 0.0 112.473 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.2 ttpp -92.26 -40.88 10.71 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.272 1.029 . . . . 0.0 112.36 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.68 153.75 31.81 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.165 -1.584 . . . . 0.0 112.687 -177.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.265 1.0 OUTLIER -109.33 115.89 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-O 123.123 1.44 . . . . 0.0 109.988 171.776 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.1 mm -77.36 125.23 86.59 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 127.111 2.164 . . . . 0.0 113.79 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -55.69 124.34 16.03 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 C-N-CA 123.625 2.883 . . . . 0.0 116.115 -177.49 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.3 4.5 mptp? 74.38 24.59 1.81 Allowed 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.692 1.997 . . . . 0.0 113.22 176.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.01 159.11 35.54 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.439 -1.413 . . . . 0.0 111.785 165.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.6 -55.44 11.17 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.62 1.711 . . . . 0.0 115.62 175.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.443 ' HB1' HD12 ' A' ' 59' ' ' ILE . . . -63.53 -46.44 86.01 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 128.065 2.546 . . . . 0.0 112.561 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -48.9 -60.63 2.6 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.317 1.447 . . . . 0.0 113.944 174.489 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.2 m -69.39 -20.05 63.82 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -69.43 -64.03 0.95 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.511 -1.368 . . . . 0.0 110.996 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.72 11.09 41.74 Favored Glycine 0 N--CA 1.429 -1.771 0 O-C-N 119.862 -1.774 . . . . 0.0 114.849 164.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 71.9 mtt85 -62.45 -51.68 66.56 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.88 1.272 . . . . 0.0 109.905 159.473 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.443 HD12 ' HB1' ' A' ' 53' ' ' ALA . 2.8 mt -79.17 128.13 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 126.104 1.762 . . . . 0.0 112.132 -176.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.93 169.65 16.0 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 123.561 1.648 . . . . 0.0 111.641 174.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 14.7 ttpp -66.23 132.06 47.57 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.675 -1.891 . . . . 0.0 112.115 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.03 5.37 68.01 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 120.971 -1.08 . . . . 0.0 114.156 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -79.59 166.36 21.97 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 118.889 1.344 . . . . 0.0 109.586 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -134.08 148.34 51.01 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.172 -1.58 . . . . 0.0 112.772 176.539 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.0 t -102.82 134.0 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 C-N-CA 124.769 1.228 . . . . 0.0 111.171 -166.425 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.9 mp -99.07 -50.65 4.09 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.5 1.12 . . . . 0.0 110.662 -177.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.84 136.54 18.07 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.314 -0.866 . . . . 0.0 112.677 -175.197 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.2 t -113.36 125.77 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 124.671 1.189 . . . . 0.0 108.424 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 65.86 30.91 9.73 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.645 1.178 . . . . 0.0 112.521 168.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 91.96 -22.74 29.95 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.897 -1.127 . . . . 0.0 113.899 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.53 121.75 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 125.633 1.573 . . . . 0.0 110.666 -167.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.9 p -71.23 131.62 43.77 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.746 -1.221 . . . . 0.0 112.433 178.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.9 mt -84.23 64.65 8.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.089 -1.632 . . . . 0.0 112.083 -175.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -89.34 116.3 27.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.466 -1.396 . . . . 0.0 112.723 -173.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.83 17.79 79.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.004 -1.06 . . . . 0.0 113.256 179.579 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.97 143.21 50.92 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -168.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 70.6 p -93.71 179.69 5.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.248 1.819 . . . . 0.0 110.597 173.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 28.8 t60 -68.35 -42.7 78.86 Favored 'General case' 0 N--CA 1.428 -1.53 0 O-C-N 119.775 -1.828 . . . . 0.0 110.001 173.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.2 tppm? -53.64 -46.34 70.5 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 125.389 1.476 . . . . 0.0 113.781 172.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -55.65 -51.28 67.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.208 1.403 . . . . 0.0 113.674 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.926 1.691 . . . . 0.0 113.686 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.7 t -66.35 -49.09 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 O-C-N 120.835 -1.165 . . . . 0.0 110.676 178.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.2 mm-40 -64.04 -31.22 72.33 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.669 -1.269 . . . . 0.0 114.03 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.3 m -69.47 -44.3 71.47 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.486 1.514 . . . . 0.0 112.234 175.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 82.6 mt -69.51 -32.31 71.08 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 172.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.61 -46.34 79.69 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.245 -1.534 . . . . 0.0 112.426 176.625 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.7 t30 -86.06 45.68 1.25 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.83 1.252 . . . . 0.0 112.648 -178.454 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.0 p -101.6 171.71 7.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.303 1.841 . . . . 0.0 108.658 172.868 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -125.38 -119.35 2.35 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.594 -1.316 . . . . 0.0 110.737 172.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -70.84 -70.25 0.32 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 124.288 1.035 . . . . 0.0 113.7 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 40.1 t -100.66 129.45 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 CA-C-O 123.136 1.446 . . . . 0.0 111.223 -175.2 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 96.9 t -122.6 104.61 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 128.466 2.706 . . . . 0.0 108.944 -174.276 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.0 t-160 -88.56 107.37 18.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.624 -1.923 . . . . 0.0 110.802 176.375 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.7 mt -94.04 144.23 25.66 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.775 -1.203 . . . . 0.0 111.242 169.238 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 31.6 tp -119.65 124.91 47.44 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 164.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.422 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.0 pp -150.58 168.29 24.7 Favored 'General case' 0 N--CA 1.429 -1.501 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -176.325 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -113.52 129.4 56.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.137 1.775 . . . . 0.0 111.041 -175.089 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? -78.41 137.14 37.84 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.455 1.502 . . . . 0.0 112.691 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -77.41 76.8 1.64 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 121.108 -0.995 . . . . 0.0 113.265 172.538 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -74.29 -15.98 60.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.59 170.08 17.07 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.652 1.981 . . . . 0.0 111.3 -174.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo . . . . . 0 N--CA 1.434 -2.012 0 CA-C-N 122.517 1.934 . . . . 0.0 116.869 -179.7 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 18.1 tptm . . . . . 0 N--CA 1.43 -1.428 0 CA-C-O 116.55 -1.691 . . . . 0.0 111.529 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -72.31 178.75 5.72 Favored 'Trans proline' 0 N--CA 1.433 -2.031 0 CA-C-N 126.337 3.299 . . . . 0.0 113.058 165.244 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 92.44 18.76 40.69 Favored Glycine 0 N--CA 1.43 -1.715 0 N-CA-C 115.563 0.985 . . . . 0.0 115.563 -179.362 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -94.8 151.8 18.94 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.085 1.354 . . . . 0.0 110.952 -179.537 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 2.1 p -93.07 156.43 16.88 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.748 1.619 . . . . 0.0 113.433 -177.634 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -147.48 134.23 20.02 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 173.361 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -90.98 137.26 32.5 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 162.46 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.7 t -124.6 93.47 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.9 -1.125 . . . . 0.0 109.011 -175.226 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.47 85.43 5.75 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.544 1.537 . . . . 0.0 110.906 173.286 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.292 1.7 pp -117.88 156.6 28.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 122.668 1.223 . . . . 0.0 112.554 -176.859 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.85 133.43 46.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.074 1.75 . . . . 0.0 112.074 -177.188 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -70.6 134.41 47.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.679 1.592 . . . . 0.0 115.228 -178.993 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.3 p -107.21 118.45 36.74 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.525 -1.359 . . . . 0.0 111.592 -178.086 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.3 t70 47.83 43.96 17.66 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.329 2.252 . . . . 0.0 115.678 175.777 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.41 -5.05 85.71 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.447 -1.408 . . . . 0.0 114.956 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 80.6 p -121.59 137.68 54.63 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.176 1.488 . . . . 0.0 114.072 -172.713 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.404 HD21 HG21 ' A' ' 92' ' ' VAL . 89.8 mt -90.61 -61.84 1.59 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.804 -1.185 . . . . 0.0 110.219 167.298 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.82 36.05 1.2 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.625 -1.922 . . . . 0.0 113.189 169.836 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -123.79 124.17 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.031 1.333 . . . . 0.0 109.986 -176.208 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.0 t -101.73 112.49 25.1 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.817 -1.177 . . . . 0.0 107.867 170.349 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.0 m -104.19 161.79 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.934 1.293 . . . . 0.0 111.664 -178.773 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -149.72 174.11 12.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.677 -1.264 . . . . 0.0 109.767 -175.172 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.42 -131.87 10.66 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 124.355 0.979 . . . . 0.0 113.519 168.334 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.83 176.89 51.04 Favored Glycine 0 N--CA 1.43 -1.758 0 N-CA-C 115.787 1.075 . . . . 0.0 115.787 174.659 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m -73.07 -6.53 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 117.356 2.354 . . . . 0.0 117.356 -170.127 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -86.05 -11.15 53.59 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.563 -1.961 . . . . 0.0 110.197 171.087 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.1 m -105.97 151.93 23.98 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.708 1.603 . . . . 0.0 106.776 -177.286 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 29.5 m -81.22 32.33 0.33 Allowed 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 118.533 -2.605 . . . . 0.0 114.587 -177.395 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.7 p -99.79 84.47 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.2 -1.562 . . . . 0.0 113.738 -165.984 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 47.9 70.21 0.45 Allowed 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.062 2.145 . . . . 0.0 114.229 176.748 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.3 m-70 69.33 -66.37 0.26 Allowed 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 127.281 2.233 . . . . 0.0 112.686 -164.682 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.18 66.96 0.04 OUTLIER Glycine 0 N--CA 1.429 -1.803 0 O-C-N 121.589 -0.694 . . . . 0.0 111.587 175.153 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -82.69 144.95 23.42 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.304 -1.115 . . . . 0.0 113.354 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 35.4 mm -93.71 123.44 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.498 -1.001 . . . . 0.0 109.16 174.501 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -123.33 154.25 39.17 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.889 -1.132 . . . . 0.0 110.215 -175.315 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.0 t -76.72 129.87 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.765 -1.21 . . . . 0.0 111.562 168.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -100.32 -50.11 4.04 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.374 1.47 . . . . 0.0 111.449 176.925 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.24 161.05 43.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.686 -1.259 . . . . 0.0 111.401 -175.793 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -115.76 125.78 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.431 1.092 . . . . 0.0 110.01 179.766 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.3 mm -77.13 115.99 53.57 Favored Pre-proline 0 N--CA 1.43 -1.455 0 C-N-CA 125.748 1.619 . . . . 0.0 112.816 -177.389 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -64.91 136.37 48.47 Favored 'Trans proline' 0 C--N 1.3 -1.988 0 CA-C-N 124.074 2.491 . . . . 0.0 113.044 -175.95 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.251 45.4 mtmt 83.94 7.0 0.63 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.852 2.861 . . . . 0.0 114.42 -175.318 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 160.22 35.93 Favored Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.97 -1.706 . . . . 0.0 114.983 176.142 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.34 -56.65 8.84 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.009 2.123 . . . . 0.0 115.994 169.542 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -45.98 83.66 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 128.231 2.612 . . . . 0.0 111.697 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.409 ' HA ' HG12 ' A' ' 47' ' ' ILE . 7.1 tm-20 -47.62 -64.61 0.74 Allowed 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.968 1.84 . . . . 0.0 115.968 169.492 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.0 m -70.13 -21.45 63.09 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 115.448 1.647 . . . . 0.0 115.448 -173.01 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.0 -65.8 0.56 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.295 1.438 . . . . 0.0 112.361 173.189 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.58 0.04 42.96 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 114.847 170.557 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -66.32 -51.73 54.32 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 118.766 1.283 . . . . 0.0 110.32 162.294 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.51 HD11 HD12 ' A' ' 94' ' ' LEU . 51.7 mt -78.26 134.96 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 124.902 1.281 . . . . 0.0 111.053 179.322 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.6 t-80 -147.59 156.78 43.15 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 122.063 0.935 . . . . 0.0 109.46 -178.78 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -65.61 126.02 27.05 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 119.501 -2.0 . . . . 0.0 114.37 -174.23 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.03 -4.86 35.98 Favored Glycine 0 N--CA 1.43 -1.758 0 CA-C-O 118.244 -1.309 . . . . 0.0 115.665 -173.229 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.363 3.1 p30 -81.58 163.41 22.63 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 121.207 2.503 . . . . 0.0 114.565 178.464 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.4 tpt85 -112.21 121.92 46.29 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.343 -1.473 . . . . 0.0 111.018 -167.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.6 t -87.94 136.24 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.105 -1.622 . . . . 0.0 110.277 -173.434 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 9.6 mp -102.3 -53.03 3.0 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 124.583 1.153 . . . . 0.0 110.494 175.776 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.93 147.43 27.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.825 -1.172 . . . . 0.0 112.209 -168.865 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.28 116.14 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 176.594 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 61.63 37.35 16.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.572 1.949 . . . . 0.0 115.073 167.723 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.18 59.62 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.522 1.058 . . . . 0.0 113.906 -175.765 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.6 t -95.44 112.62 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-N 118.546 1.173 . . . . 0.0 111.029 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.1 m -70.13 121.76 18.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.98 -1.075 . . . . 0.0 110.083 171.091 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.0 mt -72.85 -34.16 66.58 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -169.069 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -8.85 93.53 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 121.114 3.746 . . . . 0.0 121.114 -173.704 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.48 20.87 12.3 Favored Glycine 0 N--CA 1.43 -1.763 0 C-N-CA 125.134 1.35 . . . . 0.0 111.608 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.33 164.45 26.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 175.018 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -92.74 170.32 9.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.358 -1.464 . . . . 0.0 111.121 161.776 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -51.36 -56.7 11.71 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.293 1.837 . . . . 0.0 113.146 169.905 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -56.67 -36.19 69.3 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 174.231 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.7 mm-40 -55.59 -48.39 74.91 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 121.102 1.774 . . . . 0.0 113.79 175.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.95 -42.37 94.67 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.195 0.998 . . . . 0.0 113.26 177.889 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.4 t -65.43 -45.68 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 124.603 1.161 . . . . 0.0 111.266 178.489 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -62.38 -40.23 95.78 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.724 -1.235 . . . . 0.0 112.83 177.712 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.0 m -65.79 -42.27 90.95 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.435 2.294 . . . . 0.0 113.295 175.575 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.12 -36.85 84.26 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.303 1.441 . . . . 0.0 113.299 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -68.76 -30.14 68.68 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.245 -1.534 . . . . 0.0 113.133 172.032 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -84.81 45.96 1.21 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.02 1.728 . . . . 0.0 112.777 175.495 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 p -105.55 163.58 12.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 126.696 1.998 . . . . 0.0 110.214 177.793 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.92 -144.2 15.73 Favored Glycine 0 N--CA 1.43 -1.732 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 168.411 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -70.95 -60.71 2.09 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 121.191 -1.181 . . . . 0.0 113.666 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 29.5 t -98.42 119.85 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.948 1.356 . . . . 0.0 109.293 -175.345 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.404 HG21 HD21 ' A' ' 25' ' ' LEU . 88.1 t -112.78 114.87 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 C-N-CA 126.305 1.842 . . . . 0.0 109.306 -165.79 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -97.69 99.03 10.38 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.961 -1.087 . . . . 0.0 110.617 -177.932 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.51 HD12 HD11 ' A' ' 59' ' ' ILE . 21.0 mt -92.93 160.24 14.98 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 119.797 -1.814 . . . . 0.0 112.711 173.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.46 131.99 48.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.417 1.087 . . . . 0.0 108.09 165.814 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -147.86 172.98 13.3 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.395 -1.44 . . . . 0.0 112.415 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -127.49 148.63 50.31 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.162 1.785 . . . . 0.0 109.258 174.938 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -76.0 137.89 40.56 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 120.34 -1.475 . . . . 0.0 111.312 175.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.88 -158.93 34.96 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 121.316 -0.865 . . . . 0.0 111.392 173.069 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -73.75 177.82 5.22 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.849 -1.383 . . . . 0.0 113.714 -178.15 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -120.58 127.34 26.33 Favored Pre-proline 0 N--CA 1.43 -1.426 0 O-C-N 120.703 -1.248 . . . . 0.0 110.492 -171.178 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo . . . . . 0 N--CA 1.434 -2.013 0 CA-C-N 122.467 1.917 . . . . 0.0 112.657 169.218 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.0 pttm . . . . . 0 N--CA 1.43 -1.429 0 CA-C-O 119.531 -0.271 . . . . 0.0 111.597 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -78.18 177.4 8.82 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 121.84 1.693 . . . . 0.0 112.101 172.09 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.32 23.55 28.89 Favored Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 125.048 1.309 . . . . 0.0 112.351 -178.689 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -96.58 133.07 41.53 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.036 1.334 . . . . 0.0 109.206 -172.306 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.8 p -106.07 154.41 20.68 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 124.725 1.21 . . . . 0.0 112.184 178.414 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.46 143.9 29.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.694 -1.254 . . . . 0.0 108.567 -177.944 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -99.43 105.35 17.29 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.2 1.0 . . . . 0.0 109.636 -179.186 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.72 99.54 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.3 1.44 . . . . 0.0 109.457 -169.809 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -90.09 95.76 10.36 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.379 -1.451 . . . . 0.0 107.749 173.721 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -111.02 130.04 55.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.171 0.988 . . . . 0.0 110.467 -169.862 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.89 141.25 35.04 Favored 'General case' 0 CA--C 1.489 -1.372 0 O-C-N 120.471 -1.393 . . . . 0.0 109.727 172.937 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -64.42 147.22 53.13 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 178.699 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 31.3 p -116.15 122.87 46.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 167.624 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.2 t0 43.3 46.22 5.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 128.577 2.751 . . . . 0.0 114.422 -176.726 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.14 11.58 75.18 Favored Glycine 0 N--CA 1.431 -1.65 0 N-CA-C 117.891 1.917 . . . . 0.0 117.891 -178.357 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.0 m -117.32 153.67 32.58 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 119.473 1.637 . . . . 0.0 111.898 178.438 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 72.2 mt -96.11 -60.56 1.6 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.435 1.094 . . . . 0.0 108.9 165.429 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 119.14 37.58 0.8 Allowed Glycine 0 N--CA 1.43 -1.765 0 O-C-N 119.829 -1.794 . . . . 0.0 113.142 174.639 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 pt -129.5 139.17 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.173 1.389 . . . . 0.0 108.742 -175.493 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.5 m -111.79 117.7 33.56 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 157.668 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.5 m -99.05 162.59 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 124.351 1.061 . . . . 0.0 112.017 -174.631 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -150.11 -177.72 6.09 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.842 1.257 . . . . 0.0 110.001 178.168 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.53 -149.55 19.27 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.985 -1.072 . . . . 0.0 113.745 174.752 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.43 168.03 30.07 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 124.513 1.054 . . . . 0.0 112.924 -177.449 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -69.15 -17.89 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -172.218 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -82.59 -26.69 32.08 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.4 -1.438 . . . . 0.0 112.672 -171.479 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.4 p -103.46 165.57 10.95 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 120.339 -1.476 . . . . 0.0 112.054 -174.699 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.9 m -82.45 61.67 5.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.973 -1.704 . . . . 0.0 113.337 -174.878 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.6 m -100.64 -4.6 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.458 -1.401 . . . . 0.0 112.223 176.331 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.343 78.4 mtt180 72.41 117.28 0.05 OUTLIER 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.341 2.656 . . . . 0.0 114.674 -169.008 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.284 87.9 m-70 68.75 -61.29 0.42 Allowed 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 127.435 2.294 . . . . 0.0 115.314 -174.095 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.19 52.39 0.16 Allowed Glycine 0 N--CA 1.43 -1.716 0 N-CA-C 116.615 1.406 . . . . 0.0 116.615 170.623 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -75.15 156.19 48.55 Favored Glycine 0 N--CA 1.429 -1.769 0 CA-C-N 118.872 1.336 . . . . 0.0 113.429 170.8 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -96.93 121.88 47.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 175.591 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -126.71 154.26 44.36 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.854 -1.154 . . . . 0.0 110.522 -168.426 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.8 t -75.88 125.57 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.603 -1.31 . . . . 0.0 110.757 169.223 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.1 tttm -91.88 -44.92 8.65 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.738 -1.226 . . . . 0.0 110.671 178.662 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.44 148.11 29.93 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 123.129 0.572 . . . . 0.0 110.694 178.432 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -102.89 121.36 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.612 1.196 . . . . 0.0 110.121 173.962 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.4 mm -77.1 120.27 80.92 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 125.893 1.677 . . . . 0.0 114.219 -171.902 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -59.72 126.35 20.3 Favored 'Trans proline' 0 C--N 1.3 -2.013 0 CA-C-N 124.451 2.625 . . . . 0.0 115.325 -177.587 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.265 7.3 mtpm? 78.29 28.02 0.5 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.454 2.302 . . . . 0.0 112.598 -178.04 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.14 159.72 34.26 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.531 -1.356 . . . . 0.0 113.646 162.472 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.06 -60.83 2.45 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.054 2.142 . . . . 0.0 114.847 164.464 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.16 -49.19 78.63 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.191 2.996 . . . . 0.0 111.96 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -46.76 -61.58 1.78 Allowed 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 115.55 1.685 . . . . 0.0 115.55 171.089 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.8 m -68.27 -32.97 73.51 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 -173.594 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -51.01 -66.96 0.29 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.093 1.757 . . . . 0.0 113.323 176.368 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.25 -17.59 10.48 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 115.051 0.78 . . . . 0.0 115.051 174.601 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 56.9 mtt85 -71.27 -33.62 69.94 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 120.081 1.941 . . . . 0.0 112.491 170.981 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.8 mt -95.12 113.5 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.228 1.011 . . . . 0.0 109.628 176.929 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.657 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 79.9 t60 -143.65 -174.04 4.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.165 -1.584 . . . . 0.0 110.508 174.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.657 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.3 ttpt -60.15 127.65 32.89 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.32 1.848 . . . . 0.0 113.853 -174.753 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.95 -6.35 83.75 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 120.659 -1.275 . . . . 0.0 114.793 178.792 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -81.65 149.27 28.62 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.638 1.719 . . . . 0.0 112.893 -173.685 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -92.29 141.01 29.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.907 -1.745 . . . . 0.0 112.049 -170.711 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.38 119.11 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.63 1.172 . . . . 0.0 108.322 176.491 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.54 -52.46 2.99 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.355 -1.466 . . . . 0.0 111.072 -166.078 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.47 117.18 5.82 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 109.006 175.95 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.6 t -90.91 115.18 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.718 -173.134 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.0 t30 64.13 32.39 12.69 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.139 1.376 . . . . 0.0 111.853 174.909 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.42 -23.94 33.67 Favored Glycine 0 N--CA 1.429 -1.804 0 C-N-CA 124.764 1.173 . . . . 0.0 114.663 -173.495 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.5 t -87.03 111.9 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.689 -1.477 . . . . 0.0 111.698 -167.817 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.4 m -61.63 120.55 10.81 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.729 -1.232 . . . . 0.0 114.118 -179.013 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 38.9 mt -87.57 42.9 1.07 Allowed 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 112.371 -178.203 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -85.29 110.49 19.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 119.193 -2.192 . . . . 0.0 112.169 -174.335 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.3 -0.6 71.89 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 124.782 1.182 . . . . 0.0 114.228 179.412 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.03 155.09 41.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.3 1.963 . . . . 0.0 116.3 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.3 p -81.04 175.36 10.75 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.147 1.379 . . . . 0.0 112.428 174.253 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -67.28 -39.89 86.08 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.401 -1.437 . . . . 0.0 111.712 174.105 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -57.3 -48.53 78.69 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 113.607 174.953 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -56.46 -46.35 80.42 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.225 1.41 . . . . 0.0 114.503 179.044 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.08 -39.4 94.61 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.862 1.665 . . . . 0.0 114.364 175.577 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.5 t -76.19 -45.24 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.052 1.341 . . . . 0.0 111.388 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -58.99 -33.03 70.22 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 127.691 2.396 . . . . 0.0 112.19 175.761 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.6 m -72.53 -49.32 33.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.334 1.854 . . . . 0.0 113.752 170.662 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.8 mt -58.43 -45.36 88.62 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 120.641 1.564 . . . . 0.0 115.149 176.938 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 37.5 ptt85 -66.57 -28.23 68.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.831 -1.168 . . . . 0.0 113.798 -177.906 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -93.18 32.94 1.24 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.8 1.24 . . . . 0.0 113.616 -179.369 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 22.4 p -92.02 148.48 22.15 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.981 1.712 . . . . 0.0 111.384 174.142 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.25 -143.56 9.03 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.819 -1.176 . . . . 0.0 112.59 174.516 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -68.61 -59.79 2.88 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 114.871 1.434 . . . . 0.0 114.871 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.9 p -98.39 134.77 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.384 0 CA-C-O 122.919 1.342 . . . . 0.0 110.648 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.1 t -124.08 115.95 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 C-N-CA 127.525 2.33 . . . . 0.0 107.993 -171.414 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 7.3 m-70 -97.19 89.09 4.65 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.366 -1.459 . . . . 0.0 112.229 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.6 tp -93.46 130.09 39.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.376 -2.077 . . . . 0.0 110.935 -178.134 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.3 tp -87.75 126.09 34.79 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 161.474 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 6.5 tt -122.32 148.54 44.92 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.543 1.137 . . . . 0.0 109.084 -170.106 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -125.3 142.79 51.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 171.608 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -77.25 160.36 28.96 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.517 -1.365 . . . . 0.0 111.916 -177.29 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.92 -147.17 8.66 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 120.382 -1.449 . . . . 0.0 112.937 168.119 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -72.68 177.76 4.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.924 -1.927 . . . . 0.0 113.428 178.477 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 45.4 t -90.59 122.45 67.09 Favored Pre-proline 0 N--CA 1.43 -1.47 0 O-C-N 119.926 -1.734 . . . . 0.0 109.431 178.61 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo . . . . . 0 C--N 1.3 -1.974 0 CA-C-N 123.481 2.279 . . . . 0.0 111.748 173.321 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 55.4 tptt . . . . . 0 N--CA 1.43 -1.432 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -88.94 179.25 2.47 Favored 'Trans proline' 0 N--CA 1.434 -2.025 0 C-N-CA 122.184 1.923 . . . . 0.0 113.063 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.94 41.74 2.58 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.502 1.049 . . . . 0.0 113.105 167.353 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -82.23 143.31 31.45 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 121.595 -0.944 . . . . 0.0 110.107 174.436 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -98.52 155.85 17.07 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.575 -1.328 . . . . 0.0 111.638 176.599 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 133.6 21.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 122.231 1.015 . . . . 0.0 108.839 177.329 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -87.49 133.55 33.74 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.326 1.45 . . . . 0.0 109.347 169.97 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.4 t -126.3 107.15 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.853 1.261 . . . . 0.0 108.4 -169.438 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -91.38 102.05 14.73 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 120.383 -1.448 . . . . 0.0 108.393 166.376 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.2 tp -113.32 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.945 0.878 . . . . 0.0 110.509 -171.608 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 139.85 36.99 Favored 'General case' 0 N--CA 1.428 -1.527 0 O-C-N 120.223 -1.548 . . . . 0.0 107.549 170.203 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -65.23 152.75 42.9 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 115.131 1.53 . . . . 0.0 115.131 -178.487 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 30.5 p -102.48 75.57 1.47 Allowed 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.19 -1.569 . . . . 0.0 108.542 175.313 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.3 t0 61.26 61.53 1.53 Allowed 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.126 1.77 . . . . 0.0 112.321 -177.055 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.41 -30.0 5.45 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.249 -1.532 . . . . 0.0 115.191 -175.291 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.7 m -92.27 136.14 33.43 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.256 -1.732 . . . . 0.0 112.802 -167.112 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.551 HD21 HG21 ' A' ' 92' ' ' VAL . 51.9 mt -102.0 -49.17 4.02 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.627 1.571 . . . . 0.0 110.539 177.413 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 -15.87 39.3 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 120.228 -1.545 . . . . 0.0 113.967 -179.087 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.8 pt -96.39 121.83 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 CA-C-N 119.355 1.578 . . . . 0.0 112.959 -176.579 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.3 m -114.06 137.77 51.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 166.228 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.5 m -124.85 165.3 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.307 1.043 . . . . 0.0 112.946 -165.619 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.7 t -144.91 177.89 8.42 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.572 1.549 . . . . 0.0 110.567 -179.346 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.16 -136.68 12.82 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 115.945 1.138 . . . . 0.0 115.945 166.894 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.48 176.21 35.58 Favored Glycine 0 N--CA 1.43 -1.715 0 C-N-CA 126.351 1.929 . . . . 0.0 113.85 -179.025 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -77.43 25.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 O-C-N 120.437 -1.625 . . . . 0.0 113.481 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.88 -29.39 12.98 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.577 -1.952 . . . . 0.0 110.119 175.584 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 44.4 p -115.58 171.31 7.81 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 125.365 1.466 . . . . 0.0 108.568 -174.091 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 m -92.47 50.78 1.65 Allowed 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.136 -1.603 . . . . 0.0 111.531 176.352 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.94 153.05 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.958 1.303 . . . . 0.0 110.955 -177.472 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.5 mmt180 -62.08 121.72 13.74 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.756 -1.215 . . . . 0.0 112.913 179.49 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 72.16 -9.53 1.0 Allowed 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.894 2.478 . . . . 0.0 117.191 -176.443 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.7 61.75 4.79 Favored Glycine 0 N--CA 1.43 -1.719 0 O-C-N 119.804 -1.81 . . . . 0.0 114.685 179.439 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -143.52 172.17 24.96 Favored Glycine 0 N--CA 1.43 -1.746 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -177.406 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 mm -93.74 122.06 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 124.823 1.249 . . . . 0.0 108.367 -175.498 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -121.36 152.58 38.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.79 -1.194 . . . . 0.0 109.6 -175.096 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.9 129.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 O-C-N 120.455 -1.403 . . . . 0.0 111.739 174.211 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -96.21 -46.32 6.49 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 126.031 1.733 . . . . 0.0 111.761 -176.507 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.3 152.8 32.58 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.89 -1.131 . . . . 0.0 109.673 -176.846 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.27 1.0 OUTLIER -112.61 116.02 51.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 CA-C-O 122.72 1.247 . . . . 0.0 109.457 170.885 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.5 mm -76.43 127.59 84.26 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 116.218 -1.849 . . . . 0.0 114.161 -173.789 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -58.08 132.54 49.97 Favored 'Trans proline' 0 N--CA 1.433 -2.052 0 CA-C-N 124.474 2.634 . . . . 0.0 116.725 -179.035 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.278 53.8 mttp 72.15 18.97 4.66 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.35 2.26 . . . . 0.0 114.551 -174.087 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.84 157.17 45.07 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 119.394 -2.067 . . . . 0.0 112.227 170.863 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.36 -59.91 3.3 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.573 -1.545 . . . . 0.0 114.679 169.143 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.94 93.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.915 2.486 . . . . 0.0 112.263 -179.717 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -45.0 -61.75 1.5 Allowed 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.111 1.764 . . . . 0.0 114.15 173.001 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.5 t -67.75 -43.18 80.51 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -175.419 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.58 -58.08 6.65 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 127.202 2.201 . . . . 0.0 114.081 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.58 31.6 7.38 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.299 -1.5 . . . . 0.0 115.037 163.146 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 53.4 mtt180 -96.98 -29.98 13.35 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 125.291 1.436 . . . . 0.0 109.151 162.786 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.7 mt -108.54 130.01 62.0 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 125.361 1.464 . . . . 0.0 111.076 -179.486 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -141.58 170.55 15.5 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.894 -1.129 . . . . 0.0 109.579 172.842 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.8 pttm -66.59 140.96 57.98 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 118.604 -2.56 . . . . 0.0 113.74 178.119 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.5 -11.21 65.05 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.602 -0.686 . . . . 0.0 113.163 -171.535 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -79.71 154.37 28.62 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 119.162 1.481 . . . . 0.0 112.27 -177.316 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -97.73 123.75 41.79 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.241 1.416 . . . . 0.0 109.698 -174.895 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.8 t -88.11 130.63 37.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 O-C-N 120.053 -1.655 . . . . 0.0 110.17 -178.398 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -99.06 -52.29 3.59 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.079 -1.013 . . . . 0.0 111.001 -178.036 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.96 144.28 24.83 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.13 -0.981 . . . . 0.0 112.862 -172.828 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.3 t -113.51 111.72 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 66.44 35.78 5.46 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.433 1.893 . . . . 0.0 113.353 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.93 60.01 Favored Glycine 0 N--CA 1.431 -1.659 0 O-C-N 119.931 -1.73 . . . . 0.0 114.238 -175.03 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.35 104.42 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 125.308 1.443 . . . . 0.0 108.508 178.907 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.2 m -72.45 139.87 47.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.628 -1.295 . . . . 0.0 112.552 -175.29 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 98.9 mt -90.24 -2.4 58.03 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -169.297 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -67.81 105.2 1.88 Allowed 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.219 -1.551 . . . . 0.0 113.927 -176.068 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 115.1 -20.99 13.72 Favored Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 125.454 1.502 . . . . 0.0 112.969 -174.698 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.04 153.92 40.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 179.237 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 80.4 p -92.16 176.93 6.31 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.558 -1.339 . . . . 0.0 112.843 -179.914 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.9 t-80 -56.21 -53.01 62.25 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.162 1.785 . . . . 0.0 112.359 172.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -55.45 -46.97 76.74 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.622 1.169 . . . . 0.0 113.548 177.55 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.87 -51.59 68.98 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.896 1.443 . . . . 0.0 114.896 177.772 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.22 -36.69 84.95 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.448 -1.408 . . . . 0.0 114.563 176.759 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 95.6 t -72.82 -40.62 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.383 -1.448 . . . . 0.0 111.618 178.186 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -57.63 -44.98 85.96 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.258 -1.526 . . . . 0.0 111.879 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 63.7 m -61.64 -46.71 88.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.718 2.007 . . . . 0.0 114.643 178.157 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . 0.258 0.1 OUTLIER -73.15 -30.85 63.88 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 121.723 2.056 . . . . 0.0 113.893 -178.673 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.36 -39.48 92.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.795 -1.19 . . . . 0.0 111.437 169.729 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -88.94 55.68 3.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 123.02 1.39 . . . . 0.0 111.233 177.825 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.466 ' HB ' HG22 ' A' ' 92' ' ' VAL . 17.4 p -106.32 156.95 17.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.615 1.566 . . . . 0.0 109.624 174.184 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.15 -162.63 32.96 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 121.374 -0.828 . . . . 0.0 111.987 176.294 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -70.79 -48.96 51.49 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.213 1.405 . . . . 0.0 111.551 175.335 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.4 134.03 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.512 1.149 . . . . 0.0 108.044 167.515 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.551 HG21 HD21 ' A' ' 25' ' ' LEU . 82.8 t -124.4 134.95 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 128.562 2.745 . . . . 0.0 107.778 -170.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 23.2 t-160 -122.73 95.23 4.54 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.856 -1.778 . . . . 0.0 110.497 -173.009 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.6 mt -99.58 157.3 16.55 Favored 'General case' 0 N--CA 1.429 -1.517 0 O-C-N 120.02 -1.675 . . . . 0.0 114.023 -177.122 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.4 tp -127.2 131.64 50.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 162.335 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.14 163.48 32.75 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.889 -1.132 . . . . 0.0 111.165 176.251 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -117.17 144.73 44.43 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.535 1.934 . . . . 0.0 108.181 176.918 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.4 tptt -76.16 137.97 40.4 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.623 -1.298 . . . . 0.0 112.407 -177.201 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.78 123.13 25.45 Favored Glycine 0 N--CA 1.429 -1.811 0 C-N-CA 126.406 1.955 . . . . 0.0 116.209 -175.953 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -82.13 179.56 7.76 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -172.782 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.3 m -98.29 178.61 1.27 Allowed Pre-proline 0 N--CA 1.43 -1.442 0 C-N-CA 126.315 1.846 . . . . 0.0 110.739 -175.699 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 N--CA 1.434 -2.008 0 C-N-CA 122.042 1.828 . . . . 0.0 115.562 168.182 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 79.1 mttt . . . . . 0 N--CA 1.43 -1.468 0 CA-C-O 116.45 -1.738 . . . . 0.0 112.895 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -66.14 -174.22 0.39 Allowed 'Trans proline' 0 N--CA 1.433 -2.041 0 CA-C-N 125.31 2.932 . . . . 0.0 114.71 164.465 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.61 28.68 15.66 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 120.464 -1.398 . . . . 0.0 114.826 176.986 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -90.66 172.84 8.38 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 164.923 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 36.3 p -120.7 165.08 15.59 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.069 -1.644 . . . . 0.0 111.76 -178.725 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.51 144.36 28.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 121.889 0.852 . . . . 0.0 109.677 165.018 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.97 130.2 35.5 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 125.643 1.577 . . . . 0.0 109.835 168.929 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.2 t -118.49 113.12 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 124.819 1.248 . . . . 0.0 108.461 -177.283 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -94.94 108.46 20.52 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 165.934 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 21.7 tp -123.65 128.69 50.03 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.693 1.235 . . . . 0.0 110.394 -176.162 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.99 137.45 39.34 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.757 -1.839 . . . . 0.0 109.569 169.326 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -69.41 136.17 51.26 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.122 -0.986 . . . . 0.0 113.101 177.006 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.9 p -90.02 93.1 9.26 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.41 -1.431 . . . . 0.0 111.448 -171.975 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.7 t70 56.29 41.92 28.53 Favored 'General case' 0 N--CA 1.429 -1.523 0 C-N-CA 125.812 1.645 . . . . 0.0 113.26 178.023 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.03 -20.43 40.81 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.766 1.174 . . . . 0.0 115.372 -174.707 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -94.11 110.68 22.38 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.254 1.527 . . . . 0.0 114.163 -170.535 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.5 tt -125.53 64.79 1.17 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 169.856 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -82.16 74.99 2.4 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 126.754 2.121 . . . . 0.0 111.259 -164.72 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.2 pt -100.65 156.49 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 125.332 1.453 . . . . 0.0 111.149 169.774 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 46.7 t -129.05 127.6 41.89 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.138 -1.601 . . . . 0.0 107.318 158.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 m -120.49 168.2 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 124.676 1.19 . . . . 0.0 110.141 -178.525 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -149.97 -175.31 5.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.614 -1.304 . . . . 0.0 107.566 176.031 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.89 -168.7 12.62 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.888 -1.132 . . . . 0.0 114.631 168.608 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.1 161.76 18.65 Favored Glycine 0 N--CA 1.431 -1.652 0 CA-C-O 122.901 1.278 . . . . 0.0 115.039 173.076 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t -59.96 -34.66 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 127.405 2.282 . . . . 0.0 115.646 -178.151 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -78.05 -27.99 48.83 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 119.707 -1.87 . . . . 0.0 112.471 -175.569 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.3 p -99.26 156.11 17.15 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.042 1.337 . . . . 0.0 111.175 -172.296 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 16.1 m -82.27 49.63 1.46 Allowed 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.991 -1.693 . . . . 0.0 114.089 -169.754 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.2 m -93.31 10.64 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 O-C-N 119.591 -1.943 . . . . 0.0 114.309 -168.524 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.261 25.9 ttt-85 87.59 73.46 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 127.761 2.424 . . . . 0.0 111.146 -177.237 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.9 t60 90.22 -62.62 0.02 OUTLIER 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 129.474 3.11 . . . . 0.0 112.519 -176.818 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 158.87 -160.59 31.25 Favored Glycine 0 N--CA 1.431 -1.691 0 N-CA-C 106.117 -2.793 . . . . 0.0 106.117 -166.053 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.11 146.15 14.69 Favored Glycine 0 N--CA 1.43 -1.701 0 C-N-CA 125.428 1.489 . . . . 0.0 111.114 -169.298 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.9 mm -99.47 126.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 177.339 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -127.11 152.63 47.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 119.657 1.117 . . . . 0.0 111.3 -170.322 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.42 126.18 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 O-C-N 120.555 -1.34 . . . . 0.0 112.964 172.674 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 39.6 tttp -97.93 -39.5 8.94 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.191 1.396 . . . . 0.0 111.81 -175.483 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -161.29 154.69 21.55 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.226 -0.921 . . . . 0.0 110.291 173.759 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.23 120.72 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 124.252 1.021 . . . . 0.0 108.436 168.59 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.2 mm -76.62 127.1 85.1 Favored Pre-proline 0 N--CA 1.43 -1.437 0 CA-C-O 116.752 -1.594 . . . . 0.0 113.993 -169.666 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -55.26 119.89 7.28 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 123.737 2.958 . . . . 0.0 115.942 177.3 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.37 5.3 mmmp? 78.92 23.14 0.59 Allowed 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.562 2.745 . . . . 0.0 116.059 -175.155 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.04 164.46 40.66 Favored Glycine 0 N--CA 1.431 -1.673 0 O-C-N 120.544 -1.347 . . . . 0.0 112.14 163.303 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -58.71 4.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.857 1.428 . . . . 0.0 114.857 168.323 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.39 -26.85 68.64 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.376 1.871 . . . . 0.0 114.576 -177.772 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.66 -54.26 45.07 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.688 1.709 . . . . 0.0 113.057 177.156 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 t -65.88 -44.01 86.62 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 125.511 1.524 . . . . 0.0 112.985 -176.167 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -45.01 -55.79 5.23 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.232 2.613 . . . . 0.0 116.272 -172.637 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.49 6.93 35.26 Favored Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 116.965 1.546 . . . . 0.0 116.965 162.29 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -90.17 -49.42 6.57 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.804 -1.41 . . . . 0.0 109.354 167.75 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 87.3 mt -79.31 128.99 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.351 1.46 . . . . 0.0 112.242 -171.647 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -132.94 153.55 51.31 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.876 1.67 . . . . 0.0 111.047 -178.418 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -51.49 123.19 9.28 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.134 1.774 . . . . 0.0 113.763 170.436 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 93.04 0.11 68.61 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 120.868 -1.145 . . . . 0.0 115.906 -178.429 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 1.7 p30 -82.05 159.07 23.54 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 120.119 1.959 . . . . 0.0 113.936 176.006 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -100.32 130.03 46.38 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.592 -1.318 . . . . 0.0 112.788 -177.004 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -85.7 125.37 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.934 1.294 . . . . 0.0 110.014 176.112 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.36 -42.7 6.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.777 -1.202 . . . . 0.0 111.825 -174.464 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 148.9 29.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.716 -1.24 . . . . 0.0 111.647 179.795 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 t -118.73 109.4 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 171.093 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.3 t30 45.13 67.47 0.71 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.297 2.639 . . . . 0.0 116.11 173.847 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 88.48 -29.38 5.75 Favored Glycine 0 N--CA 1.43 -1.725 0 C-N-CA 124.098 0.856 . . . . 0.0 113.555 -179.476 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -94.5 111.27 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 121.084 -1.245 . . . . 0.0 109.109 -171.771 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 73.6 m -69.99 133.49 47.31 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 176.677 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.1 mt -86.5 50.06 1.92 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.847 -1.158 . . . . 0.0 111.064 -178.411 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -89.7 133.23 34.77 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.599 2.36 . . . . 0.0 109.715 178.133 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.67 3.83 22.82 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 117.232 1.653 . . . . 0.0 117.232 -179.543 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.84 148.7 45.94 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 115.645 1.72 . . . . 0.0 115.645 -170.763 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 69.2 p -90.01 174.51 7.62 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.838 -1.164 . . . . 0.0 110.481 165.063 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -52.92 -52.71 56.82 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.172 1.789 . . . . 0.0 113.715 174.758 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -55.64 -40.4 72.14 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 126.074 1.75 . . . . 0.0 114.598 -179.503 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -54.95 -57.23 12.5 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 126.883 2.073 . . . . 0.0 113.146 177.654 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.61 -37.8 83.03 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.57 1.148 . . . . 0.0 113.815 178.794 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.5 t -68.35 -48.18 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.653 -1.279 . . . . 0.0 110.722 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 53.2 mm-40 -66.52 -26.86 67.36 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.249 -1.532 . . . . 0.0 112.855 178.316 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 66.5 m -69.68 -46.19 66.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.814 1.646 . . . . 0.0 113.085 170.887 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 47.7 mt -72.23 -22.35 61.26 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 119.779 -1.826 . . . . 0.0 114.822 176.475 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -68.3 -50.72 51.62 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.137 -1.602 . . . . 0.0 111.057 166.217 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.52 60.01 5.43 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.273 1.429 . . . . 0.0 113.281 -174.071 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 44.0 p -92.23 -175.9 4.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.422 -1.424 . . . . 0.0 110.73 171.541 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.22 -150.95 23.51 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 157.759 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -71.25 -52.57 18.24 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.771 1.228 . . . . 0.0 113.358 174.596 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 17.3 t -104.74 120.48 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 122.338 1.066 . . . . 0.0 110.613 -176.915 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.8 t -109.29 139.6 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 127.623 2.369 . . . . 0.0 109.676 -169.668 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -115.49 112.97 23.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.248 -1.533 . . . . 0.0 109.325 174.178 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -107.03 158.55 16.96 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.279 1.432 . . . . 0.0 113.034 176.612 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 67.2 tp -126.29 130.8 51.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 164.119 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.78 159.23 41.98 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 121.084 -1.01 . . . . 0.0 112.713 174.528 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -101.58 137.16 40.27 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 126.137 1.775 . . . . 0.0 108.443 175.029 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -75.38 113.95 13.37 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.607 -1.308 . . . . 0.0 111.071 -171.746 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.95 137.03 40.99 Favored Glycine 0 N--CA 1.431 -1.649 0 C-N-CA 127.635 2.54 . . . . 0.0 117.539 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 29.2 mt-30 -86.36 -57.43 3.01 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.406 1.482 . . . . 0.0 110.281 -170.701 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.7 m -111.7 132.99 21.64 Favored Pre-proline 0 N--CA 1.43 -1.471 0 C-N-CA 124.287 1.035 . . . . 0.0 109.986 -178.145 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo . . . . . 0 N--CA 1.434 -2.022 0 C-N-CA 122.716 2.277 . . . . 0.0 110.767 167.928 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.433 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -79.02 179.6 6.33 Favored 'Trans proline' 0 C--N 1.299 -2.036 0 C-N-CA 122.317 2.011 . . . . 0.0 112.481 171.748 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.29 42.52 1.74 Allowed Glycine 0 N--CA 1.431 -1.649 0 N-CA-C 116.471 1.348 . . . . 0.0 116.471 168.919 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -89.42 115.6 26.98 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.797 1.239 . . . . 0.0 108.937 169.762 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -92.5 146.23 23.84 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.261 -1.524 . . . . 0.0 109.934 176.967 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 16.8 p90 -146.41 137.36 24.27 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 123.048 1.404 . . . . 0.0 109.192 179.837 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.15 141.25 34.3 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.703 1.601 . . . . 0.0 109.128 -178.795 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.5 t -130.66 113.18 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -171.824 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -107.39 75.16 1.0 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.879 1.324 . . . . 0.0 107.845 173.411 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.7 tp -94.8 135.11 36.68 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.357 1.463 . . . . 0.0 111.864 -168.552 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.49 146.08 28.63 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.269 -1.519 . . . . 0.0 111.796 173.373 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -70.27 157.97 36.74 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 115.192 1.552 . . . . 0.0 115.192 176.494 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.4 t -134.57 125.77 27.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.77 -1.206 . . . . 0.0 108.578 168.758 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 1.2 t70 50.55 40.82 24.43 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.985 2.514 . . . . 0.0 114.25 -170.49 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.1 -9.98 50.8 Favored Glycine 0 N--CA 1.431 -1.688 0 O-C-N 120.224 -1.547 . . . . 0.0 116.302 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.01 144.19 34.01 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.693 -1.475 . . . . 0.0 113.146 -166.849 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.461 HD21 HG21 ' A' ' 92' ' ' VAL . 49.8 mt -99.78 -62.28 1.26 Allowed 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.287 -0.883 . . . . 0.0 110.458 173.8 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.71 47.52 0.73 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 119.574 -1.954 . . . . 0.0 112.923 168.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.6 tt -147.53 137.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.666 1.222 . . . . 0.0 112.016 -178.741 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.7 m -105.42 133.89 49.43 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.928 1.291 . . . . 0.0 108.855 168.162 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.8 m -107.7 170.68 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.39 1.09 . . . . 0.0 110.766 178.806 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -150.41 -172.49 4.19 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.458 -1.401 . . . . 0.0 108.508 174.775 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.98 -144.84 18.56 Favored Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 124.893 1.235 . . . . 0.0 111.309 179.316 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.36 146.44 13.7 Favored Glycine 0 N--CA 1.43 -1.757 0 C-N-CA 124.098 0.856 . . . . 0.0 112.367 177.434 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t -70.02 -31.1 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.929 -1.336 . . . . 0.0 114.126 -170.154 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -91.82 -8.15 47.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.559 -1.338 . . . . 0.0 112.273 -178.666 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 25.3 m -77.86 147.12 35.28 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.328 -1.482 . . . . 0.0 108.585 178.672 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m -83.29 58.91 4.73 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 119.298 -2.126 . . . . 0.0 111.721 178.167 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.5 p -99.67 147.68 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 128.416 2.686 . . . . 0.0 108.377 178.496 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 65.8 mmt-85 -68.76 109.19 3.73 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.511 -1.368 . . . . 0.0 112.131 177.546 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.313 3.1 t60 51.96 104.94 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 129.322 3.049 . . . . 0.0 116.588 -170.28 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.15 92.3 0.03 OUTLIER Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 126.755 2.122 . . . . 0.0 117.541 -169.086 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.42 -176.35 14.5 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 173.595 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.6 mm -101.9 129.0 53.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.832 1.253 . . . . 0.0 109.091 -179.243 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -125.55 156.96 38.24 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.632 -1.293 . . . . 0.0 109.952 -170.823 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -75.31 121.07 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.398 -1.439 . . . . 0.0 111.929 173.203 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -88.33 -59.42 2.24 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.092 -1.63 . . . . 0.0 110.793 179.2 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.58 154.55 34.46 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.633 -0.667 . . . . 0.0 110.187 -172.193 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.429 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.1 tp -111.53 125.88 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 CA-C-O 121.848 0.832 . . . . 0.0 109.541 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 16.5 mm -77.67 125.18 86.21 Favored Pre-proline 0 N--CA 1.429 -1.497 0 C-N-CA 126.259 1.823 . . . . 0.0 113.473 -173.594 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.58 130.32 39.35 Favored 'Trans proline' 0 N--CA 1.434 -1.996 0 CA-C-N 124.356 2.591 . . . . 0.0 116.568 -175.492 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.275 1.8 mptp? 73.59 13.95 4.35 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 127.592 2.357 . . . . 0.0 115.004 178.916 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.12 164.21 52.64 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 119.615 -1.928 . . . . 0.0 113.767 174.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.43 -56.76 10.05 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 126.325 1.85 . . . . 0.0 114.733 168.831 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.28 -46.68 82.6 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 128.673 2.789 . . . . 0.0 112.351 178.522 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HA ' HG12 ' A' ' 47' ' ' ILE . 3.1 tm-20 -47.71 -61.97 1.68 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.996 1.851 . . . . 0.0 115.996 170.696 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 65.4 m -69.0 -26.71 65.15 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -175.654 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -55.61 -68.05 0.23 Allowed 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.942 1.697 . . . . 0.0 111.651 174.349 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.48 30.33 33.63 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.043 -1.036 . . . . 0.0 114.925 171.798 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -78.48 -47.76 16.75 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 120.727 -1.455 . . . . 0.0 108.48 147.84 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.3 111.85 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 C-N-CA 125.956 1.703 . . . . 0.0 112.636 -175.099 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -117.21 160.35 21.21 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 123.922 1.82 . . . . 0.0 113.151 -178.503 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -60.94 129.49 41.68 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.259 1.423 . . . . 0.0 113.949 -174.42 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 87.54 -4.85 85.77 Favored Glycine 0 N--CA 1.431 -1.675 0 CA-C-O 118.91 -0.939 . . . . 0.0 114.06 176.108 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -80.96 162.69 23.76 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 119.508 1.654 . . . . 0.0 112.3 -173.866 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 14.9 ttt180 -106.19 123.97 48.86 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.535 -1.353 . . . . 0.0 111.87 -159.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.1 123.28 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.976 -1.077 . . . . 0.0 110.099 -175.2 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -94.47 -44.05 8.06 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.876 -1.14 . . . . 0.0 110.625 -177.563 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.89 137.93 19.18 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.577 -0.702 . . . . 0.0 112.205 -173.043 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -111.42 126.71 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 174.422 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 71.02 14.81 6.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.267 1.827 . . . . 0.0 111.424 -179.623 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.21 89.62 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 125.956 1.741 . . . . 0.0 114.156 -170.347 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -91.77 124.62 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-N 118.868 1.334 . . . . 0.0 109.568 -179.83 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 25.4 m -72.92 135.02 45.01 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.767 -1.208 . . . . 0.0 112.817 -172.127 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.5 mt -87.34 36.34 0.74 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.684 -1.26 . . . . 0.0 114.364 -174.118 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -72.71 116.91 13.76 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.143 -2.223 . . . . 0.0 113.572 -170.933 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.23 13.09 79.78 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.13 -0.981 . . . . 0.0 114.26 -177.643 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.32 144.33 51.74 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -177.996 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 64.7 p -81.73 173.33 12.41 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.252 -1.53 . . . . 0.0 110.493 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -59.52 -48.14 82.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.874 -1.141 . . . . 0.0 111.648 172.182 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.12 -47.96 77.14 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.119 1.368 . . . . 0.0 114.23 174.145 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -58.86 -47.16 85.88 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.235 1.939 . . . . 0.0 116.235 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.35 -35.43 80.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.723 -1.235 . . . . 0.0 112.215 173.166 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.62 -45.02 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.012 -1.055 . . . . 0.0 111.077 178.951 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -58.65 -40.77 84.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.625 -1.297 . . . . 0.0 113.232 173.545 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.7 m -66.43 -38.81 88.27 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.702 1.601 . . . . 0.0 113.017 178.668 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 38.9 mt -72.61 -31.73 65.39 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.353 -1.467 . . . . 0.0 113.945 172.569 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.1 -42.16 76.49 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.485 -1.385 . . . . 0.0 112.876 173.692 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -79.04 58.17 2.38 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 124.086 1.898 . . . . 0.0 111.415 174.272 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 p -107.7 143.9 35.56 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.898 2.479 . . . . 0.0 108.88 170.951 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.77 -141.85 8.23 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 121.154 -0.966 . . . . 0.0 112.063 172.953 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.5 tt0 -62.44 -57.56 10.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.581 1.552 . . . . 0.0 113.118 174.304 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.21 142.54 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 CA-C-O 122.695 1.236 . . . . 0.0 110.487 178.231 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG21 HD21 ' A' ' 25' ' ' LEU . 64.8 t -124.23 112.35 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 128.268 2.627 . . . . 0.0 109.16 -170.834 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -97.47 108.1 20.75 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.783 -1.198 . . . . 0.0 111.637 176.744 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.1 mt -105.38 146.52 29.32 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.904 -1.122 . . . . 0.0 113.251 172.94 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.9 tp -116.33 126.59 53.74 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 162.864 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.508 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 1.1 pp -146.81 163.95 34.37 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.246 -0.909 . . . . 0.0 110.949 179.556 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -123.31 143.08 50.31 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.252 1.021 . . . . 0.0 112.151 -176.855 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -74.71 112.63 11.11 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.662 1.585 . . . . 0.0 109.177 174.199 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -43.03 137.68 3.57 Favored Glycine 0 N--CA 1.431 -1.683 0 C-N-CA 128.389 2.9 . . . . 0.0 119.964 -157.163 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -61.25 -165.32 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 129.424 3.089 . . . . 0.0 115.948 177.356 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 12.9 p -130.16 135.8 28.02 Favored Pre-proline 0 N--CA 1.43 -1.47 0 O-C-N 118.972 -2.33 . . . . 0.0 105.176 169.878 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo . . . . . 0 N--CA 1.434 -1.985 0 CA-C-N 124.524 2.651 . . . . 0.0 113.088 -177.344 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.2 pttp . . . . . 0 N--CA 1.43 -1.443 0 CA-C-O 117.676 -1.154 . . . . 0.0 108.336 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -70.82 -172.99 0.76 Allowed 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 123.274 2.205 . . . . 0.0 115.041 178.757 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.65 39.99 5.76 Favored Glycine 0 N--CA 1.429 -1.791 0 O-C-N 120.965 -1.085 . . . . 0.0 114.85 169.259 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -97.89 149.65 22.16 Favored 'General case' 0 CA--C 1.489 -1.394 0 CA-C-N 118.381 1.091 . . . . 0.0 109.944 173.146 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.0 p -91.01 159.67 16.02 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.328 1.051 . . . . 0.0 113.812 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -144.32 138.95 28.23 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.835 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -87.78 122.73 31.79 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.649 -1.282 . . . . 0.0 108.988 164.673 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 53.7 t -107.18 88.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -96.54 89.19 4.91 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.039 1.736 . . . . 0.0 108.034 177.949 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.0 tp -125.48 151.74 45.87 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.513 1.525 . . . . 0.0 109.758 -171.309 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.04 153.74 19.96 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.194 -1.566 . . . . 0.0 110.76 167.816 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -67.22 156.25 36.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 115.364 1.616 . . . . 0.0 115.364 -179.552 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 63.1 p -116.18 114.42 24.42 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.834 -1.166 . . . . 0.0 108.657 169.487 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.6 t0 40.56 56.91 2.69 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.843 2.457 . . . . 0.0 115.293 -176.701 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.75 -30.32 5.43 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 125.015 1.293 . . . . 0.0 115.488 -177.003 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.49 142.76 33.16 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.729 -1.454 . . . . 0.0 114.783 -162.749 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 95.9 mt -94.54 -60.55 1.69 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.223 1.409 . . . . 0.0 107.98 164.645 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.9 36.38 0.89 Allowed Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.873 -1.767 . . . . 0.0 112.504 167.885 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 pt -118.78 124.42 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 122.577 1.179 . . . . 0.0 111.179 -174.7 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.2 m -100.05 125.24 46.09 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 164.165 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -107.48 170.1 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 124.192 0.997 . . . . 0.0 111.438 -175.497 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -153.34 178.78 9.41 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.467 -1.396 . . . . 0.0 108.146 177.005 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.22 13.73 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.627 1.108 . . . . 0.0 114.139 175.537 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.68 152.73 10.93 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 126.239 1.876 . . . . 0.0 111.527 -177.222 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p -71.97 -33.13 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.592 -1.534 . . . . 0.0 114.755 -175.325 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 26.1 m120 -98.51 8.19 45.2 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.447 -1.408 . . . . 0.0 111.683 -175.849 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.34 -157.45 0.35 Allowed 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 124.467 1.107 . . . . 0.0 109.443 -176.445 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 73.1 m -96.46 9.56 40.96 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 118.933 -2.354 . . . . 0.0 112.403 -174.692 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.14 125.92 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.57 -1.331 . . . . 0.0 108.712 169.316 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -72.16 -40.94 67.64 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.59 -1.944 . . . . 0.0 113.07 -177.96 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 55.0 m80 -60.92 -34.65 75.02 Favored 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 114.92 1.452 . . . . 0.0 114.92 -175.637 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.0 93.01 0.69 Allowed Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 123.895 0.76 . . . . 0.0 113.014 173.577 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -172.35 169.29 42.41 Favored Glycine 0 N--CA 1.43 -1.713 0 O-C-N 120.366 -1.667 . . . . 0.0 111.622 -178.709 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.65 131.25 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 174.751 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -128.14 154.81 45.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 120.964 -1.085 . . . . 0.0 109.466 -173.141 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.6 t -77.06 122.74 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 O-C-N 120.348 -1.47 . . . . 0.0 112.656 175.029 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -92.0 -47.47 7.27 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.803 1.241 . . . . 0.0 112.18 178.862 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.69 161.83 37.14 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.174 -0.954 . . . . 0.0 110.786 -179.753 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -118.03 124.57 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.742 1.217 . . . . 0.0 109.487 -178.384 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.5 mm -77.19 121.02 83.94 Favored Pre-proline 0 N--CA 1.43 -1.454 0 CA-C-O 116.45 -1.738 . . . . 0.0 114.454 -175.214 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_exo -58.2 122.86 12.41 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 123.275 2.65 . . . . 0.0 116.202 -178.985 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.323 72.0 mmtt 76.73 31.36 0.56 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 127.064 2.146 . . . . 0.0 113.812 -177.57 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.5 162.68 38.21 Favored Glycine 0 N--CA 1.431 -1.685 0 CA-C-O 122.262 0.923 . . . . 0.0 112.117 159.107 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.98 -59.44 4.15 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.253 1.821 . . . . 0.0 114.653 166.585 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.73 -49.37 76.69 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 129.395 3.078 . . . . 0.0 111.705 -176.676 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -41.74 -66.53 0.34 Allowed 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 172.179 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.3 m -70.04 -10.82 59.96 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -176.35 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -75.55 -57.19 4.03 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 119.374 -2.079 . . . . 0.0 111.313 177.37 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.18 0.79 54.37 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.909 -1.12 . . . . 0.0 115.411 170.236 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.3 mmt-85 -66.88 -33.69 76.15 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.68 -1.482 . . . . 0.0 110.941 162.97 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 81.6 mt -90.67 113.14 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 C-N-CA 126.066 1.746 . . . . 0.0 110.727 -178.696 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -113.11 156.46 23.13 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-O 123.625 1.679 . . . . 0.0 112.698 179.352 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -69.57 128.08 35.23 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 119.999 -1.688 . . . . 0.0 111.994 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 89.14 8.01 69.36 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.628 -1.295 . . . . 0.0 114.567 -177.137 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -79.83 173.42 12.61 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 119.672 1.736 . . . . 0.0 113.34 175.617 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.8 ttt-85 -101.55 140.74 35.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 123.104 1.431 . . . . 0.0 110.644 174.956 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -99.69 136.11 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.172 -1.58 . . . . 0.0 107.507 178.768 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -100.71 -57.4 2.11 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.931 -1.73 . . . . 0.0 113.063 -176.988 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.57 139.19 20.64 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.762 -1.211 . . . . 0.0 109.596 -174.678 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.29 113.28 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-O 121.884 0.85 . . . . 0.0 109.153 179.022 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 6.7 t30 67.35 21.7 9.7 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.31 1.844 . . . . 0.0 114.648 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.81 -13.64 41.77 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 120.897 -1.127 . . . . 0.0 112.777 -175.219 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.0 t -94.14 116.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 121.218 -1.166 . . . . 0.0 109.257 -176.796 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.6 p -74.51 133.99 42.28 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.628 -1.295 . . . . 0.0 111.615 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.0 mt -86.67 22.12 2.01 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.729 -1.232 . . . . 0.0 113.531 -172.813 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.0 mm-40 -68.08 119.69 13.09 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.87 -1.769 . . . . 0.0 111.982 174.085 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.33 8.65 83.89 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 121.214 -0.929 . . . . 0.0 115.369 -176.724 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.16 144.56 46.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.796 1.776 . . . . 0.0 115.796 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 73.0 p -87.1 178.3 6.95 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.566 -1.333 . . . . 0.0 109.717 168.451 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -62.98 -46.95 85.27 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.823 -1.798 . . . . 0.0 112.12 171.477 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 4.7 tmtm? -55.0 -39.53 69.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.612 1.965 . . . . 0.0 115.436 174.686 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -58.61 -51.12 71.27 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 173.573 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.07 -35.29 79.52 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 124.651 1.18 . . . . 0.0 112.985 -178.765 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.9 t -64.89 -48.57 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 124.653 1.181 . . . . 0.0 110.846 173.94 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 75.6 mt-10 -58.81 -45.42 89.98 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.923 -1.111 . . . . 0.0 113.286 176.882 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 94.5 m -62.59 -43.75 98.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.765 2.026 . . . . 0.0 112.741 178.386 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 22.8 mt -61.48 -45.55 93.79 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.702 -1.249 . . . . 0.0 114.326 172.148 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 55.7 mtp85 -73.2 -27.56 61.69 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.444 -1.41 . . . . 0.0 113.934 -177.467 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -84.32 50.56 1.89 Allowed 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.121 -1.612 . . . . 0.0 112.039 172.006 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.412 ' HB ' HG22 ' A' ' 92' ' ' VAL . 7.4 p -106.7 149.88 26.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.409 1.884 . . . . 0.0 109.966 174.911 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.41 -153.46 20.79 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.959 -1.088 . . . . 0.0 112.496 173.478 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -68.34 -53.48 23.86 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.384 -1.657 . . . . 0.0 113.62 178.677 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 54.1 t -93.07 136.51 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.502 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 173.837 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 88' ' ' THR . 90.7 t -124.39 126.56 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 C-N-CA 125.633 1.573 . . . . 0.0 109.239 -170.183 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -105.38 95.5 5.87 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.904 -1.748 . . . . 0.0 113.329 -178.128 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.485 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 34.8 mt -94.22 153.4 18.08 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 118.581 -2.574 . . . . 0.0 113.305 176.7 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 25.3 tp -116.43 138.79 51.09 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 158.86 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.436 HD13 ' N ' ' A' ' 97' ' ' GLU . 0.4 OUTLIER -137.89 153.67 49.52 Favored 'General case' 0 N--CA 1.429 -1.522 0 C-N-CA 124.941 1.297 . . . . 0.0 109.878 -164.959 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.436 ' N ' HD13 ' A' ' 96' ' ' LEU . 41.7 tt0 -133.13 136.06 45.56 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 119.938 1.245 . . . . 0.0 111.053 169.441 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -75.9 128.43 35.09 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.328 -1.483 . . . . 0.0 111.553 -178.196 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -66.53 151.91 52.3 Favored Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 115.965 1.146 . . . . 0.0 115.965 -172.002 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.98 -50.82 4.93 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.008 1.323 . . . . 0.0 112.876 -176.165 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 9.6 m -120.91 143.79 37.59 Favored Pre-proline 0 N--CA 1.429 -1.489 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 166.852 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo . . . . . 0 N--CA 1.434 -1.99 0 CA-C-N 122.845 2.052 . . . . 0.0 111.89 179.587 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.0 pttm . . . . . 0 N--CA 1.43 -1.445 0 CA-C-O 119.54 -0.267 . . . . 0.0 111.427 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -67.55 178.27 3.37 Favored 'Trans proline' 0 N--CA 1.434 -1.99 0 C-N-CA 122.372 2.048 . . . . 0.0 114.279 167.034 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.49 25.72 7.61 Favored Glycine 0 N--CA 1.43 -1.751 0 C-N-CA 125.357 1.456 . . . . 0.0 111.892 179.912 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -84.55 112.22 20.22 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 121.171 -1.194 . . . . 0.0 109.671 -177.929 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 p -109.98 150.21 28.83 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.743 1.217 . . . . 0.0 111.69 -175.304 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.79 131.14 18.59 Favored 'General case' 0 N--CA 1.431 -1.425 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.907 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -88.51 113.55 24.21 Favored 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.825 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.4 t -99.82 100.82 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 O-C-N 120.637 -1.289 . . . . 0.0 108.964 -171.217 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.67 95.96 8.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.88 1.672 . . . . 0.0 108.559 177.427 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 51.6 tp -124.74 145.09 49.89 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.751 1.22 . . . . 0.0 111.315 -166.885 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.08 137.68 40.93 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.427 -1.421 . . . . 0.0 111.052 173.165 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -70.64 149.42 47.04 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 117.414 2.375 . . . . 0.0 117.414 -177.715 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 72.0 p -127.14 132.62 50.51 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.355 -1.466 . . . . 0.0 109.695 176.403 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 13.1 t70 64.73 16.12 10.2 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.883 2.073 . . . . 0.0 114.352 -177.981 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.37 6.93 89.0 Favored Glycine 0 N--CA 1.43 -1.734 0 O-C-N 119.647 -1.908 . . . . 0.0 114.63 -174.259 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -123.24 173.63 7.8 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 121.27 -1.135 . . . . 0.0 110.774 176.121 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -109.71 -57.57 2.17 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.534 1.134 . . . . 0.0 108.173 171.45 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.4 50.24 0.11 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 119.841 -1.787 . . . . 0.0 111.861 163.297 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.7 tt -137.51 140.63 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.102 0.953 . . . . 0.0 111.191 -171.304 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.3 t -121.81 139.08 54.06 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.11 1.364 . . . . 0.0 108.284 170.39 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.6 m -116.95 170.31 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.929 -1.107 . . . . 0.0 113.74 -167.597 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -152.59 160.06 43.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.613 -1.304 . . . . 0.0 109.776 175.969 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.29 -148.25 19.58 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.909 -1.12 . . . . 0.0 115.02 172.126 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.45 -174.23 20.96 Favored Glycine 0 N--CA 1.43 -1.719 0 C-N-CA 125.443 1.497 . . . . 0.0 109.474 -169.604 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.5 m -80.42 49.04 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 O-C-N 120.539 -1.565 . . . . 0.0 113.753 -178.683 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -98.45 -70.89 0.71 Allowed 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.415 -1.428 . . . . 0.0 108.622 174.91 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 26.7 p -102.31 177.01 5.0 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.133 1.773 . . . . 0.0 109.997 -175.232 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 75.4 m -87.16 53.14 2.71 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 119.869 -1.769 . . . . 0.0 111.54 -179.267 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.3 p -87.35 85.79 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.499 0 C-N-CA 125.545 1.538 . . . . 0.0 109.984 177.89 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 39.78 79.15 0.04 OUTLIER 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 128.336 2.654 . . . . 0.0 116.015 -172.179 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.264 97.5 m-70 72.16 -45.11 0.61 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.776 2.031 . . . . 0.0 115.004 -165.079 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.88 78.77 0.57 Allowed Glycine 0 N--CA 1.431 -1.643 0 C-N-CA 125.03 1.3 . . . . 0.0 110.721 -177.901 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -134.72 166.96 24.14 Favored Glycine 0 N--CA 1.429 -1.816 0 O-C-N 121.667 -0.902 . . . . 0.0 112.236 -176.769 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.1 mm -85.53 116.83 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 C-N-CA 124.97 1.308 . . . . 0.0 110.615 -176.978 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -114.78 156.36 25.0 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.536 -1.353 . . . . 0.0 109.68 -177.822 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -76.99 123.14 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.214 -1.554 . . . . 0.0 111.029 170.599 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 12.7 ttmm -91.15 -45.41 8.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.198 -1.564 . . . . 0.0 111.084 175.788 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.17 156.49 42.25 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 120.172 -1.58 . . . . 0.0 111.414 -179.734 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -119.32 128.13 75.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 124.485 1.114 . . . . 0.0 108.642 177.392 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.91 121.27 84.49 Favored Pre-proline 0 N--CA 1.429 -1.513 0 N-CA-C 117.004 2.224 . . . . 0.0 117.004 -171.086 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -56.01 122.95 12.67 Favored 'Trans proline' 0 N--CA 1.434 -2.017 0 C-N-CA 123.44 2.76 . . . . 0.0 116.549 -177.288 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.4 mtmm 78.43 13.0 1.52 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 128.367 2.667 . . . . 0.0 114.465 -176.168 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.95 157.77 47.45 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 120.007 -1.683 . . . . 0.0 111.682 172.852 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.21 -55.81 7.88 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.873 1.669 . . . . 0.0 114.735 170.166 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.9 -47.76 79.32 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 127.659 2.384 . . . . 0.0 113.327 178.82 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -47.48 -61.97 1.66 Allowed 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.219 1.563 . . . . 0.0 115.219 170.299 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -65.39 -31.64 72.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.993 1.317 . . . . 0.0 113.62 -171.853 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -54.89 -63.56 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.186 2.194 . . . . 0.0 113.097 174.388 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.53 47.49 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.972 -1.08 . . . . 0.0 115.344 171.76 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.437 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.0 mmp_? -76.64 -22.05 54.64 Favored 'General case' 0 N--CA 1.429 -1.481 0 CA-C-N 119.817 1.809 . . . . 0.0 112.438 171.368 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.3 mt -103.26 123.58 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.537 1.135 . . . . 0.0 108.252 171.656 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.733 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 25.9 t-80 -146.67 -171.25 3.71 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.63 1.681 . . . . 0.0 111.717 176.692 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.733 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 44.4 tttp -72.2 123.87 23.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.015 1.726 . . . . 0.0 113.785 -166.105 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.12 76.59 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.721 -1.237 . . . . 0.0 113.935 -176.266 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -80.62 155.53 26.83 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 119.313 1.556 . . . . 0.0 112.309 173.114 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.1 tpt85 -106.07 118.73 37.37 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.681 -1.262 . . . . 0.0 109.034 -174.01 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 59.2 t -91.46 122.63 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.451 -1.405 . . . . 0.0 108.522 -178.24 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -87.08 -45.0 11.12 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.157 0.983 . . . . 0.0 110.287 -177.099 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.45 139.73 21.29 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.885 0.85 . . . . 0.0 110.621 -173.829 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.8 t -118.2 122.41 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 177.845 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 64.11 25.66 13.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.582 -1.323 . . . . 0.0 114.152 172.754 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.03 -5.44 84.49 Favored Glycine 0 N--CA 1.429 -1.787 0 O-C-N 120.191 -1.568 . . . . 0.0 114.102 -175.719 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.5 t -95.41 126.08 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 C-N-CA 125.031 1.332 . . . . 0.0 109.547 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.1 t -76.8 127.57 33.0 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.52 -1.363 . . . . 0.0 110.634 -178.866 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.4 mt -82.82 2.62 33.22 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.28 -1.513 . . . . 0.0 114.227 -175.793 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -65.07 126.05 26.84 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.105 -2.247 . . . . 0.0 112.668 -178.857 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.65 -8.36 77.78 Favored Glycine 0 N--CA 1.429 -1.79 0 O-C-N 121.013 -1.054 . . . . 0.0 114.839 -175.776 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.09 146.0 46.08 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 177.216 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 24.1 p -92.37 -179.38 5.2 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.041 1.736 . . . . 0.0 111.441 171.227 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-160 -57.08 -52.93 63.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.817 1.647 . . . . 0.0 114.693 -177.881 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.3 tmtp? -56.73 -38.23 72.08 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -58.95 -53.27 60.27 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.886 1.674 . . . . 0.0 115.127 177.767 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.76 -37.26 86.69 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.255 1.422 . . . . 0.0 112.464 178.711 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.22 -51.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.577 1.151 . . . . 0.0 111.047 175.202 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -64.84 -33.53 76.22 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 178.959 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 35.3 m -75.37 -43.2 51.6 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.682 1.593 . . . . 0.0 113.252 179.568 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 27.5 mt -66.2 -42.09 89.29 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.623 -1.298 . . . . 0.0 113.062 173.03 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.9 ptt85 -72.71 -37.41 67.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.898 -1.127 . . . . 0.0 113.869 -176.854 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -85.71 59.78 5.84 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 123.412 1.577 . . . . 0.0 111.5 176.41 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' VAL . 4.9 p -107.61 153.69 22.52 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.545 1.938 . . . . 0.0 108.916 173.781 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.35 -151.89 21.87 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.846 -1.159 . . . . 0.0 112.624 -174.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -50.73 38.73 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.873 -1.369 . . . . 0.0 113.332 -179.572 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.14 137.09 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.511 1.148 . . . . 0.0 109.177 169.129 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.449 HG22 ' HB ' ' A' ' 88' ' ' THR . 40.3 t -125.3 127.1 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 127.023 2.129 . . . . 0.0 110.293 -166.917 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 18.3 m170 -105.11 114.52 28.77 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.669 -1.27 . . . . 0.0 112.432 172.623 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 9.5 mt -103.26 164.96 11.31 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.087 -1.633 . . . . 0.0 112.261 163.02 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 58.7 tp -127.28 124.63 39.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.65 1.18 . . . . 0.0 107.838 158.407 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.99 162.16 32.84 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.257 -0.902 . . . . 0.0 112.387 175.677 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -117.51 144.69 44.82 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.407 1.883 . . . . 0.0 109.64 175.108 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.09 70.33 3.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 127.458 2.303 . . . . 0.0 113.223 -174.174 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.12 -163.94 44.61 Favored Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 125.873 1.701 . . . . 0.0 114.854 178.104 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -97.51 -33.77 11.24 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.585 -1.538 . . . . 0.0 110.947 158.258 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 11.0 p -136.12 142.68 40.96 Favored Pre-proline 0 N--CA 1.43 -1.444 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 174.051 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--N 1.3 -2.014 0 CA-C-N 122.434 1.905 . . . . 0.0 115.184 173.445 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.5 mtpt . . . . . 0 N--CA 1.43 -1.455 0 CA-C-O 116.731 -1.604 . . . . 0.0 112.687 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -97.66 -164.83 0.08 OUTLIER 'Trans proline' 0 N--CA 1.433 -2.039 0 CA-C-N 125.093 2.855 . . . . 0.0 109.933 153.615 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.94 76.8 0.82 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 177.89 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -52.7 -52.7 54.9 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 126.907 2.083 . . . . 0.0 116.007 -161.387 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.7 p -123.11 149.35 44.61 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 121.827 2.103 . . . . 0.0 111.585 168.372 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.3 p90 -147.84 148.87 31.35 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.037 1.399 . . . . 0.0 109.592 171.237 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -92.88 141.62 28.22 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.334 1.854 . . . . 0.0 109.346 176.938 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.74 90.31 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.63 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.2 84.63 4.47 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.401 -1.437 . . . . 0.0 108.22 177.073 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.9 tp -113.73 145.16 41.77 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.113 1.365 . . . . 0.0 111.424 -162.716 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.58 122.43 44.37 Favored 'General case' 0 N--CA 1.429 -1.501 0 O-C-N 120.257 -1.527 . . . . 0.0 108.981 171.291 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -71.68 165.99 22.84 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 179.264 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.4 p -134.23 139.95 46.13 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 124.724 1.21 . . . . 0.0 108.53 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.6 t70 66.77 8.55 6.05 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.944 1.698 . . . . 0.0 115.081 174.205 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.99 -8.47 63.2 Favored Glycine 0 N--CA 1.431 -1.69 0 O-C-N 120.097 -1.627 . . . . 0.0 113.762 -176.279 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 66.8 m -119.47 152.06 37.54 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 118.729 1.264 . . . . 0.0 111.814 -172.346 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.6 mt -86.95 -55.24 3.92 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.259 -1.525 . . . . 0.0 111.734 176.397 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 20.05 1.78 Allowed Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.414 -1.428 . . . . 0.0 112.107 177.25 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.6 pt -115.25 150.21 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 124.941 1.296 . . . . 0.0 110.18 -177.358 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 7.7 t -127.82 123.45 35.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 163.356 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.91 163.54 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.544 1.138 . . . . 0.0 111.683 -172.207 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -150.05 173.9 13.34 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.882 1.273 . . . . 0.0 109.409 -175.441 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.86 -136.11 13.2 Favored Glycine 0 N--CA 1.43 -1.761 0 O-C-N 120.872 -1.142 . . . . 0.0 113.761 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.54 167.73 43.47 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.246 0.927 . . . . 0.0 114.41 177.258 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m -66.39 -21.08 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 115.548 1.685 . . . . 0.0 115.548 -175.17 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.8 p-10 -77.99 -15.67 58.76 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.408 -1.432 . . . . 0.0 113.004 177.062 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.3 m -106.38 151.82 24.39 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.772 1.629 . . . . 0.0 108.29 -174.576 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 22.2 p -79.11 39.68 0.39 Allowed 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.64 -1.913 . . . . 0.0 115.233 -174.035 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.2 m -92.1 169.04 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.979 1.712 . . . . 0.0 111.963 -179.488 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -70.71 119.41 14.81 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.428 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 57.49 21.87 7.47 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.533 2.333 . . . . 0.0 116.602 178.942 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.73 29.02 73.48 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.314 -1.491 . . . . 0.0 115.68 -178.817 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -77.71 155.77 43.53 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 121.78 -0.835 . . . . 0.0 114.829 -175.121 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.8 mm -100.41 125.4 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 C-N-CA 125.2 1.4 . . . . 0.0 107.38 175.18 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.1 m-85 -126.48 153.52 44.99 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.566 -1.334 . . . . 0.0 111.319 -171.562 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.5 t -75.86 122.83 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.861 -1.149 . . . . 0.0 111.987 172.195 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -91.1 -47.17 7.69 Favored 'General case' 0 N--CA 1.429 -1.498 0 C-N-CA 125.639 1.576 . . . . 0.0 110.857 177.419 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.15 165.19 37.12 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.651 -0.656 . . . . 0.0 110.402 -176.702 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -116.13 132.73 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.309 1.043 . . . . 0.0 108.342 175.021 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.5 mm -77.8 121.49 84.25 Favored Pre-proline 0 N--CA 1.429 -1.491 0 C-N-CA 126.137 1.775 . . . . 0.0 114.37 -174.854 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -59.32 123.76 14.1 Favored 'Trans proline' 0 N--CA 1.434 -2.007 0 CA-C-N 124.97 2.811 . . . . 0.0 116.795 -176.104 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.314 59.9 mmtt 68.98 30.9 4.36 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 127.773 2.429 . . . . 0.0 114.534 -176.144 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.02 163.33 39.69 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.31 -1.494 . . . . 0.0 112.8 167.899 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.36 -58.49 5.57 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.479 1.912 . . . . 0.0 114.593 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.83 -46.94 79.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.775 2.03 . . . . 0.0 112.433 -177.107 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -45.44 -62.32 1.32 Allowed 'General case' 0 N--CA 1.429 -1.506 0 C-N-CA 126.87 2.068 . . . . 0.0 115.842 170.657 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.4 m -69.55 -32.07 70.64 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -176.02 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -56.6 -56.4 21.84 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.16 1.784 . . . . 0.0 113.703 173.92 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.88 25.25 32.63 Favored Glycine 0 N--CA 1.431 -1.698 0 O-C-N 120.602 -1.311 . . . . 0.0 116.232 164.49 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.6 mmt-85 -78.89 -52.48 8.24 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.775 -1.426 . . . . 0.0 107.675 160.723 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 74.9 mt -77.82 122.08 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.1 1.36 . . . . 0.0 110.873 178.282 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.454 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 1.9 t60 -131.27 -176.47 4.03 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.033 1.397 . . . . 0.0 112.019 174.95 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 81.4 tttt -69.07 128.32 36.26 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 119.816 -1.803 . . . . 0.0 112.083 -172.295 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.91 1.8 79.26 Favored Glycine 0 N--CA 1.429 -1.772 0 CA-C-O 118.507 -1.163 . . . . 0.0 114.849 -179.408 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.16 158.61 31.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 120.092 1.946 . . . . 0.0 112.057 178.426 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.23 119.59 39.92 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.656 -1.278 . . . . 0.0 110.305 -169.286 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.4 t -85.35 124.8 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 125.985 1.714 . . . . 0.0 110.764 -169.773 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 74.0 mt -106.44 -51.45 2.95 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.319 -1.488 . . . . 0.0 113.888 -173.626 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.16 138.32 20.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.069 -1.644 . . . . 0.0 112.606 -172.042 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.706 HG11 HG21 ' A' ' 84' ' ' THR . 2.2 p -108.77 108.71 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.387 1.475 . . . . 0.0 112.204 -178.877 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.4 t30 58.46 36.94 25.66 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.17 1.788 . . . . 0.0 113.376 168.853 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.95 -9.39 68.09 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 125.829 1.681 . . . . 0.0 115.473 -172.971 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.4 t -103.0 116.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-N 120.808 2.304 . . . . 0.0 111.085 -174.895 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.3 p -69.07 126.05 28.58 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 120.355 -1.466 . . . . 0.0 113.571 179.852 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.5 mt -87.97 46.94 1.43 Allowed 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.633 -1.292 . . . . 0.0 112.852 -176.421 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -89.46 123.02 33.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.326 -2.109 . . . . 0.0 111.189 -178.448 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.58 1.97 89.36 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 121.058 -1.027 . . . . 0.0 114.798 175.041 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.86 162.9 28.77 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.737 1.754 . . . . 0.0 115.737 -178.288 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 p -83.63 173.72 11.14 Favored 'General case' 0 N--CA 1.431 -1.395 0 O-C-N 120.525 -1.359 . . . . 0.0 111.723 176.906 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-160 -56.43 -53.57 55.91 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.755 1.222 . . . . 0.0 112.798 168.298 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.35 -46.26 89.11 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.744 1.387 . . . . 0.0 114.744 179.259 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.99 -48.24 76.23 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.059 1.344 . . . . 0.0 114.505 -173.92 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.85 -42.02 96.98 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 124.833 1.253 . . . . 0.0 113.561 174.366 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.7 t -66.27 -48.84 79.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 125.126 1.371 . . . . 0.0 111.121 179.101 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -60.39 -46.32 90.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.736 1.214 . . . . 0.0 112.775 179.062 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 84' ' ' THR . . . . . 0.706 HG21 HG11 ' A' ' 68' ' ' VAL . 2.3 m -60.03 -43.99 94.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.372 1.469 . . . . 0.0 113.844 172.62 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 37.2 mt -69.72 -34.36 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.119 -1.613 . . . . 0.0 114.725 178.09 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . 0.271 42.9 ptt85 -71.95 -38.93 69.7 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.035 -1.665 . . . . 0.0 113.19 172.801 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.9 t30 -84.34 48.4 1.49 Allowed 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.787 -1.195 . . . . 0.0 113.722 175.936 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 p -99.58 150.46 22.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.032 2.133 . . . . 0.0 109.97 174.311 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.79 -163.46 17.29 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.579 1.085 . . . . 0.0 113.34 177.099 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -68.99 -47.63 65.06 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.522 -1.575 . . . . 0.0 113.799 -178.465 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.25 118.74 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 CA-C-O 122.091 0.948 . . . . 0.0 108.721 179.836 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 65.4 t -124.11 119.26 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 126.457 1.903 . . . . 0.0 110.395 -161.283 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -103.32 97.57 7.61 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.076 -1.64 . . . . 0.0 113.845 -178.433 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.39 148.58 21.94 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.703 -1.873 . . . . 0.0 111.342 176.749 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -127.75 127.97 44.53 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 171.849 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . 0.273 0.0 OUTLIER -146.13 169.59 18.41 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.349 -1.469 . . . . 0.0 113.739 -177.07 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.54 131.6 56.88 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.362 1.865 . . . . 0.0 110.493 -173.414 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.6 153.92 30.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.304 -1.498 . . . . 0.0 113.467 179.182 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.41 84.03 1.55 Allowed Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.242 0.925 . . . . 0.0 111.893 165.156 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -78.25 -49.49 13.63 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 127.614 2.366 . . . . 0.0 112.03 -176.4 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 1.4 p -130.21 126.16 22.14 Favored Pre-proline 0 N--CA 1.43 -1.474 0 C-N-CA 124.96 1.304 . . . . 0.0 109.101 -176.634 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.433 -2.073 0 C-N-CA 122.985 2.457 . . . . 0.0 114.85 -171.367 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? . . . . . 0 N--CA 1.43 -1.458 0 CA-C-O 119.106 -0.474 . . . . 0.0 109.731 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -74.19 -179.94 5.19 Favored 'Trans proline' 0 C--N 1.3 -1.993 0 C-N-CA 122.751 2.301 . . . . 0.0 112.648 -178.452 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.58 34.58 7.81 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 121.266 -0.896 . . . . 0.0 111.856 -170.107 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.77 129.52 41.68 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.711 1.605 . . . . 0.0 108.722 -176.554 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.3 p -94.29 144.52 25.46 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.473 -1.392 . . . . 0.0 112.379 -177.203 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.432 ' CE1' HD21 ' A' ' 96' ' ' LEU . 5.9 p90 -147.29 140.45 25.23 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 122.74 1.257 . . . . 0.0 107.974 177.337 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -99.43 127.05 45.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.367 1.067 . . . . 0.0 109.765 178.017 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.9 t -116.44 93.32 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.717 1.207 . . . . 0.0 108.364 -170.591 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -89.63 103.82 16.43 Favored 'General case' 0 N--CA 1.429 -1.5 0 CA-C-O 123.221 1.486 . . . . 0.0 107.831 168.668 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.7 tp -121.59 144.52 48.69 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.24 1.416 . . . . 0.0 109.047 -165.55 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.41 120.26 40.02 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 124.672 1.189 . . . . 0.0 109.333 172.059 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -69.43 129.01 38.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.202 1.401 . . . . 0.0 112.412 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.9 t -92.7 104.74 16.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.641 1.21 . . . . 0.0 110.737 -172.31 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.4 t70 33.04 60.29 0.43 Allowed 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 129.339 3.056 . . . . 0.0 116.85 -173.961 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.67 -10.27 74.21 Favored Glycine 0 N--CA 1.43 -1.767 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 178.357 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -111.64 127.11 55.65 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 120.494 2.147 . . . . 0.0 111.519 -179.748 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.0 tp -92.32 -61.49 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.05 -1.031 . . . . 0.0 111.921 -178.844 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.92 -11.8 3.12 Favored Glycine 0 N--CA 1.429 -1.78 0 O-C-N 119.663 -1.898 . . . . 0.0 115.209 170.617 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.0 pt -105.9 141.03 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 119.321 1.561 . . . . 0.0 113.29 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 m -113.23 122.74 48.38 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 159.856 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.72 170.04 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.696 1.236 . . . . 0.0 112.622 -172.933 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 t -152.52 172.35 16.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.755 -1.215 . . . . 0.0 109.602 176.354 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.71 -142.26 15.64 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 113.67 171.415 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.57 150.7 27.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.56 1.076 . . . . 0.0 112.834 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.9 p -61.6 -31.47 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -174.272 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -79.76 -16.57 55.33 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.596 1.558 . . . . 0.0 114.369 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.5 m -88.92 152.43 21.73 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 179.91 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.7 t -82.52 50.21 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.237 -2.164 . . . . 0.0 113.483 -173.222 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 15.6 m -100.4 51.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.674 -1.892 . . . . 0.0 112.452 -172.482 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 73.25 -43.52 0.56 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.604 1.961 . . . . 0.0 116.228 173.652 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 53.7 t60 -144.6 -60.93 0.37 Allowed 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.677 -1.265 . . . . 0.0 108.87 170.235 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.75 -143.66 7.21 Favored Glycine 0 N--CA 1.43 -1.756 0 N-CA-C 106.659 -2.576 . . . . 0.0 106.659 -173.797 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.58 136.91 4.66 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.312 0.958 . . . . 0.0 113.31 176.501 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.486 ' HB ' HG12 ' A' ' 65' ' ' VAL . 25.1 mm -101.69 122.04 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 124.824 1.249 . . . . 0.0 108.412 179.859 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 75.3 m-85 -127.34 152.64 47.21 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.202 -0.936 . . . . 0.0 109.706 -173.552 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -75.82 125.84 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 O-C-N 120.483 -1.386 . . . . 0.0 111.341 171.661 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -98.93 -40.69 7.95 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.634 -1.292 . . . . 0.0 112.316 -179.399 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.61 155.33 40.1 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 121.453 -0.779 . . . . 0.0 111.222 179.699 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.448 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -115.95 124.87 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 CA-C-O 122.465 1.126 . . . . 0.0 111.28 -179.827 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp -76.33 122.97 87.72 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.848 2.059 . . . . 0.0 116.136 -169.176 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -58.25 112.9 1.32 Allowed 'Trans proline' 0 N--CA 1.434 -1.997 0 C-N-CA 123.767 2.978 . . . . 0.0 117.232 -175.588 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.305 48.5 mtmt 79.06 32.27 0.27 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.875 2.87 . . . . 0.0 113.8 -178.124 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.8 159.99 35.08 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 121.418 -0.801 . . . . 0.0 112.026 167.234 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.45 -60.39 2.88 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.519 1.528 . . . . 0.0 114.426 169.46 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.75 99.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 127.396 2.278 . . . . 0.0 112.677 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.448 ' CG ' HG23 ' A' ' 47' ' ' ILE . 2.8 tm-20 -51.49 -65.36 0.57 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 125.771 1.628 . . . . 0.0 114.626 174.678 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.0 t -69.15 -23.22 63.93 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -174.345 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -51.5 -63.94 0.97 Allowed 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.079 1.752 . . . . 0.0 113.019 172.971 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.24 -12.64 28.66 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 121.288 -0.883 . . . . 0.0 114.647 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 -64.22 -56.02 17.58 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 124.409 1.084 . . . . 0.0 111.002 168.614 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.8 mt -78.55 128.73 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 124.957 1.303 . . . . 0.0 110.839 179.074 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -145.7 171.11 15.21 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.132 -0.98 . . . . 0.0 110.113 177.862 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . 0.264 0.0 OUTLIER -64.45 139.67 58.79 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 119.398 -2.064 . . . . 0.0 113.829 179.445 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.78 -7.8 67.99 Favored Glycine 0 N--CA 1.43 -1.709 0 CA-C-O 118.509 -1.162 . . . . 0.0 114.278 -172.67 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.487 ' HB3' HD23 ' A' ' 96' ' ' LEU . 97.7 m-20 -80.75 138.65 36.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 119.8 1.8 . . . . 0.0 113.363 -176.269 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -98.2 133.43 42.63 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.57 -1.331 . . . . 0.0 111.668 -174.408 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.486 HG12 ' HB ' ' A' ' 42' ' ' ILE . 0.4 OUTLIER -82.89 148.73 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.494 -1.379 . . . . 0.0 112.942 -179.384 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -109.39 -51.37 2.88 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.752 1.221 . . . . 0.0 109.689 171.028 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 143.77 25.24 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.801 -1.187 . . . . 0.0 110.925 -175.35 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 58.8 t -117.6 129.09 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.39 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 77.18 -30.46 0.17 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.407 2.683 . . . . 0.0 113.983 173.236 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.09 -17.11 1.54 Allowed Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 126.316 1.913 . . . . 0.0 109.265 -169.937 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.72 116.53 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 125.379 1.472 . . . . 0.0 109.275 -176.196 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.3 m -71.12 127.42 32.53 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.807 -1.183 . . . . 0.0 111.104 176.991 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 22.9 mt -93.88 43.02 1.1 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.027 -1.046 . . . . 0.0 112.699 -171.057 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -75.79 119.93 20.46 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.19 -2.194 . . . . 0.0 112.21 -178.344 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.23 13.2 82.26 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.117 -1.615 . . . . 0.0 115.306 -178.33 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.94 151.42 44.69 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.415 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -82.09 172.83 12.76 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.207 1.003 . . . . 0.0 111.148 176.345 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -61.08 -50.0 75.05 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.909 1.284 . . . . 0.0 113.118 175.057 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.3 -42.01 80.93 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 171.695 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -55.36 -48.78 73.72 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 114.499 1.296 . . . . 0.0 114.499 -175.428 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.96 98.38 Favored 'General case' 0 N--CA 1.431 -1.4 0 C-N-CA 125.126 1.37 . . . . 0.0 113.855 177.2 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.1 -49.87 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 C-N-CA 125.112 1.365 . . . . 0.0 110.451 177.609 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -64.26 -32.26 73.78 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.692 -1.255 . . . . 0.0 113.96 179.632 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 53.0 m -67.65 -46.48 72.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.61 1.964 . . . . 0.0 112.236 173.501 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 70.1 mt -64.02 -38.94 92.89 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.98 -1.075 . . . . 0.0 113.727 173.531 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.12 -45.22 83.67 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.967 1.707 . . . . 0.0 112.444 175.39 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -85.39 44.58 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.265 1.426 . . . . 0.0 113.224 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.3 p -106.81 160.27 15.61 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.075 -1.641 . . . . 0.0 108.739 170.02 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.82 -131.05 4.79 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.474 1.035 . . . . 0.0 110.856 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -69.77 -69.01 0.37 Allowed 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 114.729 1.381 . . . . 0.0 114.729 178.029 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 52.8 t -92.25 124.65 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 CA-C-O 122.853 1.311 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.8 t -124.15 120.82 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 127.574 2.349 . . . . 0.0 109.272 -169.622 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -100.46 113.02 25.46 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.796 -1.815 . . . . 0.0 112.212 173.683 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -97.57 149.32 22.34 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.747 -1.845 . . . . 0.0 111.672 163.336 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.9 124.64 48.77 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 161.773 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.487 HD23 ' HB3' ' A' ' 63' ' ' ASP . 0.0 OUTLIER -150.28 168.46 23.98 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.874 -1.141 . . . . 0.0 113.149 -178.423 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -119.34 144.96 46.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.478 1.511 . . . . 0.0 111.503 -177.905 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.6 tppt? -75.28 128.1 34.66 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.487 1.515 . . . . 0.0 112.755 -179.687 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.34 136.41 32.16 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.798 1.19 . . . . 0.0 115.393 -177.256 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -68.58 -34.54 75.99 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 115.752 1.76 . . . . 0.0 115.752 -175.306 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.6 p -112.11 132.25 22.14 Favored Pre-proline 0 N--CA 1.43 -1.444 0 C-N-CA 124.838 1.255 . . . . 0.0 108.442 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo . . . . . 0 C--N 1.3 -1.989 0 C-N-CA 122.699 2.266 . . . . 0.0 114.173 -177.607 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.6 mtmm . . . . . 0 N--CA 1.43 -1.442 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -78.18 179.69 6.27 Favored 'Trans proline' 0 C--N 1.3 -2.01 0 C-N-CA 122.767 2.311 . . . . 0.0 109.895 157.237 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.19 -2.02 83.21 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.596 -1.315 . . . . 0.0 113.849 175.901 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 t0 -80.96 150.79 28.81 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.303 -1.116 . . . . 0.0 110.055 179.455 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.0 p -102.55 157.57 16.84 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.339 1.055 . . . . 0.0 110.972 -178.857 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -146.16 124.35 12.2 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.713 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -88.94 108.6 19.65 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 122.69 1.233 . . . . 0.0 109.287 162.77 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.2 t -99.06 108.9 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 128.287 2.635 . . . . 0.0 109.303 -168.766 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.4 101.14 13.82 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.845 -1.159 . . . . 0.0 109.737 173.804 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -108.64 158.06 17.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.872 1.32 . . . . 0.0 108.849 172.979 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.41 145.84 29.38 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 104.406 -2.442 . . . . 0.0 104.406 152.609 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -70.03 146.82 50.75 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.899 -1.126 . . . . 0.0 112.501 171.384 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.7 p -106.07 94.72 5.32 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.47 1.129 . . . . 0.0 108.876 178.683 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.0 t0 54.75 60.07 3.72 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.339 1.856 . . . . 0.0 114.023 -178.998 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.63 -34.66 3.64 Favored Glycine 0 N--CA 1.43 -1.739 0 O-C-N 120.701 -1.25 . . . . 0.0 115.693 -176.865 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -94.19 145.63 24.57 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.191 -1.182 . . . . 0.0 113.435 -167.513 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.04 -18.49 13.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.986 -1.071 . . . . 0.0 111.714 176.648 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.63 4.73 54.57 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.483 -2.011 . . . . 0.0 114.756 175.736 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.4 pt -120.06 133.02 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 124.862 1.265 . . . . 0.0 111.293 -171.87 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -113.51 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 126.194 1.798 . . . . 0.0 107.165 168.639 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.69 162.7 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.467 1.127 . . . . 0.0 113.777 -169.014 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.2 t -144.1 178.48 7.84 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.562 1.545 . . . . 0.0 110.055 176.424 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.46 -143.22 16.6 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.979 1.276 . . . . 0.0 113.85 171.487 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.46 158.97 19.31 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 124.488 1.042 . . . . 0.0 113.028 -177.638 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m -63.25 -15.11 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 116.353 1.983 . . . . 0.0 116.353 -171.744 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -83.82 -25.06 30.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 119.903 -1.748 . . . . 0.0 113.78 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.5 p -91.64 167.92 11.86 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 121.082 -1.011 . . . . 0.0 111.2 -177.01 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.0 t -80.6 60.94 4.12 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.12 -1.613 . . . . 0.0 114.109 -176.767 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -101.45 176.12 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 127.188 2.195 . . . . 0.0 109.496 167.9 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -73.69 -61.19 1.92 Allowed 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 115.293 1.59 . . . . 0.0 115.293 -176.817 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 6.2 p80 -133.78 54.14 1.97 Allowed 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 122.058 0.932 . . . . 0.0 109.896 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.39 -121.43 26.17 Favored Glycine 0 N--CA 1.43 -1.71 0 O-C-N 120.803 -1.186 . . . . 0.0 113.78 -175.217 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.8 137.0 0.25 Allowed Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.476 1.036 . . . . 0.0 115.093 -174.994 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.6 mm -94.67 129.22 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.034 -1.862 . . . . 0.0 107.721 174.387 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.37 157.19 40.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.314 -1.491 . . . . 0.0 109.165 -176.223 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.6 130.27 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 O-C-N 121.179 -0.95 . . . . 0.0 111.066 171.202 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -99.66 -59.82 1.65 Allowed 'General case' 0 N--CA 1.431 -1.392 0 O-C-N 120.313 -1.492 . . . . 0.0 111.398 177.564 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.17 153.69 47.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 -174.947 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.428 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -108.43 122.78 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.383 1.087 . . . . 0.0 108.917 178.364 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.4 117.92 67.81 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 116.244 -1.836 . . . . 0.0 112.596 -173.23 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -64.72 124.47 13.23 Favored 'Trans proline' 0 N--CA 1.433 -2.043 0 C-N-CA 123.577 2.851 . . . . 0.0 114.131 -171.726 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.262 91.7 mttt 70.15 37.47 1.66 Allowed 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.379 2.672 . . . . 0.0 112.473 -170.989 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.54 164.54 36.27 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.018 -1.051 . . . . 0.0 113.073 163.726 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.83 -63.02 1.21 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.523 1.529 . . . . 0.0 114.68 170.415 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.82 -48.5 76.57 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 127.69 2.396 . . . . 0.0 113.738 178.543 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.428 ' HG2' HG23 ' A' ' 47' ' ' ILE . 9.6 tm-20 -43.7 -55.07 4.62 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.975 1.842 . . . . 0.0 115.975 -177.695 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.8 t -67.55 -28.01 67.43 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 114.472 -1.24 . . . . 0.0 113.785 -174.272 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -73.45 -65.54 0.8 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.499 1.12 . . . . 0.0 111.559 -178.808 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.18 10.19 34.8 Favored Glycine 0 N--CA 1.43 -1.755 0 N-CA-C 116.527 1.371 . . . . 0.0 116.527 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 67.2 mtt85 -64.3 -36.2 83.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.945 1.372 . . . . 0.0 111.022 162.265 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.6 mt -94.78 129.45 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.336 1.454 . . . . 0.0 108.82 177.326 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.0 170.07 16.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.81 1.767 . . . . 0.0 110.685 176.737 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 51.2 mtpt -61.6 123.88 19.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.605 1.562 . . . . 0.0 112.001 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 0.3 62.74 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 120.303 -1.498 . . . . 0.0 115.26 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -74.0 157.11 36.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.175 1.487 . . . . 0.0 112.339 178.089 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.5 ttt180 -88.14 125.81 34.8 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.248 1.419 . . . . 0.0 111.101 178.128 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 50.0 t -91.6 128.72 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 124.223 1.009 . . . . 0.0 109.13 178.681 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -105.41 -57.4 2.04 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.684 -1.26 . . . . 0.0 111.305 -179.305 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.95 138.0 20.32 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.857 -1.152 . . . . 0.0 111.663 -170.825 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.8 t -107.45 107.43 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.417 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 27.1 t30 57.73 52.07 8.59 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.785 1.634 . . . . 0.0 114.311 167.832 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.43 -29.4 10.33 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.95 1.262 . . . . 0.0 114.095 -176.541 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.7 118.18 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-N 118.805 1.303 . . . . 0.0 111.235 -170.443 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 57.7 m -69.76 131.67 44.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.493 -1.38 . . . . 0.0 112.413 176.196 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 25.7 mt -93.36 -6.03 48.18 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 121.026 -1.046 . . . . 0.0 112.433 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -55.22 127.52 29.68 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.576 1.55 . . . . 0.0 114.831 -179.084 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.67 -10.82 70.61 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 115.888 1.115 . . . . 0.0 115.888 -178.005 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.411 ' HB1' ' HB2' ' A' ' 80' ' ' GLN . . . -72.5 178.39 4.07 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 116.989 2.218 . . . . 0.0 116.989 -177.556 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 47.1 p -92.19 171.22 9.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.282 -1.511 . . . . 0.0 110.835 165.678 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -54.2 -42.07 69.33 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.261 1.824 . . . . 0.0 112.883 168.594 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 43.5 tptt -57.54 -42.4 82.87 Favored 'General case' 0 N--CA 1.429 -1.506 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.411 ' HB2' ' HB1' ' A' ' 76' ' ' ALA . 4.3 mp0 -58.93 -49.43 77.87 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.537 -1.352 . . . . 0.0 114.102 175.109 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.43 -44.29 84.53 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.441 1.497 . . . . 0.0 114.052 174.276 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.01 -45.54 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 124.987 1.315 . . . . 0.0 111.886 177.278 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 -64.43 -37.71 88.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 123.811 0.844 . . . . 0.0 112.586 176.602 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.8 m -63.4 -45.6 90.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.788 2.035 . . . . 0.0 113.018 174.204 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.7 mt -69.21 -21.64 63.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.031 -1.668 . . . . 0.0 114.269 174.193 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -72.15 -53.34 13.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.228 -1.545 . . . . 0.0 111.328 168.684 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -92.68 43.37 1.12 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.946 1.698 . . . . 0.0 112.842 -174.409 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . 0.287 6.2 t -106.39 160.01 15.71 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.48 -1.387 . . . . 0.0 110.905 173.164 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.75 -164.8 38.79 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.929 1.252 . . . . 0.0 113.317 -166.052 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -69.8 -49.84 48.86 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.732 -1.452 . . . . 0.0 112.66 174.095 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 59.0 t -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.907 0.86 . . . . 0.0 108.78 179.611 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -123.97 120.39 59.43 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.568 1.547 . . . . 0.0 109.725 -163.065 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 11.8 t-160 -104.82 95.48 5.9 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.633 -1.292 . . . . 0.0 112.435 -175.867 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 27.1 mt -89.99 134.58 34.15 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.762 -1.836 . . . . 0.0 113.397 -176.922 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 66.1 tp -104.89 123.0 46.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.613 -1.304 . . . . 0.0 109.114 167.748 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.37 163.9 30.69 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.47 -0.769 . . . . 0.0 111.54 175.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -127.38 140.07 52.43 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.642 1.577 . . . . 0.0 109.629 -178.892 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 125.46 29.37 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.762 -1.211 . . . . 0.0 114.033 -170.344 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.39 174.33 54.94 Favored Glycine 0 N--CA 1.43 -1.732 0 C-N-CA 125.69 1.614 . . . . 0.0 115.013 177.597 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -94.72 -68.37 0.8 Allowed 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.909 1.284 . . . . 0.0 113.146 -168.263 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.5 m -80.17 126.27 79.7 Favored Pre-proline 0 N--CA 1.431 -1.412 0 O-C-N 120.529 -1.357 . . . . 0.0 113.663 -166.474 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo . . . . . 0 N--CA 1.434 -2.021 0 C-N-CA 122.355 2.036 . . . . 0.0 112.762 173.762 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 mmmp? . . . . . 0 N--CA 1.429 -1.476 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -74.66 179.64 5.77 Favored 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 122.908 2.405 . . . . 0.0 112.287 159.451 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.67 37.79 2.0 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.54 -0.725 . . . . 0.0 114.409 165.513 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -77.89 150.93 34.04 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.947 1.299 . . . . 0.0 110.897 173.916 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -114.58 148.09 38.54 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.654 -1.278 . . . . 0.0 111.22 -176.479 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.69 149.39 32.36 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-O 121.982 0.896 . . . . 0.0 108.963 178.664 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -90.82 145.11 25.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.409 -0.807 . . . . 0.0 109.249 160.811 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.0 t -120.53 94.44 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.086 1.354 . . . . 0.0 107.613 -178.849 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 -90.47 95.66 10.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.929 1.347 . . . . 0.0 107.92 171.669 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 29.2 tp -123.99 138.36 54.47 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 125.315 1.446 . . . . 0.0 110.594 -164.136 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.62 138.59 39.33 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.699 -1.251 . . . . 0.0 108.658 173.857 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -69.48 145.55 52.63 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.22 1.563 . . . . 0.0 115.22 -178.283 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.6 p -100.09 102.21 13.48 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.962 -1.086 . . . . 0.0 109.157 176.192 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.5 t0 55.8 38.46 30.09 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.551 1.54 . . . . 0.0 114.166 179.314 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.48 -20.51 47.86 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.471 -1.393 . . . . 0.0 114.944 -176.699 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -93.56 137.95 32.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.7 -1.47 . . . . 0.0 112.248 -173.182 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.3 mt -87.58 -60.66 1.91 Allowed 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.249 -0.907 . . . . 0.0 110.306 172.21 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.6 8.93 2.69 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.365 -1.46 . . . . 0.0 113.158 175.29 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 pt -123.59 142.53 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-N 119.325 1.563 . . . . 0.0 112.052 -176.177 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.3 t -116.67 139.17 50.84 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 155.486 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.87 169.46 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 124.828 1.251 . . . . 0.0 112.293 -174.321 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -150.3 -179.22 7.02 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 126.053 1.741 . . . . 0.0 109.0 -177.999 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.65 -144.36 17.17 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.611 -1.306 . . . . 0.0 112.301 177.174 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 108.23 150.35 15.08 Favored Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 124.728 1.156 . . . . 0.0 112.937 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.21 -30.22 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -174.805 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 38.2 t30 -91.93 0.38 57.48 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.891 -1.756 . . . . 0.0 111.431 -177.409 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.523 HG22 ' H ' ' A' ' 36' ' ' SER . 26.2 m -83.55 177.5 8.4 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.819 2.048 . . . . 0.0 108.066 -179.999 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.523 ' H ' HG22 ' A' ' 35' ' ' THR . 19.3 m -70.48 -3.29 17.13 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 118.877 -2.389 . . . . 0.0 116.374 -176.483 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 14.1 m -78.87 123.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 122.472 1.129 . . . . 0.0 110.352 172.949 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 91.4 mtt180 -72.44 -34.72 67.98 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.368 -1.458 . . . . 0.0 114.867 -170.916 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 63.6 m170 -76.79 -55.42 5.51 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.6 -1.312 . . . . 0.0 112.822 178.412 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.04 102.25 2.69 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.823 -1.173 . . . . 0.0 112.534 168.705 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.48 168.62 37.49 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 177.089 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.99 136.61 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.899 1.28 . . . . 0.0 108.408 178.46 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -133.89 157.45 45.93 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 121.246 -0.908 . . . . 0.0 108.869 -175.313 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.1 t -76.48 129.73 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 119.872 -1.767 . . . . 0.0 112.338 175.504 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -93.91 -48.88 6.07 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.375 -1.453 . . . . 0.0 112.542 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.92 152.93 32.03 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 123.111 0.565 . . . . 0.0 110.572 -174.849 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -103.43 120.55 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 CA-C-O 122.841 1.305 . . . . 0.0 110.243 174.09 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.81 127.85 83.03 Favored Pre-proline 0 N--CA 1.431 -1.402 0 C-N-CA 126.331 1.852 . . . . 0.0 113.604 -172.002 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -55.73 126.3 21.97 Favored 'Trans proline' 0 N--CA 1.433 -2.042 0 C-N-CA 122.916 2.411 . . . . 0.0 117.034 -177.869 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? 77.22 13.58 2.01 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 128.864 2.866 . . . . 0.0 114.166 176.143 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.48 161.42 51.55 Favored Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.618 -1.301 . . . . 0.0 114.805 179.073 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.21 -57.67 6.34 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 126.843 2.057 . . . . 0.0 114.808 171.505 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.55 -48.53 77.09 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 128.399 2.68 . . . . 0.0 112.233 179.54 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -41.97 -63.07 0.79 Allowed 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 126.836 2.055 . . . . 0.0 114.386 173.497 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.7 m -70.22 -35.05 73.6 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.029 1.492 . . . . 0.0 115.029 -172.044 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -56.43 -68.66 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.238 1.815 . . . . 0.0 113.213 176.536 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.73 6.17 23.34 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 168.575 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -65.94 -49.52 67.64 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 119.09 1.445 . . . . 0.0 110.461 165.046 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.85 134.01 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.506 0 C-N-CA 125.58 1.552 . . . . 0.0 110.032 177.911 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 -145.61 142.36 29.03 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.409 1.084 . . . . 0.0 109.889 -174.862 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -43.74 116.02 0.9 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.231 1.812 . . . . 0.0 115.739 -178.883 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 103.99 -2.95 44.53 Favored Glycine 0 N--CA 1.428 -1.834 0 O-C-N 120.652 -1.28 . . . . 0.0 115.946 179.731 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.276 1.4 p30 -76.95 175.26 9.71 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 120.099 1.949 . . . . 0.0 115.549 -175.166 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -101.94 121.32 41.91 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.677 -1.264 . . . . 0.0 112.564 -175.395 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.12 114.75 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 123.868 0.867 . . . . 0.0 110.288 179.125 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 mp -93.75 -43.93 8.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.321 -1.487 . . . . 0.0 111.17 -176.585 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.6 142.34 24.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.864 -1.147 . . . . 0.0 111.625 -175.256 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.5 t -118.12 117.67 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 124.02 0.928 . . . . 0.0 109.01 175.763 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.3 37.31 14.07 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.985 2.114 . . . . 0.0 113.072 170.515 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.81 -33.23 6.67 Favored Glycine 0 N--CA 1.43 -1.75 0 C-N-CA 124.852 1.215 . . . . 0.0 113.444 -174.73 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -91.58 119.67 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 C-N-CA 124.974 1.309 . . . . 0.0 112.501 -165.292 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.9 m -65.81 130.3 42.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.881 -1.137 . . . . 0.0 112.88 177.796 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 44.2 mt -90.11 62.05 5.39 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.526 -1.359 . . . . 0.0 112.46 -174.892 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -90.09 136.09 33.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.642 -1.286 . . . . 0.0 111.71 174.365 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 71.32 11.47 71.5 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 121.024 -1.047 . . . . 0.0 115.454 175.366 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.0 143.03 49.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -176.236 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 48.1 p -82.35 173.64 11.86 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.995 -1.066 . . . . 0.0 111.118 167.443 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -62.26 -41.65 98.64 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.724 -1.235 . . . . 0.0 112.754 174.496 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -58.74 -47.01 86.08 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 126.069 1.748 . . . . 0.0 114.2 170.94 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -56.07 -47.82 77.24 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 126.524 1.93 . . . . 0.0 114.335 -176.447 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -56.83 -39.73 74.77 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.222 1.809 . . . . 0.0 115.025 173.192 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 79.1 t -69.01 -53.38 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 124.941 1.296 . . . . 0.0 110.862 177.947 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -59.95 -44.18 94.55 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 114.757 1.391 . . . . 0.0 114.757 -176.815 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.7 m -57.67 -40.9 80.44 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.013 2.525 . . . . 0.0 114.545 170.656 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 28.3 mt -68.77 -42.34 77.59 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 119.652 -1.905 . . . . 0.0 113.805 170.956 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 85.8 mmt-85 -60.7 -39.24 87.78 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.698 -1.251 . . . . 0.0 113.501 178.652 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -85.93 48.49 1.61 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.479 -1.388 . . . . 0.0 113.156 178.873 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.435 ' HB ' HG22 ' A' ' 92' ' ' VAL . 21.9 p -106.86 158.03 17.31 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.281 1.832 . . . . 0.0 109.657 173.293 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -98.75 -141.1 11.9 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 121.12 -0.988 . . . . 0.0 112.821 -176.383 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -69.09 -65.26 0.73 Allowed 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 121.058 -1.26 . . . . 0.0 113.251 175.727 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.2 p -98.66 133.66 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 123.14 1.448 . . . . 0.0 110.173 176.523 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.435 HG22 ' HB ' ' A' ' 88' ' ' THR . 99.0 t -124.62 128.78 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 128.297 2.639 . . . . 0.0 108.745 -162.94 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -108.9 93.93 4.78 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.752 -1.218 . . . . 0.0 112.578 -176.537 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 mt -95.27 162.14 13.81 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 119.538 -1.976 . . . . 0.0 112.411 178.002 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.9 tt -130.27 133.04 46.2 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.825 -1.172 . . . . 0.0 110.641 165.917 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.04 162.56 35.18 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 113.609 0.966 . . . . 0.0 113.609 178.527 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -113.54 138.58 49.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 125.712 1.605 . . . . 0.0 107.647 172.249 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.2 tppp? -75.76 134.65 40.4 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 122.216 1.007 . . . . 0.0 111.214 -173.209 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -72.09 149.52 44.41 Favored Glycine 0 N--CA 1.431 -1.691 0 C-N-CA 124.586 1.089 . . . . 0.0 114.638 -177.114 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -81.77 179.04 7.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -173.401 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.7 m -84.31 148.48 52.87 Favored Pre-proline 0 N--CA 1.43 -1.457 0 O-C-N 120.393 -1.442 . . . . 0.0 111.123 176.557 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 C--N 1.299 -2.028 0 C-N-CA 122.153 1.902 . . . . 0.0 112.422 175.827 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 74.8 mttt . . . . . 0 N--CA 1.431 -1.424 0 CA-C-O 115.376 -2.25 . . . . 0.0 114.421 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.11 179.51 6.25 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 CA-C-N 127.29 3.639 . . . . 0.0 111.569 155.961 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.71 -119.88 4.09 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -165.225 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -99.86 -63.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 118.492 1.146 . . . . 0.0 113.695 -174.134 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.0 p -125.98 155.42 41.42 Favored 'General case' 0 N--CA 1.431 -1.384 0 O-C-N 120.126 -1.609 . . . . 0.0 113.011 -179.107 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.475 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 12.4 p90 -145.52 142.42 29.19 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 122.943 1.354 . . . . 0.0 109.182 170.324 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -95.45 126.59 40.85 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.413 1.485 . . . . 0.0 107.955 171.22 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.3 t -118.49 117.77 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.295 1.038 . . . . 0.0 108.488 -174.722 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -100.79 88.08 3.49 Favored 'General case' 0 N--CA 1.432 -1.369 0 O-C-N 120.62 -1.3 . . . . 0.0 108.703 168.976 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 63.2 tp -95.7 137.69 34.4 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.593 1.157 . . . . 0.0 110.214 -174.226 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.32 128.95 47.25 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.185 -1.572 . . . . 0.0 108.566 172.012 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -70.42 136.43 49.55 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 121.344 -0.848 . . . . 0.0 113.123 178.416 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.0 p -107.2 121.03 43.71 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 174.376 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.9 t70 55.17 49.0 18.27 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.982 1.713 . . . . 0.0 113.753 -176.019 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.21 -9.64 6.94 Favored Glycine 0 N--CA 1.429 -1.789 0 N-CA-C 117.739 1.856 . . . . 0.0 117.739 174.315 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -121.43 156.18 33.27 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 119.207 1.503 . . . . 0.0 111.131 -168.531 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 16.4 mt -93.91 -60.4 1.76 Allowed 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.54 1.136 . . . . 0.0 110.925 -177.268 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.03 38.78 0.48 Allowed Glycine 0 N--CA 1.431 -1.657 0 O-C-N 119.373 -2.079 . . . . 0.0 110.54 174.588 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.3 pt -128.93 141.12 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 CA-C-O 121.871 0.843 . . . . 0.0 112.146 -163.208 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 29.7 t -117.77 117.36 29.1 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 166.33 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.47 160.64 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 124.529 1.132 . . . . 0.0 111.158 179.398 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.0 t -150.61 155.63 39.77 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.121 -0.987 . . . . 0.0 111.621 -178.527 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 124.03 -130.13 7.48 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 121.129 -0.982 . . . . 0.0 113.219 168.8 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 124.01 -148.81 16.83 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.182 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.6 t -125.17 -44.95 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.496 0 CA-C-O 123.451 1.596 . . . . 0.0 107.332 171.418 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -74.21 -14.85 61.0 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 126.85 2.06 . . . . 0.0 115.464 -171.239 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.1 p -84.97 -119.51 0.03 OUTLIER 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.466 1.907 . . . . 0.0 112.068 -173.487 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 40.1 p -91.49 -38.5 12.5 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.574 -1.954 . . . . 0.0 111.52 177.057 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 5.6 p -81.46 81.24 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 123.945 1.831 . . . . 0.0 112.03 -177.853 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -62.17 -26.94 68.62 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.826 1.65 . . . . 0.0 114.757 -175.697 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -66.33 -37.16 84.71 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.677 -1.264 . . . . 0.0 113.591 176.506 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.4 106.32 3.09 Favored Glycine 0 N--CA 1.429 -1.789 0 C-N-CA 124.198 0.904 . . . . 0.0 113.139 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -166.52 128.42 1.75 Allowed Glycine 0 N--CA 1.43 -1.759 0 O-C-N 122.002 -0.705 . . . . 0.0 113.887 173.783 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.7 mm -95.99 119.76 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 C-N-CA 125.851 1.66 . . . . 0.0 107.526 171.476 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -123.06 154.4 38.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.145 -0.972 . . . . 0.0 110.303 -174.528 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.6 t -76.8 119.38 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 124.387 1.075 . . . . 0.0 110.555 169.919 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -88.5 -46.83 8.79 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 124.858 1.263 . . . . 0.0 110.38 -176.471 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.75 161.39 37.01 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 123.316 0.647 . . . . 0.0 110.37 177.599 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.53 127.08 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.469 1.107 . . . . 0.0 110.303 176.329 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.1 mp -77.43 122.28 85.75 Favored Pre-proline 0 N--CA 1.43 -1.47 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -169.971 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_exo -55.29 122.13 11.16 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 C-N-CA 123.551 2.834 . . . . 0.0 116.6 179.952 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 17.6 mmtt 80.89 18.82 0.49 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 129.253 3.021 . . . . 0.0 113.488 -177.682 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.76 156.8 33.46 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.127 -1.608 . . . . 0.0 111.942 172.877 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.61 -56.28 7.53 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 125.949 1.699 . . . . 0.0 114.468 171.293 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.31 -51.14 67.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 128.308 2.643 . . . . 0.0 112.832 178.059 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.9 tm-20 -44.92 -59.65 2.46 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 172.441 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.3 t -68.1 -30.36 69.51 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.832 1.253 . . . . 0.0 113.436 -174.078 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -61.36 -55.61 29.62 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.857 1.263 . . . . 0.0 113.869 -177.141 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.59 1.43 29.18 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.516 1.367 . . . . 0.0 116.516 162.108 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.2 mmp_? -74.67 -54.6 7.09 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.5 -1.588 . . . . 0.0 110.367 164.475 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mt -78.25 128.04 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.339 1.456 . . . . 0.0 112.648 -173.607 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.01 172.64 12.71 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-O 124.14 1.924 . . . . 0.0 112.629 177.298 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -56.14 124.04 16.51 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.031 1.732 . . . . 0.0 113.822 172.136 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.88 4.2 61.79 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 113.903 178.759 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -79.11 162.31 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 119.054 1.427 . . . . 0.0 111.794 174.406 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -120.57 123.46 42.92 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.233 -1.542 . . . . 0.0 111.02 -172.978 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.6 t -83.06 125.48 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 O-C-N 120.278 -1.514 . . . . 0.0 111.83 -171.872 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 80.5 mt -103.3 -44.57 5.13 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.743 -1.223 . . . . 0.0 112.324 -177.005 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.4 ' HB3' ' HB3' ' A' ' 95' ' ' LEU . . . -149.97 140.9 22.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.504 -1.373 . . . . 0.0 112.329 -177.874 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -112.75 115.49 49.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 174.72 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 57.86 41.97 23.92 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.641 1.976 . . . . 0.0 114.993 170.606 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.45 -25.62 26.42 Favored Glycine 0 N--CA 1.431 -1.655 0 O-C-N 120.964 -1.085 . . . . 0.0 113.563 -177.008 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 t -94.06 112.25 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.926 -1.338 . . . . 0.0 110.412 -172.947 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . 0.25 81.1 p -76.36 140.66 41.51 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.212 -1.555 . . . . 0.0 112.998 176.851 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.0 mt -85.44 41.68 0.91 Allowed 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.426 1.09 . . . . 0.0 112.29 -168.9 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -72.72 121.53 19.99 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.101 -1.624 . . . . 0.0 112.047 -178.413 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 70.37 11.58 68.17 Favored Glycine 0 N--CA 1.429 -1.821 0 C-N-CA 125.191 1.377 . . . . 0.0 115.764 179.374 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.94 143.57 47.62 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -178.138 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.1 p -91.82 178.81 5.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.644 1.578 . . . . 0.0 111.728 174.34 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 30.8 t-80 -57.3 -52.73 64.16 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 115.873 1.805 . . . . 0.0 115.873 -169.6 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.6 -40.66 79.57 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 178.124 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.4 mp0 -56.92 -51.33 69.54 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.792 2.037 . . . . 0.0 113.209 -172.229 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.49 -39.09 79.06 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.556 1.942 . . . . 0.0 113.823 175.453 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 87.7 t -67.55 -53.04 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.044 1.337 . . . . 0.0 110.727 177.467 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -61.69 -38.69 88.76 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 121.009 -1.057 . . . . 0.0 113.78 -178.609 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.5 m -66.53 -40.42 89.11 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 127.032 2.133 . . . . 0.0 112.682 177.213 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.49 -42.24 87.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.431 -1.418 . . . . 0.0 113.231 171.139 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -68.2 -42.76 79.39 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.523 -1.361 . . . . 0.0 114.605 179.846 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 38.9 t-20 -86.32 57.2 4.35 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 123.036 1.398 . . . . 0.0 111.712 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -98.12 163.59 12.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.017 2.527 . . . . 0.0 109.617 175.115 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.46 -160.11 33.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.422 1.011 . . . . 0.0 110.923 168.931 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 60.1 tt0 -68.74 -52.07 34.53 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.75 -1.441 . . . . 0.0 112.998 -174.234 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.81 119.9 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 C-N-CA 124.894 1.278 . . . . 0.0 109.63 177.008 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 84.5 t -112.18 110.26 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 128.066 2.547 . . . . 0.0 110.153 -167.216 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.1 t-160 -92.8 96.7 10.3 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.7 -1.25 . . . . 0.0 112.779 -178.205 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.3 mt -89.11 156.71 18.65 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.217 -2.177 . . . . 0.0 112.677 175.773 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 95' ' ' LEU . . . . . 0.4 ' HB3' ' HB3' ' A' ' 67' ' ' ALA . 57.9 tp -127.01 129.41 48.02 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 157.611 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.475 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 3.0 pp -150.86 167.34 27.8 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.715 -1.24 . . . . 0.0 111.745 177.784 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -108.89 123.16 48.63 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.17 1.388 . . . . 0.0 110.345 -173.541 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.1 tptm -78.47 139.02 38.73 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.365 1.466 . . . . 0.0 111.37 -178.681 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -93.41 96.03 2.05 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 108.209 -1.956 . . . . 0.0 108.209 163.236 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 28.2 pt20 -65.62 -31.84 73.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 116.266 1.951 . . . . 0.0 116.266 -165.44 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.6 m -104.31 154.15 38.51 Favored Pre-proline 0 N--CA 1.43 -1.473 0 C-N-CA 125.803 1.641 . . . . 0.0 110.283 176.089 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo . . . . . 0 N--CA 1.434 -2.004 0 C-N-CA 122.746 2.298 . . . . 0.0 112.712 169.892 . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? . . . . . 0 N--CA 1.43 -1.432 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 . . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 178.88 6.65 Favored 'Trans proline' 0 N--CA 1.434 -2.006 0 C-N-CA 122.503 2.135 . . . . 0.0 111.992 165.125 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 112.62 38.24 1.34 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 124.085 0.85 . . . . 0.0 111.838 179.175 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -95.66 157.57 15.84 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 124.246 1.018 . . . . 0.0 109.986 177.799 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -96.96 149.24 22.13 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.689 -1.257 . . . . 0.0 111.256 177.102 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -147.8 143.52 27.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 122.923 1.344 . . . . 0.0 109.186 -179.087 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.6 mp0 -102.53 129.53 49.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.536 1.934 . . . . 0.0 108.12 179.12 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.7 t -125.0 97.69 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.825 -1.172 . . . . 0.0 109.753 -170.429 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -97.81 77.24 2.5 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 119.938 -1.726 . . . . 0.0 108.899 173.906 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.4 130.47 52.75 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 125.372 1.469 . . . . 0.0 109.992 -170.159 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.7 154.79 17.04 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 127.074 2.15 . . . . 0.0 112.336 176.656 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -69.12 152.03 45.66 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -175.484 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.2 p -98.77 100.48 11.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.855 -1.153 . . . . 0.0 108.689 171.114 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.3 t0 52.41 52.99 13.08 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.636 1.574 . . . . 0.0 113.798 176.19 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.14 -27.32 10.48 Favored Glycine 0 N--CA 1.429 -1.779 0 O-C-N 120.859 -1.151 . . . . 0.0 115.71 -176.122 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.0 m -98.47 128.18 44.72 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-N 119.64 1.72 . . . . 0.0 113.106 -169.849 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.6 tp -84.63 -56.3 3.67 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.487 -1.383 . . . . 0.0 109.537 175.717 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.93 28.76 0.85 Allowed Glycine 0 N--CA 1.43 -1.764 0 C-N-CA 125.205 1.383 . . . . 0.0 113.249 168.091 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.1 tt -147.19 143.94 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 CA-C-N 119.619 1.709 . . . . 0.0 112.645 -166.26 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.6 t -123.76 138.21 54.55 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.041 1.336 . . . . 0.0 108.889 165.106 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 m -113.74 163.28 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 126.153 1.781 . . . . 0.0 112.313 -177.308 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -145.35 178.15 8.31 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 126.917 2.087 . . . . 0.0 109.556 -179.255 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.97 -145.19 16.22 Favored Glycine 0 N--CA 1.431 -1.669 0 O-C-N 120.562 -1.336 . . . . 0.0 114.65 173.978 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.09 156.51 31.33 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 125.539 1.542 . . . . 0.0 114.622 176.156 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t -48.68 -47.05 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -178.586 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -88.94 18.08 5.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 119.791 -1.818 . . . . 0.0 112.306 -177.38 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 40.5 m -110.53 148.82 31.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 169.592 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.3 m -83.72 56.15 3.52 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.731 -1.856 . . . . 0.0 111.974 -176.317 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.3 p -99.37 153.2 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 127.488 2.315 . . . . 0.0 108.043 174.173 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tpt180 -56.72 116.97 3.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 125.594 1.558 . . . . 0.0 113.57 -179.609 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.4 m80 70.18 -58.15 0.55 Allowed 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.429 2.292 . . . . 0.0 115.561 -174.188 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 142.5 41.22 0.06 OUTLIER Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 124.62 1.105 . . . . 0.0 113.794 178.773 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.89 161.52 28.19 Favored Glycine 0 N--CA 1.431 -1.679 0 O-C-N 120.681 -1.481 . . . . 0.0 114.534 -173.721 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.9 mm -102.91 125.18 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 124.932 1.293 . . . . 0.0 108.255 179.884 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -128.42 155.33 44.93 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.928 -1.107 . . . . 0.0 111.341 -170.724 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.41 125.83 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.358 -1.464 . . . . 0.0 111.8 173.452 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.6 ttmt -89.02 -55.6 3.62 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.005 1.322 . . . . 0.0 110.115 177.203 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.73 150.09 30.61 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 121.502 -0.749 . . . . 0.0 110.607 -171.017 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.415 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -106.89 123.66 62.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.406 1.098 . . . . 0.0 108.306 172.373 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.3 mm -77.49 121.92 85.15 Favored Pre-proline 0 CA--C 1.489 -1.395 0 CA-C-O 115.755 -2.069 . . . . 0.0 114.346 -172.143 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -57.55 115.01 2.2 Favored 'Trans proline' 0 C--N 1.3 -1.996 0 C-N-CA 123.866 3.044 . . . . 0.0 117.151 -174.153 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.382 26.7 mtpp 71.07 41.81 0.78 Allowed 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.157 2.583 . . . . 0.0 114.913 -172.813 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.9 168.21 42.99 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.167 -1.583 . . . . 0.0 112.177 153.294 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.14 -60.02 3.55 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.23 1.812 . . . . 0.0 114.844 165.576 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.83 -42.71 97.56 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.31 2.244 . . . . 0.0 112.904 -178.026 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.415 ' CG ' HG23 ' A' ' 47' ' ' ILE . 4.8 tm-20 -47.91 -61.98 1.69 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.833 1.79 . . . . 0.0 115.833 171.376 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.5 t -68.03 -31.25 70.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.759 1.224 . . . . 0.0 112.515 -173.168 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -64.41 -65.94 0.61 Allowed 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.889 -1.132 . . . . 0.0 111.201 171.548 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 20.6 33.56 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 119.228 -2.17 . . . . 0.0 114.421 162.582 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -63.01 -44.37 96.19 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 121.341 -1.093 . . . . 0.0 109.866 157.442 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 52.0 mt -92.57 131.81 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.233 1.813 . . . . 0.0 110.495 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 60' ' ' HIS . . . . . 0.638 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 6.9 t-80 -145.24 -169.99 3.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-O 123.172 1.463 . . . . 0.0 112.727 167.828 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.638 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 40.4 ttpt -61.99 122.83 16.45 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 126.217 1.807 . . . . 0.0 113.378 -176.551 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 101.83 -4.74 53.32 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.384 -0.823 . . . . 0.0 114.073 179.725 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -74.66 161.61 29.51 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 118.925 1.363 . . . . 0.0 112.868 -177.28 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -122.09 121.3 36.63 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.771 -1.205 . . . . 0.0 111.047 -165.194 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 8.4 t -89.35 125.73 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 120.78 -1.2 . . . . 0.0 111.772 -169.103 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -102.27 -44.57 5.37 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.113 -0.992 . . . . 0.0 111.466 -177.231 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 139.36 21.21 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.681 -1.262 . . . . 0.0 111.67 -178.079 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.7 t -114.34 117.96 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.214 1.006 . . . . 0.0 109.877 177.729 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.3 t30 62.18 29.05 17.41 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 128.274 2.63 . . . . 0.0 114.24 168.808 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.01 -17.99 40.53 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.422 1.487 . . . . 0.0 113.58 -177.386 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.3 t -101.78 123.78 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 O-C-N 120.854 -1.38 . . . . 0.0 110.401 -172.97 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 m -71.27 138.15 49.16 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.105 -1.622 . . . . 0.0 112.825 179.457 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.2 mt -88.41 62.54 6.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.286 -1.509 . . . . 0.0 111.067 179.194 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -89.62 118.12 29.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.35 -1.469 . . . . 0.0 112.039 -178.18 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.34 6.72 70.65 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 125.121 1.343 . . . . 0.0 115.239 177.808 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 150.62 44.4 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 116.157 1.91 . . . . 0.0 116.157 -172.557 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 55.9 p -88.77 174.15 8.16 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.556 1.942 . . . . 0.0 111.235 175.968 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 -58.84 -48.58 80.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.646 -1.284 . . . . 0.0 113.238 177.319 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -53.55 -46.93 70.41 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.691 1.597 . . . . 0.0 114.21 176.572 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -54.89 -49.93 69.99 Favored 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 125.57 1.548 . . . . 0.0 113.633 -179.059 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.25 -38.79 88.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 176.346 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.8 t -67.71 -51.16 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.434 -1.416 . . . . 0.0 111.18 -179.058 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -33.01 74.72 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.35 1.06 . . . . 0.0 112.929 179.799 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 64.0 m -65.31 -49.65 68.66 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.459 1.904 . . . . 0.0 112.671 171.174 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -62.91 -32.48 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.168 -1.583 . . . . 0.0 114.145 174.427 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -65.07 -45.29 85.9 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.383 -1.448 . . . . 0.0 112.925 168.658 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -82.86 45.71 1.02 Allowed 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.218 -1.551 . . . . 0.0 113.755 -179.143 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 p -100.94 160.67 14.17 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 126.819 2.048 . . . . 0.0 109.251 175.485 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.71 -142.37 10.7 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.561 -1.337 . . . . 0.0 112.376 172.919 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -71.21 -59.86 2.54 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 126.294 1.838 . . . . 0.0 111.34 172.319 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 11.0 p -94.46 134.16 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.078 1.351 . . . . 0.0 111.465 -179.868 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 87.5 t -125.65 123.23 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.857 -1.152 . . . . 0.0 109.986 -169.685 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 2.2 m-70 -103.61 89.79 3.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.122 -1.611 . . . . 0.0 114.204 -176.035 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.7 mt -89.0 155.91 19.19 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.665 -2.522 . . . . 0.0 112.934 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.7 tt -129.98 128.28 41.73 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 161.297 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -154.04 170.69 20.51 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.892 -1.13 . . . . 0.0 112.934 -174.963 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -119.23 144.3 46.82 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.815 1.646 . . . . 0.0 110.461 -178.691 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? -75.31 140.78 43.33 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.626 -1.297 . . . . 0.0 111.132 174.977 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -66.23 121.1 17.39 Favored Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 125.353 1.454 . . . . 0.0 114.302 176.534 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -83.42 178.56 7.98 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 121.262 -1.14 . . . . 0.0 113.661 -177.349 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 2.9 m -98.12 114.03 64.63 Favored Pre-proline 0 N--CA 1.429 -1.491 0 O-C-N 120.821 -1.174 . . . . 0.0 110.272 175.469 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo . . . . . 0 C--N 1.3 -1.994 0 CA-C-N 123.431 2.261 . . . . 0.0 114.428 178.277 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.429 -1.494 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -81.06 -179.91 5.44 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.681 2.254 . . . . 0.0 111.906 174.597 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 92.65 23.04 27.05 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 115.54 0.976 . . . . 0.0 115.54 174.998 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -91.77 157.41 16.92 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 118.741 1.271 . . . . 0.0 110.346 174.155 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -108.04 155.3 20.52 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.76 1.224 . . . . 0.0 112.855 -177.933 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -144.83 143.31 30.56 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.492 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -93.5 137.89 32.33 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 168.114 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.421 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 26.4 t -126.07 99.53 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -175.407 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -99.39 89.79 4.31 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-O 123.049 1.404 . . . . 0.0 109.046 176.527 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.0 tp -118.11 141.14 48.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.983 1.713 . . . . 0.0 110.844 -160.499 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.59 136.85 42.53 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.509 -1.37 . . . . 0.0 111.057 175.916 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -66.84 161.46 23.81 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 117.035 2.235 . . . . 0.0 117.035 -173.267 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.5 p -113.2 99.4 7.79 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 126.532 1.933 . . . . 0.0 109.333 174.675 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.9 t70 50.14 49.91 19.57 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.726 1.61 . . . . 0.0 114.92 171.643 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.05 -18.95 55.72 Favored Glycine 0 N--CA 1.431 -1.682 0 O-C-N 120.05 -1.656 . . . . 0.0 116.345 179.873 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.7 p -113.16 161.23 17.38 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 119.312 1.556 . . . . 0.0 113.239 -177.079 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 mt -97.05 -54.97 3.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 166.508 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.22 50.34 0.34 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.005 -1.684 . . . . 0.0 110.438 171.722 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tt -146.13 142.83 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 CA-C-O 122.618 1.199 . . . . 0.0 109.751 -174.147 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.0 t -111.17 129.77 55.84 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 168.571 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 m -111.07 165.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 C-N-CA 124.642 1.177 . . . . 0.0 110.547 -178.794 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 t -151.19 170.14 20.19 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.768 -1.207 . . . . 0.0 109.865 177.996 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.72 -154.68 20.35 Favored Glycine 0 N--CA 1.431 -1.696 0 O-C-N 121.337 -0.852 . . . . 0.0 112.73 178.069 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.63 147.85 23.28 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 121.698 -0.883 . . . . 0.0 113.008 -178.068 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m -63.05 -15.9 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 N-CA-C 116.728 2.122 . . . . 0.0 116.728 -167.678 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -80.48 -23.26 40.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.35 -1.469 . . . . 0.0 113.638 -179.909 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.1 p -81.27 -136.12 0.03 OUTLIER 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.618 1.167 . . . . 0.0 113.481 -164.697 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.9 m -77.09 -39.53 49.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 119.086 -2.259 . . . . 0.0 110.96 174.642 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -78.15 123.99 35.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.511 1.124 . . . . 0.0 112.312 -175.523 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -67.75 -60.53 2.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.288 -1.508 . . . . 0.0 113.257 -177.94 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -88.97 80.46 7.06 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.372 -1.455 . . . . 0.0 109.58 169.06 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -82.86 115.54 4.04 Favored Glycine 0 N--CA 1.429 -1.779 0 CA-C-O 122.364 0.98 . . . . 0.0 114.868 -173.286 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.08 163.98 34.95 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 157.875 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.6 mm -99.97 128.51 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 177.338 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -127.12 159.06 35.35 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.795 -1.191 . . . . 0.0 109.684 -173.674 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.26 125.53 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 O-C-N 121.089 -1.007 . . . . 0.0 111.897 176.493 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -91.9 -49.11 6.41 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.381 177.879 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -159.12 157.76 31.59 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.412 -1.43 . . . . 0.0 111.33 177.602 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.39 121.38 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.656 1.217 . . . . 0.0 110.056 174.404 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 22.0 mm -77.47 133.28 67.66 Favored Pre-proline 0 N--CA 1.429 -1.477 0 C-N-CA 127.527 2.331 . . . . 0.0 115.671 -165.901 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -54.07 118.19 4.71 Favored 'Trans proline' 0 N--CA 1.434 -1.973 0 C-N-CA 123.864 3.043 . . . . 0.0 118.335 -178.704 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 61.85 40.74 12.37 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 128.949 2.9 . . . . 0.0 113.646 -177.274 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.29 164.23 36.45 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.114 -1.616 . . . . 0.0 112.86 162.785 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.62 -57.37 7.29 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.359 1.864 . . . . 0.0 114.87 164.472 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.6 -43.32 97.26 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 127.341 2.256 . . . . 0.0 112.517 -179.03 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.96 -62.38 1.56 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 167.143 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.4 t -69.52 -23.21 63.57 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.244 1.418 . . . . 0.0 114.719 -170.781 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -59.54 -58.32 9.11 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 125.837 1.655 . . . . 0.0 113.495 178.81 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.9 -13.02 10.68 Favored Glycine 0 N--CA 1.43 -1.729 0 CA-C-N 120.419 1.463 . . . . 0.0 115.651 168.347 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.5 mmt180 -75.16 -52.64 10.47 Favored 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 120.515 -1.58 . . . . 0.0 111.258 177.034 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 57.3 mt -81.06 116.38 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 126.231 1.812 . . . . 0.0 112.789 -168.738 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -117.88 164.91 14.34 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.37 1.868 . . . . 0.0 112.039 -179.262 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.76 124.34 20.46 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.551 -1.968 . . . . 0.0 114.019 176.459 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.12 6.8 68.67 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.686 -1.259 . . . . 0.0 114.736 -176.25 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -75.56 160.65 29.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.341 1.57 . . . . 0.0 111.273 174.024 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.7 ttt180 -101.44 126.71 48.26 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.794 -1.191 . . . . 0.0 110.29 -175.503 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.8 t -86.66 111.64 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.429 1.092 . . . . 0.0 108.494 -177.087 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.3 mt -91.14 -53.95 4.15 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.005 -1.684 . . . . 0.0 111.996 -171.571 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.11 146.99 27.96 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.807 -1.183 . . . . 0.0 108.881 -176.774 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.54 110.34 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 177.02 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.0 t30 63.17 34.99 13.09 Favored 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 126.424 1.89 . . . . 0.0 114.989 167.026 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 92.97 -6.01 76.24 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 121.083 -1.011 . . . . 0.0 113.884 -174.93 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.4 t -96.94 113.31 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-N 118.909 1.354 . . . . 0.0 109.719 179.057 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.3 m -70.94 123.89 23.07 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 124.551 1.14 . . . . 0.0 111.047 176.642 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 23.8 mt -84.23 0.76 47.62 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.306 -1.496 . . . . 0.0 114.381 -172.613 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.31 111.98 0.99 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.277 -1.514 . . . . 0.0 114.135 179.263 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.28 12.97 79.84 Favored Glycine 0 N--CA 1.429 -1.78 0 C-N-CA 124.499 1.047 . . . . 0.0 114.473 -179.081 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.72 160.69 31.8 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.208 -1.76 . . . . 0.0 115.742 173.085 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.9 p -89.87 173.88 8.0 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.488 -1.382 . . . . 0.0 111.131 171.505 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -59.59 -49.42 77.83 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.347 1.459 . . . . 0.0 112.186 170.179 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -55.35 -46.15 76.43 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 125.067 1.347 . . . . 0.0 114.102 173.716 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -55.92 -54.06 49.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 178.202 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.62 87.43 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 178.343 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.9 t -66.11 -49.51 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.859 -1.151 . . . . 0.0 111.372 176.377 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -66.99 -31.47 72.06 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.5 -1.375 . . . . 0.0 113.624 -179.083 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 100.0 m -65.82 -49.93 66.47 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 127.315 2.246 . . . . 0.0 111.667 171.525 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.8 mt -59.89 -41.15 90.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.466 -1.396 . . . . 0.0 113.97 174.083 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -60.33 -41.04 92.7 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.749 -1.22 . . . . 0.0 113.515 172.628 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -83.23 25.68 0.7 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.487 -1.383 . . . . 0.0 114.584 -179.618 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.442 ' HB ' HG22 ' A' ' 92' ' ' VAL . 59.0 p -87.23 150.9 23.6 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.13 -1.606 . . . . 0.0 109.056 168.783 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.74 -152.31 21.4 Favored Glycine 0 N--CA 1.429 -1.788 0 O-C-N 121.243 -0.911 . . . . 0.0 112.854 -179.667 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -69.59 -50.94 39.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.972 -1.31 . . . . 0.0 112.955 -177.409 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.0 p -97.79 134.25 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 123.094 1.426 . . . . 0.0 109.625 166.19 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.442 HG22 ' HB ' ' A' ' 88' ' ' THR . 97.4 t -122.89 123.37 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 126.735 2.014 . . . . 0.0 109.027 -164.897 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 1.2 m-70 -100.59 103.05 14.33 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.53 -1.357 . . . . 0.0 111.242 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.421 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 28.8 mt -100.45 158.61 15.78 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.608 -1.932 . . . . 0.0 112.554 175.87 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 45.9 tp -127.57 130.68 49.5 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 161.278 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -141.84 167.25 22.6 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.469 -1.395 . . . . 0.0 112.814 176.168 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -122.26 147.71 45.88 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 124.671 1.188 . . . . 0.0 110.099 179.28 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? -75.02 127.45 33.27 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.371 1.868 . . . . 0.0 110.559 179.803 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -73.69 156.43 50.78 Favored Glycine 0 N--CA 1.429 -1.768 0 C-N-CA 125.048 1.309 . . . . 0.0 116.266 -174.591 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -79.51 -82.62 0.1 Allowed 'General case' 0 N--CA 1.431 -1.398 0 C-N-CA 125.169 1.388 . . . . 0.0 113.056 -173.51 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 30.9 m -101.63 158.1 32.41 Favored Pre-proline 0 N--CA 1.43 -1.461 0 C-N-CA 125.28 1.432 . . . . 0.0 111.875 -175.824 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo . . . . . 0 N--CA 1.434 -2.002 0 C-N-CA 122.504 2.136 . . . . 0.0 112.436 167.857 . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 76.4 mttt . . . . . 0 N--CA 1.431 -1.417 0 CA-C-O 118.57 -0.729 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -77.74 178.67 7.33 Favored 'Trans proline' 0 N--CA 1.434 -2.021 0 C-N-CA 122.554 2.169 . . . . 0.0 113.024 179.633 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 96.29 -22.72 38.34 Favored Glycine 0 N--CA 1.431 -1.68 0 N-CA-C 116.267 1.267 . . . . 0.0 116.267 165.856 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.1 t0 -77.17 143.23 39.22 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 121.053 -1.263 . . . . 0.0 112.13 -178.691 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.6 p -103.45 146.13 28.98 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.796 -1.19 . . . . 0.0 111.592 -179.445 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.463 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 8.3 p90 -148.29 144.97 27.96 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-O 122.552 1.167 . . . . 0.0 109.244 171.683 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -89.8 146.16 24.66 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.99 1.716 . . . . 0.0 108.799 172.728 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 20.0 t -124.89 102.55 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.106 -1.621 . . . . 0.0 107.92 177.636 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -96.18 99.13 10.89 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 168.179 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 54.0 tp -123.44 138.51 54.57 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.279 1.432 . . . . 0.0 110.905 -167.374 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 133.84 45.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.44 -1.413 . . . . 0.0 109.763 172.151 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -65.77 153.3 42.19 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 177.627 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 62.3 p -119.88 116.47 25.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 172.236 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.1 t0 56.98 48.74 15.17 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.855 1.662 . . . . 0.0 113.723 178.598 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 -7.37 30.19 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 125.744 1.64 . . . . 0.0 116.55 177.722 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.9 m -121.19 150.23 41.62 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.266 -1.138 . . . . 0.0 111.25 -162.287 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.8 mt -97.16 -62.67 1.22 Allowed 'General case' 0 N--CA 1.429 -1.521 0 O-C-N 120.665 -1.272 . . . . 0.0 111.447 178.52 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.02 46.88 0.32 Allowed Glycine 0 N--CA 1.43 -1.755 0 O-C-N 120.4 -1.438 . . . . 0.0 111.979 171.573 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.4 tt -147.49 150.4 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 CA-C-O 122.578 1.18 . . . . 0.0 111.217 -172.883 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -123.84 132.73 53.82 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.639 1.176 . . . . 0.0 108.699 168.943 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -102.61 163.81 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.812 1.245 . . . . 0.0 113.179 -179.604 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 t -147.5 169.98 18.41 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 126.095 1.758 . . . . 0.0 109.3 -177.363 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.57 -139.31 14.34 Favored Glycine 0 N--CA 1.43 -1.708 0 O-C-N 120.707 -1.246 . . . . 0.0 113.833 171.154 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.3 -177.36 34.89 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 121.415 -1.05 . . . . 0.0 113.206 -178.656 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.1 m -65.08 -24.16 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 N-CA-C 116.695 2.109 . . . . 0.0 116.695 -172.078 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -99.07 16.05 23.89 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.85 -1.156 . . . . 0.0 111.645 -175.014 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 72.0 p -115.28 158.93 21.66 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 124.72 1.208 . . . . 0.0 109.648 168.551 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.8 t -92.37 60.42 3.62 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.261 -1.525 . . . . 0.0 112.518 -176.119 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.8 m -97.48 -2.82 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 120.428 -1.42 . . . . 0.0 112.754 -177.99 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.283 8.0 mpt_? 84.21 119.28 0.04 OUTLIER 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 129.843 3.257 . . . . 0.0 110.269 -169.418 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 68.59 -61.4 0.41 Allowed 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 127.133 2.173 . . . . 0.0 115.58 -179.794 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.5 95.47 0.27 Allowed Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.008 1.29 . . . . 0.0 110.848 179.486 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -128.95 148.24 18.02 Favored Glycine 0 N--CA 1.43 -1.758 0 C-N-CA 123.964 0.792 . . . . 0.0 114.115 -176.675 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.2 mm -93.92 130.26 43.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 126.485 1.914 . . . . 0.0 109.477 -178.882 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -126.44 163.03 24.21 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.807 -1.183 . . . . 0.0 110.222 -178.37 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.6 t -76.69 126.55 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.765 -1.209 . . . . 0.0 112.016 169.559 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -91.91 -52.05 4.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.943 -1.098 . . . . 0.0 111.875 176.937 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.6 155.57 39.67 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.079 -1.013 . . . . 0.0 109.977 -177.762 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.477 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -116.68 123.58 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.156 0.979 . . . . 0.0 108.484 175.455 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 23.2 mm -77.76 121.86 84.83 Favored Pre-proline 0 N--CA 1.43 -1.459 0 C-N-CA 125.866 1.666 . . . . 0.0 113.399 -172.399 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -59.19 131.51 41.66 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 CA-C-N 124.323 2.58 . . . . 0.0 115.821 -176.547 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 92.5 mttt 77.39 17.33 1.51 Allowed 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 127.331 2.252 . . . . 0.0 112.822 -178.613 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.1 158.78 42.66 Favored Glycine 0 N--CA 1.429 -1.8 0 O-C-N 119.864 -1.772 . . . . 0.0 113.048 173.462 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.83 -59.38 3.89 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.625 1.97 . . . . 0.0 114.193 166.674 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.5 -48.0 81.5 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.271 2.228 . . . . 0.0 112.136 179.854 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.477 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.7 tm-20 -44.7 -66.0 0.45 Allowed 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 116.318 1.97 . . . . 0.0 116.318 170.442 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 44.8 t -63.32 -25.96 68.54 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -172.895 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -54.33 -53.19 57.19 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 124.983 1.313 . . . . 0.0 113.602 179.319 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.46 -8.16 54.67 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.507 -0.746 . . . . 0.0 113.204 167.234 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -68.12 -44.84 75.22 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.229 -1.16 . . . . 0.0 111.153 168.605 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.0 mt -91.56 131.56 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.927 1.691 . . . . 0.0 112.47 -175.65 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.22 179.47 7.75 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.245 -1.534 . . . . 0.0 112.922 170.579 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -60.09 129.44 41.78 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.761 -1.837 . . . . 0.0 114.956 -175.005 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.51 3.12 78.43 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.919 -1.113 . . . . 0.0 115.07 -179.693 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 63' ' ' ASP . . . . . 0.43 ' HB3' HD13 ' A' ' 96' ' ' LEU . 86.7 m-20 -76.03 145.75 39.95 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 119.617 1.708 . . . . 0.0 111.739 176.266 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -95.3 125.5 39.97 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.252 -1.53 . . . . 0.0 110.384 -173.711 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 54.1 t -81.43 132.3 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.243 -1.535 . . . . 0.0 109.107 -178.884 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -103.24 -52.96 2.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.079 -1.013 . . . . 0.0 109.299 177.406 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.88 134.77 17.79 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 111.638 -171.799 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 84' ' ' THR . 61.1 t -110.36 120.2 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.532 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 67.81 18.54 9.7 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.51 1.924 . . . . 0.0 113.525 174.9 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.39 -17.22 54.09 Favored Glycine 0 N--CA 1.428 -1.839 0 O-C-N 120.771 -1.206 . . . . 0.0 112.981 -175.719 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.5 t -88.66 114.03 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 O-C-N 120.657 -1.496 . . . . 0.0 109.833 -178.372 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.2 m -75.65 127.85 33.95 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 120.727 -1.233 . . . . 0.0 111.279 -179.947 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.26 51.27 2.19 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.847 -1.158 . . . . 0.0 113.583 -165.302 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -74.49 111.32 9.57 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 119.162 -2.212 . . . . 0.0 115.182 -170.42 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.45 13.24 83.07 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.634 -1.291 . . . . 0.0 114.14 -179.751 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.34 159.44 34.56 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.715 1.245 . . . . 0.0 113.991 -179.133 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 45.6 p -84.68 169.77 13.97 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.512 -1.368 . . . . 0.0 111.448 172.288 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -56.25 -47.12 79.15 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.437 1.495 . . . . 0.0 112.176 168.452 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.6 tptp -50.72 -50.03 56.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.976 1.71 . . . . 0.0 113.973 174.501 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -56.27 -49.04 75.36 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 174.92 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.41 88.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.726 1.21 . . . . 0.0 114.182 174.951 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.31 -46.8 86.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 O-C-N 120.732 -1.23 . . . . 0.0 111.62 175.638 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -61.47 -34.45 75.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.557 -1.34 . . . . 0.0 114.094 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 84' ' ' THR . . . . . 0.403 HG22 HG11 ' A' ' 68' ' ' VAL . 1.5 m -77.82 -35.39 51.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.525 1.53 . . . . 0.0 113.091 174.832 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 53.1 mt -70.2 -24.29 63.09 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 119.694 -1.879 . . . . 0.0 114.783 168.997 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -69.64 -48.65 59.18 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 119.68 -1.888 . . . . 0.0 111.984 168.064 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -85.44 52.58 2.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 114.394 1.257 . . . . 0.0 114.394 -176.402 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 56.6 p -88.99 178.78 6.31 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.112 -1.617 . . . . 0.0 109.941 170.691 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.89 -165.31 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 160.836 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -70.56 -42.7 70.77 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.52 -0.988 . . . . 0.0 112.714 175.067 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 41.8 t -94.83 126.59 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 166.5 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 53.0 t -114.45 132.29 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 129.22 3.008 . . . . 0.0 108.653 -168.148 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -120.73 91.25 3.49 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 111.557 -170.845 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.9 mt -94.51 155.01 17.13 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.619 -1.926 . . . . 0.0 112.637 177.786 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.0 tt -129.62 133.13 46.98 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.456 -0.777 . . . . 0.0 109.103 161.984 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.463 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.6 pp -152.63 170.41 20.3 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 120.143 -1.598 . . . . 0.0 112.669 -175.083 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -116.53 145.51 43.28 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 125.576 1.55 . . . . 0.0 110.235 179.647 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 18.4 tptt -75.45 137.98 41.32 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 125.955 1.702 . . . . 0.0 112.524 -177.446 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -98.82 165.6 21.12 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 125.359 1.457 . . . . 0.0 112.77 176.546 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -77.18 179.75 6.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -176.766 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.2 m -111.05 154.32 43.52 Favored Pre-proline 0 N--CA 1.43 -1.456 0 O-C-N 120.404 -1.435 . . . . 0.0 111.736 -170.788 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_exo . . . . . 0 N--CA 1.434 -2.015 0 C-N-CA 123.073 2.515 . . . . 0.0 115.638 168.836 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 12.6 t70 . . . . . 0 N--CA 1.43 -1.428 0 CA-C-O 120.539 0.209 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.84 154.26 20.39 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.648 -1.907 . . . . 0.0 112.467 -175.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -146.15 141.38 27.45 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.131 0.967 . . . . 0.0 109.505 167.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -92.7 119.73 32.4 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.776 1.63 . . . . 0.0 107.276 163.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 10.9 t -107.65 101.57 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 122.485 1.136 . . . . 0.0 108.029 -174.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -92.43 79.6 4.94 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.461 1.505 . . . . 0.0 108.749 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.9 tp -104.64 133.52 49.36 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-O 122.643 1.211 . . . . 0.0 111.264 -166.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.7 146.32 27.9 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.167 -1.583 . . . . 0.0 108.848 170.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.76 158.67 34.99 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.205 -1.559 . . . . 0.0 114.558 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.2 t -112.05 105.33 13.69 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 170.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . 0.256 22.9 t70 29.64 63.29 0.15 Allowed 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.94 2.896 . . . . 0.0 117.37 -165.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.74 10.09 85.56 Favored Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 117.244 1.658 . . . . 0.0 117.244 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.6 m -121.1 134.15 55.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 119.586 1.693 . . . . 0.0 113.499 176.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.6 mt -89.98 -63.01 1.34 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.552 1.141 . . . . 0.0 111.857 167.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.35 34.35 2.51 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 119.684 -1.885 . . . . 0.0 114.378 173.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.9 pt -125.92 131.47 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.686 1.594 . . . . 0.0 110.769 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 22.4 t -105.63 106.9 17.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 166.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.7 m -110.02 152.77 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 C-N-CA 124.548 1.139 . . . . 0.0 111.414 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.1 t -150.7 175.61 11.8 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.167 -0.958 . . . . 0.0 110.974 -172.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.01 -127.5 7.13 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 121.054 -1.029 . . . . 0.0 113.527 170.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.61 -170.52 20.27 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.36 1.457 . . . . 0.0 112.174 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.43 -1.456 0 C-N-CA 124.896 1.278 . . . . 0.0 114.343 -177.968 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.704 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.4 mm -103.75 129.08 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.842 1.257 . . . . 0.0 108.155 -178.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -127.68 149.47 50.19 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 121.312 -0.868 . . . . 0.0 109.574 -171.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.5 t -77.09 122.62 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 O-C-N 120.845 -1.159 . . . . 0.0 111.684 172.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -88.33 -50.44 6.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.827 -1.171 . . . . 0.0 110.816 176.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.51 158.65 44.4 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 122.162 -0.337 . . . . 0.0 111.829 -175.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.41 120.47 64.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.706 1.202 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.68 119.55 77.9 Favored Pre-proline 0 N--CA 1.429 -1.477 0 CA-C-O 116.794 -1.574 . . . . 0.0 113.37 -169.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -63.66 128.18 21.58 Favored 'Trans proline' 0 N--CA 1.434 -2.018 0 C-N-CA 123.207 2.605 . . . . 0.0 113.931 -173.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.264 54.3 mttm 82.47 21.33 0.25 Allowed 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 128.063 2.545 . . . . 0.0 113.642 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.1 160.83 37.18 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 119.897 -1.752 . . . . 0.0 114.428 170.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -52.44 -59.78 4.02 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.341 1.856 . . . . 0.0 115.402 164.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.49 -45.23 88.23 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 128.823 2.849 . . . . 0.0 111.225 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -44.42 -64.2 0.73 Allowed 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 170.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 m -70.2 -22.37 62.94 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.565 1.691 . . . . 0.0 115.565 -177.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.45 -61.61 2.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.829 1.652 . . . . 0.0 112.603 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.88 5.0 64.71 Favored Glycine 0 N--CA 1.43 -1.717 0 N-CA-C 116.14 1.216 . . . . 0.0 116.14 169.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -77.17 -32.92 56.53 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 118.767 1.283 . . . . 0.0 109.635 160.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.7 mt -92.27 135.91 26.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.966 1.306 . . . . 0.0 109.161 170.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -159.47 160.97 35.33 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.589 -1.319 . . . . 0.0 110.014 178.144 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.5 pttt -64.87 135.49 55.79 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.383 -2.073 . . . . 0.0 114.628 -171.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.46 4.93 67.62 Favored Glycine 0 N--CA 1.43 -1.744 0 CA-C-O 118.295 -1.28 . . . . 0.0 115.436 -172.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.344 1.6 p30 -80.15 166.13 21.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 121.468 2.634 . . . . 0.0 114.375 171.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 9.9 tpt85 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.496 1.118 . . . . 0.0 109.186 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 5.0 t -85.68 139.27 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 123.748 0.819 . . . . 0.0 109.805 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.17 -53.23 2.7 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.862 -1.149 . . . . 0.0 109.291 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.69 150.62 31.31 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 112.744 -175.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.917 HG11 HG21 ' A' ' 84' ' ' THR . 2.5 p -119.38 107.74 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 125.45 1.5 . . . . 0.0 110.266 177.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.1 t30 58.93 37.05 24.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.672 -1.893 . . . . 0.0 113.282 173.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.07 -29.69 11.59 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.891 1.234 . . . . 0.0 114.023 -172.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 44.5 t -87.98 119.55 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 119.734 1.767 . . . . 0.0 110.777 -163.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.8 m -69.87 117.63 11.71 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.1 -1.0 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 18.2 mt -83.84 -4.65 58.83 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.573 -1.329 . . . . 0.0 113.873 -169.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -74.05 116.37 14.6 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.217 -1.552 . . . . 0.0 112.044 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 107.93 -20.87 30.62 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 124.175 0.893 . . . . 0.0 112.064 -175.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.35 148.79 46.68 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.772 -1.428 . . . . 0.0 112.902 172.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.414 HG22 ' H ' ' A' ' 78' ' ' HIS . 0.2 OUTLIER -90.21 -179.14 5.58 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.301 -1.499 . . . . 0.0 112.008 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . 0.414 ' H ' HG22 ' A' ' 77' ' ' THR . 10.4 t-160 -61.23 -47.6 85.35 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.463 1.905 . . . . 0.0 112.765 -174.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.68 -46.96 80.85 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 115.173 1.546 . . . . 0.0 115.173 173.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 15.9 mp0 -55.88 -51.13 68.65 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.681 1.593 . . . . 0.0 113.822 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.05 -36.42 83.51 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.1 t -67.29 -49.39 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 O-C-N 120.661 -1.274 . . . . 0.0 110.941 176.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -62.5 -37.12 84.78 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.126 0.97 . . . . 0.0 113.285 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . 0.917 HG21 HG11 ' A' ' 68' ' ' VAL . 54.0 m -58.59 -52.28 66.32 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.261 1.824 . . . . 0.0 112.57 173.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -63.27 -37.02 85.61 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 175.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.44 -42.88 99.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.108 1.363 . . . . 0.0 111.608 175.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -88.97 43.16 1.13 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.716 1.606 . . . . 0.0 112.663 177.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.6 p -100.53 156.19 17.43 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.203 -1.56 . . . . 0.0 110.184 169.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.32 -146.42 20.32 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.656 1.122 . . . . 0.0 113.141 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -69.97 -57.41 5.04 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.757 -1.437 . . . . 0.0 114.331 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.38 131.91 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 CA-C-O 122.454 1.121 . . . . 0.0 108.534 176.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -124.57 120.73 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 127.611 2.364 . . . . 0.0 108.977 -167.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -107.2 93.41 4.54 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 119.878 -1.764 . . . . 0.0 112.523 -171.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 1.1 mm? -91.54 160.04 15.62 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 118.782 -2.448 . . . . 0.0 113.794 -177.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 38.8 tp -127.87 128.92 46.03 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.289 1.436 . . . . 0.0 108.867 162.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.72 169.89 18.11 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.292 -1.505 . . . . 0.0 113.041 177.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -126.96 134.94 50.28 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.149 0.979 . . . . 0.0 112.873 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.47 0 C-N-CA 126.415 1.886 . . . . 0.0 113.444 -177.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.429 -1.478 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 48.4 p -100.14 162.59 12.87 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.416 -1.427 . . . . 0.0 113.276 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.62 149.86 34.34 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 168.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -104.03 119.11 38.23 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-O 122.719 1.247 . . . . 0.0 109.242 167.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.8 t -98.07 108.48 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.588 1.955 . . . . 0.0 108.344 -175.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -104.42 86.47 2.53 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.196 1.398 . . . . 0.0 108.443 173.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 52.5 tp -120.38 142.29 49.31 Favored 'General case' 0 N--CA 1.431 -1.379 0 C-N-CA 125.111 1.364 . . . . 0.0 110.609 -165.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 140.59 35.9 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.651 1.58 . . . . 0.0 110.585 173.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -69.71 158.79 34.72 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.9 p -112.61 105.7 13.95 Favored 'General case' 0 N--CA 1.429 -1.518 0 C-N-CA 125.076 1.35 . . . . 0.0 108.761 172.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.2 t70 55.34 45.38 25.62 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.437 1.895 . . . . 0.0 113.656 -176.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.44 -5.26 64.61 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.349 -1.47 . . . . 0.0 115.563 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 60.5 p -107.92 149.78 27.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -174.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.0 mt -100.83 -56.25 2.37 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.229 1.411 . . . . 0.0 108.278 172.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 51' ' ' GLY . . . 106.06 55.71 0.68 Allowed Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.324 -1.485 . . . . 0.0 111.863 173.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.5 tt -143.39 142.26 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 CA-C-O 122.295 1.045 . . . . 0.0 110.401 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 44.3 t -112.79 115.09 27.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.435 1.894 . . . . 0.0 107.441 171.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.6 m -101.4 160.1 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 122.43 1.11 . . . . 0.0 111.84 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.5 t -144.05 -179.46 6.51 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 125.253 1.421 . . . . 0.0 107.906 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.1 -155.43 16.3 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 121.085 -1.009 . . . . 0.0 113.722 173.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.2 152.68 22.55 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.692 1.139 . . . . 0.0 114.173 176.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.43 -1.456 0 N-CA-C 115.208 1.559 . . . . 0.0 115.208 -170.247 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.752 0 CA-C-O 121.661 0.59 . . . . 0.0 114.313 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 46.7 mm -103.69 127.72 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 125.487 1.515 . . . . 0.0 108.082 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -130.92 157.01 44.08 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 121.07 -1.019 . . . . 0.0 112.6 -168.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.4 t -75.87 124.4 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.97 -1.081 . . . . 0.0 111.168 169.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -93.15 -46.43 7.43 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.246 -0.909 . . . . 0.0 110.61 170.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.53 153.5 34.68 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 111.121 177.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.16 121.68 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-O 123.016 1.389 . . . . 0.0 109.052 176.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 33.2 mm -76.53 126.27 86.37 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 127.028 2.131 . . . . 0.0 113.157 -166.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -60.63 138.42 79.83 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 124.722 2.722 . . . . 0.0 113.976 -173.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm 53.43 37.08 24.73 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 116.822 2.156 . . . . 0.0 116.822 -169.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 26' ' ' GLY . . . -84.72 160.74 35.97 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.078 -1.639 . . . . 0.0 113.225 159.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.75 -56.37 12.34 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.252 -1.734 . . . . 0.0 115.658 163.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.71 -47.65 77.57 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.196 2.999 . . . . 0.0 112.517 -179.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -40.81 -64.88 0.48 Allowed 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.656 1.582 . . . . 0.0 113.975 164.696 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 12.9 t -67.65 -34.89 77.84 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.456 1.102 . . . . 0.0 113.887 -170.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -53.46 -65.43 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.616 1.966 . . . . 0.0 113.906 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.22 -10.78 24.45 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 115.496 0.959 . . . . 0.0 115.496 172.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -72.72 -24.75 61.03 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 119.634 1.717 . . . . 0.0 113.194 172.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 67.5 mt -105.4 135.93 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.542 1.537 . . . . 0.0 108.452 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -154.15 158.25 40.1 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.844 -1.16 . . . . 0.0 112.169 -170.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -51.83 122.78 8.85 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.007 -1.683 . . . . 0.0 115.49 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.59 -5.51 64.63 Favored Glycine 0 N--CA 1.429 -1.771 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 0.3 OUTLIER -80.19 171.83 14.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.923 1.861 . . . . 0.0 114.343 -175.823 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -119.74 125.73 49.35 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.402 -1.436 . . . . 0.0 112.709 -169.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.0 t -82.61 127.85 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.734 -1.229 . . . . 0.0 110.027 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.41 -46.45 5.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 110.525 176.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.79 136.57 17.13 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.556 -1.34 . . . . 0.0 114.003 -177.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -104.37 116.93 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 124.536 1.135 . . . . 0.0 108.525 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.5 t30 59.38 39.47 22.13 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.137 -1.602 . . . . 0.0 113.767 175.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.09 -33.5 5.21 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 121.209 -0.932 . . . . 0.0 113.889 -174.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -87.03 117.75 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 C-N-CA 124.725 1.21 . . . . 0.0 111.471 -167.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 t -76.55 139.32 40.68 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.318 -1.489 . . . . 0.0 112.628 -174.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.2 mt -89.69 20.86 3.79 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -171.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -62.17 117.71 6.4 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 119.829 -1.794 . . . . 0.0 114.591 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 84.94 10.8 78.02 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 124.483 1.039 . . . . 0.0 113.65 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.72 157.14 38.46 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.3 p -91.22 170.03 10.34 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.863 -1.148 . . . . 0.0 109.677 170.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -53.91 -55.2 29.09 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.889 1.276 . . . . 0.0 113.322 170.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -56.44 -44.34 80.34 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.049 1.499 . . . . 0.0 115.049 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -61.06 -46.05 92.25 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -175.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.98 -33.43 75.71 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.809 1.244 . . . . 0.0 112.669 172.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.06 -48.34 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.463 1.105 . . . . 0.0 110.381 178.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -59.05 -42.24 89.81 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.714 -1.241 . . . . 0.0 113.043 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.6 m -62.03 -48.06 81.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.036 2.134 . . . . 0.0 112.858 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 33.4 mt -65.54 -37.12 85.82 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.109 1.364 . . . . 0.0 114.246 175.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -68.69 -31.54 70.71 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.337 -1.477 . . . . 0.0 112.474 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -88.51 48.58 1.66 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 124.828 1.251 . . . . 0.0 112.139 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.6 p -98.82 154.48 17.98 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.132 1.773 . . . . 0.0 107.894 166.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.66 -157.76 30.82 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.803 -1.186 . . . . 0.0 112.007 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? -69.43 -49.08 58.46 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 121.099 -1.236 . . . . 0.0 112.6 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 56.4 t -99.16 132.72 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.43 1.092 . . . . 0.0 108.325 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 74.4 t -120.3 124.8 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 126.556 1.943 . . . . 0.0 109.649 -165.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -113.58 87.46 2.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.627 1.171 . . . . 0.0 112.196 -174.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.279 3.1 pp -123.5 148.28 46.4 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 117.794 2.516 . . . . 0.0 117.794 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 49.9 tp -105.82 128.31 53.65 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.878 1.671 . . . . 0.0 108.433 -176.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.34 158.68 43.65 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 121.999 0.904 . . . . 0.0 110.822 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -95.52 150.98 19.72 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 165.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 122.221 1.01 . . . . 0.0 109.791 165.393 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t70 . . . . . 0 N--CA 1.43 -1.474 0 N-CA-C 113.113 0.782 . . . . 0.0 113.113 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 38.5 p -121.86 154.42 37.09 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 121.077 -1.014 . . . . 0.0 112.79 -174.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.2 139.65 27.36 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.072 -1.017 . . . . 0.0 109.082 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -92.72 131.0 38.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.86 -1.15 . . . . 0.0 109.899 168.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.8 t -116.71 111.83 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.057 1.343 . . . . 0.0 108.656 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -102.55 78.06 1.68 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.419 -1.425 . . . . 0.0 109.288 172.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.5 tp -94.74 146.83 23.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 124.297 1.039 . . . . 0.0 111.063 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.48 127.59 50.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.085 -1.634 . . . . 0.0 108.932 167.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.1 ptmt -70.15 149.55 47.44 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 p -106.55 111.44 23.99 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.272 -1.517 . . . . 0.0 111.635 -174.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.0 t0 54.26 39.46 30.85 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.424 2.29 . . . . 0.0 113.522 -175.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.02 -7.22 78.71 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.281 -1.512 . . . . 0.0 115.713 -176.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.8 t -109.39 150.38 28.14 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-N 119.15 1.475 . . . . 0.0 112.005 -172.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.4 mt -100.71 -61.59 1.35 Allowed 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.237 -1.539 . . . . 0.0 112.151 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.53 33.81 0.91 Allowed Glycine 0 N--CA 1.43 -1.746 0 O-C-N 119.914 -1.741 . . . . 0.0 111.497 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 pt -124.38 150.36 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.429 1.092 . . . . 0.0 111.261 -174.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 35.4 m -126.67 134.33 50.74 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 156.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 m -117.84 161.58 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 CA-C-O 122.346 1.07 . . . . 0.0 112.102 -170.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.64 -173.35 4.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 124.2 1.0 . . . . 0.0 109.595 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.06 -152.41 20.25 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.994 -1.067 . . . . 0.0 115.437 171.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.67 172.66 30.62 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 125.593 1.568 . . . . 0.0 111.621 -176.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.43 -1.463 0 C-N-CA 125.065 1.346 . . . . 0.0 113.065 176.169 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.682 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.2 mm -95.32 127.72 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.239 1.416 . . . . 0.0 108.584 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -125.7 155.58 40.69 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 120.757 -1.214 . . . . 0.0 111.404 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.5 t -75.96 122.26 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.999 -1.063 . . . . 0.0 110.945 169.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.0 ttmm -87.9 -42.06 12.76 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.376 1.47 . . . . 0.0 109.703 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.24 160.0 38.2 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.77 -0.581 . . . . 0.0 109.946 175.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -119.17 121.36 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 C-N-CA 124.348 1.059 . . . . 0.0 108.841 174.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.46 119.38 77.22 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 115.872 -2.013 . . . . 0.0 116.144 -169.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -59.86 123.24 12.83 Favored 'Trans proline' 0 N--CA 1.434 -2.024 0 CA-C-N 124.659 2.7 . . . . 0.0 114.916 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.254 83.7 mttt 81.74 26.53 0.19 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 128.229 2.612 . . . . 0.0 111.921 -172.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.61 157.49 31.39 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 119.768 -1.833 . . . . 0.0 111.812 164.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.57 -58.74 5.47 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.59 -2.123 . . . . 0.0 114.287 160.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.1 -40.12 95.54 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 127.45 2.3 . . . . 0.0 112.826 -177.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 -52.07 -59.74 4.01 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 166.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.5 t -68.82 -25.21 64.56 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 125.837 1.655 . . . . 0.0 114.905 -167.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -46.48 -63.15 1.08 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.1 1.76 . . . . 0.0 113.964 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 114.48 -2.51 23.5 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.217 -0.927 . . . . 0.0 114.324 171.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.6 mtm180 -85.81 -28.64 24.36 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.006 -1.29 . . . . 0.0 113.095 171.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.1 mt -108.61 132.07 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 C-N-CA 126.445 1.898 . . . . 0.0 110.664 -170.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.12 -176.71 4.91 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.356 -1.465 . . . . 0.0 112.424 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -68.43 121.19 15.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.416 -1.428 . . . . 0.0 112.738 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 105.41 -2.52 39.88 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 121.418 -0.801 . . . . 0.0 114.393 -175.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -80.35 147.8 30.91 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 119.419 1.609 . . . . 0.0 112.393 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 23.5 ttm180 -97.07 134.34 40.56 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.838 -1.164 . . . . 0.0 110.452 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.1 t -86.45 127.39 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.96 -1.087 . . . . 0.0 109.196 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.47 -45.94 4.71 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.496 -1.377 . . . . 0.0 111.253 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.0 128.69 12.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.489 -1.382 . . . . 0.0 111.584 -176.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 t -108.9 124.04 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 66.55 28.1 9.47 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.521 -1.362 . . . . 0.0 113.666 170.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.74 -12.53 66.92 Favored Glycine 0 N--CA 1.429 -1.809 0 O-C-N 119.962 -1.712 . . . . 0.0 113.773 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.9 t -96.14 116.09 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.155 -1.203 . . . . 0.0 109.026 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 92.7 p -75.36 140.83 43.27 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.357 -1.464 . . . . 0.0 111.592 177.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.2 mt -88.29 50.93 2.06 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.652 -1.28 . . . . 0.0 112.744 -166.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -73.67 125.07 27.21 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.977 -1.702 . . . . 0.0 112.19 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.79 10.64 61.51 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.237 1.399 . . . . 0.0 115.453 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.26 139.4 50.0 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 115.898 1.814 . . . . 0.0 115.898 -170.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.8 p -91.64 173.26 7.98 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 124.868 1.267 . . . . 0.0 110.27 176.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -58.96 -49.41 77.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.962 -1.086 . . . . 0.0 113.531 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -56.33 -40.29 74.2 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 175.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -53.9 51.56 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.565 1.546 . . . . 0.0 113.766 179.069 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.5 87.73 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.472 1.509 . . . . 0.0 113.86 177.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.62 -48.15 88.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.772 1.229 . . . . 0.0 110.894 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -63.21 -41.27 99.11 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 175.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.3 m -61.48 -45.95 92.08 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 125.96 1.704 . . . . 0.0 113.277 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.64 -30.4 67.02 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.269 -1.519 . . . . 0.0 113.91 176.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.58 -45.03 92.29 Favored 'General case' 0 CA--C 1.488 -1.419 0 O-C-N 120.453 -1.405 . . . . 0.0 112.025 167.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -78.02 48.81 0.75 Allowed 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 128.116 2.567 . . . . 0.0 113.679 176.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 35.3 p -106.03 156.0 18.84 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.268 -1.52 . . . . 0.0 110.218 174.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.21 -164.19 38.35 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.778 -1.201 . . . . 0.0 111.036 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -69.78 -47.81 61.52 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 118.922 1.361 . . . . 0.0 112.236 172.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.27 123.82 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-O 123.171 1.463 . . . . 0.0 107.505 169.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.4 t -113.2 103.59 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 126.956 2.103 . . . . 0.0 109.019 -168.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.6 t-160 -89.2 101.57 14.23 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 123.784 0.834 . . . . 0.0 111.523 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.6 mt -102.97 162.12 13.2 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-O 122.665 1.221 . . . . 0.0 113.822 172.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.5 tt -129.04 132.19 47.44 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.036 1.335 . . . . 0.0 108.021 159.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.01 164.64 28.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.012 -1.055 . . . . 0.0 113.23 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -113.88 142.47 46.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.405 1.882 . . . . 0.0 109.918 177.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 19.7 tptt . . . . . 0 N--CA 1.43 -1.442 0 C-N-CA 125.818 1.647 . . . . 0.0 112.794 177.58 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.6 t0 . . . . . 0 N--CA 1.431 -1.423 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.0 p -101.83 150.47 23.14 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.375 -1.453 . . . . 0.0 112.532 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.76 134.88 22.76 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.903 -1.123 . . . . 0.0 108.72 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -91.04 121.4 32.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.334 1.454 . . . . 0.0 109.615 174.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.19 102.77 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.803 -1.186 . . . . 0.0 108.236 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -104.46 81.88 1.85 Allowed 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.123 1.369 . . . . 0.0 108.226 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.6 tp -111.78 149.27 31.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.694 1.198 . . . . 0.0 110.325 -165.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.89 144.81 30.72 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.347 -1.471 . . . . 0.0 108.869 170.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -70.12 154.64 41.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.609 -1.307 . . . . 0.0 112.638 173.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.6 p -112.92 100.79 8.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.836 -1.165 . . . . 0.0 109.066 175.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 22.0 t0 58.01 45.42 18.01 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 126.014 1.726 . . . . 0.0 113.248 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.54 -10.99 67.4 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 125.049 1.309 . . . . 0.0 115.226 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 62.1 m -104.04 148.78 25.83 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.787 1.293 . . . . 0.0 113.561 -169.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.0 mt -119.31 -54.03 2.21 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.999 1.32 . . . . 0.0 109.354 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.5 43.32 1.86 Allowed Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 127.036 2.255 . . . . 0.0 113.877 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 pt -121.52 121.15 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 CA-C-N 119.394 1.597 . . . . 0.0 115.031 -167.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.4 m -116.72 123.83 48.16 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.549 -1.345 . . . . 0.0 109.202 165.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.46 173.91 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.072 1.349 . . . . 0.0 111.709 -171.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.7 t -146.31 168.47 21.01 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.059 1.344 . . . . 0.0 108.515 174.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.67 -154.18 17.15 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.842 -1.161 . . . . 0.0 115.149 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 101.5 165.99 27.43 Favored Glycine 0 N--CA 1.429 -1.785 0 C-N-CA 125.247 1.403 . . . . 0.0 112.379 -179.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 N--CA 1.43 -1.467 0 N-CA-C 115.937 1.829 . . . . 0.0 115.937 -171.173 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.714 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.72 125.76 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.876 1.271 . . . . 0.0 107.972 178.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -128.88 157.49 41.42 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.602 -1.312 . . . . 0.0 111.398 -172.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.8 t -76.39 126.54 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.495 1.518 . . . . 0.0 111.181 172.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -109.79 -51.67 2.85 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.338 -1.477 . . . . 0.0 113.164 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.0 157.01 43.49 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 121.226 -0.921 . . . . 0.0 109.975 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -125.77 126.09 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 C-N-CA 123.988 0.915 . . . . 0.0 109.195 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.6 mm -77.26 122.45 86.16 Favored Pre-proline 0 N--CA 1.429 -1.493 0 CA-C-O 116.238 -1.839 . . . . 0.0 114.507 -173.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -57.28 127.6 26.24 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 CA-C-N 124.506 2.645 . . . . 0.0 116.18 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.292 50.8 mttp 79.36 22.64 0.56 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 127.545 2.338 . . . . 0.0 113.385 -177.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.17 156.3 30.76 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.9 -1.75 . . . . 0.0 112.16 165.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.09 -55.33 12.53 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.824 1.65 . . . . 0.0 115.268 170.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.36 -48.51 75.25 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.89 2.476 . . . . 0.0 111.448 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 tm-20 -47.49 -59.15 3.44 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 173.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.0 t -68.37 -30.37 69.29 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.647 1.179 . . . . 0.0 113.387 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -65.02 -60.43 3.05 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.963 1.305 . . . . 0.0 111.199 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.96 31.07 15.73 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.45 -1.406 . . . . 0.0 116.431 167.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -83.3 -39.82 20.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 121.458 -1.025 . . . . 0.0 108.747 159.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mt -79.17 99.81 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 123.933 0.893 . . . . 0.0 110.313 175.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -122.81 156.77 33.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.82 1.295 . . . . 0.0 109.627 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.1 pttt -67.78 131.27 45.24 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.136 -1.602 . . . . 0.0 113.379 -171.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.87 -19.52 32.84 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.164 -0.96 . . . . 0.0 114.1 -172.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -79.51 157.1 27.51 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 120.152 1.976 . . . . 0.0 113.312 -173.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 70.6 ttt-85 -108.88 134.93 50.9 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.154 -1.591 . . . . 0.0 111.289 -173.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.11 132.75 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 119.945 -1.722 . . . . 0.0 110.986 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.72 -52.4 4.9 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.914 -1.116 . . . . 0.0 111.788 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.96 140.14 20.3 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.907 -0.496 . . . . 0.0 112.016 -165.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.1 t -109.22 118.24 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 171.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 63.18 20.89 12.55 Favored 'General case' 0 N--CA 1.429 -1.514 0 C-N-CA 125.968 1.707 . . . . 0.0 113.974 -178.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 86.52 -0.55 86.94 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.279 -1.513 . . . . 0.0 114.069 -174.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -86.05 117.56 30.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.853 1.261 . . . . 0.0 109.045 176.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.0 p -75.63 132.36 40.55 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.774 -1.204 . . . . 0.0 113.702 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 67.6 mt -84.77 -13.19 51.95 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -168.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -63.63 131.74 48.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.595 -1.941 . . . . 0.0 112.72 174.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.18 -30.35 9.22 Favored Glycine 0 N--CA 1.431 -1.697 0 C-N-CA 124.518 1.056 . . . . 0.0 113.674 -171.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.23 156.87 39.04 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -88.23 172.61 9.34 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.244 1.018 . . . . 0.0 111.681 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -63.82 -43.35 96.48 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.554 -1.341 . . . . 0.0 112.151 175.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -54.8 -44.87 74.18 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 126.646 1.978 . . . . 0.0 114.416 171.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -56.03 -55.05 37.48 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.93 -34.85 78.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.61 -53.76 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.33 1.052 . . . . 0.0 110.566 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -61.92 -39.43 92.01 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.011 0.91 . . . . 0.0 113.036 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 97.0 m -66.86 -42.38 85.78 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.452 1.901 . . . . 0.0 113.219 179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 65.5 mt -69.54 -36.92 76.83 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.068 -1.02 . . . . 0.0 113.082 173.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -53.55 56.4 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.789 -1.195 . . . . 0.0 113.03 173.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -81.04 43.06 0.68 Allowed 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.863 1.665 . . . . 0.0 112.748 -177.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.416 ' HB ' HG22 ' A' ' 92' ' ' VAL . 26.1 p -91.76 155.37 18.3 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 127.425 2.29 . . . . 0.0 108.814 168.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.98 -140.7 7.01 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.973 -1.079 . . . . 0.0 114.078 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 2.1 tm0? -71.02 -53.48 14.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.329 -1.101 . . . . 0.0 111.993 177.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 95.0 t -97.89 135.89 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.397 1.57 . . . . 0.0 109.17 169.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 88' ' ' THR . 48.2 t -111.43 117.66 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 128.574 2.75 . . . . 0.0 108.131 -176.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 52.9 m170 -105.23 104.41 14.14 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.872 -1.143 . . . . 0.0 111.244 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -106.73 163.75 12.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.884 -1.135 . . . . 0.0 113.799 171.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.3 tp -128.2 134.11 48.97 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 124.856 1.263 . . . . 0.0 108.36 158.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.8 pp -145.17 164.87 29.98 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.637 -1.29 . . . . 0.0 111.285 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -121.42 149.72 42.59 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.023 1.729 . . . . 0.0 110.894 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.463 0 C-N-CA 125.482 1.513 . . . . 0.0 110.761 176.178 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.7 t70 . . . . . 0 N--CA 1.43 -1.453 0 N-CA-C 114.867 1.432 . . . . 0.0 114.867 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -123.56 154.73 38.82 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-N 119.419 1.009 . . . . 0.0 110.596 163.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -144.43 149.92 36.83 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 123.882 0.873 . . . . 0.0 109.438 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -99.63 125.85 45.53 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.123 1.369 . . . . 0.0 109.275 167.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.46 94.88 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 O-C-N 120.481 -1.387 . . . . 0.0 107.954 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -90.62 81.54 5.87 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.658 -1.276 . . . . 0.0 109.387 169.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 49.2 tp -96.39 133.6 40.6 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.652 1.181 . . . . 0.0 111.642 -171.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.16 138.72 38.73 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 119.878 -1.764 . . . . 0.0 110.147 172.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -68.25 156.51 37.49 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.726 1.21 . . . . 0.0 113.721 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.4 t -129.25 135.8 49.27 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 172.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.0 t70 33.34 52.12 0.35 Allowed 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 128.248 2.619 . . . . 0.0 116.57 -173.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.68 -5.45 69.49 Favored Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 117.678 1.831 . . . . 0.0 117.678 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.7 m -121.57 150.63 41.38 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.535 1.668 . . . . 0.0 113.988 -169.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 46.9 mt -101.28 -60.24 1.56 Allowed 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.232 1.413 . . . . 0.0 109.606 168.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.18 41.82 2.02 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.874 1.702 . . . . 0.0 114.63 175.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.3 pt -112.53 156.58 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 CA-C-N 118.417 1.109 . . . . 0.0 111.994 177.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -131.39 132.52 44.46 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.115 -1.615 . . . . 0.0 109.258 149.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.5 m -114.75 160.2 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.478 1.511 . . . . 0.0 110.882 -175.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 t -148.8 -178.96 6.64 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.541 -1.349 . . . . 0.0 110.651 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.4 -123.97 7.07 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 120.763 -1.21 . . . . 0.0 114.463 167.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.47 171.27 26.9 Favored Glycine 0 N--CA 1.43 -1.75 0 CA-C-O 122.671 1.151 . . . . 0.0 113.208 178.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -172.977 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.73 0 CA-C-O 122.067 0.815 . . . . 0.0 113.55 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.1 mm -102.81 117.18 47.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 125.798 1.639 . . . . 0.0 108.222 -176.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.23 149.81 44.23 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.166 -0.958 . . . . 0.0 109.947 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -78.12 122.59 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.506 -1.371 . . . . 0.0 113.14 177.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.52 -39.26 10.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.614 -1.304 . . . . 0.0 112.799 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.26 158.86 42.28 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.441 -1.412 . . . . 0.0 111.466 -177.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.412 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -122.46 120.8 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-O 122.965 1.364 . . . . 0.0 110.824 176.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.75 121.66 85.18 Favored Pre-proline 0 N--CA 1.43 -1.468 0 C-N-CA 125.802 1.641 . . . . 0.0 113.189 -171.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.42 134.37 41.39 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 CA-C-N 123.98 2.457 . . . . 0.0 112.689 179.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 56.7 mttm 82.29 20.35 0.29 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 129.173 2.989 . . . . 0.0 113.785 -172.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.51 154.85 30.23 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 119.966 -1.709 . . . . 0.0 115.938 169.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.47 -58.72 5.1 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.986 2.115 . . . . 0.0 115.562 158.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.06 -46.54 86.98 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.99 2.916 . . . . 0.0 111.612 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.412 ' HA ' HG12 ' A' ' 47' ' ' ILE . 2.6 tm-20 -41.73 -59.58 1.62 Allowed 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 169.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.0 t -69.54 -34.6 74.46 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -62.08 -46.81 87.44 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.015 -1.678 . . . . 0.0 113.542 -171.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 108.07 -6.69 34.86 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.359 -1.463 . . . . 0.0 116.08 155.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.482 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.4 mmp_? -70.23 -35.48 73.87 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.918 -1.342 . . . . 0.0 111.131 169.138 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.5 mt -87.22 128.94 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 126.396 1.878 . . . . 0.0 108.766 176.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -164.28 123.21 1.89 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.6 -1.312 . . . . 0.0 107.798 -176.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.17 112.92 0.31 Allowed 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 116.846 2.165 . . . . 0.0 116.846 -167.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.15 -8.66 12.32 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 118.552 -1.138 . . . . 0.0 113.616 -164.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -79.84 164.34 23.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 120.799 2.299 . . . . 0.0 113.019 175.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.1 ttt180 -125.57 124.79 42.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.153 -0.967 . . . . 0.0 110.877 -171.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.5 t -87.74 135.49 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 O-C-N 120.106 -1.621 . . . . 0.0 109.815 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.4 mp -106.24 -44.06 4.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.721 1.208 . . . . 0.0 111.111 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.96 132.54 15.79 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.705 -1.247 . . . . 0.0 111.255 -177.064 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 t -109.97 119.39 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.524 1.13 . . . . 0.0 108.518 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.87 24.6 9.7 Favored 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 126.146 1.778 . . . . 0.0 114.125 173.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 90.48 -9.9 76.15 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 120.147 -1.596 . . . . 0.0 114.182 -173.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.66 119.99 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.552 1.141 . . . . 0.0 108.098 -176.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.7 t -76.04 145.93 39.81 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.444 -1.41 . . . . 0.0 112.476 -174.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 95.9 mt -91.49 8.13 37.91 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.516 -1.365 . . . . 0.0 113.251 -175.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 77.1 mt-10 -68.27 107.73 2.92 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 119.535 -1.978 . . . . 0.0 113.934 -176.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.27 4.3 68.68 Favored Glycine 0 N--CA 1.429 -1.782 0 O-C-N 120.773 -1.205 . . . . 0.0 113.715 -175.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.52 148.11 45.34 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 121.139 -1.213 . . . . 0.0 113.79 168.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.3 p -80.51 173.92 12.12 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.852 -1.155 . . . . 0.0 111.845 169.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -55.54 -52.29 64.21 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.364 1.865 . . . . 0.0 112.368 168.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -57.14 -43.12 82.14 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 115.043 1.498 . . . . 0.0 115.043 173.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -56.27 -42.72 77.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.806 1.78 . . . . 0.0 115.806 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.6 -36.12 83.2 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.804 -1.185 . . . . 0.0 112.904 175.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.9 -44.36 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 O-C-N 120.662 -1.274 . . . . 0.0 111.191 177.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -54.04 -37.91 64.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.977 1.711 . . . . 0.0 113.247 171.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -73.36 -52.21 14.64 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.901 2.08 . . . . 0.0 112.224 177.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 48.3 mt -64.41 -31.47 72.7 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -70.05 -26.46 64.03 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.18 -1.575 . . . . 0.0 112.982 174.336 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.3 t30 -91.6 39.71 1.01 Allowed 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.563 1.545 . . . . 0.0 112.887 178.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 p -94.28 155.47 17.0 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 126.29 1.836 . . . . 0.0 111.786 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -146.59 20.65 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.038 -1.039 . . . . 0.0 112.587 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -69.68 -56.27 7.68 Favored 'General case' 0 N--CA 1.429 -1.523 0 O-C-N 121.2 -1.176 . . . . 0.0 112.38 173.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.1 t -98.54 128.47 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.826 1.298 . . . . 0.0 108.418 178.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.7 t -114.46 109.41 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 128.385 2.674 . . . . 0.0 109.024 -171.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -88.84 109.37 20.14 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 120.634 -1.291 . . . . 0.0 110.597 174.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -101.23 153.66 19.43 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.641 -1.287 . . . . 0.0 111.136 161.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -123.02 128.2 49.85 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 157.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -142.46 163.44 32.84 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 121.473 -0.767 . . . . 0.0 111.779 -171.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.51 136.02 53.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.399 1.88 . . . . 0.0 109.145 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.1 tptm . . . . . 0 N--CA 1.43 -1.452 0 O-C-N 119.766 -1.834 . . . . 0.0 112.707 176.3 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 44.0 t0 . . . . . 0 N--CA 1.43 -1.451 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -104.96 160.75 14.78 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 121.02 -1.05 . . . . 0.0 110.593 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.86 139.12 26.09 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 170.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.34 131.71 37.31 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.964 1.306 . . . . 0.0 109.412 165.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.1 t -119.73 115.04 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -177.371 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 -107.53 91.17 3.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.227 1.411 . . . . 0.0 107.81 177.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.23 132.77 54.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.593 1.157 . . . . 0.0 112.241 -162.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.15 137.96 33.5 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.14 -1.6 . . . . 0.0 111.871 176.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 27.9 mttp -70.13 148.42 48.73 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 115.214 1.561 . . . . 0.0 115.214 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 37.3 p -113.59 118.78 35.37 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.965 1.306 . . . . 0.0 109.76 173.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.7 t0 59.49 32.51 21.74 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.532 1.933 . . . . 0.0 114.172 -176.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.62 79.03 Favored Glycine 0 N--CA 1.429 -1.832 0 O-C-N 119.763 -1.835 . . . . 0.0 114.869 -173.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.4 p -121.5 144.56 48.63 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.72 -1.459 . . . . 0.0 112.151 178.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 74.2 mt -85.62 -60.42 2.03 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.923 -1.11 . . . . 0.0 109.943 165.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.04 46.87 0.5 Allowed Glycine 0 N--CA 1.43 -1.708 0 O-C-N 119.983 -1.698 . . . . 0.0 109.749 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.2 tt -140.73 144.71 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 123.337 1.541 . . . . 0.0 110.296 -175.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.6 t -118.83 133.3 55.93 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 166.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 m -108.44 164.67 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.49 1.116 . . . . 0.0 110.449 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 t -147.85 178.36 8.57 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.554 1.142 . . . . 0.0 108.481 176.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.99 -162.41 27.42 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.515 -1.366 . . . . 0.0 113.548 176.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.56 165.93 22.67 Favored Glycine 0 N--CA 1.431 -1.665 0 C-N-CA 124.753 1.168 . . . . 0.0 110.707 -173.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.2 t . . . . . 0 N--CA 1.43 -1.45 0 O-C-N 121.073 -1.251 . . . . 0.0 113.941 -176.231 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.73 0 CA-C-O 121.118 0.288 . . . . 0.0 113.272 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.64 127.8 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 170.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -128.03 157.64 40.1 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.465 -1.397 . . . . 0.0 111.218 -169.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.3 t -75.44 120.65 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 O-C-N 121.02 -1.05 . . . . 0.0 111.044 169.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -90.84 -52.09 5.04 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.626 1.571 . . . . 0.0 110.542 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.08 154.72 36.48 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.15 124.16 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 174.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.72 121.31 84.59 Favored Pre-proline 0 N--CA 1.429 -1.523 0 C-N-CA 126.671 1.989 . . . . 0.0 113.956 -167.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -57.7 123.41 13.67 Favored 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 124.448 2.624 . . . . 0.0 116.408 -172.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.268 3.9 mtpm? 76.84 25.99 0.82 Allowed 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 128.137 2.575 . . . . 0.0 114.855 -178.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.42 169.18 47.14 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.175 -1.578 . . . . 0.0 113.495 168.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.5 -58.76 5.01 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.084 2.154 . . . . 0.0 114.668 165.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.59 -47.71 77.63 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 128.861 2.864 . . . . 0.0 112.762 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -46.1 -59.03 3.12 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 116.845 2.165 . . . . 0.0 116.845 172.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 t -69.82 -27.71 65.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 124.848 1.259 . . . . 0.0 113.556 -175.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -50.79 -62.6 1.51 Allowed 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.838 2.055 . . . . 0.0 113.305 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.28 -45.36 1.16 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.969 -0.457 . . . . 0.0 113.087 168.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.46 -19.01 65.68 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 115.079 1.511 . . . . 0.0 115.079 -172.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.8 mt -96.31 117.19 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.519 0 C-N-CA 124.967 1.307 . . . . 0.0 109.06 172.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.7 m80 -118.57 159.45 23.54 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.773 -1.204 . . . . 0.0 110.879 -178.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -62.29 129.26 39.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.015 -1.678 . . . . 0.0 113.099 173.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.14 -0.3 72.0 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.886 -1.134 . . . . 0.0 114.831 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -79.62 152.23 30.14 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.768 -1.43 . . . . 0.0 111.289 178.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.8 ttt-85 -105.28 131.13 53.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.031 -1.668 . . . . 0.0 111.261 -168.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 38.3 t -85.34 136.88 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.963 -1.71 . . . . 0.0 110.941 -174.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -105.97 -56.65 2.15 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.908 -1.12 . . . . 0.0 109.386 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.7 137.22 18.79 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.186 -0.946 . . . . 0.0 111.925 -173.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.55 125.8 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 67.73 14.72 9.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.078 -1.639 . . . . 0.0 115.263 169.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.13 -13.26 52.26 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 119.748 -1.845 . . . . 0.0 112.913 -175.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -92.85 104.87 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 124.369 1.068 . . . . 0.0 109.333 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.3 t -74.26 126.71 31.23 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.665 -1.272 . . . . 0.0 109.589 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 85.1 mt -83.51 55.18 3.09 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.019 1.118 . . . . 0.0 114.019 -158.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -71.43 122.16 19.89 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 119.543 -1.973 . . . . 0.0 114.342 -172.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.63 5.09 72.59 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.186 -1.571 . . . . 0.0 115.437 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.62 140.59 49.81 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.255 1.946 . . . . 0.0 116.255 -171.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.2 p -93.3 178.86 5.59 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.496 2.319 . . . . 0.0 111.747 172.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 20.9 t-160 -57.48 -48.16 79.98 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 126.656 1.982 . . . . 0.0 114.463 179.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.3 tptt -56.66 -42.92 79.81 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 174.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.4 -50.48 73.8 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.868 1.667 . . . . 0.0 114.515 178.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.25 -38.31 83.07 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.038 1.335 . . . . 0.0 113.518 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 70.4 t -66.42 -46.92 85.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 O-C-N 120.792 -1.192 . . . . 0.0 111.851 173.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -54.65 -48.5 72.23 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.689 1.596 . . . . 0.0 112.359 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 13.6 m -64.84 -45.97 83.87 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.856 2.463 . . . . 0.0 114.048 175.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.1 mt -64.04 -34.1 77.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 119.29 -2.131 . . . . 0.0 114.675 174.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 17.6 mtp-105 -65.21 -36.58 84.63 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 112.851 172.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -86.52 46.22 1.33 Allowed 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 125.62 1.568 . . . . 0.0 112.712 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.418 ' HB ' HG22 ' A' ' 92' ' ' VAL . 25.1 p -107.12 155.99 19.27 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.65 1.58 . . . . 0.0 109.657 173.546 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.33 -156.4 32.29 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.647 -1.283 . . . . 0.0 112.53 178.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -68.88 -54.94 12.77 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.175 -1.191 . . . . 0.0 111.772 176.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 130.8 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 CA-C-O 122.497 1.141 . . . . 0.0 108.314 170.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.418 HG22 ' HB ' ' A' ' 88' ' ' THR . 63.6 t -118.47 121.27 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 127.029 2.132 . . . . 0.0 109.743 -168.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -97.28 113.68 25.34 Favored 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 121.314 -0.866 . . . . 0.0 111.244 173.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.2 155.76 19.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.581 1.152 . . . . 0.0 112.639 169.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 40.3 tp -127.11 128.79 46.77 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 158.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.7 pp -142.3 170.15 16.25 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.671 -1.268 . . . . 0.0 111.213 175.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -114.7 145.74 41.71 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.267 1.827 . . . . 0.0 109.165 178.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.2 tptt . . . . . 0 N--CA 1.43 -1.454 0 C-N-CA 124.804 1.241 . . . . 0.0 111.308 -179.944 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.7 t0 . . . . . 0 N--CA 1.431 -1.391 0 CA-C-O 121.77 0.795 . . . . 0.0 109.171 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -114.01 149.8 34.84 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.805 1.242 . . . . 0.0 109.451 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -145.85 127.79 15.48 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -87.88 113.55 23.65 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 164.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 t -99.05 110.38 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 124.512 1.125 . . . . 0.0 109.702 -169.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.7 mt-10 -104.94 87.25 2.61 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.381 1.086 . . . . 0.0 110.242 -177.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.21 147.6 23.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.073 -1.017 . . . . 0.0 110.593 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.88 112.79 25.91 Favored 'General case' 0 N--CA 1.428 -1.544 0 C-N-CA 124.107 0.963 . . . . 0.0 108.593 160.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.6 ttmt -70.16 126.12 28.74 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.442 1.497 . . . . 0.0 112.608 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.8 p -104.27 123.35 47.21 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.045 -1.659 . . . . 0.0 110.894 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.8 t70 63.61 24.7 14.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.591 1.557 . . . . 0.0 113.861 170.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.6 4.81 89.95 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 119.51 -1.994 . . . . 0.0 115.189 -175.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.5 m -105.35 104.21 13.89 Favored 'General case' 0 N--CA 1.429 -1.477 0 CA-C-N 119.195 1.497 . . . . 0.0 111.629 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 11.9 tp -80.81 -45.51 16.81 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 120.563 -1.336 . . . . 0.0 111.475 173.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.06 28.08 3.23 Favored Glycine 0 N--CA 1.429 -1.773 0 C-N-CA 125.574 1.559 . . . . 0.0 113.547 170.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.9 tt -148.99 136.02 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 120.014 1.907 . . . . 0.0 114.694 -168.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.3 m -110.83 126.6 54.82 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.847 1.659 . . . . 0.0 108.48 167.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -104.24 172.01 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.219 1.007 . . . . 0.0 111.905 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.4 t -157.3 176.96 12.0 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.504 -1.372 . . . . 0.0 110.803 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 115.35 -128.33 8.03 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.457 1.027 . . . . 0.0 112.276 169.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.32 134.84 8.16 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.163 0.887 . . . . 0.0 111.279 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.7 m . . . . . 0 N--CA 1.43 -1.438 0 N-CA-C 115.702 1.741 . . . . 0.0 115.702 -170.244 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.702 0 N-CA-C 112.166 -0.374 . . . . 0.0 112.166 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.7 mm -104.13 125.59 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.945 1.298 . . . . 0.0 109.664 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -126.84 158.81 35.68 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 120.276 -1.515 . . . . 0.0 112.182 -172.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.2 t -76.23 120.35 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 125.135 1.374 . . . . 0.0 112.689 175.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -93.93 -47.05 6.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.586 -1.321 . . . . 0.0 112.109 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.71 152.25 24.99 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 121.113 -0.992 . . . . 0.0 111.435 178.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.39 122.29 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 C-N-CA 126.136 1.774 . . . . 0.0 109.378 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 9.3 mm -77.58 123.93 86.66 Favored Pre-proline 0 N--CA 1.429 -1.495 0 C-N-CA 127.014 2.126 . . . . 0.0 114.352 -175.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -57.55 125.74 19.71 Favored 'Trans proline' 0 N--CA 1.434 -1.998 0 CA-C-N 124.607 2.681 . . . . 0.0 116.526 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.313 63.1 mttm 83.01 16.34 0.32 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 128.46 2.704 . . . . 0.0 113.72 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.06 162.48 38.83 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.116 -1.615 . . . . 0.0 114.128 169.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.41 -55.78 11.89 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.02 1.728 . . . . 0.0 114.977 170.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.89 -47.78 81.8 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.735 2.814 . . . . 0.0 112.59 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -48.44 -61.08 2.19 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 173.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.7 m -69.1 -32.59 72.11 Favored 'General case' 0 N--CA 1.429 -1.507 0 CA-C-N 115.499 -0.773 . . . . 0.0 112.859 -173.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -58.91 -70.28 0.16 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.947 1.699 . . . . 0.0 113.411 175.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.27 14.76 43.75 Favored Glycine 0 N--CA 1.43 -1.712 0 O-C-N 120.38 -1.45 . . . . 0.0 114.9 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -65.27 -26.47 68.1 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.707 -1.467 . . . . 0.0 111.691 159.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 71.6 mt -106.55 130.75 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 C-N-CA 126.686 1.994 . . . . 0.0 109.223 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -126.95 170.01 12.72 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-O 123.062 1.411 . . . . 0.0 110.835 169.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -60.59 129.69 42.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.01 -1.681 . . . . 0.0 113.388 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.31 4.15 86.44 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.291 -1.506 . . . . 0.0 115.608 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -75.46 161.98 28.74 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-N 119.835 1.817 . . . . 0.0 111.665 175.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.1 tpt85 -108.57 116.83 32.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.892 -1.13 . . . . 0.0 110.945 -170.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.6 t -84.66 130.6 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 O-C-N 120.511 -1.368 . . . . 0.0 108.283 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.31 -36.58 5.53 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.824 1.25 . . . . 0.0 112.401 -166.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 152.36 33.53 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.234 -1.541 . . . . 0.0 110.11 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.1 t -120.79 114.64 44.31 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 170.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 54.04 48.53 20.88 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.906 2.083 . . . . 0.0 115.535 170.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.06 -18.45 44.61 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 120.834 -1.166 . . . . 0.0 114.571 -177.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.6 t -94.21 105.8 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 O-C-N 120.82 -1.4 . . . . 0.0 109.004 -178.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.8 p -72.23 138.8 47.77 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.688 -1.257 . . . . 0.0 111.761 178.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 53.7 mt -87.15 32.62 0.68 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.636 -1.29 . . . . 0.0 112.777 -169.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -69.61 130.21 41.78 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.189 -2.195 . . . . 0.0 112.66 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.03 8.73 44.12 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 125.645 1.593 . . . . 0.0 116.253 -176.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.33 142.08 50.43 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -171.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 40.6 p -87.32 175.25 8.1 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.051 1.34 . . . . 0.0 110.312 173.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.1 t-160 -61.82 -40.22 94.5 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.644 -1.285 . . . . 0.0 111.757 174.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -54.93 -47.16 74.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.355 1.862 . . . . 0.0 114.928 173.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -56.6 -51.81 67.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 -179.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.32 -42.38 95.45 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.233 1.013 . . . . 0.0 113.28 177.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.08 -48.07 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.984 -1.073 . . . . 0.0 111.137 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -63.97 -41.31 97.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 3.5 m -61.0 -47.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 126.225 1.81 . . . . 0.0 112.874 175.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.7 mt -68.43 -29.67 68.38 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 175.33 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.4 ttt180 -62.76 -36.26 82.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.382 -1.449 . . . . 0.0 113.039 173.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -94.83 49.82 1.27 Allowed 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.643 -1.286 . . . . 0.0 111.76 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 37.0 p -107.34 139.68 41.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.325 1.45 . . . . 0.0 110.256 170.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.26 -142.95 12.25 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 123.564 0.602 . . . . 0.0 112.654 173.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -69.38 -60.98 1.98 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.303 -1.116 . . . . 0.0 113.401 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 t -92.02 118.24 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 122.701 1.239 . . . . 0.0 109.773 -176.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.6 t -117.93 111.1 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 126.122 1.769 . . . . 0.0 109.525 -166.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.8 m170 -99.71 103.01 14.65 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.092 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.5 mt -92.85 168.16 11.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.75 -1.844 . . . . 0.0 112.153 171.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.6 tp -129.05 137.67 51.43 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.016 1.326 . . . . 0.0 107.63 157.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.7 161.2 39.78 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.732 -1.23 . . . . 0.0 112.845 174.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -96.46 144.89 26.15 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 164.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.9 tmtt? . . . . . 0 N--CA 1.43 -1.451 0 O-C-N 120.859 -1.151 . . . . 0.0 108.279 162.913 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.9 t0 . . . . . 0 N--CA 1.429 -1.496 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -88.94 139.22 30.68 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.368 -1.458 . . . . 0.0 110.837 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.27 0.0 OUTLIER -147.4 140.48 25.12 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.277 1.513 . . . . 0.0 110.637 175.155 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -90.32 146.51 24.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.483 1.913 . . . . 0.0 109.323 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.5 t -122.81 110.46 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 125.008 1.323 . . . . 0.0 107.488 -174.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -105.83 84.2 2.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 CA-C-O 122.214 1.007 . . . . 0.0 108.458 174.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.3 tp -110.84 145.1 38.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.01 1.324 . . . . 0.0 110.283 -167.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.31 138.38 40.16 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 119.842 -1.786 . . . . 0.0 110.109 168.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -70.86 149.02 47.21 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 169.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.9 t -109.72 111.56 23.1 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.733 -1.229 . . . . 0.0 109.225 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.9 t0 43.34 50.27 5.98 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.923 2.489 . . . . 0.0 114.778 -178.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.97 -39.42 2.79 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.452 1.025 . . . . 0.0 115.043 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 m -102.03 148.72 25.03 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.731 -1.452 . . . . 0.0 114.793 -161.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -106.65 -61.37 1.54 Allowed 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.161 -0.962 . . . . 0.0 112.041 176.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.91 32.32 1.58 Allowed Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.669 -1.895 . . . . 0.0 112.798 175.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 pt -124.09 139.71 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 C-N-CA 125.105 1.362 . . . . 0.0 108.693 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.1 t -129.28 125.64 37.27 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 36.0 m -108.38 168.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.986 0.898 . . . . 0.0 112.63 -172.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.8 160.08 43.55 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.853 1.661 . . . . 0.0 109.095 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.86 -142.9 15.44 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.729 -1.232 . . . . 0.0 113.614 169.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.37 166.42 13.68 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 116.039 1.176 . . . . 0.0 116.039 174.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.431 -1.401 0 O-C-N 120.757 -1.437 . . . . 0.0 114.64 -179.015 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 31.7 mm -103.41 120.85 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 172.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -124.57 160.98 27.17 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.788 -1.195 . . . . 0.0 109.119 -175.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.37 128.3 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.731 -1.231 . . . . 0.0 110.475 171.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 29.1 ttmt -89.94 -50.45 6.02 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.87 -1.144 . . . . 0.0 110.325 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.58 150.79 33.92 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 123.396 0.678 . . . . 0.0 109.873 -174.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -110.31 121.82 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 170.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 20.9 mm -76.64 121.0 84.08 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 126.219 1.808 . . . . 0.0 113.256 -171.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -58.31 122.93 12.52 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.83 2.353 . . . . 0.0 116.184 -175.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.321 64.7 mttt 82.5 20.16 0.27 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.367 2.267 . . . . 0.0 113.801 176.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.07 161.89 40.07 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.227 -0.921 . . . . 0.0 114.832 170.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.81 -57.04 7.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.131 2.172 . . . . 0.0 114.396 170.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.87 -52.55 62.67 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.58 2.352 . . . . 0.0 112.278 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -42.56 -64.86 0.54 Allowed 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.553 2.057 . . . . 0.0 116.553 174.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.9 m -69.94 -14.21 62.61 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -175.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.84 -64.32 1.03 Allowed 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.712 -1.243 . . . . 0.0 110.353 174.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.33 48.01 7.1 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 117.292 1.677 . . . . 0.0 117.292 170.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.7 mtt180 -84.56 -39.87 18.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 146.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 55.8 mt -83.42 121.47 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 126.162 1.785 . . . . 0.0 111.45 176.509 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 46.7 m-70 -122.08 171.75 8.75 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.243 1.497 . . . . 0.0 111.398 170.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -60.62 127.79 33.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.555 -1.34 . . . . 0.0 112.428 175.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.73 0.91 71.53 Favored Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 115.684 1.034 . . . . 0.0 115.684 -178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -82.17 150.05 27.61 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.83 1.815 . . . . 0.0 112.505 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -90.17 127.82 36.2 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.126 -1.609 . . . . 0.0 113.548 -177.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 30.4 t -83.12 132.79 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.787 177.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.93 -51.86 2.86 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.124 -0.985 . . . . 0.0 111.775 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.27 141.33 22.13 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.096 -1.627 . . . . 0.0 112.799 -175.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.8 t -114.94 120.28 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.343 1.057 . . . . 0.0 108.963 177.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 74.35 16.49 3.35 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.931 1.692 . . . . 0.0 114.558 169.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.54 -1.48 81.74 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.622 -1.299 . . . . 0.0 112.745 -170.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -98.28 117.36 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 125.353 1.461 . . . . 0.0 108.114 176.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t -74.21 125.86 29.34 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.3 -1.5 . . . . 0.0 109.346 178.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . 0.327 0.7 OUTLIER -92.27 39.32 1.02 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.314 1.531 . . . . 0.0 112.183 -176.251 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -76.36 121.37 22.91 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.135 -1.603 . . . . 0.0 110.753 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 81.5 17.79 70.2 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.757 1.17 . . . . 0.0 113.731 -172.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.25 154.26 41.09 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 123.226 1.489 . . . . 0.0 115.001 171.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.2 p -91.57 173.6 7.8 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.337 -1.477 . . . . 0.0 110.892 171.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -51.68 -51.93 52.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.439 1.896 . . . . 0.0 112.416 168.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.27 -53.19 61.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 115.446 1.647 . . . . 0.0 115.446 172.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -60.62 -42.74 97.46 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 -170.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.24 -29.65 68.91 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.168 1.387 . . . . 0.0 114.162 171.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.4 t -79.74 -44.28 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 125.033 1.333 . . . . 0.0 111.49 174.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -58.2 -37.24 74.4 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.335 -1.478 . . . . 0.0 112.745 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.7 m -65.83 -41.23 92.06 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 127.176 2.191 . . . . 0.0 113.54 172.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.9 mt -71.23 -40.14 71.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 175.182 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -72.08 -20.05 61.72 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.544 -1.973 . . . . 0.0 112.453 178.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -94.39 53.48 1.7 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.511 -1.368 . . . . 0.0 112.019 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.0 p -107.05 143.34 35.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.135 -1.603 . . . . 0.0 110.9 176.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.34 -154.97 18.49 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.76 -1.212 . . . . 0.0 111.242 171.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -66.5 -52.96 40.43 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.604 -1.527 . . . . 0.0 114.009 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.3 t -95.74 126.23 48.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 123.138 1.447 . . . . 0.0 109.567 177.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -109.82 109.36 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 127.298 2.239 . . . . 0.0 107.833 -175.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -93.73 111.44 23.13 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.091 -1.006 . . . . 0.0 108.988 172.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.9 mt -110.14 160.71 16.25 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.182 0.993 . . . . 0.0 112.457 170.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.95 133.11 49.2 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.413 1.485 . . . . 0.0 108.157 164.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.83 166.12 29.46 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.469 0.652 . . . . 0.0 112.536 178.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -101.86 144.74 30.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 121.046 -1.033 . . . . 0.0 111.179 173.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.6 tttt . . . . . 0 N--CA 1.43 -1.47 0 C-N-CA 125.615 1.566 . . . . 0.0 112.48 167.013 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.9 t0 . . . . . 0 N--CA 1.429 -1.503 0 CA-C-O 121.134 0.493 . . . . 0.0 110.745 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -119.93 137.72 53.88 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.42 1.488 . . . . 0.0 108.993 -174.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.08 140.76 28.28 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-O 122.827 1.298 . . . . 0.0 109.739 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -100.52 112.53 24.91 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.297 1.839 . . . . 0.0 108.039 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.8 t -103.81 102.08 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 O-C-N 120.608 -1.307 . . . . 0.0 108.769 -172.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.73 102.1 14.85 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 167.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.8 tp -120.03 138.02 53.76 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.701 1.201 . . . . 0.0 110.002 -172.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.17 122.3 43.37 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.27 -1.519 . . . . 0.0 109.486 173.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -71.42 171.51 11.14 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.289 -1.507 . . . . 0.0 114.408 177.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.2 t -97.03 -149.81 0.33 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.711 -1.243 . . . . 0.0 108.287 169.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.39 74.67 3.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.03 -2.294 . . . . 0.0 112.571 -175.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.36 -4.8 77.38 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.531 1.539 . . . . 0.0 115.509 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.2 t -121.57 135.83 54.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.104 -1.233 . . . . 0.0 112.015 -173.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.3 mt -103.92 -55.31 2.4 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.851 1.66 . . . . 0.0 110.113 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.0 30.03 0.59 Allowed Glycine 0 N--CA 1.431 -1.693 0 C-N-CA 125.369 1.462 . . . . 0.0 112.56 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.454 HD12 HD13 ' A' ' 85' ' ' LEU . 11.1 pt -125.95 141.44 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 CA-C-N 118.586 1.193 . . . . 0.0 113.477 -163.401 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.2 m -129.47 138.13 51.23 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.375 1.07 . . . . 0.0 109.005 158.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.4 m -118.34 169.58 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.525 0 C-N-CA 124.949 1.299 . . . . 0.0 112.49 -174.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.25 169.84 18.53 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 172.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 133.41 -147.94 19.19 Favored Glycine 0 N--CA 1.428 -1.836 0 O-C-N 120.572 -1.33 . . . . 0.0 115.53 165.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.17 172.26 24.17 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.43 1.014 . . . . 0.0 112.998 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.1 t . . . . . 0 N--CA 1.429 -1.501 0 C-N-CA 124.828 1.251 . . . . 0.0 112.917 -172.454 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.751 0 N-CA-C 115.932 1.133 . . . . 0.0 115.932 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 mm -99.17 129.18 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.833 2.053 . . . . 0.0 107.819 175.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -126.71 158.07 37.42 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.903 -1.123 . . . . 0.0 109.521 -174.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.9 t -75.95 117.36 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 O-C-N 121.023 -1.048 . . . . 0.0 111.377 174.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.8 tttp -88.33 -45.12 10.28 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.871 1.268 . . . . 0.0 110.83 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.0 163.19 39.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 121.252 -0.905 . . . . 0.0 108.995 173.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 tp -117.95 121.73 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 170.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.64 124.08 87.73 Favored Pre-proline 0 N--CA 1.429 -1.482 0 C-N-CA 126.076 1.75 . . . . 0.0 113.749 -165.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -59.26 127.42 23.93 Favored 'Trans proline' 0 C--N 1.299 -2.057 0 C-N-CA 122.778 2.319 . . . . 0.0 114.904 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.281 11.7 mptt 82.07 21.76 0.27 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 128.538 2.735 . . . . 0.0 112.649 -177.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.91 153.39 29.57 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.962 -1.711 . . . . 0.0 113.711 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.93 -54.87 13.69 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 126.464 1.906 . . . . 0.0 113.877 166.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -54.08 45.97 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 127.576 2.35 . . . . 0.0 112.265 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -40.95 -59.58 1.41 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 177.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.0 t -70.2 -29.99 66.98 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -66.2 -52.5 47.39 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.751 -1.218 . . . . 0.0 113.44 -172.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.11 21.7 9.86 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 120.663 -1.273 . . . . 0.0 115.946 158.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -85.15 -36.87 20.79 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.716 -1.461 . . . . 0.0 109.557 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.9 mt -100.48 124.73 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 125.781 1.632 . . . . 0.0 109.098 -176.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.497 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 3.4 t-80 -142.36 -175.39 4.43 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.117 1.437 . . . . 0.0 112.274 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.4 ttpp -68.95 123.56 21.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.027 -1.67 . . . . 0.0 113.307 -170.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.71 3.7 62.37 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.418 -0.801 . . . . 0.0 114.492 -178.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -78.72 156.38 28.94 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 119.423 1.612 . . . . 0.0 111.743 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -102.5 123.36 46.11 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.208 -1.558 . . . . 0.0 110.446 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 7.4 t -88.86 119.23 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 O-C-N 120.371 -1.456 . . . . 0.0 110.814 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 98.2 mt -94.09 -46.32 7.17 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.01 -1.056 . . . . 0.0 112.118 -175.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.37 144.01 25.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.855 -1.153 . . . . 0.0 112.484 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.816 HG11 HG21 ' A' ' 84' ' ' THR . 2.9 p -113.42 111.71 37.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 C-N-CA 125.938 1.695 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.9 t30 57.23 34.75 25.25 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.771 -1.83 . . . . 0.0 113.674 170.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.19 -28.56 13.32 Favored Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.314 1.435 . . . . 0.0 114.336 -172.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -98.07 129.45 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.235 2.017 . . . . 0.0 110.627 -163.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 26.6 p -71.37 132.33 44.68 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.164 -1.585 . . . . 0.0 112.607 -177.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 47.9 mt -99.45 35.96 1.86 Allowed 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.498 -1.376 . . . . 0.0 111.912 -178.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -89.67 144.26 26.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.714 -1.241 . . . . 0.0 109.486 167.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.26 -32.07 2.31 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.914 -1.117 . . . . 0.0 114.778 -176.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.66 152.28 44.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -175.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.8 p -91.76 175.36 6.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.985 -1.072 . . . . 0.0 112.012 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -58.64 -46.8 86.32 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.514 1.525 . . . . 0.0 112.249 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 30.0 tttp -54.69 -47.93 73.07 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 115.574 1.694 . . . . 0.0 115.574 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -58.67 -47.5 84.29 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.667 1.187 . . . . 0.0 113.652 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -61.67 -38.74 88.89 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.613 1.565 . . . . 0.0 114.22 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.22 -49.03 76.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 C-N-CA 124.866 1.266 . . . . 0.0 111.251 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -68.32 -30.13 69.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.771 -1.205 . . . . 0.0 112.168 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . 0.816 HG21 HG11 ' A' ' 68' ' ' VAL . 38.8 m -64.33 -43.41 94.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.199 1.4 . . . . 0.0 114.691 167.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.454 HD13 HD12 ' A' ' 27' ' ' ILE . 67.3 mt -63.63 -37.03 85.8 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.074 -1.641 . . . . 0.0 114.171 173.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -67.09 -31.79 72.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.552 -1.342 . . . . 0.0 113.401 170.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -85.26 51.09 2.09 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.852 1.661 . . . . 0.0 112.1 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 p -106.59 148.48 28.24 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.442 -1.411 . . . . 0.0 109.867 171.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.66 -164.22 36.37 Favored Glycine 0 N--CA 1.43 -1.737 0 C-N-CA 123.778 0.704 . . . . 0.0 111.75 168.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -69.7 -46.27 66.38 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.732 -1.452 . . . . 0.0 114.65 -177.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 47.3 t -103.95 118.7 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 CA-C-O 122.437 1.113 . . . . 0.0 108.761 176.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.2 t -111.6 119.17 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 127.928 2.491 . . . . 0.0 109.926 -164.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -104.3 91.89 4.11 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.772 -1.205 . . . . 0.0 113.308 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -91.5 160.78 15.26 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.046 -2.284 . . . . 0.0 113.694 179.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.8 tp -127.0 128.06 45.77 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 161.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.32 158.48 44.32 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.989 -1.069 . . . . 0.0 112.213 176.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -110.07 140.71 43.83 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.047 1.339 . . . . 0.0 108.7 172.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.8 tptm . . . . . 0 N--CA 1.43 -1.434 0 C-N-CA 124.832 1.253 . . . . 0.0 111.476 -177.31 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 42.7 t0 . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.3 p -120.83 150.14 41.48 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.48 -1.388 . . . . 0.0 110.985 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' A' ' 96' ' ' LEU . 2.2 p90 -147.4 136.26 22.11 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.307 1.527 . . . . 0.0 109.412 172.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 21.4 mp0 -89.13 128.01 35.75 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 126.899 2.08 . . . . 0.0 108.581 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 74.6 t -109.82 94.87 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.497 0 O-C-N 121.036 -1.04 . . . . 0.0 108.252 -174.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -90.54 102.78 15.52 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-O 123.399 1.571 . . . . 0.0 109.61 169.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.6 tp -124.75 143.41 50.8 Favored 'General case' 0 N--CA 1.431 -1.395 0 C-N-CA 124.597 1.159 . . . . 0.0 110.678 -169.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.95 39.53 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.061 -1.649 . . . . 0.0 109.642 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -69.68 153.21 43.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.537 -1.352 . . . . 0.0 112.231 172.043 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.0 t -141.28 133.95 28.64 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 174.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 33.6 t0 50.93 39.48 22.83 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.959 2.104 . . . . 0.0 113.142 -172.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.13 3.05 55.52 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 120.11 -1.619 . . . . 0.0 116.898 -176.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 84.7 p -112.82 144.49 42.27 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 118.895 1.348 . . . . 0.0 114.03 -167.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 54.0 mt -102.84 -63.15 1.19 Allowed 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.92 1.288 . . . . 0.0 109.598 169.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.03 11.21 10.2 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 119.371 -2.081 . . . . 0.0 115.208 172.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 pt -100.56 131.58 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 CA-C-N 118.922 1.361 . . . . 0.0 111.188 174.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -110.8 121.61 45.76 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.055 -1.028 . . . . 0.0 108.7 168.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.9 m -105.49 165.68 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.702 1.201 . . . . 0.0 113.02 -173.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -149.25 162.53 39.83 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.328 1.451 . . . . 0.0 109.737 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.77 -135.14 12.45 Favored Glycine 0 N--CA 1.431 -1.698 0 CA-C-O 122.658 1.143 . . . . 0.0 115.853 163.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.55 172.6 44.27 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 121.253 -1.145 . . . . 0.0 113.407 -176.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.43 -1.443 0 N-CA-C 115.973 1.842 . . . . 0.0 115.973 -174.391 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.728 0 N-CA-C 110.221 -1.152 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -100.22 123.24 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.5 m-85 -123.59 157.21 34.24 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 121.059 -1.026 . . . . 0.0 110.667 -175.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.44 125.53 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 O-C-N 120.573 -1.329 . . . . 0.0 112.038 168.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -95.75 -35.62 11.47 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 120.397 -1.44 . . . . 0.0 112.457 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.51 158.03 36.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.854 -1.154 . . . . 0.0 112.221 -176.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -116.69 123.05 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.59 1.556 . . . . 0.0 109.881 175.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.2 mm -77.01 119.49 77.72 Favored Pre-proline 0 N--CA 1.43 -1.431 0 C-N-CA 125.93 1.692 . . . . 0.0 113.714 -176.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.74 124.39 12.27 Favored 'Trans proline' 0 C--N 1.299 -2.06 0 CA-C-N 124.744 2.73 . . . . 0.0 113.981 -172.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 10.5 mmmm 79.07 29.67 0.35 Allowed 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 129.334 3.054 . . . . 0.0 113.587 -175.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 162.66 38.14 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.507 -1.37 . . . . 0.0 113.102 162.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.08 -60.01 3.15 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 126.947 2.099 . . . . 0.0 114.911 166.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.32 -46.09 88.27 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 129.517 3.127 . . . . 0.0 112.391 -179.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -43.31 -65.67 0.46 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 171.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.5 t -67.72 -26.99 66.43 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -175.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.89 -56.82 16.99 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.265 -1.522 . . . . 0.0 111.8 174.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.19 2.57 64.03 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.72 -1.238 . . . . 0.0 114.733 157.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 65.0 mtt85 -56.04 -44.11 78.47 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.025 1.33 . . . . 0.0 110.793 159.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.5 mt -82.03 131.09 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 127.698 2.399 . . . . 0.0 111.759 -176.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 11.6 m-70 -122.72 155.44 36.45 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 128.314 2.646 . . . . 0.0 109.228 174.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 pttt -73.15 106.81 5.16 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.931 -1.73 . . . . 0.0 111.631 173.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.29 -31.35 2.06 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-O 119.16 -0.8 . . . . 0.0 113.733 -165.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.371 4.0 p30 -80.24 159.44 25.9 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 120.109 1.955 . . . . 0.0 116.112 -166.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.4 ttt85 -110.02 125.85 53.34 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.562 -1.336 . . . . 0.0 112.151 -162.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.5 t -82.11 135.07 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.488 -1.383 . . . . 0.0 111.173 -173.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 95.9 mt -103.83 -54.01 2.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.126 -0.983 . . . . 0.0 111.213 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.78 146.06 26.14 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.189 -1.569 . . . . 0.0 111.927 -174.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.0 t -114.04 107.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 123.704 0.802 . . . . 0.0 108.964 175.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.5 t30 61.81 45.17 7.93 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.967 2.107 . . . . 0.0 113.86 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.35 -24.25 14.89 Favored Glycine 0 N--CA 1.431 -1.68 0 O-C-N 121.136 -0.977 . . . . 0.0 113.571 -174.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.3 t -87.08 111.66 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.482 -1.599 . . . . 0.0 109.981 -175.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 p -69.31 128.62 37.24 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.721 1.209 . . . . 0.0 111.837 178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 50.5 mt -86.03 52.18 2.41 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.168 -1.583 . . . . 0.0 111.869 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -78.9 121.16 24.51 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.592 -1.942 . . . . 0.0 113.48 -169.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.64 24.0 65.72 Favored Glycine 0 N--CA 1.431 -1.679 0 C-N-CA 124.873 1.225 . . . . 0.0 114.753 -176.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.96 42.34 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -170.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 74.6 p -91.65 170.5 9.87 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 124.688 1.195 . . . . 0.0 111.096 171.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 7.3 t-160 -58.44 -58.14 9.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.357 1.463 . . . . 0.0 114.41 -175.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -58.02 -29.74 65.55 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 116.169 1.914 . . . . 0.0 116.169 176.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.52 -52.18 66.46 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.411 1.484 . . . . 0.0 113.017 178.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.64 -45.13 89.93 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.066 1.746 . . . . 0.0 113.624 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.8 t -64.53 -48.73 83.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.146 1.378 . . . . 0.0 111.27 -179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.3 mm-40 -65.75 -33.02 74.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.0 m -67.52 -45.37 75.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.525 1.93 . . . . 0.0 112.413 174.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.4 mt -58.89 -42.85 90.53 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 124.791 1.236 . . . . 0.0 113.508 172.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -69.97 -14.72 62.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 115.26 1.578 . . . . 0.0 115.26 178.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -95.65 36.63 1.26 Allowed 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.478 -2.014 . . . . 0.0 112.023 172.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 77.4 p -107.27 144.8 33.56 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.249 -1.532 . . . . 0.0 110.651 172.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.53 23.66 Favored Glycine 0 N--CA 1.429 -1.774 0 C-N-CA 123.965 0.793 . . . . 0.0 112.514 -177.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -60.9 -56.2 23.94 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.3 t -101.49 126.29 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 CA-C-O 122.282 1.039 . . . . 0.0 109.561 172.117 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 67.4 t -115.45 137.33 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 129.664 3.186 . . . . 0.0 108.662 -166.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 13.5 t-160 -124.22 106.33 10.21 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.505 -1.372 . . . . 0.0 111.394 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 18.7 mt -97.06 160.17 14.5 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 119.356 -2.09 . . . . 0.0 113.239 170.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 64.9 tp -127.96 131.87 49.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 161.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.567 HD11 ' CE2' ' A' ' 14' ' ' PHE . 2.0 pp -148.19 169.03 20.94 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.933 -1.104 . . . . 0.0 112.833 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -117.01 143.46 45.71 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.576 1.55 . . . . 0.0 111.371 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.3 tptm . . . . . 0 N--CA 1.429 -1.52 0 C-N-CA 126.921 2.088 . . . . 0.0 113.386 -175.883 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.8 t0 . . . . . 0 N--CA 1.43 -1.454 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 p -106.96 149.53 27.41 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.13 -0.982 . . . . 0.0 112.524 -177.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -145.01 132.78 21.09 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.914 -1.116 . . . . 0.0 108.178 -176.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.87 120.01 28.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.39 1.476 . . . . 0.0 108.255 169.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 84.6 t -116.44 100.87 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 124.627 1.171 . . . . 0.0 109.328 -168.149 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -90.18 104.92 17.44 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.352 -1.468 . . . . 0.0 108.999 170.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.2 tp -119.95 130.67 54.89 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 124.91 1.284 . . . . 0.0 110.543 -169.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 146.12 28.54 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.722 -1.861 . . . . 0.0 109.64 173.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -67.93 166.02 16.55 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.933 1.827 . . . . 0.0 115.933 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 28.6 p -132.23 130.73 41.35 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.681 1.592 . . . . 0.0 108.163 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 46.6 44.43 13.5 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.925 2.09 . . . . 0.0 114.905 -175.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.88 -14.63 30.77 Favored Glycine 0 N--CA 1.429 -1.818 0 O-C-N 119.855 -1.778 . . . . 0.0 117.041 178.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 t -121.84 175.18 6.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 119.716 1.758 . . . . 0.0 112.113 -174.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 94.2 mt -99.96 -60.58 1.5 Allowed 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.702 1.201 . . . . 0.0 110.46 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.15 44.04 0.38 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.15 -1.594 . . . . 0.0 111.222 174.243 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 tt -144.06 147.86 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.068 1.413 . . . . 0.0 110.985 -172.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -124.57 117.69 24.89 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 125.071 1.348 . . . . 0.0 108.532 170.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 m -95.93 166.17 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 124.496 1.118 . . . . 0.0 112.726 -178.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.1 t -151.85 172.43 16.2 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.472 1.509 . . . . 0.0 110.247 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.47 -144.3 16.98 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.256 -0.902 . . . . 0.0 113.74 172.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.82 162.52 23.11 Favored Glycine 0 N--CA 1.43 -1.722 0 CA-C-O 122.489 1.049 . . . . 0.0 112.677 -177.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.5 p . . . . . 0 N--CA 1.43 -1.474 0 C-N-CA 125.497 1.519 . . . . 0.0 114.508 -174.84 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.711 0 CA-C-O 121.426 0.459 . . . . 0.0 113.564 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.5 mm -90.98 114.22 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.511 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 171.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -113.93 151.84 31.68 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.315 1.055 . . . . 0.0 110.012 -171.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.9 t -76.18 120.58 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.625 -1.297 . . . . 0.0 110.357 169.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -93.72 -48.59 6.25 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.707 -1.246 . . . . 0.0 110.587 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.43 157.99 43.92 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.491 -0.755 . . . . 0.0 109.51 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.533 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.5 tp -124.47 123.92 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.4 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -77.33 122.46 86.12 Favored Pre-proline 0 N--CA 1.43 -1.446 0 CA-C-O 116.454 -1.736 . . . . 0.0 112.817 -170.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -58.11 128.6 29.39 Favored 'Trans proline' 0 N--CA 1.434 -1.991 0 CA-C-N 124.39 2.604 . . . . 0.0 115.797 -174.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.296 52.1 mtmt 76.07 17.52 2.12 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.283 2.233 . . . . 0.0 113.629 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.96 160.25 38.62 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.386 -1.446 . . . . 0.0 111.705 170.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.58 -56.47 8.32 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.14 -1.8 . . . . 0.0 115.837 168.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.0 -44.51 95.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.567 1.947 . . . . 0.0 112.399 -177.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.533 ' HG2' HG23 ' A' ' 47' ' ' ILE . 7.4 tm-20 -51.06 -65.21 0.6 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.297 1.592 . . . . 0.0 115.297 167.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 94.1 p -65.66 -26.94 68.02 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -169.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -55.47 -57.77 10.52 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.977 1.711 . . . . 0.0 113.228 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.63 -9.91 25.89 Favored Glycine 0 N--CA 1.43 -1.741 0 O-C-N 120.822 -1.174 . . . . 0.0 114.643 159.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.4 mtt180 -64.61 -32.4 74.05 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.763 1.225 . . . . 0.0 111.454 167.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 mt -96.91 124.76 49.89 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 C-N-CA 125.932 1.693 . . . . 0.0 110.762 -177.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 10.0 m80 -128.77 166.85 18.21 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.391 1.477 . . . . 0.0 109.487 170.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.0 ptpt -68.06 132.99 48.24 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.125 -1.609 . . . . 0.0 111.661 174.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 99.36 -7.9 60.19 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.026 -1.046 . . . . 0.0 114.524 -171.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -78.89 156.27 28.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-N 119.58 1.69 . . . . 0.0 112.41 -178.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -114.36 124.27 51.54 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.743 -1.223 . . . . 0.0 110.725 -168.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 10.7 t -87.67 131.29 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.296 -1.502 . . . . 0.0 110.162 -174.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.64 -44.8 5.46 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.684 -1.26 . . . . 0.0 110.307 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.32 143.22 25.67 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.598 -0.689 . . . . 0.0 110.814 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 39.9 t -124.93 124.06 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 173.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 63.82 33.79 12.42 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.966 1.707 . . . . 0.0 114.214 170.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.99 -15.76 62.75 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 120.693 -1.254 . . . . 0.0 113.698 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.38 116.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 121.554 -0.968 . . . . 0.0 110.202 -173.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -73.98 130.71 40.41 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.778 -1.202 . . . . 0.0 110.831 176.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.5 mt -85.48 44.2 1.08 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.866 -1.147 . . . . 0.0 114.065 -165.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -80.85 133.04 35.52 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.996 -2.315 . . . . 0.0 112.046 -177.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.53 13.07 67.78 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.488 -1.382 . . . . 0.0 114.793 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.31 142.72 48.85 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.767 1.395 . . . . 0.0 114.767 -178.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 36.0 p -90.56 178.18 6.16 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.013 1.725 . . . . 0.0 110.061 171.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -60.31 -48.98 79.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.837 -1.164 . . . . 0.0 112.971 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.0 mmtt -54.58 -38.51 66.78 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 126.365 1.866 . . . . 0.0 115.523 175.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -51.05 71.34 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.223 1.809 . . . . 0.0 113.187 -177.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.58 -34.05 73.6 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.516 1.527 . . . . 0.0 113.386 176.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.05 -53.44 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.375 0 C-N-CA 124.768 1.227 . . . . 0.0 110.127 178.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -60.79 -39.27 88.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 121.22 -0.925 . . . . 0.0 112.947 178.132 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 69.7 m -63.65 -40.64 97.37 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 124.828 1.251 . . . . 0.0 113.605 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 64.6 mt -72.0 -37.09 69.9 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.764 -1.21 . . . . 0.0 113.748 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 27.3 mtp180 -64.02 -47.35 80.59 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.188 -1.57 . . . . 0.0 112.793 176.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -88.14 58.97 5.05 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.716 1.246 . . . . 0.0 111.712 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.8 p -105.11 157.02 17.54 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.895 2.078 . . . . 0.0 110.052 176.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.26 -146.21 9.35 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.509 -1.37 . . . . 0.0 111.741 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.2 tt0 -71.85 -56.64 5.36 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.604 -1.527 . . . . 0.0 113.139 170.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 14.2 p -100.53 140.02 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.961 1.304 . . . . 0.0 109.316 179.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 72.5 t -124.22 122.85 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 127.496 2.318 . . . . 0.0 108.273 -170.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.8 m170 -100.52 101.36 12.27 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.058 -1.651 . . . . 0.0 110.561 177.179 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 8.7 mt -92.87 160.39 14.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.862 -1.774 . . . . 0.0 111.655 172.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.29 131.21 46.92 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 157.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.7 pp -143.4 166.85 23.62 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.993 -1.692 . . . . 0.0 112.312 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -112.73 146.24 39.11 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.406 1.882 . . . . 0.0 108.589 175.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.43 -1.427 0 O-C-N 120.784 -1.197 . . . . 0.0 110.57 176.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.6 t0 . . . . . 0 N--CA 1.43 -1.439 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.7 p -97.43 162.32 13.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 122.11 0.957 . . . . 0.0 112.534 -176.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -144.82 138.19 26.9 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -93.66 115.38 27.83 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 126.301 1.84 . . . . 0.0 107.149 166.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.403 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 32.7 t -111.87 99.78 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -175.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -90.05 100.09 12.98 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.351 -1.468 . . . . 0.0 109.593 176.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.0 tp -116.59 136.91 52.59 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.744 1.218 . . . . 0.0 111.032 -162.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.66 145.81 29.51 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.443 -1.41 . . . . 0.0 109.006 169.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -70.81 141.66 51.34 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.924 -1.11 . . . . 0.0 113.677 174.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.9 t -137.95 142.7 40.53 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.426 -1.421 . . . . 0.0 109.619 174.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.1 t0 54.55 34.71 21.84 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.107 2.163 . . . . 0.0 113.906 -177.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.55 63.26 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 124.877 1.227 . . . . 0.0 115.948 -174.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 71.7 p -121.32 142.41 49.99 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-N 118.886 1.343 . . . . 0.0 114.033 -171.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.4 mt -89.72 -61.61 1.65 Allowed 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 159.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.79 48.19 0.55 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 118.98 -2.325 . . . . 0.0 112.711 163.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.3 tt -145.94 150.11 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.334 1.064 . . . . 0.0 110.006 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.4 t -122.94 125.66 45.74 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 164.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 m -106.15 157.74 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 125.338 1.455 . . . . 0.0 110.025 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.9 t -141.95 170.34 15.9 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.094 0.958 . . . . 0.0 109.71 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -132.09 10.96 Favored Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 123.885 0.755 . . . . 0.0 113.228 173.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.45 -179.83 42.07 Favored Glycine 0 N--CA 1.431 -1.696 0 CA-C-O 122.46 1.033 . . . . 0.0 111.747 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.429 -1.499 0 O-C-N 120.923 -1.339 . . . . 0.0 113.274 -169.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.784 0 N-CA-C 115.401 0.92 . . . . 0.0 115.401 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.2 mm -103.7 117.56 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.716 1.607 . . . . 0.0 107.373 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -124.98 150.0 47.13 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.795 -1.19 . . . . 0.0 110.171 -168.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 32.2 t -75.66 122.31 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.456 -1.402 . . . . 0.0 113.201 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -89.3 -56.48 3.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.363 1.065 . . . . 0.0 109.686 173.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.46 156.19 43.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.117 -0.989 . . . . 0.0 111.454 -173.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.63 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -119.2 117.97 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.06 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 28.7 mm -76.89 125.06 87.49 Favored Pre-proline 0 N--CA 1.43 -1.451 0 CA-C-O 115.391 -2.242 . . . . 0.0 113.0 -165.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -53.33 136.95 64.08 Favored 'Trans proline' 0 C--N 1.3 -1.979 0 C-N-CA 123.628 2.886 . . . . 0.0 116.899 -171.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.277 6.6 mtpm? 51.67 26.1 3.21 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 119.168 3.025 . . . . 0.0 119.168 -169.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.31 169.65 54.91 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 118.995 -2.316 . . . . 0.0 113.201 170.083 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.21 -60.86 2.55 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.121 1.768 . . . . 0.0 114.136 165.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.9 -45.48 92.33 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 129.01 2.924 . . . . 0.0 112.646 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.5 tm-20 -43.66 -68.25 0.21 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.826 1.65 . . . . 0.0 114.818 166.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 74.9 m -69.89 -14.84 62.93 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 116.367 1.988 . . . . 0.0 116.367 -174.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -61.38 -55.72 28.4 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.82 1.248 . . . . 0.0 111.751 170.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.29 4.7 77.1 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 120.301 -1.5 . . . . 0.0 115.699 167.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -75.17 -38.3 60.91 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.243 -1.739 . . . . 0.0 110.326 163.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.5 mt -77.59 120.63 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 126.352 1.861 . . . . 0.0 111.122 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -117.99 166.09 12.94 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 125.895 1.678 . . . . 0.0 111.153 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 48.0 tttm -63.98 127.3 30.81 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 119.966 -1.709 . . . . 0.0 111.936 171.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.59 0.94 68.98 Favored Glycine 0 N--CA 1.431 -1.662 0 O-C-N 121.29 -0.882 . . . . 0.0 113.992 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.06 153.47 43.59 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 119.178 1.489 . . . . 0.0 112.792 179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 65.1 ttt-85 -105.46 122.06 45.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.832 0.825 . . . . 0.0 109.299 -176.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.4 t -82.89 134.95 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.751 -1.218 . . . . 0.0 109.81 -177.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.2 mp -105.64 -50.08 3.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.856 -1.152 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.15 151.2 32.74 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.369 -1.457 . . . . 0.0 111.88 -175.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.97 HG11 HG21 ' A' ' 84' ' ' THR . 3.4 p -118.06 110.21 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 122.379 1.085 . . . . 0.0 112.393 172.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 55.26 39.68 31.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.943 -1.723 . . . . 0.0 114.913 164.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.96 -13.42 60.55 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-O 119.324 -0.709 . . . . 0.0 114.5 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.9 t -102.17 111.12 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.614 2.207 . . . . 0.0 109.302 -176.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 43.6 m -76.27 119.73 20.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.213 -1.554 . . . . 0.0 110.625 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 87.2 mt -92.41 35.47 1.01 Allowed 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.66 -1.275 . . . . 0.0 112.223 -167.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -88.61 91.19 8.71 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 119.619 -1.926 . . . . 0.0 112.52 -168.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 96.93 10.55 54.99 Favored Glycine 0 N--CA 1.429 -1.812 0 C-N-CA 125.202 1.382 . . . . 0.0 112.157 -171.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.85 157.7 37.4 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-O 122.532 1.158 . . . . 0.0 113.535 171.356 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 41.5 p -83.49 172.91 11.94 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.255 -1.528 . . . . 0.0 113.169 -175.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-80 -58.41 -46.17 86.96 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.386 1.474 . . . . 0.0 113.613 170.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -57.96 -43.06 86.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 172.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.91 -55.15 36.04 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 114.432 1.271 . . . . 0.0 114.432 -175.136 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.3 -43.3 64.41 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 116.284 1.957 . . . . 0.0 116.284 171.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.57 -52.04 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.756 -1.215 . . . . 0.0 111.461 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -64.64 -30.63 71.65 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.19 -0.944 . . . . 0.0 111.886 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . 0.97 HG21 HG11 ' A' ' 68' ' ' VAL . 39.4 m -63.87 -51.41 64.7 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.186 1.394 . . . . 0.0 113.509 170.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.6 mt -60.42 -37.01 79.51 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 120.565 1.53 . . . . 0.0 113.789 176.275 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -61.93 -44.41 96.83 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.493 1.517 . . . . 0.0 113.763 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -94.54 55.91 2.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.539 1.536 . . . . 0.0 112.682 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.45 145.36 31.87 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.533 -1.355 . . . . 0.0 109.983 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.02 -141.32 4.8 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.658 -1.276 . . . . 0.0 111.889 176.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -70.69 -58.31 3.78 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.383 -1.657 . . . . 0.0 113.791 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 t -109.57 137.76 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.533 1.133 . . . . 0.0 110.947 -176.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.6 t -125.13 122.56 63.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 C-N-CA 128.924 2.89 . . . . 0.0 110.911 -173.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.0 t-160 -100.81 95.9 6.94 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.139 -2.226 . . . . 0.0 113.085 176.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.403 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 23.5 mt -88.2 154.83 20.12 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 118.92 -2.363 . . . . 0.0 113.328 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 39.0 tp -127.25 135.46 50.64 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 163.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -150.63 168.91 22.89 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.889 -1.132 . . . . 0.0 111.942 175.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.92 141.68 47.63 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.078 2.151 . . . . 0.0 109.142 172.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.453 0 C-N-CA 125.13 1.372 . . . . 0.0 112.305 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.5 t0 . . . . . 0 N--CA 1.431 -1.404 0 CA-C-O 121.276 0.56 . . . . 0.0 111.183 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.86 139.61 44.73 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.364 -1.46 . . . . 0.0 110.325 -176.48 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -146.52 154.99 42.18 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-O 123.037 1.398 . . . . 0.0 110.298 174.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -108.6 142.24 39.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.893 1.677 . . . . 0.0 107.362 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.5 t -122.63 106.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.684 1.193 . . . . 0.0 108.648 -171.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -95.16 97.78 10.15 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 121.002 -1.061 . . . . 0.0 109.275 169.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.9 tp -119.79 129.93 54.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 123.787 0.835 . . . . 0.0 112.601 -168.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.71 123.55 44.08 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.365 -1.46 . . . . 0.0 109.452 171.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -69.61 114.83 8.19 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.507 1.523 . . . . 0.0 113.183 -177.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.3 t -96.53 129.67 43.86 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.323 -1.486 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.6 t70 41.48 49.41 3.55 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.337 2.655 . . . . 0.0 114.917 -175.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.29 10.61 70.01 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 117.336 1.695 . . . . 0.0 117.336 -178.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 85.3 p -120.97 129.12 53.3 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 119.86 1.83 . . . . 0.0 113.977 -175.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 82.5 mt -85.8 -58.31 2.7 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.823 -1.173 . . . . 0.0 111.077 168.184 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.37 23.05 4.25 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 119.4 -2.062 . . . . 0.0 113.598 176.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 pt -122.41 141.28 43.44 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 CA-C-O 123.092 1.425 . . . . 0.0 113.348 -174.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.9 t -113.45 126.61 55.53 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 159.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 m -115.59 159.54 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.03 1.332 . . . . 0.0 110.749 -177.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.21 166.11 28.01 Favored 'General case' 0 N--CA 1.428 -1.532 0 C-N-CA 124.862 1.265 . . . . 0.0 109.424 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.35 -143.0 16.79 Favored Glycine 0 N--CA 1.429 -1.815 0 O-C-N 120.155 -1.591 . . . . 0.0 114.674 160.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 103.56 161.63 25.09 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.548 1.07 . . . . 0.0 111.514 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.43 -1.45 0 O-C-N 120.547 -1.56 . . . . 0.0 114.068 -171.405 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.748 0 CA-C-O 121.639 0.577 . . . . 0.0 114.128 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.0 mm -84.97 129.87 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.923 1.689 . . . . 0.0 109.104 174.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -122.89 150.37 43.0 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.166 -0.959 . . . . 0.0 109.271 -175.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -77.77 127.7 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.433 -1.417 . . . . 0.0 112.019 170.106 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.7 ttpp -94.91 -44.1 7.88 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.704 -1.247 . . . . 0.0 111.747 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.91 153.85 33.86 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.878 -1.139 . . . . 0.0 112.926 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.271 1.0 OUTLIER -102.94 118.14 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 CA-C-O 122.644 1.211 . . . . 0.0 110.038 168.822 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.9 mm -76.38 124.11 87.98 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 126.436 1.894 . . . . 0.0 112.366 -173.18 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -56.29 129.96 37.62 Favored 'Trans proline' 0 N--CA 1.434 -1.992 0 C-N-CA 122.835 2.357 . . . . 0.0 115.166 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.8 mtmt 75.4 22.34 1.67 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.265 1.826 . . . . 0.0 114.771 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.44 167.17 42.65 Favored Glycine 0 N--CA 1.43 -1.743 0 O-C-N 119.722 -1.861 . . . . 0.0 115.26 169.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.63 -63.35 1.15 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.3 98.09 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 129.087 2.955 . . . . 0.0 112.824 -176.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -42.21 -55.72 3.18 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 168.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.0 t -68.53 -38.15 80.61 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.74 -51.66 68.01 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 126.067 1.747 . . . . 0.0 112.171 177.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.31 1.02 72.6 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.606 -1.309 . . . . 0.0 114.421 159.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -67.87 -44.11 77.82 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.315 1.446 . . . . 0.0 110.498 166.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 36.0 mt -85.64 129.66 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 125.532 1.533 . . . . 0.0 109.8 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.38 167.33 29.09 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.288 1.035 . . . . 0.0 110.961 -171.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.0 tttm -50.72 121.41 5.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -178.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.07 7.6 67.83 Favored Glycine 0 N--CA 1.429 -1.804 0 CA-C-O 117.904 -1.498 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.296 1.7 p30 -77.51 152.64 34.02 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-N 120.786 2.293 . . . . 0.0 112.767 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -102.17 120.59 40.7 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -176.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.11 128.74 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.077 -1.015 . . . . 0.0 109.768 -176.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.1 mt -99.26 -45.29 5.93 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.435 -1.416 . . . . 0.0 111.446 -175.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.67 145.17 25.67 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.673 -1.267 . . . . 0.0 111.658 -178.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.1 t -112.31 108.52 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.051 0.94 . . . . 0.0 109.445 173.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.0 t30 60.08 38.82 20.32 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.879 1.672 . . . . 0.0 114.547 166.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -16.21 60.14 Favored Glycine 0 N--CA 1.43 -1.718 0 C-N-CA 125.307 1.432 . . . . 0.0 114.214 -177.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.4 t -97.14 120.68 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 121.008 -1.29 . . . . 0.0 110.58 -176.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.9 t -75.33 133.89 41.15 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.486 -1.384 . . . . 0.0 111.956 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 88.2 mt -88.21 12.62 13.34 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.908 -1.12 . . . . 0.0 113.628 -176.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 39.2 mm-40 -64.96 128.43 35.74 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 119.934 -1.729 . . . . 0.0 112.414 173.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.25 -6.57 67.29 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 125.314 1.435 . . . . 0.0 116.115 -176.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.6 149.71 45.37 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 116.953 2.205 . . . . 0.0 116.953 -174.524 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 30.5 p -93.19 -179.61 5.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 125.704 1.602 . . . . 0.0 110.943 171.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -63.91 -50.35 69.07 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.541 -1.349 . . . . 0.0 111.765 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 38.0 mttp -56.46 -39.35 73.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.915 1.45 . . . . 0.0 114.915 175.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -57.37 -54.3 48.41 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 114.51 1.3 . . . . 0.0 114.51 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.51 -36.13 81.97 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 124.63 1.172 . . . . 0.0 113.124 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.6 t -64.18 -51.27 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 120.949 -1.094 . . . . 0.0 110.706 174.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.581 -1.324 . . . . 0.0 113.608 178.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 87.8 m -62.87 -51.14 68.14 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.702 2.001 . . . . 0.0 112.874 173.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 74.3 mt -65.84 -32.05 73.35 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.95 -1.719 . . . . 0.0 114.988 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -68.18 -28.46 67.29 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.497 -1.377 . . . . 0.0 111.667 173.062 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -93.25 41.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.215 -1.553 . . . . 0.0 112.543 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -98.88 153.96 18.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.147 -1.596 . . . . 0.0 110.907 172.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -106.78 -138.33 8.93 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 124.777 1.18 . . . . 0.0 110.81 174.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -70.05 -66.9 0.54 Allowed 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -177.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.3 120.65 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 122.287 1.041 . . . . 0.0 109.256 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 71.3 t -114.54 119.53 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 128.51 2.724 . . . . 0.0 108.966 -167.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.1 t-160 -107.38 88.87 2.83 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.733 -1.229 . . . . 0.0 113.298 -174.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.1 mt -92.37 157.13 16.78 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.82 -1.8 . . . . 0.0 113.868 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 55.4 tp -127.47 129.09 46.82 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.743 1.217 . . . . 0.0 108.177 170.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.43 161.52 37.83 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-O 122.307 1.051 . . . . 0.0 113.715 179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -120.35 132.07 55.12 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.108 1.363 . . . . 0.0 109.645 175.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.2 tptm . . . . . 0 N--CA 1.43 -1.426 0 O-C-N 120.803 -1.186 . . . . 0.0 113.758 -164.773 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.7 t0 . . . . . 0 N--CA 1.431 -1.417 0 CA-C-O 122.063 0.935 . . . . 0.0 112.661 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 45.0 p -105.41 161.45 14.31 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.211 1.405 . . . . 0.0 113.181 -175.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.22 140.66 25.46 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 167.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -88.54 132.96 34.3 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-O 122.264 1.031 . . . . 0.0 109.471 163.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 t -120.8 98.18 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 126.053 1.741 . . . . 0.0 109.727 -169.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.09 102.29 15.04 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.355 -1.466 . . . . 0.0 109.972 174.026 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.519 HD11 ' HA ' ' A' ' 53' ' ' ALA . 0.4 OUTLIER -123.1 128.64 50.38 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.85 -1.156 . . . . 0.0 111.33 -166.805 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.23 125.19 47.83 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 119.967 -1.708 . . . . 0.0 110.354 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 47.9 mtpt -69.69 150.17 47.26 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.517 1.673 . . . . 0.0 115.517 -173.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.8 p -102.91 87.39 2.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.852 1.261 . . . . 0.0 109.407 178.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.2 t0 45.92 64.83 1.32 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.348 2.659 . . . . 0.0 116.127 -175.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.74 -29.54 9.04 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 121.06 -1.025 . . . . 0.0 113.549 -178.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.9 m -97.42 136.19 38.21 Favored 'General case' 0 N--CA 1.43 -1.445 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -169.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.2 mt -85.26 -60.5 2.02 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.23 1.412 . . . . 0.0 110.691 171.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.35 27.58 1.79 Allowed Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.404 -2.06 . . . . 0.0 111.292 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 pt -124.88 155.96 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.555 1.142 . . . . 0.0 110.961 -170.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.6 t -129.8 130.38 45.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 152.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -104.82 157.93 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.914 1.286 . . . . 0.0 109.617 -177.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -140.33 169.71 17.17 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.717 -1.24 . . . . 0.0 109.111 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.52 -140.29 15.32 Favored Glycine 0 N--CA 1.43 -1.734 0 CA-C-O 122.372 0.984 . . . . 0.0 114.876 164.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.23 157.53 32.23 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 122.235 0.908 . . . . 0.0 112.838 -174.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 N--CA 1.431 -1.408 0 N-CA-C 116.951 2.204 . . . . 0.0 116.951 -166.179 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.726 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.8 mm -99.67 119.27 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -120.36 149.79 41.79 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.898 -1.126 . . . . 0.0 110.366 -171.221 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.8 t -76.75 112.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 O-C-N 121.022 -1.049 . . . . 0.0 111.67 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.36 -41.92 11.22 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 120.804 -1.185 . . . . 0.0 112.109 -174.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.61 151.99 35.97 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.82 -1.175 . . . . 0.0 110.411 176.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.98 119.91 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.5 1.143 . . . . 0.0 108.819 173.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.21 125.61 86.3 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 117.042 2.238 . . . . 0.0 117.042 -166.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -53.84 119.08 5.68 Favored 'Trans proline' 0 N--CA 1.434 -2.011 0 C-N-CA 123.645 2.897 . . . . 0.0 116.512 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.255 67.2 mmtt 76.16 30.0 0.73 Allowed 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 128.267 2.627 . . . . 0.0 112.421 -177.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 158.07 33.7 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.617 -1.302 . . . . 0.0 111.119 168.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -59.23 3.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.794 -1.416 . . . . 0.0 113.346 166.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.519 ' HA ' HD11 ' A' ' 18' ' ' LEU . . . -63.24 -46.69 85.77 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 128.553 2.741 . . . . 0.0 113.914 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -42.78 -60.62 1.51 Allowed 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 172.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.17 -30.96 69.29 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -60.93 -62.79 1.6 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 125.655 1.582 . . . . 0.0 113.336 -178.079 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.94 6.17 49.42 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 116.987 1.555 . . . . 0.0 116.987 166.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.7 mmt85 -72.33 -37.22 68.93 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-N 119.541 1.67 . . . . 0.0 110.805 164.123 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.9 mt -92.27 124.28 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.922 1.289 . . . . 0.0 108.11 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -145.6 176.86 9.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.387 -1.446 . . . . 0.0 111.619 175.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -65.59 126.4 28.23 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.298 1.039 . . . . 0.0 113.023 -170.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.24 80.65 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 121.128 -0.983 . . . . 0.0 115.533 -179.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.51 157.97 25.97 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 119.117 1.458 . . . . 0.0 111.911 -177.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -105.12 121.66 44.28 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.088 -1.008 . . . . 0.0 111.212 -172.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.43 HG13 HD11 ' A' ' 94' ' ' LEU . 58.9 t -82.31 134.39 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.406 0 C-N-CA 125.727 1.611 . . . . 0.0 107.895 -176.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -119.42 -52.14 2.27 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.96 -1.087 . . . . 0.0 113.715 -167.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.85 113.28 4.96 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.626 -1.296 . . . . 0.0 111.138 -173.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -93.59 111.64 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.164 -0.96 . . . . 0.0 108.945 -175.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 61.68 36.15 16.66 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.901 2.08 . . . . 0.0 113.407 177.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.39 -9.89 75.34 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 125.001 1.286 . . . . 0.0 113.669 -176.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.4 t -90.94 101.96 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.11 -1.818 . . . . 0.0 109.019 -176.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.3 m -66.79 133.21 49.67 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.707 -1.246 . . . . 0.0 112.125 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.2 mt -85.97 45.95 1.27 Allowed 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.293 1.037 . . . . 0.0 112.262 -171.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -74.82 118.99 18.4 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.93 -1.731 . . . . 0.0 112.295 -171.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.52 22.88 75.23 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 124.031 0.824 . . . . 0.0 114.825 -175.143 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.92 145.34 50.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -176.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.3 p -90.13 170.84 9.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.872 1.269 . . . . 0.0 110.835 168.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.3 t-160 -53.04 -50.58 64.01 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.324 1.85 . . . . 0.0 113.563 175.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -56.42 -43.25 79.23 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.436 1.494 . . . . 0.0 113.776 175.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.75 -47.04 77.67 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.302 1.841 . . . . 0.0 114.198 -175.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.31 -45.51 93.15 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.791 1.636 . . . . 0.0 113.176 174.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.1 t -66.29 -43.34 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 125.166 1.386 . . . . 0.0 111.717 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -59.37 -43.69 92.85 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.971 -1.08 . . . . 0.0 113.027 177.221 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -72.04 -36.54 69.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.3 1.04 . . . . 0.0 113.724 176.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.9 mt -63.81 -35.62 81.21 Favored 'General case' 0 CA--C 1.489 -1.393 0 O-C-N 120.056 -1.653 . . . . 0.0 114.832 171.181 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -71.57 -30.9 66.38 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.134 -1.604 . . . . 0.0 112.308 173.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -84.85 50.31 1.9 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.968 1.707 . . . . 0.0 112.628 174.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.3 p -106.3 164.28 12.14 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 125.512 1.525 . . . . 0.0 110.923 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -100.6 -168.99 28.81 Favored Glycine 0 N--CA 1.429 -1.786 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 164.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -68.56 -46.76 68.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-N 118.348 1.074 . . . . 0.0 113.71 -175.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.7 t -95.99 118.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 122.864 1.316 . . . . 0.0 109.843 172.01 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.6 t -109.74 118.88 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 127.09 2.156 . . . . 0.0 110.143 -169.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -101.7 94.61 5.94 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.505 -1.372 . . . . 0.0 112.249 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.43 HD11 HG13 ' A' ' 65' ' ' VAL . 19.9 tp -96.92 141.47 30.06 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 119.353 -2.092 . . . . 0.0 110.375 173.537 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 9.0 tt -104.98 130.45 53.18 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.97 -1.706 . . . . 0.0 108.823 162.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.9 pp -134.74 165.71 24.63 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.911 -1.118 . . . . 0.0 112.58 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -112.92 142.2 45.87 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.172 1.789 . . . . 0.0 109.44 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.429 -1.498 0 O-C-N 120.64 -1.288 . . . . 0.0 111.056 178.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.0 t0 . . . . . 0 N--CA 1.429 -1.51 0 N-CA-C 109.173 -0.676 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.19 146.99 33.25 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.842 1.257 . . . . 0.0 108.758 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.19 140.67 26.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.998 0.904 . . . . 0.0 108.875 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -88.92 136.87 32.78 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-O 122.615 1.198 . . . . 0.0 107.901 161.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.3 t -117.98 114.06 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -104.31 88.76 3.05 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 169.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.9 tp -105.18 139.42 39.86 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 121.408 -0.808 . . . . 0.0 109.4 -173.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.64 123.63 45.96 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.495 -1.378 . . . . 0.0 107.85 167.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -68.22 128.91 38.27 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.885 2.474 . . . . 0.0 112.427 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.3 p -101.24 125.93 47.92 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.702 -1.248 . . . . 0.0 110.952 -178.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.4 t70 56.96 32.66 21.98 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.105 1.762 . . . . 0.0 114.837 177.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.57 -5.83 67.45 Favored Glycine 0 N--CA 1.431 -1.675 0 O-C-N 119.744 -1.848 . . . . 0.0 116.269 -179.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 74.3 m -112.04 135.23 52.94 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 118.77 1.285 . . . . 0.0 111.549 -171.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.6 mt -86.47 -62.86 1.42 Allowed 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.634 -1.292 . . . . 0.0 109.481 167.134 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.15 51.71 0.43 Allowed Glycine 0 N--CA 1.43 -1.764 0 O-C-N 119.291 -2.131 . . . . 0.0 111.52 170.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tt -142.69 142.7 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.505 0 CA-C-O 122.601 1.191 . . . . 0.0 111.008 -176.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.9 t -117.7 132.53 56.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 124.983 1.313 . . . . 0.0 107.667 167.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.4 m -113.15 164.5 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.681 1.192 . . . . 0.0 111.965 -176.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -144.09 172.53 12.76 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.119 1.368 . . . . 0.0 109.435 174.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.72 -143.12 16.54 Favored Glycine 0 N--CA 1.429 -1.828 0 C-N-CA 124.541 1.067 . . . . 0.0 115.243 171.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.7 -149.67 18.07 Favored Glycine 0 N--CA 1.429 -1.813 0 C-N-CA 124.823 1.201 . . . . 0.0 112.502 178.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.6 p . . . . . 0 N--CA 1.43 -1.426 0 O-C-N 120.578 -1.542 . . . . 0.0 112.57 178.424 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.724 0 CA-C-O 121.386 0.437 . . . . 0.0 112.048 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 15.0 mm -86.6 126.03 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 172.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -122.42 154.02 38.31 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.996 -1.065 . . . . 0.0 109.461 -174.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.6 t -76.16 118.86 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.967 -1.083 . . . . 0.0 111.524 175.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -88.53 -43.01 11.72 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.919 1.288 . . . . 0.0 110.123 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.66 150.82 23.36 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 121.105 -0.997 . . . . 0.0 109.123 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.551 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.2 117.66 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 170.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.04 117.67 65.67 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 115.296 -2.287 . . . . 0.0 113.369 -161.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -53.74 129.59 34.76 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 124.025 3.15 . . . . 0.0 116.387 -169.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 34.9 mttt 77.56 14.71 1.72 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.374 1.87 . . . . 0.0 114.474 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.85 165.81 46.16 Favored Glycine 0 N--CA 1.429 -1.794 0 O-C-N 119.658 -1.901 . . . . 0.0 113.421 173.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.31 -58.9 4.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 167.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.01 -50.18 71.74 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 128.935 2.894 . . . . 0.0 112.175 -178.6 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.551 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -41.78 -71.04 0.09 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.782 2.033 . . . . 0.0 114.997 166.515 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.9 t -70.02 -14.96 62.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -170.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -64.9 -59.25 4.4 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.743 -1.848 . . . . 0.0 111.946 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 97.78 29.46 7.71 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.046 -1.659 . . . . 0.0 116.682 165.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -92.92 -41.57 9.96 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.392 -1.064 . . . . 0.0 108.864 160.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.0 mt -97.88 118.76 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.399 1.88 . . . . 0.0 110.811 -170.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -128.59 174.77 9.1 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-O 123.085 1.421 . . . . 0.0 111.438 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -62.41 130.44 45.22 Favored 'General case' 0 N--CA 1.431 -1.387 0 O-C-N 119.579 -1.951 . . . . 0.0 112.583 176.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.8 -5.35 61.84 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.712 -0.618 . . . . 0.0 113.697 -177.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -77.54 156.37 30.99 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 118.661 1.23 . . . . 0.0 111.641 -176.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -106.93 123.0 47.55 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.579 1.181 . . . . 0.0 110.185 -172.479 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.5 t -85.64 133.68 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 O-C-N 120.217 -1.552 . . . . 0.0 111.089 -175.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.47 -51.62 2.88 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.025 -1.047 . . . . 0.0 111.073 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.76 148.26 28.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.958 -1.089 . . . . 0.0 113.137 -176.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.97 111.04 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.096 0.958 . . . . 0.0 110.303 173.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.6 t30 61.01 39.9 15.87 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.78 2.032 . . . . 0.0 113.323 172.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.07 -27.34 19.66 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 125.309 1.433 . . . . 0.0 113.459 -178.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.2 t -84.64 119.8 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 124.95 1.3 . . . . 0.0 110.817 -172.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.2 p -72.23 136.5 46.37 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.462 -1.399 . . . . 0.0 112.296 177.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 35.9 mt -87.95 -6.16 58.17 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.475 -1.391 . . . . 0.0 113.896 -175.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -68.71 95.26 0.65 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 119.581 -1.949 . . . . 0.0 115.878 -174.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.96 -15.13 5.14 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.819 1.2 . . . . 0.0 111.151 -177.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.4 158.88 35.52 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.8 p -87.52 179.12 6.61 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.712 -1.242 . . . . 0.0 111.115 172.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -67.21 -46.75 72.91 Favored 'General case' 0 N--CA 1.431 -1.393 0 O-C-N 120.703 -1.248 . . . . 0.0 110.755 173.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.7 tppt? -57.4 -40.93 79.28 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.201 1.401 . . . . 0.0 113.972 174.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.8 mm100 -56.93 -51.39 69.32 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.555 1.142 . . . . 0.0 114.076 176.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.99 -40.52 96.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.255 1.422 . . . . 0.0 113.519 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -66.17 -45.98 88.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.846 -1.159 . . . . 0.0 111.329 176.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -58.81 -40.07 83.04 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.629 -1.294 . . . . 0.0 112.95 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 84.2 m -68.2 -42.63 79.59 Favored 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 125.963 1.705 . . . . 0.0 113.569 178.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 72.9 mt -68.99 -33.55 73.86 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.987 -1.696 . . . . 0.0 114.391 176.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -72.35 -33.04 66.99 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 119.644 -1.91 . . . . 0.0 112.675 171.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -78.58 44.73 0.54 Allowed 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.854 2.061 . . . . 0.0 114.25 170.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -105.79 154.88 19.89 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.224 -2.172 . . . . 0.0 108.842 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.23 -146.56 17.64 Favored Glycine 0 N--CA 1.429 -1.776 0 O-C-N 120.916 -1.115 . . . . 0.0 112.921 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -70.85 -61.06 1.9 Allowed 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.402 1.081 . . . . 0.0 112.312 169.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.72 127.5 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 123.567 1.651 . . . . 0.0 110.244 177.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 73.3 t -120.61 114.17 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.398 1.879 . . . . 0.0 108.772 -162.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 m170 -101.86 94.1 5.64 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.044 0.938 . . . . 0.0 112.144 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -102.37 160.07 14.86 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.638 -1.914 . . . . 0.0 114.297 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.2 tp -128.35 132.8 48.59 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 124.869 1.268 . . . . 0.0 108.505 163.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.08 164.5 31.93 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.929 -1.107 . . . . 0.0 113.371 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -116.97 134.84 54.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 127.021 2.129 . . . . 0.0 107.773 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? . . . . . 0 N--CA 1.43 -1.463 0 O-C-N 120.355 -1.466 . . . . 0.0 112.671 -175.237 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.5 t70 . . . . . 0 N--CA 1.43 -1.462 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.8 p -105.62 150.63 25.24 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-N 120.166 1.348 . . . . 0.0 110.206 166.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.611 ' CE1' HD21 ' A' ' 96' ' ' LEU . 27.1 p90 -147.69 164.43 33.58 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.635 1.207 . . . . 0.0 108.918 161.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -126.19 143.0 51.3 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.205 1.802 . . . . 0.0 106.858 -168.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.69 111.91 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 O-C-N 120.848 -1.157 . . . . 0.0 109.118 -173.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -103.1 94.16 5.39 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 125.762 1.625 . . . . 0.0 107.998 169.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.1 tp -123.86 134.36 53.59 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-O 122.208 1.004 . . . . 0.0 113.521 -167.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.62 137.37 39.11 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 125.67 1.588 . . . . 0.0 110.352 177.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -69.11 162.12 27.63 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 115.19 1.552 . . . . 0.0 115.19 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 39.5 p -130.97 114.91 15.8 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 26.9 t70 50.65 59.49 4.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.461 1.904 . . . . 0.0 113.844 -177.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.65 -36.05 2.83 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.13 -1.606 . . . . 0.0 115.663 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 61.5 m -106.38 149.31 27.12 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.346 1.458 . . . . 0.0 112.059 -162.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -96.22 -57.12 2.42 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 172.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.61 23.46 1.88 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 120.153 -1.592 . . . . 0.0 113.075 172.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 pt -115.21 125.53 72.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.085 1.354 . . . . 0.0 110.178 -176.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 t -112.39 128.49 56.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.302 -0.874 . . . . 0.0 108.796 170.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 163.55 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 111.896 -174.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.6 t -133.51 164.78 26.38 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.677 1.191 . . . . 0.0 108.015 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.39 -154.92 20.17 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.899 -1.125 . . . . 0.0 112.913 171.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.94 145.83 18.6 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.192 1.377 . . . . 0.0 110.445 -169.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.43 -1.447 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -172.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 107.959 -2.057 . . . . 0.0 107.959 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.8 mm -103.3 120.15 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -128.0 153.76 46.38 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.924 -1.11 . . . . 0.0 110.496 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 20.5 t -76.0 121.96 29.04 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.577 -1.327 . . . . 0.0 112.687 178.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmt? -97.84 -45.94 6.13 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.741 1.216 . . . . 0.0 112.503 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.51 154.79 27.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.104 -0.998 . . . . 0.0 110.466 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.417 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -111.3 126.14 68.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 CA-C-O 122.235 1.017 . . . . 0.0 109.742 175.461 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 14.1 mm -77.09 118.78 74.24 Favored Pre-proline 0 N--CA 1.43 -1.467 0 CA-C-O 116.043 -1.932 . . . . 0.0 113.761 -174.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -60.19 123.79 13.88 Favored 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 125.003 2.822 . . . . 0.0 115.763 -176.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.378 39.8 mtmt 75.59 31.76 0.73 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 127.372 2.269 . . . . 0.0 114.426 -175.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.09 162.39 36.89 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.819 -1.176 . . . . 0.0 112.96 159.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.07 -56.23 11.67 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 126.715 2.006 . . . . 0.0 114.489 165.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.22 -48.79 74.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 128.33 2.652 . . . . 0.0 111.813 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.417 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.4 tm-20 -41.84 -59.21 1.76 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 116.22 1.933 . . . . 0.0 116.22 176.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -69.86 -28.32 65.57 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.535 1.534 . . . . 0.0 114.359 -172.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.32 -56.57 20.15 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.981 1.712 . . . . 0.0 113.687 -173.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.54 -4.88 26.34 Favored Glycine 0 N--CA 1.429 -1.801 0 O-C-N 120.587 -1.32 . . . . 0.0 115.42 164.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 14' ' ' PHE . 95.1 mtt180 -74.84 -61.86 1.74 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.628 -1.513 . . . . 0.0 110.605 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 94' ' ' LEU . 97.0 mt -67.69 125.69 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.886 1.674 . . . . 0.0 113.527 -177.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -141.7 159.49 42.11 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.49 1.614 . . . . 0.0 114.089 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 ttpt -52.55 127.21 22.0 Favored 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.521 2.328 . . . . 0.0 114.918 177.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 98.06 -7.31 62.43 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.031 0.824 . . . . 0.0 114.571 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.72 160.6 24.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 119.363 1.581 . . . . 0.0 112.508 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.7 ttt-85 -105.23 132.92 50.82 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.943 1.697 . . . . 0.0 111.192 -174.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.77 136.21 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 119.85 -1.781 . . . . 0.0 111.231 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -100.83 -60.66 1.48 Allowed 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.37 -1.457 . . . . 0.0 110.945 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.81 125.94 10.66 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.907 -1.12 . . . . 0.0 112.366 -171.078 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.9 t -99.04 114.33 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 123.837 0.855 . . . . 0.0 109.367 177.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.7 t30 59.52 35.28 22.7 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.042 1.737 . . . . 0.0 115.1 168.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.51 -10.74 66.98 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 124.971 1.272 . . . . 0.0 114.186 -177.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.31 107.88 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.782 -1.422 . . . . 0.0 109.659 -176.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.5 t -73.04 126.33 29.72 Favored 'General case' 0 N--CA 1.431 -1.391 0 O-C-N 120.777 -1.202 . . . . 0.0 111.177 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.4 mt -84.95 37.74 0.68 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -169.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -74.77 120.54 20.46 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.929 1.691 . . . . 0.0 110.656 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.11 11.95 79.3 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 120.49 -1.381 . . . . 0.0 114.412 -175.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.89 140.64 51.12 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 114.652 1.353 . . . . 0.0 114.652 -175.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.8 p -90.86 -179.28 5.45 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.689 1.195 . . . . 0.0 111.19 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -69.23 -45.43 69.81 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.752 -1.217 . . . . 0.0 110.317 179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -56.89 -41.63 78.4 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 170.274 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -53.1 62.05 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.671 -1.268 . . . . 0.0 113.915 178.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.95 -44.02 73.86 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.82 1.248 . . . . 0.0 113.575 178.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.4 -49.07 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.64 -1.288 . . . . 0.0 111.806 -177.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -65.73 -32.42 73.96 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.744 -1.222 . . . . 0.0 112.087 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 36.0 m -66.98 -45.06 78.79 Favored 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 125.774 1.63 . . . . 0.0 113.101 173.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 54.3 mt -68.64 -29.31 67.77 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.123 -1.611 . . . . 0.0 114.293 174.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.6 mtp180 -73.68 -47.46 39.5 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.227 -1.546 . . . . 0.0 113.159 171.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -89.18 55.67 3.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.148 -1.595 . . . . 0.0 113.543 -176.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.4 p -84.5 177.91 7.92 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.126 1.771 . . . . 0.0 111.531 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.8 -157.66 27.67 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 120.123 -1.61 . . . . 0.0 110.375 164.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.5 tm0? -71.33 -50.52 31.53 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.819 -1.989 . . . . 0.0 110.861 169.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.51 135.99 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.309 1.444 . . . . 0.0 109.844 174.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.7 t -107.72 126.16 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 C-N-CA 129.047 2.939 . . . . 0.0 108.448 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.9 t-160 -105.21 110.07 22.3 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.434 HD11 HD11 ' A' ' 59' ' ' ILE 0.389 4.0 pp -125.1 151.24 45.97 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 117.032 2.234 . . . . 0.0 117.032 166.867 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.8 tp -114.97 134.23 55.36 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.839 2.056 . . . . 0.0 107.527 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.611 HD21 ' CE1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -152.75 174.37 14.12 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.035 -1.041 . . . . 0.0 113.639 -179.21 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -119.39 132.47 55.84 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 125.712 1.605 . . . . 0.0 111.146 -175.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.435 0 O-C-N 120.112 -1.617 . . . . 0.0 113.644 -179.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.6 t0 . . . . . 0 N--CA 1.43 -1.462 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.7 p -95.97 153.67 17.64 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.869 -1.769 . . . . 0.0 111.863 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.68 ' CZ ' HD22 ' A' ' 96' ' ' LEU . 37.4 p90 -146.6 137.51 24.11 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 173.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -94.72 128.06 41.15 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.593 -1.317 . . . . 0.0 109.942 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.41 88.85 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -178.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.4 ' HG2' ' CD2' ' A' ' 93' ' ' HIS . 61.0 mt-10 -93.85 83.33 4.37 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 169.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.419 HD13 ' HB1' ' A' ' 52' ' ' ALA 0.288 1.8 pp -109.2 162.75 13.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.771 1.272 . . . . 0.0 111.233 -178.035 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 133.73 46.88 Favored 'General case' 0 N--CA 1.428 -1.527 0 C-N-CA 124.728 1.211 . . . . 0.0 107.924 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -70.6 121.87 18.69 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.458 -1.401 . . . . 0.0 112.32 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 29.2 p -94.7 119.61 33.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.669 -1.269 . . . . 0.0 110.039 -174.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 t70 61.13 7.7 1.7 Allowed 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.056 2.142 . . . . 0.0 116.416 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 107.41 2.27 35.34 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.984 -1.698 . . . . 0.0 114.846 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 63.2 m -121.93 132.02 54.33 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.911 1.855 . . . . 0.0 113.306 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 85.5 mt -73.7 -44.24 57.03 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.712 -1.242 . . . . 0.0 111.425 164.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.5 29.74 3.31 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 119.767 -1.833 . . . . 0.0 111.719 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 pt -107.31 135.22 46.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.625 1.202 . . . . 0.0 114.215 -162.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 17.7 m -131.3 109.68 10.54 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.758 -1.839 . . . . 0.0 108.969 155.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.03 163.82 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-O 122.153 0.978 . . . . 0.0 112.145 -177.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.6 t -145.81 172.6 13.07 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.13 1.372 . . . . 0.0 108.28 175.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 -175.61 33.68 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.734 -1.229 . . . . 0.0 114.125 176.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 149.6 177.61 23.83 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -171.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.434 1.272 . . . . 0.0 114.434 -173.828 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.691 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.7 mm -102.39 123.34 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.894 1.678 . . . . 0.0 107.464 175.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -124.4 155.16 39.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.935 -1.103 . . . . 0.0 111.307 -170.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.1 t -76.05 119.31 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.883 -1.136 . . . . 0.0 110.789 169.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.9 pttt -95.51 -36.59 11.24 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.471 -1.393 . . . . 0.0 112.445 173.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -155.88 160.95 40.6 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.921 -1.112 . . . . 0.0 110.539 177.1 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.436 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -120.15 125.88 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 124.404 1.082 . . . . 0.0 109.216 177.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.8 mm -77.42 124.93 86.85 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.623 1.969 . . . . 0.0 114.265 -176.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_exo -56.57 133.87 60.73 Favored 'Trans proline' 0 N--CA 1.435 -1.968 0 CA-C-N 124.034 2.476 . . . . 0.0 116.237 176.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt 83.53 0.77 1.06 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 129.012 2.925 . . . . 0.0 114.71 -177.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.05 156.08 46.88 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.121 -1.612 . . . . 0.0 113.104 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HB1' HD13 ' A' ' 18' ' ' LEU . . . -49.35 -53.14 23.78 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 172.495 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.2 -45.76 86.91 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 128.951 2.901 . . . . 0.0 112.622 177.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.436 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.6 tm-20 -50.21 -57.99 6.57 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 123.101 1.429 . . . . 0.0 114.656 171.144 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.4 t -68.02 -25.39 65.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.193 1.397 . . . . 0.0 113.717 -171.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -61.56 -71.94 0.13 Allowed 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.695 1.598 . . . . 0.0 112.501 173.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.76 -6.52 37.98 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 121.108 -0.995 . . . . 0.0 115.284 177.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.1 mtm180 -65.22 -35.47 81.15 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.867 -1.961 . . . . 0.0 111.893 165.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 73.3 mt -85.36 134.21 27.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 124.884 1.273 . . . . 0.0 109.683 176.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -139.17 161.31 37.73 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.807 -1.183 . . . . 0.0 108.922 177.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -54.71 125.05 18.37 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.985 1.714 . . . . 0.0 113.934 172.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.84 -2.25 66.41 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 124.286 0.946 . . . . 0.0 114.802 -178.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -82.12 160.18 23.19 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-N 119.614 1.707 . . . . 0.0 110.535 178.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -112.37 132.48 54.98 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.619 -1.3 . . . . 0.0 112.151 -168.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.7 t -87.14 127.68 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.319 -1.488 . . . . 0.0 110.657 178.588 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 88.1 mt -98.15 -48.1 5.23 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 121.132 -0.98 . . . . 0.0 111.253 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.44 134.6 18.16 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.995 -1.065 . . . . 0.0 109.787 -176.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.7 t -114.23 125.85 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 67.25 30.06 7.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.259 1.424 . . . . 0.0 111.721 175.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 85.19 -18.84 25.84 Favored Glycine 0 N--CA 1.431 -1.682 0 C-N-CA 125.058 1.313 . . . . 0.0 114.802 -173.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.85 123.27 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 O-C-N 120.776 -1.426 . . . . 0.0 110.521 -171.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.5 m -63.88 135.27 56.42 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.776 -1.202 . . . . 0.0 113.956 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 78.1 mt -86.17 56.52 4.02 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.754 -1.216 . . . . 0.0 111.65 177.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -78.85 123.11 26.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.571 -1.331 . . . . 0.0 112.508 -175.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 58.59 20.87 48.03 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 125.349 1.452 . . . . 0.0 115.139 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.64 144.66 51.04 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -164.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -76.58 178.45 6.67 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.611 1.164 . . . . 0.0 110.511 169.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -68.25 -48.84 63.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.427 -1.421 . . . . 0.0 111.738 172.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 41.2 mmtm -58.48 -31.67 68.05 Favored 'General case' 0 N--CA 1.429 -1.512 0 N-CA-C 116.012 1.856 . . . . 0.0 116.012 174.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 mm100 -56.35 -55.74 29.76 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 120.324 1.42 . . . . 0.0 114.181 175.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.53 87.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.198 0.999 . . . . 0.0 113.195 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -68.35 -48.39 73.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.028 1.331 . . . . 0.0 111.208 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -62.94 -36.82 84.68 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.482 -1.386 . . . . 0.0 112.791 177.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.1 m -67.26 -45.88 75.38 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.646 1.578 . . . . 0.0 113.188 175.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 20.8 mt -66.28 -34.74 78.68 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.399 -1.438 . . . . 0.0 114.031 175.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.51 -31.64 65.51 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.32 -1.488 . . . . 0.0 113.684 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -88.68 48.93 1.7 Allowed 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 122.185 0.993 . . . . 0.0 112.066 173.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 p -107.17 154.33 21.35 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.102 -1.624 . . . . 0.0 109.14 170.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -108.83 -132.5 6.61 Favored Glycine 0 N--CA 1.43 -1.718 0 CA-C-O 121.964 0.758 . . . . 0.0 113.823 -172.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.0 tm0? -70.82 -68.84 0.4 Allowed 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 121.308 -1.113 . . . . 0.0 113.54 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 9.2 p -98.33 131.98 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.873 1.32 . . . . 0.0 109.882 174.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.6 t -125.23 111.96 29.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 126.139 1.776 . . . . 0.0 110.209 -162.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . 0.4 ' CD2' ' HG2' ' A' ' 17' ' ' GLU . 30.4 m170 -93.14 101.15 13.44 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -178.243 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -92.73 146.19 23.84 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 120.113 -1.617 . . . . 0.0 112.602 168.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 60.5 tp -113.87 127.54 56.03 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 155.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.68 HD22 ' CZ ' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -136.22 151.69 49.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 121.098 -1.001 . . . . 0.0 111.356 -171.172 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -117.34 131.63 56.75 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 123.404 1.573 . . . . 0.0 111.622 176.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? . . . . . 0 N--CA 1.43 -1.445 0 C-N-CA 127.133 2.173 . . . . 0.0 110.798 177.318 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.3 t0 . . . . . 0 N--CA 1.43 -1.443 0 CA-C-O 121.585 0.707 . . . . 0.0 110.851 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 p -100.1 158.43 15.85 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.884 1.674 . . . . 0.0 112.541 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -144.67 146.71 32.37 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 171.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -89.57 113.19 24.58 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 165.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 t -98.77 99.66 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -90.38 94.36 9.7 Favored 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 174.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -105.14 126.48 52.12 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-O 122.464 1.126 . . . . 0.0 110.045 -174.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.82 139.25 38.64 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.133 -1.604 . . . . 0.0 110.225 176.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -66.18 130.86 44.66 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.002 -1.061 . . . . 0.0 113.075 175.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.9 p -91.09 84.72 5.75 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.228 -1.545 . . . . 0.0 110.378 177.161 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.1 t70 59.27 53.43 5.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.457 1.903 . . . . 0.0 113.487 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.96 -11.31 72.47 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.746 -1.221 . . . . 0.0 115.295 -176.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.5 t -94.53 112.92 24.69 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.419 -1.636 . . . . 0.0 113.519 -173.099 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 7.5 tp -125.84 63.03 1.22 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.662 1.585 . . . . 0.0 109.985 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -85.64 62.21 4.46 Favored Glycine 0 N--CA 1.43 -1.717 0 O-C-N 119.43 -2.043 . . . . 0.0 113.462 -164.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.93 127.34 55.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 124.74 1.216 . . . . 0.0 107.975 168.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.43 121.79 45.85 Favored 'General case' 0 CA--C 1.489 -1.371 0 C-N-CA 123.626 0.77 . . . . 0.0 109.442 177.438 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.0 m -104.46 170.42 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.724 1.209 . . . . 0.0 112.736 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -150.24 173.79 13.55 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.198 1.399 . . . . 0.0 108.51 173.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.83 -138.03 14.67 Favored Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 167.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.87 162.31 27.79 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.52 1.533 . . . . 0.0 113.023 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 N--CA 1.43 -1.445 0 C-N-CA 125.603 1.561 . . . . 0.0 114.988 177.453 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.742 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.9 mm -97.85 131.98 43.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.69 1.196 . . . . 0.0 108.577 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.84 159.4 33.99 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.777 -1.202 . . . . 0.0 110.305 -175.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.68 119.53 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.694 -1.253 . . . . 0.0 111.023 174.28 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 57.2 tttm -91.43 -50.85 5.57 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 124.11 0.964 . . . . 0.0 111.85 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.09 155.83 31.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.038 -1.039 . . . . 0.0 110.904 -177.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.41 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -114.09 120.63 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-O 122.611 1.196 . . . . 0.0 109.643 172.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 34.6 mm -76.06 128.22 83.52 Favored Pre-proline 0 N--CA 1.43 -1.447 0 CA-C-O 116.09 -1.909 . . . . 0.0 113.252 -170.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -55.0 133.85 60.42 Favored 'Trans proline' 0 N--CA 1.434 -2.002 0 C-N-CA 124.416 3.411 . . . . 0.0 115.65 178.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? 67.76 13.76 9.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.526 1.53 . . . . 0.0 114.478 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.31 173.13 47.9 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 119.592 -1.942 . . . . 0.0 112.517 172.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.87 9.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 169.32 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.81 -40.1 95.83 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 126.595 1.958 . . . . 0.0 115.273 -173.022 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.41 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.0 OUTLIER -41.35 -60.08 1.37 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 129.423 3.089 . . . . 0.0 113.607 178.02 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.5 t -70.2 -33.84 72.21 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 111.693 -2.503 . . . . 0.0 115.847 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -62.43 -48.57 79.1 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.272 1.429 . . . . 0.0 113.129 -165.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.64 -19.92 45.9 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.506 -1.371 . . . . 0.0 115.421 162.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.2 mmt-85 -75.74 -4.34 39.89 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 118.429 1.115 . . . . 0.0 112.764 172.308 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.5 mt -117.91 126.97 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.525 0 C-N-CA 125.259 1.423 . . . . 0.0 107.981 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -132.25 163.83 27.73 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.617 -1.302 . . . . 0.0 109.797 170.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -67.91 123.29 20.17 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.215 -1.553 . . . . 0.0 112.773 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 100.01 0.83 56.09 Favored Glycine 0 N--CA 1.431 -1.7 0 O-C-N 121.678 -0.639 . . . . 0.0 114.099 -174.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -80.17 164.86 22.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-N 119.555 1.678 . . . . 0.0 110.455 173.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.18 136.68 51.29 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.602 1.192 . . . . 0.0 111.722 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -91.15 125.12 43.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 126.113 1.765 . . . . 0.0 109.76 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 49.1 mt -103.89 -56.89 2.12 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.42 -1.425 . . . . 0.0 110.589 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.74 118.62 6.66 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 121.165 -0.959 . . . . 0.0 111.163 -176.157 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.45 HG22 HD13 ' A' ' 94' ' ' LEU . 57.7 t -98.47 115.79 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -176.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.9 t30 60.84 42.41 13.23 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 124.796 1.238 . . . . 0.0 114.321 165.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.17 -18.35 57.01 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.53 1.062 . . . . 0.0 114.05 -177.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.66 117.93 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.851 -1.381 . . . . 0.0 109.331 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 54.9 m -72.79 105.89 4.53 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 121.138 -0.976 . . . . 0.0 110.959 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 33.8 mt -89.8 25.67 2.0 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.695 -1.253 . . . . 0.0 112.092 -175.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -77.83 122.55 25.59 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.088 -1.632 . . . . 0.0 109.563 173.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 76.11 15.08 81.66 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 120.657 -1.277 . . . . 0.0 115.672 -170.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.28 163.11 28.28 Favored 'General case' 0 N--CA 1.429 -1.492 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 178.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.6 p -93.5 171.13 9.1 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.128 1.371 . . . . 0.0 111.196 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 64.8 t-80 -62.47 -51.06 68.95 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.476 -1.39 . . . . 0.0 114.185 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 mtmt -57.12 -42.58 81.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 174.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -56.58 -45.91 81.09 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.355 1.862 . . . . 0.0 114.241 -173.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.69 -39.63 94.59 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.902 1.681 . . . . 0.0 114.732 172.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.2 t -68.7 -49.26 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.011 1.324 . . . . 0.0 110.415 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 82.3 mt-10 -66.41 -33.33 75.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.341 -1.474 . . . . 0.0 113.552 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.8 m -61.2 -41.6 97.11 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.744 1.618 . . . . 0.0 113.072 169.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 76.0 mt -71.7 -30.69 65.94 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.361 -1.462 . . . . 0.0 114.276 173.126 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -67.28 -46.51 73.41 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.073 -1.642 . . . . 0.0 112.587 173.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -93.74 64.75 3.53 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.644 -1.285 . . . . 0.0 110.653 177.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 p -101.46 164.42 11.77 Favored 'General case' 0 N--CA 1.429 -1.512 0 C-N-CA 128.043 2.537 . . . . 0.0 109.329 173.16 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -92.8 -139.75 9.38 Favored Glycine 0 N--CA 1.431 -1.678 0 O-C-N 121.043 -1.035 . . . . 0.0 110.689 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -71.14 -68.47 0.44 Allowed 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.189 -1.183 . . . . 0.0 114.039 170.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.4 t -105.51 128.77 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 CA-C-O 122.509 1.147 . . . . 0.0 108.619 -176.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.04 117.99 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 128.409 2.683 . . . . 0.0 108.996 -170.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -98.2 102.13 13.79 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.486 -1.383 . . . . 0.0 111.192 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.45 HD13 HG22 ' A' ' 68' ' ' VAL . 31.7 tp -99.93 132.88 45.01 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.207 -1.558 . . . . 0.0 111.388 175.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -87.44 121.55 30.02 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.163 -1.792 . . . . 0.0 106.163 163.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.0 tt -123.45 143.63 50.02 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 123.689 0.796 . . . . 0.0 109.804 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -111.22 136.33 50.45 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 109.22 174.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? . . . . . 0 N--CA 1.43 -1.433 0 O-C-N 121.196 -0.94 . . . . 0.0 111.851 175.366 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 35.5 t70 . . . . . 0 N--CA 1.43 -1.463 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.31 135.16 43.26 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.338 -0.851 . . . . 0.0 109.653 158.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.251 0.0 OUTLIER -146.77 146.51 30.3 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 122.458 1.123 . . . . 0.0 109.454 159.235 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.34 145.89 24.27 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.405 -1.434 . . . . 0.0 109.035 174.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 47.9 t -106.01 93.44 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 74.9 mt-10 -92.2 89.77 7.03 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.978 1.711 . . . . 0.0 108.426 175.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 65.6 tp -124.91 148.39 48.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 121.304 -0.873 . . . . 0.0 110.629 -171.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.66 48.48 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.219 1.408 . . . . 0.0 109.015 171.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -71.17 154.86 41.37 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 115.871 1.804 . . . . 0.0 115.871 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 77.5 p -121.08 131.55 54.34 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.849 -1.157 . . . . 0.0 109.482 171.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.1 t70 57.78 38.83 27.43 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 176.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.65 -16.14 16.06 Favored Glycine 0 N--CA 1.431 -1.656 0 O-C-N 119.477 -2.015 . . . . 0.0 114.985 -176.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.8 p -115.14 157.93 22.92 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.779 2.032 . . . . 0.0 112.551 -164.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.404 HD13 ' HA ' ' A' ' 25' ' ' LEU . 3.7 mm? -102.06 -60.64 1.5 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.677 -1.264 . . . . 0.0 108.957 173.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.86 56.64 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.555 -1.966 . . . . 0.0 110.838 169.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tt -147.24 145.29 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 CA-C-O 122.43 1.11 . . . . 0.0 110.784 -171.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.6 t -108.94 132.36 54.15 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 166.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.1 m -112.92 155.92 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 O-C-N 121.14 -0.975 . . . . 0.0 111.344 -175.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 t -129.0 168.02 16.63 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 124.084 0.954 . . . . 0.0 109.33 174.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.09 -151.68 18.31 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.418 -0.801 . . . . 0.0 113.928 167.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.48 139.63 10.65 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 123.975 0.798 . . . . 0.0 112.481 -176.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.43 -1.465 0 O-C-N 120.829 -1.395 . . . . 0.0 113.933 -178.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.772 0 N-CA-C 107.133 -2.387 . . . . 0.0 107.133 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.4 mm -103.78 114.79 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.286 1.434 . . . . 0.0 107.573 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.1 m-85 -123.58 157.05 34.57 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.206 1.003 . . . . 0.0 110.52 -171.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -75.03 122.5 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 C-N-CA 124.542 1.137 . . . . 0.0 110.713 175.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -93.18 -51.83 4.84 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.846 -1.159 . . . . 0.0 111.574 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.86 158.9 41.48 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.413 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -113.56 125.27 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 CA-C-O 122.565 1.174 . . . . 0.0 109.057 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -76.58 124.19 87.8 Favored Pre-proline 0 N--CA 1.429 -1.487 0 CA-C-O 116.344 -1.788 . . . . 0.0 113.679 -167.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_exo -58.9 124.64 16.16 Favored 'Trans proline' 0 N--CA 1.433 -2.036 0 CA-C-N 124.566 2.667 . . . . 0.0 115.396 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 47.9 mtpt 74.88 30.74 0.93 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 127.101 2.16 . . . . 0.0 114.069 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.33 160.72 33.49 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.204 -0.935 . . . . 0.0 114.097 161.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.07 -54.03 14.48 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.982 2.113 . . . . 0.0 114.444 160.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.93 -46.48 87.56 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 127.586 2.354 . . . . 0.0 113.416 179.095 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.2 tm-20 -41.6 -64.57 0.55 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 116.415 2.005 . . . . 0.0 116.415 173.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 57.8 m -68.51 -18.46 64.38 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.557 1.943 . . . . 0.0 115.843 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.16 -56.84 16.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 CA-C-N 119.657 1.117 . . . . 0.0 112.52 -174.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 107.04 -25.81 21.06 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 115.151 0.82 . . . . 0.0 115.151 176.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -72.36 -29.17 63.54 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.951 1.875 . . . . 0.0 112.221 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.0 mt -90.34 120.71 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 120.591 -1.318 . . . . 0.0 111.024 174.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -124.32 168.67 12.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.937 1.351 . . . . 0.0 111.435 173.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -65.72 117.54 8.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.726 1.61 . . . . 0.0 113.43 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.13 11.21 57.75 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.744 -1.222 . . . . 0.0 114.563 -176.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -81.22 159.45 24.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.22 1.51 . . . . 0.0 111.909 173.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -112.97 124.49 52.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.109 1.363 . . . . 0.0 111.163 -166.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 39.0 t -92.08 121.31 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.381 0 O-C-N 120.288 -1.508 . . . . 0.0 110.716 179.54 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 78.3 mt -89.11 -45.52 9.54 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.102 -0.999 . . . . 0.0 110.749 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.63 143.47 24.62 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 121.378 -0.826 . . . . 0.0 110.709 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 44.9 t -111.14 114.45 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.053 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.7 t30 63.88 34.04 12.06 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 165.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.16 -17.35 59.45 Favored Glycine 0 N--CA 1.431 -1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 113.83 -175.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.6 t -99.03 121.34 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.41 . . . . 0.0 109.983 -175.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 20.3 t -75.32 138.69 41.97 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.255 -1.528 . . . . 0.0 112.03 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 76.8 mt -90.4 13.56 15.25 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.223 -0.923 . . . . 0.0 113.447 -176.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -61.15 111.99 1.93 Allowed 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 119.94 -1.725 . . . . 0.0 114.348 -177.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.95 0.29 83.53 Favored Glycine 0 N--CA 1.43 -1.704 0 C-N-CA 124.903 1.239 . . . . 0.0 115.463 -178.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.63 147.41 47.56 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 115.68 1.733 . . . . 0.0 115.68 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.9 p -92.79 178.68 5.7 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.797 1.239 . . . . 0.0 112.529 176.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -56.33 -56.61 18.93 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.977 1.711 . . . . 0.0 114.673 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 tppt? -57.39 -39.79 76.85 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.812 1.245 . . . . 0.0 113.317 -178.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.58 -50.4 72.03 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 126.634 1.974 . . . . 0.0 113.852 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.21 -41.45 99.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.862 1.665 . . . . 0.0 114.165 174.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.02 -49.03 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.215 1.406 . . . . 0.0 111.051 177.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -60.82 -39.17 88.0 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 124.691 1.196 . . . . 0.0 112.85 177.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.1 m -63.41 -49.79 72.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 126.998 2.119 . . . . 0.0 113.033 173.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 63.8 mt -66.66 -29.57 69.62 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.196 -1.565 . . . . 0.0 114.405 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -68.8 -49.25 60.12 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.598 -1.314 . . . . 0.0 112.274 169.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -85.02 64.65 8.82 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.414 -1.429 . . . . 0.0 111.641 177.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 p -106.18 160.08 15.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 128.792 2.837 . . . . 0.0 109.258 173.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.69 -163.61 39.08 Favored Glycine 0 N--CA 1.429 -1.77 0 O-C-N 121.046 -1.033 . . . . 0.0 111.584 176.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -66.69 -52.55 43.46 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.757 -1.437 . . . . 0.0 113.152 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.34 130.07 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 CA-C-O 122.695 1.236 . . . . 0.0 108.054 170.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.0 t -117.92 128.54 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 127.597 2.359 . . . . 0.0 108.029 -166.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.2 m80 -120.67 92.54 3.79 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -170.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.18 146.55 25.32 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 119.398 -2.064 . . . . 0.0 112.068 175.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 24.9 tp -104.6 116.56 32.28 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 162.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.4 tt -132.44 137.14 47.16 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.564 0.697 . . . . 0.0 111.927 -164.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.5 tt0 -108.87 126.65 53.29 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.866 -1.146 . . . . 0.0 109.267 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.5 tmtt? . . . . . 0 N--CA 1.43 -1.436 0 O-C-N 120.674 -1.266 . . . . 0.0 112.433 -174.027 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 N--CA 1.429 -1.479 0 N-CA-C 115.655 1.724 . . . . 0.0 115.655 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -119.35 148.2 43.47 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 121.121 1.782 . . . . 0.0 109.618 164.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 11.1 p90 -146.8 147.02 30.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 123.21 1.481 . . . . 0.0 109.23 171.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -104.1 120.5 41.22 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.317 2.247 . . . . 0.0 107.738 -178.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.3 t -114.04 103.69 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 119.975 -1.703 . . . . 0.0 109.83 -171.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -90.08 88.67 7.37 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.306 -1.496 . . . . 0.0 109.239 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 tp -100.92 130.39 46.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.761 -1.212 . . . . 0.0 112.702 -167.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.47 128.23 49.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.279 -1.513 . . . . 0.0 109.456 170.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -69.73 132.66 46.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.217 1.562 . . . . 0.0 115.217 -172.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 47.6 p -107.48 114.89 29.19 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.503 -1.373 . . . . 0.0 111.498 -176.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.4 t70 55.66 39.35 30.88 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.214 2.205 . . . . 0.0 113.12 172.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.73 4.5 90.29 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 119.514 -1.991 . . . . 0.0 115.583 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.6 t -121.48 134.59 55.07 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-N 118.549 1.175 . . . . 0.0 111.345 -176.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 86.2 mt -89.65 -42.52 11.32 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.826 -1.171 . . . . 0.0 109.99 173.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.28 9.27 22.2 Favored Glycine 0 N--CA 1.43 -1.731 0 O-C-N 120.833 -1.167 . . . . 0.0 114.503 175.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.8 pt -129.42 125.65 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 CA-C-N 118.466 1.133 . . . . 0.0 112.555 -166.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -110.15 139.83 44.88 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.974 -1.079 . . . . 0.0 109.233 166.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 m -111.05 170.71 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.81 1.244 . . . . 0.0 112.725 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -150.96 172.26 15.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.559 1.943 . . . . 0.0 108.2 174.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.1 -131.37 10.58 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 121.052 -1.03 . . . . 0.0 113.731 169.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 72.22 -175.36 42.75 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.936 1.255 . . . . 0.0 113.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.1 t . . . . . 0 N--CA 1.43 -1.447 0 C-N-CA 126.4 1.88 . . . . 0.0 113.325 177.937 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.745 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.79 114.74 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.507 1.123 . . . . 0.0 109.238 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -111.9 153.62 26.41 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.261 -0.899 . . . . 0.0 110.225 -173.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.5 t -76.57 116.85 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 124.924 1.289 . . . . 0.0 112.473 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.2 ttpp -92.26 -40.88 10.71 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.272 1.029 . . . . 0.0 112.36 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.68 153.75 31.81 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.165 -1.584 . . . . 0.0 112.687 -177.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.265 1.0 OUTLIER -109.33 115.89 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-O 123.123 1.44 . . . . 0.0 109.988 171.776 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.1 mm -77.36 125.23 86.59 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 127.111 2.164 . . . . 0.0 113.79 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -55.69 124.34 16.03 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 C-N-CA 123.625 2.883 . . . . 0.0 116.115 -177.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.3 4.5 mptp? 74.38 24.59 1.81 Allowed 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.692 1.997 . . . . 0.0 113.22 176.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.01 159.11 35.54 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.439 -1.413 . . . . 0.0 111.785 165.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.6 -55.44 11.17 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.62 1.711 . . . . 0.0 115.62 175.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.443 ' HB1' HD12 ' A' ' 59' ' ' ILE . . . -63.53 -46.44 86.01 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 128.065 2.546 . . . . 0.0 112.561 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -48.9 -60.63 2.6 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.317 1.447 . . . . 0.0 113.944 174.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.2 m -69.39 -20.05 63.82 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -69.43 -64.03 0.95 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.511 -1.368 . . . . 0.0 110.996 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.72 11.09 41.74 Favored Glycine 0 N--CA 1.429 -1.771 0 O-C-N 119.862 -1.774 . . . . 0.0 114.849 164.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 71.9 mtt85 -62.45 -51.68 66.56 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.88 1.272 . . . . 0.0 109.905 159.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.443 HD12 ' HB1' ' A' ' 53' ' ' ALA . 2.8 mt -79.17 128.13 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 126.104 1.762 . . . . 0.0 112.132 -176.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.93 169.65 16.0 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 123.561 1.648 . . . . 0.0 111.641 174.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 14.7 ttpp -66.23 132.06 47.57 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.675 -1.891 . . . . 0.0 112.115 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.03 5.37 68.01 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 120.971 -1.08 . . . . 0.0 114.156 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -79.59 166.36 21.97 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 118.889 1.344 . . . . 0.0 109.586 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -134.08 148.34 51.01 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.172 -1.58 . . . . 0.0 112.772 176.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.0 t -102.82 134.0 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 C-N-CA 124.769 1.228 . . . . 0.0 111.171 -166.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.9 mp -99.07 -50.65 4.09 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.5 1.12 . . . . 0.0 110.662 -177.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.84 136.54 18.07 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.314 -0.866 . . . . 0.0 112.677 -175.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.2 t -113.36 125.77 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 124.671 1.189 . . . . 0.0 108.424 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 65.86 30.91 9.73 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.645 1.178 . . . . 0.0 112.521 168.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 91.96 -22.74 29.95 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.897 -1.127 . . . . 0.0 113.899 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.53 121.75 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 125.633 1.573 . . . . 0.0 110.666 -167.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.9 p -71.23 131.62 43.77 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.746 -1.221 . . . . 0.0 112.433 178.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.9 mt -84.23 64.65 8.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.089 -1.632 . . . . 0.0 112.083 -175.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -89.34 116.3 27.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.466 -1.396 . . . . 0.0 112.723 -173.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.83 17.79 79.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.004 -1.06 . . . . 0.0 113.256 179.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.97 143.21 50.92 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -168.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 70.6 p -93.71 179.69 5.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.248 1.819 . . . . 0.0 110.597 173.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 49.3 t-80 -68.35 -42.7 78.86 Favored 'General case' 0 N--CA 1.428 -1.53 0 O-C-N 119.775 -1.828 . . . . 0.0 110.001 173.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.2 tppm? -53.64 -46.34 70.5 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 125.389 1.476 . . . . 0.0 113.781 172.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.412 ' C ' HE21 ' A' ' 80' ' ' GLN . 0.0 OUTLIER -55.65 -51.28 67.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.208 1.403 . . . . 0.0 113.674 176.686 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.926 1.691 . . . . 0.0 113.686 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.7 t -66.35 -49.09 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 O-C-N 120.835 -1.165 . . . . 0.0 110.676 178.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.2 mm-40 -64.04 -31.22 72.33 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.669 -1.269 . . . . 0.0 114.03 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.3 m -69.47 -44.3 71.47 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.486 1.514 . . . . 0.0 112.234 175.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 82.6 mt -69.51 -32.31 71.08 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 172.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.61 -46.34 79.69 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.245 -1.534 . . . . 0.0 112.426 176.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.7 t30 -86.06 45.68 1.25 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.83 1.252 . . . . 0.0 112.648 -178.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.0 p -101.6 171.71 7.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.303 1.841 . . . . 0.0 108.658 172.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -125.38 -119.35 2.35 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.594 -1.316 . . . . 0.0 110.737 172.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -70.84 -70.25 0.32 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 124.288 1.035 . . . . 0.0 113.7 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 40.1 t -100.66 129.45 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 CA-C-O 123.136 1.446 . . . . 0.0 111.223 -175.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 96.9 t -122.6 104.61 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 128.466 2.706 . . . . 0.0 108.944 -174.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.0 t-160 -88.56 107.37 18.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.624 -1.923 . . . . 0.0 110.802 176.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.7 mt -94.04 144.23 25.66 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.775 -1.203 . . . . 0.0 111.242 169.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 31.6 tp -119.65 124.91 47.44 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 164.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.422 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.0 pp -150.58 168.29 24.7 Favored 'General case' 0 N--CA 1.429 -1.501 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -176.325 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -113.52 129.4 56.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.137 1.775 . . . . 0.0 111.041 -175.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? . . . . . 0 N--CA 1.431 -1.401 0 C-N-CA 125.455 1.502 . . . . 0.0 112.691 179.233 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.7 t0 . . . . . 0 N--CA 1.431 -1.414 0 CA-C-O 121.152 0.501 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 2.1 p -93.07 156.43 16.88 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.748 1.619 . . . . 0.0 113.433 -177.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -147.48 134.23 20.02 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 173.361 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -90.98 137.26 32.5 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 162.46 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.7 t -124.6 93.47 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.9 -1.125 . . . . 0.0 109.011 -175.226 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.47 85.43 5.75 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.544 1.537 . . . . 0.0 110.906 173.286 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.292 1.7 pp -117.88 156.6 28.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 122.668 1.223 . . . . 0.0 112.554 -176.859 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.85 133.43 46.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.074 1.75 . . . . 0.0 112.074 -177.188 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -70.6 134.41 47.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.679 1.592 . . . . 0.0 115.228 -178.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.3 p -107.21 118.45 36.74 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.525 -1.359 . . . . 0.0 111.592 -178.086 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.3 t70 47.83 43.96 17.66 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.329 2.252 . . . . 0.0 115.678 175.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.41 -5.05 85.71 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.447 -1.408 . . . . 0.0 114.956 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 80.6 p -121.59 137.68 54.63 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.176 1.488 . . . . 0.0 114.072 -172.713 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.404 HD21 HG21 ' A' ' 92' ' ' VAL . 89.8 mt -90.61 -61.84 1.59 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.804 -1.185 . . . . 0.0 110.219 167.298 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.82 36.05 1.2 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.625 -1.922 . . . . 0.0 113.189 169.836 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -123.79 124.17 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.031 1.333 . . . . 0.0 109.986 -176.208 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.0 t -101.73 112.49 25.1 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.817 -1.177 . . . . 0.0 107.867 170.349 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.0 m -104.19 161.79 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.934 1.293 . . . . 0.0 111.664 -178.773 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -149.72 174.11 12.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.677 -1.264 . . . . 0.0 109.767 -175.172 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.42 -131.87 10.66 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 124.355 0.979 . . . . 0.0 113.519 168.334 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.83 176.89 51.04 Favored Glycine 0 N--CA 1.43 -1.758 0 N-CA-C 115.787 1.075 . . . . 0.0 115.787 174.659 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.43 -1.468 0 N-CA-C 117.356 2.354 . . . . 0.0 117.356 -170.127 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.762 0 CA-C-O 120.932 0.185 . . . . 0.0 113.354 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 35.4 mm -93.71 123.44 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.498 -1.001 . . . . 0.0 109.16 174.501 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -123.33 154.25 39.17 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.889 -1.132 . . . . 0.0 110.215 -175.315 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.0 t -76.72 129.87 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.765 -1.21 . . . . 0.0 111.562 168.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -100.32 -50.11 4.04 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.374 1.47 . . . . 0.0 111.449 176.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.24 161.05 43.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.686 -1.259 . . . . 0.0 111.401 -175.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -115.76 125.78 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.431 1.092 . . . . 0.0 110.01 179.766 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.3 mm -77.13 115.99 53.57 Favored Pre-proline 0 N--CA 1.43 -1.455 0 C-N-CA 125.748 1.619 . . . . 0.0 112.816 -177.389 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -64.91 136.37 48.47 Favored 'Trans proline' 0 C--N 1.3 -1.988 0 CA-C-N 124.074 2.491 . . . . 0.0 113.044 -175.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.251 45.4 mtmt 83.94 7.0 0.63 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.852 2.861 . . . . 0.0 114.42 -175.318 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 160.22 35.93 Favored Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.97 -1.706 . . . . 0.0 114.983 176.142 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.34 -56.65 8.84 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.009 2.123 . . . . 0.0 115.994 169.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -45.98 83.66 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 128.231 2.612 . . . . 0.0 111.697 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.409 ' HA ' HG12 ' A' ' 47' ' ' ILE . 7.1 tm-20 -47.62 -64.61 0.74 Allowed 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.968 1.84 . . . . 0.0 115.968 169.492 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.0 m -70.13 -21.45 63.09 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 115.448 1.647 . . . . 0.0 115.448 -173.01 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.0 -65.8 0.56 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.295 1.438 . . . . 0.0 112.361 173.189 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.58 0.04 42.96 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 114.847 170.557 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -66.32 -51.73 54.32 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 118.766 1.283 . . . . 0.0 110.32 162.294 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.51 HD11 HD12 ' A' ' 94' ' ' LEU . 51.7 mt -78.26 134.96 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 124.902 1.281 . . . . 0.0 111.053 179.322 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.6 t-80 -147.59 156.78 43.15 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 122.063 0.935 . . . . 0.0 109.46 -178.78 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -65.61 126.02 27.05 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 119.501 -2.0 . . . . 0.0 114.37 -174.23 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.03 -4.86 35.98 Favored Glycine 0 N--CA 1.43 -1.758 0 CA-C-O 118.244 -1.309 . . . . 0.0 115.665 -173.229 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.363 3.1 p30 -81.58 163.41 22.63 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 121.207 2.503 . . . . 0.0 114.565 178.464 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.4 tpt85 -112.21 121.92 46.29 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.343 -1.473 . . . . 0.0 111.018 -167.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.6 t -87.94 136.24 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.105 -1.622 . . . . 0.0 110.277 -173.434 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 9.6 mp -102.3 -53.03 3.0 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 124.583 1.153 . . . . 0.0 110.494 175.776 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.93 147.43 27.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.825 -1.172 . . . . 0.0 112.209 -168.865 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.28 116.14 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 176.594 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 61.63 37.35 16.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.572 1.949 . . . . 0.0 115.073 167.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.18 59.62 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.522 1.058 . . . . 0.0 113.906 -175.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.6 t -95.44 112.62 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-N 118.546 1.173 . . . . 0.0 111.029 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.1 m -70.13 121.76 18.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.98 -1.075 . . . . 0.0 110.083 171.091 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.0 mt -72.85 -34.16 66.58 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -169.069 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -8.85 93.53 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 121.114 3.746 . . . . 0.0 121.114 -173.704 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.48 20.87 12.3 Favored Glycine 0 N--CA 1.43 -1.763 0 C-N-CA 125.134 1.35 . . . . 0.0 111.608 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.33 164.45 26.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 175.018 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -92.74 170.32 9.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.358 -1.464 . . . . 0.0 111.121 161.776 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -51.36 -56.7 11.71 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.293 1.837 . . . . 0.0 113.146 169.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -56.67 -36.19 69.3 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 174.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.7 mm-40 -55.59 -48.39 74.91 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 121.102 1.774 . . . . 0.0 113.79 175.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.95 -42.37 94.67 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.195 0.998 . . . . 0.0 113.26 177.889 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.4 t -65.43 -45.68 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 124.603 1.161 . . . . 0.0 111.266 178.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -62.38 -40.23 95.78 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.724 -1.235 . . . . 0.0 112.83 177.712 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.0 m -65.79 -42.27 90.95 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.435 2.294 . . . . 0.0 113.295 175.575 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.12 -36.85 84.26 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.303 1.441 . . . . 0.0 113.299 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -68.76 -30.14 68.68 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.245 -1.534 . . . . 0.0 113.133 172.032 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -84.81 45.96 1.21 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.02 1.728 . . . . 0.0 112.777 175.495 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 p -105.55 163.58 12.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 126.696 1.998 . . . . 0.0 110.214 177.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.92 -144.2 15.73 Favored Glycine 0 N--CA 1.43 -1.732 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 168.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -70.95 -60.71 2.09 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 121.191 -1.181 . . . . 0.0 113.666 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 29.5 t -98.42 119.85 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.948 1.356 . . . . 0.0 109.293 -175.345 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.404 HG21 HD21 ' A' ' 25' ' ' LEU . 88.1 t -112.78 114.87 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 C-N-CA 126.305 1.842 . . . . 0.0 109.306 -165.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -97.69 99.03 10.38 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.961 -1.087 . . . . 0.0 110.617 -177.932 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.51 HD12 HD11 ' A' ' 59' ' ' ILE . 21.0 mt -92.93 160.24 14.98 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 119.797 -1.814 . . . . 0.0 112.711 173.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.46 131.99 48.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.417 1.087 . . . . 0.0 108.09 165.814 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -147.86 172.98 13.3 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.395 -1.44 . . . . 0.0 112.415 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -127.49 148.63 50.31 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.162 1.785 . . . . 0.0 109.258 174.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 27.5 tptt . . . . . 0 N--CA 1.429 -1.492 0 O-C-N 120.34 -1.475 . . . . 0.0 111.312 175.716 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 t0 . . . . . 0 N--CA 1.43 -1.46 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.8 p -106.07 154.41 20.68 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 124.725 1.21 . . . . 0.0 112.184 178.414 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.46 143.9 29.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.694 -1.254 . . . . 0.0 108.567 -177.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -99.43 105.35 17.29 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.2 1.0 . . . . 0.0 109.636 -179.186 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.72 99.54 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.3 1.44 . . . . 0.0 109.457 -169.809 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -90.09 95.76 10.36 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.379 -1.451 . . . . 0.0 107.749 173.721 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -111.02 130.04 55.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.171 0.988 . . . . 0.0 110.467 -169.862 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.89 141.25 35.04 Favored 'General case' 0 CA--C 1.489 -1.372 0 O-C-N 120.471 -1.393 . . . . 0.0 109.727 172.937 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -64.42 147.22 53.13 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 178.699 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 31.3 p -116.15 122.87 46.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 167.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.2 t0 43.3 46.22 5.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 128.577 2.751 . . . . 0.0 114.422 -176.726 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.14 11.58 75.18 Favored Glycine 0 N--CA 1.431 -1.65 0 N-CA-C 117.891 1.917 . . . . 0.0 117.891 -178.357 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.0 m -117.32 153.67 32.58 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 119.473 1.637 . . . . 0.0 111.898 178.438 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 72.2 mt -96.11 -60.56 1.6 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.435 1.094 . . . . 0.0 108.9 165.429 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 119.14 37.58 0.8 Allowed Glycine 0 N--CA 1.43 -1.765 0 O-C-N 119.829 -1.794 . . . . 0.0 113.142 174.639 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 pt -129.5 139.17 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.173 1.389 . . . . 0.0 108.742 -175.493 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.5 m -111.79 117.7 33.56 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 157.668 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.5 m -99.05 162.59 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 124.351 1.061 . . . . 0.0 112.017 -174.631 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -150.11 -177.72 6.09 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.842 1.257 . . . . 0.0 110.001 178.168 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.53 -149.55 19.27 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.985 -1.072 . . . . 0.0 113.745 174.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.43 168.03 30.07 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 124.513 1.054 . . . . 0.0 112.924 -177.449 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.431 -1.419 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -172.218 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.769 0 CA-C-O 121.42 0.456 . . . . 0.0 113.429 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -96.93 121.88 47.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 175.591 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -126.71 154.26 44.36 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.854 -1.154 . . . . 0.0 110.522 -168.426 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.8 t -75.88 125.57 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.603 -1.31 . . . . 0.0 110.757 169.223 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.1 tttm -91.88 -44.92 8.65 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.738 -1.226 . . . . 0.0 110.671 178.662 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.44 148.11 29.93 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 123.129 0.572 . . . . 0.0 110.694 178.432 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -102.89 121.36 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.612 1.196 . . . . 0.0 110.121 173.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.4 mm -77.1 120.27 80.92 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 125.893 1.677 . . . . 0.0 114.219 -171.902 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -59.72 126.35 20.3 Favored 'Trans proline' 0 C--N 1.3 -2.013 0 CA-C-N 124.451 2.625 . . . . 0.0 115.325 -177.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.265 7.3 mtpm? 78.29 28.02 0.5 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.454 2.302 . . . . 0.0 112.598 -178.04 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.14 159.72 34.26 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.531 -1.356 . . . . 0.0 113.646 162.472 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.06 -60.83 2.45 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.054 2.142 . . . . 0.0 114.847 164.464 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.16 -49.19 78.63 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.191 2.996 . . . . 0.0 111.96 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -46.76 -61.58 1.78 Allowed 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 115.55 1.685 . . . . 0.0 115.55 171.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.8 m -68.27 -32.97 73.51 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 -173.594 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -51.01 -66.96 0.29 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.093 1.757 . . . . 0.0 113.323 176.368 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.25 -17.59 10.48 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 115.051 0.78 . . . . 0.0 115.051 174.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 56.9 mtt85 -71.27 -33.62 69.94 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 120.081 1.941 . . . . 0.0 112.491 170.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.8 mt -95.12 113.5 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.228 1.011 . . . . 0.0 109.628 176.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.657 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 79.9 t60 -143.65 -174.04 4.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.165 -1.584 . . . . 0.0 110.508 174.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.657 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.3 ttpt -60.15 127.65 32.89 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.32 1.848 . . . . 0.0 113.853 -174.753 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.95 -6.35 83.75 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 120.659 -1.275 . . . . 0.0 114.793 178.792 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -81.65 149.27 28.62 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.638 1.719 . . . . 0.0 112.893 -173.685 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -92.29 141.01 29.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.907 -1.745 . . . . 0.0 112.049 -170.711 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.38 119.11 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.63 1.172 . . . . 0.0 108.322 176.491 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.54 -52.46 2.99 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.355 -1.466 . . . . 0.0 111.072 -166.078 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.47 117.18 5.82 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 109.006 175.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.6 t -90.91 115.18 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.718 -173.134 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.0 t30 64.13 32.39 12.69 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.139 1.376 . . . . 0.0 111.853 174.909 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.42 -23.94 33.67 Favored Glycine 0 N--CA 1.429 -1.804 0 C-N-CA 124.764 1.173 . . . . 0.0 114.663 -173.495 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.5 t -87.03 111.9 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.689 -1.477 . . . . 0.0 111.698 -167.817 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.4 m -61.63 120.55 10.81 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.729 -1.232 . . . . 0.0 114.118 -179.013 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 38.9 mt -87.57 42.9 1.07 Allowed 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 112.371 -178.203 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -85.29 110.49 19.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 119.193 -2.192 . . . . 0.0 112.169 -174.335 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.3 -0.6 71.89 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 124.782 1.182 . . . . 0.0 114.228 179.412 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.03 155.09 41.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.3 1.963 . . . . 0.0 116.3 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.3 p -81.04 175.36 10.75 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.147 1.379 . . . . 0.0 112.428 174.253 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -67.28 -39.89 86.08 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.401 -1.437 . . . . 0.0 111.712 174.105 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -57.3 -48.53 78.69 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 113.607 174.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -56.46 -46.35 80.42 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.225 1.41 . . . . 0.0 114.503 179.044 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.08 -39.4 94.61 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.862 1.665 . . . . 0.0 114.364 175.577 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.5 t -76.19 -45.24 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.052 1.341 . . . . 0.0 111.388 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -58.99 -33.03 70.22 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 127.691 2.396 . . . . 0.0 112.19 175.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.6 m -72.53 -49.32 33.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.334 1.854 . . . . 0.0 113.752 170.662 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.8 mt -58.43 -45.36 88.62 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 120.641 1.564 . . . . 0.0 115.149 176.938 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 37.5 ptt85 -66.57 -28.23 68.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.831 -1.168 . . . . 0.0 113.798 -177.906 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -93.18 32.94 1.24 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.8 1.24 . . . . 0.0 113.616 -179.369 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 22.4 p -92.02 148.48 22.15 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.981 1.712 . . . . 0.0 111.384 174.142 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.25 -143.56 9.03 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.819 -1.176 . . . . 0.0 112.59 174.516 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -68.61 -59.79 2.88 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 114.871 1.434 . . . . 0.0 114.871 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.9 p -98.39 134.77 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.384 0 CA-C-O 122.919 1.342 . . . . 0.0 110.648 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.1 t -124.08 115.95 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 C-N-CA 127.525 2.33 . . . . 0.0 107.993 -171.414 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -97.19 89.09 4.65 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.366 -1.459 . . . . 0.0 112.229 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.6 tp -93.46 130.09 39.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.376 -2.077 . . . . 0.0 110.935 -178.134 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.3 tp -87.75 126.09 34.79 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 161.474 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 6.5 tt -122.32 148.54 44.92 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.543 1.137 . . . . 0.0 109.084 -170.106 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -125.3 142.79 51.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 171.608 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.6 tptm . . . . . 0 N--CA 1.43 -1.463 0 O-C-N 120.517 -1.365 . . . . 0.0 111.916 -177.29 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t0 . . . . . 0 N--CA 1.43 -1.442 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -98.52 155.85 17.07 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.575 -1.328 . . . . 0.0 111.638 176.599 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 133.6 21.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 122.231 1.015 . . . . 0.0 108.839 177.329 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -87.49 133.55 33.74 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.326 1.45 . . . . 0.0 109.347 169.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.4 t -126.3 107.15 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.853 1.261 . . . . 0.0 108.4 -169.438 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -91.38 102.05 14.73 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 120.383 -1.448 . . . . 0.0 108.393 166.376 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.2 tp -113.32 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.945 0.878 . . . . 0.0 110.509 -171.608 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 139.85 36.99 Favored 'General case' 0 N--CA 1.428 -1.527 0 O-C-N 120.223 -1.548 . . . . 0.0 107.549 170.203 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -65.23 152.75 42.9 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 115.131 1.53 . . . . 0.0 115.131 -178.487 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 30.5 p -102.48 75.57 1.47 Allowed 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.19 -1.569 . . . . 0.0 108.542 175.313 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.3 t0 61.26 61.53 1.53 Allowed 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.126 1.77 . . . . 0.0 112.321 -177.055 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.41 -30.0 5.45 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.249 -1.532 . . . . 0.0 115.191 -175.291 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.7 m -92.27 136.14 33.43 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.256 -1.732 . . . . 0.0 112.802 -167.112 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.551 HD21 HG21 ' A' ' 92' ' ' VAL . 51.9 mt -102.0 -49.17 4.02 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.627 1.571 . . . . 0.0 110.539 177.413 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 -15.87 39.3 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 120.228 -1.545 . . . . 0.0 113.967 -179.087 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.8 pt -96.39 121.83 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 CA-C-N 119.355 1.578 . . . . 0.0 112.959 -176.579 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.3 m -114.06 137.77 51.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 166.228 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.5 m -124.85 165.3 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.307 1.043 . . . . 0.0 112.946 -165.619 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.7 t -144.91 177.89 8.42 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.572 1.549 . . . . 0.0 110.567 -179.346 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.16 -136.68 12.82 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 115.945 1.138 . . . . 0.0 115.945 166.894 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.48 176.21 35.58 Favored Glycine 0 N--CA 1.43 -1.715 0 C-N-CA 126.351 1.929 . . . . 0.0 113.85 -179.025 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.43 -1.43 0 O-C-N 120.437 -1.625 . . . . 0.0 113.481 179.813 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.746 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 mm -93.74 122.06 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 124.823 1.249 . . . . 0.0 108.367 -175.498 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -121.36 152.58 38.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.79 -1.194 . . . . 0.0 109.6 -175.096 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.9 129.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 O-C-N 120.455 -1.403 . . . . 0.0 111.739 174.211 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -96.21 -46.32 6.49 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 126.031 1.733 . . . . 0.0 111.761 -176.507 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.3 152.8 32.58 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.89 -1.131 . . . . 0.0 109.673 -176.846 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.27 1.0 OUTLIER -112.61 116.02 51.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 CA-C-O 122.72 1.247 . . . . 0.0 109.457 170.885 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.5 mm -76.43 127.59 84.26 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 116.218 -1.849 . . . . 0.0 114.161 -173.789 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -58.08 132.54 49.97 Favored 'Trans proline' 0 N--CA 1.433 -2.052 0 CA-C-N 124.474 2.634 . . . . 0.0 116.725 -179.035 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.278 53.8 mttp 72.15 18.97 4.66 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.35 2.26 . . . . 0.0 114.551 -174.087 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.84 157.17 45.07 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 119.394 -2.067 . . . . 0.0 112.227 170.863 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.36 -59.91 3.3 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.573 -1.545 . . . . 0.0 114.679 169.143 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.94 93.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.915 2.486 . . . . 0.0 112.263 -179.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -45.0 -61.75 1.5 Allowed 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.111 1.764 . . . . 0.0 114.15 173.001 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.5 t -67.75 -43.18 80.51 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -175.419 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.58 -58.08 6.65 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 127.202 2.201 . . . . 0.0 114.081 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.58 31.6 7.38 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.299 -1.5 . . . . 0.0 115.037 163.146 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 53.4 mtt180 -96.98 -29.98 13.35 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 125.291 1.436 . . . . 0.0 109.151 162.786 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.7 mt -108.54 130.01 62.0 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 125.361 1.464 . . . . 0.0 111.076 -179.486 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -141.58 170.55 15.5 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.894 -1.129 . . . . 0.0 109.579 172.842 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.8 pttm -66.59 140.96 57.98 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 118.604 -2.56 . . . . 0.0 113.74 178.119 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.5 -11.21 65.05 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.602 -0.686 . . . . 0.0 113.163 -171.535 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -79.71 154.37 28.62 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 119.162 1.481 . . . . 0.0 112.27 -177.316 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -97.73 123.75 41.79 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.241 1.416 . . . . 0.0 109.698 -174.895 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.8 t -88.11 130.63 37.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 O-C-N 120.053 -1.655 . . . . 0.0 110.17 -178.398 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -99.06 -52.29 3.59 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.079 -1.013 . . . . 0.0 111.001 -178.036 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.96 144.28 24.83 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.13 -0.981 . . . . 0.0 112.862 -172.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.3 t -113.51 111.72 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 66.44 35.78 5.46 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.433 1.893 . . . . 0.0 113.353 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.93 60.01 Favored Glycine 0 N--CA 1.431 -1.659 0 O-C-N 119.931 -1.73 . . . . 0.0 114.238 -175.03 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.35 104.42 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 125.308 1.443 . . . . 0.0 108.508 178.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.2 m -72.45 139.87 47.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.628 -1.295 . . . . 0.0 112.552 -175.29 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 98.9 mt -90.24 -2.4 58.03 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -169.297 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -67.81 105.2 1.88 Allowed 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.219 -1.551 . . . . 0.0 113.927 -176.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 115.1 -20.99 13.72 Favored Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 125.454 1.502 . . . . 0.0 112.969 -174.698 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.04 153.92 40.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 179.237 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 80.4 p -92.16 176.93 6.31 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.558 -1.339 . . . . 0.0 112.843 -179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.9 t-80 -56.21 -53.01 62.25 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.162 1.785 . . . . 0.0 112.359 172.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -55.45 -46.97 76.74 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.622 1.169 . . . . 0.0 113.548 177.55 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.87 -51.59 68.98 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.896 1.443 . . . . 0.0 114.896 177.772 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.22 -36.69 84.95 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.448 -1.408 . . . . 0.0 114.563 176.759 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 95.6 t -72.82 -40.62 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.383 -1.448 . . . . 0.0 111.618 178.186 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -57.63 -44.98 85.96 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.258 -1.526 . . . . 0.0 111.879 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 63.7 m -61.64 -46.71 88.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.718 2.007 . . . . 0.0 114.643 178.157 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . 0.258 0.1 OUTLIER -73.15 -30.85 63.88 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 121.723 2.056 . . . . 0.0 113.893 -178.673 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.36 -39.48 92.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.795 -1.19 . . . . 0.0 111.437 169.729 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -88.94 55.68 3.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 123.02 1.39 . . . . 0.0 111.233 177.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.466 ' HB ' HG22 ' A' ' 92' ' ' VAL . 17.4 p -106.32 156.95 17.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.615 1.566 . . . . 0.0 109.624 174.184 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.15 -162.63 32.96 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 121.374 -0.828 . . . . 0.0 111.987 176.294 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -70.79 -48.96 51.49 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.213 1.405 . . . . 0.0 111.551 175.335 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.4 134.03 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.512 1.149 . . . . 0.0 108.044 167.515 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.551 HG21 HD21 ' A' ' 25' ' ' LEU . 82.8 t -124.4 134.95 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 128.562 2.745 . . . . 0.0 107.778 -170.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 23.2 t-160 -122.73 95.23 4.54 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.856 -1.778 . . . . 0.0 110.497 -173.009 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.6 mt -99.58 157.3 16.55 Favored 'General case' 0 N--CA 1.429 -1.517 0 O-C-N 120.02 -1.675 . . . . 0.0 114.023 -177.122 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.4 tp -127.2 131.64 50.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 162.335 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.14 163.48 32.75 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.889 -1.132 . . . . 0.0 111.165 176.251 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -117.17 144.73 44.43 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.535 1.934 . . . . 0.0 108.181 176.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.4 tptt . . . . . 0 N--CA 1.431 -1.419 0 O-C-N 120.623 -1.298 . . . . 0.0 112.407 -177.201 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 46.4 t0 . . . . . 0 N--CA 1.429 -1.484 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 36.3 p -120.7 165.08 15.59 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.069 -1.644 . . . . 0.0 111.76 -178.725 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.51 144.36 28.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 121.889 0.852 . . . . 0.0 109.677 165.018 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.97 130.2 35.5 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 125.643 1.577 . . . . 0.0 109.835 168.929 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.2 t -118.49 113.12 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 124.819 1.248 . . . . 0.0 108.461 -177.283 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -94.94 108.46 20.52 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 165.934 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 21.7 tp -123.65 128.69 50.03 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.693 1.235 . . . . 0.0 110.394 -176.162 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.99 137.45 39.34 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.757 -1.839 . . . . 0.0 109.569 169.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -69.41 136.17 51.26 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.122 -0.986 . . . . 0.0 113.101 177.006 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.9 p -90.02 93.1 9.26 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.41 -1.431 . . . . 0.0 111.448 -171.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.7 t70 56.29 41.92 28.53 Favored 'General case' 0 N--CA 1.429 -1.523 0 C-N-CA 125.812 1.645 . . . . 0.0 113.26 178.023 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.03 -20.43 40.81 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.766 1.174 . . . . 0.0 115.372 -174.707 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -94.11 110.68 22.38 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.254 1.527 . . . . 0.0 114.163 -170.535 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.5 tt -125.53 64.79 1.17 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 169.856 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -82.16 74.99 2.4 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 126.754 2.121 . . . . 0.0 111.259 -164.72 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.2 pt -100.65 156.49 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 125.332 1.453 . . . . 0.0 111.149 169.774 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 46.7 t -129.05 127.6 41.89 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.138 -1.601 . . . . 0.0 107.318 158.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 m -120.49 168.2 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 124.676 1.19 . . . . 0.0 110.141 -178.525 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -149.97 -175.31 5.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.614 -1.304 . . . . 0.0 107.566 176.031 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.89 -168.7 12.62 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.888 -1.132 . . . . 0.0 114.631 168.608 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.1 161.76 18.65 Favored Glycine 0 N--CA 1.431 -1.652 0 CA-C-O 122.901 1.278 . . . . 0.0 115.039 173.076 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.43 -1.438 0 C-N-CA 127.405 2.282 . . . . 0.0 115.646 -178.151 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.701 0 N-CA-C 111.114 -0.795 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.9 mm -99.47 126.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 177.339 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -127.11 152.63 47.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 119.657 1.117 . . . . 0.0 111.3 -170.322 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.42 126.18 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 O-C-N 120.555 -1.34 . . . . 0.0 112.964 172.674 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 39.6 tttp -97.93 -39.5 8.94 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.191 1.396 . . . . 0.0 111.81 -175.483 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -161.29 154.69 21.55 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.226 -0.921 . . . . 0.0 110.291 173.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.23 120.72 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 124.252 1.021 . . . . 0.0 108.436 168.59 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.2 mm -76.62 127.1 85.1 Favored Pre-proline 0 N--CA 1.43 -1.437 0 CA-C-O 116.752 -1.594 . . . . 0.0 113.993 -169.666 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -55.26 119.89 7.28 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 123.737 2.958 . . . . 0.0 115.942 177.3 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.37 5.3 mmmp? 78.92 23.14 0.59 Allowed 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.562 2.745 . . . . 0.0 116.059 -175.155 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.04 164.46 40.66 Favored Glycine 0 N--CA 1.431 -1.673 0 O-C-N 120.544 -1.347 . . . . 0.0 112.14 163.303 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -58.71 4.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.857 1.428 . . . . 0.0 114.857 168.323 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.39 -26.85 68.64 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.376 1.871 . . . . 0.0 114.576 -177.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.66 -54.26 45.07 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.688 1.709 . . . . 0.0 113.057 177.156 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 t -65.88 -44.01 86.62 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 125.511 1.524 . . . . 0.0 112.985 -176.167 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -45.01 -55.79 5.23 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.232 2.613 . . . . 0.0 116.272 -172.637 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.49 6.93 35.26 Favored Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 116.965 1.546 . . . . 0.0 116.965 162.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -90.17 -49.42 6.57 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.804 -1.41 . . . . 0.0 109.354 167.75 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 87.3 mt -79.31 128.99 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.351 1.46 . . . . 0.0 112.242 -171.647 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -132.94 153.55 51.31 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.876 1.67 . . . . 0.0 111.047 -178.418 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -51.49 123.19 9.28 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.134 1.774 . . . . 0.0 113.763 170.436 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 93.04 0.11 68.61 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 120.868 -1.145 . . . . 0.0 115.906 -178.429 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 1.7 p30 -82.05 159.07 23.54 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 120.119 1.959 . . . . 0.0 113.936 176.006 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -100.32 130.03 46.38 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.592 -1.318 . . . . 0.0 112.788 -177.004 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -85.7 125.37 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.934 1.294 . . . . 0.0 110.014 176.112 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.36 -42.7 6.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.777 -1.202 . . . . 0.0 111.825 -174.464 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 148.9 29.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.716 -1.24 . . . . 0.0 111.647 179.795 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 t -118.73 109.4 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 171.093 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.3 t30 45.13 67.47 0.71 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.297 2.639 . . . . 0.0 116.11 173.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 88.48 -29.38 5.75 Favored Glycine 0 N--CA 1.43 -1.725 0 C-N-CA 124.098 0.856 . . . . 0.0 113.555 -179.476 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -94.5 111.27 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 121.084 -1.245 . . . . 0.0 109.109 -171.771 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 73.6 m -69.99 133.49 47.31 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 176.677 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.1 mt -86.5 50.06 1.92 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.847 -1.158 . . . . 0.0 111.064 -178.411 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -89.7 133.23 34.77 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.599 2.36 . . . . 0.0 109.715 178.133 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.67 3.83 22.82 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 117.232 1.653 . . . . 0.0 117.232 -179.543 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.84 148.7 45.94 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 115.645 1.72 . . . . 0.0 115.645 -170.763 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 69.2 p -90.01 174.51 7.62 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.838 -1.164 . . . . 0.0 110.481 165.063 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -52.92 -52.71 56.82 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.172 1.789 . . . . 0.0 113.715 174.758 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -55.64 -40.4 72.14 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 126.074 1.75 . . . . 0.0 114.598 -179.503 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -54.95 -57.23 12.5 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 126.883 2.073 . . . . 0.0 113.146 177.654 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.61 -37.8 83.03 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.57 1.148 . . . . 0.0 113.815 178.794 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.5 t -68.35 -48.18 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.653 -1.279 . . . . 0.0 110.722 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 53.2 mm-40 -66.52 -26.86 67.36 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.249 -1.532 . . . . 0.0 112.855 178.316 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 66.5 m -69.68 -46.19 66.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.814 1.646 . . . . 0.0 113.085 170.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 47.7 mt -72.23 -22.35 61.26 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 119.779 -1.826 . . . . 0.0 114.822 176.475 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -68.3 -50.72 51.62 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.137 -1.602 . . . . 0.0 111.057 166.217 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.52 60.01 5.43 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.273 1.429 . . . . 0.0 113.281 -174.071 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 44.0 p -92.23 -175.9 4.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.422 -1.424 . . . . 0.0 110.73 171.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.22 -150.95 23.51 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 157.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -71.25 -52.57 18.24 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.771 1.228 . . . . 0.0 113.358 174.596 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 17.3 t -104.74 120.48 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 122.338 1.066 . . . . 0.0 110.613 -176.915 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.8 t -109.29 139.6 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 127.623 2.369 . . . . 0.0 109.676 -169.668 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -115.49 112.97 23.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.248 -1.533 . . . . 0.0 109.325 174.178 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -107.03 158.55 16.96 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.279 1.432 . . . . 0.0 113.034 176.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 67.2 tp -126.29 130.8 51.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 164.119 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.78 159.23 41.98 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 121.084 -1.01 . . . . 0.0 112.713 174.528 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -101.58 137.16 40.27 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 126.137 1.775 . . . . 0.0 108.443 175.029 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.431 -1.41 0 O-C-N 120.607 -1.308 . . . . 0.0 111.071 -171.746 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.6 t0 . . . . . 0 N--CA 1.43 -1.436 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -92.5 146.23 23.84 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.261 -1.524 . . . . 0.0 109.934 176.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 16.8 p90 -146.41 137.36 24.27 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 123.048 1.404 . . . . 0.0 109.192 179.837 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.15 141.25 34.3 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.703 1.601 . . . . 0.0 109.128 -178.795 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.5 t -130.66 113.18 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -171.824 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -107.39 75.16 1.0 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.879 1.324 . . . . 0.0 107.845 173.411 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.7 tp -94.8 135.11 36.68 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.357 1.463 . . . . 0.0 111.864 -168.552 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.49 146.08 28.63 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.269 -1.519 . . . . 0.0 111.796 173.373 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -70.27 157.97 36.74 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 115.192 1.552 . . . . 0.0 115.192 176.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.4 t -134.57 125.77 27.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.77 -1.206 . . . . 0.0 108.578 168.758 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 1.2 t70 50.55 40.82 24.43 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.985 2.514 . . . . 0.0 114.25 -170.49 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.1 -9.98 50.8 Favored Glycine 0 N--CA 1.431 -1.688 0 O-C-N 120.224 -1.547 . . . . 0.0 116.302 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.01 144.19 34.01 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.693 -1.475 . . . . 0.0 113.146 -166.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.461 HD21 HG21 ' A' ' 92' ' ' VAL . 49.8 mt -99.78 -62.28 1.26 Allowed 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.287 -0.883 . . . . 0.0 110.458 173.8 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.71 47.52 0.73 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 119.574 -1.954 . . . . 0.0 112.923 168.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.6 tt -147.53 137.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.666 1.222 . . . . 0.0 112.016 -178.741 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.7 m -105.42 133.89 49.43 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.928 1.291 . . . . 0.0 108.855 168.162 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.8 m -107.7 170.68 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.39 1.09 . . . . 0.0 110.766 178.806 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -150.41 -172.49 4.19 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.458 -1.401 . . . . 0.0 108.508 174.775 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.98 -144.84 18.56 Favored Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 124.893 1.235 . . . . 0.0 111.309 179.316 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.36 146.44 13.7 Favored Glycine 0 N--CA 1.43 -1.757 0 C-N-CA 124.098 0.856 . . . . 0.0 112.367 177.434 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t . . . . . 0 N--CA 1.43 -1.441 0 O-C-N 120.929 -1.336 . . . . 0.0 114.126 -170.154 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.797 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.6 mm -101.9 129.0 53.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.832 1.253 . . . . 0.0 109.091 -179.243 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -125.55 156.96 38.24 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.632 -1.293 . . . . 0.0 109.952 -170.823 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -75.31 121.07 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.398 -1.439 . . . . 0.0 111.929 173.203 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -88.33 -59.42 2.24 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.092 -1.63 . . . . 0.0 110.793 179.2 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.58 154.55 34.46 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.633 -0.667 . . . . 0.0 110.187 -172.193 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.429 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.1 tp -111.53 125.88 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 CA-C-O 121.848 0.832 . . . . 0.0 109.541 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 16.5 mm -77.67 125.18 86.21 Favored Pre-proline 0 N--CA 1.429 -1.497 0 C-N-CA 126.259 1.823 . . . . 0.0 113.473 -173.594 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.58 130.32 39.35 Favored 'Trans proline' 0 N--CA 1.434 -1.996 0 CA-C-N 124.356 2.591 . . . . 0.0 116.568 -175.492 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.275 1.8 mptp? 73.59 13.95 4.35 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 127.592 2.357 . . . . 0.0 115.004 178.916 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.12 164.21 52.64 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 119.615 -1.928 . . . . 0.0 113.767 174.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.43 -56.76 10.05 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 126.325 1.85 . . . . 0.0 114.733 168.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.28 -46.68 82.6 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 128.673 2.789 . . . . 0.0 112.351 178.522 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HA ' HG12 ' A' ' 47' ' ' ILE . 3.1 tm-20 -47.71 -61.97 1.68 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.996 1.851 . . . . 0.0 115.996 170.696 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 65.4 m -69.0 -26.71 65.15 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -175.654 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -55.61 -68.05 0.23 Allowed 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.942 1.697 . . . . 0.0 111.651 174.349 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.48 30.33 33.63 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.043 -1.036 . . . . 0.0 114.925 171.798 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -78.48 -47.76 16.75 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 120.727 -1.455 . . . . 0.0 108.48 147.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.3 111.85 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 C-N-CA 125.956 1.703 . . . . 0.0 112.636 -175.099 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -117.21 160.35 21.21 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 123.922 1.82 . . . . 0.0 113.151 -178.503 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -60.94 129.49 41.68 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.259 1.423 . . . . 0.0 113.949 -174.42 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 87.54 -4.85 85.77 Favored Glycine 0 N--CA 1.431 -1.675 0 CA-C-O 118.91 -0.939 . . . . 0.0 114.06 176.108 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -80.96 162.69 23.76 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 119.508 1.654 . . . . 0.0 112.3 -173.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 14.9 ttt180 -106.19 123.97 48.86 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.535 -1.353 . . . . 0.0 111.87 -159.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.1 123.28 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.976 -1.077 . . . . 0.0 110.099 -175.2 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -94.47 -44.05 8.06 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.876 -1.14 . . . . 0.0 110.625 -177.563 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.89 137.93 19.18 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.577 -0.702 . . . . 0.0 112.205 -173.043 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -111.42 126.71 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 174.422 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 71.02 14.81 6.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.267 1.827 . . . . 0.0 111.424 -179.623 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.21 89.62 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 125.956 1.741 . . . . 0.0 114.156 -170.347 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -91.77 124.62 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-N 118.868 1.334 . . . . 0.0 109.568 -179.83 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 25.4 m -72.92 135.02 45.01 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.767 -1.208 . . . . 0.0 112.817 -172.127 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.5 mt -87.34 36.34 0.74 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.684 -1.26 . . . . 0.0 114.364 -174.118 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -72.71 116.91 13.76 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.143 -2.223 . . . . 0.0 113.572 -170.933 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.23 13.09 79.78 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.13 -0.981 . . . . 0.0 114.26 -177.643 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.32 144.33 51.74 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -177.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 64.7 p -81.73 173.33 12.41 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.252 -1.53 . . . . 0.0 110.493 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -59.52 -48.14 82.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.874 -1.141 . . . . 0.0 111.648 172.182 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.12 -47.96 77.14 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.119 1.368 . . . . 0.0 114.23 174.145 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -58.86 -47.16 85.88 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.235 1.939 . . . . 0.0 116.235 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.35 -35.43 80.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.723 -1.235 . . . . 0.0 112.215 173.166 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.62 -45.02 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.012 -1.055 . . . . 0.0 111.077 178.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -58.65 -40.77 84.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.625 -1.297 . . . . 0.0 113.232 173.545 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.7 m -66.43 -38.81 88.27 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.702 1.601 . . . . 0.0 113.017 178.668 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 38.9 mt -72.61 -31.73 65.39 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.353 -1.467 . . . . 0.0 113.945 172.569 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.1 -42.16 76.49 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.485 -1.385 . . . . 0.0 112.876 173.692 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -79.04 58.17 2.38 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 124.086 1.898 . . . . 0.0 111.415 174.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 p -107.7 143.9 35.56 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.898 2.479 . . . . 0.0 108.88 170.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.77 -141.85 8.23 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 121.154 -0.966 . . . . 0.0 112.063 172.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.5 tt0 -62.44 -57.56 10.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.581 1.552 . . . . 0.0 113.118 174.304 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.21 142.54 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 CA-C-O 122.695 1.236 . . . . 0.0 110.487 178.231 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG21 HD21 ' A' ' 25' ' ' LEU . 64.8 t -124.23 112.35 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 128.268 2.627 . . . . 0.0 109.16 -170.834 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -97.47 108.1 20.75 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.783 -1.198 . . . . 0.0 111.637 176.744 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.1 mt -105.38 146.52 29.32 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.904 -1.122 . . . . 0.0 113.251 172.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.9 tp -116.33 126.59 53.74 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 162.864 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.508 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 1.1 pp -146.81 163.95 34.37 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.246 -0.909 . . . . 0.0 110.949 179.556 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -123.31 143.08 50.31 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.252 1.021 . . . . 0.0 112.151 -176.855 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.4 tptm . . . . . 0 N--CA 1.43 -1.43 0 C-N-CA 125.662 1.585 . . . . 0.0 109.177 174.199 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.2 t70 . . . . . 0 CA--C 1.489 -1.394 0 CA-C-O 121.489 0.661 . . . . 0.0 109.944 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.0 p -91.01 159.67 16.02 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.328 1.051 . . . . 0.0 113.812 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -144.32 138.95 28.23 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -87.78 122.73 31.79 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.649 -1.282 . . . . 0.0 108.988 164.673 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 53.7 t -107.18 88.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -96.54 89.19 4.91 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.039 1.736 . . . . 0.0 108.034 177.949 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.0 tp -125.48 151.74 45.87 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.513 1.525 . . . . 0.0 109.758 -171.309 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.04 153.74 19.96 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.194 -1.566 . . . . 0.0 110.76 167.816 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -67.22 156.25 36.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 115.364 1.616 . . . . 0.0 115.364 -179.552 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 63.1 p -116.18 114.42 24.42 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.834 -1.166 . . . . 0.0 108.657 169.487 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.6 t0 40.56 56.91 2.69 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.843 2.457 . . . . 0.0 115.293 -176.701 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.75 -30.32 5.43 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 125.015 1.293 . . . . 0.0 115.488 -177.003 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.49 142.76 33.16 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.729 -1.454 . . . . 0.0 114.783 -162.749 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 95.9 mt -94.54 -60.55 1.69 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.223 1.409 . . . . 0.0 107.98 164.645 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.9 36.38 0.89 Allowed Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.873 -1.767 . . . . 0.0 112.504 167.885 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 pt -118.78 124.42 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 122.577 1.179 . . . . 0.0 111.179 -174.7 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.2 m -100.05 125.24 46.09 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 164.165 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -107.48 170.1 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 124.192 0.997 . . . . 0.0 111.438 -175.497 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -153.34 178.78 9.41 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.467 -1.396 . . . . 0.0 108.146 177.005 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.22 13.73 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.627 1.108 . . . . 0.0 114.139 175.537 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.68 152.73 10.93 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 126.239 1.876 . . . . 0.0 111.527 -177.222 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.43 -1.441 0 O-C-N 120.592 -1.534 . . . . 0.0 114.755 -175.325 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.713 0 N-CA-C 111.622 -0.591 . . . . 0.0 111.622 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.65 131.25 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 174.751 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -128.14 154.81 45.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 120.964 -1.085 . . . . 0.0 109.466 -173.141 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.6 t -77.06 122.74 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 O-C-N 120.348 -1.47 . . . . 0.0 112.656 175.029 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -92.0 -47.47 7.27 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.803 1.241 . . . . 0.0 112.18 178.862 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.69 161.83 37.14 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.174 -0.954 . . . . 0.0 110.786 -179.753 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -118.03 124.57 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.742 1.217 . . . . 0.0 109.487 -178.384 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.5 mm -77.19 121.02 83.94 Favored Pre-proline 0 N--CA 1.43 -1.454 0 CA-C-O 116.45 -1.738 . . . . 0.0 114.454 -175.214 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_exo -58.2 122.86 12.41 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 123.275 2.65 . . . . 0.0 116.202 -178.985 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.323 72.0 mmtt 76.73 31.36 0.56 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 127.064 2.146 . . . . 0.0 113.812 -177.57 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.5 162.68 38.21 Favored Glycine 0 N--CA 1.431 -1.685 0 CA-C-O 122.262 0.923 . . . . 0.0 112.117 159.107 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.98 -59.44 4.15 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.253 1.821 . . . . 0.0 114.653 166.585 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.73 -49.37 76.69 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 129.395 3.078 . . . . 0.0 111.705 -176.676 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -41.74 -66.53 0.34 Allowed 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 172.179 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.3 m -70.04 -10.82 59.96 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -176.35 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -75.55 -57.19 4.03 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 119.374 -2.079 . . . . 0.0 111.313 177.37 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.18 0.79 54.37 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.909 -1.12 . . . . 0.0 115.411 170.236 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.3 mmt-85 -66.88 -33.69 76.15 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.68 -1.482 . . . . 0.0 110.941 162.97 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 81.6 mt -90.67 113.14 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 C-N-CA 126.066 1.746 . . . . 0.0 110.727 -178.696 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -113.11 156.46 23.13 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-O 123.625 1.679 . . . . 0.0 112.698 179.352 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -69.57 128.08 35.23 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 119.999 -1.688 . . . . 0.0 111.994 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 89.14 8.01 69.36 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.628 -1.295 . . . . 0.0 114.567 -177.137 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -79.83 173.42 12.61 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 119.672 1.736 . . . . 0.0 113.34 175.617 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.8 ttt-85 -101.55 140.74 35.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 123.104 1.431 . . . . 0.0 110.644 174.956 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -99.69 136.11 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.172 -1.58 . . . . 0.0 107.507 178.768 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -100.71 -57.4 2.11 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.931 -1.73 . . . . 0.0 113.063 -176.988 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.57 139.19 20.64 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.762 -1.211 . . . . 0.0 109.596 -174.678 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.29 113.28 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-O 121.884 0.85 . . . . 0.0 109.153 179.022 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 6.7 t30 67.35 21.7 9.7 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.31 1.844 . . . . 0.0 114.648 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.81 -13.64 41.77 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 120.897 -1.127 . . . . 0.0 112.777 -175.219 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.0 t -94.14 116.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 121.218 -1.166 . . . . 0.0 109.257 -176.796 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.6 p -74.51 133.99 42.28 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.628 -1.295 . . . . 0.0 111.615 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.0 mt -86.67 22.12 2.01 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.729 -1.232 . . . . 0.0 113.531 -172.813 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.0 mm-40 -68.08 119.69 13.09 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.87 -1.769 . . . . 0.0 111.982 174.085 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.33 8.65 83.89 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 121.214 -0.929 . . . . 0.0 115.369 -176.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.16 144.56 46.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.796 1.776 . . . . 0.0 115.796 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 73.0 p -87.1 178.3 6.95 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.566 -1.333 . . . . 0.0 109.717 168.451 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -62.98 -46.95 85.27 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.823 -1.798 . . . . 0.0 112.12 171.477 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 4.7 tmtm? -55.0 -39.53 69.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.612 1.965 . . . . 0.0 115.436 174.686 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -58.61 -51.12 71.27 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 173.573 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.07 -35.29 79.52 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 124.651 1.18 . . . . 0.0 112.985 -178.765 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.9 t -64.89 -48.57 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 124.653 1.181 . . . . 0.0 110.846 173.94 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 75.6 mt-10 -58.81 -45.42 89.98 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.923 -1.111 . . . . 0.0 113.286 176.882 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 94.5 m -62.59 -43.75 98.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.765 2.026 . . . . 0.0 112.741 178.386 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 22.8 mt -61.48 -45.55 93.79 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.702 -1.249 . . . . 0.0 114.326 172.148 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 55.7 mtp85 -73.2 -27.56 61.69 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.444 -1.41 . . . . 0.0 113.934 -177.467 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -84.32 50.56 1.89 Allowed 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.121 -1.612 . . . . 0.0 112.039 172.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.412 ' HB ' HG22 ' A' ' 92' ' ' VAL . 7.4 p -106.7 149.88 26.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.409 1.884 . . . . 0.0 109.966 174.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.41 -153.46 20.79 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.959 -1.088 . . . . 0.0 112.496 173.478 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -68.34 -53.48 23.86 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.384 -1.657 . . . . 0.0 113.62 178.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 54.1 t -93.07 136.51 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.502 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 173.837 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 88' ' ' THR . 90.7 t -124.39 126.56 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 C-N-CA 125.633 1.573 . . . . 0.0 109.239 -170.183 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -105.38 95.5 5.87 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.904 -1.748 . . . . 0.0 113.329 -178.128 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.485 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 34.8 mt -94.22 153.4 18.08 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 118.581 -2.574 . . . . 0.0 113.305 176.7 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 25.3 tp -116.43 138.79 51.09 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 158.86 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.436 HD13 ' N ' ' A' ' 97' ' ' GLU . 0.4 OUTLIER -137.89 153.67 49.52 Favored 'General case' 0 N--CA 1.429 -1.522 0 C-N-CA 124.941 1.297 . . . . 0.0 109.878 -164.959 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.436 ' N ' HD13 ' A' ' 96' ' ' LEU . 41.7 tt0 -133.13 136.06 45.56 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 119.938 1.245 . . . . 0.0 111.053 169.441 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? . . . . . 0 N--CA 1.43 -1.472 0 O-C-N 120.328 -1.483 . . . . 0.0 111.553 -178.196 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.6 t0 . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 p -109.98 150.21 28.83 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.743 1.217 . . . . 0.0 111.69 -175.304 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.79 131.14 18.59 Favored 'General case' 0 N--CA 1.431 -1.425 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.907 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -88.51 113.55 24.21 Favored 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.4 t -99.82 100.82 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 O-C-N 120.637 -1.289 . . . . 0.0 108.964 -171.217 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.67 95.96 8.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.88 1.672 . . . . 0.0 108.559 177.427 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 51.6 tp -124.74 145.09 49.89 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.751 1.22 . . . . 0.0 111.315 -166.885 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.08 137.68 40.93 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.427 -1.421 . . . . 0.0 111.052 173.165 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -70.64 149.42 47.04 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 117.414 2.375 . . . . 0.0 117.414 -177.715 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 72.0 p -127.14 132.62 50.51 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.355 -1.466 . . . . 0.0 109.695 176.403 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 13.1 t70 64.73 16.12 10.2 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.883 2.073 . . . . 0.0 114.352 -177.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.37 6.93 89.0 Favored Glycine 0 N--CA 1.43 -1.734 0 O-C-N 119.647 -1.908 . . . . 0.0 114.63 -174.259 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -123.24 173.63 7.8 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 121.27 -1.135 . . . . 0.0 110.774 176.121 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -109.71 -57.57 2.17 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.534 1.134 . . . . 0.0 108.173 171.45 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.4 50.24 0.11 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 119.841 -1.787 . . . . 0.0 111.861 163.297 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.7 tt -137.51 140.63 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.102 0.953 . . . . 0.0 111.191 -171.304 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.3 t -121.81 139.08 54.06 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.11 1.364 . . . . 0.0 108.284 170.39 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.6 m -116.95 170.31 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.929 -1.107 . . . . 0.0 113.74 -167.597 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -152.59 160.06 43.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.613 -1.304 . . . . 0.0 109.776 175.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.29 -148.25 19.58 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.909 -1.12 . . . . 0.0 115.02 172.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.45 -174.23 20.96 Favored Glycine 0 N--CA 1.43 -1.719 0 C-N-CA 125.443 1.497 . . . . 0.0 109.474 -169.604 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 N--CA 1.431 -1.422 0 O-C-N 120.539 -1.565 . . . . 0.0 113.753 -178.683 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.816 0 N-CA-C 112.236 -0.346 . . . . 0.0 112.236 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.1 mm -85.53 116.83 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 C-N-CA 124.97 1.308 . . . . 0.0 110.615 -176.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -114.78 156.36 25.0 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.536 -1.353 . . . . 0.0 109.68 -177.822 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -76.99 123.14 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.214 -1.554 . . . . 0.0 111.029 170.599 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 12.7 ttmm -91.15 -45.41 8.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.198 -1.564 . . . . 0.0 111.084 175.788 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.17 156.49 42.25 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 120.172 -1.58 . . . . 0.0 111.414 -179.734 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -119.32 128.13 75.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 124.485 1.114 . . . . 0.0 108.642 177.392 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.91 121.27 84.49 Favored Pre-proline 0 N--CA 1.429 -1.513 0 N-CA-C 117.004 2.224 . . . . 0.0 117.004 -171.086 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -56.01 122.95 12.67 Favored 'Trans proline' 0 N--CA 1.434 -2.017 0 C-N-CA 123.44 2.76 . . . . 0.0 116.549 -177.288 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.4 mtmm 78.43 13.0 1.52 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 128.367 2.667 . . . . 0.0 114.465 -176.168 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.95 157.77 47.45 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 120.007 -1.683 . . . . 0.0 111.682 172.852 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.21 -55.81 7.88 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.873 1.669 . . . . 0.0 114.735 170.166 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.9 -47.76 79.32 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 127.659 2.384 . . . . 0.0 113.327 178.82 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -47.48 -61.97 1.66 Allowed 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.219 1.563 . . . . 0.0 115.219 170.299 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -65.39 -31.64 72.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.993 1.317 . . . . 0.0 113.62 -171.853 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -54.89 -63.56 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.186 2.194 . . . . 0.0 113.097 174.388 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.53 47.49 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.972 -1.08 . . . . 0.0 115.344 171.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . 0.437 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.0 mmp_? -76.64 -22.05 54.64 Favored 'General case' 0 N--CA 1.429 -1.481 0 CA-C-N 119.817 1.809 . . . . 0.0 112.438 171.368 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.3 mt -103.26 123.58 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.537 1.135 . . . . 0.0 108.252 171.656 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.733 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 25.9 t-80 -146.67 -171.25 3.71 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.63 1.681 . . . . 0.0 111.717 176.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.733 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 44.4 tttp -72.2 123.87 23.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.015 1.726 . . . . 0.0 113.785 -166.105 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.12 76.59 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.721 -1.237 . . . . 0.0 113.935 -176.266 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -80.62 155.53 26.83 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 119.313 1.556 . . . . 0.0 112.309 173.114 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.1 tpt85 -106.07 118.73 37.37 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.681 -1.262 . . . . 0.0 109.034 -174.01 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 59.2 t -91.46 122.63 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.451 -1.405 . . . . 0.0 108.522 -178.24 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -87.08 -45.0 11.12 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.157 0.983 . . . . 0.0 110.287 -177.099 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.45 139.73 21.29 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.885 0.85 . . . . 0.0 110.621 -173.829 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.8 t -118.2 122.41 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 177.845 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 64.11 25.66 13.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.582 -1.323 . . . . 0.0 114.152 172.754 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.03 -5.44 84.49 Favored Glycine 0 N--CA 1.429 -1.787 0 O-C-N 120.191 -1.568 . . . . 0.0 114.102 -175.719 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.5 t -95.41 126.08 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 C-N-CA 125.031 1.332 . . . . 0.0 109.547 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.1 t -76.8 127.57 33.0 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.52 -1.363 . . . . 0.0 110.634 -178.866 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.4 mt -82.82 2.62 33.22 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.28 -1.513 . . . . 0.0 114.227 -175.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -65.07 126.05 26.84 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.105 -2.247 . . . . 0.0 112.668 -178.857 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.65 -8.36 77.78 Favored Glycine 0 N--CA 1.429 -1.79 0 O-C-N 121.013 -1.054 . . . . 0.0 114.839 -175.776 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.09 146.0 46.08 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 177.216 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 24.1 p -92.37 -179.38 5.2 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.041 1.736 . . . . 0.0 111.441 171.227 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-160 -57.08 -52.93 63.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.817 1.647 . . . . 0.0 114.693 -177.881 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.3 tmtp? -56.73 -38.23 72.08 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -58.95 -53.27 60.27 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.886 1.674 . . . . 0.0 115.127 177.767 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.76 -37.26 86.69 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.255 1.422 . . . . 0.0 112.464 178.711 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.22 -51.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.577 1.151 . . . . 0.0 111.047 175.202 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -64.84 -33.53 76.22 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 178.959 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 35.3 m -75.37 -43.2 51.6 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.682 1.593 . . . . 0.0 113.252 179.568 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 27.5 mt -66.2 -42.09 89.29 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.623 -1.298 . . . . 0.0 113.062 173.03 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.9 ptt85 -72.71 -37.41 67.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.898 -1.127 . . . . 0.0 113.869 -176.854 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -85.71 59.78 5.84 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 123.412 1.577 . . . . 0.0 111.5 176.41 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' VAL . 4.9 p -107.61 153.69 22.52 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.545 1.938 . . . . 0.0 108.916 173.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.35 -151.89 21.87 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.846 -1.159 . . . . 0.0 112.624 -174.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -50.73 38.73 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.873 -1.369 . . . . 0.0 113.332 -179.572 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.14 137.09 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.511 1.148 . . . . 0.0 109.177 169.129 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.449 HG22 ' HB ' ' A' ' 88' ' ' THR . 40.3 t -125.3 127.1 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 127.023 2.129 . . . . 0.0 110.293 -166.917 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 18.3 m170 -105.11 114.52 28.77 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.669 -1.27 . . . . 0.0 112.432 172.623 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 9.5 mt -103.26 164.96 11.31 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.087 -1.633 . . . . 0.0 112.261 163.02 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 58.7 tp -127.28 124.63 39.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.65 1.18 . . . . 0.0 107.838 158.407 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.99 162.16 32.84 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.257 -0.902 . . . . 0.0 112.387 175.677 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -117.51 144.69 44.82 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.407 1.883 . . . . 0.0 109.64 175.108 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.431 -1.408 0 C-N-CA 127.458 2.303 . . . . 0.0 113.223 -174.174 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 36.3 t70 . . . . . 0 N--CA 1.431 -1.391 0 N-CA-C 116.007 1.855 . . . . 0.0 116.007 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.7 p -123.11 149.35 44.61 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 121.827 2.103 . . . . 0.0 111.585 168.372 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.3 p90 -147.84 148.87 31.35 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.037 1.399 . . . . 0.0 109.592 171.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -92.88 141.62 28.22 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.334 1.854 . . . . 0.0 109.346 176.938 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.74 90.31 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.63 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.2 84.63 4.47 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.401 -1.437 . . . . 0.0 108.22 177.073 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.9 tp -113.73 145.16 41.77 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.113 1.365 . . . . 0.0 111.424 -162.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.58 122.43 44.37 Favored 'General case' 0 N--CA 1.429 -1.501 0 O-C-N 120.257 -1.527 . . . . 0.0 108.981 171.291 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -71.68 165.99 22.84 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 179.264 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.4 p -134.23 139.95 46.13 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 124.724 1.21 . . . . 0.0 108.53 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.6 t70 66.77 8.55 6.05 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.944 1.698 . . . . 0.0 115.081 174.205 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.99 -8.47 63.2 Favored Glycine 0 N--CA 1.431 -1.69 0 O-C-N 120.097 -1.627 . . . . 0.0 113.762 -176.279 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 66.8 m -119.47 152.06 37.54 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 118.729 1.264 . . . . 0.0 111.814 -172.346 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.6 mt -86.95 -55.24 3.92 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.259 -1.525 . . . . 0.0 111.734 176.397 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 20.05 1.78 Allowed Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.414 -1.428 . . . . 0.0 112.107 177.25 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.6 pt -115.25 150.21 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 124.941 1.296 . . . . 0.0 110.18 -177.358 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 7.7 t -127.82 123.45 35.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 163.356 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.91 163.54 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.544 1.138 . . . . 0.0 111.683 -172.207 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -150.05 173.9 13.34 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.882 1.273 . . . . 0.0 109.409 -175.441 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.86 -136.11 13.2 Favored Glycine 0 N--CA 1.43 -1.761 0 O-C-N 120.872 -1.142 . . . . 0.0 113.761 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.54 167.73 43.47 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.246 0.927 . . . . 0.0 114.41 177.258 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 N--CA 1.43 -1.442 0 N-CA-C 115.548 1.685 . . . . 0.0 115.548 -175.17 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.778 0 CA-C-O 121.924 0.736 . . . . 0.0 114.829 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.8 mm -100.41 125.4 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 C-N-CA 125.2 1.4 . . . . 0.0 107.38 175.18 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.1 m-85 -126.48 153.52 44.99 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.566 -1.334 . . . . 0.0 111.319 -171.562 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.5 t -75.86 122.83 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.861 -1.149 . . . . 0.0 111.987 172.195 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -91.1 -47.17 7.69 Favored 'General case' 0 N--CA 1.429 -1.498 0 C-N-CA 125.639 1.576 . . . . 0.0 110.857 177.419 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.15 165.19 37.12 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.651 -0.656 . . . . 0.0 110.402 -176.702 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -116.13 132.73 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.309 1.043 . . . . 0.0 108.342 175.021 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.5 mm -77.8 121.49 84.25 Favored Pre-proline 0 N--CA 1.429 -1.491 0 C-N-CA 126.137 1.775 . . . . 0.0 114.37 -174.854 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -59.32 123.76 14.1 Favored 'Trans proline' 0 N--CA 1.434 -2.007 0 CA-C-N 124.97 2.811 . . . . 0.0 116.795 -176.104 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.314 59.9 mmtt 68.98 30.9 4.36 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 127.773 2.429 . . . . 0.0 114.534 -176.144 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.02 163.33 39.69 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.31 -1.494 . . . . 0.0 112.8 167.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.36 -58.49 5.57 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.479 1.912 . . . . 0.0 114.593 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.83 -46.94 79.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.775 2.03 . . . . 0.0 112.433 -177.107 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -45.44 -62.32 1.32 Allowed 'General case' 0 N--CA 1.429 -1.506 0 C-N-CA 126.87 2.068 . . . . 0.0 115.842 170.657 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.4 m -69.55 -32.07 70.64 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -176.02 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -56.6 -56.4 21.84 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.16 1.784 . . . . 0.0 113.703 173.92 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.88 25.25 32.63 Favored Glycine 0 N--CA 1.431 -1.698 0 O-C-N 120.602 -1.311 . . . . 0.0 116.232 164.49 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.6 mmt-85 -78.89 -52.48 8.24 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.775 -1.426 . . . . 0.0 107.675 160.723 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 74.9 mt -77.82 122.08 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.1 1.36 . . . . 0.0 110.873 178.282 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.454 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 9.4 t-160 -131.27 -176.47 4.03 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.033 1.397 . . . . 0.0 112.019 174.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 81.4 tttt -69.07 128.32 36.26 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 119.816 -1.803 . . . . 0.0 112.083 -172.295 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.91 1.8 79.26 Favored Glycine 0 N--CA 1.429 -1.772 0 CA-C-O 118.507 -1.163 . . . . 0.0 114.849 -179.408 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.16 158.61 31.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 120.092 1.946 . . . . 0.0 112.057 178.426 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.23 119.59 39.92 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.656 -1.278 . . . . 0.0 110.305 -169.286 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.4 t -85.35 124.8 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 125.985 1.714 . . . . 0.0 110.764 -169.773 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 74.0 mt -106.44 -51.45 2.95 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.319 -1.488 . . . . 0.0 113.888 -173.626 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.16 138.32 20.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.069 -1.644 . . . . 0.0 112.606 -172.042 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.706 HG11 HG21 ' A' ' 84' ' ' THR . 2.2 p -108.77 108.71 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.387 1.475 . . . . 0.0 112.204 -178.877 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.4 t30 58.46 36.94 25.66 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.17 1.788 . . . . 0.0 113.376 168.853 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.95 -9.39 68.09 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 125.829 1.681 . . . . 0.0 115.473 -172.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.4 t -103.0 116.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-N 120.808 2.304 . . . . 0.0 111.085 -174.895 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.3 p -69.07 126.05 28.58 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 120.355 -1.466 . . . . 0.0 113.571 179.852 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.5 mt -87.97 46.94 1.43 Allowed 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.633 -1.292 . . . . 0.0 112.852 -176.421 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -89.46 123.02 33.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.326 -2.109 . . . . 0.0 111.189 -178.448 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.58 1.97 89.36 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 121.058 -1.027 . . . . 0.0 114.798 175.041 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.86 162.9 28.77 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.737 1.754 . . . . 0.0 115.737 -178.288 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 p -83.63 173.72 11.14 Favored 'General case' 0 N--CA 1.431 -1.395 0 O-C-N 120.525 -1.359 . . . . 0.0 111.723 176.906 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-160 -56.43 -53.57 55.91 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.755 1.222 . . . . 0.0 112.798 168.298 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.35 -46.26 89.11 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.744 1.387 . . . . 0.0 114.744 179.259 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.99 -48.24 76.23 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.059 1.344 . . . . 0.0 114.505 -173.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.85 -42.02 96.98 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 124.833 1.253 . . . . 0.0 113.561 174.366 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.7 t -66.27 -48.84 79.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 125.126 1.371 . . . . 0.0 111.121 179.101 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -60.39 -46.32 90.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.736 1.214 . . . . 0.0 112.775 179.062 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . 0.706 HG21 HG11 ' A' ' 68' ' ' VAL . 2.3 m -60.03 -43.99 94.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.372 1.469 . . . . 0.0 113.844 172.62 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 37.2 mt -69.72 -34.36 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.119 -1.613 . . . . 0.0 114.725 178.09 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . 0.271 42.9 ptt85 -71.95 -38.93 69.7 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.035 -1.665 . . . . 0.0 113.19 172.801 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.9 t30 -84.34 48.4 1.49 Allowed 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.787 -1.195 . . . . 0.0 113.722 175.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 p -99.58 150.46 22.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.032 2.133 . . . . 0.0 109.97 174.311 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.79 -163.46 17.29 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.579 1.085 . . . . 0.0 113.34 177.099 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -68.99 -47.63 65.06 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.522 -1.575 . . . . 0.0 113.799 -178.465 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.25 118.74 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 CA-C-O 122.091 0.948 . . . . 0.0 108.721 179.836 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 65.4 t -124.11 119.26 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 126.457 1.903 . . . . 0.0 110.395 -161.283 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -103.32 97.57 7.61 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.076 -1.64 . . . . 0.0 113.845 -178.433 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.39 148.58 21.94 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.703 -1.873 . . . . 0.0 111.342 176.749 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -127.75 127.97 44.53 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 171.849 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . 0.273 0.0 OUTLIER -146.13 169.59 18.41 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.349 -1.469 . . . . 0.0 113.739 -177.07 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.54 131.6 56.88 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.362 1.865 . . . . 0.0 110.493 -173.414 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.485 0 O-C-N 120.304 -1.498 . . . . 0.0 113.467 179.182 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.431 -1.419 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.3 p -94.29 144.52 25.46 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.473 -1.392 . . . . 0.0 112.379 -177.203 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.432 ' CE1' HD21 ' A' ' 96' ' ' LEU . 5.9 p90 -147.29 140.45 25.23 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 122.74 1.257 . . . . 0.0 107.974 177.337 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -99.43 127.05 45.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.367 1.067 . . . . 0.0 109.765 178.017 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.9 t -116.44 93.32 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.717 1.207 . . . . 0.0 108.364 -170.591 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -89.63 103.82 16.43 Favored 'General case' 0 N--CA 1.429 -1.5 0 CA-C-O 123.221 1.486 . . . . 0.0 107.831 168.668 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.7 tp -121.59 144.52 48.69 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.24 1.416 . . . . 0.0 109.047 -165.55 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.41 120.26 40.02 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 124.672 1.189 . . . . 0.0 109.333 172.059 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -69.43 129.01 38.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.202 1.401 . . . . 0.0 112.412 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.9 t -92.7 104.74 16.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.641 1.21 . . . . 0.0 110.737 -172.31 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.4 t70 33.04 60.29 0.43 Allowed 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 129.339 3.056 . . . . 0.0 116.85 -173.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.67 -10.27 74.21 Favored Glycine 0 N--CA 1.43 -1.767 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 178.357 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -111.64 127.11 55.65 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 120.494 2.147 . . . . 0.0 111.519 -179.748 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.0 tp -92.32 -61.49 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.05 -1.031 . . . . 0.0 111.921 -178.844 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.92 -11.8 3.12 Favored Glycine 0 N--CA 1.429 -1.78 0 O-C-N 119.663 -1.898 . . . . 0.0 115.209 170.617 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.0 pt -105.9 141.03 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 119.321 1.561 . . . . 0.0 113.29 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 m -113.23 122.74 48.38 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 159.856 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.72 170.04 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.696 1.236 . . . . 0.0 112.622 -172.933 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 t -152.52 172.35 16.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.755 -1.215 . . . . 0.0 109.602 176.354 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.71 -142.26 15.64 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 113.67 171.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.57 150.7 27.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.56 1.076 . . . . 0.0 112.834 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.9 p . . . . . 0 N--CA 1.429 -1.485 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -174.272 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.429 -1.801 0 CA-C-O 121.259 0.366 . . . . 0.0 113.31 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.486 ' HB ' HG12 ' A' ' 65' ' ' VAL . 25.1 mm -101.69 122.04 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 124.824 1.249 . . . . 0.0 108.412 179.859 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 75.3 m-85 -127.34 152.64 47.21 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.202 -0.936 . . . . 0.0 109.706 -173.552 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -75.82 125.84 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 O-C-N 120.483 -1.386 . . . . 0.0 111.341 171.661 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -98.93 -40.69 7.95 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.634 -1.292 . . . . 0.0 112.316 -179.399 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.61 155.33 40.1 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 121.453 -0.779 . . . . 0.0 111.222 179.699 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.448 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -115.95 124.87 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 CA-C-O 122.465 1.126 . . . . 0.0 111.28 -179.827 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp -76.33 122.97 87.72 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.848 2.059 . . . . 0.0 116.136 -169.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -58.25 112.9 1.32 Allowed 'Trans proline' 0 N--CA 1.434 -1.997 0 C-N-CA 123.767 2.978 . . . . 0.0 117.232 -175.588 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.305 48.5 mtmt 79.06 32.27 0.27 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.875 2.87 . . . . 0.0 113.8 -178.124 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.8 159.99 35.08 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 121.418 -0.801 . . . . 0.0 112.026 167.234 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.45 -60.39 2.88 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.519 1.528 . . . . 0.0 114.426 169.46 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.75 99.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 127.396 2.278 . . . . 0.0 112.677 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.448 ' CG ' HG23 ' A' ' 47' ' ' ILE . 2.8 tm-20 -51.49 -65.36 0.57 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 125.771 1.628 . . . . 0.0 114.626 174.678 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.0 t -69.15 -23.22 63.93 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -174.345 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -51.5 -63.94 0.97 Allowed 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.079 1.752 . . . . 0.0 113.019 172.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.24 -12.64 28.66 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 121.288 -0.883 . . . . 0.0 114.647 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 -64.22 -56.02 17.58 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 124.409 1.084 . . . . 0.0 111.002 168.614 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.8 mt -78.55 128.73 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 124.957 1.303 . . . . 0.0 110.839 179.074 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -145.7 171.11 15.21 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.132 -0.98 . . . . 0.0 110.113 177.862 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . 0.264 0.0 OUTLIER -64.45 139.67 58.79 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 119.398 -2.064 . . . . 0.0 113.829 179.445 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.78 -7.8 67.99 Favored Glycine 0 N--CA 1.43 -1.709 0 CA-C-O 118.509 -1.162 . . . . 0.0 114.278 -172.67 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.487 ' HB3' HD23 ' A' ' 96' ' ' LEU . 97.7 m-20 -80.75 138.65 36.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 119.8 1.8 . . . . 0.0 113.363 -176.269 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -98.2 133.43 42.63 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.57 -1.331 . . . . 0.0 111.668 -174.408 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.486 HG12 ' HB ' ' A' ' 42' ' ' ILE . 0.4 OUTLIER -82.89 148.73 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.494 -1.379 . . . . 0.0 112.942 -179.384 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -109.39 -51.37 2.88 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.752 1.221 . . . . 0.0 109.689 171.028 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 143.77 25.24 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.801 -1.187 . . . . 0.0 110.925 -175.35 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 58.8 t -117.6 129.09 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.39 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 77.18 -30.46 0.17 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.407 2.683 . . . . 0.0 113.983 173.236 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.09 -17.11 1.54 Allowed Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 126.316 1.913 . . . . 0.0 109.265 -169.937 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.72 116.53 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 125.379 1.472 . . . . 0.0 109.275 -176.196 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.3 m -71.12 127.42 32.53 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.807 -1.183 . . . . 0.0 111.104 176.991 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 22.9 mt -93.88 43.02 1.1 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.027 -1.046 . . . . 0.0 112.699 -171.057 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -75.79 119.93 20.46 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.19 -2.194 . . . . 0.0 112.21 -178.344 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.23 13.2 82.26 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.117 -1.615 . . . . 0.0 115.306 -178.33 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.94 151.42 44.69 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -82.09 172.83 12.76 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.207 1.003 . . . . 0.0 111.148 176.345 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -61.08 -50.0 75.05 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.909 1.284 . . . . 0.0 113.118 175.057 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.3 -42.01 80.93 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 171.695 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -55.36 -48.78 73.72 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 114.499 1.296 . . . . 0.0 114.499 -175.428 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.96 98.38 Favored 'General case' 0 N--CA 1.431 -1.4 0 C-N-CA 125.126 1.37 . . . . 0.0 113.855 177.2 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.1 -49.87 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 C-N-CA 125.112 1.365 . . . . 0.0 110.451 177.609 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -64.26 -32.26 73.78 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.692 -1.255 . . . . 0.0 113.96 179.632 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 53.0 m -67.65 -46.48 72.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.61 1.964 . . . . 0.0 112.236 173.501 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 70.1 mt -64.02 -38.94 92.89 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.98 -1.075 . . . . 0.0 113.727 173.531 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.12 -45.22 83.67 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.967 1.707 . . . . 0.0 112.444 175.39 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -85.39 44.58 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.265 1.426 . . . . 0.0 113.224 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.3 p -106.81 160.27 15.61 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.075 -1.641 . . . . 0.0 108.739 170.02 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.82 -131.05 4.79 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.474 1.035 . . . . 0.0 110.856 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -69.77 -69.01 0.37 Allowed 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 114.729 1.381 . . . . 0.0 114.729 178.029 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 52.8 t -92.25 124.65 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 CA-C-O 122.853 1.311 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.8 t -124.15 120.82 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 127.574 2.349 . . . . 0.0 109.272 -169.622 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -100.46 113.02 25.46 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.796 -1.815 . . . . 0.0 112.212 173.683 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -97.57 149.32 22.34 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.747 -1.845 . . . . 0.0 111.672 163.336 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.9 124.64 48.77 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 161.773 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.487 HD23 ' HB3' ' A' ' 63' ' ' ASP . 0.0 OUTLIER -150.28 168.46 23.98 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.874 -1.141 . . . . 0.0 113.149 -178.423 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -119.34 144.96 46.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.478 1.511 . . . . 0.0 111.503 -177.905 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.6 tppt? . . . . . 0 N--CA 1.43 -1.459 0 C-N-CA 125.487 1.515 . . . . 0.0 112.755 -179.687 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 t0 . . . . . 0 N--CA 1.43 -1.431 0 CA-C-O 121.296 0.569 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.0 p -102.55 157.57 16.84 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.339 1.055 . . . . 0.0 110.972 -178.857 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -146.16 124.35 12.2 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.713 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -88.94 108.6 19.65 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 122.69 1.233 . . . . 0.0 109.287 162.77 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.2 t -99.06 108.9 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 128.287 2.635 . . . . 0.0 109.303 -168.766 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.4 101.14 13.82 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.845 -1.159 . . . . 0.0 109.737 173.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -108.64 158.06 17.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.872 1.32 . . . . 0.0 108.849 172.979 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.41 145.84 29.38 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 104.406 -2.442 . . . . 0.0 104.406 152.609 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -70.03 146.82 50.75 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.899 -1.126 . . . . 0.0 112.501 171.384 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.7 p -106.07 94.72 5.32 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.47 1.129 . . . . 0.0 108.876 178.683 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.0 t0 54.75 60.07 3.72 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.339 1.856 . . . . 0.0 114.023 -178.998 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.63 -34.66 3.64 Favored Glycine 0 N--CA 1.43 -1.739 0 O-C-N 120.701 -1.25 . . . . 0.0 115.693 -176.865 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -94.19 145.63 24.57 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.191 -1.182 . . . . 0.0 113.435 -167.513 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.04 -18.49 13.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.986 -1.071 . . . . 0.0 111.714 176.648 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.63 4.73 54.57 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.483 -2.011 . . . . 0.0 114.756 175.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.4 pt -120.06 133.02 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 124.862 1.265 . . . . 0.0 111.293 -171.87 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -113.51 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 126.194 1.798 . . . . 0.0 107.165 168.639 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.69 162.7 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.467 1.127 . . . . 0.0 113.777 -169.014 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.2 t -144.1 178.48 7.84 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.562 1.545 . . . . 0.0 110.055 176.424 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.46 -143.22 16.6 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.979 1.276 . . . . 0.0 113.85 171.487 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.46 158.97 19.31 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 124.488 1.042 . . . . 0.0 113.028 -177.638 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m . . . . . 0 N--CA 1.43 -1.44 0 N-CA-C 116.353 1.983 . . . . 0.0 116.353 -171.744 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.747 0 N-CA-C 115.093 0.797 . . . . 0.0 115.093 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.6 mm -94.67 129.22 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.034 -1.862 . . . . 0.0 107.721 174.387 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.37 157.19 40.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.314 -1.491 . . . . 0.0 109.165 -176.223 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.6 130.27 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 O-C-N 121.179 -0.95 . . . . 0.0 111.066 171.202 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -99.66 -59.82 1.65 Allowed 'General case' 0 N--CA 1.431 -1.392 0 O-C-N 120.313 -1.492 . . . . 0.0 111.398 177.564 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.17 153.69 47.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 -174.947 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.428 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -108.43 122.78 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.383 1.087 . . . . 0.0 108.917 178.364 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.4 117.92 67.81 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 116.244 -1.836 . . . . 0.0 112.596 -173.23 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -64.72 124.47 13.23 Favored 'Trans proline' 0 N--CA 1.433 -2.043 0 C-N-CA 123.577 2.851 . . . . 0.0 114.131 -171.726 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.262 91.7 mttt 70.15 37.47 1.66 Allowed 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.379 2.672 . . . . 0.0 112.473 -170.989 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.54 164.54 36.27 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.018 -1.051 . . . . 0.0 113.073 163.726 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.83 -63.02 1.21 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.523 1.529 . . . . 0.0 114.68 170.415 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.82 -48.5 76.57 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 127.69 2.396 . . . . 0.0 113.738 178.543 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.428 ' HG2' HG23 ' A' ' 47' ' ' ILE . 9.6 tm-20 -43.7 -55.07 4.62 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.975 1.842 . . . . 0.0 115.975 -177.695 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.8 t -67.55 -28.01 67.43 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 114.472 -1.24 . . . . 0.0 113.785 -174.272 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -73.45 -65.54 0.8 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.499 1.12 . . . . 0.0 111.559 -178.808 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.18 10.19 34.8 Favored Glycine 0 N--CA 1.43 -1.755 0 N-CA-C 116.527 1.371 . . . . 0.0 116.527 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 67.2 mtt85 -64.3 -36.2 83.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.945 1.372 . . . . 0.0 111.022 162.265 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.6 mt -94.78 129.45 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.336 1.454 . . . . 0.0 108.82 177.326 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.0 170.07 16.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.81 1.767 . . . . 0.0 110.685 176.737 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 51.2 mtpt -61.6 123.88 19.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.605 1.562 . . . . 0.0 112.001 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 0.3 62.74 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 120.303 -1.498 . . . . 0.0 115.26 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -74.0 157.11 36.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.175 1.487 . . . . 0.0 112.339 178.089 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.5 ttt180 -88.14 125.81 34.8 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.248 1.419 . . . . 0.0 111.101 178.128 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 50.0 t -91.6 128.72 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 124.223 1.009 . . . . 0.0 109.13 178.681 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -105.41 -57.4 2.04 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.684 -1.26 . . . . 0.0 111.305 -179.305 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.95 138.0 20.32 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.857 -1.152 . . . . 0.0 111.663 -170.825 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.8 t -107.45 107.43 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.417 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 27.1 t30 57.73 52.07 8.59 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.785 1.634 . . . . 0.0 114.311 167.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.43 -29.4 10.33 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.95 1.262 . . . . 0.0 114.095 -176.541 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.7 118.18 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-N 118.805 1.303 . . . . 0.0 111.235 -170.443 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 57.7 m -69.76 131.67 44.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.493 -1.38 . . . . 0.0 112.413 176.196 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 25.7 mt -93.36 -6.03 48.18 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 121.026 -1.046 . . . . 0.0 112.433 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -55.22 127.52 29.68 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.576 1.55 . . . . 0.0 114.831 -179.084 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.67 -10.82 70.61 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 115.888 1.115 . . . . 0.0 115.888 -178.005 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . 0.411 ' HB1' ' HB2' ' A' ' 80' ' ' GLN . . . -72.5 178.39 4.07 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 116.989 2.218 . . . . 0.0 116.989 -177.556 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 47.1 p -92.19 171.22 9.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.282 -1.511 . . . . 0.0 110.835 165.678 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -54.2 -42.07 69.33 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.261 1.824 . . . . 0.0 112.883 168.594 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 43.5 tptt -57.54 -42.4 82.87 Favored 'General case' 0 N--CA 1.429 -1.506 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.411 ' HB2' ' HB1' ' A' ' 76' ' ' ALA . 4.3 mp0 -58.93 -49.43 77.87 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.537 -1.352 . . . . 0.0 114.102 175.109 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.43 -44.29 84.53 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.441 1.497 . . . . 0.0 114.052 174.276 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.01 -45.54 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 124.987 1.315 . . . . 0.0 111.886 177.278 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 -64.43 -37.71 88.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 123.811 0.844 . . . . 0.0 112.586 176.602 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.8 m -63.4 -45.6 90.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.788 2.035 . . . . 0.0 113.018 174.204 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.7 mt -69.21 -21.64 63.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.031 -1.668 . . . . 0.0 114.269 174.193 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -72.15 -53.34 13.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.228 -1.545 . . . . 0.0 111.328 168.684 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -92.68 43.37 1.12 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.946 1.698 . . . . 0.0 112.842 -174.409 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . 0.287 6.2 t -106.39 160.01 15.71 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.48 -1.387 . . . . 0.0 110.905 173.164 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.75 -164.8 38.79 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.929 1.252 . . . . 0.0 113.317 -166.052 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -69.8 -49.84 48.86 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.732 -1.452 . . . . 0.0 112.66 174.095 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 59.0 t -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.907 0.86 . . . . 0.0 108.78 179.611 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -123.97 120.39 59.43 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.568 1.547 . . . . 0.0 109.725 -163.065 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 11.8 t-160 -104.82 95.48 5.9 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.633 -1.292 . . . . 0.0 112.435 -175.867 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 27.1 mt -89.99 134.58 34.15 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.762 -1.836 . . . . 0.0 113.397 -176.922 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 66.1 tp -104.89 123.0 46.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.613 -1.304 . . . . 0.0 109.114 167.748 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.37 163.9 30.69 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.47 -0.769 . . . . 0.0 111.54 175.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -127.38 140.07 52.43 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.642 1.577 . . . . 0.0 109.629 -178.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.476 0 O-C-N 120.762 -1.211 . . . . 0.0 114.033 -170.344 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.7 t0 . . . . . 0 N--CA 1.431 -1.421 0 CA-C-O 120.567 0.222 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -114.58 148.09 38.54 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.654 -1.278 . . . . 0.0 111.22 -176.479 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.69 149.39 32.36 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-O 121.982 0.896 . . . . 0.0 108.963 178.664 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -90.82 145.11 25.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.409 -0.807 . . . . 0.0 109.249 160.811 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.0 t -120.53 94.44 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.086 1.354 . . . . 0.0 107.613 -178.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 -90.47 95.66 10.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.929 1.347 . . . . 0.0 107.92 171.669 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 29.2 tp -123.99 138.36 54.47 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 125.315 1.446 . . . . 0.0 110.594 -164.136 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.62 138.59 39.33 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.699 -1.251 . . . . 0.0 108.658 173.857 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -69.48 145.55 52.63 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.22 1.563 . . . . 0.0 115.22 -178.283 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.6 p -100.09 102.21 13.48 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.962 -1.086 . . . . 0.0 109.157 176.192 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.5 t0 55.8 38.46 30.09 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.551 1.54 . . . . 0.0 114.166 179.314 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.48 -20.51 47.86 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.471 -1.393 . . . . 0.0 114.944 -176.699 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -93.56 137.95 32.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.7 -1.47 . . . . 0.0 112.248 -173.182 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.3 mt -87.58 -60.66 1.91 Allowed 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.249 -0.907 . . . . 0.0 110.306 172.21 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.6 8.93 2.69 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.365 -1.46 . . . . 0.0 113.158 175.29 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 pt -123.59 142.53 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-N 119.325 1.563 . . . . 0.0 112.052 -176.177 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.3 t -116.67 139.17 50.84 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 155.486 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.87 169.46 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 124.828 1.251 . . . . 0.0 112.293 -174.321 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -150.3 -179.22 7.02 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 126.053 1.741 . . . . 0.0 109.0 -177.999 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.65 -144.36 17.17 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.611 -1.306 . . . . 0.0 112.301 177.174 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 108.23 150.35 15.08 Favored Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 124.728 1.156 . . . . 0.0 112.937 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -174.805 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.737 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.99 136.61 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.899 1.28 . . . . 0.0 108.408 178.46 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -133.89 157.45 45.93 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 121.246 -0.908 . . . . 0.0 108.869 -175.313 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.1 t -76.48 129.73 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 119.872 -1.767 . . . . 0.0 112.338 175.504 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -93.91 -48.88 6.07 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.375 -1.453 . . . . 0.0 112.542 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.92 152.93 32.03 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 123.111 0.565 . . . . 0.0 110.572 -174.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -103.43 120.55 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 CA-C-O 122.841 1.305 . . . . 0.0 110.243 174.09 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.81 127.85 83.03 Favored Pre-proline 0 N--CA 1.431 -1.402 0 C-N-CA 126.331 1.852 . . . . 0.0 113.604 -172.002 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -55.73 126.3 21.97 Favored 'Trans proline' 0 N--CA 1.433 -2.042 0 C-N-CA 122.916 2.411 . . . . 0.0 117.034 -177.869 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? 77.22 13.58 2.01 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 128.864 2.866 . . . . 0.0 114.166 176.143 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.48 161.42 51.55 Favored Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.618 -1.301 . . . . 0.0 114.805 179.073 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.21 -57.67 6.34 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 126.843 2.057 . . . . 0.0 114.808 171.505 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.55 -48.53 77.09 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 128.399 2.68 . . . . 0.0 112.233 179.54 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -41.97 -63.07 0.79 Allowed 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 126.836 2.055 . . . . 0.0 114.386 173.497 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.7 m -70.22 -35.05 73.6 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.029 1.492 . . . . 0.0 115.029 -172.044 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -56.43 -68.66 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.238 1.815 . . . . 0.0 113.213 176.536 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.73 6.17 23.34 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 168.575 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -65.94 -49.52 67.64 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 119.09 1.445 . . . . 0.0 110.461 165.046 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.85 134.01 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.506 0 C-N-CA 125.58 1.552 . . . . 0.0 110.032 177.911 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 -145.61 142.36 29.03 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.409 1.084 . . . . 0.0 109.889 -174.862 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -43.74 116.02 0.9 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.231 1.812 . . . . 0.0 115.739 -178.883 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 103.99 -2.95 44.53 Favored Glycine 0 N--CA 1.428 -1.834 0 O-C-N 120.652 -1.28 . . . . 0.0 115.946 179.731 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.276 1.4 p30 -76.95 175.26 9.71 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 120.099 1.949 . . . . 0.0 115.549 -175.166 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -101.94 121.32 41.91 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.677 -1.264 . . . . 0.0 112.564 -175.395 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.12 114.75 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 123.868 0.867 . . . . 0.0 110.288 179.125 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 mp -93.75 -43.93 8.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.321 -1.487 . . . . 0.0 111.17 -176.585 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.6 142.34 24.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.864 -1.147 . . . . 0.0 111.625 -175.256 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.5 t -118.12 117.67 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 124.02 0.928 . . . . 0.0 109.01 175.763 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.3 37.31 14.07 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.985 2.114 . . . . 0.0 113.072 170.515 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.81 -33.23 6.67 Favored Glycine 0 N--CA 1.43 -1.75 0 C-N-CA 124.852 1.215 . . . . 0.0 113.444 -174.73 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -91.58 119.67 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 C-N-CA 124.974 1.309 . . . . 0.0 112.501 -165.292 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.9 m -65.81 130.3 42.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.881 -1.137 . . . . 0.0 112.88 177.796 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 44.2 mt -90.11 62.05 5.39 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.526 -1.359 . . . . 0.0 112.46 -174.892 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -90.09 136.09 33.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.642 -1.286 . . . . 0.0 111.71 174.365 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 71.32 11.47 71.5 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 121.024 -1.047 . . . . 0.0 115.454 175.366 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.0 143.03 49.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -176.236 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 48.1 p -82.35 173.64 11.86 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.995 -1.066 . . . . 0.0 111.118 167.443 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -62.26 -41.65 98.64 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.724 -1.235 . . . . 0.0 112.754 174.496 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -58.74 -47.01 86.08 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 126.069 1.748 . . . . 0.0 114.2 170.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -56.07 -47.82 77.24 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 126.524 1.93 . . . . 0.0 114.335 -176.447 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -56.83 -39.73 74.77 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.222 1.809 . . . . 0.0 115.025 173.192 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 79.1 t -69.01 -53.38 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 124.941 1.296 . . . . 0.0 110.862 177.947 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -59.95 -44.18 94.55 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 114.757 1.391 . . . . 0.0 114.757 -176.815 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.7 m -57.67 -40.9 80.44 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.013 2.525 . . . . 0.0 114.545 170.656 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 28.3 mt -68.77 -42.34 77.59 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 119.652 -1.905 . . . . 0.0 113.805 170.956 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 85.8 mmt-85 -60.7 -39.24 87.78 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.698 -1.251 . . . . 0.0 113.501 178.652 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -85.93 48.49 1.61 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.479 -1.388 . . . . 0.0 113.156 178.873 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.435 ' HB ' HG22 ' A' ' 92' ' ' VAL . 21.9 p -106.86 158.03 17.31 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.281 1.832 . . . . 0.0 109.657 173.293 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -98.75 -141.1 11.9 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 121.12 -0.988 . . . . 0.0 112.821 -176.383 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -69.09 -65.26 0.73 Allowed 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 121.058 -1.26 . . . . 0.0 113.251 175.727 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.2 p -98.66 133.66 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 123.14 1.448 . . . . 0.0 110.173 176.523 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.435 HG22 ' HB ' ' A' ' 88' ' ' THR . 99.0 t -124.62 128.78 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 128.297 2.639 . . . . 0.0 108.745 -162.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -108.9 93.93 4.78 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.752 -1.218 . . . . 0.0 112.578 -176.537 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 mt -95.27 162.14 13.81 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 119.538 -1.976 . . . . 0.0 112.411 178.002 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.9 tt -130.27 133.04 46.2 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.825 -1.172 . . . . 0.0 110.641 165.917 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.04 162.56 35.18 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 113.609 0.966 . . . . 0.0 113.609 178.527 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -113.54 138.58 49.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 125.712 1.605 . . . . 0.0 107.647 172.249 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.2 tppp? . . . . . 0 N--CA 1.429 -1.495 0 CA-C-O 122.216 1.007 . . . . 0.0 111.214 -173.209 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t70 . . . . . 0 N--CA 1.43 -1.439 0 N-CA-C 113.695 0.998 . . . . 0.0 113.695 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.0 p -125.98 155.42 41.42 Favored 'General case' 0 N--CA 1.431 -1.384 0 O-C-N 120.126 -1.609 . . . . 0.0 113.011 -179.107 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.475 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 12.4 p90 -145.52 142.42 29.19 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 122.943 1.354 . . . . 0.0 109.182 170.324 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -95.45 126.59 40.85 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.413 1.485 . . . . 0.0 107.955 171.22 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.3 t -118.49 117.77 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.295 1.038 . . . . 0.0 108.488 -174.722 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -100.79 88.08 3.49 Favored 'General case' 0 N--CA 1.432 -1.369 0 O-C-N 120.62 -1.3 . . . . 0.0 108.703 168.976 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 63.2 tp -95.7 137.69 34.4 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.593 1.157 . . . . 0.0 110.214 -174.226 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.32 128.95 47.25 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.185 -1.572 . . . . 0.0 108.566 172.012 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -70.42 136.43 49.55 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 121.344 -0.848 . . . . 0.0 113.123 178.416 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.0 p -107.2 121.03 43.71 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 174.376 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.9 t70 55.17 49.0 18.27 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.982 1.713 . . . . 0.0 113.753 -176.019 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.21 -9.64 6.94 Favored Glycine 0 N--CA 1.429 -1.789 0 N-CA-C 117.739 1.856 . . . . 0.0 117.739 174.315 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -121.43 156.18 33.27 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 119.207 1.503 . . . . 0.0 111.131 -168.531 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 16.4 mt -93.91 -60.4 1.76 Allowed 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.54 1.136 . . . . 0.0 110.925 -177.268 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.03 38.78 0.48 Allowed Glycine 0 N--CA 1.431 -1.657 0 O-C-N 119.373 -2.079 . . . . 0.0 110.54 174.588 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.3 pt -128.93 141.12 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 CA-C-O 121.871 0.843 . . . . 0.0 112.146 -163.208 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 29.7 t -117.77 117.36 29.1 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 166.33 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.47 160.64 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 124.529 1.132 . . . . 0.0 111.158 179.398 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.0 t -150.61 155.63 39.77 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.121 -0.987 . . . . 0.0 111.621 -178.527 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 124.03 -130.13 7.48 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 121.129 -0.982 . . . . 0.0 113.219 168.8 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 124.01 -148.81 16.83 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.182 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.6 t . . . . . 0 N--CA 1.429 -1.496 0 CA-C-O 123.451 1.596 . . . . 0.0 107.332 171.418 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.759 0 N-CA-C 113.887 0.315 . . . . 0.0 113.887 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.7 mm -95.99 119.76 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 C-N-CA 125.851 1.66 . . . . 0.0 107.526 171.476 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -123.06 154.4 38.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.145 -0.972 . . . . 0.0 110.303 -174.528 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.6 t -76.8 119.38 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 124.387 1.075 . . . . 0.0 110.555 169.919 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -88.5 -46.83 8.79 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 124.858 1.263 . . . . 0.0 110.38 -176.471 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.75 161.39 37.01 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 123.316 0.647 . . . . 0.0 110.37 177.599 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.53 127.08 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.469 1.107 . . . . 0.0 110.303 176.329 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.1 mp -77.43 122.28 85.75 Favored Pre-proline 0 N--CA 1.43 -1.47 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -169.971 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_exo -55.29 122.13 11.16 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 C-N-CA 123.551 2.834 . . . . 0.0 116.6 179.952 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 17.6 mmtt 80.89 18.82 0.49 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 129.253 3.021 . . . . 0.0 113.488 -177.682 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.76 156.8 33.46 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.127 -1.608 . . . . 0.0 111.942 172.877 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.61 -56.28 7.53 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 125.949 1.699 . . . . 0.0 114.468 171.293 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.31 -51.14 67.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 128.308 2.643 . . . . 0.0 112.832 178.059 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.9 tm-20 -44.92 -59.65 2.46 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 172.441 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.3 t -68.1 -30.36 69.51 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.832 1.253 . . . . 0.0 113.436 -174.078 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -61.36 -55.61 29.62 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.857 1.263 . . . . 0.0 113.869 -177.141 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.59 1.43 29.18 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.516 1.367 . . . . 0.0 116.516 162.108 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.2 mmp_? -74.67 -54.6 7.09 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.5 -1.588 . . . . 0.0 110.367 164.475 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mt -78.25 128.04 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.339 1.456 . . . . 0.0 112.648 -173.607 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.01 172.64 12.71 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-O 124.14 1.924 . . . . 0.0 112.629 177.298 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -56.14 124.04 16.51 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.031 1.732 . . . . 0.0 113.822 172.136 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.88 4.2 61.79 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 113.903 178.759 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -79.11 162.31 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 119.054 1.427 . . . . 0.0 111.794 174.406 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -120.57 123.46 42.92 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.233 -1.542 . . . . 0.0 111.02 -172.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.6 t -83.06 125.48 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 O-C-N 120.278 -1.514 . . . . 0.0 111.83 -171.872 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 80.5 mt -103.3 -44.57 5.13 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.743 -1.223 . . . . 0.0 112.324 -177.005 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.4 ' HB3' ' HB3' ' A' ' 95' ' ' LEU . . . -149.97 140.9 22.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.504 -1.373 . . . . 0.0 112.329 -177.874 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -112.75 115.49 49.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 174.72 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 57.86 41.97 23.92 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.641 1.976 . . . . 0.0 114.993 170.606 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.45 -25.62 26.42 Favored Glycine 0 N--CA 1.431 -1.655 0 O-C-N 120.964 -1.085 . . . . 0.0 113.563 -177.008 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 t -94.06 112.25 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.926 -1.338 . . . . 0.0 110.412 -172.947 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . 0.25 81.1 p -76.36 140.66 41.51 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.212 -1.555 . . . . 0.0 112.998 176.851 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.0 mt -85.44 41.68 0.91 Allowed 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.426 1.09 . . . . 0.0 112.29 -168.9 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -72.72 121.53 19.99 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.101 -1.624 . . . . 0.0 112.047 -178.413 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 70.37 11.58 68.17 Favored Glycine 0 N--CA 1.429 -1.821 0 C-N-CA 125.191 1.377 . . . . 0.0 115.764 179.374 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.94 143.57 47.62 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -178.138 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.1 p -91.82 178.81 5.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.644 1.578 . . . . 0.0 111.728 174.34 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 30.8 t-80 -57.3 -52.73 64.16 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 115.873 1.805 . . . . 0.0 115.873 -169.6 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.6 -40.66 79.57 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 178.124 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.4 mp0 -56.92 -51.33 69.54 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.792 2.037 . . . . 0.0 113.209 -172.229 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.49 -39.09 79.06 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.556 1.942 . . . . 0.0 113.823 175.453 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 87.7 t -67.55 -53.04 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.044 1.337 . . . . 0.0 110.727 177.467 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -61.69 -38.69 88.76 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 121.009 -1.057 . . . . 0.0 113.78 -178.609 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.5 m -66.53 -40.42 89.11 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 127.032 2.133 . . . . 0.0 112.682 177.213 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.49 -42.24 87.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.431 -1.418 . . . . 0.0 113.231 171.139 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -68.2 -42.76 79.39 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.523 -1.361 . . . . 0.0 114.605 179.846 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 38.9 t-20 -86.32 57.2 4.35 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 123.036 1.398 . . . . 0.0 111.712 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -98.12 163.59 12.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.017 2.527 . . . . 0.0 109.617 175.115 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.46 -160.11 33.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.422 1.011 . . . . 0.0 110.923 168.931 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 60.1 tt0 -68.74 -52.07 34.53 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.75 -1.441 . . . . 0.0 112.998 -174.234 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.81 119.9 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 C-N-CA 124.894 1.278 . . . . 0.0 109.63 177.008 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 84.5 t -112.18 110.26 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 128.066 2.547 . . . . 0.0 110.153 -167.216 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.1 t-160 -92.8 96.7 10.3 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.7 -1.25 . . . . 0.0 112.779 -178.205 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.3 mt -89.11 156.71 18.65 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.217 -2.177 . . . . 0.0 112.677 175.773 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . 0.4 ' HB3' ' HB3' ' A' ' 67' ' ' ALA . 57.9 tp -127.01 129.41 48.02 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 157.611 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.475 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 3.0 pp -150.86 167.34 27.8 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.715 -1.24 . . . . 0.0 111.745 177.784 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -108.89 123.16 48.63 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.17 1.388 . . . . 0.0 110.345 -173.541 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.1 tptm . . . . . 0 N--CA 1.429 -1.484 0 C-N-CA 125.365 1.466 . . . . 0.0 111.37 -178.681 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.3 t70 . . . . . 0 N--CA 1.429 -1.49 0 CA-C-O 121.306 0.574 . . . . 0.0 109.986 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -96.96 149.24 22.13 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.689 -1.257 . . . . 0.0 111.256 177.102 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -147.8 143.52 27.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 122.923 1.344 . . . . 0.0 109.186 -179.087 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.6 mp0 -102.53 129.53 49.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.536 1.934 . . . . 0.0 108.12 179.12 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.7 t -125.0 97.69 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.825 -1.172 . . . . 0.0 109.753 -170.429 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -97.81 77.24 2.5 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 119.938 -1.726 . . . . 0.0 108.899 173.906 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.4 130.47 52.75 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 125.372 1.469 . . . . 0.0 109.992 -170.159 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.7 154.79 17.04 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 127.074 2.15 . . . . 0.0 112.336 176.656 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -69.12 152.03 45.66 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -175.484 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.2 p -98.77 100.48 11.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.855 -1.153 . . . . 0.0 108.689 171.114 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.3 t0 52.41 52.99 13.08 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.636 1.574 . . . . 0.0 113.798 176.19 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.14 -27.32 10.48 Favored Glycine 0 N--CA 1.429 -1.779 0 O-C-N 120.859 -1.151 . . . . 0.0 115.71 -176.122 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.0 m -98.47 128.18 44.72 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-N 119.64 1.72 . . . . 0.0 113.106 -169.849 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.6 tp -84.63 -56.3 3.67 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.487 -1.383 . . . . 0.0 109.537 175.717 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.93 28.76 0.85 Allowed Glycine 0 N--CA 1.43 -1.764 0 C-N-CA 125.205 1.383 . . . . 0.0 113.249 168.091 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.1 tt -147.19 143.94 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 CA-C-N 119.619 1.709 . . . . 0.0 112.645 -166.26 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.6 t -123.76 138.21 54.55 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.041 1.336 . . . . 0.0 108.889 165.106 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 m -113.74 163.28 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 126.153 1.781 . . . . 0.0 112.313 -177.308 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -145.35 178.15 8.31 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 126.917 2.087 . . . . 0.0 109.556 -179.255 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.97 -145.19 16.22 Favored Glycine 0 N--CA 1.431 -1.669 0 O-C-N 120.562 -1.336 . . . . 0.0 114.65 173.978 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.09 156.51 31.33 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 125.539 1.542 . . . . 0.0 114.622 176.156 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.429 -1.487 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -178.586 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.679 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.9 mm -102.91 125.18 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 124.932 1.293 . . . . 0.0 108.255 179.884 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -128.42 155.33 44.93 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.928 -1.107 . . . . 0.0 111.341 -170.724 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.41 125.83 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.358 -1.464 . . . . 0.0 111.8 173.452 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.6 ttmt -89.02 -55.6 3.62 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.005 1.322 . . . . 0.0 110.115 177.203 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.73 150.09 30.61 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 121.502 -0.749 . . . . 0.0 110.607 -171.017 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.415 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -106.89 123.66 62.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.406 1.098 . . . . 0.0 108.306 172.373 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.3 mm -77.49 121.92 85.15 Favored Pre-proline 0 CA--C 1.489 -1.395 0 CA-C-O 115.755 -2.069 . . . . 0.0 114.346 -172.143 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -57.55 115.01 2.2 Favored 'Trans proline' 0 C--N 1.3 -1.996 0 C-N-CA 123.866 3.044 . . . . 0.0 117.151 -174.153 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.382 26.7 mtpp 71.07 41.81 0.78 Allowed 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.157 2.583 . . . . 0.0 114.913 -172.813 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.9 168.21 42.99 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.167 -1.583 . . . . 0.0 112.177 153.294 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.14 -60.02 3.55 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.23 1.812 . . . . 0.0 114.844 165.576 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.83 -42.71 97.56 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.31 2.244 . . . . 0.0 112.904 -178.026 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.415 ' CG ' HG23 ' A' ' 47' ' ' ILE . 4.8 tm-20 -47.91 -61.98 1.69 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.833 1.79 . . . . 0.0 115.833 171.376 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.5 t -68.03 -31.25 70.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.759 1.224 . . . . 0.0 112.515 -173.168 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -64.41 -65.94 0.61 Allowed 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.889 -1.132 . . . . 0.0 111.201 171.548 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 20.6 33.56 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 119.228 -2.17 . . . . 0.0 114.421 162.582 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -63.01 -44.37 96.19 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 121.341 -1.093 . . . . 0.0 109.866 157.442 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 52.0 mt -92.57 131.81 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.233 1.813 . . . . 0.0 110.495 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . 0.638 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 6.9 t-80 -145.24 -169.99 3.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-O 123.172 1.463 . . . . 0.0 112.727 167.828 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.638 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 40.4 ttpt -61.99 122.83 16.45 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 126.217 1.807 . . . . 0.0 113.378 -176.551 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 101.83 -4.74 53.32 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.384 -0.823 . . . . 0.0 114.073 179.725 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -74.66 161.61 29.51 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 118.925 1.363 . . . . 0.0 112.868 -177.28 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -122.09 121.3 36.63 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.771 -1.205 . . . . 0.0 111.047 -165.194 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 8.4 t -89.35 125.73 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 120.78 -1.2 . . . . 0.0 111.772 -169.103 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -102.27 -44.57 5.37 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.113 -0.992 . . . . 0.0 111.466 -177.231 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 139.36 21.21 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.681 -1.262 . . . . 0.0 111.67 -178.079 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.7 t -114.34 117.96 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.214 1.006 . . . . 0.0 109.877 177.729 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.3 t30 62.18 29.05 17.41 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 128.274 2.63 . . . . 0.0 114.24 168.808 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.01 -17.99 40.53 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.422 1.487 . . . . 0.0 113.58 -177.386 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.3 t -101.78 123.78 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 O-C-N 120.854 -1.38 . . . . 0.0 110.401 -172.97 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 m -71.27 138.15 49.16 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.105 -1.622 . . . . 0.0 112.825 179.457 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.2 mt -88.41 62.54 6.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.286 -1.509 . . . . 0.0 111.067 179.194 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -89.62 118.12 29.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.35 -1.469 . . . . 0.0 112.039 -178.18 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.34 6.72 70.65 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 125.121 1.343 . . . . 0.0 115.239 177.808 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 150.62 44.4 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 116.157 1.91 . . . . 0.0 116.157 -172.557 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 55.9 p -88.77 174.15 8.16 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.556 1.942 . . . . 0.0 111.235 175.968 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 -58.84 -48.58 80.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.646 -1.284 . . . . 0.0 113.238 177.319 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -53.55 -46.93 70.41 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.691 1.597 . . . . 0.0 114.21 176.572 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -54.89 -49.93 69.99 Favored 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 125.57 1.548 . . . . 0.0 113.633 -179.059 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.25 -38.79 88.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 176.346 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.8 t -67.71 -51.16 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.434 -1.416 . . . . 0.0 111.18 -179.058 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -33.01 74.72 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.35 1.06 . . . . 0.0 112.929 179.799 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 64.0 m -65.31 -49.65 68.66 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.459 1.904 . . . . 0.0 112.671 171.174 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -62.91 -32.48 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.168 -1.583 . . . . 0.0 114.145 174.427 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -65.07 -45.29 85.9 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.383 -1.448 . . . . 0.0 112.925 168.658 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -82.86 45.71 1.02 Allowed 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.218 -1.551 . . . . 0.0 113.755 -179.143 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 p -100.94 160.67 14.17 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 126.819 2.048 . . . . 0.0 109.251 175.485 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.71 -142.37 10.7 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.561 -1.337 . . . . 0.0 112.376 172.919 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -71.21 -59.86 2.54 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 126.294 1.838 . . . . 0.0 111.34 172.319 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 11.0 p -94.46 134.16 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.078 1.351 . . . . 0.0 111.465 -179.868 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 87.5 t -125.65 123.23 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.857 -1.152 . . . . 0.0 109.986 -169.685 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -103.61 89.79 3.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.122 -1.611 . . . . 0.0 114.204 -176.035 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.7 mt -89.0 155.91 19.19 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.665 -2.522 . . . . 0.0 112.934 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.7 tt -129.98 128.28 41.73 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 161.297 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -154.04 170.69 20.51 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.892 -1.13 . . . . 0.0 112.934 -174.963 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -119.23 144.3 46.82 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.815 1.646 . . . . 0.0 110.461 -178.691 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? . . . . . 0 N--CA 1.43 -1.447 0 O-C-N 120.626 -1.297 . . . . 0.0 111.132 174.977 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.4 t0 . . . . . 0 N--CA 1.429 -1.478 0 CA-C-O 121.187 0.518 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -108.04 155.3 20.52 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.76 1.224 . . . . 0.0 112.855 -177.933 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -144.83 143.31 30.56 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.492 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -93.5 137.89 32.33 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 168.114 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.421 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 26.4 t -126.07 99.53 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -175.407 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -99.39 89.79 4.31 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-O 123.049 1.404 . . . . 0.0 109.046 176.527 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.0 tp -118.11 141.14 48.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.983 1.713 . . . . 0.0 110.844 -160.499 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.59 136.85 42.53 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.509 -1.37 . . . . 0.0 111.057 175.916 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -66.84 161.46 23.81 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 117.035 2.235 . . . . 0.0 117.035 -173.267 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.5 p -113.2 99.4 7.79 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 126.532 1.933 . . . . 0.0 109.333 174.675 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.9 t70 50.14 49.91 19.57 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.726 1.61 . . . . 0.0 114.92 171.643 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.05 -18.95 55.72 Favored Glycine 0 N--CA 1.431 -1.682 0 O-C-N 120.05 -1.656 . . . . 0.0 116.345 179.873 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.7 p -113.16 161.23 17.38 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 119.312 1.556 . . . . 0.0 113.239 -177.079 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 mt -97.05 -54.97 3.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 166.508 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.22 50.34 0.34 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.005 -1.684 . . . . 0.0 110.438 171.722 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tt -146.13 142.83 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 CA-C-O 122.618 1.199 . . . . 0.0 109.751 -174.147 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.0 t -111.17 129.77 55.84 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 168.571 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 m -111.07 165.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 C-N-CA 124.642 1.177 . . . . 0.0 110.547 -178.794 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 t -151.19 170.14 20.19 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.768 -1.207 . . . . 0.0 109.865 177.996 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.72 -154.68 20.35 Favored Glycine 0 N--CA 1.431 -1.696 0 O-C-N 121.337 -0.852 . . . . 0.0 112.73 178.069 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.63 147.85 23.28 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 121.698 -0.883 . . . . 0.0 113.008 -178.068 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 N--CA 1.431 -1.421 0 N-CA-C 116.728 2.122 . . . . 0.0 116.728 -167.678 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.689 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.6 mm -99.97 128.51 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 177.338 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -127.12 159.06 35.35 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.795 -1.191 . . . . 0.0 109.684 -173.674 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.26 125.53 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 O-C-N 121.089 -1.007 . . . . 0.0 111.897 176.493 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -91.9 -49.11 6.41 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.381 177.879 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -159.12 157.76 31.59 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.412 -1.43 . . . . 0.0 111.33 177.602 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.39 121.38 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.656 1.217 . . . . 0.0 110.056 174.404 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 22.0 mm -77.47 133.28 67.66 Favored Pre-proline 0 N--CA 1.429 -1.477 0 C-N-CA 127.527 2.331 . . . . 0.0 115.671 -165.901 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -54.07 118.19 4.71 Favored 'Trans proline' 0 N--CA 1.434 -1.973 0 C-N-CA 123.864 3.043 . . . . 0.0 118.335 -178.704 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 61.85 40.74 12.37 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 128.949 2.9 . . . . 0.0 113.646 -177.274 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.29 164.23 36.45 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.114 -1.616 . . . . 0.0 112.86 162.785 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.62 -57.37 7.29 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.359 1.864 . . . . 0.0 114.87 164.472 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.6 -43.32 97.26 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 127.341 2.256 . . . . 0.0 112.517 -179.03 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.96 -62.38 1.56 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 167.143 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.4 t -69.52 -23.21 63.57 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.244 1.418 . . . . 0.0 114.719 -170.781 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -59.54 -58.32 9.11 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 125.837 1.655 . . . . 0.0 113.495 178.81 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.9 -13.02 10.68 Favored Glycine 0 N--CA 1.43 -1.729 0 CA-C-N 120.419 1.463 . . . . 0.0 115.651 168.347 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.5 mmt180 -75.16 -52.64 10.47 Favored 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 120.515 -1.58 . . . . 0.0 111.258 177.034 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 57.3 mt -81.06 116.38 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 126.231 1.812 . . . . 0.0 112.789 -168.738 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -117.88 164.91 14.34 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.37 1.868 . . . . 0.0 112.039 -179.262 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.76 124.34 20.46 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.551 -1.968 . . . . 0.0 114.019 176.459 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.12 6.8 68.67 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.686 -1.259 . . . . 0.0 114.736 -176.25 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -75.56 160.65 29.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.341 1.57 . . . . 0.0 111.273 174.024 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.7 ttt180 -101.44 126.71 48.26 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.794 -1.191 . . . . 0.0 110.29 -175.503 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.8 t -86.66 111.64 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.429 1.092 . . . . 0.0 108.494 -177.087 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.3 mt -91.14 -53.95 4.15 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.005 -1.684 . . . . 0.0 111.996 -171.571 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.11 146.99 27.96 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.807 -1.183 . . . . 0.0 108.881 -176.774 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.54 110.34 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 177.02 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.0 t30 63.17 34.99 13.09 Favored 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 126.424 1.89 . . . . 0.0 114.989 167.026 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 92.97 -6.01 76.24 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 121.083 -1.011 . . . . 0.0 113.884 -174.93 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.4 t -96.94 113.31 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-N 118.909 1.354 . . . . 0.0 109.719 179.057 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.3 m -70.94 123.89 23.07 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 124.551 1.14 . . . . 0.0 111.047 176.642 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 23.8 mt -84.23 0.76 47.62 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.306 -1.496 . . . . 0.0 114.381 -172.613 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.31 111.98 0.99 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.277 -1.514 . . . . 0.0 114.135 179.263 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.28 12.97 79.84 Favored Glycine 0 N--CA 1.429 -1.78 0 C-N-CA 124.499 1.047 . . . . 0.0 114.473 -179.081 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.72 160.69 31.8 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.208 -1.76 . . . . 0.0 115.742 173.085 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.9 p -89.87 173.88 8.0 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.488 -1.382 . . . . 0.0 111.131 171.505 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -59.59 -49.42 77.83 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.347 1.459 . . . . 0.0 112.186 170.179 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -55.35 -46.15 76.43 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 125.067 1.347 . . . . 0.0 114.102 173.716 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -55.92 -54.06 49.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 178.202 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.62 87.43 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 178.343 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.9 t -66.11 -49.51 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.859 -1.151 . . . . 0.0 111.372 176.377 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -66.99 -31.47 72.06 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.5 -1.375 . . . . 0.0 113.624 -179.083 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 100.0 m -65.82 -49.93 66.47 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 127.315 2.246 . . . . 0.0 111.667 171.525 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.8 mt -59.89 -41.15 90.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.466 -1.396 . . . . 0.0 113.97 174.083 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -60.33 -41.04 92.7 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.749 -1.22 . . . . 0.0 113.515 172.628 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -83.23 25.68 0.7 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.487 -1.383 . . . . 0.0 114.584 -179.618 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.442 ' HB ' HG22 ' A' ' 92' ' ' VAL . 59.0 p -87.23 150.9 23.6 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.13 -1.606 . . . . 0.0 109.056 168.783 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.74 -152.31 21.4 Favored Glycine 0 N--CA 1.429 -1.788 0 O-C-N 121.243 -0.911 . . . . 0.0 112.854 -179.667 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -69.59 -50.94 39.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.972 -1.31 . . . . 0.0 112.955 -177.409 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.0 p -97.79 134.25 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 123.094 1.426 . . . . 0.0 109.625 166.19 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.442 HG22 ' HB ' ' A' ' 88' ' ' THR . 97.4 t -122.89 123.37 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 126.735 2.014 . . . . 0.0 109.027 -164.897 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -100.59 103.05 14.33 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.53 -1.357 . . . . 0.0 111.242 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.421 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 28.8 mt -100.45 158.61 15.78 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.608 -1.932 . . . . 0.0 112.554 175.87 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 45.9 tp -127.57 130.68 49.5 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 161.278 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -141.84 167.25 22.6 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.469 -1.395 . . . . 0.0 112.814 176.168 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -122.26 147.71 45.88 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 124.671 1.188 . . . . 0.0 110.099 179.28 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? . . . . . 0 N--CA 1.43 -1.448 0 C-N-CA 126.371 1.868 . . . . 0.0 110.559 179.803 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.1 t0 . . . . . 0 N--CA 1.43 -1.475 0 CA-C-O 121.073 0.463 . . . . 0.0 112.13 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.6 p -103.45 146.13 28.98 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.796 -1.19 . . . . 0.0 111.592 -179.445 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.463 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 8.3 p90 -148.29 144.97 27.96 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-O 122.552 1.167 . . . . 0.0 109.244 171.683 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -89.8 146.16 24.66 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.99 1.716 . . . . 0.0 108.799 172.728 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 20.0 t -124.89 102.55 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.106 -1.621 . . . . 0.0 107.92 177.636 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -96.18 99.13 10.89 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 168.179 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 54.0 tp -123.44 138.51 54.57 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.279 1.432 . . . . 0.0 110.905 -167.374 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 133.84 45.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.44 -1.413 . . . . 0.0 109.763 172.151 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -65.77 153.3 42.19 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 177.627 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 62.3 p -119.88 116.47 25.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 172.236 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.1 t0 56.98 48.74 15.17 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.855 1.662 . . . . 0.0 113.723 178.598 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 -7.37 30.19 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 125.744 1.64 . . . . 0.0 116.55 177.722 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.9 m -121.19 150.23 41.62 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.266 -1.138 . . . . 0.0 111.25 -162.287 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.8 mt -97.16 -62.67 1.22 Allowed 'General case' 0 N--CA 1.429 -1.521 0 O-C-N 120.665 -1.272 . . . . 0.0 111.447 178.52 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.02 46.88 0.32 Allowed Glycine 0 N--CA 1.43 -1.755 0 O-C-N 120.4 -1.438 . . . . 0.0 111.979 171.573 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.4 tt -147.49 150.4 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 CA-C-O 122.578 1.18 . . . . 0.0 111.217 -172.883 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -123.84 132.73 53.82 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.639 1.176 . . . . 0.0 108.699 168.943 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -102.61 163.81 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.812 1.245 . . . . 0.0 113.179 -179.604 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 t -147.5 169.98 18.41 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 126.095 1.758 . . . . 0.0 109.3 -177.363 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.57 -139.31 14.34 Favored Glycine 0 N--CA 1.43 -1.708 0 O-C-N 120.707 -1.246 . . . . 0.0 113.833 171.154 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.3 -177.36 34.89 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 121.415 -1.05 . . . . 0.0 113.206 -178.656 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 N--CA 1.43 -1.465 0 N-CA-C 116.695 2.109 . . . . 0.0 116.695 -172.078 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.43 -1.758 0 N-CA-C 114.115 0.406 . . . . 0.0 114.115 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.2 mm -93.92 130.26 43.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 126.485 1.914 . . . . 0.0 109.477 -178.882 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -126.44 163.03 24.21 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.807 -1.183 . . . . 0.0 110.222 -178.37 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.6 t -76.69 126.55 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.765 -1.209 . . . . 0.0 112.016 169.559 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -91.91 -52.05 4.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.943 -1.098 . . . . 0.0 111.875 176.937 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.6 155.57 39.67 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.079 -1.013 . . . . 0.0 109.977 -177.762 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.477 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -116.68 123.58 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.156 0.979 . . . . 0.0 108.484 175.455 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 23.2 mm -77.76 121.86 84.83 Favored Pre-proline 0 N--CA 1.43 -1.459 0 C-N-CA 125.866 1.666 . . . . 0.0 113.399 -172.399 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -59.19 131.51 41.66 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 CA-C-N 124.323 2.58 . . . . 0.0 115.821 -176.547 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 92.5 mttt 77.39 17.33 1.51 Allowed 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 127.331 2.252 . . . . 0.0 112.822 -178.613 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.1 158.78 42.66 Favored Glycine 0 N--CA 1.429 -1.8 0 O-C-N 119.864 -1.772 . . . . 0.0 113.048 173.462 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.83 -59.38 3.89 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.625 1.97 . . . . 0.0 114.193 166.674 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.5 -48.0 81.5 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.271 2.228 . . . . 0.0 112.136 179.854 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.477 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.7 tm-20 -44.7 -66.0 0.45 Allowed 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 116.318 1.97 . . . . 0.0 116.318 170.442 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 44.8 t -63.32 -25.96 68.54 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -172.895 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -54.33 -53.19 57.19 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 124.983 1.313 . . . . 0.0 113.602 179.319 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.46 -8.16 54.67 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.507 -0.746 . . . . 0.0 113.204 167.234 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -68.12 -44.84 75.22 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.229 -1.16 . . . . 0.0 111.153 168.605 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.0 mt -91.56 131.56 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.927 1.691 . . . . 0.0 112.47 -175.65 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.22 179.47 7.75 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.245 -1.534 . . . . 0.0 112.922 170.579 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -60.09 129.44 41.78 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.761 -1.837 . . . . 0.0 114.956 -175.005 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.51 3.12 78.43 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.919 -1.113 . . . . 0.0 115.07 -179.693 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 63' ' ' ASP . . . . . 0.43 ' HB3' HD13 ' A' ' 96' ' ' LEU . 86.7 m-20 -76.03 145.75 39.95 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 119.617 1.708 . . . . 0.0 111.739 176.266 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -95.3 125.5 39.97 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.252 -1.53 . . . . 0.0 110.384 -173.711 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 54.1 t -81.43 132.3 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.243 -1.535 . . . . 0.0 109.107 -178.884 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -103.24 -52.96 2.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.079 -1.013 . . . . 0.0 109.299 177.406 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.88 134.77 17.79 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 111.638 -171.799 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 84' ' ' THR . 61.1 t -110.36 120.2 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.532 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 67.81 18.54 9.7 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.51 1.924 . . . . 0.0 113.525 174.9 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.39 -17.22 54.09 Favored Glycine 0 N--CA 1.428 -1.839 0 O-C-N 120.771 -1.206 . . . . 0.0 112.981 -175.719 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.5 t -88.66 114.03 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 O-C-N 120.657 -1.496 . . . . 0.0 109.833 -178.372 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.2 m -75.65 127.85 33.95 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 120.727 -1.233 . . . . 0.0 111.279 -179.947 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.26 51.27 2.19 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.847 -1.158 . . . . 0.0 113.583 -165.302 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -74.49 111.32 9.57 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 119.162 -2.212 . . . . 0.0 115.182 -170.42 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.45 13.24 83.07 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.634 -1.291 . . . . 0.0 114.14 -179.751 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.34 159.44 34.56 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.715 1.245 . . . . 0.0 113.991 -179.133 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 45.6 p -84.68 169.77 13.97 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.512 -1.368 . . . . 0.0 111.448 172.288 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -56.25 -47.12 79.15 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.437 1.495 . . . . 0.0 112.176 168.452 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.6 tptp -50.72 -50.03 56.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.976 1.71 . . . . 0.0 113.973 174.501 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -56.27 -49.04 75.36 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 174.92 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.41 88.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.726 1.21 . . . . 0.0 114.182 174.951 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.31 -46.8 86.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 O-C-N 120.732 -1.23 . . . . 0.0 111.62 175.638 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -61.47 -34.45 75.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.557 -1.34 . . . . 0.0 114.094 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . 0.403 HG22 HG11 ' A' ' 68' ' ' VAL . 1.5 m -77.82 -35.39 51.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.525 1.53 . . . . 0.0 113.091 174.832 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 53.1 mt -70.2 -24.29 63.09 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 119.694 -1.879 . . . . 0.0 114.783 168.997 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -69.64 -48.65 59.18 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 119.68 -1.888 . . . . 0.0 111.984 168.064 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -85.44 52.58 2.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 114.394 1.257 . . . . 0.0 114.394 -176.402 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 56.6 p -88.99 178.78 6.31 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.112 -1.617 . . . . 0.0 109.941 170.691 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.89 -165.31 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 160.836 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -70.56 -42.7 70.77 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.52 -0.988 . . . . 0.0 112.714 175.067 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 41.8 t -94.83 126.59 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 166.5 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 53.0 t -114.45 132.29 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 129.22 3.008 . . . . 0.0 108.653 -168.148 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -120.73 91.25 3.49 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 111.557 -170.845 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.9 mt -94.51 155.01 17.13 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.619 -1.926 . . . . 0.0 112.637 177.786 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.0 tt -129.62 133.13 46.98 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.456 -0.777 . . . . 0.0 109.103 161.984 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.463 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.6 pp -152.63 170.41 20.3 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 120.143 -1.598 . . . . 0.0 112.669 -175.083 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -116.53 145.51 43.28 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 125.576 1.55 . . . . 0.0 110.235 179.647 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 18.4 tptt . . . . . 0 N--CA 1.43 -1.441 0 C-N-CA 125.955 1.702 . . . . 0.0 112.524 -177.446 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.6 pttp . . . . . 0 N--CA 1.43 -1.469 0 CA-C-O 119.204 -0.427 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -84.05 178.5 5.28 Favored 'Trans proline' 0 N--CA 1.434 -2.019 0 C-N-CA 122.639 2.226 . . . . 0.0 111.908 163.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.47 49.87 3.11 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 116.593 1.397 . . . . 0.0 116.593 163.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -96.14 135.07 38.43 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-N 119.104 1.452 . . . . 0.0 110.484 173.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.84 154.26 20.39 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.648 -1.907 . . . . 0.0 112.467 -175.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -146.15 141.38 27.45 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.131 0.967 . . . . 0.0 109.505 167.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 35.3 mt-10 -92.7 119.73 32.4 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.776 1.63 . . . . 0.0 107.276 163.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.455 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 10.9 t -107.65 101.57 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 122.485 1.136 . . . . 0.0 108.029 -174.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 25.1 mt-10 -92.43 79.6 4.94 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.461 1.505 . . . . 0.0 108.749 -179.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.9 tp -104.64 133.52 49.36 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-O 122.643 1.211 . . . . 0.0 111.264 -166.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.7 146.32 27.9 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.167 -1.583 . . . . 0.0 108.848 170.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -69.76 158.67 34.99 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.205 -1.559 . . . . 0.0 114.558 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.2 t -112.05 105.33 13.69 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 170.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . 0.256 22.9 t70 29.64 63.29 0.15 Allowed 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.94 2.896 . . . . 0.0 117.37 -165.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.74 10.09 85.56 Favored Glycine 0 N--CA 1.43 -1.739 0 N-CA-C 117.244 1.658 . . . . 0.0 117.244 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 32.6 m -121.1 134.15 55.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 119.586 1.693 . . . . 0.0 113.499 176.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.6 mt -89.98 -63.01 1.34 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.552 1.141 . . . . 0.0 111.857 167.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.35 34.35 2.51 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 119.684 -1.885 . . . . 0.0 114.378 173.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.9 pt -125.92 131.47 71.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.686 1.594 . . . . 0.0 110.769 -179.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 22.4 t -105.63 106.9 17.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 166.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.7 m -110.02 152.77 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 C-N-CA 124.548 1.139 . . . . 0.0 111.414 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 2.1 t -150.7 175.61 11.8 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.167 -0.958 . . . . 0.0 110.974 -172.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 120.01 -127.5 7.13 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 121.054 -1.029 . . . . 0.0 113.527 170.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.61 -170.52 20.27 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.36 1.457 . . . . 0.0 112.174 -179.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.7 p -104.5 -34.16 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.896 1.278 . . . . 0.0 114.343 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -94.06 -4.2 49.87 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.437 -2.039 . . . . 0.0 113.959 -166.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 30.2 p -94.76 -139.97 0.24 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.49 1.116 . . . . 0.0 110.866 -167.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 27.2 t -74.19 -39.89 62.87 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.749 -1.844 . . . . 0.0 112.821 177.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 34.8 m -77.24 129.08 37.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.786 -1.196 . . . . 0.0 114.098 -172.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -72.6 -29.44 63.51 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 126.119 1.768 . . . . 0.0 113.237 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -63.48 -25.98 68.51 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 116.955 2.205 . . . . 0.0 116.955 -166.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.85 68.05 1.68 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.016 -1.052 . . . . 0.0 114.748 171.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 179.05 171.12 41.88 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 121.113 -1.228 . . . . 0.0 110.772 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.4 mm -103.75 129.08 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.842 1.257 . . . . 0.0 108.155 -178.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -127.68 149.47 50.19 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 121.312 -0.868 . . . . 0.0 109.574 -171.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.5 t -77.09 122.62 32.04 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 O-C-N 120.845 -1.159 . . . . 0.0 111.684 172.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -88.33 -50.44 6.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.827 -1.171 . . . . 0.0 110.816 176.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.51 158.65 44.4 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 122.162 -0.337 . . . . 0.0 111.829 -175.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.41 120.47 64.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.706 1.202 . . . . 0.0 109.971 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.68 119.55 77.9 Favored Pre-proline 0 N--CA 1.429 -1.477 0 CA-C-O 116.794 -1.574 . . . . 0.0 113.37 -169.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -63.66 128.18 21.58 Favored 'Trans proline' 0 N--CA 1.434 -2.018 0 C-N-CA 123.207 2.605 . . . . 0.0 113.931 -173.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.264 54.3 mttm 82.47 21.33 0.25 Allowed 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 128.063 2.545 . . . . 0.0 113.642 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.1 160.83 37.18 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 119.897 -1.752 . . . . 0.0 114.428 170.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -52.44 -59.78 4.02 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.341 1.856 . . . . 0.0 115.402 164.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.49 -45.23 88.23 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 128.823 2.849 . . . . 0.0 111.225 -179.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.2 tm-20 -44.42 -64.2 0.73 Allowed 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 170.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.5 m -70.2 -22.37 62.94 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.565 1.691 . . . . 0.0 115.565 -177.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -58.45 -61.61 2.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.829 1.652 . . . . 0.0 112.603 175.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.88 5.0 64.71 Favored Glycine 0 N--CA 1.43 -1.717 0 N-CA-C 116.14 1.216 . . . . 0.0 116.14 169.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -77.17 -32.92 56.53 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-N 118.767 1.283 . . . . 0.0 109.635 160.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.7 mt -92.27 135.91 26.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.966 1.306 . . . . 0.0 109.161 170.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.3 t60 -159.47 160.97 35.33 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.589 -1.319 . . . . 0.0 110.014 178.144 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.5 pttt -64.87 135.49 55.79 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.383 -2.073 . . . . 0.0 114.628 -171.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.46 4.93 67.62 Favored Glycine 0 N--CA 1.43 -1.744 0 CA-C-O 118.295 -1.28 . . . . 0.0 115.436 -172.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.344 1.6 p30 -80.15 166.13 21.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 121.468 2.634 . . . . 0.0 114.375 171.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 9.9 tpt85 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.496 1.118 . . . . 0.0 109.186 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 5.0 t -85.68 139.27 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 123.748 0.819 . . . . 0.0 109.805 -178.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.1 mp -105.17 -53.23 2.7 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.862 -1.149 . . . . 0.0 109.291 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.69 150.62 31.31 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 112.744 -175.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.917 HG11 HG21 ' A' ' 84' ' ' THR . 2.5 p -119.38 107.74 22.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 125.45 1.5 . . . . 0.0 110.266 177.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.1 t30 58.93 37.05 24.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.672 -1.893 . . . . 0.0 113.282 173.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.07 -29.69 11.59 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.891 1.234 . . . . 0.0 114.023 -172.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 44.5 t -87.98 119.55 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 119.734 1.767 . . . . 0.0 110.777 -163.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.8 m -69.87 117.63 11.71 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.1 -1.0 . . . . 0.0 111.052 -179.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 18.2 mt -83.84 -4.65 58.83 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.573 -1.329 . . . . 0.0 113.873 -169.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -74.05 116.37 14.6 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.217 -1.552 . . . . 0.0 112.044 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 107.93 -20.87 30.62 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 124.175 0.893 . . . . 0.0 112.064 -175.105 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.35 148.79 46.68 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.772 -1.428 . . . . 0.0 112.902 172.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.414 HG22 ' H ' ' A' ' 78' ' ' HIS . 0.2 OUTLIER -90.21 -179.14 5.58 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.301 -1.499 . . . . 0.0 112.008 -179.851 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . 0.414 ' H ' HG22 ' A' ' 77' ' ' THR . 10.4 t-160 -61.23 -47.6 85.35 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.463 1.905 . . . . 0.0 112.765 -174.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -56.68 -46.96 80.85 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 115.173 1.546 . . . . 0.0 115.173 173.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 15.9 mp0 -55.88 -51.13 68.65 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.681 1.593 . . . . 0.0 113.822 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.05 -36.42 83.51 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.1 t -67.29 -49.39 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 O-C-N 120.661 -1.274 . . . . 0.0 110.941 176.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -62.5 -37.12 84.78 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.126 0.97 . . . . 0.0 113.285 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . 0.917 HG21 HG11 ' A' ' 68' ' ' VAL . 54.0 m -58.59 -52.28 66.32 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.261 1.824 . . . . 0.0 112.57 173.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 92.6 mt -63.27 -37.02 85.61 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.151 1.167 . . . . 0.0 114.151 175.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.44 -42.88 99.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.108 1.363 . . . . 0.0 111.608 175.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.4 t30 -88.97 43.16 1.13 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.716 1.606 . . . . 0.0 112.663 177.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.6 p -100.53 156.19 17.43 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.203 -1.56 . . . . 0.0 110.184 169.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.32 -146.42 20.32 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.656 1.122 . . . . 0.0 113.141 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -69.97 -57.41 5.04 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.757 -1.437 . . . . 0.0 114.331 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 43.0 t -104.38 131.91 52.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 CA-C-O 122.454 1.121 . . . . 0.0 108.534 176.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -124.57 120.73 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 127.611 2.364 . . . . 0.0 108.977 -167.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -107.2 93.41 4.54 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 119.878 -1.764 . . . . 0.0 112.523 -171.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 1.1 mm? -91.54 160.04 15.62 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 118.782 -2.448 . . . . 0.0 113.794 -177.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 38.8 tp -127.87 128.92 46.03 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.289 1.436 . . . . 0.0 108.867 162.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.72 169.89 18.11 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.292 -1.505 . . . . 0.0 113.041 177.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -126.96 134.94 50.28 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.149 0.979 . . . . 0.0 112.873 -176.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 76.71 4.16 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 126.415 1.886 . . . . 0.0 113.444 -177.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 84.5 145.35 7.06 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 125.146 1.355 . . . . 0.0 115.368 168.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -97.01 -62.01 1.32 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.744 1.259 . . . . 0.0 110.024 164.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.6 m -102.75 134.08 20.07 Favored Pre-proline 0 N--CA 1.43 -1.446 0 C-N-CA 125.345 1.458 . . . . 0.0 110.029 -177.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo . . . . . 0 C--N 1.3 -1.995 0 C-N-CA 122.241 1.96 . . . . 0.0 114.691 173.891 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.429 -1.479 0 CA-C-O 119.809 -0.138 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -82.07 61.78 7.9 Favored 'Trans proline' 0 N--CA 1.435 -1.969 0 C-N-CA 124.005 3.137 . . . . 0.0 114.439 -168.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 124.38 61.41 0.18 Allowed Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.707 -1.246 . . . . 0.0 116.037 176.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -98.34 -179.02 4.22 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 155.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 48.4 p -100.14 162.59 12.87 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.416 -1.427 . . . . 0.0 113.276 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.62 149.86 34.34 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 168.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -104.03 119.11 38.23 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-O 122.719 1.247 . . . . 0.0 109.242 167.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.8 t -98.07 108.48 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.588 1.955 . . . . 0.0 108.344 -175.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -104.42 86.47 2.53 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.196 1.398 . . . . 0.0 108.443 173.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 52.5 tp -120.38 142.29 49.31 Favored 'General case' 0 N--CA 1.431 -1.379 0 C-N-CA 125.111 1.364 . . . . 0.0 110.609 -165.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 140.59 35.9 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.651 1.58 . . . . 0.0 110.585 173.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 80.5 mttt -69.71 158.79 34.72 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 115.582 1.697 . . . . 0.0 115.582 -178.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.9 p -112.61 105.7 13.95 Favored 'General case' 0 N--CA 1.429 -1.518 0 C-N-CA 125.076 1.35 . . . . 0.0 108.761 172.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.2 t70 55.34 45.38 25.62 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.437 1.895 . . . . 0.0 113.656 -176.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.44 -5.26 64.61 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.349 -1.47 . . . . 0.0 115.563 -178.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 60.5 p -107.92 149.78 27.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -174.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.0 mt -100.83 -56.25 2.37 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.229 1.411 . . . . 0.0 108.278 172.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 51' ' ' GLY . . . 106.06 55.71 0.68 Allowed Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.324 -1.485 . . . . 0.0 111.863 173.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.5 tt -143.39 142.26 25.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 CA-C-O 122.295 1.045 . . . . 0.0 110.401 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 44.3 t -112.79 115.09 27.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.435 1.894 . . . . 0.0 107.441 171.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.6 m -101.4 160.1 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 122.43 1.11 . . . . 0.0 111.84 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 8.5 t -144.05 -179.46 6.51 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 125.253 1.421 . . . . 0.0 107.906 176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 113.1 -155.43 16.3 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 121.085 -1.009 . . . . 0.0 113.722 173.172 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.2 152.68 22.55 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.692 1.139 . . . . 0.0 114.173 176.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.1 p -79.06 -17.21 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 115.208 1.559 . . . . 0.0 115.208 -170.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -79.5 -21.7 44.97 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 119.391 -2.068 . . . . 0.0 111.202 -178.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.05 168.59 10.67 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 126.937 2.095 . . . . 0.0 109.541 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 79.1 p -81.1 53.6 2.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.99 -1.694 . . . . 0.0 112.68 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 75.6 t -94.3 134.92 30.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 O-C-N 119.871 -1.768 . . . . 0.0 109.185 -171.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 37.2 ttp-105 -70.52 110.5 5.43 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.149 -0.969 . . . . 0.0 110.807 -177.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.278 1.8 t-80 72.81 2.75 4.48 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 127.405 2.282 . . . . 0.0 116.57 -170.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.86 63.85 Favored Glycine 0 N--CA 1.431 -1.66 0 N-CA-C 118.873 2.309 . . . . 0.0 118.873 167.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -80.2 179.29 53.42 Favored Glycine 0 N--CA 1.43 -1.752 0 CA-C-N 118.944 1.372 . . . . 0.0 114.313 -176.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 46.7 mm -103.69 127.72 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 125.487 1.515 . . . . 0.0 108.082 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -130.92 157.01 44.08 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 121.07 -1.019 . . . . 0.0 112.6 -168.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.4 t -75.87 124.4 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.97 -1.081 . . . . 0.0 111.168 169.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.5 ttmt -93.15 -46.43 7.43 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.246 -0.909 . . . . 0.0 110.61 170.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.53 153.5 34.68 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 111.121 177.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.499 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.16 121.68 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 CA-C-O 123.016 1.389 . . . . 0.0 109.052 176.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 33.2 mm -76.53 126.27 86.37 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 127.028 2.131 . . . . 0.0 113.157 -166.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -60.63 138.42 79.83 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 124.722 2.722 . . . . 0.0 113.976 -173.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.2 mttm 53.43 37.08 24.73 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 116.822 2.156 . . . . 0.0 116.822 -169.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.404 ' HA3' ' HA3' ' A' ' 26' ' ' GLY . . . -84.72 160.74 35.97 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.078 -1.639 . . . . 0.0 113.225 159.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.75 -56.37 12.34 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.252 -1.734 . . . . 0.0 115.658 163.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.71 -47.65 77.57 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.196 2.999 . . . . 0.0 112.517 -179.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.499 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -40.81 -64.88 0.48 Allowed 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.656 1.582 . . . . 0.0 113.975 164.696 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 12.9 t -67.65 -34.89 77.84 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.456 1.102 . . . . 0.0 113.887 -170.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -53.46 -65.43 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.616 1.966 . . . . 0.0 113.906 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.22 -10.78 24.45 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 115.496 0.959 . . . . 0.0 115.496 172.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 93.1 mtt180 -72.72 -24.75 61.03 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 119.634 1.717 . . . . 0.0 113.194 172.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 67.5 mt -105.4 135.93 41.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.542 1.537 . . . . 0.0 108.452 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -154.15 158.25 40.1 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.844 -1.16 . . . . 0.0 112.169 -170.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 41.2 ttmt -51.83 122.78 8.85 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.007 -1.683 . . . . 0.0 115.49 177.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 96.59 -5.51 64.63 Favored Glycine 0 N--CA 1.429 -1.771 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 179.262 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 0.3 OUTLIER -80.19 171.83 14.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.923 1.861 . . . . 0.0 114.343 -175.823 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -119.74 125.73 49.35 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.402 -1.436 . . . . 0.0 112.709 -169.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.0 t -82.61 127.85 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.734 -1.229 . . . . 0.0 110.027 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.41 -46.45 5.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.121 -0.987 . . . . 0.0 110.525 176.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.79 136.57 17.13 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.556 -1.34 . . . . 0.0 114.003 -177.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -104.37 116.93 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 124.536 1.135 . . . . 0.0 108.525 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.5 t30 59.38 39.47 22.13 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.137 -1.602 . . . . 0.0 113.767 175.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.09 -33.5 5.21 Favored Glycine 0 N--CA 1.431 -1.67 0 O-C-N 121.209 -0.932 . . . . 0.0 113.889 -174.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -87.03 117.75 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 C-N-CA 124.725 1.21 . . . . 0.0 111.471 -167.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 t -76.55 139.32 40.68 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.318 -1.489 . . . . 0.0 112.628 -174.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.2 mt -89.69 20.86 3.79 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 113.951 1.093 . . . . 0.0 113.951 -171.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -62.17 117.71 6.4 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 119.829 -1.794 . . . . 0.0 114.591 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 84.94 10.8 78.02 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 124.483 1.039 . . . . 0.0 113.65 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.72 157.14 38.46 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 66.3 p -91.22 170.03 10.34 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.863 -1.148 . . . . 0.0 109.677 170.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 19.5 t-80 -53.91 -55.2 29.09 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.889 1.276 . . . . 0.0 113.322 170.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.3 ttpp -56.44 -44.34 80.34 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.049 1.499 . . . . 0.0 115.049 177.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 17.5 tt0 -61.06 -46.05 92.25 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.299 1.592 . . . . 0.0 115.299 -175.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.98 -33.43 75.71 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.809 1.244 . . . . 0.0 112.669 172.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.4 t -69.06 -48.34 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.463 1.105 . . . . 0.0 110.381 178.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -59.05 -42.24 89.81 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.714 -1.241 . . . . 0.0 113.043 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.6 m -62.03 -48.06 81.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.036 2.134 . . . . 0.0 112.858 176.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 33.4 mt -65.54 -37.12 85.82 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.109 1.364 . . . . 0.0 114.246 175.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -68.69 -31.54 70.71 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.337 -1.477 . . . . 0.0 112.474 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -88.51 48.58 1.66 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 124.828 1.251 . . . . 0.0 112.139 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.6 p -98.82 154.48 17.98 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.132 1.773 . . . . 0.0 107.894 166.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.66 -157.76 30.82 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.803 -1.186 . . . . 0.0 112.007 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? -69.43 -49.08 58.46 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 121.099 -1.236 . . . . 0.0 112.6 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 56.4 t -99.16 132.72 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.43 1.092 . . . . 0.0 108.325 171.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 74.4 t -120.3 124.8 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 126.556 1.943 . . . . 0.0 109.649 -165.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -113.58 87.46 2.62 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.627 1.171 . . . . 0.0 112.196 -174.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . 0.279 3.1 pp -123.5 148.28 46.4 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 117.794 2.516 . . . . 0.0 117.794 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 49.9 tp -105.82 128.31 53.65 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.878 1.671 . . . . 0.0 108.433 -176.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.34 158.68 43.65 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 121.999 0.904 . . . . 0.0 110.822 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -95.52 150.98 19.72 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 165.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.5 tppt? -75.82 152.89 37.19 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.221 1.01 . . . . 0.0 109.791 165.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -115.72 164.75 12.17 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.94 1.257 . . . . 0.0 110.87 178.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -75.58 179.48 5.3 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 114.688 1.366 . . . . 0.0 114.688 -178.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 30.9 m -87.47 143.61 34.39 Favored Pre-proline 0 N--CA 1.431 -1.409 0 O-C-N 120.545 -1.347 . . . . 0.0 112.682 -177.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo . . . . . 0 N--CA 1.434 -2.011 0 C-N-CA 123.309 2.672 . . . . 0.0 112.725 161.209 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.7 pttm . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 119.326 -0.368 . . . . 0.0 111.387 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.04 176.5 9.95 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 121.894 1.73 . . . . 0.0 112.173 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.95 12.18 62.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.859 -0.526 . . . . 0.0 112.759 -176.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -81.1 156.02 25.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.321 1.848 . . . . 0.0 113.113 -168.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 38.5 p -121.86 154.42 37.09 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 121.077 -1.014 . . . . 0.0 112.79 -174.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.2 139.65 27.36 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.072 -1.017 . . . . 0.0 109.082 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -92.72 131.0 38.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.86 -1.15 . . . . 0.0 109.899 168.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 17.8 t -116.71 111.83 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.057 1.343 . . . . 0.0 108.656 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -102.55 78.06 1.68 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.419 -1.425 . . . . 0.0 109.288 172.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.5 tp -94.74 146.83 23.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 124.297 1.039 . . . . 0.0 111.063 -171.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.48 127.59 50.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.085 -1.634 . . . . 0.0 108.932 167.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.1 ptmt -70.15 149.55 47.44 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 113.969 1.1 . . . . 0.0 113.969 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.2 p -106.55 111.44 23.99 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.272 -1.517 . . . . 0.0 111.635 -174.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.0 t0 54.26 39.46 30.85 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.424 2.29 . . . . 0.0 113.522 -175.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.02 -7.22 78.71 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.281 -1.512 . . . . 0.0 115.713 -176.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.8 t -109.39 150.38 28.14 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-N 119.15 1.475 . . . . 0.0 112.005 -172.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 37.4 mt -100.71 -61.59 1.35 Allowed 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.237 -1.539 . . . . 0.0 112.151 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.53 33.81 0.91 Allowed Glycine 0 N--CA 1.43 -1.746 0 O-C-N 119.914 -1.741 . . . . 0.0 111.497 178.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 pt -124.38 150.36 29.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.429 1.092 . . . . 0.0 111.261 -174.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 35.4 m -126.67 134.33 50.74 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 156.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.1 m -117.84 161.58 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 CA-C-O 122.346 1.07 . . . . 0.0 112.102 -170.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.64 -173.35 4.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 124.2 1.0 . . . . 0.0 109.595 179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.06 -152.41 20.25 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.994 -1.067 . . . . 0.0 115.437 171.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.67 172.66 30.62 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 125.593 1.568 . . . . 0.0 111.621 -176.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t -60.24 -37.26 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 125.065 1.346 . . . . 0.0 113.065 176.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.5 p-10 -73.88 -22.68 59.64 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 126.283 1.833 . . . . 0.0 113.809 -173.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 26.8 m -98.72 141.9 30.95 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 124.627 1.171 . . . . 0.0 108.444 -174.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 14.2 m -78.02 61.02 2.5 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 119.975 -1.703 . . . . 0.0 114.112 -176.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 19.4 m -100.58 7.08 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 127.1 2.16 . . . . 0.0 114.548 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 58.1 ttp85 78.71 120.62 0.05 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.556 2.342 . . . . 0.0 112.064 -171.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 39.6 t60 72.47 -69.77 0.18 Allowed 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.947 1.699 . . . . 0.0 115.512 172.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 144.97 95.57 0.19 Allowed Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 110.532 -1.027 . . . . 0.0 110.532 -174.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -157.17 152.14 23.46 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.2 mm -95.32 127.72 47.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.239 1.416 . . . . 0.0 108.584 -177.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -125.7 155.58 40.69 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 120.757 -1.214 . . . . 0.0 111.404 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.5 t -75.96 122.26 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.999 -1.063 . . . . 0.0 110.945 169.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.0 ttmm -87.9 -42.06 12.76 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.376 1.47 . . . . 0.0 109.703 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.24 160.0 38.2 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.77 -0.581 . . . . 0.0 109.946 175.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -119.17 121.36 66.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 C-N-CA 124.348 1.059 . . . . 0.0 108.841 174.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.46 119.38 77.22 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 115.872 -2.013 . . . . 0.0 116.144 -169.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_exo -59.86 123.24 12.83 Favored 'Trans proline' 0 N--CA 1.434 -2.024 0 CA-C-N 124.659 2.7 . . . . 0.0 114.916 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.254 83.7 mttt 81.74 26.53 0.19 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 128.229 2.612 . . . . 0.0 111.921 -172.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.61 157.49 31.39 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 119.768 -1.833 . . . . 0.0 111.812 164.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.57 -58.74 5.47 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.59 -2.123 . . . . 0.0 114.287 160.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.1 -40.12 95.54 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 127.45 2.3 . . . . 0.0 112.826 -177.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 -52.07 -59.74 4.01 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 116.027 1.862 . . . . 0.0 116.027 166.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 32.5 t -68.82 -25.21 64.56 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 125.837 1.655 . . . . 0.0 114.905 -167.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -46.48 -63.15 1.08 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.1 1.76 . . . . 0.0 113.964 174.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 114.48 -2.51 23.5 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.217 -0.927 . . . . 0.0 114.324 171.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.6 mtm180 -85.81 -28.64 24.36 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.006 -1.29 . . . . 0.0 113.095 171.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.1 mt -108.61 132.07 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 C-N-CA 126.445 1.898 . . . . 0.0 110.664 -170.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.12 -176.71 4.91 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.356 -1.465 . . . . 0.0 112.424 173.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 4.5 ttpm? -68.43 121.19 15.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.416 -1.428 . . . . 0.0 112.738 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 105.41 -2.52 39.88 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 121.418 -0.801 . . . . 0.0 114.393 -175.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -80.35 147.8 30.91 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 119.419 1.609 . . . . 0.0 112.393 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 23.5 ttm180 -97.07 134.34 40.56 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.838 -1.164 . . . . 0.0 110.452 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.1 t -86.45 127.39 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.96 -1.087 . . . . 0.0 109.196 177.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -103.47 -45.94 4.71 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.496 -1.377 . . . . 0.0 111.253 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.0 128.69 12.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.489 -1.382 . . . . 0.0 111.584 -176.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 t -108.9 124.04 65.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 66.55 28.1 9.47 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.521 -1.362 . . . . 0.0 113.666 170.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.74 -12.53 66.92 Favored Glycine 0 N--CA 1.429 -1.809 0 O-C-N 119.962 -1.712 . . . . 0.0 113.773 -175.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.9 t -96.14 116.09 37.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.155 -1.203 . . . . 0.0 109.026 -175.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 92.7 p -75.36 140.83 43.27 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.357 -1.464 . . . . 0.0 111.592 177.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.2 mt -88.29 50.93 2.06 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.652 -1.28 . . . . 0.0 112.744 -166.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -73.67 125.07 27.21 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.977 -1.702 . . . . 0.0 112.19 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.79 10.64 61.51 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.237 1.399 . . . . 0.0 115.453 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.26 139.4 50.0 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 115.898 1.814 . . . . 0.0 115.898 -170.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.8 p -91.64 173.26 7.98 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 124.868 1.267 . . . . 0.0 110.27 176.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -58.96 -49.41 77.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.962 -1.086 . . . . 0.0 113.531 178.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -56.33 -40.29 74.2 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 114.232 1.197 . . . . 0.0 114.232 175.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.11 -53.9 51.56 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.565 1.546 . . . . 0.0 113.766 179.069 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.47 -37.5 87.73 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.472 1.509 . . . . 0.0 113.86 177.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.62 -48.15 88.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.772 1.229 . . . . 0.0 110.894 177.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.7 mt-10 -63.21 -41.27 99.11 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 175.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 93.3 m -61.48 -45.95 92.08 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 125.96 1.704 . . . . 0.0 113.277 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.64 -30.4 67.02 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.269 -1.519 . . . . 0.0 113.91 176.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -63.58 -45.03 92.29 Favored 'General case' 0 CA--C 1.488 -1.419 0 O-C-N 120.453 -1.405 . . . . 0.0 112.025 167.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 40.4 t-20 -78.02 48.81 0.75 Allowed 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 128.116 2.567 . . . . 0.0 113.679 176.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 35.3 p -106.03 156.0 18.84 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.268 -1.52 . . . . 0.0 110.218 174.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.21 -164.19 38.35 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.778 -1.201 . . . . 0.0 111.036 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -69.78 -47.81 61.52 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 118.922 1.361 . . . . 0.0 112.236 172.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 88.7 t -91.27 123.82 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-O 123.171 1.463 . . . . 0.0 107.505 169.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.4 t -113.2 103.59 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 126.956 2.103 . . . . 0.0 109.019 -168.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.6 t-160 -89.2 101.57 14.23 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 123.784 0.834 . . . . 0.0 111.523 -178.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.6 mt -102.97 162.12 13.2 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-O 122.665 1.221 . . . . 0.0 113.822 172.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.5 tt -129.04 132.19 47.44 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.036 1.335 . . . . 0.0 108.021 159.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.01 164.64 28.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.012 -1.055 . . . . 0.0 113.23 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -113.88 142.47 46.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.405 1.882 . . . . 0.0 109.918 177.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 19.7 tptt -75.31 133.14 41.35 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.818 1.647 . . . . 0.0 112.794 177.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -54.32 127.87 40.27 Favored Glycine 0 N--CA 1.43 -1.709 0 C-N-CA 127.519 2.485 . . . . 0.0 117.211 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -73.22 -39.97 65.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.652 2.381 . . . . 0.0 114.127 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.4 p -141.16 126.35 10.89 Favored Pre-proline 0 N--CA 1.429 -1.484 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 170.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo . . . . . 0 N--CA 1.434 -2.028 0 CA-C-N 122.853 2.055 . . . . 0.0 113.904 175.148 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 91.3 mttt . . . . . 0 N--CA 1.431 -1.406 0 CA-C-O 118.824 -0.608 . . . . 0.0 111.028 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_exo -67.07 179.11 2.49 Favored 'Trans proline' 0 N--CA 1.434 -1.999 0 C-N-CA 122.725 2.283 . . . . 0.0 115.592 173.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.44 24.04 5.49 Favored Glycine 0 N--CA 1.429 -1.777 0 C-N-CA 124.008 0.813 . . . . 0.0 114.585 -175.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -85.72 131.99 34.23 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.33 1.452 . . . . 0.0 109.342 175.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.0 p -101.83 150.47 23.14 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.375 -1.453 . . . . 0.0 112.532 -176.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.76 134.88 22.76 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.903 -1.123 . . . . 0.0 108.72 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -91.04 121.4 32.81 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.334 1.454 . . . . 0.0 109.615 174.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.5 t -100.19 102.77 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.803 -1.186 . . . . 0.0 108.236 179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -104.46 81.88 1.85 Allowed 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.123 1.369 . . . . 0.0 108.226 177.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.6 tp -111.78 149.27 31.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.694 1.198 . . . . 0.0 110.325 -165.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.89 144.81 30.72 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.347 -1.471 . . . . 0.0 108.869 170.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 93.0 mttt -70.12 154.64 41.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.609 -1.307 . . . . 0.0 112.638 173.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.6 p -112.92 100.79 8.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.836 -1.165 . . . . 0.0 109.066 175.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 22.0 t0 58.01 45.42 18.01 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 126.014 1.726 . . . . 0.0 113.248 176.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.54 -10.99 67.4 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 125.049 1.309 . . . . 0.0 115.226 -177.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 62.1 m -104.04 148.78 25.83 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.787 1.293 . . . . 0.0 113.561 -169.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.0 mt -119.31 -54.03 2.21 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.999 1.32 . . . . 0.0 109.354 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 103.5 43.32 1.86 Allowed Glycine 0 N--CA 1.43 -1.727 0 C-N-CA 127.036 2.255 . . . . 0.0 113.877 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.2 pt -121.52 121.15 63.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 CA-C-N 119.394 1.597 . . . . 0.0 115.031 -167.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 49.4 m -116.72 123.83 48.16 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.549 -1.345 . . . . 0.0 109.202 165.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.46 173.91 2.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.072 1.349 . . . . 0.0 111.709 -171.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.7 t -146.31 168.47 21.01 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.059 1.344 . . . . 0.0 108.515 174.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.67 -154.18 17.15 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.842 -1.161 . . . . 0.0 115.149 171.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 101.5 165.99 27.43 Favored Glycine 0 N--CA 1.429 -1.785 0 C-N-CA 125.247 1.403 . . . . 0.0 112.379 -179.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.7 m -84.28 17.13 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 115.937 1.829 . . . . 0.0 115.937 -171.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 41.8 t30 -97.88 -64.29 1.05 Allowed 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 119.421 -2.049 . . . . 0.0 110.507 176.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 51.9 m -79.75 155.91 27.73 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.545 1.538 . . . . 0.0 108.81 -176.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 65.6 p -75.09 60.99 1.06 Allowed 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.665 -1.897 . . . . 0.0 114.642 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 14.8 t -99.4 89.41 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.24 -1.537 . . . . 0.0 108.772 176.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? 38.75 67.24 0.44 Allowed 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 128.599 2.759 . . . . 0.0 115.961 -179.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 69.27 -3.21 1.62 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.9 84.7 1.7 Allowed Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.577 -1.327 . . . . 0.0 111.417 -169.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -137.53 168.66 24.37 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 167.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.4 mm -103.72 125.76 58.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.876 1.271 . . . . 0.0 107.972 178.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -128.88 157.49 41.42 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.602 -1.312 . . . . 0.0 111.398 -172.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 19.8 t -76.39 126.54 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.495 1.518 . . . . 0.0 111.181 172.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 66.4 tttt -109.79 -51.67 2.85 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.338 -1.477 . . . . 0.0 113.164 -178.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -147.0 157.01 43.49 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 121.226 -0.921 . . . . 0.0 109.975 178.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.5 tp -125.77 126.09 69.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 C-N-CA 123.988 0.915 . . . . 0.0 109.195 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.6 mm -77.26 122.45 86.16 Favored Pre-proline 0 N--CA 1.429 -1.493 0 CA-C-O 116.238 -1.839 . . . . 0.0 114.507 -173.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_exo -57.28 127.6 26.24 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 CA-C-N 124.506 2.645 . . . . 0.0 116.18 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.292 50.8 mttp 79.36 22.64 0.56 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 127.545 2.338 . . . . 0.0 113.385 -177.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.17 156.3 30.76 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.9 -1.75 . . . . 0.0 112.16 165.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.09 -55.33 12.53 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.824 1.65 . . . . 0.0 115.268 170.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.36 -48.51 75.25 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.89 2.476 . . . . 0.0 111.448 178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.4 tm-20 -47.49 -59.15 3.44 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 116.7 2.111 . . . . 0.0 116.7 173.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 23.0 t -68.37 -30.37 69.29 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.647 1.179 . . . . 0.0 113.387 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -65.02 -60.43 3.05 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.963 1.305 . . . . 0.0 111.199 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.96 31.07 15.73 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.45 -1.406 . . . . 0.0 116.431 167.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.7 mmt180 -83.3 -39.82 20.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 121.458 -1.025 . . . . 0.0 108.747 159.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mt -79.17 99.81 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 123.933 0.893 . . . . 0.0 110.313 175.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -122.81 156.77 33.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.82 1.295 . . . . 0.0 109.627 178.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.1 pttt -67.78 131.27 45.24 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.136 -1.602 . . . . 0.0 113.379 -171.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.87 -19.52 32.84 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.164 -0.96 . . . . 0.0 114.1 -172.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -79.51 157.1 27.51 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 120.152 1.976 . . . . 0.0 113.312 -173.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 70.6 ttt-85 -108.88 134.93 50.9 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.154 -1.591 . . . . 0.0 111.289 -173.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.7 t -96.11 132.75 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 119.945 -1.722 . . . . 0.0 110.986 -175.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -90.72 -52.4 4.9 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.914 -1.116 . . . . 0.0 111.788 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.96 140.14 20.3 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.907 -0.496 . . . . 0.0 112.016 -165.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.1 t -109.22 118.24 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 171.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 63.18 20.89 12.55 Favored 'General case' 0 N--CA 1.429 -1.514 0 C-N-CA 125.968 1.707 . . . . 0.0 113.974 -178.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 86.52 -0.55 86.94 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.279 -1.513 . . . . 0.0 114.069 -174.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -86.05 117.56 30.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 124.853 1.261 . . . . 0.0 109.045 176.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.0 p -75.63 132.36 40.55 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.774 -1.204 . . . . 0.0 113.702 -172.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 67.6 mt -84.77 -13.19 51.95 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -168.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -63.63 131.74 48.95 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.595 -1.941 . . . . 0.0 112.72 174.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 97.18 -30.35 9.22 Favored Glycine 0 N--CA 1.431 -1.697 0 C-N-CA 124.518 1.056 . . . . 0.0 113.674 -171.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.23 156.87 39.04 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 114.956 1.465 . . . . 0.0 114.956 -177.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -88.23 172.61 9.34 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.244 1.018 . . . . 0.0 111.681 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -63.82 -43.35 96.48 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.554 -1.341 . . . . 0.0 112.151 175.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -54.8 -44.87 74.18 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 126.646 1.978 . . . . 0.0 114.416 171.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 71.3 mm-40 -56.03 -55.05 37.48 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 113.825 1.046 . . . . 0.0 113.825 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.93 -34.85 78.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.5 t -63.61 -53.76 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.33 1.052 . . . . 0.0 110.566 174.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.7 mm-40 -61.92 -39.43 92.01 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 122.011 0.91 . . . . 0.0 113.036 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 97.0 m -66.86 -42.38 85.78 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.452 1.901 . . . . 0.0 113.219 179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 65.5 mt -69.54 -36.92 76.83 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.068 -1.02 . . . . 0.0 113.082 173.214 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -53.55 56.4 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.789 -1.195 . . . . 0.0 113.03 173.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 -81.04 43.06 0.68 Allowed 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.863 1.665 . . . . 0.0 112.748 -177.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.416 ' HB ' HG22 ' A' ' 92' ' ' VAL . 26.1 p -91.76 155.37 18.3 Favored 'General case' 0 N--CA 1.429 -1.492 0 C-N-CA 127.425 2.29 . . . . 0.0 108.814 168.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.98 -140.7 7.01 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.973 -1.079 . . . . 0.0 114.078 -175.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 2.1 tm0? -71.02 -53.48 14.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.329 -1.101 . . . . 0.0 111.993 177.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 95.0 t -97.89 135.89 30.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.397 1.57 . . . . 0.0 109.17 169.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.416 HG22 ' HB ' ' A' ' 88' ' ' THR . 48.2 t -111.43 117.66 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 128.574 2.75 . . . . 0.0 108.131 -176.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 52.9 m170 -105.23 104.41 14.14 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.872 -1.143 . . . . 0.0 111.244 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -106.73 163.75 12.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.884 -1.135 . . . . 0.0 113.799 171.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.3 tp -128.2 134.11 48.97 Favored 'General case' 0 N--CA 1.431 -1.411 0 C-N-CA 124.856 1.263 . . . . 0.0 108.36 158.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.8 pp -145.17 164.87 29.98 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.637 -1.29 . . . . 0.0 111.285 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -121.42 149.72 42.59 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.023 1.729 . . . . 0.0 110.894 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.01 121.28 20.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.482 1.513 . . . . 0.0 110.761 176.178 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -76.39 -178.19 44.98 Favored Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 125.593 1.568 . . . . 0.0 114.22 -178.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -81.69 178.71 8.17 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.842 -1.387 . . . . 0.0 112.615 -175.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 39.2 t -113.26 102.57 54.97 Favored Pre-proline 0 N--CA 1.43 -1.472 0 O-C-N 120.793 -1.192 . . . . 0.0 110.377 -171.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo . . . . . 0 C--N 1.301 -1.97 0 C-N-CA 121.958 1.772 . . . . 0.0 110.591 155.664 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 82.7 tttt . . . . . 0 N--CA 1.43 -1.461 0 CA-C-O 117.451 -1.261 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -76.2 23.22 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.079 0 C-N-CA 122.853 2.369 . . . . 0.0 118.069 -170.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.13 59.8 1.45 Allowed Glycine 0 N--CA 1.431 -1.688 0 N-CA-C 108.965 -1.654 . . . . 0.0 108.965 -170.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -53.86 -58.47 7.14 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.867 1.432 . . . . 0.0 114.867 -163.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 p -123.56 154.73 38.82 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-N 119.419 1.009 . . . . 0.0 110.596 163.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.2 m-85 -144.43 149.92 36.83 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 123.882 0.873 . . . . 0.0 109.438 -179.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -99.63 125.85 45.53 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.123 1.369 . . . . 0.0 109.275 167.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.46 94.88 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 O-C-N 120.481 -1.387 . . . . 0.0 107.954 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.1 mp0 -90.62 81.54 5.87 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.658 -1.276 . . . . 0.0 109.387 169.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 49.2 tp -96.39 133.6 40.6 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.652 1.181 . . . . 0.0 111.642 -171.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.16 138.72 38.73 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 119.878 -1.764 . . . . 0.0 110.147 172.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -68.25 156.51 37.49 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.726 1.21 . . . . 0.0 113.721 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.4 t -129.25 135.8 49.27 Favored 'General case' 0 N--CA 1.43 -1.464 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 172.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.0 t70 33.34 52.12 0.35 Allowed 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 128.248 2.619 . . . . 0.0 116.57 -173.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.68 -5.45 69.49 Favored Glycine 0 N--CA 1.43 -1.742 0 N-CA-C 117.678 1.831 . . . . 0.0 117.678 176.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.7 m -121.57 150.63 41.38 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.535 1.668 . . . . 0.0 113.988 -169.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 46.9 mt -101.28 -60.24 1.56 Allowed 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.232 1.413 . . . . 0.0 109.606 168.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.18 41.82 2.02 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.874 1.702 . . . . 0.0 114.63 175.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.3 pt -112.53 156.58 13.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 CA-C-N 118.417 1.109 . . . . 0.0 111.994 177.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -131.39 132.52 44.46 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.115 -1.615 . . . . 0.0 109.258 149.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.5 m -114.75 160.2 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 125.478 1.511 . . . . 0.0 110.882 -175.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.8 t -148.8 -178.96 6.64 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.541 -1.349 . . . . 0.0 110.651 -177.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.4 -123.97 7.07 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 120.763 -1.21 . . . . 0.0 114.463 167.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 102.47 171.27 26.9 Favored Glycine 0 N--CA 1.43 -1.75 0 CA-C-O 122.671 1.151 . . . . 0.0 113.208 178.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.8 p -77.62 -28.26 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.138 1.162 . . . . 0.0 114.138 -172.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -74.96 -46.29 36.45 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 120.391 -1.443 . . . . 0.0 114.209 -171.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 3.8 t -87.67 175.75 7.74 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.716 -1.24 . . . . 0.0 113.491 -172.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 78.4 p -83.28 46.09 1.1 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.345 1.858 . . . . 0.0 115.34 -171.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.49 -177.11 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 O-C-N 119.749 -1.844 . . . . 0.0 110.018 170.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -71.63 102.43 2.76 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.901 -1.749 . . . . 0.0 111.532 -178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 56.69 19.21 4.16 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 128.975 2.91 . . . . 0.0 118.636 174.38 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.24 69.33 1.41 Allowed Glycine 0 N--CA 1.43 -1.745 0 O-C-N 120.729 -1.232 . . . . 0.0 114.728 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.98 175.55 21.48 Favored Glycine 0 N--CA 1.43 -1.73 0 O-C-N 121.467 -1.019 . . . . 0.0 113.55 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.1 mm -102.81 117.18 47.8 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 125.798 1.639 . . . . 0.0 108.222 -176.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -123.23 149.81 44.23 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.166 -0.958 . . . . 0.0 109.947 -169.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 50.4 t -78.12 122.59 33.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.506 -1.371 . . . . 0.0 113.14 177.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.52 -39.26 10.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.614 -1.304 . . . . 0.0 112.799 -178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.26 158.86 42.28 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.441 -1.412 . . . . 0.0 111.466 -177.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.412 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -122.46 120.8 62.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-O 122.965 1.364 . . . . 0.0 110.824 176.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.75 121.66 85.18 Favored Pre-proline 0 N--CA 1.43 -1.468 0 C-N-CA 125.802 1.641 . . . . 0.0 113.189 -171.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -64.42 134.37 41.39 Favored 'Trans proline' 0 C--N 1.3 -2.004 0 CA-C-N 123.98 2.457 . . . . 0.0 112.689 179.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 56.7 mttm 82.29 20.35 0.29 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 129.173 2.989 . . . . 0.0 113.785 -172.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.51 154.85 30.23 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 119.966 -1.709 . . . . 0.0 115.938 169.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.47 -58.72 5.1 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.986 2.115 . . . . 0.0 115.562 158.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.06 -46.54 86.98 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.99 2.916 . . . . 0.0 111.612 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.412 ' HA ' HG12 ' A' ' 47' ' ' ILE . 2.6 tm-20 -41.73 -59.58 1.62 Allowed 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 169.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.0 t -69.54 -34.6 74.46 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -62.08 -46.81 87.44 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.015 -1.678 . . . . 0.0 113.542 -171.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 108.07 -6.69 34.86 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.359 -1.463 . . . . 0.0 116.08 155.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.482 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.4 mmp_? -70.23 -35.48 73.87 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.918 -1.342 . . . . 0.0 111.131 169.138 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 51.5 mt -87.22 128.94 39.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 126.396 1.878 . . . . 0.0 108.766 176.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -164.28 123.21 1.89 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.6 -1.312 . . . . 0.0 107.798 -176.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.17 112.92 0.31 Allowed 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 116.846 2.165 . . . . 0.0 116.846 -167.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.15 -8.66 12.32 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 118.552 -1.138 . . . . 0.0 113.616 -164.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -79.84 164.34 23.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 120.799 2.299 . . . . 0.0 113.019 175.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.1 ttt180 -125.57 124.79 42.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.153 -0.967 . . . . 0.0 110.877 -171.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 15.5 t -87.74 135.49 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 O-C-N 120.106 -1.621 . . . . 0.0 109.815 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.4 mp -106.24 -44.06 4.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.721 1.208 . . . . 0.0 111.111 -177.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.96 132.54 15.79 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.705 -1.247 . . . . 0.0 111.255 -177.064 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.3 t -109.97 119.39 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.524 1.13 . . . . 0.0 108.518 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 66.87 24.6 9.7 Favored 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 126.146 1.778 . . . . 0.0 114.125 173.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 90.48 -9.9 76.15 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 120.147 -1.596 . . . . 0.0 114.182 -173.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.0 t -96.66 119.99 45.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.552 1.141 . . . . 0.0 108.098 -176.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.7 t -76.04 145.93 39.81 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.444 -1.41 . . . . 0.0 112.476 -174.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 95.9 mt -91.49 8.13 37.91 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.516 -1.365 . . . . 0.0 113.251 -175.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 77.1 mt-10 -68.27 107.73 2.92 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 119.535 -1.978 . . . . 0.0 113.934 -176.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 91.27 4.3 68.68 Favored Glycine 0 N--CA 1.429 -1.782 0 O-C-N 120.773 -1.205 . . . . 0.0 113.715 -175.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.52 148.11 45.34 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 121.139 -1.213 . . . . 0.0 113.79 168.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.3 p -80.51 173.92 12.12 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.852 -1.155 . . . . 0.0 111.845 169.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -55.54 -52.29 64.21 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.364 1.865 . . . . 0.0 112.368 168.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -57.14 -43.12 82.14 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 115.043 1.498 . . . . 0.0 115.043 173.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.3 mp0 -56.27 -42.72 77.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.806 1.78 . . . . 0.0 115.806 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.6 -36.12 83.2 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.804 -1.185 . . . . 0.0 112.904 175.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -72.9 -44.36 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 O-C-N 120.662 -1.274 . . . . 0.0 111.191 177.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -54.04 -37.91 64.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.977 1.711 . . . . 0.0 113.247 171.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -73.36 -52.21 14.64 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.901 2.08 . . . . 0.0 112.224 177.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 48.3 mt -64.41 -31.47 72.7 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -70.05 -26.46 64.03 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.18 -1.575 . . . . 0.0 112.982 174.336 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 29.3 t30 -91.6 39.71 1.01 Allowed 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.563 1.545 . . . . 0.0 112.887 178.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 14.7 p -94.28 155.47 17.0 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 126.29 1.836 . . . . 0.0 111.786 177.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -146.59 20.65 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.038 -1.039 . . . . 0.0 112.587 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -69.68 -56.27 7.68 Favored 'General case' 0 N--CA 1.429 -1.523 0 O-C-N 121.2 -1.176 . . . . 0.0 112.38 173.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.1 t -98.54 128.47 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.826 1.298 . . . . 0.0 108.418 178.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 88.7 t -114.46 109.41 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 128.385 2.674 . . . . 0.0 109.024 -171.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 25.9 m170 -88.84 109.37 20.14 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 120.634 -1.291 . . . . 0.0 110.597 174.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 38.0 mt -101.23 153.66 19.43 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.641 -1.287 . . . . 0.0 111.136 161.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -123.02 128.2 49.85 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 105.414 -2.069 . . . . 0.0 105.414 157.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.6 pp -142.46 163.44 32.84 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 121.473 -0.767 . . . . 0.0 111.779 -171.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.51 136.02 53.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.399 1.88 . . . . 0.0 109.145 -179.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.1 tptm -77.66 148.03 35.22 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.766 -1.834 . . . . 0.0 112.707 176.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.76 119.43 5.29 Favored Glycine 0 N--CA 1.43 -1.735 0 C-N-CA 125.106 1.336 . . . . 0.0 112.327 176.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -77.91 178.62 7.3 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.076 1.51 . . . . 0.0 115.076 -172.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.3 m -114.45 161.98 25.74 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 124.606 1.162 . . . . 0.0 110.459 -176.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo . . . . . 0 N--CA 1.434 -2.014 0 C-N-CA 122.174 1.916 . . . . 0.0 115.215 168.936 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 97.8 mttt . . . . . 0 N--CA 1.43 -1.444 0 CA-C-O 118.062 -0.97 . . . . 0.0 108.901 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -77.85 62.55 7.91 Favored 'Trans proline' 0 N--CA 1.433 -2.034 0 C-N-CA 124.174 3.249 . . . . 0.0 113.425 -179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.49 48.55 0.26 Allowed Glycine 0 N--CA 1.429 -1.778 0 C-N-CA 124.893 1.235 . . . . 0.0 114.158 177.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -89.55 167.52 12.89 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 160.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -104.96 160.75 14.78 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 121.02 -1.05 . . . . 0.0 110.593 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.86 139.12 26.09 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 170.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.34 131.71 37.31 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.964 1.306 . . . . 0.0 109.412 165.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.1 t -119.73 115.04 46.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -177.371 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 -107.53 91.17 3.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.227 1.411 . . . . 0.0 107.81 177.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.23 132.77 54.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.593 1.157 . . . . 0.0 112.241 -162.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.15 137.96 33.5 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.14 -1.6 . . . . 0.0 111.871 176.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 27.9 mttp -70.13 148.42 48.73 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 115.214 1.561 . . . . 0.0 115.214 178.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 37.3 p -113.59 118.78 35.37 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.965 1.306 . . . . 0.0 109.76 173.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.7 t0 59.49 32.51 21.74 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.532 1.933 . . . . 0.0 114.172 -176.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.62 79.03 Favored Glycine 0 N--CA 1.429 -1.832 0 O-C-N 119.763 -1.835 . . . . 0.0 114.869 -173.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.4 p -121.5 144.56 48.63 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.72 -1.459 . . . . 0.0 112.151 178.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 74.2 mt -85.62 -60.42 2.03 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.923 -1.11 . . . . 0.0 109.943 165.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 117.04 46.87 0.5 Allowed Glycine 0 N--CA 1.43 -1.708 0 O-C-N 119.983 -1.698 . . . . 0.0 109.749 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.2 tt -140.73 144.71 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 123.337 1.541 . . . . 0.0 110.296 -175.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 8.6 t -118.83 133.3 55.93 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 166.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 m -108.44 164.67 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.49 1.116 . . . . 0.0 110.449 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.6 t -147.85 178.36 8.57 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.554 1.142 . . . . 0.0 108.481 176.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 91.99 -162.41 27.42 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.515 -1.366 . . . . 0.0 113.548 176.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.56 165.93 22.67 Favored Glycine 0 N--CA 1.431 -1.665 0 C-N-CA 124.753 1.168 . . . . 0.0 110.707 -173.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.62 -20.34 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.073 -1.251 . . . . 0.0 113.941 -176.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -66.49 -30.4 70.73 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.055 1.742 . . . . 0.0 113.784 179.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.6 t -114.63 166.88 11.25 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.982 -1.074 . . . . 0.0 110.089 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.3 m -84.12 36.38 0.57 Allowed 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.577 -1.952 . . . . 0.0 115.903 -165.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 17.0 m -81.84 175.98 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 119.97 -1.706 . . . . 0.0 112.328 -178.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -72.09 104.75 3.69 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.561 -1.337 . . . . 0.0 113.847 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 8.6 t60 48.35 51.88 14.4 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.138 2.575 . . . . 0.0 117.853 169.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 70.82 45.77 49.93 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.632 -1.293 . . . . 0.0 115.768 175.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -104.64 140.23 14.91 Favored Glycine 0 N--CA 1.43 -1.73 0 O-C-N 120.963 -1.316 . . . . 0.0 113.272 -178.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.7 mm -98.64 127.8 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 105.289 -2.115 . . . . 0.0 105.289 170.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 80.3 m-85 -128.03 157.64 40.1 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.465 -1.397 . . . . 0.0 111.218 -169.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.3 t -75.44 120.65 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 O-C-N 121.02 -1.05 . . . . 0.0 111.044 169.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 22.1 tptp -90.84 -52.09 5.04 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.626 1.571 . . . . 0.0 110.542 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.08 154.72 36.48 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.15 124.16 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 174.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.72 121.31 84.59 Favored Pre-proline 0 N--CA 1.429 -1.523 0 C-N-CA 126.671 1.989 . . . . 0.0 113.956 -167.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -57.7 123.41 13.67 Favored 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 124.448 2.624 . . . . 0.0 116.408 -172.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.268 3.9 mtpm? 76.84 25.99 0.82 Allowed 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 128.137 2.575 . . . . 0.0 114.855 -178.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.42 169.18 47.14 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.175 -1.578 . . . . 0.0 113.495 168.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.5 -58.76 5.01 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.084 2.154 . . . . 0.0 114.668 165.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.59 -47.71 77.63 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 128.861 2.864 . . . . 0.0 112.762 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -46.1 -59.03 3.12 Favored 'General case' 0 N--CA 1.43 -1.446 0 N-CA-C 116.845 2.165 . . . . 0.0 116.845 172.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.7 t -69.82 -27.71 65.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 124.848 1.259 . . . . 0.0 113.556 -175.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -50.79 -62.6 1.51 Allowed 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 126.838 2.055 . . . . 0.0 113.305 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 126.28 -45.36 1.16 Allowed Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.969 -0.457 . . . . 0.0 113.087 168.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.46 -19.01 65.68 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 115.079 1.511 . . . . 0.0 115.079 -172.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.8 mt -96.31 117.19 40.11 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.519 0 C-N-CA 124.967 1.307 . . . . 0.0 109.06 172.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 2.7 m80 -118.57 159.45 23.54 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.773 -1.204 . . . . 0.0 110.879 -178.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.8 ttpp -62.29 129.26 39.9 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.015 -1.678 . . . . 0.0 113.099 173.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.14 -0.3 72.0 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.886 -1.134 . . . . 0.0 114.831 -177.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.3 m-20 -79.62 152.23 30.14 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.768 -1.43 . . . . 0.0 111.289 178.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.8 ttt-85 -105.28 131.13 53.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.031 -1.668 . . . . 0.0 111.261 -168.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 38.3 t -85.34 136.88 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.963 -1.71 . . . . 0.0 110.941 -174.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -105.97 -56.65 2.15 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.908 -1.12 . . . . 0.0 109.386 177.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.7 137.22 18.79 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.186 -0.946 . . . . 0.0 111.925 -173.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 42.5 t -113.55 125.8 70.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 67.73 14.72 9.56 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.078 -1.639 . . . . 0.0 115.263 169.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 104.13 -13.26 52.26 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 119.748 -1.845 . . . . 0.0 112.913 -175.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.7 t -92.85 104.87 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 124.369 1.068 . . . . 0.0 109.333 -176.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.3 t -74.26 126.71 31.23 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.665 -1.272 . . . . 0.0 109.589 173.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 85.1 mt -83.51 55.18 3.09 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.019 1.118 . . . . 0.0 114.019 -158.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -71.43 122.16 19.89 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 119.543 -1.973 . . . . 0.0 114.342 -172.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 74.63 5.09 72.59 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.186 -1.571 . . . . 0.0 115.437 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.62 140.59 49.81 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 116.255 1.946 . . . . 0.0 116.255 -171.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.2 p -93.3 178.86 5.59 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.496 2.319 . . . . 0.0 111.747 172.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 20.9 t-160 -57.48 -48.16 79.98 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 126.656 1.982 . . . . 0.0 114.463 179.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.3 tptt -56.66 -42.92 79.81 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 174.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -59.4 -50.48 73.8 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.868 1.667 . . . . 0.0 114.515 178.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.25 -38.31 83.07 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.038 1.335 . . . . 0.0 113.518 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 70.4 t -66.42 -46.92 85.52 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 O-C-N 120.792 -1.192 . . . . 0.0 111.851 173.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -54.65 -48.5 72.23 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.689 1.596 . . . . 0.0 112.359 178.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 13.6 m -64.84 -45.97 83.87 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.856 2.463 . . . . 0.0 114.048 175.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.1 mt -64.04 -34.1 77.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 119.29 -2.131 . . . . 0.0 114.675 174.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 17.6 mtp-105 -65.21 -36.58 84.63 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.437 -1.414 . . . . 0.0 112.851 172.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -86.52 46.22 1.33 Allowed 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 125.62 1.568 . . . . 0.0 112.712 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.418 ' HB ' HG22 ' A' ' 92' ' ' VAL . 25.1 p -107.12 155.99 19.27 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.65 1.58 . . . . 0.0 109.657 173.546 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.33 -156.4 32.29 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.647 -1.283 . . . . 0.0 112.53 178.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -68.88 -54.94 12.77 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.175 -1.191 . . . . 0.0 111.772 176.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 130.8 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.379 0 CA-C-O 122.497 1.141 . . . . 0.0 108.314 170.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.418 HG22 ' HB ' ' A' ' 88' ' ' THR . 63.6 t -118.47 121.27 66.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 127.029 2.132 . . . . 0.0 109.743 -168.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -97.28 113.68 25.34 Favored 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 121.314 -0.866 . . . . 0.0 111.244 173.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.2 155.76 19.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 124.581 1.152 . . . . 0.0 112.639 169.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 40.3 tp -127.11 128.79 46.77 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.173 -1.418 . . . . 0.0 107.173 158.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.7 pp -142.3 170.15 16.25 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.671 -1.268 . . . . 0.0 111.213 175.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -114.7 145.74 41.71 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.267 1.827 . . . . 0.0 109.165 178.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.2 tptt -75.89 138.67 41.2 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.804 1.241 . . . . 0.0 111.308 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.16 130.28 38.37 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.822 -1.174 . . . . 0.0 114.135 -179.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -83.89 -61.46 1.82 Allowed 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.654 -0.909 . . . . 0.0 112.063 -171.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.2 m -98.49 144.14 27.57 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 124.288 1.035 . . . . 0.0 112.572 -177.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo . . . . . 0 N--CA 1.434 -2.026 0 C-N-CA 122.917 2.411 . . . . 0.0 114.005 166.975 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.269 32.4 ttmt . . . . . 0 N--CA 1.431 -1.423 0 CA-C-O 115.4 -2.238 . . . . 0.0 114.338 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -62.34 63.84 0.13 Allowed 'Trans proline' 0 N--CA 1.434 -2.007 0 C-N-CA 125.039 3.826 . . . . 0.0 117.538 168.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.06 27.43 1.7 Allowed Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 126.193 1.854 . . . . 0.0 112.622 -175.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -82.07 156.44 24.58 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 118.294 1.047 . . . . 0.0 109.171 167.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -114.01 149.8 34.84 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.805 1.242 . . . . 0.0 109.451 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -145.85 127.79 15.48 Favored 'General case' 0 N--CA 1.43 -1.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -87.88 113.55 23.65 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 164.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 t -99.05 110.38 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 124.512 1.125 . . . . 0.0 109.702 -169.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 27.7 mt-10 -104.94 87.25 2.61 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.381 1.086 . . . . 0.0 110.242 -177.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.1 mt -90.21 147.6 23.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.073 -1.017 . . . . 0.0 110.593 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.88 112.79 25.91 Favored 'General case' 0 N--CA 1.428 -1.544 0 C-N-CA 124.107 0.963 . . . . 0.0 108.593 160.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.6 ttmt -70.16 126.12 28.74 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.442 1.497 . . . . 0.0 112.608 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 23.8 p -104.27 123.35 47.21 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.045 -1.659 . . . . 0.0 110.894 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.8 t70 63.61 24.7 14.07 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.591 1.557 . . . . 0.0 113.861 170.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.6 4.81 89.95 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 119.51 -1.994 . . . . 0.0 115.189 -175.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.5 m -105.35 104.21 13.89 Favored 'General case' 0 N--CA 1.429 -1.477 0 CA-C-N 119.195 1.497 . . . . 0.0 111.629 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 11.9 tp -80.81 -45.51 16.81 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 120.563 -1.336 . . . . 0.0 111.475 173.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.06 28.08 3.23 Favored Glycine 0 N--CA 1.429 -1.773 0 C-N-CA 125.574 1.559 . . . . 0.0 113.547 170.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.9 tt -148.99 136.02 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-N 120.014 1.907 . . . . 0.0 114.694 -168.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.3 m -110.83 126.6 54.82 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.847 1.659 . . . . 0.0 108.48 167.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -104.24 172.01 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.219 1.007 . . . . 0.0 111.905 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.4 t -157.3 176.96 12.0 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.504 -1.372 . . . . 0.0 110.803 175.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 115.35 -128.33 8.03 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.457 1.027 . . . . 0.0 112.276 169.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.32 134.84 8.16 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.163 0.887 . . . . 0.0 111.279 -178.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.7 m -66.95 -23.09 30.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 N-CA-C 115.702 1.741 . . . . 0.0 115.702 -170.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -99.17 4.49 46.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.779 1.632 . . . . 0.0 112.488 -176.018 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 2.6 m -87.57 -135.62 0.09 Allowed 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.118 -1.614 . . . . 0.0 110.908 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.5 m -80.24 -32.26 38.39 Favored 'General case' 0 N--CA 1.431 -1.377 0 O-C-N 118.39 -2.694 . . . . 0.0 110.036 177.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.6 m -83.74 92.13 2.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 126.135 1.774 . . . . 0.0 110.181 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.8 ttt-85 -70.03 109.99 4.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.582 -1.949 . . . . 0.0 111.706 -174.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 10.9 m170 58.8 45.66 15.19 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 125.818 1.647 . . . . 0.0 112.893 -167.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -71.53 -58.48 5.4 Favored Glycine 0 N--CA 1.429 -1.787 0 N-CA-C 115.66 1.024 . . . . 0.0 115.66 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 108.91 -177.92 20.62 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 124.917 1.246 . . . . 0.0 112.166 -165.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 28.7 mm -104.13 125.59 58.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 124.945 1.298 . . . . 0.0 109.664 178.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -126.84 158.81 35.68 Favored 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 120.276 -1.515 . . . . 0.0 112.182 -172.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.2 t -76.23 120.35 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 125.135 1.374 . . . . 0.0 112.689 175.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 26.0 ttpp -93.93 -47.05 6.9 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.586 -1.321 . . . . 0.0 112.109 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.71 152.25 24.99 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 121.113 -0.992 . . . . 0.0 111.435 178.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -108.39 122.29 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 C-N-CA 126.136 1.774 . . . . 0.0 109.378 175.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 9.3 mm -77.58 123.93 86.66 Favored Pre-proline 0 N--CA 1.429 -1.495 0 C-N-CA 127.014 2.126 . . . . 0.0 114.352 -175.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_exo -57.55 125.74 19.71 Favored 'Trans proline' 0 N--CA 1.434 -1.998 0 CA-C-N 124.607 2.681 . . . . 0.0 116.526 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.313 63.1 mttm 83.01 16.34 0.32 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 128.46 2.704 . . . . 0.0 113.72 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.06 162.48 38.83 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.116 -1.615 . . . . 0.0 114.128 169.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.41 -55.78 11.89 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.02 1.728 . . . . 0.0 114.977 170.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.89 -47.78 81.8 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.735 2.814 . . . . 0.0 112.59 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -48.44 -61.08 2.19 Favored 'General case' 0 N--CA 1.428 -1.537 0 N-CA-C 115.611 1.708 . . . . 0.0 115.611 173.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 37.7 m -69.1 -32.59 72.11 Favored 'General case' 0 N--CA 1.429 -1.507 0 CA-C-N 115.499 -0.773 . . . . 0.0 112.859 -173.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -58.91 -70.28 0.16 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.947 1.699 . . . . 0.0 113.411 175.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.27 14.76 43.75 Favored Glycine 0 N--CA 1.43 -1.712 0 O-C-N 120.38 -1.45 . . . . 0.0 114.9 173.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.2 mmp_? -65.27 -26.47 68.1 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.707 -1.467 . . . . 0.0 111.691 159.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 71.6 mt -106.55 130.75 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 C-N-CA 126.686 1.994 . . . . 0.0 109.223 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 76.2 m-70 -126.95 170.01 12.72 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-O 123.062 1.411 . . . . 0.0 110.835 169.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -60.59 129.69 42.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.01 -1.681 . . . . 0.0 113.388 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 85.31 4.15 86.44 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.291 -1.506 . . . . 0.0 115.608 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 -75.46 161.98 28.74 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-N 119.835 1.817 . . . . 0.0 111.665 175.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 10.1 tpt85 -108.57 116.83 32.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.892 -1.13 . . . . 0.0 110.945 -170.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.6 t -84.66 130.6 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 O-C-N 120.511 -1.368 . . . . 0.0 108.283 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 tp -111.31 -36.58 5.53 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.824 1.25 . . . . 0.0 112.401 -166.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 152.36 33.53 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.234 -1.541 . . . . 0.0 110.11 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 27.1 t -120.79 114.64 44.31 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 170.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 54.04 48.53 20.88 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.906 2.083 . . . . 0.0 115.535 170.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.06 -18.45 44.61 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 120.834 -1.166 . . . . 0.0 114.571 -177.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.6 t -94.21 105.8 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 O-C-N 120.82 -1.4 . . . . 0.0 109.004 -178.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.8 p -72.23 138.8 47.77 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.688 -1.257 . . . . 0.0 111.761 178.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 53.7 mt -87.15 32.62 0.68 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.636 -1.29 . . . . 0.0 112.777 -169.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -69.61 130.21 41.78 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.189 -2.195 . . . . 0.0 112.66 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.03 8.73 44.12 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 125.645 1.593 . . . . 0.0 116.253 -176.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.33 142.08 50.43 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 115.771 1.767 . . . . 0.0 115.771 -171.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 40.6 p -87.32 175.25 8.1 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.051 1.34 . . . . 0.0 110.312 173.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.1 t-160 -61.82 -40.22 94.5 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.644 -1.285 . . . . 0.0 111.757 174.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.4 tppt? -54.93 -47.16 74.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.355 1.862 . . . . 0.0 114.928 173.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -56.6 -51.81 67.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.237 1.199 . . . . 0.0 114.237 -179.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.32 -42.38 95.45 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 124.233 1.013 . . . . 0.0 113.28 177.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.2 t -65.08 -48.07 85.32 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.984 -1.073 . . . . 0.0 111.137 178.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 73.5 mt-10 -63.97 -41.31 97.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 3.5 m -61.0 -47.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 126.225 1.81 . . . . 0.0 112.874 175.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.7 mt -68.43 -29.67 68.38 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 175.33 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.4 ttt180 -62.76 -36.26 82.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.382 -1.449 . . . . 0.0 113.039 173.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -94.83 49.82 1.27 Allowed 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.643 -1.286 . . . . 0.0 111.76 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 37.0 p -107.34 139.68 41.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.325 1.45 . . . . 0.0 110.256 170.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.26 -142.95 12.25 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 123.564 0.602 . . . . 0.0 112.654 173.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.4 tt0 -69.38 -60.98 1.98 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.303 -1.116 . . . . 0.0 113.401 -178.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.7 t -92.02 118.24 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 122.701 1.239 . . . . 0.0 109.773 -176.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 90.6 t -117.93 111.1 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 126.122 1.769 . . . . 0.0 109.525 -166.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.8 m170 -99.71 103.01 14.65 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 121.105 -0.997 . . . . 0.0 111.092 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.5 mt -92.85 168.16 11.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.75 -1.844 . . . . 0.0 112.153 171.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.6 tp -129.05 137.67 51.43 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.016 1.326 . . . . 0.0 107.63 157.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.7 161.2 39.78 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.732 -1.23 . . . . 0.0 112.845 174.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 -96.46 144.89 26.15 Favored 'General case' 0 N--CA 1.431 -1.406 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 164.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.9 tmtt? -77.17 127.5 32.74 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.859 -1.151 . . . . 0.0 108.279 162.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.9 103.85 0.19 Allowed Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 125.735 1.636 . . . . 0.0 116.223 -166.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -65.49 -67.89 0.41 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 116.246 1.943 . . . . 0.0 116.246 -164.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 10.9 p -108.91 136.81 20.0 Favored Pre-proline 0 N--CA 1.429 -1.51 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.06 175.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo . . . . . 0 N--CA 1.434 -2.016 0 C-N-CA 122.438 2.092 . . . . 0.0 114.317 176.109 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.0 pttm . . . . . 0 N--CA 1.43 -1.438 0 CA-C-O 119.028 -0.511 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_exo -69.82 -177.26 1.81 Allowed 'Trans proline' 0 N--CA 1.433 -2.031 0 C-N-CA 123.302 2.668 . . . . 0.0 115.631 -177.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.15 24.75 28.46 Favored Glycine 0 N--CA 1.43 -1.729 0 O-C-N 121.848 -0.533 . . . . 0.0 113.039 172.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -85.88 117.52 24.8 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.353 1.061 . . . . 0.0 108.982 -178.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 p -88.94 139.22 30.68 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.368 -1.458 . . . . 0.0 110.837 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.27 0.0 OUTLIER -147.4 140.48 25.12 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 123.277 1.513 . . . . 0.0 110.637 175.155 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 7.0 mt-10 -90.32 146.51 24.14 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.483 1.913 . . . . 0.0 109.323 177.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.5 t -122.81 110.46 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 C-N-CA 125.008 1.323 . . . . 0.0 107.488 -174.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -105.83 84.2 2.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 CA-C-O 122.214 1.007 . . . . 0.0 108.458 174.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 26.3 tp -110.84 145.1 38.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.01 1.324 . . . . 0.0 110.283 -167.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.31 138.38 40.16 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 119.842 -1.786 . . . . 0.0 110.109 168.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -70.86 149.02 47.21 Favored 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 169.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 11.9 t -109.72 111.56 23.1 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.733 -1.229 . . . . 0.0 109.225 179.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 17.9 t0 43.34 50.27 5.98 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.923 2.489 . . . . 0.0 114.778 -178.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.97 -39.42 2.79 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.452 1.025 . . . . 0.0 115.043 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 41.9 m -102.03 148.72 25.03 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.731 -1.452 . . . . 0.0 114.793 -161.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -106.65 -61.37 1.54 Allowed 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.161 -0.962 . . . . 0.0 112.041 176.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.91 32.32 1.58 Allowed Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.669 -1.895 . . . . 0.0 112.798 175.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 pt -124.09 139.71 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 C-N-CA 125.105 1.362 . . . . 0.0 108.693 -177.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.1 t -129.28 125.64 37.27 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 36.0 m -108.38 168.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.986 0.898 . . . . 0.0 112.63 -172.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -148.8 160.08 43.55 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.853 1.661 . . . . 0.0 109.095 -179.002 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 121.86 -142.9 15.44 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.729 -1.232 . . . . 0.0 113.614 169.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 118.37 166.42 13.68 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 116.039 1.176 . . . . 0.0 116.039 174.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p -88.93 -28.32 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 O-C-N 120.757 -1.437 . . . . 0.0 114.64 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -83.94 -17.0 42.13 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.004 -1.685 . . . . 0.0 111.589 179.355 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -94.54 146.76 23.88 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.804 2.041 . . . . 0.0 109.677 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.5 m -86.31 60.58 6.32 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 120.71 -1.244 . . . . 0.0 112.004 -173.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.9 m -100.34 -128.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 126.338 1.855 . . . . 0.0 111.321 -177.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -62.78 -61.13 2.62 Favored 'General case' 0 N--CA 1.432 -1.366 0 O-C-N 120.165 -1.584 . . . . 0.0 113.614 -177.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.0 t-160 151.34 65.43 0.0 OUTLIER 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 128.978 2.911 . . . . 0.0 106.174 -167.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 64.69 49.18 65.45 Favored Glycine 0 N--CA 1.429 -1.819 0 O-C-N 120.318 -1.489 . . . . 0.0 115.936 178.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -119.7 137.8 12.73 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.171 -1.194 . . . . 0.0 111.136 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 31.7 mm -103.41 120.85 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 172.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -124.57 160.98 27.17 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.788 -1.195 . . . . 0.0 109.119 -175.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.3 t -75.37 128.3 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.731 -1.231 . . . . 0.0 110.475 171.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 29.1 ttmt -89.94 -50.45 6.02 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.87 -1.144 . . . . 0.0 110.325 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.58 150.79 33.92 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 123.396 0.678 . . . . 0.0 109.873 -174.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -110.31 121.82 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 170.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 20.9 mm -76.64 121.0 84.08 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 126.219 1.808 . . . . 0.0 113.256 -171.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -58.31 122.93 12.52 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.83 2.353 . . . . 0.0 116.184 -175.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.321 64.7 mttt 82.5 20.16 0.27 Allowed 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 127.367 2.267 . . . . 0.0 113.801 176.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.07 161.89 40.07 Favored Glycine 0 N--CA 1.429 -1.796 0 O-C-N 121.227 -0.921 . . . . 0.0 114.832 170.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.81 -57.04 7.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.131 2.172 . . . . 0.0 114.396 170.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.87 -52.55 62.67 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.58 2.352 . . . . 0.0 112.278 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.3 tm-20 -42.56 -64.86 0.54 Allowed 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 116.553 2.057 . . . . 0.0 116.553 174.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 16.9 m -69.94 -14.21 62.61 Favored 'General case' 0 N--CA 1.429 -1.486 0 N-CA-C 115.273 1.583 . . . . 0.0 115.273 -175.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.84 -64.32 1.03 Allowed 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.712 -1.243 . . . . 0.0 110.353 174.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 79.33 48.01 7.1 Favored Glycine 0 N--CA 1.43 -1.731 0 N-CA-C 117.292 1.677 . . . . 0.0 117.292 170.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.7 mtt180 -84.56 -39.87 18.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.095 -1.817 . . . . 0.0 106.095 146.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 55.8 mt -83.42 121.47 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 126.162 1.785 . . . . 0.0 111.45 176.509 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 46.7 m-70 -122.08 171.75 8.75 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.243 1.497 . . . . 0.0 111.398 170.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 75.6 tttt -60.62 127.79 33.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.555 -1.34 . . . . 0.0 112.428 175.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.73 0.91 71.53 Favored Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 115.684 1.034 . . . . 0.0 115.684 -178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -82.17 150.05 27.61 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.83 1.815 . . . . 0.0 112.505 -177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -90.17 127.82 36.2 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.126 -1.609 . . . . 0.0 113.548 -177.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 30.4 t -83.12 132.79 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.787 177.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -106.93 -51.86 2.86 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.124 -0.985 . . . . 0.0 111.775 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -151.27 141.33 22.13 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.096 -1.627 . . . . 0.0 112.799 -175.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 26.8 t -114.94 120.28 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.343 1.057 . . . . 0.0 108.963 177.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 74.35 16.49 3.35 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.931 1.692 . . . . 0.0 114.558 169.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.54 -1.48 81.74 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.622 -1.299 . . . . 0.0 112.745 -170.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.6 t -98.28 117.36 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 125.353 1.461 . . . . 0.0 108.114 176.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.6 t -74.21 125.86 29.34 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.3 -1.5 . . . . 0.0 109.346 178.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . 0.327 0.7 OUTLIER -92.27 39.32 1.02 Allowed 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 123.314 1.531 . . . . 0.0 112.183 -176.251 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -76.36 121.37 22.91 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.135 -1.603 . . . . 0.0 110.753 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 81.5 17.79 70.2 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.757 1.17 . . . . 0.0 113.731 -172.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.25 154.26 41.09 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 123.226 1.489 . . . . 0.0 115.001 171.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.2 p -91.57 173.6 7.8 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.337 -1.477 . . . . 0.0 110.892 171.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 23.7 t-160 -51.68 -51.93 52.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.439 1.896 . . . . 0.0 112.416 168.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.27 -53.19 61.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 115.446 1.647 . . . . 0.0 115.446 172.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.0 tt0 -60.62 -42.74 97.46 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 -170.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.24 -29.65 68.91 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.168 1.387 . . . . 0.0 114.162 171.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.4 t -79.74 -44.28 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 125.033 1.333 . . . . 0.0 111.49 174.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -58.2 -37.24 74.4 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.335 -1.478 . . . . 0.0 112.745 174.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.7 m -65.83 -41.23 92.06 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 127.176 2.191 . . . . 0.0 113.54 172.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 29.9 mt -71.23 -40.14 71.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 115.095 1.517 . . . . 0.0 115.095 175.182 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -72.08 -20.05 61.72 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.544 -1.973 . . . . 0.0 112.453 178.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 32.4 t-20 -94.39 53.48 1.7 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.511 -1.368 . . . . 0.0 112.019 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.0 p -107.05 143.34 35.31 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.135 -1.603 . . . . 0.0 110.9 176.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.34 -154.97 18.49 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 120.76 -1.212 . . . . 0.0 111.242 171.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -66.5 -52.96 40.43 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.604 -1.527 . . . . 0.0 114.009 -178.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.3 t -95.74 126.23 48.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 123.138 1.447 . . . . 0.0 109.567 177.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.7 t -109.82 109.36 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 127.298 2.239 . . . . 0.0 107.833 -175.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -93.73 111.44 23.13 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.091 -1.006 . . . . 0.0 108.988 172.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 31.9 mt -110.14 160.71 16.25 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.182 0.993 . . . . 0.0 112.457 170.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.95 133.11 49.2 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.413 1.485 . . . . 0.0 108.157 164.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.83 166.12 29.46 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.469 0.652 . . . . 0.0 112.536 178.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -101.86 144.74 30.14 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 121.046 -1.033 . . . . 0.0 111.179 173.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.6 tttt -75.86 126.82 31.73 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.615 1.566 . . . . 0.0 112.48 167.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -79.08 -166.88 32.25 Favored Glycine 0 N--CA 1.431 -1.656 0 CA-C-O 123.405 1.559 . . . . 0.0 116.883 178.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.2 pt20 -94.95 -171.46 2.44 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 126.006 1.723 . . . . 0.0 111.288 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 46.0 t -80.16 117.84 69.53 Favored Pre-proline 0 N--CA 1.43 -1.43 0 CA-C-O 117.951 -1.023 . . . . 0.0 109.363 174.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo . . . . . 0 N--CA 1.434 -2.024 0 C-N-CA 122.41 2.073 . . . . 0.0 113.234 -174.912 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mmtt . . . . . 0 N--CA 1.431 -1.408 0 CA-C-O 116.372 -1.775 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -75.77 -179.56 5.28 Favored 'Trans proline' 0 N--CA 1.433 -2.041 0 CA-C-N 126.464 3.344 . . . . 0.0 112.408 175.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.92 6.89 66.69 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 120.951 -1.093 . . . . 0.0 114.017 178.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -78.41 157.7 28.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 O-C-N 121.123 -1.222 . . . . 0.0 110.745 175.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -119.93 137.72 53.88 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.42 1.488 . . . . 0.0 108.993 -174.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -145.08 140.76 28.28 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-O 122.827 1.298 . . . . 0.0 109.739 -175.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.1 mt-10 -100.52 112.53 24.91 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.297 1.839 . . . . 0.0 108.039 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.8 t -103.81 102.08 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.378 0 O-C-N 120.608 -1.307 . . . . 0.0 108.769 -172.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -90.73 102.1 14.85 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 167.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 33.8 tp -120.03 138.02 53.76 Favored 'General case' 0 N--CA 1.429 -1.482 0 C-N-CA 124.701 1.201 . . . . 0.0 110.002 -172.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.17 122.3 43.37 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.27 -1.519 . . . . 0.0 109.486 173.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -71.42 171.51 11.14 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.289 -1.507 . . . . 0.0 114.408 177.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 15.2 t -97.03 -149.81 0.33 Allowed 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.711 -1.243 . . . . 0.0 108.287 169.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.39 74.67 3.16 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.03 -2.294 . . . . 0.0 112.571 -175.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.36 -4.8 77.38 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.531 1.539 . . . . 0.0 115.509 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.2 t -121.57 135.83 54.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.104 -1.233 . . . . 0.0 112.015 -173.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 12.3 mt -103.92 -55.31 2.4 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.851 1.66 . . . . 0.0 110.113 178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.0 30.03 0.59 Allowed Glycine 0 N--CA 1.431 -1.693 0 C-N-CA 125.369 1.462 . . . . 0.0 112.56 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.454 HD12 HD13 ' A' ' 85' ' ' LEU . 11.1 pt -125.95 141.44 45.62 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 CA-C-N 118.586 1.193 . . . . 0.0 113.477 -163.401 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.2 m -129.47 138.13 51.23 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.375 1.07 . . . . 0.0 109.005 158.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.4 m -118.34 169.58 8.88 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.525 0 C-N-CA 124.949 1.299 . . . . 0.0 112.49 -174.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.25 169.84 18.53 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 172.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 133.41 -147.94 19.19 Favored Glycine 0 N--CA 1.428 -1.836 0 O-C-N 120.572 -1.33 . . . . 0.0 115.53 165.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.17 172.26 24.17 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.43 1.014 . . . . 0.0 112.998 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.1 t -90.79 -51.88 11.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 C-N-CA 124.828 1.251 . . . . 0.0 112.917 -172.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -92.82 5.15 52.25 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.431 -1.418 . . . . 0.0 111.936 -169.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.7 m -78.14 170.18 17.04 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.461 2.304 . . . . 0.0 108.082 175.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.6 m -67.78 -6.74 22.67 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.16 -2.212 . . . . 0.0 115.921 177.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 3.3 m -78.12 89.83 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.548 1.166 . . . . 0.0 110.631 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 64.2 mtt85 -73.21 54.3 0.41 Allowed 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.849 -1.782 . . . . 0.0 115.123 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -123.98 -68.99 0.83 Allowed 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 126.052 1.741 . . . . 0.0 108.946 -177.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.69 -51.09 0.56 Allowed Glycine 0 N--CA 1.429 -1.803 0 O-C-N 120.729 -1.232 . . . . 0.0 112.352 176.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -83.64 176.47 52.38 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 115.932 1.133 . . . . 0.0 115.932 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 mm -99.17 129.18 49.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.833 2.053 . . . . 0.0 107.819 175.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -126.71 158.07 37.42 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.903 -1.123 . . . . 0.0 109.521 -174.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.9 t -75.95 117.36 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 O-C-N 121.023 -1.048 . . . . 0.0 111.377 174.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 33.8 tttp -88.33 -45.12 10.28 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.871 1.268 . . . . 0.0 110.83 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.0 163.19 39.33 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 121.252 -0.905 . . . . 0.0 108.995 173.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.7 tp -117.95 121.73 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 170.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.64 124.08 87.73 Favored Pre-proline 0 N--CA 1.429 -1.482 0 C-N-CA 126.076 1.75 . . . . 0.0 113.749 -165.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 81.7 Cg_exo -59.26 127.42 23.93 Favored 'Trans proline' 0 C--N 1.299 -2.057 0 C-N-CA 122.778 2.319 . . . . 0.0 114.904 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.281 11.7 mptt 82.07 21.76 0.27 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 128.538 2.735 . . . . 0.0 112.649 -177.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.91 153.39 29.57 Favored Glycine 0 N--CA 1.43 -1.755 0 O-C-N 119.962 -1.711 . . . . 0.0 113.711 172.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.93 -54.87 13.69 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 126.464 1.906 . . . . 0.0 113.877 166.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.23 -54.08 45.97 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 127.576 2.35 . . . . 0.0 112.265 176.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -40.95 -59.58 1.41 Allowed 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 177.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 17.0 t -70.2 -29.99 66.98 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -174.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -66.2 -52.5 47.39 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.751 -1.218 . . . . 0.0 113.44 -172.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.11 21.7 9.86 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 120.663 -1.273 . . . . 0.0 115.946 158.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 -85.15 -36.87 20.79 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.716 -1.461 . . . . 0.0 109.557 164.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.9 mt -100.48 124.73 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 125.781 1.632 . . . . 0.0 109.098 -176.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.497 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 3.4 t-80 -142.36 -175.39 4.43 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.117 1.437 . . . . 0.0 112.274 176.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.4 ttpp -68.95 123.56 21.33 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.027 -1.67 . . . . 0.0 113.307 -170.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.71 3.7 62.37 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.418 -0.801 . . . . 0.0 114.492 -178.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -78.72 156.38 28.94 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 119.423 1.612 . . . . 0.0 111.743 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 8.5 tpt180 -102.5 123.36 46.11 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.208 -1.558 . . . . 0.0 110.446 -173.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 7.4 t -88.86 119.23 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 O-C-N 120.371 -1.456 . . . . 0.0 110.814 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 98.2 mt -94.09 -46.32 7.17 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.01 -1.056 . . . . 0.0 112.118 -175.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.37 144.01 25.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.855 -1.153 . . . . 0.0 112.484 -177.028 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.816 HG11 HG21 ' A' ' 84' ' ' THR . 2.9 p -113.42 111.71 37.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 C-N-CA 125.938 1.695 . . . . 0.0 112.504 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.9 t30 57.23 34.75 25.25 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.771 -1.83 . . . . 0.0 113.674 170.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.19 -28.56 13.32 Favored Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.314 1.435 . . . . 0.0 114.336 -172.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -98.07 129.45 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.235 2.017 . . . . 0.0 110.627 -163.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 26.6 p -71.37 132.33 44.68 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.164 -1.585 . . . . 0.0 112.607 -177.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 47.9 mt -99.45 35.96 1.86 Allowed 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.498 -1.376 . . . . 0.0 111.912 -178.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 10.1 mm-40 -89.67 144.26 26.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.714 -1.241 . . . . 0.0 109.486 167.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.26 -32.07 2.31 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.914 -1.117 . . . . 0.0 114.778 -176.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.66 152.28 44.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -175.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.8 p -91.76 175.36 6.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.985 -1.072 . . . . 0.0 112.012 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -58.64 -46.8 86.32 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.514 1.525 . . . . 0.0 112.249 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 30.0 tttp -54.69 -47.93 73.07 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 115.574 1.694 . . . . 0.0 115.574 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -58.67 -47.5 84.29 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.667 1.187 . . . . 0.0 113.652 179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -61.67 -38.74 88.89 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.613 1.565 . . . . 0.0 114.22 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.22 -49.03 76.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 C-N-CA 124.866 1.266 . . . . 0.0 111.251 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 91.8 mt-10 -68.32 -30.13 69.03 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.771 -1.205 . . . . 0.0 112.168 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . 0.816 HG21 HG11 ' A' ' 68' ' ' VAL . 38.8 m -64.33 -43.41 94.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.199 1.4 . . . . 0.0 114.691 167.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.454 HD13 HD12 ' A' ' 27' ' ' ILE . 67.3 mt -63.63 -37.03 85.8 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.074 -1.641 . . . . 0.0 114.171 173.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -67.09 -31.79 72.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.552 -1.342 . . . . 0.0 113.401 170.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -85.26 51.09 2.09 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.852 1.661 . . . . 0.0 112.1 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 p -106.59 148.48 28.24 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.442 -1.411 . . . . 0.0 109.867 171.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.66 -164.22 36.37 Favored Glycine 0 N--CA 1.43 -1.737 0 C-N-CA 123.778 0.704 . . . . 0.0 111.75 168.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 51.7 tt0 -69.7 -46.27 66.38 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.732 -1.452 . . . . 0.0 114.65 -177.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 47.3 t -103.95 118.7 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 CA-C-O 122.437 1.113 . . . . 0.0 108.761 176.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 99.2 t -111.6 119.17 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 127.928 2.491 . . . . 0.0 109.926 -164.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -104.3 91.89 4.11 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.772 -1.205 . . . . 0.0 113.308 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -91.5 160.78 15.26 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.046 -2.284 . . . . 0.0 113.694 179.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 53.8 tp -127.0 128.06 45.77 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 161.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.32 158.48 44.32 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.989 -1.069 . . . . 0.0 112.213 176.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -110.07 140.71 43.83 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.047 1.339 . . . . 0.0 108.7 172.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.8 tptm -76.27 127.57 33.16 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.832 1.253 . . . . 0.0 111.476 -177.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -72.45 147.99 41.46 Favored Glycine 0 N--CA 1.43 -1.751 0 C-N-CA 125.541 1.543 . . . . 0.0 113.415 -174.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 38.7 mt-30 -78.26 177.13 8.65 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -170.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 3.5 p -147.73 128.0 6.78 Favored Pre-proline 0 N--CA 1.43 -1.428 0 N-CA-C 105.868 -1.901 . . . . 0.0 105.868 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo . . . . . 0 C--N 1.3 -1.993 0 CA-C-N 122.417 1.899 . . . . 0.0 113.8 172.943 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? . . . . . 0 N--CA 1.429 -1.483 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -86.3 -173.94 1.36 Allowed 'Trans proline' 0 C--N 1.3 -2.008 0 C-N-CA 122.777 2.318 . . . . 0.0 112.777 -173.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.69 41.32 0.42 Allowed Glycine 0 N--CA 1.429 -1.771 0 C-N-CA 124.874 1.226 . . . . 0.0 115.643 172.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -87.81 153.95 20.93 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 124.914 1.286 . . . . 0.0 108.881 164.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.3 p -120.83 150.14 41.48 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.48 -1.388 . . . . 0.0 110.985 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.567 ' CE2' HD11 ' A' ' 96' ' ' LEU . 2.2 p90 -147.4 136.26 22.11 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.307 1.527 . . . . 0.0 109.412 172.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 21.4 mp0 -89.13 128.01 35.75 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 126.899 2.08 . . . . 0.0 108.581 175.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 74.6 t -109.82 94.87 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.497 0 O-C-N 121.036 -1.04 . . . . 0.0 108.252 -174.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -90.54 102.78 15.52 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-O 123.399 1.571 . . . . 0.0 109.61 169.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 37.6 tp -124.75 143.41 50.8 Favored 'General case' 0 N--CA 1.431 -1.395 0 C-N-CA 124.597 1.159 . . . . 0.0 110.678 -169.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.91 137.95 39.53 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.061 -1.649 . . . . 0.0 109.642 169.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 43.0 mtmt -69.68 153.21 43.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.537 -1.352 . . . . 0.0 112.231 172.043 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 8.0 t -141.28 133.95 28.64 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 174.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 33.6 t0 50.93 39.48 22.83 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.959 2.104 . . . . 0.0 113.142 -172.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.13 3.05 55.52 Favored Glycine 0 N--CA 1.431 -1.677 0 O-C-N 120.11 -1.619 . . . . 0.0 116.898 -176.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 84.7 p -112.82 144.49 42.27 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 118.895 1.348 . . . . 0.0 114.03 -167.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 54.0 mt -102.84 -63.15 1.19 Allowed 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.92 1.288 . . . . 0.0 109.598 169.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.03 11.21 10.2 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 119.371 -2.081 . . . . 0.0 115.208 172.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.1 pt -100.56 131.58 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.501 0 CA-C-N 118.922 1.361 . . . . 0.0 111.188 174.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 10.6 t -110.8 121.61 45.76 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.055 -1.028 . . . . 0.0 108.7 168.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.9 m -105.49 165.68 3.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.702 1.201 . . . . 0.0 113.02 -173.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -149.25 162.53 39.83 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.328 1.451 . . . . 0.0 109.737 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.77 -135.14 12.45 Favored Glycine 0 N--CA 1.431 -1.698 0 CA-C-O 122.658 1.143 . . . . 0.0 115.853 163.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.55 172.6 44.27 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 121.253 -1.145 . . . . 0.0 113.407 -176.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m -73.2 -24.39 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 115.973 1.842 . . . . 0.0 115.973 -174.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -100.43 19.88 15.91 Favored 'General case' 0 N--CA 1.428 -1.535 0 O-C-N 120.573 -1.33 . . . . 0.0 113.025 -170.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . 0.254 12.5 t -116.35 -155.94 0.6 Allowed 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.428 -1.42 . . . . 0.0 109.975 170.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 29.4 p -71.73 -28.54 63.75 Favored 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 126.169 1.788 . . . . 0.0 115.048 -172.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 5.7 m -73.82 94.79 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 CA-C-O 123.422 1.582 . . . . 0.0 112.837 176.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 12.4 ptt180 -71.17 -13.6 61.99 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.112 -1.618 . . . . 0.0 114.655 -174.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 33.8 m-70 -71.38 -38.34 71.51 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.28 -1.512 . . . . 0.0 112.91 171.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.19 105.11 0.66 Allowed Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 124.44 1.019 . . . . 0.0 113.946 179.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -167.08 155.11 25.98 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 120.754 -1.439 . . . . 0.0 110.221 173.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -100.22 123.24 52.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.5 m-85 -123.59 157.21 34.24 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 121.059 -1.026 . . . . 0.0 110.667 -175.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.7 t -76.44 125.53 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 O-C-N 120.573 -1.329 . . . . 0.0 112.038 168.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 16.3 ptpt -95.75 -35.62 11.47 Favored 'General case' 0 N--CA 1.431 -1.405 0 O-C-N 120.397 -1.44 . . . . 0.0 112.457 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.51 158.03 36.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.854 -1.154 . . . . 0.0 112.221 -176.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -116.69 123.05 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.59 1.556 . . . . 0.0 109.881 175.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.2 mm -77.01 119.49 77.72 Favored Pre-proline 0 N--CA 1.43 -1.431 0 C-N-CA 125.93 1.692 . . . . 0.0 113.714 -176.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.74 124.39 12.27 Favored 'Trans proline' 0 C--N 1.299 -2.06 0 CA-C-N 124.744 2.73 . . . . 0.0 113.981 -172.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 10.5 mmmm 79.07 29.67 0.35 Allowed 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 129.334 3.054 . . . . 0.0 113.587 -175.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.53 162.66 38.14 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.507 -1.37 . . . . 0.0 113.102 162.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.08 -60.01 3.15 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 126.947 2.099 . . . . 0.0 114.911 166.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.32 -46.09 88.27 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 129.517 3.127 . . . . 0.0 112.391 -179.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -43.31 -65.67 0.46 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 114.972 1.471 . . . . 0.0 114.972 171.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.5 t -67.72 -26.99 66.43 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 114.094 1.146 . . . . 0.0 114.094 -175.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.89 -56.82 16.99 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.265 -1.522 . . . . 0.0 111.8 174.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 94.19 2.57 64.03 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.72 -1.238 . . . . 0.0 114.733 157.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 65.0 mtt85 -56.04 -44.11 78.47 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.025 1.33 . . . . 0.0 110.793 159.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.5 mt -82.03 131.09 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 127.698 2.399 . . . . 0.0 111.759 -176.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 11.6 m-70 -122.72 155.44 36.45 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 128.314 2.646 . . . . 0.0 109.228 174.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 pttt -73.15 106.81 5.16 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.931 -1.73 . . . . 0.0 111.631 173.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.29 -31.35 2.06 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-O 119.16 -0.8 . . . . 0.0 113.733 -165.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.371 4.0 p30 -80.24 159.44 25.9 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-N 120.109 1.955 . . . . 0.0 116.112 -166.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.4 ttt85 -110.02 125.85 53.34 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.562 -1.336 . . . . 0.0 112.151 -162.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 12.5 t -82.11 135.07 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.488 -1.383 . . . . 0.0 111.173 -173.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 95.9 mt -103.83 -54.01 2.65 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.126 -0.983 . . . . 0.0 111.213 176.057 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.78 146.06 26.14 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.189 -1.569 . . . . 0.0 111.927 -174.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 43.0 t -114.04 107.61 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 123.704 0.802 . . . . 0.0 108.964 175.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 21.5 t30 61.81 45.17 7.93 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.967 2.107 . . . . 0.0 113.86 171.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.35 -24.25 14.89 Favored Glycine 0 N--CA 1.431 -1.68 0 O-C-N 121.136 -0.977 . . . . 0.0 113.571 -174.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.3 t -87.08 111.66 22.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 O-C-N 120.482 -1.599 . . . . 0.0 109.981 -175.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.0 p -69.31 128.62 37.24 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 124.721 1.209 . . . . 0.0 111.837 178.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 50.5 mt -86.03 52.18 2.41 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.168 -1.583 . . . . 0.0 111.869 -177.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -78.9 121.16 24.51 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 119.592 -1.942 . . . . 0.0 113.48 -169.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 62.64 24.0 65.72 Favored Glycine 0 N--CA 1.431 -1.679 0 C-N-CA 124.873 1.225 . . . . 0.0 114.753 -176.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.62 153.96 42.34 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.579 1.696 . . . . 0.0 115.579 -170.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 74.6 p -91.65 170.5 9.87 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 124.688 1.195 . . . . 0.0 111.096 171.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 7.3 t-160 -58.44 -58.14 9.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.357 1.463 . . . . 0.0 114.41 -175.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -58.02 -29.74 65.55 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 116.169 1.914 . . . . 0.0 116.169 176.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.52 -52.18 66.46 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.411 1.484 . . . . 0.0 113.017 178.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.64 -45.13 89.93 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.066 1.746 . . . . 0.0 113.624 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.8 t -64.53 -48.73 83.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.146 1.378 . . . . 0.0 111.27 -179.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.3 mm-40 -65.75 -33.02 74.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.526 0.936 . . . . 0.0 113.526 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.0 m -67.52 -45.37 75.95 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.525 1.93 . . . . 0.0 112.413 174.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 80.4 mt -58.89 -42.85 90.53 Favored 'General case' 0 N--CA 1.431 -1.392 0 C-N-CA 124.791 1.236 . . . . 0.0 113.508 172.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.3 mtt180 -69.97 -14.72 62.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 115.26 1.578 . . . . 0.0 115.26 178.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -95.65 36.63 1.26 Allowed 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.478 -2.014 . . . . 0.0 112.023 172.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 77.4 p -107.27 144.8 33.56 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.249 -1.532 . . . . 0.0 110.651 172.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.25 -149.53 23.66 Favored Glycine 0 N--CA 1.429 -1.774 0 C-N-CA 123.965 0.793 . . . . 0.0 112.514 -177.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -60.9 -56.2 23.94 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.3 t -101.49 126.29 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 CA-C-O 122.282 1.039 . . . . 0.0 109.561 172.117 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 67.4 t -115.45 137.33 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 129.664 3.186 . . . . 0.0 108.662 -166.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 13.5 t-160 -124.22 106.33 10.21 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.505 -1.372 . . . . 0.0 111.394 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 18.7 mt -97.06 160.17 14.5 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 119.356 -2.09 . . . . 0.0 113.239 170.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 64.9 tp -127.96 131.87 49.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 161.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.567 HD11 ' CE2' ' A' ' 14' ' ' PHE . 2.0 pp -148.19 169.03 20.94 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.933 -1.104 . . . . 0.0 112.833 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -117.01 143.46 45.71 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.576 1.55 . . . . 0.0 111.371 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.3 tptm -76.19 151.7 36.83 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 126.921 2.088 . . . . 0.0 113.386 -175.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -99.71 -161.11 28.85 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 125.777 1.656 . . . . 0.0 113.023 178.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -70.39 177.78 3.22 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 -167.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.12 124.4 35.38 Favored Pre-proline 0 N--CA 1.43 -1.455 0 O-C-N 120.586 -1.321 . . . . 0.0 109.696 -174.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_exo . . . . . 0 N--CA 1.434 -1.981 0 C-N-CA 123.238 2.625 . . . . 0.0 115.601 174.775 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.8 pttp . . . . . 0 N--CA 1.43 -1.467 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_exo -71.44 177.68 6.45 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 122.025 1.817 . . . . 0.0 115.983 175.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.28 2.26 74.1 Favored Glycine 0 N--CA 1.43 -1.729 0 O-C-N 121.704 -0.623 . . . . 0.0 111.796 -178.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 18.8 t0 -93.96 139.0 31.45 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.635 1.974 . . . . 0.0 109.496 -171.226 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.2 p -106.96 149.53 27.41 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.13 -0.982 . . . . 0.0 112.524 -177.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -145.01 132.78 21.09 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.914 -1.116 . . . . 0.0 108.178 -176.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.87 120.01 28.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.39 1.476 . . . . 0.0 108.255 169.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 84.6 t -116.44 100.87 11.27 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 124.627 1.171 . . . . 0.0 109.328 -168.149 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -90.18 104.92 17.44 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.352 -1.468 . . . . 0.0 108.999 170.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 57.2 tp -119.95 130.67 54.89 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 124.91 1.284 . . . . 0.0 110.543 -169.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 146.12 28.54 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.722 -1.861 . . . . 0.0 109.64 173.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 75.3 mttt -67.93 166.02 16.55 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.933 1.827 . . . . 0.0 115.933 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 28.6 p -132.23 130.73 41.35 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 125.681 1.592 . . . . 0.0 108.163 168.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 46.6 44.43 13.5 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.925 2.09 . . . . 0.0 114.905 -175.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.88 -14.63 30.77 Favored Glycine 0 N--CA 1.429 -1.818 0 O-C-N 119.855 -1.778 . . . . 0.0 117.041 178.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 t -121.84 175.18 6.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 CA-C-N 119.716 1.758 . . . . 0.0 112.113 -174.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 94.2 mt -99.96 -60.58 1.5 Allowed 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.702 1.201 . . . . 0.0 110.46 178.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.15 44.04 0.38 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.15 -1.594 . . . . 0.0 111.222 174.243 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.3 tt -144.06 147.86 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 123.068 1.413 . . . . 0.0 110.985 -172.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 58.7 m -124.57 117.69 24.89 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 125.071 1.348 . . . . 0.0 108.532 170.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 m -95.93 166.17 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.417 0 C-N-CA 124.496 1.118 . . . . 0.0 112.726 -178.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.1 t -151.85 172.43 16.2 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.472 1.509 . . . . 0.0 110.247 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.47 -144.3 16.98 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.256 -0.902 . . . . 0.0 113.74 172.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.82 162.52 23.11 Favored Glycine 0 N--CA 1.43 -1.722 0 CA-C-O 122.489 1.049 . . . . 0.0 112.677 -177.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.5 p -66.07 -21.21 28.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.497 1.519 . . . . 0.0 114.508 -174.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -69.82 -27.26 64.73 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.902 1.681 . . . . 0.0 114.486 174.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 20.5 m -107.69 148.05 29.91 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.25 -1.531 . . . . 0.0 108.774 -174.18 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.7 t -78.56 58.66 2.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 119.434 -2.041 . . . . 0.0 113.944 -177.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 22.5 m -99.56 21.98 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 126.022 1.729 . . . . 0.0 114.561 -172.673 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.262 75.7 mtt180 82.44 98.02 0.05 OUTLIER 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.19 2.196 . . . . 0.0 110.494 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 42.5 m170 66.55 -73.43 0.07 Allowed 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 126.953 2.101 . . . . 0.0 113.142 -166.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 158.6 40.62 0.02 OUTLIER Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.725 -1.234 . . . . 0.0 111.377 178.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -75.86 151.83 41.5 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.639 -0.918 . . . . 0.0 113.564 -173.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.5 mm -90.98 114.22 27.99 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.511 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 171.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -113.93 151.84 31.68 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.315 1.055 . . . . 0.0 110.012 -171.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.9 t -76.18 120.58 26.46 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.625 -1.297 . . . . 0.0 110.357 169.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -93.72 -48.59 6.25 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.707 -1.246 . . . . 0.0 110.587 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.43 157.99 43.92 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.491 -0.755 . . . . 0.0 109.51 176.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.533 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.5 tp -124.47 123.92 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.462 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 177.4 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -77.33 122.46 86.12 Favored Pre-proline 0 N--CA 1.43 -1.446 0 CA-C-O 116.454 -1.736 . . . . 0.0 112.817 -170.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -58.11 128.6 29.39 Favored 'Trans proline' 0 N--CA 1.434 -1.991 0 CA-C-N 124.39 2.604 . . . . 0.0 115.797 -174.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.296 52.1 mtmt 76.07 17.52 2.12 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.283 2.233 . . . . 0.0 113.629 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -82.96 160.25 38.62 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.386 -1.446 . . . . 0.0 111.705 170.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.58 -56.47 8.32 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.14 -1.8 . . . . 0.0 115.837 168.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.0 -44.51 95.84 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 126.567 1.947 . . . . 0.0 112.399 -177.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.533 ' HG2' HG23 ' A' ' 47' ' ' ILE . 7.4 tm-20 -51.06 -65.21 0.6 Allowed 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.297 1.592 . . . . 0.0 115.297 167.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 94.1 p -65.66 -26.94 68.02 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.051 1.5 . . . . 0.0 115.051 -169.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -55.47 -57.77 10.52 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.977 1.711 . . . . 0.0 113.228 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.63 -9.91 25.89 Favored Glycine 0 N--CA 1.43 -1.741 0 O-C-N 120.822 -1.174 . . . . 0.0 114.643 159.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.4 mtt180 -64.61 -32.4 74.05 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.763 1.225 . . . . 0.0 111.454 167.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 mt -96.91 124.76 49.89 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 C-N-CA 125.932 1.693 . . . . 0.0 110.762 -177.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 10.0 m80 -128.77 166.85 18.21 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 125.391 1.477 . . . . 0.0 109.487 170.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 7.0 ptpt -68.06 132.99 48.24 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.125 -1.609 . . . . 0.0 111.661 174.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 99.36 -7.9 60.19 Favored Glycine 0 N--CA 1.43 -1.7 0 O-C-N 121.026 -1.046 . . . . 0.0 114.524 -171.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -78.89 156.27 28.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-N 119.58 1.69 . . . . 0.0 112.41 -178.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -114.36 124.27 51.54 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.743 -1.223 . . . . 0.0 110.725 -168.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 10.7 t -87.67 131.29 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.296 -1.502 . . . . 0.0 110.162 -174.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.64 -44.8 5.46 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.684 -1.26 . . . . 0.0 110.307 -176.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.32 143.22 25.67 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.598 -0.689 . . . . 0.0 110.814 -177.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 39.9 t -124.93 124.06 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 173.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.4 t-20 63.82 33.79 12.42 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.966 1.707 . . . . 0.0 114.214 170.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.99 -15.76 62.75 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 120.693 -1.254 . . . . 0.0 113.698 -179.632 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.38 116.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 121.554 -0.968 . . . . 0.0 110.202 -173.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -73.98 130.71 40.41 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.778 -1.202 . . . . 0.0 110.831 176.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.5 mt -85.48 44.2 1.08 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.866 -1.147 . . . . 0.0 114.065 -165.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -80.85 133.04 35.52 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.996 -2.315 . . . . 0.0 112.046 -177.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 69.53 13.07 67.78 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.488 -1.382 . . . . 0.0 114.793 -174.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.31 142.72 48.85 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.767 1.395 . . . . 0.0 114.767 -178.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 36.0 p -90.56 178.18 6.16 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.013 1.725 . . . . 0.0 110.061 171.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -60.31 -48.98 79.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.837 -1.164 . . . . 0.0 112.971 175.007 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.0 mmtt -54.58 -38.51 66.78 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 126.365 1.866 . . . . 0.0 115.523 175.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.11 -51.05 71.34 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.223 1.809 . . . . 0.0 113.187 -177.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -69.58 -34.05 73.6 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.516 1.527 . . . . 0.0 113.386 176.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.05 -53.44 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.375 0 C-N-CA 124.768 1.227 . . . . 0.0 110.127 178.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -60.79 -39.27 88.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 121.22 -0.925 . . . . 0.0 112.947 178.132 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 69.7 m -63.65 -40.64 97.37 Favored 'General case' 0 N--CA 1.428 -1.534 0 C-N-CA 124.828 1.251 . . . . 0.0 113.605 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 64.6 mt -72.0 -37.09 69.9 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.764 -1.21 . . . . 0.0 113.748 171.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 27.3 mtp180 -64.02 -47.35 80.59 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.188 -1.57 . . . . 0.0 112.793 176.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -88.14 58.97 5.05 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.716 1.246 . . . . 0.0 111.712 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.8 p -105.11 157.02 17.54 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.895 2.078 . . . . 0.0 110.052 176.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.26 -146.21 9.35 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.509 -1.37 . . . . 0.0 111.741 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 21.2 tt0 -71.85 -56.64 5.36 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.604 -1.527 . . . . 0.0 113.139 170.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 14.2 p -100.53 140.02 20.53 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.961 1.304 . . . . 0.0 109.316 179.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 72.5 t -124.22 122.85 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 127.496 2.318 . . . . 0.0 108.273 -170.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 42.8 m170 -100.52 101.36 12.27 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.058 -1.651 . . . . 0.0 110.561 177.179 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 8.7 mt -92.87 160.39 14.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.862 -1.774 . . . . 0.0 111.655 172.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.29 131.21 46.92 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 157.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.7 pp -143.4 166.85 23.62 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.993 -1.692 . . . . 0.0 112.312 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -112.73 146.24 39.11 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.406 1.882 . . . . 0.0 108.589 175.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -75.79 127.25 32.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.784 -1.197 . . . . 0.0 110.57 176.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -64.06 133.5 39.95 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 125.677 1.608 . . . . 0.0 113.379 -175.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -69.47 -34.71 74.77 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 115.435 1.643 . . . . 0.0 115.435 -166.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.3 m -132.58 160.52 67.97 Favored Pre-proline 0 N--CA 1.429 -1.484 0 O-C-N 121.469 -0.769 . . . . 0.0 109.435 -175.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo . . . . . 0 N--CA 1.434 -1.98 0 C-N-CA 122.697 2.264 . . . . 0.0 111.627 170.308 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.442 0 CA-C-O 115.739 -2.077 . . . . 0.0 112.142 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -73.69 178.94 6.12 Favored 'Trans proline' 0 N--CA 1.434 -1.997 0 CA-C-N 126.363 3.308 . . . . 0.0 113.007 173.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.91 7.69 68.08 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 121.105 -0.997 . . . . 0.0 114.358 174.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.6 t0 -95.92 152.21 18.72 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.197 0.999 . . . . 0.0 108.872 177.27 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.7 p -97.43 162.32 13.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 122.11 0.957 . . . . 0.0 112.534 -176.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -144.82 138.19 26.9 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -93.66 115.38 27.83 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 126.301 1.84 . . . . 0.0 107.149 166.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.403 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 32.7 t -111.87 99.78 9.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -175.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -90.05 100.09 12.98 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.351 -1.468 . . . . 0.0 109.593 176.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 22.0 tp -116.59 136.91 52.59 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 124.744 1.218 . . . . 0.0 111.032 -162.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.66 145.81 29.51 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.443 -1.41 . . . . 0.0 109.006 169.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 22.8 ttmt -70.81 141.66 51.34 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.924 -1.11 . . . . 0.0 113.677 174.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.9 t -137.95 142.7 40.53 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.426 -1.421 . . . . 0.0 109.619 174.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.1 t0 54.55 34.71 21.84 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.107 2.163 . . . . 0.0 113.906 -177.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 69.96 9.55 63.26 Favored Glycine 0 N--CA 1.43 -1.745 0 C-N-CA 124.877 1.227 . . . . 0.0 115.948 -174.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 71.7 p -121.32 142.41 49.99 Favored 'General case' 0 N--CA 1.43 -1.46 0 CA-C-N 118.886 1.343 . . . . 0.0 114.033 -171.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 65.4 mt -89.72 -61.61 1.65 Allowed 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 159.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 114.79 48.19 0.55 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 118.98 -2.325 . . . . 0.0 112.711 163.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.3 tt -145.94 150.11 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.334 1.064 . . . . 0.0 110.006 -176.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 16.4 t -122.94 125.66 45.74 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 164.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.9 m -106.15 157.74 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 125.338 1.455 . . . . 0.0 110.025 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.9 t -141.95 170.34 15.9 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.094 0.958 . . . . 0.0 109.71 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.14 -132.09 10.96 Favored Glycine 0 N--CA 1.431 -1.685 0 C-N-CA 123.885 0.755 . . . . 0.0 113.228 173.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.45 -179.83 42.07 Favored Glycine 0 N--CA 1.431 -1.696 0 CA-C-O 122.46 1.033 . . . . 0.0 111.747 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -84.36 -8.68 11.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.499 0 O-C-N 120.923 -1.339 . . . . 0.0 113.274 -169.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -71.95 -51.36 22.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.341 -1.474 . . . . 0.0 113.082 -178.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.7 p -92.3 169.92 10.2 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.341 1.056 . . . . 0.0 110.662 178.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 67.3 m -92.09 60.97 3.89 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.935 -1.728 . . . . 0.0 111.47 -179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 6.2 p -83.17 160.83 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.435 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 166.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.64 104.74 0.11 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.202 1.401 . . . . 0.0 114.742 -172.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 3.5 t60 58.78 13.87 2.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 128.131 2.573 . . . . 0.0 117.474 -174.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.17 23.29 61.48 Favored Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.158 -1.589 . . . . 0.0 115.135 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -81.03 174.49 54.78 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 121.396 -1.061 . . . . 0.0 115.401 -177.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.2 mm -103.7 117.56 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.716 1.607 . . . . 0.0 107.373 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -124.98 150.0 47.13 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.795 -1.19 . . . . 0.0 110.171 -168.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 32.2 t -75.66 122.31 29.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.456 -1.402 . . . . 0.0 113.201 178.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -89.3 -56.48 3.25 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.363 1.065 . . . . 0.0 109.686 173.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -145.46 156.19 43.58 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.117 -0.989 . . . . 0.0 111.454 -173.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.63 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.0 OUTLIER -119.2 117.97 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 175.06 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 28.7 mm -76.89 125.06 87.49 Favored Pre-proline 0 N--CA 1.43 -1.451 0 CA-C-O 115.391 -2.242 . . . . 0.0 113.0 -165.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -53.33 136.95 64.08 Favored 'Trans proline' 0 C--N 1.3 -1.979 0 C-N-CA 123.628 2.886 . . . . 0.0 116.899 -171.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.277 6.6 mtpm? 51.67 26.1 3.21 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 119.168 3.025 . . . . 0.0 119.168 -169.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.31 169.65 54.91 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 118.995 -2.316 . . . . 0.0 113.201 170.083 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.21 -60.86 2.55 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.121 1.768 . . . . 0.0 114.136 165.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.9 -45.48 92.33 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 129.01 2.924 . . . . 0.0 112.646 -178.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.63 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.5 tm-20 -43.66 -68.25 0.21 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.826 1.65 . . . . 0.0 114.818 166.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 74.9 m -69.89 -14.84 62.93 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 116.367 1.988 . . . . 0.0 116.367 -174.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -61.38 -55.72 28.4 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.82 1.248 . . . . 0.0 111.751 170.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.29 4.7 77.1 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 120.301 -1.5 . . . . 0.0 115.699 167.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 64.8 mtt180 -75.17 -38.3 60.91 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.243 -1.739 . . . . 0.0 110.326 163.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.5 mt -77.59 120.63 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 126.352 1.861 . . . . 0.0 111.122 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -117.99 166.09 12.94 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 125.895 1.678 . . . . 0.0 111.153 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 48.0 tttm -63.98 127.3 30.81 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 119.966 -1.709 . . . . 0.0 111.936 171.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 92.59 0.94 68.98 Favored Glycine 0 N--CA 1.431 -1.662 0 O-C-N 121.29 -0.882 . . . . 0.0 113.992 -178.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -67.06 153.47 43.59 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 119.178 1.489 . . . . 0.0 112.792 179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 65.1 ttt-85 -105.46 122.06 45.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.832 0.825 . . . . 0.0 109.299 -176.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 45.4 t -82.89 134.95 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.751 -1.218 . . . . 0.0 109.81 -177.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.2 mp -105.64 -50.08 3.28 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.856 -1.152 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.15 151.2 32.74 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.369 -1.457 . . . . 0.0 111.88 -175.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.97 HG11 HG21 ' A' ' 84' ' ' THR . 3.4 p -118.06 110.21 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 122.379 1.085 . . . . 0.0 112.393 172.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 55.26 39.68 31.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.943 -1.723 . . . . 0.0 114.913 164.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.96 -13.42 60.55 Favored Glycine 0 N--CA 1.429 -1.828 0 CA-C-O 119.324 -0.709 . . . . 0.0 114.5 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.9 t -102.17 111.12 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 CA-C-N 120.614 2.207 . . . . 0.0 109.302 -176.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 43.6 m -76.27 119.73 20.56 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.213 -1.554 . . . . 0.0 110.625 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 87.2 mt -92.41 35.47 1.01 Allowed 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 120.66 -1.275 . . . . 0.0 112.223 -167.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 36.6 mt-10 -88.61 91.19 8.71 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 119.619 -1.926 . . . . 0.0 112.52 -168.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 96.93 10.55 54.99 Favored Glycine 0 N--CA 1.429 -1.812 0 C-N-CA 125.202 1.382 . . . . 0.0 112.157 -171.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.85 157.7 37.4 Favored 'General case' 0 N--CA 1.429 -1.491 0 CA-C-O 122.532 1.158 . . . . 0.0 113.535 171.356 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 41.5 p -83.49 172.91 11.94 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.255 -1.528 . . . . 0.0 113.169 -175.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-80 -58.41 -46.17 86.96 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.386 1.474 . . . . 0.0 113.613 170.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -57.96 -43.06 86.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 115.472 1.656 . . . . 0.0 115.472 172.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.91 -55.15 36.04 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 114.432 1.271 . . . . 0.0 114.432 -175.136 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -52.3 -43.3 64.41 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 116.284 1.957 . . . . 0.0 116.284 171.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 94.6 t -70.57 -52.04 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 120.756 -1.215 . . . . 0.0 111.461 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -64.64 -30.63 71.65 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.19 -0.944 . . . . 0.0 111.886 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . 0.97 HG21 HG11 ' A' ' 68' ' ' VAL . 39.4 m -63.87 -51.41 64.7 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.186 1.394 . . . . 0.0 113.509 170.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 55.6 mt -60.42 -37.01 79.51 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 120.565 1.53 . . . . 0.0 113.789 176.275 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 9.0 mmm180 -61.93 -44.41 96.83 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.493 1.517 . . . . 0.0 113.763 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -94.54 55.91 2.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.539 1.536 . . . . 0.0 112.682 178.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 7.4 p -106.45 145.36 31.87 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.533 -1.355 . . . . 0.0 109.983 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.02 -141.32 4.8 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.658 -1.276 . . . . 0.0 111.889 176.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 48.1 tt0 -70.69 -58.31 3.78 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.383 -1.657 . . . . 0.0 113.791 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.1 t -109.57 137.76 40.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 124.533 1.133 . . . . 0.0 110.947 -176.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.6 t -125.13 122.56 63.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 C-N-CA 128.924 2.89 . . . . 0.0 110.911 -173.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 19.0 t-160 -100.81 95.9 6.94 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.139 -2.226 . . . . 0.0 113.085 176.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.403 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 23.5 mt -88.2 154.83 20.12 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 118.92 -2.363 . . . . 0.0 113.328 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 39.0 tp -127.25 135.46 50.64 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 163.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -150.63 168.91 22.89 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.889 -1.132 . . . . 0.0 111.942 175.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.0 tt0 -114.92 141.68 47.63 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.078 2.151 . . . . 0.0 109.142 172.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.14 121.25 22.57 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.13 1.372 . . . . 0.0 112.305 179.269 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -86.0 138.44 16.07 Favored Glycine 0 N--CA 1.429 -1.77 0 C-N-CA 126.894 2.188 . . . . 0.0 114.307 -169.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -90.71 -176.26 4.65 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 121.368 -1.078 . . . . 0.0 113.89 -175.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 21.2 m -113.45 151.79 44.74 Favored Pre-proline 0 CA--C 1.489 -1.399 0 O-C-N 120.767 -1.208 . . . . 0.0 110.389 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 N--CA 1.434 -2.015 0 C-N-CA 122.322 2.015 . . . . 0.0 112.903 179.825 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 48.2 mtmt . . . . . 0 N--CA 1.429 -1.485 0 CA-C-O 116.222 -1.847 . . . . 0.0 115.126 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -77.07 -178.56 4.67 Favored 'Trans proline' 0 N--CA 1.434 -1.997 0 CA-C-N 125.962 3.165 . . . . 0.0 113.432 -176.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.44 3.75 55.22 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 121.46 -0.775 . . . . 0.0 112.928 -176.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.5 t0 -75.68 152.46 37.52 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 125.168 1.387 . . . . 0.0 111.183 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.86 139.61 44.73 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.364 -1.46 . . . . 0.0 110.325 -176.48 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -146.52 154.99 42.18 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-O 123.037 1.398 . . . . 0.0 110.298 174.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -108.6 142.24 39.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.893 1.677 . . . . 0.0 107.362 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.5 t -122.63 106.09 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 124.684 1.193 . . . . 0.0 108.648 -171.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -95.16 97.78 10.15 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 121.002 -1.061 . . . . 0.0 109.275 169.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.9 tp -119.79 129.93 54.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 123.787 0.835 . . . . 0.0 112.601 -168.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -99.71 123.55 44.08 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.365 -1.46 . . . . 0.0 109.452 171.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -69.61 114.83 8.19 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.507 1.523 . . . . 0.0 113.183 -177.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.3 t -96.53 129.67 43.86 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.323 -1.486 . . . . 0.0 111.197 -175.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.6 t70 41.48 49.41 3.55 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.337 2.655 . . . . 0.0 114.917 -175.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 71.29 10.61 70.01 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 117.336 1.695 . . . . 0.0 117.336 -178.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 85.3 p -120.97 129.12 53.3 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 119.86 1.83 . . . . 0.0 113.977 -175.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 82.5 mt -85.8 -58.31 2.7 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.823 -1.173 . . . . 0.0 111.077 168.184 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.37 23.05 4.25 Favored Glycine 0 N--CA 1.43 -1.728 0 O-C-N 119.4 -2.062 . . . . 0.0 113.598 176.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 pt -122.41 141.28 43.44 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 CA-C-O 123.092 1.425 . . . . 0.0 113.348 -174.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.9 t -113.45 126.61 55.53 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 159.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 m -115.59 159.54 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.03 1.332 . . . . 0.0 110.749 -177.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.2 t -147.21 166.11 28.01 Favored 'General case' 0 N--CA 1.428 -1.532 0 C-N-CA 124.862 1.265 . . . . 0.0 109.424 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.35 -143.0 16.79 Favored Glycine 0 N--CA 1.429 -1.815 0 O-C-N 120.155 -1.591 . . . . 0.0 114.674 160.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 103.56 161.63 25.09 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.548 1.07 . . . . 0.0 111.514 -175.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.3 p -71.43 -25.78 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.547 -1.56 . . . . 0.0 114.068 -171.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.2 t-20 -91.4 1.48 57.09 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.433 1.493 . . . . 0.0 111.521 179.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.611 HG22 ' H ' ' A' ' 36' ' ' SER . 24.3 m -102.39 179.94 4.16 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.144 -2.169 . . . . 0.0 105.144 176.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.611 ' H ' HG22 ' A' ' 35' ' ' THR . 32.7 p -76.53 34.67 0.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 118.932 -2.355 . . . . 0.0 115.999 -172.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.1 t -96.46 110.32 24.49 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.456 -1.402 . . . . 0.0 110.118 -174.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 23.6 ptt85 -71.83 -31.47 66.56 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.282 -1.511 . . . . 0.0 112.61 -178.596 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 4.0 t-160 -85.86 -3.0 58.81 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.651 1.18 . . . . 0.0 113.07 178.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 64.92 72.69 0.68 Allowed Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 125.578 1.561 . . . . 0.0 116.866 170.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -175.69 172.72 45.71 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 118.891 -1.623 . . . . 0.0 114.128 177.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.0 mm -84.97 129.87 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.923 1.689 . . . . 0.0 109.104 174.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -122.89 150.37 43.0 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.166 -0.959 . . . . 0.0 109.271 -175.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 71.0 t -77.77 127.7 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.433 -1.417 . . . . 0.0 112.019 170.106 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 21.7 ttpp -94.91 -44.1 7.88 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.704 -1.247 . . . . 0.0 111.747 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.91 153.85 33.86 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.878 -1.139 . . . . 0.0 112.926 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.271 1.0 OUTLIER -102.94 118.14 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 CA-C-O 122.644 1.211 . . . . 0.0 110.038 168.822 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.9 mm -76.38 124.11 87.98 Favored Pre-proline 0 N--CA 1.43 -1.438 0 C-N-CA 126.436 1.894 . . . . 0.0 112.366 -173.18 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -56.29 129.96 37.62 Favored 'Trans proline' 0 N--CA 1.434 -1.992 0 C-N-CA 122.835 2.357 . . . . 0.0 115.166 -179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.8 mtmt 75.4 22.34 1.67 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.265 1.826 . . . . 0.0 114.771 -179.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.44 167.17 42.65 Favored Glycine 0 N--CA 1.43 -1.743 0 O-C-N 119.722 -1.861 . . . . 0.0 115.26 169.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.63 -63.35 1.15 Allowed 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 115.629 1.715 . . . . 0.0 115.629 165.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.72 -41.3 98.09 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 129.087 2.955 . . . . 0.0 112.824 -176.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -42.21 -55.72 3.18 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.849 1.796 . . . . 0.0 115.849 168.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 3.0 t -68.53 -38.15 80.61 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 115.04 1.496 . . . . 0.0 115.04 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.74 -51.66 68.01 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 126.067 1.747 . . . . 0.0 112.171 177.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.31 1.02 72.6 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.606 -1.309 . . . . 0.0 114.421 159.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -67.87 -44.11 77.82 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 125.315 1.446 . . . . 0.0 110.498 166.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 36.0 mt -85.64 129.66 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 125.532 1.533 . . . . 0.0 109.8 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.38 167.33 29.09 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.288 1.035 . . . . 0.0 110.961 -171.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 24.0 tttm -50.72 121.41 5.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.744 1.757 . . . . 0.0 115.744 -178.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.07 7.6 67.83 Favored Glycine 0 N--CA 1.429 -1.804 0 CA-C-O 117.904 -1.498 . . . . 0.0 115.679 176.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.296 1.7 p30 -77.51 152.64 34.02 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-N 120.786 2.293 . . . . 0.0 112.767 175.217 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 1.3 tmt_? -102.17 120.59 40.7 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 -176.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.7 t -83.11 128.74 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 121.077 -1.015 . . . . 0.0 109.768 -176.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.1 mt -99.26 -45.29 5.93 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.435 -1.416 . . . . 0.0 111.446 -175.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.67 145.17 25.67 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.673 -1.267 . . . . 0.0 111.658 -178.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.1 t -112.31 108.52 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.051 0.94 . . . . 0.0 109.445 173.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.0 t30 60.08 38.82 20.32 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.879 1.672 . . . . 0.0 114.547 166.243 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -16.21 60.14 Favored Glycine 0 N--CA 1.43 -1.718 0 C-N-CA 125.307 1.432 . . . . 0.0 114.214 -177.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.4 t -97.14 120.68 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 121.008 -1.29 . . . . 0.0 110.58 -176.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.9 t -75.33 133.89 41.15 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.486 -1.384 . . . . 0.0 111.956 -178.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 88.2 mt -88.21 12.62 13.34 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.908 -1.12 . . . . 0.0 113.628 -176.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 39.2 mm-40 -64.96 128.43 35.74 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 119.934 -1.729 . . . . 0.0 112.414 173.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.25 -6.57 67.29 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 125.314 1.435 . . . . 0.0 116.115 -176.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.6 149.71 45.37 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 116.953 2.205 . . . . 0.0 116.953 -174.524 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 30.5 p -93.19 -179.61 5.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 125.704 1.602 . . . . 0.0 110.943 171.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 18.8 t-160 -63.91 -50.35 69.07 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.541 -1.349 . . . . 0.0 111.765 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 38.0 mttp -56.46 -39.35 73.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.915 1.45 . . . . 0.0 114.915 175.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -57.37 -54.3 48.41 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 114.51 1.3 . . . . 0.0 114.51 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.51 -36.13 81.97 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 124.63 1.172 . . . . 0.0 113.124 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 73.6 t -64.18 -51.27 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 120.949 -1.094 . . . . 0.0 110.706 174.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -59.93 -35.77 75.63 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.581 -1.324 . . . . 0.0 113.608 178.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 87.8 m -62.87 -51.14 68.14 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.702 2.001 . . . . 0.0 112.874 173.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 74.3 mt -65.84 -32.05 73.35 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.95 -1.719 . . . . 0.0 114.988 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 10.9 mmm180 -68.18 -28.46 67.29 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.497 -1.377 . . . . 0.0 111.667 173.062 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -93.25 41.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.215 -1.553 . . . . 0.0 112.543 175.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -98.88 153.96 18.4 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 120.147 -1.596 . . . . 0.0 110.907 172.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -106.78 -138.33 8.93 Favored Glycine 0 N--CA 1.429 -1.793 0 C-N-CA 124.777 1.18 . . . . 0.0 110.81 174.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -70.05 -66.9 0.54 Allowed 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 114.862 1.43 . . . . 0.0 114.862 -177.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.4 t -99.3 120.65 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 CA-C-O 122.287 1.041 . . . . 0.0 109.256 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 71.3 t -114.54 119.53 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 128.51 2.724 . . . . 0.0 108.966 -167.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.1 t-160 -107.38 88.87 2.83 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.733 -1.229 . . . . 0.0 113.298 -174.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.1 mt -92.37 157.13 16.78 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.82 -1.8 . . . . 0.0 113.868 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 55.4 tp -127.47 129.09 46.82 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 124.743 1.217 . . . . 0.0 108.177 170.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.43 161.52 37.83 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-O 122.307 1.051 . . . . 0.0 113.715 179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -120.35 132.07 55.12 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.108 1.363 . . . . 0.0 109.645 175.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.2 tptm -77.2 134.32 38.66 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.803 -1.186 . . . . 0.0 113.758 -164.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -88.29 162.41 32.12 Favored Glycine 0 N--CA 1.429 -1.784 0 CA-C-O 122.144 0.858 . . . . 0.0 114.553 -173.159 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 26.7 tt0 -87.03 176.23 7.73 Favored 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 124.411 1.084 . . . . 0.0 111.903 -178.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.5 p -135.63 117.18 11.99 Favored Pre-proline 0 N--CA 1.429 -1.479 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 166.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.434 -2.008 0 CA-C-N 123.391 2.247 . . . . 0.0 113.061 -170.962 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . 0.262 1.3 mptp? . . . . . 0 N--CA 1.43 -1.462 0 CA-C-O 116.252 -1.832 . . . . 0.0 112.527 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -75.93 178.65 7.17 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 CA-C-N 125.829 3.117 . . . . 0.0 112.967 175.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.15 -30.09 10.1 Favored Glycine 0 N--CA 1.429 -1.785 0 O-C-N 121.241 -0.912 . . . . 0.0 113.963 -177.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.7 t0 -80.79 167.91 19.4 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-N 118.373 1.087 . . . . 0.0 112.661 -176.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 45.0 p -105.41 161.45 14.31 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.211 1.405 . . . . 0.0 113.181 -175.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.22 140.66 25.46 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 167.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -88.54 132.96 34.3 Favored 'General case' 0 N--CA 1.431 -1.421 0 CA-C-O 122.264 1.031 . . . . 0.0 109.471 163.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 t -120.8 98.18 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 126.053 1.741 . . . . 0.0 109.727 -169.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.09 102.29 15.04 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.355 -1.466 . . . . 0.0 109.972 174.026 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.519 HD11 ' HA ' ' A' ' 53' ' ' ALA . 0.4 OUTLIER -123.1 128.64 50.38 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.85 -1.156 . . . . 0.0 111.33 -166.805 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.23 125.19 47.83 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 119.967 -1.708 . . . . 0.0 110.354 -175.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 47.9 mtpt -69.69 150.17 47.26 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 115.517 1.673 . . . . 0.0 115.517 -173.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.8 p -102.91 87.39 2.92 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.852 1.261 . . . . 0.0 109.407 178.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.2 t0 45.92 64.83 1.32 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.348 2.659 . . . . 0.0 116.127 -175.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.74 -29.54 9.04 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 121.06 -1.025 . . . . 0.0 113.549 -178.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 49.9 m -97.42 136.19 38.21 Favored 'General case' 0 N--CA 1.43 -1.445 0 N-CA-C 114.689 1.366 . . . . 0.0 114.689 -169.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.2 mt -85.26 -60.5 2.02 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.23 1.412 . . . . 0.0 110.691 171.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.35 27.58 1.79 Allowed Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.404 -2.06 . . . . 0.0 111.292 178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 pt -124.88 155.96 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.555 1.142 . . . . 0.0 110.961 -170.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 11.6 t -129.8 130.38 45.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 152.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.1 m -104.82 157.93 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.914 1.286 . . . . 0.0 109.617 -177.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -140.33 169.71 17.17 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.717 -1.24 . . . . 0.0 109.111 176.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.52 -140.29 15.32 Favored Glycine 0 N--CA 1.43 -1.734 0 CA-C-O 122.372 0.984 . . . . 0.0 114.876 164.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.23 157.53 32.23 Favored Glycine 0 N--CA 1.43 -1.706 0 CA-C-O 122.235 0.908 . . . . 0.0 112.838 -174.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.5 m -66.34 -39.22 83.59 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 116.951 2.204 . . . . 0.0 116.951 -166.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -100.17 23.04 10.53 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.208 -1.558 . . . . 0.0 114.994 -167.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . 0.252 14.8 t -107.5 -145.18 0.39 Allowed 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.731 -1.231 . . . . 0.0 109.481 173.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 63.7 p -77.83 -24.74 48.58 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 118.875 -2.391 . . . . 0.0 114.502 -177.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.8 m -79.77 108.12 12.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 CA-C-O 123.769 1.747 . . . . 0.0 111.748 175.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 6.9 ttm105 -73.04 120.29 18.46 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.23 -1.544 . . . . 0.0 111.727 -178.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 13.7 m170 61.44 38.88 15.64 Favored 'General case' 0 CA--C 1.489 -1.372 0 C-N-CA 126.431 1.892 . . . . 0.0 113.322 -167.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -67.1 126.01 25.44 Favored Glycine 0 N--CA 1.43 -1.76 0 CA-C-O 122.455 1.031 . . . . 0.0 114.974 -176.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -79.81 -176.18 49.02 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 121.27 -1.135 . . . . 0.0 111.125 158.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 32.8 mm -99.67 119.27 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 178.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 85.9 m-85 -120.36 149.79 41.79 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.898 -1.126 . . . . 0.0 110.366 -171.221 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.8 t -76.75 112.44 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 O-C-N 121.022 -1.049 . . . . 0.0 111.67 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.36 -41.92 11.22 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 120.804 -1.185 . . . . 0.0 112.109 -174.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.61 151.99 35.97 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.82 -1.175 . . . . 0.0 110.411 176.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -115.98 119.91 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 CA-C-O 122.5 1.143 . . . . 0.0 108.819 173.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.21 125.61 86.3 Favored Pre-proline 0 N--CA 1.431 -1.414 0 N-CA-C 117.042 2.238 . . . . 0.0 117.042 -166.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -53.84 119.08 5.68 Favored 'Trans proline' 0 N--CA 1.434 -2.011 0 C-N-CA 123.645 2.897 . . . . 0.0 116.512 178.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.255 67.2 mmtt 76.16 30.0 0.73 Allowed 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 128.267 2.627 . . . . 0.0 112.421 -177.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 158.07 33.7 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.617 -1.302 . . . . 0.0 111.119 168.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -59.23 3.98 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.794 -1.416 . . . . 0.0 113.346 166.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.519 ' HA ' HD11 ' A' ' 18' ' ' LEU . . . -63.24 -46.69 85.77 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 128.553 2.741 . . . . 0.0 113.914 -179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -42.78 -60.62 1.51 Allowed 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 172.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -69.17 -30.96 69.29 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 -177.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -60.93 -62.79 1.6 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 125.655 1.582 . . . . 0.0 113.336 -178.079 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.94 6.17 49.42 Favored Glycine 0 N--CA 1.431 -1.696 0 N-CA-C 116.987 1.555 . . . . 0.0 116.987 166.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.7 mmt85 -72.33 -37.22 68.93 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-N 119.541 1.67 . . . . 0.0 110.805 164.123 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.9 mt -92.27 124.28 44.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 124.922 1.289 . . . . 0.0 108.11 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 1.2 t-80 -145.6 176.86 9.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.387 -1.446 . . . . 0.0 111.619 175.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 2.9 ttpm? -65.59 126.4 28.23 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.298 1.039 . . . . 0.0 113.023 -170.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.98 -3.24 80.65 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 121.128 -0.983 . . . . 0.0 115.533 -179.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -80.51 157.97 25.97 Favored 'General case' 0 N--CA 1.43 -1.427 0 CA-C-N 119.117 1.458 . . . . 0.0 111.911 -177.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -105.12 121.66 44.28 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 121.088 -1.008 . . . . 0.0 111.212 -172.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.43 HG13 HD11 ' A' ' 94' ' ' LEU . 58.9 t -82.31 134.39 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.406 0 C-N-CA 125.727 1.611 . . . . 0.0 107.895 -176.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -119.42 -52.14 2.27 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.96 -1.087 . . . . 0.0 113.715 -167.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.85 113.28 4.96 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.626 -1.296 . . . . 0.0 111.138 -173.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -93.59 111.64 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.164 -0.96 . . . . 0.0 108.945 -175.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 10.6 t-20 61.68 36.15 16.66 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.901 2.08 . . . . 0.0 113.407 177.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.39 -9.89 75.34 Favored Glycine 0 N--CA 1.431 -1.67 0 C-N-CA 125.001 1.286 . . . . 0.0 113.669 -176.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.4 t -90.94 101.96 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.11 -1.818 . . . . 0.0 109.019 -176.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.3 m -66.79 133.21 49.67 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.707 -1.246 . . . . 0.0 112.125 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.2 mt -85.97 45.95 1.27 Allowed 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 124.293 1.037 . . . . 0.0 112.262 -171.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -74.82 118.99 18.4 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.93 -1.731 . . . . 0.0 112.295 -171.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 68.52 22.88 75.23 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 124.031 0.824 . . . . 0.0 114.825 -175.143 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.92 145.34 50.21 Favored 'General case' 0 N--CA 1.431 -1.41 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -176.022 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 42.3 p -90.13 170.84 9.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.872 1.269 . . . . 0.0 110.835 168.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.3 t-160 -53.04 -50.58 64.01 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.324 1.85 . . . . 0.0 113.563 175.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? -56.42 -43.25 79.23 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.436 1.494 . . . . 0.0 113.776 175.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -55.75 -47.04 77.67 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.302 1.841 . . . . 0.0 114.198 -175.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.31 -45.51 93.15 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.791 1.636 . . . . 0.0 113.176 174.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.1 t -66.29 -43.34 91.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 125.166 1.386 . . . . 0.0 111.717 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 74.2 mm-40 -59.37 -43.69 92.85 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.971 -1.08 . . . . 0.0 113.027 177.221 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -72.04 -36.54 69.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.3 1.04 . . . . 0.0 113.724 176.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.9 mt -63.81 -35.62 81.21 Favored 'General case' 0 CA--C 1.489 -1.393 0 O-C-N 120.056 -1.653 . . . . 0.0 114.832 171.181 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.0 mtt180 -71.57 -30.9 66.38 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.134 -1.604 . . . . 0.0 112.308 173.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -84.85 50.31 1.9 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.968 1.707 . . . . 0.0 112.628 174.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.3 p -106.3 164.28 12.14 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 125.512 1.525 . . . . 0.0 110.923 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -100.6 -168.99 28.81 Favored Glycine 0 N--CA 1.429 -1.786 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 164.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -68.56 -46.76 68.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-N 118.348 1.074 . . . . 0.0 113.71 -175.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.7 t -95.99 118.71 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 CA-C-O 122.864 1.316 . . . . 0.0 109.843 172.01 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 97.6 t -109.74 118.88 57.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 127.09 2.156 . . . . 0.0 110.143 -169.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -101.7 94.61 5.94 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.505 -1.372 . . . . 0.0 112.249 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.43 HD11 HG13 ' A' ' 65' ' ' VAL . 19.9 tp -96.92 141.47 30.06 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 119.353 -2.092 . . . . 0.0 110.375 173.537 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 9.0 tt -104.98 130.45 53.18 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.97 -1.706 . . . . 0.0 108.823 162.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 3.9 pp -134.74 165.71 24.63 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.911 -1.118 . . . . 0.0 112.58 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -112.92 142.2 45.87 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.172 1.789 . . . . 0.0 109.44 176.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.27 123.03 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 120.64 -1.288 . . . . 0.0 111.056 178.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -82.33 145.29 24.09 Favored Glycine 0 N--CA 1.429 -1.779 0 C-N-CA 124.664 1.126 . . . . 0.0 112.003 178.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -96.86 -34.76 11.15 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 121.376 -1.073 . . . . 0.0 112.728 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 25.4 t -81.93 143.24 49.48 Favored Pre-proline 0 N--CA 1.43 -1.449 0 CA-C-O 117.372 -1.299 . . . . 0.0 108.986 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo . . . . . 0 N--CA 1.433 -2.064 0 CA-C-N 123.901 2.429 . . . . 0.0 113.398 167.639 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 43.3 pttt . . . . . 0 N--CA 1.43 -1.448 0 N-CA-C 110.616 -0.142 . . . . 0.0 110.616 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -80.54 62.39 8.52 Favored 'Trans proline' 0 C--N 1.3 -2.025 0 C-N-CA 125.066 3.844 . . . . 0.0 114.969 -166.091 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.43 61.33 0.19 Allowed Glycine 0 N--CA 1.43 -1.719 0 O-C-N 120.764 -1.21 . . . . 0.0 110.962 -176.387 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -91.23 166.85 12.72 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 124.642 1.177 . . . . 0.0 109.173 175.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -109.19 146.99 33.25 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.842 1.257 . . . . 0.0 108.758 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.19 140.67 26.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 CA-C-O 121.998 0.904 . . . . 0.0 108.875 179.197 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 -88.92 136.87 32.78 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-O 122.615 1.198 . . . . 0.0 107.901 161.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.3 t -117.98 114.06 44.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -104.31 88.76 3.05 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 169.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 50.9 tp -105.18 139.42 39.86 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 121.408 -0.808 . . . . 0.0 109.4 -173.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.64 123.63 45.96 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.495 -1.378 . . . . 0.0 107.85 167.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -68.22 128.91 38.27 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.885 2.474 . . . . 0.0 112.427 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.3 p -101.24 125.93 47.92 Favored 'General case' 0 N--CA 1.429 -1.494 0 O-C-N 120.702 -1.248 . . . . 0.0 110.952 -178.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.4 t70 56.96 32.66 21.98 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.105 1.762 . . . . 0.0 114.837 177.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.57 -5.83 67.45 Favored Glycine 0 N--CA 1.431 -1.675 0 O-C-N 119.744 -1.848 . . . . 0.0 116.269 -179.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 74.3 m -112.04 135.23 52.94 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-N 118.77 1.285 . . . . 0.0 111.549 -171.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 40.6 mt -86.47 -62.86 1.42 Allowed 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.634 -1.292 . . . . 0.0 109.481 167.134 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.15 51.71 0.43 Allowed Glycine 0 N--CA 1.43 -1.764 0 O-C-N 119.291 -2.131 . . . . 0.0 111.52 170.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 tt -142.69 142.7 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.505 0 CA-C-O 122.601 1.191 . . . . 0.0 111.008 -176.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.9 t -117.7 132.53 56.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 124.983 1.313 . . . . 0.0 107.667 167.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.4 m -113.15 164.5 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.681 1.192 . . . . 0.0 111.965 -176.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.7 t -144.09 172.53 12.76 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.119 1.368 . . . . 0.0 109.435 174.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.72 -143.12 16.54 Favored Glycine 0 N--CA 1.429 -1.828 0 C-N-CA 124.541 1.067 . . . . 0.0 115.243 171.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.7 -149.67 18.07 Favored Glycine 0 N--CA 1.429 -1.813 0 C-N-CA 124.823 1.201 . . . . 0.0 112.502 178.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 6.6 p -97.2 12.53 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.578 -1.542 . . . . 0.0 112.57 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -83.3 -61.77 1.76 Allowed 'General case' 0 N--CA 1.429 -1.51 0 O-C-N 118.872 -2.393 . . . . 0.0 111.963 -178.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 21.2 p -94.81 174.85 6.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.535 1.134 . . . . 0.0 110.979 -175.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 46.4 m -83.14 56.55 3.55 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.895 -1.753 . . . . 0.0 113.259 -175.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.8 m -100.54 4.22 10.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 O-C-N 120.493 -1.379 . . . . 0.0 113.716 -176.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.307 33.5 mmt180 93.03 123.0 0.02 OUTLIER 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.818 2.447 . . . . 0.0 108.894 -162.318 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 11.5 m170 -60.48 100.37 0.1 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 114.66 1.356 . . . . 0.0 114.66 -166.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.14 15.7 29.85 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 121.02 -1.05 . . . . 0.0 112.867 -177.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -80.35 92.66 1.4 Allowed Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.416 1.007 . . . . 0.0 112.048 177.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 15.0 mm -86.6 126.03 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 172.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 39.7 m-85 -122.42 154.02 38.31 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.996 -1.065 . . . . 0.0 109.461 -174.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 26.6 t -76.16 118.86 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.967 -1.083 . . . . 0.0 111.524 175.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -88.53 -43.01 11.72 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 124.919 1.288 . . . . 0.0 110.123 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.66 150.82 23.36 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 121.105 -0.997 . . . . 0.0 109.123 174.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.551 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -110.2 117.66 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 170.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 37.8 mm -76.04 117.67 65.67 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 115.296 -2.287 . . . . 0.0 113.369 -161.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_exo -53.74 129.59 34.76 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 124.025 3.15 . . . . 0.0 116.387 -169.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 34.9 mttt 77.56 14.71 1.72 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.374 1.87 . . . . 0.0 114.474 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.85 165.81 46.16 Favored Glycine 0 N--CA 1.429 -1.794 0 O-C-N 119.658 -1.901 . . . . 0.0 113.421 173.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.31 -58.9 4.26 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.724 1.75 . . . . 0.0 115.724 167.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.01 -50.18 71.74 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 128.935 2.894 . . . . 0.0 112.175 -178.6 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.551 ' HG2' HG23 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -41.78 -71.04 0.09 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.782 2.033 . . . . 0.0 114.997 166.515 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 2.9 t -70.02 -14.96 62.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 114.94 1.459 . . . . 0.0 114.94 -170.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -64.9 -59.25 4.4 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.743 -1.848 . . . . 0.0 111.946 173.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 97.78 29.46 7.71 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.046 -1.659 . . . . 0.0 116.682 165.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.1 mmt180 -92.92 -41.57 9.96 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.392 -1.064 . . . . 0.0 108.864 160.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 21.0 mt -97.88 118.76 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 C-N-CA 126.399 1.88 . . . . 0.0 110.811 -170.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -128.59 174.77 9.1 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-O 123.085 1.421 . . . . 0.0 111.438 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.1 ttmt -62.41 130.44 45.22 Favored 'General case' 0 N--CA 1.431 -1.387 0 O-C-N 119.579 -1.951 . . . . 0.0 112.583 176.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.8 -5.35 61.84 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.712 -0.618 . . . . 0.0 113.697 -177.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -77.54 156.37 30.99 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 118.661 1.23 . . . . 0.0 111.641 -176.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 4.4 tpt180 -106.93 123.0 47.55 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.579 1.181 . . . . 0.0 110.185 -172.479 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.5 t -85.64 133.68 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 O-C-N 120.217 -1.552 . . . . 0.0 111.089 -175.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.7 mp -107.47 -51.62 2.88 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.025 -1.047 . . . . 0.0 111.073 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.76 148.26 28.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.958 -1.089 . . . . 0.0 113.137 -176.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -117.97 111.04 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.096 0.958 . . . . 0.0 110.303 173.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.6 t30 61.01 39.9 15.87 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.78 2.032 . . . . 0.0 113.323 172.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.07 -27.34 19.66 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 125.309 1.433 . . . . 0.0 113.459 -178.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 22.2 t -84.64 119.8 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 124.95 1.3 . . . . 0.0 110.817 -172.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 60.2 p -72.23 136.5 46.37 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.462 -1.399 . . . . 0.0 112.296 177.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 35.9 mt -87.95 -6.16 58.17 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.475 -1.391 . . . . 0.0 113.896 -175.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.4 tt0 -68.71 95.26 0.65 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 119.581 -1.949 . . . . 0.0 115.878 -174.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 131.96 -15.13 5.14 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.819 1.2 . . . . 0.0 111.151 -177.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.4 158.88 35.52 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 179.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 26.8 p -87.52 179.12 6.61 Favored 'General case' 0 N--CA 1.431 -1.389 0 O-C-N 120.712 -1.242 . . . . 0.0 111.115 172.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -67.21 -46.75 72.91 Favored 'General case' 0 N--CA 1.431 -1.393 0 O-C-N 120.703 -1.248 . . . . 0.0 110.755 173.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.7 tppt? -57.4 -40.93 79.28 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.201 1.401 . . . . 0.0 113.972 174.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 26.8 mm100 -56.93 -51.39 69.32 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.555 1.142 . . . . 0.0 114.076 176.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.99 -40.52 96.56 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.255 1.422 . . . . 0.0 113.519 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -66.17 -45.98 88.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 O-C-N 120.846 -1.159 . . . . 0.0 111.329 176.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -58.81 -40.07 83.04 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 120.629 -1.294 . . . . 0.0 112.95 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 84.2 m -68.2 -42.63 79.59 Favored 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 125.963 1.705 . . . . 0.0 113.569 178.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 72.9 mt -68.99 -33.55 73.86 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.987 -1.696 . . . . 0.0 114.391 176.724 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -72.35 -33.04 66.99 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 119.644 -1.91 . . . . 0.0 112.675 171.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -78.58 44.73 0.54 Allowed 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.854 2.061 . . . . 0.0 114.25 170.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.1 p -105.79 154.88 19.89 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.224 -2.172 . . . . 0.0 108.842 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.23 -146.56 17.64 Favored Glycine 0 N--CA 1.429 -1.776 0 O-C-N 120.916 -1.115 . . . . 0.0 112.921 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -70.85 -61.06 1.9 Allowed 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 124.402 1.081 . . . . 0.0 112.312 169.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.1 p -94.72 127.5 46.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 CA-C-O 123.567 1.651 . . . . 0.0 110.244 177.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 73.3 t -120.61 114.17 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.398 1.879 . . . . 0.0 108.772 -162.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.5 m170 -101.86 94.1 5.64 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 124.044 0.938 . . . . 0.0 112.144 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -102.37 160.07 14.86 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.638 -1.914 . . . . 0.0 114.297 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.2 tp -128.35 132.8 48.59 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 124.869 1.268 . . . . 0.0 108.505 163.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -146.08 164.5 31.93 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.929 -1.107 . . . . 0.0 113.371 176.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -116.97 134.84 54.24 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 127.021 2.129 . . . . 0.0 107.773 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -77.58 144.94 37.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.355 -1.466 . . . . 0.0 112.671 -175.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -61.61 112.52 4.85 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 125.769 1.652 . . . . 0.0 114.423 174.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -70.3 -28.98 65.61 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.876 1.27 . . . . 0.0 113.545 -178.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 7.2 p -116.66 112.15 41.05 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 120.914 -1.116 . . . . 0.0 108.427 163.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo . . . . . 0 C--N 1.3 -2.014 0 C-N-CA 122.696 2.264 . . . . 0.0 113.63 -177.697 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt . . . . . 0 N--CA 1.43 -1.438 0 CA-C-O 115.212 -2.328 . . . . 0.0 112.866 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -74.64 -178.64 4.2 Favored 'Trans proline' 0 N--CA 1.433 -2.033 0 CA-C-N 126.533 3.369 . . . . 0.0 113.073 163.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 121.92 95.7 1.35 Allowed Glycine 0 N--CA 1.43 -1.747 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -164.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -53.12 -60.69 2.97 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 129.924 3.29 . . . . 0.0 113.159 -169.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.8 p -105.62 150.63 25.24 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-N 120.166 1.348 . . . . 0.0 110.206 166.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.611 ' CE1' HD21 ' A' ' 96' ' ' LEU . 27.1 p90 -147.69 164.43 33.58 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-O 122.635 1.207 . . . . 0.0 108.918 161.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -126.19 143.0 51.3 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 126.205 1.802 . . . . 0.0 106.858 -168.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.69 111.91 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 O-C-N 120.848 -1.157 . . . . 0.0 109.118 -173.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -103.1 94.16 5.39 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 125.762 1.625 . . . . 0.0 107.998 169.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 30.1 tp -123.86 134.36 53.59 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-O 122.208 1.004 . . . . 0.0 113.521 -167.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.62 137.37 39.11 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 125.67 1.588 . . . . 0.0 110.352 177.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -69.11 162.12 27.63 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 115.19 1.552 . . . . 0.0 115.19 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 39.5 p -130.97 114.91 15.8 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 26.9 t70 50.65 59.49 4.55 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.461 1.904 . . . . 0.0 113.844 -177.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 83.65 -36.05 2.83 Favored Glycine 0 N--CA 1.43 -1.726 0 O-C-N 120.13 -1.606 . . . . 0.0 115.663 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 61.5 m -106.38 149.31 27.12 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.346 1.458 . . . . 0.0 112.059 -162.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -96.22 -57.12 2.42 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 172.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.61 23.46 1.88 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 120.153 -1.592 . . . . 0.0 113.075 172.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.3 pt -115.21 125.53 72.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.085 1.354 . . . . 0.0 110.178 -176.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 t -112.39 128.49 56.31 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.302 -0.874 . . . . 0.0 108.796 170.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.5 m -109.66 163.55 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 111.896 -174.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.6 t -133.51 164.78 26.38 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 124.677 1.191 . . . . 0.0 108.015 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.39 -154.92 20.17 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 120.899 -1.125 . . . . 0.0 112.913 171.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.94 145.83 18.6 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.192 1.377 . . . . 0.0 110.445 -169.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -58.68 -34.17 50.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 N-CA-C 115.044 1.498 . . . . 0.0 115.044 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.57 -19.84 59.02 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 114.905 1.446 . . . . 0.0 114.905 -172.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.0 t -94.29 162.29 13.9 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.477 -1.389 . . . . 0.0 107.585 174.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 12.4 p -81.86 46.81 1.03 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.045 -1.659 . . . . 0.0 113.973 -168.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.1 m -92.13 133.77 32.47 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 O-C-N 120.403 -1.436 . . . . 0.0 110.154 173.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 2.9 tmt_? -73.28 -29.53 62.79 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.185 . . . . 0.0 110.451 167.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 19.8 m170 -43.44 -42.0 4.55 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 128.473 2.709 . . . . 0.0 116.744 178.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.71 61.17 7.05 Favored Glycine 0 N--CA 1.43 -1.71 0 N-CA-C 115.948 1.139 . . . . 0.0 115.948 169.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 172.33 178.52 42.57 Favored Glycine 0 N--CA 1.43 -1.759 0 N-CA-C 107.959 -2.057 . . . . 0.0 107.959 -177.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 34.8 mm -103.3 120.15 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 176.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -128.0 153.76 46.38 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.924 -1.11 . . . . 0.0 110.496 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 20.5 t -76.0 121.96 29.04 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.577 -1.327 . . . . 0.0 112.687 178.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmt? -97.84 -45.94 6.13 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 124.741 1.216 . . . . 0.0 112.503 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.51 154.79 27.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.104 -0.998 . . . . 0.0 110.466 -178.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.417 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -111.3 126.14 68.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 CA-C-O 122.235 1.017 . . . . 0.0 109.742 175.461 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 14.1 mm -77.09 118.78 74.24 Favored Pre-proline 0 N--CA 1.43 -1.467 0 CA-C-O 116.043 -1.932 . . . . 0.0 113.761 -174.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -60.19 123.79 13.88 Favored 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 125.003 2.822 . . . . 0.0 115.763 -176.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.378 39.8 mtmt 75.59 31.76 0.73 Allowed 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 127.372 2.269 . . . . 0.0 114.426 -175.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.09 162.39 36.89 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 120.819 -1.176 . . . . 0.0 112.96 159.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.07 -56.23 11.67 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 126.715 2.006 . . . . 0.0 114.489 165.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.22 -48.79 74.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 128.33 2.652 . . . . 0.0 111.813 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.417 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.4 tm-20 -41.84 -59.21 1.76 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 116.22 1.933 . . . . 0.0 116.22 176.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -69.86 -28.32 65.57 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.535 1.534 . . . . 0.0 114.359 -172.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -57.32 -56.57 20.15 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 125.981 1.712 . . . . 0.0 113.687 -173.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.54 -4.88 26.34 Favored Glycine 0 N--CA 1.429 -1.801 0 O-C-N 120.587 -1.32 . . . . 0.0 115.42 164.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 14' ' ' PHE . 95.1 mtt180 -74.84 -61.86 1.74 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.628 -1.513 . . . . 0.0 110.605 169.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.434 HD11 HD11 ' A' ' 94' ' ' LEU . 97.0 mt -67.69 125.69 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 125.886 1.674 . . . . 0.0 113.527 -177.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 22.0 t-80 -141.7 159.49 42.11 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.49 1.614 . . . . 0.0 114.089 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 29.1 ttpt -52.55 127.21 22.0 Favored 'General case' 0 N--CA 1.429 -1.5 0 C-N-CA 127.521 2.328 . . . . 0.0 114.918 177.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 98.06 -7.31 62.43 Favored Glycine 0 N--CA 1.43 -1.762 0 C-N-CA 124.031 0.824 . . . . 0.0 114.571 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.72 160.6 24.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 119.363 1.581 . . . . 0.0 112.508 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 66.7 ttt-85 -105.23 132.92 50.82 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.943 1.697 . . . . 0.0 111.192 -174.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.77 136.21 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 119.85 -1.781 . . . . 0.0 111.231 -176.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.6 mp -100.83 -60.66 1.48 Allowed 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.37 -1.457 . . . . 0.0 110.945 178.042 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.81 125.94 10.66 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.907 -1.12 . . . . 0.0 112.366 -171.078 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 23.9 t -99.04 114.33 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 123.837 0.855 . . . . 0.0 109.367 177.534 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.7 t30 59.52 35.28 22.7 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 126.042 1.737 . . . . 0.0 115.1 168.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.51 -10.74 66.98 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 124.971 1.272 . . . . 0.0 114.186 -177.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.31 107.88 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.782 -1.422 . . . . 0.0 109.659 -176.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.5 t -73.04 126.33 29.72 Favored 'General case' 0 N--CA 1.431 -1.391 0 O-C-N 120.777 -1.202 . . . . 0.0 111.177 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 55.4 mt -84.95 37.74 0.68 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 -169.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -74.77 120.54 20.46 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.929 1.691 . . . . 0.0 110.656 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.11 11.95 79.3 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 120.49 -1.381 . . . . 0.0 114.412 -175.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.89 140.64 51.12 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 114.652 1.353 . . . . 0.0 114.652 -175.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 71.8 p -90.86 -179.28 5.45 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.689 1.195 . . . . 0.0 111.19 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -69.23 -45.43 69.81 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.752 -1.217 . . . . 0.0 110.317 179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 mptt -56.89 -41.63 78.4 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 114.626 1.343 . . . . 0.0 114.626 170.274 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.66 -53.1 62.05 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.671 -1.268 . . . . 0.0 113.915 178.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -68.95 -44.02 73.86 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.82 1.248 . . . . 0.0 113.575 178.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.4 -49.07 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.64 -1.288 . . . . 0.0 111.806 -177.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 7.5 mm-40 -65.73 -32.42 73.96 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.744 -1.222 . . . . 0.0 112.087 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 36.0 m -66.98 -45.06 78.79 Favored 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 125.774 1.63 . . . . 0.0 113.101 173.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 54.3 mt -68.64 -29.31 67.77 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.123 -1.611 . . . . 0.0 114.293 174.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.6 mtp180 -73.68 -47.46 39.5 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.227 -1.546 . . . . 0.0 113.159 171.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -89.18 55.67 3.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.148 -1.595 . . . . 0.0 113.543 -176.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.4 p -84.5 177.91 7.92 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.126 1.771 . . . . 0.0 111.531 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.8 -157.66 27.67 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 120.123 -1.61 . . . . 0.0 110.375 164.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.5 tm0? -71.33 -50.52 31.53 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 119.819 -1.989 . . . . 0.0 110.861 169.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.4 t -98.51 135.99 31.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.309 1.444 . . . . 0.0 109.844 174.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 42.7 t -107.72 126.16 64.13 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 C-N-CA 129.047 2.939 . . . . 0.0 108.448 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.9 t-160 -105.21 110.07 22.3 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 167.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.434 HD11 HD11 ' A' ' 59' ' ' ILE 0.389 4.0 pp -125.1 151.24 45.97 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 117.032 2.234 . . . . 0.0 117.032 166.867 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.8 tp -114.97 134.23 55.36 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.839 2.056 . . . . 0.0 107.527 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.611 HD21 ' CE1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -152.75 174.37 14.12 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.035 -1.041 . . . . 0.0 113.639 -179.21 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -119.39 132.47 55.84 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 125.712 1.605 . . . . 0.0 111.146 -175.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.63 145.95 34.37 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.112 -1.617 . . . . 0.0 113.644 -179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.25 78.77 1.97 Allowed Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.168 -1.582 . . . . 0.0 111.03 170.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -84.38 176.95 8.35 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 116.122 1.897 . . . . 0.0 116.122 -159.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 88.4 t -108.37 118.51 52.07 Favored Pre-proline 0 N--CA 1.43 -1.455 0 O-C-N 120.921 -1.112 . . . . 0.0 110.104 -177.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo . . . . . 0 N--CA 1.434 -2.007 0 C-N-CA 122.866 2.378 . . . . 0.0 113.164 166.527 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.43 -1.455 0 CA-C-O 115.45 -2.214 . . . . 0.0 114.421 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -67.54 177.5 3.95 Favored 'Trans proline' 0 C--N 1.299 -2.036 0 CA-C-N 126.255 3.269 . . . . 0.0 116.738 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.39 33.08 8.25 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -161.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -96.99 136.29 37.77 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.419 1.887 . . . . 0.0 109.752 -176.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.7 p -95.97 153.67 17.64 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.869 -1.769 . . . . 0.0 111.863 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.68 ' CZ ' HD22 ' A' ' 96' ' ' LEU . 37.4 p90 -146.6 137.51 24.11 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 173.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -94.72 128.06 41.15 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.593 -1.317 . . . . 0.0 109.942 176.187 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 t -114.41 88.85 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 -178.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.4 ' HG2' ' CD2' ' A' ' 93' ' ' HIS . 61.0 mt-10 -93.85 83.33 4.37 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 169.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.419 HD13 ' HB1' ' A' ' 52' ' ' ALA 0.288 1.8 pp -109.2 162.75 13.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.771 1.272 . . . . 0.0 111.233 -178.035 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.41 133.73 46.88 Favored 'General case' 0 N--CA 1.428 -1.527 0 C-N-CA 124.728 1.211 . . . . 0.0 107.924 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 34.6 ttmt -70.6 121.87 18.69 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.458 -1.401 . . . . 0.0 112.32 -178.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 29.2 p -94.7 119.61 33.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.669 -1.269 . . . . 0.0 110.039 -174.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.8 t70 61.13 7.7 1.7 Allowed 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 127.056 2.142 . . . . 0.0 116.416 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 107.41 2.27 35.34 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.984 -1.698 . . . . 0.0 114.846 -177.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 63.2 m -121.93 132.02 54.33 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.911 1.855 . . . . 0.0 113.306 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 85.5 mt -73.7 -44.24 57.03 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.712 -1.242 . . . . 0.0 111.425 164.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.5 29.74 3.31 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 119.767 -1.833 . . . . 0.0 111.719 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 pt -107.31 135.22 46.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 CA-C-O 122.625 1.202 . . . . 0.0 114.215 -162.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 17.7 m -131.3 109.68 10.54 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.758 -1.839 . . . . 0.0 108.969 155.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -100.03 163.82 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-O 122.153 0.978 . . . . 0.0 112.145 -177.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.6 t -145.81 172.6 13.07 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.13 1.372 . . . . 0.0 108.28 175.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 -175.61 33.68 Favored Glycine 0 N--CA 1.43 -1.756 0 O-C-N 120.734 -1.229 . . . . 0.0 114.125 176.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 149.6 177.61 23.83 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -171.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.2 p -78.35 -41.61 26.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.434 1.272 . . . . 0.0 114.434 -173.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -98.65 7.77 45.72 Favored 'General case' 0 N--CA 1.431 -1.416 0 O-C-N 120.021 -1.675 . . . . 0.0 111.219 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 10.6 m -84.02 158.23 21.55 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.035 1.734 . . . . 0.0 109.022 -177.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 34.3 p -74.48 47.74 0.32 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 126.247 1.819 . . . . 0.0 115.838 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 26.3 m -92.25 -178.25 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 C-N-CA 126.758 2.023 . . . . 0.0 106.885 161.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 22.4 mtm180 -69.74 -53.67 17.36 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.766 -1.834 . . . . 0.0 113.746 -175.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 23.4 t60 -128.69 -45.39 1.31 Allowed 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 157.14 85.69 0.05 OUTLIER Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.858 -1.151 . . . . 0.0 111.54 -177.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -144.32 155.74 26.44 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.459 -1.024 . . . . 0.0 111.461 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.7 mm -102.39 123.34 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.894 1.678 . . . . 0.0 107.464 175.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -124.4 155.16 39.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.935 -1.103 . . . . 0.0 111.307 -170.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 62.1 t -76.05 119.31 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.883 -1.136 . . . . 0.0 110.789 169.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.9 pttt -95.51 -36.59 11.24 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.471 -1.393 . . . . 0.0 112.445 173.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -155.88 160.95 40.6 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.921 -1.112 . . . . 0.0 110.539 177.1 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.436 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -120.15 125.88 74.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 124.404 1.082 . . . . 0.0 109.216 177.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.8 mm -77.42 124.93 86.85 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.623 1.969 . . . . 0.0 114.265 -176.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_exo -56.57 133.87 60.73 Favored 'Trans proline' 0 N--CA 1.435 -1.968 0 CA-C-N 124.034 2.476 . . . . 0.0 116.237 176.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt 83.53 0.77 1.06 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 129.012 2.925 . . . . 0.0 114.71 -177.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.05 156.08 46.88 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.121 -1.612 . . . . 0.0 113.104 176.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HB1' HD13 ' A' ' 18' ' ' LEU . . . -49.35 -53.14 23.78 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 116.233 1.938 . . . . 0.0 116.233 172.495 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.2 -45.76 86.91 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 128.951 2.901 . . . . 0.0 112.622 177.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.436 ' HA ' HG12 ' A' ' 47' ' ' ILE . 5.6 tm-20 -50.21 -57.99 6.57 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 123.101 1.429 . . . . 0.0 114.656 171.144 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.4 t -68.02 -25.39 65.37 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 125.193 1.397 . . . . 0.0 113.717 -171.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -61.56 -71.94 0.13 Allowed 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.695 1.598 . . . . 0.0 112.501 173.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.76 -6.52 37.98 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 121.108 -0.995 . . . . 0.0 115.284 177.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.1 mtm180 -65.22 -35.47 81.15 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 119.867 -1.961 . . . . 0.0 111.893 165.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 73.3 mt -85.36 134.21 27.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 124.884 1.273 . . . . 0.0 109.683 176.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -139.17 161.31 37.73 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.807 -1.183 . . . . 0.0 108.922 177.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.2 ttpt -54.71 125.05 18.37 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.985 1.714 . . . . 0.0 113.934 172.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.84 -2.25 66.41 Favored Glycine 0 N--CA 1.43 -1.72 0 C-N-CA 124.286 0.946 . . . . 0.0 114.802 -178.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -82.12 160.18 23.19 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-N 119.614 1.707 . . . . 0.0 110.535 178.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.2 ttt180 -112.37 132.48 54.98 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.619 -1.3 . . . . 0.0 112.151 -168.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.7 t -87.14 127.68 40.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 O-C-N 120.319 -1.488 . . . . 0.0 110.657 178.588 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 88.1 mt -98.15 -48.1 5.23 Favored 'General case' 0 N--CA 1.429 -1.495 0 O-C-N 121.132 -0.98 . . . . 0.0 111.253 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.44 134.6 18.16 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.995 -1.065 . . . . 0.0 109.787 -176.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.7 t -114.23 125.85 71.62 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.475 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 67.25 30.06 7.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.259 1.424 . . . . 0.0 111.721 175.28 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 85.19 -18.84 25.84 Favored Glycine 0 N--CA 1.431 -1.682 0 C-N-CA 125.058 1.313 . . . . 0.0 114.802 -173.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.7 t -90.85 123.27 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 O-C-N 120.776 -1.426 . . . . 0.0 110.521 -171.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.5 m -63.88 135.27 56.42 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.776 -1.202 . . . . 0.0 113.956 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 78.1 mt -86.17 56.52 4.02 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.754 -1.216 . . . . 0.0 111.65 177.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -78.85 123.11 26.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.571 -1.331 . . . . 0.0 112.508 -175.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 58.59 20.87 48.03 Favored Glycine 0 N--CA 1.43 -1.746 0 C-N-CA 125.349 1.452 . . . . 0.0 115.139 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.64 144.66 51.04 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 115.338 1.607 . . . . 0.0 115.338 -164.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 72.3 p -76.58 178.45 6.67 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 124.611 1.164 . . . . 0.0 110.511 169.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 32.4 t-80 -68.25 -48.84 63.99 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.427 -1.421 . . . . 0.0 111.738 172.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 41.2 mmtm -58.48 -31.67 68.05 Favored 'General case' 0 N--CA 1.429 -1.512 0 N-CA-C 116.012 1.856 . . . . 0.0 116.012 174.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 10.1 mm100 -56.35 -55.74 29.76 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-N 120.324 1.42 . . . . 0.0 114.181 175.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.41 -37.53 87.85 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.198 0.999 . . . . 0.0 113.195 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -68.35 -48.39 73.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.028 1.331 . . . . 0.0 111.208 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -62.94 -36.82 84.68 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.482 -1.386 . . . . 0.0 112.791 177.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.1 m -67.26 -45.88 75.38 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.646 1.578 . . . . 0.0 113.188 175.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 20.8 mt -66.28 -34.74 78.68 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.399 -1.438 . . . . 0.0 114.031 175.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -72.51 -31.64 65.51 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.32 -1.488 . . . . 0.0 113.684 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -88.68 48.93 1.7 Allowed 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 122.185 0.993 . . . . 0.0 112.066 173.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 34.1 p -107.17 154.33 21.35 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.102 -1.624 . . . . 0.0 109.14 170.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -108.83 -132.5 6.61 Favored Glycine 0 N--CA 1.43 -1.718 0 CA-C-O 121.964 0.758 . . . . 0.0 113.823 -172.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 10.0 tm0? -70.82 -68.84 0.4 Allowed 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 121.308 -1.113 . . . . 0.0 113.54 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 9.2 p -98.33 131.98 44.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.873 1.32 . . . . 0.0 109.882 174.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 59.6 t -125.23 111.96 29.61 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 126.139 1.776 . . . . 0.0 110.209 -162.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . 0.4 ' CD2' ' HG2' ' A' ' 17' ' ' GLU . 30.4 m170 -93.14 101.15 13.44 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -178.243 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -92.73 146.19 23.84 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 120.113 -1.617 . . . . 0.0 112.602 168.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 60.5 tp -113.87 127.54 56.03 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 155.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.68 HD22 ' CZ ' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -136.22 151.69 49.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 121.098 -1.001 . . . . 0.0 111.356 -171.172 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -117.34 131.63 56.75 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 123.404 1.573 . . . . 0.0 111.622 176.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -75.86 128.56 35.36 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.133 2.173 . . . . 0.0 110.798 177.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.05 -160.86 36.92 Favored Glycine 0 N--CA 1.431 -1.658 0 O-C-N 121.351 -0.843 . . . . 0.0 111.221 177.508 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 -73.64 177.4 5.43 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.706 -1.467 . . . . 0.0 114.349 -175.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 58.6 t -98.85 133.68 22.15 Favored Pre-proline 0 N--CA 1.431 -1.423 0 CA-C-O 117.468 -1.253 . . . . 0.0 108.796 -176.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo . . . . . 0 N--CA 1.433 -2.085 0 C-N-CA 122.619 2.213 . . . . 0.0 113.414 177.398 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 25.1 mtpp . . . . . 0 N--CA 1.43 -1.454 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -83.42 178.77 5.45 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 CA-C-N 124.214 2.541 . . . . 0.0 111.587 171.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 96.76 17.73 32.12 Favored Glycine 0 N--CA 1.431 -1.677 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 168.151 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.3 t0 -87.4 164.4 16.23 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 120.097 1.949 . . . . 0.0 110.851 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 18.0 p -100.1 158.43 15.85 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.884 1.674 . . . . 0.0 112.541 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -144.67 146.71 32.37 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 171.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 58.3 mt-10 -89.57 113.19 24.58 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 165.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 t -98.77 99.66 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.498 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -90.38 94.36 9.7 Favored 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 174.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -105.14 126.48 52.12 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-O 122.464 1.126 . . . . 0.0 110.045 -174.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.82 139.25 38.64 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.133 -1.604 . . . . 0.0 110.225 176.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 82.6 mttt -66.18 130.86 44.66 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 121.002 -1.061 . . . . 0.0 113.075 175.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 16.9 p -91.09 84.72 5.75 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.228 -1.545 . . . . 0.0 110.378 177.161 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.1 t70 59.27 53.43 5.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.457 1.903 . . . . 0.0 113.487 179.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 91.96 -11.31 72.47 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.746 -1.221 . . . . 0.0 115.295 -176.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.5 t -94.53 112.92 24.69 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.419 -1.636 . . . . 0.0 113.519 -173.099 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 7.5 tp -125.84 63.03 1.22 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.662 1.585 . . . . 0.0 109.985 178.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -85.64 62.21 4.46 Favored Glycine 0 N--CA 1.43 -1.717 0 O-C-N 119.43 -2.043 . . . . 0.0 113.462 -164.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.93 127.34 55.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 C-N-CA 124.74 1.216 . . . . 0.0 107.975 168.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -112.43 121.79 45.85 Favored 'General case' 0 CA--C 1.489 -1.371 0 C-N-CA 123.626 0.77 . . . . 0.0 109.442 177.438 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.0 m -104.46 170.42 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.724 1.209 . . . . 0.0 112.736 -179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.2 t -150.24 173.79 13.55 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.198 1.399 . . . . 0.0 108.51 173.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.83 -138.03 14.67 Favored Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 167.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.87 162.31 27.79 Favored Glycine 0 N--CA 1.43 -1.736 0 C-N-CA 125.52 1.533 . . . . 0.0 113.023 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 16.6 m -63.0 -20.42 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 125.603 1.561 . . . . 0.0 114.988 177.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 -81.7 -10.33 59.41 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.611 1.965 . . . . 0.0 112.152 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.2 m -115.18 143.95 44.44 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.148 1.379 . . . . 0.0 108.864 -176.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.7 t -87.43 61.81 6.8 Favored 'General case' 0 N--CA 1.429 -1.482 0 O-C-N 119.597 -1.94 . . . . 0.0 110.783 177.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.8 p -100.02 41.79 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.489 0 C-N-CA 126.075 1.75 . . . . 0.0 113.064 -165.107 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 21.1 mmt85 59.73 64.85 1.22 Allowed 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 119.672 -1.892 . . . . 0.0 111.863 -166.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.31 38.2 m80 75.01 157.57 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 127.647 2.379 . . . . 0.0 113.812 -173.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -80.14 86.33 1.29 Allowed Glycine 0 N--CA 1.431 -1.647 0 O-C-N 120.212 -1.555 . . . . 0.0 115.167 -167.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -146.46 171.07 27.39 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 124.144 0.878 . . . . 0.0 110.962 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.9 mm -97.85 131.98 43.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 124.69 1.196 . . . . 0.0 108.577 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -126.84 159.4 33.99 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.777 -1.202 . . . . 0.0 110.305 -175.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.68 119.53 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.694 -1.253 . . . . 0.0 111.023 174.28 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 57.2 tttm -91.43 -50.85 5.57 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 124.11 0.964 . . . . 0.0 111.85 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -157.09 155.83 31.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.038 -1.039 . . . . 0.0 110.904 -177.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.41 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -114.09 120.63 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 CA-C-O 122.611 1.196 . . . . 0.0 109.643 172.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 34.6 mm -76.06 128.22 83.52 Favored Pre-proline 0 N--CA 1.43 -1.447 0 CA-C-O 116.09 -1.909 . . . . 0.0 113.252 -170.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_exo -55.0 133.85 60.42 Favored 'Trans proline' 0 N--CA 1.434 -2.002 0 C-N-CA 124.416 3.411 . . . . 0.0 115.65 178.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? 67.76 13.76 9.3 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.526 1.53 . . . . 0.0 114.478 -178.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.31 173.13 47.9 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 119.592 -1.942 . . . . 0.0 112.517 172.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.2 -56.87 9.25 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 115.213 1.56 . . . . 0.0 115.213 169.32 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.81 -40.1 95.83 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 126.595 1.958 . . . . 0.0 115.273 -173.022 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.41 ' HG2' HG23 ' A' ' 47' ' ' ILE . 1.0 OUTLIER -41.35 -60.08 1.37 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 129.423 3.089 . . . . 0.0 113.607 178.02 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.5 t -70.2 -33.84 72.21 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-N 111.693 -2.503 . . . . 0.0 115.847 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -62.43 -48.57 79.1 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.272 1.429 . . . . 0.0 113.129 -165.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.64 -19.92 45.9 Favored Glycine 0 N--CA 1.429 -1.798 0 O-C-N 120.506 -1.371 . . . . 0.0 115.421 162.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.2 mmt-85 -75.74 -4.34 39.89 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 118.429 1.115 . . . . 0.0 112.764 172.308 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.5 mt -117.91 126.97 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.525 0 C-N-CA 125.259 1.423 . . . . 0.0 107.981 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -132.25 163.83 27.73 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.617 -1.302 . . . . 0.0 109.797 170.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.0 tttp -67.91 123.29 20.17 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.215 -1.553 . . . . 0.0 112.773 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 100.01 0.83 56.09 Favored Glycine 0 N--CA 1.431 -1.7 0 O-C-N 121.678 -0.639 . . . . 0.0 114.099 -174.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -80.17 164.86 22.97 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-N 119.555 1.678 . . . . 0.0 110.455 173.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.18 136.68 51.29 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-O 122.602 1.192 . . . . 0.0 111.722 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 23.2 t -91.15 125.12 43.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 126.113 1.765 . . . . 0.0 109.76 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 49.1 mt -103.89 -56.89 2.12 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.42 -1.425 . . . . 0.0 110.589 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.74 118.62 6.66 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 121.165 -0.959 . . . . 0.0 111.163 -176.157 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.45 HG22 HD13 ' A' ' 94' ' ' LEU . 57.7 t -98.47 115.79 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -176.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 40.9 t30 60.84 42.41 13.23 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 124.796 1.238 . . . . 0.0 114.321 165.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 94.17 -18.35 57.01 Favored Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 124.53 1.062 . . . . 0.0 114.05 -177.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.66 117.93 42.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 O-C-N 120.851 -1.381 . . . . 0.0 109.331 -170.035 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 54.9 m -72.79 105.89 4.53 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 121.138 -0.976 . . . . 0.0 110.959 179.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 33.8 mt -89.8 25.67 2.0 Allowed 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.695 -1.253 . . . . 0.0 112.092 -175.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -77.83 122.55 25.59 Favored 'General case' 0 N--CA 1.431 -1.401 0 O-C-N 120.088 -1.632 . . . . 0.0 109.563 173.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 76.11 15.08 81.66 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 120.657 -1.277 . . . . 0.0 115.672 -170.369 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.28 163.11 28.28 Favored 'General case' 0 N--CA 1.429 -1.492 0 N-CA-C 115.279 1.585 . . . . 0.0 115.279 178.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.6 p -93.5 171.13 9.1 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.128 1.371 . . . . 0.0 111.196 173.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 64.8 t-80 -62.47 -51.06 68.95 Favored 'General case' 0 N--CA 1.429 -1.506 0 O-C-N 120.476 -1.39 . . . . 0.0 114.185 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 33.1 mtmt -57.12 -42.58 81.12 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 114.924 1.454 . . . . 0.0 114.924 174.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 7.1 tt0 -56.58 -45.91 81.09 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.355 1.862 . . . . 0.0 114.241 -173.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.69 -39.63 94.59 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.902 1.681 . . . . 0.0 114.732 172.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.2 t -68.7 -49.26 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.011 1.324 . . . . 0.0 110.415 179.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 82.3 mt-10 -66.41 -33.33 75.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.341 -1.474 . . . . 0.0 113.552 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.8 m -61.2 -41.6 97.11 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 125.744 1.618 . . . . 0.0 113.072 169.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 76.0 mt -71.7 -30.69 65.94 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.361 -1.462 . . . . 0.0 114.276 173.126 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.3 mpt_? -67.28 -46.51 73.41 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.073 -1.642 . . . . 0.0 112.587 173.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -93.74 64.75 3.53 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.644 -1.285 . . . . 0.0 110.653 177.544 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.6 p -101.46 164.42 11.77 Favored 'General case' 0 N--CA 1.429 -1.512 0 C-N-CA 128.043 2.537 . . . . 0.0 109.329 173.16 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -92.8 -139.75 9.38 Favored Glycine 0 N--CA 1.431 -1.678 0 O-C-N 121.043 -1.035 . . . . 0.0 110.689 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -71.14 -68.47 0.44 Allowed 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.189 -1.183 . . . . 0.0 114.039 170.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 23.4 t -105.51 128.77 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 CA-C-O 122.509 1.147 . . . . 0.0 108.619 -176.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.3 t -103.04 117.99 49.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 128.409 2.683 . . . . 0.0 108.996 -170.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 30.8 m170 -98.2 102.13 13.79 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.486 -1.383 . . . . 0.0 111.192 178.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.45 HD13 HG22 ' A' ' 68' ' ' VAL . 31.7 tp -99.93 132.88 45.01 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.207 -1.558 . . . . 0.0 111.388 175.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -87.44 121.55 30.02 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.163 -1.792 . . . . 0.0 106.163 163.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.0 tt -123.45 143.63 50.02 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 123.689 0.796 . . . . 0.0 109.804 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -111.22 136.33 50.45 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.596 1.158 . . . . 0.0 109.22 174.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 13.9 tppt? -77.89 126.97 31.65 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 121.196 -0.94 . . . . 0.0 111.851 175.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.06 -140.22 6.19 Favored Glycine 0 N--CA 1.431 -1.683 0 CA-C-O 122.418 1.01 . . . . 0.0 114.18 177.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . 0.422 ' H ' ' NE2' ' A' ' 100' ' ' GLN . 1.4 pm0 -80.71 -155.71 0.12 Allowed 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 125.796 1.638 . . . . 0.0 114.242 -172.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.4 m -80.2 146.37 62.48 Favored Pre-proline 0 N--CA 1.43 -1.435 0 O-C-N 119.336 -2.102 . . . . 0.0 109.842 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo . . . . . 0 C--N 1.299 -2.043 0 C-N-CA 122.254 1.969 . . . . 0.0 114.606 -155.721 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 41.8 mtmt . . . . . 0 N--CA 1.43 -1.468 0 CA-C-O 116.384 -1.77 . . . . 0.0 113.494 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -78.38 -161.59 0.15 Allowed 'Trans proline' 0 C--N 1.3 -1.996 0 CA-C-N 125.704 3.073 . . . . 0.0 112.853 174.174 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.82 77.61 0.4 Allowed Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 108.022 -2.031 . . . . 0.0 108.022 -155.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -53.12 -58.76 5.91 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 128.75 2.82 . . . . 0.0 111.777 -172.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.31 135.16 43.26 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.338 -0.851 . . . . 0.0 109.653 158.431 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . 0.251 0.0 OUTLIER -146.77 146.51 30.3 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 122.458 1.123 . . . . 0.0 109.454 159.235 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.34 145.89 24.27 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.405 -1.434 . . . . 0.0 109.035 174.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 47.9 t -106.01 93.44 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 178.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 74.9 mt-10 -92.2 89.77 7.03 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.978 1.711 . . . . 0.0 108.426 175.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 65.6 tp -124.91 148.39 48.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 121.304 -0.873 . . . . 0.0 110.629 -171.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 130.66 48.48 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.219 1.408 . . . . 0.0 109.015 171.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 14.6 ptpt -71.17 154.86 41.37 Favored 'General case' 0 N--CA 1.43 -1.468 0 N-CA-C 115.871 1.804 . . . . 0.0 115.871 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 77.5 p -121.08 131.55 54.34 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.849 -1.157 . . . . 0.0 109.482 171.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.1 t70 57.78 38.83 27.43 Favored 'General case' 0 N--CA 1.43 -1.46 0 N-CA-C 115.35 1.611 . . . . 0.0 115.35 176.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.65 -16.14 16.06 Favored Glycine 0 N--CA 1.431 -1.656 0 O-C-N 119.477 -2.015 . . . . 0.0 114.985 -176.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.8 p -115.14 157.93 22.92 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.779 2.032 . . . . 0.0 112.551 -164.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.404 HD13 ' HA ' ' A' ' 25' ' ' LEU . 3.7 mm? -102.06 -60.64 1.5 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.677 -1.264 . . . . 0.0 108.957 173.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.86 56.64 0.09 OUTLIER Glycine 0 N--CA 1.43 -1.702 0 O-C-N 119.555 -1.966 . . . . 0.0 110.838 169.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.1 tt -147.24 145.29 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 CA-C-O 122.43 1.11 . . . . 0.0 110.784 -171.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.6 t -108.94 132.36 54.15 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 166.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.1 m -112.92 155.92 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 O-C-N 121.14 -0.975 . . . . 0.0 111.344 -175.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.5 t -129.0 168.02 16.63 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 124.084 0.954 . . . . 0.0 109.33 174.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.09 -151.68 18.31 Favored Glycine 0 N--CA 1.43 -1.722 0 O-C-N 121.418 -0.801 . . . . 0.0 113.928 167.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.48 139.63 10.65 Favored Glycine 0 N--CA 1.431 -1.698 0 C-N-CA 123.975 0.798 . . . . 0.0 112.481 -176.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -71.18 -11.28 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 O-C-N 120.829 -1.395 . . . . 0.0 113.933 -178.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 9.1 p-10 -69.66 -33.98 73.33 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.181 -1.575 . . . . 0.0 113.764 178.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.5 t -107.53 169.32 8.65 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 120.898 -1.126 . . . . 0.0 111.563 -173.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 55.3 m -82.85 62.54 6.49 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.259 -1.525 . . . . 0.0 113.647 -174.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.8 t -72.44 -43.51 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 C-N-CA 125.679 1.592 . . . . 0.0 110.79 171.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 74.8 mtt85 67.94 37.89 2.95 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 128.297 2.639 . . . . 0.0 112.122 -169.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 21.0 t-160 -150.61 -52.35 0.14 Allowed 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.501 -0.749 . . . . 0.0 110.583 -179.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.62 66.13 1.62 Allowed Glycine 0 N--CA 1.43 -1.729 0 O-C-N 120.59 -1.319 . . . . 0.0 115.253 169.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -156.77 171.09 34.27 Favored Glycine 0 N--CA 1.429 -1.772 0 N-CA-C 107.133 -2.387 . . . . 0.0 107.133 175.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.4 mm -103.78 114.79 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.286 1.434 . . . . 0.0 107.573 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 69.1 m-85 -123.58 157.05 34.57 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.206 1.003 . . . . 0.0 110.52 -171.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -75.03 122.5 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 C-N-CA 124.542 1.137 . . . . 0.0 110.713 175.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 81.7 tttt -93.18 -51.83 4.84 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.846 -1.159 . . . . 0.0 111.574 -177.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.86 158.9 41.48 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.413 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -113.56 125.27 70.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 CA-C-O 122.565 1.174 . . . . 0.0 109.057 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 19.5 mm -76.58 124.19 87.8 Favored Pre-proline 0 N--CA 1.429 -1.487 0 CA-C-O 116.344 -1.788 . . . . 0.0 113.679 -167.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_exo -58.9 124.64 16.16 Favored 'Trans proline' 0 N--CA 1.433 -2.036 0 CA-C-N 124.566 2.667 . . . . 0.0 115.396 -177.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.318 47.9 mtpt 74.88 30.74 0.93 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 127.101 2.16 . . . . 0.0 114.069 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.33 160.72 33.49 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.204 -0.935 . . . . 0.0 114.097 161.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.07 -54.03 14.48 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.982 2.113 . . . . 0.0 114.444 160.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.93 -46.48 87.56 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 127.586 2.354 . . . . 0.0 113.416 179.095 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.413 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.2 tm-20 -41.6 -64.57 0.55 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 116.415 2.005 . . . . 0.0 116.415 173.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 57.8 m -68.51 -18.46 64.38 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 126.557 1.943 . . . . 0.0 115.843 -179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.16 -56.84 16.99 Favored 'General case' 0 N--CA 1.43 -1.474 0 CA-C-N 119.657 1.117 . . . . 0.0 112.52 -174.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 107.04 -25.81 21.06 Favored Glycine 0 N--CA 1.43 -1.72 0 N-CA-C 115.151 0.82 . . . . 0.0 115.151 176.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -72.36 -29.17 63.54 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.951 1.875 . . . . 0.0 112.221 175.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.0 mt -90.34 120.71 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 O-C-N 120.591 -1.318 . . . . 0.0 111.024 174.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 82.9 t60 -124.32 168.67 12.68 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 122.937 1.351 . . . . 0.0 111.435 173.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 63.8 tttt -65.72 117.54 8.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.726 1.61 . . . . 0.0 113.43 179.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.13 11.21 57.75 Favored Glycine 0 N--CA 1.43 -1.716 0 O-C-N 120.744 -1.222 . . . . 0.0 114.563 -176.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -81.22 159.45 24.56 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-N 119.22 1.51 . . . . 0.0 111.909 173.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.5 ttt180 -112.97 124.49 52.75 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.109 1.363 . . . . 0.0 111.163 -166.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 39.0 t -92.08 121.31 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.381 0 O-C-N 120.288 -1.508 . . . . 0.0 110.716 179.54 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 78.3 mt -89.11 -45.52 9.54 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 121.102 -0.999 . . . . 0.0 110.749 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.63 143.47 24.62 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 121.378 -0.826 . . . . 0.0 110.709 -178.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 44.9 t -111.14 114.45 47.13 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.475 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.053 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 14.7 t30 63.88 34.04 12.06 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 165.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.16 -17.35 59.45 Favored Glycine 0 N--CA 1.431 -1.663 0 O-C-N 121.229 -0.92 . . . . 0.0 113.83 -175.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 17.6 t -99.03 121.34 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 O-C-N 120.803 -1.41 . . . . 0.0 109.983 -175.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 20.3 t -75.32 138.69 41.97 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.255 -1.528 . . . . 0.0 112.03 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 76.8 mt -90.4 13.56 15.25 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 121.223 -0.923 . . . . 0.0 113.447 -176.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -61.15 111.99 1.93 Allowed 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 119.94 -1.725 . . . . 0.0 114.348 -177.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.95 0.29 83.53 Favored Glycine 0 N--CA 1.43 -1.704 0 C-N-CA 124.903 1.239 . . . . 0.0 115.463 -178.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.63 147.41 47.56 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 115.68 1.733 . . . . 0.0 115.68 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 81.9 p -92.79 178.68 5.7 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 124.797 1.239 . . . . 0.0 112.529 176.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.6 t-160 -56.33 -56.61 18.93 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.977 1.711 . . . . 0.0 114.673 -177.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 13.7 tppt? -57.39 -39.79 76.85 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 124.812 1.245 . . . . 0.0 113.317 -178.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.58 -50.4 72.03 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 126.634 1.974 . . . . 0.0 113.852 179.318 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.21 -41.45 99.14 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 125.862 1.665 . . . . 0.0 114.165 174.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 69.7 t -64.02 -49.03 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.215 1.406 . . . . 0.0 111.051 177.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -60.82 -39.17 88.0 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 124.691 1.196 . . . . 0.0 112.85 177.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.1 m -63.41 -49.79 72.38 Favored 'General case' 0 N--CA 1.43 -1.446 0 C-N-CA 126.998 2.119 . . . . 0.0 113.033 173.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 63.8 mt -66.66 -29.57 69.62 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 120.196 -1.565 . . . . 0.0 114.405 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -68.8 -49.25 60.12 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.598 -1.314 . . . . 0.0 112.274 169.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -85.02 64.65 8.82 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.414 -1.429 . . . . 0.0 111.641 177.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 p -106.18 160.08 15.61 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 128.792 2.837 . . . . 0.0 109.258 173.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -90.69 -163.61 39.08 Favored Glycine 0 N--CA 1.429 -1.77 0 O-C-N 121.046 -1.033 . . . . 0.0 111.584 176.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.6 tt0 -66.69 -52.55 43.46 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.757 -1.437 . . . . 0.0 113.152 179.416 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.34 130.07 48.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 CA-C-O 122.695 1.236 . . . . 0.0 108.054 170.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.0 t -117.92 128.54 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 127.597 2.359 . . . . 0.0 108.029 -166.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 21.2 m80 -120.67 92.54 3.79 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 113.159 0.8 . . . . 0.0 113.159 -170.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.18 146.55 25.32 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 119.398 -2.064 . . . . 0.0 112.068 175.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 24.9 tp -104.6 116.56 32.28 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 162.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 7.4 tt -132.44 137.14 47.16 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.564 0.697 . . . . 0.0 111.927 -164.07 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 55.5 tt0 -108.87 126.65 53.29 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.866 -1.146 . . . . 0.0 109.267 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.5 tmtt? -79.98 140.03 36.77 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.674 -1.266 . . . . 0.0 112.433 -174.027 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.47 74.97 2.28 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.197 -1.565 . . . . 0.0 111.133 173.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -60.79 -50.09 74.87 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.221 1.408 . . . . 0.0 114.307 -170.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 60.5 t -106.67 113.58 62.76 Favored Pre-proline 0 N--CA 1.429 -1.501 0 C-N-CA 124.351 1.061 . . . . 0.0 108.554 172.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo . . . . . 0 C--N 1.299 -2.071 0 C-N-CA 122.65 2.234 . . . . 0.0 112.419 165.46 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 73.2 mmtt . . . . . 0 N--CA 1.429 -1.492 0 CA-C-O 115.458 -2.21 . . . . 0.0 113.009 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_exo -71.91 -173.48 1.06 Allowed 'Trans proline' 0 N--CA 1.433 -2.057 0 CA-C-N 126.345 3.302 . . . . 0.0 115.008 176.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.41 81.59 0.54 Allowed Glycine 0 N--CA 1.429 -1.784 0 C-N-CA 124.903 1.24 . . . . 0.0 110.293 -165.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -53.03 -50.02 65.1 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 129.543 3.137 . . . . 0.0 115.655 -163.119 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -119.35 148.2 43.47 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 121.121 1.782 . . . . 0.0 109.618 164.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 11.1 p90 -146.8 147.02 30.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 123.21 1.481 . . . . 0.0 109.23 171.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -104.1 120.5 41.22 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 127.317 2.247 . . . . 0.0 107.738 -178.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.3 t -114.04 103.69 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 119.975 -1.703 . . . . 0.0 109.83 -171.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -90.08 88.67 7.37 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 120.306 -1.496 . . . . 0.0 109.239 173.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 tp -100.92 130.39 46.91 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.761 -1.212 . . . . 0.0 112.702 -167.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.47 128.23 49.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 120.279 -1.513 . . . . 0.0 109.456 170.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -69.73 132.66 46.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.217 1.562 . . . . 0.0 115.217 -172.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 47.6 p -107.48 114.89 29.19 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.503 -1.373 . . . . 0.0 111.498 -176.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.4 t70 55.66 39.35 30.88 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.214 2.205 . . . . 0.0 113.12 172.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.73 4.5 90.29 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 119.514 -1.991 . . . . 0.0 115.583 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.6 t -121.48 134.59 55.07 Favored 'General case' 0 N--CA 1.429 -1.518 0 CA-C-N 118.549 1.175 . . . . 0.0 111.345 -176.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 86.2 mt -89.65 -42.52 11.32 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.826 -1.171 . . . . 0.0 109.99 173.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.28 9.27 22.2 Favored Glycine 0 N--CA 1.43 -1.731 0 O-C-N 120.833 -1.167 . . . . 0.0 114.503 175.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.8 pt -129.42 125.65 62.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 CA-C-N 118.466 1.133 . . . . 0.0 112.555 -166.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.4 m -110.15 139.83 44.88 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.974 -1.079 . . . . 0.0 109.233 166.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 m -111.05 170.71 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.81 1.244 . . . . 0.0 112.725 -175.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.6 t -150.96 172.26 15.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 126.559 1.943 . . . . 0.0 108.2 174.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.1 -131.37 10.58 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 121.052 -1.03 . . . . 0.0 113.731 169.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 72.22 -175.36 42.75 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.936 1.255 . . . . 0.0 113.712 -177.03 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.1 t -68.32 -9.71 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 126.4 1.88 . . . . 0.0 113.325 177.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -75.25 -24.65 57.67 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 118.658 -2.526 . . . . 0.0 112.113 173.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.1 m -115.56 152.25 33.38 Favored 'General case' 0 N--CA 1.428 -1.549 0 C-N-CA 125.64 1.576 . . . . 0.0 109.014 -173.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.9 p -81.7 60.72 4.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 119.09 -2.256 . . . . 0.0 115.031 -175.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 1.5 t -92.25 47.48 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.396 0 O-C-N 119.605 -1.934 . . . . 0.0 111.937 -175.482 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.252 26.7 ttt-85 36.61 41.91 0.18 Allowed 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 129.495 3.118 . . . . 0.0 117.974 -174.088 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.6 t60 151.4 -67.35 0.0 OUTLIER 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 129.729 3.212 . . . . 0.0 105.513 -172.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 120.92 97.1 1.54 Allowed Glycine 0 N--CA 1.429 -1.767 0 C-N-CA 123.881 0.753 . . . . 0.0 111.65 -177.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -126.0 156.31 19.55 Favored Glycine 0 N--CA 1.43 -1.745 0 N-CA-C 109.932 -1.267 . . . . 0.0 109.932 178.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 44.5 mm -92.79 114.74 30.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.507 1.123 . . . . 0.0 109.238 -175.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -111.9 153.62 26.41 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 121.261 -0.899 . . . . 0.0 110.225 -173.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.5 t -76.57 116.85 20.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 124.924 1.289 . . . . 0.0 112.473 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.2 ttpp -92.26 -40.88 10.71 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.272 1.029 . . . . 0.0 112.36 178.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -154.68 153.75 31.81 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.165 -1.584 . . . . 0.0 112.687 -177.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.265 1.0 OUTLIER -109.33 115.89 50.73 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-O 123.123 1.44 . . . . 0.0 109.988 171.776 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.1 mm -77.36 125.23 86.59 Favored Pre-proline 0 N--CA 1.429 -1.484 0 C-N-CA 127.111 2.164 . . . . 0.0 113.79 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_exo -55.69 124.34 16.03 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 C-N-CA 123.625 2.883 . . . . 0.0 116.115 -177.49 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.3 4.5 mptp? 74.38 24.59 1.81 Allowed 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 126.692 1.997 . . . . 0.0 113.22 176.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.01 159.11 35.54 Favored Glycine 0 N--CA 1.43 -1.704 0 O-C-N 120.439 -1.413 . . . . 0.0 111.785 165.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.6 -55.44 11.17 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 115.62 1.711 . . . . 0.0 115.62 175.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.443 ' HB1' HD12 ' A' ' 59' ' ' ILE . . . -63.53 -46.44 86.01 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 128.065 2.546 . . . . 0.0 112.561 179.189 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -48.9 -60.63 2.6 Favored 'General case' 0 N--CA 1.431 -1.417 0 C-N-CA 125.317 1.447 . . . . 0.0 113.944 174.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 4.2 m -69.39 -20.05 63.82 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -174.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -69.43 -64.03 0.95 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.511 -1.368 . . . . 0.0 110.996 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.72 11.09 41.74 Favored Glycine 0 N--CA 1.429 -1.771 0 O-C-N 119.862 -1.774 . . . . 0.0 114.849 164.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 71.9 mtt85 -62.45 -51.68 66.56 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.88 1.272 . . . . 0.0 109.905 159.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.443 HD12 ' HB1' ' A' ' 53' ' ' ALA . 2.8 mt -79.17 128.13 38.69 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 C-N-CA 126.104 1.762 . . . . 0.0 112.132 -176.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -131.93 169.65 16.0 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 123.561 1.648 . . . . 0.0 111.641 174.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 14.7 ttpp -66.23 132.06 47.57 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.675 -1.891 . . . . 0.0 112.115 178.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 91.03 5.37 68.01 Favored Glycine 0 N--CA 1.43 -1.767 0 O-C-N 120.971 -1.08 . . . . 0.0 114.156 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -79.59 166.36 21.97 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 118.889 1.344 . . . . 0.0 109.586 169.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -134.08 148.34 51.01 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.172 -1.58 . . . . 0.0 112.772 176.539 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 19.0 t -102.82 134.0 45.03 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.392 0 C-N-CA 124.769 1.228 . . . . 0.0 111.171 -166.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.9 mp -99.07 -50.65 4.09 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.5 1.12 . . . . 0.0 110.662 -177.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.84 136.54 18.07 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.314 -0.866 . . . . 0.0 112.677 -175.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 41.2 t -113.36 125.77 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 124.671 1.189 . . . . 0.0 108.424 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 65.86 30.91 9.73 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 124.645 1.178 . . . . 0.0 112.521 168.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 91.96 -22.74 29.95 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.897 -1.127 . . . . 0.0 113.899 -174.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.53 121.75 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 125.633 1.573 . . . . 0.0 110.666 -167.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.9 p -71.23 131.62 43.77 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.746 -1.221 . . . . 0.0 112.433 178.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.9 mt -84.23 64.65 8.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.089 -1.632 . . . . 0.0 112.083 -175.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -89.34 116.3 27.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.466 -1.396 . . . . 0.0 112.723 -173.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.83 17.79 79.4 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 121.004 -1.06 . . . . 0.0 113.256 179.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.97 143.21 50.92 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -168.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 70.6 p -93.71 179.69 5.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 126.248 1.819 . . . . 0.0 110.597 173.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 49.3 t-80 -68.35 -42.7 78.86 Favored 'General case' 0 N--CA 1.428 -1.53 0 O-C-N 119.775 -1.828 . . . . 0.0 110.001 173.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 1.2 tppm? -53.64 -46.34 70.5 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 125.389 1.476 . . . . 0.0 113.781 172.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.412 ' C ' HE21 ' A' ' 80' ' ' GLN . 0.0 OUTLIER -55.65 -51.28 67.74 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.208 1.403 . . . . 0.0 113.674 176.686 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.16 -43.15 87.78 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.926 1.691 . . . . 0.0 113.686 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.7 t -66.35 -49.09 78.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 O-C-N 120.835 -1.165 . . . . 0.0 110.676 178.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.2 mm-40 -64.04 -31.22 72.33 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.669 -1.269 . . . . 0.0 114.03 178.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.3 m -69.47 -44.3 71.47 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.486 1.514 . . . . 0.0 112.234 175.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 82.6 mt -69.51 -32.31 71.08 Favored 'General case' 0 N--CA 1.43 -1.444 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 172.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.61 -46.34 79.69 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.245 -1.534 . . . . 0.0 112.426 176.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.7 t30 -86.06 45.68 1.25 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 124.83 1.252 . . . . 0.0 112.648 -178.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 36.0 p -101.6 171.71 7.4 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.303 1.841 . . . . 0.0 108.658 172.868 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -125.38 -119.35 2.35 Favored Glycine 0 N--CA 1.429 -1.775 0 O-C-N 120.594 -1.316 . . . . 0.0 110.737 172.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -70.84 -70.25 0.32 Allowed 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 124.288 1.035 . . . . 0.0 113.7 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 40.1 t -100.66 129.45 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.518 0 CA-C-O 123.136 1.446 . . . . 0.0 111.223 -175.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 96.9 t -122.6 104.61 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 128.466 2.706 . . . . 0.0 108.944 -174.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.0 t-160 -88.56 107.37 18.86 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 119.624 -1.923 . . . . 0.0 110.802 176.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 28.7 mt -94.04 144.23 25.66 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.775 -1.203 . . . . 0.0 111.242 169.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 31.6 tp -119.65 124.91 47.44 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 106.082 -1.822 . . . . 0.0 106.082 164.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.422 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.0 pp -150.58 168.29 24.7 Favored 'General case' 0 N--CA 1.429 -1.501 0 N-CA-C 114.541 1.312 . . . . 0.0 114.541 -176.325 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -113.52 129.4 56.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.137 1.775 . . . . 0.0 111.041 -175.089 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? -78.41 137.14 37.84 Favored 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 125.455 1.502 . . . . 0.0 112.691 179.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -77.41 76.8 1.64 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 121.108 -0.995 . . . . 0.0 113.265 172.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -74.29 -15.98 60.95 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.1 m -80.59 170.08 17.07 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.652 1.981 . . . . 0.0 111.3 -174.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo . . . . . 0 N--CA 1.434 -2.012 0 CA-C-N 122.517 1.934 . . . . 0.0 116.869 -179.7 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 18.1 tptm . . . . . 0 N--CA 1.43 -1.428 0 CA-C-O 116.55 -1.691 . . . . 0.0 111.529 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -72.31 178.75 5.72 Favored 'Trans proline' 0 N--CA 1.433 -2.031 0 CA-C-N 126.337 3.299 . . . . 0.0 113.058 165.244 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 92.44 18.76 40.69 Favored Glycine 0 N--CA 1.43 -1.715 0 N-CA-C 115.563 0.985 . . . . 0.0 115.563 -179.362 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -94.8 151.8 18.94 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.085 1.354 . . . . 0.0 110.952 -179.537 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 2.1 p -93.07 156.43 16.88 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.748 1.619 . . . . 0.0 113.433 -177.634 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -147.48 134.23 20.02 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 173.361 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -90.98 137.26 32.5 Favored 'General case' 0 N--CA 1.43 -1.475 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 162.46 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 39.7 t -124.6 93.47 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.9 -1.125 . . . . 0.0 109.011 -175.226 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -91.47 85.43 5.75 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.544 1.537 . . . . 0.0 110.906 173.286 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . 0.292 1.7 pp -117.88 156.6 28.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 122.668 1.223 . . . . 0.0 112.554 -176.859 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.85 133.43 46.62 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.074 1.75 . . . . 0.0 112.074 -177.188 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 36.1 ttmt -70.6 134.41 47.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.679 1.592 . . . . 0.0 115.228 -178.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 41.3 p -107.21 118.45 36.74 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.525 -1.359 . . . . 0.0 111.592 -178.086 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 6.3 t70 47.83 43.96 17.66 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 127.329 2.252 . . . . 0.0 115.678 175.777 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.41 -5.05 85.71 Favored Glycine 0 N--CA 1.43 -1.727 0 O-C-N 120.447 -1.408 . . . . 0.0 114.956 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 80.6 p -121.59 137.68 54.63 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.176 1.488 . . . . 0.0 114.072 -172.713 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.404 HD21 HG21 ' A' ' 92' ' ' VAL . 89.8 mt -90.61 -61.84 1.59 Allowed 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.804 -1.185 . . . . 0.0 110.219 167.298 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.82 36.05 1.2 Allowed Glycine 0 N--CA 1.43 -1.762 0 O-C-N 119.625 -1.922 . . . . 0.0 113.189 169.836 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -123.79 124.17 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 C-N-CA 125.031 1.333 . . . . 0.0 109.986 -176.208 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.0 t -101.73 112.49 25.1 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.817 -1.177 . . . . 0.0 107.867 170.349 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.0 m -104.19 161.79 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.934 1.293 . . . . 0.0 111.664 -178.773 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -149.72 174.11 12.95 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.677 -1.264 . . . . 0.0 109.767 -175.172 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.42 -131.87 10.66 Favored Glycine 0 N--CA 1.43 -1.708 0 C-N-CA 124.355 0.979 . . . . 0.0 113.519 168.334 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.83 176.89 51.04 Favored Glycine 0 N--CA 1.43 -1.758 0 N-CA-C 115.787 1.075 . . . . 0.0 115.787 174.659 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m -73.07 -6.53 8.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.468 0 N-CA-C 117.356 2.354 . . . . 0.0 117.356 -170.127 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -86.05 -11.15 53.59 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.563 -1.961 . . . . 0.0 110.197 171.087 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 36.1 m -105.97 151.93 23.98 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 125.708 1.603 . . . . 0.0 106.776 -177.286 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 29.5 m -81.22 32.33 0.33 Allowed 'General case' 0 N--CA 1.431 -1.404 0 O-C-N 118.533 -2.605 . . . . 0.0 114.587 -177.395 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.7 p -99.79 84.47 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 120.2 -1.562 . . . . 0.0 113.738 -165.984 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 47.9 70.21 0.45 Allowed 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 127.062 2.145 . . . . 0.0 114.229 176.748 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 41.3 m-70 69.33 -66.37 0.26 Allowed 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 127.281 2.233 . . . . 0.0 112.686 -164.682 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.18 66.96 0.04 OUTLIER Glycine 0 N--CA 1.429 -1.803 0 O-C-N 121.589 -0.694 . . . . 0.0 111.587 175.153 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -82.69 144.95 23.42 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 121.304 -1.115 . . . . 0.0 113.354 179.958 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 35.4 mm -93.71 123.44 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 121.498 -1.001 . . . . 0.0 109.16 174.501 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -123.33 154.25 39.17 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.889 -1.132 . . . . 0.0 110.215 -175.315 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 29.0 t -76.72 129.87 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.765 -1.21 . . . . 0.0 111.562 168.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 32.7 ttmt -100.32 -50.11 4.04 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.374 1.47 . . . . 0.0 111.449 176.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -151.24 161.05 43.42 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.686 -1.259 . . . . 0.0 111.401 -175.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.409 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.2 tp -115.76 125.78 73.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 C-N-CA 124.431 1.092 . . . . 0.0 110.01 179.766 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 17.3 mm -77.13 115.99 53.57 Favored Pre-proline 0 N--CA 1.43 -1.455 0 C-N-CA 125.748 1.619 . . . . 0.0 112.816 -177.389 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -64.91 136.37 48.47 Favored 'Trans proline' 0 C--N 1.3 -1.988 0 CA-C-N 124.074 2.491 . . . . 0.0 113.044 -175.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.251 45.4 mtmt 83.94 7.0 0.63 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.852 2.861 . . . . 0.0 114.42 -175.318 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.45 160.22 35.93 Favored Glycine 0 N--CA 1.43 -1.754 0 O-C-N 119.97 -1.706 . . . . 0.0 114.983 176.142 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.34 -56.65 8.84 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 127.009 2.123 . . . . 0.0 115.994 169.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -45.98 83.66 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 128.231 2.612 . . . . 0.0 111.697 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.409 ' HA ' HG12 ' A' ' 47' ' ' ILE . 7.1 tm-20 -47.62 -64.61 0.74 Allowed 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 115.968 1.84 . . . . 0.0 115.968 169.492 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.0 m -70.13 -21.45 63.09 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 115.448 1.647 . . . . 0.0 115.448 -173.01 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -57.0 -65.8 0.56 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 125.295 1.438 . . . . 0.0 112.361 173.189 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.58 0.04 42.96 Favored Glycine 0 N--CA 1.431 -1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 114.847 170.557 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -66.32 -51.73 54.32 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 118.766 1.283 . . . . 0.0 110.32 162.294 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.51 HD11 HD12 ' A' ' 94' ' ' LEU . 51.7 mt -78.26 134.96 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 124.902 1.281 . . . . 0.0 111.053 179.322 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.6 t-80 -147.59 156.78 43.15 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 122.063 0.935 . . . . 0.0 109.46 -178.78 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -65.61 126.02 27.05 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 119.501 -2.0 . . . . 0.0 114.37 -174.23 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 107.03 -4.86 35.98 Favored Glycine 0 N--CA 1.43 -1.758 0 CA-C-O 118.244 -1.309 . . . . 0.0 115.665 -173.229 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.363 3.1 p30 -81.58 163.41 22.63 Favored 'General case' 0 N--CA 1.431 -1.379 0 CA-C-N 121.207 2.503 . . . . 0.0 114.565 178.464 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.4 tpt85 -112.21 121.92 46.29 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.343 -1.473 . . . . 0.0 111.018 -167.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 44.6 t -87.94 136.24 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 O-C-N 120.105 -1.622 . . . . 0.0 110.277 -173.434 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 9.6 mp -102.3 -53.03 3.0 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 124.583 1.153 . . . . 0.0 110.494 175.776 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.93 147.43 27.89 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.825 -1.172 . . . . 0.0 112.209 -168.865 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.28 116.14 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 176.594 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 61.63 37.35 16.14 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.572 1.949 . . . . 0.0 115.073 167.723 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.16 -17.18 59.62 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.522 1.058 . . . . 0.0 113.906 -175.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.6 t -95.44 112.62 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-N 118.546 1.173 . . . . 0.0 111.029 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 24.1 m -70.13 121.76 18.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.98 -1.075 . . . . 0.0 110.083 171.091 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.0 mt -72.85 -34.16 66.58 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -169.069 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -8.85 93.53 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 121.114 3.746 . . . . 0.0 121.114 -173.704 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 101.48 20.87 12.3 Favored Glycine 0 N--CA 1.43 -1.763 0 C-N-CA 125.134 1.35 . . . . 0.0 111.608 179.306 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.33 164.45 26.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 175.018 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -92.74 170.32 9.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.358 -1.464 . . . . 0.0 111.121 161.776 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -51.36 -56.7 11.71 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.293 1.837 . . . . 0.0 113.146 169.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -56.67 -36.19 69.3 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 116.368 1.988 . . . . 0.0 116.368 174.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 35.7 mm-40 -55.59 -48.39 74.91 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 121.102 1.774 . . . . 0.0 113.79 175.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -64.95 -42.37 94.67 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.195 0.998 . . . . 0.0 113.26 177.889 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 88.4 t -65.43 -45.68 92.26 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 C-N-CA 124.603 1.161 . . . . 0.0 111.266 178.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -62.38 -40.23 95.78 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.724 -1.235 . . . . 0.0 112.83 177.712 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 52.0 m -65.79 -42.27 90.95 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.435 2.294 . . . . 0.0 113.295 175.575 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.12 -36.85 84.26 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.303 1.441 . . . . 0.0 113.299 173.309 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -68.76 -30.14 68.68 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.245 -1.534 . . . . 0.0 113.133 172.032 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 7.2 t-20 -84.81 45.96 1.21 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.02 1.728 . . . . 0.0 112.777 175.495 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.5 p -105.55 163.58 12.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 126.696 1.998 . . . . 0.0 110.214 177.793 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.92 -144.2 15.73 Favored Glycine 0 N--CA 1.43 -1.732 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 168.411 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -70.95 -60.71 2.09 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 121.191 -1.181 . . . . 0.0 113.666 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 29.5 t -98.42 119.85 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.948 1.356 . . . . 0.0 109.293 -175.345 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.404 HG21 HD21 ' A' ' 25' ' ' LEU . 88.1 t -112.78 114.87 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 C-N-CA 126.305 1.842 . . . . 0.0 109.306 -165.79 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 16.5 m170 -97.69 99.03 10.38 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.961 -1.087 . . . . 0.0 110.617 -177.932 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.51 HD12 HD11 ' A' ' 59' ' ' ILE . 21.0 mt -92.93 160.24 14.98 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 119.797 -1.814 . . . . 0.0 112.711 173.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -128.46 131.99 48.39 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.417 1.087 . . . . 0.0 108.09 165.814 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -147.86 172.98 13.3 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.395 -1.44 . . . . 0.0 112.415 177.759 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -127.49 148.63 50.31 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.162 1.785 . . . . 0.0 109.258 174.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 27.5 tptt -76.0 137.89 40.56 Favored 'General case' 0 N--CA 1.429 -1.492 0 O-C-N 120.34 -1.475 . . . . 0.0 111.312 175.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -89.88 -158.93 34.96 Favored Glycine 0 N--CA 1.429 -1.772 0 O-C-N 121.316 -0.865 . . . . 0.0 111.392 173.069 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -73.75 177.82 5.22 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.849 -1.383 . . . . 0.0 113.714 -178.15 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -120.58 127.34 26.33 Favored Pre-proline 0 N--CA 1.43 -1.426 0 O-C-N 120.703 -1.248 . . . . 0.0 110.492 -171.178 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo . . . . . 0 N--CA 1.434 -2.013 0 CA-C-N 122.467 1.917 . . . . 0.0 112.657 169.218 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 26.0 pttm . . . . . 0 N--CA 1.43 -1.429 0 CA-C-O 119.531 -0.271 . . . . 0.0 111.597 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -78.18 177.4 8.82 Favored 'Trans proline' 0 C--N 1.3 -1.99 0 C-N-CA 121.84 1.693 . . . . 0.0 112.101 172.09 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.32 23.55 28.89 Favored Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 125.048 1.309 . . . . 0.0 112.351 -178.689 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -96.58 133.07 41.53 Favored 'General case' 0 N--CA 1.43 -1.46 0 C-N-CA 125.036 1.334 . . . . 0.0 109.206 -172.306 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.8 p -106.07 154.41 20.68 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 124.725 1.21 . . . . 0.0 112.184 178.414 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -146.46 143.9 29.3 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.694 -1.254 . . . . 0.0 108.567 -177.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -99.43 105.35 17.29 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 124.2 1.0 . . . . 0.0 109.636 -179.186 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.9 t -98.72 99.54 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.3 1.44 . . . . 0.0 109.457 -169.809 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -90.09 95.76 10.36 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.379 -1.451 . . . . 0.0 107.749 173.721 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 38.9 tp -111.02 130.04 55.72 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 124.171 0.988 . . . . 0.0 110.467 -169.862 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.89 141.25 35.04 Favored 'General case' 0 CA--C 1.489 -1.372 0 O-C-N 120.471 -1.393 . . . . 0.0 109.727 172.937 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -64.42 147.22 53.13 Favored 'General case' 0 N--CA 1.429 -1.504 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 178.699 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 31.3 p -116.15 122.87 46.35 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 167.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 2.2 t0 43.3 46.22 5.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 128.577 2.751 . . . . 0.0 114.422 -176.726 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.14 11.58 75.18 Favored Glycine 0 N--CA 1.431 -1.65 0 N-CA-C 117.891 1.917 . . . . 0.0 117.891 -178.357 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.0 m -117.32 153.67 32.58 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 119.473 1.637 . . . . 0.0 111.898 178.438 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 72.2 mt -96.11 -60.56 1.6 Allowed 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.435 1.094 . . . . 0.0 108.9 165.429 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 119.14 37.58 0.8 Allowed Glycine 0 N--CA 1.43 -1.765 0 O-C-N 119.829 -1.794 . . . . 0.0 113.142 174.639 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 pt -129.5 139.17 52.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 125.173 1.389 . . . . 0.0 108.742 -175.493 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 26.5 m -111.79 117.7 33.56 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 157.668 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 29.5 m -99.05 162.59 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 124.351 1.061 . . . . 0.0 112.017 -174.631 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 t -150.11 -177.72 6.09 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 124.842 1.257 . . . . 0.0 110.001 178.168 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.53 -149.55 19.27 Favored Glycine 0 N--CA 1.43 -1.738 0 O-C-N 120.985 -1.072 . . . . 0.0 113.745 174.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.43 168.03 30.07 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 124.513 1.054 . . . . 0.0 112.924 -177.449 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -69.15 -17.89 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 N-CA-C 116.221 1.934 . . . . 0.0 116.221 -172.218 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -82.59 -26.69 32.08 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.4 -1.438 . . . . 0.0 112.672 -171.479 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.4 p -103.46 165.57 10.95 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 120.339 -1.476 . . . . 0.0 112.054 -174.699 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.9 m -82.45 61.67 5.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.973 -1.704 . . . . 0.0 113.337 -174.878 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.6 m -100.64 -4.6 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 O-C-N 120.458 -1.401 . . . . 0.0 112.223 176.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.343 78.4 mtt180 72.41 117.28 0.05 OUTLIER 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.341 2.656 . . . . 0.0 114.674 -169.008 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.284 87.9 m-70 68.75 -61.29 0.42 Allowed 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 127.435 2.294 . . . . 0.0 115.314 -174.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 126.19 52.39 0.16 Allowed Glycine 0 N--CA 1.43 -1.716 0 N-CA-C 116.615 1.406 . . . . 0.0 116.615 170.623 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -75.15 156.19 48.55 Favored Glycine 0 N--CA 1.429 -1.769 0 CA-C-N 118.872 1.336 . . . . 0.0 113.429 170.8 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 25.6 mm -96.93 121.88 47.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 106.666 -1.605 . . . . 0.0 106.666 175.591 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -126.71 154.26 44.36 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.854 -1.154 . . . . 0.0 110.522 -168.426 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.8 t -75.88 125.57 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.603 -1.31 . . . . 0.0 110.757 169.223 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 25.1 tttm -91.88 -44.92 8.65 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.738 -1.226 . . . . 0.0 110.671 178.662 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -148.44 148.11 29.93 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 123.129 0.572 . . . . 0.0 110.694 178.432 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.2 tp -102.89 121.36 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 CA-C-O 122.612 1.196 . . . . 0.0 110.121 173.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.4 mm -77.1 120.27 80.92 Favored Pre-proline 0 N--CA 1.43 -1.427 0 C-N-CA 125.893 1.677 . . . . 0.0 114.219 -171.902 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_exo -59.72 126.35 20.3 Favored 'Trans proline' 0 C--N 1.3 -2.013 0 CA-C-N 124.451 2.625 . . . . 0.0 115.325 -177.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.265 7.3 mtpm? 78.29 28.02 0.5 Allowed 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 127.454 2.302 . . . . 0.0 112.598 -178.04 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.14 159.72 34.26 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.531 -1.356 . . . . 0.0 113.646 162.472 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.06 -60.83 2.45 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.054 2.142 . . . . 0.0 114.847 164.464 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.16 -49.19 78.63 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 129.191 2.996 . . . . 0.0 111.96 179.778 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.9 tm-20 -46.76 -61.58 1.78 Allowed 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 115.55 1.685 . . . . 0.0 115.55 171.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 39.8 m -68.27 -32.97 73.51 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 -173.594 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -51.01 -66.96 0.29 Allowed 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 126.093 1.757 . . . . 0.0 113.323 176.368 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.25 -17.59 10.48 Favored Glycine 0 N--CA 1.43 -1.705 0 N-CA-C 115.051 0.78 . . . . 0.0 115.051 174.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 56.9 mtt85 -71.27 -33.62 69.94 Favored 'General case' 0 N--CA 1.429 -1.489 0 CA-C-N 120.081 1.941 . . . . 0.0 112.491 170.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.8 mt -95.12 113.5 29.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.228 1.011 . . . . 0.0 109.628 176.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.657 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 79.9 t60 -143.65 -174.04 4.13 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.165 -1.584 . . . . 0.0 110.508 174.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.657 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 21.3 ttpt -60.15 127.65 32.89 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.32 1.848 . . . . 0.0 113.853 -174.753 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.95 -6.35 83.75 Favored Glycine 0 N--CA 1.43 -1.749 0 O-C-N 120.659 -1.275 . . . . 0.0 114.793 178.792 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -81.65 149.27 28.62 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-N 119.638 1.719 . . . . 0.0 112.893 -173.685 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -92.29 141.01 29.03 Favored 'General case' 0 N--CA 1.429 -1.498 0 O-C-N 119.907 -1.745 . . . . 0.0 112.049 -170.711 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 20.3 t -89.38 119.11 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.473 0 C-N-CA 124.63 1.172 . . . . 0.0 108.322 176.491 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -103.54 -52.46 2.99 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.355 -1.466 . . . . 0.0 111.072 -166.078 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.47 117.18 5.82 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.278 -0.889 . . . . 0.0 109.006 175.95 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.6 t -90.91 115.18 29.6 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.718 -173.134 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.0 t30 64.13 32.39 12.69 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.139 1.376 . . . . 0.0 111.853 174.909 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.42 -23.94 33.67 Favored Glycine 0 N--CA 1.429 -1.804 0 C-N-CA 124.764 1.173 . . . . 0.0 114.663 -173.495 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 24.5 t -87.03 111.9 22.35 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 O-C-N 120.689 -1.477 . . . . 0.0 111.698 -167.817 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.4 m -61.63 120.55 10.81 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.729 -1.232 . . . . 0.0 114.118 -179.013 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 38.9 mt -87.57 42.9 1.07 Allowed 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 121.263 -0.898 . . . . 0.0 112.371 -178.203 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 25.1 pt-20 -85.29 110.49 19.11 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 119.193 -2.192 . . . . 0.0 112.169 -174.335 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 92.3 -0.6 71.89 Favored Glycine 0 N--CA 1.43 -1.726 0 C-N-CA 124.782 1.182 . . . . 0.0 114.228 179.412 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.03 155.09 41.23 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.3 1.963 . . . . 0.0 116.3 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.3 p -81.04 175.36 10.75 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.147 1.379 . . . . 0.0 112.428 174.253 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -67.28 -39.89 86.08 Favored 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.401 -1.437 . . . . 0.0 111.712 174.105 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 21.3 ttpt -57.3 -48.53 78.69 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.126 -0.984 . . . . 0.0 113.607 174.953 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -56.46 -46.35 80.42 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.225 1.41 . . . . 0.0 114.503 179.044 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.08 -39.4 94.61 Favored 'General case' 0 N--CA 1.429 -1.477 0 C-N-CA 125.862 1.665 . . . . 0.0 114.364 175.577 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.5 t -76.19 -45.24 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 C-N-CA 125.052 1.341 . . . . 0.0 111.388 -179.408 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -58.99 -33.03 70.22 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 127.691 2.396 . . . . 0.0 112.19 175.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.6 m -72.53 -49.32 33.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 126.334 1.854 . . . . 0.0 113.752 170.662 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 49.8 mt -58.43 -45.36 88.62 Favored 'General case' 0 N--CA 1.43 -1.468 0 CA-C-N 120.641 1.564 . . . . 0.0 115.149 176.938 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 37.5 ptt85 -66.57 -28.23 68.36 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.831 -1.168 . . . . 0.0 113.798 -177.906 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -93.18 32.94 1.24 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.8 1.24 . . . . 0.0 113.616 -179.369 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 22.4 p -92.02 148.48 22.15 Favored 'General case' 0 N--CA 1.429 -1.508 0 C-N-CA 125.981 1.712 . . . . 0.0 111.384 174.142 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.25 -143.56 9.03 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.819 -1.176 . . . . 0.0 112.59 174.516 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 20.9 mm100 -68.61 -59.79 2.88 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 114.871 1.434 . . . . 0.0 114.871 179.394 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 7.9 p -98.39 134.77 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.384 0 CA-C-O 122.919 1.342 . . . . 0.0 110.648 179.686 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.1 t -124.08 115.95 46.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 C-N-CA 127.525 2.33 . . . . 0.0 107.993 -171.414 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -97.19 89.09 4.65 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.366 -1.459 . . . . 0.0 112.229 179.738 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.6 tp -93.46 130.09 39.4 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 119.376 -2.077 . . . . 0.0 110.935 -178.134 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 47.3 tp -87.75 126.09 34.79 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 161.474 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 6.5 tt -122.32 148.54 44.92 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.543 1.137 . . . . 0.0 109.084 -170.106 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -125.3 142.79 51.29 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 171.608 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -77.25 160.36 28.96 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.517 -1.365 . . . . 0.0 111.916 -177.29 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -84.92 -147.17 8.66 Favored Glycine 0 N--CA 1.429 -1.786 0 O-C-N 120.382 -1.449 . . . . 0.0 112.937 168.119 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -72.68 177.76 4.56 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 119.924 -1.927 . . . . 0.0 113.428 178.477 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 45.4 t -90.59 122.45 67.09 Favored Pre-proline 0 N--CA 1.43 -1.47 0 O-C-N 119.926 -1.734 . . . . 0.0 109.431 178.61 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo . . . . . 0 C--N 1.3 -1.974 0 CA-C-N 123.481 2.279 . . . . 0.0 111.748 173.321 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 55.4 tptt . . . . . 0 N--CA 1.43 -1.432 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -88.94 179.25 2.47 Favored 'Trans proline' 0 N--CA 1.434 -2.025 0 C-N-CA 122.184 1.923 . . . . 0.0 113.063 -172.259 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.94 41.74 2.58 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.502 1.049 . . . . 0.0 113.105 167.353 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -82.23 143.31 31.45 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 121.595 -0.944 . . . . 0.0 110.107 174.436 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 20.7 p -98.52 155.85 17.07 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.575 -1.328 . . . . 0.0 111.638 176.599 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -145.68 133.6 21.31 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 122.231 1.015 . . . . 0.0 108.839 177.329 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 23.1 mt-10 -87.49 133.55 33.74 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.326 1.45 . . . . 0.0 109.347 169.97 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.4 t -126.3 107.15 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.853 1.261 . . . . 0.0 108.4 -169.438 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -91.38 102.05 14.73 Favored 'General case' 0 N--CA 1.431 -1.394 0 O-C-N 120.383 -1.448 . . . . 0.0 108.393 166.376 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.2 tp -113.32 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 121.945 0.878 . . . . 0.0 110.509 -171.608 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.92 139.85 36.99 Favored 'General case' 0 N--CA 1.428 -1.527 0 O-C-N 120.223 -1.548 . . . . 0.0 107.549 170.203 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -65.23 152.75 42.9 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 115.131 1.53 . . . . 0.0 115.131 -178.487 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 30.5 p -102.48 75.57 1.47 Allowed 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 120.19 -1.569 . . . . 0.0 108.542 175.313 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 16.3 t0 61.26 61.53 1.53 Allowed 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.126 1.77 . . . . 0.0 112.321 -177.055 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.41 -30.0 5.45 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 120.249 -1.532 . . . . 0.0 115.191 -175.291 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 24.7 m -92.27 136.14 33.43 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.256 -1.732 . . . . 0.0 112.802 -167.112 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.551 HD21 HG21 ' A' ' 92' ' ' VAL . 51.9 mt -102.0 -49.17 4.02 Favored 'General case' 0 N--CA 1.431 -1.399 0 C-N-CA 125.627 1.571 . . . . 0.0 110.539 177.413 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 107.13 -15.87 39.3 Favored Glycine 0 N--CA 1.43 -1.711 0 O-C-N 120.228 -1.545 . . . . 0.0 113.967 -179.087 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.8 pt -96.39 121.83 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 CA-C-N 119.355 1.578 . . . . 0.0 112.959 -176.579 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 60.3 m -114.06 137.77 51.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 166.228 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.5 m -124.85 165.3 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.307 1.043 . . . . 0.0 112.946 -165.619 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.7 t -144.91 177.89 8.42 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.572 1.549 . . . . 0.0 110.567 -179.346 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.16 -136.68 12.82 Favored Glycine 0 N--CA 1.43 -1.766 0 N-CA-C 115.945 1.138 . . . . 0.0 115.945 166.894 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 74.48 176.21 35.58 Favored Glycine 0 N--CA 1.43 -1.715 0 C-N-CA 126.351 1.929 . . . . 0.0 113.85 -179.025 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -77.43 25.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 O-C-N 120.437 -1.625 . . . . 0.0 113.481 179.813 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.88 -29.39 12.98 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 119.577 -1.952 . . . . 0.0 110.119 175.584 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 44.4 p -115.58 171.31 7.81 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 125.365 1.466 . . . . 0.0 108.568 -174.091 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 m -92.47 50.78 1.65 Allowed 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.136 -1.603 . . . . 0.0 111.531 176.352 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 9.4 p -82.94 153.05 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.958 1.303 . . . . 0.0 110.955 -177.472 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 24.5 mmt180 -62.08 121.72 13.74 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.756 -1.215 . . . . 0.0 112.913 179.49 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 72.16 -9.53 1.0 Allowed 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 127.894 2.478 . . . . 0.0 117.191 -176.443 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.7 61.75 4.79 Favored Glycine 0 N--CA 1.43 -1.719 0 O-C-N 119.804 -1.81 . . . . 0.0 114.685 179.439 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -143.52 172.17 24.96 Favored Glycine 0 N--CA 1.43 -1.746 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -177.406 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.2 mm -93.74 122.06 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 124.823 1.249 . . . . 0.0 108.367 -175.498 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -121.36 152.58 38.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.79 -1.194 . . . . 0.0 109.6 -175.096 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.2 t -75.9 129.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 O-C-N 120.455 -1.403 . . . . 0.0 111.739 174.211 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -96.21 -46.32 6.49 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 126.031 1.733 . . . . 0.0 111.761 -176.507 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.3 152.8 32.58 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.89 -1.131 . . . . 0.0 109.673 -176.846 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . 0.27 1.0 OUTLIER -112.61 116.02 51.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.43 0 CA-C-O 122.72 1.247 . . . . 0.0 109.457 170.885 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 12.5 mm -76.43 127.59 84.26 Favored Pre-proline 0 N--CA 1.43 -1.435 0 CA-C-O 116.218 -1.849 . . . . 0.0 114.161 -173.789 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -58.08 132.54 49.97 Favored 'Trans proline' 0 N--CA 1.433 -2.052 0 CA-C-N 124.474 2.634 . . . . 0.0 116.725 -179.035 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.278 53.8 mttp 72.15 18.97 4.66 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 127.35 2.26 . . . . 0.0 114.551 -174.087 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.84 157.17 45.07 Favored Glycine 0 N--CA 1.429 -1.789 0 O-C-N 119.394 -2.067 . . . . 0.0 112.227 170.863 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.36 -59.91 3.3 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.573 -1.545 . . . . 0.0 114.679 169.143 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.45 -44.94 93.04 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 127.915 2.486 . . . . 0.0 112.263 -179.717 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -45.0 -61.75 1.5 Allowed 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.111 1.764 . . . . 0.0 114.15 173.001 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 5.5 t -67.75 -43.18 80.51 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -175.419 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -50.58 -58.08 6.65 Favored 'General case' 0 N--CA 1.431 -1.397 0 C-N-CA 127.202 2.201 . . . . 0.0 114.081 179.432 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 95.58 31.6 7.38 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.299 -1.5 . . . . 0.0 115.037 163.146 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 53.4 mtt180 -96.98 -29.98 13.35 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 125.291 1.436 . . . . 0.0 109.151 162.786 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 15.7 mt -108.54 130.01 62.0 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 C-N-CA 125.361 1.464 . . . . 0.0 111.076 -179.486 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -141.58 170.55 15.5 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.894 -1.129 . . . . 0.0 109.579 172.842 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.8 pttm -66.59 140.96 57.98 Favored 'General case' 0 N--CA 1.431 -1.4 0 O-C-N 118.604 -2.56 . . . . 0.0 113.74 178.119 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 97.5 -11.21 65.05 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.602 -0.686 . . . . 0.0 113.163 -171.535 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -79.71 154.37 28.62 Favored 'General case' 0 N--CA 1.431 -1.404 0 CA-C-N 119.162 1.481 . . . . 0.0 112.27 -177.316 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 36.0 ttt180 -97.73 123.75 41.79 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.241 1.416 . . . . 0.0 109.698 -174.895 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.8 t -88.11 130.63 37.4 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 O-C-N 120.053 -1.655 . . . . 0.0 110.17 -178.398 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -99.06 -52.29 3.59 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 121.079 -1.013 . . . . 0.0 111.001 -178.036 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.96 144.28 24.83 Favored 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 121.13 -0.981 . . . . 0.0 112.862 -172.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 6.3 t -113.51 111.72 37.28 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 66.44 35.78 5.46 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.433 1.893 . . . . 0.0 113.353 179.552 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.93 60.01 Favored Glycine 0 N--CA 1.431 -1.659 0 O-C-N 119.931 -1.73 . . . . 0.0 114.238 -175.03 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.35 104.42 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 C-N-CA 125.308 1.443 . . . . 0.0 108.508 178.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 68.2 m -72.45 139.87 47.97 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.628 -1.295 . . . . 0.0 112.552 -175.29 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 98.9 mt -90.24 -2.4 58.03 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -169.297 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -67.81 105.2 1.88 Allowed 'General case' 0 N--CA 1.431 -1.414 0 O-C-N 120.219 -1.551 . . . . 0.0 113.927 -176.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 115.1 -20.99 13.72 Favored Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 125.454 1.502 . . . . 0.0 112.969 -174.698 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.04 153.92 40.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 179.237 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 80.4 p -92.16 176.93 6.31 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.558 -1.339 . . . . 0.0 112.843 -179.914 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 61.9 t-80 -56.21 -53.01 62.25 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.162 1.785 . . . . 0.0 112.359 172.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 24.1 tptm -55.45 -46.97 76.74 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.622 1.169 . . . . 0.0 113.548 177.55 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.87 -51.59 68.98 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.896 1.443 . . . . 0.0 114.896 177.772 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -65.22 -36.69 84.95 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 120.448 -1.408 . . . . 0.0 114.563 176.759 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 95.6 t -72.82 -40.62 60.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 O-C-N 120.383 -1.448 . . . . 0.0 111.618 178.186 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 5.9 mm-40 -57.63 -44.98 85.96 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.258 -1.526 . . . . 0.0 111.879 169.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 63.7 m -61.64 -46.71 88.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 126.718 2.007 . . . . 0.0 114.643 178.157 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . 0.258 0.1 OUTLIER -73.15 -30.85 63.88 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-N 121.723 2.056 . . . . 0.0 113.893 -178.673 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.36 -39.48 92.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.795 -1.19 . . . . 0.0 111.437 169.729 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -88.94 55.68 3.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 123.02 1.39 . . . . 0.0 111.233 177.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.466 ' HB ' HG22 ' A' ' 92' ' ' VAL . 17.4 p -106.32 156.95 17.97 Favored 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.615 1.566 . . . . 0.0 109.624 174.184 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.15 -162.63 32.96 Favored Glycine 0 N--CA 1.43 -1.752 0 O-C-N 121.374 -0.828 . . . . 0.0 111.987 176.294 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -70.79 -48.96 51.49 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.213 1.405 . . . . 0.0 111.551 175.335 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.4 134.03 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.512 1.149 . . . . 0.0 108.044 167.515 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.551 HG21 HD21 ' A' ' 25' ' ' LEU . 82.8 t -124.4 134.95 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 128.562 2.745 . . . . 0.0 107.778 -170.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 23.2 t-160 -122.73 95.23 4.54 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.856 -1.778 . . . . 0.0 110.497 -173.009 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 23.6 mt -99.58 157.3 16.55 Favored 'General case' 0 N--CA 1.429 -1.517 0 O-C-N 120.02 -1.675 . . . . 0.0 114.023 -177.122 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.4 tp -127.2 131.64 50.62 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 162.335 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.14 163.48 32.75 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.889 -1.132 . . . . 0.0 111.165 176.251 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -117.17 144.73 44.43 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.535 1.934 . . . . 0.0 108.181 176.918 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.4 tptt -76.16 137.97 40.4 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.623 -1.298 . . . . 0.0 112.407 -177.201 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.78 123.13 25.45 Favored Glycine 0 N--CA 1.429 -1.811 0 C-N-CA 126.406 1.955 . . . . 0.0 116.209 -175.953 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -82.13 179.56 7.76 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -172.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 17.3 m -98.29 178.61 1.27 Allowed Pre-proline 0 N--CA 1.43 -1.442 0 C-N-CA 126.315 1.846 . . . . 0.0 110.739 -175.699 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo . . . . . 0 N--CA 1.434 -2.008 0 C-N-CA 122.042 1.828 . . . . 0.0 115.562 168.182 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 79.1 mttt . . . . . 0 N--CA 1.43 -1.468 0 CA-C-O 116.45 -1.738 . . . . 0.0 112.895 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_exo -66.14 -174.22 0.39 Allowed 'Trans proline' 0 N--CA 1.433 -2.041 0 CA-C-N 125.31 2.932 . . . . 0.0 114.71 164.465 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.61 28.68 15.66 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 120.464 -1.398 . . . . 0.0 114.826 176.986 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 46.4 t0 -90.66 172.84 8.38 Favored 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 164.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 36.3 p -120.7 165.08 15.59 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.069 -1.644 . . . . 0.0 111.76 -178.725 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.51 144.36 28.49 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 121.889 0.852 . . . . 0.0 109.677 165.018 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.97 130.2 35.5 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 125.643 1.577 . . . . 0.0 109.835 168.929 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 19.2 t -118.49 113.12 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.445 0 C-N-CA 124.819 1.248 . . . . 0.0 108.461 -177.283 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -94.94 108.46 20.52 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 165.934 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 21.7 tp -123.65 128.69 50.03 Favored 'General case' 0 N--CA 1.431 -1.423 0 CA-C-O 122.693 1.235 . . . . 0.0 110.394 -176.162 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -100.99 137.45 39.34 Favored 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 119.757 -1.839 . . . . 0.0 109.569 169.326 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -69.41 136.17 51.26 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.122 -0.986 . . . . 0.0 113.101 177.006 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 10.9 p -90.02 93.1 9.26 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.41 -1.431 . . . . 0.0 111.448 -171.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.7 t70 56.29 41.92 28.53 Favored 'General case' 0 N--CA 1.429 -1.523 0 C-N-CA 125.812 1.645 . . . . 0.0 113.26 178.023 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.03 -20.43 40.81 Favored Glycine 0 N--CA 1.43 -1.733 0 C-N-CA 124.766 1.174 . . . . 0.0 115.372 -174.707 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.5 t -94.11 110.68 22.38 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 119.254 1.527 . . . . 0.0 114.163 -170.535 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 1.5 tt -125.53 64.79 1.17 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 169.856 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -82.16 74.99 2.4 Favored Glycine 0 N--CA 1.429 -1.83 0 C-N-CA 126.754 2.121 . . . . 0.0 111.259 -164.72 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.2 pt -100.65 156.49 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 C-N-CA 125.332 1.453 . . . . 0.0 111.149 169.774 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 46.7 t -129.05 127.6 41.89 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.138 -1.601 . . . . 0.0 107.318 158.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 m -120.49 168.2 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 124.676 1.19 . . . . 0.0 110.141 -178.525 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -149.97 -175.31 5.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.614 -1.304 . . . . 0.0 107.566 176.031 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.89 -168.7 12.62 Favored Glycine 0 N--CA 1.43 -1.705 0 O-C-N 120.888 -1.132 . . . . 0.0 114.631 168.608 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 110.1 161.76 18.65 Favored Glycine 0 N--CA 1.431 -1.652 0 CA-C-O 122.901 1.278 . . . . 0.0 115.039 173.076 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 t -59.96 -34.66 57.06 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 127.405 2.282 . . . . 0.0 115.646 -178.151 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -78.05 -27.99 48.83 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 119.707 -1.87 . . . . 0.0 112.471 -175.569 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.3 p -99.26 156.11 17.15 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.042 1.337 . . . . 0.0 111.175 -172.296 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 16.1 m -82.27 49.63 1.46 Allowed 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 119.991 -1.693 . . . . 0.0 114.089 -169.754 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.2 m -93.31 10.64 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 O-C-N 119.591 -1.943 . . . . 0.0 114.309 -168.524 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.261 25.9 ttt-85 87.59 73.46 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 127.761 2.424 . . . . 0.0 111.146 -177.237 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 49.9 t60 90.22 -62.62 0.02 OUTLIER 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 129.474 3.11 . . . . 0.0 112.519 -176.818 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 158.87 -160.59 31.25 Favored Glycine 0 N--CA 1.431 -1.691 0 N-CA-C 106.117 -2.793 . . . . 0.0 106.117 -166.053 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.11 146.15 14.69 Favored Glycine 0 N--CA 1.43 -1.701 0 C-N-CA 125.428 1.489 . . . . 0.0 111.114 -169.298 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.9 mm -99.47 126.38 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 177.339 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 82.9 m-85 -127.11 152.63 47.06 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-N 119.657 1.117 . . . . 0.0 111.3 -170.322 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.42 126.18 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 O-C-N 120.555 -1.34 . . . . 0.0 112.964 172.674 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 39.6 tttp -97.93 -39.5 8.94 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 125.191 1.396 . . . . 0.0 111.81 -175.483 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -161.29 154.69 21.55 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 121.226 -0.921 . . . . 0.0 110.291 173.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -114.23 120.72 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 C-N-CA 124.252 1.021 . . . . 0.0 108.436 168.59 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.2 mm -76.62 127.1 85.1 Favored Pre-proline 0 N--CA 1.43 -1.437 0 CA-C-O 116.752 -1.594 . . . . 0.0 113.993 -169.666 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_exo -55.26 119.89 7.28 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 123.737 2.958 . . . . 0.0 115.942 177.3 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.37 5.3 mmmp? 78.92 23.14 0.59 Allowed 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 128.562 2.745 . . . . 0.0 116.059 -175.155 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.04 164.46 40.66 Favored Glycine 0 N--CA 1.431 -1.673 0 O-C-N 120.544 -1.347 . . . . 0.0 112.14 163.303 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.63 -58.71 4.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.857 1.428 . . . . 0.0 114.857 168.323 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.39 -26.85 68.64 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.376 1.871 . . . . 0.0 114.576 -177.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -61.66 -54.26 45.07 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 123.688 1.709 . . . . 0.0 113.057 177.156 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.0 t -65.88 -44.01 86.62 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 125.511 1.524 . . . . 0.0 112.985 -176.167 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -45.01 -55.79 5.23 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 128.232 2.613 . . . . 0.0 116.272 -172.637 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 106.49 6.93 35.26 Favored Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 116.965 1.546 . . . . 0.0 116.965 162.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -90.17 -49.42 6.57 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.804 -1.41 . . . . 0.0 109.354 167.75 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 87.3 mt -79.31 128.99 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 C-N-CA 125.351 1.46 . . . . 0.0 112.242 -171.647 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 61.5 t-80 -132.94 153.55 51.31 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.876 1.67 . . . . 0.0 111.047 -178.418 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 9.5 tmtt? -51.49 123.19 9.28 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.134 1.774 . . . . 0.0 113.763 170.436 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 93.04 0.11 68.61 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 120.868 -1.145 . . . . 0.0 115.906 -178.429 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.335 1.7 p30 -82.05 159.07 23.54 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-N 120.119 1.959 . . . . 0.0 113.936 176.006 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -100.32 130.03 46.38 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.592 -1.318 . . . . 0.0 112.788 -177.004 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -85.7 125.37 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.483 0 C-N-CA 124.934 1.294 . . . . 0.0 110.014 176.112 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.2 mp -99.36 -42.7 6.87 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.777 -1.202 . . . . 0.0 111.825 -174.464 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.9 148.9 29.0 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.716 -1.24 . . . . 0.0 111.647 179.795 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 18.3 t -118.73 109.4 26.77 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.377 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 171.093 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 55.3 t30 45.13 67.47 0.71 Allowed 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 128.297 2.639 . . . . 0.0 116.11 173.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 88.48 -29.38 5.75 Favored Glycine 0 N--CA 1.43 -1.725 0 C-N-CA 124.098 0.856 . . . . 0.0 113.555 -179.476 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.3 t -94.5 111.27 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 O-C-N 121.084 -1.245 . . . . 0.0 109.109 -171.771 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 73.6 m -69.99 133.49 47.31 Favored 'General case' 0 N--CA 1.429 -1.483 0 O-C-N 121.159 -0.963 . . . . 0.0 110.546 176.677 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.1 mt -86.5 50.06 1.92 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.847 -1.158 . . . . 0.0 111.064 -178.411 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -89.7 133.23 34.77 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.599 2.36 . . . . 0.0 109.715 178.133 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 66.67 3.83 22.82 Favored Glycine 0 N--CA 1.43 -1.714 0 N-CA-C 117.232 1.653 . . . . 0.0 117.232 -179.543 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.84 148.7 45.94 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 115.645 1.72 . . . . 0.0 115.645 -170.763 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 69.2 p -90.01 174.51 7.62 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.838 -1.164 . . . . 0.0 110.481 165.063 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -52.92 -52.71 56.82 Favored 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 126.172 1.789 . . . . 0.0 113.715 174.758 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.9 ttpt -55.64 -40.4 72.14 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 126.074 1.75 . . . . 0.0 114.598 -179.503 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -54.95 -57.23 12.5 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 126.883 2.073 . . . . 0.0 113.146 177.654 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.61 -37.8 83.03 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.57 1.148 . . . . 0.0 113.815 178.794 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 71.5 t -68.35 -48.18 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.653 -1.279 . . . . 0.0 110.722 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 53.2 mm-40 -66.52 -26.86 67.36 Favored 'General case' 0 N--CA 1.43 -1.426 0 O-C-N 120.249 -1.532 . . . . 0.0 112.855 178.316 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 66.5 m -69.68 -46.19 66.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.814 1.646 . . . . 0.0 113.085 170.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 47.7 mt -72.23 -22.35 61.26 Favored 'General case' 0 N--CA 1.43 -1.473 0 O-C-N 119.779 -1.826 . . . . 0.0 114.822 176.475 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -68.3 -50.72 51.62 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.137 -1.602 . . . . 0.0 111.057 166.217 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.1 t30 -88.52 60.01 5.43 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.273 1.429 . . . . 0.0 113.281 -174.071 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 44.0 p -92.23 -175.9 4.19 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.422 -1.424 . . . . 0.0 110.73 171.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.22 -150.95 23.51 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 157.759 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 55.2 tt0 -71.25 -52.57 18.24 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 124.771 1.228 . . . . 0.0 113.358 174.596 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 17.3 t -104.74 120.48 55.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 122.338 1.066 . . . . 0.0 110.613 -176.915 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.8 t -109.29 139.6 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 127.623 2.369 . . . . 0.0 109.676 -169.668 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.4 t-160 -115.49 112.97 23.05 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.248 -1.533 . . . . 0.0 109.325 174.178 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 20.6 mt -107.03 158.55 16.96 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 125.279 1.432 . . . . 0.0 113.034 176.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 67.2 tp -126.29 130.8 51.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 164.119 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.78 159.23 41.98 Favored 'General case' 0 N--CA 1.431 -1.403 0 O-C-N 121.084 -1.01 . . . . 0.0 112.713 174.528 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -101.58 137.16 40.27 Favored 'General case' 0 N--CA 1.429 -1.497 0 C-N-CA 126.137 1.775 . . . . 0.0 108.443 175.029 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -75.38 113.95 13.37 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.607 -1.308 . . . . 0.0 111.071 -171.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -53.95 137.03 40.99 Favored Glycine 0 N--CA 1.431 -1.649 0 C-N-CA 127.635 2.54 . . . . 0.0 117.539 -167.126 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 29.2 mt-30 -86.36 -57.43 3.01 Favored 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 125.406 1.482 . . . . 0.0 110.281 -170.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 14.7 m -111.7 132.99 21.64 Favored Pre-proline 0 N--CA 1.43 -1.471 0 C-N-CA 124.287 1.035 . . . . 0.0 109.986 -178.145 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo . . . . . 0 N--CA 1.434 -2.022 0 C-N-CA 122.716 2.277 . . . . 0.0 110.767 167.928 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.433 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -79.02 179.6 6.33 Favored 'Trans proline' 0 C--N 1.299 -2.036 0 C-N-CA 122.317 2.011 . . . . 0.0 112.481 171.748 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.29 42.52 1.74 Allowed Glycine 0 N--CA 1.431 -1.649 0 N-CA-C 116.471 1.348 . . . . 0.0 116.471 168.919 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -89.42 115.6 26.98 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 124.797 1.239 . . . . 0.0 108.937 169.762 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.6 p -92.5 146.23 23.84 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.261 -1.524 . . . . 0.0 109.934 176.967 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 16.8 p90 -146.41 137.36 24.27 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 123.048 1.404 . . . . 0.0 109.192 179.837 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -101.15 141.25 34.3 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.703 1.601 . . . . 0.0 109.128 -178.795 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.5 t -130.66 113.18 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -171.824 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -107.39 75.16 1.0 Allowed 'General case' 0 N--CA 1.43 -1.468 0 CA-C-O 122.879 1.324 . . . . 0.0 107.845 173.411 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.7 tp -94.8 135.11 36.68 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.357 1.463 . . . . 0.0 111.864 -168.552 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.49 146.08 28.63 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 120.269 -1.519 . . . . 0.0 111.796 173.373 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -70.27 157.97 36.74 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 115.192 1.552 . . . . 0.0 115.192 176.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.4 t -134.57 125.77 27.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.77 -1.206 . . . . 0.0 108.578 168.758 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 1.2 t70 50.55 40.82 24.43 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.985 2.514 . . . . 0.0 114.25 -170.49 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 81.1 -9.98 50.8 Favored Glycine 0 N--CA 1.431 -1.688 0 O-C-N 120.224 -1.547 . . . . 0.0 116.302 -179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.01 144.19 34.01 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.693 -1.475 . . . . 0.0 113.146 -166.849 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.461 HD21 HG21 ' A' ' 92' ' ' VAL . 49.8 mt -99.78 -62.28 1.26 Allowed 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 121.287 -0.883 . . . . 0.0 110.458 173.8 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 111.71 47.52 0.73 Allowed Glycine 0 N--CA 1.431 -1.685 0 O-C-N 119.574 -1.954 . . . . 0.0 112.923 168.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.6 tt -147.53 137.45 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.666 1.222 . . . . 0.0 112.016 -178.741 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 39.7 m -105.42 133.89 49.43 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 124.928 1.291 . . . . 0.0 108.855 168.162 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 30.8 m -107.7 170.68 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.39 1.09 . . . . 0.0 110.766 178.806 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.9 t -150.41 -172.49 4.19 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.458 -1.401 . . . . 0.0 108.508 174.775 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.98 -144.84 18.56 Favored Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 124.893 1.235 . . . . 0.0 111.309 179.316 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 106.36 146.44 13.7 Favored Glycine 0 N--CA 1.43 -1.757 0 C-N-CA 124.098 0.856 . . . . 0.0 112.367 177.434 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.6 t -70.02 -31.1 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.929 -1.336 . . . . 0.0 114.126 -170.154 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -91.82 -8.15 47.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.559 -1.338 . . . . 0.0 112.273 -178.666 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 25.3 m -77.86 147.12 35.28 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.328 -1.482 . . . . 0.0 108.585 178.672 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m -83.29 58.91 4.73 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 119.298 -2.126 . . . . 0.0 111.721 178.167 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 12.5 p -99.67 147.68 7.14 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 128.416 2.686 . . . . 0.0 108.377 178.496 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 65.8 mmt-85 -68.76 109.19 3.73 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.511 -1.368 . . . . 0.0 112.131 177.546 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.313 3.1 t60 51.96 104.94 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 129.322 3.049 . . . . 0.0 116.588 -170.28 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -57.15 92.3 0.03 OUTLIER Glycine 0 N--CA 1.43 -1.739 0 C-N-CA 126.755 2.122 . . . . 0.0 117.541 -169.086 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.42 -176.35 14.5 Favored Glycine 0 N--CA 1.429 -1.797 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 173.595 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 42.6 mm -101.9 129.0 53.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 124.832 1.253 . . . . 0.0 109.091 -179.243 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -125.55 156.96 38.24 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.632 -1.293 . . . . 0.0 109.952 -170.823 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -75.31 121.07 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 120.398 -1.439 . . . . 0.0 111.929 173.203 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 30.6 ttmt -88.33 -59.42 2.24 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.092 -1.63 . . . . 0.0 110.793 179.2 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -153.58 154.55 34.46 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 121.633 -0.667 . . . . 0.0 110.187 -172.193 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.429 HG12 ' HA ' ' A' ' 54' ' ' GLU . 1.1 tp -111.53 125.88 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 CA-C-O 121.848 0.832 . . . . 0.0 109.541 -179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 16.5 mm -77.67 125.18 86.21 Favored Pre-proline 0 N--CA 1.429 -1.497 0 C-N-CA 126.259 1.823 . . . . 0.0 113.473 -173.594 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -56.58 130.32 39.35 Favored 'Trans proline' 0 N--CA 1.434 -1.996 0 CA-C-N 124.356 2.591 . . . . 0.0 116.568 -175.492 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.275 1.8 mptp? 73.59 13.95 4.35 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 127.592 2.357 . . . . 0.0 115.004 178.916 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -77.12 164.21 52.64 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 119.615 -1.928 . . . . 0.0 113.767 174.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.43 -56.76 10.05 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 126.325 1.85 . . . . 0.0 114.733 168.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.28 -46.68 82.6 Favored 'General case' 0 N--CA 1.429 -1.51 0 C-N-CA 128.673 2.789 . . . . 0.0 112.351 178.522 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.429 ' HA ' HG12 ' A' ' 47' ' ' ILE . 3.1 tm-20 -47.71 -61.97 1.68 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.996 1.851 . . . . 0.0 115.996 170.696 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 65.4 m -69.0 -26.71 65.15 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 114.301 1.223 . . . . 0.0 114.301 -175.654 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -55.61 -68.05 0.23 Allowed 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.942 1.697 . . . . 0.0 111.651 174.349 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.48 30.33 33.63 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 121.043 -1.036 . . . . 0.0 114.925 171.798 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 24.2 mtt180 -78.48 -47.76 16.75 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 120.727 -1.455 . . . . 0.0 108.48 147.84 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.3 111.85 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 C-N-CA 125.956 1.703 . . . . 0.0 112.636 -175.099 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -117.21 160.35 21.21 Favored 'General case' 0 N--CA 1.43 -1.461 0 CA-C-O 123.922 1.82 . . . . 0.0 113.151 -178.503 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 61.3 tttt -60.94 129.49 41.68 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 125.259 1.423 . . . . 0.0 113.949 -174.42 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 87.54 -4.85 85.77 Favored Glycine 0 N--CA 1.431 -1.675 0 CA-C-O 118.91 -0.939 . . . . 0.0 114.06 176.108 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 76.1 m-20 -80.96 162.69 23.76 Favored 'General case' 0 N--CA 1.429 -1.484 0 CA-C-N 119.508 1.654 . . . . 0.0 112.3 -173.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 14.9 ttt180 -106.19 123.97 48.86 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.535 -1.353 . . . . 0.0 111.87 -159.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.1 123.28 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.976 -1.077 . . . . 0.0 110.099 -175.2 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -94.47 -44.05 8.06 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 120.876 -1.14 . . . . 0.0 110.625 -177.563 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.89 137.93 19.18 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.577 -0.702 . . . . 0.0 112.205 -173.043 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 38.4 t -111.42 126.71 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 174.422 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 71.02 14.81 6.76 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 126.267 1.827 . . . . 0.0 111.424 -179.623 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 82.38 0.21 89.62 Favored Glycine 0 N--CA 1.43 -1.742 0 C-N-CA 125.956 1.741 . . . . 0.0 114.156 -170.347 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -91.77 124.62 44.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-N 118.868 1.334 . . . . 0.0 109.568 -179.83 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 25.4 m -72.92 135.02 45.01 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.767 -1.208 . . . . 0.0 112.817 -172.127 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.5 mt -87.34 36.34 0.74 Allowed 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.684 -1.26 . . . . 0.0 114.364 -174.118 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 32.1 mt-10 -72.71 116.91 13.76 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.143 -2.223 . . . . 0.0 113.572 -170.933 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.23 13.09 79.78 Favored Glycine 0 N--CA 1.429 -1.767 0 O-C-N 121.13 -0.981 . . . . 0.0 114.26 -177.643 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.32 144.33 51.74 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -177.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 64.7 p -81.73 173.33 12.41 Favored 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 120.252 -1.53 . . . . 0.0 110.493 175.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -59.52 -48.14 82.8 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 120.874 -1.141 . . . . 0.0 111.648 172.182 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -56.12 -47.96 77.14 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.119 1.368 . . . . 0.0 114.23 174.145 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -58.86 -47.16 85.88 Favored 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 116.235 1.939 . . . . 0.0 116.235 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.35 -35.43 80.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.723 -1.235 . . . . 0.0 112.215 173.166 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.6 t -67.62 -45.02 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.444 0 O-C-N 121.012 -1.055 . . . . 0.0 111.077 178.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 60.8 mt-10 -58.65 -40.77 84.42 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 120.625 -1.297 . . . . 0.0 113.232 173.545 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 99.7 m -66.43 -38.81 88.27 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.702 1.601 . . . . 0.0 113.017 178.668 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 38.9 mt -72.61 -31.73 65.39 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.353 -1.467 . . . . 0.0 113.945 172.569 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.1 -42.16 76.49 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.485 -1.385 . . . . 0.0 112.876 173.692 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 -79.04 58.17 2.38 Favored 'General case' 0 N--CA 1.43 -1.473 0 CA-C-O 124.086 1.898 . . . . 0.0 111.415 174.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 9.7 p -107.7 143.9 35.56 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 127.898 2.479 . . . . 0.0 108.88 170.951 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -88.77 -141.85 8.23 Favored Glycine 0 N--CA 1.43 -1.714 0 O-C-N 121.154 -0.966 . . . . 0.0 112.063 172.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 40.5 tt0 -62.44 -57.56 10.81 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.581 1.552 . . . . 0.0 113.118 174.304 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.6 p -102.21 142.54 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 CA-C-O 122.695 1.236 . . . . 0.0 110.487 178.231 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG21 HD21 ' A' ' 25' ' ' LEU . 64.8 t -124.23 112.35 32.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 C-N-CA 128.268 2.627 . . . . 0.0 109.16 -170.834 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 15.4 t-160 -97.47 108.1 20.75 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.783 -1.198 . . . . 0.0 111.637 176.744 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.1 mt -105.38 146.52 29.32 Favored 'General case' 0 N--CA 1.429 -1.475 0 O-C-N 120.904 -1.122 . . . . 0.0 113.251 172.94 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 62.9 tp -116.33 126.59 53.74 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 162.864 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.508 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 1.1 pp -146.81 163.95 34.37 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 121.246 -0.909 . . . . 0.0 110.949 179.556 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 27.7 tt0 -123.31 143.08 50.31 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 124.252 1.021 . . . . 0.0 112.151 -176.855 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -74.71 112.63 11.11 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.662 1.585 . . . . 0.0 109.177 174.199 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -43.03 137.68 3.57 Favored Glycine 0 N--CA 1.431 -1.683 0 C-N-CA 128.389 2.9 . . . . 0.0 119.964 -157.163 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -61.25 -165.32 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.401 0 C-N-CA 129.424 3.089 . . . . 0.0 115.948 177.356 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 12.9 p -130.16 135.8 28.02 Favored Pre-proline 0 N--CA 1.43 -1.47 0 O-C-N 118.972 -2.33 . . . . 0.0 105.176 169.878 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo . . . . . 0 N--CA 1.434 -1.985 0 CA-C-N 124.524 2.651 . . . . 0.0 113.088 -177.344 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 14.2 pttp . . . . . 0 N--CA 1.43 -1.443 0 CA-C-O 117.676 -1.154 . . . . 0.0 108.336 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -70.82 -172.99 0.76 Allowed 'Trans proline' 0 C--N 1.3 -2.018 0 CA-C-N 123.274 2.205 . . . . 0.0 115.041 178.757 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.65 39.99 5.76 Favored Glycine 0 N--CA 1.429 -1.791 0 O-C-N 120.965 -1.085 . . . . 0.0 114.85 169.259 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -97.89 149.65 22.16 Favored 'General case' 0 CA--C 1.489 -1.394 0 CA-C-N 118.381 1.091 . . . . 0.0 109.944 173.146 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.0 p -91.01 159.67 16.02 Favored 'General case' 0 N--CA 1.43 -1.428 0 C-N-CA 124.328 1.051 . . . . 0.0 113.812 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -144.32 138.95 28.23 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -87.78 122.73 31.79 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.649 -1.282 . . . . 0.0 108.988 164.673 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.485 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 53.7 t -107.18 88.13 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -96.54 89.19 4.91 Favored 'General case' 0 N--CA 1.43 -1.443 0 C-N-CA 126.039 1.736 . . . . 0.0 108.034 177.949 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.0 tp -125.48 151.74 45.87 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 125.513 1.525 . . . . 0.0 109.758 -171.309 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.04 153.74 19.96 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.194 -1.566 . . . . 0.0 110.76 167.816 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -67.22 156.25 36.78 Favored 'General case' 0 N--CA 1.43 -1.431 0 N-CA-C 115.364 1.616 . . . . 0.0 115.364 -179.552 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 63.1 p -116.18 114.42 24.42 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.834 -1.166 . . . . 0.0 108.657 169.487 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.6 t0 40.56 56.91 2.69 Favored 'General case' 0 N--CA 1.431 -1.418 0 C-N-CA 127.843 2.457 . . . . 0.0 115.293 -176.701 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 88.75 -30.32 5.43 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 125.015 1.293 . . . . 0.0 115.488 -177.003 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.49 142.76 33.16 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.729 -1.454 . . . . 0.0 114.783 -162.749 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 95.9 mt -94.54 -60.55 1.69 Allowed 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.223 1.409 . . . . 0.0 107.98 164.645 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.9 36.38 0.89 Allowed Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.873 -1.767 . . . . 0.0 112.504 167.885 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.3 pt -118.78 124.42 73.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 CA-C-O 122.577 1.179 . . . . 0.0 111.179 -174.7 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.2 m -100.05 125.24 46.09 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 164.165 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.3 m -107.48 170.1 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 124.192 0.997 . . . . 0.0 111.438 -175.497 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.0 t -153.34 178.78 9.41 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.467 -1.396 . . . . 0.0 108.146 177.005 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.36 -138.22 13.73 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.627 1.108 . . . . 0.0 114.139 175.537 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.68 152.73 10.93 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 126.239 1.876 . . . . 0.0 111.527 -177.222 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.3 p -71.97 -33.13 46.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 O-C-N 120.592 -1.534 . . . . 0.0 114.755 -175.325 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 26.1 m120 -98.51 8.19 45.2 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.447 -1.408 . . . . 0.0 111.683 -175.849 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.34 -157.45 0.35 Allowed 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 124.467 1.107 . . . . 0.0 109.443 -176.445 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 73.1 m -96.46 9.56 40.96 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 118.933 -2.354 . . . . 0.0 112.403 -174.692 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.4 p -88.14 125.92 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.57 -1.331 . . . . 0.0 108.712 169.316 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -72.16 -40.94 67.64 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 119.59 -1.944 . . . . 0.0 113.07 -177.96 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 55.0 m80 -60.92 -34.65 75.02 Favored 'General case' 0 N--CA 1.431 -1.412 0 N-CA-C 114.92 1.452 . . . . 0.0 114.92 -175.637 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.0 93.01 0.69 Allowed Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 123.895 0.76 . . . . 0.0 113.014 173.577 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -172.35 169.29 42.41 Favored Glycine 0 N--CA 1.43 -1.713 0 O-C-N 120.366 -1.667 . . . . 0.0 111.622 -178.709 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 33.0 mm -103.65 131.25 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 174.751 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -128.14 154.81 45.34 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 120.964 -1.085 . . . . 0.0 109.466 -173.141 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 92.6 t -77.06 122.74 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 O-C-N 120.348 -1.47 . . . . 0.0 112.656 175.029 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -92.0 -47.47 7.27 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 124.803 1.241 . . . . 0.0 112.18 178.862 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.69 161.83 37.14 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.174 -0.954 . . . . 0.0 110.786 -179.753 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -118.03 124.57 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.742 1.217 . . . . 0.0 109.487 -178.384 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.5 mm -77.19 121.02 83.94 Favored Pre-proline 0 N--CA 1.43 -1.454 0 CA-C-O 116.45 -1.738 . . . . 0.0 114.454 -175.214 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_exo -58.2 122.86 12.41 Favored 'Trans proline' 0 N--CA 1.433 -2.03 0 C-N-CA 123.275 2.65 . . . . 0.0 116.202 -178.985 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.323 72.0 mmtt 76.73 31.36 0.56 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 127.064 2.146 . . . . 0.0 113.812 -177.57 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.5 162.68 38.21 Favored Glycine 0 N--CA 1.431 -1.685 0 CA-C-O 122.262 0.923 . . . . 0.0 112.117 159.107 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.98 -59.44 4.15 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 126.253 1.821 . . . . 0.0 114.653 166.585 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.73 -49.37 76.69 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 129.395 3.078 . . . . 0.0 111.705 -176.676 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -41.74 -66.53 0.34 Allowed 'General case' 0 N--CA 1.429 -1.498 0 N-CA-C 115.516 1.672 . . . . 0.0 115.516 172.179 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 29.3 m -70.04 -10.82 59.96 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -176.35 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -75.55 -57.19 4.03 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 119.374 -2.079 . . . . 0.0 111.313 177.37 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.18 0.79 54.37 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 120.909 -1.12 . . . . 0.0 115.411 170.236 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.3 mmt-85 -66.88 -33.69 76.15 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.68 -1.482 . . . . 0.0 110.941 162.97 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 81.6 mt -90.67 113.14 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 C-N-CA 126.066 1.746 . . . . 0.0 110.727 -178.696 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -113.11 156.46 23.13 Favored 'General case' 0 N--CA 1.431 -1.417 0 CA-C-O 123.625 1.679 . . . . 0.0 112.698 179.352 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 37.4 ttpt -69.57 128.08 35.23 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 119.999 -1.688 . . . . 0.0 111.994 -179.817 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 89.14 8.01 69.36 Favored Glycine 0 N--CA 1.43 -1.742 0 O-C-N 120.628 -1.295 . . . . 0.0 114.567 -177.137 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -79.83 173.42 12.61 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 119.672 1.736 . . . . 0.0 113.34 175.617 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 42.8 ttt-85 -101.55 140.74 35.43 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-O 123.104 1.431 . . . . 0.0 110.644 174.956 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.7 t -99.69 136.11 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 O-C-N 120.172 -1.58 . . . . 0.0 107.507 178.768 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -100.71 -57.4 2.11 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.931 -1.73 . . . . 0.0 113.063 -176.988 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.57 139.19 20.64 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.762 -1.211 . . . . 0.0 109.596 -174.678 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 61.9 t -110.29 113.28 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 CA-C-O 121.884 0.85 . . . . 0.0 109.153 179.022 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 6.7 t30 67.35 21.7 9.7 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.31 1.844 . . . . 0.0 114.648 167.574 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.81 -13.64 41.77 Favored Glycine 0 N--CA 1.429 -1.783 0 O-C-N 120.897 -1.127 . . . . 0.0 112.777 -175.219 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.0 t -94.14 116.91 36.54 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 O-C-N 121.218 -1.166 . . . . 0.0 109.257 -176.796 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.6 p -74.51 133.99 42.28 Favored 'General case' 0 N--CA 1.43 -1.425 0 O-C-N 120.628 -1.295 . . . . 0.0 111.615 179.907 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 96.0 mt -86.67 22.12 2.01 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.729 -1.232 . . . . 0.0 113.531 -172.813 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 46.0 mm-40 -68.08 119.69 13.09 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 119.87 -1.769 . . . . 0.0 111.982 174.085 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.33 8.65 83.89 Favored Glycine 0 N--CA 1.431 -1.687 0 O-C-N 121.214 -0.929 . . . . 0.0 115.369 -176.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.16 144.56 46.83 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.796 1.776 . . . . 0.0 115.796 176.459 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 73.0 p -87.1 178.3 6.95 Favored 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.566 -1.333 . . . . 0.0 109.717 168.451 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -62.98 -46.95 85.27 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 119.823 -1.798 . . . . 0.0 112.12 171.477 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 4.7 tmtm? -55.0 -39.53 69.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.612 1.965 . . . . 0.0 115.436 174.686 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 25.5 mm100 -58.61 -51.12 71.27 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 173.573 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -67.07 -35.29 79.52 Favored 'General case' 0 N--CA 1.431 -1.406 0 C-N-CA 124.651 1.18 . . . . 0.0 112.985 -178.765 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 76.9 t -64.89 -48.57 83.73 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 124.653 1.181 . . . . 0.0 110.846 173.94 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 75.6 mt-10 -58.81 -45.42 89.98 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.923 -1.111 . . . . 0.0 113.286 176.882 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 94.5 m -62.59 -43.75 98.03 Favored 'General case' 0 N--CA 1.43 -1.438 0 C-N-CA 126.765 2.026 . . . . 0.0 112.741 178.386 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 22.8 mt -61.48 -45.55 93.79 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.702 -1.249 . . . . 0.0 114.326 172.148 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 55.7 mtp85 -73.2 -27.56 61.69 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.444 -1.41 . . . . 0.0 113.934 -177.467 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -84.32 50.56 1.89 Allowed 'General case' 0 N--CA 1.43 -1.432 0 O-C-N 120.121 -1.612 . . . . 0.0 112.039 172.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.412 ' HB ' HG22 ' A' ' 92' ' ' VAL . 7.4 p -106.7 149.88 26.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.409 1.884 . . . . 0.0 109.966 174.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -85.41 -153.46 20.79 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.959 -1.088 . . . . 0.0 112.496 173.478 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 42.1 tt0 -68.34 -53.48 23.86 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.384 -1.657 . . . . 0.0 113.62 178.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 54.1 t -93.07 136.51 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.502 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 173.837 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 88' ' ' THR . 90.7 t -124.39 126.56 72.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 C-N-CA 125.633 1.573 . . . . 0.0 109.239 -170.183 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 58.0 m170 -105.38 95.5 5.87 Favored 'General case' 0 N--CA 1.431 -1.406 0 O-C-N 119.904 -1.748 . . . . 0.0 113.329 -178.128 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.485 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 34.8 mt -94.22 153.4 18.08 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 118.581 -2.574 . . . . 0.0 113.305 176.7 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 25.3 tp -116.43 138.79 51.09 Favored 'General case' 0 N--CA 1.43 -1.425 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 158.86 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.436 HD13 ' N ' ' A' ' 97' ' ' GLU . 0.4 OUTLIER -137.89 153.67 49.52 Favored 'General case' 0 N--CA 1.429 -1.522 0 C-N-CA 124.941 1.297 . . . . 0.0 109.878 -164.959 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.436 ' N ' HD13 ' A' ' 96' ' ' LEU . 41.7 tt0 -133.13 136.06 45.56 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 119.938 1.245 . . . . 0.0 111.053 169.441 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -75.9 128.43 35.09 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.328 -1.483 . . . . 0.0 111.553 -178.196 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -66.53 151.91 52.3 Favored Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 115.965 1.146 . . . . 0.0 115.965 -172.002 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 11.7 pt20 -94.98 -50.82 4.93 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 125.008 1.323 . . . . 0.0 112.876 -176.165 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 9.6 m -120.91 143.79 37.59 Favored Pre-proline 0 N--CA 1.429 -1.489 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 166.852 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo . . . . . 0 N--CA 1.434 -1.99 0 CA-C-N 122.845 2.052 . . . . 0.0 111.89 179.587 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 22.0 pttm . . . . . 0 N--CA 1.43 -1.445 0 CA-C-O 119.54 -0.267 . . . . 0.0 111.427 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -67.55 178.27 3.37 Favored 'Trans proline' 0 N--CA 1.434 -1.99 0 C-N-CA 122.372 2.048 . . . . 0.0 114.279 167.034 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.49 25.72 7.61 Favored Glycine 0 N--CA 1.43 -1.751 0 C-N-CA 125.357 1.456 . . . . 0.0 111.892 179.912 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.6 t0 -84.55 112.22 20.22 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 121.171 -1.194 . . . . 0.0 109.671 -177.929 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.0 p -109.98 150.21 28.83 Favored 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 124.743 1.217 . . . . 0.0 111.69 -175.304 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -145.79 131.14 18.59 Favored 'General case' 0 N--CA 1.431 -1.425 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.907 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -88.51 113.55 24.21 Favored 'General case' 0 N--CA 1.431 -1.407 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 168.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 42.4 t -99.82 100.82 11.17 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 O-C-N 120.637 -1.289 . . . . 0.0 108.964 -171.217 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -96.67 95.96 8.29 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.88 1.672 . . . . 0.0 108.559 177.427 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 51.6 tp -124.74 145.09 49.89 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.751 1.22 . . . . 0.0 111.315 -166.885 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.08 137.68 40.93 Favored 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.427 -1.421 . . . . 0.0 111.052 173.165 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -70.64 149.42 47.04 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 117.414 2.375 . . . . 0.0 117.414 -177.715 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 72.0 p -127.14 132.62 50.51 Favored 'General case' 0 N--CA 1.431 -1.415 0 O-C-N 120.355 -1.466 . . . . 0.0 109.695 176.403 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 13.1 t70 64.73 16.12 10.2 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 126.883 2.073 . . . . 0.0 114.352 -177.981 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 80.37 6.93 89.0 Favored Glycine 0 N--CA 1.43 -1.734 0 O-C-N 119.647 -1.908 . . . . 0.0 114.63 -174.259 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -123.24 173.63 7.8 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 121.27 -1.135 . . . . 0.0 110.774 176.121 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -109.71 -57.57 2.17 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 124.534 1.134 . . . . 0.0 108.173 171.45 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.4 50.24 0.11 Allowed Glycine 0 N--CA 1.429 -1.767 0 O-C-N 119.841 -1.787 . . . . 0.0 111.861 163.297 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.7 tt -137.51 140.63 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.428 0 CA-C-O 122.102 0.953 . . . . 0.0 111.191 -171.304 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 14.3 t -121.81 139.08 54.06 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.11 1.364 . . . . 0.0 108.284 170.39 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 31.6 m -116.95 170.31 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.418 0 O-C-N 120.929 -1.107 . . . . 0.0 113.74 -167.597 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 t -152.59 160.06 43.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.613 -1.304 . . . . 0.0 109.776 175.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.29 -148.25 19.58 Favored Glycine 0 N--CA 1.43 -1.764 0 O-C-N 120.909 -1.12 . . . . 0.0 115.02 172.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 105.45 -174.23 20.96 Favored Glycine 0 N--CA 1.43 -1.719 0 C-N-CA 125.443 1.497 . . . . 0.0 109.474 -169.604 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.5 m -80.42 49.04 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.422 0 O-C-N 120.539 -1.565 . . . . 0.0 113.753 -178.683 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -98.45 -70.89 0.71 Allowed 'General case' 0 N--CA 1.431 -1.411 0 O-C-N 120.415 -1.428 . . . . 0.0 108.622 174.91 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 26.7 p -102.31 177.01 5.0 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 126.133 1.773 . . . . 0.0 109.997 -175.232 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 75.4 m -87.16 53.14 2.71 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 119.869 -1.769 . . . . 0.0 111.54 -179.267 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.3 p -87.35 85.79 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.499 0 C-N-CA 125.545 1.538 . . . . 0.0 109.984 177.89 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER 39.78 79.15 0.04 OUTLIER 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 128.336 2.654 . . . . 0.0 116.015 -172.179 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . 0.264 97.5 m-70 72.16 -45.11 0.61 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.776 2.031 . . . . 0.0 115.004 -165.079 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 119.88 78.77 0.57 Allowed Glycine 0 N--CA 1.431 -1.643 0 C-N-CA 125.03 1.3 . . . . 0.0 110.721 -177.901 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -134.72 166.96 24.14 Favored Glycine 0 N--CA 1.429 -1.816 0 O-C-N 121.667 -0.902 . . . . 0.0 112.236 -176.769 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.1 mm -85.53 116.83 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 C-N-CA 124.97 1.308 . . . . 0.0 110.615 -176.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -114.78 156.36 25.0 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.536 -1.353 . . . . 0.0 109.68 -177.822 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -76.99 123.14 32.98 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 O-C-N 120.214 -1.554 . . . . 0.0 111.029 170.599 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 12.7 ttmm -91.15 -45.41 8.68 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.198 -1.564 . . . . 0.0 111.084 175.788 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.17 156.49 42.25 Favored 'General case' 0 N--CA 1.431 -1.398 0 O-C-N 120.172 -1.58 . . . . 0.0 111.414 -179.734 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -119.32 128.13 75.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 124.485 1.114 . . . . 0.0 108.642 177.392 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 1.5 mp -76.91 121.27 84.49 Favored Pre-proline 0 N--CA 1.429 -1.513 0 N-CA-C 117.004 2.224 . . . . 0.0 117.004 -171.086 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_exo -56.01 122.95 12.67 Favored 'Trans proline' 0 N--CA 1.434 -2.017 0 C-N-CA 123.44 2.76 . . . . 0.0 116.549 -177.288 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 29.4 mtmm 78.43 13.0 1.52 Allowed 'General case' 0 N--CA 1.431 -1.403 0 C-N-CA 128.367 2.667 . . . . 0.0 114.465 -176.168 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.95 157.77 47.45 Favored Glycine 0 N--CA 1.429 -1.784 0 O-C-N 120.007 -1.683 . . . . 0.0 111.682 172.852 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.21 -55.81 7.88 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 125.873 1.669 . . . . 0.0 114.735 170.166 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.9 -47.76 79.32 Favored 'General case' 0 N--CA 1.431 -1.413 0 C-N-CA 127.659 2.384 . . . . 0.0 113.327 178.82 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -47.48 -61.97 1.66 Allowed 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.219 1.563 . . . . 0.0 115.219 170.299 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.8 t -65.39 -31.64 72.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 124.993 1.317 . . . . 0.0 113.62 -171.853 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -54.89 -63.56 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 127.186 2.194 . . . . 0.0 113.097 174.388 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.53 47.49 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 120.972 -1.08 . . . . 0.0 115.344 171.76 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.437 ' HA ' ' HE ' ' A' ' 58' ' ' ARG . 2.0 mmp_? -76.64 -22.05 54.64 Favored 'General case' 0 N--CA 1.429 -1.481 0 CA-C-N 119.817 1.809 . . . . 0.0 112.438 171.368 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 70.3 mt -103.26 123.58 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.537 1.135 . . . . 0.0 108.252 171.656 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.733 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 25.9 t-80 -146.67 -171.25 3.71 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.63 1.681 . . . . 0.0 111.717 176.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.733 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 44.4 tttp -72.2 123.87 23.83 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 126.015 1.726 . . . . 0.0 113.785 -166.105 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 80.49 16.12 76.59 Favored Glycine 0 N--CA 1.431 -1.689 0 O-C-N 120.721 -1.237 . . . . 0.0 113.935 -176.266 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -80.62 155.53 26.83 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 119.313 1.556 . . . . 0.0 112.309 173.114 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 35.1 tpt85 -106.07 118.73 37.37 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.681 -1.262 . . . . 0.0 109.034 -174.01 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 59.2 t -91.46 122.63 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 O-C-N 120.451 -1.405 . . . . 0.0 108.522 -178.24 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -87.08 -45.0 11.12 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.157 0.983 . . . . 0.0 110.287 -177.099 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.45 139.73 21.29 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 121.885 0.85 . . . . 0.0 110.621 -173.829 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 93.8 t -118.2 122.41 69.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 177.845 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.8 t-20 64.11 25.66 13.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 120.582 -1.323 . . . . 0.0 114.152 172.754 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 89.03 -5.44 84.49 Favored Glycine 0 N--CA 1.429 -1.787 0 O-C-N 120.191 -1.568 . . . . 0.0 114.102 -175.719 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 45.5 t -95.41 126.08 47.99 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.405 0 C-N-CA 125.031 1.332 . . . . 0.0 109.547 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.1 t -76.8 127.57 33.0 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.52 -1.363 . . . . 0.0 110.634 -178.866 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.4 mt -82.82 2.62 33.22 Favored 'General case' 0 N--CA 1.429 -1.502 0 O-C-N 120.28 -1.513 . . . . 0.0 114.227 -175.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.5 mm-40 -65.07 126.05 26.84 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 119.105 -2.247 . . . . 0.0 112.668 -178.857 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 87.65 -8.36 77.78 Favored Glycine 0 N--CA 1.429 -1.79 0 O-C-N 121.013 -1.054 . . . . 0.0 114.839 -175.776 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -73.09 146.0 46.08 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 114.457 1.28 . . . . 0.0 114.457 177.216 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 24.1 p -92.37 -179.38 5.2 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 126.041 1.736 . . . . 0.0 111.441 171.227 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.2 t-160 -57.08 -52.93 63.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.817 1.647 . . . . 0.0 114.693 -177.881 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 5.3 tmtp? -56.73 -38.23 72.08 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -58.95 -53.27 60.27 Favored 'General case' 0 N--CA 1.43 -1.457 0 C-N-CA 125.886 1.674 . . . . 0.0 115.127 177.767 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -63.76 -37.26 86.69 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.255 1.422 . . . . 0.0 112.464 178.711 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.22 -51.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 124.577 1.151 . . . . 0.0 111.047 175.202 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.7 mt-10 -64.84 -33.53 76.22 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 114.399 1.259 . . . . 0.0 114.399 178.959 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 35.3 m -75.37 -43.2 51.6 Favored 'General case' 0 N--CA 1.431 -1.425 0 C-N-CA 125.682 1.593 . . . . 0.0 113.252 179.568 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 27.5 mt -66.2 -42.09 89.29 Favored 'General case' 0 N--CA 1.431 -1.409 0 O-C-N 120.623 -1.298 . . . . 0.0 113.062 173.03 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 11.9 ptt85 -72.71 -37.41 67.82 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.898 -1.127 . . . . 0.0 113.869 -176.854 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -85.71 59.78 5.84 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-O 123.412 1.577 . . . . 0.0 111.5 176.41 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' VAL . 4.9 p -107.61 153.69 22.52 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.545 1.938 . . . . 0.0 108.916 173.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -87.35 -151.89 21.87 Favored Glycine 0 N--CA 1.43 -1.715 0 O-C-N 120.846 -1.159 . . . . 0.0 112.624 -174.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -69.98 -50.73 38.73 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 120.873 -1.369 . . . . 0.0 113.332 -179.572 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 8.6 p -104.14 137.09 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.511 1.148 . . . . 0.0 109.177 169.129 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.449 HG22 ' HB ' ' A' ' 88' ' ' THR . 40.3 t -125.3 127.1 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 127.023 2.129 . . . . 0.0 110.293 -166.917 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 18.3 m170 -105.11 114.52 28.77 Favored 'General case' 0 N--CA 1.429 -1.496 0 O-C-N 120.669 -1.27 . . . . 0.0 112.432 172.623 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 9.5 mt -103.26 164.96 11.31 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.087 -1.633 . . . . 0.0 112.261 163.02 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 58.7 tp -127.28 124.63 39.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.65 1.18 . . . . 0.0 107.838 158.407 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.99 162.16 32.84 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 121.257 -0.902 . . . . 0.0 112.387 175.677 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -117.51 144.69 44.82 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.407 1.883 . . . . 0.0 109.64 175.108 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.09 70.33 3.47 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 127.458 2.303 . . . . 0.0 113.223 -174.174 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.12 -163.94 44.61 Favored Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 125.873 1.701 . . . . 0.0 114.854 178.104 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -97.51 -33.77 11.24 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.585 -1.538 . . . . 0.0 110.947 158.258 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 11.0 p -136.12 142.68 40.96 Favored Pre-proline 0 N--CA 1.43 -1.444 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 174.051 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo . . . . . 0 C--N 1.3 -2.014 0 CA-C-N 122.434 1.905 . . . . 0.0 115.184 173.445 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 21.5 mtpt . . . . . 0 N--CA 1.43 -1.455 0 CA-C-O 116.731 -1.604 . . . . 0.0 112.687 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -97.66 -164.83 0.08 OUTLIER 'Trans proline' 0 N--CA 1.433 -2.039 0 CA-C-N 125.093 2.855 . . . . 0.0 109.933 153.615 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.94 76.8 0.82 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 177.89 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -52.7 -52.7 54.9 Favored 'General case' 0 N--CA 1.431 -1.391 0 C-N-CA 126.907 2.083 . . . . 0.0 116.007 -161.387 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 21.7 p -123.11 149.35 44.61 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 121.827 2.103 . . . . 0.0 111.585 168.372 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.3 p90 -147.84 148.87 31.35 Favored 'General case' 0 N--CA 1.43 -1.466 0 CA-C-O 123.037 1.399 . . . . 0.0 109.592 171.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -92.88 141.62 28.22 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 126.334 1.854 . . . . 0.0 109.346 176.938 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.74 90.31 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 178.63 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.7 tt0 -94.2 84.63 4.47 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.401 -1.437 . . . . 0.0 108.22 177.073 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 40.9 tp -113.73 145.16 41.77 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 125.113 1.365 . . . . 0.0 111.424 -162.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.58 122.43 44.37 Favored 'General case' 0 N--CA 1.429 -1.501 0 O-C-N 120.257 -1.527 . . . . 0.0 108.981 171.291 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -71.68 165.99 22.84 Favored 'General case' 0 N--CA 1.43 -1.434 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 179.264 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.4 p -134.23 139.95 46.13 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 124.724 1.21 . . . . 0.0 108.53 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 3.6 t70 66.77 8.55 6.05 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.944 1.698 . . . . 0.0 115.081 174.205 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.99 -8.47 63.2 Favored Glycine 0 N--CA 1.431 -1.69 0 O-C-N 120.097 -1.627 . . . . 0.0 113.762 -176.279 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 66.8 m -119.47 152.06 37.54 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 118.729 1.264 . . . . 0.0 111.814 -172.346 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 41.6 mt -86.95 -55.24 3.92 Favored 'General case' 0 N--CA 1.43 -1.469 0 O-C-N 120.259 -1.525 . . . . 0.0 111.734 176.397 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 20.05 1.78 Allowed Glycine 0 N--CA 1.429 -1.772 0 O-C-N 120.414 -1.428 . . . . 0.0 112.107 177.25 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.6 pt -115.25 150.21 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 C-N-CA 124.941 1.296 . . . . 0.0 110.18 -177.358 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 7.7 t -127.82 123.45 35.18 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 163.356 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.91 163.54 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 124.544 1.138 . . . . 0.0 111.683 -172.207 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -150.05 173.9 13.34 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 124.882 1.273 . . . . 0.0 109.409 -175.441 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 112.86 -136.11 13.2 Favored Glycine 0 N--CA 1.43 -1.761 0 O-C-N 120.872 -1.142 . . . . 0.0 113.761 168.755 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.54 167.73 43.47 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 124.246 0.927 . . . . 0.0 114.41 177.258 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m -66.39 -21.08 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 115.548 1.685 . . . . 0.0 115.548 -175.17 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.8 p-10 -77.99 -15.67 58.76 Favored 'General case' 0 N--CA 1.431 -1.396 0 O-C-N 120.408 -1.432 . . . . 0.0 113.004 177.062 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.3 m -106.38 151.82 24.39 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 125.772 1.629 . . . . 0.0 108.29 -174.576 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 22.2 p -79.11 39.68 0.39 Allowed 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 119.64 -1.913 . . . . 0.0 115.233 -174.035 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.2 m -92.1 169.04 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.441 0 C-N-CA 125.979 1.712 . . . . 0.0 111.963 -179.488 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -70.71 119.41 14.81 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.428 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 38.0 m-70 57.49 21.87 7.47 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 127.533 2.333 . . . . 0.0 116.602 178.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 67.73 29.02 73.48 Favored Glycine 0 N--CA 1.43 -1.744 0 O-C-N 120.314 -1.491 . . . . 0.0 115.68 -178.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -77.71 155.77 43.53 Favored Glycine 0 N--CA 1.429 -1.778 0 O-C-N 121.78 -0.835 . . . . 0.0 114.829 -175.121 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.8 mm -100.41 125.4 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.514 0 C-N-CA 125.2 1.4 . . . . 0.0 107.38 175.18 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.1 m-85 -126.48 153.52 44.99 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.566 -1.334 . . . . 0.0 111.319 -171.562 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.5 t -75.86 122.83 30.67 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 O-C-N 120.861 -1.149 . . . . 0.0 111.987 172.195 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 15.0 tppt? -91.1 -47.17 7.69 Favored 'General case' 0 N--CA 1.429 -1.498 0 C-N-CA 125.639 1.576 . . . . 0.0 110.857 177.419 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -156.15 165.19 37.12 Favored 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.651 -0.656 . . . . 0.0 110.402 -176.702 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.4 tp -116.13 132.73 64.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.415 0 C-N-CA 124.309 1.043 . . . . 0.0 108.342 175.021 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.5 mm -77.8 121.49 84.25 Favored Pre-proline 0 N--CA 1.429 -1.491 0 C-N-CA 126.137 1.775 . . . . 0.0 114.37 -174.854 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -59.32 123.76 14.1 Favored 'Trans proline' 0 N--CA 1.434 -2.007 0 CA-C-N 124.97 2.811 . . . . 0.0 116.795 -176.104 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.314 59.9 mmtt 68.98 30.9 4.36 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 127.773 2.429 . . . . 0.0 114.534 -176.144 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.02 163.33 39.69 Favored Glycine 0 N--CA 1.43 -1.709 0 O-C-N 120.31 -1.494 . . . . 0.0 112.8 167.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -50.36 -58.49 5.57 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 126.479 1.912 . . . . 0.0 114.593 167.673 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.83 -46.94 79.83 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.775 2.03 . . . . 0.0 112.433 -177.107 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.4 tm-20 -45.44 -62.32 1.32 Allowed 'General case' 0 N--CA 1.429 -1.506 0 C-N-CA 126.87 2.068 . . . . 0.0 115.842 170.657 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.4 m -69.55 -32.07 70.64 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 -176.02 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -56.6 -56.4 21.84 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.16 1.784 . . . . 0.0 113.703 173.92 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.88 25.25 32.63 Favored Glycine 0 N--CA 1.431 -1.698 0 O-C-N 120.602 -1.311 . . . . 0.0 116.232 164.49 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 80.6 mmt-85 -78.89 -52.48 8.24 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.775 -1.426 . . . . 0.0 107.675 160.723 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 74.9 mt -77.82 122.08 31.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 125.1 1.36 . . . . 0.0 110.873 178.282 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.454 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 9.4 t-160 -131.27 -176.47 4.03 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 123.033 1.397 . . . . 0.0 112.019 174.95 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 81.4 tttt -69.07 128.32 36.26 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 119.816 -1.803 . . . . 0.0 112.083 -172.295 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.91 1.8 79.26 Favored Glycine 0 N--CA 1.429 -1.772 0 CA-C-O 118.507 -1.163 . . . . 0.0 114.849 -179.408 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 64.7 m-20 -76.16 158.61 31.52 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 120.092 1.946 . . . . 0.0 112.057 178.426 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -108.23 119.59 39.92 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.656 -1.278 . . . . 0.0 110.305 -169.286 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 37.4 t -85.35 124.8 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 C-N-CA 125.985 1.714 . . . . 0.0 110.764 -169.773 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 74.0 mt -106.44 -51.45 2.95 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.319 -1.488 . . . . 0.0 113.888 -173.626 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.16 138.32 20.34 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.069 -1.644 . . . . 0.0 112.606 -172.042 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.706 HG11 HG21 ' A' ' 84' ' ' THR . 2.2 p -108.77 108.71 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 C-N-CA 125.387 1.475 . . . . 0.0 112.204 -178.877 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.4 t30 58.46 36.94 25.66 Favored 'General case' 0 N--CA 1.43 -1.455 0 C-N-CA 126.17 1.788 . . . . 0.0 113.376 168.853 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.95 -9.39 68.09 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 125.829 1.681 . . . . 0.0 115.473 -172.971 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.4 t -103.0 116.79 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 CA-C-N 120.808 2.304 . . . . 0.0 111.085 -174.895 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 13.3 p -69.07 126.05 28.58 Favored 'General case' 0 N--CA 1.431 -1.402 0 O-C-N 120.355 -1.466 . . . . 0.0 113.571 179.852 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 63.5 mt -87.97 46.94 1.43 Allowed 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.633 -1.292 . . . . 0.0 112.852 -176.421 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -89.46 123.02 33.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 119.326 -2.109 . . . . 0.0 111.189 -178.448 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.58 1.97 89.36 Favored Glycine 0 N--CA 1.431 -1.684 0 O-C-N 121.058 -1.027 . . . . 0.0 114.798 175.041 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.86 162.9 28.77 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 115.737 1.754 . . . . 0.0 115.737 -178.288 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 46.2 p -83.63 173.72 11.14 Favored 'General case' 0 N--CA 1.431 -1.395 0 O-C-N 120.525 -1.359 . . . . 0.0 111.723 176.906 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 14.4 t-160 -56.43 -53.57 55.91 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 124.755 1.222 . . . . 0.0 112.798 168.298 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.35 -46.26 89.11 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 114.744 1.387 . . . . 0.0 114.744 179.259 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -55.99 -48.24 76.23 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 125.059 1.344 . . . . 0.0 114.505 -173.92 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -60.85 -42.02 96.98 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 124.833 1.253 . . . . 0.0 113.561 174.366 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 77.7 t -66.27 -48.84 79.81 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 C-N-CA 125.126 1.371 . . . . 0.0 111.121 179.101 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -60.39 -46.32 90.41 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.736 1.214 . . . . 0.0 112.775 179.062 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . 0.706 HG21 HG11 ' A' ' 68' ' ' VAL . 2.3 m -60.03 -43.99 94.92 Favored 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.372 1.469 . . . . 0.0 113.844 172.62 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 37.2 mt -69.72 -34.36 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.119 -1.613 . . . . 0.0 114.725 178.09 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . 0.271 42.9 ptt85 -71.95 -38.93 69.7 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.035 -1.665 . . . . 0.0 113.19 172.801 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 26.9 t30 -84.34 48.4 1.49 Allowed 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.787 -1.195 . . . . 0.0 113.722 175.936 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 p -99.58 150.46 22.22 Favored 'General case' 0 N--CA 1.429 -1.487 0 C-N-CA 127.032 2.133 . . . . 0.0 109.97 174.311 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.79 -163.46 17.29 Favored Glycine 0 N--CA 1.43 -1.748 0 C-N-CA 124.579 1.085 . . . . 0.0 113.34 177.099 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.6 tt0 -68.99 -47.63 65.06 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 120.522 -1.575 . . . . 0.0 113.799 -178.465 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 42.7 t -106.25 118.74 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.49 0 CA-C-O 122.091 0.948 . . . . 0.0 108.721 179.836 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 65.4 t -124.11 119.26 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 126.457 1.903 . . . . 0.0 110.395 -161.283 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -103.32 97.57 7.61 Favored 'General case' 0 N--CA 1.431 -1.39 0 O-C-N 120.076 -1.64 . . . . 0.0 113.845 -178.433 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 15.8 mt -93.39 148.58 21.94 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 119.703 -1.873 . . . . 0.0 111.342 176.749 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -127.75 127.97 44.53 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 171.849 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . 0.273 0.0 OUTLIER -146.13 169.59 18.41 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.349 -1.469 . . . . 0.0 113.739 -177.07 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -115.54 131.6 56.88 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.362 1.865 . . . . 0.0 110.493 -173.414 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.6 153.92 30.73 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.304 -1.498 . . . . 0.0 113.467 179.182 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -87.41 84.03 1.55 Allowed Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 124.242 0.925 . . . . 0.0 111.893 165.156 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 46.1 tt0 -78.25 -49.49 13.63 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 127.614 2.366 . . . . 0.0 112.03 -176.4 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 1.4 p -130.21 126.16 22.14 Favored Pre-proline 0 N--CA 1.43 -1.474 0 C-N-CA 124.96 1.304 . . . . 0.0 109.101 -176.634 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 N--CA 1.433 -2.073 0 C-N-CA 122.985 2.457 . . . . 0.0 114.85 -171.367 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? . . . . . 0 N--CA 1.43 -1.458 0 CA-C-O 119.106 -0.474 . . . . 0.0 109.731 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -74.19 -179.94 5.19 Favored 'Trans proline' 0 C--N 1.3 -1.993 0 C-N-CA 122.751 2.301 . . . . 0.0 112.648 -178.452 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 90.58 34.58 7.81 Favored Glycine 0 N--CA 1.43 -1.72 0 O-C-N 121.266 -0.896 . . . . 0.0 111.856 -170.107 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -94.77 129.52 41.68 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 125.711 1.605 . . . . 0.0 108.722 -176.554 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.3 p -94.29 144.52 25.46 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.473 -1.392 . . . . 0.0 112.379 -177.203 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.432 ' CE1' HD21 ' A' ' 96' ' ' LEU . 5.9 p90 -147.29 140.45 25.23 Favored 'General case' 0 N--CA 1.43 -1.456 0 CA-C-O 122.74 1.257 . . . . 0.0 107.974 177.337 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -99.43 127.05 45.45 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.367 1.067 . . . . 0.0 109.765 178.017 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 41.9 t -116.44 93.32 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 C-N-CA 124.717 1.207 . . . . 0.0 108.364 -170.591 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 mt-10 -89.63 103.82 16.43 Favored 'General case' 0 N--CA 1.429 -1.5 0 CA-C-O 123.221 1.486 . . . . 0.0 107.831 168.668 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.7 tp -121.59 144.52 48.69 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 125.24 1.416 . . . . 0.0 109.047 -165.55 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.41 120.26 40.02 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 124.672 1.189 . . . . 0.0 109.333 172.059 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 40.9 ttmt -69.43 129.01 38.54 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 125.202 1.401 . . . . 0.0 112.412 -179.088 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.9 t -92.7 104.74 16.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.641 1.21 . . . . 0.0 110.737 -172.31 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.4 t70 33.04 60.29 0.43 Allowed 'General case' 0 N--CA 1.429 -1.509 0 C-N-CA 129.339 3.056 . . . . 0.0 116.85 -173.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.67 -10.27 74.21 Favored Glycine 0 N--CA 1.43 -1.767 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 178.357 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -111.64 127.11 55.65 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-N 120.494 2.147 . . . . 0.0 111.519 -179.748 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.0 tp -92.32 -61.49 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 121.05 -1.031 . . . . 0.0 111.921 -178.844 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 139.92 -11.8 3.12 Favored Glycine 0 N--CA 1.429 -1.78 0 O-C-N 119.663 -1.898 . . . . 0.0 115.209 170.617 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.0 pt -105.9 141.03 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 CA-C-N 119.321 1.561 . . . . 0.0 113.29 -178.391 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 21.5 m -113.23 122.74 48.38 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 159.856 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.72 170.04 1.81 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 CA-C-O 122.696 1.236 . . . . 0.0 112.622 -172.933 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 t -152.52 172.35 16.7 Favored 'General case' 0 N--CA 1.431 -1.421 0 O-C-N 120.755 -1.215 . . . . 0.0 109.602 176.354 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.71 -142.26 15.64 Favored Glycine 0 N--CA 1.43 -1.707 0 O-C-N 121.318 -0.864 . . . . 0.0 113.67 171.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.57 150.7 27.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.56 1.076 . . . . 0.0 112.834 -179.916 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.9 p -61.6 -31.47 50.81 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -174.272 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -79.76 -16.57 55.33 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 125.596 1.558 . . . . 0.0 114.369 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.5 m -88.92 152.43 21.73 Favored 'General case' 0 N--CA 1.431 -1.413 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 179.91 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 6.7 t -82.52 50.21 1.6 Allowed 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 119.237 -2.164 . . . . 0.0 113.483 -173.222 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 15.6 m -100.4 51.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 O-C-N 119.674 -1.892 . . . . 0.0 112.452 -172.482 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 73.25 -43.52 0.56 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 126.604 1.961 . . . . 0.0 116.228 173.652 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 53.7 t60 -144.6 -60.93 0.37 Allowed 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.677 -1.265 . . . . 0.0 108.87 170.235 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 173.75 -143.66 7.21 Favored Glycine 0 N--CA 1.43 -1.756 0 N-CA-C 106.659 -2.576 . . . . 0.0 106.659 -173.797 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.58 136.91 4.66 Favored Glycine 0 N--CA 1.429 -1.801 0 C-N-CA 124.312 0.958 . . . . 0.0 113.31 176.501 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.486 ' HB ' HG12 ' A' ' 65' ' ' VAL . 25.1 mm -101.69 122.04 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 124.824 1.249 . . . . 0.0 108.412 179.859 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 75.3 m-85 -127.34 152.64 47.21 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 121.202 -0.936 . . . . 0.0 109.706 -173.552 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -75.82 125.84 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.453 0 O-C-N 120.483 -1.386 . . . . 0.0 111.341 171.661 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 ttpt -98.93 -40.69 7.95 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.634 -1.292 . . . . 0.0 112.316 -179.399 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -149.61 155.33 40.1 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 121.453 -0.779 . . . . 0.0 111.222 179.699 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.448 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -115.95 124.87 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 CA-C-O 122.465 1.126 . . . . 0.0 111.28 -179.827 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp -76.33 122.97 87.72 Favored Pre-proline 0 N--CA 1.43 -1.452 0 C-N-CA 126.848 2.059 . . . . 0.0 116.136 -169.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -58.25 112.9 1.32 Allowed 'Trans proline' 0 N--CA 1.434 -1.997 0 C-N-CA 123.767 2.978 . . . . 0.0 117.232 -175.588 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.305 48.5 mtmt 79.06 32.27 0.27 Allowed 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 128.875 2.87 . . . . 0.0 113.8 -178.124 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.8 159.99 35.08 Favored Glycine 0 N--CA 1.43 -1.746 0 O-C-N 121.418 -0.801 . . . . 0.0 112.026 167.234 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.45 -60.39 2.88 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.519 1.528 . . . . 0.0 114.426 169.46 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -41.75 99.44 Favored 'General case' 0 N--CA 1.43 -1.462 0 C-N-CA 127.396 2.278 . . . . 0.0 112.677 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.448 ' CG ' HG23 ' A' ' 47' ' ' ILE . 2.8 tm-20 -51.49 -65.36 0.57 Allowed 'General case' 0 N--CA 1.43 -1.432 0 C-N-CA 125.771 1.628 . . . . 0.0 114.626 174.678 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 8.0 t -69.15 -23.22 63.93 Favored 'General case' 0 N--CA 1.43 -1.451 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -174.345 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -51.5 -63.94 0.97 Allowed 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 126.079 1.752 . . . . 0.0 113.019 172.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.24 -12.64 28.66 Favored Glycine 0 N--CA 1.431 -1.693 0 O-C-N 121.288 -0.883 . . . . 0.0 114.647 167.642 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 -64.22 -56.02 17.58 Favored 'General case' 0 N--CA 1.429 -1.52 0 C-N-CA 124.409 1.084 . . . . 0.0 111.002 168.614 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 53.8 mt -78.55 128.73 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.423 0 C-N-CA 124.957 1.303 . . . . 0.0 110.839 179.074 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 5.8 t-80 -145.7 171.11 15.21 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 121.132 -0.98 . . . . 0.0 110.113 177.862 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . 0.264 0.0 OUTLIER -64.45 139.67 58.79 Favored 'General case' 0 N--CA 1.431 -1.386 0 O-C-N 119.398 -2.064 . . . . 0.0 113.829 179.445 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.78 -7.8 67.99 Favored Glycine 0 N--CA 1.43 -1.709 0 CA-C-O 118.509 -1.162 . . . . 0.0 114.278 -172.67 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.487 ' HB3' HD23 ' A' ' 96' ' ' LEU . 97.7 m-20 -80.75 138.65 36.3 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 119.8 1.8 . . . . 0.0 113.363 -176.269 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.7 ttt-85 -98.2 133.43 42.63 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.57 -1.331 . . . . 0.0 111.668 -174.408 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.486 HG12 ' HB ' ' A' ' 42' ' ' ILE . 0.4 OUTLIER -82.89 148.73 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.45 0 O-C-N 120.494 -1.379 . . . . 0.0 112.942 -179.384 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -109.39 -51.37 2.88 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.752 1.221 . . . . 0.0 109.689 171.028 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 143.77 25.24 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.801 -1.187 . . . . 0.0 110.925 -175.35 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 58.8 t -117.6 129.09 74.59 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.39 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 22.1 t-20 77.18 -30.46 0.17 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 128.407 2.683 . . . . 0.0 113.983 173.236 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 147.09 -17.11 1.54 Allowed Glycine 0 N--CA 1.43 -1.734 0 C-N-CA 126.316 1.913 . . . . 0.0 109.265 -169.937 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.72 116.53 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.432 0 C-N-CA 125.379 1.472 . . . . 0.0 109.275 -176.196 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.3 m -71.12 127.42 32.53 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.807 -1.183 . . . . 0.0 111.104 176.991 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 22.9 mt -93.88 43.02 1.1 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 121.027 -1.046 . . . . 0.0 112.699 -171.057 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -75.79 119.93 20.46 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 119.19 -2.194 . . . . 0.0 112.21 -178.344 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 80.23 13.2 82.26 Favored Glycine 0 N--CA 1.43 -1.721 0 O-C-N 120.117 -1.615 . . . . 0.0 115.306 -178.33 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -70.94 151.42 44.69 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 11.3 p -82.09 172.83 12.76 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 124.207 1.003 . . . . 0.0 111.148 176.345 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -61.08 -50.0 75.05 Favored 'General case' 0 N--CA 1.43 -1.458 0 C-N-CA 124.909 1.284 . . . . 0.0 113.118 175.057 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.3 -42.01 80.93 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 171.695 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 11.1 mm-40 -55.36 -48.78 73.72 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 114.499 1.296 . . . . 0.0 114.499 -175.428 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.96 98.38 Favored 'General case' 0 N--CA 1.431 -1.4 0 C-N-CA 125.126 1.37 . . . . 0.0 113.855 177.2 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.3 t -66.1 -49.87 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 C-N-CA 125.112 1.365 . . . . 0.0 110.451 177.609 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -64.26 -32.26 73.78 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.692 -1.255 . . . . 0.0 113.96 179.632 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 53.0 m -67.65 -46.48 72.3 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.61 1.964 . . . . 0.0 112.236 173.501 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 70.1 mt -64.02 -38.94 92.89 Favored 'General case' 0 N--CA 1.429 -1.515 0 O-C-N 120.98 -1.075 . . . . 0.0 113.727 173.531 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.12 -45.22 83.67 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 125.967 1.707 . . . . 0.0 112.444 175.39 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 -85.39 44.58 1.11 Allowed 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.265 1.426 . . . . 0.0 113.224 -179.911 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 41.3 p -106.81 160.27 15.61 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.075 -1.641 . . . . 0.0 108.739 170.02 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -115.82 -131.05 4.79 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.474 1.035 . . . . 0.0 110.856 179.369 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -69.77 -69.01 0.37 Allowed 'General case' 0 N--CA 1.431 -1.417 0 N-CA-C 114.729 1.381 . . . . 0.0 114.729 178.029 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 52.8 t -92.25 124.65 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 CA-C-O 122.853 1.311 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.8 t -124.15 120.82 60.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 C-N-CA 127.574 2.349 . . . . 0.0 109.272 -169.622 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 17.7 t-160 -100.46 113.02 25.46 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 119.796 -1.815 . . . . 0.0 112.212 173.683 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -97.57 149.32 22.34 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 119.747 -1.845 . . . . 0.0 111.672 163.336 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.9 124.64 48.77 Favored 'General case' 0 N--CA 1.429 -1.477 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 161.773 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.487 HD23 ' HB3' ' A' ' 63' ' ' ASP . 0.0 OUTLIER -150.28 168.46 23.98 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.874 -1.141 . . . . 0.0 113.149 -178.423 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -119.34 144.96 46.56 Favored 'General case' 0 N--CA 1.43 -1.468 0 C-N-CA 125.478 1.511 . . . . 0.0 111.503 -177.905 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 11.6 tppt? -75.28 128.1 34.66 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 125.487 1.515 . . . . 0.0 112.755 -179.687 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -67.34 136.41 32.16 Favored Glycine 0 N--CA 1.431 -1.673 0 C-N-CA 124.798 1.19 . . . . 0.0 115.393 -177.256 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 9.4 pt20 -68.58 -34.54 75.99 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 115.752 1.76 . . . . 0.0 115.752 -175.306 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 6.6 p -112.11 132.25 22.14 Favored Pre-proline 0 N--CA 1.43 -1.444 0 C-N-CA 124.838 1.255 . . . . 0.0 108.442 -178.701 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo . . . . . 0 C--N 1.3 -1.989 0 C-N-CA 122.699 2.266 . . . . 0.0 114.173 -177.607 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 19.6 mtmm . . . . . 0 N--CA 1.43 -1.442 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -78.18 179.69 6.27 Favored 'Trans proline' 0 C--N 1.3 -2.01 0 C-N-CA 122.767 2.311 . . . . 0.0 109.895 157.237 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.19 -2.02 83.21 Favored Glycine 0 N--CA 1.43 -1.762 0 O-C-N 120.596 -1.315 . . . . 0.0 113.849 175.901 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.4 t0 -80.96 150.79 28.81 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 121.303 -1.116 . . . . 0.0 110.055 179.455 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.0 p -102.55 157.57 16.84 Favored 'General case' 0 N--CA 1.43 -1.473 0 C-N-CA 124.339 1.055 . . . . 0.0 110.972 -178.857 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -146.16 124.35 12.2 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.713 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -88.94 108.6 19.65 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 122.69 1.233 . . . . 0.0 109.287 162.77 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 25.2 t -99.06 108.9 23.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 C-N-CA 128.287 2.635 . . . . 0.0 109.303 -168.766 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.4 101.14 13.82 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.845 -1.159 . . . . 0.0 109.737 173.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -108.64 158.06 17.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 CA-C-O 122.872 1.32 . . . . 0.0 108.849 172.979 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.41 145.84 29.38 Favored 'General case' 0 N--CA 1.43 -1.456 0 N-CA-C 104.406 -2.442 . . . . 0.0 104.406 152.609 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 12.0 ptpt -70.03 146.82 50.75 Favored 'General case' 0 N--CA 1.429 -1.48 0 O-C-N 120.899 -1.126 . . . . 0.0 112.501 171.384 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 17.7 p -106.07 94.72 5.32 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.47 1.129 . . . . 0.0 108.876 178.683 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.0 t0 54.75 60.07 3.72 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.339 1.856 . . . . 0.0 114.023 -178.998 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 87.63 -34.66 3.64 Favored Glycine 0 N--CA 1.43 -1.739 0 O-C-N 120.701 -1.25 . . . . 0.0 115.693 -176.865 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -94.19 145.63 24.57 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.191 -1.182 . . . . 0.0 113.435 -167.513 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.04 -18.49 13.78 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.986 -1.071 . . . . 0.0 111.714 176.648 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.63 4.73 54.57 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 119.483 -2.011 . . . . 0.0 114.756 175.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.4 pt -120.06 133.02 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.492 0 C-N-CA 124.862 1.265 . . . . 0.0 111.293 -171.87 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 36.9 t -113.51 128.84 56.59 Favored 'General case' 0 N--CA 1.43 -1.426 0 C-N-CA 126.194 1.798 . . . . 0.0 107.165 168.639 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.69 162.7 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 CA-C-O 122.467 1.127 . . . . 0.0 113.777 -169.014 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.2 t -144.1 178.48 7.84 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 125.562 1.545 . . . . 0.0 110.055 176.424 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.46 -143.22 16.6 Favored Glycine 0 N--CA 1.429 -1.791 0 C-N-CA 124.979 1.276 . . . . 0.0 113.85 171.487 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 80.46 158.97 19.31 Favored Glycine 0 N--CA 1.429 -1.772 0 C-N-CA 124.488 1.042 . . . . 0.0 113.028 -177.638 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.6 m -63.25 -15.11 15.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.44 0 N-CA-C 116.353 1.983 . . . . 0.0 116.353 -171.744 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -83.82 -25.06 30.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 O-C-N 119.903 -1.748 . . . . 0.0 113.78 -179.933 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 66.5 p -91.64 167.92 11.86 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 121.082 -1.011 . . . . 0.0 111.2 -177.01 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.0 t -80.6 60.94 4.12 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.12 -1.613 . . . . 0.0 114.109 -176.767 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 2.8 m -101.45 176.12 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 C-N-CA 127.188 2.195 . . . . 0.0 109.496 167.9 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 21.5 mmt180 -73.69 -61.19 1.92 Allowed 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 115.293 1.59 . . . . 0.0 115.293 -176.817 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 6.2 p80 -133.78 54.14 1.97 Allowed 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 122.058 0.932 . . . . 0.0 109.896 -179.629 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 61.39 -121.43 26.17 Favored Glycine 0 N--CA 1.43 -1.71 0 O-C-N 120.803 -1.186 . . . . 0.0 113.78 -175.217 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.8 137.0 0.25 Allowed Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 124.476 1.036 . . . . 0.0 115.093 -174.994 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.6 mm -94.67 129.22 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 O-C-N 120.034 -1.862 . . . . 0.0 107.721 174.387 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -127.37 157.19 40.63 Favored 'General case' 0 N--CA 1.43 -1.444 0 O-C-N 120.314 -1.491 . . . . 0.0 109.165 -176.223 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.6 130.27 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 O-C-N 121.179 -0.95 . . . . 0.0 111.066 171.202 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 18.9 ttmt -99.66 -59.82 1.65 Allowed 'General case' 0 N--CA 1.431 -1.392 0 O-C-N 120.313 -1.492 . . . . 0.0 111.398 177.564 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.17 153.69 47.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 121.269 -0.894 . . . . 0.0 110.149 -174.947 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.428 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.1 tp -108.43 122.78 63.44 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.383 1.087 . . . . 0.0 108.917 178.364 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 26.5 mm -76.4 117.92 67.81 Favored Pre-proline 0 N--CA 1.429 -1.475 0 CA-C-O 116.244 -1.836 . . . . 0.0 112.596 -173.23 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -64.72 124.47 13.23 Favored 'Trans proline' 0 N--CA 1.433 -2.043 0 C-N-CA 123.577 2.851 . . . . 0.0 114.131 -171.726 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.262 91.7 mttt 70.15 37.47 1.66 Allowed 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 128.379 2.672 . . . . 0.0 112.473 -170.989 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.54 164.54 36.27 Favored Glycine 0 N--CA 1.43 -1.737 0 O-C-N 121.018 -1.051 . . . . 0.0 113.073 163.726 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -48.83 -63.02 1.21 Allowed 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.523 1.529 . . . . 0.0 114.68 170.415 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.82 -48.5 76.57 Favored 'General case' 0 N--CA 1.429 -1.483 0 C-N-CA 127.69 2.396 . . . . 0.0 113.738 178.543 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.428 ' HG2' HG23 ' A' ' 47' ' ' ILE . 9.6 tm-20 -43.7 -55.07 4.62 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.975 1.842 . . . . 0.0 115.975 -177.695 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 13.8 t -67.55 -28.01 67.43 Favored 'General case' 0 N--CA 1.431 -1.414 0 CA-C-N 114.472 -1.24 . . . . 0.0 113.785 -174.272 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -73.45 -65.54 0.8 Allowed 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.499 1.12 . . . . 0.0 111.559 -178.808 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.18 10.19 34.8 Favored Glycine 0 N--CA 1.43 -1.755 0 N-CA-C 116.527 1.371 . . . . 0.0 116.527 168.55 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 67.2 mtt85 -64.3 -36.2 83.33 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 118.945 1.372 . . . . 0.0 111.022 162.265 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 6.6 mt -94.78 129.45 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 C-N-CA 125.336 1.454 . . . . 0.0 108.82 177.326 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.0 170.07 16.46 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 123.81 1.767 . . . . 0.0 110.685 176.737 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 51.2 mtpt -61.6 123.88 19.14 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 125.605 1.562 . . . . 0.0 112.001 177.812 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 95.59 0.3 62.74 Favored Glycine 0 N--CA 1.43 -1.733 0 O-C-N 120.303 -1.498 . . . . 0.0 115.26 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -74.0 157.11 36.76 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 119.175 1.487 . . . . 0.0 112.339 178.089 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 21.5 ttt180 -88.14 125.81 34.8 Favored 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 125.248 1.419 . . . . 0.0 111.101 178.128 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 50.0 t -91.6 128.72 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.438 0 C-N-CA 124.223 1.009 . . . . 0.0 109.13 178.681 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -105.41 -57.4 2.04 Favored 'General case' 0 N--CA 1.431 -1.417 0 O-C-N 120.684 -1.26 . . . . 0.0 111.305 -179.305 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.95 138.0 20.32 Favored 'General case' 0 N--CA 1.429 -1.504 0 O-C-N 120.857 -1.152 . . . . 0.0 111.663 -170.825 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 48.8 t -107.45 107.43 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 176.417 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 27.1 t30 57.73 52.07 8.59 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.785 1.634 . . . . 0.0 114.311 167.832 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 96.43 -29.4 10.33 Favored Glycine 0 N--CA 1.43 -1.765 0 C-N-CA 124.95 1.262 . . . . 0.0 114.095 -176.541 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 58.1 t -97.7 118.18 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 CA-C-N 118.805 1.303 . . . . 0.0 111.235 -170.443 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 57.7 m -69.76 131.67 44.89 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.493 -1.38 . . . . 0.0 112.413 176.196 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 25.7 mt -93.36 -6.03 48.18 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 121.026 -1.046 . . . . 0.0 112.433 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -55.22 127.52 29.68 Favored 'General case' 0 N--CA 1.431 -1.405 0 C-N-CA 125.576 1.55 . . . . 0.0 114.831 -179.084 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 88.67 -10.82 70.61 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 115.888 1.115 . . . . 0.0 115.888 -178.005 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.411 ' HB1' ' HB2' ' A' ' 80' ' ' GLN . . . -72.5 178.39 4.07 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 116.989 2.218 . . . . 0.0 116.989 -177.556 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 47.1 p -92.19 171.22 9.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 120.282 -1.511 . . . . 0.0 110.835 165.678 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -54.2 -42.07 69.33 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 126.261 1.824 . . . . 0.0 112.883 168.594 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 43.5 tptt -57.54 -42.4 82.87 Favored 'General case' 0 N--CA 1.429 -1.506 0 N-CA-C 114.542 1.312 . . . . 0.0 114.542 178.364 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.411 ' HB2' ' HB1' ' A' ' 76' ' ' ALA . 4.3 mp0 -58.93 -49.43 77.87 Favored 'General case' 0 N--CA 1.43 -1.427 0 O-C-N 120.537 -1.352 . . . . 0.0 114.102 175.109 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -57.43 -44.29 84.53 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 125.441 1.497 . . . . 0.0 114.052 174.276 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 75.8 t -66.01 -45.54 90.5 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.425 0 C-N-CA 124.987 1.315 . . . . 0.0 111.886 177.278 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 92.3 mt-10 -64.43 -37.71 88.48 Favored 'General case' 0 N--CA 1.43 -1.433 0 C-N-CA 123.811 0.844 . . . . 0.0 112.586 176.602 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.8 m -63.4 -45.6 90.25 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.788 2.035 . . . . 0.0 113.018 174.204 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 84.7 mt -69.21 -21.64 63.93 Favored 'General case' 0 N--CA 1.431 -1.388 0 O-C-N 120.031 -1.668 . . . . 0.0 114.269 174.193 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -72.15 -53.34 13.0 Favored 'General case' 0 N--CA 1.431 -1.419 0 O-C-N 120.228 -1.545 . . . . 0.0 111.328 168.684 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -92.68 43.37 1.12 Allowed 'General case' 0 N--CA 1.43 -1.465 0 C-N-CA 125.946 1.698 . . . . 0.0 112.842 -174.409 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . 0.287 6.2 t -106.39 160.01 15.71 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 120.48 -1.387 . . . . 0.0 110.905 173.164 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.75 -164.8 38.79 Favored Glycine 0 N--CA 1.43 -1.753 0 C-N-CA 124.929 1.252 . . . . 0.0 113.317 -166.052 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -69.8 -49.84 48.86 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.732 -1.452 . . . . 0.0 112.66 174.095 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 59.0 t -105.96 122.38 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-O 121.907 0.86 . . . . 0.0 108.78 179.611 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -123.97 120.39 59.43 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 C-N-CA 125.568 1.547 . . . . 0.0 109.725 -163.065 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 11.8 t-160 -104.82 95.48 5.9 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 120.633 -1.292 . . . . 0.0 112.435 -175.867 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 27.1 mt -89.99 134.58 34.15 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 119.762 -1.836 . . . . 0.0 113.397 -176.922 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 66.1 tp -104.89 123.0 46.96 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.613 -1.304 . . . . 0.0 109.114 167.748 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.37 163.9 30.69 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.47 -0.769 . . . . 0.0 111.54 175.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -127.38 140.07 52.43 Favored 'General case' 0 N--CA 1.43 -1.466 0 C-N-CA 125.642 1.577 . . . . 0.0 109.629 -178.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.71 125.46 29.37 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.762 -1.211 . . . . 0.0 114.033 -170.344 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -80.39 174.33 54.94 Favored Glycine 0 N--CA 1.43 -1.732 0 C-N-CA 125.69 1.614 . . . . 0.0 115.013 177.597 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -94.72 -68.37 0.8 Allowed 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 124.909 1.284 . . . . 0.0 113.146 -168.263 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.5 m -80.17 126.27 79.7 Favored Pre-proline 0 N--CA 1.431 -1.412 0 O-C-N 120.529 -1.357 . . . . 0.0 113.663 -166.474 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo . . . . . 0 N--CA 1.434 -2.021 0 C-N-CA 122.355 2.036 . . . . 0.0 112.762 173.762 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 1.9 mmmp? . . . . . 0 N--CA 1.429 -1.476 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -74.66 179.64 5.77 Favored 'Trans proline' 0 N--CA 1.433 -2.062 0 C-N-CA 122.908 2.405 . . . . 0.0 112.287 159.451 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 108.67 37.79 2.0 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.54 -0.725 . . . . 0.0 114.409 165.513 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 19.7 t0 -77.89 150.93 34.04 Favored 'General case' 0 N--CA 1.431 -1.421 0 C-N-CA 124.947 1.299 . . . . 0.0 110.897 173.916 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 p -114.58 148.09 38.54 Favored 'General case' 0 N--CA 1.429 -1.507 0 O-C-N 120.654 -1.278 . . . . 0.0 111.22 -176.479 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -147.69 149.39 32.36 Favored 'General case' 0 N--CA 1.43 -1.471 0 CA-C-O 121.982 0.896 . . . . 0.0 108.963 178.664 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -90.82 145.11 25.04 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.409 -0.807 . . . . 0.0 109.249 160.811 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 24.0 t -120.53 94.44 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.086 1.354 . . . . 0.0 107.613 -178.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 66.2 mt-10 -90.47 95.66 10.28 Favored 'General case' 0 N--CA 1.43 -1.426 0 CA-C-O 122.929 1.347 . . . . 0.0 107.92 171.669 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 29.2 tp -123.99 138.36 54.47 Favored 'General case' 0 N--CA 1.429 -1.486 0 C-N-CA 125.315 1.446 . . . . 0.0 110.594 -164.136 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -102.62 138.59 39.33 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 120.699 -1.251 . . . . 0.0 108.658 173.857 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -69.48 145.55 52.63 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.22 1.563 . . . . 0.0 115.22 -178.283 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.6 p -100.09 102.21 13.48 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.962 -1.086 . . . . 0.0 109.157 176.192 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 8.5 t0 55.8 38.46 30.09 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 125.551 1.54 . . . . 0.0 114.166 179.314 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.48 -20.51 47.86 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.471 -1.393 . . . . 0.0 114.944 -176.699 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.2 t -93.56 137.95 32.32 Favored 'General case' 0 N--CA 1.43 -1.453 0 O-C-N 120.7 -1.47 . . . . 0.0 112.248 -173.182 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 20.3 mt -87.58 -60.66 1.91 Allowed 'General case' 0 N--CA 1.43 -1.449 0 O-C-N 121.249 -0.907 . . . . 0.0 110.306 172.21 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.6 8.93 2.69 Favored Glycine 0 N--CA 1.43 -1.765 0 O-C-N 120.365 -1.46 . . . . 0.0 113.158 175.29 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 pt -123.59 142.53 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 CA-C-N 119.325 1.563 . . . . 0.0 112.052 -176.177 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 34.3 t -116.67 139.17 50.84 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 155.486 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.4 m -111.87 169.46 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 C-N-CA 124.828 1.251 . . . . 0.0 112.293 -174.321 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.8 t -150.3 -179.22 7.02 Favored 'General case' 0 N--CA 1.429 -1.476 0 C-N-CA 126.053 1.741 . . . . 0.0 109.0 -177.999 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.65 -144.36 17.17 Favored Glycine 0 N--CA 1.43 -1.747 0 O-C-N 120.611 -1.306 . . . . 0.0 112.301 177.174 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 108.23 150.35 15.08 Favored Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 124.728 1.156 . . . . 0.0 112.937 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p -69.21 -30.22 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.469 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -174.805 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 38.2 t30 -91.93 0.38 57.48 Favored 'General case' 0 N--CA 1.429 -1.489 0 O-C-N 119.891 -1.756 . . . . 0.0 111.431 -177.409 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.523 HG22 ' H ' ' A' ' 36' ' ' SER . 26.2 m -83.55 177.5 8.4 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 126.819 2.048 . . . . 0.0 108.066 -179.999 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.523 ' H ' HG22 ' A' ' 35' ' ' THR . 19.3 m -70.48 -3.29 17.13 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 118.877 -2.389 . . . . 0.0 116.374 -176.483 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 14.1 m -78.87 123.4 35.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 CA-C-O 122.472 1.129 . . . . 0.0 110.352 172.949 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 91.4 mtt180 -72.44 -34.72 67.98 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.368 -1.458 . . . . 0.0 114.867 -170.916 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 63.6 m170 -76.79 -55.42 5.51 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.6 -1.312 . . . . 0.0 112.822 178.412 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 103.04 102.25 2.69 Favored Glycine 0 N--CA 1.431 -1.674 0 O-C-N 120.823 -1.173 . . . . 0.0 112.534 168.705 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -162.48 168.62 37.49 Favored Glycine 0 N--CA 1.43 -1.737 0 N-CA-C 108.391 -1.884 . . . . 0.0 108.391 177.089 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.99 136.61 30.55 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 124.899 1.28 . . . . 0.0 108.408 178.46 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -133.89 157.45 45.93 Favored 'General case' 0 N--CA 1.429 -1.508 0 O-C-N 121.246 -0.908 . . . . 0.0 108.869 -175.313 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.1 t -76.48 129.73 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 119.872 -1.767 . . . . 0.0 112.338 175.504 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.2 tttt -93.91 -48.88 6.07 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.375 -1.453 . . . . 0.0 112.542 -179.246 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -152.92 152.93 32.03 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 123.111 0.565 . . . . 0.0 110.572 -174.849 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -103.43 120.55 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.413 0 CA-C-O 122.841 1.305 . . . . 0.0 110.243 174.09 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 15.7 mm -76.81 127.85 83.03 Favored Pre-proline 0 N--CA 1.431 -1.402 0 C-N-CA 126.331 1.852 . . . . 0.0 113.604 -172.002 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -55.73 126.3 21.97 Favored 'Trans proline' 0 N--CA 1.433 -2.042 0 C-N-CA 122.916 2.411 . . . . 0.0 117.034 -177.869 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 10.9 mmpt? 77.22 13.58 2.01 Favored 'General case' 0 N--CA 1.431 -1.419 0 C-N-CA 128.864 2.866 . . . . 0.0 114.166 176.143 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -76.48 161.42 51.55 Favored Glycine 0 N--CA 1.43 -1.74 0 O-C-N 120.618 -1.301 . . . . 0.0 114.805 179.073 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.21 -57.67 6.34 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 126.843 2.057 . . . . 0.0 114.808 171.505 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.55 -48.53 77.09 Favored 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 128.399 2.68 . . . . 0.0 112.233 179.54 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -41.97 -63.07 0.79 Allowed 'General case' 0 N--CA 1.431 -1.415 0 C-N-CA 126.836 2.055 . . . . 0.0 114.386 173.497 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.7 m -70.22 -35.05 73.6 Favored 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.029 1.492 . . . . 0.0 115.029 -172.044 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -56.43 -68.66 0.19 Allowed 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.238 1.815 . . . . 0.0 113.213 176.536 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 112.73 6.17 23.34 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 168.575 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 30.6 mmt180 -65.94 -49.52 67.64 Favored 'General case' 0 N--CA 1.429 -1.517 0 CA-C-N 119.09 1.445 . . . . 0.0 110.461 165.046 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.85 134.01 27.91 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.506 0 C-N-CA 125.58 1.552 . . . . 0.0 110.032 177.911 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 -145.61 142.36 29.03 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 124.409 1.084 . . . . 0.0 109.889 -174.862 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.7 ttmt -43.74 116.02 0.9 Allowed 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.231 1.812 . . . . 0.0 115.739 -178.883 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 103.99 -2.95 44.53 Favored Glycine 0 N--CA 1.428 -1.834 0 O-C-N 120.652 -1.28 . . . . 0.0 115.946 179.731 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . 0.276 1.4 p30 -76.95 175.26 9.71 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 120.099 1.949 . . . . 0.0 115.549 -175.166 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -101.94 121.32 41.91 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.677 -1.264 . . . . 0.0 112.564 -175.395 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 21.5 t -88.12 114.75 27.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.447 0 C-N-CA 123.868 0.867 . . . . 0.0 110.288 179.125 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.7 mp -93.75 -43.93 8.39 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.321 -1.487 . . . . 0.0 111.17 -176.585 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.6 142.34 24.62 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.864 -1.147 . . . . 0.0 111.625 -175.256 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 80.5 t -118.12 117.67 55.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 124.02 0.928 . . . . 0.0 109.01 175.763 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 7.1 t30 62.3 37.31 14.07 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.985 2.114 . . . . 0.0 113.072 170.515 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.81 -33.23 6.67 Favored Glycine 0 N--CA 1.43 -1.75 0 C-N-CA 124.852 1.215 . . . . 0.0 113.444 -174.73 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.2 t -91.58 119.67 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.446 0 C-N-CA 124.974 1.309 . . . . 0.0 112.501 -165.292 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.9 m -65.81 130.3 42.8 Favored 'General case' 0 N--CA 1.43 -1.439 0 O-C-N 120.881 -1.137 . . . . 0.0 112.88 177.796 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 44.2 mt -90.11 62.05 5.39 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.526 -1.359 . . . . 0.0 112.46 -174.892 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -90.09 136.09 33.26 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.642 -1.286 . . . . 0.0 111.71 174.365 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 71.32 11.47 71.5 Favored Glycine 0 N--CA 1.43 -1.748 0 O-C-N 121.024 -1.047 . . . . 0.0 115.454 175.366 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.0 143.03 49.33 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -176.236 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 48.1 p -82.35 173.64 11.86 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.995 -1.066 . . . . 0.0 111.118 167.443 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -62.26 -41.65 98.64 Favored 'General case' 0 N--CA 1.43 -1.436 0 O-C-N 120.724 -1.235 . . . . 0.0 112.754 174.496 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -58.74 -47.01 86.08 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 126.069 1.748 . . . . 0.0 114.2 170.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -56.07 -47.82 77.24 Favored 'General case' 0 N--CA 1.43 -1.475 0 C-N-CA 126.524 1.93 . . . . 0.0 114.335 -176.447 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -56.83 -39.73 74.77 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 126.222 1.809 . . . . 0.0 115.025 173.192 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 79.1 t -69.01 -53.38 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 124.941 1.296 . . . . 0.0 110.862 177.947 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -59.95 -44.18 94.55 Favored 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 114.757 1.391 . . . . 0.0 114.757 -176.815 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 2.7 m -57.67 -40.9 80.44 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.013 2.525 . . . . 0.0 114.545 170.656 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 28.3 mt -68.77 -42.34 77.59 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 119.652 -1.905 . . . . 0.0 113.805 170.956 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 85.8 mmt-85 -60.7 -39.24 87.78 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.698 -1.251 . . . . 0.0 113.501 178.652 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 34.5 t30 -85.93 48.49 1.61 Allowed 'General case' 0 N--CA 1.43 -1.464 0 O-C-N 120.479 -1.388 . . . . 0.0 113.156 178.873 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.435 ' HB ' HG22 ' A' ' 92' ' ' VAL . 21.9 p -106.86 158.03 17.31 Favored 'General case' 0 N--CA 1.43 -1.461 0 C-N-CA 126.281 1.832 . . . . 0.0 109.657 173.293 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -98.75 -141.1 11.9 Favored Glycine 0 N--CA 1.429 -1.768 0 O-C-N 121.12 -0.988 . . . . 0.0 112.821 -176.383 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -69.09 -65.26 0.73 Allowed 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 121.058 -1.26 . . . . 0.0 113.251 175.727 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 12.2 p -98.66 133.66 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-O 123.14 1.448 . . . . 0.0 110.173 176.523 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.435 HG22 ' HB ' ' A' ' 88' ' ' THR . 99.0 t -124.62 128.78 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.474 0 C-N-CA 128.297 2.639 . . . . 0.0 108.745 -162.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -108.9 93.93 4.78 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 120.752 -1.218 . . . . 0.0 112.578 -176.537 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 19.9 mt -95.27 162.14 13.81 Favored 'General case' 0 N--CA 1.431 -1.42 0 O-C-N 119.538 -1.976 . . . . 0.0 112.411 178.002 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 1.9 tt -130.27 133.04 46.2 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.825 -1.172 . . . . 0.0 110.641 165.917 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -142.04 162.56 35.18 Favored 'General case' 0 N--CA 1.43 -1.428 0 N-CA-C 113.609 0.966 . . . . 0.0 113.609 178.527 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -113.54 138.58 49.94 Favored 'General case' 0 N--CA 1.43 -1.439 0 C-N-CA 125.712 1.605 . . . . 0.0 107.647 172.249 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.2 tppp? -75.76 134.65 40.4 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 122.216 1.007 . . . . 0.0 111.214 -173.209 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -72.09 149.52 44.41 Favored Glycine 0 N--CA 1.431 -1.691 0 C-N-CA 124.586 1.089 . . . . 0.0 114.638 -177.114 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 23.7 pt20 -81.77 179.04 7.98 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 115.072 1.508 . . . . 0.0 115.072 -173.401 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.7 m -84.31 148.48 52.87 Favored Pre-proline 0 N--CA 1.43 -1.457 0 O-C-N 120.393 -1.442 . . . . 0.0 111.123 176.557 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo . . . . . 0 C--N 1.299 -2.028 0 C-N-CA 122.153 1.902 . . . . 0.0 112.422 175.827 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 74.8 mttt . . . . . 0 N--CA 1.431 -1.424 0 CA-C-O 115.376 -2.25 . . . . 0.0 114.421 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -76.11 179.51 6.25 Favored 'Trans proline' 0 C--N 1.3 -2.003 0 CA-C-N 127.29 3.639 . . . . 0.0 111.569 155.961 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.71 -119.88 4.09 Favored Glycine 0 N--CA 1.431 -1.653 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -165.225 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -99.86 -63.91 1.09 Allowed 'General case' 0 N--CA 1.43 -1.439 0 CA-C-N 118.492 1.146 . . . . 0.0 113.695 -174.134 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.0 p -125.98 155.42 41.42 Favored 'General case' 0 N--CA 1.431 -1.384 0 O-C-N 120.126 -1.609 . . . . 0.0 113.011 -179.107 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.475 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 12.4 p90 -145.52 142.42 29.19 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 122.943 1.354 . . . . 0.0 109.182 170.324 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -95.45 126.59 40.85 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 125.413 1.485 . . . . 0.0 107.955 171.22 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.3 t -118.49 117.77 55.71 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 124.295 1.038 . . . . 0.0 108.488 -174.722 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -100.79 88.08 3.49 Favored 'General case' 0 N--CA 1.432 -1.369 0 O-C-N 120.62 -1.3 . . . . 0.0 108.703 168.976 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 63.2 tp -95.7 137.69 34.4 Favored 'General case' 0 N--CA 1.43 -1.471 0 C-N-CA 124.593 1.157 . . . . 0.0 110.214 -174.226 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.32 128.95 47.25 Favored 'General case' 0 N--CA 1.429 -1.505 0 O-C-N 120.185 -1.572 . . . . 0.0 108.566 172.012 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 38.9 mtmt -70.42 136.43 49.55 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 121.344 -0.848 . . . . 0.0 113.123 178.416 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 13.0 p -107.2 121.03 43.71 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 174.376 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 18.9 t70 55.17 49.0 18.27 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.982 1.713 . . . . 0.0 113.753 -176.019 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.21 -9.64 6.94 Favored Glycine 0 N--CA 1.429 -1.789 0 N-CA-C 117.739 1.856 . . . . 0.0 117.739 174.315 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.4 t -121.43 156.18 33.27 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 119.207 1.503 . . . . 0.0 111.131 -168.531 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 16.4 mt -93.91 -60.4 1.76 Allowed 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.54 1.136 . . . . 0.0 110.925 -177.268 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.03 38.78 0.48 Allowed Glycine 0 N--CA 1.431 -1.657 0 O-C-N 119.373 -2.079 . . . . 0.0 110.54 174.588 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.3 pt -128.93 141.12 47.45 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 CA-C-O 121.871 0.843 . . . . 0.0 112.146 -163.208 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 29.7 t -117.77 117.36 29.1 Favored 'General case' 0 N--CA 1.429 -1.483 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 166.33 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.8 m -108.47 160.64 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 C-N-CA 124.529 1.132 . . . . 0.0 111.158 179.398 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 10.0 t -150.61 155.63 39.77 Favored 'General case' 0 N--CA 1.43 -1.435 0 O-C-N 121.121 -0.987 . . . . 0.0 111.621 -178.527 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 124.03 -130.13 7.48 Favored Glycine 0 N--CA 1.43 -1.75 0 O-C-N 121.129 -0.982 . . . . 0.0 113.219 168.8 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 124.01 -148.81 16.83 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 -179.182 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.6 t -125.17 -44.95 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.429 -1.496 0 CA-C-O 123.451 1.596 . . . . 0.0 107.332 171.418 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.3 p-10 -74.21 -14.85 61.0 Favored 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 126.85 2.06 . . . . 0.0 115.464 -171.239 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 38.1 p -84.97 -119.51 0.03 OUTLIER 'General case' 0 N--CA 1.43 -1.43 0 C-N-CA 126.466 1.907 . . . . 0.0 112.068 -173.487 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 40.1 p -91.49 -38.5 12.5 Favored 'General case' 0 N--CA 1.43 -1.456 0 O-C-N 119.574 -1.954 . . . . 0.0 111.52 177.057 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 5.6 p -81.46 81.24 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-O 123.945 1.831 . . . . 0.0 112.03 -177.853 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -62.17 -26.94 68.62 Favored 'General case' 0 N--CA 1.429 -1.485 0 C-N-CA 125.826 1.65 . . . . 0.0 114.757 -175.697 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 17.5 t-80 -66.33 -37.16 84.71 Favored 'General case' 0 N--CA 1.43 -1.468 0 O-C-N 120.677 -1.264 . . . . 0.0 113.591 176.506 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.4 106.32 3.09 Favored Glycine 0 N--CA 1.429 -1.789 0 C-N-CA 124.198 0.904 . . . . 0.0 113.139 179.579 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -166.52 128.42 1.75 Allowed Glycine 0 N--CA 1.43 -1.759 0 O-C-N 122.002 -0.705 . . . . 0.0 113.887 173.783 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.7 mm -95.99 119.76 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 C-N-CA 125.851 1.66 . . . . 0.0 107.526 171.476 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -123.06 154.4 38.58 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 121.145 -0.972 . . . . 0.0 110.303 -174.528 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 22.6 t -76.8 119.38 25.03 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 124.387 1.075 . . . . 0.0 110.555 169.919 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 48.9 tttt -88.5 -46.83 8.79 Favored 'General case' 0 N--CA 1.429 -1.493 0 C-N-CA 124.858 1.263 . . . . 0.0 110.38 -176.471 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -158.75 161.39 37.01 Favored 'General case' 0 N--CA 1.431 -1.422 0 C-N-CA 123.316 0.647 . . . . 0.0 110.37 177.599 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.3 tp -116.53 127.08 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 C-N-CA 124.469 1.107 . . . . 0.0 110.303 176.329 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 2.1 mp -77.43 122.28 85.75 Favored Pre-proline 0 N--CA 1.43 -1.47 0 N-CA-C 117.23 2.307 . . . . 0.0 117.23 -169.971 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_exo -55.29 122.13 11.16 Favored 'Trans proline' 0 C--N 1.299 -2.073 0 C-N-CA 123.551 2.834 . . . . 0.0 116.6 179.952 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.312 17.6 mmtt 80.89 18.82 0.49 Allowed 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 129.253 3.021 . . . . 0.0 113.488 -177.682 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.76 156.8 33.46 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.127 -1.608 . . . . 0.0 111.942 172.877 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -47.61 -56.28 7.53 Favored 'General case' 0 N--CA 1.429 -1.491 0 C-N-CA 125.949 1.699 . . . . 0.0 114.468 171.293 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.31 -51.14 67.28 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 128.308 2.643 . . . . 0.0 112.832 178.059 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.9 tm-20 -44.92 -59.65 2.46 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 172.441 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 40.3 t -68.1 -30.36 69.51 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.832 1.253 . . . . 0.0 113.436 -174.078 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -61.36 -55.61 29.62 Favored 'General case' 0 N--CA 1.43 -1.429 0 C-N-CA 124.857 1.263 . . . . 0.0 113.869 -177.141 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 110.59 1.43 29.18 Favored Glycine 0 N--CA 1.429 -1.768 0 N-CA-C 116.516 1.367 . . . . 0.0 116.516 162.108 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 17.2 mmp_? -74.67 -54.6 7.09 Favored 'General case' 0 N--CA 1.431 -1.412 0 O-C-N 120.5 -1.588 . . . . 0.0 110.367 164.475 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 3.0 mt -78.25 128.04 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 125.339 1.456 . . . . 0.0 112.648 -173.607 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -137.01 172.64 12.71 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-O 124.14 1.924 . . . . 0.0 112.629 177.298 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.1 tttt -56.14 124.04 16.51 Favored 'General case' 0 N--CA 1.43 -1.436 0 C-N-CA 126.031 1.732 . . . . 0.0 113.822 172.136 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 94.88 4.2 61.79 Favored Glycine 0 N--CA 1.43 -1.735 0 O-C-N 121.425 -0.797 . . . . 0.0 113.903 178.759 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -79.11 162.31 25.91 Favored 'General case' 0 N--CA 1.429 -1.498 0 CA-C-N 119.054 1.427 . . . . 0.0 111.794 174.406 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.4 ttt180 -120.57 123.46 42.92 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.233 -1.542 . . . . 0.0 111.02 -172.978 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 6.6 t -83.06 125.48 40.05 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 O-C-N 120.278 -1.514 . . . . 0.0 111.83 -171.872 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 80.5 mt -103.3 -44.57 5.13 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.743 -1.223 . . . . 0.0 112.324 -177.005 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.4 ' HB3' ' HB3' ' A' ' 95' ' ' LEU . . . -149.97 140.9 22.85 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.504 -1.373 . . . . 0.0 112.329 -177.874 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 21.6 t -112.75 115.49 49.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 174.72 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 26.2 t30 57.86 41.97 23.92 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 126.641 1.976 . . . . 0.0 114.993 170.606 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.45 -25.62 26.42 Favored Glycine 0 N--CA 1.431 -1.655 0 O-C-N 120.964 -1.085 . . . . 0.0 113.563 -177.008 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 29.9 t -94.06 112.25 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 O-C-N 120.926 -1.338 . . . . 0.0 110.412 -172.947 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . 0.25 81.1 p -76.36 140.66 41.51 Favored 'General case' 0 N--CA 1.429 -1.487 0 O-C-N 120.212 -1.555 . . . . 0.0 112.998 176.851 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 97.0 mt -85.44 41.68 0.91 Allowed 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 124.426 1.09 . . . . 0.0 112.29 -168.9 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -72.72 121.53 19.99 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.101 -1.624 . . . . 0.0 112.047 -178.413 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 70.37 11.58 68.17 Favored Glycine 0 N--CA 1.429 -1.821 0 C-N-CA 125.191 1.377 . . . . 0.0 115.764 179.374 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.94 143.57 47.62 Favored 'General case' 0 N--CA 1.43 -1.44 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -178.138 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.1 p -91.82 178.81 5.8 Favored 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 125.644 1.578 . . . . 0.0 111.728 174.34 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 30.8 t-80 -57.3 -52.73 64.16 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 115.873 1.805 . . . . 0.0 115.873 -169.6 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.6 -40.66 79.57 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.345 1.609 . . . . 0.0 115.345 178.124 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 13.4 mp0 -56.92 -51.33 69.54 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 126.792 2.037 . . . . 0.0 113.209 -172.229 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.49 -39.09 79.06 Favored 'General case' 0 N--CA 1.429 -1.505 0 C-N-CA 126.556 1.942 . . . . 0.0 113.823 175.453 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 87.7 t -67.55 -53.04 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 C-N-CA 125.044 1.337 . . . . 0.0 110.727 177.467 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -61.69 -38.69 88.76 Favored 'General case' 0 N--CA 1.43 -1.434 0 O-C-N 121.009 -1.057 . . . . 0.0 113.78 -178.609 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 39.5 m -66.53 -40.42 89.11 Favored 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 127.032 2.133 . . . . 0.0 112.682 177.213 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.0 mt -66.49 -42.24 87.73 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.431 -1.418 . . . . 0.0 113.231 171.139 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -68.2 -42.76 79.39 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.523 -1.361 . . . . 0.0 114.605 179.846 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 38.9 t-20 -86.32 57.2 4.35 Favored 'General case' 0 N--CA 1.43 -1.455 0 CA-C-O 123.036 1.398 . . . . 0.0 111.712 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -98.12 163.59 12.68 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 128.017 2.527 . . . . 0.0 109.617 175.115 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.46 -160.11 33.22 Favored Glycine 0 N--CA 1.43 -1.759 0 C-N-CA 124.422 1.011 . . . . 0.0 110.923 168.931 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 60.1 tt0 -68.74 -52.07 34.53 Favored 'General case' 0 N--CA 1.43 -1.465 0 O-C-N 120.75 -1.441 . . . . 0.0 112.998 -174.234 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 48.6 t -103.81 119.9 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 C-N-CA 124.894 1.278 . . . . 0.0 109.63 177.008 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 84.5 t -112.18 110.26 31.56 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.419 0 C-N-CA 128.066 2.547 . . . . 0.0 110.153 -167.216 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 20.1 t-160 -92.8 96.7 10.3 Favored 'General case' 0 N--CA 1.429 -1.488 0 O-C-N 120.7 -1.25 . . . . 0.0 112.779 -178.205 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 43.3 mt -89.11 156.71 18.65 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 119.217 -2.177 . . . . 0.0 112.677 175.773 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . 0.4 ' HB3' ' HB3' ' A' ' 67' ' ' ALA . 57.9 tp -127.01 129.41 48.02 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 157.611 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.475 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 3.0 pp -150.86 167.34 27.8 Favored 'General case' 0 N--CA 1.43 -1.462 0 O-C-N 120.715 -1.24 . . . . 0.0 111.745 177.784 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -108.89 123.16 48.63 Favored 'General case' 0 N--CA 1.43 -1.445 0 C-N-CA 125.17 1.388 . . . . 0.0 110.345 -173.541 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.1 tptm -78.47 139.02 38.73 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 125.365 1.466 . . . . 0.0 111.37 -178.681 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -93.41 96.03 2.05 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 108.209 -1.956 . . . . 0.0 108.209 163.236 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 28.2 pt20 -65.62 -31.84 73.09 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 116.266 1.951 . . . . 0.0 116.266 -165.44 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 4.6 m -104.31 154.15 38.51 Favored Pre-proline 0 N--CA 1.43 -1.473 0 C-N-CA 125.803 1.641 . . . . 0.0 110.283 176.089 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo . . . . . 0 N--CA 1.434 -2.004 0 C-N-CA 122.746 2.298 . . . . 0.0 112.712 169.892 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 8.9 mtmp? . . . . . 0 N--CA 1.43 -1.432 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -74.95 178.88 6.65 Favored 'Trans proline' 0 N--CA 1.434 -2.006 0 C-N-CA 122.503 2.135 . . . . 0.0 111.992 165.125 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 112.62 38.24 1.34 Allowed Glycine 0 N--CA 1.43 -1.707 0 C-N-CA 124.085 0.85 . . . . 0.0 111.838 179.175 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -95.66 157.57 15.84 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 124.246 1.018 . . . . 0.0 109.986 177.799 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 p -96.96 149.24 22.13 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.689 -1.257 . . . . 0.0 111.256 177.102 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -147.8 143.52 27.55 Favored 'General case' 0 N--CA 1.43 -1.458 0 CA-C-O 122.923 1.344 . . . . 0.0 109.186 -179.087 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 34.6 mp0 -102.53 129.53 49.09 Favored 'General case' 0 N--CA 1.43 -1.442 0 C-N-CA 126.536 1.934 . . . . 0.0 108.12 179.12 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 40.7 t -125.0 97.69 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 O-C-N 120.825 -1.172 . . . . 0.0 109.753 -170.429 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -97.81 77.24 2.5 Favored 'General case' 0 N--CA 1.431 -1.399 0 O-C-N 119.938 -1.726 . . . . 0.0 108.899 173.906 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.4 130.47 52.75 Favored 'General case' 0 N--CA 1.43 -1.434 0 C-N-CA 125.372 1.469 . . . . 0.0 109.992 -170.159 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -95.7 154.79 17.04 Favored 'General case' 0 N--CA 1.432 -1.374 0 C-N-CA 127.074 2.15 . . . . 0.0 112.336 176.656 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 84.8 mttt -69.12 152.03 45.66 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 115.389 1.625 . . . . 0.0 115.389 -175.484 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.2 p -98.77 100.48 11.69 Favored 'General case' 0 N--CA 1.429 -1.476 0 O-C-N 120.855 -1.153 . . . . 0.0 108.689 171.114 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.3 t0 52.41 52.99 13.08 Favored 'General case' 0 N--CA 1.431 -1.41 0 C-N-CA 125.636 1.574 . . . . 0.0 113.798 176.19 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.14 -27.32 10.48 Favored Glycine 0 N--CA 1.429 -1.779 0 O-C-N 120.859 -1.151 . . . . 0.0 115.71 -176.122 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.0 m -98.47 128.18 44.72 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-N 119.64 1.72 . . . . 0.0 113.106 -169.849 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 15.6 tp -84.63 -56.3 3.67 Favored 'General case' 0 N--CA 1.43 -1.429 0 O-C-N 120.487 -1.383 . . . . 0.0 109.537 175.717 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.93 28.76 0.85 Allowed Glycine 0 N--CA 1.43 -1.764 0 C-N-CA 125.205 1.383 . . . . 0.0 113.249 168.091 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.1 tt -147.19 143.94 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.393 0 CA-C-N 119.619 1.709 . . . . 0.0 112.645 -166.26 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 20.6 t -123.76 138.21 54.55 Favored 'General case' 0 N--CA 1.429 -1.478 0 C-N-CA 125.041 1.336 . . . . 0.0 108.889 165.106 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 m -113.74 163.28 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 C-N-CA 126.153 1.781 . . . . 0.0 112.313 -177.308 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.3 t -145.35 178.15 8.31 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 126.917 2.087 . . . . 0.0 109.556 -179.255 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.97 -145.19 16.22 Favored Glycine 0 N--CA 1.431 -1.669 0 O-C-N 120.562 -1.336 . . . . 0.0 114.65 173.978 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.09 156.51 31.33 Favored Glycine 0 N--CA 1.429 -1.786 0 C-N-CA 125.539 1.542 . . . . 0.0 114.622 176.156 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 42.8 t -48.68 -47.05 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -178.586 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -88.94 18.08 5.16 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 119.791 -1.818 . . . . 0.0 112.306 -177.38 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 40.5 m -110.53 148.82 31.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 169.592 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.3 m -83.72 56.15 3.52 Favored 'General case' 0 N--CA 1.431 -1.422 0 O-C-N 119.731 -1.856 . . . . 0.0 111.974 -176.317 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.3 p -99.37 153.2 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 C-N-CA 127.488 2.315 . . . . 0.0 108.043 174.173 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 5.4 tpt180 -56.72 116.97 3.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 C-N-CA 125.594 1.558 . . . . 0.0 113.57 -179.609 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 32.4 m80 70.18 -58.15 0.55 Allowed 'General case' 0 N--CA 1.43 -1.444 0 C-N-CA 127.429 2.292 . . . . 0.0 115.561 -174.188 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 142.5 41.22 0.06 OUTLIER Glycine 0 N--CA 1.43 -1.729 0 C-N-CA 124.62 1.105 . . . . 0.0 113.794 178.773 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.89 161.52 28.19 Favored Glycine 0 N--CA 1.431 -1.679 0 O-C-N 120.681 -1.481 . . . . 0.0 114.534 -173.721 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.9 mm -102.91 125.18 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 C-N-CA 124.932 1.293 . . . . 0.0 108.255 179.884 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -128.42 155.33 44.93 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.928 -1.107 . . . . 0.0 111.341 -170.724 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.41 125.83 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 O-C-N 120.358 -1.464 . . . . 0.0 111.8 173.452 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 27.6 ttmt -89.02 -55.6 3.62 Favored 'General case' 0 N--CA 1.43 -1.474 0 C-N-CA 125.005 1.322 . . . . 0.0 110.115 177.203 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.73 150.09 30.61 Favored 'General case' 0 N--CA 1.429 -1.479 0 O-C-N 121.502 -0.749 . . . . 0.0 110.607 -171.017 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.415 HG23 ' CG ' ' A' ' 54' ' ' GLU . 1.2 tp -106.89 123.66 62.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 CA-C-O 122.406 1.098 . . . . 0.0 108.306 172.373 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 21.3 mm -77.49 121.92 85.15 Favored Pre-proline 0 CA--C 1.489 -1.395 0 CA-C-O 115.755 -2.069 . . . . 0.0 114.346 -172.143 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_exo -57.55 115.01 2.2 Favored 'Trans proline' 0 C--N 1.3 -1.996 0 C-N-CA 123.866 3.044 . . . . 0.0 117.151 -174.153 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . 0.382 26.7 mtpp 71.07 41.81 0.78 Allowed 'General case' 0 N--CA 1.429 -1.479 0 C-N-CA 128.157 2.583 . . . . 0.0 114.913 -172.813 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -84.9 168.21 42.99 Favored Glycine 0 N--CA 1.431 -1.692 0 O-C-N 120.167 -1.583 . . . . 0.0 112.177 153.294 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -51.14 -60.02 3.55 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 126.23 1.812 . . . . 0.0 114.844 165.576 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.83 -42.71 97.56 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 127.31 2.244 . . . . 0.0 112.904 -178.026 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.415 ' CG ' HG23 ' A' ' 47' ' ' ILE . 4.8 tm-20 -47.91 -61.98 1.69 Allowed 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 115.833 1.79 . . . . 0.0 115.833 171.376 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.5 t -68.03 -31.25 70.78 Favored 'General case' 0 N--CA 1.43 -1.435 0 C-N-CA 124.759 1.224 . . . . 0.0 112.515 -173.168 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -64.41 -65.94 0.61 Allowed 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 120.889 -1.132 . . . . 0.0 111.201 171.548 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 92.77 20.6 33.56 Favored Glycine 0 N--CA 1.43 -1.736 0 O-C-N 119.228 -2.17 . . . . 0.0 114.421 162.582 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -63.01 -44.37 96.19 Favored 'General case' 0 N--CA 1.429 -1.509 0 O-C-N 121.341 -1.093 . . . . 0.0 109.866 157.442 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 52.0 mt -92.57 131.81 38.6 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 C-N-CA 126.233 1.813 . . . . 0.0 110.495 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . 0.638 ' CG ' ' H ' ' A' ' 61' ' ' LYS . 6.9 t-80 -145.24 -169.99 3.33 Favored 'General case' 0 N--CA 1.43 -1.457 0 CA-C-O 123.172 1.463 . . . . 0.0 112.727 167.828 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.638 ' H ' ' CG ' ' A' ' 60' ' ' HIS . 40.4 ttpt -61.99 122.83 16.45 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 126.217 1.807 . . . . 0.0 113.378 -176.551 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 101.83 -4.74 53.32 Favored Glycine 0 N--CA 1.431 -1.691 0 O-C-N 121.384 -0.823 . . . . 0.0 114.073 179.725 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -74.66 161.61 29.51 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 118.925 1.363 . . . . 0.0 112.868 -177.28 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -122.09 121.3 36.63 Favored 'General case' 0 N--CA 1.429 -1.481 0 O-C-N 120.771 -1.205 . . . . 0.0 111.047 -165.194 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 8.4 t -89.35 125.73 42.34 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.42 0 O-C-N 120.78 -1.2 . . . . 0.0 111.772 -169.103 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.8 mp -102.27 -44.57 5.37 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 121.113 -0.992 . . . . 0.0 111.466 -177.231 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.17 139.36 21.21 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 120.681 -1.262 . . . . 0.0 111.67 -178.079 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 60.7 t -114.34 117.96 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 CA-C-O 122.214 1.006 . . . . 0.0 109.877 177.729 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 19.3 t30 62.18 29.05 17.41 Favored 'General case' 0 N--CA 1.43 -1.427 0 C-N-CA 128.274 2.63 . . . . 0.0 114.24 168.808 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.01 -17.99 40.53 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 125.422 1.487 . . . . 0.0 113.58 -177.386 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 42.3 t -101.78 123.78 55.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 O-C-N 120.854 -1.38 . . . . 0.0 110.401 -172.97 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 23.1 m -71.27 138.15 49.16 Favored 'General case' 0 N--CA 1.43 -1.474 0 O-C-N 120.105 -1.622 . . . . 0.0 112.825 179.457 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 89.2 mt -88.41 62.54 6.67 Favored 'General case' 0 N--CA 1.43 -1.46 0 O-C-N 120.286 -1.509 . . . . 0.0 111.067 179.194 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -89.62 118.12 29.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 O-C-N 120.35 -1.469 . . . . 0.0 112.039 -178.18 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 73.34 6.72 70.65 Favored Glycine 0 N--CA 1.429 -1.814 0 C-N-CA 125.121 1.343 . . . . 0.0 115.239 177.808 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.67 150.62 44.4 Favored 'General case' 0 N--CA 1.429 -1.485 0 N-CA-C 116.157 1.91 . . . . 0.0 116.157 -172.557 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 55.9 p -88.77 174.15 8.16 Favored 'General case' 0 N--CA 1.431 -1.424 0 C-N-CA 126.556 1.942 . . . . 0.0 111.235 175.968 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 62.9 t-80 -58.84 -48.58 80.84 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.646 -1.284 . . . . 0.0 113.238 177.319 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 50.6 tttp -53.55 -46.93 70.41 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.691 1.597 . . . . 0.0 114.21 176.572 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -54.89 -49.93 69.99 Favored 'General case' 0 N--CA 1.429 -1.504 0 C-N-CA 125.57 1.548 . . . . 0.0 113.633 -179.059 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -66.25 -38.79 88.68 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 176.346 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 55.8 t -67.71 -51.16 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 O-C-N 120.434 -1.416 . . . . 0.0 111.18 -179.058 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -33.01 74.72 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 124.35 1.06 . . . . 0.0 112.929 179.799 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 64.0 m -65.31 -49.65 68.66 Favored 'General case' 0 N--CA 1.43 -1.449 0 C-N-CA 126.459 1.904 . . . . 0.0 112.671 171.174 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 43.8 mt -62.91 -32.48 73.77 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.168 -1.583 . . . . 0.0 114.145 174.427 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -65.07 -45.29 85.9 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.383 -1.448 . . . . 0.0 112.925 168.658 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 16.2 t30 -82.86 45.71 1.02 Allowed 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.218 -1.551 . . . . 0.0 113.755 -179.143 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 p -100.94 160.67 14.17 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 126.819 2.048 . . . . 0.0 109.251 175.485 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -91.71 -142.37 10.7 Favored Glycine 0 N--CA 1.429 -1.814 0 O-C-N 120.561 -1.337 . . . . 0.0 112.376 172.919 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -71.21 -59.86 2.54 Favored 'General case' 0 N--CA 1.431 -1.396 0 C-N-CA 126.294 1.838 . . . . 0.0 111.34 172.319 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 11.0 p -94.46 134.16 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 C-N-CA 125.078 1.351 . . . . 0.0 111.465 -179.868 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 87.5 t -125.65 123.23 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.416 0 O-C-N 120.857 -1.152 . . . . 0.0 109.986 -169.685 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 22.9 m170 -103.61 89.79 3.46 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.122 -1.611 . . . . 0.0 114.204 -176.035 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 21.7 mt -89.0 155.91 19.19 Favored 'General case' 0 N--CA 1.43 -1.463 0 O-C-N 118.665 -2.522 . . . . 0.0 112.934 179.674 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.7 tt -129.98 128.28 41.73 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 161.297 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -154.04 170.69 20.51 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.892 -1.13 . . . . 0.0 112.934 -174.963 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -119.23 144.3 46.82 Favored 'General case' 0 N--CA 1.43 -1.467 0 C-N-CA 125.815 1.646 . . . . 0.0 110.461 -178.691 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 tppp? -75.31 140.78 43.33 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 120.626 -1.297 . . . . 0.0 111.132 174.977 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -66.23 121.1 17.39 Favored Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 125.353 1.454 . . . . 0.0 114.302 176.534 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -83.42 178.56 7.98 Favored 'General case' 0 N--CA 1.43 -1.433 0 O-C-N 121.262 -1.14 . . . . 0.0 113.661 -177.349 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 2.9 m -98.12 114.03 64.63 Favored Pre-proline 0 N--CA 1.429 -1.491 0 O-C-N 120.821 -1.174 . . . . 0.0 110.272 175.469 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo . . . . . 0 C--N 1.3 -1.994 0 CA-C-N 123.431 2.261 . . . . 0.0 114.428 178.277 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.429 -1.494 0 CA-C-O 118.75 -0.643 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -81.06 -179.91 5.44 Favored 'Trans proline' 0 C--N 1.299 -2.035 0 C-N-CA 122.681 2.254 . . . . 0.0 111.906 174.597 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 92.65 23.04 27.05 Favored Glycine 0 N--CA 1.43 -1.707 0 N-CA-C 115.54 0.976 . . . . 0.0 115.54 174.998 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -91.77 157.41 16.92 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 118.741 1.271 . . . . 0.0 110.346 174.155 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 33.5 p -108.04 155.3 20.52 Favored 'General case' 0 N--CA 1.43 -1.452 0 C-N-CA 124.76 1.224 . . . . 0.0 112.855 -177.933 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -144.83 143.31 30.56 Favored 'General case' 0 N--CA 1.429 -1.488 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 174.492 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -93.5 137.89 32.33 Favored 'General case' 0 N--CA 1.43 -1.435 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 168.114 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.421 ' HB ' ' HB2' ' A' ' 94' ' ' LEU . 26.4 t -126.07 99.53 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -175.407 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 -99.39 89.79 4.31 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-O 123.049 1.404 . . . . 0.0 109.046 176.527 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 58.0 tp -118.11 141.14 48.79 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 125.983 1.713 . . . . 0.0 110.844 -160.499 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -103.59 136.85 42.53 Favored 'General case' 0 N--CA 1.43 -1.442 0 O-C-N 120.509 -1.37 . . . . 0.0 111.057 175.916 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -66.84 161.46 23.81 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 117.035 2.235 . . . . 0.0 117.035 -173.267 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.5 p -113.2 99.4 7.79 Favored 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 126.532 1.933 . . . . 0.0 109.333 174.675 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.9 t70 50.14 49.91 19.57 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 125.726 1.61 . . . . 0.0 114.92 171.643 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.05 -18.95 55.72 Favored Glycine 0 N--CA 1.431 -1.682 0 O-C-N 120.05 -1.656 . . . . 0.0 116.345 179.873 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.7 p -113.16 161.23 17.38 Favored 'General case' 0 N--CA 1.43 -1.464 0 CA-C-N 119.312 1.556 . . . . 0.0 113.239 -177.079 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 35.1 mt -97.05 -54.97 3.01 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 166.508 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.22 50.34 0.34 Allowed Glycine 0 N--CA 1.43 -1.718 0 O-C-N 120.005 -1.684 . . . . 0.0 110.438 171.722 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 11.2 tt -146.13 142.83 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.477 0 CA-C-O 122.618 1.199 . . . . 0.0 109.751 -174.147 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 32.0 t -111.17 129.77 55.84 Favored 'General case' 0 N--CA 1.43 -1.462 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 168.571 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 16.7 m -111.07 165.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.485 0 C-N-CA 124.642 1.177 . . . . 0.0 110.547 -178.794 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.5 t -151.19 170.14 20.19 Favored 'General case' 0 N--CA 1.429 -1.484 0 O-C-N 120.768 -1.207 . . . . 0.0 109.865 177.996 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 97.72 -154.68 20.35 Favored Glycine 0 N--CA 1.431 -1.696 0 O-C-N 121.337 -0.852 . . . . 0.0 112.73 178.069 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.63 147.85 23.28 Favored Glycine 0 N--CA 1.43 -1.763 0 O-C-N 121.698 -0.883 . . . . 0.0 113.008 -178.068 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m -63.05 -15.9 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.421 0 N-CA-C 116.728 2.122 . . . . 0.0 116.728 -167.678 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -80.48 -23.26 40.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.35 -1.469 . . . . 0.0 113.638 -179.909 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.1 p -81.27 -136.12 0.03 OUTLIER 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 124.618 1.167 . . . . 0.0 113.481 -164.697 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 57.9 m -77.09 -39.53 49.32 Favored 'General case' 0 N--CA 1.43 -1.437 0 O-C-N 119.086 -2.259 . . . . 0.0 110.96 174.642 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 7.7 p -78.15 123.99 35.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 C-N-CA 124.511 1.124 . . . . 0.0 112.312 -175.523 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -67.75 -60.53 2.46 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.288 -1.508 . . . . 0.0 113.257 -177.94 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 2.8 p80 -88.97 80.46 7.06 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.372 -1.455 . . . . 0.0 109.58 169.06 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -82.86 115.54 4.04 Favored Glycine 0 N--CA 1.429 -1.779 0 CA-C-O 122.364 0.98 . . . . 0.0 114.868 -173.286 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.08 163.98 34.95 Favored Glycine 0 N--CA 1.431 -1.689 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 157.875 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.6 mm -99.97 128.51 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.424 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 177.338 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -127.12 159.06 35.35 Favored 'General case' 0 N--CA 1.431 -1.41 0 O-C-N 120.795 -1.191 . . . . 0.0 109.684 -173.674 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -76.26 125.53 36.07 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.482 0 O-C-N 121.089 -1.007 . . . . 0.0 111.897 176.493 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -91.9 -49.11 6.41 Favored 'General case' 0 N--CA 1.43 -1.437 0 C-N-CA 125.073 1.349 . . . . 0.0 110.381 177.879 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -159.12 157.76 31.59 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 120.412 -1.43 . . . . 0.0 111.33 177.602 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 1.1 tp -111.39 121.38 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.656 1.217 . . . . 0.0 110.056 174.404 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 22.0 mm -77.47 133.28 67.66 Favored Pre-proline 0 N--CA 1.429 -1.477 0 C-N-CA 127.527 2.331 . . . . 0.0 115.671 -165.901 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -54.07 118.19 4.71 Favored 'Trans proline' 0 N--CA 1.434 -1.973 0 C-N-CA 123.864 3.043 . . . . 0.0 118.335 -178.704 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 61.85 40.74 12.37 Favored 'General case' 0 N--CA 1.429 -1.48 0 C-N-CA 128.949 2.9 . . . . 0.0 113.646 -177.274 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -86.29 164.23 36.45 Favored Glycine 0 N--CA 1.431 -1.686 0 O-C-N 120.114 -1.616 . . . . 0.0 112.86 162.785 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.62 -57.37 7.29 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 126.359 1.864 . . . . 0.0 114.87 164.472 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.6 -43.32 97.26 Favored 'General case' 0 N--CA 1.429 -1.49 0 C-N-CA 127.341 2.256 . . . . 0.0 112.517 -179.03 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -48.96 -62.38 1.56 Allowed 'General case' 0 N--CA 1.43 -1.455 0 N-CA-C 115.603 1.705 . . . . 0.0 115.603 167.143 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.4 t -69.52 -23.21 63.57 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 125.244 1.418 . . . . 0.0 114.719 -170.781 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -59.54 -58.32 9.11 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 125.837 1.655 . . . . 0.0 113.495 178.81 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 119.9 -13.02 10.68 Favored Glycine 0 N--CA 1.43 -1.729 0 CA-C-N 120.419 1.463 . . . . 0.0 115.651 168.347 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 20.5 mmt180 -75.16 -52.64 10.47 Favored 'General case' 0 N--CA 1.429 -1.511 0 O-C-N 120.515 -1.58 . . . . 0.0 111.258 177.034 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 57.3 mt -81.06 116.38 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.479 0 C-N-CA 126.231 1.812 . . . . 0.0 112.789 -168.738 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -117.88 164.91 14.34 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 126.37 1.868 . . . . 0.0 112.039 -179.262 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.76 124.34 20.46 Favored 'General case' 0 N--CA 1.429 -1.49 0 O-C-N 119.551 -1.968 . . . . 0.0 114.019 176.459 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 90.12 6.8 68.67 Favored Glycine 0 N--CA 1.43 -1.703 0 O-C-N 120.686 -1.259 . . . . 0.0 114.736 -176.25 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -75.56 160.65 29.92 Favored 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 119.341 1.57 . . . . 0.0 111.273 174.024 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 80.7 ttt180 -101.44 126.71 48.26 Favored 'General case' 0 N--CA 1.43 -1.472 0 O-C-N 120.794 -1.191 . . . . 0.0 110.29 -175.503 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 17.8 t -86.66 111.64 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.484 0 C-N-CA 124.429 1.092 . . . . 0.0 108.494 -177.087 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 87.3 mt -91.14 -53.95 4.15 Favored 'General case' 0 N--CA 1.43 -1.461 0 O-C-N 120.005 -1.684 . . . . 0.0 111.996 -171.571 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.11 146.99 27.96 Favored 'General case' 0 N--CA 1.429 -1.486 0 O-C-N 120.807 -1.183 . . . . 0.0 108.881 -176.774 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 46.6 t -121.54 110.34 27.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.488 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 177.02 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.0 t30 63.17 34.99 13.09 Favored 'General case' 0 N--CA 1.428 -1.526 0 C-N-CA 126.424 1.89 . . . . 0.0 114.989 167.026 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 92.97 -6.01 76.24 Favored Glycine 0 N--CA 1.431 -1.695 0 O-C-N 121.083 -1.011 . . . . 0.0 113.884 -174.93 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.4 t -96.94 113.31 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.449 0 CA-C-N 118.909 1.354 . . . . 0.0 109.719 179.057 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 44.3 m -70.94 123.89 23.07 Favored 'General case' 0 N--CA 1.43 -1.472 0 C-N-CA 124.551 1.14 . . . . 0.0 111.047 176.642 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 23.8 mt -84.23 0.76 47.62 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 120.306 -1.496 . . . . 0.0 114.381 -172.613 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.31 111.98 0.99 Allowed 'General case' 0 N--CA 1.43 -1.452 0 O-C-N 120.277 -1.514 . . . . 0.0 114.135 179.263 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 82.28 12.97 79.84 Favored Glycine 0 N--CA 1.429 -1.78 0 C-N-CA 124.499 1.047 . . . . 0.0 114.473 -179.081 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -72.72 160.69 31.8 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 120.208 -1.76 . . . . 0.0 115.742 173.085 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 51.9 p -89.87 173.88 8.0 Favored 'General case' 0 N--CA 1.431 -1.423 0 O-C-N 120.488 -1.382 . . . . 0.0 111.131 171.505 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -59.59 -49.42 77.83 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 125.347 1.459 . . . . 0.0 112.186 170.179 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 10.8 mptt -55.35 -46.15 76.43 Favored 'General case' 0 N--CA 1.43 -1.469 0 C-N-CA 125.067 1.347 . . . . 0.0 114.102 173.716 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -55.92 -54.06 49.31 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 178.202 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -59.45 -40.62 87.43 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 178.343 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 72.9 t -66.11 -49.51 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.458 0 O-C-N 120.859 -1.151 . . . . 0.0 111.372 176.377 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -66.99 -31.47 72.06 Favored 'General case' 0 N--CA 1.43 -1.458 0 O-C-N 120.5 -1.375 . . . . 0.0 113.624 -179.083 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 100.0 m -65.82 -49.93 66.47 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 127.315 2.246 . . . . 0.0 111.667 171.525 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 41.8 mt -59.89 -41.15 90.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 O-C-N 120.466 -1.396 . . . . 0.0 113.97 174.083 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 96.6 mtt180 -60.33 -41.04 92.7 Favored 'General case' 0 N--CA 1.43 -1.451 0 O-C-N 120.749 -1.22 . . . . 0.0 113.515 172.628 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -83.23 25.68 0.7 Allowed 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 120.487 -1.383 . . . . 0.0 114.584 -179.618 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.442 ' HB ' HG22 ' A' ' 92' ' ' VAL . 59.0 p -87.23 150.9 23.6 Favored 'General case' 0 N--CA 1.431 -1.424 0 O-C-N 120.13 -1.606 . . . . 0.0 109.056 168.783 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.74 -152.31 21.4 Favored Glycine 0 N--CA 1.429 -1.788 0 O-C-N 121.243 -0.911 . . . . 0.0 112.854 -179.667 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -69.59 -50.94 39.84 Favored 'General case' 0 N--CA 1.43 -1.43 0 O-C-N 120.972 -1.31 . . . . 0.0 112.955 -177.409 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.0 p -97.79 134.25 36.68 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 123.094 1.426 . . . . 0.0 109.625 166.19 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.442 HG22 ' HB ' ' A' ' 88' ' ' THR . 97.4 t -122.89 123.37 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.47 0 C-N-CA 126.735 2.014 . . . . 0.0 109.027 -164.897 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -100.59 103.05 14.33 Favored 'General case' 0 N--CA 1.43 -1.466 0 O-C-N 120.53 -1.357 . . . . 0.0 111.242 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.421 ' HB2' ' HB ' ' A' ' 16' ' ' VAL . 28.8 mt -100.45 158.61 15.78 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 119.608 -1.932 . . . . 0.0 112.554 175.87 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 45.9 tp -127.57 130.68 49.5 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 161.278 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -141.84 167.25 22.6 Favored 'General case' 0 N--CA 1.43 -1.431 0 O-C-N 120.469 -1.395 . . . . 0.0 112.814 176.168 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 31.6 tt0 -122.26 147.71 45.88 Favored 'General case' 0 N--CA 1.431 -1.412 0 C-N-CA 124.671 1.188 . . . . 0.0 110.099 179.28 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 14.6 tppt? -75.02 127.45 33.27 Favored 'General case' 0 N--CA 1.43 -1.448 0 C-N-CA 126.371 1.868 . . . . 0.0 110.559 179.803 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -73.69 156.43 50.78 Favored Glycine 0 N--CA 1.429 -1.768 0 C-N-CA 125.048 1.309 . . . . 0.0 116.266 -174.591 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -79.51 -82.62 0.1 Allowed 'General case' 0 N--CA 1.431 -1.398 0 C-N-CA 125.169 1.388 . . . . 0.0 113.056 -173.51 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 30.9 m -101.63 158.1 32.41 Favored Pre-proline 0 N--CA 1.43 -1.461 0 C-N-CA 125.28 1.432 . . . . 0.0 111.875 -175.824 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo . . . . . 0 N--CA 1.434 -2.002 0 C-N-CA 122.504 2.136 . . . . 0.0 112.436 167.857 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 76.4 mttt . . . . . 0 N--CA 1.431 -1.417 0 CA-C-O 118.57 -0.729 . . . . 0.0 111.653 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -77.74 178.67 7.33 Favored 'Trans proline' 0 N--CA 1.434 -2.021 0 C-N-CA 122.554 2.169 . . . . 0.0 113.024 179.633 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 96.29 -22.72 38.34 Favored Glycine 0 N--CA 1.431 -1.68 0 N-CA-C 116.267 1.267 . . . . 0.0 116.267 165.856 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 34.1 t0 -77.17 143.23 39.22 Favored 'General case' 0 N--CA 1.43 -1.475 0 O-C-N 121.053 -1.263 . . . . 0.0 112.13 -178.691 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.6 p -103.45 146.13 28.98 Favored 'General case' 0 N--CA 1.431 -1.418 0 O-C-N 120.796 -1.19 . . . . 0.0 111.592 -179.445 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.463 ' CZ ' HD11 ' A' ' 96' ' ' LEU . 8.3 p90 -148.29 144.97 27.96 Favored 'General case' 0 N--CA 1.43 -1.443 0 CA-C-O 122.552 1.167 . . . . 0.0 109.244 171.683 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -89.8 146.16 24.66 Favored 'General case' 0 N--CA 1.43 -1.47 0 C-N-CA 125.99 1.716 . . . . 0.0 108.799 172.728 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 20.0 t -124.89 102.55 10.83 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.439 0 O-C-N 120.106 -1.621 . . . . 0.0 107.92 177.636 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -96.18 99.13 10.89 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 168.179 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 54.0 tp -123.44 138.51 54.57 Favored 'General case' 0 N--CA 1.43 -1.425 0 C-N-CA 125.279 1.432 . . . . 0.0 110.905 -167.374 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -101.82 133.84 45.94 Favored 'General case' 0 N--CA 1.43 -1.446 0 O-C-N 120.44 -1.413 . . . . 0.0 109.763 172.151 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -65.77 153.3 42.19 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 114.023 1.12 . . . . 0.0 114.023 177.627 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 62.3 p -119.88 116.47 25.9 Favored 'General case' 0 N--CA 1.43 -1.454 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 172.236 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 12.1 t0 56.98 48.74 15.17 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 125.855 1.662 . . . . 0.0 113.723 178.598 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 76.16 -7.37 30.19 Favored Glycine 0 N--CA 1.43 -1.747 0 C-N-CA 125.744 1.64 . . . . 0.0 116.55 177.722 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 18.9 m -121.19 150.23 41.62 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.266 -1.138 . . . . 0.0 111.25 -162.287 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 38.8 mt -97.16 -62.67 1.22 Allowed 'General case' 0 N--CA 1.429 -1.521 0 O-C-N 120.665 -1.272 . . . . 0.0 111.447 178.52 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.02 46.88 0.32 Allowed Glycine 0 N--CA 1.43 -1.755 0 O-C-N 120.4 -1.438 . . . . 0.0 111.979 171.573 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 12.4 tt -147.49 150.4 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 CA-C-O 122.578 1.18 . . . . 0.0 111.217 -172.883 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 23.2 t -123.84 132.73 53.82 Favored 'General case' 0 N--CA 1.43 -1.459 0 C-N-CA 124.639 1.176 . . . . 0.0 108.699 168.943 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 27.8 m -102.61 163.81 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.431 0 C-N-CA 124.812 1.245 . . . . 0.0 113.179 -179.604 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 14.6 t -147.5 169.98 18.41 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 126.095 1.758 . . . . 0.0 109.3 -177.363 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.57 -139.31 14.34 Favored Glycine 0 N--CA 1.43 -1.708 0 O-C-N 120.707 -1.246 . . . . 0.0 113.833 171.154 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.3 -177.36 34.89 Favored Glycine 0 N--CA 1.43 -1.757 0 O-C-N 121.415 -1.05 . . . . 0.0 113.206 -178.656 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.1 m -65.08 -24.16 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.465 0 N-CA-C 116.695 2.109 . . . . 0.0 116.695 -172.078 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -99.07 16.05 23.89 Favored 'General case' 0 N--CA 1.43 -1.441 0 O-C-N 120.85 -1.156 . . . . 0.0 111.645 -175.014 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 72.0 p -115.28 158.93 21.66 Favored 'General case' 0 N--CA 1.431 -1.409 0 C-N-CA 124.72 1.208 . . . . 0.0 109.648 168.551 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.8 t -92.37 60.42 3.62 Favored 'General case' 0 N--CA 1.43 -1.428 0 O-C-N 120.261 -1.525 . . . . 0.0 112.518 -176.119 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.8 m -97.48 -2.82 10.09 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 O-C-N 120.428 -1.42 . . . . 0.0 112.754 -177.99 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . 0.283 8.0 mpt_? 84.21 119.28 0.04 OUTLIER 'General case' 0 N--CA 1.43 -1.464 0 C-N-CA 129.843 3.257 . . . . 0.0 110.269 -169.418 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 68.59 -61.4 0.41 Allowed 'General case' 0 N--CA 1.431 -1.404 0 C-N-CA 127.133 2.173 . . . . 0.0 115.58 -179.794 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 140.5 95.47 0.27 Allowed Glycine 0 N--CA 1.43 -1.703 0 C-N-CA 125.008 1.29 . . . . 0.0 110.848 179.486 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -128.95 148.24 18.02 Favored Glycine 0 N--CA 1.43 -1.758 0 C-N-CA 123.964 0.792 . . . . 0.0 114.115 -176.675 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 38.2 mm -93.92 130.26 43.11 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.434 0 C-N-CA 126.485 1.914 . . . . 0.0 109.477 -178.882 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -126.44 163.03 24.21 Favored 'General case' 0 N--CA 1.429 -1.477 0 O-C-N 120.807 -1.183 . . . . 0.0 110.222 -178.37 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 23.6 t -76.69 126.55 37.46 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.472 0 O-C-N 120.765 -1.209 . . . . 0.0 112.016 169.559 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -91.91 -52.05 4.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 120.943 -1.098 . . . . 0.0 111.875 176.937 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -150.6 155.57 39.67 Favored 'General case' 0 N--CA 1.43 -1.445 0 O-C-N 121.079 -1.013 . . . . 0.0 109.977 -177.762 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.477 HG23 ' HG2' ' A' ' 54' ' ' GLU . 1.3 tp -116.68 123.58 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.437 0 CA-C-O 122.156 0.979 . . . . 0.0 108.484 175.455 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 23.2 mm -77.76 121.86 84.83 Favored Pre-proline 0 N--CA 1.43 -1.459 0 C-N-CA 125.866 1.666 . . . . 0.0 113.399 -172.399 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -59.19 131.51 41.66 Favored 'Trans proline' 0 C--N 1.3 -1.992 0 CA-C-N 124.323 2.58 . . . . 0.0 115.821 -176.547 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 92.5 mttt 77.39 17.33 1.51 Allowed 'General case' 0 N--CA 1.431 -1.423 0 C-N-CA 127.331 2.252 . . . . 0.0 112.822 -178.613 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -80.1 158.78 42.66 Favored Glycine 0 N--CA 1.429 -1.8 0 O-C-N 119.864 -1.772 . . . . 0.0 113.048 173.462 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -49.83 -59.38 3.89 Favored 'General case' 0 N--CA 1.431 -1.42 0 C-N-CA 126.625 1.97 . . . . 0.0 114.193 166.674 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.5 -48.0 81.5 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 127.271 2.228 . . . . 0.0 112.136 179.854 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.477 ' HG2' HG23 ' A' ' 47' ' ' ILE . 2.7 tm-20 -44.7 -66.0 0.45 Allowed 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 116.318 1.97 . . . . 0.0 116.318 170.442 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 44.8 t -63.32 -25.96 68.54 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -172.895 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -54.33 -53.19 57.19 Favored 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 124.983 1.313 . . . . 0.0 113.602 179.319 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 102.46 -8.16 54.67 Favored Glycine 0 N--CA 1.43 -1.759 0 O-C-N 121.507 -0.746 . . . . 0.0 113.204 167.234 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 -68.12 -44.84 75.22 Favored 'General case' 0 N--CA 1.43 -1.467 0 O-C-N 121.229 -1.16 . . . . 0.0 111.153 168.605 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 7.0 mt -91.56 131.56 38.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.454 0 C-N-CA 125.927 1.691 . . . . 0.0 112.47 -175.65 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 60' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -148.22 179.47 7.75 Favored 'General case' 0 N--CA 1.43 -1.454 0 O-C-N 120.245 -1.534 . . . . 0.0 112.922 170.579 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -60.09 129.44 41.78 Favored 'General case' 0 N--CA 1.43 -1.471 0 O-C-N 119.761 -1.837 . . . . 0.0 114.956 -175.005 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 88.51 3.12 78.43 Favored Glycine 0 N--CA 1.43 -1.725 0 O-C-N 120.919 -1.113 . . . . 0.0 115.07 -179.693 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 63' ' ' ASP . . . . . 0.43 ' HB3' HD13 ' A' ' 96' ' ' LEU . 86.7 m-20 -76.03 145.75 39.95 Favored 'General case' 0 N--CA 1.431 -1.403 0 CA-C-N 119.617 1.708 . . . . 0.0 111.739 176.266 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 11.2 tpt180 -95.3 125.5 39.97 Favored 'General case' 0 N--CA 1.431 -1.408 0 O-C-N 120.252 -1.53 . . . . 0.0 110.384 -173.711 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 54.1 t -81.43 132.3 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.481 0 O-C-N 120.243 -1.535 . . . . 0.0 109.107 -178.884 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.3 mp -103.24 -52.96 2.91 Favored 'General case' 0 N--CA 1.43 -1.455 0 O-C-N 121.079 -1.013 . . . . 0.0 109.299 177.406 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -149.88 134.77 17.79 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 121.185 -0.947 . . . . 0.0 111.638 -171.799 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.403 HG11 HG22 ' A' ' 84' ' ' THR . 61.1 t -110.36 120.2 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.532 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 67.81 18.54 9.7 Favored 'General case' 0 N--CA 1.429 -1.484 0 C-N-CA 126.51 1.924 . . . . 0.0 113.525 174.9 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.39 -17.22 54.09 Favored Glycine 0 N--CA 1.428 -1.839 0 O-C-N 120.771 -1.206 . . . . 0.0 112.981 -175.719 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.5 t -88.66 114.03 26.37 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 O-C-N 120.657 -1.496 . . . . 0.0 109.833 -178.372 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 49.2 m -75.65 127.85 33.95 Favored 'General case' 0 N--CA 1.429 -1.493 0 O-C-N 120.727 -1.233 . . . . 0.0 111.279 -179.947 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.26 51.27 2.19 Favored 'General case' 0 N--CA 1.43 -1.44 0 O-C-N 120.847 -1.158 . . . . 0.0 113.583 -165.302 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -74.49 111.32 9.57 Favored 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 119.162 -2.212 . . . . 0.0 115.182 -170.42 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 75.45 13.24 83.07 Favored Glycine 0 N--CA 1.43 -1.766 0 O-C-N 120.634 -1.291 . . . . 0.0 114.14 -179.751 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -71.34 159.44 34.56 Favored 'General case' 0 N--CA 1.43 -1.475 0 CA-C-O 122.715 1.245 . . . . 0.0 113.991 -179.133 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 45.6 p -84.68 169.77 13.97 Favored 'General case' 0 N--CA 1.429 -1.485 0 O-C-N 120.512 -1.368 . . . . 0.0 111.448 172.288 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 26.5 t-80 -56.25 -47.12 79.15 Favored 'General case' 0 N--CA 1.43 -1.44 0 C-N-CA 125.437 1.495 . . . . 0.0 112.176 168.452 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.6 tptp -50.72 -50.03 56.28 Favored 'General case' 0 N--CA 1.43 -1.454 0 C-N-CA 125.976 1.71 . . . . 0.0 113.973 174.501 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -56.27 -49.04 75.36 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 115.062 1.504 . . . . 0.0 115.062 174.92 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 81' ' ' ALA . . . . . . . . . . . . . . . -58.66 -42.41 88.34 Favored 'General case' 0 N--CA 1.43 -1.431 0 C-N-CA 124.726 1.21 . . . . 0.0 114.182 174.951 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.31 -46.8 86.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.487 0 O-C-N 120.732 -1.23 . . . . 0.0 111.62 175.638 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.2 mt-10 -61.47 -34.45 75.47 Favored 'General case' 0 N--CA 1.431 -1.407 0 O-C-N 120.557 -1.34 . . . . 0.0 114.094 178.966 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . 0.403 HG22 HG11 ' A' ' 68' ' ' VAL . 1.5 m -77.82 -35.39 51.3 Favored 'General case' 0 N--CA 1.43 -1.456 0 C-N-CA 125.525 1.53 . . . . 0.0 113.091 174.832 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 53.1 mt -70.2 -24.29 63.09 Favored 'General case' 0 N--CA 1.429 -1.499 0 O-C-N 119.694 -1.879 . . . . 0.0 114.783 168.997 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 38.7 mtt180 -69.64 -48.65 59.18 Favored 'General case' 0 N--CA 1.43 -1.443 0 O-C-N 119.68 -1.888 . . . . 0.0 111.984 168.064 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -85.44 52.58 2.49 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 114.394 1.257 . . . . 0.0 114.394 -176.402 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 56.6 p -88.99 178.78 6.31 Favored 'General case' 0 N--CA 1.43 -1.459 0 O-C-N 120.112 -1.617 . . . . 0.0 109.941 170.691 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.89 -165.31 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 160.836 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 90' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -70.56 -42.7 70.77 Favored 'General case' 0 N--CA 1.43 -1.438 0 O-C-N 121.52 -0.988 . . . . 0.0 112.714 175.067 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 41.8 t -94.83 126.59 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.402 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 166.5 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 53.0 t -114.45 132.29 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.471 0 C-N-CA 129.22 3.008 . . . . 0.0 108.653 -168.148 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 93' ' ' HIS . . . . . . . . . . . . . 6.6 m80 -120.73 91.25 3.49 Favored 'General case' 0 N--CA 1.43 -1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 111.557 -170.845 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 22.9 mt -94.51 155.01 17.13 Favored 'General case' 0 N--CA 1.429 -1.478 0 O-C-N 119.619 -1.926 . . . . 0.0 112.637 177.786 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 95' ' ' LEU . . . . . . . . . . . . . 7.0 tt -129.62 133.13 46.98 Favored 'General case' 0 N--CA 1.43 -1.47 0 O-C-N 121.456 -0.777 . . . . 0.0 109.103 161.984 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.463 HD11 ' CZ ' ' A' ' 14' ' ' PHE . 2.6 pp -152.63 170.41 20.3 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 120.143 -1.598 . . . . 0.0 112.669 -175.083 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 -116.53 145.51 43.28 Favored 'General case' 0 N--CA 1.429 -1.475 0 C-N-CA 125.576 1.55 . . . . 0.0 110.235 179.647 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 18.4 tptt -75.45 137.98 41.32 Favored 'General case' 0 N--CA 1.43 -1.441 0 C-N-CA 125.955 1.702 . . . . 0.0 112.524 -177.446 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -98.82 165.6 21.12 Favored Glycine 0 N--CA 1.43 -1.721 0 C-N-CA 125.359 1.457 . . . . 0.0 112.77 176.546 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 100' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -77.18 179.75 6.14 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -176.766 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.2 m -111.05 154.32 43.52 Favored Pre-proline 0 N--CA 1.43 -1.456 0 O-C-N 120.404 -1.435 . . . . 0.0 111.736 -170.788 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_exo . . . . . 0 N--CA 1.434 -2.015 0 C-N-CA 123.073 2.515 . . . . 0.0 115.638 168.836 . . . . . . . . 0 0 . 1 stop_ save_